<SEC-DOCUMENT>0001804220-23-000008.txt : 20230206
<SEC-HEADER>0001804220-23-000008.hdr.sgml : 20230206
<ACCEPTANCE-DATETIME>20230206092324
ACCESSION NUMBER:		0001804220-23-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230206
DATE AS OF CHANGE:		20230206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REGENERON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000872589
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133444607
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19034
		FILM NUMBER:		23588837

	BUSINESS ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591
		BUSINESS PHONE:		9148477000

	MAIL ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REGENERON PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>regn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:042488f0-a666-455c-8991-c514440b53f2,g:8bd10ba8-749e-45a5-bb1c-c1abec558824,d:c18bad8bf5314e3e9f4c348a9f859317--><html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:regn="http://www.regeneron.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>regn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV80LTEtMS0xLTE3NDM2Mg_54589224-a6e7-45eb-ae3f-adb5ee9197b9">0000872589</ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV85LTEtMS0xLTE3NDM2Mg_8a1bcede-c8c9-41ef-bff7-12b21f95d3fa">2022</ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV8xMC0xLTEtMS0xNzQzNjI_c0de6ecf-6843-4763-a92c-da0fab184c0e">FY</ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV8xMS0xLTEtMS0xNzQzNjI_3d927943-54ca-430c-b8c2-33406e3501f7">false</ix:nonNumeric><ix:nonNumeric contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="regn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f67bb65c7484dc2b0c8012f58e5cf0d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i850a77a234774bf5a4783c3c0030ca8e_I20230126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2d34534410754ab1a8baa62248370c82_I20230126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a293af7f1a454b8c850b4caf8e4c3f_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d21c3111e2741a386578f848272cd46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:AggregateSalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a7782ebd8c4cae90c0de536db35b84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8f6f217bafb048fd906869bf77577910_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef5f55864fa481ca4cc0c510430e3e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i783cf29968664c1cba1a9576242c71ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ef055062c84a5e958dead58e5ac1d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e78ed4547174cfb8fb6f17834e6e280_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5815b19f7c243a9bef193f7182d4504_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0f43af2adc4ac9932414df23261641_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32343f1d31f45ac91df7774f62751d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofiCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb172db0f4c40f4a010b6c1e387157a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofiCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5eff728cc34a73ac8a0e7575138379_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofiCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9eda36fe2b3493fba4bcd24c7f40343_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d2d84b10ee49a78ff80e825d16507c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8125997c22b4a2aaf3b8071ba41f4fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8632402ae5742efb1d686222b335e92_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2052b209c6de41c9a910b9b4862dbf9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1cdfba9891941a6a7d17fd635d19308_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8986e8b381c40169962c1d089395044_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc263c8f9c744cdb933cb195b372c5ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714163480a9a4f66aa296cf9c53130f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29a659882534aef807d28ba085ed2cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034cb1f338a14cdb98427fcd16a6f4bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5358609c29a1448aac4097e872d7c506_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib492caa05ff2478cac6ccfaa46f83cdb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54e4119f42e4422bbe1589864186444_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548c389088d843f3991fec42e82011bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15a99297fdea45a3aac29a3823f628b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3461f1e014c34ede904505072218051f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0e234fb8004f8688e0132e0687751f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09eb064653cc48138003ea93e9fb6cfa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537fb80c394c4504bbb568309e3d34f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a9bb7780cb644e2bf4abf693651eabd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55644888ab1b4dfa9869ab896e024903_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8220af90ab304d119e3feac29aceae08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8049544cda8b4dafaed97a8723f7337d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370f4685af6144d1917cfe1061627472_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e1b802d10c4170b70f673c07516261_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc93395b4534195a6e703327ee8276e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439b09eaccf14173ac24671a7d691568_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2d0c6bc9f4458b8e7efb5109a2426e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if784455c39a741cca476b0900201d0f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65b59d5da2340a0940c3e1995d7021f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12be5553e41d40be83ba97a5fe81845b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666d725ef2cf4065b50048f5296edab9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83be0f48228e4464a3d79b1afd625715_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if802f07034c74a87a67853bdd63c7037_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic572b99252494005bc30f8d6d54277fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070f93a0d90d444baf671f55dbf55f10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca914c1a8484668a3a14d372c8d453b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3919061e6c614ec5a67ef420703684b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f56d798d2de4fd58840b7e15ab5383e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a6ec2800b049a390ee894f424cd007_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3d4bf60775b4d869dd15f70b0ce4725_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie33b2737ad5f4d81a64471a8087f6b6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801c30702fbc4a43994e5257eeedd771_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6785130a464ace9f5ea5f75c6c368b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>regn:product</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>regn:segment</xbrli:measure></xbrli:unit><xbrli:context id="i00bac7cbbc5e4246b3f94989f1a587b7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:ThreeIndividualCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6732651b19384641aff2c7fa3e18b1b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:ThreeIndividualCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3a33c797844c159114ad188489310b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492786f7a1b94a1594a932e2b271fa8a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c27db3739642f99f43796472a8d403_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a49d235b3214cedb524b0736433ccc3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664445be718b4d0faeb4a37890e76062_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3488dea3c9b405e93bf3bd0b9ede622_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied28a835f8bf44bc81d3a306a92462e4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae532f4ad2e45a094632cb65f59ff1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2401c340b8d640b0bd0f2bd3310a8b34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib758c557c5a84357b4ca9aad9468df85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e9c05bba964dbaa707ecf5784772a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4219c796f9c244188971065d5bd4f038_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9aaec3bce84131820f016e635d46b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56d50e41b1b4f2283a73daac3abdfc3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ca5e7fcd0b4a008a735d158813a139_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0393079c0cc944b1a50dfee3c963918e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7e6722d81c44259a1bd92561905f63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd108a8c5454a57937befeca7f6ca59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a9ca7f6313f4b6ca75caf2fbb0aff86_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a3c64382b1c47e282eed691c8527a02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16587113c4db4d869776e4a8f0e3f76f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36561e66271d42cd8f9d4959cf8bae47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d528e548bca464498145136edb95408_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4796a01991465192b9b356e943e2e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e8d230b07841e08ef6b9cf34364982_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d6b917256442e2bcb1f93418c6a3bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15db8997a2b427788f94a1cbbec97c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb8aa02c16b445d7882b24cfd1ce3f1e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045372e85f2c49249ac8ffc7ff4ee23f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37be60752f94dc4afcf263599f81827_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13b570c4cf204eefb544c1454a2796d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3691c35b41bd49019bc22c52a92bb9e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19de0a1ac17e448ab689d53f955adc7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31d29839cf14beabac4560e466ab9df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d710a5f61ac45fe86461104c9643b4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14dd5c1f226d4087af59c57f97a899aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fd1be2ecad4837bb9a616be6b49006_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344fed0429da45b2a1e885495c218a51_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b8fe8cae5f463cad7e8105fe984c3d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af24d3fc5514e589feb09538e6786e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1783ece527234057a38c1fec76fdaa70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5923b8955547f1a59fc39eda60bec4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79035aaa4aca45619bc98627f48db24d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibed642c5d8464dd4ab25fed90d1a28b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaac0693be9b45a28174b13694aa0f4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36a49d6ddd04419a0f5b0f1b8c1c942_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4003730ec2f4d02b252a6fe11601f2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55504a180d724f1ebaac6dc86a38d8a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400385b2589b49f595ff5af66bdd5ade_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4797ff0491840d0b9237549db0ebcf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011e5e369ab847fa9843f4109e14c84b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669cdcc9c1e246469a2358ff978102e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6b4f57919043638cc0e4b7b9319f9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140d0e936e944736a5e1983367a30409_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3bf9e21feb34e239d88bb219da800f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icebca5c748034d6284466eddd3b67472_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d04b81b0d04870a748890c3df2cd84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0edb01a74bf4469a5cee578568c2d72_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf53692132846bdbb98eb842acd5e55_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf7a6f088a44d8c92a8778a84dbc88f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b16833ca23845bea5a41107085ed872_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5549277e904fcf83d210cf6514f72a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3af9d8607c4bcb8acf3c8ebc5b9724_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ba1f9253744de2b4207de915788712_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc9281a149a43a6a468ee18b2d84cf2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0115b1778749402f91e8cc15e18d4904_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia777bee1ba8248c483a61586e012c702_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96bb9eb29d642bc83bbfe650b831b53_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e3a3b0502c4423ad39c725eb715497_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12afa83d8539401a99a900866df1fa36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ce6c9a943648f89bc598bd4d43f36c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1098ae33301f499691dd988767b567e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f529cd92f434fb1a4cedfbac373d940_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9379b307875b4618a634289637cb38fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f5efff9c1341368743087b362bfb90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b2e844e32b48cba3e0f9a0086990d6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a7a5ff4b315478cbf0aad95a657b855_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766d690fe05a4cd1aedfdac8bcaac956_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98f436ad8214c2f880b651b95e5dad2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f38cde3c9ce4d3199de6ef8a0bd8843_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c16e48fda34e60b3f5035db52b587d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd9317470c24cb790bc85ce993a30eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84b946ec54c41148f176f9146ca5bf4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af8b58cda784c98a6fa9c2b3c890073_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb55a76cf4c4a3487a985658b5c16a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40fc6180f85a4a7f9625db7362ac76de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1990e2efe34d48b17cc48fed693450_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8813ce5c13e64d47b2b5439b9dc755f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf8f5e721504480c84d395aaa308c019_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe81139390d42459544d73a062fac93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6265b4f0bd0845d39208a99685ef72d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f01400d1f5f4ab88a047bc5a42ad47e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08844a1258e34c188ef387c945bb338e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051041a979024065b21211e82f9cdf21_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bee21e9d49947c3a10d37cddc0d58ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9102b7c37a5540bd87a27183334b342a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1499e9e4c3cb42b29dbe231e9c8cbca2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareOfLibtayoUSGrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ad83d17ed14bf6986ec0a3067634ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareOfLibtayoUSGrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ae9b363c444357b3a5692e04f07a21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareOfLibtayoUSGrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if782b4fb146742af8dd0fb0dfa6d0f36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e2a1ed354949eb9a8bc01eeb0918c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic964826dc2d046ca8a21b1f261865199_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc08b7de58d43ffa7092aa7f8bb0810_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25739cf76b545759fc2d04ae78628e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3cfd1bc015b4dbe9079b20e66709ea4_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica111cf830ee452b94a3ed1fa3edd4ac_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16d17ebcbaf4806a375d33fb5402f61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92098519881447bc802ea9a38d5455bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df3bd7c2a0041b6ab7f312261481025_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cadc8fc7e24c3d9ff92f91bad83c6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35d85587ab1424a9a59091f3cf09bf6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcc771627f73408eb92c1b64295c2e4b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3d8ea7d0184f31933cf11c201c1047_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic416426a749b4b799097f4def70ef266_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ae15c5525a4644af133a200d4375fc_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07abc9790d746bcb14fa6e3f0c1ea51_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AmendedIODiscoveryAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82399ac549a40d5978b791c9447413e_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:IOLicenseandCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cd8df873044150844eb0ad18f0b00f_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesBasedMilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2edbcd603c4e4104a5be3200e42d13d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesBasedMilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida00ad5e29154c468a4e0cc72eecae59_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id36294acc59c4a11a0b25a3fdda18f81_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb765df6920d4b6383231c53791eadb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9968c18075514aa49e06f8c1a6cb6cdd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AmendedIODiscoveryAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i662e6bf4027d426e82807c2558c35ae6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AmendedIODiscoveryAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f9658cc2ff458f98c65823bbf93768_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ff682a1bf3046e59c581283c15cd463_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f127c8b7cde442e8f388b671f809753_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3153e0c1409546939c8330d63e4b6f96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1144a7790544218f74de1883b49bf3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031e83e10e9e4d98a468c3b9d072d89f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3313afbfc9d443d3919f6a7a44e3fa4d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab9f0ecc7f6469f8f6f13959ec2c1c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f4b4ccfc364728a38bf1a2879c55df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b2ada6cf67454e9cc60972f8641090_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4071c884ce284e40bc787d87c171aee2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56187dada534884b655d5a6e52af578_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i377212e618da453c9025dd02c5593bd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15bad177eea4c829136e32f7d94e3d1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ea98825b3b48b79de2a000301ebc7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f6c2b8f017469fb82cab1366cbc891_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67456caf2c74fb5a00b7ecdac095418_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6d6e78614245739b4f9317ec964d69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a1426d20a84b1ba447ab97089b66db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd8680e50f643d098a5cb1c5b5231a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c64d785c95b442cb84245281603aa97_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1488b28acd4712947288f81c0b3d62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00e86a2286a4587b02c4df300896c50_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60cc7d156a5a435fb977176336cbf529_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>regn:dose</xbrli:measure></xbrli:unit><xbrli:context id="iadbeb25484b8461ba47918e533c9948f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444e097b9a96467fb3f9bcce2f2dbf2f_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ebb955ca6e41b3a41e451e1855aa43_D20210901-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3634f1dd450c457f96f0a93baa2fe330_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9910bd6f76874c749d53d66bb258402f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i557ade655aa34c1cbd2c4cb2be4a929a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id400cead2cc04f689d186fa70f6b0bc7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920dc4f12d2f4619b92a360f1580099a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81aa8c9a653b433692636458e8fd345f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c91b71a44844a9a8775d4250688b382_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib113af71423044e1bdf03d2a055e837d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03fc22e78596486394e84faff1c467ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128800b6b8e7426faa3758b24792c793_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e95202a8f2e4aefb1e1dfc0454a551f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacafdf0d5b114325b26e61a9a412e131_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">regn:AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbee9a8b29934d8b8b7b1e850d856f99_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd928207d61c49b880a0b85bdb41a6a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">regn:CheckmatePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6667fb912e984e6fa6353a1eed3e8fc4_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">regn:CheckmatePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cfcdda3880e4f87bb8ab780435bee97_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c78bdc526b34938a7fd5ed6077bef4d_D20160101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02c2984d363403d9b1e823ad3d81d18_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ac5aacea45414aaa675930ed342a3f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3c36d0466748cea4e130f324d5e2dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f32e181f6564471b1774eaf0ab52226_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf862611445f4a27954a5d9467250c21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ec656e3d9234cddbabc7b72805e843c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5cc30a6e150429d8a9faa24528ade10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be45733794a4b498cd7a86c3b02531c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i756ea3fa11624c548b132cede643b135_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c85832e072499f9f789894f4319fb1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670b1994d88c42c7ad5592e062721992_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic065ee9eda414cb697e07e323cbe487d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f360e272324c199aae4f0c50e9210f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice448a0cbfc94b15af1148fe41fd6000_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f165da14524f83ab4e24f33f72fa7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieff3294615794346a9b85255e14fd794_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe27a11c61a240e4b0a067ec0dd7d798_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93ec21dd364485abcb9d4f5a58113b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea2ced853b94e24a4d22f70bd4fd29e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22141dab4f53412ea6de7ff444ac262c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50af84a4e2f049f5993f9b56288daed0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c9255c54ab4b2d8041ec8cf8ed2d76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4cd0cb429064df7ac32623abbd44a07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fe982b399644ca994a70d8d2ad5e97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc86526bc33f401eaef37c46de2730c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i467a55c788544f30ad74454d840569e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01edbc55a346434a8547a03cdf3f8b8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id596959620f7472daf2da370a9c6e4ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ab5450159345e4a7a8d5d1becc66f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5c2e9a61694f1b8288a4d46747d122_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df6b754d9874865849815ce0ff1fa35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5812ccf9fa340d68bb0fb9ae362fd55_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb2285eff7124799bf35474f9b77d3a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37cc523007314e81a486975a1e802e30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9444b58a5bf44713b0a53669ccd879a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac51098e276e4ab68f338afabe7e88ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0604eb2ce2824a94b18ba840c03422bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e07af51cdfe402cb73cf12cdaa18875_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaac5082db1042e2a542c59aaed88125_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76805457ac75462bb9be58fc14847bbd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie322fb4fa7024b1baee4c74f133d24f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e37a666e97345adad33738c64a2c8ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814e9188987a4eb6818cb5e646b4c49c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i397a4c2affbe4db4b8abb7c9195877b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4cb2ea77d6466a814509f17d146b81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900991202ef2412f84b8b49bbd1fd697_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id958dea12f9f4daf9596b2e6ca4b664d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c4864785e4460bbe8e8603d9e6e3c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55cd0cb5a7dc469dacd573bace8619db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59b77df52a94d3d94be86824b44ccac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf857f344764403832320f65a37a8aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e3d9acb4aa14bb882392991f7def806_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f19239807454691aa94fa166a33be9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ddbcb7106de49f49d710399f917f536_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d07dab80a0497089de881dd7911c76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f9a85d3b6c4ab58982bdab11c05ddd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7268de767d8943b9bee7565a5fc1ee35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7acba5123d245669d2c0b2930d140f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3c12ae98b546ceb6fe3e88dc64b1b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85cf341222be46a193f1ef088c6436ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bc3760e9e940d0b37cebc198b73cf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b618f73a8fa43489c55a045ed15c1f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e308ff0e87e482fba35dd4da2bd8aa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8312eadb6504455aaaac7b194804e4ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2058d7e3d9452b8becd26693bb4b7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5efd5732c8647d88223929f0c134b0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2aa3f436384eb7abe5169c1fb29a5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56431b74b0b46708d25ec5b1f24d48c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f9acbdc085411abc64332f0e5e0849_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if77c2ea74bfe40038cd4646e360bb2e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib29e6005f6d24c0491ed2bbf66621fb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib23273ac9b554855b189599419ac153a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65b5f7083d14d56803e3599a24e7f4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d3fbb1c2f4484da5b302c4846b440f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442040e783844ed382aecdc0af74fc39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350934777cd641749f3726d6f2e3a777_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a2e7c68cbd450986ed5230d81ffae1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1294c19697a4d5989612dcdbb557eaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8931c24c9647998f454d826d5ea54f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78ea7aa3b8b48818411bc781e1be355_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie864f6dc154f4872aff761e5a7f37949_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:FurnitureOfficeEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1098f1326d3c46fab6616d650ec27d81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:FurnitureOfficeEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f9bc6743594e108ea3ba33a0b1df17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769d8dda3fd84c6492c24d8b5d8397c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa561036943849f6970887e7e93d601b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55fbf7200cd34a90a17cae423a49cac1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe2b2c162d74aceaa748b1c4bb2cc4d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">regn:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac94305b0cdd490190861cea74735d96_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">regn:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02495c8017b455681cd9f0f892654ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">regn:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a704809d9454f6091c067635a04adeb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5586b0412de74f4681a571d3e1c5bfbb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566e4366831c4bc9b4395cd536a3c5d4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce0c7f100084a6dad54ebe67493652f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie345030098ed4a68855b720eadea8248_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47d053711fd4bdc82cf9d70aa578c00_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie424218a88a74b00b19453fe4888916c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a9aa37e4c1457a976919d9730f8e80_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7310c177364143f2bf10f9d6b7aaf971_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12579be01dc47cfbb463231b2c8f01d_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261cf06513ba49e388568bf4932270e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c01c03f3a4444d1b5c5abebba7521b9_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bbfaa6d6caa478986a0fd252d1994d6_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e773031061f47068bfb7d9af0a6f623_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b091a819e7f463a80413ebcc76b6b92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78cab400df7439280370205f9c3d004_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d999cff105340e388c8d3d0fae950fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a901ef13b914e98a6b6ae594630e3ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109147ff73454c9fb1005363d4c3549c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc3a52eb4104b5aa8911f6741d3eee6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc58844910a4e119a03ecefec012869_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079d9f100fb942469a90e889b3b42209_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012c8a6940324ac49f3899e2c90dc896_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice406a54e051445e8e2f53b1c1e07740_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a2e9c56f7e416f8da3fc7358beb047_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b5cb43390f40c79c55e8db0b798b1a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib132e77f1248490f82fe430c0a335704_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d20e3c5247b4d598e751c21b3f4f608_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">regn:ThroughDecember312023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d41d00df44446baa4014ec1a2a8b14_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">regn:January12024ThroughDecember312026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83c963269194f2fbfdc09f02cc5d592_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78394eb2a794ed4ac4431dca866af29_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96fa6ba59e84ea08d01d27873b5696b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>regn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i4e0c0f7f9e7245159ae317600a59a97f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1f29e4d0084509aad565f88da92c75_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ed95697fc6411f82f5d2215701a1ce_D20191101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898556ab5e034bf8a39f1f7ffdcff4b6_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if149e3b2ed184d9cb47a5f1e416db711_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramNovember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4688a81ec54e3e81135fe0cef6a811_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramNovember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa856a8273104bae9abb9e9bd006496c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b3516f1f374f9ba681ff3469a1d79b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa56acec5b6c42e6a0c418417df45e87_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2184e2e59fa45c7b4e39f4a72edfc26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife75b59764cd4329a476ef09a7789b4f_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffed57e1fcf04b469127e38751ea1244_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">regn:AmendedRestatedLongTermIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd3089f49fe4ad18bf060be6041dc8d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">regn:LongTermIncentivePlan2000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c4af83a9954f7a928a982e2a427940_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">regn:LongTermIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa909c892214ee795c9bf21ee208f05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0528c01e20994e37b110ba9db8971e61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8074da28c47b44eb8134011e2bfd7c77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20a52b8adf44b65bc4aed375198294a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061dabef95db47dcbeacf4d95b0043d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3ca35c957f4ea784da91f7c995a52c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc41ab2a621442839e2f788a04d55cce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44560f336e474452ae29c854f6be95dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f758f9b4de4edbbd24b0a3c80d2099_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b8165ff3c84cc2b0b3ef6c846d0857_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic976d25c5e3d49f49a38da896bf4b995_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3bb26f27c440bca9bd206e40fb92e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f140ca61272416db70327e6fc368a13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f39b7d8fbc4c3db0ae510abf05e506_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A226PatentAnd992PatentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EYLEAAfliberceptInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="request"><xbrli:measure>regn:request</xbrli:measure></xbrli:unit><xbrli:context id="ie1e3a47e6a80444d990b27b30d75132a_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:CelltrionIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>regn:claim</xbrli:measure></xbrli:unit><xbrli:context id="icacf904bc9524621b2a1108d36ed04c7_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:ApotexIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic126e7de56fd4102a3b3234acc2542c7_I20200716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id00ff500fe5d47c79cce7113ad54ecef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec0ed1241324a98bc46dd1af446a761_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60296a00df8b476a897b09a51d123985_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5bac9dad6b340e2b278dca087384319_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zODg_9ba51cac-f3d1-49b8-83a8-272c57df6835">10-K</ix:nonNumeric> </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:105.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:193.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:193.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF8xLTAtMS0xLTE3NDM2Mg_3005242a-4626-4fa8-9214-c530a928ca3a">&#9746;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF8yLTEtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmRhY2FiZWE5MWZkNjRiMGRiNzRiYTViNzEzMWUyM2UzXzMw_dd7a5e07-37e5-43e9-84af-b8e1b83c41c5"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF8yLTEtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmRhY2FiZWE5MWZkNjRiMGRiNzRiYTViNzEzMWUyM2UzXzMw_fc0df25b-4567-4b9c-9665-0a58492e901d">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">OR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF80LTAtMS0xLTE3NDM2Mg_863ef566-2216-4f26-8709-f3782682094c">&#9744;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from __________ to __________</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:439.50pt"><tr><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commission File Number: <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NjI3YjE0YjM1OTg4NDc3Y2JkZDg2ODM0OTE0ZTRjMTQvdGFibGVyYW5nZTo2MjdiMTRiMzU5ODg0NzdjYmRkODY4MzQ5MTRlNGMxNF8wLTEtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmE2YjIyNTI4ZmU4YzRhMzc5ODdmZWJkMDQxOTNjODI2XzI4_c49a6f2a-b380-4045-ba1f-d43579e582f5">000-19034</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTI_5e8d5a29-cbdb-4d3d-8c76-ae5755d99c69">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:373.50pt"><tr><td style="width:1.0pt"></td><td style="width:232.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NmUwNzg5ZTE5ZDg4NDFiMGFkNWFiZmJmYmFhZTA3MmMvdGFibGVyYW5nZTo2ZTA3ODllMTlkODg0MWIwYWQ1YWJmYmZiYWFlMDcyY18wLTAtMS0xLTE3NDM2Mg_a5ac5136-0d39-4424-9db5-e117987292f1">New York</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NmUwNzg5ZTE5ZDg4NDFiMGFkNWFiZmJmYmFhZTA3MmMvdGFibGVyYW5nZTo2ZTA3ODllMTlkODg0MWIwYWQ1YWJmYmZiYWFlMDcyY18wLTItMS0xLTE3NDM2Mg_775b7305-7d1f-484e-8fcd-2004a7e90f12">13-3444607</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:294.75pt"><tr><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzQ_320f8ac5-1ba7-4003-b4d0-ca85fa8cdb09">777 Old Saw Mill River Road</ix:nonNumeric>  <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzg_52394e4c-37d3-444b-8e71-3c9aa14ef734">Tarrytown</ix:nonNumeric>, <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzEy_07e89d96-5f95-45e7-883e-908ccf191c1b">New York</ix:nonNumeric>  <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzE2_59c25867-3d16-449a-9b8a-4a39feacc1cd">10591-6707</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTM_129757d0-848a-4016-a520-b5ca4faa11b6">914</ix:nonNumeric>) <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTQ_8b4aa351-5e87-4a69-bb19-302cd9690258">847-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:41.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6OWExMmI1MDQyZWE3NDNjY2FlOTlmMDA3ZGE2MjIzODcvdGFibGVyYW5nZTo5YTEyYjUwNDJlYTc0M2NjYWU5OWYwMDdkYTYyMjM4N18xLTAtMS0xLTE3NDM2Mg_c2dcc423-8153-4eaf-b232-f050f2632063">Common Stock - par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6OWExMmI1MDQyZWE3NDNjY2FlOTlmMDA3ZGE2MjIzODcvdGFibGVyYW5nZTo5YTEyYjUwNDJlYTc0M2NjYWU5OWYwMDdkYTYyMjM4N18xLTEtMS0xLTE3NDM2Mg_fde59aec-b5d4-450f-a6e6-ed065fcf8b21">REGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6OWExMmI1MDQyZWE3NDNjY2FlOTlmMDA3ZGE2MjIzODcvdGFibGVyYW5nZTo5YTEyYjUwNDJlYTc0M2NjYWU5OWYwMDdkYTYyMjM4N18xLTItMS0xLTE3NDM2Mg_c8b5d10a-c26d-4bdf-95e1-77e6a834f28e">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV8wLTEtMS0xLTE3NDM2Mg_dded19b2-a8dd-4aa9-bab0-dd086fc04c3d">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV8yLTMtMS0xLTE3NDM2Mg_68ff3214-a3c9-4c0f-9615-31aad3ed000b">No</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV80LTEtMS0xLTE3NDM2Mg_78f5774d-bcd1-4f74-bba8-ce3fdb0a9106">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV82LTEtMS0xLTE3NDM2Mg_e67edce4-8d29-4411-8073-9afa0ddc01ab">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:14.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NTRjMzE5OWYzYjg5NDhmZThjM2U5Njk5MGExOTg1MmQvdGFibGVyYW5nZTo1NGMzMTk5ZjNiODk0OGZlOGMzZTk2OTkwYTE5ODUyZF8wLTAtMS0xLTE3NDM2Mg_ca6a5a54-35b6-4ea6-b6c2-1788392fa9c6">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NTRjMzE5OWYzYjg5NDhmZThjM2U5Njk5MGExOTg1MmQvdGFibGVyYW5nZTo1NGMzMTk5ZjNiODk0OGZlOGMzZTk2OTkwYTE5ODUyZF8wLTEwLTEtMS0xNzQzNjI_5fccb210-155f-48d1-9df0-b7537efd0639">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NTRjMzE5OWYzYjg5NDhmZThjM2U5Njk5MGExOTg1MmQvdGFibGVyYW5nZTo1NGMzMTk5ZjNiODk0OGZlOGMzZTk2OTkwYTE5ODUyZF8wLTEzLTEtMS0xNzQzNjI_32776cd2-0e01-4b55-ab7b-3729697cd733">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzkwZjEyNTMwMmQxNDlkMmIyYzZhYzVmYmNiMTc5NmIvdGFibGVyYW5nZTozOTBmMTI1MzAyZDE0OWQyYjJjNmFjNWZiY2IxNzk2Yl8yLTQtMS0xLTE3NDM2Mg_7c529dfe-ed94-4971-bd37-4580ac634078">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzkwZjEyNTMwMmQxNDlkMmIyYzZhYzVmYmNiMTc5NmIvdGFibGVyYW5nZTozOTBmMTI1MzAyZDE0OWQyYjJjNmFjNWZiY2IxNzk2Yl80LTItMS0xLTE3NDM2Mg_bc423492-3295-46d5-be28-3e3270aaea7a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="i6f67bb65c7484dc2b0c8012f58e5cf0d_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzkwZjEyNTMwMmQxNDlkMmIyYzZhYzVmYmNiMTc5NmIvdGFibGVyYW5nZTozOTBmMTI1MzAyZDE0OWQyYjJjNmFjNWZiY2IxNzk2Yl82LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmNkMjg5MDg3ODA4ODQ4MTVhN2I0ZTViNDNiYzlkMzU1XzEzMg_1326c197-ba73-4a1f-b621-10b89b3b23ee">62.0</ix:nonFraction> billion, computed by reference to the closing sales price of the stock on NASDAQ on June 30, 2022, the last trading day of the registrant's most recently completed second fiscal quarter. For purposes of this calculation only, the registrant has assumed that all of its directors and executive officers, and no other persons, are its affiliates. This determination of affiliate status is not necessarily a determination for other purposes.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The number of shares outstanding of each of the registrant's classes of common stock as of January&#160;26, 2023:</span></div></td></tr></table></div><div style="margin-bottom:4pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.005%"><tr><td style="width:1.0%"></td><td style="width:54.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class A Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i850a77a234774bf5a4783c3c0030ca8e_I20230126" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjAxYWE5YjA4ZjgyNDFkMjkwMjc5ZjBjM2JjNWU3NzIvdGFibGVyYW5nZToyMDFhYTliMDhmODI0MWQyOTAyNzlmMGMzYmM1ZTc3Ml8xLTItMS0xLTE3NDM2Mg_7588d5bb-7105-478a-a35b-9228b687768e">1,818,146</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d34534410754ab1a8baa62248370c82_I20230126" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjAxYWE5YjA4ZjgyNDFkMjkwMjc5ZjBjM2JjNWU3NzIvdGFibGVyYW5nZToyMDFhYTliMDhmODI0MWQyOTAyNzlmMGMzYmM1ZTc3Ml8yLTItMS0xLTE3NDM2Mg_cf6a2301-c2a0-4e97-b93a-e79d261e9b3b">107,507,386</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTA_1a86e5a4-5877-452d-bde8-fbcd1f520f3e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Specified portions of the Registrant's definitive proxy statement to be filed in connection with solicitation of proxies for its 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Form 10-K. Exhibit index is located on pages 96 to 101 of this filing. </span></td></tr></table></ix:nonNumeric></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.775%"><tr><td style="width:1.0%"></td><td style="width:10.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page Numbers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_13">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_22">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_22">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_22">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_25">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_25">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_28">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_28">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_28">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_31">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_31">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_31">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_34">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_34">74</a></span></div></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_37">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_40">Item 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_40">Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_40">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_43">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_43">[R</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_43">eserved</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_43">]</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_43">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_46">Item 7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_46">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_46">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_64">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_64">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_67">Item 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_67">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_70">Item 9.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_70">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_70">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_73">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_73">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_73">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_76">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_76">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_76">94</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_79">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_79">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_79">94</a></span></div></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Item 10.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Item 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Item 12.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Item 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Item 14.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_82">95</a></span></div></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_88">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_88">Item 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_88">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_88">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_91">Item 16.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_91">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_91">101</a></span></div></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_94">SIGNATURE PAGE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_94">102</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"Altibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" (in the United States), "REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron Genetics Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "RGC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Veloci-Bi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociHum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," and "ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements.&#160;Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.&#160;These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators&#8217; ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron&#8217;s Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;(aflibercept) Injection, Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;(dupilumab) Injection, Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(cemiplimab) Injection, Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;(alirocumab) Injection, Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;(sarilumab) Injection, Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> (evinacumab), aflibercept 8 mg, pozelimab, odronextamab, itepekimab, fianlimab, garetosmab, linvoseltamab, REGN5713-5714-5715, Regeneron's other oncology programs (including its costimulatory bispecific portfolio), Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those listed above; the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; our ability to manufacture and manage supply chains for multiple products and product candidates; the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in  Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.&#160;These statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any such statements.&#160;In evaluating such statements, shareholders and potential investors should specifically consider the various factors identified under Part I, Item 1A. "Risk Factors," which could cause actual events and results to differ materially from those indicated by such forward-looking statements. We do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events, or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Our objective is to continue to be an integrated, multi-product biotechnology company that provides patients and medical professionals with important medicines for preventing and treating human diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.925%"><tr><td style="width:1.0%"></td><td style="width:50.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,172.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,071.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this report, references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators or licensees and references to our product candidates encompass product candidates in development by us and/or our collaborators or licensees (in the case of collaborated or licensed products or product candidates under the terms of the applicable collaboration or license agreements), unless otherwise stated or required by the context.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that have received marketing approval are summarized in the table below.</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA (aflibercept) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular age-related macular degeneration ("wet AMD")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic macular edema ("DME")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Macular edema following retinal vein occlusion ("RVO"), which includes macular edema following central retinal vein occlusion ("CRVO") and macular edema following branch retinal vein occlusion ("BRVO")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myopic choroidal neovascularization ("mCNV")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic retinopathy ("DR")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular glaucoma ("NVG")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retinopathy of prematurity ("ROP")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in pediatrics 6 months&#8211;5 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyposis ("CRSwNP")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eosinophilic esophagitis ("EoE") (in adults and adolescents)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prurigo nodularis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced first-line non-small cell lung cancer ("NSCLC")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced first-line NSCLC (in combination with chemotherapy)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced basal cell carcinoma ("BCC")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced cutaneous squamous cell carcinoma ("CSCC")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or recurrent second-line cervical cancer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent (alirocumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDL-lowering in heterozygous familial hypercholesterolemia ("HeFH") or clinical atherosclerotic cardiovascular disease ("ASCVD")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular risk reduction in patients with established cardiovascular disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Homozygous familial hypercholesterolemia ("HoFH")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara (sarilumab) Solution for Subcutaneous Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis ("RA")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza (evinacumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH (in adults and adolescents)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (atoltivimab, maftivimab, and odesivimab-ebgn) Injection</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rilonacept) Injection for Subcutaneous Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cryopyrin-associated periodic syndromes ("CAPS"), including familial cold auto-inflammatory syndrome ("FCAS") and Muckle-Wells syndrome ("MWS") (in adults and adolescents)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficiency of interleukin-1 receptor antagonist ("DIRA") (in adults and pediatrics)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent pericarditis (in adults and adolescents)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ziv-aflibercept) Injection for Intravenous Infusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic colorectal cancer ("mCRC")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note: Refer to table below (net product sales of Regeneron-discovered products) for information regarding whether net product sales for a particular product are recorded by us or others. In addition, unless otherwise noted, products in the table above are generally approved for use in adults in the above-referenced diseases.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Bayer outside the United States</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi prior to July 2022. Effective July 2022, the Company is solely responsible for the development, commercialization, and manufacturing of Libtayo. Refer to "Collaboration, License, and Other Agreements" section below for further details.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The Company is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Rest of world ("ROW"). A checkmark in this column indicates that the product has received marketing approval in at least one country outside of the United States, European Union ("EU"), or Japan.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> in other countries. </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The Company is solely responsible for the development and commercialization of Evkeeza in the United States. In January 2022, the Company entered into a license and collaboration agreement for Ultragenyx to develop and commercialize Evkeeza outside of the United States.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kiniksa is solely responsible for the development and commercialization of ARCALYST.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi is solely responsible for the development and commercialization of ZALTRAP.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of Regeneron-discovered products consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.114%"><tr><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.911%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,647.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,243.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,767.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,668.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,681.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,713.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,198.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective January 1, 2022, the Company and Bayer commenced sharing equally in profits and losses based on sales from Bayer to its distributor in Japan. Previously, the Company received from Bayer a tiered percentage of sales based on sales by Bayer's distributor in Japan. Consequently, the prior year net product sales amount has been revised for comparability purposes.</span></div></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of EYLEA in the United States. Bayer records net product sales of EYLEA outside the United States. The Company records its share of profits/losses in connection with sales of EYLEA outside the United States.</span></div></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi records global net product sales of Dupixent and Kevzara. The Company records its share of profits/losses in connection with global sales of Dupixent and Kevzara.</span></div></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. The parties equally shared profits/losses in connection with global sales of Libtayo. Effective July 1, 2022, the Company began recording net product sales of Libtayo outside the United States and pays Sanofi a royalty on global sales. Refer to "Collaboration, License, and Other Agreements" section below for further details. Included in this line item is approximately $34 million of net product sales recorded by Sanofi in the second half of 2022 in connection with sales in certain markets (Sanofi will record net product sales in such markets during a transition period until inventory on hand as of July 1, 2022 is sold through to the end customers).</span></div></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, Regeneron records net product sales of Praluent in the United States. Also effective April 1, 2020, Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales. Previously, Sanofi recorded global net product sales of Praluent and the Company recorded its share of profits/losses in connection with such sales.</span></div></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of REGEN-COV in the United States and Roche records net product sales of Ronapreve outside the United States. The parties share gross profits from global sales of REGEN-COV and Ronapreve based on a pre-specified formula.</span></div></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in this line item are products which are sold by the Company and others. Refer to Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations - Revenues" for a complete listing of net product sales recorded by the Company. Not included in this line item are net product sales of ARCALYST subsequent to the first quarter of 2021, which are recorded by Kiniksa.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Programs in Clinical Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates in clinical development, which are being developed by us and/or our collaborators, are summarized in the table below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development (including any post-approval studies), uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes to drug pricing and reimbursement regulations and requirements, and changes in the competitive landscape affecting a product candidate. The planning, execution, and results of our clinical programs are significant factors that can affect our operating and financial results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part I, Item 1A. "Risk Factors" for a description of risks and uncertainties that may affect our clinical programs. Any of such risks and uncertainties may, among other matters, negatively impact the development timelines set forth in the table below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 and 2023 <br/>Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ophthalmology</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EYLEA (aflibercept)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;ROP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;ROP (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Granted pediatric exclusivity by U.S. Food and Drug Administration ("FDA") in connection with ROP study, extending period of EYLEA U.S. market exclusivity by six months through May 17, 2024</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by European Commission ("EC") for ROP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by Ministry of Health, Labour and Welfare ("MHLW") for ROP in Japan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Withdrew supplemental Biologics License Application ("sBLA") for every-16-weeks dosing regimen in patients with DR</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on sBLA for ROP (target action date of February 11, 2023)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aflibercept 8 mg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Wet AMD</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;DME</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Wet AMD and DME (U.S.)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trials in wet AMD and DME met their primary endpoints</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on BLA for wet AMD and DME (third quarter 2023) <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit regulatory application in the EU for wet AMD and DME (first quarter 2023)<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report two-year data from Phase 3 studies in wet AMD and DME (third quarter 2023)</span></td></tr><tr style="height:62pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 and 2023 <br/>Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology &amp; Inflammation</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dupixent (dupilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-4R alpha subunit</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;EoE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in pediatrics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic obstructive pulmonary disease ("COPD")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Bullous pemphigoid (Phase 2/3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic spontaneous urticaria ("CSU")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic inducible urticaria - cold</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic rhinosinusitis without nasal polyposis </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Allergic fungal rhinosinusitis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic pruritus of unknown origin </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Atopic dermatitis in pediatrics (6 months&#8211;5 years of age) (EU) and in pediatrics and adolescents (6 months&#8211;14 years of age (Japan)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prurigo nodularis (Japan)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CSU in adults and adolescents (U.S.)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA for atopic dermatitis in pediatrics (6 months&#8211;5 years of age)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") adopted positive opinion for atopic dermatitis in pediatrics (6 months&#8211;5 years of age)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by EC for severe asthma in pediatrics (6&#8211;11 years of age)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA and EC for EoE in adults and adolescents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial in EoE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in pediatrics (1&#8211;11 years of age) met its primary endpoint</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA and EC for prurigo nodularis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Stopped one of the Phase 3 trials in CSU (in patients refractory to omalizumab) due to futility, based on pre-specified interim analysis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiated additional Phase 3 trial in CSU (in biologic-na&#239;ve patients)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Discontinued further clinical development in peanut allergy</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;EC decision on regulatory submission for atopic dermatitis in pediatrics (6 months&#8211;5 years of age) (first half 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MHLW decision on regulatory submission for atopic dermatitis in pediatrics and adolescents (6 months&#8211;14 years of age) in Japan (second half 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA for EoE in pediatrics (mid-2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from first Phase 3 study in COPD (first half 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on sBLA for CSU in adults and adolescents (second half 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 3 study in chronic inducible urticaria - cold (first half 2023)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 and 2023 <br/>Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevzara (sarilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-6R</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Polyarticular-course juvenile idiopathic arthritis ("pcJIA")<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Systemic juvenile idiopathic arthritis ("sJIA")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;Polymyalgia rheumatica ("PMR") (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on sBLA for PMR (target action date of February 28, 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3500)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-33</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COPD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 3 study in COPD (2024)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5713-5714-5715</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to Bet v 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Birch allergy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solid Organ Oncology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Libtayo (cemiplimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)(g)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PD-1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Neoadjuvant CSCC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Second-line cervical cancer, ISA101b combination</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Adjuvant CSCC</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line NSCLC, chemotherapy combination (EU)</span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA in combination with chemotherapy for NSCLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by EC and MHLW for cervical cancer</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Voluntarily withdrew sBLA for cervical cancer due to inability to align with FDA on certain post-marketing studies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Positive data from Phase 2 trial in neoadjuvant CSCC presented at European Society for Medical Oncology ("ESMO") Congress 2022 and published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">New England Journal of Medicine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;EC decision on regulatory submission for NSCLC, chemotherapy combination (first half 2023)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fianlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3767)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to LAG-3 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors and advanced hematologic malignancies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line metastatic melanoma<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line adjuvant melanoma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Presented positive data from Phase 1 trial (in combination with Libtayo) in advanced melanoma at ESMO Congress 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 study (in combination with Libtayo) in perioperative melanoma (mid-2023) </span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 and 2023 <br/>Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fianlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Positive initial data from Phase 1 trial (in combination with Libtayo) in NSCLC presented at ESMO Immuno-Oncology Congress 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 2/3 studies (in combination with Libtayo) in first-line advanced NSCLC (first half 2023) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 2 study (in combination with Libtayo) in perioperative NSCLC (second half 2023) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vidutolimod</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Immune activator targeting TLR9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 2 study in melanoma </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ubamatamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN4018)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Platinum-resistant ovarian cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;Presented positive initial data from monotherapy dose escalation portion of Phase 1/2 study in platinum-resistant ovarian cancer at ESMO Congress 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 1/2 study (in combination with Libtayo) in platinum-resistant ovarian cancer (2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(o)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Platinum-resistant ovarian cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5678</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting PSMA and CD28</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prostate cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported preliminary data from dose escalation portion of Phase 1/2 study (in combination with Libtayo) in prostate cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report additional results from Phase 1/2 study (in combination with Libtayo) in prostate cancer (2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN4336</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting PSMA and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting two distinct MET epitopes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MET-altered advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Presented positive initial data from dose escalation portion of Phase 1/2 study in MET-altered advanced NSCLC at ESMO Congress 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093-M114</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody-drug conjugate targeting two distinct MET epitopes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MET overexpressing advanced cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN6569</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to GITR</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 and 2023 <br/>Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7075</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting EGFR and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hematology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Odronextamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (REGN1979)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting CD20 and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Certain B-cell malignancies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(m)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;B-cell non-Hodgkin lymphoma</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;("B-NHL")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (pivotal study)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Presented positive data from two cohorts of pivotal Phase 2 study in patients with diffuse large B-cell lymphoma ("DLBCL") and follicular lymphoma ("FL") at American Society of Hematology ("ASH") Annual Meeting</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 studies in FL and DLBCL, including earlier lines of therapy (first half 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit BLA for relapsed/refractory FL and DLBCL (second half 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Linvoseltamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN5458)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Multiple myeloma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Multiple myeloma (pivotal study)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Completed enrollment in pivotal Phase 2 study in multiple myeloma</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Presented positive data from pivotal Phase 2 study in multiple myeloma at ASH Annual Meeting</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 study in multiple myeloma, including earlier lines of therapy (first half 2023) <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit BLA for relapsed/refractory multiple myeloma (second half 2023)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Transplant desensitization in patients with chronic kidney disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pozelimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3918)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to C5; studied as monotherapy and in combination with cemdisiran</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CD55-deficient protein-losing enteropathy ("CHAPLE"), monotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (potentially pivotal study)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Myasthenia gravis, cemdisiran combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Paroxysmal nocturnal hemoglobinuria ("PNH"), cemdisiran combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(k)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CHAPLE, monotherapy (U.S.)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on BLA for CHAPLE, monotherapy (second half 2023)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7257</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL2Rg</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Aplastic anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NTLA-2001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">TTR gene knockout using CRISPR/Cas9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Transthyretin ("ATTR") amyloidosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported positive interim data from Phase 1 trial in ATTR</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN9933</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Factor XI</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Thrombosis<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 and 2023 <br/>Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7508</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Factor XI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Thrombosis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7999</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to TMPRSS6</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Transfusion dependent iron overload</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Medicine</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">"Next Generation" Covid Antibodies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibodies to SARS-CoV-2 variants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate clinical development of "next generation" antibody</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Praluent (alirocumab)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PCSK9</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;HeFH in pediatrics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA for HeFH in pediatrics (mid-2023)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(evinacumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)(l)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to ANGPTL3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;HoFH in pediatrics (5&#8211;11 years of age) (U.S.)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial for HoFH in pediatrics (5&#8211;11 years of age) met its primary endpoint</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on sBLA for HoFH in pediatrics (5&#8211;11 years of age) (target action date of March 30, 2023)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Garetosmab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN2477)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Activin A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Fibrodysplasia ossificans progressiva </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("FOP")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mibavademab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN4461)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to leptin receptor ("LEPR")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Generalized lipodystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Partial lipodystrophy</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5381/REGN9035</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to NPR1/reversal agent to REGN5381</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reversal agent in healthy volunteers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Heart failure</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report initial data in healthy volunteers (2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-HSD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(p)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting HSD17B13</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Nonalcoholic steatohepatitis<br/>("NASH")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported preliminary data from Phase 1 study in NASH</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 2 study in NASH (first quarter 2023)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-PNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting PNPLA3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;NASH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-APP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting APP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Early-onset Alzheimer&#8217;s disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 1 study in early-onset Alzheimer&#8217;s disease (mid-2023)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note 1: For purposes of the table above, a program is classified in Phase 1, 2, or 3 clinical development after recruitment for the corresponding study or studies has commenced.</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note 2: We have discontinued further clinical development of fasinumab (REGN475), an antibody to NGF, which was previously being studied in osteoarthritis pain of the knee or hip in collaboration with Teva and Mitsubishi Tanabe Pharma Corporation ("MTPC"); REGN6490, an antibody to IL-36R, which was previously being studied in palmo-plantar pustulosis; and the Phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1, in cat allergy, due to futility.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Bayer outside the United States</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Sanofi</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted orphan drug designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA granted Breakthrough Therapy designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Fast Track designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi did not opt-in to or elected not to continue to co-develop the product candidate. Under the terms of our agreement, Sanofi is entitled to receive royalties on sales of the product, if any.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Studied as monotherapy and in combination with other antibodies and treatments</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Information in this column relates to U.S., EU, and Japan regulatory submissions only</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Zai Lab in mainland China, Hong Kong, Taiwan, and Macau</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Intellia</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Alnylam</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Ultragenyx outside the United States</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Fast Track designation for follicular lymphoma and diffuse large B-cell lymphoma</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Sanofi prior to July 2022. Effective July 2022, the Company is solely responsible for the research, development, and commercialization of Libtayo. Refer to "Collaboration, License, and Other Agreements" section below for further details.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Studied in combination with ubamatamab</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(p)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Alnylam elected to opt-out of the product candidate. Under the terms of our agreement, Alnylam is entitled to receive royalties on sales of the product, if any.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Information - Clinical Development Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aflibercept 8 mg</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company announced that the primary endpoints were met in two pivotal trials investigating aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wet AMD. The PHOTON trial in DME and the PULSAR trial in wet AMD both demonstrated that aflibercept 8 mg 12- and 16-week dosing regimens achieved non-inferiority in vision gains compared to the EYLEA 8-week dosing regimen. Furthermore, of the patients randomized to 12- and 16-week dosing intervals, 91% and 89% of DME patients, respectively, and 79% and 77% of wet AMD patients, respectively, maintained those intervals through 48 weeks. The safety of aflibercept 8 mg was similar to EYLEA in both trials, and consistent with the known safety profile of EYLEA from previous clinical trials. The Company is utilizing a priority review voucher in connection with the December 2022 submission of the BLA for DME and wet AMD.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REGEN-COV, a multi-antibody therapy to SARS-CoV-2 virus, previously received an EUA for use in certain&#8239;post-exposure prophylaxis&#8239;settings and as a treatment for people with mild to moderate COVID-19 who are at high risk of serious consequences from COVID-19. Based on laboratory data, in January 2022, the FDA revised the EUA for REGEN-COV to exclude its use in geographic regions where, based on available information including variant susceptibility and regional variant frequency, infection or exposure is likely due to a variant such as an Omicron-lineage variant that is not susceptible to the treatment. With this EUA revision, REGEN-COV is not currently authorized for use in any U.S. states, territories, or jurisdictions, since Omicron-lineage variants are currently dominant across the United States. In December 2022, the FDA issued a complete response letter ("CRL") on the BLA for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Descriptions of Marketed Products Studied in Additional Indications and Product Candidates in Late-Stage Clinical Development </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EYLEA (aflibercept)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA is a soluble fusion protein that acts as a vascular endothelial growth factor ("VEGF") inhibitor, formulated as a 2 mg intravitreal injection for the eye. It is designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and PLGF, two growth factors involved in angiogenesis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aflibercept 8 mg</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aflibercept 8 mg is an investigational soluble fusion protein that acts as a VEGF inhibitor. Through a novel formulation, it is designed to deliver a concentrated dose of aflibercept to block VEGF-A and PLGF and inhibit the growth of new blood vessels and decrease vascular permeability. Aflibercept 8 mg is being studied in wet AMD and DME using extended dosing intervals of every 12 weeks and every 16 weeks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent (dupilumab)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dupixent is a fully human monoclonal antibody that inhibits signaling of the IL-4 and IL-13 pathways, and is not an immunosuppressant. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, and potentially other chronic allergic and inflammatory diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kevzara (sarilumab)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevzara is a fully human monoclonal antibody that binds specifically to the IL-6 receptor and inhibits IL-6-mediated signaling. IL-6 is a signaling protein produced in increased quantities in patients with RA and has been associated with disease activity, joint destruction, and other systemic problems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Itepekimab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Itepekimab is an investigational, fully human monoclonal antibody that inhibits IL-33, a protein that is believed to play a key role in lung inflammation in COPD.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGN5713-5714-5715</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch pollen allergy is one of the most common causes of seasonal allergies that occur in the spring, and is also believed to trigger "oral allergy syndrome" food reactions to related allergens found in nuts and fruits such as apples, pears, and cherries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Libtayo (cemiplimab)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. The PD-1/PD-L1 immune checkpoint pathway is a well-known mechanism by which cancers evade immune destruction. Regeneron is studying Libtayo as monotherapy and in combination with either conventional or novel therapeutic approaches in various solid tumors and blood cancers. It is also being studied in combination with proprietary anti-cancer assets of other companies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fianlimab</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fianlimab is an investigational, fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T-cells. In melanoma, LAG-3 expression in the tumor microenvironment may be associated with therapeutic resistance to PD-1 inhibitors. Fianlimab is being investigated in combination with Libtayo to determine whether concurrent blockade of LAG-3 and PD-1 can help overcome this resistance and release the brakes on T-cell activation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Odronextamab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Odronextamab is an investigational bispecific monoclonal antibody designed to bind to a component of the T-cell receptor ("TCR") complex (CD3), while also binding and bridging T-cells to a protein expressed on B-cells (CD20). We are studying whether odronextamab may help to activate T-cells via their CD3 receptors and trigger targeted, T-cell mediated killing of cancerous cells in several types of B-cell non-Hodgkin lymphoma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Linvoseltamab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Linvoseltamab is an investigational bispecific monoclonal antibody designed to bind to CD3 while also binding and bridging T-cells to the BCMA protein on multiple myeloma cells. We are studying whether linvoseltamab may help to activate T-cells via their CD3 receptors and trigger targeted, T-cell mediated killing of multiple myeloma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pozelimab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pozelimab is an investigational, fully human monoclonal antibody designed to block complement factor C5 in order to treat diseases mediated by abnormal complement pathway activity, including PNH, CHAPLE, and myasthenia gravis. Pozelimab is being studied as monotherapy and also in combination with Alnylam&#8217;s investigational small interfering RNA ("siRNA") therapy, cemdisiran.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Praluent (alirocumab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praluent is a fully human monoclonal antibody that inhibits the binding of PCSK9 to the LDL receptor. Through inhibiting PCSK9, Praluent increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL cholesterol levels in the blood. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evkeeza (evinacumab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evkeeza is a fully human monoclonal antibody that specifically binds to and blocks ANGPTL3. ANGPTL3 plays a key role in regulating plasma lipid levels, including triglycerides, LDL cholesterol, and HDL cholesterol, through inhibition of lipase enzymes (lipoprotein lipase and endothelial lipase).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garetosmab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Garetosmab is an investigational, fully-human monoclonal antibody that binds to and neutralizes Activin A, which drives the abnormal bone formation that is the main pathology of the ultra-rare genetic disorder FOP. This abnormal bone formation in soft tissue outside of the normal skeleton, a process known as heterotopic ossification, leads to loss of mobility and premature death in FOP patients. Garetosmab is being investigated to determine whether it can help reduce and/or prevent the formation of heterotopic bone lesions by neutralizing the Activin A protein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical research programs include the areas of oncology/immuno-oncology, angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain and neurobiology, auditory conditions, enzyme replacement therapy, cardiovascular diseases, infectious diseases, and diseases related to aging. These preclinical research programs include both rare diseases and those involving broader populations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Technologies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many proteins that play an important role in biology and disease are secreted by cells or located on the cell surface. Moreover, cells communicate through secreted factors and surface molecules. Our scientists have developed two different technologies to make protein therapeutics that potently and specifically block, activate, or inhibit the action of specific cell surface or secreted molecules. The first technology fuses receptor components to the constant region of an antibody molecule to make a class of drugs we call "Traps". EYLEA, ZALTRAP, and ARCALYST are drugs generated using our Trap technology. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our second technology platform, which is used for discovering, developing, and producing fully human antibodies that can address both secreted and cell-surface targets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VelociSuite </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> consists of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> VelociMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Veloci-Bi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> VelociHum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and other related technologies. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> mouse platform is utilized to produce fully human antibodies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was generated by leveraging our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> technology (see below), in a process in which six megabases of mouse immunoglobulin gene loci were replaced, or "humanized," with corresponding human immunoglobulin gene loci. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> mice can be used efficiently to generate fully human antibodies to targets of therapeutic interest. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and our entire </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> offer the potential to increase the speed and efficiency through which human antibody therapeutics may be discovered and validated, thereby improving the overall efficiency of our early-stage drug development activities. We are utilizing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> technology to produce our next generation of therapeutic antibody drug candidates for preclinical and clinical development.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform allows custom and precise manipulation of very large sequences of DNA to produce highly customized alterations of a specified target gene, or genes, and accelerates the production of knock-out and transgenic expression models. In producing knock-out models, a color or fluorescent marker may be substituted in place of the actual gene sequence, allowing for high-resolution visualization of precisely where the gene is active in the body during normal body functioning as well as in disease processes. For the optimization of preclinical development and pharmacology programs, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offers the opportunity to humanize targets by replacing the mouse gene with the human homolog or variants thereof. Thus, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows scientists to rapidly identify the physical and biological effects of deleting or over-expressing the target gene, as well as to characterize and test potential therapeutic molecules.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform allows for the direct and immediate generation of genetically altered mice from embryonic stem cells ("ES cells"), thereby avoiding the lengthy process involved in generating and breeding knockout mice from chimeras. Mice generated through this method are normal and healthy and exhibit a 100% germ-line transmission. Furthermore, mice developed using our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology are suitable for direct phenotyping or other studies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform for the rapid screening of antibodies and rapid generation of expression cell lines for our Traps and our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> human antibodies.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have utilized our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociSuite </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">technologies to develop a class of potential drug candidates, known as bispecific antibodies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Veloci-Bi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;allows for the generation of full-length bispecific antibodies similar to native antibodies that are amenable to production by standard antibody manufacturing techniques, and are likely to have favorable antibody-like pharmacokinetic properties. In the area of immunotherapies in oncology, we are exploring the use of bispecific antibodies that target tumor antigens and the CD3 receptor on T-cells to harness the oncolytic properties of T-cells. We are exploring additional indications and applications for our bispecific technologies, including a new class of CD28 and 4-1BB costimulatory bispecifics. We are also exploring a variety of alternative antibody formats (Altibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) that can bring binding partners together in restrained geometries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;mouse extends our research and drug discovery capabilities into cell-mediated immunity and therapeutic TCRs for oncology and other indications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;was developed by using our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;technology to humanize genes encoding TCR&#945;&#160;and TCR&#946;&#160;variable sequences, CD4 and CD8 co-receptors, &#946;2m, and class-I and -II major histocompatibility complexes. As a result, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;mice generate fully human TCRs, providing for customized modeling of T-cell function in different diseases and a powerful platform for the discovery of unique TCR-based therapies. We are also able to produce antibodies that recognize intracellular peptides bound in the groove of human leukocyte antigen ("HLA"), enabling the targeting of intracellular proteins in cancer cells.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociHum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models. Through genetic humanizations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelociHum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> mice have been optimized to allow for better development of human immune cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as well as to allow for engraftment of primary patient-derived tumors that do not take in other commercially available mice.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regeneron Genetics Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Genetics Center LLC (RGC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., leverages de-identified clinical, genomic, and other types of molecular data from properly consented human volunteers from around the world to identify medically relevant associations in a blinded fashion designed to preserve a patients' privacy while uncovering the unique characteristics of their health and wellness. The objective of RGC is to expand the use of human genetics for discovering and validating genetic factors that cause or influence a range of diseases where there are major unmet medical needs, with the prospect of improving the drug discovery and development process and to advance innovation in clinical care design. RGC is undertaking multiple collaborative approaches to study design and implementation, including large population-based efforts that engage study participants to more discrete disease specific and founder populations with data on strategic phenotypes of interest. RGC utilizes laboratory automation and innovative approaches to cloud computing to achieve high-quality throughput, attaining approximately 2 million samples sequenced to date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Central to the work of RGC is the portfolio of collaborations with over 100 academic and clinical collaborators around the world, including the University of Colorado, Geisinger Health System, Mayo Clinic, University of Pennsylvania, UCLA Medical Center, UK Biobank, University of Oxford, University of Cambridge, and the University of Helsinki. These collaborations provide access to biological samples and associated phenotype data from properly consented patient volunteers for purposes of genomic research. RGC undertakes genetic sequencing of these samples to create a unique resource of de-identified genetic data and associated phenotype data for research. Furthermore, the RGC has deployed bulk RNA sequencing, whole genome sequencing, and an O-LINK proteomic assay to complement whole exome sequencing and genotyping. In addition, the RGC leverages organoid models, siRNA, and CRISPR knockout models to validate genetic associations that lead to new therapeutic targets. The RGC continues to publish results from its research efforts in journals and publications in partnership with its collaborators to advance the field of genomics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These efforts at the RGC have led to the identification of more than 20 novel genetic targets. Through our Regeneron Genetics Medicines initiative, we are currently advancing these targets using either our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies or other technologies, such as siRNA gene silencing, genome editing, and targeted viral-based gene delivery and expression. See the "Collaboration, License, and Other Agreements" section below for descriptions of our collaborations with Alnylam and Intellia.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Agreements Related to COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Government</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company expanded its Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of our costs incurred for research and development activities related to COVID-19 treatments. In 2020, the Company also entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. The agreement, as subsequently amended, provided for payments to the Company of up to $465.9&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish, storage, and other activities. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an agreement with the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase 1.25 million doses of drug product, resulting in payments to the Company of $2.625 billion. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an amendment to its January 2021 agreement to supply the U.S. government with an additional 1.4&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government was obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of $2.940&#160;billion in the aggregate. Additionally, Roche supplied a portion of the doses to Regeneron to fulfill our agreement with the U.S. government (see "Roche" section below for further details regarding our collaboration agreement with Roche).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had completed its final deliveries of drug product under the agreements described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we entered into a collaboration agreement with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve in other countries). We have the right to distribute the product in the United States and Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Collaboration, License, and Other Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Sanofi on the global development and commercialization of Dupixent, Kevzara, and itepekimab (the "Antibody Collaboration"). Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. We are obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi based on our share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, we were required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of Regeneron&#8217;s share of profits used to reimburse Sanofi for such development costs increased from 10% to 20%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement, Sanofi records product sales for commercialized products, and Regeneron has the right to co-commercialize such products on a country-by-country basis. We co-commercialize Dupixent in the United States and in certain countries outside the United States.&#160;We supply certain commercial bulk product to Sanofi. We and Sanofi equally share profits and losses from sales within the United States. We and Sanofi share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55% (Sanofi)/45% (us), and share losses outside the United States at 55% (Sanofi)/45% (us). In each of 2020 and 2021, we earned a $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion and $1.5&#160;billion, respectively, on a rolling twelve-month basis. In 2022, we earned two additional $50.0&#160;million sales-based milestones, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion and $2.5&#160;billion, respectively, on a rolling twelve-month basis. We are entitled to receive the final sales milestone payment of $50.0&#160;million when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi pays the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company does not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously collaborated with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. We had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;R IO LCA"). In connection with the A&amp;R IO LCA, in 2022, the Company made a $900.0&#160;million up-front payment to Sanofi, as well as a $100.0 million regulatory milestone payment. In addition, Sanofi earned a $65.0 million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022, and is eligible to receive an additional $35.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023. We also pay </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi an 11% royalty on net product sales of Libtayo through March 31, 2034. The parties have also entered into a transition services agreement, a transitional distribution agreement, and a manufacturing services agreement, pursuant to which, during certain transitional periods, Sanofi will perform for Regeneron certain transition, distribution, and manufacturing services, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended and Restated Immuno-oncology Discovery and Development Agreement, we were obligated to reimburse Sanofi for half of the development costs it funded that were attributable to clinical development of product candidates from our share of profits from commercialized IO Collaboration products. Under the A&amp;R IO LCA, the amount of development costs incurred under the IO Collaboration for which we are obligated to reimburse Sanofi was $35.0 million as of the effective date of the A&amp;R IO LCA, and we pay Sanofi a 0.5% royalty on net product sales of Libtayo until all such development costs have been reimbursed by us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Bayer are parties to a license and collaboration agreement for the global development and commercialization of EYLEA and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. Bayer markets EYLEA outside the United States, and the companies share equally in profits and losses from such sales. In Japan, we were entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net sales through 2021, and, effective January 1, 2022, the companies share equally in profits and losses from sales. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to reimburse Bayer for 50% of the development costs that it has incurred under the agreement from our share of the collaboration profits. The reimbursement payment in any quarter will equal 5% of the then outstanding repayment obligation, but never more than our share of the collaboration profits in the quarter unless we elect to reimburse Bayer at a faster rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, we retain exclusive commercialization rights and are entitled to all profits from such sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Teva are parties to a collaboration agreement to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with MTPC. In connection with the agreement, Teva made a $250.0 million non-refundable up-front payment in 2016. We led global development activities, including the manufacturing of fasinumab, and the parties shared development costs equally. As of December 31, 2022, we had received an aggregate $120.0 million of development milestones from Teva.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we discontinued further clinical development of fasinumab.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alnylam</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we and Alnylam Pharmaceuticals, Inc. entered into a collaboration to discover RNA interference ("RNAi") therapeutics for NASH and potentially other related diseases, as well as to research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts (including ALN-HSD, which is currently in clinical development). Under the terms of the collaboration agreement, the parties share development costs equally. During the fourth quarter of 2022, Alnylam elected to opt-out of further development activities related to ALN-HSD; as a result, we retain the exclusive right to develop and commercialize such product and Alnylam will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we and Alnylam entered into a global, strategic collaboration to discover, develop, and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver. In connection with the collaboration, the Company made an up-front payment of $400.0&#160;million to Alnylam, and also purchased shares of Alnylam common stock for $400.0 million. For each program, we provide Alnylam with a specified amount of funding at program initiation and at lead candidate designation, and Alnylam is eligible to receive up to an aggregate of $200.0 million in clinical proof-of-principle milestones for eye and CNS programs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, the parties plan to perform discovery research until designation of lead candidates. Following designation of a lead candidate, the parties may further advance such lead candidate under either a co-development/co-commercialization collaboration agreement ("Co-Co Collaboration Agreement") (under which the parties are advancing ALN-APP and ALN-PNP, which are currently in clinical development) or a License Agreement structure. The initial target nomination and discovery period is five years (which may under certain situations automatically be extended for up to seven years in the aggregate) (the "Research Term"). In addition, we have an option to extend the Research Term for an additional five-year period for a research extension fee ranging from $200.0 million to $400.0 million; the actual amount of the fee will be determined based on the acceptance of one or more Investigational New Drug Applications ("INDs") (or their equivalent in certain other countries) for programs in the eye and CNS.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the stage of designation of a lead candidate for CNS programs and liver programs, the parties have alternating rights to be a lead party for collaboration products. At the stage of designation of a lead candidate for eye programs, we have the sole right to take the product forward as a licensee. The lead party is required to take the program forward under the License Agreement structure unless the other party exercises its rights to opt-in to a Co-Co Collaboration Agreement as a participating party, in which case the lead party is required to take the program forward under the Co-Co Collaboration Agreement structure. Alnylam does not have rights to opt-in to a Co-Co Collaboration Agreement for eye programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a License Agreement, the lead party is designated as the licensee and has the right to develop and commercialize the collaboration product under such program. The licensee will be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products under the License Agreement. The licensee will pay to the licensor certain development and/or commercialization milestone payments, as well as certain tiered royalty payments to the licensor based on the aggregate annual net sales of the collaboration product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CNS programs and liver programs, under a Co-Co Collaboration Agreement, the party designated as the lead party will lead development and commercialization of the program and the parties will split profits and share costs equally, subject to certain co-funding opt-outs at specified clinical trial phases or under other conditions. If a party exercises its co-funding opt-out right, the lead party will be required to make certain tiered royalty payments to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the co-funding opt-out right.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, when we are the licensee under a License Agreement or the lead party under a Co-Co Collaboration Agreement, Alnylam will be responsible for the manufacture and supply of the product to us for Phase 1 and Phase 2 clinical trials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2019, the parties entered into a Co-Co Collaboration Agreement for cemdisiran, an siRNA therapeutic targeting the C5 component of the human complement pathway being developed by Alnylam, with Alnylam as the lead party, and a License Agreement for a combination consisting of cemdisiran and pozelimab, with us as the licensee. Under the C5 siRNA Co-Co Collaboration Agreement, the parties shared costs equally, and under the License Agreement, we as the licensee are responsible for our own costs and expenses. The C5 siRNA License Agreement contains a flat low double-digit royalty payable to Alnylam on potential future net sales of the combination only subject to customary reductions, as well as up to $325.0&#160;million in sales milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, we elected to opt-out of further development activities pursuant to the Co-Co Collaboration Agreement for cemdisiran as a monotherapy; as a result, Alnylam retains the right to develop and commercialize such product and we will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic development. NTLA-2001, which is in clinical development, is subject to a co-development and co-commercialization arrangement pursuant to which Intellia will lead development and commercialization activities and the parties share an agreed-upon percentage of development expenses and profits (if commercialized).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B, with Regeneron leading development and commercialization activities. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene edited products. In connection with the 2020 agreement, we made a $70.0 million up-front payment to Intellia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and BARDA are parties to agreements pursuant to which HHS provided certain funding to develop, test, and manufacture a treatment for Ebola virus infection. In 2020, HHS exercised its option under an existing agreement to provide additional funding for the manufacture and supply of Inmazeb. We expect to deliver a pre-specified number of Inmazeb treatment doses over the course of approximately six years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See "Agreements Related to COVID-19 - U.S. Government" section above for information related to our COVID-19 agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kiniksa</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to a 2017 license agreement, we granted Kiniksa Pharmaceuticals, Ltd. the right to develop and commercialize certain new indications for ARCALYST. During the first quarter of 2021, Kiniksa received marketing approval in the United States for a new indication of ARCALYST, recurrent pericarditis. The quarterly period ended March 31, 2021 was the last quarter for which the Company recorded net product sales of ARCALYST.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following this approval, Kiniksa is solely responsible for the U.S. development and commercialization of ARCALYST in all approved indications, and Regeneron will continue to supply clinical and commercial product to Kiniksa. Kiniksa will pay Regeneron 50% of its profits from sales of ARCALYST and the parties will not share in any losses incurred by Kiniksa in connection with commercialization of ARCALYST.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ultragenyx </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, we entered into a license and collaboration agreement for Ultragenyx Pharmaceutical Inc. to develop and commercialize Evkeeza in countries outside of the United States. In connection with the agreement, Ultragenyx made a $30.0 million non-refundable up-front payment to the Company. Ultragenyx will share in certain costs for global trials led by the Company and also have the right to continue to clinically develop Evkeeza in countries outside of the U.S. We will supply commercial product to Ultragenyx at a tiered purchase price, which is calculated as a percentage of net sales of the product (subject to adjustment in certain circumstances), and are eligible to receive additional regulatory and sales milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Checkmate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. for a total equity value of approximately $250 million. In connection with the acquisition, the Company obtained the rights to vidutolimod, which is in clinical development for oncology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture bulk drug materials and products at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland. These facilities consist of owned and leased research, manufacturing, office, laboratory, and warehouse space. In addition, the construction of a fill/finish facility in Rensselaer, New York is in process.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have approximately 100,000 liters of cell culture capacity at our Rensselaer facility and approximately 120,000 liters of cell culture capacity at our Limerick facility. Each of these facilities is approved by the FDA and certain other regulatory agencies to manufacture our bulk drug materials and products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bulk drug materials and products are also manufactured by our collaborators, and certain raw materials or products necessary for the manufacture and formulation of our products and product candidates are provided by single-source unaffiliated third-party suppliers. In addition, we rely on our collaborators or third parties to perform packaging, filling, finishing, labeling, distribution, laboratory testing, and other services related to the manufacture of our products and product candidates, and to supply various raw materials and other products. See Part I, Item 1A. "Risk Factors - Risks Related to Manufacturing and Supply" for further information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the conditions for regulatory marketing approval of a medicine is the requirement that the prospective manufacturer's quality control and manufacturing procedures conform to the good manufacturing practice ("GMP") regulations of the health authority. In complying with standards set forth in these regulations, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to ensure full technical compliance. Manufacturing establishments, both foreign and domestic, are also subject to inspections by or under the authority of the FDA and by other national, federal, state, and local agencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medicines are marketed through our commercial group, which includes experienced professionals in the fields of marketing, sales, professional education, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell our marketed products primarily to wholesalers and specialty distributors that serve pharmacies, hospitals, government agencies, physicians, and other healthcare providers. We had sales to two customers (Besse Medical, a subsidiary of AmerisourceBergen Corporation, and McKesson Corporation) that each accounted for more than 10% of total gross product revenue for the year ended December&#160;31, 2022. On a combined basis, our product sales to these customers accounted for 83% of our total gross product revenue for the year ended December&#160;31, 2022. We promote approved medicines to healthcare professionals via our team of field employees, as well as medical journals, medical exhibitions, distribution of literature and samples, and online channels. In addition, we advertise certain products directly to consumers and maintain websites with information about our medicines. The commercial group also evaluates opportunities for our targets and product candidates and prepares for market launches of new medicines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established certain commercial capabilities outside the United States in connection with co-commercializing some products in accordance with our collaboration agreements. In addition, we are in process of building additional commercial capabilities outside the United States as a result of us obtaining the rights, in 2022, to commercialize Libtayo outside the United States. Refer to "Collaboration, License, and Other Agreements" section above for additional information related to these agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and other factors.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides an overview of the current competitive landscape for the key products marketed by us and/or our collaborators in such products' currently approved indications. The table below is provided for illustrative purposes only and is not exhaustive. For additional information regarding the substantial competition these marketed products face, including potential future competition from product candidates in clinical development, see also Part I, Item 1A. "Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketed Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competitor Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competitor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lucentis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ranibizumab injection)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG and Genentech/Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME, macular edema following RVO (including CRVO and BRVO), diabetic retinopathy, mCNV, and ROP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Byooviz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ranibizumab-nuna) (biosimilar referencing Lucentis)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Samsung Bioepis Co., Ltd. and Biogen Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME, macular edema following RVO (including CRVO and BRVO), diabetic retinopathy, and mCNV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ximluci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ranibizumab) (biosimilar referencing Lucentis)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xbrane Biopharma AB, Bausch + Lomb, and STADA Arzneimittel AG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME, macular edema following RVO (including CRVO and BRVO), diabetic retinopathy, and CNV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cimerli</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ranibizumab-eqrn) (biosimilar referencing Lucentis)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formycon AG, Bioeq AG, Coherus BioSciences, Inc., and Teva Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME, macular edema following RVO (including CRVO and BRVO), diabetic retinopathy, and CNV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Susvimo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ranibizumab ocular implant) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech/Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vabysmo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (faricimab-svoa)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech/Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (bevacizumab) (off-label and repackaged)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech/Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME, and macular edema following RVO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beovu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brolucizumab) Injection</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ozurdex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (dexamethasone intravitreal implant) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergan/AbbVie Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DME, RVO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketed Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competitor Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competitor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iluvien</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (fluocinolone acetonide intravitreal implant)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimera Sciences, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conbercept</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chengdu Kanghong Pharmaceutical Group Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wet AMD, DME, mCNV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eucrisa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/Staquis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(crisaborole)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mild-to-moderate atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Opzelura</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ruxolitinib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mild-to-moderate atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Olumiant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(baricitinib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company/Incyte Corporation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate-to-severe atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU, Japan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cibinqo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (abrocitinib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate-to-severe atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rinvoq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (upadacitinib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate-to-severe atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adbry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/Adtralza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (tralokinumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LEO Pharma Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate-to-severe atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corectim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (delgocitinib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan Tobacco Inc./Torii Pharmaceutical Co., Ltd.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mitchga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (nemolizumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maruho Co., Ltd./Chugai Pharmaceutical Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pruritus associated with atopic dermatitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xolair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(omalizumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche/Novartis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma, nasal polyps</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide (asthma); United States, EU (nasal polyps)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucala</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(mepolizumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GlaxoSmithKline ("GSK")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma, nasal polyps</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Worldwide (asthma); United States, EU (nasal polyps)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cinqair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (reslizumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teva</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fasenra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(benralizumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tezspire</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (tezepelumab-ekko)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca/Amgen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (pembrolizumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck &amp; Co., Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (nivolumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (atezolizumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imfinzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (durvalumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bavencio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (avelumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer/Merck KGaA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jemperli</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (dostarlimab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease; primary hyperlipidemia; and HoFH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide<br/></span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketed Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competitor Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competitor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leqvio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (inclisiran) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States, EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actemra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (tocilizumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech/Roche/Chugai Pharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orencia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(abatacept)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xeljanz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(tofacitinib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(baricitinib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly/Incyte</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rinvoq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (upadacitinib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (filgotinib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilead Sciences, Inc./Galapagos NV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU, Japan</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> This table focuses primarily on the United States, EU, and Japan. "Worldwide" indicates that the relevant product is approved in the United States, EU, Japan, and at least one other country. </span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our late-stage and earlier-stage clinical candidates (including those being developed in collaboration with our collaborators) face competition from many pharmaceutical and biotechnology companies. For example, we are aware of other pharmaceutical and biotechnology companies actively engaged in the research and development of antibody-based products against targets that are also the targets of our early- and late-stage product candidates. These companies are using various technologies in competition with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology and our other antibody generation technologies, including their own antibody generation technologies and other approaches such as RNAi, chimeric antigen receptor T cell (CAR-T cell), and gene therapy technologies. We are also aware of several companies developing or marketing small molecules that may compete with our antibody product candidates in various indications, if such product candidates obtain regulatory approval in those indications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our product candidates (including those being developed in collaboration with our collaborators) and the substantial competition they face, see also Part I, Item 1A. "Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Areas</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many pharmaceutical and biotechnology companies are attempting to discover new therapeutics for indications in which we invest substantial time and resources. In these and related areas, intellectual property rights have been sought and certain rights have been granted to competitors and potential competitors of ours, and we may be at a substantial competitive disadvantage in such areas as a result of, among other things, our inferior intellectual property position or lack of experience, trained personnel, and expertise. A number of corporate and academic competitors are involved in the discovery and development of novel therapeutics that are the focus of other research or development programs we are now conducting. Some of these competitors are currently conducting advanced preclinical and clinical research programs in these areas. These and other competitors also may have established substantial intellectual property and other competitive advantages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other competitors announces a successful clinical study involving a product that may be competitive with one of our product candidates or the grant of marketing approval by a regulatory agency for a competitive product, such developments may have an adverse effect on our business, operating results, financial condition, cash flows, or future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete with academic institutions, governmental agencies, and other public or private research organizations, which conduct research, seek patent and other intellectual property protection, and establish collaborative arrangements for the development and marketing of products that would provide royalties or other consideration for use of their technology. These institutions are becoming more active in seeking patent and other intellectual property protection and licensing arrangements to collect royalties or other consideration for use of the technology they have developed. Products developed in this manner may compete directly with products we develop. We also compete with others in acquiring technology from these institutions, agencies, and organizations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks, and Trade Secrets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of intellectual property laws, including patent, trademark, copyright, trade secret, and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to obtain patents, maintain trade secret protection, and operate without infringing on the proprietary rights of third parties (see Part I, Item 1A. "Risk Factors - Risks Related to Intellectual Property and Market Exclusivity - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"; and Note 16 to our Consolidated Financial Statements). Our policy is to file patent applications to protect technology, inventions, and improvements that we consider important to our business and operations. We hold an ownership interest in a number of issued patents in the United States and foreign countries with respect to our products and technologies. In addition, we hold an ownership interest in thousands of patent applications in the United States and foreign countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes granted patents and pending patent applications covering our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies, including our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mouse platform which produces fully human antibodies. Our issued patents covering these technologies generally expire between 2022 and 2032. However, we continue to file patent applications directed to improvements to these technology platforms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio also includes issued patents and pending applications relating to commercialized products and our product candidates in clinical development. These patents cover, among other things, proteins, DNA and RNA molecules, manufacturing patents, method of use patents, and pharmaceutical compositions and formulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes our U.S. patents, European patents ("EP"), and Japanese patents ("JP") that are of particular relevance to key products marketed or otherwise commercialized by us and/or our collaborators, including the territory, patent number, general subject matter class, and expected expiration dates. The noted expiration dates include any patent term adjustments. Certain of these patents may also be entitled to term extensions. We continue to pursue additional patents and patent term extensions in the United States and other jurisdictions covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table below. One or more patents with the same or earlier expiry date may fall under the same "general subject matter class" for certain products and may not be separately listed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">aflibercept</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,070,959</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 16, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092,803</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 21, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,464,992</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,857,231</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,066,458</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084,865</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,254,338</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 22, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,857,205</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 11, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,828,345</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 11, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,888,601</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 11, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,253,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 11, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,406,226</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1183353</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter (Supplementary Protection Certificate)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(May 23, 2025)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2364691</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2944306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,723,140</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Composition of Matter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 29, 2022 &#8211; December 25, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,273,746</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 24, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,216,002</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Formulation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 27, 2028 &#8211; October 1, 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dupilumab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,608,693</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,945,559</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2032</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,238,692</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,435,473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,896</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075,887</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 17, 2028</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,337,839</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2027</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,290,574</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 10, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,574,004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2033</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,421,036</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 10, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,137,193</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2036</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,485,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 21, 2037</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,059,771</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,214,621</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 11, 2036</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,167,004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 21, 2037</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,034,768</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2039</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,292,847</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2039</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2356151</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2356151</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Supplementary Protection Certificate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(September 28, 2032)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3010539</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2888281</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 20, 2033</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3064511</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2029</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3107575</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2035</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3470432</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 20, 2033</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3019191</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 10, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2624865</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3354280</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,291,802</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 27, 2029 &#8211; October 27, 2034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,918,246</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Formulation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 5, 2031 &#8211; September 14, 2035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,306,588</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 20, 2033 &#8211; August 29, 2034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,353,838</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 4, 2033</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,673,840</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 20, 2035</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,463,351</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 20, 2034 &#8211; September 2, 2035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,861,630</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 13, 2035</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,164,530</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 21, 2037</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cemiplimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,987,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 18, 2035</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,737,113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 10, 2035</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,457,725</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2037</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,292,842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 18, 2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,505,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2, 2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3097119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 23, 2035</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3455258</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2037</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3932951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2037</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,425,730</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">January 23, 2035</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,999,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 12, 2037</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,054,680</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 12, 2037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">alirocumab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,062,640</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2029</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,023,654</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2029</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,472,425</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 27, 2032</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,357,371</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2029</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550,837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2029</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724,411</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,246,925</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 11, 2032</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306,155</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 16, 2035</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,428,157</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 26, 2037</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,544,232</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2035</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,995,150</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 6, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,116,839</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2033</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2358756</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2358756</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Supplementary Protection Certificate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(September 25, 2030)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3156422</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2029</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2756004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 12, 2032</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3055333</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 10, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3689913</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 10, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3169353</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 16, 2035</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3169362</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 16, 2035</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3004171</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 6, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3068803</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3395836</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Manufacturing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 27, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">sarilumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,582,298</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 22, 2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,072,086</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 19, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098,127</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,080,248</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,568,721</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,943,594</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 28, 2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,927,435</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 10, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041177</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041177</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Supplementary Protection Certificate)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(June 1, 2032)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2766039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 10, 2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3071230</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 21, 2034</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3409269</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3756652</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">January 7, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,307,708</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of Matter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 1, 2027 &#8211; August 22, 2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,805,660</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Formulation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">January 7, 2031 &#8211; October 24, 2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,122,018</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 10, 2032 &#8211; March 29, 2033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,025,477</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 10, 2032</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,657,089</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 21, 2034</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,166,925</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of Treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 7, 2037</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> See Note 16 to our Consolidated Financial Statements for information regarding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> review and post-grant review petitions filed in the U.S. Patent and Trademark Office relating to EYLEA and patent infringement proceedings relating to Praluent.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> A patent term extension has been granted by the U.S. Patent and Trademark Office, extending the original patent term (May 23, 2020), insofar as it covers EYLEA, to June 16, 2023.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Supplementary protection certificates ("SPCs") are pending and/or have been granted in various European countries, extending the original patent terms in those countries, where granted, to the applicable dates indicated in parentheses.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The patent term extension ("PTE") system in Japan allows for a patent to be extended more than once provided the later approval is directed to a different indication from that of the previous approval. This may result in multiple PTE approvals for a given patent, each with its own expiration date. In this table, date ranges are shown for the expiration of Japanese patents for which multiple PTEs have been granted, with the later date indicating the latest expiring PTE for the corresponding patent.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A patent term extension has been granted by the U.S. Patent and Trademark Office, extending the original patent term (October 2, 2027), insofar as it covers Dupixent, to March 28, 2031.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> This table excludes Japanese patents related to Praluent because Praluent is not being commercialized in Japan at this time.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> A patent term extension has been granted by the U.S. Patent and Trademark Office, extending the original patent term (June 1, 2027), insofar as it covers Kevzara, to May 22, 2031.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our patent portfolio, in the United States and certain other countries, our competitive position may be enhanced due to the availability of market exclusivity under relevant law (for additional information regarding market exclusivity, see Part I, Item 1A. "Risk Factors - Risks Related to Intellectual Property and Market Exclusivity - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"). For example, in the United States, the regulatory exclusivity period for EYLEA (i.e., the period during which no biosimilar product can be approved by the FDA) extends through May 17, 2024 following the pediatric exclusivity granted by the FDA. The effect of expiration of a patent relating to a particular product also depends upon other factors, such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product, and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are the nonexclusive licensee of a number of additional patents and patent applications. These include a license agreement with Bristol-Myers Squibb, E. R. Squibb &amp; Sons, L.L.C., and Ono Pharmaceutical Co., Ltd. to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo. Under the agreement, we pay royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and royalties of 2.5% from January 1, 2024 through December 31, 2026. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent law relating to the patentability and scope of claims in the biotechnology field is evolving and our patent rights are subject to this additional uncertainty. The degree of patent protection that will be afforded to our products in the United States and other important commercial markets is uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, and governments in these countries. There is no certainty that our existing patents or others, if obtained, will provide us protection from competition or provide commercial benefit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may independently develop similar products or processes to those developed by us, duplicate any of our products or processes or, if patents are issued to us, design around any products and processes covered by our patents. We expect to continue, when appropriate, to file product and process applications with respect to our inventions. However, we may not file any such applications or, if filed, the patents may not be issued. Patents issued to or licensed by us may be infringed by the products or processes of others.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to file and maintain trademarks around the world based on commercial activities in most jurisdictions where we have, or desire to have, a business presence for a particular product or service. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense and enforcement of our intellectual property rights is expensive and time consuming, even if the outcome is favorable to us. It is possible that patents issued or licensed to us will be successfully challenged, that a court may find that we are infringing validly issued patents of third parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to take into account patent rights of third parties (see Part I, Item 1A. "Risk Factors - Risks Related to Intellectual Property </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Market Exclusivity - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"; and Note 16 to our Consolidated Financial Statements).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation by government authorities in the United States and foreign countries is a significant factor in the research, development, manufacture, and marketing of our products and our product candidates. A summary of the primary areas of government regulation that are relevant to our business is provided below. For a description of material regulatory risks we face, also refer to Part I, Item 1A. "Risk Factors."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Requirements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities required before a product candidate may be marketed in the United States or elsewhere begin with preclinical tests. Preclinical tests include laboratory evaluations of, among other things, product chemistry and formulation and toxicological and pharmacological studies in animal species to assess the toxicity and dosing of the product candidate. In the United States, certain preclinical trials must comply with the FDA's Good Laboratory Practice requirements ("GLPs") and the U.S. Department of Agriculture's Animal Welfare Act. The results of these studies must be submitted to the FDA or the relevant regulatory authority outside the United States as part of an IND or clinical trial application (as applicable), which must be reviewed by the FDA or the relevant government authority before proposed clinical testing can begin in the applicable country or jurisdiction. In the United States, unless the FDA raises concerns, the IND becomes effective 30 days following its receipt by the FDA, and the clinical trial proposed in the IND may begin. The FDA or other regulatory authorities may ask for additional data in order to begin a clinical trial. Rules that are equivalent in scope but which vary in application apply in foreign countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Approval</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates require regulatory approval by relevant government authorities before they can be commercialized. In particular, human therapeutic products are subject to rigorous preclinical and clinical trials and other pre-market approval requirements by the FDA, EMA, and other foreign regulatory authorities. The structure and substance of the FDA and foreign pharmaceutical regulatory practices may evolve over time. The ultimate outcome and impact of such developments cannot be predicted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of a drug to healthy human volunteers or to patients under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA's bioresearch monitoring regulations and Good Clinical Practice requirements ("GCPs"), which establish standards for conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board ("IRB") for each clinical site within the United States or, where applicable, an Ethics Committee and/or the competent authority for clinical sites outside the United States. Companies sponsoring the clinical trials, investigators, and IRBs/Ethics Committees also must comply with, as applicable, regulations and guidelines for obtaining informed consent from the study patients, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the United States. Data from a foreign study not conducted under an IND may be submitted in support of a BLA if the study was conducted in accordance with GCPs and the FDA is able to validate the data. The sponsor of a clinical trial or the sponsor's designated responsible party may be required to register certain information about the trial and disclose certain results on government or independent registry websites, such as clinicaltrials.gov.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, clinical testing involves a three-phase process, which may overlap or be subdivided in some cases. Phase 1 trials are usually conducted with a small number of healthy volunteers to determine the early safety profile, metabolism, and pharmacological actions of the product candidate, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. Although Phase 1 trials are typically conducted in healthy human subjects, in some instances, the trial subjects are patients with the targeted disease or condition. Phase 2 clinical trials are conducted with a relatively small sample of the intended patient population to provide enough data to evaluate the preliminary safety, tolerability, and efficacy of different potential doses of the product candidate. Phase 3 clinical trials are larger trials conducted with patients with the target disease or disorder intended to gather additional information about dosage, safety, and effectiveness necessary to evaluate the drug's overall risk-benefit profile. Phase 3 data often form the core basis on which the FDA and comparable foreign regulatory authorities evaluate a product candidate's safety and effectiveness when considering the product application for regulatory approval. If concerns arise about the safety of the product candidate, the FDA or other regulatory authorities can stop clinical trials by placing them on a "clinical hold" pending receipt of additional data, which can result in a delay or termination of a clinical development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program. The sponsoring company, the FDA or other regulatory authorities, or the IRB or Ethics Committee and competent authority may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical and clinical testing of a biologic product candidate are then submitted to the FDA in the form of a BLA for evaluation to determine whether the product candidate may be approved for commercial sale under the Public Health Service Act. Under the Prescription Drug User Fee Act, we typically must pay fees to the FDA for review of any BLA. When a BLA is submitted, the FDA makes an initial determination as to whether the application is sufficiently complete to be accepted for review. If the application is not, the FDA may refuse to accept the BLA for filing and request additional information. A refusal to file, which requires resubmission of the BLA with the requested additional information, delays review of the application. If the application is accepted for review, the FDA reviews the application to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product's identity, strength, quality, and purity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA performance goals generally provide for action on a BLA within 10 months of the 60-day filing date (or within 12 months of the BLA submission). That deadline can be extended by FDA under certain circumstances, including by the FDA's requests for additional information. The targeted action date can be 6 months after the 60-day filing date (or 8 months after BLA submission) for product candidates that are granted priority review designation because they are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The FDA has other programs to expedite development and review of product candidates that address serious or life-threatening conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some BLAs, the FDA may convene an advisory committee to seek insights and recommendations on issues relevant to approval of the application. Although the FDA is not bound by the recommendation of an advisory committee, the agency considers such recommendations carefully when making decisions. Before approving a new drug or biologic product, the FDA also requires that the facilities at which the product will be manufactured or advanced through the supply chain be in compliance with current Good Manufacturing Practices, or cGMP, requirements and regulations governing, among other things, the manufacture, shipment, and storage of the product. The FDA also can audit the sponsor of the BLA to determine if the clinical studies were conducted in compliance with current GCPs. After review of a BLA, the FDA may grant marketing approval, request additional information, or issue a CRL outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional preclinical or clinical data, for the FDA to reconsider the application. Even if such additional information and data are submitted, the FDA may decide that the BLA still does not meet the standards for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor. If FDA grants approval, an approval letter authorizes commercial marketing of the product candidate with specific prescribing information for specific indications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any approval required by the FDA for any of our product candidates may not be obtained on a timely basis, or at all. The designation of a clinical trial as being of a particular phase is not necessarily indicative that such a trial will be sufficient to satisfy the parameters of a particular phase, and a clinical trial may contain elements of more than one phase notwithstanding the designation of the trial as being of a particular phase. The results of preclinical studies or early-stage clinical trials may not predict long-term safety or efficacy of our compounds when they are tested or used more broadly in humans. Additionally, as a condition of approval, the FDA may impose restrictions that could affect the commercial prospects of a product and increase our costs, such as a Risk Evaluation and Mitigation Strategy ("REMS") to mitigate certain specific safety risks, and/or post-approval commitments or requirements to conduct additional clinical trials or non-clinical studies or to conduct surveillance programs to monitor the product's effects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a product candidate by comparable regulatory authorities in foreign countries is generally required prior to commencement of marketing of the product in those countries. The approval procedure varies among countries and may involve different or additional testing, and the time required to obtain such approval may differ from that required for FDA approval. Approval by a regulatory authority in one jurisdiction does not guarantee approval by comparable regulatory authorities in other jurisdictions. In the European Economic Area ("EEA") (which is comprised of 27 Member States of the EU plus Norway, Iceland, and Liechtenstein), medicinal products can only be commercialized after a related Marketing Authorization has been granted. Marketing authorization for biologics must be obtained through a centralized procedure, which allows a company to submit a single application to the EMA. If a related positive opinion is provided by the EMA, the EC will grant a centralized marketing authorization that is valid in the EEA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many jurisdictions, pediatric data or an approved Pediatric Investigation Plan ("PIP"), or a waiver of such studies, is required to have been approved by regulatory authorities prior to submission of a marketing application. In some EU countries, we may also be required to have an approved PIP before we can begin enrolling pediatric patients in a clinical trial. In the United States, under the Pediatric Research Equity Act ("PREA"), certain applications for approval must include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject product in relevant pediatric populations, unless a waiver or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferral is granted. However, a pediatric study plan is not required for orphan products and the timing of the submission is subject to negotiation with FDA, but such plan cannot be submitted later than submission of a BLA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various federal, state, and foreign statutes and regulations also govern or influence the research, manufacture, safety, labeling, storage, record keeping, marketing, transport, and other aspects of developing and commercializing pharmaceutical product candidates. The lengthy process of seeking these approvals and the compliance with applicable statutes and regulations require the expenditure of substantial resources. Any failure by us or our collaborators or licensees to obtain, or any delay in obtaining, regulatory approvals could adversely affect the manufacturing or marketing of our products and our ability to receive product or royalty revenue. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding U.S. and foreign regulatory approval processes and requirements, see Part I, Item 1A. "Risk Factors - Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emergency Use Authorization</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secretary of HHS may authorize unapproved medical products to be marketed in the context of an actual or potential emergency that has been designated by the U.S. government. The COVID-19 pandemic has been designated as such a national emergency, with such designation currently expected to expire on May 11, 2023. After an emergency has been announced, the Secretary of HHS may authorize the issuance of, and the FDA Commissioner may issue, EUAs for the use of specific products based on criteria established by the Food, Drug, and Cosmetic Act, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. Although the criteria of an EUA differ from the criteria for approval of a BLA, EUAs nevertheless require the development and submission of data to satisfy the relevant FDA standards, as well as a number of ongoing compliance obligations. The FDA expects EUA holders to work toward submission of full applications, such as a BLA, as soon as possible. An EUA is also subject to additional conditions and restrictions and is product-specific. An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. The FDA may revoke, revise, or restrict an EUA for a variety of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasons, including where it is determined that the underlying health emergency no longer exists or warrants such authorization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the medical product is no longer effective in diagnosing, treating, or preventing the underlying health emergency</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory authorities in other jurisdictions may also require us to conduct additional clinical trials or to make certain changes related to a product after granting approval of the product. The FDA has the explicit authority to require postmarketing studies (also referred to as post-approval or Phase 4 studies) and labeling changes based on new safety information, and may impose and enforce a REMS at the time of approval or after the product is on the market. Post-approval modifications to the drug, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional preclinical studies or clinical trials, to be submitted in a new or supplemental BLA, which would require FDA approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, the FDA and comparable regulatory authorities outside the United States regulate the marketing and promotion of our products, which must comply with the Food, Drug, and Cosmetic Act and applicable FDA regulations and standards thereunder and equivalent foreign laws. The review of promotional activities by the FDA and comparable regulatory authorities outside the United States includes, but is not limited to, healthcare provider-directed and direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, promotional activities involving the Internet, and sales representatives' communications. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA and comparable foreign regulatory authorities. FDA and comparable foreign regulatory authorities' regulations impose restrictions on manufacturers' communications regarding unapproved uses, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding such use. Failure to comply with applicable FDA and comparable foreign regulatory authorities' requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities and comparable regulatory authorities outside the United States. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug. See Part I, Item 1A. "Risk Factors - Other Regulatory and Litigation Risks - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse-event reporting and submission of periodic reports are required following marketing approval. The FDA requires BLA holders to employ a system for obtaining and reviewing safety information, adverse events, and product complaints associated with each drug and to submit safety reports to the FDA, with expedited reporting timelines in certain situations. Based on new safety information after approval, the FDA can, among other things, mandate product labeling changes, require new post-marketing studies, impose or modify a risk evaluation and mitigation strategy for the product, or suspend or withdraw approval of the product. We may be subject to audits by the FDA and other regulatory authorities to ensure that we are complying with the applicable requirements. Rules that are equivalent in scope but which vary in application apply in foreign countries in which we conduct clinical trials.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of an EU marketing authorization for a medicinal product must also comply with the EU's pharmacovigilance legislation. This includes requirements to conduct pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. Marketing authorization holders are required to maintain a Pharmacovigilance System Master File ("PSMF"), which supports and documents the compliance of the marketing authorization holder with the requirements of EU pharmacovigilance legislation. Marketing authorization holders are also required to have a Qualified Person for Pharmacovigilance ("QPPV"), who, among other things, maintains the PSMF. A QPPV must reside in the EEA and must also prepare pharmacovigilance reports, respond to potential requests from competent authorities concerning pharmacovigilance on a 24 hour basis, and provide competent authorities with any other information that may be relevant to the safety of the medicinal product in accordance with Good Pharmacovigilance Practices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EC can also require marketing authorization holders to conduct post-authorization safety and/or efficacy studies. A post-authorization safety study ("PASS") is a study that is carried out after a medicinal product has been authorized to obtain further information on a medicinal product's safety, or to measure the effectiveness of risk-management measures. Such studies may be clinical trials or non-interventional studies. A post-authorization efficacy study ("PAES") is a study that is carried out for complementing available efficacy data in the light of well-reasoned scientific uncertainties on aspects of the evidence of benefits that is to be or only can be addressed post-authorization. The EC may, in particular, impose a PASS and/or PAES on marketing authorization holders when a marketing authorization is granted upon conditions. The EC may grant conditional marketing authorizations in the interest of public health, when there is less comprehensive clinical data available than would be required, if the EC considers that the benefit of immediate availability may outweigh the risk that the absence of the required clinical data poses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and our third-party suppliers are required to maintain compliance with cGMP, and are subject to inspections by the FDA or comparable regulatory authorities in other jurisdictions to confirm such compliance. Changes of suppliers or modifications of methods of manufacturing may require amending our application(s) to the FDA or such comparable foreign regulatory authorities and acceptance of the change by the FDA or such comparable foreign regulatory authorities prior to release of product(s). FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and our third-party suppliers. Prescription drug manufacturers in the U.S. must comply with applicable provisions of the Drug Supply Chain Security Act and provide and receive product tracing information, maintain appropriate licenses, ensure they only work with other properly licensed entities, and have procedures in place to identify and properly handle suspect and illegitimate products. We may also be subject to state regulations related to the manufacturing and distribution of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these laws, regulations, and conditions of product approval may lead the FDA and comparable regulatory authorities in other jurisdictions to take regulatory action or seek sanctions, including fines, issuance of warning letters, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval of a product, seizure or recall of products, and criminal prosecution.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing and Reimbursement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales in the United States of our marketed products are dependent, in large part, on the availability and extent of reimbursement from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid. Sales of our marketed products in other countries are dependent, in large part, on coverage and reimbursement mechanisms and programs administered by health authorities in those countries. See Part I, Item 1A. "Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in, and have certain price reporting obligations to, the Medicaid Drug Rebate program, state Medicaid supplemental rebate program(s), and other governmental pricing programs. We also have obligations to report the average sales price for certain drugs to the Medicare program. Under the Medicaid Drug Rebate program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid program as a condition of having federal funds being made available for our drugs under Medicaid and Part B of the Medicare program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid is a joint federal and state program that is administered by the states for low-income and disabled beneficiaries. Medicaid rebates are based on pricing data reported by us on a monthly and quarterly basis to the Centers for Medicare &amp; Medicaid Services ("CMS"), the federal agency that administers the Medicaid and Medicare programs. These data include the average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the U.S. in any pricing structure, calculated to include all sales and associated rebates, discounts, and other price concessions. The amount of the rebate is adjusted upward if average manufacturer price increases more than inflation (measured by reference to the Consumer Price Index - Urban). Currently, the rebate is capped at 100 percent of the average manufacturer price, but effective January 1, 2024, this cap on the rebate will be removed, and our rebate liability could increase accordingly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due, which revisions could affect our rebate liability for prior quarters. The federal Patient Protection and Affordable Care Act (the "PPACA") made significant changes to the Medicaid Drug Rebate program, and CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the PPACA. CMS recently modified Medicaid Drug Rebate program regulations to, among other things, permit reporting multiple best price figures with regard to value&#8209;based purchasing arrangements and provide definitions for "line extension," "new formulation," and related terms with the practical effect of expanding the scope of drugs considered to be line extensions (beginning in 2022).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program that is administered by the federal government that covers individuals age 65 and over or that are disabled as well as those with certain health conditions. Medicare Part B generally covers drugs that must be administered by physicians or other health care practitioners; are provided in connection with certain durable medical equipment; or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. Medicare Part B pays for such drugs under a payment methodology based on the average sales price of the drugs. Manufacturers, including us, are required to report average sales price information to CMS on a quarterly basis. The manufacturer-submitted information may be used by CMS to calculate Medicare payment rates. Starting in 2023, manufacturers must pay refunds to Medicare for single-source drugs or biological products, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties. Further, starting in 2023, the Inflation Reduction Act ("IRA") establishes a Medicare Part B inflation rebate scheme under which, generally speaking, manufacturers will owe rebates if the average sales price of a Part B drug increases faster than the pace of inflation. Failure to timely pay a Part B inflation rebate is subject to a civil monetary penalty. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA also creates a drug price negotiation program under which, after being on the market for a certain period of time, the prices for certain high Medicare spending drugs and biological products provided to Medicare patients without generic or biosimilar competition will be capped by reference to, among other things, a specified non-federal average manufacturer price, starting in 2026. Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and a civil monetary penalty. This or any other legislative change could impact the market conditions for our products. See Part I, Item 1A. "Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false pricing or other information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, or if we fail to submit the required data on a timely basis. Such conduct also could be grounds for CMS to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that any company that participates in the Medicaid Drug Rebate program also participate in the Public Health Service's 340B drug pricing program (the "340B program") in order for federal funds to be available for the manufacturer's drugs under Medicaid and Medicare Part B. The 340B program, which is administered by the Health Resources and Services Administration ("HRSA"), requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B "ceiling price" for the manufacturer's covered outpatient drugs. Covered entities include hospitals that serve a disproportionate share of financially needy patients, community health clinics, and other entities that receive certain types of grants under the Public Health Service Act. The PPACA expanded the list of covered entities to include certain free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals, but exempts "orphan drugs" from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ceiling price requirements for these covered entities. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and Medicaid rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate program. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. It is currently unclear how HRSA will apply its enforcement authority under this regulation. Any charge by HRSA that we have violated the requirements of the regulation could result in civil monetary penalties. Moreover, under a final regulation effective January 13, 2021, HRSA established a new administrative dispute resolution ("ADR") process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. On November 30, 2022, HRSA issued a notice of proposed rulemaking that proposes several changes to the ADR process. HRSA also implemented a price reporting system under which we are required to report our 340B ceiling prices to HRSA on a quarterly basis, which then publishes those prices to 340B covered entities. In addition, legislation could be passed that would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we participate in the U.S. Department of Veterans Affairs ("VA") Federal Supply Schedule ("FSS") pricing program. FSS participation is required for our products to be purchased by the VA, Department of Defense ("DoD"), Coast Guard, and Public Health Service ("PHS"). Prices for innovator drugs purchased by the VA, DoD, Coast Guard, and PHS are subject to a cap (known as the "Federal Ceiling Price") equal to 76% of the annual non-federal average manufacturer price ("non-FAMP") minus, if applicable, an additional discount. The additional discount applies if non-FAMP increases more than inflation (measured by reference to the Consumer Price Index - Urban). We also participate in the Tricare Retail Pharmacy Program, under which we pay quarterly rebates to DoD for prescriptions of our innovator drugs dispensed to Tricare beneficiaries through Tricare Retail network pharmacies. The governing statute provides for civil monetary penalties for failure to provide information timely or for knowing submission of false information to the government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government and, subject to detailed program rules and government oversight, each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time to time. The prescription drug plans negotiate pricing with manufacturers and pharmacies, and may condition formulary placement on the availability of manufacturer discounts. In addition, manufacturers, including us, are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. The IRA includes a sunset provision with respect to the coverage gap discount program starting in 2025 and replaces it with a new manufacturer discount program. In addition, as of October 2022, the IRA established a Medicare Part D inflation rebate scheme under which, generally speaking, manufacturers will owe additional rebates if the average manufacturer price of a Part D drug increases faster than the pace of inflation. Failure to timely pay a Part D inflation rebate is subject to a civil monetary penalty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private payor healthcare and insurance providers, health maintenance organizations, and pharmacy benefit managers in the United States are adopting more aggressive utilization management techniques and are increasingly requiring significant discounts and rebates from manufacturers as a condition to including products on formulary with favorable coverage and copayment/coinsurance. These payors may not cover or adequately reimburse for use of our products or may do so at levels that disadvantage them relative to competitive products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, within the EU, our products are paid for by a variety of payors, with governments being the primary source of payment. Government health authorities in the EU determine or influence reimbursement of products, and set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing, and reference pricing (i.e., referencing prices in other countries or prices of competitive products and using those reference prices to set a price). Budgetary pressures in many EU countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates, and expanded generic substitution and patient cost-sharing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to health care "fraud and abuse" laws, such as the federal civil False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state anti-kickback laws prohibit, among other things, payments or other remuneration to induce or reward someone to purchase, prescribe, endorse, or recommend a product that is reimbursed under federal or state healthcare programs. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds, or knowingly making, or causing to be made, a false statement to get a false claim paid. See Part I, Item 1A. "Risk Factors - Other Regulatory and Litigation Risks - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. See Part I, Item 1A. "Risk Factors - Other Regulatory and Litigation Risks - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there are numerous federal and state laws and regulations governing data privacy of personal data and the collection, use, disclosure, and protection of health data, genetic data, consumer data, and children's data. Such laws and regulations include the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively, "HIPAA"), as well as state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws (such as Section 5 of the Federal Trade Commission Act (the "FTC Act") and the California Consumer Privacy Act (the "CCPA")). Many of these laws differ from each other in significant ways and have different effects. Many of the state laws enable a state attorney general to bring actions and provide private rights of action to consumers as enforcement mechanisms. There is also heightened sensitivity around certain types of health data, which may be subject to additional protections. The landscape of federal and state laws regulating personal data is constantly evolving. Failure to comply with these laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation, and/or adverse publicity. Federal regulators, state attorneys general, and plaintiffs' attorneys have been active in this space. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes privacy and security obligations on covered entity health care providers, health plans, and health care clearinghouses, as well as their "business associates" &#8211; certain persons or covered entities that create, receive, maintain, or transmit protected health information ("PHI") in connection with providing a specified service or performing a function on behalf of a covered entity. Most health care providers, including research institutions from which we or our collaborators obtain clinical trial data, are subject to HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly receive PHI maintained by a HIPAA-covered entity in a manner that is not permitted under HIPAA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Trade Commission ("FTC") also sets expectations for failing to take appropriate steps to keep consumers' personal information secure, or failing to provide a level of security commensurate to promises made to individuals about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. The FTC expects a company's data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merit stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers' personal information; and any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. The FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we collect California resident personal data, we are also subject to the CCPA. The CCPA, which became effective on January 1, 2020, created new transparency requirements and granted California residents several new rights with regard to their personal data. In addition, in November 2020, California voters approved the California Privacy Rights Act ("CPRA") ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency ("CPPA"). The amendments introduced by the CPRA go into effect on January 1, 2023, and new implementing regulations are expected to be introduced by the CPPA. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with data privacy incidents involving certain elements of personal data. These claims may result in significant liability and damages. Similarly, there are a number of legislative proposals in the United States, at both the federal and state level, that could impose new obligations or limitations in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the area of consumer protection. For example, states such as Virginia, Colorado, and Utah have enacted similar privacy laws that impose new obligations or limitations in areas affecting our business, and efforts at the federal level to enact similar laws have been ongoing. We may be subject to fines, penalties, or private actions in the event of non-compliance with such laws. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, our clinical trial programs, research collaborations, and other processing activities implicate international data protection laws, including the EU General Data Protection Regulation 2016/679 ("GDPR"). The GDPR has increased our responsibility and liability in relation to the processing of personal data of individuals located in the EU. The GDPR, together with the national legislation of the EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data and samples from clinical trials and adverse event reporting. In particular, these obligations and restrictions may concern the consent of the individuals to whom the personal data relate, the information provided to the individuals, the sharing of personal data with third parties, the transfer of personal data out of the EU, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for violations of the data protection obligations. With respect to the transfer of personal data outside of the EU, while there are legal mechanisms available to lawfully transfer personal data outside of the EU, including to the United States, there are certain unsettled legal issues regarding such data transfers, the resolution of which may adversely affect our ability to transfer personal data or otherwise may cause us to incur significant costs to come into compliance with applicable data transfer impact assessments and implementation of legal data transfer mechanisms. In 2021, the European Commission published new standard contractual clauses required to be incorporated into new and existing agreements within prescribed timeframes in order to continue to lawfully transfer personal data outside of the EU. Different EU member states, as well as the United Kingdom and Switzerland, have promulgated national privacy laws that impose additional requirements, which add to the complexity of processing and transferring EU personal data. In October 2022, the United States issued an executive order to implement EU-U.S. data privacy safeguards. The European Commission is now expected to review the executive order and could propose an adequacy decision concerning the level of personal data protection in the United States under which personal data could flow freely from the EU to the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some countries outside of the EU have reacted to the GDPR by promulgating and enacting new privacy legislation that reflects similar principles and obligations on companies that operate and process their citizens' personal data. Any failure or perceived failure to comply with privacy-related legal obligations, or any compromise of security of personal data, may result in governmental enforcement actions, litigation, contractual indemnity claims, or restraining orders that would impact our ability to process and share data globally. As we expand our presence into new countries, we must continue to assess our privacy controls to enable the processing of personal data. Guidance on implementation and compliance practices are often updated or otherwise revised. See Part I, Item 1A. "Risk Factors - Other Regulatory and Litigation Risks - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face risks related to the personal data we collect, process, and share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing, our present business is, and our future business may be, subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our business as one segment which includes all activities related to the discovery, development, and commercialization of medicines for serious diseases. For financial information related to our one segment, see our Consolidated Financial Statements and related notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the highly competitive biotechnology and pharmaceuticals industries. Attracting, developing, and retaining skilled and experienced employees in research and development, manufacturing, sales and marketing, and other positions is crucial to our ability to compete effectively. Our ability to recruit and retain such employees depends on a number of factors, including our corporate culture and work environment, informed by our values and behaviors (which we call The Regeneron Way) and our philosophy of "Doing Well by Doing Good"; talent development and career opportunities; and compensation and benefits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrity is a core value at Regeneron. Both the Company and each of our employees have a responsibility to act ethically and with integrity at all times. Our Code of Business Conduct and Ethics brings together Regeneron's key policy principles and establishes the Company's expectations for all of our employees to act in accordance with applicable laws, rules, and regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Profile</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 11,851 full-time employees, consisting of 9,843 employed in the United States, 1,721 employed in Ireland, and 287 employed in other countries (primarily in the United Kingdom and Germany). Of these employees, 2,174 were within our research and preclinical development organization, 1,669 were within our global clinical development and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory affairs organization, and 5,534 were within our industrial operations and product supply organization. Company-wide, nearly 1,400 of our full-time employees hold a Ph.D. and/or M.D. We also supplement our workforce with independent contractors, contingent workers, and temporary workers, as needed. None of our employees are represented by a labor union, and our management considers its relations with our employees to be good.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees represent a broad range of backgrounds, just like the people who take our medicines, and bring a wide array of perspectives and experiences that have helped us achieve our leadership position in the biotechnology and pharmaceuticals industries and the global marketplace. A key component of our culture is our commitment to diversity, equity, and inclusion ("DEI"). We believe this commitment allows us to better drive innovation and achieve our mission to repeatedly bring important new medicines to patients with serious diseases. Our DEI principles are reflected in our efforts in building a better workplace where employees can be themselves and succeed, advance medicine for all with better science, and use their voice and influence to create a better world. We empower employee-led cross-functional resource groups, functional/site-level DEI councils, and other interest groups, who connect around a common passion to build a culture of inclusion and collaborate to support under-served science and global communities. In 2022, we introduced inclusive leadership education for some of our most senior leaders and launched a pilot mentorship program focused on our diverse talent base to increase visibility, connection, and the leadership skills of underrepresented talent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are proud of our workforce diversity representation shown in the table below, we seek to continuously improve in this area. In April 2020, we announced our 2025 global responsibility goals, including a commitment to increase diversity in leadership and foster inclusion. Making progress toward this goal, since then we hired our Chief DEI Officer; launched a DEI strategy focused on creating a better workplace, better science, and better world; and implemented a new governance model that includes both an executive DEI council and a DEI leadership council. These councils are comprised of senior leaders who provide oversight and guidance on our DEI efforts and support the execution of our DEI strategy. In order to better understand our employees' perspectives, we also measure inclusion and belonging as part of our annual employee engagement survey. Our board of directors receives a detailed update on our DEI efforts at least once a year and continues to monitor our progress.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:302.25pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Workforce Diversity Representation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Female Representation (Global)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.8%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">People of Color Representation (U.S. Only)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">**</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.7%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Based on full-time employees as of December 31, 2022</span></div></td></tr><tr style="height:56pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Represents the percentage of our full-time employees in the United States that self-identified as belonging to a racial or ethnic minority group. The denominator used in this calculation includes employees who did not disclose information related to their race or ethnicity. Excluding those that did not disclose such information, the percentage shown in this table would be 33.6%.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Externally, we support DEI efforts in our community, including by supporting young scientific talent in underrepresented communities. For example, as part of our $100 million, 10-year commitment to support the Regeneron Science Talent Search, we allocate $3.1 million annually to fund the Society for Science&#8217;s science, technology, engineering, and math ("STEM") outreach and equity programs. In 2022, we also continued our $24 million, 5-year title sponsorship of Regeneron International Science and Engineering Fair, with representation from over 1,700 student scientists representing 63 countries and 49 U.S. states. In addition, we have developed a STEM pilot program with post-primary-school and high-school students in the New York State Capital Region and Limerick, Ireland that aspires to build long-term relationships with students from disadvantaged socio-economic groups, to encourage and support them in their studies, to inspire them to attend college, and, ultimately, to build a deeper more diverse talent pipeline. We also continue to take steps to further integrate diversity considerations into the design and selection of sites for our clinical studies to make sure they reflect the diversity of patients with the diseases under investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Wellness, Health, and Safety</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The wellbeing of our employees is a primary focus as we believe that the most productive people are those who are at their best, both physically and mentally. We provide several programs related to employee health and wellness, including onsite amenities and programs such as meditation and prayer rooms and fitness centers. We also prioritize mental health initiatives and have taken further action to reduce or remove barriers to quality mental healthcare for our employees and their family members. In addition, we provide support for work-life balance through flex-time, remote working arrangements, child and elder care, and paid parental leave, among others.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Occupational health and safety is critical to our success. We are committed to meeting or exceeding all environmental, health, safety ("EHS") and security regulations and have a range of programs, plans, and procedures to ensure the safety of all people </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who come to work at Regeneron. In addition, our 2025 global responsibility goals include a commitment to focus on workplace injury prevention in our drive toward zero incidents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Growth and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest significant resources to develop talent with the right capabilities to deliver the growth and innovation needed to support our continued success. Our Talent department is dedicated to promoting individual, leader, team, and organizational development through a number of tools and services. We offer a variety of professional development courses for our employees and support employee continuing education, including through educational reimbursement and tuition forgiveness programs. In addition, we continue to invest in our current and future leaders through a number of leadership development courses and programs and feedback and coaching opportunities. In 2022, nearly 30% of job openings were filled by existing employees who were seeking career development opportunities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Engagement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe engaging our employees, from their first day and throughout their career, is key to fostering new ideas and driving commitment and productivity. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, company forums and summits, annual engagement surveys, and pulse surveys.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also committed to fostering employee volunteerism to reach our 2025 global responsibility goal of driving employee volunteer levels above national standards. Employees are encouraged and empowered to support organizations and causes that are important to them including through, among other things, our matching gift program, volunteer-time-off policy, and our annual company-wide service event, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Day for Doing Good</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2022, nearly 7,000 employees volunteered approximately 31,200 hours, including approximately 55% of our employees who volunteered nearly 20,000 hours to approximately 190 nonprofits during our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Day for Doing Good</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, through our Matching Gift Program, we matched over $2 million in employee contributions in 2022, supporting over 2,000 charities. In 2022, we were named to the Civic 50 of most community-minded companies in the United States for the sixth consecutive year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our employee engagement efforts is demonstrated by our employee retention rate of 91% in 2022, as well as the fact that 87% of our employees who responded to our annual engagement survey said Regeneron is a great place to work. Additionally, we have placed in the top five for the past 12 years in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Science</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> magazine&#8217;s annual "Top Employers Survey" of the global biotechnology and pharmaceutical industry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to rewarding and supporting our employees in order to continue to attract and retain top talent. We believe this commitment supports our core strategy of creating and advancing a high-quality product pipeline and delivering medicines to people in need. Employee engagement, commitment, and achievements are key drivers of pipeline success and therefore our long-term performance. The primary underpinning of our pay philosophy is to award equity-based pay to all eligible employees to ensure that when we deliver for patients and for shareholders, everyone shares in the upside growth. Our practice, therefore, has been to award initial equity grants to all new hires, in addition to our comprehensive annual equity program. Total employee compensation packages (which varies by country and region) include market-competitive pay (with the opportunity to receive above-market rewards), broad-based grants of equity-based awards, comprehensive healthcare benefits, parental leave, child and elder care support, retirement savings options, and matching contributions. We annually review our workforce demographic and pay equity data to track our performance and inform new initiatives. Our analysis indicates favorable performance in these areas, and we are committed to continued monitoring.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of New York in 1988 and publicly listed in 1991. Our principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and our telephone number at that address is (914) 847-7000. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our Internet website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission ("SEC"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and other interested parties should note that we use our media and investor relations website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://newsroom.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and our social media channels to publish important information about Regeneron, including information that may be deemed material to investors. We encourage investors and other interested parties to review the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information we may publish through our media and investor relations website and the social media channels listed on our media and investor relations website, in addition to our SEC filings, press releases, conference calls, and webcasts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our websites and social media channels is not included as a part of, or incorporated by reference into, this report. </span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_22"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an environment that involves a number of significant risks and uncertainties. We caution you to read the following risk factors, which have affected, and/or in the future could affect, our business, prospects, operating results, and financial condition. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, prospects, operating results, and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this report and should also be considered by our investors. For purposes of this section (as well as this report in general), references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators or licensees; and references to our product candidates encompass product candidates in development by us and/or our collaborators or licensees (in the case of collaborated or licensed products or product candidates under the terms of the applicable collaboration or license agreements), unless otherwise stated or required by the context. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above, we are subject to a number of risks that if realized could materially harm our business, prospects, operating results, and financial condition. Some of the more significant risks and uncertainties we face include those summarized below. The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in this "Risk Factors" section. Please carefully consider all of the information in this Form 10-K, including the full set of risks set forth in this "Risk Factors" section, and in our other filings with the SEC before making an investment decision regarding Regeneron.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be further adversely affected by the effects of the COVID-19 pandemic, including those impacting our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers, as well as the demand for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to the development, manufacturing, and potential future commercialization of monoclonal antibodies targeting SARS-CoV-2.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization Risks </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of EYLEA and Dupixent. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of our products are dependent on the availability and extent of reimbursement from third-party payors, including private payors and government programs such as Medicare and Medicaid, which could change due to various factors such as drug price control measures that have been or may be enacted or introduced in the United States by various federal and state authorities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of our products is subject to significant competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Development Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serious complications or side effects in connection with the use or development of our products or product candidates could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our products are intended to be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Market Exclusivity Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect the confidentiality of our trade secrets, and our patents or other means of defending our intellectual property may be insufficient to protect our proprietary rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents or proprietary rights of others may restrict our development, manufacturing, and/or commercialization efforts and subject us to patent litigation and other proceedings that could find us liable for damages.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products, including EYLEA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our products and to advance our clinical pipeline. As we increase our production in response to higher product demand or in anticipation of a potential regulatory approval, our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our products approved for marketing and could jeopardize our clinical development programs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party service or supply failures, failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, or failures at the facilities of any other party participating in the supply chain would adversely affect our ability to supply our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks from the improper conduct of our employees, agents, contractors, or collaborators, including those relating to potential non-compliance with relevant laws and regulations such as the Foreign Corrupt Practices Act and the U.K. Bribery Act.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tax liabilities and risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to the personal data we collect, process, and share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on or Transactions with Third Parties</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our collaborations with Sanofi or Bayer or other third parties are terminated or breached, our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have undertaken and may in the future undertake strategic acquisitions, and any difficulties from integrating such acquisitions could adversely affect our business, operating results, and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks Factors &#8211; Risks Related to Employees, Information Technology, Financial Results and Liquidity, and Our Common Stock</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on our key personnel and will be harmed if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness could adversely impact our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is extremely volatile.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*       *       *</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be further adversely affected by the effects of the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. It has since spread around the world, evolved into multiple new variants, and caused a global pandemic. This pandemic has adversely affected and/or has the potential to adversely affect, among other things, the economic and financial markets and labor resources of the countries in which we operate; our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers; and the demand for our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has previously resulted and may again result in the imposition of various restrictions and mandates around the world to reduce the spread of the disease, including governmental orders that direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, maintain social distancing, order cessation of non-essential travel, and require proof of vaccination and/or negative COVID-19 test results. The COVID-19 pandemic has continued to ebb and flow, with different jurisdictions having higher levels of infections than others and new variants of the SARS-CoV-2 virus (such as the Omicron-lineage variants) emerging and spreading more easily and quickly than other variants. The trajectory and the ultimate impact of the pandemic are highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. These effects could have a material impact on our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, continuation or re-imposition of various government-imposed or private-sector measures relating to the COVID-19 pandemic (including those we previously implemented, such as work-from-home policies for some employees) may further negatively impact productivity, disrupt our business, and delay our clinical programs and development timelines beyond the delays we have already experienced and disclosed. Such restrictions and limitations may also further negatively impact our access to regulatory authorities (which are affected, among other things, by applicable travel restrictions and may be delayed in responding to inquiries, reviewing filings, and conducting inspections); our ability to perform regularly scheduled quality checks and maintenance; and our ability to obtain services from third-party specialty vendors and other providers or to access their expertise as fully and timely as needed. The COVID-19 pandemic may also result in the loss of some of our key personnel, either temporarily or permanently. We and our employees may also be subject to government vaccine mandates, which may have a negative impact on our ability to retain employees or hire new employees and could adversely impact our business. In addition, our sales and marketing efforts were previously negatively impacted and may be further negatively impacted by postponement or cancellation of face-to-face meetings and restrictions on access by non-essential personnel to hospitals or clinics to the extent such measures slow down adoption or further commercialization of our marketed products. The demand for our marketed products may also be adversely impacted by the restrictions and limitations adopted in response to the COVID-19 pandemic, particularly to the extent they affect the patients' ability or willingness to start or continue treatment with our marketed products. Any of the foregoing factors may result in lower net product sales of our marketed products. For example, net product sales of EYLEA in the United States decreased for the three months ended June 30, 2020, compared to the same period in 2019, due in part to the impact of the COVID-19 pandemic. Demand for some or all of our marketed products may be further reduced if shelter-in-place, social distancing, or similar orders remain in effect or are re-implemented and, as a result, some of our inventory may become obsolete and may need to be written off, impacting our operating results. These and similar, and perhaps more severe, disruptions in our operations may materially adversely impact our business, prospects, operating results, and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various government-imposed or private-sector measures relating to the COVID-19 pandemic (or the perception that such restrictions or limitations on the conduct of business operations could occur) previously impacted, and may impact in the future, personnel at our research and manufacturing facilities, our suppliers, and other third parties on which we rely, as well as the availability or cost of materials produced by or purchased from such parties, resulting in supply chain strains or disruptions that may become material. While some materials and services may be obtained from more than one supplier or provider, port closures and other restrictions, whether resulting from the COVID-19 pandemic or otherwise (including any government restrictions or limitations, such as those that may be imposed under the Defense Production Act), could materially disrupt our supply chain or limit our ability to obtain sufficient materials or services (including fill/finish services) required for the development and manufacturing of our products and product candidates as well as our research efforts. If microbial, viral (including COVID-19), or other contaminations are discovered in our products, product candidates, the materials used for their production, or in our facilities, or in the facilities of our collaborators, third-party contract manufacturers, or other providers or suppliers, the affected facilities may need to be closed or may otherwise be affected for an extended period of time, or the contamination may result in other delays or disruptions in our direct or indirect supply chain. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, infections, hospitalizations, and deaths related to COVID-19 previously disrupted and may in the future disrupt the healthcare and healthcare regulatory systems in the United States and abroad. These and other possible disruptions relating to the COVID-19 pandemic could divert healthcare resources away from, or materially delay, regulatory review and potential approval of our product candidates and new indications for our marketed products. In addition, some of our clinical trials were previously and may in the future be affected by the COVID-19 pandemic. This impact could result in further delays in site initiation and patient enrollment due to prioritization of hospital resources toward the COVID-19 pandemic, patients' inability to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, and restrictions on trial initiations imposed by hospitals and other trial sites as a result of the COVID-19 pandemic. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, was previously and may in the future be delayed or disrupted. Any such disruptions may further negatively impact the progress of our clinical trials, including the readouts of trial results, the timing of regulatory review, and any anticipated program milestones. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, it previously caused significant disruption of global financial markets and could cause more economic disruption in the future, making it more difficult for us to access capital if needed. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the COVID-19 pandemic adversely affects our business, prospects, operating results, or financial condition, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to the development, manufacturing, and potential future commercialization of monoclonal antibodies targeting SARS-CoV-2.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we developed REGEN-COV (known as Ronapreve in countries outside the United States), a novel investigational antibody cocktail treatment designed to prevent and treat infection from the SARS-CoV-2 virus. REGEN-COV received an EUA from the FDA in November 2020 for the treatment of mild to moderate COVID-19 in certain patients, which was revised in January 2022 to exclude its use in geographic regions (currently including all U.S. states, territories, and jurisdictions) where infection or exposure is likely due to a variant such as an Omicron-lineage variant that is not susceptible to the treatment. In December 2022, the FDA issued a complete response letter concerning our BLA for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. In light of these developments, we cannot predict whether (if at all) or to what extent REGEN-COV may be reauthorized or approved for use by the FDA in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in this report, we are progressing "next generation" monoclonal antibodies targeting SARS-CoV-2 (together with REGEN-COV referred to below as "our COVID-19 monoclonal antibodies"). There can be no assurance as to the timing or success of any of these efforts or studies evaluating "next generation" antibodies and whether any of such antibodies will retain activity against present or future variants of concern. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks related to our significant investment in the development, supply, allocation, distribution, pricing, and potential future commercialization of our COVID-19 monoclonal antibodies. We have committed and may continue to commit significant capital and resources to fund and supply clinical trials and to accelerate and scale up the production of our COVID-19 monoclonal antibodies, which involves a complex manufacturing process that is both resource- and time-sensitive. For example, the impact of prioritizing certain manufacturing-related resources for our COVID-19 monoclonal antibodies has included and may in the future include, among other things, drawing down inventory safety stock levels for certain of our other products (including Dupixent and EYLEA). Depending on the demand for our products (including any future demand for our COVID-19 monoclonal antibodies), our ability to re-establish successfully our customary manufacturing cadence, and other relevant factors, we may not be able to replenish our inventory safety stock to the levels we deem prudent or supply our products and product candidates in sufficient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quantities to satisfy our commercial and development needs. We expect our investment in the development and manufacture of our COVID-19 monoclonal antibodies to continue in 2023 and potentially beyond, although the magnitude of our investment will be subject to clinical data results, the duration of the COVID-19 pandemic, and other factors, including regulatory outcomes. If we are unable to obtain a new EUA for any of our "next generation" monoclonal antibodies, or obtain regulatory approvals for any of the foregoing, or if we make a strategic decision to discontinue development of, or not commercialize, our "next generation" COVID-19 monoclonal antibodies or are otherwise not successful in their commercialization, we may be unable to recoup our significant expenses incurred to date and/or in the future related to the development and production of such antibodies. While we previously recognized significant revenues in connection with sales of REGEN-COV, the degree to which any future sales of our COVID-19 monoclonal antibodies will continue to impact our results of operations is highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of EYLEA and Dupixent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA net product sales represent a substantial portion of our revenues and this concentration of our net sales in a single product makes us substantially dependent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on that product. For the years ended December&#160;31, 2022 and 2021, EYLEA net product sales in the United States represented 51% and 36% of our total revenues, respectively, with EYLEA net product sales as a percentage of our total revenues for the year ended December 31, 2021 being significantly lower due to the net product sales of REGEN-COV we recorded in that period under our agreements with the U.S. government. If we were to experience difficulty with the commercialization of EYLEA in the United States or if Bayer were to experience any difficulty with the commercialization of EYLEA outside the United States (including as a result of the COVID-19 pandemic discussed above), or if we and Bayer are unable to maintain current marketing approvals of EYLEA, we may experience a reduction in revenue and may not be able to sustain profitability, and our business, prospects, operating results, and financial condition would be materially harmed. In the United States, the regulatory exclusivity period for EYLEA (i.e., the period during which no biosimilar product can be approved by the FDA) will expire after May 17, 2024. See "Risks Related to Intellectual Property and Market Exclusivity - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below. As a result, we face the risk of lower EYLEA net product sales due to biosimilar competition following such expiration, which may have a material adverse impact on our results of operations. While we have submitted a BLA for aflibercept 8 mg with the FDA, the degree to which any future net product sales of aflibercept 8 mg (if approved) may offset any potential decrease in EYLEA net product sales is highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are dependent on our share of profits from the commercialization of Dupixent under our Antibody Collaboration with Sanofi. If we or Sanofi were to experience any difficulty with the commercialization of Dupixent or if we or Sanofi are unable to maintain current marketing approvals of Dupixent, we may experience a reduction in revenue and our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the degree of commercial success of our marketed products will continue to depend on many factors, including the following (as applicable):</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any continued or future impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on our business and the demand for our marketed products, as well as any continued or future impact on, among other things, our employees, collaborators, suppliers, and other third parties on which we rely, our ability to continue to manage our supply chain, and the global economy (as further discussed above under "Risks Related to the COVID-19 Pandemic - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be further adversely affected by the effects of the COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of the commercial strategy in and outside the United States for the marketing of our products, including pricing strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient coverage of, and reimbursement for, our marketed products by third-party payors, including Medicare and Medicaid in the United States and other government and private payors in the United States and foreign jurisdictions, as well as U.S. and foreign payor restrictions on eligible patient populations and the reimbursement process (including drug price control measures that have been or may be enacted or introduced in the United States by various federal and state authorities);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our collaborators' ability to maintain sales of our marketed products in the face of competitive products and to differentiate our marketed products from competitive products, including as applicable product candidates currently in clinical development (such as aflibercept 8 mg); and, in the case of EYLEA, the existing and potential new branded and biosimilar competition for EYLEA (discussed further under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" below) and the willingness of retinal specialists and patients to start or continue treatment with EYLEA or to switch from another product to EYLEA;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of existing and new health care laws and regulations currently being considered or implemented in the United States, including measures requiring the U.S. government in the future to negotiate the prices of certain drugs and price reporting and other disclosure requirements and the potential impact of such requirements on physician prescribing practices and payor coverage;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious complications or side effects in connection with the use of our marketed products, as discussed under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and successfully monitoring commercial manufacturing arrangements for our marketed products with third parties who perform fill/finish or other steps in the manufacture of such products to ensure that they meet our standards and those of regulatory authorities, including the FDA, which extensively regulate and monitor pharmaceutical manufacturing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the demand for commercial supplies of our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the pending proceedings relating to EYLEA, Praluent, and REGEN-COV (described further in Note 16 to our Consolidated Financial Statements included in this report), as well as other risks relating to our marketed products and product candidates associated with intellectual property of other parties and pending or future litigation relating thereto (as discussed under "Risks Related to Intellectual Property and Market Exclusivity" below);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the pending government proceedings and investigations and other matters described in Note 16 to our Consolidated Financial Statements included in this report (including the civil complaint filed against us on June 24, 2020 in the U.S. District Court for the District of Massachusetts by the U.S. Attorney's Office for the District of Massachusetts); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and studies of other products that could implicate an entire class of products or are perceived to do so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More detailed information about the risks related to the commercialization of our marketed products is provided in the risk factors below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or our collaborators commercialize. If we or our collaborators fail to maintain regulatory compliance for any of such products, the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or they commercialize for the products' currently approved indications in the United States, EU, and other countries where such products are approved. If we or our collaborators fail to maintain regulatory compliance or satisfy other obligations for such products' currently approved indications (including because the product does not meet the relevant endpoints of any required post-approval studies (such as those required under an accelerated approval by the FDA or other similar type of approval), or for any of the reasons discussed below under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition. Failure to comply may also subject us to sanctions, product recalls, or withdrawals of previously approved marketing applications. See also "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our marketed products in the United States are dependent, in large part, on the availability and extent of reimbursement from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies ("PBMs"), and government programs such as Medicare and Medicaid. Sales of our marketed products in other countries are dependent, in large part, on similar reimbursement mechanisms and programs in those countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future revenues and profitability will be adversely affected in a material manner if such third-party payors do not adequately defray or reimburse the cost of our marketed products. If these entities do not provide coverage and reimbursement with respect to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our marketed products or provide an insufficient level of coverage and reimbursement, such products may be too costly for many patients to afford them, and physicians may not prescribe them. Many third-party payors cover only selected drugs, or may prefer selected drugs, making drugs that are not covered or preferred by such payors more expensive for patients. Third-party payors may also require prior authorization for reimbursement, or require failure on another type of treatment before covering a particular drug, particularly with respect to higher-priced drugs. As our currently marketed products and most of our product candidates are biologics, bringing them to market may cost more than bringing traditional, small-molecule drugs to market due to the complexity associated with the research, development, production, supply, and regulatory review of such products. Given cost sensitivities in many health care systems (which may continue to be exacerbated as a result of the COVID-19 pandemic), our currently marketed products and product candidates are likely to be subject to continued pricing pressures, which may have an adverse impact on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order for private insurance and governmental payors (such as Medicare and Medicaid in the United States) to reimburse the cost of our marketed products, we must maintain, among other things, our FDA registration and our National Drug Code, formulary approval by PBMs, and recognition by insurance companies and CMS. There is no certainty that we will be able to obtain or maintain the applicable requirements for reimbursement (including relevant formulary coverage, as discussed further below) of our current and future marketed products, which may have a material adverse effect on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other third-party payors (including PBMs) are challenging the prices charged for healthcare products and increasingly limiting, and attempting to limit, both coverage and level of reimbursement for prescription drugs, such as by requiring outcomes-based or other pay-for-performance pricing arrangements. They are also imposing restrictions on eligible patient populations and the reimbursement process, including by means of required prior authorizations and utilization management criteria, such as step therapy (i.e., requiring the use of less costly medications before more costly medications are approved for coverage). Some states are also considering legislation that would control the prices and reimbursement of prescription drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any prescription drug for which supplemental rebates are not being paid. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform measures in the future that will impose additional constraints on prices and reimbursements for our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there have been several recent U.S. Congressional inquiries and recently approved or proposed federal and state legislation and policies (in addition to those already in effect) designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. Notably, the U.S. Congress recently passed the IRA, which includes measures requiring the government to negotiate, with respect to drugs provided to Medicare patients and subject to a specified cap, the prices of a set number of certain high Medicare spending drugs and biological products per year starting in 2026 (including those covered under Medicare Part B, such as EYLEA and, potentially in the future, aflibercept 8 mg), measures penalizing manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and measures redesigning the Medicare Part D benefit to limit patient out-of-pocket drug costs and shift liabilities among stakeholders, including manufacturers. While enacted into law, it is unclear how the provisions of the IRA will be implemented and the extent to which the policy changes will ultimately impact reimbursement levels of our marketed products, including those covered under Medicare Part B (such as EYLEA) or our product candidates that may in the future be covered under Medicare Part B (such as aflibercept 8 mg). At the state level, legislatures are becoming increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and price and marketing cost disclosure and transparency measures. In some cases, these measures are designed to encourage importation from other countries and bulk purchasing. A reduction in the availability or extent of reimbursement from U.S. government programs (including as a result of the legislation, proposals, initiatives, and developments described above) could have a material adverse effect on the sales of EYLEA or our other marketed products. Economic pressure on state budgets may also have a similar impact. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, PBMs and other managed-care organizations often develop formularies to reduce their cost for medications. The breadth of the products covered by formularies varies considerably from one PBM to another. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our marketed products. If our marketed products are not included within an adequate number of formularies, adequate reimbursement levels are not provided, the eligible insured patient population for our products is limited, or a key payor refuses to provide reimbursement for our products in a particular jurisdiction altogether, this could have a material adverse effect on our and our collaborators' ability to commercialize the applicable product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain foreign countries, pricing, coverage, and level of reimbursement of prescription drugs are subject to governmental control, and we and our collaborators may be unable to obtain coverage, pricing, and/or reimbursement on terms that are favorable to us or necessary for us or our collaborators to successfully commercialize our marketed products in those countries. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governing drug pricing and reimbursement vary widely from country to country, and may take into account the clinical effectiveness, cost, and service impact of existing, new, and emerging drugs and treatments. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Our results of operations may suffer if we or our collaborators are unable to market our products in foreign countries or if coverage and reimbursement for our marketed products in foreign countries is limited or delayed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our products and product candidates is subject to significant competition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial competition in the biotechnology and pharmaceutical industries from biotechnology, pharmaceutical, and chemical companies. Many of our competitors have substantially greater research, preclinical and clinical product development and manufacturing capabilities, as well as financial, marketing, and human resources, than we do. Our competitors, regardless of their size, may also enhance their competitive position if they acquire or discover patentable inventions, form collaborative arrangements, or merge with other pharmaceutical or biotechnology companies. There is significant actual and potential future competition for each of our marketed products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EYLEA and (if approved) aflibercept 8 mg.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA faces and, if approved, aflibercept 8 mg will face, significant competition in the marketplace. For example, EYLEA competes in one or more of its approved indications with other VEGF inhibitors, including Novartis and Genentech/Roche's Lucentis, Novartis' Beovu, and Genentech/Roche's Susvimo and Vabysmo, as well as biosimilar versions of Lucentis commercialized in the United States by Biogen Inc. and Coherus BioSciences, Inc. Ophthalmologists are also using off-label, third-party repackaged versions of Genentech/Roche's approved VEGF antagonist, bevacizumab, for the treatment of certain of EYLEA's indications, and we are aware of another company developing an ophthalmic formulation of such product. In DME and RVO, EYLEA also competes with intravitreal implants of corticosteroids. We are also aware of a number of companies working on the development of product candidates and extended delivery devices for the potential treatment of one or more of EYLEA's indications, including those that act by blocking VEGF and VEGF receptors (including therapies designed to extend the treatment interval) and/or other targets. In addition, we are aware of several companies developing biosimilar versions of EYLEA and other approved anti-VEGF treatments. Other potentially competitive products in development include products for use in combination with EYLEA and/or other anti-VEGF treatments, small-molecule tyrosine kinase inhibitors, gene therapies, and other eye-drop formulations, devices, and oral therapies. There also is a risk that third parties repackage ZALTRAP for off-label use and sale for the treatment of diseases of the eye, even though ZALTRAP has not been manufactured and formulated for use in intravitreal injections. We are aware of claims by third parties, including those based on published clinical data, alleging that ZALTRAP may be safely administered to the eye. If approved, we expect that aflibercept 8 mg will be entering a highly competitive environment; and our success in potentially commercializing aflibercept 8 mg will depend on a number of factors, including the extent to which we and our collaborators are able to differentiate aflibercept 8 mg from competitive products and the applicability of any restrictions imposed by payors at the time, such as step therapy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The market for Dupixent's current and potential future indications is also increasingly competitive. In atopic dermatitis, there are topical and systemic JAK inhibitors and an antibody against IL-13 approved for atopic dermatitis and others are in development. In addition, a number of companies are developing antibodies against IL-4Ra, IL-13Ra1, OX40(L), and/or IL-31R that may compete with Dupixent in atopic dermatitis and other indications (including asthma and/or prurigo nodularis), as applicable. In asthma, competitors to Dupixent include antibodies against the IL-5 ligand or the IL-5 receptor, immunoglobulin E, or thymic stromal lymphopoietin ("TSLP"); and some of these antibodies are either approved or in development for indications that also compete or may compete in the future with Dupixent in CRSwNP and EoE. There are several other potentially competitive products in development that may compete with Dupixent in asthma, as well as potential future indications, including antibodies against the IL-33 ligand or receptor. Dupixent also faces competition from inhaled products in asthma and potential future indications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Libtayo.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Libtayo also faces significant competition. There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda, Bristol-Myers Squibb's Opdivo, Roche's Tecentriq, and AstraZeneca's Imfinzi.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other marketed products.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant actual and potential future competition for other products marketed or otherwise commercialized by us and/or our collaborators under our collaboration agreements with them. For example, there are several companies that are marketing and/or developing antibodies or other molecules (such as small interfering RNA molecules, or siRNAs) against PCSK9, ANGPTL3 and IL-6 and/or IL-6R, which currently (or, for product candidates in development, may in the future if approved) compete with Praluent, Evkeeza, and Kevzara, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Candidates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies using various technologies, including antibody generation technologies and other approaches such as RNAi, chimeric antigen receptor T cell (CAR-T cell), and gene therapy technologies. For example, we are aware of other pharmaceutical and biotechnology companies actively engaged in the research and development of antibody-based products against targets that are also the targets of our early- and late-stage product candidates. We are also aware of other companies developing or marketing small molecules or other treatments that may compete with our antibody-based product candidates in various indications, if such product candidates obtain regulatory approval in those indications. If any of these or other competitors announces a successful clinical study involving a product that may be competitive with one of our product candidates or the grant of marketing approval by a regulatory agency for a competitive product, such developments may have an adverse effect on our business or future prospects. In addition, the first product to reach the market in a therapeutic area is often at a significant competitive advantage relative to later entrants to the market. Accordingly, the relative speed with which we, or our collaborators, can develop our product candidates, complete the clinical trials and approval processes, and, if such product candidates are approved for marketing and sale, supply commercial quantities to the market is expected to continue to be an important competitive factor. Due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for a product against any particular target, which may have a material adverse effect on our business or future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have established our own sales and marketing organization for EYLEA in the United States for its currently approved indications, we have no sales, marketing, commercial, or distribution capabilities for EYLEA outside the United States. Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA (and, if approved, will rely on Bayer for such activities relating to aflibercept 8 mg) in countries outside the United States.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of our Antibody Collaboration, we and Sanofi co-commercialize Dupixent in the United States and, as further discussed below, certain jurisdictions outside the United States. As a result, we rely in part on Sanofi's sales and marketing organization for Dupixent. If we and Sanofi fail to coordinate our sales and marketing efforts effectively, sales of Dupixent may be materially affected. Sanofi also maintains other important responsibilities relating to Dupixent. For example, Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product. We also rely on Sanofi for sales, marketing, and distribution of Dupixent in countries outside the United States. While we exercised our option under the Antibody Collaboration to co-commercialize Dupixent in certain jurisdictions outside the United States, we will continue to rely in part on Sanofi's sales and marketing organization in such jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are unsuccessful in continuing to commercialize the marketed products subject to such collaborations, or if Bayer or Sanofi terminate their respective collaborations with us, our business, prospects, operating results, and financial condition would be materially impaired. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities. Therefore, termination of the Bayer collaboration agreement or our Antibody Collaboration would create substantial new and additional risks to the successful commercialization of the applicable products, particularly outside the United States. For additional information regarding our collaborations with Bayer and Sanofi, see "Risks Related to Our Reliance on or Transactions with Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below and "Risks Related to Our Reliance on or Transactions with Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our Antibody Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of products we commercialize in the United States and our collaborators' sales of products they commercialize or co-commercialize with us under our collaboration agreements with them in the United States and other countries (which impact our share of any profits or losses from the commercialization of these products under the relevant collaboration agreements and, therefore, our results of operations) may be reduced if the applicable product is imported into those countries from lower priced markets, whether legally or illegally (a practice known as parallel trading or reimportation). Parallel traders (who may repackage or otherwise alter the original product or sell it through alternative channels such as mail order or the Internet) take advantage of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the price differentials between markets arising from factors including sales costs, market conditions (such as intermediate trading stages), tax rates, or national regulation of prices. Under our arrangement with Bayer, pricing and reimbursement for EYLEA outside the United States is the responsibility of Bayer. Similarly, under our Antibody Collaboration with Sanofi, pricing and reimbursement for the products commercialized or co-commercialized thereunder outside the United States are the responsibility of Sanofi. Prices for our marketed products in jurisdictions outside the United States are based on local market economics and competition and are likely to differ from country to country. In the United States, prices for pharmaceuticals are generally higher than in the bordering nations of Canada and Mexico and sales of our marketed products in the United States may be reduced if the applicable product marketed in those bordering nations is imported into the United States. In addition, there are proposals to legalize the import of pharmaceuticals from outside the United States into the United States. If such proposals were implemented, our future revenues derived from sales of our marketed products could be reduced. Parallel-trading practices also are of particular relevance to the EU, where they have been encouraged by the current regulatory framework. These types of imports may exert pressure on the pricing of our marketed products in a particular market or reduce sales recorded by us or our collaborators, thereby adversely affecting our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would materially and adversely affect our business, profitability, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if clinical trials demonstrate the safety and effectiveness of any of our product candidates for a specific disease and the necessary regulatory approvals are obtained, the commercial success of any of our product candidates or new indications for our marketed products will depend upon, among other things, their acceptance by patients, the medical community, and third-party payors and on our and our collaborators' ability to successfully manufacture, market, and distribute those products in substantial commercial quantities or to establish and manage the required infrastructure to do so, including large-scale information technology systems and a large-scale distribution network. Establishing and maintaining sales, marketing, and distribution capabilities are expensive and time-consuming. Even if we obtain regulatory approval for our product candidates or new indications, if they are not successfully commercialized, we will not be able to recover the significant investment we have made in developing such products and our business, prospects, operating results, and financial condition would be severely harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our products may also be adversely affected by guidelines or recommendations to healthcare providers, administrators, payors, and patient communities that result in decreased use of our products. Such guidelines or recommendations may be published not only by governmental agencies, but also professional societies, practice management groups, private foundations, and other interested parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are delivered either by intravenous infusion or by intravitreal or subcutaneous injections, which are generally less well received by patients than tablet or capsule delivery and this could adversely affect the commercial success of those products if they receive marketing approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our marketed products for which we record net product sales in the United States to several distributors and specialty pharmacies, as applicable, which generally sell the product directly to healthcare providers or other pharmacies (as applicable). For the years ended December&#160;31, 2022 and 2021, our gross product sales of such products to two customers accounted on a combined basis for 83% and 48% of our total gross product revenue, respectively, and gross product sales of REGEN-COV to the U.S. government accounted for an additional 43% of our total gross product revenue for the year ended December 31, 2021. We expect significant customer concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to continue for the foreseeable future. Our ability to generate and grow sales of these products will depend, in part, on the extent to which our distributors and specialty pharmacies are able to provide adequate distribution of these products to healthcare providers. Although we believe we can find additional distributors, if necessary, our revenue during any period of disruption could suffer and we might incur additional costs. In addition, these customers are responsible for a significant portion of our net trade accounts receivable balances. The loss of any large customer, a significant reduction in sales we make to them, any cancellation of orders they have made with us, or any failure to pay for the products we have shipped to them could adversely affect our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited commercial capabilities outside the United States and do not currently have a fully established organization for the sales, marketing, and distribution of marketed products outside the United States. We will need to establish some or all of these capabilities outside the United States for any product we decide to independently commercialize or co-commercialize outside the United States. For example, following the exercise of our option under the Antibody Collaboration to co-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize Dupixent in certain jurisdictions outside the United States, we have established certain commercial capabilities for Dupixent in some of these jurisdictions and are in the process of establishing these capabilities in others. In addition, in 2022, we and Sanofi amended the IO Collaboration to transfer all rights to develop, commercialize, and manufacture Libtayo exclusively to our Company, on a worldwide basis, over the course of a defined transition period, and we will need to establish certain sales, marketing, distribution, and manufacturing capabilities for Libtayo to support certain markets outside the United States. See Part I, Item 1. "Business - Collaboration, License, and Other Agreements - Sanofi." We will also need to obtain and/or maintain regulatory approvals for Libtayo in many jurisdictions outside of the United States. There may be other circumstances in which we need to establish commercial capabilities outside the United States, including because we decide to commercialize a particular product independently; we are unable to find an appropriate collaborator; or an existing collaborator decides to opt out or breaches its obligations to us with respect to a particular product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize or co-commercialize any products outside the United States, we must build our sales, marketing, distribution, regulatory, managerial, and other capabilities in the relevant markets or make arrangements with third parties to perform these services, any of which will likely be expensive and time consuming and could delay product launch or the co-commercialization of a product in one or more markets outside the United States. We cannot be certain that we will be able to successfully develop commercial capabilities outside the United States (including as it relates to Dupixent and Libtayo) within an acceptable time frame, without incurring substantial expenses, or at all. These and other difficulties relating to commercializing our products outside the United States may harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot sell or market products without regulatory approval or other authorization. If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications of our marketed products (or are materially delayed in doing so), the value of our Company and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we (which, for purposes of this risk factor, includes our collaborators, unless otherwise stated or required by the context) must obtain and maintain approval from the FDA for each drug we intend to sell. Obtaining FDA approval for a new drug or indication is typically a lengthy and expensive process, and approval is highly uncertain. We cannot predict with certainty if or when we might submit for regulatory approval for any of our product candidates currently under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions, or contra-indications with respect to conditions of use. Additionally, the FDA may determine that a REMS is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. The FDA has substantial discretion in the approval process (including with respect to setting specific conditions for submission) and may either refuse to accept an application for substantive review or may form the opinion after review of an application that the application is insufficient to allow approval of a product candidate. If the FDA does not accept our application for review or approve our application, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit the data before it will reconsider our application. Depending on the extent of these or any other studies that might be required, approval of any applications that we submit may be delayed significantly, or we may be required to expend more resources. It is also possible that any such additional studies, if performed and completed, may not be considered sufficient by the FDA to make our applications approvable. If any of these outcomes occur, we may be forced to delay or abandon our applications for approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances (such as when we use a biomarker-based test to identify and enroll specific patients in a clinical trial), regulatory approval of a companion diagnostic to our therapeutic product candidate may be required as a condition to regulatory approval of the therapeutic product candidate. We may need to rely on third parties to provide companion diagnostics for use with our product candidates. Such third parties may be unable or unwilling on terms acceptable to us to provide such companion diagnostics or to obtain timely regulatory approval of or product labeling updates for such companion diagnostics, which could negatively impact regulatory approval of our product candidates or may result in increased development costs or delays.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require us to conduct additional clinical trials after granting approval of a product. The FDA has the explicit authority to require post-marketing studies (also referred to as post-approval or Phase 4 studies), labeling changes based on new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety information, and compliance with FDA-approved risk evaluation and mitigation strategies. Post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other data about our marketed products (or data about products similar to our marketed products that implicate an entire class of products or are perceived to do so) may result in changes in product labeling, restrictions on use, product withdrawal or recall, loss of approval, or lower sales of our products. Obligations equivalent in scope, but which can vary widely in application, apply in foreign countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the FDA policies under the Prescription Drug User Fee Act, the FDA system of review times for new drugs includes standard review and priority review. The FDA's goal for a standard review is to review the application within a 10-month time frame from the time the application is filed by the FDA (filing date), which typically occurs approximately 60 days following submission of the application by the applicant. The FDA has stated the goal to act on 90% of standard new molecular entity ("NME") New Drug Application ("NDA") and original BLA submissions within 10 months of the filing date. A priority review designation is given to drugs that treat a serious condition and offer major advances in treatment, or provide a treatment where no adequate therapy exists, and may also be afforded to a human drug application based on a priority review voucher. The FDA has stated the goal to act on 90% of priority NME NDA and original BLA submissions within six months of the filing date. However, the FDA's review goals are subject to change and the duration of the FDA's review depends on a number of factors, including the number and types of other applications that are submitted to the FDA around the same time period or are pending, and may be delayed for reasons beyond our control. For example, an FDA travel complication related to scheduling a routine clinical trial site inspection in eastern Europe recently delayed the FDA's approval of our sBLA for the combination treatment of Libtayo with chemotherapy in NSCLC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we believe we meet eligibility requirements, we may apply for various regulatory incentives in the United States, such as breakthrough therapy designation, fast track designation, accelerated approval, or priority review, where available, that serve to expedite drug development and/or review, and we may also seek similar designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not product candidates qualify for such regulatory incentives and benefits, and we cannot guarantee we would be successful in obtaining beneficial regulatory designations by the FDA or other regulatory agencies. Even if obtained, such designations may not result in faster development processes, reviews, or approvals compared to drugs considered for approval under conventional FDA procedures. In addition, the FDA may later decide that any of our development programs no longer meets the conditions for a beneficial regulatory designation (including due to factors beyond our control, such as intervening competitive developments) or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities enforce GCPs and other regulations and legal requirements through periodic inspections of trial sponsors, clinical research organizations ("CROs"), principal investigators, and trial sites. If we or any of the third parties conducting our clinical studies are determined to have failed to fully comply with GCPs, the study protocol or applicable regulations, the clinical data generated in those studies may be deemed unreliable. This and similar instances of non-compliance with GCPs could result in non-approval of our product candidates by the FDA or foreign regulatory authorities such as the EC, or we or the FDA or such other regulatory authorities may decide to conduct additional inspections or require additional clinical studies, which would delay our development programs, require us to incur additional costs, and could substantially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a new drug or biologic product, the FDA and such comparable foreign regulatory authorities require that the facilities at which the product will be manufactured or advanced through the supply chain be in compliance with current Good Manufacturing Practices, or cGMP, requirements and regulations governing the manufacture, shipment, and storage of the product. Additionally, manufacturers of biological products and their facilities are subject to payment of substantial user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and adherence to any commitments made in the applicable BLA. These cGMP requirements and regulations are not prescriptive instructions on how to manufacture products, but rather a series of principles that must be observed during manufacturing; as a result, their implementation may not be clearly delineated and may present a challenging task. Manufacturing product candidates in compliance with these regulatory requirements is complex, time-consuming, and expensive. To be successful, our products must be manufactured in compliance with regulatory requirements, and at competitive costs. If we or any of our third-party manufacturers, product packagers, labelers, or other parties performing steps in the supply chain are unable to maintain regulatory compliance with cGMP, the FDA and comparable foreign regulatory authorities can impose monetary penalties or other civil or criminal sanctions, including, among other things, refusal to approve a pending application for a new drug or biologic product, or revocation of a pre-existing approval. For additional information, see "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Our business, prospects, operating results, and financial condition may be materially harmed as a result of noncompliance with the requirements and regulations described in this paragraph.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to ongoing requirements imposed by the FDA and comparable foreign regulatory authorities governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping, and reporting of safety and other post-marketing information. The holder of an approved BLA or foreign equivalent is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA or foreign equivalent must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Advertising and promotional materials must comply with FDA regulations and those of foreign regulatory authorities and may be subject to other potentially applicable federal and state laws. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the standard drug approval process, the Secretary of HHS may authorize the issuance of, and the FDA Commissioner may issue, an EUA to allow an unapproved medical product to be used in an emergency based on criteria established by the Food, Drug, and Cosmetic Act, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA terminates when the emergency determination underlying the EUA terminates. The FDA may also revoke, revise, or restrict an EUA for a variety of reasons, including where it is determined that the underlying health emergency no longer exists or warrants such authorization or the medical product is no longer effective in diagnosing, treating, or preventing the underlying health emergency. For example, in January 2022, the FDA revised the EUA previously granted for REGEN-COV to exclude its use in geographic regions (currently including all U.S. states, territories, and jurisdictions) where, based on available information including variant susceptibility and regional variant frequency, infection or exposure is likely due to a variant such as an Omicron-lineage variant that is not susceptible to the treatment. Any such termination, revocation, or revision of an EUA could adversely impact our business in a variety of ways, including by having to absorb related manufacturing and overhead costs as well as potential inventory write-offs if regulatory approval is not obtained timely or at all. For example, we have recorded a charge to write down inventory related to REGEN-COV as described in Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FDA and other regulatory agency regulations in the United States, we are subject to a variety of foreign regulatory requirements governing human clinical trials, manufacturing, marketing and approval of drugs, and commercial sale and distribution of drugs in foreign countries. The foreign regulatory approval process is similarly a lengthy and expensive process, the result of which is highly uncertain, and foreign regulatory requirements include all of the risks associated with FDA approval as well as country specific regulations. We and our collaborators must maintain regulatory compliance for the products we or they commercialize in foreign jurisdictions.&#160;From time to time, we may hold a product's marketing approval in a jurisdiction outside the United States where we may have less experience and where our regulatory capabilities may be more limited.&#160;In addition, actions by a regulatory agency in a country or region with respect to a product candidate may have an impact on the approval process for that product candidate in another country or region. Foreign regulatory authorities may ask for additional data in order to begin a clinical study, including Phase 3 clinical trials required to submit a Marketing Authorization Application ("MAA") in the EU. In addition, such authorities often have the authority to require post-approval studies, such as a PASS and/or PAES, which involve various risks similar to those described above. Whether or not we obtain FDA approval for a product in the United States, we must obtain approval of the product by the comparable regulatory authorities in foreign countries before we can market that product or any other product in those countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are subject to pharmacovigilance reporting and other pharmacovigilance requirements, which may differ in the numerous countries in which we conduct clinical trials. Failure to comply with any such requirements may result in the premature closure of the clinical trials and other enforcement actions by the relevant regulatory authorities. For example, if we do not manage to retain a QPPV, to maintain a PSMF, or to comply with other pharmacovigilance obligations in the EEA, we may be at risk of our clinical trials being closed prematurely, our marketing authorization being suspended, and we may be subject to other enforcement actions by the national competent authorities of the EEA or the EC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical studies required for our product candidates and new indications of our marketed products are expensive and time-consuming, and their outcome is highly uncertain. If any such studies are delayed or yield unfavorable results, regulatory approval for our product candidates or new indications of our marketed products may be delayed or become unobtainable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we must conduct extensive testing of our product candidates and new indications of our marketed products before we can obtain regulatory approval to market and sell them. We need to conduct both preclinical animal testing and human clinical trials. Conducting such studies is a lengthy, time-consuming, and expensive process. These tests and trials may not achieve favorable results for many reasons, including, among others, failure of the product candidate to demonstrate safety or efficacy, the development of serious or life-threatening adverse events (or side effects) caused by or connected with exposure to the product candidate (or prior or concurrent exposure to other products or product candidates), difficulty in enrolling and maintaining subjects in a clinical trial, clinical trial design that may not make it possible to enroll or retain a sufficient number of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients to achieve a statistically significant result or the desired level of statistical significance for the endpoint in question, lack of sufficient supplies of the product candidate or comparator drug, and the failure of clinical investigators, trial monitors, contractors, consultants, or trial subjects to comply with the trial plan, protocol, or applicable regulations related to the FDA's GLPs or GCPs. A clinical trial may also fail because the dose(s) of the investigational drug included in the trial were either too low or too high to determine the optimal effect of the investigational drug in the disease setting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, conducting clinical trials in foreign countries presents additional risks, including political and economic risks that are not present in the United States, such as armed conflict and economic embargoes or boycotts. For example, we and our collaborators are currently conducting and may in the future conduct or initiate clinical trials with sites in Russia and/or Ukraine. While we currently do not expect the conflict between Russia and Ukraine and related developments to have a significant impact on our ability to obtain results from clinical trials conducted by us or our collaborators, actions taken by Russia or potentially other countries in Ukraine and surrounding areas may adversely affect our ability to adequately conduct certain clinical trials and maintain compliance with relevant protocols due to, among other reasons, the prioritization of hospital resources away from clinical trials, reallocation or evacuation of site staff and subjects, or as a result of government-imposed curfews, warfare, violence, or other governmental action or other events that restrict movement. These developments may also result in our inability to access sites for monitoring or to obtain data from affected sites or patients going forward. We could also experience disruptions in our supply chain or limits to our ability to provide sufficient investigational materials in Ukraine and surrounding regions. Clinical trial sites may suspend or terminate the trials being conducted and patients could be forced to evacuate or choose to relocate, making them unavailable for initial or further participation in such trials. Alternative sites in these areas may not be available and we may need to find other countries to conduct the relevant trials. Furthermore, military action may prevent the FDA or other regulatory agencies from inspecting clinical sites in these countries. Such interruptions may delay our plans for clinical development and approvals for our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to reevaluate any drug candidate that does not test favorably and either conduct new studies, which are expensive and time consuming, or abandon that drug development program. If preclinical testing yields unfavorable results, product candidates may not advance to clinical trials. The failure of clinical trials to demonstrate the safety and effectiveness of our clinical candidates for the desired indication(s) would preclude the successful development of those candidates for such indication(s), in which event our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, some of our products and product candidates (such as Libtayo) are studied in combination with agents and treatments developed by us or our collaborators. There may be additional risks and unforeseen safety issues resulting from such combined administration, any of which may materially adversely impact clinical development of these product candidates and our ability to obtain regulatory approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some jurisdictions such as the EU, initiating Phase 3 clinical trials and clinical trials in the pediatric population is subject to a requirement to obtain approval or a waiver from the competent authorities of the EU Member States and/or the EMA. If we do not obtain such approval, our ability to conduct clinical trials and obtain marketing authorizations or approvals may be severely impaired and our business may be adversely impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our research and development activities are conducted at our existing facilities primarily located in Tarrytown, New York. As we continue to expand, we may lease, operate, purchase, or construct additional facilities to expand our research and development capabilities in the future. Expanding our research and laboratory facilities may require significant time and resources. Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions. Any related delays may interfere with our research and development efforts and our business may be adversely impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful development of our current and future product candidates is uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small minority of all research and development programs ultimately result in commercially successful drugs. Clinical trials may not demonstrate statistically sufficient effectiveness and safety to obtain the requisite regulatory approvals for these product candidates in these indications. Many companies in the biopharmaceutical industry, including our Company, have suffered significant setbacks in clinical trials, even after promising results had been obtained in earlier trials. In a number of instances, we have terminated the development of product candidates due to a lack of or only modest effectiveness and/or safety concerns, and clinical trials evaluating our product candidates have failed to meet the relevant endpoints. Moreover, even if we obtain positive results from preclinical testing or clinical trials, we may not achieve the same success in future trials, or the FDA and analogous foreign regulatory authorities may deem the results insufficient for an approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our clinical trials are conducted under the oversight of Independent Data Monitoring Committees ("IDMCs"). These independent oversight bodies are made up of external experts who review the progress of ongoing clinical trials, including available safety and efficacy data, and make recommendations concerning a trial's continuation, modification, or termination based on interim, unblinded data. Any of our ongoing clinical trials may be discontinued or amended in response to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommendations made by responsible IDMCs based on their review of such interim trial results. For example, we previously discontinued actively treating patients with fasinumab following a recommendation from the responsible IDMC that the program be terminated based on available evidence to date; and we later discontinued further clinical development of fasinumab. The recommended termination or material modification of any of our ongoing late-stage clinical trials by an IDMC could negatively impact the future development of our product candidate(s), and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying our product candidates in a wide variety of indications in clinical trials. Many of these trials are exploratory studies designed to evaluate the safety profile of these compounds and to identify what diseases and uses, if any, are best suited for these product candidates. These product candidates may not demonstrate the requisite efficacy and/or safety profile to support continued development for some or all of the indications that are being, or are planned to be, studied, which would diminish our clinical "pipeline" and could negatively affect our future prospects and the value of our Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Various illnesses, injuries, and discomforts have been reported from time-to-time during clinical trials of our product candidates and new indications for our marketed products. It is possible that as we test our drug candidates or new indications in larger, longer, and more extensive clinical programs, or as use of these drugs becomes more widespread if they receive regulatory approval, illnesses, injuries, and discomforts that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients after approval. If additional clinical experience indicates that any of our product candidates or new indications for our marketed products has many side effects or causes serious or life-threatening side effects, the development of the product candidate may be delayed or fail, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to EYLEA and aflibercept 8 mg, there are many potential safety concerns associated with significant blockade of VEGF that may limit our ability to further successfully commercialize EYLEA and to obtain regulatory approval for aflibercept 8 mg. These serious and potentially life-threatening risks, based on clinical and preclinical experience of VEGF inhibitors, include bleeding, intestinal perforation, hypertension, proteinuria, congestive heart failure, heart attack, and stroke. Other VEGF blockers have reported side effects that became evident only after large-scale trials or after marketing approval when large numbers of patients were treated. There are risks inherent in the intravitreal administration of drugs like aflibercept (such as intraocular inflammation ("IOI"), sterile and culture positive endophthalmitis, corneal decomposition, retinal detachment, and retinal tear), which can cause injury to the eye and other complications. The side effects previously reported for aflibercept include conjunctival hemorrhage, macular degeneration, eye pain, retinal hemorrhage, and vitreous floaters. There is no guarantee that we will be able to successfully obtain regulatory approval for aflibercept 8 mg. In addition, commercialization of EYLEA or our other products and potential future commercialization of aflibercept 8 mg or our other product candidates may be impacted by actions of third parties on which we rely, such as manufacturers of syringes or other devices used in the administration of our products. These and other complications or issues or side effects could harm further development and/or commercialization of EYLEA as well as further development and potential future commercialization of aflibercept 8 mg. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dupixent and Libtayo are being studied in additional indications, as shown in the table under Part I, Item 1. "Business - Programs in Clinical Development." There is no guarantee that regulatory approval of Dupixent or Libtayo (as applicable) in any of these indications will be successfully obtained. The side effects previously reported for Dupixent include hypersensitivity reactions, eye problems (including conjunctivitis and keratitis), injection-site reactions, eye and eyelid inflammation, cold sores, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, joint pain (arthralgia), parasitic (helminth) infections, and facial rash or redness; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions that may occur in any organ system or tissue, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea. These and other complications or side effects could harm further development and/or commercialization of Dupixent and Libtayo (as applicable).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also are risks inherent in subcutaneous injections (which are used for administering most of our antibody-based products and product candidates), such as injection-site reactions (including redness, itching, swelling, pain, and tenderness) and other side effects. In addition, there are risks inherent in intravenous administration (which are used for some of our antibody-based products and product candidates), such as infusion-related reactions (including nausea, pyrexia, rash, and dyspnea). These and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complications or side effects could harm further development and/or commercialization of our antibody-based products and product candidates utilizing this method of administration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our product candidates in development are recombinant proteins that could cause an immune response, resulting in the creation of harmful or neutralizing antibodies against the therapeutic protein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by our product candidates, the administration of recombinant proteins frequently causes an immune response, sometimes resulting in the creation of antibodies against the therapeutic protein. The antibodies can have no effect or can totally neutralize the effectiveness of the protein, or require that higher doses be used to obtain a therapeutic effect. In some cases, the antibody can cross-react with the patient's own proteins, resulting in an "auto-immune" type disease. Whether antibodies will be created can often not be predicted from preclinical or clinical experiments, and their detection or appearance is often delayed, so neutralizing antibodies may be detected at a later date, in some cases even after pivotal clinical trials have been completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to continue to develop suitable product formulations or manufacturing processes to support large-scale clinical testing of our product candidates, including our antibody-based product candidates, we may be unable to supply necessary materials for our clinical trials, which would delay or prevent the development of our product candidates. Similarly, if we are unable, directly or through our collaborators or third parties, to supply sufficient quantities of our products or develop formulations of our product candidates suitable for commercial use, we will be unable to obtain regulatory approval for those product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products are used and some of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system. For example, in the United States and the EU, EYLEA is approved in the 2mg pre-filled syringe. The success of our products and product candidates may depend to a significant extent on the performance of such devices, some of which may be novel or comprised of complex components. Given the increased complexity of the review process when approval of the product and device is sought under a single marketing application and the additional risks resulting from a product candidate's designation as a combination product discussed below, our product candidates used with such drug-delivery devices may be substantially delayed in receiving regulatory approval or may not be approved at all. The FDA review process and criteria for such applications are not well established, which could also lead to delays in the approval process. In addition, some of these drug-delivery devices may be provided by single-source, third-party providers or our collaborators. In any such case, we may be dependent on the sustained cooperation of those third-party providers or collaborators to supply and manufacture the devices; to conduct the studies and prepare related documentation required for approval or clearance by the applicable regulatory agencies; and to continue to meet the applicable regulatory and other requirements to maintain approval or clearance once it has been received. In addition, other parties may allege that our drug-delivery devices infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 16 to our Consolidated Financial Statements. Failure to successfully develop or supply the devices, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or the third-party providers to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in a product or product candidate reaching the market. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop or supply and manufacture these devices, or to gain or maintain their approval, could adversely affect sales of the related products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug, biologic, or device. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Although a single marketing application is generally sufficient for the approval, clearance, or licensure of a combination product, the FDA may determine that separate marketing applications are necessary. In addition, submitting separate marketing applications may be necessary to receive some benefit that accrues only from approval under a particular type of application. This could significantly increase the resources and time required to bring a particular combination product to market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property and Market Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this subsection, references to our intellectual property (including patents, trademarks, copyrights, and trade secrets) include that of our collaborators and licensees, unless otherwise stated or required by the context.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires using sensitive and proprietary technology and other information that we protect as trade secrets. We seek to prevent improper disclosure of these trade secrets through confidentiality agreements and other means. If our trade secrets are improperly disclosed, by our current or former employees, our collaborators, or otherwise, it could help our competitors and adversely affect our business. We will be able to protect our proprietary rights only to the extent that our proprietary technologies and other information are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of biotechnology companies, including our Company, involves complex legal and factual questions and, therefore, enforceability cannot be predicted with certainty. Our patents may be challenged, invalidated, held to be unenforceable, or circumvented. For example, certain of our U.S. patents (including those pertaining to our key products, such as EYLEA) have been and may in the future be challenged by parties who file a request for post-grant review or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review under the America Invents Act of 2011 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination, as described in Note 16 to our Consolidated Financial Statements included in this report. Post-grant proceedings are increasingly common in the United States and are costly to defend. In addition, patent applications filed outside the United States may be challenged by other parties, for example, by filing pre-grant third-party observations that argue against patentability or a post-grant opposition. Such opposition proceedings are increasingly common in Europe and are costly to defend. For example, in 2021, anonymous parties initiated opposition proceedings in the European Patent Office ("EPO") against our European Patent No. 2,944,306 (which concerns pre-filled syringes comprising ophthalmic formulations containing VEGF antagonists such as aflibercept for intravitreal administration), as described in Note 16 to our Consolidated Financial Statements included in this report. We have pending patent applications in the United States Patent and Trademark Office (the "USPTO"), the EPO, and the patent offices of other foreign jurisdictions, and it is likely that we will need to defend patents from challenges by others from time to time in the future. Our patent rights may not provide us with a proprietary position or competitive advantages against competitors. Furthermore, even if the outcome is favorable to us, the enforcement of our intellectual property rights can be extremely expensive and time consuming.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions or our ability to obtain, maintain, and enforce our intellectual property rights. Any such changes could also affect the value of our intellectual property or narrow the scope of our patents. For example, the World Trade Organization ("WTO") is currently considering an extension of a recently adopted waiver of certain intellectual property rights under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights for COVID-19 vaccines to include therapeutics. The timing of a decision on whether or not to extend the waiver is unknown. We cannot be certain that our intellectual property rights related to our COVID-19 monoclonal antibodies or any other current or future product or product candidate or technology would not be eliminated, narrowed, or weakened by any such extension or other rulemaking.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the United States and other government actions related to Russia's invasion of Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. Further, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patent holders from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also currently hold issued trademark registrations and have trademark applications pending in the United States and other jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our&#160;trademarks&#160;to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering, or using&#160;trademarks that infringe, dilute or otherwise violate our trademark rights, our business could be adversely affected.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of others (including those relating to trademarks, copyrights, and trade secrets). Other parties may allege that they own blocking patents to our products in clinical development or even to products that have received regulatory approval and are being or have been commercialized, either because they claim to hold proprietary rights to the composition of a product or the way it is manufactured or the way it is used. Moreover, other parties may allege that they have blocking patents to antibody-based products </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made using our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, or any other of our technologies, either because of the way the antibodies are discovered or produced or because of a proprietary composition covering an antibody or the antibody's target.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been in the past, are currently, and may in the future be involved in patent litigation and other proceedings involving patents and other intellectual property. For example, we and/or Sanofi are currently party to patent infringement proceedings initiated by Amgen against us and/or Sanofi relating to Praluent, as described in Note 16 to our Consolidated Financial Statements. In addition, we are currently party to patent infringement and other proceedings relating to EYLEA and REGEN-COV, as described in Note 16 to our Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and pending patent applications owned by others that claim compositions and methods of treatment relating to targets and conditions that we are also pursuing with our products and/or product candidates. Although we do not believe that any of our products or our late-stage antibody-based product candidates infringe any valid claim in these patents or patent applications,</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these other parties could initiate lawsuits for patent infringement and assert that their patents are valid and cover our products or our late-stage antibody-based product candidates, similar to the patent infringement proceedings referred to above. Further, we are aware of a number of patent applications of others that, if granted with claims as currently drafted, may cover our current or planned activities. It could be determined that our products and/or actions in manufacturing or selling our products or product candidates infringe such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent holders could assert claims against us for damages and seek to prevent us from manufacturing, selling, or developing our products or product candidates, and a court may find that we are infringing validly issued patents of others. In the event that the manufacture, use, or sale of any of our products or product candidates infringes on the patents or violates other proprietary rights of others, we may be prevented from pursuing product development, manufacturing, and commercialization of those drugs and may be required to pay costly damages. In addition, in the event that we assert our patent rights against other parties that we believe are infringing our patent rights, such parties may challenge the validity of our patents and we may become the target of litigation, which may result in an outcome that is unfavorable to us. Any of these adverse developments may materially harm our business, prospects, operating results, and financial condition. In any event, legal disputes are likely to be costly and time consuming to defend.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to obtain licenses to patents when, in our judgment, such licenses are needed or advisable. For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb &amp; Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo. If any licenses are required, we may not be able to obtain such licenses on commercially reasonable terms, if at all. The failure to obtain any such license could prevent us from developing or commercializing any one or more of our products or product candidates, which could severely harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other parties may have regulatory exclusivity in the United States or foreign jurisdictions for products relating to targets or conditions we are also pursuing, which could prevent or delay our ability to apply for or obtain regulatory approval for our product candidates in such jurisdictions. For example, in the EU, a designated orphan drug is provided up to 10 years of market exclusivity in the orphan indication, during which time the EMA is generally precluded from accepting a MAA for a similar medicinal product unless it can be demonstrated that it is safer, more effective, or otherwise clinically superior to the original orphan medicinal product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical and biotechnology industries, the majority of an innovative product's commercial value is usually realized during the period in which it has market exclusivity. In the United States and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there usually are very substantial and rapid declines in the product's sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our late-stage product candidates or other clinical candidates are approved for marketing in the United States or elsewhere, market exclusivity for those products will generally be based upon patent rights and/or certain regulatory forms of exclusivity. As described above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" the scope and enforceability of our patent rights may vary from country to country. The failure to obtain patent and other intellectual property rights, or limitations on the use, or the loss, of such rights could materially harm us. Absent patent protection or regulatory exclusivity for our products, it is possible, both in the United States and elsewhere, that generic, biosimilar, and/or interchangeable versions of those products may be approved and marketed, which would likely result in substantial and rapid reductions in revenues from sales of those products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PPACA, there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-approved biological product. The PPACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened if, for example, the PPACA is amended.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the EU has had an established regulatory pathway for biosimilars since 2005.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increased likelihood of biosimilar competition has increased the risk of loss of innovators' market exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. Due to this risk, and uncertainties regarding patent protection, it is not possible to predict the length of market exclusivity for any particular product we currently or may in the future commercialize with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. We are aware of several companies developing biosimilar versions of EYLEA, as discussed further under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" above. In the United States, the regulatory exclusivity period for EYLEA (i.e., the period during which no biosimilar product can be approved by the FDA) extends through May 17, 2024 following the pediatric exclusivity granted by the FDA. The loss of market exclusivity for a product (such as EYLEA) would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing and Supply</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our marketed products and, if approved, our product candidates and to advance our clinical pipeline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have large-scale manufacturing operations in Rensselaer, New York and Limerick, Ireland. Manufacturing facilities operated by us and by third-party contract manufacturers engaged by us would be inadequate to produce the active pharmaceutical ingredients of our current marketed products and our product candidates in sufficient clinical quantities if our clinical pipeline advances as planned. In addition to expanding our internal capacity, we intend to continue to rely on our collaborators, and may also rely on contract manufacturers, to produce commercial quantities of drug material needed for commercialization of our products. For example, as described in Part I, Item 1. "Business," in 2020, we entered into a collaboration agreement with Roche to develop, manufacture, and distribute REGEN-COV (known as Ronapreve in other countries outside the United States). As we increase our production in anticipation of potential regulatory approval for our product candidates, our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes. The COVID-19 pandemic has exacerbated and may in the future further exacerbate certain of these risks. For example, the impact of prioritizing certain manufacturing-related resources for our COVID-19 monoclonal antibodies has included and may in the future include, among other things, drawing down inventory safety stock levels for certain of our other products (including Dupixent and EYLEA). Depending on the demand for our products (including any future demand for our COVID-19 monoclonal antibodies), our ability to re-establish successfully our customary manufacturing cadence, and other relevant factors, we may not be able to replenish our inventory safety stock to the levels we deem prudent or supply our products and product candidates in sufficient quantities to satisfy our commercial and development needs. We also rely entirely on other parties and our collaborators for filling and finishing services. Generally, in order for other parties to perform any step in the manufacturing and supply chain, we must transfer technology to the other party, which can be time consuming and may not be successfully accomplished without considerable cost and expense, or at all. We will have to depend on these other parties to perform effectively on a timely basis and to comply with regulatory requirements. If for any reason they are unable to do so, and as a result we are unable to directly or through other parties manufacture and supply sufficient commercial and clinical quantities of our products on acceptable terms, or if we should encounter delays or other difficulties with our collaborators, contract manufacturers, warehouses, shipping, testing laboratories, or other parties involved in our supply chain which adversely affect the timely manufacture and supply of our products or product candidates, our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our marketed products and product candidates or other indications for our marketed products if they are approved for marketing and could jeopardize our current and future clinical development programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing manufacturing facilities in Rensselaer, New York and Limerick, Ireland, we may lease, operate, purchase, or construct additional facilities to conduct expanded manufacturing or other related activities in the future. Expanding our manufacturing capacity to supply commercial quantities of the active pharmaceutical ingredients for our marketed products and our product candidates if they are approved for marketing, and to supply clinical drug material to support the continued growth of our clinical programs, will require substantial additional expenditures, time, and various regulatory approvals and permits. This also holds true for establishing fill/finish capabilities in the future, for which we are in the process of constructing fill/finish facilities (refer to Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources" for information about expected capital expenditures relating to this and other projects). In addition, we may need to develop or acquire additional manufacturing capabilities to the extent we or our collaborators pursue the development of drugs generated by means other than our existing "Trap" or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies, such as siRNA gene silencing, genome editing, and targeted viral-based gene delivery and expression. Further, we will need to hire and train significant numbers of employees and managerial personnel to staff our expanding manufacturing and supply chain operations, as well as any future fill/finish activities. Start-up costs can be large, and scale-up entails significant risks related to process development and manufacturing yields. In addition, we may face difficulties or delays in developing or acquiring the necessary production equipment and technology to manufacture sufficient quantities of our product candidates at reasonable costs and in compliance with applicable regulatory requirements. The FDA and analogous foreign regulatory authorities must determine that our existing and any expanded manufacturing facilities and any future fill/finish activities comply, or continue to comply, with cGMP requirements for both clinical and commercial production and license them, or continue to license them, accordingly, and such facilities must also comply with applicable environmental, safety, and other governmental permitting requirements. We may not successfully expand or establish sufficient manufacturing or any future fill/finish capabilities or manufacture our products economically or in compliance with cGMPs and other regulatory requirements, and we and our collaborators may not be able to build or procure additional capacity in the required timeframe to meet commercial demand for our product candidates if they receive regulatory approval, and to continue to meet the requirements of our clinical programs. This would interfere with our efforts to successfully commercialize our marketed products, and it could also delay or require us to discontinue one or more of our clinical development programs. As a result, our business, prospects, operating results, and financial condition could be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to manufacture products in our Rensselaer, New York and Limerick, Ireland facilities and at additional facilities (if any) in the future (including our ability to conduct any fill/finish activities in the future), the ability of our collaborators to manufacture products at their facilities, and our ability to utilize other third parties to produce our products, to supply raw materials or other products, or to perform fill/finish services or other steps in our manufacture and supply chain, depends on our and their ability to operate without infringing the patents or other intellectual property rights of others. Other parties may allege that our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain (which may be located in jurisdictions outside the United States), infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 16 to our Consolidated Financial Statements. A judicial or regulatory decision in favor of one or more parties making such allegations could directly or indirectly preclude the manufacture of our products to which those intellectual property rights apply on a temporary or permanent basis, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our manufacturing facilities primarily to produce bulk product for commercial supply of our marketed products and clinical and preclinical candidates for ourselves and our collaborations. We also plan to use such facilities to produce bulk product for commercial supply of new indications of our marketed products and new product candidates if they are approved for marketing or otherwise authorized for use. If our clinical candidates are discontinued or their clinical development is delayed, if the launch of new indications for our marketed products or new product candidates is delayed or does not occur, or if such products are launched and the launch is unsuccessful or the product is subsequently recalled or marketing approval is rescinded, we may have to absorb one hundred percent of related overhead costs and inefficiencies, as well as similar costs of third-party contract manufacturers performing services for us. In addition, if we or our collaborators experience excess inventory, it may be necessary to write down or write off such excess inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results. For example, during each of the years ended December 31, 2022 and 2021, we recorded a charge to write down inventory related to REGEN-COV as described in Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party service or supply failures, or other failures, business interruptions, or other disasters affecting our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, the manufacturing facilities of our collaborators, or the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, as well as at our collaborators' facilities. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates are very difficult to manufacture. As our products and most of our product candidates are biologics, they require processing steps that are more difficult than those required for many other chemical pharmaceuticals. Accordingly, multiple steps are needed to control the manufacturing processes. Problems with these manufacturing processes, even minor deviations from the normal process or from the materials used in the manufacturing process (which may not be detectable by us or our collaborators in a timely manner), could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims, and insufficient inventory. Also, the complexity of our manufacturing process may make it difficult, time-consuming, and expensive to transfer our technology to our collaborators or contract manufacturers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain raw materials or other products necessary for the manufacture and formulation of our marketed products and product candidates, some of which are difficult to source, are provided by single-source unaffiliated third-party suppliers. In addition, we rely on certain third parties or our collaborators to perform filling, finishing, distribution, laboratory testing, and other services related to the manufacture of our marketed products and product candidates, and to supply various raw materials and other products. We would be unable to obtain these raw materials, other products, or services for an indeterminate period of time if any of these third parties were to cease or interrupt production or otherwise fail to supply these materials, products, or services to us for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contaminations, business interruptions, or labor shortages or disputes (in each case, including as a result of the COVID-19 pandemic and Russia's invasion of Ukraine, which have exacerbated many of these issues). In any such circumstances, we may not be able to engage a backup or alternative supplier or service provider in a timely manner or at all. This, in turn, could materially and adversely affect our or our collaborators' ability to manufacture or supply marketed products and product candidates, which could materially and adversely affect our business and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin. There are certain regulatory restrictions on using these biological source materials. If we or our collaborators are required to substitute for these sources to comply with such regulatory requirements, our clinical development or commercial activities may be delayed or interrupted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators and other third-party providers are required to maintain compliance with cGMPs, and are subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm such compliance. Changes of suppliers or modifications of methods of manufacturing may require amending our application(s) to the FDA or such comparable foreign agencies and acceptance of the change by the FDA or such comparable foreign agencies prior to release of product(s). Because we produce multiple products and product candidates at our facilities in Rensselaer, New York and Limerick, Ireland, there are increased risks associated with cGMP compliance. Our inability, or the inability of our collaborators and third-party fill/finish or other service providers, to demonstrate ongoing cGMP compliance could require us to engage in lengthy and expensive remediation efforts, withdraw or recall product, halt or interrupt clinical trials, and/or interrupt commercial supply of any marketed products, and could also delay or prevent our obtaining regulatory approval for our product candidates or new indications for our marketed products. Any delay, interruption, or other issue that arises in the manufacture, fill/finish, packaging, or storage of any drug product or product candidate as a result of a failure of our facilities or the facilities or operations of our collaborators or other third parties to pass any regulatory agency inspection or maintain cGMP compliance could significantly impair our ability to develop, obtain approval for, and successfully commercialize our products, which would substantially harm our business, prospects, operating results, and financial condition. Any finding of non-compliance could also increase our costs, cause us to delay the development of our product candidates, result in delay in our obtaining, or our not obtaining, regulatory approval of product candidates or new indications for our marketed products, and cause us to lose revenue from any marketed products, which could be seriously detrimental to our business, prospects, operating results, and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacturing, marketing, and sale of drugs for use in people expose us to product liability risk. Any informed consent or waivers obtained from people who enroll in our clinical trials may not protect us from liability or the cost of litigation. We may also be subject to claims by patients who use our approved products, or our product candidates if those product candidates receive regulatory approval and become commercially available, that they have been injured by a side effect associated with the drug. Even in a circumstance in which we do not believe that an adverse event is related to our products or product candidates, the related investigation may be time consuming or inconclusive and may have a negative impact on our reputation or business. We may face product liability claims and be found responsible even if injury arises from the acts or omissions of third parties who provide fill/finish or other services. To the extent we maintain product liability insurance in relevant periods, such insurance may not cover all potential liabilities or may not completely cover any liability arising from any such litigation. Moreover, in the future we may not have access to liability insurance or be able to maintain our insurance on acceptable terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the marketing and promotion of our products, which must comply with the Food, Drug, and Cosmetic Act and applicable FDA implementing standards. The FDA's review of promotional activities includes healthcare provider-directed and direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and sales representatives' communications. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug. Any such failures could also cause significant reputational harm. The FDA may take enforcement action for promoting unapproved uses of a product or other violations of its advertising laws and regulations. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA and related regulatory requirements, we are subject to health care "fraud and abuse" laws, such as the federal civil False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. The U.S. federal healthcare program anti-kickback statute (the "AKS") prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving payments or other remuneration, directly or indirectly, to induce or reward someone to purchase, prescribe, endorse, arrange for, or recommend a product or service that is reimbursed under federal healthcare programs such as Medicare or Medicaid. If we provide payments or other remuneration to a healthcare professional to induce the prescribing of our products, we could face liability under state and federal anti-kickback laws. The Bipartisan Budget Act of 2018 has increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the federal anti-kickback statute.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The False Claims Act also permits a private individual acting as a "whistleblower" to bring actions on behalf of the federal government alleging violations of the statute and to share in any monetary recovery. Pharmaceutical companies have been investigated and/or prosecuted under these laws for a variety of alleged promotional and marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in promotion for uses that the FDA has not approved, known as off-label uses, that caused claims to be submitted to Medicaid for non-covered off-label uses; and submitting inflated best price information to the Medicaid Rebate program. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal fraud and false statement statutes that extend to non-government health benefit programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, damages, exclusion of a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for individuals and the curtailment or restructuring of operations. Even if it is determined that we have not violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which would harm our business, prospects, operating results, and financial condition. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be challenged under one or more of such laws. As described further in Note 16 to our Consolidated Financial Statements included in this report, we are party to civil litigation initiated in 2020 by the U.S. Attorney's Office for the District of Massachusetts concerning our support of a 501(c)(3) organization that provides financial assistance to patients; and we are cooperating with pending government investigations concerning certain other business activities. Any adverse decision, finding, allegation, or exercise of enforcement or regulatory discretion in any such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings or investigations could harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the PPACA, the federal government requires that pharmaceutical manufacturers record any "transfers of value" made to U.S. licensed physicians and teaching hospitals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as ownership and investment interests held by physicians and their immediate family members. Information provided by companies is aggregated and posted annually on an "Open Payments" website, which is managed by CMS, the agency responsible for implementing these disclosure requirements. Applicable manufacturers also are required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives. We also have similar reporting obligations in other countries based on laws, regulations, and/or industry trade association requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to dedicate significant resources to comply with these requirements and need to be prepared to comply with additional reporting obligations outside the United States that may apply in the future. In addition, several states have legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities; restrict when pharmaceutical companies may provide meals or gifts to prescribers or engage in other marketing-related activities; require identification or licensing of sales representatives; and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Many of these requirements and standards are new or uncertain, and the penalties for failure to comply with these requirements may be unclear. If we are found not to be in full compliance with these laws, we could face enforcement actions, fines, and other penalties, and could receive adverse publicity, which would harm our business, prospects, operating results, and financial condition. Additionally, access to such data by fraud-and-abuse investigators and industry critics may draw scrutiny to our collaborations with reported entities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate program, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Health Service's 340B drug pricing program (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"340B program") (which is administered by the Health Resources and Services Administration ("HRSA")), the U.S. Department of Veterans Affairs ("VA") Federal Supply Schedule ("FSS") pricing program, and the Tricare Retail Pharmacy Program. See Part I, Item 1, "Business - Government Regulation - Pricing and Reimbursement" for a description of these programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. Such interpretation can change and evolve over time. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate our Medicaid drug rebate agreement, or HRSA could decide to terminate our 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively impact our financial results. The final regulation governing the Medicaid Drug Rebate program issued by CMS has increased and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we have taken in our implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program may have a similar impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the final regulation issued by HRSA regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities has affected our obligations and potential liability under the 340B program. We are also required to report the 340B ceiling prices for our covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that we have violated the requirements of the program or the regulation could negatively impact our financial results. Moreover, under a final regulation effective January 13, 2021, HRSA established an ADR process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. On November 30, 2022, HRSA issued a notice of proposed rulemaking that proposes several changes to the ADR process. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the PPACA or otherwise could affect our 340B ceiling price calculations and negatively impact our results of operations.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obligations to report the average sales price for certain of our drugs to the Medicare program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2023, manufacturers must pay refunds to Medicare for single-source drugs or biological products, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract&#8209;based requirements under the VA/FSS and/or Tricare programs can subject a manufacturer to civil monetary penalties. These program and contract-based obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our business activities outside the United States (which have recently increased, and are expected to continue to increase, due to, in part, our efforts to establish our commercialization and co-commercialization capabilities in certain jurisdictions outside the United States) are subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to expand internationally, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated biotechnology company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, infectious agents (such as viruses, bacteria, and fungi), radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations that could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changing rules and regulations of various federal and state governmental authorities as well as the stock exchange on which our Common Stock is listed. These entities, including the SEC and The NASDAQ Stock Market LLC, have issued a significant number of new and increasingly complex requirements and regulations over the course of the last several years and continue to develop additional requirements and regulations. For example, in March 2022, the SEC proposed new rules for extensive and prescriptive climate-related disclosure in annual reports and registration statements, which would also require inclusion of certain climate-related financial metrics in companies' audited financial statements. Also in March 2022, the SEC proposed rules that are intended to enhance and standardize disclosures regarding cybersecurity risk management, strategy, and governance, as well as cybersecurity incident reporting, by public companies. Our efforts to comply with these requirements and regulations (as well as corporate governance and disclosure expectations of investors and other stakeholders) have resulted in, and are likely to continue to result in, an increase in expenses and a diversion of management's time from other business activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of our business, including research and development, manufacturing, marketing, pricing, sales, intellectual property rights, and the framework for dispute resolution and asserting our rights against others, are subject to extensive legislation and regulation. Changes in applicable federal and state laws and agency regulations could have a materially negative impact on our business. These include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the FDA and foreign regulatory processes for new therapeutics that may delay or prevent the approval of any of our current or future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new laws, regulations, or judicial decisions related to healthcare availability or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign cGMP requirements that may make it more difficult and costly for us to maintain regulatory compliance and/or manufacture our marketed product and product candidates in accordance with cGMPs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, the PPACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal or state governments could carry out other significant changes in legislation, regulation, or government policy, including with respect to government reimbursement changes or drug price control measures (such as those discussed above under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") or the PPACA or other healthcare reform laws. While it is not possible to predict whether and when any such changes will occur, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our products could adversely affect our business. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA. For example, a prolonged shutdown may significantly delay the FDA's ability to timely review and process any submissions we have filed or may file or cause other regulatory delays, which could materially and adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with our operations outside the United States could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and conduct business in several countries outside the United States and we plan to expand these activities. For example, as discussed above, we perform co-commercialization activities under the Antibody Collaboration related to Dupixent in certain jurisdictions outside the United States and we will need to establish commercial capabilities related to Libtayo in certain markets outside the United States following the amendment to the IO Collaboration. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries, and many of these risks will increase as we expand our activities in such jurisdictions. These risks include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfamiliar foreign laws or regulatory requirements or unexpected changes to those laws or requirements, including those with which we and/or our collaborators must comply in order to maintain our marketing authorizations outside the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other laws and regulatory and industry trade association requirements to which our business activities abroad are subject, such as the FCPA and the U.K. Bribery Act (discussed in greater detail above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">");</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the political or economic condition of a specific country or region, including as a result of Russia's invasion of Ukraine;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the value of foreign currency versus the U.S. dollar;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs, trade protection measures, import or export licensing requirements, trade embargoes, and sanctions (including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury), and other trade barriers; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in attracting and retaining qualified personnel; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in the conduct of business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have large-scale manufacturing operations in Limerick, Ireland and have also established offices in the United Kingdom, Germany, and other countries outside the United States. Changes impacting our ability to conduct business in the those countries, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or changes to the regulatory regime applicable to our operations in those countries (such as with respect to the approval of our product candidates), may materially and adversely impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional tax liabilities related to our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in the United States and various foreign jurisdictions. Significant judgment is required in determining our worldwide tax liabilities, and our effective tax rate is derived from a combination of the applicable statutory rates in the various jurisdictions in which we operate. We record liabilities for uncertain tax positions that involve significant management judgment as to the application of law. The Internal Revenue Service or other domestic or foreign taxing authorities have previously disagreed, and may in the future disagree, with our interpretation of tax law as applied to the operations of Regeneron and its subsidiaries or with the positions we may take with respect to particular tax issues on our tax returns (see also Note 15 to our Consolidated Financial Statements included in this report). Consequently, our reported effective tax rate and our after-tax cash flows may be materially and adversely affected by tax assessments or judgments in excess of accrued amounts we have estimated in preparing our financial statements. Further, our effective tax rate may also be adversely affected by numerous other factors, including changes in the mix of our profitability from country to country, changes in tax laws and regulations, and tax effects of the accounting for stock-based compensation (which depend in part on the price of our stock and, therefore, are beyond our control). For example, the IRA has created a new corporate alternative minimum tax of 15% on adjusted financial statement income that applies to certain corporations for tax years beginning after December 31, 2022. Further specifics of this legislation will be outlined in Treasury regulations and any impact to the Company will depend on a number of factors, including any offsets for foreign tax credits or general business credits. The IRA also created an excise tax of 1% of the value of certain stock repurchases after December 31, 2022 that generally applies to publicly traded domestic corporations. We are in the process of evaluating the potential impact of these alternative minimum and excise tax provisions of the IRA. Other changes to U.S. tax laws and/or recommendations from the Organization for Economic Co-operation and Development (the "OECD") regarding a global minimum tax and other changes being considered and/or implemented in countries where we operate could materially impact our tax provision, cash tax liability, and effective tax rate. In addition, recommendations by the OECD and the EU could require companies to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny. Even though we regularly assess the information provided to tax authorities in determining the appropriateness of our tax reserves, such tax authorities could take a position that is contrary to our expectations, and the result could adversely affect our provision for income tax and our current rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to the personal data we collect, process, and share.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to conduct our business is significantly dependent on the data that we collect, process, and share in discovering, developing, and commercializing drug products. These data are often considered personal data and are therefore regulated by data privacy laws in applicable jurisdictions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities outside the U.S., including clinical trial programs and research collaborations (such as our consortium with a group of companies to fund the generation of genetic exome sequence data from the UK Biobank health resource), implicate non-U.S. data protection laws, including the EU's General Data Protection Regulations ("GDPR"). The GDPR has a wide range of compliance obligations, including increased transparency requirements and data subject rights. Violations of the GDPR carry significant financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher)). In addition to the GDPR, certain EU Member States have issued or will be issuing their own implementation legislation. In June 2021, the European Commission introduced new standard contractual clauses required to be incorporated into certain new and existing agreements within prescribed timeframes in order to continue to lawfully transfer personal data outside the EU. Compliance with these requirements has been and is expected to continue to be costly and time consuming.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct clinical trials in many countries around the world, which have new or evolving data privacy laws that have resulted in increased liability in the management of clinical trial data, and additional contractual and due-diligence obligations that could lead to a delay in clinical trial site start-up. There is an increase of enforcement activities in various EU countries that require evidence of compliance with local data privacy requirements. While we continue to monitor these developments, there remains some uncertainty surrounding the legal and regulatory environment for these evolving privacy and data protection laws. Complying with varying jurisdictional requirements could increase the costs and complexity of compliance, including the risk of substantial financial penalties for insufficient notice and consent, failure to respond to data subject rights requests, lack of a legal basis for the transfer of personal information out of the EU, or improper processing of personal data under the GDPR. Failure by our collaborators to comply with the strict rules on the transfer of personal data outside the EU into the U.S. may result in the imposition of criminal and administrative sanctions on such collaborators or impact the flow of personal data outside the EU, which could adversely affect our business and could create liability for us. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most U.S. health care providers, including research institutions from which we or our collaborators obtain clinical trial data, are subject to privacy and security regulations promulgated under HIPAA. For example, as part of our human genetics initiative, our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wholly-owned subsidiary, Regeneron Genetics Center LLC, has entered into collaborations with many research institutions, which are subject to HIPAA. Regeneron is not a covered entity or business associate under HIPAA and thus is not subject to its requirements. However, we could be subject to criminal penalties if we, our affiliates, or our agents knowingly receive PHI in a manner that is not permitted under HIPAA. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive PHI from a health care provider or research institution that has not satisfied HIPAA's requirements for its disclosure. There are instances where we collect and maintain personal data, which may include health information that is outside the scope of HIPAA but within the scope of state health privacy laws or similar state level privacy legislation. This information may be received throughout the clinical trial process, in the course of our research collaborations, directly from individuals who enroll in our patient assistance programs, and from our own employees in a pandemic response process (such as in connection with the COVID-19 pandemic).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer protection laws impact the manner in which we develop and maintain processes to support our patient assistance programs, product marketing activities, and the sharing of employee and clinical data for internal and third-party commercial activities. Several U.S. states have proposed and passed consumer privacy laws, which were modeled after the CCPA and influenced by the GDPR. The CCPA is a consumer protection law that establishes requirements for data use and sharing transparency and provides California residents with personal data privacy rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regarding the use, disclosure, and retention of their personal data. Amendments to the CCPA have, among other things, imposed new obligations to provide notice where personal data will be de-identified. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with data privacy incidents involving certain elements of personal data. These claims may result in significant liability and damages. These laws and regulations are constantly evolving and may impose limitations on our business activities. Several other U.S. states have introduced similar consumer protection laws, some of which are set to go into effect in the near future. At the federal level, Section 5 of the FTC Act is a consumer protection law that bars unfair and deceptive acts and practices and requires, among other things, companies to notify individuals that they will safeguard their personal data and that they will fulfil the commitments made in their privacy notices. The FTC has brought legal actions against organizations that have violated consumers' privacy rights or have misled them by failing to maintain appropriate security.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, health privacy laws, data breach notification laws, consumer protection laws, data localization laws, and genetic privacy laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals' health and other personal data. New state level genetic privacy and consumer protection laws in the United States may require additional transparency and permissions in our informed consent forms. Moreover, individuals about whom we or our collaborators obtain health or other personal data, as well as the providers and third parties who share this information with us, may have statutory or contractual limits that impact our ability to use and disclose the information. We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws both inside and outside the United States. Many of these laws differ from each other in significant ways and have different effects. Many of the state laws enable a state attorney general to bring actions and provide private rights of action to consumers as enforcement mechanisms. Compliance with these laws requires a flexible privacy framework as they are constantly evolving. Failure to comply with these laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation, and/or adverse publicity. Federal regulators, state attorneys general, and plaintiffs' attorneys have been active in this space. Claims that we have violated individuals' privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any collaborators fail to comply with applicable federal, state, local, or foreign regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators' ability to commercialize our products and could harm, prevent, or substantially increase the cost of marketing and sales of any affected products that we are able to commercialize. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is a risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal data of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on or Transactions with Third Parties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Antibody Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on support from Sanofi to develop, manufacture, and commercialize certain of our products and product candidates. With respect to the products that we are co-developing with Sanofi under our Antibody Collaboration (currently consisting of Dupixent, Kevzara, and itepekimab), Sanofi funds a significant portion of development expenses incurred in connection with the development of these products. In addition, we rely on Sanofi to lead much of the clinical development efforts, assist with or lead efforts to obtain and maintain regulatory approvals, and lead the commercialization efforts for these products and product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi terminates the Antibody Collaboration or fails to comply with its payment obligations under any of our collaborations, our business, prospects, operating results, and financial condition would be materially harmed. We would be required to either expend substantially more resources than we have anticipated to support our research and development efforts, which could require us to seek additional funding that might not be available on favorable terms or at all, or materially cut back on such activities. If Sanofi does not perform its obligations with respect to the product candidates it is co-developing with us, our ability to develop, manufacture, and commercialize these product candidates will be significantly adversely affected. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities for products commercialized under our Antibody Collaboration (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Antibody Collaboration would create substantial new and additional risks to the successful development and commercialization of the products subject to such collaborations, particularly outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on Bayer with respect to the commercialization of EYLEA outside the United States (and, if approved, will rely on Bayer with respect to any potential future commercialization of aflibercept 8 mg outside the United States, including the activities discussed below). Bayer is responsible for obtaining and maintaining regulatory approval outside the United States, as well as providing all sales, marketing, and commercial support for the product outside the United States. In particular, Bayer has responsibility for selling EYLEA outside the United States using its sales force and, in Japan, in cooperation with Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate. If Bayer and, in Japan, Santen do not perform their obligations in a timely manner, or at all, our ability to commercialize EYLEA outside the United States will be significantly adversely affected. Bayer has the right to terminate its collaboration agreement with us at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination. If Bayer were to terminate its collaboration agreement with us, we may not have the resources or skills to replace those of our collaborator, which could require us to seek another collaboration that might not be available on favorable terms or at all, and could cause significant issues for the commercialization of EYLEA outside the United States and result in substantial additional costs and/or lower revenues to us. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Bayer collaboration agreement would create substantial new and additional risks to the successful commercialization of EYLEA and, if approved, any potential future commercialization of aflibercept 8 mg outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon third-party collaborators, including Sanofi and Bayer, and service providers such as CROs, outside testing laboratories, clinical investigator sites, third-party manufacturers, fill/finish providers, and product packagers and labelers, to assist us in the manufacture and preclinical and clinical development of our product candidates. We also depend, or will depend, on some of these or other third parties in connection with the commercialization of our marketed products and our product candidates and new indications for our marketed products if they are approved for marketing. If any of our existing collaborators or service providers breaches or terminates its agreement with us or does not perform its development or manufacturing services under an agreement in a timely manner (including as a result of its inability to perform due to financial or other relevant constraints, such as due to Russia's invasion of Ukraine) or in compliance with applicable GMPs, GLPs, or GCP standards, we could experience additional costs, delays, and difficulties in the manufacture or development of, or in obtaining approval by regulatory authorities for, or successfully commercializing our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators rely on third-party service providers to support the distribution of our marketed products and for many other related activities in connection with the commercialization of these marketed products. Despite our or our collaborators' arrangements with them, these third parties may not perform adequately. If these service providers do not perform their services adequately, sales of our marketed products will suffer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have undertaken and may in the future undertake strategic acquisitions, and any difficulties from integrating such acquisitions could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire companies, businesses, products, or product candidates that complement or augment our existing business. For example, in May 2022, we completed our acquisition of Checkmate Pharmaceuticals, Inc. The process of proposing, negotiating, completing, and integrating any such acquisition is lengthy and complex. Other companies may compete with us for such acquisitions. In addition, we may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational, and financial resources, result in a loss of key personnel of the acquired business, and could prove to be more difficult or expensive than we predict. The diversion of our management&#8217;s attention and any delay or difficulties encountered in connection with any acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses, products, or product candidates, which may result in dilution for shareholders or the incurrence of indebtedness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our efforts to acquire companies, businesses, products, or product candidates or to enter into other significant transactions, we will conduct business, legal, and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we have consummated or may consummate in the future, whether as a result of unidentified risks or liabilities, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, operating results, and financial condition could be adversely affected. For any acquired product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval, and the market for any such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants, and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in-process research and development charges. In either case, the incurrence of these charges could adversely affect our operating results for particular periods.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on certain of our executive officers, other key members of our senior management team, and the Chair of our board of directors. If we are not able to retain (or for any other reason lose the services of) any of these persons, our business may suffer. In particular, we depend on the services of P. Roy Vagelos, M.D., the Chair of our board of directors; Leonard S. Schleifer, M.D., Ph.D., our President and Chief Executive Officer; and George D. Yancopoulos, M.D., Ph.D., our President and Chief Scientific Officer. We are also highly dependent on the expertise and services of other senior management members leading our research, development, manufacturing, and commercialization efforts. There is intense competition in the biotechnology industry for qualified scientists and managerial personnel in the research, development, manufacture, and commercialization of drugs. We may not be able to continue to attract and retain the qualified personnel necessary to continue to advance our business and achieve our strategic objectives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Technology Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex, and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. These systems are also critical to enable remote working arrangements, which have been growing in importance due in part to the COVID-19 pandemic and related developments. The size and complexity of our computer systems make us potentially vulnerable to IT system breakdowns, internal and external malicious intrusion, and computer viruses and ransomware, which may impact product production and key business processes. We also have outsourced significant elements of our information technology infrastructure and operations to third parties, which may allow them to access our confidential information and may also make our systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by such third parties or others.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our systems are potentially vulnerable to data security breaches - whether by employees or others - which may expose sensitive data to unauthorized persons. Data security breaches could lead to the loss of trade secrets or other intellectual property, result in demands for ransom or other forms of blackmail, or lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, and others. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage or extortion) and expertise, including by organized criminal groups, "hacktivists," nation states, and others. As a company with an increasingly global presence, our systems are subject to frequent attacks. There is the potential that our systems may be directly or indirectly affected as nation-states conduct global cyberwarfare, including in connection with the current Russia-Ukraine hostilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology, and to oversee and monitor the security measures of our suppliers and/or service providers, there can be no assurance that our efforts will prevent service interruptions or security breaches. In addition, we depend in part on third-party security measures over which we do not have full control to protect against data security breaches.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our suppliers and/or service providers fail to maintain or protect our information technology systems and data security effectively and in compliance with U.S. and foreign laws, or fail to anticipate, plan for, or manage significant disruptions to these systems, we or our suppliers and/or service providers could have difficulty preventing, detecting, or controlling such disruptions or security breaches, which could result in legal proceedings, liability under U.S. and foreign laws that protect the privacy of personal information, disruptions to our operations, government investigations, breach of contract claims, and damage to our reputation (in each case in the U.S. or globally), which could have a material adverse effect on our business, prospects, operating results, and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Results, Liquidity, and Need for Additional Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expend substantial resources for research and development, including costs associated with clinical testing of our product candidates and new indications of our marketed products, the commercialization of products, and capital expenditures. We believe our existing capital resources and borrowing availability under our revolving credit facility, together with funds generated by our current and anticipated EYLEA net product sales and funding we are entitled to receive under our collaboration agreements and other similar agreements (including our share of profits in connection with commercialization of EYLEA and Dupixent under our collaboration agreements with Bayer and Sanofi, respectively), will enable us to meet our anticipated operating needs for the foreseeable future. However, one or more of our collaboration agreements may terminate, our revenues may fall short of our projections or be delayed, or our expenses may increase, any of which could result in our capital being consumed significantly faster than anticipated. Our expenses may increase for many reasons, including expenses in connection with the commercialization of our marketed products and the potential commercial launches of our product candidates and new indications for our marketed products, manufacturing scale-up, expenses related to clinical trials testing of antibody-based product candidates we are developing on our own (without a collaborator), and expenses for which we are responsible in accordance with the terms of our collaboration agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that our existing capital resources and our current and anticipated revenues will be sufficient to meet our operating needs. We may require additional financing in the future and we may not be able to raise additional funds on acceptable terms or at all. For example, there is no guarantee that we will have the ability to pay the principal amount due on our senior unsecured notes at maturity or redeem, repurchase, or refinance the notes prior to maturity on acceptable terms or at all. In addition, in March 2022, we completed an extension of the $720.0 million lease financing for our existing corporate headquarters and other rentable area consisting of approximately 150 acres of predominately office buildings and laboratory space located in Tarrytown, New York, which is set to expire in March 2027. Refer to Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tarrytown, New York Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for further details. Our ability to refinance or to obtain additional financing could be adversely affected if there is a significant decline in the demand for our products or other significantly unfavorable changes in economic conditions. Volatility in the financial markets could increase borrowing costs or affect our ability to raise capital. If additional financing is necessary and we obtain it through the sale of equity securities, such sales will likely be dilutive to our shareholders. Debt financing arrangements may require us to pledge certain assets or enter into covenants that would restrict our business activities or our ability to incur further indebtedness and may be at interest rates and contain other terms that are not favorable to our shareholders. Should we require and be unable to raise sufficient funds (i) to complete the development of our product candidates, (ii) to successfully commercialize our product candidates or new indications for our marketed products if they obtain regulatory approval, and (iii) to continue our manufacturing and marketing of our marketed products, we may face delay, reduction, or elimination of our research and development or preclinical or clinical programs and our commercialization activities, which would significantly limit our potential to generate revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our indebtedness could adversely impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain indebtedness and contingent liabilities, including milestone and royalty payment obligations. As of December&#160;31, 2022, we had an aggregate of $2.701 billion of outstanding indebtedness under our senior unsecured notes and the lease financing facility. We may also incur additional debt in the future. Any such indebtedness could:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development, and mergers and acquisitions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to competitors that have less debt.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in foreign currency exchange rates could have a material adverse effect on our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue from outside the United States will increase as our products, whether marketed or otherwise commercialized by us or our collaborators, gain marketing approval in such jurisdictions. Our primary foreign currency exposure relates to movements in the Japanese yen, euro, British pound sterling, Canadian dollar, and Australian dollar. If the U.S. dollar weakens against a specific foreign currency, our revenues will increase, having a positive impact on net income, but our overall expenses will increase, having a negative impact. Conversely, if the U.S. dollar strengthens against a specific foreign currency, our revenues will decrease, having a negative impact on net income, but our overall expenses will decrease, having a positive impact. Therefore, significant changes in foreign exchange rates can impact our operating results and the financial condition of our Company. See Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $3.106 billion in cash and cash equivalents and $11.228 billion in marketable securities (including $1.210 billion in equity securities). Our investments consist primarily of debt securities, including investment-grade corporate bonds. These fixed-income investments are subject to external factors that may adversely affect their market value or liquidity, such as interest rate, liquidity, market, and issuer credit risks, including actual or anticipated changes in credit ratings. The equity securities we hold may experience significant volatility and may decline in value or become worthless if the issuer experiences an adverse development. Furthermore, our equity investments could be subject to dilution (and decline in value) as a result of the issuance of additional equity interests by the applicable issuer. If any of our investments suffer market price declines, such declines may have an adverse effect on our financial condition and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is extremely volatile.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been significant volatility in our stock price and generally in the market prices of biotechnology companies' securities. Various factors and events may have a significant impact on the market price of our Common Stock. These factors include, by way of example:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">net product sales of our marketed products (as recorded by us or our collaborators), in particular EYLEA, Dupixent, and Libtayo, as well as our overall operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our product candidates (such as aflibercept 8 mg) or our new indications for our marketed products receive regulatory approval, net product sales of, and profits from, these product candidates and new indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of, and the market share for, our marketed products, especially EYLEA, Dupixent, and Libtayo;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our net product sales and net profits underperform, meet, or exceed the expectations of investors or analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of actions by the FDA or foreign regulatory authorities or their respective advisory committees regarding our, or our collaborators', or our competitors', currently pending or future application(s) for regulatory approval of product candidate(s) or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of submission of an application for regulatory approval of one or more of our, or our competitors', product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress, delays, or results in clinical trials of our or our competitors' product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the COVID-19 pandemic on our business, including the degree of success (if any) of our efforts to develop "next generation" COVID-19 monoclonal antibodies and any potential future sales of our COVID-19 monoclonal antibodies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of technological innovations or product candidates by us or competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims by others that our products or technologies infringe their patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges by others to our patents in the EPO and in the USPTO;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety or effectiveness of any of our marketed products or product candidates or new indications for our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement actions, decisions, or recommendations by government authorities, insurers, or other organizations (such as health maintenance organizations and PBMs) affecting the coverage, reimbursement, or use of any of our marketed products or competitors' products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital as needed on favorable terms;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in our relationships with collaborators or key customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in the biotechnology industry or in government regulation of healthcare, including those relating to compounding (i.e., a practice in which a pharmacist, a physician, or, in the case of an outsourcing facility, a person under the supervision of a pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">large sales of our Common Stock by our executive officers or other employees, directors, or significant shareholders (or the expectation of any such sales);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax rates, laws, or interpretation of tax laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrivals and departures of key personnel; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repurchase our Common Stock under any share repurchase program on favorable terms or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading activity that results from the rebalancing of stock indices in which our Common Stock is included, or the inclusion or exclusion of our Common Stock from such indices; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors identified in these "Risk Factors"; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by the investment community or our shareholders of any of the foregoing factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Common Stock has been, and could continue to be, subject to wide fluctuations in response to these and other factors, including the sale or attempted sale of a large amount of our Common Stock in the market. As discussed in greater detail under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below, a large percentage of our Common Stock is owned by a small number of our principal shareholders. As a result, the public float of our Common Stock (i.e., the portion of our Common Stock held by public investors, as opposed to the Common Stock held by our directors, officers, and principal shareholders) may be lower than the public float of other large public companies with broader public ownership. Therefore, the trading price of our Common Stock may fluctuate significantly more than the stock market as a whole. These factors may exacerbate the volatility in the trading price of our Common Stock and may negatively impact your ability to liquidate your investment in Regeneron at the time you wish at a price you consider satisfactory. Broad market fluctuations may also adversely affect the market price of our Common Stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price. This type of litigation could result in substantial costs and divert our management's attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation, which may harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A small number of our shareholders beneficially own a substantial amount of our Common Stock. As of December&#160;31, 2022, our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 39.4% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of December&#160;31, 2022. If our significant shareholders or we sell substantial amounts of our Common Stock in the public market, or there is a perception that such sales may occur, the market price of our Common Stock could fall. Sales of Common Stock by our significant shareholders also might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will repurchase shares of our Common Stock or that we will repurchase shares at favorable prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, our board of directors authorized a share repurchase program to repurchase up to $3.0 billion of our Common Stock (of which $745.2 million remained available as of December&#160;31, 2022); and, in January 2023, our board of directors authorized an additional $3.0&#160;billion for share repurchases. There can be no assurance of any future share repurchases or share repurchase program authorizations. Any share repurchases will depend upon, among other factors, our cash balances and potential future capital requirements, our results of operations and financial condition, the price of our Common Stock on the NASDAQ Global Select Market, and other factors that we may deem relevant. We can provide no assurance that we will repurchase shares of our Common Stock at favorable prices, if at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A Stock, who are generally the shareholders who purchased their stock from us before our initial public offering, are entitled to ten votes per share, while holders of Common Stock are entitled to one vote per share. As of December&#160;31, 2022, holders of Class A Stock held 14.4% of the combined voting power of all shares of Common Stock and Class A Stock then outstanding. These shareholders, if acting together, would be in a position to substantially influence the election of our directors and the vote on certain corporate transactions that require majority or supermajority approval of the combined classes, including mergers and other business combinations. This may result in our taking corporate actions that other shareholders may not consider to be in their best interest and may affect the price of our Common Stock. As of December&#160;31, 2022:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current executive officers and directors beneficially owned 7.1% of our outstanding shares of Common Stock, assuming conversion of their Class A Stock into Common Stock and the exercise of all options held by such persons which are exercisable within 60 days of December&#160;31, 2022, and 18.5% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by such persons which are exercisable within 60 days of December&#160;31, 2022; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 39.4% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of December&#160;31, 2022. In addition, these five shareholders plus our Chief Executive Officer held approximately 46.6% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by our Chief Executive Officer which are exercisable within 60 days of December&#160;31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The anti-takeover effects of provisions of our charter, by-laws, and of New York corporate law, as well as the contractual provisions in our investor and collaboration agreements and certain provisions of our compensation plans and agreements, could deter, delay, or prevent an acquisition or other "change of control" of us and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, our by-laws, and the New York Business Corporation Law contain various provisions that could have the effect of delaying or preventing a change in control of our Company or our management that shareholders may consider favorable or beneficial. Some of these provisions could discourage proxy contests and make it more difficult for shareholders to elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock. These provisions include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorization to issue "blank check" preferred stock, which is preferred stock that can be created and issued by the board of directors without prior shareholder approval, with rights senior to those of our Common Stock and Class A Stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors, so that it would take three successive annual shareholder meetings to replace all of our directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that removal of directors may only be effected for cause and only upon the affirmative vote of at least eighty percent (80%) of the outstanding shares entitled to vote for directors, as well as a requirement that any vacancy on the board of directors may be filled only by the remaining directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provision whereby any action required or permitted to be taken at any meeting of shareholders may be taken without a meeting, only if, prior to such action, all of our shareholders consent, the effect of which is to require that shareholder action may only be taken at a duly convened meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that any shareholder seeking to bring business before an annual meeting of shareholders must provide timely notice of this intention in writing and meet various other requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">under the New York Business Corporation Law, in addition to certain restrictions which may apply to "business combinations" involving our Company and an "interested shareholder," a plan of merger or consolidation of our Company must be approved by two-thirds of the votes of all outstanding shares entitled to vote thereon. See the risk factor above captioned "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, certain of our collaborators are currently bound by "standstill" provisions under their respective agreements with us. These include the January 2014 amended and restated investor agreement between us and Sanofi, as amended, and our 2016 ANG2 license and collaboration agreement with Bayer, which contractually prohibit Sanofi and Bayer, respectively, from seeking to directly or indirectly exert control of our Company or acquiring more than a specified percentage of our Class A Stock and Common Stock, taken together (30% in the case of Sanofi and 20% in the case of Bayer). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Change in Control Severance Plan and the employment agreement with our Chief Executive Officer, each as amended and restated, provide for severance benefits in the event of termination as a result of a change in control of our Company. Also, equity awards issued under our long-term incentive plans may become fully vested in connection with a "change in control" of our Company, as defined in the plans. These contractual provisions may also have the effect of deterring, delaying, or preventing an acquisition or other change in control.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_25"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_28"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our research, development, manufacturing, and administrative activities at our owned and leased facilities. A summary of our significant owned and leased properties is provided below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tarrytown, New York</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our Tarrytown, New York location, we lease approximately 1,467,000 square feet of laboratory and office space. Refer to Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tarrytown, New York Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for further details. We also own an approximate 100-acre parcel of land adjacent to our Tarrytown, New York location, which we are in the process of developing, primarily in connection with expanding our research and support facilities to accommodate our growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rensselaer, New York</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own facilities in Rensselaer, New York totaling approximately 1,189,000 square feet of manufacturing, research, office, and warehouse space. This includes approximately 452,000 square feet of warehouse, laboratory, and office space which we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constructed on a 130-acre parcel of land near our Rensselaer facility. We are in the process of further developing this property, primarily in connection with constructing a fill/finish facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limerick, Ireland</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own a facility in Limerick, Ireland totaling approximately 555,000 square feet of manufacturing, warehouse, laboratory, and  office space. </span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the information set forth in Note 16 to our Consolidated Financial Statements included in this report.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_34"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_37"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_40"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant's Common Equity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock, par value $.001 per share, is quoted on The NASDAQ Global Select Market under the symbol "REGN." Our Class A Stock, par value $.001 per share, is not publicly quoted or traded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;26, 2023, there were 161 shareholders of record of our Common Stock and 14 shareholders of record of our Class A Stock.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our Common Stock or Class A Stock and do not anticipate paying any in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK PERFORMANCE GRAPH</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a line graph comparing the cumulative total shareholder return on Regeneron's Common Stock with the cumulative total return of (i) the NASDAQ US Benchmark Pharmaceuticals Total Return Index ("NQ US Pharma TR Index"), and (ii) Standard &amp; Poor's 500 Stock Index ("S&amp;P 500") for the period from December 31, 2017 through December&#160;31, 2022. The comparison assumes that $100 was invested on December 31, 2017 in our Common Stock and in both of the foregoing indices. All values assume reinvestment of the pre-tax value of dividends paid by companies included in these indices. The historical stock price performance of our Common Stock shown in the graph below is not necessarily indicative of future stock price performance.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><img src="regn-20221231_g1.jpg" alt="regn-20221231_g1.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"></td><td style="width:34.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NQ US Pharma TR Index</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference into any filing of ours under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as shall be expressly set forth by specific reference to such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects shares of Common Stock we repurchased under our share repurchase programs, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended December 31, 2022. Refer to Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" for further details of our share repurchase programs.</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:18.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Purchased Under the Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/1/2022&#8211;10/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/1/2022&#8211;11/30/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2022&#8211;12/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,031&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced programs relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In January 2023, our board of directors authorized a new share repurchase program to repurchase up to an additional $3.0 billion of our Common Stock. See Item 7. "Liquidity and Capital Resources - Share Repurchase Programs" for further details.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_46"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results and Results of Operations</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the consolidated financial statements and related notes included elsewhere in this report. Refer to Part II, Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed with the SEC on February 7, 2022) for additional discussion of our financial condition and results of operations for the year ended December 31, 2020, as well as our financial condition and results of operations for the year ended December 31, 2021 compared to the year ended December 31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have nine FDA-approved products that have received marketing approval and approximately 35 product candidates in clinical development, almost all of which were homegrown in our laboratories. In addition, REGEN-COV was authorized under an EUA for COVID-19 from November 2020 until January 2022 when the EUA was revised to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment (see Part I, Item 1. "Business - Additional Information - Clinical Development Programs"). Refer to Part I, Item 1. "Business - Products" and "Business - Programs in Clinical Development" for additional information related to marketed products and product candidates.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits and to generate positive cash flow from operations over the next several years depends significantly on the continued success in commercializing EYLEA and Dupixent, as well as on whether we are able to obtain regulatory approval for aflibercept 8 mg and are successful in commercializing it. We expect to continue to incur substantial expenses related to our research and development activities, a portion of which we expect to be reimbursed by our collaborators. In addition, our research and development activities and related costs which are not reimbursed are expected to expand and require additional resources. We also expect to incur substantial costs related to the commercialization of our marketed products. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate. We cannot predict whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such product(s) and whether or when they may become profitable.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. Critical accounting estimates are those estimates made in accordance with GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our results of operations or financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate. However, if actual experience differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the resulting changes could have a material adverse effect on our results of operations, and, in certain situations, could have a material adverse effect on our liquidity and financial condition. The critical accounting estimates that impact our Consolidated Financial Statements are described below.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition - Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales at a point in time when our customer is deemed to have obtained control of the product, which generally occurs upon receipt or acceptance by our customer. The amount of revenue we recognize from product sales may vary due to rebates, chargebacks, and discounts provided under governmental and other programs, distribution-related fees, and other sales-related deductions. In order to determine the transaction price, we estimate, utilizing the expected value method, the amount of variable consideration to which we will be entitled. This estimate is based upon contracts with customers, healthcare providers, payors and government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, estimated payor mix, and other relevant factors. Calculating these provisions involves estimates and judgments. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review our estimates of rebates, chargebacks, and other applicable provisions each period and record any necessary adjustments in the current period's net product sales. Refer to the "Results of Operations - Revenues - Net Product Sales" section below for further details regarding our provisions, and credits/payments, for sales-related deductions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaborative arrangements to research, develop, manufacture, and commercialize products and/or product candidates. Our collaboration agreements may require us to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is "distinct"), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up-front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (i.e., over time) typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion (see "Results of Operations - Expenses - Other Operating (Income) Expense" below for further information related to amounts recognized in connection with such estimates). We review our estimates each period and make revisions to such estimates as necessary. Due to the variability in the scope of activities and length of time necessary to develop a drug product, potential delays in development programs, changes to development plans and budgets as programs progress, including if we and our collaborators decide to expand or contract our clinical plans for a drug candidate in various disease indications, and uncertainty in the ultimate requirements to obtain governmental approval for commercialization, revisions to our estimates are likely to occur periodically, potentially resulting in material changes to amounts recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborator performs research and development work or commercialization-related activities and the parties share the related costs, we also recognize, as expense (e.g., research and development expense or selling, general and administrative expense, as applicable) in the period when our collaborator incurs such expenses, the portion of the collaborator's expenses that we are obligated to reimburse. Our collaborators provide us with estimated expenses for the most recent fiscal quarter. The estimates are revised, if necessary, in subsequent periods if actual expenses differ from those estimates.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where we:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the collaborator (however, recognition of such cost reimbursements may be deferred until the product is sold by our collaborator to third-party customers); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share in any profits or losses arising from the commercialization of such products, we record our share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive royalties and/or sales-based milestone payments from our collaborator, we recognize such amounts in the period earned.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborators provide us with estimates of product sales and our share of profits or losses, as applicable, for each quarter. The estimates are revised, if necessary, in subsequent periods if our actual share of profits or losses differ from those estimates.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for equity grants under our long-term incentive plans to employees and non-employee members of our board of directors (as applicable) based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In addition, we reassess our forfeiture rate assumptions at least annually, considering both historical forfeiture experience and an estimate of future forfeitures for currently outstanding unvested awards. The assumptions used in computing the fair value of equity awards reflect our best estimates but involve uncertainties related to market and other conditions, many of which are outside our control. Changes in any of these assumptions may materially affect the fair value of awards granted and the amount of stock-based compensation recognized in future periods. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of our Common Stock price, (ii) the periods of time over which employees and members of our board of directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on our Common Stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities with maturities approximating the options' expected lives. Expected volatility is estimated based on actual movements in our stock price over the most recent historical periods equivalent to the options' expected lives. Expected lives are principally based on our historical exercise experience with previously issued employee and board of director option grants. The expected dividend yield is zero as we have never paid dividends and do not currently anticipate paying any in the foreseeable future. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a Monte Carlo simulation to compute the estimated fair value of performance-based restricted stock units that are subject to vesting based on the Company's attainment of pre-established performance criteria that include a market condition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance-based restricted stock units that contain a performance condition, we recognize stock-based compensation expense if and when we determine that it is probable the performance condition will be achieved (based on the number of shares expected to be vested and issued). We reassess the probability of achievement at each reporting period and adjust compensation cost, as necessary. If there are any changes in our probability assessment, we recognize a cumulative catch-up adjustment in the period of the change in estimate, with the remaining unrecognized expense recognized prospectively over the remaining requisite service period. If we subsequently determine that the performance criteria are not met or are not expected to be met, any amounts previously recognized as compensation expense are reversed in the period when such determination is made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 to our Consolidated Financial Statements for stock-based compensation expense and related assumptions used in determining the fair value of our awards.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns, including deferred tax assets and liabilities for expected amounts of global intangible low-taxed income ("GILTI") inclusions. Deferred tax assets and liabilities are determined as the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on all available evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, results of recent operations, and our historical earnings experience by taxing jurisdiction. Significant judgment is required in making this assessment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the financial statement effects of a tax position when management's assessment is that there is more than a 50% probability that the position will be sustained upon examination by a taxing authority based upon its technical merits. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. Significant judgment is required in making this assessment, and, therefore, we re-evaluate uncertain tax positions and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. We adjust the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with our products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically analyze our inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and write down such inventories as appropriate. In addition, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, we record a charge to write down such inventory to its estimated realizable value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Results of Operations - Expenses - Cost of Goods Sold" below for further information related to our inventory write-offs and reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in connection with an asset acquisition are recorded at cost. Intangible assets are amortized over the estimated useful lives of the assets based on the pattern in which the economic benefits of the intangible assets are consumed; if that pattern cannot be reliably determined, a straight-line basis is used. If contingent consideration is recognized subsequent to the acquisition date in an asset acquisition, the amount of such consideration is recorded as an addition to the cost basis of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset with a cumulative catch-up adjustment for amortization expense as if the additional amount of consideration had been accrued from the outset of the acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets are reviewed for recoverability whenever events or changes in circumstances (e.g., changes in economic, regulatory, or legal conditions) indicate that the carrying amount of the asset may not be recoverable. If an indicator of impairment exists, we compare the projected undiscounted cash flows to be generated by the asset to the intangible asset's carrying amount. If the projected undiscounted cash flows of the intangible asset are less than the carrying amount, the intangible asset is written down to its fair value in the period in which the impairment occurs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Part I, Item 1. "Business - Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology," effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under the A&amp;R IO LCA with Sanofi. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset. Due to the complexity of the terms of the amendments to the collaboration agreements in contemplation of the acquisition of the worldwide rights to Libtayo, significant judgment was applied in identifying the elements of the transaction and evaluating the timing and recognition of contingent consideration.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to our Consolidated Financial Statements for further information related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue, based on management's judgment, for an estimated loss when the potential loss from claims or legal proceedings is considered probable and the amount can be reasonably estimated. As additional information becomes available, or, based on specific events such as the outcome of litigation or settlement of claims, we reassess the potential liability related to pending claims and litigation, and may change our estimates. </span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.264%"><tr><td style="width:1.0%"></td><td style="width:52.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,172.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,071.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,434.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,124.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,920.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,738.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,946.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,325.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:34.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA - U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo - U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo - ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent - U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV - U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,828.0)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza - U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb - U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST - U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">***</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,117.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,294.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,541.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,172.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,071.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,566.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Not meaningful</span></div></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of Praluent in the United States were recorded by Sanofi prior to April 1, 2020.</span></div></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">***</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of EYLEA in the United States increased in 2022, compared to 2021, due to higher sales volume partly offset by an increase in sales-related deductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Part I, Item. 1. "Business - Collaboration, License, and Other Agreements - Sanofi - Immuno-oncology", effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the years ended December&#160;31, 2021 and 2020, we recorded net product sales of REGEN-COV in connection with our agreements with the U.S. government. As of December 31, 2021, the Company had completed its final deliveries of drug product under its agreements with the U.S. government; as a result, there were no net product sales of REGEN-COV in the United States recorded during the year ended December&#160;31, 2022. Refer to Part I, Item 1. "Business - Agreements Related to COVID-19 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">" for further details.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks, and discounts; distribution-related fees; and other sales-related deductions. The following table summarizes the provisions, and credits/payments, for sales-related deductions.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.327%"><tr><td style="width:1.0%"></td><td style="width:33.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks,<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution-<br/>Related Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Sales-<br/>Related Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,034.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,523.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,398.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sanofi Collaboration Revenue</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.637%"><tr><td style="width:1.0%"></td><td style="width:60.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Antibody</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immuno-oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by the Company in connection with such production is recorded within Cost of collaboration and contract manufacturing</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the A&amp;R IO LCA became effective July 1, 2022, the three months ended June 30, 2022 was the last period in which Sanofi collaboration revenue was recognized in connection with the immuno-oncology collaborative arrangement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global net product sales of Dupixent and Kevzara are recorded by Sanofi. The increase in our share of profits in connection with commercialization of antibodies during the year ended December&#160;31, 2022, compared to 2021, was driven by profits associated with higher Dupixent sales, partly offset by the impact of the amendment to the Antibody License and Collaboration Agreement. As described in Part I, Item 1. "Business - Collaboration, License, and Other Agreements - Sanofi - Antibody", on July 1, 2022, an amendment to the Antibody License and Collaboration Agreement became effective, pursuant to which the percentage of Regeneron's share of profits in any calendar quarter used to reimburse Sanofi for development costs which were funded by Sanofi increased from 10% to 20%. In addition, the amount of our share of profits we earned in connection with commercialization of antibodies outside the United States was adversely impacted in 2022 by the U.S. dollar strengthening against foreign currencies, including the Japanese yen and the euro.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's share of profits in connection with the commercialization of Dupixent, Praluent (through March 31, 2020), and Kevzara is summarized below:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.310%"><tr><td style="width:1.0%"></td><td style="width:59.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent, Praluent, and Kevzara net product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,039.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,536.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,394.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266.6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with amendment to the Antibody License and Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits as a percentage of Dupixent, Praluent, and Kevzara net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Global net product sales of Dupixent and Kevzara are recorded by Sanofi. The quarter ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses in connection with Sanofi's global net sales and the related commercialization of Praluent (see further details below); therefore, the quarter ended March 31, 2020 was the last quarter for which net product sales of Praluent were included in the table above. </span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Part I, Item 1. "Business - Collaboration, License, and Other Agreements - Sanofi - Antibody", effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States. Under the new agreement, Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States, and pays the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2022, we earned two $50.0&#160;million sales-based milestones from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion and $2.5&#160;billion, respectively, on a rolling twelve-month basis. During the year ended December 31, 2021, we earned a $50.0 million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.5&#160;billion on a rolling twelve-month basis. We are entitled to receive the final sales milestone payment of $50.0&#160;million that would be earned when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in reimbursements for manufacturing of commercial supplies in 2022, compared to 2021, was primarily due to higher Dupixent sales, as revenue for such cost reimbursements is recognized when the product is sold by Sanofi to third-party customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bayer Collaboration Revenue</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.752%"><tr><td style="width:1.0%"></td><td style="width:57.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by the Company in connection with such production is recorded within Cost of collaboration and contract manufacturing</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bayer records net product sales of EYLEA outside the United States. The amount of the share of profits we earned in connection with commercialization of EYLEA outside the United States was adversely impacted in 2022 by the U.S. dollar strengthening against foreign currencies, including the Japanese yen and the euro.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States is summarized below: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.752%"><tr><td style="width:1.0%"></td><td style="width:57.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA net product sales outside the United States </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450.9*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820.7*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profit from sales outside the United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.9)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107.9</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits as a percentage of EYLEA net product sales outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td></tr><tr style="height:5pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective January 1, 2022, the Company and Bayer commenced sharing equally in profits and losses based on sales from Bayer to its distributor in Japan. Previously, the Company received from Bayer a tiered percentage of sales based on sales by Bayer's distributor in Japan. Consequently, the prior year net product sales amount has been revised for comparability purposes.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Roche Collaboration Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Part I, Item 1. "Business - Agreements Related to COVID-19 - Roche", Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from worldwide sales of REGEN-COV and Ronapreve, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the Company recognized $627.3&#160;million and $361.8&#160;million, respectively, of global gross profit payments from Roche within collaboration revenue. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue increased in 2022, compared to 2021, primarily due to higher reimbursements for the manufacture of commercial supplies for Sanofi related to Praluent outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except headcount data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,647.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(973.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,434.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,124.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,920.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average headcount</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Includes costs incurred net of any cost reimbursements from collaborators who are not deemed to be our customers</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Cost of collaboration and contract manufacturing includes costs we incur in connection with producing commercial drug supplies for collaborators and others.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses in 2022, 2021, and 2020 included a total of $725.0 million, $601.7 million, and $432.0 million, respectively, of stock-based compensation expense related to equity awards granted under our long-term incentive plans. As of December 31, 2022, unrecognized stock-based compensation expense related to unvested stock options and unvested restricted stock (including performance-based restricted stock units) was $572.0 million and $1.064&#160;billion, respectively. We expect to recognize this stock-based compensation expense related to stock options and restricted stock over weighted-average periods of 1.8 years and 2.6 years, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our estimates of direct research and development expenses by clinical development program and other significant categories of research and development expenses. Direct research and development expenses are comprised primarily of costs paid to third parties for clinical and product development activities, including costs related to preclinical research activities, clinical trials, and the portion of research and development expenses incurred by our collaborators that we are obligated to reimburse. Indirect research and development expenses have not been allocated directly to each program, and primarily consist of costs to compensate personnel, overhead and infrastructure costs to maintain our facilities, and other costs related to activities that benefit multiple projects. Clinical manufacturing costs primarily consist of costs to manufacture bulk drug product for clinical development purposes as well as related external drug filling, packaging, and labeling costs. Clinical manufacturing costs also includes pre-launch commercial supplies which did not meet the criteria to be capitalized as inventory (see "Critical Accounting Policies and Use of Estimates - Inventories" above). The table below also includes reimbursements of research and development expenses by collaborators, as when we are entitled to reimbursement of all or a portion of such expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.258%"><tr><td style="width:1.0%"></td><td style="width:39.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA and aflibercept 8 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pozelimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Odronextamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linvoseltamab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fianlimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product candidates in clinical development and other research programs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab supplies and other research and development costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy and other operating costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,885.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manufacturing costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses by collaborators</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,647.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Certain prior year amounts have been reclassified to conform to the current year's presentation</span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses increased in 2022, compared to 2021, partially due to the impact of the amendments to the Sanofi collaboration agreements described above in Part I, Item 1. "Business - Collaboration, License, and Other Agreements - Sanofi," as (i) Sanofi is no longer reimbursing us for 50% of Libtayo development costs, and (ii) effective July 1, 2022, we recognize our 50% share of research and development expenses in connection with the Sanofi Antibody Collaboration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses included stock-based compensation expense of $406.8 million and $316.6 million in 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development expenses by collaborators included reimbursements from Roche related to REGEN-COV of $128.1&#160;million for the year ended December&#160;31, 2021. For the year ended December&#160;31, 2022, such reimbursements from Roche related to REGEN-COV were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development, uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes in the competitive landscape affecting a product candidate, and other risks and uncertainties described in Part I, Item 1A. "Risk Factors". There is also variability in the duration and costs necessary to develop a pharmaceutical product, potential opportunities and/or uncertainties related to future indications to be studied, and the estimated cost and scope of the projects. The lengthy process of seeking FDA and other applicable approvals, and subsequent compliance with applicable statutes and regulations, require the expenditure of substantial resources. Any failure by us to obtain, or delay in obtaining, regulatory approvals could materially adversely affect our business. We are unable to reasonably estimate if our product candidates in clinical development will generate material product revenues and net cash inflows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-process Research and Development ("IPR&amp;D")</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D in 2022 included a $195.0&#160;million charge related to our acquisition of Checkmate, a $30.0&#160;million up-front payment in connection with our collaboration agreement with CytomX Therapeutics, Inc., and a $20.0&#160;million opt-in payment in connection with a product candidate under our collaboration agreement with Adicet Bio, Inc. Acquired IPR&amp;D in 2021 included $34.0&#160;million in aggregate up-front payments in connection with our collaboration agreement with Nykode Therapeutics and in 2020 included $85.0&#160;million in aggregate up-front payments in connection with our collaboration agreement with Intellia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased in 2022, compared to 2021, primarily due to higher headcount and headcount-related costs, an increase in commercialization-related expenses for Libtayo (as effective July 1, 2022, the Company became solely responsible for the commercialization of Libtayo worldwide), and higher contributions to an independent not-for-profit patient assistance organization, partly offset by costs in 2021 for educational campaigns related to COVID-19 that did not recur during 2022. Selling, general, and administrative expenses also included $256.4 million and $213.3 million of stock-based compensation expense in 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold decreased in 2022, compared to 2021, primarily due to the Company recognizing REGEN-COV net product sales (and corresponding cost of goods sold) in the United States during 2021 and a 2021 payment of $259.6&#160;million owed in connection with global gross profits under our Roche collaboration agreement; such transactions did not recur in 2022. Cost of goods sold also decreased during 2022 since effective July 1, 2022, as a result of the A&amp;R IO LCA described in Part I, Item 1. "Business - Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology", we are no longer obligated to pay Sanofi for their share of Libtayo U.S. gross profits (during the six months ended June 30, 2022, Cost of goods sold included $70.1 million related to our obligation for Sanofi's share of Libtayo U.S. gross profits compared to $133.0 million for full year 2021). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold in 2022 also decreased, compared to 2021, due to lower inventory write-offs and reserves. Inventory write-offs and reserves were $258.7&#160;million in 2022 (including $157.4&#160;million in the fourth quarter of 2022) compared to $457.1&#160;million in 2021 (including $269.2&#160;million in the fourth quarter of 2021). These inventory write-offs and reserves were primarily related to REGEN-COV. Refer to Part I, Item 1. "Business - Additional Information - Clinical Development Programs - REGEN-COV (casirivimab and imdevimab)" for further information related to regulatory developments for REGEN-COV which negatively impacted the estimated realizable value of inventory on hand. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Collaboration and Contract Manufacturing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration and contract manufacturing increased in 2022, compared to 2021, primarily due to the recognition of costs in connection with manufacturing additional commercial supplies for Sanofi related to Praluent outside the United States and Dupixent, and manufacturing costs associated with EYLEA outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating (Income) Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating (income) expense, net, includes recognition of a portion of amounts previously deferred in connection with up-front and development milestone payments, as applicable, received in connection with Sanofi IO, Teva, and MTPC collaborative arrangements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company discontinued further clinical development of fasinumab, and, as a result, recorded $44.4&#160;million (as an increase to other operating income) related to our Teva and MTPC collaborative arrangements as we deemed our obligation to provide development services in connection with these collaborative arrangements to be complete.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the A&amp;R IO LCA became effective July 1, 2022, the three months ended June 30, 2022 was the last period in which such amounts were recognized in connection with our Sanofi immuno-oncology collaborative arrangement. During 2021, we updated our estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the Sanofi IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $66.9&#160;million as a reduction to other operating income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.689%"><tr><td style="width:1.0%"></td><td style="width:54.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains on equity securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"><tr><td style="width:1.0%"></td><td style="width:52.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except effective tax rate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8%</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for 2022, compared to 2021, included a favorable benefit from the proportion of income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate (including the impact from REGEN-COV income earned in the United States during 2021).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.580%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,838.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,334.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,532.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,884.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,014.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(791.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,742.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,082.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings and finance lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The $719.7 million related to finance lease liabilities was classified within current liabilities as of December 31, 2021. See "Tarrytown, New York Leases" section below for details. </span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we also had borrowing availability of $750.0 million under a revolving credit facility (see further description under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash for the Years Ended December&#160;31, 2022, 2021, and 2020 </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:40.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,066.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,463.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,784.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,384.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,314.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,009.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,005.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,970.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Accounts receivable had decreased by $707.8 million, compared to December&#160;31, 2021, driven by the Company's collection of amounts due from the U.S. government in connection with REGEN-COV sales in the fourth quarter of 2021. Other non-cash items, net, in 2022 included inventory write-offs and reserves. As of December 31, 2022, deferred tax assets increased by $746.4 million, compared to December 31, 2021, primarily related to the impact of the Tax Cuts and Jobs Act of 2017, which requires, for tax purposes, the capitalization and amortization of research and development expenses effective for years beginning after December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Accounts receivable had increased by $1.927 billion, compared to December 31, 2020, primarily due to REGEN-COV sales in connection with our September 2021 agreement to supply drug product to the U.S. government. Other non-cash items, net, in 2021 included inventory write-offs and reserves. Accounts payable, accrued expenses, and other liabilities as of December 31, 2021 included a $259.6 million fourth quarter 2021 payment owed in connection with global gross profits under our Roche collaboration agreement. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, Accounts receivable had increased by $1.356 billion, compared to December 31, 2019, partly as a result of extending payment terms to EYLEA customers due to the COVID-19 pandemic. Inventories increased as of December 31, 2020, compared to December 31, 2019, partially as a result of purchasing additional raw materials in anticipation of potential disruptions to our supply chain due to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures in 2022 included costs associated with the expansion of our manufacturing facilities in Rensselaer, New York (including the ongoing construction of a fill/finish facility and related equipment) and Limerick, Ireland, as well as costs incurred in connection with the expansion of the Tarrytown, New York campus. We expect to incur capital expenditures of $825 million to $950 million in 2023 primarily in connection with the continued expansion of our research, preclinical manufacturing, and support facilities at our Tarrytown, New York campus and our manufacturing facilities (including the fill/finish facility). We expect continued significant capital expenditures over the next several years in connection with the planned expansion of our Tarrytown, New York campus.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for Libtayo intangible asset of $1.027 billion in 2022 were related to our acquisition of the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset acquisition, net of cash acquired, of $230.3 million in 2022 was related to our acquisition of Checkmate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuances of Common Stock, in connection with exercises of employee stock options, were&#160;$1.520 billion during 2022, compared to&#160;$1.672 billion during 2021 and $2.575 billion during 2020. For additional information related to cash flows from financing activities, see "Share Repurchase Programs", "Sanofi Funding of Certain Development Costs", "Secondary Offering and Purchase of Regeneron Common Stock Held by Sanofi", and "Issuance of Senior Notes" sections below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into an agreement with a syndicate of lenders (the "2018 Credit Agreement") which provided for a $750.0 million senior unsecured five-year revolving credit facility. The 2018 Credit Agreement, which was set to mature in December 2023, included an option for us to elect to increase the commitments under the Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $250.0 million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we entered into an agreement with a syndicate of lenders (the "2022 Credit Agreement") which provides for a $750.0 million senior unsecured five-year revolving credit facility (the "2022 Credit Facility") and replaces the 2018 Credit Agreement, which was contemporaneously terminated.  The 2022 Credit Agreement includes an option for the Company to elect to increase the commitments under the 2022 Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $500.0 million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions. The 2022 Credit Agreement also provides a $50.0 million sublimit for letters of credit. As set forth in the 2022 Credit Agreement, we have the option to amend the 2022 Credit Agreement to establish environmental, social, and governance targets which will be used to adjust pricing under the 2022 Credit Facility, subject to parameters to be provided in the 2022 Credit Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds of the loans under the 2022 Credit Facility may be used to finance working capital needs, and for general corporate or other lawful purposes, of Regeneron and its subsidiaries. Regeneron Pharmaceuticals, Inc. has guaranteed all obligations under the 2022 Credit Facility. The 2022 Credit Agreement includes an option for us to elect to extend the maturity date of the 2022 Credit Facility beyond December 2027, subject to the consent of the extending lenders and certain other conditions. Amounts borrowed under the 2022 Credit Facility may be prepaid, and the commitments under the 2022 Credit Facility may be terminated, at any time without premium or penalty. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no borrowings outstanding under the 2022 Credit Facility as of December&#160;31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement contains operating covenants and a maximum total leverage ratio financial covenant. We were in compliance with all covenants of the 2022 Credit Agreement as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to $1.0&#160;billion of our Common Stock. The share repurchase program permitted the Company to make repurchases through a variety of methods, including open-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $1.0&#160;billion of its Common Stock that it was authorized to repurchase under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our board of directors authorized a share repurchase program to repurchase up to $1.5&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program. As of December&#160;31, 2021, the Company had repurchased the entire $1.5&#160;billion of its Common Stock that it was authorized to repurchase under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, our board of directors authorized a share repurchase program to repurchase up to $3.0&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. As of December&#160;31, 2022, $745.2&#160;million remained available for share repurchases under the November 2021 program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of our Common Stock we repurchased under the programs described above and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.620%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our board of directors authorized a new share repurchase program to repurchase up to an additional $3.0&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share repurchases may be made from time to time at management's discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. There can be no assurance as to the timing or number of shares of any repurchases in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a 2018 agreement, we agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to Libtayo development and/or certain activities relating to dupilumab and itepekimab incurred in periods through September 30, 2020 by selling shares of our Common Stock owned by Sanofi. During 2020, Sanofi elected to sell, and we elected to purchase, shares of our Common Stock to satisfy Sanofi's funding obligation related to such activities. Consequently, we recorded the cost of the shares received, or $135.0&#160;million, as Treasury Stock during 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Secondary Offering and Purchase of Regeneron Common Stock Held by Sanofi </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares of our Common Stock directly from Sanofi for an aggregate purchase amount of $5.0&#160;billion (the "Stock Purchase").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the Stock Purchase with a combination of cash on hand, proceeds from the sale of marketable securities, and proceeds from loans under a $1.5&#160;billion senior unsecured bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The Bridge Facility was repaid in August 2020 following the issuance and sale of the Company's senior unsecured notes (as described below).  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Senior Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes") and $750 million aggregate principal amount of senior unsecured notes due 2050 (the "2050 Notes" and, together with the 2030 Notes, the "Notes"). Net proceeds from the issuance and sale of the Notes (after deducting underwriting discounts and offering expenses) were used in part to repay in full the Bridge Facility described above, including accrued interest and related fees and expenses in connection therewith. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes accrue interest at the rate of 1.750% per year and will mature on September 15, 2030. The 2050 Notes accrue interest at the rate of 2.800% per year and will mature on September 15, 2050. Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at the Company&#8217;s option at any time at 100% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes also contain certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tarrytown, New York Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease laboratory and office facilities in Tarrytown, New York (the "Facility"). In 2016, we entered into a Purchase Agreement with the then lessor, pursuant to which we agreed to purchase the Facility for a purchase price of $720.0 million. In March 2017, we entered into a Participation Agreement with BA Leasing BSC, LCC, an affiliate of Banc of America Leasing &amp; Capital, LLC ("BAL"), as lessor, and a syndicate of lenders (collectively with BAL, the "Lease Participants"), which provided for lease financing in connection with the acquisition by BAL of the Facility and our lease of the Facility from BAL. In March 2017, we assigned our right to take title to the Facility under the Purchase Agreement to BAL, and the Lease Participants advanced $720.0 million, which was used by BAL to finance the purchase price for the Facility. Concurrent with entering into the Participation Agreement, we also entered into a lease agreement for the Facility with BAL for a five-year term that was set to expire in March 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into a Second Amended and Restated Lease and Remedies Agreement (the "Restated Lease") with BAL, as lessor (the "Lessor"), which amends, restates, and extends our lease of the Facility. In March 2022, we also entered into a Second Amended and Restated Participation Agreement (the "Restated Participation Agreement") with Bank of America, N.A., as administrative agent, the Lessor, and a syndicate of financial institutions as rent assignees (collectively with the Lessor, the "Participants"), which amends and restates the original Participation Agreement entered into in March 2017.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Participation Agreement and certain related agreements were amended and restated in order to, among other things, (i) effect a&#160;five-year extension of the original March 2022 maturity date of the $720.0 million lease financing and the end of the term of our lease of the Facility from the Lessor to March 2027, at which time all amounts outstanding thereunder will become due and payable in full, and (ii) modify the rate of the interest or yield that is payable to the Participants. In accordance with the terms of the Restated Lease, we continue to pay all maintenance, insurance, taxes, and other costs arising out of the use of the Facility. We are also required to make monthly payments of basic rent during the term of the Restated Lease in an amount equal to a variable rate per annum, which was modified in connection with the Restated Lease, to be an adjusted one-month forward-looking term rate based on the Secured Overnight Financing Rate ("SOFR"), plus an applicable margin that varies with our debt rating and total leverage ratio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Participation Agreement and Restated Lease include an option for us to elect to further extend the maturity date of the Restated Participation Agreement and the term of the Restated Lease for an additional five-year period, subject to the consent of all the Participants and certain other conditions. We also have the option prior to the end of the term of the Restated Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants' advances under the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Participation Agreement, Restated Lease, and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Lease is classified as a finance lease as we have the option to purchase the Facility under terms that make it reasonably certain to be exercised. The agreements governing the Restated Lease financing contain financial and operating covenants. Such financial covenants and certain of the operating covenants are substantially similar to the covenants set forth in our 2018 Credit Agreement. The Company was in compliance with all such covenants as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Funding Requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount required to fund operations will depend on various factors, including the potential regulatory approval and commercialization of our product candidates and the timing thereof and the extent and cost of our research and development programs. We believe that our existing capital resources, borrowing availability under the 2022 Credit Facility, funds generated by anticipated product sales, and funding for reimbursement of research and development costs that we are entitled to receive under our collaboration agreements, will enable us to meet our anticipated operating needs for the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect continued increases in our expenditures, particularly in connection with our research and development activities (including preclinical and clinical programs). The amount of funding that will be required for our clinical programs depends upon the results of our research and preclinical programs and early-stage clinical trials, regulatory requirements, the duration and results of clinical trials underway and of additional clinical trials that we decide to initiate, and the various factors that affect the cost of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each trial, including the size of trials, fees charged for services provided by clinical trial investigators and other third parties, the costs for manufacturing the product candidate for use in the trials, and other expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate continuing to incur substantial commercialization costs for our marketed products. Commercialization costs over the next few years will depend on, among other things, the market potential for product candidates, whether commercialization costs are shared with a collaborator, and regulatory approval of additional product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that expenses related to the filing, prosecution, defense, and enforcement of patents and other intellectual property will be substantial. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for unrecognized tax benefits totaled $542.8 million as of December&#160;31, 2022. Due to their nature, there is a high degree of uncertainty regarding the period and amounts of potential future cash settlement with tax authorities. See Note 15 to our Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration and licensing agreements that may require us to pay (i) amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones), which, in the aggregate, could be significant, and/or (ii) royalties calculated based on a percentage of net product sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring and for which the specific timing cannot be predicted. See Note 3 and Note 11 to our Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Bayer for EYLEA outside the United States and our Antibody Collaboration with Sanofi, we and our collaborator share profits and losses in connection with commercialization of drug products. If the applicable collaboration is profitable, we have contingent contractual obligations to reimburse Bayer and Sanofi for a defined percentage (generally 50%) of agreed-upon development expenses funded by Bayer and Sanofi (i.e., "development balance"). These reimbursements are deducted each quarter, in accordance with a formula, from our share of the collaboration profits otherwise payable to us, unless, in the case of EYLEA, we elect to reimburse these expenses at a faster rate. As of December&#160;31, 2022, our contingent reimbursement obligation to Bayer for EYLEA was approximately $273 million and our contingent reimbursement obligation to Sanofi in connection with the companies' Antibody Collaboration was approximately $2.864 billion. Therefore, we expect that, for the foreseeable future, a portion of our share of profits from sales under our collaborations with Bayer and Sanofi will be used to reimburse our collaborators for these obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our consolidated financial position or results of operations.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Impact of Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the future adoption of recently issued accounting standards is not expected to have a material impact on the Company's financial position or results of operations.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and cash flows are subject to fluctuations due to changes in interest rates, principally in connection with our investments in marketable securities, which consist primarily of corporate bonds and U.S. treasury securities. We do not believe we are materially exposed to changes in interest rates related to our investments, and we do not currently use interest rate derivative instruments to manage exposure to interest rate changes of our investments. We estimate that a 100 basis point, or 1%, unfavorable change in interest rates would have resulted in approximately a $102.7 million and $120.0 million decrease in the fair value of our investment portfolio as of December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to market risk for changes in interest rates, including the interest rate risk relating to our variable rate Tarrytown, New York lease (as described in Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tarrytown, New York Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"). Our interest rate exposure is primarily offset by our investments in marketable securities. We continue to monitor our interest rate risk and may utilize derivative instruments and/or other strategies in the future to further mitigate our interest rate exposure. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Quality Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. Nonetheless, deterioration of the credit quality of an investment security subsequent to purchase may subject us to the risk of not being able to recover the full principal value of the security. In 2022, 2021, and 2020, we did not record any charges for credit-related impairments of our available-for-sale debt securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk associated with the receivables due from our collaborators, including Bayer and Sanofi. We are also subject to credit risk in connection with trade accounts receivable due from our customers from our product sales. We have contractual payment terms with each of our collaborators and customers. We also monitor financial performance and credit worthiness so that we can properly assess and respond to any changes in collaborator and/or customer credit profiles. In 2022, 2021 and 2020, we did not recognize any charges for write-offs and allowances of accounts receivable related to credit risk for our collaborators or customers. As of December&#160;31, 2022, two customers accounted on a combined basis for 86% of our net trade accounts receivables.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further above, our collaborators market certain products outside the United States, and we share in profits and losses with these collaborators from commercialization of products. In addition, pursuant to the applicable terms of the agreements with our collaborators, we also share in certain worldwide development expenses incurred by our collaborators. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also incur worldwide development expenses for clinical products we are developing independently, incur expenses outside of the United States in connection with our international operations, and, effective July 1, 2022, market Libtayo outside of the United States as a result of obtaining worldwide rights to Libtayo under an A&amp;R IO LCA with Sanofi. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, significant changes in foreign exchange rates of the countries outside the United States where our products are sold, where development expenses are incurred by us or our collaborators, or where we incur operating expenses can impact our operating results and financial condition. As sales outside the United States continue to grow, and as we expand our international operations, we will continue to assess potential steps, including foreign currency hedging and other strategies, to mitigate our foreign exchange risk.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Price Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to price risk on equity securities included in our investment portfolio. Our marketable securities include equity investments in publicly traded stock of companies, including common stock of companies with which we have entered into collaboration arrangements. Changes in the fair value of our equity investments are included in Other income (expense), net on the Consolidated Statements of Income. We recorded $39.8 million of net unrealized losses and $386.1 million of net unrealized gains on equity securities in Other income (expense), net in 2022 and 2021, respectively.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_67"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth beginning on page F-1 of this report and is incorporated herein by reference.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our principal executive officer and principal financial officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported on a timely basis, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) or 15d-15(f) under the Exchange Act. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2022 using the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2022. The effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears under Part IV, Item 15. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) or 15d-15(f) under the Exchange Act) during the quarter ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the system are met and cannot detect all deviations. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or deviations, if any, within the company have been detected. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item (other than the information set forth in the next paragraph in this Item 10) will be included in our definitive proxy statement with respect to our 2023 Annual Meeting of Shareholders to be filed with the SEC, and is incorporated herein by reference.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics that applies to our officers, directors, and employees. The full text of our code of business conduct and ethics can be found on our website (http://www.regeneron.com) under the "Governance" heading on the "Investors &amp; Media" page. We may satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding an amendment to, or a waiver from, a provision of our code of business conduct and ethics that applies to our principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions, by posting such information on our website where it is accessible through the same link noted above.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item will be included in our definitive proxy statement with respect to our 2023 Annual Meeting of Shareholders to be filed with the SEC, and is incorporated herein by reference. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item will be included in our definitive proxy statement with respect to our 2023 Annual Meeting of Shareholders to be filed with the SEC, and is incorporated herein by reference.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item will be included in our definitive proxy statement with respect to our 2023 Annual Meeting of Shareholders to be filed with the SEC, and is incorporated herein by reference.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item will be included in our definitive proxy statement with respect to our 2023 Annual Meeting of Shareholders to be filed with the SEC, and is incorporated herein by reference. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_88"></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.  Financial Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this report are listed on the Index to Financial Statements on page F-1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2.  Financial Statement Schedules</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.  Exhibits</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.471%"><tr><td style="width:1.0%"></td><td style="width:10.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217615000029/regn-ex_31x06302015x10q.htm">Restated Certificate of Incorporation, as amended. (Incorporated by reference from the Form 10-Q for Regeneron Pharmaceuticals, Inc. (the "Registrant"), for the quarter ended June 30, 2015, filed August 4, 2015.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465916163216/a16-23471_1ex3d2.htm">Amended and Restated By-Laws. (Incorporated by reference from the Form 8-K for the Registrant filed December 21, 2016.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex41xdescriptiono.htm">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">Indenture, dated August 12, 2020, between the Registrant and U.S. Bank National Association. (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-2.htm">First Supplemental Indenture, dated August 12, 2020, between the Registrant and U.S. Bank National Association. (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-2.htm">Form of 1.750% Senior Note due 2030 (included in Exhibit 4.3). </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-2.htm">Form of 2.800% Senior Note due 2050 (included in Exhibit 4.3). </a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677411001374/exhibit99-1.htm">Regeneron Pharmaceuticals, Inc. Second Amended and Restated 2000 Long-Term Incentive Plan. (Incorporated by reference from the Registration Statement on Form S-8 for the Registrant, filed June 13, 2011.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.1 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677409000907/exhibit10-1.htm">Form of option agreement and related notice of grant for use in connection with the grant of time based vesting stock options to the Registrant's non-employee directors and executive officers under the Regeneron Pharmaceuticals, Inc. Second Amended and Restated 2000 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended March 31, 2009, filed April 30, 2009.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.2 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677412000709/exhibit10-1_9.htm">Form of option agreement and related notice of grant for use in connection with the grant of time based vesting stock options to the Registrant's non-employee directors under the Regeneron Pharmaceuticals, Inc. Second Amended and Restated 2000 Long-Term Incentive Plan (revised). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2011, filed February 21, 2012.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.3 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217614000008/exhibit10110.htm">Amendment No. 1 to the Regeneron Pharmaceuticals, Inc. Second Amended and Restated 2000 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2013, filed February 13, 2014.) </a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465917038718/a17-14867_1ex99d1.htm">Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Registration Statement on Form S-8 for the Registrant, filed June 12, 2017.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.1 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000119312514240075/d741250dex101.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 8-K for the Registrant, filed June 18, 2014.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.2 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000119312514240075/d741250dex103.htm">Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 8-K for the Registrant, filed June 18, 2014.)</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.471%"><tr><td style="width:1.0%"></td><td style="width:10.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.3 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000119312514240075/d741250dex104.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 8-K for the Registrant, filed June 18, 2014.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.4 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217616000045/regn-ex_1025x12312015x10k.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2015, filed February 11, 2016.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.5 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465915080234/a15-23696_1ex10d1.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised). (Incorporated by reference from the Form 8-K for the Registrant, filed November 19, 2015.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.6 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465915080234/a15-23696_1ex10d3.htm">Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised). (Incorporated by reference from the Form 8-K for the Registrant, filed November 19, 2015.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.7 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217616000045/regn-ex_10210x12312015x10k.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2015, filed February 11, 2016.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.8 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217618000013/regn-ex_10211xar2014ltipnq.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2017, filed February 8, 2018.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.9 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217618000013/regn-ex_10213xar2014ltipnq.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2017, filed February 8, 2018.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.10 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217618000013/regn-ex_10215xar2014ltiprs.htm">Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2017, filed February 8, 2018.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.11 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217618000013/regn-ex_10216xar2014ltipnq.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2017, filed February 8, 2018.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.12 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000009/regn-ex_10217xstockoptiona.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2018). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2018, filed February 7, 2019.) </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.13 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000009/regn-ex_10218xstockoptiona.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2018). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2018, filed February 7, 2019.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.14 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000009/regn-ex_10219xar2014ltiprs.htm">Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2018). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2018, filed February 7, 2019.) </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.15 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000009/regn-ex_10220xar2014ltipnq.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2018). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2018, filed February 7, 2019.) </a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.471%"><tr><td style="width:1.0%"></td><td style="width:10.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.16 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000009/regn-ex_10221xar2014ltiprs.htm">Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2018, filed February 7, 2019.) </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.17 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10217ar2014ltip.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2019). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.18 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10218ar2014ltip.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2019). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.19 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10219ar2014ltip.htm">Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2019). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.20 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10220ar2014ltip.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2019). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.21 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10221ar2014ltip.htm">Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2019). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.22 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10222ar2014ltip.htm">Form of performance restricted stock unit award agreement and related notice of grant for use in connection with the grant of performance restricted stock units to Leonard S. Schleifer, M.D., Ph.D., George D. Yancopoulos, M.D., Ph.D., and P. Roy Vagelos, M.D. under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920073764/tm2022552d1_ex99-1.htm">Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Registration Statement on Form S-8 for the Registrant, filed June 16, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.1 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1031x12312020x10k.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.2 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1032x12312020x10k.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.3 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1033x12312020x10k.htm">Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.4 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1034x12312020x10k.htm">Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to P. Roy Vagelos, M.D. under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.5 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1035x12312020x10k.htm">Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.471%"><tr><td style="width:1.0%"></td><td style="width:10.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.6 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1036x12312020x10k.htm">Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.7 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422021000008/regn-ex_1037x12312020x10k.htm">Form of performance restricted stock unit award agreement and related notice of grant for use in connection with the grant of performance restricted stock units to Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D. under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677409000338/exhibit10-3.htm">Amended and Restated Employment Agreement, dated as of November 14, 2008, between the Registrant and Leonard S. Schleifer, M.D., Ph.D. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2008, filed February 26, 2009.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5* +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000095012305002979/y06183exv10w7.txt">Employment Agreement, dated as of December 31, 1998, between the Registrant and P. Roy Vagelos, M.D. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2004, filed March 11, 2005.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000119312513365438/d596986dex101.htm">Offer Letter for Robert E. Landry effective September 9, 2013. (Incorporated by reference from the Form 8-K for the Registrant, filed September 12, 2013.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 +</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677409000338/exhibit10-5.htm">Regeneron Pharmaceuticals, Inc. Change in Control Severance Plan, amended and restated effective as of November 14, 2008. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2008, filed February 26, 2009.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 +</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465915045962/a15-14252_1ex10d1.htm">Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan. (Incorporated by reference from the Form 8-K for the Registrant, filed June 17, 2015.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677409001498/exhibit10-1.htm">IL-1 Antibody Termination Agreement by and between Novartis Pharma AG, Novartis Pharmaceuticals Corporation and the Registrant, dated as of June 8, 2009. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2009, filed August 4, 2009.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000095012306013527/y26593exv10w1.htm">License and Collaboration Agreement, dated as of October 18, 2006, by and between Bayer HealthCare LLC and the Registrant. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended September 30, 2006, filed November 6, 2006.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217615000008/regn-ex_10101x12312014x10k.htm">Restated Amendment Agreement, dated December 30, 2014 and entered into effective as of May 7, 2012, by and between Bayer HealthCare LLC and the Registrant. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2014, filed February 12, 2015.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10.2**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217620000008/regn-ex10102secondamen.htm">Second Amendment Agreement, dated December 19, 2019, by and between Bayer HealthCare LLC and the Registrant. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2019, filed February 7, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000120677410001385/exhibit10-15.htm">Amended and Restated License and Collaboration Agreement, dated as of November 10, 2009, by and among Aventis Pharmaceuticals Inc., sanofi-aventis Amerique du Nord, and the Registrant. (Incorporated by reference from the Form 10-K/A for the Registrant, for the year ended December 31, 2009, filed June 2, 2010.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217613000022/regn-ex_105x6302013x10q.htm">First Amendment to Amended and Restated License and Collaboration Agreement by and between the Registrant and Aventis Pharmaceuticals Inc., dated May 1, 2013. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2013, filed August 6, 2013.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217615000037/regn-ex_104x09302015x10q.htm">Amendment No. 2 to Amended and Restated License and Collaboration Agreement, dated July 27, 2015 and entered into effective as of July 1, 2015, by and between the Registrant and Sanofi Biotechnology SAS, as successor-in-interest to Aventis Pharmaceuticals, Inc. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended September 30, 2015, filed November 4, 2015.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.3**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422020000022/regn-ex103x06302020x10q.htm">Third Amendment to Amended and Restated License and Collaboration Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2020, filed August 5, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.4**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422022000007/regen-ex_10144x12312021x10k.htm">Fourth Amendment to Amended and Restated License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422022000007/regen-ex_10144x12312021x10k.htm"> (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2021, filed February 7, 2022.)</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.471%"><tr><td style="width:1.0%"></td><td style="width:10.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.5**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422022000023/regn-ex_103x6302022x10q.htm">Fifth Amendment to Amended and Restated License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2022, filed August 3, 2022.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422020000022/regn-ex104x06302020x10q.htm">Praluent Cross License &amp; Commercialization Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant and Sanofi Biotechnology SAS. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2020, filed August 5, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000119312514008775/d659864dex101.htm">Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, sanofi-aventis US LLC, Aventis Pharmaceuticals Inc., sanofi-aventis Amerique du Nord, and the Registrant. (Incorporated by reference from the Form 8-K for the Registrant, filed January 13, 2014.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920067752/tm2021201d1_ex10-2.htm">Amendment to the Amended and Restated Investor Agreement, dated as of May 25, 2020, by and among the Registrant, Sanofi, Sanofi-Aventis US LLC, and Aventisub LLC. (Incorporated by reference from the Form 8-K for the Registrant, filed May 29, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14***</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465922128613/tm2233051d1_ex10-1.htm">Credit Agreement, dated as of December 19, 2022, by and among the Registrant, as a borrower and guarantor, certain direct subsidiaries of the Registrant, as the initial subsidiary borrowers, the lenders and issuing banks party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. (Incorporated by reference from the Form 8-K for the Registrant, filed December 20, 2022.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422022000023/regn-ex_102x06302022x10q.htm">Amended and Restated Immuno-oncology License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant and Sanofi Biotechnology SAS. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2022, filed August 3, 2022.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217616000055/regn-ex_102x03312016x10q.htm">ANG2 License and Collaboration Agreement, dated as of March 23, 2016, by and between Bayer HealthCare LLC and the Registrant. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended March 31, 2016, filed May 5, 2016.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217617000008/regn-ex_1035xlandmarkpsaex.htm">Purchase Agreement, dated as of December 30, 2016, by and among BMR-Landmark at Eastview LLC and BMR-Landmark at Eastview IV LLC and the Registrant. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2016, filed February 9, 2017.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18***</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465922031232/tm222431d2_ex10-1.htm">Second Amended and Restated Participation Agreement, dated as of March 2, 2022, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time. (Incorporated by reference from the Form 8-K for the Registrant, filed March 8, 2022.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19***</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465922031232/tm222431d2_ex10-2.htm">Second Amended and Restated Lease and Remedies Agreement, dated as of March 2, 2022, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor. (Incorporated by reference from the Form 8-K for the Registrant, filed March 8, 2022.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20***</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465922031232/tm222431d2_ex10-3.htm">Second Amended and Restated Guaranty, dated as of March 2, 2022, made by the Registrant, Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors. (Incorporated by reference from the Form 8-K for the Registrant, filed March 8, 2022.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex104.htm">Master Agreement, dated as of April 8, 2019, by and between the Registrant and Alnylam Pharmaceuticals, Inc. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2019, filed August 6, 2019.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21.1**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex1041.htm">Form of Co-Co Collaboration Agreement (Exhibit B to Master Agreement contained in Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex1041.htm">21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex1041.htm">).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21.2**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex1042.htm">Form of License Agreement (Exhibit C to Master Agreement contained in Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex1042.htm">21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000153217619000026/regn-ex1042.htm">).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000180422020000030/regn-ex103x09302020x10q.htm">License Agreement, dated as of August 18, 2020, by and among the Registrant, F. Hoffman-La Roche Ltd, and Genentech, Inc. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended September 30, 2020, filed November 5, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_211x12312022x10k.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_231x12312022x10k.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_94">Power of Attorney (included on the signature page of this Annual Report on Form 10-K).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_311x12312022x10k.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_312x12312022x10k.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_32x12312022x10k.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.471%"><tr><td style="width:1.0%"></td><td style="width:10.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Consolidated Balance Sheets as of December 31, 2022 and 2021; (ii) the Registrant's Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2022, 2021, and 2020; (iii) the Registrant's Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2022, 2021, and 2020; (iv) the Registrant's Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021, and 2020; and (v) the notes to the Registrant's Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.597%"><tr><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portions of this document have been omitted and filed separately with the Securities and Exchange Commission pursuant to requests for confidential treatment pursuant to Rule 24b-2.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain confidential portions of this Exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all confidential portions of this Exhibit that were omitted to the Securities and Exchange Commission upon its request.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain of the exhibits and/or schedules to this Exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules of this Exhibit to the Securities and Exchange Commission upon its request.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr></table></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ LEONARD S. SCHLEIFER</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Leonard S. Schleifer, President and Chief Executive Officer, and Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer, and each of them, his or her true and lawful attorney-in-fact and agent, with the full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities therewith, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.068%"><tr><td style="width:1.0%"></td><td style="width:37.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   LEONARD S. SCHLEIFER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer, and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   ROBERT E. LANDRY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   CHRISTOPHER R. FENIMORE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President, Controller (Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher R. Fenimore</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   GEORGE D. YANCOPOULOS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Scientific Officer, and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">George D. Yancopoulos, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   P. ROY VAGELOS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P. Roy Vagelos, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   BONNIE L. BASSLER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonnie L. Bassler, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   MICHAEL S. BROWN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael S. Brown, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   N. ANTHONY COLES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N. Anthony Coles, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   JOSEPH L. GOLDSTEIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph L. Goldstein, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   CHRISTINE A. POON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine A. Poon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   ARTHUR F. RYAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arthur F. Ryan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   GEORGE L. SING</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">George L. Sing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   MARC TESSIER-LAVIGNE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Tessier-Lavigne, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   CRAIG B. THOMPSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig B. Thompson, M.D. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   HUDA Y. ZOGHBI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huda Y. Zoghbi, M.D. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.362%"><tr><td style="width:1.0%"></td><td style="width:84.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page Numbers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_100">Report of Independent Registered Public Accounting Firm (PCAOB ID </a><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN185Ny9mcmFnOjI1MWI2MzYyNmJlODQ0MGFhOGVhYTM5OWZiZTkwMjJlL3RhYmxlOjZmZThlNjUzMTQwMzRiZGE5MTA2ZmY5MmQ4OGIxNzQ0L3RhYmxlcmFuZ2U6NmZlOGU2NTMxNDAzNGJkYTkxMDZmZjkyZDg4YjE3NDRfMS0wLTEtMS0xNzQzNjIvdGV4dHJlZ2lvbjpkMTlkZTc0OGQ2Y2I0MWRhYTE1YTI1MzczODM3YzJlZF83MQ_94abe652-461d-45a3-9596-62705ca03f32">238</ix:nonNumeric><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_100">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_100">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_100">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_103">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_103">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_103">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_106">Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_106">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_106">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_109">Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_109">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_109">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_112">Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_112">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_112">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_115">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_115">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_115">9</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_166">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_166">44</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Regeneron Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Regeneron Pharmaceuticals, Inc. and its subsidiaries (the "Company") as of December&#160;31, 2022 and 2021, and the related consolidated statements of operations and comprehensive income, of stockholders' equity and of cash flows for each of the three years in the period ended December&#160;31, 2022, including the related notes (collectively referred to as the "consolidated financial statements").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited the Company's internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for the Acquisition of the Worldwide Rights to Libtayo</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 1, 3, and 8 to the consolidated financial statements, in July 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi. The transaction was accounted for as an asset acquisition. Amounts paid in connection with obtaining the worldwide rights to Libtayo, which included an up-front payment of $<ix:nonFraction unitRef="usd" contextRef="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzIwNQ_56af7f89-b086-43f1-8831-8fb5a2499c62">900</ix:nonFraction>&#160;million, offset by the remaining up-front payments of $<ix:nonFraction unitRef="usd" contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701" decimals="-5" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzI1Mw_7b3a42fd-8759-4443-a571-0c931fdb0207">241</ix:nonFraction>&#160;million previously received under the Immuno-oncology License and Collaboration Agreement, were recorded as an intangible asset. The Company recorded additions to the Libtayo intangible asset primarily related to contingent consideration due to Sanofi in connection with obtaining the worldwide rights to Libtayo. As disclosed by management, due to the complexity of the terms of the amendments to the collaboration agreements in contemplation of the acquisition of the worldwide rights to Libtayo, significant judgment was applied by management in identifying the elements of the transaction and evaluating the timing and recognition of contingent consideration including the following: royalties, which are recorded in the period in which the underlying sales occur; sales-based milestones up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ib7a293af7f1a454b8c850b4caf8e4c3f_D20220701-20220731" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzIyMQ_fa781e00-58f0-4a0f-9bcb-fe6c1d521f7c">100</ix:nonFraction>&#160;million, which are recorded when the milestone is deemed probable by the Company of being achieved; a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i4d21c3111e2741a386578f848272cd46_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzIzNg_5933efe9-6d0a-414b-8b56-60d4a09392ef">100</ix:nonFraction>&#160;million, which is recorded upon achievement; and a portion of the value associated with the increase in the reimbursement percentage pursuant to the amendment to the Company's Antibody License and Collaboration Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the accounting for the acquisition of the worldwide rights to Libtayo is a critical audit matter are (i) the significant judgment by management in identifying the elements of the transaction and in evaluating the timing and recognition of contingent consideration, (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the accounting for the transaction and related disclosures, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls over management's accounting for the amendments to the collaboration agreements including controls over the identification of the elements of the transaction and evaluating the timing and recognition of contingent consideration. These procedures also included, among others (i) reviewing the Amended and Restated Immuno-oncology License and Collaboration Agreement and the amended Antibody License and Collaboration Agreement and other agreements related to the transaction; (ii) evaluating management's identification of the elements of the transaction; and (iii) evaluating the timing and recognition of contingent consideration. Professionals with specialized skill and knowledge were used to assist in evaluating the identification of the elements of the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzkzNzc_79669278-f4da-4971-a566-6e902b634342">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzkzNzE_e2fc5584-9884-4a8c-a004-831b9dc1803c">Florham Park, New Jersey</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;6, 2023 </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1989.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQtMS0xLTEtMTc0MzYy_305511be-8de1-4848-9e97-a63e4fbbb21b">3,105.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQtMy0xLTEtMTc0MzYy_8ec24fc3-5e53-42b5-b154-900578403b38">2,885.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzUtMS0xLTEtMTc0MzYy_47106067-9263-466e-9f85-5d06e1ccf5e2">4,636.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzUtMy0xLTEtMTc0MzYy_047b4555-c4a0-41c1-b1d3-adae3c6c345a">2,809.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzYtMS0xLTEtMTc0MzYy_3127728c-0f43-4253-b59b-ef0deaaba222">5,328.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzYtMy0xLTEtMTc0MzYy_9f72fe17-9689-4ef3-94d1-0af374d84f08">6,036.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzctMS0xLTEtMTc0MzYy_26fe3289-038f-4cfd-95bf-2ba518e0eaa2">2,401.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzctMy0xLTEtMTc0MzYy_e93031af-bbda-4e7a-840f-b4e9a3eb19e3">1,951.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzgtMS0xLTEtMTc0MzYy_f4a3d71c-9b4d-4848-914d-9eab100aefab">411.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzgtMy0xLTEtMTc0MzYy_d6a70520-a96c-4df0-9f4a-c809d23a8d37">332.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzktMS0xLTEtMTc0MzYy_3ce702ec-bf3a-411c-9869-4c8aeed4206c">15,884.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzktMy0xLTEtMTc0MzYy_b82be131-0dce-449e-b170-3ea69b39e860">14,014.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzExLTEtMS0xLTE3NDM2Mg_7665b915-9f02-4051-974a-114fae7252f8">6,591.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzExLTMtMS0xLTE3NDM2Mg_a3c0c9d3-6768-4bfb-bb3d-d72cb9cafd64">6,838.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEyLTEtMS0xLTE3NDM2Mg_bb9e9e47-230f-4c3d-bbf8-e4da4955b53f">3,763.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEyLTMtMS0xLTE3NDM2Mg_8999436f-2aca-4c02-8464-8cdcaba62814">3,482.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTEtMS0xLTE3Njk2MQ_2baedb67-2aa6-4358-b33b-c3bbc4079659">915.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTMtMS0xLTE3Njk2MQ_7e9e5989-70a0-40c6-936a-ab4ed44d7e96">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTEtMS0xLTE3NDM2Mg_cabc7d33-6963-4afa-9b0c-cc7609592153">1,723.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTMtMS0xLTE3NDM2Mg_0eacb45e-026f-45a1-8f12-90476cfa4250">876.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE0LTEtMS0xLTE3NDM2Mg_b4e7ba8d-defa-40ea-94aa-d84fe68fb712">336.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE0LTMtMS0xLTE3NDM2Mg_33c0b67d-d8ba-43a9-b0d5-0fe92799160e">216.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE1LTEtMS0xLTE3NDM2Mg_5e2a8c88-818f-4d70-a4dd-8da3d49c8966">29,214.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE1LTMtMS0xLTE3NDM2Mg_39c4a35e-23fe-4672-82a3-bd887588c369">25,434.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE5LTEtMS0xLTE3NDM2Mg_e35478ac-2187-400a-86e5-ddf3fc3955cf">589.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE5LTMtMS0xLTE3NDM2Mg_a27ad203-3091-4d35-a821-df95b4816458">564.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIwLTEtMS0xLTE3NDM2Mg_bf361362-fcd7-42c3-8849-328af9a99012">2,074.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIwLTMtMS0xLTE3NDM2Mg_20d6b32a-7ca8-4e55-ba2b-13e20b9f7f60">2,206.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIxLTEtMS0xLTE3NDM2Mg_113ed7fa-ebb1-4b01-8d20-22478daa41fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIxLTMtMS0xLTE3NDM2Mg_6f2bcd58-495c-4a9e-860f-3d0f09971778">719.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIyLTEtMS0xLTE3NDM2Mg_8e86b302-20d3-4040-a30c-5fb21225bc30">477.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIyLTMtMS0xLTE3NDM2Mg_65c1c80d-926e-4053-869f-a935b94a94ee">442.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIzLTEtMS0xLTE3NDM2Mg_c4928329-6c38-4624-8308-7f4cb8647056">3,141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIzLTMtMS0xLTE3NDM2Mg_67958e70-a516-41ba-a5cf-f28e8526bc70">3,932.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI1LTEtMS0xLTE3NDM2Mg_dcd61621-2111-4998-ba1d-dcde4e17bd93">1,981.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI1LTMtMS0xLTE3NDM2Mg_c250915b-f7ae-4a7f-819e-0ac3e89a45e2">1,980.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI2LTEtMS0xLTE3NDM2Mg_01acd0ad-8e87-4f3c-8dbc-658e42a8b349">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI2LTMtMS0xLTE3NDM2Mg_31cdf9a2-4aa1-41b3-9b32-60160bc88e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI3LTEtMS0xLTE3NDM2Mg_7aacafe7-8ef1-4324-8ce2-ae77fce72d66">69.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI3LTMtMS0xLTE3NDM2Mg_772825eb-6606-4180-b412-1342da24f299">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI4LTEtMS0xLTE3NDM2Mg_86002a7b-d56e-408d-a76b-5c6b1e303e90">638.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI4LTMtMS0xLTE3NDM2Mg_3938e596-0afe-4abf-a81e-29153740991b">680.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI5LTEtMS0xLTE3NDM2Mg_4bd5d64f-0c82-40ed-be52-b0df91fcc750">6,550.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI5LTMtMS0xLTE3NDM2Mg_83f02de3-b16d-4a90-8bb4-bf59896de819">6,666.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzMxLTEtMS0xLTE3NDM2Mg_7951e91e-e7fa-4587-94ff-b064c68f21ac"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzMxLTMtMS0xLTE3NDM2Mg_8072a75e-a4e8-4bf1-b1e8-b62245c9ead3"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzIx_677f2a95-53d1-4c75-ad96-c0a2b9f9fa85"><ix:nonFraction unitRef="usdPerShare" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzIx_bc29d0fe-ffa0-406c-8cdb-73eca584590a">.01</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzM1_12564c48-a690-4fc5-b189-e16e792f0c6a"><ix:nonFraction unitRef="shares" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzM1_f2b4a6e0-ced7-4111-976d-cd51e4e4ac54">30.0</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_35056692-f747-4f99-9b39-f8f663d9f3bf"><ix:nonFraction unitRef="shares" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_a3937fd6-78db-41ae-8ed3-c67c75e0cac1"><ix:nonFraction unitRef="shares" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_a5fa6eec-116b-4847-aa60-18c0c72e2472"><ix:nonFraction unitRef="shares" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_b15b35c8-a107-4c16-90b6-6ef0adb401a2">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTEtMS0xLTE3NDM2Mg_4b469567-8d2a-41e6-8bed-c4cc1fb788fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTMtMS0xLTE3NDM2Mg_7cf94409-f511-4215-ad3c-2c111bb1e6ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A Stock, convertible, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzMy_7610260b-2fde-4ad6-b5e5-dc39bfb6b1b0"><ix:nonFraction unitRef="usdPerShare" contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzMy_97532feb-4766-419c-9b37-ed7b213b97e8">.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzQ2_93887cb1-67f6-4824-834b-4fbcd8bbcf50"><ix:nonFraction unitRef="shares" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzQ2_b7107518-b6a1-4d7f-82e4-86289eefb678">40.0</ix:nonFraction></ix:nonFraction> shares authorized; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_251d6c53-1c8c-4404-84dd-14bb7afd8e62"><ix:nonFraction unitRef="shares" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_c596f633-a9e2-4061-ae3e-89e450fa2c32"><ix:nonFraction unitRef="shares" contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_d9ed1926-9eb5-4bba-be6d-415761926ff1"><ix:nonFraction unitRef="shares" contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_ee43723c-0ef0-4236-88f4-a234f9df13fc">1.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTEtMS0xLTE3NDM2Mg_a4229a3a-2c1d-42dc-88db-88fd255d7f00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTMtMS0xLTE3NDM2Mg_54c1dafd-6686-407f-9c33-0e67551590da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzE4_567b34cb-7474-4660-a829-51d496b30977"><ix:nonFraction unitRef="usdPerShare" contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzE4_e280e5b7-5827-42c0-9faa-3c370086edd8">.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzMy_0c031f4b-faf8-44a5-88db-ec385aac67af"><ix:nonFraction unitRef="shares" contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzMy_4175dfe2-3c26-4799-a523-a0b4f1702880">320.0</ix:nonFraction></ix:nonFraction> shares authorized; shares issued - <ix:nonFraction unitRef="shares" contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzcw_cbc4631d-1716-46cb-bb81-908369a076fd">130.4</ix:nonFraction> in 2022 and <ix:nonFraction unitRef="shares" contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzg1_ca9583b9-01f1-40a3-b83a-e15311b1f32d">126.2</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTEtMS0xLTE3NDM2Mg_0708ee9e-77f4-4cd5-9380-21b71b986c3d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTMtMS0xLTE3NDM2Mg_83f22cc0-aa8e-440b-9afb-ae19bcc4db8c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM3LTEtMS0xLTE3NDM2Mg_1bfc4667-4d72-4bb3-bc95-215df26827d9">9,949.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM3LTMtMS0xLTE3NDM2Mg_57de0ed9-1cb2-412b-bca6-ff84662b28c4">8,087.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM4LTEtMS0xLTE3NDM2Mg_14e88829-460f-49fd-963f-7a7eb5131091">23,306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM4LTMtMS0xLTE3NDM2Mg_3063f7d9-db83-4289-a59d-3f039f707d8e">18,968.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM5LTEtMS0xLTE3NDM2Mg_02bb38c2-682a-4eeb-aac8-d40bc29acb2b">238.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM5LTMtMS0xLTE3NDM2Mg_0788dd52-e6c3-487b-bcfd-8cdddd9a4679">26.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjljZjE3NzU4YmY3NjQwMWM4ZjdiOTU1Nzg3NTQ3NGNkXzI5_3d777e14-4c3f-4cba-a0ee-ea5ed7a0a3cc">22.6</ix:nonFraction> shares in 2022 and <ix:nonFraction unitRef="shares" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjljZjE3NzU4YmY3NjQwMWM4ZjdiOTU1Nzg3NTQ3NGNkXzUx_00949858-2bf7-4eca-af3c-11b31817f8b3">19.4</ix:nonFraction> shares in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTEtMS0xLTE3NDM2Mg_ecc62364-ec30-498f-b2d7-c7f884059d1f">10,353.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTMtMS0xLTE3NDM2Mg_f2b8b9f2-0f16-437f-ab23-6a095c2b6c2d">8,260.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQxLTEtMS0xLTE3NDM2Mg_5cda0f85-256b-4232-a2b2-8dd8d5f0342d">22,664.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQxLTMtMS0xLTE3NDM2Mg_4da4729b-9f1c-4ebb-86ee-92d4f50e1e98">18,768.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQyLTEtMS0xLTE3NDM2Mg_a91af9bf-c32a-403d-bf66-fc99fc1c4a3f">29,214.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQyLTMtMS0xLTE3NDM2Mg_16f817c1-98d7-4a42-9146-17b2cf79e1e2">25,434.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 13.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:53.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e78ed4547174cfb8fb6f17834e6e280_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQtMi0xLTEtMTc0MzYy_ed69ea18-7bcb-423f-ba3d-0536fffc1bc5">6,893.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5815b19f7c243a9bef193f7182d4504_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQtNC0xLTEtMTc0MzYy_09c0d72f-63e2-46fe-8344-fe0ba37b9391">12,117.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0f43af2adc4ac9932414df23261641_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQtNi0xLTEtMTc0MzYy_031cf7fa-53b2-4048-90a0-aee2cfcac44e">5,567.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32343f1d31f45ac91df7774f62751d8_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzUtMi0xLTEtMTc0MzYy_c080624a-2962-4c3e-8a9a-99f9d8e8ecfd">2,855.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb172db0f4c40f4a010b6c1e387157a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzUtNC0xLTEtMTc0MzYy_2adf3926-75c1-4088-a377-7d509387af1f">1,902.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5eff728cc34a73ac8a0e7575138379_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzUtNi0xLTEtMTc0MzYy_d8e06836-4904-4936-b58c-d0b3b2ac3cc3">1,186.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9eda36fe2b3493fba4bcd24c7f40343_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzYtMi0xLTEtMTc0MzYy_51a1c01c-f4a3-440d-920b-67709a7383a9">2,058.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2d84b10ee49a78ff80e825d16507c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzYtNC0xLTEtMTc0MzYy_9f0274d4-536f-4680-a6c3-b2a96c60f272">1,771.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8125997c22b4a2aaf3b8071ba41f4fb_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzYtNi0xLTEtMTc0MzYy_c36b0530-3d07-437e-ba63-7d1cd72d79f8">1,186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8632402ae5742efb1d686222b335e92_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzctMi0xLTEtMTc0MzYy_a135a0a3-37a5-4b4f-9978-e55f63ee3f88">365.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2052b209c6de41c9a910b9b4862dbf9d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzctNC0xLTEtMTc0MzYy_fcd8196d-6339-4ce5-899e-6d35c6763951">281.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cdfba9891941a6a7d17fd635d19308_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzctNi0xLTEtMTc0MzYy_968e4f12-189b-4f95-82c6-a50937c2dbb6">557.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzgtMi0xLTEtMTc0MzYy_def18e84-b260-4c97-a570-11a09a424ef9">12,172.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzgtNC0xLTEtMTc0MzYy_ee6fc6ad-e3f2-4a1a-be25-0a2e6bedd30e">16,071.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzgtNi0xLTEtMTc0MzYy_c5dee8ae-b0e3-46a8-879e-61253d64e5ce">8,497.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzExLTItMS0xLTE3NDM2Mg_aeffc617-25a6-4838-a91c-80c4030e4b0d">3,592.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzExLTQtMS0xLTE3NDM2Mg_4e32607c-96ca-4055-bd87-18be89d8cd5d">2,860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzExLTYtMS0xLTE3NDM2Mg_c140d3cb-0c41-463b-971a-926d1295371b">2,647.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTItMS0xLTE4MjkwMw_d04d36f8-b6d1-41b1-81a2-b1ee8d42066e">255.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTQtMS0xLTE4MjkwMw_87d51197-367c-485b-81aa-4a5d6c933e96">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTYtMS0xLTE4MjkwMw_4d3fc267-1a28-4010-8b2c-d83b9337b366">88.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTItMS0xLTE3NDM2Mg_29f59dba-28bc-408f-ad39-d038d7b838ca">2,115.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTQtMS0xLTE3NDM2Mg_4a0653cf-5ac7-4d7d-a88e-13a0461084c1">1,824.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTYtMS0xLTE3NDM2Mg_e1d7f73b-fff7-4dbb-b145-8ce28eb06335">1,346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e78ed4547174cfb8fb6f17834e6e280_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEzLTItMS0xLTE3NDM2Mg_7d8b3fb0-15d9-403a-9cc1-5542b81507c8">800.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5815b19f7c243a9bef193f7182d4504_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEzLTQtMS0xLTE3NDM2Mg_7eea3d78-aece-416c-9779-8a1694f55694">1,773.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0f43af2adc4ac9932414df23261641_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEzLTYtMS0xLTE3NDM2Mg_daa2ff65-3e13-4013-a468-22c2fb12a310">491.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8986e8b381c40169962c1d089395044_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE0LTItMS0xLTE3NDM2Mg_58e1c11a-4d44-4fc3-a0a5-0326c4511f8e">760.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc263c8f9c744cdb933cb195b372c5ec_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE0LTQtMS0xLTE3NDM2Mg_08ad9f8f-fe65-4cb2-ab81-9d68bb5dc62b">664.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714163480a9a4f66aa296cf9c53130f7_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE0LTYtMS0xLTE3NDM2Mg_17c5b932-71d2-459c-adae-76ccde57aa54">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE1LTItMS0xLTE3NDM2Mg_3dc235f1-2380-4ecc-9627-1f7ad1c775d3">89.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE1LTQtMS0xLTE3NDM2Mg_94cb6853-ee61-4786-a178-a74618805213">45.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE1LTYtMS0xLTE3NDM2Mg_8354884d-c3b4-4087-ac08-2186f09be080">280.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE2LTItMS0xLTE3NDM2Mg_562787a3-f112-4683-b0fe-398d8a95eb9f">7,434.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE2LTQtMS0xLTE3NDM2Mg_38f014de-0b6f-49b4-a1aa-270c4291e2da">7,124.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE2LTYtMS0xLTE3NDM2Mg_04de25d4-e974-43f3-a529-12ea2ac0080f">4,920.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE4LTItMS0xLTE3NDM2Mg_3b270fe7-51bb-4ee8-bc3c-a8e382f3d90a">4,738.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE4LTQtMS0xLTE3NDM2Mg_fdcf4bcb-efb1-4b12-a834-86f2fb12aff3">8,946.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE4LTYtMS0xLTE3NDM2Mg_747f8b5d-e297-4eea-bcdb-defe7d39d702">3,576.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIxLTItMS0xLTE3NDM2Mg_d9608a69-e65c-4ee6-825a-3aec0e7ef5e3">179.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIxLTQtMS0xLTE3NDM2Mg_229f0b71-2aa5-4a98-a8ce-8a392cc59bc4">436.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIxLTYtMS0xLTE3NDM2Mg_53c6b25b-a301-4069-a786-62626c0d86e2">290.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIyLTItMS0xLTE3NDM2Mg_99a4323f-024a-432b-ad47-f9fb81cdac1c">59.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIyLTQtMS0xLTE3NDM2Mg_7e424f2a-a69f-4d09-92c7-3594d9f96afe">57.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIyLTYtMS0xLTE3NDM2Mg_071ac281-5272-4213-a26b-ae3f2c5d066a">56.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIzLTItMS0xLTE3NDM2Mg_226636f2-e6b2-4754-bc3f-aeb686823259">119.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIzLTQtMS0xLTE3NDM2Mg_ae34888f-ca00-4545-aee5-34a20e22c675">379.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIzLTYtMS0xLTE3NDM2Mg_a7307f74-2435-46d5-a51f-48b9fa884a23">233.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI1LTItMS0xLTE3NDM2Mg_f8b99b7f-d44f-4c7c-82a8-a67dea5f9fc2">4,858.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI1LTQtMS0xLTE3NDM2Mg_df114fca-9f4c-4e53-bce2-472abe4691b0">9,325.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI1LTYtMS0xLTE3NDM2Mg_0d243767-6d01-4f7c-8cd6-0d0e8fad9bbb">3,810.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI3LTItMS0xLTE3NDM2Mg_1812ff75-5909-49d8-ad86-f23bf25b61ef">520.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI3LTQtMS0xLTE3NDM2Mg_2336b5bb-0fa9-42ce-898a-3ab9c9ff5a31">1,250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI3LTYtMS0xLTE3NDM2Mg_a44334dd-21e5-45c7-9564-20b8d438568f">297.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI5LTItMS0xLTE3NDM2Mg_0c81fbbc-c5e2-4686-a11f-b1a54f50bcb9">4,338.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI5LTQtMS0xLTE3NDM2Mg_e8504f41-d91b-45ca-aae3-bea2c2e5bf33">8,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI5LTYtMS0xLTE3NDM2Mg_5955652e-ec44-4ab4-8bc3-959f698d4319">3,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMxLTItMS0xLTE3NDM2Mg_13d6a368-ca1b-4ca8-a6fa-810af6ecdd7d">40.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMxLTQtMS0xLTE3NDM2Mg_2b79975d-c04f-4c22-ab9f-68dfd65c2501">76.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMxLTYtMS0xLTE3NDM2Mg_9666fe9a-8b08-409c-aea8-a6309196c506">32.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMyLTItMS0xLTE3NDM2Mg_4ae2eb02-4a56-4142-9559-3ab373b9ee5f">38.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMyLTQtMS0xLTE3NDM2Mg_85e58e62-7b04-4236-a13a-beb94c077809">71.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMyLTYtMS0xLTE3NDM2Mg_32187d9b-be7c-4c1b-a852-ddc427e2552c">30.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM0LTItMS0xLTE3NDM2Mg_dfb3a7c4-7142-4703-b3c0-8c13dc0203d7">107.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM0LTQtMS0xLTE3NDM2Mg_0c3e4181-5772-4e71-a2f6-be2b4a83e4be">105.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM0LTYtMS0xLTE3NDM2Mg_d4ab192f-fec3-4c1f-92bf-da234ae2ff42">107.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM1LTItMS0xLTE3NDM2Mg_04c3b122-659d-4790-8c19-e7a464b26ecc">113.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM1LTQtMS0xLTE3NDM2Mg_917e3752-96aa-47ee-a1c7-c5ba801dec5c">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM1LTYtMS0xLTE3NDM2Mg_88d3e40e-ba28-4b15-90a6-4d13272cf8db">115.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Comprehensive Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM4LTItMS0xLTE3NDM2Mg_ad8574fd-8052-4c57-8f66-e6054c7675d4">4,338.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM4LTQtMS0xLTE3NDM2Mg_ab6537a1-4d0e-4508-b1ee-87d08c1a2fb4">8,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM4LTYtMS0xLTE3NDM2Mg_9387cb86-74d9-403a-99b9-4f45f31c1034">3,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQwLTItMS0xLTE3NDM2Mg_b84c75a1-ca8a-4771-9abc-7da1ea52d3cc">213.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQwLTQtMS0xLTE3NDM2Mg_48c86011-e823-4b1a-ab38-7440a8400361">56.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQwLTYtMS0xLTE3NDM2Mg_5c7abaf5-c467-4171-b799-1d280f82b337">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQxLTItMS0xLTE3NDM2Mg_5c2add3f-c249-4bbc-86b5-d881e3e0c06e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQxLTQtMS0xLTE3NDM2Mg_6de4f596-78b8-4ac4-abf3-a8c30cd68c3a">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQxLTYtMS0xLTE3NDM2Mg_8cff6fd0-a7b0-4f09-960b-60cd5b82f920">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQyLTItMS0xLTE3NDM2Mg_21ba12d8-c691-45ac-9ac3-5b6b502bf305">4,125.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQyLTQtMS0xLTE3NDM2Mg_9b93461d-cc25-433a-ab91-74a754015dfd">8,019.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQyLTYtMS0xLTE3NDM2Mg_56d20d1d-b266-47d5-b0e6-48e30bc8404b">3,521.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Years Ended December 31, 2022, 2021, and 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.983%"><tr><td style="width:1.0%"></td><td style="width:25.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic29a659882534aef807d28ba085ed2cc_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMi0xLTEtMTc0MzYy_4ce20f09-76d0-4b4d-a252-92d8d749d2da">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a659882534aef807d28ba085ed2cc_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItNC0xLTEtMTc0MzYy_2a9cfdc4-8809-4986-8cdd-bd806c9121d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i034cb1f338a14cdb98427fcd16a6f4bf_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItNi0xLTEtMTc0MzYy_c73338ff-6c34-4f40-903c-243c013b8a08">113.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034cb1f338a14cdb98427fcd16a6f4bf_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItOC0xLTEtMTc0MzYy_cd1912a1-5877-423c-b8a9-89257d7c796f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5358609c29a1448aac4097e872d7c506_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTAtMS0xLTE3NDM2Mg_621d07de-ab82-4ce0-9843-d739b1901199">4,428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib492caa05ff2478cac6ccfaa46f83cdb_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTItMS0xLTE3NDM2Mg_3073b0e9-8bd9-4eae-9a67-80e936467d7e">7,379.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54e4119f42e4422bbe1589864186444_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTQtMS0xLTE3NDM2Mg_474654aa-edd8-4fb1-aced-2818f4b4a413">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i548c389088d843f3991fec42e82011bc_I20191231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTYtMS0xLTE3NDM2Mg_e8b699a9-441b-433d-996b-77a9756af8fe">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i548c389088d843f3991fec42e82011bc_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTgtMS0xLTE3NDM2Mg_1582a780-b8e9-4e61-9dec-f7de400d3f8e">739.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMjAtMS0xLTE3NDM2Mg_6f97d786-2e04-4c4f-8742-0a899e165e28">11,089.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15a99297fdea45a3aac29a3823f628b4_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMtNi0xLTEtMTc0MzYy_10628454-fb39-46de-a604-64c18e4745de">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMtMTAtMS0xLTE3NDM2Mg_dddcf90a-0e8e-4c01-8651-7de415831885">2,576.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMtMjAtMS0xLTE3NDM2Mg_7ccc9f10-e0e8-4fb0-89ee-bb3187efe846">2,576.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i15a99297fdea45a3aac29a3823f628b4_D20200101-20201231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzQtNi0xLTEtMTc0MzYy_32b35833-fdc7-4e9a-8fb3-fe798157bcf9">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzQtMTAtMS0xLTE3NDM2Mg_262dbd63-00d8-4cbc-bec8-70f2abde8ae2">768.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzQtMjAtMS0xLTE3NDM2Mg_2e0db603-51d9-40ca-a7f0-04756eca0b6a">768.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMTAtMS0xLTE3NDM2Mg_c9604d22-250f-4fe9-a7d9-c3d206050969">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMTYtMS0xLTE3NDM2Mg_eebb1aea-42b1-464f-9171-f59f74d4242b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMTgtMS0xLTE3NDM2Mg_7f26873d-1f8e-43f4-886b-ae8acb8c9e6f">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMjAtMS0xLTE3NDM2Mg_630053c5-1c41-434c-8803-1ed86a6c95a6">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzYtMTYtMS0xLTE3NDM2Mg_af1fe25b-0489-4a19-a0a5-90193b5da3f3">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzYtMTgtMS0xLTE3NDM2Mg_4830c758-242c-4f23-a682-e833750200d0">5,880.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzYtMjAtMS0xLTE3NDM2Mg_d84557f6-bd84-4469-8a20-3d82a44ec3ae">5,880.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzgtMTAtMS0xLTE3NDM2Mg_61eed7f9-829a-44f9-9ebc-d76b85fddbaf">442.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzgtMjAtMS0xLTE3NDM2Mg_126475f9-8f41-42f4-ba85-ea0b2edc3957">442.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0e234fb8004f8688e0132e0687751f_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEwLTEyLTEtMS0xNzQzNjI_9e25fba8-930a-4b75-a0c7-18af6287a888">3,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEwLTIwLTEtMS0xNzQzNjI_8a97af3a-3a87-4b71-9077-9797113c8aab">3,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09eb064653cc48138003ea93e9fb6cfa_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzExLTE0LTEtMS0xNzQzNjI_f839e2b7-6ba9-447f-a030-5fac476c9ae9">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzExLTIwLTEtMS0xNzQzNjI_c2a507f0-fe8a-49df-98b3-cff90aef219f">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i537fb80c394c4504bbb568309e3d34f4_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTItMS0xLTE3NDM2Mg_90f5cc5d-a32e-40b3-a3eb-c8c7ee676c8c">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537fb80c394c4504bbb568309e3d34f4_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTQtMS0xLTE3NDM2Mg_d83db85a-1db0-43b2-8051-6d74f312ec1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a9bb7780cb644e2bf4abf693651eabd_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTYtMS0xLTE3NDM2Mg_a860ec84-ec91-4130-b8f7-e9c342dc9161">121.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a9bb7780cb644e2bf4abf693651eabd_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTgtMS0xLTE3NDM2Mg_952aeb4c-6ab1-4e72-bcd6-0ca2225811d6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55644888ab1b4dfa9869ab896e024903_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTEwLTEtMS0xNzQzNjI_fea82ea7-b224-4b18-aa94-5a15ab0ddb0e">6,716.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8220af90ab304d119e3feac29aceae08_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTEyLTEtMS0xNzQzNjI_433f3b23-ad1e-40cc-928e-c7307cadb32a">10,893.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8049544cda8b4dafaed97a8723f7337d_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTE0LTEtMS0xNzQzNjI_64b89c7e-5eeb-4be0-9097-96cb67da37fb">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i370f4685af6144d1917cfe1061627472_I20201231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTE2LTEtMS0xNzQzNjI_530a14cd-1109-4575-a457-e55c0bc00c61">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i370f4685af6144d1917cfe1061627472_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTE4LTEtMS0xNzQzNjI_b87abeee-1528-411f-bcfd-37a1d8a1da83">6,613.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTIwLTEtMS0xNzQzNjI_3f5cdd4f-2735-44bc-b93e-9282afdd5cef">11,025.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabc93395b4534195a6e703327ee8276e_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEzLTYtMS0xLTE3NDM2Mg_e2ea1e3d-0086-4938-8bdb-d7839b6c52f1">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEzLTEwLTEtMS0xNzQzNjI_216d9501-dfa1-49c9-b8e4-612ab18d607e">1,676.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEzLTIwLTEtMS0xNzQzNjI_2746b6f8-ca08-45b8-b5c8-7a3e75ba818e">1,676.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iabc93395b4534195a6e703327ee8276e_D20210101-20211231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE0LTYtMS0xLTE3NDM2Mg_7a0863f6-6c42-4aeb-b9f1-2a12b722ef37">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE0LTEwLTEtMS0xNzQzNjI_f85e373a-7781-4007-a348-0ae8731c5c27">944.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE0LTIwLTEtMS0xNzQzNjI_3da3565b-0a3e-4e3c-9b49-95c2a2b85fec">944.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTEwLTEtMS0xNzQzNjI_110d160d-f53d-42f5-bb55-fc1b751f541b">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTE2LTEtMS0xNzQzNjI_5c870729-034d-4113-ad9b-0f8329fa475e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTE4LTEtMS0xNzQzNjI_c6f8cc5a-ebef-4481-b9b8-3969a265223d">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTIwLTEtMS0xNzQzNjI_3b595a7b-c716-4503-b52e-f4efb6611e1f">48.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE2LTE2LTEtMS0xNzQzNjI_60495beb-cbf6-45cb-b34c-fb1798dfb224">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE2LTE4LTEtMS0xNzQzNjI_7101ad6f-2b43-44ce-8398-7619e0ae6747">1,655.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE2LTIwLTEtMS0xNzQzNjI_e6796368-784a-4017-86bf-0aaec307245e">1,655.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE3LTEwLTEtMS0xNzQzNjI_c7398ea5-9634-4b7c-90aa-71e35afb3562">599.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE3LTIwLTEtMS0xNzQzNjI_dda15514-d1d1-4ea0-ac5e-ca6c6b42c0cc">599.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2d0c6bc9f4458b8e7efb5109a2426e_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE4LTEyLTEtMS0xNzQzNjI_055db923-4c11-4682-ac12-28a0319c90ec">8,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE4LTIwLTEtMS0xNzQzNjI_711b3fb1-c491-4cd0-b55f-ca2cca7f74a4">8,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if784455c39a741cca476b0900201d0f9_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE5LTE0LTEtMS0xNzQzNjI_32dc5e30-6a74-4930-a8d7-80d478a73586">55.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE5LTIwLTEtMS0xNzQzNjI_561b77ce-05c4-4242-834f-95c394a421e6">55.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id65b59d5da2340a0940c3e1995d7021f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTItMS0xLTE3NDM2Mg_91700743-edc2-4a33-84fb-459fe08165a3">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65b59d5da2340a0940c3e1995d7021f_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTQtMS0xLTE3NDM2Mg_9006bc92-7be5-4024-a212-fe4a42b6e235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12be5553e41d40be83ba97a5fe81845b_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTYtMS0xLTE3NDM2Mg_bbc38a2d-dad0-4ea3-8c4f-8f1c45555a08">126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12be5553e41d40be83ba97a5fe81845b_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTgtMS0xLTE3NDM2Mg_27ab7543-266f-472b-a907-76ef2e69cadf">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666d725ef2cf4065b50048f5296edab9_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTEwLTEtMS0xNzQzNjI_a39c2b9f-6ba4-4527-8009-b5ae909c2ef0">8,087.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83be0f48228e4464a3d79b1afd625715_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTEyLTEtMS0xNzQzNjI_0c70ea71-bc2e-4f38-9989-dd6d071578b5">18,968.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if802f07034c74a87a67853bdd63c7037_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTE0LTEtMS0xNzQzNjI_7f07b702-6b57-4b72-8c69-a660051e2cd7">26.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic572b99252494005bc30f8d6d54277fb_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTE2LTEtMS0xNzQzNjI_7eccab63-38bc-4da6-9d81-fbdd0bba82ec">19.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic572b99252494005bc30f8d6d54277fb_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTE4LTEtMS0xNzQzNjI_a519337b-40ce-41a5-8245-67340a3c2c9a">8,260.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTIwLTEtMS0xNzQzNjI_3870c173-bff4-435b-af2a-6fadf8059093">18,768.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:120pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.983%"><tr><td style="width:1.0%"></td><td style="width:25.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="63" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i070f93a0d90d444baf671f55dbf55f10_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI1LTYtMS0xLTE3NDM2Mg_a5f2d0a1-f6c7-433c-a376-0e04d3e667c6">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI1LTEwLTEtMS0xNzQzNjI_f3555a15-d29a-4f00-ac00-921813b71ab5">1,517.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI1LTIwLTEtMS0xNzQzNjI_bd83565a-3832-4dfb-b08d-6f4bbf5b0997">1,517.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i070f93a0d90d444baf671f55dbf55f10_D20220101-20221231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI2LTYtMS0xLTE3NDM2Mg_76b34d2c-a17d-493a-ba4d-171dba078651">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI2LTEwLTEtMS0xNzQzNjI_ad1a44d4-3e35-4f20-9287-db3785083835">445.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI2LTIwLTEtMS0xNzQzNjI_6e094153-5802-4edb-b091-20d9ce055e24">445.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTEwLTEtMS0xNzQzNjI_441e34d6-02a2-4a0b-aff8-6147797cc395">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTE2LTEtMS0xNzQzNjI_b0b6d775-4bdc-4a2e-b0fa-9efd80bcc285">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTE4LTEtMS0xNzQzNjI_82e2caf5-2fbf-4a45-8368-125ae0ec8972">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTIwLTEtMS0xNzQzNjI_db96c772-b61d-4f9e-a1f1-089539e09b49">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI4LTE2LTEtMS0xNzQzNjI_5776f970-c257-42d1-9c00-4d867fbf6fc7">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI4LTE4LTEtMS0xNzQzNjI_97938856-68e5-48ff-8024-148905369280">2,099.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI4LTIwLTEtMS0xNzQzNjI_5e194e76-51a1-49f1-9d2d-9c887043e5f5">2,099.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI5LTEwLTEtMS0xNzQzNjI_e1dfbaec-c84d-4ab6-93cb-1b5eb05865b5">737.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI5LTIwLTEtMS0xNzQzNjI_d91c00b9-c0c7-4f4f-9111-d6d5980800ec">737.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca914c1a8484668a3a14d372c8d453b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMwLTEyLTEtMS0xNzQzNjI_100a1212-c818-43b9-82b1-27abf68f8f93">4,338.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMwLTIwLTEtMS0xNzQzNjI_7433e449-c66e-4b36-8b28-aa0bd55e4103">4,338.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3919061e6c614ec5a67ef420703684b6_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMxLTE0LTEtMS0xNzQzNjI_06540420-841a-4bb5-9899-d0fe0582669e">212.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMxLTIwLTEtMS0xNzQzNjI_9699cf17-0d7e-4ec3-a58e-34c0b2923eec">212.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f56d798d2de4fd58840b7e15ab5383e_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTItMS0xLTE3NDM2Mg_f29492ad-063b-478c-aad4-3085ac51a83b">1.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f56d798d2de4fd58840b7e15ab5383e_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTQtMS0xLTE3NDM2Mg_b6b3836d-f1af-4890-b8c0-2637dda07815">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43a6ec2800b049a390ee894f424cd007_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTYtMS0xLTE3NDM2Mg_5339700c-8454-42c2-8ca6-58dc4f396e62">130.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a6ec2800b049a390ee894f424cd007_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTgtMS0xLTE3NDM2Mg_f565760e-3cc4-40a2-802a-e4aff83f9982">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d4bf60775b4d869dd15f70b0ce4725_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTEwLTEtMS0xNzQzNjI_0993eb71-321c-404e-b837-2c6d74885042">9,949.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33b2737ad5f4d81a64471a8087f6b6b_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTEyLTEtMS0xNzQzNjI_3e88489b-9810-408d-923b-d7c7a63f5386">23,306.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i801c30702fbc4a43994e5257eeedd771_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTE0LTEtMS0xNzQzNjI_a0615f2e-fa0b-47e6-88fb-d0bf1bd18691">238.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2e6785130a464ace9f5ea5f75c6c368b_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTE2LTEtMS0xNzQzNjI_4eb47eaa-2f22-497f-8daf-e772bf5aa0ed">22.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e6785130a464ace9f5ea5f75c6c368b_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTE4LTEtMS0xNzQzNjI_f7cb71fe-2957-46dd-a316-011b0af5a340">10,353.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTIwLTEtMS0xNzQzNjI_ec6cab89-f0d3-4bfc-9e0e-7f3421a062f0">22,664.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="63" style="padding:0 1pt"></td></tr><tr><td colspan="63" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:59.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMtMi0xLTEtMTc0MzYy_9305dfbe-2b83-4798-80dd-d328e5f7ee35">4,338.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMtNC0xLTEtMTc0MzYy_f771612a-1113-4dc7-887f-d47832e2939a">8,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMtNi0xLTEtMTc0MzYy_0f32d25b-5fe7-4458-b27e-f26a4c7e6e4b">3,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzUtMi0xLTEtMTc0MzYy_48fe0b3e-3a27-46a0-b230-652ac463b70e">341.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzUtNC0xLTEtMTc0MzYy_6e43a69d-af20-4d0f-b626-f0e36d428e3f">286.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzUtNi0xLTEtMTc0MzYy_6074bd87-079f-4572-b809-05561fe437b8">235.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzYtMi0xLTEtMTc0MzYy_1cacda1d-1858-4d2c-adef-72cf8f775b43">725.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzYtNC0xLTEtMTc0MzYy_7b95bff0-09ea-4ee7-8118-656407dd0496">601.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzYtNi0xLTEtMTc0MzYy_7217e8d6-062e-4b1c-9f96-6f33daee2764">432.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses (gains) on marketable and other securities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="regn:MarketableAndOtherSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzctMi0xLTEtMTc0MzYy_33605dfd-43b0-4211-bb78-9b524892973d">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:MarketableAndOtherSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzctNC0xLTEtMTc0MzYy_0e9c5075-3dff-4a81-8ea8-33c37de65e8b">387.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:MarketableAndOtherSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzctNi0xLTEtMTc0MzYy_860a3629-e840-4bb5-aa13-950f5c88402c">221.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzgtMi0xLTEtMTc0MzYy_5483f9c6-75c2-4aa1-a7fc-5f01403ec08d">368.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzgtNC0xLTEtMTc0MzYy_9f8cbe87-d78d-4fd6-b558-b5cca84d1a13">568.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzgtNi0xLTEtMTc0MzYy_4d5a310d-e749-4c73-a19c-7de3a5ac7785">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzktMi0xLTEtMTc0MzYy_ba53558c-c7a4-4441-bac6-63dc1f17daa3">746.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzktNC0xLTEtMTc0MzYy_e48bac1a-45bf-466a-9d6a-966009a829d8">147.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzktNi0xLTEtMTc0MzYy_18e5f78e-9130-4b06-badd-7638ebd7e5de">75.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development in connection with asset acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEwLTItMS0xLTE3NTY4Nw_f570ca0c-a953-4403-9de8-c7eebe08d067">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEwLTQtMS0xLTE3NTY4Nw_18dece85-0b8c-43ed-b315-ff527b812993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEwLTYtMS0xLTE3NTY4Nw_4f03a2b6-7998-4dd7-ae85-39eb874a5920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzExLTItMS0xLTE3NDM2Mg_b6892edb-d786-4add-a948-40abd44df21b">707.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzExLTQtMS0xLTE3NDM2Mg_bfc2c627-6268-4c6a-a1b9-bd2b2c3e411d">1,927.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzExLTYtMS0xLTE3NDM2Mg_2114159c-2c1f-401c-a71d-75c2cc6cdab1">1,356.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEyLTItMS0xLTE3NDM2Mg_4a896c6f-0497-4435-9bb5-9bbd3b47d4b2">696.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEyLTQtMS0xLTE3NDM2Mg_5d96fadd-878c-46bf-a2fd-c956abeabc90">494.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEyLTYtMS0xLTE3NDM2Mg_327172e4-d142-4e22-be4b-eef6a6afe0b8">529.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEzLTItMS0xLTE3NDM2Mg_b28f6cf9-d045-407f-972b-06f42de2519a">148.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEzLTQtMS0xLTE3NDM2Mg_83001fcb-a492-4d3d-a1bb-de25d1f29e54">240.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEzLTYtMS0xLTE3NDM2Mg_b1f1f66c-d586-4ca7-8858-4700dfbf1184">114.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE0LTItMS0xLTE3NDM2Mg_df010df5-1e25-4b25-94f7-6ac8cb09d498">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE0LTQtMS0xLTE3NDM2Mg_b1eee65b-9e56-49fe-a9a3-1521cd2bbb37">120.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE0LTYtMS0xLTE3NDM2Mg_eb71a82b-18e8-42df-8ec5-a66e60ad3f9c">148.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in accounts payable, accrued expenses, and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE1LTItMS0xLTE3NDM2Mg_29a2ba70-f2ab-4e4c-b0d5-d3e9789553ef">138.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE1LTQtMS0xLTE3NDM2Mg_1f0f0ad1-6ef9-4c2b-b6fb-fc0df42429eb">866.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE1LTYtMS0xLTE3NDM2Mg_9fff4ae6-e67b-40a6-8e36-0e70968b130b">118.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE2LTItMS0xLTE3NDM2Mg_7a70574e-6172-4031-9d1d-6ace5cd1a228">676.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE2LTQtMS0xLTE3NDM2Mg_ad801d71-9b66-4c35-95e6-7e8fe1339b6e">994.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE2LTYtMS0xLTE3NDM2Mg_046622d5-4275-4618-9ad3-65d9330144a0">895.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE3LTItMS0xLTE3NDM2Mg_dbf3aac1-0c14-4648-a065-06ace72e9e9d">5,014.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE3LTQtMS0xLTE3NDM2Mg_ee69e17a-d516-4615-9b70-0021d7060c92">7,081.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE3LTYtMS0xLTE3NDM2Mg_4817fc21-b1a3-472e-b8cd-a6bc86d8cc68">2,618.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable and other securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIwLTItMS0xLTE3NDM2Mg_306e9004-72a7-45be-8ef2-bddb8be66726">7,487.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIwLTQtMS0xLTE3NDM2Mg_96f6f367-4b2a-471d-9af0-1b9f151cfee9">7,048.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIwLTYtMS0xLTE3NDM2Mg_2952e524-caef-4d4f-a54b-ff6a55e183bd">3,241.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales or maturities of marketable and other securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIxLTItMS0xLTE3NDM2Mg_606e5c30-4a26-4aa9-883e-2f338aea3a2c">5,550.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIxLTQtMS0xLTE3NDM2Mg_83c755de-f4ae-4af0-995a-cc916543955f">2,215.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIxLTYtMS0xLTE3NDM2Mg_c87de4bd-f16f-4c02-b6ee-50d5868a9b4f">3,785.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIyLTItMS0xLTE3NDM2Mg_5bb9220a-b6aa-4b07-acbe-a09b6004bfc7">590.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIyLTQtMS0xLTE3NDM2Mg_7b95cb64-17ac-4f3c-b0d5-16bf413fee2e">551.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIyLTYtMS0xLTE3NDM2Mg_5f954096-5066-4121-82c3-31011d30810c">614.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for Libtayo intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:PaymentsToAcquireIntangibleAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI0LTItMS0xLTE3NTcwNg_bbb8d981-2ff4-4da1-8892-f4111cfbe909">1,026.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:PaymentsToAcquireIntangibleAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI0LTQtMS0xLTE3NTcwNg_ff2252fd-1461-4f8a-ac41-ac04db5ce2a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:PaymentsToAcquireIntangibleAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI0LTYtMS0xLTE3NTcwNg_e633342c-db38-4cb2-94e6-0f63ae3e9e6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset acquisition, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:PaymentsForAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI1LTItMS0xLTE3NTcwNg_e5789212-58d4-4a63-a320-71ee649d843c">230.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:PaymentsForAssetAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI1LTQtMS0xLTE3NTcwNg_b9294e04-ca75-4016-80bd-e3a76fb0f044">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:PaymentsForAssetAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI1LTYtMS0xLTE3NTcwNg_2317acc1-d734-4ffb-aeef-70f6fb23fbac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIzLTItMS0xLTE3NDM2Mg_153d6f8d-9e4d-4542-8dc8-accc516c3533">3,784.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIzLTQtMS0xLTE3NDM2Mg_93991a2a-35fe-483c-abc9-127b4448b7ca">5,384.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIzLTYtMS0xLTE3NDM2Mg_09074359-d635-47a1-a9ce-59a65e4955f4">70.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI2LTItMS0xLTE3NDM2Mg_98884a68-b9e0-443b-9e6e-909d03cd0fe8">1,519.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI2LTQtMS0xLTE3NDM2Mg_b7613a82-eea2-4ed8-9436-b6f92d3400fc">1,672.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI2LTYtMS0xLTE3NDM2Mg_46f4b9ef-f880-43f1-b082-c4a3efa81e70">2,575.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments in connection with Common Stock tendered for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI3LTItMS0xLTE3NDM2Mg_ee418d79-1e1b-431c-8a71-8507c0cb21fa">445.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI3LTQtMS0xLTE3NDM2Mg_d213eaa6-b44b-41d8-b6e9-87f437105946">1,032.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI3LTYtMS0xLTE3NDM2Mg_78327d36-da76-4e58-8e12-1907d23e4796">680.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI4LTItMS0xLTE3NDM2Mg_9db7a6d1-24c3-411f-93a9-af291ea84677">2,082.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI4LTQtMS0xLTE3NDM2Mg_5091b8bd-9bf4-4149-b2ed-3adc38eec567">1,645.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI4LTYtMS0xLTE3NDM2Mg_37210de4-d2a7-4501-a1fd-cb018451bd77">5,846.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI5LTItMS0xLTE3NDM2Mg_0f13cb9b-3385-4665-854b-0591283814a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI5LTQtMS0xLTE3NDM2Mg_81fb150a-07c6-412e-af40-ab2392f76383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI5LTYtMS0xLTE3NDM2Mg_6fcf93db-0f05-44cd-bc35-249068ebe6c2">1,981.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from bridge loan facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMwLTItMS0xLTE3NDM2Mg_685515ec-f51f-4d0a-b979-2847cf9303f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMwLTQtMS0xLTE3NDM2Mg_e9660039-4cfc-46f5-9760-33957b7a9945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMwLTYtMS0xLTE3NDM2Mg_0c9a04ad-f2cb-4876-9781-77e31eb578e1">1,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of bridge loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMxLTItMS0xLTE3NDM2Mg_f07ed6d5-2534-46b8-8167-39d995f34e68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMxLTQtMS0xLTE3NDM2Mg_0efdea81-d3f8-4833-a985-97ea6797d13c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMxLTYtMS0xLTE3NDM2Mg_3d14474a-6855-4f7e-afba-634a257d37ba">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMyLTItMS0xLTE3NDM2Mg_c59283f2-995b-43fe-baae-5903130c6993">1,009.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMyLTQtMS0xLTE3NDM2Mg_fa59023d-9e73-4732-8b51-3f7f8ef5be96">1,005.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMyLTYtMS0xLTE3NDM2Mg_cab6472d-6350-45b6-a1c5-27939a927207">1,970.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM0LTItMS0xLTE3NDM2Mg_fc92d3ad-ce08-41d2-a88c-2560a5df3cb1">221.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM0LTQtMS0xLTE3NDM2Mg_2cd01263-cc1f-4f5b-b7c7-735a5e11172b">690.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM0LTYtMS0xLTE3NDM2Mg_6b8907d7-076d-4d24-8d6c-37946be9be00">577.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM2LTItMS0xLTE3NDM2Mg_d7b47dac-73f1-41fe-9a3d-5a3ee1a9f950">2,898.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM2LTQtMS0xLTE3NDM2Mg_7c5ea345-b8c4-47c0-a2e7-d982bf345169">2,207.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM2LTYtMS0xLTE3NDM2Mg_29cf7bf4-6422-4612-b7ab-79d41254ca43">1,630.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM4LTItMS0xLTE3NDM2Mg_12fb036c-6263-4934-aaad-4a99ae1ce720">3,119.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM4LTQtMS0xLTE3NDM2Mg_9a18379a-2088-4d0f-942d-702efafab066">2,898.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM4LTYtMS0xLTE3NDM2Mg_26548118-74e8-4ade-ba16-f47d0e6a9379">2,207.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest (net of amounts capitalized)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQxLTItMS0xLTE3NDM2Mg_f4ced759-f8bb-43ad-bbf2-8fcfd9e539de">53.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQxLTQtMS0xLTE3NDM2Mg_afb7ddee-ea6c-4fab-884c-bc044f30dd02">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQxLTYtMS0xLTE3NDM2Mg_6a200fbc-852d-43d2-98c0-ba1a8ab465a3">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQyLTItMS0xLTE3NDM2Mg_0c3841df-c29f-4bbc-9072-83d96dc64404">1,502.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQyLTQtMS0xLTE3NDM2Mg_ef19fb14-5508-4096-8f0e-2aa10a9db50c">1,218.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQyLTYtMS0xLTE3NDM2Mg_471a2b29-fb76-4326-8da9-73768827f2e4">188.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_118"></div><div style="margin-bottom:8pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjIw_565e77f6-8603-415f-95b5-eac1fd302306" continuedAt="i9ccbbfd7d1fb4861b6bf6469521a4ed9" escape="true">Business Overview and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i9ccbbfd7d1fb4861b6bf6469521a4ed9" continuedAt="i460dc9d19e104fc6afbd19d85fb20cc4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The Company currently has <ix:nonFraction unitRef="product" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="INF" name="regn:NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM2NQ_8f8a2af7-4928-491b-8dc6-0c7d4df637d1">nine</ix:nonFraction> products that have received marketing approval by the U.S. Food and Drug Administration ("FDA"). In addition, REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was authorized under an Emergency Use Authorization ("EUA") from November 2020 until January 2022 when the EUA was revised to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment; with this EUA revision, REGEN-COV is not currently authorized for use in any U.S. states, territories, or jurisdictions. The Company is a party to collaboration agreements to develop and commercialize, as applicable, certain products and product candidates (see Note 3).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzgxOA_ce7b0571-e18a-4d32-8874-39ead4ae3602">one</ix:nonFraction> business segment, which includes all activities related to the discovery, development, and commercialization of medicines for serious diseases. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting research activities, product development, obtaining regulatory approvals, competition, and obtaining and enforcing patents.</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTM3_09811e45-72be-405f-b2ba-f8a2bad1ff47" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Regeneron and its wholly-owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the first quarter of 2022, the Company added a new line item, Acquired in-process research and development, to its Consolidated Statements of Operations and Comprehensive Income. This line item includes in-process research and development acquired in connection with asset acquisitions as well as up-front/opt-in payments related to license and collaboration agreements. Amounts recorded in this line item during the year ended December 31, 2022 would have historically been recorded to Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation, including in connection with the addition of Acquired in-process research and development described above.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjkx_bffc3562-1ffd-419d-8a31-910bc1a1548c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTc4_3e48999e-dc9c-4d3a-a594-a6dbba2ecc72" continuedAt="i26346d03f6694800b99061987a55ec45" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain investments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties.  </span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i26346d03f6694800b99061987a55ec45">Concentrations of credit risk with respect to customer and collaborator accounts receivable are significant.</ix:continuation> As of December&#160;31, 2022, two individual customers accounted for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i00bac7cbbc5e4246b3f94989f1a587b7_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzI5NDA_c2b6607a-21c4-40fd-8b48-158a85d1a653">86</ix:nonFraction>% of the Company's net trade accounts receivable balances. Three individual customers accounted for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6732651b19384641aff2c7fa3e18b1b4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzMwODc_0ca3fc43-738d-4169-a7b6-885fda21ce03">91</ix:nonFraction>% (including <ix:nonFraction unitRef="number" contextRef="iad3a33c797844c159114ad188489310b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzI3NDg3NzkwOTc2MTY_feafeb2c-6a09-441f-a554-2e264cfdda68">29</ix:nonFraction>% related to the U.S. government) of the Company's net trade accounts receivable balances as of December 31, 2021. The Company has contractual payment terms with each of its collaborators and customers, and the Company monitors their financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. As of December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_0c1cb847-52d5-49ac-a5cc-2040a9839a2b"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_2e618d9c-6c90-4269-b515-bed92ff21b80"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_50795ed9-7eab-49f6-94d0-b1ce8a6f9803"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_c7678a5d-30bf-4bea-bf16-647f7f6dc5aa">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> write-offs and allowances of accounts receivable related to credit risk for the Company's collaborators or customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTk3_6adecc81-9dc8-4bc5-a7b5-308f44a594b1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. The carrying amount reported in the Consolidated Balance Sheet for cash and cash equivalents approximates its fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i460dc9d19e104fc6afbd19d85fb20cc4" continuedAt="ic91dbade5c424db6b8cd8f52f0308ab7"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjkz_1147843b-cbaf-48a9-bed2-1292ed3a9681" continuedAt="i5d730d5732aa48b9807ec4a607c53388" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt and Equity Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. The Company invests its cash primarily in debt securities. The Company considers its investments in debt securities to be "available-for-sale," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Realized gains and losses on available-for-sale debt securities are included in other income (expense), net. The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in net income, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss). </span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d730d5732aa48b9807ec4a607c53388">The Company also has investments in equity securities that are carried at fair value with changes in fair value recognized within other income (expense), net. The Company has elected to measure certain equity investments it holds that do not have readily determinable fair values at cost less impairment, if any, and adjusts for observable price changes in orderly transactions for identical or similar investments of the same issuer within other income (expense), net.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjk0_1f1166a7-a890-413c-9456-f48422f3e9fd" continuedAt="ic072f38b9a5441348fa841cd15efa3d7" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic072f38b9a5441348fa841cd15efa3d7">The Company's trade accounts receivable arise from product sales and represent amounts due from its customers. In addition, the Company records accounts receivable arising from its collaboration and licensing agreements. The Company monitors the financial performance and credit worthiness of its counterparties so that it can properly assess and respond to changes in their credit profile. The Company provides allowances against receivables for estimated losses, if any, that may result from a counterparty's inability to pay. Amounts determined to be uncollectible are written-off against the allowance.</ix:continuation> </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjgz_c6660c00-802f-45b5-9058-9daf99ec5b13" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such inventory to its estimated realizable value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTk5_207bb80c-77f3-4dc7-a2c2-873c66b72481" continuedAt="i53092d1d65b74b928c078d9054aaa514" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant, and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Costs of construction of certain long-lived assets include capitalized interest, which is amortized over the estimated useful life of the related asset. Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized within income from operations. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjI3_87fa2589-ac0c-456c-bbb7-c22a38b151d0" continuedAt="i39235f3010044e6eb660cf9c7ca55e94" escape="true">The estimated useful lives of property, plant, and equipment are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><ix:continuation id="i39235f3010044e6eb660cf9c7ca55e94" continuedAt="ib5111bb7f6014b308826ed6b6d9bf371"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"><tr><td style="width:1.0%"></td><td style="width:67.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i492786f7a1b94a1594a932e2b271fa8a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzAtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246OWU2NzQ1NzAzNzU0NDk5OGFkY2E0NjNhNTM5OTFhOTFfNA_3ceffc11-d30e-4bfa-bc6e-76d0147cd442">10</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="ia9c27db3739642f99f43796472a8d403_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzAtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246OWU2NzQ1NzAzNzU0NDk5OGFkY2E0NjNhNTM5OTFhOTFfNw_3d2a98ca-2482-4275-a28a-4f481eef74d4">50</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6a49d235b3214cedb524b0736433ccc3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzEtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246YzhiZDA3MzdhZTEzNDQ3NGE4NWNjZTJkNWMwYjdiZWRfNA_f2b59473-211b-483d-b43f-3bad74a3b552">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i664445be718b4d0faeb4a37890e76062_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzEtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246YzhiZDA3MzdhZTEzNDQ3NGE4NWNjZTJkNWMwYjdiZWRfNw_a0df8f3f-c66b-45ed-86a3-20f5ceed7719">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3488dea3c9b405e93bf3bd0b9ede622_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzItMi0xLTEtMTc0MzYyL3RleHRyZWdpb246ZDU2NjAyNDVkMDJjNDRjMzk0MjE0ODQ3YjhiN2NiODVfNA_3e8a723a-08bd-4029-9c53-aef9b0d25f2d">5</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i53092d1d65b74b928c078d9054aaa514">The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ic91dbade5c424db6b8cd8f52f0308ab7" continuedAt="ib98b905c1b8f4934b4874b8ed4ab02cf"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjQw_9853d2e2-db3d-48de-9e85-0bdbf42679d5" continuedAt="i43d3626c778247148f4cb7278a6f5608" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease considering whether there is an identified asset and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company's lease terms may include options to extend or terminate a lease when it is reasonably certain that it will exercise that option. The Company accounts for lease components (e.g., rental payments) separately from non-lease components (e.g., common area maintenance costs).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, unless there is a transfer of title or purchase option the Company is reasonably certain to exercise. For leases where an implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on information available at the lease commencement date to determine the present value of future lease payments. Lease expense for operating leases is recognized on a straight-line basis over the expected lease term.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzY1OTcwNjk3OTQxODc_a736ed15-f693-4fce-9b0c-f24d0523e804" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company makes a determination of whether an asset or set of assets acquired constitute a business. If it is determined that substantially all of the fair value of gross assets acquired in a transaction are concentrated in a single identifiable asset, then the transaction is accounted for as an asset acquisition. Intangible assets acquired in connection with an asset acquisition are recorded at cost. Such amounts may include up-front payments and contingent consideration. With regard to contingent consideration, the Company recognizes regulatory milestones upon achievement, royalties in the period in which the underlying sales occur, and sales-based milestones when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets are amortized to Cost of goods sold over the estimated useful lives of the assets based on the pattern in which the economic benefits of the intangible assets are consumed; if that pattern cannot be reliably determined, a straight-line basis is used. If contingent consideration is recognized subsequent to the acquisition date in an asset acquisition, the amount of such consideration is recorded as an addition to the cost basis of the intangible asset with a cumulative catch-up adjustment for amortization expense as if the additional amount of consideration had been accrued from the outset of the acquisition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's intangible assets are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If an indicator of impairment exists, the Company compares the projected undiscounted cash flows to be generated by the asset to the intangible asset's carrying amount. If the projected undiscounted cash flows of the intangible asset are less than the carrying amount, the intangible asset is written down to its fair value in the period in which the impairment occurs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjU1_26919a44-57d5-494e-b0ee-b78343c24be4" continuedAt="i98b9d96f067149c4959736e6284f3905" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition - Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized at a point in time when the Company's customer is deemed to have obtained control of the product, which generally occurs upon receipt or acceptance by its customer. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue the Company recognizes from product sales may vary due to rebates, chargebacks, and discounts provided under governmental and other programs, distribution-related fees, and other sales-related deductions. In order to determine the transaction price, the Company estimates, utilizing the expected value method, the amount of variable consideration to which the Company will be entitled. This estimate is based upon contracts with customers, healthcare providers, payors, and government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, estimated payor mix, and other relevant factors. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rebates include amounts paid to managed care organizations, group purchasing organizations, state Medicaid programs, and other rebate programs. The Company estimates reductions to product sales for each type of rebate and records an allowance for rebates in the same period in which the related product sales are recognized. The Company's liability for rebates consists of estimates for claims related to the current and prior periods that have not been paid and estimates for claims that will be made related to inventory that exists in the distribution channel at the end of the period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ib98b905c1b8f4934b4874b8ed4ab02cf" continuedAt="i54ec8a935aa8484b9e967884298af953"><ix:continuation id="i98b9d96f067149c4959736e6284f3905" continuedAt="i5d5aa53c63554127aa16082e2bd31218"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's reserves related to discounted pricing to eligible physicians, Veterans' Administration ("VA"), Public Health Services, and others (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the discounted selling price to the qualified healthcare providers. The Company estimates reductions to product sales for each type of chargeback and records an allowance for chargebacks in the same period that the related product sales are recognized. The Company's reserve for chargebacks consists of amounts for which it expects to issue credit based on expected sales by its customers to qualified healthcare providers and chargebacks that customers have claimed but for which the Company has not yet issued credit.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Distribution-Related Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers generally based on gross sales.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other Sales-Related Deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's other sales-related deductions include co-pay assistance programs and product returns. The Company estimates and records other sales-related deductions generally based on gross sales, written contracts, and other relevant factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company generally offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers, using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various collaborative arrangements to research, develop, manufacture, and commercialize products and/or product candidates. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTUy_b8519178-2c0f-4a0d-9cfd-1d546bbe83b2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"></td><td style="width:49.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front/opt-in and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements involving multiple goods or services promised to be transferred to the Company's collaborator, the Company must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is "distinct"), or whether such </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i54ec8a935aa8484b9e967884298af953" continuedAt="i157ba5b96b124f1ba9929a5a7dc8c598"><ix:continuation id="i5d5aa53c63554127aa16082e2bd31218" continuedAt="i80c1d99d5d744641a0a232434a68dc0d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promises should be combined as a single unit of account. When the Company has a combined unit of account which includes a license and providing research and development services to its collaborator, recognition of up-front payments and development milestones earned from its collaborator is deferred (as a liability) and recognized over the development period (i.e., over time) typically using an input method on the basis of the Company's research and development costs incurred relative to the total expected cost which determines the extent of the Company's progress toward completion. The Company reviews its estimates each period and makes revisions to such estimates as necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company is entitled to reimbursement of all or a portion of the expenses (e.g., research and development expenses) that it incurs under a collaboration, it records those reimbursable amounts in the period in which such costs are incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company's collaborator performs research and development work or commercialization-related activities and the parties share the related costs, the Company also recognizes, as expense (e.g., research and development expense or selling, general, and administrative expense, as applicable) in the period when its collaborator incurs such expenses, the portion of the collaborator's expenses that the Company is obligated to reimburse. The Company's collaborators provide the Company with estimated expenses for the most recent fiscal quarter. The estimates are revised, if necessary, in subsequent periods if actual expenses differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where the Company:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplies commercial product to its collaborator, the Company may be reimbursed for its manufacturing costs as commercial product is shipped to the collaborator (however, recognition of such cost reimbursements may be deferred until the product is sold by the Company's collaborator to third-party customers); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares in any profits or losses arising from the commercialization of such products, the Company records its share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receives royalties and/or sales-based milestone payments from its collaborator, the Company recognizes such amounts in the period earned.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i80c1d99d5d744641a0a232434a68dc0d">The Company's collaborators provide it with estimates of product sales and the Company's share of profits or losses, as applicable, for each quarter. The estimates are revised, if necessary, in subsequent periods if the Company's actual share of profits or losses differ from those estimates.</ix:continuation>  </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTU2_c14528a4-e1bd-4383-aca1-51cc46c718c8" continuedAt="i391c93e0001540a7b2ff083043187ec4" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, clinical trial expenses, the cost of services provided by outside contractors, including services related to the Company's clinical trials, the full cost of manufacturing drug for use in research and development, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs. Costs associated with research and development are expensed.  </span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i391c93e0001540a7b2ff083043187ec4">For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter and remain in the trial, and/or the period over which clinical investigators, contract research organizations ("CROs"), or other third-party service providers are expected to provide services. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining noncancelable obligations associated with the winding-down of the clinical trial, including any applicable penalties.</ix:continuation>  </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjU3_6fbf054a-3e50-4578-ab98-ef51edaf7b36" continuedAt="ided8a3f062b24027b35fa55b4d437796" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity grants under the Company's long-term incentive plans (including stock options, restricted stock awards, and restricted stock units (both time-based and performance-based)) to employees and non-employee members of the Company's board of directors (as applicable) based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In addition, the Company reassesses its forfeiture rate assumptions at least annually, considering both historical forfeiture experience and an estimate of future forfeitures for currently outstanding unvested awards. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i157ba5b96b124f1ba9929a5a7dc8c598"><ix:continuation id="ided8a3f062b24027b35fa55b4d437796"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation to compute the estimated fair value of performance-based restricted stock units that are subject to vesting based on the Company&#8217;s attainment of pre-established criteria that include a market condition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance-based restricted stock units that contain a performance condition, the Company recognizes stock-based compensation expense if and when the Company determines that it is probable the performance condition will be achieved (based on the number of shares expected to be vested and issued). The Company reassesses the probability of achievement at each reporting period and adjusts compensation cost, as necessary. If there are any changes in the Company's probability assessment, the Company recognizes a cumulative catch-up adjustment in the period of the change in estimate, with the remaining unrecognized expense recognized prospectively over the remaining requisite service period. If the Company subsequently determines that the performance criteria are not met or are not expected to be met, any amounts previously recognized as compensation expense are reversed in the period when such determination is made.</span></div></ix:continuation><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNzI1_df4e5837-d83a-45bb-b52c-17a255e68df2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes U.S. federal, state, local, and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns, including deferred tax assets and liabilities for expected amounts of global intangible low-taxed income ("GILTI") inclusions, are recognized on the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the financial statement effects of a tax position when management's assessment is that there is more than a 50% probability that the position will be sustained upon examination by a taxing authority based upon its technical merits. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjYw_a21d7476-e50c-4692-96f5-f6202fe82efd" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Per Share Data</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Basic net income per share excludes restricted stock until vested. Diluted net income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include outstanding stock options and unvested restricted stock under the Company's long-term incentive plans, which are included under the treasury stock method when dilutive.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk5Ng_39108683-3045-48cb-a2f3-f793860bf278" continuedAt="ia1cd02523b4544fd9bb7b4076b696023" escape="true">Product Sales </ix:nonNumeric></span></div><ix:continuation id="ia1cd02523b4544fd9bb7b4076b696023" continuedAt="i3a882ccb18d0405785c1eacdc3487349"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk3OA_8f907907-9d76-44d3-9d16-331308a9233b" continuedAt="if53f52fab74a4ebe975c63a4c10704d5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.189%"><tr><td style="width:1.0%"></td><td style="width:23.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied28a835f8bf44bc81d3a306a92462e4_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzItMi0xLTEtMTc0MzYy_83ffaacf-ccc1-42b2-b0a4-015d21080c65">6,264.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae532f4ad2e45a094632cb65f59ff1d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzItNC0xLTEtMTc0MzYy_b6111be0-f3ef-40fd-89a1-9b2e280b8e1e">5,792.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401c340b8d640b0bd0f2bd3310a8b34_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzItNi0xLTEtMTc0MzYy_efcca39e-9728-4204-9cc3-46a989f927c2">4,947.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib758c557c5a84357b4ca9aad9468df85_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzMtMi0xLTEtMTc0MzYy_94c0f868-b7b2-4d66-a310-47d39375b1e2">374.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e9c05bba964dbaa707ecf5784772a5_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzMtNC0xLTEtMTc0MzYy_7a2bb5c6-d0eb-4616-ab9a-95fc2f39357e">306.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4219c796f9c244188971065d5bd4f038_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzMtNi0xLTEtMTc0MzYy_b813a699-fc47-48c2-84b6-9e5c2bd0ced2">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9aaec3bce84131820f016e635d46b2_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtMy0xLTEtMTg0MzEx_8e6152d5-712b-4afd-82ee-955b6ffdb256">73.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id56d50e41b1b4f2283a73daac3abdfc3_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNS0xLTEtMTg0MzEx_08cbb8f6-df42-4f12-9b30-9a6c8d075f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ca5e7fcd0b4a008a735d158813a139_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNy0xLTEtMTg0MzEx_cc8c3731-2ade-44d1-bb7b-700df41aae94">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0393079c0cc944b1a50dfee3c963918e_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtMi0xLTEtMTc0MzYy_bacbee2a-5d7c-47f0-aa45-474a7fd4dc9f">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7e6722d81c44259a1bd92561905f63_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNC0xLTEtMTc0MzYy_552a55e3-e969-472c-87a1-0231cddfb4f2">170.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd108a8c5454a57937befeca7f6ca59_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNi0xLTEtMTc4NjIw_f7f7a09d-885f-45e1-8a9a-e2944bee651b">150.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a9ca7f6313f4b6ca75caf2fbb0aff86_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzUtMi0xLTEtMTc0MzYy_37a71d55-ca79-4a82-a6d5-c5297a965193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3c64382b1c47e282eed691c8527a02_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzUtNC0xLTEtMTc0MzYy_bb89517c-dd90-4ffc-b274-c00793db47b2">5,828.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16587113c4db4d869776e4a8f0e3f76f_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzUtNi0xLTEtMTc0MzYy_f4e68137-07fe-4fa1-afba-0b920424da83">185.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36561e66271d42cd8f9d4959cf8bae47_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzYtMi0xLTEtMTc0MzYy_90b10081-28f7-4b81-b099-35f349416223">48.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d528e548bca464498145136edb95408_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzYtNC0xLTEtMTc0MzYy_5f0f8350-77ea-4893-8d92-c9719e149d1c">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c4796a01991465192b9b356e943e2e5_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzYtNi0xLTEtMTc0MzYy_afd0b08d-c819-4737-bdd8-3d3f3a67d65c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e8d230b07841e08ef6b9cf34364982_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtMy0xLTEtMTgyMDAx_f0c9b79b-47a9-41b1-b026-36e39bb751d2">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d6b917256442e2bcb1f93418c6a3bc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNS0xLTEtMTgyMDA1_b6469427-38dd-435e-b064-343e275a9b20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15db8997a2b427788f94a1cbbec97c5_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNy0xLTEtMTgyMDA5_3ff9ef38-b654-4d3e-8fe1-290d68fed0b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(e) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8aa02c16b445d7882b24cfd1ce3f1e_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzctMi0xLTEtMTc0MzYy_d077a5b1-9342-4836-8973-d65aaf7f6226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045372e85f2c49249ac8ffc7ff4ee23f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzctNC0xLTEtMTc0MzYy_cc235c0e-3ac6-4c46-bc4b-f187a21e3df1">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37be60752f94dc4afcf263599f81827_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzctNi0xLTEtMTc0MzYy_166f3955-3f65-4839-a6df-c84d6254d773">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b570c4cf204eefb544c1454a2796d5_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtMi0xLTEtMTc0MzYy_0b04d0ad-177c-433e-84d2-c070b411a899">6,893.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3691c35b41bd49019bc22c52a92bb9e4_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNC0xLTEtMTc0MzYy_9b69162d-c3b7-445e-a0a7-5bdd8383ef83">12,117.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19de0a1ac17e448ab689d53f955adc7d_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNi0xLTEtMTc0MzYy_25fad0ae-beb8-4cdd-b730-f38f99fd54f2">5,567.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia31d29839cf14beabac4560e466ab9df_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzEwMg_dc716646-6907-446a-ba9d-97ed0e8a614c">3.586</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i0d710a5f61ac45fe86461104c9643b4b_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzEwOQ_69458612-0225-4423-835e-4232fc37a202">5.059</ix:nonFraction>&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December&#160;31, 2022, 2021, and 2020. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk5MQ_c7bf5c5a-ac2b-4aec-afc5-0b68b5dc2870" continuedAt="i82d44aae5fad4d60961507d287398d24" escape="true">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><ix:continuation id="i82d44aae5fad4d60961507d287398d24"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.913%"><tr><td style="width:1.0%"></td><td style="width:60.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14dd5c1f226d4087af59c57f97a899aa_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzItMS0xLTEtMTc0MzYy_6a73b6b6-c182-423d-8d13-828d617837f2">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34fd1be2ecad4837bb9a616be6b49006_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzItMy0xLTEtMTc0MzYy_7dda9c04-088d-4ea6-99c4-b8a83906d456">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i344fed0429da45b2a1e885495c218a51_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzItNS0xLTEtMTc0MzYy_110adf47-2e72-4596-9da0-3190a0f600be">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4b8fe8cae5f463cad7e8105fe984c3d_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzMtMS0xLTEtMTc0MzYy_b9326fe0-b5a4-4959-af76-16348106880b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6af24d3fc5514e589feb09538e6786e0_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzMtMy0xLTEtMTc0MzYy_fcb06207-3c15-41b4-b1a1-e4f441869df6">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1783ece527234057a38c1fec76fdaa70_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzMtNS0xLTEtMTc0MzYy_fd03fa60-777d-4631-9707-2870f7621ea5">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e5923b8955547f1a59fc39eda60bec4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzQtMy0xLTEtMTg1MzM0_e2eba7f6-7ec3-486a-a63b-51a0126c8b1d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales to the U.S. government represented less than 10% of total gross product revenue during the period</span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks, and discounts, distribution-related fees, and other sales-related deductions. Accruals for chargebacks and discounts are recorded as a direct reduction to accounts receivable. Accruals for rebates, distribution-related fees, and other sales-related deductions are recorded within accrued liabilities. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="regn:ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk4MQ_4c14021f-f742-40da-8671-ff9b368a2d67" continuedAt="ie3577c61b279405e9fbe042bac497038" escape="true">The following table summarizes the provisions, and credits/payments, for sales-related deductions.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><ix:continuation id="i3a882ccb18d0405785c1eacdc3487349"><ix:continuation id="ie3577c61b279405e9fbe042bac497038"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"></td><td style="width:37.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks,<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution-<br/>Related Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Sales-<br/>Related Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79035aaa4aca45619bc98627f48db24d_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtMS0xLTEtMTc0MzYy_9a199c07-5586-462b-a5a9-c80fcb7eae03">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed642c5d8464dd4ab25fed90d1a28b9_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtMy0xLTEtMTc0MzYy_53368f91-76b5-4e8d-b0e4-0fadf1bdb263">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaac0693be9b45a28174b13694aa0f4d_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtNS0xLTEtMTc0MzYy_1ee21acc-5599-4ecf-b427-432cdc31bf0a">29.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtNy0xLTEtMTc0MzYy_907525f7-48f0-4b5c-8d3d-bc5aca023126">156.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36a49d6ddd04419a0f5b0f1b8c1c942_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItMS0xLTEtMTc0MzYy_f6daed5f-da6e-4b7f-b976-128b5737a53f">762.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4003730ec2f4d02b252a6fe11601f2f_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItMy0xLTEtMTc0MzYy_0125095c-b53f-450e-ba03-b5089ddf005a">279.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55504a180d724f1ebaac6dc86a38d8a1_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItNS0xLTEtMTc0MzYy_66e8933b-bd03-4e52-b68c-952164fa093a">94.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItNy0xLTEtMTc0MzYy_8ea69533-6703-471d-95fe-68fb645124e1">1,136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia36a49d6ddd04419a0f5b0f1b8c1c942_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtMS0xLTEtMTc0MzYy_58a15685-6dce-460c-96a8-a14cd2fc4c1e">641.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4003730ec2f4d02b252a6fe11601f2f_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtMy0xLTEtMTc0MzYy_4a968665-9730-428d-a5de-6609f37af8ef">249.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55504a180d724f1ebaac6dc86a38d8a1_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtNS0xLTEtMTc0MzYy_f05f0238-b94b-4345-9eae-16787047fc37">78.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtNy0xLTEtMTc0MzYy_152a2d92-701d-421c-b234-9eda81305926">968.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400385b2589b49f595ff5af66bdd5ade_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtMS0xLTEtMTc0MzYy_6b0897ac-3490-4100-aff1-7e1dfca3f9c7">202.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4797ff0491840d0b9237549db0ebcf6_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtMy0xLTEtMTc0MzYy_1d8ca901-1c4d-4e24-a3b3-e8c737d6c983">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011e5e369ab847fa9843f4109e14c84b_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtNS0xLTEtMTc0MzYy_dde3f91c-8abb-40c0-aae9-4fd11e5d0f4d">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtNy0xLTEtMTc0MzYy_518f0fe7-d0ba-4cd4-b3ec-1f8b76f80364">324.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669cdcc9c1e246469a2358ff978102e3_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtMS0xLTEtMTc0MzYy_29d74396-3833-417b-9513-71b6b91fef95">1,047.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b4f57919043638cc0e4b7b9319f9b_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtMy0xLTEtMTc0MzYy_91c7dd5c-2cc9-4e1e-8421-48d32daef372">363.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140d0e936e944736a5e1983367a30409_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtNS0xLTEtMTc0MzYy_2ddf0227-6886-46d1-ae18-7b84d22fec7d">150.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtNy0xLTEtMTc0MzYy_7266f32a-c0aa-4432-b7dc-960e468eb7f2">1,561.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i669cdcc9c1e246469a2358ff978102e3_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtMS0xLTEtMTc0MzYy_aeba4d9c-366a-4ff6-bd12-4ff85812e46c">1,034.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b4f57919043638cc0e4b7b9319f9b_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtMy0xLTEtMTc0MzYy_7a13dc71-390d-4357-94e1-8b131d854d0b">360.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140d0e936e944736a5e1983367a30409_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtNS0xLTEtMTc0MzYy_19d3c0e3-c4bb-49c9-bd11-c88baebd0e0e">127.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtNy0xLTEtMTc0MzYy_94282cc8-a8ca-435f-8e5e-f3b95a32d27a">1,523.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3bf9e21feb34e239d88bb219da800f5_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctMS0xLTEtMTc0MzYy_27189304-ab9d-48c7-8657-2d4cb08d7e8f">214.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebca5c748034d6284466eddd3b67472_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctMy0xLTEtMTc0MzYy_09624499-8ecd-4083-97ab-79baf1216c4d">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d04b81b0d04870a748890c3df2cd84_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctNS0xLTEtMTc0MzYy_3048f624-8eb5-45a0-a01e-5bc70239e28e">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctNy0xLTEtMTc0MzYy_603785c2-5b1d-49e7-9e98-f90af3af14cd">362.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0edb01a74bf4469a5cee578568c2d72_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtMS0xLTEtMTc0MzYy_20fa7155-e7eb-49b4-8dbe-522598f6ba3d">1,537.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf53692132846bdbb98eb842acd5e55_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtMy0xLTEtMTc0MzYy_3fb0fcc3-b0ac-4dc6-938f-99a91ebfef1a">431.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf7a6f088a44d8c92a8778a84dbc88f_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtNS0xLTEtMTc0MzYy_c4226011-b9f2-460d-b07b-81dcea0bafe6">141.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtNy0xLTEtMTc0MzYy_e6a9af0f-5f44-491c-b780-d5dc0c9d2907">2,109.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0edb01a74bf4469a5cee578568c2d72_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktMS0xLTEtMTc0MzYy_0121ca7e-08c5-42e9-ae26-bf7140c1b416">1,398.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebf53692132846bdbb98eb842acd5e55_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktMy0xLTEtMTc0MzYy_68576e83-a68a-49a6-9302-d807a0f64544">399.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddf7a6f088a44d8c92a8778a84dbc88f_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktNS0xLTEtMTc0MzYy_d3014d18-9488-4da2-ac2a-74fd42395d86">127.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktNy0xLTEtMTc0MzYy_52c3730c-fa27-427e-9901-dcea9791d55b">1,924.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b16833ca23845bea5a41107085ed872_I20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTEtMS0xLTE3NDM2Mg_378d2eef-e83a-461d-9483-0e23ea3b7178">353.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5549277e904fcf83d210cf6514f72a_I20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTMtMS0xLTE3NDM2Mg_e27b54c7-f4da-46a4-819d-258accf89103">111.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3af9d8607c4bcb8acf3c8ebc5b9724_I20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTUtMS0xLTE3NDM2Mg_62506d4f-5cbb-43b7-93ba-2d6543754158">81.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTctMS0xLTE3NDM2Mg_353d1418-1893-484d-815e-d33c9c57d461">546.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTc3_cc22af67-5033-45a3-acb6-7bf6fd890ea4" continuedAt="ic78f95f044cc4ce9bb1a5b9eee7fb72d" escape="true">Collaboration, License, and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="ic78f95f044cc4ce9bb1a5b9eee7fb72d" continuedAt="i4687595b77b34f898e3ecfe1e2f8598e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi </span></div><ix:continuation id="if53f52fab74a4ebe975c63a4c10704d5" continuedAt="i6d5a4c4dab874260b51ea1a0f192023a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its collaborations with Sanofi are detailed below: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"><tr><td style="width:1.0%"></td><td style="width:36.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ba1f9253744de2b4207de915788712_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzMtNC0xLTEtMTc0MzYy_57f204b1-47eb-4630-8ab1-d79f906ac5e5">2,082.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc9281a149a43a6a468ee18b2d84cf2_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzMtNi0xLTEtMTc0MzYy_988dd79d-fc6f-437c-8f71-8be21b64d027">1,363.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0115b1778749402f91e8cc15e18d4904_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzMtOC0xLTEtMTc0MzYy_bed3c945-9c06-4472-9404-a012b5fa28ce">785.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia777bee1ba8248c483a61586e012c702_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzQtNC0xLTEtMTc0MzYy_89aceae8-dbe5-4f49-becc-433dd657c887">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96bb9eb29d642bc83bbfe650b831b53_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzQtNi0xLTEtMTc0MzYy_6662944e-e58d-4756-b94f-54a34e9829b5">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e3a3b0502c4423ad39c725eb715497_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzQtOC0xLTEtMTc0MzYy_3b9dd487-0c18-432c-b615-66efe161708b">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12afa83d8539401a99a900866df1fa36_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzUtNC0xLTEtMTc0MzYy_7226122d-5a0d-4bb0-9f9f-aa00cc5e8871">633.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ce6c9a943648f89bc598bd4d43f36c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzUtNi0xLTEtMTc0MzYy_df18e146-5a1e-4417-be40-46c9589604c4">488.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1098ae33301f499691dd988767b567e2_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzUtOC0xLTEtMTc0MzYy_3fdfdba3-429d-4a48-92d5-af4d004c8773">368.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f529cd92f434fb1a4cedfbac373d940_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNC0xLTEtMTc2NzQ4_db33c951-1df5-4b1b-a27b-e19e94e0398b">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9379b307875b4618a634289637cb38fa_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNi0xLTEtMTc2NzQ4_ac28d53c-8234-4938-ba3a-1ce8ec865844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f5efff9c1341368743087b362bfb90_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtOC0xLTEtMTc2NzQ4_850946f3-2f8e-4bf3-97f9-54d9504d848c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59b2e844e32b48cba3e0f9a0086990d6_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNC0xLTEtMTc0MzYy_e8388ef6-5a3c-412e-a3e4-1e1ef85ef5fe">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7a5ff4b315478cbf0aad95a657b855_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNi0xLTEtMTc0MzYy_aeaff16a-f158-4423-95f5-84eb0111832e">129.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766d690fe05a4cd1aedfdac8bcaac956_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtOC0xLTEtMTc0MzYy_2cb60f71-0e73-441e-8ca8-9d3e84eb56fe">149.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98f436ad8214c2f880b651b95e5dad2_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzgtNC0xLTEtMTc0MzYy_d5da3306-9197-4d6b-9a85-84cc10eefeca">437.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f38cde3c9ce4d3199de6ef8a0bd8843_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzgtNi0xLTEtMTc0MzYy_b104dfbd-e653-4593-bd17-a09d22c0a42a">320.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c16e48fda34e60b3f5035db52b587d_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzgtOC0xLTEtMTc0MzYy_86058e79-3c4e-42d2-bdf2-5e120254a7b1">359.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd9317470c24cb790bc85ce993a30eb_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzExLTQtMS0xLTE3NDM2Mg_127e5b05-5b80-48d4-b7d1-26ba8c52d655">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id84b946ec54c41148f176f9146ca5bf4_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzExLTYtMS0xLTE3NDM2Mg_00ba4e7d-47f4-4f7b-9fc9-92ac3af1840f">13.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6af8b58cda784c98a6fa9c2b3c890073_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzExLTgtMS0xLTE3NDM2Mg_3a7542a9-c6d1-40c2-abe9-728f8d05d588">25.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb55a76cf4c4a3487a985658b5c16a1_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEyLTQtMS0xLTE3NDM2Mg_ac2ea6db-74a9-4c12-8ff1-f86216ec614d">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fc6180f85a4a7f9625db7362ac76de_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEyLTYtMS0xLTE3NDM2Mg_3c2fd3c1-3b6f-43bf-8f27-b41690cccc5b">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1990e2efe34d48b17cc48fed693450_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEyLTgtMS0xLTE3NDM2Mg_0a3d744e-24c7-424c-b838-a4e64026f770">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8813ce5c13e64d47b2b5439b9dc755f1_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEzLTQtMS0xLTE3NDM2Mg_e6dfe8d6-aa4d-4c68-9a3f-236bfb3ed608">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8f5e721504480c84d395aaa308c019_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEzLTYtMS0xLTE3NDM2Mg_0d5c8a39-fac0-49ed-b0de-4f76611a6d90">85.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe81139390d42459544d73a062fac93_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEzLTgtMS0xLTE3NDM2Mg_f1a6acea-a889-49de-b026-7cb7ba544f77">166.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6265b4f0bd0845d39208a99685ef72d5_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE0LTQtMS0xLTE3NDM2Mg_c3daa1d8-88d3-49d2-aa5e-561045ae3439">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f01400d1f5f4ab88a047bc5a42ad47e_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE0LTYtMS0xLTE3NDM2Mg_798695a9-e590-402e-8b31-71e35b74ebb0">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08844a1258e34c188ef387c945bb338e_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE0LTgtMS0xLTE3NDM2Mg_f12301b4-00a1-478b-adec-6afb59ac5b00">64.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i051041a979024065b21211e82f9cdf21_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE1LTQtMS0xLTE3NDM2Mg_ff427b42-1931-400e-ba38-8c2ba6f77669">19.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bee21e9d49947c3a10d37cddc0d58ad_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE1LTYtMS0xLTE3NDM2Mg_44ee151b-db8f-4f6b-9b8a-e5a7cc6fd2cd">36.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9102b7c37a5540bd87a27183334b342a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE1LTgtMS0xLTE3NDM2Mg_6bd47293-6ef1-431b-99ee-484e77f3c7e2">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1499e9e4c3cb42b29dbe231e9c8cbca2_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE2LTQtMS0xLTE3NDM2Mg_53c75ee6-2d19-4fae-90ec-0989f1bac5dd">70.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9ad83d17ed14bf6986ec0a3067634ad_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE2LTYtMS0xLTE3NDM2Mg_6373e577-8106-4b9e-b420-3ae099171bb7">133.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ae9b363c444357b3a5692e04f07a21_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE2LTgtMS0xLTE3NDM2Mg_e172b6ff-9a54-4b1d-a843-66fbfc642adf">119.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if782b4fb146742af8dd0fb0dfa6d0f36_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE3LTQtMS0xLTE3NDM2Mg_8d4a5bdb-2f89-4e00-af2c-98b9e44783fe">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e2a1ed354949eb9a8bc01eeb0918c1_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE3LTYtMS0xLTE3NDM2Mg_5b9bdabc-7e73-4e66-8e38-3d9c9790859f">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic964826dc2d046ca8a21b1f261865199_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE3LTgtMS0xLTE3NDM2Mg_1e142203-af97-4218-92ad-75b715a45cc7">210.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of one-time payment of $<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:PaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE5LTAtMS0xLTE4MjM5My90ZXh0cmVnaW9uOjcwYjNkNjBhZDUzMTRkMWJhMDhiMmVhOTZkYjQ2YzQ5XzU0OTc1NTgxNDAzNg_a8bae39e-3dd0-48ac-8d70-a049618132b0">56.9</ix:nonFraction> million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide</span></div></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (dupilumab), Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (sarilumab), and itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding <ix:nonFraction unitRef="number" contextRef="i1bc08b7de58d43ffa7092aa7f8bb0810_D20220101-20221231" decimals="2" name="regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU1OQ_edc8f867-b472-47d2-a311-134234419050">80</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib25739cf76b545759fc2d04ae78628e0_D20220101-20221231" decimals="2" name="regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU2Mg_4f9bb5d9-aa1a-4788-a637-ad3606bcaf1c">100</ix:nonFraction>% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for <ix:nonFraction unitRef="number" contextRef="i1bc08b7de58d43ffa7092aa7f8bb0810_D20220101-20221231" decimals="2" name="regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzY0MA_77c347a7-8333-425e-b5a6-00b4f3873ae5">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib25739cf76b545759fc2d04ae78628e0_D20220101-20221231" decimals="2" name="regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzY0Mw_1dae72b3-6b32-4aef-996e-8e6ef56e0721">50</ix:nonFraction>% of worldwide development expenses that were funded by Sanofi based on the Company's share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, the Company was required to apply <ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="2" name="regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzg4Mg_1b2eaa1c-c40c-439b-ae14-9a6c2394d4db">10</ix:nonFraction>% of its share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of the Company's share of profits used to reimburse Sanofi for such development costs increased from <ix:nonFraction unitRef="number" contextRef="ib3cfd1bc015b4dbe9079b20e66709ea4_D20220630-20220630" decimals="2" name="regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg1MjA3NA_3ecd419f-bfb4-4e29-9595-1c611ab35624">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ica111cf830ee452b94a3ed1fa3edd4ac_D20220701-20220701" decimals="2" name="regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg1MjA4MQ_068c0017-5cf4-4961-98b1-3fe2f801445a">20</ix:nonFraction>%. A portion of the value associated with the increase in reimbursement percentage was deemed to be contingent consideration attributable to the Company's acquisition of the Libtayo rights described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below; this portion will be recorded as an increase to the Libtayo intangible asset over time as the Company repays such development costs to Sanofi. The Company's contingent reimbursement </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i4687595b77b34f898e3ecfe1e2f8598e" continuedAt="ia8733e392ad54cefa660108d8ae194df"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligation (development balance) to Sanofi under the Antibody Collaboration was approximately $<ix:nonFraction unitRef="usd" contextRef="if16d17ebcbaf4806a375d33fb5402f61_I20221231" decimals="-6" name="regn:ContingentReimbursementObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzExNTE_6a93594c-49bf-4704-9eb7-ae5e79e1c105">2.864</ix:nonFraction> billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. The Company co-commercializes Dupixent in the United States and in certain countries outside the United States. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at <ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="INF" name="regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwOTk_d5810204-1967-48ff-b1a6-54e7d9e65f84">65</ix:nonFraction>% (Sanofi)/<ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="INF" name="regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxMTE_ca97cd3f-d97a-411a-a50b-bab156497b7f">35</ix:nonFraction>% (Regeneron) and ending at <ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="INF" name="regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNDA_2ca7df70-556d-460c-a31d-02ef634c4e7c">55</ix:nonFraction>% (Sanofi)/<ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="INF" name="regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNTI_c818c502-89ad-457a-b5ae-ca906426e242">45</ix:nonFraction>% (Regeneron), and losses outside the United States at <ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="INF" name="regn:ShareOfLossesOutsideUnitedStatesForCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIyMDg_011bb1ca-5b3c-42cf-aca1-85c11af179d0">55</ix:nonFraction>% (Sanofi)/<ix:nonFraction unitRef="number" contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231" decimals="INF" name="regn:ShareOfLossesOutsideUnitedStatesForCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIyMjA_55af6577-de73-4280-8a64-5d47e358ba68">45</ix:nonFraction>% (Regeneron). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In each of 2020 and 2021, the Company earned a $<ix:nonFraction unitRef="usd" contextRef="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI0MjM_ecde4cff-97f9-4030-8868-2375d7627f61">50.0</ix:nonFraction>&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $<ix:nonFraction unitRef="usd" contextRef="i92098519881447bc802ea9a38d5455bb_D20200101-20201231" decimals="-8" name="regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1NjA_acd7d785-9d66-42fb-b8a8-5bc7f8c091e3">1.0</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i4df3bd7c2a0041b6ab7f312261481025_D20210101-20211231" decimals="-8" name="regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1Njc_ac6d236f-e1a8-4ff1-9923-7e66156f974c">1.5</ix:nonFraction>&#160;billion, respectively, on a rolling <ix:nonNumeric contextRef="i4df3bd7c2a0041b6ab7f312261481025_D20210101-20211231" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NDE_792a0bea-1228-4bbb-9751-878afa86ce0c">twelve-month</ix:nonNumeric> basis. In 2022, the Company earned two additional $<ix:nonFraction unitRef="usd" contextRef="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMDg3NTY_ecde4cff-97f9-4030-8868-2375d7627f61">50.0</ix:nonFraction>&#160;million sales-based milestones from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $<ix:nonFraction unitRef="usd" contextRef="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231" decimals="-8" name="regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg1MjUyMA_3e38642f-f107-488b-9a23-ce7080683faf">2.0</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i88cadc8fc7e24c3d9ff92f91bad83c6e_D20220101-20221231" decimals="-8" name="regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMDkxOTQ_72fea739-67fa-4625-9991-f6315496e58e">2.5</ix:nonFraction>&#160;billion, respectively, on a rolling <ix:nonNumeric contextRef="i88cadc8fc7e24c3d9ff92f91bad83c6e_D20220101-20221231" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTE1_7a070ffc-8e6a-4344-b8ca-8e80eeaf07bd">twelve-month</ix:nonNumeric> basis. The Company is entitled to receive the final sales milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ic35d85587ab1424a9a59091f3cf09bf6_I20221231" decimals="-5" name="regn:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3Njk_65b22db0-28d8-4828-8453-80054982c0f1">50.0</ix:nonFraction>&#160;million when such sales outside the United States exceed $<ix:nonFraction unitRef="usd" contextRef="ibcc771627f73408eb92c1b64295c2e4b_D20220101-20221231" decimals="-8" name="regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI4NDI_c43338f8-63e2-4e86-a10e-90fc4a12c4a7">3.0</ix:nonFraction>&#160;billion on a rolling <ix:nonNumeric contextRef="ibcc771627f73408eb92c1b64295c2e4b_D20220101-20221231" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTg4_9df93852-926c-4557-a0d3-ce82e1d7f99e">twelve-month</ix:nonNumeric> basis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant promised goods and services in connection with the Antibody Collaboration consist of providing research and development services, including the manufacturing of clinical supplies; and providing commercial-related services, including the manufacturing of commercial supplies. The Company recognizes amounts in connection with the Antibody Collaboration based on the amount it has the right to invoice and such amount corresponds directly with the Company's performance to date; therefore, the Company does not disclose the value of the transaction price (i.e., the amount of consideration the Company expects to be entitled to) allocated to its remaining unsatisfied obligations. </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTMy_c5d32d5c-2822-4ea7-9f8b-de6f13d1e552" continuedAt="id791162a36324051ad0ec9756ce10353" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"></td><td style="width:54.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if16d17ebcbaf4806a375d33fb5402f61_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzItMi0xLTEtMTc0MzYy_1c611c72-117f-4958-835f-110865c62096">692.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3d8ea7d0184f31933cf11c201c1047_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzItNC0xLTEtMTc0MzYy_a788772e-7dfa-4689-a6e6-2fab4140b4f4">504.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if16d17ebcbaf4806a375d33fb5402f61_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzMtMi0xLTEtMTc0MzYy_e33afb9c-5e92-4cbc-a752-f0d3271fc5c4">415.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3d8ea7d0184f31933cf11c201c1047_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzMtNC0xLTEtMTc0MzYy_db08a940-d0bb-4c92-86c3-587c3da4b84c">368.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, became solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi pays the Company a <ix:nonFraction unitRef="number" contextRef="ic416426a749b4b799097f4def70ef266_D20200401-20200401" decimals="INF" name="regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTcxMzU_adad7d99-99f1-42d5-9bfd-1d0dd7111169">5</ix:nonFraction>% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company does not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party is responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company continues to supply drug substance to Sanofi and Sanofi continues to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each are solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to <ix:nonFraction unitRef="number" contextRef="if2ae15c5525a4644af133a200d4375fc_D20200401-20200401" decimals="INF" name="regn:PercentageOfRoyaltyPaymentThatCanBeOffset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTcxNjM_cfab35be-1b51-4297-b675-9e8e90cee797">50</ix:nonFraction>% of any Praluent royalty payment owed to Regeneron). The parties each bear <ix:nonFraction unitRef="number" contextRef="ic416426a749b4b799097f4def70ef266_D20200401-20200401" decimals="INF" name="regn:LossContingencyPercentageOfDamagesResponsibleFor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTcxNzY_9f8bfcd0-50b5-4c22-bd3b-0f4124401dc1">50</ix:nonFraction>% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 16 for discussion of legal proceedings related to Praluent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was previously a party to a collaboration with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration was governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement ("IO License and Collaboration Agreement"). In connection with the execution of the original Immuno-oncology Discovery and Development Agreement in 2015 ("2015 IO Discovery Agreement"), which was subsequently replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $<ix:nonFraction unitRef="usd" contextRef="ia07abc9790d746bcb14fa6e3f0c1ea51_D20150101-20151231" decimals="-5" name="regn:UpFrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NDM_374c8cbf-3a77-4edb-a439-7fc65a3a9b6d">265.0</ix:nonFraction>&#160;million non-refundable up-front payment to the Company. Pursuant to the 2015 IO Discovery Agreement, the Company was to identify and validate potential immuno-oncology targets and develop therapeutic antibodies against such targets through clinical proof-of-concept. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ia8733e392ad54cefa660108d8ae194df" continuedAt="i89d8e2210ed546b6bda5035930b3c61a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 and (ii) MUC16 and CD3 through clinical proof-of-concept. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, the Company retains the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any). In addition, the Company has no further obligations to develop drug product candidates under the Amended IO Discovery Agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the IO License and Collaboration Agreement in 2015, Sanofi made a $<ix:nonFraction unitRef="usd" contextRef="ie82399ac549a40d5978b791c9447413e_D20150101-20151231" decimals="-5" name="regn:UpFrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzkxNTQ_cbd6eb5e-3129-48fc-9176-2f70fd96cc71">375.0</ix:nonFraction> million non-refundable up-front payment to the Company. Under the terms of the IO License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. The Company had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;R IO LCA"). In connection with the A&amp;R IO LCA, in 2022, the Company made a $<ix:nonFraction unitRef="usd" contextRef="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTc0Njg_56af7f89-b086-43f1-8831-8fb5a2499c62">900.0</ix:nonFraction>&#160;million up-front payment to Sanofi, as well as a $<ix:nonFraction unitRef="usd" contextRef="ib7a293af7f1a454b8c850b4caf8e4c3f_D20220701-20220731" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NzQ_fa781e00-58f0-4a0f-9bcb-fe6c1d521f7c">100.0</ix:nonFraction>&#160;million regulatory milestone payment. In addition, Sanofi earned a $<ix:nonFraction unitRef="usd" contextRef="ia3cd8df873044150844eb0ad18f0b00f_D20220701-20220731" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NTk_64ac376a-732f-4da8-8dc8-50f1c7d1dc5d">65.0</ix:nonFraction>&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022, and is eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="i2edbcd603c4e4104a5be3200e42d13d4_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTc4MDE_4d44dcb2-fd05-474c-8b82-1981013cb707">35.0</ix:nonFraction>&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023 (aggregate of $<ix:nonFraction unitRef="usd" contextRef="i4d21c3111e2741a386578f848272cd46_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTc5NjI_5933efe9-6d0a-414b-8b56-60d4a09392ef">100.0</ix:nonFraction>&#160;million in sales-based milestones eligible to be earned under the terms of the A&amp;R IO LCA). The Company also pays Sanofi an <ix:nonFraction unitRef="number" contextRef="ida00ad5e29154c468a4e0cc72eecae59_D20220701-20220731" decimals="2" name="regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTc5NDg_d091cc50-f5e3-4e9d-8e3d-07308a71715e">11</ix:nonFraction>% royalty on net product sales of Libtayo through March 31, 2034. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset. See Note 8 for additional information related to the intangible asset recorded in connection with the transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Amended IO Discovery Agreement, the Company was obligated to reimburse Sanofi for half of the development costs it funded that were attributable to clinical development of product candidates from the Company's share of profits from commercialized IO Collaboration products. Under the A&amp;R IO LCA, the amount of development costs incurred under the IO Collaboration for which the Company was obligated to reimburse Sanofi was $<ix:nonFraction unitRef="usd" contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTg1NTM_0023552d-fba4-47f6-bf56-fb919ca79e8c">35.0</ix:nonFraction>&#160;million as of the effective date of the A&amp;R IO LCA, and the Company pays Sanofi a <ix:nonFraction unitRef="number" contextRef="id36294acc59c4a11a0b25a3fdda18f81_D20220701-20220701" decimals="3" name="regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTg2MzE_2dbc2987-6ec0-4b5d-b6de-a0bc4fce384f">0.5</ix:nonFraction>% royalty on net product sales of Libtayo until all such development costs have been reimbursed by Regeneron. </span></div><ix:continuation id="id791162a36324051ad0ec9756ce10353" continuedAt="ic1fa02bd765a44fabc7b2a6e15e7bc23"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"></td><td style="width:54.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzItMi0xLTEtMTc0MzYy_8403eae4-0485-4ea3-b3f6-0614136ace17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb765df6920d4b6383231c53791eadb4_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzItNC0xLTEtMTc0MzYy_4f89fe42-593a-4dd4-b26f-ef34b9e8ee6c">22.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzMtMi0xLTEtMTc0MzYy_6d2285d0-5ce0-4e82-8ff6-53bfc56d5f2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb765df6920d4b6383231c53791eadb4_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzMtNC0xLTEtMTc0MzYy_bb4190b0-56a0-4d2e-b8b4-089852139be4">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231" decimals="-5" name="us-gaap:OtherLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzQtMi0xLTEtMTc0MzYy_95b9fc53-0148-4ed0-83c0-4f7e277cb5ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb765df6920d4b6383231c53791eadb4_I20211231" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzQtNC0xLTEtMTc0MzYy_d27c197a-2bea-484e-b742-10fa89b340dc">276.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities included up-front payments received from Sanofi for which recognition had been deferred. Such amounts were being recognized over the remaining period in which the Company was obligated to perform development activities. In connection with the A&amp;R IO LCA described above, the remaining IO Collaboration Other liabilities balance of $<ix:nonFraction unitRef="usd" contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701" decimals="-5" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg2NDMzNA_7b3a42fd-8759-4443-a571-0c931fdb0207">241.0</ix:nonFraction>&#160;million as of July 1, 2022 was recognized as a reduction to the intangible asset during the third quarter of 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company updated its estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $<ix:nonFraction unitRef="usd" contextRef="i9968c18075514aa49e06f8c1a6cb6cdd_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg2NDc0Mg_fe2f19d5-c805-45a6-9869-76373fbd78f5">66.9</ix:nonFraction>&#160;million as a reduction to other operating income. During 2020, the Company updated its estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $<ix:nonFraction unitRef="usd" contextRef="i662e6bf4027d426e82807c2558c35ae6_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg2NTA3Ng_f032603d-5afe-486a-b63a-4d96f7b0104e">135.4</ix:nonFraction> million as an increase to other operating income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i89d8e2210ed546b6bda5035930b3c61a" continuedAt="i9e23b196a029457e9369dc3be0cdb436"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA (aflibercept) and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. The Company is also obligated to use commercially reasonable efforts to supply clinical and commercial bulk product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, the Company is responsible for commercialization and retains profits from such sales. Bayer markets EYLEA outside the United States and the companies share equally in profits and losses from sales. In Japan, the Company was entitled to receive a tiered percentage of between <ix:nonFraction unitRef="number" contextRef="i19f9658cc2ff458f98c65823bbf93768_D20210101-20211231" decimals="INF" name="regn:RevenueBasedOnPercentageOfAnnualSalesInJapan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0MjI0_c902897e-4362-475a-9f4c-9b74f765085d">33.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1ff682a1bf3046e59c581283c15cd463_D20210101-20211231" decimals="INF" name="regn:RevenueBasedOnPercentageOfAnnualSalesInJapan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0MjMx_6c807c91-409f-4403-95b1-287f4ed64b5d">40.0</ix:nonFraction>% of EYLEA net product sales through 2021, and effective January 1, 2022, the companies share equally in profits and losses from sales in Japan. The Company is obligated to reimburse Bayer out of its share of the collaboration profits for <ix:nonFraction unitRef="number" contextRef="i6f127c8b7cde442e8f388b671f809753_D20220101-20221231" decimals="INF" name="regn:PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0NjE0_58900903-d7da-4d9d-9634-b9e50e68034b">50</ix:nonFraction>% of the agreed-upon development expenses that Bayer has incurred in accordance with a formula based on the amount of development expenses that Bayer has incurred and the Company's share of the collaboration profits, or at a faster rate at the Company's option. The Company's contingent reimbursement obligation to Bayer was approximately $<ix:nonFraction unitRef="usd" contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231" decimals="-6" name="regn:ContingentReimbursementObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0OTU0_6c7a2c34-25c0-4625-9f78-fea3a481db49">273</ix:nonFraction> million as of December&#160;31, 2022.</span></div><ix:continuation id="i6d5a4c4dab874260b51ea1a0f192023a" continuedAt="i22744028e94b4ffa921d7771c8fb981e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.810%"><tr><td style="width:1.0%"></td><td style="width:37.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.327%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1144a7790544218f74de1883b49bf3_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzItNC0xLTEtMTc0MzYy_7f44093f-5094-4983-9f74-6872a965e01b">1,317.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031e83e10e9e4d98a468c3b9d072d89f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzItNi0xLTEtMTc0MzYy_708c259c-40dd-4b2c-99a3-28ab6ee47f65">1,349.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3313afbfc9d443d3919f6a7a44e3fa4d_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzItOC0xLTEtMTc0MzYy_fce4f4aa-e5b9-4a82-916d-1822f1c3fa2f">1,107.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9f0ecc7f6469f8f6f13959ec2c1c9_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzMtNC0xLTEtMTc0MzYy_719578dc-d1c0-47ca-a43f-511b6cb2e590">91.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f4b4ccfc364728a38bf1a2879c55df_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzMtNi0xLTEtMTc0MzYy_f8b96b5f-14c7-4370-bb07-537531103eaa">60.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b2ada6cf67454e9cc60972f8641090_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzMtOC0xLTEtMTc0MzYy_65f6d394-4733-4502-be06-f7ad6dc079de">78.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4071c884ce284e40bc787d87c171aee2_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNC0xLTEtMTgyNjYy_625a4a43-d0da-4a68-8df2-3722d59afec9">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56187dada534884b655d5a6e52af578_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNi0xLTEtMTgyNjYy_90288eb1-9b3a-47be-b459-4aaef29f85c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377212e618da453c9025dd02c5593bd7_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtOC0xLTEtMTgyNjYy_17f16fd6-d22c-4102-b63c-20389ae0dfa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15bad177eea4c829136e32f7d94e3d1_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNC0xLTEtMTc0MzYy_df03fbd0-7ad2-4009-bbf7-c4a4472e4d08">51.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ea98825b3b48b79de2a000301ebc7d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNi0xLTEtMTc0MzYy_aaa496ea-138d-4dd5-936a-8801223d04e2">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f6c2b8f017469fb82cab1366cbc891_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtOC0xLTEtMTc0MzYy_3dc363ad-ea64-4021-8810-6aa252f11e8e">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic67456caf2c74fb5a00b7ecdac095418_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzUtNC0xLTEtMTc0MzYy_ecd93032-4114-4099-b4f7-f29752cea811">34.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d6d6e78614245739b4f9317ec964d69_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzUtNi0xLTEtMTc0MzYy_9c674106-5451-483c-a761-efd80dc29cf2">40.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a1426d20a84b1ba447ab97089b66db_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzUtOC0xLTEtMTc0MzYy_6e00154f-6986-4d39-b6b8-744530f494ae">35.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="ic1fa02bd765a44fabc7b2a6e15e7bc23" continuedAt="i7c095a9d66d548ab9146d335c64d21e7"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Bayer collaboration:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:48.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzItMi0xLTEtMTc0MzYy_13fd7619-5763-47ea-bfd9-62a3b0b4e467">348.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd8680e50f643d098a5cb1c5b5231a8_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzItNC0xLTEtMTc0MzYy_681b1352-0038-4d58-b5dd-e8e82e713aeb">355.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzMtMi0xLTEtMTc0MzYy_4d462f6e-a936-43fb-86b9-4f9c8d6c0234">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd8680e50f643d098a5cb1c5b5231a8_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzMtNC0xLTEtMTc0MzYy_a06961b4-b82b-4410-aedb-555285e2a4c7">129.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2016 agreement, the parties agreed to a target selection process, whereby the Company may obtain exclusive rights in up to 10 targets to be chosen by the Company during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Certain targets that either the Company or Intellia selects pursuant to the target selection process may be subject to a co-development and co-commercialization arrangement at the Company's option or Intellia&#8217;s option, as applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company expanded its existing collaboration with Intellia to provide the Company with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, the Company also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene edited products. In connection with the agreement, in 2020, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i6c64d785c95b442cb84245281603aa97_D20200101-20201231" decimals="-5" name="regn:CollaborativeArrangementUpfrontPaymentMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE5OTUy_f2c82767-fc25-4c1f-af64-c8a6766afa0b">70.0</ix:nonFraction>&#160;million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ifa1488b28acd4712947288f81c0b3d62_I20201231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwMDUz_d057b1b5-1da2-467d-a84e-e9121184ddd8">30.0</ix:nonFraction>&#160;million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $<ix:nonFraction unitRef="usd" contextRef="i6c64d785c95b442cb84245281603aa97_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwMTYx_d047ab84-cf8c-4bd1-b58b-670830cb4abe">15.0</ix:nonFraction>&#160;million, were recorded to Acquired in-process research and development expense. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i9e23b196a029457e9369dc3be0cdb436" continuedAt="i88ac6d47d9d245bba1b1083deba843e3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d. U.S. Government </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company expanded its Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of the Company's costs incurred for research and development activities related to COVID-19 treatments. In 2020, the Company also entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. The agreement, as subsequently amended, provided for payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="ib00e86a2286a4587b02c4df300896c50_D20220101-20221231" decimals="-5" name="regn:MaximumTransactionAgreementPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwOTU3_7220f481-9288-4b1b-aa55-5990b9aaa934">465.9</ix:nonFraction>&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish, storage, and other activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an agreement with the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase <ix:nonFraction unitRef="dose" contextRef="i60cc7d156a5a435fb977176336cbf529_D20210101-20210630" decimals="INF" name="regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxMzg2_505591c5-61c8-45fa-a170-3ac7043c131f">1.25</ix:nonFraction>&#160;million doses of drug product, which the Company delivered by June 30, 2021, resulting in payments to the Company of $<ix:nonFraction unitRef="usd" contextRef="iadbeb25484b8461ba47918e533c9948f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNDg5_67603a9b-0417-4e50-888e-fe906022c2a9">2.625</ix:nonFraction>&#160;billion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an amendment to its January 2021 agreement to supply the U.S. government with an additional <ix:nonFraction unitRef="dose" contextRef="i444e097b9a96467fb3f9bcce2f2dbf2f_D20210901-20210930" decimals="INF" name="regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNjI2_2af0f8b4-6f3f-4549-96ff-577d4b32a4f2">1.4</ix:nonFraction>&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government was obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of $<ix:nonFraction unitRef="usd" contextRef="i62ebb955ca6e41b3a41e451e1855aa43_D20210901-20220131" decimals="-6" name="regn:MaximumTransactionAgreementPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxODU1_a8ccb9a9-ea96-4b2b-bf53-dba7a851f32d">2.940</ix:nonFraction>&#160;billion in the aggregate. Roche supplied a portion of the doses to Regeneron to fulfill the Company's agreement with the U.S. government (see "Roche" below for further details regarding the Company's collaboration agreement with Roche).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had completed its final deliveries of drug product under the agreements described above. See Note 2 for REGEN-COV net product sales recognized during the years ended December 31, 2021 and 2020 in connection with these agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">e. Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in other countries). Under the terms of the collaboration agreement, the Company leads global development activities for REGEN-COV, and the parties jointly fund certain studies. The Company has the right to distribute the product in the United States and Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Other collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.</span></div><ix:continuation id="i22744028e94b4ffa921d7771c8fb981e" continuedAt="iab5284ea175b4dd2b183fd621c239446"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3634f1dd450c457f96f0a93baa2fe330_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzItNC0xLTEtMTc0MzYy_8a25ad24-78a4-4125-b797-1e05a8cbb4e0">627.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9910bd6f76874c749d53d66bb258402f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzItNi0xLTEtMTc0MzYy_655b9699-2430-47fc-9123-dde2bc1fa224">361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557ade655aa34c1cbd2c4cb2be4a929a_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzItOC0xLTEtMTgyNzE5_839de6fa-aac6-4475-bdc9-9b8e64826d71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id400cead2cc04f689d186fa70f6b0bc7_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzMtNC0xLTEtMTc0MzYy_2f6fb929-b530-4955-b1c7-08f2052f5284">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920dc4f12d2f4619b92a360f1580099a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzMtNi0xLTEtMTc0MzYy_fe95e97d-fab2-491c-a8c3-537d83ea519f">128.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81aa8c9a653b433692636458e8fd345f_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzMtOC0xLTEtMTgyNzE5_2166214e-10b3-4971-a4f0-f16ffccaf072">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment to Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c91b71a44844a9a8775d4250688b382_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzQtNC0xLTEtMTc0MzYy_f0b9b3cd-7f42-4250-880c-fbdefc1bdc26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib113af71423044e1bdf03d2a055e837d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzQtNi0xLTEtMTc0MzYy_692a065f-d457-4dc1-b1ac-47642e8284d2">259.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03fc22e78596486394e84faff1c467ba_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzQtOC0xLTEtMTg0NDk3_76a8e93f-0271-4ea7-9cd3-c2c4736c3114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="i7c095a9d66d548ab9146d335c64d21e7" continuedAt="i46f581f67e404ea38d981c55ddea6f7f"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.764%"><tr><td style="width:1.0%"></td><td style="width:49.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128800b6b8e7426faa3758b24792c793_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzItMi0xLTEtMTc0MzYy_83a53e62-287c-4f1e-8a50-810003f5f1b3">396.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e95202a8f2e4aefb1e1dfc0454a551f_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzItNC0xLTEtMTc0MzYy_936b81b6-1a62-4c13-bb51-57530e87b2ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128800b6b8e7426faa3758b24792c793_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzMtMi0xLTEtMTc0MzYy_3576b7e6-6871-4c1d-a35b-1cc5279c87f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e95202a8f2e4aefb1e1dfc0454a551f_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzMtNC0xLTEtMTc0MzYy_646e11db-6b62-4843-b959-72149268b5b1">268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i88ac6d47d9d245bba1b1083deba843e3" continuedAt="i1b837c02840946669bf4e72c872ce88d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">f. Alnylam</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company and Alnylam Pharmaceuticals, Inc. entered into a collaboration to discover RNA interference ("RNAi") therapeutics for nonalcoholic steatohepatitis ("NASH") and potentially other related diseases, as well as to research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts (including ALN-HSD, which is currently in clinical development). Under the terms of the collaboration agreement, the parties share development costs equally. During the fourth quarter of 2022, Alnylam elected to opt-out of further development activities related to ALN-HSD; as a result, the Company retains the exclusive right to develop and commercialize such product and Alnylam will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company and Alnylam entered into a global, strategic collaboration to discover, develop, and commercialize RNA interference therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver. In connection with the collaboration, the Company made an up-front payment of $<ix:nonFraction unitRef="usd" contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231" decimals="-5" name="regn:UpfrontPaymentMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI0MzA5_b958cb15-aff7-4135-9de2-c4d5e0d12fc5">400.0</ix:nonFraction>&#160;million to Alnylam, and also purchased shares of Alnylam common stock for $<ix:nonFraction unitRef="usd" contextRef="iacafdf0d5b114325b26e61a9a412e131_D20190101-20191231" decimals="-5" name="regn:PaymentsMadeToAcquireEquityWithinACollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjM0MDMwNjk_25f59bb4-88e3-4729-9d98-2ceb8c620943">400.0</ix:nonFraction>&#160;million. For each program, the Company provides Alnylam with a specified amount of funding at program initiation and at lead candidate designation, and Alnylam is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231" decimals="-5" name="regn:CollaborativeArrangementAdditionalPaymentEligibleMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI0NTc4_0062cf7a-39fa-4c5d-bc80-b347d460652d">200.0</ix:nonFraction> million in clinical proof-of-principle milestones for eye and CNS programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, the parties plan to perform discovery research until designation of lead candidates. Following designation of a lead candidate, the parties may further advance such lead candidate under either a co-development/co-commercialization collaboration agreement ("Co-Co Collaboration Agreement") (under which the parties are advancing ALN-APP and ALN-PNP, which are currently in clinical development) or License Agreement structure. The initial target nomination and discovery period is <ix:nonNumeric contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231" name="regn:InitialResearchTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MDAy_e96e7f2c-c5bf-4aac-8486-83a159da0ce6">five years</ix:nonNumeric> (which may under certain situations automatically be extended for up to <ix:nonNumeric contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231" name="regn:PotentialExtensionOfResearchTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MDc3_b5f5dadd-ffd9-4564-9cff-115035df2fab">seven years</ix:nonNumeric> in the aggregate) (the "Research Term"). In addition, the Company has an option to extend the Research Term for an additional <ix:nonNumeric contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231" name="regn:OptionToExtendResearchTermPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTk0_433f6f40-8f91-4a14-bf5d-da81ac5ef59c">five-year</ix:nonNumeric> period for a research extension fee ranging from $<ix:nonFraction unitRef="usd" contextRef="ibbee9a8b29934d8b8b7b1e850d856f99_D20190101-20191231" decimals="-5" name="regn:ExtensionOfResearchTermFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MjU1_a82251b5-bd5d-4846-b456-50d1cd75e89c">200.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="icd928207d61c49b880a0b85bdb41a6a6_D20190101-20191231" decimals="-5" name="regn:ExtensionOfResearchTermFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MjYx_98574a71-0073-46f2-b412-1e4430bc3b8d">400.0</ix:nonFraction>&#160;million; the actual amount of the fee will be determined based on the acceptance of one or more Investigational New Drug Applications ("INDs") (or their equivalent in certain other countries) for programs in the eye and CNS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2019, the parties entered into a Co-Co Collaboration Agreement for cemdisiran, a small interfering RNA ("siRNA") therapeutic targeting the C5 component of the human complement pathway being developed by Alnylam, with Alnylam as the lead party, and a License Agreement for a combination consisting of cemdisiran and a fully human monoclonal antibody targeting C5 being developed by the Company (pozelimab), with the Company as the licensee. Under the C5 siRNA Co-Co Collaboration Agreement, the parties shared costs equally and under the License Agreement, the Company as the licensee is responsible for its own costs and expenses. The C5 siRNA License Agreement contains a flat low double-digit royalty payable to Alnylam on potential future net sales of the combination only subject to customary reductions, as well as up to $<ix:nonFraction unitRef="usd" contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231" decimals="-5" name="regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI2NDc3_e447f404-1781-47ba-a51e-a4673fea752c">325.0</ix:nonFraction>&#160;million in sales milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company elected to opt-out of further development activities pursuant to the Co-Co Collaboration Agreement for cemdisiran as a monotherapy; as a result, Alnylam retains the right to develop and commercialize such product and the Company will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Alnylam agreements described above were not material for the years ended December 31, 2022, 2021, and 2020. In addition, contract balances in the Company's Balance Sheets were not material as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">g. Checkmate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. (&#8220;Checkmate&#8221;) for a total equity value of approximately $<ix:nonFraction unitRef="usd" contextRef="if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0NDk2Mg_36903c0b-4a03-4394-a36c-7c81a912459c">250</ix:nonFraction>&#160;million. The Company made an assessment as to whether the set of assets acquired constituted a business and should be accounted for as a business combination. Given that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, vidutolimod, which is in clinical development for oncology, the transaction was accounted for as an asset acquisition. As a result of the acquisition, the Company recorded (i) a charge of $<ix:nonFraction unitRef="usd" contextRef="if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0NTAyMA_50a462b2-9688-406e-a5bb-c6e0fb586da6">195.0</ix:nonFraction>&#160;million to Acquired in-process research and development and (ii) net assets of $<ix:nonFraction unitRef="usd" contextRef="i6667fb912e984e6fa6353a1eed3e8fc4_I20220531" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0NDk5MA_f61cada9-1afb-46c2-a5cc-09bedd2d8824">35.3</ix:nonFraction>&#160;million, net of cash, related to the assets acquired (including deferred tax assets and investments) and liabilities assumed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">h. Teva </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Teva are parties to a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to the Company's collaboration agreement with Mitsubishi Tanabe Pharma Corporation. Under the terms of the Teva Collaboration Agreement, the Company led global development activities and the parties share development costs equally.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i1b837c02840946669bf4e72c872ce88d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, Teva made a $<ix:nonFraction unitRef="usd" contextRef="i0cfcdda3880e4f87bb8ab780435bee97_D20160101-20161231" decimals="-5" name="regn:UpFrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzEyNjQ0MzgzODA5OTg2_e4901cc7-d9a6-4a86-ae62-be46343e636c">250.0</ix:nonFraction> million non-refundable up-front payment in 2016, and as of December 31, 2022, the Company had received an aggregate $<ix:nonFraction unitRef="usd" contextRef="i5c78bdc526b34938a7fd5ed6077bef4d_D20160101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0ODI1Nw_e32649fc-712a-42ff-8309-26be3b7b2692">120.0</ix:nonFraction>&#160;million of development milestones from Teva. </span></div><ix:continuation id="iab5284ea175b4dd2b183fd621c239446"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.206%"><tr><td style="width:1.0%"></td><td style="width:37.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.736%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02c2984d363403d9b1e823ad3d81d18_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmY2NlYjBiYTA2NmI0YjBmOTlmYzRlMWQ5ZmYzYjcxYi90YWJsZXJhbmdlOmZjY2ViMGJhMDY2YjRiMGY5OWZjNGUxZDlmZjNiNzFiXzMtNC0xLTEtMTc3ODcw_ee996f93-99ac-4000-8422-f1131ef65e43">33.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ac5aacea45414aaa675930ed342a3f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmY2NlYjBiYTA2NmI0YjBmOTlmYzRlMWQ5ZmYzYjcxYi90YWJsZXJhbmdlOmZjY2ViMGJhMDY2YjRiMGY5OWZjNGUxZDlmZjNiNzFiXzMtNi0xLTEtMTc3ODcw_3cc4b906-557c-4aa2-8ec1-5be38d9bc6f3">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3c36d0466748cea4e130f324d5e2dc_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmY2NlYjBiYTA2NmI0YjBmOTlmYzRlMWQ5ZmYzYjcxYi90YWJsZXJhbmdlOmZjY2ViMGJhMDY2YjRiMGY5OWZjNGUxZDlmZjNiNzFiXzMtOC0xLTEtMTc3ODcw_b20f3cd4-58ca-4276-b159-a3f14bc4318b">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company recognized reimbursement of R&amp;D expenses (as a reduction of R&amp;D expense) of $<ix:nonFraction unitRef="usd" contextRef="i0f32e181f6564471b1774eaf0ab52226_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTk1NTY0MQ_221024d0-b4f8-4eec-928d-c156c8463cc6">42.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf862611445f4a27954a5d9467250c21_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTk1NTY0OQ_f2b5a959-81a2-4eb0-ac62-88075b3ee0f8">109.4</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively. Such amount was not material for the year ended December 31, 2022.</span></div></ix:continuation><ix:continuation id="i46f581f67e404ea38d981c55ddea6f7f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"></td><td style="width:54.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzItMi0xLTEtMTc3ODcw_d1f91cec-f4af-40d9-af2c-cb9d34108d96">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec656e3d9234cddbabc7b72805e843c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzItNC0xLTEtMTc3ODcw_31251c07-62f3-47c6-b1ee-29f97e8b94d9">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231" decimals="-5" name="us-gaap:OtherLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzMtMi0xLTEtMTc4NjU2_8224464a-ca8c-44bd-9179-81c67d81b525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec656e3d9234cddbabc7b72805e843c_I20211231" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzMtNC0xLTEtMTc4NjU2_02bb25ea-7378-476c-9db4-c06e8935346b">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities included up-front and development milestone payments received from Teva for which recognition had been deferred. During 2022, the Company discontinued further clinical development of fasinumab and, as a result, recorded $<ix:nonFraction unitRef="usd" contextRef="ib5cc30a6e150429d8a9faa24528ade10_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTkzODUxMg_feea0dff-e4b3-4ac5-9940-bff367881f8f">31.9</ix:nonFraction>&#160;million as an increase to Other operating income as the Company deemed its obligation to provide development services in connection with the Teva Collaboration Agreement to be complete.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaboration agreements discussed above, the Company has various other collaboration agreements that are not individually significant to its operating results or financial condition at this time. Pursuant to the terms of those agreements, the Company may be required to pay, or it may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones) which in the aggregate could be significant. The Company may also incur, or get reimbursed for, significant research and development costs. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay, or it may receive, royalties on future sales. The payment or receipt of these amounts, however, is contingent upon the occurrence of various future events.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1ODg_f9b9c41a-399c-4323-8b12-c4404412cf1c" continuedAt="i478a1cefe034443e973ecc5c38fc896a" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i478a1cefe034443e973ecc5c38fc896a" continuedAt="ie74abbb6c1ac4862a0a05048cdbe1ca2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of December&#160;31, 2022 and 2021 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 5) as well as equity securities of publicly traded companies (see Note 5). </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1OTY_82c6ce93-e84b-456b-ab54-b698551a81e2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:53.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItMi0xLTEtMTc0MzYy_3761c99b-2f00-4ed6-a5c6-880a8231e398">6,975.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItNC0xLTEtMTc0MzYy_4c20cb44-6e2e-4b0d-8c5c-7b611d0c455b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItNi0xLTEtMTc0MzYy_2d0479ee-8dc2-4851-be30-a21b93f0a20c">291.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItOC0xLTEtMTc0MzYy_9875449b-cb0f-4829-a1ed-0059a1e8a95a">6,684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtMi0xLTEtMTc0MzYy_82bf8b02-1e3c-47ac-b2ec-f775ff0bf2ee">2,945.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtNC0xLTEtMTc0MzYy_fd9bb2f4-c942-41d4-8988-ea6ad96b9e3d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtNi0xLTEtMTc0MzYy_b0f34a3b-efb3-449e-a459-52c5c8f68638">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtOC0xLTEtMTc0MzYy_7f4f29e1-45bd-4abd-b25f-94b1fff93379">2,939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtMi0xLTEtMTc0MzYy_14e35f15-7cc5-4872-96e3-808075d39410">67.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtNC0xLTEtMTc0MzYy_6d55f6d4-804e-4b78-9d70-46055f9dc237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtNi0xLTEtMTc0MzYy_838e9837-b395-47b4-8729-c10c51b5a20e">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtOC0xLTEtMTc0MzYy_394542b9-a3f5-4e2a-b213-5224206e1f26">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c85832e072499f9f789894f4319fb1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtMi0xLTEtMTc0MzYy_55325aaa-f47f-4134-93d1-20645654b8ba">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c85832e072499f9f789894f4319fb1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtNC0xLTEtMTc0MzYy_db31fde3-ba24-4f21-9acb-04a926154b83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c85832e072499f9f789894f4319fb1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtNi0xLTEtMTc0MzYy_75f661a5-593d-4642-a34a-ab5b9b3e1c8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c85832e072499f9f789894f4319fb1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtOC0xLTEtMTc0MzYy_0cbf53e6-5ab1-410b-9f3e-6eeb66e42828">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtMi0xLTEtMTc0MzYy_d173d5f2-d7f2-4eae-9bb0-3e8255ec6849">182.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtNC0xLTEtMTc0MzYy_ffa7a068-1e2d-4d7f-8e2c-4a86d2f885e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtNi0xLTEtMTc0MzYy_a4ba167e-20df-496b-a6c3-667d089e61ec">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtOC0xLTEtMTc0MzYy_272bc3ae-47ed-4695-a544-0cb50713ad21">182.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctMi0xLTEtMTc0MzYy_85f0f59a-146d-4d5c-91a2-64a22320e017">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctNC0xLTEtMTc0MzYy_eb564ba6-7f61-4ab5-a106-2a30032ce511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctNi0xLTEtMTc0MzYy_9f66daa5-218b-4122-87cb-06b209d29f28">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctOC0xLTEtMTc0MzYy_82b13cdf-8b59-4bff-bc57-739572e3dace">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtMi0xLTEtMTc0MzYy_9ed4b029-9060-4e39-a6ef-31baf287492b">10,320.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtNC0xLTEtMTc0MzYy_3434a727-7624-4d07-b1d9-c00a5dfa043c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtNi0xLTEtMTc0MzYy_94c0979f-ef04-4617-996e-1bb134dc34b1">302.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtOC0xLTEtMTc0MzYy_a6a770b9-d680-4b7d-907b-ec3683778683">10,018.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTItMS0xLTE3NDM2Mg_44bb1497-9c1f-43c9-a978-53909e460a42">7,518.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTQtMS0xLTE3NDM2Mg_5ed87b8d-3bab-4fdb-987a-1cc8939ecff8">10.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTYtMS0xLTE3NDM2Mg_d363ba13-5440-4c31-9527-a0400e47217a">40.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTgtMS0xLTE3NDM2Mg_99913466-0a5b-4cf1-9cc9-c04b11bffcb7">7,487.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTItMS0xLTE3NDM2Mg_b89c2759-3741-4f45-b43d-5e0560740492">109.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTQtMS0xLTE3NDM2Mg_5e8d1acc-7d6b-4aa1-8705-6bf1f806b2a8">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTYtMS0xLTE3NDM2Mg_30a54775-b467-4719-8ed9-acaaf1192a46">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTgtMS0xLTE3NDM2Mg_0e807722-e86f-4c87-bbf9-d0a275b8a824">108.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTItMS0xLTE3NDM2Mg_20d8c57f-48d4-47ec-9c21-575e57b822bc">64.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTQtMS0xLTE3NDM2Mg_7cabb769-7207-4e6d-a7b9-dfa2a3189c01">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTYtMS0xLTE3NDM2Mg_16c7310c-31e9-481a-9a24-e65918ec17df">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTgtMS0xLTE3NDM2Mg_77465622-2eee-41cb-8e87-ef0881bb3e70">64.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTItMS0xLTE3NDM2Mg_45c5fc14-e90b-4b5c-81e5-b47af4509e61">439.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTQtMS0xLTE3NDM2Mg_637ceb98-27db-4353-8cca-797079cfdd89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTYtMS0xLTE3NDM2Mg_00585cab-c9a2-4fbb-b14b-50406856b8bc">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTgtMS0xLTE3NDM2Mg_0fab6f5d-eca3-4d72-8abb-a3894b18e4b3">439.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTItMS0xLTE3NzIzNA_d6702926-5db9-4850-94a6-6de174b057cd">255.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTQtMS0xLTE3NzIzNA_434079e1-614f-44c1-9bfb-34556de22461">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTYtMS0xLTE3NzIzNA_89e96288-9618-49c2-897c-9afe401fd589">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTgtMS0xLTE3NzI0Mg_656ba468-9796-4cdc-82bd-42796efd8af5">255.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTItMS0xLTE3NDM2Mg_2fe81e69-d7da-42e8-8384-a6b8735d3ec7">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTQtMS0xLTE3NDM2Mg_e45032a6-db97-440d-bb77-6096a0b56df6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTYtMS0xLTE3NDM2Mg_a6d2296b-e510-4e83-bec9-a48600a6fdf9">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTgtMS0xLTE3NDM2Mg_efaf5927-fd65-495c-afc4-62c325914fa2">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTItMS0xLTE3NDM2Mg_907d4b33-ebbb-4ad1-965f-66f7b40954de">8,428.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTQtMS0xLTE3NDM2Mg_1e50ef67-2b5c-4cdb-9b7c-162cf4e6aee2">10.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTYtMS0xLTE3NDM2Mg_fb6dcfa0-526a-4993-a9d8-b0729990d03b">42.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTgtMS0xLTE3NDM2Mg_a80aaf02-a202-46e1-8218-47be3af1559c">8,397.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of December&#160;31, 2022 mature at various dates through April 2028. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1ODc_00fce661-290e-4af4-bb14-83164a26c8fe" continuedAt="i570a0e6ddf6140938fa3944888628c90" escape="true">The fair values of available-for-sale debt securities by contractual maturity consist of the following:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i570a0e6ddf6140938fa3944888628c90"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.235%"><tr><td style="width:1.0%"></td><td style="width:65.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzItMi0xLTEtMTc0MzYy_09f3d9a2-f79e-4aae-9ef0-6e15708ac518">4,636.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzItNC0xLTEtMTc0MzYy_e2c5bb54-66b6-47fd-86a0-65d449bc78d0">2,809.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzMtMi0xLTEtMTc0MzYy_e954f56c-984b-4960-a5a7-e81e629efdb9">5,381.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzMtNC0xLTEtMTc0MzYy_3053dc91-7cf7-4760-a5ad-79159d6974fa">5,588.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtMi0xLTEtMTk3MzA4_0d0d9004-511e-4fb6-82d7-a3a52742ee8d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtNC0xLTEtMTk3MzA4_4497e6f8-9f90-4014-ad58-d31eb1fdde44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtMi0xLTEtMTc0MzYy_e81dd90a-c9ed-481d-a1ff-29803273aa20">10,018.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtNC0xLTEtMTc0MzYy_8fc66978-4d53-44fa-8f5b-23cd28ac6e3a">8,397.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1Nzk_d141a33e-0b08-4ba2-b5ff-f73ee0766fe7" continuedAt="ib900a7c1424b4dcfb84584cd7178f269" escape="true">The following table shows the fair value of the Company's available-for-sale debt securities that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position. </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ie74abbb6c1ac4862a0a05048cdbe1ca2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="ib900a7c1424b4dcfb84584cd7178f269"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItMS0xLTEtMTc0MzYy_db499d2f-d282-4c59-9f0a-b42dd3781a8a">2,445.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItMy0xLTEtMTc0MzYy_cc2a5031-f486-44e3-8965-d65c36a4be35">73.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItNS0xLTEtMTc0MzYy_66b23188-ea86-47a5-986d-a7db72268ad2">4,200.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItNy0xLTEtMTc0MzYy_28472f3d-824d-4b91-ac70-318a39b37008">218.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItOS0xLTEtMTc0MzYy_d5cd8f43-bcc3-48ca-97cc-39cd5dca383e">6,645.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItMTEtMS0xLTE3NDM2Mg_2bf1c73a-1381-4bfc-b7ad-de3fdfb1058d">291.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtMS0xLTEtMTc0MzYy_d496bc68-62d8-4311-89df-071a33fce768">785.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtMy0xLTEtMTc0MzYy_71ba60d4-4a7c-46b4-8e14-c457e25c3049">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtNS0xLTEtMTc0MzYy_fe6698c5-ff17-4ec3-a52b-f56e5e363d2b">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtNy0xLTEtMTc0MzYy_4cb480e6-0a5b-4df4-9e36-fc76b6739d57">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtOS0xLTEtMTc0MzYy_acddf06e-8d67-40be-adc3-1baf0fdbf40b">856.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i756ea3fa11624c548b132cede643b135_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtMTEtMS0xLTE3NDM2Mg_5165061d-4b80-49a9-9740-06af1218fd49">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtMS0xLTEtMTc0MzYy_3a73980d-f52b-4af9-b7d1-161007bae61a">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtMy0xLTEtMTc0MzYy_50ec7244-720b-4bbc-a9a4-cf60afa3e590">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtNS0xLTEtMTc0MzYy_8df59dac-3661-4757-9f78-5f03aa7e08e4">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtNy0xLTEtMTc0MzYy_289618d2-6b4a-4389-95ec-311308110925">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtOS0xLTEtMTc0MzYy_893aa376-3f9c-43db-97b7-cb495ee4e32a">64.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtMTEtMS0xLTE3NDM2Mg_315c2c15-9eb5-44b6-ba67-83fe5510db82">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtMS0xLTEtMTc0MzYy_92e18381-bf9a-40ac-a8c4-822a60394f97">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtMy0xLTEtMTc0MzYy_8b2760c8-c605-4ed1-bf6d-0bc35e409522">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtNS0xLTEtMTc0MzYy_b5fbaffd-998a-4d37-ba32-049c1d401fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtNy0xLTEtMTc0MzYy_8ecda46d-c975-4111-8e5c-5276f7e365a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtOS0xLTEtMTc0MzYy_fea037f1-2e8e-4780-9f97-112398b43a59">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtMTEtMS0xLTE3NDM2Mg_8ab65da4-65c2-411f-a2f2-98abba69cb83">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctMS0xLTEtMTc0MzYy_d6791250-7f6e-4f3d-955f-18fde0d6cebd">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctMy0xLTEtMTc0MzYy_80572485-5b8b-480d-a6bf-1697299d8368">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctNS0xLTEtMTc0MzYy_3b1b3c5a-577a-426a-99c8-16941e5094b1">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctNy0xLTEtMTc0MzYy_4598da12-c228-407b-8798-96beacd31018">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctOS0xLTEtMTc0MzYy_8c008c84-e181-43ca-b076-1c1daf190e94">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670b1994d88c42c7ad5592e062721992_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctMTEtMS0xLTE3NDM2Mg_fe97b676-499b-4180-ab8c-dbe96c540fde">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtMS0xLTEtMTc0MzYy_f1c2d760-87a9-4821-a415-865857bb5f72">3,300.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtMy0xLTEtMTc0MzYy_af4a4a78-c481-45ec-8ab9-8d90e379c3d8">76.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtNS0xLTEtMTc0MzYy_06821ca7-f979-4fe6-851f-b36fbaf1323f">4,332.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtNy0xLTEtMTc0MzYy_3a893145-ef3f-4e53-b973-947c641d9257">225.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtOS0xLTEtMTc0MzYy_b7eb19f8-d704-4f01-8d33-30fd3ea9c3a2">7,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtMTEtMS0xLTE3NDM2Mg_151762bf-a99c-43b4-bbe1-4692be0836e5">302.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTEtMS0xLTE3NDM2Mg_8ecc1dbe-6731-421a-8e17-c47cc3441789">5,889.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTMtMS0xLTE3NDM2Mg_324cf3f3-a7e1-4839-9380-a11682068673">40.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTUtMS0xLTE3NDM2Mg_d52c07fc-60fe-4fd4-bc0a-cc65117eb017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTctMS0xLTE3NDM2Mg_c7f047b7-d7dc-4b2b-b7a3-9d7116ff1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTktMS0xLTE3NDM2Mg_2e0cb157-1fdd-4ba8-ad15-efaa105b876f">5,889.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTExLTEtMS0xNzQzNjI_095102ae-72a3-43ba-8dc5-29fc18146a50">40.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTEtMS0xLTE3NzI3Mg_dc79ba3c-3dc5-41bc-b466-92ab8a11ca0f">90.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTMtMS0xLTE3NzI3Mg_28503491-1299-435e-beab-4456fd080026">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTUtMS0xLTE3NzI3Mg_3381c573-7a52-4aac-b1c3-3bb2a900497f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTctMS0xLTE3NzI3Mg_68a047ff-8731-47cb-ba08-e8ff5e89c0f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTktMS0xLTE3NzI3Mg_68385dce-0fbc-4d5e-8137-890c0c834a03">90.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTExLTEtMS0xNzcyNzI_502eb4c2-2dca-4b86-bf48-69f527ae5681">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTEtMS0xLTE3NzI3Mg_e87e9ab8-6b95-4221-94eb-627ec7823f1c">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTMtMS0xLTE3NzI3Mg_64e6344d-5dd1-4348-b56f-c161e4d8952d">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTUtMS0xLTE3NzI3Mg_0fc75842-26f9-480c-aced-afe28a90a094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTctMS0xLTE3NzI3Mg_baf40d52-a9ed-4e56-ac9a-236aa1f75ec3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTktMS0xLTE3NzI3Mg_fc616538-a707-42d3-a52a-3a5c64821e4e">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTExLTEtMS0xNzcyNzI_9f8a5dbd-5214-4570-8a8a-7ee806f0f241">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTEtMS0xLTE3NzI3Mg_c8e2636e-9d9a-4a78-be23-4c8857a68dcf">295.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTMtMS0xLTE3NzI3Mg_b88a3851-eef0-48f4-85fd-6399c990bbf3">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTUtMS0xLTE3NzI3Mg_b6002234-c1fd-4282-9cb6-9c6ee05e88ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTctMS0xLTE3NzI3Mg_e0880b33-bf7a-4572-b45f-2dea3b8f57e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTktMS0xLTE3NzI3Mg_3c33f049-559b-42de-a7f0-0524bd001272">295.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTExLTEtMS0xNzcyNzI_e21de8f4-d2bd-46b9-b202-b145fbfd525f">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTEtMS0xLTE3NzI3Mg_225d15aa-6b16-4829-85d2-8e6828b94d0d">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTMtMS0xLTE3NzI3Mg_66fdf075-a32e-4343-98e0-fe19bdd397ae">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTUtMS0xLTE3NzI3Mg_b80bd1ea-311b-4d87-808a-f7bcb3702d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTctMS0xLTE3NzI3Mg_67a4fd00-3a0b-47aa-868f-53da2f60dbea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTktMS0xLTE3NzI3Mg_7aef737b-1af6-4086-9e09-e4dfe7c7d948">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTExLTEtMS0xNzcyNzI_eb4aad6e-2aec-4dd6-87be-bd90d02fd869">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTEtMS0xLTE3NzI3Mg_0e920d04-1c44-4c9a-b7d2-69a87c968f92">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTMtMS0xLTE3NzI3Mg_88b95fa3-e59d-4a8a-89ac-8ccf0d4b7b9a">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTUtMS0xLTE3NzI3Mg_5f5a8f14-7992-4498-95a3-95ab8f362542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTctMS0xLTE3NzI3Mg_0b5668a4-780d-4594-b632-49fc20c50c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTktMS0xLTE3NzI3Mg_87dc9ce5-bf5e-4bd3-bd75-e0731f6137ec">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTExLTEtMS0xNzcyNzI_17c50a40-ca51-4580-8abb-7cb66063ec1b">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTEtMS0xLTE3ODY2MA_0cee43e5-812b-4cf8-9f64-0891fcecabd3">6,516.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTMtMS0xLTE3ODY2MA_e4213360-1541-4995-a598-4c7eeeeba83a">42.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTUtMS0xLTE3ODY2MA_e05cbae1-63ac-487d-b30f-e8c6f6d103c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTctMS0xLTE3ODY2MA_4f518548-43d5-4090-a7fd-d926405dc4a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTktMS0xLTE3ODY2MA_4e1c1ea9-2a6a-4ddb-9695-e4885cc07b6f">6,516.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTExLTEtMS0xNzg2NjA_f4d0060f-7789-4cc5-a68c-fdcc92078879">42.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses on corporate bonds as of December 31, 2022 were primarily driven by increases in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to marketable securities, for the years ended December 31, 2022, 2021, and 2020, amounts reclassified from Accumulated other comprehensive income (loss) into Other income (expense), net were related to realized gains and losses on sales of available-for-sale debt securities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of marketable securities were not material for the years ended December 31, 2022, 2021, and 2020. Interest income of $<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:InterestIncomeDebtSecuritiesOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE2NDkyNjc0NDgzNjY_da44eac4-d616-4556-a7fb-427d84d25c73">160.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:InterestIncomeDebtSecuritiesOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE2NDkyNjc0NDgzNzE_25277626-af01-4114-8f7e-1a07d8623916">45.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:InterestIncomeDebtSecuritiesOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE2NDkyNjc0NDgzODA_fbc225cc-db3e-4cd2-911a-9df6814f88e6">75.4</ix:nonFraction> million for the years ended December 31, 2022, 2021, and 2020, respectively, was recognized in Other income (expense), net.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzE0MjQ_8a2dbe91-4bed-4120-9f77-8084c6dca806" continuedAt="iacaa7f73405f4f3eaebd75f199155862" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="iacaa7f73405f4f3eaebd75f199155862"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzE0MTM_0c1dbfa7-f9d4-4dbb-8c76-81115ef3eaad" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.965%"><tr><td style="width:1.0%"></td><td style="width:49.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f165da14524f83ab4e24f33f72fa7c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzMtMS0xLTEtMTc0MzYy_4e77a9ef-0b38-438b-81b9-a6fc200bde4c">6,684.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff3294615794346a9b85255e14fd794_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzMtMy0xLTEtMTc0MzYy_833182f5-008b-45d0-812e-a211a03482fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe27a11c61a240e4b0a067ec0dd7d798_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzMtNS0xLTEtMTc0MzYy_6a972de9-12a5-4e8f-9aab-640c5cdf7ae7">6,684.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93ec21dd364485abcb9d4f5a58113b1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzQtMS0xLTEtMTc0MzYy_89fe9ebb-0c19-47c0-9f60-3aa1a7147215">2,939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea2ced853b94e24a4d22f70bd4fd29e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzQtMy0xLTEtMTc0MzYy_b91b93d1-726f-4edf-a66e-5487ff0f1ba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22141dab4f53412ea6de7ff444ac262c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzQtNS0xLTEtMTc0MzYy_2ec962a4-c8cd-47ed-87ac-c9ac5fd0f897">2,939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50af84a4e2f049f5993f9b56288daed0_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzUtMS0xLTEtMTc0MzYy_4693d726-0fe7-4f3c-9231-f074d13526bf">64.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c9255c54ab4b2d8041ec8cf8ed2d76_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzUtMy0xLTEtMTc0MzYy_ae2c5793-908d-4db8-bd75-b7cddb5e844c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4cd0cb429064df7ac32623abbd44a07_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzUtNS0xLTEtMTc0MzYy_750be6ca-0710-44a0-a4b9-79a68fe28d06">64.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fe982b399644ca994a70d8d2ad5e97_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzYtMS0xLTEtMTc0MzYy_59c6a4af-d15d-4d57-b2d7-5b44cd55a8b7">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc86526bc33f401eaef37c46de2730c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzYtMy0xLTEtMTc0MzYy_6dbfdb22-c75e-4b80-8494-8c41886573c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467a55c788544f30ad74454d840569e2_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzYtNS0xLTEtMTc0MzYy_cb7ec8d1-7d3a-4e69-abbc-461406530c32">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01edbc55a346434a8547a03cdf3f8b8c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzctMS0xLTEtMTc0MzYy_4f7020b3-f311-4908-b3eb-2cdc55843c03">182.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id596959620f7472daf2da370a9c6e4ee_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzctMy0xLTEtMTc0MzYy_23de75a6-4da3-4333-b34b-77fb2a748a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab5450159345e4a7a8d5d1becc66f3_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzctNS0xLTEtMTc0MzYy_9515cb10-64b1-4efa-b11b-a184189448ce">182.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5c2e9a61694f1b8288a4d46747d122_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzgtMS0xLTEtMTc0MzYy_8c2e40f6-2dac-482e-8036-2b55a5c3701d">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df6b754d9874865849815ce0ff1fa35_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzgtMy0xLTEtMTc0MzYy_ddf77d24-3898-4bd6-9f28-da3210f9d98b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5812ccf9fa340d68bb0fb9ae362fd55_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzgtNS0xLTEtMTc0MzYy_ffc4c551-1f21-4830-ac2a-c1ad283f52bd">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb2285eff7124799bf35474f9b77d3a5_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzktMS0xLTEtMTc0MzYy_e54ce234-af8d-45f9-a63a-a5029f15c297">24.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37cc523007314e81a486975a1e802e30_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzktMy0xLTEtMTc0MzYy_f5cbceb4-10f4-4031-9f7e-7ad24424a7f6">24.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9444b58a5bf44713b0a53669ccd879a9_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzktNS0xLTEtMTc0MzYy_c3e2aa8f-2eb8-4a73-bba0-e2e15c0c40e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac51098e276e4ab68f338afabe7e88ed_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzEwLTEtMS0xLTE3NDM2Mg_4e4d75c7-48ba-4417-9d20-defac375346d">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0604eb2ce2824a94b18ba840c03422bc_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzEwLTMtMS0xLTE3NDM2Mg_d9f71f33-4027-44a8-b623-38cd0b708b73">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e07af51cdfe402cb73cf12cdaa18875_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzEwLTUtMS0xLTE3NDM2Mg_1731c46d-79c9-4518-878c-280671d7865d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaac5082db1042e2a542c59aaed88125_I20221231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzExLTEtMS0xLTE3NDM2Mg_cde73d69-5c35-4615-b073-197365af617e">11,228.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76805457ac75462bb9be58fc14847bbd_I20221231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzExLTMtMS0xLTE3NDM2Mg_8509653b-9f82-418f-baec-d2a888f2ba36">1,210.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie322fb4fa7024b1baee4c74f133d24f0_I20221231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzExLTUtMS0xLTE3NDM2Mg_95d0791a-11fd-45ec-a716-80699f1f4fa8">10,018.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e37a666e97345adad33738c64a2c8ef_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE1LTEtMS0xLTE3NDM2Mg_87a94e47-b880-48a7-ba46-c3ea3aad155c">7,487.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814e9188987a4eb6818cb5e646b4c49c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE1LTMtMS0xLTE3NDM2Mg_218b4ee7-6a79-4815-b376-4f21a741fa16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397a4c2affbe4db4b8abb7c9195877b4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE1LTUtMS0xLTE3NDM2Mg_b51328de-08db-443f-967e-54ca4acd1cb2">7,487.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4cb2ea77d6466a814509f17d146b81_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE2LTEtMS0xLTE3NDM2Mg_03087b06-6e8d-4313-9e6b-842f7e155e7f">108.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900991202ef2412f84b8b49bbd1fd697_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE2LTMtMS0xLTE3NDM2Mg_0aca85b5-1b02-421c-b4d8-5b470a42f586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id958dea12f9f4daf9596b2e6ca4b664d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE2LTUtMS0xLTE3NDM2Mg_87834463-cccf-4ccd-9a4d-1ce57432d038">108.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c4864785e4460bbe8e8603d9e6e3c8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE3LTEtMS0xLTE3NDM2Mg_be29f228-509f-4377-ac1d-62c0826aaca5">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55cd0cb5a7dc469dacd573bace8619db_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE3LTMtMS0xLTE3NDM2Mg_2c0263f4-a441-495e-a899-23dbd115b3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59b77df52a94d3d94be86824b44ccac_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE3LTUtMS0xLTE3NDM2Mg_78ce77d1-88f8-4b68-8250-47672bc8c782">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf857f344764403832320f65a37a8aa_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE4LTEtMS0xLTE3NDM2Mg_b3732979-e16a-423d-9b4f-c1be3746993a">439.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3d9acb4aa14bb882392991f7def806_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE4LTMtMS0xLTE3NDM2Mg_7782267c-e5f2-4bd7-9b18-33468c80a3bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f19239807454691aa94fa166a33be9c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE4LTUtMS0xLTE3NDM2Mg_b4659c0e-fde0-499f-8c46-5eab18b94432">439.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddbcb7106de49f49d710399f917f536_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE5LTEtMS0xLTE3NDM2Mg_3036d4cf-04f9-4281-b0ec-3de7b2c2aefc">255.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d07dab80a0497089de881dd7911c76_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE5LTMtMS0xLTE3NDM2Mg_471324ec-eacf-4bb7-834d-32c63e27a227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f9a85d3b6c4ab58982bdab11c05ddd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE5LTUtMS0xLTE3NDM2Mg_a8f7eac3-6a7f-41aa-9e46-8abcf4ea0986">255.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7268de767d8943b9bee7565a5fc1ee35_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTEtMS0xLTE4NTYzMw_13ac3774-449a-499d-82ee-6ec5f7367a16">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7acba5123d245669d2c0b2930d140f4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTMtMS0xLTE4NTYzMw_65195544-ea1c-46f0-b13c-5c40b9d8aed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3c12ae98b546ceb6fe3e88dc64b1b6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTUtMS0xLTE4NTYzMw_5570f6ab-b01b-4fe9-bb42-d770e21d4546">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cf341222be46a193f1ef088c6436ed_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTEtMS0xLTE3NDM2Mg_0d436c7a-27da-4e30-abe9-f7f4cc897c10">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bc3760e9e940d0b37cebc198b73cf0_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTMtMS0xLTE3NDM2Mg_22a65684-8bb7-4bda-98f0-f8f689e1a08f">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b618f73a8fa43489c55a045ed15c1f7_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTUtMS0xLTE3NDM2Mg_bacac83d-4490-42a4-809e-888aea7dca6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e308ff0e87e482fba35dd4da2bd8aa0_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIxLTEtMS0xLTE3NDM2Mg_f0ee00cb-9aeb-4cc5-930d-c25c6f05ae87">1,191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8312eadb6504455aaaac7b194804e4ab_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIxLTMtMS0xLTE3NDM2Mg_d9c3f91c-67f7-4bd0-b64c-c1eea6c441d6">1,191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2058d7e3d9452b8becd26693bb4b7e_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIxLTUtMS0xLTE3NDM2Mg_5b4becb0-2dee-4f9e-b9a8-1950cb498c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5efd5732c8647d88223929f0c134b0e_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIyLTEtMS0xLTE3NDM2Mg_386393c2-9588-4c69-bb3a-3812636ef49b">9,647.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2aa3f436384eb7abe5169c1fb29a5a_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIyLTMtMS0xLTE3NDM2Mg_db03f85c-c20e-45dc-962f-53f2181c9b2e">1,249.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56431b74b0b46708d25ec5b1f24d48c_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIyLTUtMS0xLTE3NDM2Mg_f36bbbbe-3d6f-4498-91ee-4eff03fc1394">8,397.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of December&#160;31, 2022 which are subject to transfer restrictions that expire at various dates throug</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwNDQ1MzYwNDY1Njc4_99a971d4-5e06-42bc-a1c4-5cce4bbdf617">39.8</ix:nonFraction> million of net unrealized losses on equity securities in Other income (expense), net. During the years ended December 31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwNDQ1MzYwNDY1Njg2_69d49ddb-29f4-4092-b7de-ab4279b89de5">386.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzU0OTc1NTgxNTkzOQ_70eb3cbb-7936-45b1-bcc9-08c3e398f5d2">196.0</ix:nonFraction> million, respectively, of net unrealized gains on equity securities in Other income (expense), net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above, as of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwNzc_087383de-de4e-432d-a376-d9c6cb4a98a4">48.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwODQ_a8526ce9-b67b-4728-af0f-49269cd65d5a">40.0</ix:nonFraction> million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's long-term debt (see Note 10), which was determined based on Level 2 inputs, was estimated to be</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEzNTY_4e600bcf-ef3b-433c-9466-d4dc346d861e">1.443</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEzNjM_9ad4c5f8-ff8c-40df-8569-3ed801fc294e">1.887</ix:nonFraction> billion as of December 31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2Xzg1NQ_082c3b31-cfb0-460a-9efb-29e0e74024ea" continuedAt="id108c8c2c7ff4500bd7defcfd5edf18e" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="id108c8c2c7ff4500bd7defcfd5edf18e"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2Xzg0Ng_5f1e4e9e-a252-4fd6-acfb-a0f7429e3506" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.477%"><tr><td style="width:1.0%"></td><td style="width:48.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzItMS0xLTEtMTc0MzYy_92eef01c-3375-4ff9-9664-d634e0e966a0">818.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzItMy0xLTEtMTc0MzYy_d47b756e-184f-4011-a3a3-baa594a5a9a1">721.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzMtMS0xLTEtMTc0MzYy_121abca2-40b5-4077-86eb-5e9cf6bc733b">963.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzMtMy0xLTEtMTc0MzYy_024a6398-a97a-43eb-812b-eee899ad068d">707.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzQtMS0xLTEtMTc0MzYy_4ff17459-e28d-4a21-b0f1-0c5223b689de">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzQtMy0xLTEtMTc0MzYy_f44f4c72-ac78-4c40-8384-120a020f93a2">73.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzUtMS0xLTEtMTc0MzYy_aec92935-e43d-40ab-b6e6-e3bea01ab489">521.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzUtMy0xLTEtMTc0MzYy_2cfb0f03-893f-423a-8227-5a4119a98e36">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzYtMS0xLTEtMTc0MzYy_f44a4de4-5b94-4afe-a784-a7397d28fe44">2,401.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzYtMy0xLTEtMTc0MzYy_d6014284-fd09-4bce-9e40-26fc22d4e2c6">1,951.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances in the table above are net of reserves of $<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzE1OTM_9958c02c-0770-491b-9e43-eb5043f0ce47">720.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzE1ODI_93ad89cf-5a9c-4a38-aa7c-513c8141fcd4">510.0</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively. Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred. For the years ended December&#160;31, 2022 and 2021, Cost of goods sold included inventory write-offs and reserves of $<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzI1NTk_2d9d6e45-4328-4aeb-b873-a772d011f9ea">258.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzI0OTA_ca31ed83-fd3f-41dc-92ce-5e4887fc33f4">457.1</ix:nonFraction>&#160;million, respectively, primarily related to REGEN-COV. Inventory write-offs and reserves for the year ended December&#160;31, 2020 were <ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzIxOTkwMjMyNTY2OTI_46c6062a-51ee-4418-b4fb-84f598a41e22">not</ix:nonFraction> material.</span></div></ix:continuation><div id="ic18bad8bf5314e3e9f4c348a9f859317_136"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzYzNA_233e1e4f-94ca-4c79-8355-c3ca682d00ff" continuedAt="i713eecf5a9db480d8fe1ae1d678eac05" escape="true">Property, Plant, and Equipment</ix:nonNumeric></span></div><ix:continuation id="i713eecf5a9db480d8fe1ae1d678eac05"><ix:continuation id="ib5111bb7f6014b308826ed6b6d9bf371"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.201%"><tr><td style="width:1.0%"></td><td style="width:46.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f9acbdc085411abc64332f0e5e0849_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzItMS0xLTEtMTc0MzYy_93dbbe2d-53ae-4748-8cc2-ff3026bb49ac">264.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77c2ea74bfe40038cd4646e360bb2e8_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzItMy0xLTEtMTc0MzYy_2ada0f11-a646-430e-a7e3-f9ace9dcea32">248.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib29e6005f6d24c0491ed2bbf66621fb9_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzMtMS0xLTEtMTc0MzYy_00ed6832-f97b-4fd9-be8a-5fe6350c1ec7">2,270.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23273ac9b554855b189599419ac153a_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzMtMy0xLTEtMTc0MzYy_86766a30-1fcf-4373-bdb3-dfb0a3a9ae83">2,088.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65b5f7083d14d56803e3599a24e7f4e_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzQtMS0xLTEtMTc0MzYy_08e7b366-8023-4b4d-a382-59b810188adc">114.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d3fbb1c2f4484da5b302c4846b440f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzQtMy0xLTEtMTc0MzYy_88bc0a0e-7b5e-4382-9096-1b7ade62596d">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442040e783844ed382aecdc0af74fc39_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzUtMS0xLTEtMTc0MzYy_05ac148c-28d0-423e-935f-a0eeac15756d">980.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350934777cd641749f3726d6f2e3a777_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzUtMy0xLTEtMTc0MzYy_2a0b0347-b774-401e-984b-6d3dfabdcd10">767.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a2e7c68cbd450986ed5230d81ffae1_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzYtMS0xLTEtMTc0MzYy_1f4f61a7-d663-45f9-a5dd-4b9a2bfeafa4">1,315.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1294c19697a4d5989612dcdbb557eaf_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzYtMy0xLTEtMTc0MzYy_0b37e29b-c87b-45b7-962f-f2ac0b13de53">1,225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8931c24c9647998f454d826d5ea54f_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzctMS0xLTEtMTc0MzYy_11063a3a-dd6d-49ef-a970-7f0752886ee9">337.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78ea7aa3b8b48818411bc781e1be355_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzctMy0xLTEtMTc0MzYy_aa6f397e-464d-4ba5-b0c7-fcab8e42a264">291.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office equipment, and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie864f6dc154f4872aff761e5a7f37949_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzgtMS0xLTEtMTc0MzYy_2b90d7bc-7560-4d14-965f-1b08430f437d">150.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1098f1326d3c46fab6616d650ec27d81_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzgtMy0xLTEtMTc0MzYy_332a12e2-a969-4586-8afd-d727a6e1f01c">145.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzktMS0xLTEtMTc0MzYy_2fa3ad45-6b19-412f-b18b-1599cade740b">5,432.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzktMy0xLTEtMTc0MzYy_60aaecf7-5bd3-4cd5-8992-0a5af5fcdb4f">4,880.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less, accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzEwLTEtMS0xLTE3NDM2Mg_1f2e27f1-847c-43ca-b9b2-ad2dd3c4c7a7">1,669.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzEwLTMtMS0xLTE3NDM2Mg_e2925bc5-4993-47d7-9a34-2d09ab6bbaba">1,398.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzExLTEtMS0xLTE3NDM2Mg_f68e2bdd-cd77-4fa9-a24b-f3cb8301e447">3,763.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzExLTMtMS0xLTE3NDM2Mg_99378518-0679-4378-8e7a-daace83c7798">3,482.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment in the table above includes leased property under the Company's finance lease at its Tarrytown, New York facility. See Note 11.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense on property, plant, and equipment was $<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzMzNA_8737d860-836b-4595-9c4c-7fb146663945">303.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzMzOA_058fd76d-2292-462f-a959-729133629bdc">281.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzM0Ng_c3eda643-4aa5-4199-8819-73e6ae8a5912">230.8</ix:nonFraction> million for the years ended December 31, 2022, 2021, and 2020, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i51f9bc6743594e108ea3ba33a0b1df17_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzQ0Mw_358f5895-234f-453d-ab32-557204f19fa2">2.960</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i769d8dda3fd84c6492c24d8b5d8397c5_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzQ1MA_ac7766eb-11de-4ac8-96ec-61c8d2f1774e">2.684</ix:nonFraction>&#160;billion, respectively, of the Company's net property, plant, and equipment was located in the United States and $<ix:nonFraction unitRef="usd" contextRef="iaa561036943849f6970887e7e93d601b_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzU1Nw_8f99f328-44bc-490a-bdaf-48d3b503834b">803.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i55fbf7200cd34a90a17cae423a49cac1_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzU2NA_561cc16b-472b-43e0-8231-67a79d21eb78">797.8</ix:nonFraction>&#160;million, respectively, was located outside the United States (primarily in Ireland).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_1511"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjU4NDQ2_2fe93867-9739-456e-9554-df2eeac4575e" continuedAt="i7ce7f8d1f54945b096b618d09276e2ce" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i7ce7f8d1f54945b096b618d09276e2ce"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjU4NDQ3_0cc18544-6ee1-422f-9088-18279c70d223" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired product rights - Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iabe2b2c162d74aceaa748b1c4bb2cc4d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTItMS0xLTE3NjkxOC90ZXh0cmVnaW9uOjQ2ODYwYTFhZDFiMDRmZDQ5NmU4MWZiODBmNzBmYzhjXzQ_8a586507-8b1a-4a40-a3d4-ef4f09602a95">13</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac94305b0cdd490190861cea74735d96_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTQtMS0xLTE3ODY3MA_9f1da480-2ef3-410f-9d23-593f7fa7d577">946.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac94305b0cdd490190861cea74735d96_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTYtMS0xLTE3ODY3MA_d063c92a-fd9b-43dd-81ee-3707fee97e8c">35.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac94305b0cdd490190861cea74735d96_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTgtMS0xLTE3ODY3MA_55a30128-f6b0-456c-a513-08d74d7c5c68">910.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02495c8017b455681cd9f0f892654ff_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTEwLTEtMS0xNzg2NzA_12feba4a-c6f8-4eb7-bcc5-170d05d43661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02495c8017b455681cd9f0f892654ff_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTEyLTEtMS0xNzg2NzA_f7490624-4b9e-4275-9006-370bfec447ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02495c8017b455681cd9f0f892654ff_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTE0LTEtMS0xNzg2NzA_118d1812-5b1f-4ecf-87a5-adf6643b9f0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a704809d9454f6091c067635a04adeb_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTItMS0xLTE3NjkxOC90ZXh0cmVnaW9uOmJiNjRkODUyZmJhNDRiM2JhNDU2Y2Q3OGM3MGU4ZGI5XzQ_bee99377-5157-4717-a364-90f5096d93d4">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i5586b0412de74f4681a571d3e1c5bfbb_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTItMS0xLTE3NjkxOC90ZXh0cmVnaW9uOmJiNjRkODUyZmJhNDRiM2JhNDU2Y2Q3OGM3MGU4ZGI5Xzc_f7013e3c-1164-48e8-abb4-93bf74de5465">8</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566e4366831c4bc9b4395cd536a3c5d4_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTQtMS0xLTE3ODY3MA_657ba353-6d05-4bd6-93e0-a42de4c5ec4f">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i566e4366831c4bc9b4395cd536a3c5d4_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTYtMS0xLTE3ODY3MA_23cad6c6-17ac-49b1-a434-f910fc71a797">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566e4366831c4bc9b4395cd536a3c5d4_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTgtMS0xLTE3ODY3MA_62b177e7-5aa5-4496-8a94-1d8fd6af3459">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce0c7f100084a6dad54ebe67493652f_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTEwLTEtMS0xNzg2NzA_489d3bb6-cbf5-42ef-a243-6cbf4d2789ca">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ce0c7f100084a6dad54ebe67493652f_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTEyLTEtMS0xNzg2NzA_55bf1e36-2ca6-47bc-98e8-41d7fe092458">22.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce0c7f100084a6dad54ebe67493652f_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTE0LTEtMS0xNzg2NzA_ff738c75-5335-4037-adba-78c007030064">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie345030098ed4a68855b720eadea8248_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTQtMS0xLTE3ODY3MA_0b0ec7ea-e0c5-4c8a-9078-a14172b25447">956.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie345030098ed4a68855b720eadea8248_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTYtMS0xLTE3ODY3MA_d1550b87-c418-49fc-a81b-7aa47f83c107">40.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie345030098ed4a68855b720eadea8248_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTgtMS0xLTE3ODY3MA_d7f3483b-0887-4fe5-bfaa-9d9f118e80f6">915.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTEwLTEtMS0xNzg2NzA_d47f8928-1ab2-4e8f-9fbc-067c424143b8">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTEyLTEtMS0xNzg2NzA_1739abd9-c3cf-4dac-8a1c-112fd7ea432b">22.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTE0LTEtMS0xNzg2NzA_398edaf5-2a08-47ab-85d2-0b8612292563">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, the Company recorded an intangible asset in connection with obtaining the exclusive right to develop, commercialize, and manufacture Libtayo worldwide. The intangible asset recognized upon the effective date of the A&amp;R IO LCA primarily consisted of the $<ix:nonFraction unitRef="usd" contextRef="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjYwNzcw_bc7264a5-ba36-4be3-a6e3-8393ccdbf9c1">900.0</ix:nonFraction>&#160;million up-front payment, offset by the remaining IO Collaboration Other liabilities balance of $<ix:nonFraction unitRef="usd" contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701" decimals="-5" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjYwNzg2_fa46f3f5-6523-484f-84b4-fd45f14216ae">241.0</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2022, the Company recorded additions to the Libtayo intangible asset primarily related to contingent consideration (including regulatory and sales-based milestones, as described in Note 3) and other amounts due to Sanofi in connection with obtaining the worldwide rights to Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="if47d053711fd4bdc82cf9d70aa578c00_D20221001-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2NDU0_ef899944-4eec-4631-b1fc-9ec259895202">37.6</ix:nonFraction>&#160;million for the year ended December 31, 2022. Amortization expense for the years ended December 31, 2021 and 2020 was not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, assuming no changes in the gross carrying amount of intangible assets, amortization expense is estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_21daae67-bfc6-4d40-8921-2a8e71214560"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_38e1f91c-65f8-4496-a645-75ca4ec0421d"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_4f00eabf-8fa3-43ab-9cc4-0494fd9d3852"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_b191f97b-8a59-43d4-84b6-e210141926c7"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_e86c8825-08ba-435b-9a19-01786bb85be3">72</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million for each of the years ending December 31, 2023 through December 31, 2027.</span></div></ix:continuation><div id="ic18bad8bf5314e3e9f4c348a9f859317_139"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90ZXh0cmVnaW9uOjA1YWZiZTVkYThmMTRiMjFiNDFhYWMxMzdmYmY2ZjUxXzEzNg_f050ac24-bd06-4d49-84bd-f9a624d4e550" continuedAt="i47e10474b4214e64abaf5c9c4ab86167" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i47e10474b4214e64abaf5c9c4ab86167"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90ZXh0cmVnaW9uOjA1YWZiZTVkYThmMTRiMjFiNDFhYWMxMzdmYmY2ZjUxXzEyOA_b09f39d3-5dc6-45fb-ba25-233c683f2368" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.040%"><tr><td style="width:1.0%"></td><td style="width:49.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzItMS0xLTEtMTc0MzYy_ea130302-643f-49e8-9911-7df5ede32cb4">497.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzItMy0xLTEtMTc0MzYy_24c73b13-501c-4f6c-89fb-fd566b530117">440.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="regn:AccruedClinicalTrialExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzMtMS0xLTEtMTc0MzYy_6e4193b6-d642-4aae-b87e-5223a1af75d1">295.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="regn:AccruedClinicalTrialExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzMtMy0xLTEtMTc0MzYy_1ebf8fa2-d60c-4e5c-9115-4ddc907c673e">295.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="regn:AccrualForSalesRelatedCostsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzQtMS0xLTEtMTc0MzYy_ec51f146-8cf2-4517-b596-ffd0a0a2a346">633.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="regn:AccrualForSalesRelatedCostsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzQtMy0xLTEtMTc0MzYy_e5ad4fba-1067-4661-b388-6c32c0599a99">472.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzUtMS0xLTEtMTc0MzYy_1d88e194-2df5-42e4-afdb-1245a6ba0fec">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzUtMy0xLTEtMTc0MzYy_8859bc51-48fe-483a-a57b-d030460fabb5">326.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaborators (see Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="regn:CollaborativeAgreementsObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzYtMS0xLTEtMTc0MzYy_cad3782a-58c1-4a5a-b2ae-eee1393b66b2">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="regn:CollaborativeAgreementsObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzYtMy0xLTEtMTc0MzYy_b7053ecf-3fad-4edf-94cc-4948ce779811">287.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzctMS0xLTEtMTc0MzYy_9666d86a-38e9-47d1-8e64-fb0f8ce006d4">637.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzctMy0xLTEtMTc0MzYy_a5e5f4b7-cabb-461c-8b46-76f4ca58a71c">383.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzgtMS0xLTEtMTc0MzYy_ccbb6005-230b-4c10-9cc7-0fefecc59442">2,074.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzgtMy0xLTEtMTc0MzYy_abc79f09-afef-405a-b2e0-8a5fa42a22c3">2,206.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzM3NTE_b7212499-68e3-489c-a803-073e909174b0" continuedAt="iaa95aeca2d6a465d947f2862621f9643" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="iaa95aeca2d6a465d947f2862621f9643"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into an agreement with a syndicate of lenders (the "2018 Credit Agreement") which provided for a $<ix:nonFraction unitRef="usd" contextRef="ie424218a88a74b00b19453fe4888916c_I20181231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzYwNDczMTM5NTY2OTc_7895eedc-c7cb-47bd-ade6-50ea1636ded7">750.0</ix:nonFraction> million senior unsecured <ix:nonNumeric contextRef="ib5a9aa37e4c1457a976919d9730f8e80_D20181201-20181231" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3NTQ_ae1213d3-a125-4b38-8bd5-db828c1d3351">five-year</ix:nonNumeric> revolving credit facility. The 2018 Credit Agreement, which was to mature in December 2023, included an option for the Company to elect to increase the commitments under the Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ie424218a88a74b00b19453fe4888916c_I20181231" decimals="INF" name="regn:LineOfCreditFacilityIncreaseLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3MjA_04287a36-656f-42ff-b195-75b27a8f3d36">250.0</ix:nonFraction>&#160;million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into an agreement with a syndicate of lenders (the "2022 Credit Agreement") which provides for a $<ix:nonFraction unitRef="usd" contextRef="i7310c177364143f2bf10f9d6b7aaf971_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzI3NDg3NzkwODYxNjg_9fbdbfac-0c07-4dab-8774-f59191fa2088">750.0</ix:nonFraction>&#160;million senior unsecured <ix:nonNumeric contextRef="ib12579be01dc47cfbb463231b2c8f01d_D20221201-20221231" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3NTU_e92709db-b177-4121-8c50-a7c2e6dbb729">five-year</ix:nonNumeric> revolving credit facility (the "2022 Credit Facility") and replaces the 2018 Credit Agreement, which was contemporaneously terminated. The 2022 Credit Agreement includes an option for the Company to elect to increase the commitments under the 2022 Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i7310c177364143f2bf10f9d6b7aaf971_I20221231" decimals="INF" name="regn:LineOfCreditFacilityIncreaseLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc2NjA_534ae625-f052-49de-8486-2488ab654c4c">500.0</ix:nonFraction>&#160;million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions. The 2022 Credit Agreement also provides a $<ix:nonFraction unitRef="usd" contextRef="i261cf06513ba49e388568bf4932270e8_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc2OTA_a0407051-97c0-44d6-99a6-0f08e8a46a74">50.0</ix:nonFraction>&#160;million sublimit for letters of credit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth in the 2022 Credit Agreement, the Company has the option to amend the 2022 Credit Agreement to establish environmental, social, and governance targets which will be used to adjust pricing under the 2022 Credit Facility, subject to parameters to be provided in the 2022 Credit Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds of the loans under the 2022 Credit Facility may be used to finance working capital needs, and for general corporate or other lawful purposes, of Regeneron and its subsidiaries. Regeneron Pharmaceuticals, Inc. has guaranteed all obligations under the 2022 Credit Facility. The 2022 Credit Agreement includes an option for the Company to elect to extend the maturity date of the 2022 Credit Facility beyond December 2027, subject to the consent of the extending lenders and certain other conditions. Amounts borrowed under the 2022 Credit Facility may be prepaid, and the commitments under the 2022 Credit Facility may be terminated, at any time without premium or penalty. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i7310c177364143f2bf10f9d6b7aaf971_I20221231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3NTY_908ceca4-ae26-4b83-9863-b2691efd21f2">no</ix:nonFraction> borrowings outstanding under the 2022 Credit Facility as of December&#160;31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement contains operating covenants and a maximum total leverage ratio financial covenant. The Company was in compliance with all covenants of the 2022 Credit Agreement as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued and sold $<ix:nonFraction unitRef="usd" contextRef="i6c01c03f3a4444d1b5c5abebba7521b9_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIyNjE_59c5110b-176b-4b97-b6b9-95126a639225">1.250</ix:nonFraction>&#160;billion aggregate principal amount of senior unsecured notes due 2030 and $<ix:nonFraction unitRef="usd" contextRef="i5bbfaa6d6caa478986a0fd252d1994d6_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIzMzA_f2ef1c70-ea1e-4847-a820-1ae13bca3f9f">750</ix:nonFraction> million aggregate principal amount of senior unsecured notes due 2050 (collectively, the "Notes"). The underwriting discounts and offering expenses are being amortized as additional interest expense over the period from issuance through maturity.</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzM3NTk_105a6bfb-d949-4d44-b35f-67370b07df72" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt in connection with the Notes, net of underwriting discounts and offering expenses, consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:29.25pt;padding-right:29.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.149%"><tr><td style="width:1.0%"></td><td style="width:61.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e773031061f47068bfb7d9af0a6f623_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzItMC0xLTEtMTc0MzYyL3RleHRyZWdpb246M2U3ZWE1MDY1OTE5NGU0NWIwM2IzZThhOTc2MDQwZWZfNA_42feb9ea-dac2-429e-8371-6d1dcf2d64cb">1.750</ix:nonFraction>% Senior Notes due September 2030</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e773031061f47068bfb7d9af0a6f623_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzItMS0xLTEtMTc0MzYy_d6c3d5e8-2120-4c41-943b-eff34cc3bc9e">1,241.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b091a819e7f463a80413ebcc76b6b92_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzItMy0xLTEtMTc0MzYy_0c2b92a7-d03b-4031-a1e3-2c694f336710">1,239.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie78cab400df7439280370205f9c3d004_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzMtMC0xLTEtMTc0MzYyL3RleHRyZWdpb246NzFhNzU4MDY2YWYzNGExZmI1MWQxNWUyZjY4MmRmMzFfNA_5e191821-df21-4144-a8c3-883de2e1477a">2.800</ix:nonFraction>% Senior Notes due September 2050</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78cab400df7439280370205f9c3d004_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzMtMS0xLTEtMTc0MzYy_fb5a248b-cc2e-4b2e-8787-81791c9ca1e8">740.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d999cff105340e388c8d3d0fae950fd_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzMtMy0xLTEtMTc0MzYy_1f4fe7b8-87fe-459b-a60c-aace999db681">740.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a901ef13b914e98a6b6ae594630e3ab_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzQtMS0xLTEtMTc0MzYy_77da4972-c86d-4740-a008-c7e3629ee9c7">1,981.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109147ff73454c9fb1005363d4c3549c_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzQtMy0xLTEtMTc0MzYy_48752678-ff0e-4635-9c0f-d62720a5a91a">1,980.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates. Interest expense related to the Notes was $<ix:nonFraction unitRef="usd" contextRef="i4dc3a52eb4104b5aa8911f6741d3eee6_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzMwOTY_467b71ed-cf02-420a-a91f-f1344b97896e">44.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibdc58844910a4e119a03ecefec012869_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzMxMDM_62a4796b-5d37-468a-a7c9-591c559db547">44.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i079d9f100fb942469a90e889b3b42209_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzYwNDczMTM5NjkxNjE_ca69e43c-703e-498d-8d9b-5dc6cfc037a2">17.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at the Company&#8217;s option at any time at <ix:nonFraction unitRef="number" contextRef="i012c8a6940324ac49f3899e2c90dc896_D20200801-20200831" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzMyMTg_04e56cae-13c9-4d46-9ed6-bd1bebf6d236">100</ix:nonFraction>% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i012c8a6940324ac49f3899e2c90dc896_D20200801-20200831" decimals="INF" name="regn:DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzM1MTc_35c6639d-e632-4414-9367-9b050194abc0">101</ix:nonFraction>% of the principal amount plus accrued and unpaid interest. The Notes also contain certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MDI_ab1c5ca4-2662-4ba3-b19d-131837e997d8" continuedAt="i4c3ebbb294104376a2ccc5e76abbc028" escape="true">Commitments and Contingencies</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c3ebbb294104376a2ccc5e76abbc028" continuedAt="i47cf9767b65e47f8ada8570337ff6a5a">&#160;&#160;&#160;&#160;</ix:continuation></span></div><ix:continuation id="i47cf9767b65e47f8ada8570337ff6a5a" continuedAt="ic16a57532271465cb770406c6366f455"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16 for disclosures related to legal contingencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. <ix:continuation id="i43d3626c778247148f4cb7278a6f5608" continuedAt="if9250b870b6b4ce7aa0e3dffb6e466b5">Leases</ix:continuation></span></div><ix:continuation id="if9250b870b6b4ce7aa0e3dffb6e466b5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts certain of its research, development, and administrative activities at leased facilities. The Company also leases vehicles and other assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Consolidated Balance Sheets and Statements of Operations included in this report associated with operating leases were not material. Operating lease right-of-use assets are included within Other noncurrent assets, and lease liabilities are included in Accrued expenses and other current liabilities and Other noncurrent liabilities.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a Participation Agreement with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing &amp; Capital LLC ("BAL"), as lessor, and a syndicate of lenders (collectively with BAL, the "Lease Participants"), which provided for $<ix:nonFraction unitRef="usd" contextRef="ice406a54e051445e8e2f53b1c1e07740_I20170331" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzkwNw_f685a781-ae44-4189-a301-530bd957e3d6">720.0</ix:nonFraction>&#160;million of lease financing from the Lease Participants for the acquisition of laboratory and office facilities in Tarrytown, New York (the "Facility"). In March 2017, the Company also entered into a Lease and Remedies Agreement with BAL, pursuant to which the Company leased the Facility from BAL for a&#160;<ix:nonNumeric contextRef="i50a2e9c56f7e416f8da3fc7358beb047_I20170331" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MTc_636c0c7f-1757-4363-9a4d-c93768449161">five-year</ix:nonNumeric> term which ended in March 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into a Second Amended and Restated Lease and Remedies Agreement (the "Restated Lease") with BAL, as lessor (the "Lessor"), which amends, restates, and extends its lease of the Facility. In March 2022, the Company also entered into a Second Amended and Restated Participation Agreement (the "Restated Participation Agreement") with Bank of America, N.A., as administrative agent, the Lessor, and a syndicate of financial institutions as rent assignees (collectively with the Lessor, the "Participants"), which amends and restates the original Participation Agreement entered into in March 2017. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Participation Agreement and certain related agreements were amended and restated in order to, among other things, (i) effect a&#160;<ix:nonNumeric contextRef="i50a2e9c56f7e416f8da3fc7358beb047_I20170331" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MTg_191a13d1-d903-4b14-ae7f-8cd6912e4493">five-year</ix:nonNumeric> extension of the original March 2022 maturity date of the $<ix:nonFraction unitRef="usd" contextRef="ice406a54e051445e8e2f53b1c1e07740_I20170331" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU0OTc1NTgyNTc5NQ_2ec92a98-d5ec-4f19-9518-7d183d626861">720.0</ix:nonFraction>&#160;million lease financing and the end of the term of the Company's lease of the Facility from the Lessor to March 2027, at which time all amounts outstanding thereunder will become due and payable in full, and (ii) modify the rate of the interest or yield that is payable to the Participants. In accordance with the terms of the Restated Lease, the Company continues to pay all maintenance, insurance, taxes, and other costs arising out of the use of the Facility. The Company is also required to make monthly payments of basic rent during the term of the Restated Lease in an amount equal to a variable rate per annum, which was modified in connection with the Restated Lease, to be an adjusted one-month forward-looking term rate based on the Secured Overnight Financing Rate ("SOFR"), plus an applicable margin that varies with the Company's debt rating and total leverage ratio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Participation Agreement and Restated Lease include an option for the Company to elect to further extend the maturity date of the Restated Participation Agreement and the term of the Restated Lease for an additional <ix:nonNumeric contextRef="ia2b5cb43390f40c79c55e8db0b798b1a_I20210930" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MDY_775fff22-cbfe-4392-a624-058e0e6cdf6a">five-year</ix:nonNumeric> period, subject to the consent of all the Participants and certain other conditions. The Company also has the option prior to the end of the term of the Restated Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants' advances under the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Participation Agreement, Restated Lease, and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the original lease, the Restated Lease continues to be classified as a finance lease as the Company has the option to purchase the Facility under terms that make it reasonably certain to be exercised. The agreements governing the Restated Lease financing contain financial and operating covenants. Such financial covenants and certain of the operating covenants are substantially similar to the covenants set forth in the Company's $<ix:nonFraction unitRef="usd" contextRef="ie424218a88a74b00b19453fe4888916c_I20181231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU0OTc1NTgyMzE1Mw_7895eedc-c7cb-47bd-ade6-50ea1636ded7">750.0</ix:nonFraction> million 2018 Credit Agreement. The Company was in compliance with all such covenants as of December&#160;31, 2022.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ic16a57532271465cb770406c6366f455" continuedAt="i993ad9e3bf2b4c4f86c94e3cbfc5b1c3"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="regn:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MTQ_6402fe7f-82e6-4bad-8460-4fa8502de064" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Consolidated Balance Sheet related to the Lease are included in the table below. Other than the Lease described above, the Company had no leases accounted for as finance leases as of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"></td><td style="width:30.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItNC0xLTEtMTc0MzYy_5b6934cb-df12-4f5b-883d-75a416306336">620.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItNi0xLTEtMTc0MzYy_c0245986-a40e-4ac0-a3b7-badaa7712e37">631.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzMtNC0xLTEtMTc0MzYy_01acd0ad-8e87-4f3c-8dbc-658e42a8b349">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzMtNi0xLTEtMTc0MzYy_6f2bcd58-495c-4a9e-860f-3d0f09971778">719.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Finance lease right-of-use assets were recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzUtMC0xLTEtMTc0MzYyL3RleHRyZWdpb246NWE5YjQ0YTQ2OTZkNDU5OGFhZThiMzkyZjMwZDRjNWRfOTI_e08263b0-8259-4893-a4c7-6d5f9e4bd275">119.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzUtMC0xLTEtMTc0MzYyL3RleHRyZWdpb246NWE5YjQ0YTQ2OTZkNDU5OGFhZThiMzkyZjMwZDRjNWRfOTk_569da33b-10b3-475e-b7fc-5b40365ebdd0">104.9</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU4OTU_d27320e6-3280-4112-8c02-5ba336108e1f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.160%"><tr><td style="width:1.0%"></td><td style="width:52.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzItMi0xLTEtMTc0MzYy_cb44724b-446e-4b63-b5fd-9d4649da94ec">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzItNC0xLTEtMTc0MzYy_68fc8695-c4e7-4a14-bee3-62a6a0976b96">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzMtMi0xLTEtMTc0MzYy_30b3326f-203e-487a-9a07-fedf9e995dc8">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzMtNC0xLTEtMTc0MzYy_55f360a2-b482-44ae-84a2-3897893b20fb">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzQtMi0xLTEtMTc0MzYy_c973f142-6a1b-4bb2-8e6e-e267c85ea0eb">36.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzQtNC0xLTEtMTc0MzYy_a4502e74-4f0a-42a6-9d87-60f0f81e182e">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to the Company's finance lease includes the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"><tr><td style="width:1.0%"></td><td style="width:51.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="regn:FinanceLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzItMi0xLTEtMTc0MzYy_d6c24003-6766-4483-8887-a70f912b851b">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" name="regn:FinanceLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzItNC0xLTEtMTc0MzYy_31ff56df-1a68-43d7-8ce5-c62a72bac25b">0.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="4" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzMtMi0xLTEtMTc0MzYy_bd7bd76d-612f-49c1-b9bb-faf04a046f82">4.84</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="4" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzMtNC0xLTEtMTc0MzYy_18d32e81-f898-420c-8a21-01fcb99fc1fd">1.68</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental information </span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU4OTY_0712aab2-e88c-4689-9132-c55496641223" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of the Company's finance lease liability:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.908%"><tr><td style="width:1.0%"></td><td style="width:60.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzEtMi0xLTEtMTc0MzYy_6bdfc55d-f686-4436-ba06-c4aff4a1b2b9">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzItMi0xLTEtMTc0MzYy_a0ca7225-f93f-4b97-a50c-064fe6188392">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzMtMi0xLTEtMTc0MzYy_6909f722-baba-4e6f-bc11-c3a8341438d3">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzQtMi0xLTEtMTc0MzYy_78655405-e47f-479d-92bb-1f2e5fff9ebf">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzUtMi0xLTEtMTc0MzYy_36f2996f-c637-4a39-8991-88d1701bcef8">727.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzctMi0xLTEtMTc0MzYy_95cdf19c-f3d5-4826-b249-4874944eac3a">873.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzgtMi0xLTEtMTc0MzYy_42b3b322-64a9-4b9e-8977-45eb7c5267fe">153.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzEwLTItMS0xLTE3NDM2Mg_71c06bb7-2321-4d54-9c6e-ff94697ed242">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Research Collaboration and Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with other companies, universities, and other organizations. These agreements contain varying terms and provisions which include fees to be paid by the Company, services to be provided, and license rights to certain proprietary technology developed under the agreements. Some of these agreements may require the Company to pay additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones). Additionally, the Company has in-licensed patent and/or technology pursuant to agreements which contain provisions that require the Company to pay royalties, as defined, at rates that range from <ix:nonFraction unitRef="number" contextRef="ib132e77f1248490f82fe430c0a335704_D20220101-20221231" decimals="INF" name="regn:RoyaltyRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzUxNjg_086c5e93-ad95-438b-b742-2c3e4c477b18">0.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib132e77f1248490f82fe430c0a335704_D20220101-20221231" decimals="INF" name="regn:RoyaltyRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzUxNzQ_e1f7bb5c-aa45-4fa8-a44d-3f827a13c475">12.0</ix:nonFraction>%, in the event the Company sells or licenses any proprietary products developed under the respective agreements. The Company also has contingent reimbursement obligations to its collaborators Sanofi and Bayer out of the respective collaboration's profits, if they are sufficient for that purpose. See Note 3 for a more detailed description of collaboration, license, and other agreements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i993ad9e3bf2b4c4f86c94e3cbfc5b1c3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, as a result of obtaining worldwide rights to Libtayo, the Company pays Sanofi a royalty on net product sales of Libtayo. In addition, in 2018, the Company and Sanofi entered into a license agreement with Bristol-Myers Squibb Company, E. R. Squibb &amp; Sons, L.L.C., and Ono Pharmaceutical Co., Ltd. to obtain a license under certain patents owned and/or exclusively licensed by one or more of those parties that includes the right to develop and sell Libtayo. Under the agreement, the Company is obligated to pay royalties of <ix:nonFraction unitRef="number" contextRef="i5d20e3c5247b4d598e751c21b3f4f608_D20180801-20180831" decimals="INF" name="regn:PaymentsForRoyaltiesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzIxOTkwMjMyODI4NDM_3f35c40f-491f-45f9-a753-dc0d6d20879e">8.0</ix:nonFraction>% on worldwide sales of Libtayo through December 31, 2023, and royalties of <ix:nonFraction unitRef="number" contextRef="i21d41d00df44446baa4014ec1a2a8b14_D20180801-20180831" decimals="INF" name="regn:PaymentsForRoyaltiesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzIxOTkwMjMyODI4NTQ_5f73819a-5468-4ee0-8cc8-c95b824ab702">2.5</ix:nonFraction>% from January 1, 2024 through December 31, 2026. Prior to July 1, 2022, royalties on such sales were shared equally by the Company and Sanofi.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, the Company recorded royalty expense (net of reimbursements from collaborators, as applicable) in Cost of goods sold and Cost of collaboration and contract manufacturing of $<ix:nonFraction unitRef="usd" contextRef="ib132e77f1248490f82fe430c0a335704_D20220101-20221231" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU3NzQ_833c0ef2-a4c0-4a9b-a662-dbbfaa99948f">84.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie83c963269194f2fbfdc09f02cc5d592_D20210101-20211231" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU3Nzg_d7787ddd-3975-44c6-8def-fce268ee0112">66.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="if78394eb2a794ed4ac4431dca866af29_D20200101-20201231" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU3ODY_3a95108e-37ba-472c-8489-217b7ad6c2ed">56.5</ix:nonFraction> million, respectively, based on product sales under various licensing agreements.</span></div></ix:continuation><div id="ic18bad8bf5314e3e9f4c348a9f859317_148"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzY0MDc_f212ae4b-74eb-4b54-b149-f9316586644a" continuedAt="if1174e2914884ce3b050995e3962a8e6" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><ix:continuation id="if1174e2914884ce3b050995e3962a8e6" continuedAt="ifaa4106cd6864b57883b0950ca627b42"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Restated Certificate of Incorporation, as amended, provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzEzMQ_b0d13b19-3d51-43d2-80c9-977b4d49517b">40</ix:nonFraction> million shares of Class A Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f6f217bafb048fd906869bf77577910_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE2OQ_35722217-8bdc-4755-9042-166add003d89">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE4Nw_e1cc8b93-b56b-4f8b-b7b8-2c613c569676">320</ix:nonFraction> million shares of Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzIyNA_cbb5c6cc-eab3-4a6b-982a-0051cc1efb7a">0.001</ix:nonFraction> per share. Shares of Class A Stock are convertible, at any time, at the option of the holder into shares of Common Stock on a share-for-share basis. Holders of Class A Stock have rights and privileges identical to Common Stockholders except that each share of Class A is entitled to <ix:nonFraction unitRef="vote" contextRef="ia96fa6ba59e84ea08d01d27873b5696b_D20220101-20221231" decimals="INF" name="regn:NumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzUxMA_1a80ca30-56bc-4e96-b348-aafe60c80ace">ten</ix:nonFraction> votes per share, while each share of Common Stock is entitled to <ix:nonFraction unitRef="vote" contextRef="i4e0c0f7f9e7245159ae317600a59a97f_D20220101-20221231" decimals="INF" name="regn:NumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU3OA_5b021d11-7cb7-423f-bf9d-d3af59bf9802">one</ix:nonFraction> vote per share. Class A Stock may only be transferred to specified Permitted Transferees, as defined. Under the Company's Restated Certificate of Incorporation, the Company's board of directors is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzgwNA_75b2d274-e404-457a-81fc-7f88708d376f">30</ix:nonFraction> million shares of Preferred Stock, in series, with rights, privileges, and qualifications of each series determined by the board of directors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company's board of directors authorized a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i7a1f29e4d0084509aad565f88da92c75_I20191130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzEwNjg_2c2b1304-1e18-40f0-9c37-b035eae7a0bd">1.0</ix:nonFraction>&#160;billion of the Company's Common Stock. The share repurchase program permitted the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $<ix:nonFraction unitRef="usd" contextRef="i07ed95697fc6411f82f5d2215701a1ce_D20191101-20201231" decimals="INF" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE1MzE_8100721f-1618-47b8-b17c-508532ba20e6">1.0</ix:nonFraction>&#160;billion it was authorized to repurchase under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company's board of directors authorized a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i898556ab5e034bf8a39f1f7ffdcff4b6_I20210131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE2ODM_31d340c4-d17b-4415-ba42-cb8c8b6279fa">1.5</ix:nonFraction>&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program described above. As of December&#160;31, 2021, the Company had repurchased the entire $<ix:nonFraction unitRef="usd" contextRef="i898556ab5e034bf8a39f1f7ffdcff4b6_I20210131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE4OTU_31d340c4-d17b-4415-ba42-cb8c8b6279fa">1.5</ix:nonFraction>&#160;billion of its Common Stock that it was authorized to repurchase under the program.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company's board of directors authorized an additional share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="if149e3b2ed184d9cb47a5f1e416db711_I20211130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzIwODU_7acd295f-a34e-429a-ada1-792102ddf2ae">3.0</ix:nonFraction>&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i4d4688a81ec54e3e81135fe0cef6a811_I20221231" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU0OTc1NTgyMTY2Nw_4cce1059-8b4c-4c1b-82e3-6334bb85ccc1">745.2</ix:nonFraction>&#160;million remained available for share repurchases under the November 2021 program.</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzY0MTM_1bef3101-1e90-4623-bbf2-26e83ecf7bac" escape="true"><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of the Company's Common Stock it repurchased under the programs and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.701%"><tr><td style="width:1.0%"></td><td style="width:48.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzItMi0xLTEtMTc0MzYy_a38e3628-80c7-4707-b357-ba49758f6cbe">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa856a8273104bae9abb9e9bd006496c_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzItNC0xLTEtMTc0MzYy_56ff3ff8-43e6-43ce-9f7b-4c6112656649">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00b3516f1f374f9ba681ff3469a1d79b_D20200101-20201231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzItNi0xLTEtMTc0MzYy_0bbe2611-2ac3-4faf-a98b-785d2a87b596">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzMtMi0xLTEtMTc0MzYy_b3ae85fb-b2ab-4cbe-9222-a995cf1df1c6">2,099.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa856a8273104bae9abb9e9bd006496c_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzMtNC0xLTEtMTc0MzYy_78ad9bca-3b7f-41aa-9f13-d75a3e3558b9">1,655.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b3516f1f374f9ba681ff3469a1d79b_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzMtNi0xLTEtMTc0MzYy_dea0f940-7451-4c43-87ed-486b4203843b">746.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company's board of directors authorized a new share repurchase program to repurchase up to an additional $<ix:nonFraction unitRef="usd" contextRef="iaa56acec5b6c42e6a0c418417df45e87_I20230131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU0OTc1NTgyNDU0Ng_37cac0be-632a-46c7-85bd-1723120380ee">3.0</ix:nonFraction>&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ifaa4106cd6864b57883b0950ca627b42"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company and Sanofi entered into an agreement, which, among other things, granted Sanofi a limited waiver of Sanofi's lock-up obligations under the amended and restated investor agreement between the Company and Sanofi in order to allow Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or certain activities relating to dupilumab and itepekimab incurred in quarterly periods through September 30, 2020 by selling shares of the Company's Common Stock owned by Sanofi. During 2020, Sanofi elected to sell, and the Company elected to purchase, shares of our Common Stock to satisfy Sanofi's funding obligation related to such activities. Consequently, the Company recorded the cost of the shares received, or $<ix:nonFraction unitRef="usd" contextRef="id2184e2e59fa45c7b4e39f4a72edfc26_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzM2NTI_68771b1c-c9e8-4dc5-9449-7397c03b10a2">135.0</ix:nonFraction>&#160;million, as Treasury Stock during 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Stock Purchased from Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of <ix:nonFraction unitRef="shares" contextRef="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzM3OTQ_5dd1d153-b285-4b45-ac62-c243fe2a4208">13,014,646</ix:nonFraction> shares of the Company's Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, the Company also purchased <ix:nonFraction unitRef="shares" contextRef="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzM5NDI_cf3f694b-f80b-47b9-9938-4a12fe6aafe6">9,806,805</ix:nonFraction> shares directly from Sanofi for an aggregate purchase amount of $<ix:nonFraction unitRef="usd" contextRef="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzQwMDk_446d89d7-f3e5-4a72-964a-8547d9d47317">5.0</ix:nonFraction>&#160;billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of the Company's Common Stock, other than <ix:nonFraction unitRef="shares" contextRef="ife75b59764cd4329a476ef09a7789b4f_I20200531" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzQyMDY_c1cc1e6c-29ee-406e-b969-71196049e1bb">400,000</ix:nonFraction> shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (a portion of which Sanofi used for the funding of certain development costs described above).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an amendment to the amended and restated investor agreement, which provides, among other things, that following the Secondary Offering and Stock Purchase, the &#8220;standstill&#8221; provisions, which contractually prohibit Sanofi from seeking to directly or indirectly exert control of the Company, continue to apply pursuant to their terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arrangements with Other Collaborators</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's license and collaboration agreement with Bayer for the joint development and commercialization outside the United States of antibody product candidates to Ang2, Bayer is bound by certain "standstill" provisions, which contractually prohibit Bayer from seeking to influence the control of the Company or acquiring more than <ix:nonFraction unitRef="number" contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231" decimals="2" name="regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU0Mjc_ce6c2cb9-ed38-4257-89b1-6ff96478edd3">20</ix:nonFraction>% of the Company's outstanding shares of Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the termination of the agreement (which will occur on November 1, 2023) or (ii) other specified events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, pursuant to the 2016 Teva Collaboration Agreement, Teva and its affiliates are bound by certain "standstill" provisions, which contractually prohibit them from seeking to directly or indirectly exert control of the Company or acquiring more than <ix:nonFraction unitRef="number" contextRef="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231" decimals="2" name="regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzYxNDU_b1bc03d9-1c95-4170-aa80-5d18ab1fd71b">5</ix:nonFraction>% of the Company's Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the expiration or earlier termination of the agreement or (ii) other specified events.</span></div></ix:continuation><div id="ic18bad8bf5314e3e9f4c348a9f859317_151"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5NDY_cd33690a-7695-4194-99e2-2eb040817b4e" continuedAt="id67a12356c3346e89565510ec4dff9be" escape="true">Long-Term Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="id67a12356c3346e89565510ec4dff9be" continuedAt="i4d0b3789bf154a8da589d727694f4071"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and non-employees, including non-employee members of the Company's board of directors (collectively, "Participants"). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the "Committee"). The incentive plan currently used by the Company is the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Second Amended and Restated 2014 Incentive Plan"). It was most recently adopted and approved by the Company's shareholders in 2020. As of the most recent shareholder approval date, the Second Amended and Restated 2014 Incentive Plan provided for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="iffed57e1fcf04b469127e38751ea1244_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzk4MA_6c356352-b5c2-411f-8f27-97d0ac203939">22.3</ix:nonFraction> million shares of Common Stock in respect of awards. In addition, upon expiration, forfeiture, surrender, exchange, cancellation, or termination of any award previously granted under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Amended and Restated 2014 Incentive Plan"), the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Original 2014 Incentive Plan"), or the Second Amended and Restated 2000 Long-Term Incentive Plan (the "2000 Incentive Plan"), any shares subject to such award are added to the pool of shares available for grant under the Second Amended and Restated 2014 Incentive Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The awards that may be made under the Second Amended and Restated 2014 Incentive Plan include: (a) incentive stock options and non-qualified stock options, (b) restricted stock awards, (c) shares of phantom stock (also referred to as restricted stock units, which may be time- or performance-based), and (d) other awards. Any award granted may (but is not required to) be subject to vesting based on the attainment by the Company of performance goals pre-established by the Committee. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards grant Participants the right to purchase shares of Common Stock at prices determined by the Committee, with exercise prices that are equal to or greater than the average of the high and low market prices of the Company's Common Stock on the date of grant (the "Market Price"). Options vest over a period of time determined by the Committee, generally on a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i4d0b3789bf154a8da589d727694f4071" continuedAt="i80a80e3bdc324d7bb15a25e467df9c9f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pro rata basis over a <ix:nonNumeric contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5MzI_d6164d5f-d68b-41bc-939c-7a009d4f07c1">four-year</ix:nonNumeric> period. The Committee also determines the expiration date of each option. The maximum term of options that have been awarded under the 2000 Incentive Plan, the Original 2014 Incentive Plan, the Amended and Restated 2014 Incentive Plan, and the Second Amended and Restated 2014 Incentive Plan (collectively, the "Incentive Plans") is <ix:nonNumeric contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" name="regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzI4NjI_6281f315-8bde-42be-ae70-009a41b7e333">ten years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards grant Participants shares of restricted Common Stock or allow Participants to purchase such shares at a price determined by the Committee. Such shares are nontransferable for a period determined by the Committee ("vesting period"). Should employment terminate, as specified in the Incentive Plans, except as determined by the Committee in its discretion and subject to the applicable Incentive Plan documents, the ownership of any unvested restricted stock awards will be transferred to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phantom stock awards provide the Participant the right to receive Common Stock or an amount of cash based on the value of the Common Stock at a future date. The award is subject to such restrictions, if any, as the Committee may impose at the date of grant or thereafter, including a specified period of employment or the achievement of performance goals. Time-based restricted stock units and performance-based restricted stock units are each a type of phantom stock award permitted under the Second Amended and Restated 2014 Incentive Plan.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Incentive Plans contain provisions that allow for the Committee to provide for the immediate vesting of awards upon a change in control of the Company, as defined in the Incentive Plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="iffed57e1fcf04b469127e38751ea1244_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQxNjA_1126906c-f97a-4f25-a235-15c510b116bb">15.9</ix:nonFraction> million shares available for future grants under the Second Amended and Restated 2014 Incentive Plan. <ix:nonFraction unitRef="shares" contextRef="i9dd3089f49fe4ad18bf060be6041dc8d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQyNTc_acbf9ff5-8710-42b2-af9d-59b919606e31"><ix:nonFraction unitRef="shares" contextRef="i89c4af83a9954f7a928a982e2a427940_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQyNTc_e258620e-5e48-40c2-ac16-48eb57ce2d2d">No</ix:nonFraction></ix:nonFraction> additional awards may be made under the 2000 Incentive Plan, the Original 2014 Incentive Plan, or the Amended and Restated 2014 Incentive Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5MDI_ea693e0e-0e73-448a-aff4-fc499a01958e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions involving stock option awards during 2022 under the Company's Incentive Plans are summarized in the table below.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.045%"><tr><td style="width:1.0%"></td><td style="width:5.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic Value </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fa909c892214ee795c9bf21ee208f05_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzEtMy0xLTEtMTc0MzYy_0b6b8393-c450-455f-a2fa-b39d12288a9b">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1fa909c892214ee795c9bf21ee208f05_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzEtNS0xLTEtMTc0MzYy_bbba0c27-d407-4e18-8f65-7d9cb028c1e6">435.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzItMy0xLTEtMTc0MzYy_7b933cd5-9191-4232-9e2f-68e7d92db186">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzItNS0xLTEtMTc0MzYy_fb067534-50b1-45c6-a889-910a984c79cf">705.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzMtMy0xLTEtMTc0MzYy_7f48319f-1ada-437c-b558-af413736b52f">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzMtNS0xLTEtMTc0MzYy_38ebab38-39da-4cbf-97e4-e1480706e37f">500.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzQtMy0xLTEtMTc0MzYy_bb291188-0d12-4305-adea-4c67fbbd4a0e">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzQtNS0xLTEtMTc0MzYy_d09b4acf-8a1b-47eb-9929-5251a25e5ed5">382.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtMy0xLTEtMTc0MzYy_50c3c2d2-85f1-4db5-b79d-10d794b13ac9">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtNS0xLTEtMTc0MzYy_672e6f4b-5904-410f-bc22-82bef7bc6e35">481.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtNy0xLTEtMTc0MzYy_0ba8580c-0263-4c32-8745-501bb85baf4b">6.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtOS0xLTEtMTc0MzYy_73b834c1-9d2e-4219-ab03-3d5191b1aeaf">3,685.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctMy0xLTEtMTc0MzYy_386ccc23-5a6c-48ce-93be-29b903cdb944">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctNS0xLTEtMTc0MzYy_58957596-d7f0-4e40-ab68-019dd61beca2">476.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctNy0xLTEtMTc0MzYy_aa42892d-c8ea-46cf-b924-225753ea27ca">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctOS0xLTEtMTc0MzYy_347089b3-5e78-4992-b3c1-46a22a8709e3">3,632.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktMy0xLTEtMTc0MzYy_b265cf6c-6d57-4200-9455-991c3f7de0c1">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktNS0xLTEtMTc0MzYy_0f2eef62-0311-4ff6-90b5-335bcd7710a1">420.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktNy0xLTEtMTc0MzYy_279927a5-cbcd-4212-9646-6c11db9e2fe0">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktOS0xLTEtMTc0MzYy_0424d36d-4237-44ca-a9a6-495b6a7d13e7">2,991.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfies stock option exercises with newly issued shares of the Company's Common Stock. The total intrinsic value of stock options exercised during 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQ3Mjg_8577503f-7e4b-4f7e-9013-745b410ec9bb">1.214</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTEwMjg_cec30c88-3682-4725-a720-6e6882f59001">1.707</ix:nonFraction>&#160;billion, and $<ix:nonFraction unitRef="usd" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTA2NjI_04e38d4c-043e-4127-8d9b-0be66c35bea9">2.251</ix:nonFraction>&#160;billion, respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i80a80e3bdc324d7bb15a25e467df9c9f" continuedAt="id7b744f0bdcf487297bb88f16dbc9d67"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg4ODY_52f36119-3e09-463d-8ec7-4e05114db5ec" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2022, 2021, and 2020. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.678%"><tr><td style="width:1.0%"></td><td style="width:47.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options Granted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzItMi0xLTEtMTc0MzYy_7b933cd5-9191-4232-9e2f-68e7d92db186">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzItNC0xLTEtMTc0MzYy_fb067534-50b1-45c6-a889-910a984c79cf">705.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzItNi0xLTEtMTc0MzYy_b3dc6b3e-8b0a-4ecb-ae88-943d1564d7f7">220.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzQtMi0xLTEtMTc0MzYy_bd0655db-4e4f-4569-9d56-089dd3bce281">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzQtNC0xLTEtMTc0MzYy_344dfaab-8a9a-42eb-8e99-9dc8fbf57729">628.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzQtNi0xLTEtMTc0MzYy_2204540f-c92d-441f-9593-d7c777af59cc">174.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzYtMi0xLTEtMTc0MzYy_63a64431-8711-4320-9476-d7fbc776ba5c">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzYtNC0xLTEtMTc0MzYy_b9f872c5-ab47-4a0c-9c97-932f9a3713fa">492.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzYtNi0xLTEtMTc0MzYy_61a01a17-1b01-4f87-870a-3e49f742770e">126.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021, and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8074da28c47b44eb8134011e2bfd7c77_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzUxNDQ_c0292063-7f05-4eec-8a1a-c904338da337">341.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic20a52b8adf44b65bc4aed375198294a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTA4NTE_0e8a73f3-dbbd-4ecc-a65d-e80d900ec4ad">328.7</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i061dabef95db47dcbeacf4d95b0043d3_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTA4Njc_645c3f8e-27d7-4bd1-90c8-ff9333324c49">329.5</ix:nonFraction>&#160;million, respectively, of stock-based compensation expense related to stock option awards (net of amounts capitalized as inventory, which were not material for each of the three years). As of December 31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="idc3ca35c957f4ea784da91f7c995a52c_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzUzNzk_35f999f2-d0ea-47b4-ad08-eb85ce218888">572.0</ix:nonFraction> million of stock-based compensation cost related to unvested stock options, net of estimated forfeitures, which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period of <ix:nonNumeric contextRef="i8074da28c47b44eb8134011e2bfd7c77_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzU2MDU_e17af112-d798-4c66-b7ae-3a94cf173b8b">1.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Assumptions:</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5NjI_38fb6889-0aba-4911-947f-0a9ec132ef34" continuedAt="i839c2141c5fe4696bd0b46c61089512e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2022, 2021, and 2020.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.770%"><tr><td style="width:1.0%"></td><td style="width:48.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzEtMi0xLTEtMTc0MzYy_feeebe61-ba69-4e70-b628-9a3e2552f93b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzEtNC0xLTEtMTc0MzYy_0b2128c6-882a-4191-877c-ed08e540ed9f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzEtNi0xLTEtMTc0MzYy_278b34d2-d3ea-4c20-bb9c-12fc6144211d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives from grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzItMi0xLTEtMTc0MzYy_b44f48f3-a6d8-49d7-bda6-e8c869638f73">5.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzItNC0xLTEtMTc0MzYy_96a5fc9f-e5c5-48c1-a123-a2573fcd06e7">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzItNi0xLTEtMTc0MzYy_26002c4a-5d4e-4954-8823-182904fc6424">5.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzMtMi0xLTEtMTc0MzYy_35a8dbfb-a18d-4c67-a9c2-11a06c6a9d97">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzMtNC0xLTEtMTc0MzYy_0d2d249d-d1c6-44c3-8e18-995c363d95d9">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzMtNi0xLTEtMTc0MzYy_1dd0d825-899e-4d73-9312-915e3114bd30">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzQtMi0xLTEtMTc0MzYy_43176354-12be-4275-8385-cf0016d7a775">3.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzQtNC0xLTEtMTc0MzYy_792a8f4b-6d39-4e81-ad94-16416816fc90">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzQtNi0xLTEtMTc0MzYy_bccbd02a-d180-42e1-bd7a-b1d325a82403">0.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility has been estimated based on actual movements in the Company's stock price over the most recent historical periods equivalent to the options' expected lives. Expected lives are principally based on the Company's historical exercise experience with previously issued employee and board of directors' option grants. The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzYxNTA_ebe0e719-7fee-4018-9a70-0c5e1597a185">zero</ix:nonFraction> as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the options' expected lives.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards and Time-Based Restricted Stock Units</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg4Nzk_6e4a222f-26bd-46e1-868c-c7492de0e7f4" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's activity related to restricted stock awards and time-based restricted stock units (excluding performance-based restricted stock units, which are detailed further below) (collectively, "restricted stock") during 2022 is summarized below. </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"><tr><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares/Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant <br/>Date Fair Value</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc41ab2a621442839e2f788a04d55cce_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzEtMy0xLTEtMTc0MzYy_e3c6d30f-eb7c-498b-baa5-eb779b67132b">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc41ab2a621442839e2f788a04d55cce_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzEtNS0xLTEtMTc0MzYy_c35e110d-e346-4118-bb27-72e2eaae3c22">499.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzItMy0xLTEtMTc0MzYy_6c1b02cf-7a56-4583-bf02-3452ab5ae772">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzItNS0xLTEtMTc0MzYy_c7a129d5-4bc9-420c-8045-ac8cb3b00d5a">702.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzMtMy0xLTEtMTc0MzYy_a0f2dab2-87e2-4967-8543-aea5edf1b68e">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzMtNS0xLTEtMTc0MzYy_31d78039-c5ce-49a4-9561-cae28e830922">477.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzQtMy0xLTEtMTc0MzYy_2b31faf2-3b0d-4070-974b-970b17cfb152">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzQtNS0xLTEtMTc0MzYy_14f5f8fe-b71f-47d6-acc9-a8eb7ae98548">522.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44560f336e474452ae29c854f6be95dd_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzUtMy0xLTEtMTc0MzYy_86da3337-019d-4766-a685-c6e46fafb129">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44560f336e474452ae29c854f6be95dd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzUtNS0xLTEtMTc0MzYy_c033cac9-d369-4aa7-8118-a0e9d456a044">571.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021, and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE2MDQ_6706ca55-3675-467c-8035-8e33b279c97a">331.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie0f758f9b4de4edbbd24b0a3c80d2099_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE2MDk_2c32c6a1-2164-4c60-8ff2-f6e95ebf63c1">221.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i98b8165ff3c84cc2b0b3ef6c846d0857_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE2MTg_ff146b32-9fdd-479c-b562-c3de148c399c">102.5</ix:nonFraction> million, respectively, of stock-based compensation expense related to restricted stock (net of amounts capitalized as inventory, which were not material for each of the three years). As of December 31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i44560f336e474452ae29c854f6be95dd_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzcwMTM_73c5e323-ea52-467d-b054-66b0b888df37">907.7</ix:nonFraction> million of stock-based </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="id7b744f0bdcf487297bb88f16dbc9d67"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation cost related to unvested restricted stock which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period of <ix:nonNumeric contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzcyMTE_f731cbd6-41ea-4b19-b818-dbce9782dc20">2.1</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance-based restricted stock units ("PSUs") have been granted to certain members of senior management of the Company. PSUs may be earned based upon the attainment of pre-established performance criteria, which may include a market and/or performance condition. Depending on the terms of the PSUs and the outcome of the pre-established performance criteria, a recipient may ultimately earn the target number of PSUs granted or a specified multiple thereof at the end of a <ix:nonNumeric contextRef="ic976d25c5e3d49f49a38da896bf4b995_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzgyNDYzMzcyMzAxOTA_ef583ca7-fd35-4844-ae7d-9fd6917f80ae">4</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i4e3bb26f27c440bca9bd206e40fb92e5_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzIxOTkwMjMyNzc0NTU_79256669-343a-4c89-a07c-2ac5cdfd0da0">6</ix:nonNumeric> year vesting period, as applicable.</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzIxOTkwMjMyNzY4MDg_783d23d8-b9ed-4e2c-ba2f-40e3a062673b" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes activity related to PSUs during 2022. The number of PSUs granted represents the maximum number of units that are eligible to be earned.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"><tr><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares/Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant <br/>Date Fair Value</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzEtMy0xLTEtMjAzNTI4_90d13b9d-9cdc-4a70-9ad6-fdedb13fbb92">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzEtNS0xLTEtMjAzNTMy_6759ce0a-c64f-41b4-9194-b2b3c2094bd5">209.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzItMy0xLTEtMjAzNTY3_cb3b460d-9af4-4f69-ab0a-d1512104c92d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzItNS0xLTEtMjAzNTc0_9880a5b3-a20a-486e-9165-f0fee62e96d7">485.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f140ca61272416db70327e6fc368a13_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzMtMy0xLTEtMjAzNTMw_fce90612-8281-40cf-bae1-570699d88cca">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f140ca61272416db70327e6fc368a13_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzMtNS0xLTEtMjAzNTM0_68ac5491-6618-437c-a8e6-9e0351a087f6">245.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended December 31, 2022, and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE3MDk_b345ebd6-4d1a-4758-8f58-ce3420ed5fad"><ix:nonFraction unitRef="usd" contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE3MDk_f61ecff1-a4b7-48b2-8a19-f3b4aad5e710">52.0</ix:nonFraction></ix:nonFraction>&#160;million of stock-based compensation expense related to PSUs. The Company did <ix:nonFraction unitRef="usd" contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzgyODI_e56afd59-1fd7-48d9-b906-5bef2b74323b">no</ix:nonFraction>t recognize stock-based compensation expense related to PSUs in 2020 (as PSUs granted in 2020 were granted on December 31, 2020 and are expensed over the vesting period). As of December 31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i4f140ca61272416db70327e6fc368a13_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg0OTU_4908b2f0-5b42-4f42-8b6f-b13d22c2f48f">156.1</ix:nonFraction>&#160;million of stock-based compensation cost related to unvested PSUs which had not yet been recognized. The Company expects to recognize this compensation cost on a straight-line basis over a weighted average period of <ix:nonNumeric contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg2ODk_186146e2-31af-4736-a2a0-de210b0faab3">3.3</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Assumptions:</span></div><ix:continuation id="i839c2141c5fe4696bd0b46c61089512e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average values of the assumptions used in computing the fair value of PSUs that were granted during 2022 and 2020. The Company did not grant PSUs during 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.431%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzEtMi0xLTEtMTc0MzYy_2e2e81e1-411d-4d7e-a782-34cded4405b0">32</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzEtNC0xLTEtMTc0MzYy_35a982ff-e6b3-49fe-8e0e-c7b38680eb89">35</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzItMi0xLTEtMTc0MzYy_8e3b8b61-fef1-4f6b-b29b-8cca6a43355f">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzItNC0xLTEtMTc0MzYy_fe97446c-c19b-462b-a3af-dc4484efbc9d">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzMtMi0xLTEtMTc0MzYy_6a73ab9b-5022-4368-8e31-511455c51d39">3.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzMtNC0xLTEtMTc0MzYy_1a3d4859-5952-4c67-a7c2-78b6644eb9d6">0.4</ix:nonFraction>%</span></td></tr></table></div></ix:continuation></ix:continuation><div id="ic18bad8bf5314e3e9f4c348a9f859317_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzY3OQ_b32ba9df-f2cb-4570-a8fd-3bd950a0aecd" continuedAt="i263a17eec4124c9990d3dd908ede69eb" escape="true">Employee Savings Plans</ix:nonNumeric></span></div><ix:continuation id="i263a17eec4124c9990d3dd908ede69eb"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the Regeneron Pharmaceuticals, Inc. 401(k) Savings Plan, as amended and restated (the "Savings Plan"). The terms of the Savings Plan allow U.S. employees (as defined by the Savings Plan) to contribute to the Savings Plan a percentage of their compensation. In addition, the Company may make discretionary contributions, as defined, to the accounts of participants under the Savings Plan. The Company also maintains additional employee savings plans outside of the United States, which cover eligible employees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses recognized by the Company related to contributions to such plans were $<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzU0OTc1NTgxNDY4Ng_e40f2f3a-94ed-4f39-9499-be59666afbff">67.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzU0OTc1NTgxNDc0NA_94ffa73d-455e-461f-a0b3-7ea0aa2f9b5c">55.5</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzU0OTc1NTgxNDc1OQ_077e74e0-a2d4-47b7-98fe-784551702471">49.9</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MTM_4ed25565-48b4-4bb7-af94-738cd1f5974a" continuedAt="i638c0e1382174013ab7d4536bbb360fb" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i638c0e1382174013ab7d4536bbb360fb" continuedAt="i54c0ea560f0a41b1ac9592be8202b21e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, state, and foreign income taxes. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MTA_45ae81ba-978c-49bc-a3b1-412a1536e16f" continuedAt="ib0391b65d0a04d58a7641c008bde3e6b" escape="true">Components of income before income taxes consist of the following: </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><ix:continuation id="ib0391b65d0a04d58a7641c008bde3e6b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.448%"><tr><td style="width:1.0%"></td><td style="width:27.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzItMS0xLTEtMTc0MzYy_e5695048-1e78-4028-88b0-3b78746411ac">839.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzItMy0xLTEtMTc0MzYy_45e67093-8fd2-4de1-8098-5ffc3aba7a86">5,944.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzItNS0xLTEtMTc0MzYy_fd96c813-266a-44ed-a714-684334da2542">2,442.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzMtMS0xLTEtMTc0MzYy_81d42267-1a3e-4332-b063-9d9cc8cd857d">4,018.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzMtMy0xLTEtMTc0MzYy_ba79a43e-1c57-4bc6-9bf0-46fde5762286">3,381.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzMtNS0xLTEtMTc0MzYy_fd02511f-b5d3-444d-8d10-aae6d7c8c0be">1,368.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzQtMS0xLTEtMTc0MzYy_e78788b3-86e6-45f0-9782-ce7721372fe7">4,858.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzQtMy0xLTEtMTc0MzYy_f1b598e5-c52a-4b6e-a9ae-5a40e24c7f3e">9,325.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzQtNS0xLTEtMTc0MzYy_a0623825-f08c-4a96-a49e-8de31c8aeced">3,810.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzIzOTI_6bfc113d-8647-4721-8c72-ec5564cc14a2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.109%"><tr><td style="width:1.0%"></td><td style="width:43.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzMtMS0xLTEtMTc0MzYy_325db0e3-8827-4055-b608-1130f58bfe78">968.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzMtMy0xLTEtMTc0MzYy_96b433e8-b723-43a4-b542-47bde6bf7b88">1,429.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzMtNS0xLTEtMTc0MzYy_d792db49-283c-416c-9501-1237a8c42b1f">199.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzQtMS0xLTEtMTc0MzYy_5df3aeb7-92e5-4137-a54d-6f3f6700fda6">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzQtMy0xLTEtMTc0MzYy_a1530ad8-2506-463f-ae80-02ff1e129d58">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzQtNS0xLTEtMTc0MzYy_b7bc6eae-f4ce-4ba9-8e60-d4c2a3e5a152">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzUtMS0xLTEtMTc0MzYy_ee268ba7-7d9d-4cbe-aa90-228691a76ee0">290.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzUtMy0xLTEtMTc0MzYy_4508cf53-fb98-4dfe-a5fb-9f40c5261245">38.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzUtNS0xLTEtMTc0MzYy_de737731-c702-4632-8480-aed12a5feac9">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzYtMS0xLTEtMTc0MzYy_a7f3fa75-d1f9-4832-98a6-2e73fafa2453">1,266.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzYtMy0xLTEtMTc0MzYy_da850d3b-573c-491e-aeae-f66cfbeac1e4">1,397.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzYtNS0xLTEtMTc0MzYy_142dd152-94da-4898-81a3-bb4f11a7fa68">221.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzgtMS0xLTEtMTc0MzYy_f09b2489-7af9-4e67-b17e-9f74cfafaac3">797.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzgtMy0xLTEtMTc0MzYy_589beffd-a107-4122-a42c-36589a6dadc7">423.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzgtNS0xLTEtMTc0MzYy_2020d6a0-fbc3-420c-a978-034e6570430d">109.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzktMS0xLTEtMTc0MzYy_a9f3b75d-46c7-4688-a131-e9e947d104b1">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzktMy0xLTEtMTc0MzYy_cf26126c-185b-4cdb-9aca-c992bbe1033c">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzktNS0xLTEtMTc0MzYy_14332c1b-3117-4272-bdf8-c38fc10ce4e0">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEwLTEtMS0xLTE3NDM2Mg_18011cd7-8f12-4ace-9fda-36a338ebc9f4">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEwLTMtMS0xLTE3NDM2Mg_6325f979-c945-4279-8703-7eacce81c554">276.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEwLTUtMS0xLTE3NDM2Mg_8404f2a0-ae6c-45f0-9c63-cfc9eda48be3">31.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzExLTEtMS0xLTE3NDM2Mg_4c39cb58-a778-4799-885d-b0db7a02ce1a">746.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzExLTMtMS0xLTE3NDM2Mg_573a7819-cc3e-4ddb-8858-6b1af25c7917">147.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzExLTUtMS0xLTE3NDM2Mg_5caaaac3-3484-490c-9b71-eff041942757">75.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEyLTEtMS0xLTE3NDM2Mg_d7c1df88-32c0-4037-b4db-bf2b46270754">520.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEyLTMtMS0xLTE3NDM2Mg_01a429a8-1609-41a4-ba2d-7ac62b92d055">1,250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEyLTUtMS0xLTE3NDM2Mg_434fca02-2d67-4d20-9b2f-3e09b378fe12">297.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzIzODM_c031d8ba-e10e-4c9a-9eb9-4324d7b59ea6" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. statutory income tax rate to the Company's effective income tax rate is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.080%"><tr><td style="width:1.0%"></td><td style="width:56.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzItMS0xLTEtMTc0MzYy_b25ffb51-956e-46ce-ab7e-6d1b4143343f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzItMy0xLTEtMTc0MzYy_809cc01e-4d92-4468-98d5-b631c02770ba">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzItNS0xLTEtMTc0MzYy_a7ec1974-bc02-4f50-88fe-a7f4e17e1743">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxation of non-U.S. operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzMtMS0xLTEtMTc0MzYy_dd1c2f3b-c9ef-4bf9-981c-0a03b180a678">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzMtMy0xLTEtMTc0MzYy_ce31af84-e4eb-4226-b6bd-be9a54bb0234">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzMtNS0xLTEtMTc0MzYy_bc921d07-d799-46de-a7ae-235a3acf6697">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzQtMS0xLTEtMTc0MzYy_68d1663b-c3b1-4251-822b-461d68e3f8a8">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzQtMy0xLTEtMTc0MzYy_e7b99382-6a84-4be8-8902-2a12b3eaeab0">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzQtNS0xLTEtMTc0MzYy_5eaec296-17a4-45b0-833e-8d09b3880e0d">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzYtMS0xLTEtMTc0MzYy_c95ead65-680c-4675-8c51-b30d2f7b6f13">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzYtMy0xLTEtMTc0MzYy_e453faf8-9155-455c-9cad-ff6fc5ecb2ee">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzYtNS0xLTEtMTc0MzYy_f323770f-5869-4886-88ca-901f5cbc0524">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzUtMS0xLTEtMTc0MzYy_0bd29c63-a83a-4ec4-8075-12c1b802cbaf">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzUtMy0xLTEtMTc0MzYy_eed833ac-de56-41d2-9bb9-c6577791c56e">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" name="regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzUtNS0xLTEtMTc0MzYy_bf155c5a-21bd-46f9-bd30-e0ef2a7f566c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-inventory related assets between foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzctMS0xLTEtMTc0MzYy_816b152f-f1ec-4acd-ae1a-33b059b29260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzctMy0xLTEtMTc0MzYy_622d1297-b322-4022-9767-66f5e6f49401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" sign="-" name="regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzctNS0xLTEtMTc0MzYy_2af602c4-a425-46ca-b97a-41a45351a926">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzgtMS0xLTEtMTc0MzYy_cb633d98-c57c-4579-aa9e-f29c14e3cc37">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzgtMy0xLTEtMTc0MzYy_7d7400a1-a742-46e3-aa07-d30cfa06dc95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzgtNS0xLTEtMTc0MzYy_8a42de07-b616-4aa8-bc01-3a6d71b7ff58">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzktMS0xLTEtMTc0MzYy_e192b333-923d-494f-8e47-54e2127dc446">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzktMy0xLTEtMTc0MzYy_edd4c843-5585-4e9e-bd4d-c3b94eb956ed">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzktNS0xLTEtMTc0MzYy_45fc7671-34fb-4bc3-b02f-4d165c95d0f9">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i54c0ea560f0a41b1ac9592be8202b21e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MDc_75937d54-cfc4-4d9d-8c58-298e628b71fd" continuedAt="icd07b1c24f154dab8a2e2cfb71c03e3f" escape="true">Significant components of the Company's deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="icd07b1c24f154dab8a2e2cfb71c03e3f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.488%"><tr><td style="width:1.0%"></td><td style="width:68.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtMi0xLTEtMjAzNjEw_d5da0653-a48a-4233-8140-e34f5e6529c8">845.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtNC0xLTEtMjAzNjEw_2ae4c300-bbfd-4480-a917-ff471c3061fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtMi0xLTEtMTc0MzYy_ecb2aa53-530a-4e32-99c7-40780893d9a8">416.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtNC0xLTEtMTc0MzYy_5bb28a2b-6378-4f60-952d-45523cab45bb">406.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzQtMi0xLTEtMTc0MzYy_c3c67296-ea6f-4cf8-a1d4-94d4b906f46b">235.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzQtNC0xLTEtMTc0MzYy_1a719ad6-0615-46cf-afe8-5e3d12d6a2d8">262.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzUtMi0xLTEtMTc0MzYy_eb92921c-7fe8-4a5a-9687-bd7415cac781">227.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzUtNC0xLTEtMTc0MzYy_298e40cb-de5d-4e1f-a9e2-64edd950d526">257.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax attribute carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtMi0xLTEtMjAzNjE0_fcd1fac1-3f5c-4403-8d32-fae63455fc0b">41.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtNC0xLTEtMjAzNjE0_66c8d5cf-ee96-4eed-978d-4e02738a89fe">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzctMi0xLTEtMTc0MzYy_8865a678-e703-41dc-af5c-82bffa321a5c">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzctNC0xLTEtMTc0MzYy_cd014528-ac65-424e-ab2f-0c133d7322c4">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtMi0xLTEtMjA4MDAw_b05776a3-45ce-4f16-88d5-187d3121628a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtNC0xLTEtMjA4MDAw_3948ef73-47fe-4588-9312-b93c85825365">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtMi0xLTEtMTc0MzYy_39123e7b-f5d9-46a5-92b6-b652edd7c552">1,781.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtNC0xLTEtMTc0MzYy_8204e04e-82e4-4741-ba9d-b4afd3ec6e4e">1,000.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzExLTItMS0xLTE3NDM2Mg_bf55a11f-1972-4106-98c4-da56369f0a9b">58.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzExLTQtMS0xLTE3NDM2Mg_d6152522-3f60-484c-aaad-0cd86791e214">123.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzEyLTItMS0xLTE3NDM2Mg_707267e8-1dcb-4128-ac39-54f3d16ede2d">1,723.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzEyLTQtMS0xLTE3NDM2Mg_4fd1daad-5dbe-4e6b-8833-04b0ec214941">876.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's federal income tax returns for 2017 through 2021 remain open to examination by the IRS. The Company's 2017 and 2018 federal income tax returns are currently under audit by the IRS. In general, the Company's state income tax returns from 2018 to 2021 remain open to examination. The Company's income tax returns outside of the United States remain open to examination from 2018 to 2021. The United States and many states generally have statutes of limitation ranging from 3 to 5 years; however, those statutes could be extended due to the Company's tax credit carryforward position. In general, tax authorities have the ability to review income tax returns in which the statute of limitation has previously expired to adjust the tax credits generated in those years.</span></div><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MDI_c1459734-a0af-4595-a73d-c285f840d453" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net unrecognized tax benefits that, if settled, would impact the effective tax rate is $<ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzgyNDYzMzcyMTk2NTc_34f6248a-3d03-4197-9aa6-e3400100fa7e">373.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzE2MjE_f3d5de89-4d74-4bd9-87db-cb254859f61b">321.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzE2Mjk_20387965-5f49-414a-afa0-8c264ec76f3a">267.0</ix:nonFraction> million as of December 31, 2022, 2021, and 2020, respectively. The following table reconciles the beginning and ending amounts of unrecognized tax benefits. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"></td><td style="width:58.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzEtMi0xLTEtMTc0MzYy_26c4a5da-21da-42e5-a7d4-2cf562a3f072">410.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzEtNC0xLTEtMTc0MzYy_083bcd9c-2277-4320-ae17-3f8642c46b45">267.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzEtNi0xLTEtMTc0MzYy_6f1347ee-ba0d-4ffc-9c3f-1948f7fccdae">210.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzItMi0xLTEtMTc0MzYy_12258915-1c75-40e0-8d57-2507f9b7ed91">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzItNC0xLTEtMTc0MzYy_69c12538-94c6-4aca-9df8-0b7af8fd3a55">182.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzItNi0xLTEtMTc0MzYy_0276be58-7394-42d2-ae5e-1d27ea8e5bcc">76.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross (decreases) increases related to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzMtMi0xLTEtMTc0MzYy_5df0fc98-8189-4768-a0d6-638780ea891d">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzMtNC0xLTEtMTc0MzYy_79794d2b-927a-4615-8801-cc2ca337e85c">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzMtNi0xLTEtMTc0MzYy_08654982-3e4e-4be4-9c5d-8706aa02ef07">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases due to settlements and lapse of statutes of limitations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzQtMi0xLTEtMTc0MzYy_a820fb3a-c2b8-4859-ad93-6bdfe17dff49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzQtNC0xLTEtMTc0MzYy_b06b7d9e-4d1a-4273-8118-49c386c7d3d8">41.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzQtNi0xLTEtMTc0MzYy_33d8f9d5-9613-44b7-904e-632b59980cbf">27.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzUtMi0xLTEtMTc0MzYy_b02d04ed-19df-4fc7-afe0-857a43b03d57">542.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzUtNC0xLTEtMTc0MzYy_479cf150-249d-4426-a60d-e1d9059d69e4">410.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzUtNi0xLTEtMTc0MzYy_b5cdb338-45b4-466d-9b5a-729b156322a8">267.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, 2021, and 2020, the increases in unrecognized tax benefits primarily related to the Company's calculation of certain tax credits and other items related to the Company's international operations. The decrease in unrecognized tax benefits in 2021 was related to the closing of audits for the Company's federal income tax returns for 2015 and 2016. Interest expense related to unrecognized tax benefits was not material in 2022, 2021, and 2020. The Company does not believe that it is reasonably possible that the resolution of tax exposures within the next twelve months would have a material impact on the consolidated financial statements as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 ("IRA") was signed into law in the United States. The IRA created a new corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases. The provisions of the IRA will be effective for periods beginning after December&#160;31, 2022. The enactment of the IRA did not result in any material adjustments to the Company's income tax provisions or net deferred tax assets as of December&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_160"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzMxNTkw_77647d83-3005-4172-a438-f61687803e11" continuedAt="iaf09730d95bc4ade8295798e6126acbc" escape="true">Legal Matters</ix:nonNumeric></span></div><ix:continuation id="iaf09730d95bc4ade8295798e6126acbc" continuedAt="id9df2920647f49feb4a62e7b0b701422"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzIxOTkwMjM0MTc1MTg_b6776034-549f-4f4c-8a6f-fa8ecb86c7c1" escape="true">Costs associated with the Company's involvement in legal proceedings are expensed as incurred</ix:nonNumeric>. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of December 31, 2022 and 2021, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. In addition, as described below, the Company filed a lawsuit against Amgen alleging that Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As previously reported, on February 11, 2021, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc with the Federal Circuit, which was denied on June 21, 2021. On November 4, 2022, the United States Supreme Court granted Amgen's petition for writ of certiorari. An oral hearing has been scheduled for March 27, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, the Company filed a lawsuit against Amgen in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1, 2022, Amgen filed a motion to dismiss the complaint. On August 11, 2022, Amgen filed a motion to stay these proceedings pending resolution of the patent litigation described in the preceding paragraph. An oral hearing on Amgen's motion to dismiss and motion to stay has been scheduled for January 6, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in certain countries in Europe. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). Following the EPO's decision, each of the '124 Patent infringement proceedings initiated by Amgen against the Company and certain of Sanofi's affiliated entities in these countries was dismissed, including in Germany. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. As a result of the overturned injunction in Germany discussed in the preceding sentence, the Company and/or certain of Sanofi's affiliated entities are seeking damages caused by Amgen's enforcement of the injunction. As part of its opposition to these damages claims, on March 23, 2022, Amgen filed a counterclaim that asserted the German designation of European Patent No. 2,641,917 (the "'917 Patent") and seeks, among other things, a judgment of patent infringement, injunctive relief, and monetary damages. The '917 Patent is a divisional patent of the '124 Patent discussed above (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent but contains claims to a different invention). The '917 Patent is also subject to opposition proceedings in the EPO, which were initiated by Sanofi on May 5, 2021. An oral hearing before the EPO has been scheduled for February 21, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Dupixent (dupilumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), a patent owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the EPO opposition proceedings initiated </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="id9df2920647f49feb4a62e7b0b701422" continuedAt="ifb23cc619ed849ec83af320eeb78241d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018, which appeal was withdrawn at an oral hearing before the TBA on March 10, 2022 following the TBA's ruling discussed below. On May 18, 2022, the revocation action in the U.K. Patents Court was dismissed following the EPO's revocation of the '665 Patent. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#8211;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019. At an oral hearing before the TBA on March 10, 2022, the TBA maintained the invalidity and revocation of the '420 Patent. The original patent term of the Immunex patents expired in May 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, anonymous parties filed <ix:nonFraction unitRef="request" contextRef="i73f39b7d8fbc4c3db0ae510abf05e506_I20200211" decimals="INF" name="regn:LossContingencyExParteReexaminationFiledNumber" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYyNQ_87d6a88b-7ad7-4a46-8ce5-15f5bd63e695">two</ix:nonFraction> requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of the Company's U.S. Patent Nos. 10,406,226 and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests to initiate reexamination proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, Mylan Pharmaceuticals Inc. filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review ("IPR") petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent. On November 10, 2021, the USPTO issued a decision instituting both IPR proceedings. On December 9, 2021, Apotex Inc. and Celltrion, Inc. each filed <ix:nonFraction unitRef="claim" contextRef="ie1e3a47e6a80444d990b27b30d75132a_I20211209" decimals="INF" name="regn:NumberOfInterPartiesReviewIPRPetitionsFiled" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYyMA_89e7eb2c-c52d-474b-b6bc-8fac72288096"><ix:nonFraction unitRef="claim" contextRef="icacf904bc9524621b2a1108d36ed04c7_I20211209" decimals="INF" name="regn:NumberOfInterPartiesReviewIPRPetitionsFiled" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYyMA_a002ff35-9fbc-4740-af60-ff15208022e6">two</ix:nonFraction></ix:nonFraction> separate IPR petitions against the Company's '338 and '069 Patents requesting that their IPRs be instituted and joined with the IPR proceedings initiated by Mylan concerning the '338 and '069 Patents, which petitions were granted on February 9, 2022. An oral hearing was held on August 10, 2022. On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2021, Celltrion, Inc. filed a post-grant review ("PGR") petition in the USPTO against the Company's U.S. Patent No. 10,857,231 (the "'231 Patent") seeking a declaration of invalidity of the '231 Patent. On March 14, 2022, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '231 Patent. As a result, on March 15, 2022, the USPTO denied institution of Celltrion's PGR petition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Mylan filed IPR petitions against the Company's U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") (each filed July 1, 2022) and 10,857,205 (filed October 28, 2022) seeking declarations of invalidity of each of these patents. On January 11, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent. On January 6, 2023, Samsung Bioepis Co., Ltd. filed a separate IPR petition against the Company's '681 Patent seeking a declaration of invalidity of the '681 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2022, Apotex filed an IPR petition against the Company's U.S. Patent No. 11,253,572 (the "'572 Patent") seeking a declaration of invalidity of the '572 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2023, Celltrion, Inc. filed an IPR petition against the '992 Patent seeking a declaration of invalidity of the '992 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for a U.S. Food and Drug Administration approval of an aflibercept biosimilar infringes certain Company patents. A trial has been scheduled to begin on June 12, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ifb23cc619ed849ec83af320eeb78241d" continuedAt="i3a1bd6e821cd4e6cb77bdb011e9f86ab"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Canada</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, July 15, August 30, and October 4, 2022, the Company and Bayer Inc. filed patent infringement lawsuits against BGP Pharma ULC d.b.a Viatris Canada ("Viatris Canada") in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent) and 3,007,276 (the "'276 Patent") (in the lawsuit filed on June 15, 2022); the Company's Canadian Patent No. 2,965,495 (the "'495 Patent") (in the lawsuit filed on July 15, 2022); the Company's Canadian Patent No. 2,906,768 (the "'768 Patent") (in the lawsuit filed on August 30, 2022, which has been joined with the lawsuit filed on July 15, 2022); and the Company's Canadian Patent No. 3,129,193 (the "'193 Patent") (in the lawsuit filed on October 4, 2022). A trial for the lawsuit concerning the '510 Patent and the '276 Patent has been scheduled for March 2024; a trial for the lawsuit concerning the '193 Patent has been scheduled for May 2024; and a trial for the lawsuit concerning the '495 Patent and the '768 Patent has been scheduled for November/December 2024. The filing of the lawsuit concerning the '510 Patent and the '276 Patent resulted in a statutory 24-month stay of regulatory approval of Viatris Canada's aflibercept biosimilar in Canada unless the lawsuit is resolved earlier.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">South Korea</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811, respectively, seeking revocation of each of such patents in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#8217;s U.S. Patent No. 9,220,631 (the "'631 Patent"). The ITC instituted the investigation on July 22, 2020 and a trial was scheduled for April 19&#8211;23, 2021. On March 26, 2021, the staff attorney appointed by the ITC's Office of Unfair Import Investigations ("OUII")&#8212;an independent government party to the case representing the public interest&#8212;determined that the '631 Patent is invalid on several grounds. On April 8, 2021, Novartis moved to terminate the ITC investigation in its entirety based on its withdrawal of the complaint; and, on May 3, 2021, the ITC terminated the investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis also filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated <ix:nonFraction unitRef="claim" contextRef="ic126e7de56fd4102a3b3234acc2542c7_I20200716" decimals="INF" name="regn:NumberOfInterPartiesReviewIPRPetitionsFiled" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYxNA_c6bb0dfb-5dc3-4a38-a0ea-f56755b26c2f">two</ix:nonFraction> IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On January 15, 2021, the USPTO declined to institute an IPR proceeding on procedural grounds in light of the pending ITC investigation discussed above; the other IPR petition has been withdrawn. Following Novartis's motion to terminate the ITC investigation discussed above, on April 16, 2021 the Company filed a new IPR petition seeking a declaration of invalidity of the '631 Patent based on the same grounds that were the basis for the OUII staff attorney's determination discussed above. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i3a1bd6e821cd4e6cb77bdb011e9f86ab" continuedAt="i86969fa24251489c949642d3315151b3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On November 5, 2021, the Company filed a motion to stay these proceedings in light of the pending IPR proceeding discussed above. On January 31, 2022, the court denied the Company's motion to stay these proceedings and granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney&#8217;s Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to CMS. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Department of Insurance Subpoena</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Initiated by Other Payors Relating to Patient Assistance Organization Support</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to several lawsuits relating to the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="i86969fa24251489c949642d3315151b3" continuedAt="i77e10f9c990a4b4cbc98ad93199700b9"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court discussed under "Department of Justice Matters" above; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Shareholder Demands</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 30, 2020, March 30, 2022, and March 31, 2022, the Company's board of directors received three demand letters from purported shareholders of the Company. The demands allege that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letters request that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, investigated and evaluated the allegations in the demand letters and has concluded that pursuing the claims alleged in the demands would not be in the Company's best interests at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Shareholder Derivative Complaint</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i77e10f9c990a4b4cbc98ad93199700b9">On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 23, 2021, the plaintiff moved to remand the case to the New York Supreme Court. Also on September 23, 2021, the individual defendants moved to dismiss the complaint in its entirety. On December 19, 2022, the U.S. District Court for the Southern District of New York denied the plaintiff's motion to remand the case and granted a motion to stay the case pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. As a result of the stay, the court also terminated the Company's motion to dismiss the complaint without prejudice to renew upon conclusion of the stay.</ix:continuation> </span></div><div id="ic18bad8bf5314e3e9f4c348a9f859317_163"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90ZXh0cmVnaW9uOmE5ZDQ3ODdhYTMxYzQ2YmQ4ZTg2YTU0YjYwMjA5YWNlXzI1Mg_57e0a9fe-d7bd-48a8-b47e-707462a959d1" continuedAt="ic355503a51214c689b884eb5c07d575c" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="ic355503a51214c689b884eb5c07d575c" continuedAt="ifb57748bdf3f44bebcc695b8ad371427"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90ZXh0cmVnaW9uOmE5ZDQ3ODdhYTMxYzQ2YmQ4ZTg2YTU0YjYwMjA5YWNlXzI2MA_7a293c4e-fb38-4260-9c83-44372f404c86" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted net income per share are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.155%"><tr><td style="width:1.0%"></td><td style="width:56.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzItMi0xLTEtMTc0MzYy_0ac6f739-95a1-4be8-b531-b121c9306d73">4,338.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzItNC0xLTEtMTc0MzYy_81ff7ad4-0417-47de-9c01-a58d563cafb5">8,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzItNi0xLTEtMTc0MzYy_7ff2f8cd-f05c-4ba8-8307-1d6ee5e8ad75">3,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzQtMi0xLTEtMTc0MzYy_dfb3a7c4-7142-4703-b3c0-8c13dc0203d7">107.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzQtNC0xLTEtMTc0MzYy_0c3e4181-5772-4e71-a2f6-be2b4a83e4be">105.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzQtNi0xLTEtMTc0MzYy_d4ab192f-fec3-4c1f-92bf-da234ae2ff42">107.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzYtMi0xLTEtMTc0MzYy_b9fb5cfd-8bbb-4983-9e2b-1bc5b139432f">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzYtNC0xLTEtMTc0MzYy_ecfacadc-6b79-4436-bb47-bf2e7484641f">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzYtNi0xLTEtMTc0MzYy_adfc0991-2e5a-443a-8a91-dbf77e896862">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzctMi0xLTEtMTc0MzYy_c8558fae-767e-470a-8749-922cef97e164">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0f758f9b4de4edbbd24b0a3c80d2099_D20210101-20211231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzctNC0xLTEtMTc0MzYy_99c321dc-13da-470a-8492-bd48dc8a5bee">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98b8165ff3c84cc2b0b3ef6c846d0857_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzctNi0xLTEtMTc0MzYy_d24bb6fd-819c-4013-bf45-5348b73dbc85">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzgtMi0xLTEtMTc0MzYy_2860d13c-f509-4375-9770-54b0ea3cc874">113.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzgtNC0xLTEtMTc0MzYy_0d255765-ae22-4605-93bb-1d5192e916c4">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzgtNi0xLTEtMTc0MzYy_214ef372-fd9d-4042-bc04-e253163425fa">115.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzEwLTItMS0xLTE3NDM2Mg_13d6a368-ca1b-4ca8-a6fa-810af6ecdd7d">40.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzEwLTQtMS0xLTE3NDM2Mg_2b79975d-c04f-4c22-ab9f-68dfd65c2501">76.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzEwLTYtMS0xLTE3NDM2Mg_9666fe9a-8b08-409c-aea8-a6309196c506">32.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzExLTItMS0xLTE3NDM2Mg_4ae2eb02-4a56-4142-9559-3ab373b9ee5f">38.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzExLTQtMS0xLTE3NDM2Mg_85e58e62-7b04-4236-a13a-beb94c077809">71.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzExLTYtMS0xLTE3NDM2Mg_32187d9b-be7c-4c1b-a852-ddc427e2552c">30.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18bad8bf5314e3e9f4c348a9f859317_7">Table of Contents</a></span></div></div><ix:continuation id="ifb57748bdf3f44bebcc695b8ad371427"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90ZXh0cmVnaW9uOmE5ZDQ3ODdhYTMxYzQ2YmQ4ZTg2YTU0YjYwMjA5YWNlXzI2Mw_187b9ad4-8888-4725-886c-b3f544551837" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"></td><td style="width:57.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id00ff500fe5d47c79cce7113ad54ecef_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTpkMGFmNmE4MzVmNWQ0N2E2YjU0MWQxOWUwYTAxNzcwZC90YWJsZXJhbmdlOmQwYWY2YTgzNWY1ZDQ3YTZiNTQxZDE5ZTBhMDE3NzBkXzItMi0xLTEtMTc0MzYy_f8cb5281-b34e-4002-b7ae-0a89fbc43299">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ec0ed1241324a98bc46dd1af446a761_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTpkMGFmNmE4MzVmNWQ0N2E2YjU0MWQxOWUwYTAxNzcwZC90YWJsZXJhbmdlOmQwYWY2YTgzNWY1ZDQ3YTZiNTQxZDE5ZTBhMDE3NzBkXzItNC0xLTEtMTc0MzYy_869a7321-d5d1-40d8-940c-e991f44579bb">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60296a00df8b476a897b09a51d123985_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTpkMGFmNmE4MzVmNWQ0N2E2YjU0MWQxOWUwYTAxNzcwZC90YWJsZXJhbmdlOmQwYWY2YTgzNWY1ZDQ3YTZiNTQxZDE5ZTBhMDE3NzBkXzItNi0xLTEtMTc0MzYy_d4aa5ae3-feed-4277-9886-c067aa48705e">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic18bad8bf5314e3e9f4c348a9f859317_166"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzYwMA_f3025c3b-b1ba-42a2-82e3-0cdb5ce99fa0" continuedAt="ief21689f433547b6b2f94bb6b3820543" escape="true">Statement of Cash Flows</ix:nonNumeric></span></div><ix:continuation id="ief21689f433547b6b2f94bb6b3820543"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzU5OA_78fe8a7a-9640-42c9-b7d4-f1de19d776aa" escape="true"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzU5OA_dab07c36-3311-45b6-8357-a944dfb91903" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"><tr><td style="width:1.0%"></td><td style="width:50.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzItMi0xLTEtMTc0MzYy_305511be-8de1-4848-9e97-a63e4fbbb21b">3,105.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzItNC0xLTEtMTc0MzYy_8ec24fc3-5e53-42b5-b154-900578403b38">2,885.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzItNi0xLTEtMTc0MzYy_6f50cf35-0625-4bf9-872a-bba047ec4ac6">2,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzMtMi0xLTEtMTc0MzYy_3efea8d7-72d6-4719-a3b5-7bc4c48b8724">13.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzMtNC0xLTEtMTc0MzYy_988d6318-382c-416f-8c2e-1e49fd24d298">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzMtNi0xLTEtMTc0MzYy_2cf1b35e-3d4c-45c9-a050-5afa4259c586">13.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzQtMi0xLTEtMTc0MzYy_5ce15a19-631f-40b1-8f9a-a8552b53ae24">3,119.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzQtNC0xLTEtMTc0MzYy_2dc043c7-7057-4b0a-87e2-9b96b153f3cb">2,898.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1b802d10c4170b70f673c07516261_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzQtNi0xLTEtMTc0MzYy_f62b0782-6bf9-407f-a086-fbe5cad8eecb">2,207.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><ix:nonNumeric contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzIxOTkwMjMyNTYzMTY_ff99fb80-0b11-4987-981a-35628645322c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.747%"><tr><td style="width:1.0%"></td><td style="width:37.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzItMS0xLTEtMTc4NjEx_68a36c7d-971e-477a-a38d-efeba3b1ddac">70.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5bac9dad6b340e2b278dca087384319_D20210101-20210331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzItMy0xLTEtMTc4NjEx_112d034b-1ecc-4a85-8e5a-a09fd6a93c81">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzItNS0xLTEtMTc4NjEx_a169aba0-c4b5-4cfa-8466-d212db37f3f3">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payments for Libtayo intangible asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzMtMS0xLTEtMTc4NjEx_d6e794a0-7619-4aac-a5ab-15c8cb184d1f">135.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5bac9dad6b340e2b278dca087384319_D20210101-20210331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzMtMy0xLTEtMTc4NjEx_2cff754c-841e-4ea4-bf12-c70c19b97aa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzMtNS0xLTEtMTc4NjEx_5a04e638-1200-41af-a4fc-7c79941e52a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>regn-ex_211x12312022x10k.htm
<DESCRIPTION>SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id4ec9d706bd4463985d540e62b26b3fe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 21.1 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:6.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">State or Other Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Checkmate Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eastside Campus Holdings LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loop Road Holdings LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Old Saw Mill Holdings LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OSMR Holdings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Assurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Atlantic Holdings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Belgium BV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Canada Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Genetics Center LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Healthcare Solutions, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron India Private Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron International Holdings LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Ireland Designated Activity Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Japan KK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron NL B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Netherlands</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Spain, S.L.U.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rockwood Road Holdings LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*  Directly or indirectly wholly owned by Regeneron Pharmaceuticals, Inc.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>regn-ex_231x12312022x10k.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibadf7c1e3c984a25b651eae90a4f81aa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 23.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-260763) and Form S&#8209;8</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, 333-198794, 333-218669, and 333-239209) of Regeneron Pharmaceuticals, Inc. of our report dated February 6, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey                                                                       </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 6, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>regn-ex_311x12312022x10k.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4599857541c34b70b10d1684ee8ce287_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leonard S. Schleifer, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>regn-ex_312x12312022x10k.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7a176bbfb6af46b4a3628f07565d89a0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert E. Landry, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>regn-ex_32x12312022x10k.htm
<DESCRIPTION>CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i05bdaf5004e04408b09841af1454ba51_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Regeneron Pharmaceuticals, Inc. (the &#34;Company&#34;) on Form 10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2023</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>regn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:042488f0-a666-455c-8991-c514440b53f2,g:8bd10ba8-749e-45a5-bb1c-c1abec558824-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:regn="http://www.regeneron.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.regeneron.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.regeneron.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.regeneron.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandSummaryofSignificantAccountingPolicies" roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Business Overview and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.regeneron.com/role/ProductSales">
        <link:definition>0000009 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreements" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements">
        <link:definition>0000010 - Disclosure - Collaboration, License, and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.regeneron.com/role/MarketableSecurities">
        <link:definition>0000011 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.regeneron.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.regeneron.com/role/Inventories">
        <link:definition>0000013 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.regeneron.com/role/PropertyPlantandEquipment">
        <link:definition>0000014 - Disclosure - Property, Plant, and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.regeneron.com/role/IntangibleAssets">
        <link:definition>0000015 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.regeneron.com/role/Debt">
        <link:definition>0000017 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.regeneron.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.regeneron.com/role/StockholdersEquity">
        <link:definition>0000019 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlans" roleURI="http://www.regeneron.com/role/LongTermIncentivePlans">
        <link:definition>0000020 - Disclosure - Long-Term Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeSavingsPlans" roleURI="http://www.regeneron.com/role/EmployeeSavingsPlans">
        <link:definition>0000021 - Disclosure - Employee Savings Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.regeneron.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.regeneron.com/role/LegalMatters">
        <link:definition>0000023 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.regeneron.com/role/NetIncomePerShare">
        <link:definition>0000024 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlows" roleURI="http://www.regeneron.com/role/StatementofCashFlows">
        <link:definition>0000025 - Disclosure - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000026 - Disclosure - Business Overview and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000027 - Disclosure - Business Overview and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.regeneron.com/role/ProductSalesTables">
        <link:definition>0000028 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTables" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables">
        <link:definition>0000029 - Disclosure - Collaboration, License, and Other Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables">
        <link:definition>0000030 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables">
        <link:definition>0000031 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.regeneron.com/role/InventoriesTables">
        <link:definition>0000032 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentTables">
        <link:definition>0000033 - Disclosure - Property, Plant, and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.regeneron.com/role/IntangibleAssetsTables">
        <link:definition>0000034 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.regeneron.com/role/DebtTables">
        <link:definition>0000036 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000037 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.regeneron.com/role/StockholdersEquityTables">
        <link:definition>0000038 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansTables" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansTables">
        <link:definition>0000039 - Disclosure - Long-Term Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.regeneron.com/role/IncomeTaxesTables">
        <link:definition>0000040 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.regeneron.com/role/NetIncomePerShareTables">
        <link:definition>0000041 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsTables" roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables">
        <link:definition>0000042 - Disclosure - Statement of Cash Flows (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000043 - Disclosure - Business Overview and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails">
        <link:definition>0000044 - Disclosure - Business Overview and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofNetProductSalesDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails">
        <link:definition>0000045 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesNarrativeDetails" roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails">
        <link:definition>0000046 - Disclosure - Product Sales - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
        <link:definition>0000047 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofSalesRelatedDeductionsActivityDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails">
        <link:definition>0000048 - Disclosure - Product Sales - Schedule of Sales Related Deductions Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails">
        <link:definition>0000049 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
        <link:definition>0000050 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails">
        <link:definition>0000051 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, Antibody Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
        <link:definition>0000052 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails">
        <link:definition>0000053 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, IO Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails">
        <link:definition>0000054 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails">
        <link:definition>0000055 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Bayer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails">
        <link:definition>0000056 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaborative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails">
        <link:definition>0000057 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails">
        <link:definition>0000058 - Disclosure - Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails">
        <link:definition>0000059 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails">
        <link:definition>0000060 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails">
        <link:definition>0000061 - Disclosure - Collaboration, License, and Other Agreements - Alnylam Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails">
        <link:definition>0000062 - Disclosure - Collaboration, License, and Other Agreements - Checkmate Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails">
        <link:definition>0000063 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails">
        <link:definition>0000064 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails">
        <link:definition>0000065 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
        <link:definition>0000066 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails">
        <link:definition>0000067 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
        <link:definition>0000068 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>0000069 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000070 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000071 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000072 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.regeneron.com/role/InventoriesNarrativeDetails">
        <link:definition>0000073 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000074 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>0000075 - Disclosure - Property, Plant, and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000076 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>0000077 - Disclosure - Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000078 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.regeneron.com/role/DebtNarrativeDetails">
        <link:definition>0000079 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofIssuedSeniorUnsecuredNotesDetails" roleURI="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails">
        <link:definition>0000080 - Disclosure - Debt - Summary of Issued Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeasesnarrativeDetails" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails">
        <link:definition>0000081 - Disclosure - Commitments and Contingencies - Leases narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails">
        <link:definition>0000082 - Disclosure - Commitments and Contingencies - Amounts recognized in Condensed Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFinanceleasecostsDetails" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails">
        <link:definition>0000083 - Disclosure - Commitments and Contingencies - Finance lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails">
        <link:definition>0000084 - Disclosure - Commitments and Contingencies - Other information related to finance lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails">
        <link:definition>0000085 - Disclosure - Commitments and Contingencies - Analysis of lease liability maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1">
        <link:definition>0000085 - Disclosure - Commitments and Contingencies - Analysis of lease liability maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails" roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails">
        <link:definition>0000086 - Disclosure - Commitments and Contingencies - Research Collaboration and Licensing Agreements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000087 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRepurchasedSharesDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails">
        <link:definition>0000088 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansNarrativeDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails">
        <link:definition>0000089 - Disclosure - Long-Term Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails">
        <link:definition>0000090 - Disclosure - Long-Term Incentive Plans - Summary of transactions involving stock option awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails">
        <link:definition>0000091 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average exercise prices and weighted-average grant-date fair values of options issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails">
        <link:definition>0000092 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of option grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails">
        <link:definition>0000093 - Disclosure - Long-Term Incentive Plans - Summary of activity related to restricted stock awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails">
        <link:definition>0000094 - Disclosure - Long-Term Incentive Plans - Summary of activity related to performance-based awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails" roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails">
        <link:definition>0000095 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of performance-based options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeSavingsPlansDetails" roleURI="http://www.regeneron.com/role/EmployeeSavingsPlansDetails">
        <link:definition>0000096 - Disclosure - Employee Savings Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofincomebeforeincometaxDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails">
        <link:definition>0000097 - Disclosure - Income Taxes - Schedule of income before income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails">
        <link:definition>0000098 - Disclosure - Income Taxes - Schedule of components of income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails">
        <link:definition>0000099 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails">
        <link:definition>0000100 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000101 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails">
        <link:definition>0000102 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMattersDetails" roleURI="http://www.regeneron.com/role/LegalMattersDetails">
        <link:definition>0000103 - Disclosure - Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>0000104 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
        <link:definition>0000105 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000106 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails" roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails">
        <link:definition>0000107 - Disclosure - Statement of Cash Flows - Summary of Non-Cash Investing and Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" abstract="false" name="ShareOfLossesOutsideUnitedStatesForCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_ContingentReimbursementObligation" abstract="false" name="ContingentReimbursementObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_LaboratoryAndOfficeFacilitiesMember" abstract="true" name="LaboratoryAndOfficeFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="regn_SanofisShareOfLibtayoUSGrossProfitsMember" abstract="true" name="SanofisShareOfLibtayoUSGrossProfitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AccrualForSalesRelatedCostsCurrent" abstract="false" name="AccrualForSalesRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" abstract="true" name="ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_DistributionRelatedFeesMember" abstract="true" name="DistributionRelatedFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EYLEAAfliberceptInjectionMember" abstract="true" name="EYLEAAfliberceptInjectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ArcalystNetProductSalesMember" abstract="true" name="ArcalystNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LossContingencyExParteReexaminationFiledNumber" abstract="false" name="LossContingencyExParteReexaminationFiledNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_LongTermIncentivePlan2000Member" abstract="true" name="LongTermIncentivePlan2000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" abstract="false" name="PaymentsMadeToAcquireEquityWithinACollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramNovember2021Member" abstract="true" name="ShareRepurchaseProgramNovember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentDomain" abstract="true" name="ClassificationOfInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementImmunooncologyMember" abstract="true" name="SanofiCollaborationAgreementImmunooncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_BARDAOtherTransactionAgreementMember" abstract="true" name="BARDAOtherTransactionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" abstract="true" name="AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_InmazebMember" abstract="true" name="InmazebMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PaymentToCollaboratingParty" abstract="false" name="PaymentToCollaboratingParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" abstract="false" name="PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_RonapreveMember" abstract="true" name="RonapreveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RoyaltyRateMinimum" abstract="false" name="RoyaltyRateMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_A338PatentAnd069PatentMember" abstract="true" name="A338PatentAnd069PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementAntibodyMember" abstract="true" name="SanofiCollaborationAgreementAntibodyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" abstract="false" name="PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_January12024ThroughDecember312026Member" abstract="true" name="January12024ThroughDecember312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ThreeIndividualCustomersMember" abstract="true" name="ThreeIndividualCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AmendedRestatedLongTermIncentivePlan2014Member" abstract="true" name="AmendedRestatedLongTermIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ExtensionOfResearchTermFee" abstract="false" name="ExtensionOfResearchTermFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_RoyaltyRateMaximum" abstract="false" name="RoyaltyRateMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_CheckmatePharmaceuticalsIncMember" abstract="true" name="CheckmatePharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UpFrontPaymentReceived" abstract="false" name="UpFrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" abstract="false" name="Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_RestrictedMember" abstract="true" name="RestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AggregateSalesBasedMilestoneMember" abstract="true" name="AggregateSalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestonesAxis" abstract="true" name="SalesMilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" abstract="false" name="PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" abstract="false" name="NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" abstract="false" name="MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_ApotexIncMember" abstract="true" name="ApotexIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_FurnitureOfficeEquipmentAndOtherMember" abstract="true" name="FurnitureOfficeEquipmentAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" abstract="false" name="MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_BayerCollaborationAgreementMember" abstract="true" name="BayerCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" abstract="false" name="RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_RegulatoryMilestoneMember" abstract="true" name="RegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_TevaPharmaceuticalsCollaborationAgreementMember" abstract="true" name="TevaPharmaceuticalsCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementOfCommercializationRelatedExpensesMember" abstract="true" name="ReimbursementOfCommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CelltrionIncMember" abstract="true" name="CelltrionIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_OtherCollaborationAgreementsMember" abstract="true" name="OtherCollaborationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_A631PatentMember" abstract="true" name="A631PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" abstract="false" name="RevenueBasedOnPercentageOfAnnualSalesInJapan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_FinanceLeaseRemainingLeaseTerm" abstract="false" name="FinanceLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" abstract="false" name="StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" abstract="false" name="CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentAxis" abstract="true" name="ClassificationOfInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" abstract="false" name="StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_OptionToExtendResearchTermPeriod" abstract="false" name="OptionToExtendResearchTermPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RocheCollaborationAgreementMember" abstract="true" name="RocheCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PaymentsForRoyaltiesPercentage" abstract="false" name="PaymentsForRoyaltiesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingArrangementsTable" abstract="true" name="ResearchCollaborationAndLicensingArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_PaymentsToAcquireIntangibleAssets1" abstract="false" name="PaymentsToAcquireIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_AmendedIODiscoveryAgreementMember" abstract="true" name="AmendedIODiscoveryAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PercentageOfRoyaltyPaymentThatCanBeOffset" abstract="false" name="PercentageOfRoyaltyPaymentThatCanBeOffset" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_PraluentCrossLicenseAndCommercializationAgreementMember" abstract="true" name="PraluentCrossLicenseAndCommercializationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingAgreementsAxis" abstract="true" name="ResearchCollaborationAndLicensingAgreementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_ThroughDecember312023Member" abstract="true" name="ThroughDecember312023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_InitialResearchTerm" abstract="false" name="InitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PotentialExtensionOfResearchTerm" abstract="false" name="PotentialExtensionOfResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_ShareOfLossesOutsideUnitedStatesForCompany" abstract="false" name="ShareOfLossesOutsideUnitedStatesForCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" abstract="false" name="CollaborativeArrangementAdditionalPaymentEligibleMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PaymentsForAssetAcquisition" abstract="false" name="PaymentsForAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_IntelliaCollaborationAgreementMember" abstract="true" name="IntelliaCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_NonPerformanceBasedStockOptionsMember" abstract="true" name="NonPerformanceBasedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_MarketableAndOtherSecuritiesGainLoss" abstract="false" name="MarketableAndOtherSecuritiesGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" abstract="true" name="ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_OtherSalesRelatedDeductionsMember" abstract="true" name="OtherSalesRelatedDeductionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationRevenueMember" abstract="true" name="SanofiCollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpensesMember" abstract="true" name="ReimbursementOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" abstract="false" name="PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingArrangementsLineItems" abstract="true" name="ResearchCollaborationAndLicensingArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" abstract="true" name="AmountsRecognizedInConnectionWithUpFrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" abstract="false" name="EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborativeArrangementUpfrontPaymentMade" abstract="false" name="CollaborativeArrangementUpfrontPaymentMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_A226PatentAnd992PatentMember" abstract="true" name="A226PatentAnd992PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" abstract="true" name="AlnylamPharmaceuticalsInc.CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramsMember" abstract="true" name="ShareRepurchaseProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" abstract="false" name="ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="regn_CollaborativeAgreementsObligationsCurrent" abstract="false" name="CollaborativeAgreementsObligationsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingAgreementsDomain" abstract="true" name="ResearchCollaborationAndLicensingAgreementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ProductRightsMember" abstract="true" name="ProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestoneOneMember" abstract="true" name="SalesBasedMilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" abstract="false" name="UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_SalesBasedMilestoneTwoMember" abstract="true" name="SalesBasedMilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" abstract="true" name="LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" abstract="true" name="RegeneronsShareOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" abstract="false" name="DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RegeneronsShareOfCommercialExpensesMember" abstract="true" name="RegeneronsShareOfCommercialExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" abstract="false" name="DepreciationDepletionAndAmortizationExcludingIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PraluentNetProductSalesMember" abstract="true" name="PraluentNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UpfrontPaymentMade" abstract="false" name="UpfrontPaymentMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_GrossProductRevenueMember" abstract="true" name="GrossProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" abstract="true" name="ShareOfProfitsLossesInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneThreeMember" abstract="true" name="SalesMilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" abstract="true" name="SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneOneMember" abstract="true" name="SalesMilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LossContingencyPercentageOfDamagesResponsibleFor" abstract="false" name="LossContingencyPercentageOfDamagesResponsibleFor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_MaximumTransactionAgreementPayments" abstract="false" name="MaximumTransactionAgreementPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" abstract="false" name="EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_SalesMilestoneFourMember" abstract="true" name="SalesMilestoneFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_NetProfitInConnectionWithCommercializationMember" abstract="true" name="NetProfitInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LIBTAYONetProductSalesMember" abstract="true" name="LIBTAYONetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneTwoMember" abstract="true" name="SalesMilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramJanuary2023Member" abstract="true" name="ShareRepurchaseProgramJanuary2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_IOLicenseandCollaborationAgreementMember" abstract="true" name="IOLicenseandCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UnrestrictedMember" abstract="true" name="UnrestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" abstract="true" name="OneTimePaymentInConnectionWithChangeInJapanArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_EvkeezaMember" abstract="true" name="EvkeezaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SeniorUnsecuredNotesDue2050Member" abstract="true" name="SeniorUnsecuredNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_NumberOfVotesPerShare" abstract="false" name="NumberOfVotesPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" abstract="false" name="PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_REGENCOVMember" abstract="true" name="REGENCOVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneFiveMember" abstract="true" name="SalesMilestoneFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestonesDomain" abstract="true" name="SalesMilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UpFrontPaymentToCollaboratingParty" abstract="false" name="UpFrontPaymentToCollaboratingParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_LongTermIncentivePlan2014Member" abstract="true" name="LongTermIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CostOfGoodsSoldMember" abstract="true" name="CostOfGoodsSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ReimbursementForManufacturingOfCommercialSuppliesMember" abstract="true" name="ReimbursementForManufacturingOfCommercialSuppliesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborationandContractManufacturingMember" abstract="true" name="CollaborationandContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SeniorUnsecuredNotesDue2030Member" abstract="true" name="SeniorUnsecuredNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="regn_LineOfCreditFacilityIncreaseLimit" abstract="false" name="LineOfCreditFacilityIncreaseLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramJanuary2021Member" abstract="true" name="ShareRepurchaseProgramJanuary2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RebatesAndChargebacksMember" abstract="true" name="RebatesAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestoneEarnedMember" abstract="true" name="SalesBasedMilestoneEarnedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareRepurchaseProgram2019Member" abstract="true" name="ShareRepurchaseProgram2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" abstract="false" name="RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_BesseMedicalMember" abstract="true" name="BesseMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_NumberOfInterPartiesReviewIPRPetitionsFiled" abstract="false" name="NumberOfInterPartiesReviewIPRPetitionsFiled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" abstract="true" name="ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_EyleaNetProductSalesMember" abstract="true" name="EyleaNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>regn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:042488f0-a666-455c-8991-c514440b53f2,g:8bd10ba8-749e-45a5-bb1c-c1abec558824-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15820242-c9f4-45a8-8017-905f2c8c2bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:to="loc_us-gaap_AssetsCurrent_15820242-c9f4-45a8-8017-905f2c8c2bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_ea9eb429-7c4f-4847-9595-d0b5db11028b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_ea9eb429-7c4f-4847-9595-d0b5db11028b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5b0bb65e-c6f3-4b8c-9371-d1899eaee149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5b0bb65e-c6f3-4b8c-9371-d1899eaee149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6ad27302-1a1d-458c-b8ee-0aa632368ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6ad27302-1a1d-458c-b8ee-0aa632368ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fdec8439-3295-4a93-9bd0-be59e07ade0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fdec8439-3295-4a93-9bd0-be59e07ade0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_358b525d-6aef-4988-988c-a874a80dae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_422df947-0fa1-4b6f-9517-bc6a5f0fd45f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_358b525d-6aef-4988-988c-a874a80dae9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3b770dd5-cbed-4ab0-8a51-7b64ea244914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_69dcea18-ebe2-48a1-8582-bff98436ce6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b770dd5-cbed-4ab0-8a51-7b64ea244914" xlink:to="loc_us-gaap_AccountsPayableCurrent_69dcea18-ebe2-48a1-8582-bff98436ce6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_487aff64-1a9d-4213-a4a7-a0d46da15409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b770dd5-cbed-4ab0-8a51-7b64ea244914" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_487aff64-1a9d-4213-a4a7-a0d46da15409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ae67728b-1562-4ebc-b848-2e9ba1dee5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b770dd5-cbed-4ab0-8a51-7b64ea244914" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ae67728b-1562-4ebc-b848-2e9ba1dee5c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d5dd76d9-5060-482a-b5dd-52ccf7f18ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b770dd5-cbed-4ab0-8a51-7b64ea244914" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d5dd76d9-5060-482a-b5dd-52ccf7f18ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c30db625-5a18-4eac-8c32-66a3c711812a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1439dc32-4bcd-4366-a08c-0dd0a9f9fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c30db625-5a18-4eac-8c32-66a3c711812a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1439dc32-4bcd-4366-a08c-0dd0a9f9fb0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_27f6c3c1-ee07-4028-a15c-75ecefc2f3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c30db625-5a18-4eac-8c32-66a3c711812a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_27f6c3c1-ee07-4028-a15c-75ecefc2f3fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_32a08fba-7263-49da-a9ce-98e300125afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c30db625-5a18-4eac-8c32-66a3c711812a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_32a08fba-7263-49da-a9ce-98e300125afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_eabaf521-dc5c-4159-b531-50c0dfaca668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c30db625-5a18-4eac-8c32-66a3c711812a" xlink:to="loc_us-gaap_InventoryNet_eabaf521-dc5c-4159-b531-50c0dfaca668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d6c7d7c-8ff6-41ea-828d-e8adc3ff8b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c30db625-5a18-4eac-8c32-66a3c711812a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d6c7d7c-8ff6-41ea-828d-e8adc3ff8b00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_21c6a6fc-dd4d-46c3-a77e-75c3b4240695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:to="loc_us-gaap_PreferredStockValue_21c6a6fc-dd4d-46c3-a77e-75c3b4240695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bfe95734-ddf0-44f0-a9c0-e46724aa89b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:to="loc_us-gaap_CommonStockValue_bfe95734-ddf0-44f0-a9c0-e46724aa89b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_17f63bd9-affc-4957-8c25-681bb4333ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:to="loc_us-gaap_AdditionalPaidInCapital_17f63bd9-affc-4957-8c25-681bb4333ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_69abd3cf-0436-49f9-bcea-7bf566ffd6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_69abd3cf-0436-49f9-bcea-7bf566ffd6f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_edc29f95-2ba1-4fb3-82c2-3e8d12fe114e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_edc29f95-2ba1-4fb3-82c2-3e8d12fe114e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_86a6f734-4d09-474a-b988-e37e963d5364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0f8d115f-a533-4a32-97a7-5d689eee1252" xlink:to="loc_us-gaap_TreasuryStockCommonValue_86a6f734-4d09-474a-b988-e37e963d5364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ff9c008-31b6-4bbe-b638-70e2e1686cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0521bd8-4a62-43c3-b628-855ca8e5c045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ff9c008-31b6-4bbe-b638-70e2e1686cae" xlink:to="loc_us-gaap_StockholdersEquity_f0521bd8-4a62-43c3-b628-855ca8e5c045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d6ec2d7f-389b-4ab6-935f-e22784798379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ff9c008-31b6-4bbe-b638-70e2e1686cae" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d6ec2d7f-389b-4ab6-935f-e22784798379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6f7c9557-d127-4417-b46c-fec384771329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ff9c008-31b6-4bbe-b638-70e2e1686cae" xlink:to="loc_us-gaap_Liabilities_6f7c9557-d127-4417-b46c-fec384771329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_da298428-9c9d-4738-83b7-d3601cd2086c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_32c7f50f-d57b-438c-8fb7-c16d5ec7ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da298428-9c9d-4738-83b7-d3601cd2086c" xlink:to="loc_us-gaap_LiabilitiesCurrent_32c7f50f-d57b-438c-8fb7-c16d5ec7ddaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6e1d23c6-d7fd-41ce-bc1b-95f863bf4647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da298428-9c9d-4738-83b7-d3601cd2086c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6e1d23c6-d7fd-41ce-bc1b-95f863bf4647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_844bf606-34b6-446a-9614-fcba63c67e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da298428-9c9d-4738-83b7-d3601cd2086c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_844bf606-34b6-446a-9614-fcba63c67e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a2f74940-7038-4e6e-842e-26f8681665b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da298428-9c9d-4738-83b7-d3601cd2086c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a2f74940-7038-4e6e-842e-26f8681665b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c08f3d65-0857-411b-b04f-23ea54f79e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da298428-9c9d-4738-83b7-d3601cd2086c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c08f3d65-0857-411b-b04f-23ea54f79e18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3d713ec9-1da7-4118-a103-9ac9bca8f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1cdef6a5-8269-46af-8fff-2e6c1de01b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3d713ec9-1da7-4118-a103-9ac9bca8f8fb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1cdef6a5-8269-46af-8fff-2e6c1de01b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a31e9b9c-22f7-4cb9-8b30-aad8af492777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3d713ec9-1da7-4118-a103-9ac9bca8f8fb" xlink:to="loc_us-gaap_InterestExpense_a31e9b9c-22f7-4cb9-8b30-aad8af492777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_407f56be-5e55-4b30-a5ba-b2d3ac8349a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_07a3b20a-92e2-4794-a7cf-2035bb955a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_407f56be-5e55-4b30-a5ba-b2d3ac8349a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_07a3b20a-92e2-4794-a7cf-2035bb955a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bce4fe13-d63d-4d0f-911b-489f4d880c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_407f56be-5e55-4b30-a5ba-b2d3ac8349a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bce4fe13-d63d-4d0f-911b-489f4d880c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f232a7d-550f-4aed-b03a-e1a0f3067227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9e074b9-5bfd-4f0e-9a0f-b7523a486705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0f232a7d-550f-4aed-b03a-e1a0f3067227" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9e074b9-5bfd-4f0e-9a0f-b7523a486705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_72cf1b9c-33c6-4049-8b04-d7ec919772bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0f232a7d-550f-4aed-b03a-e1a0f3067227" xlink:to="loc_us-gaap_CostsAndExpenses_72cf1b9c-33c6-4049-8b04-d7ec919772bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_205e0007-b367-4b27-9768-b8c30d6c38f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d10e911c-e1bd-454c-a4ad-dc1cd89309d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_205e0007-b367-4b27-9768-b8c30d6c38f3" xlink:to="loc_us-gaap_NetIncomeLoss_d10e911c-e1bd-454c-a4ad-dc1cd89309d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_64f77c54-afd8-4628-b292-3bba08564fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_205e0007-b367-4b27-9768-b8c30d6c38f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_64f77c54-afd8-4628-b292-3bba08564fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8e399017-a44e-40af-b0eb-b32ad11029ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_205e0007-b367-4b27-9768-b8c30d6c38f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8e399017-a44e-40af-b0eb-b32ad11029ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ecb4566-a296-469d-a11f-7f5ad7f9b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_97080e5a-ae25-4329-924a-f23a7593b85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ecb4566-a296-469d-a11f-7f5ad7f9b4a2" xlink:to="loc_us-gaap_OperatingIncomeLoss_97080e5a-ae25-4329-924a-f23a7593b85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46176bed-c4da-49ed-beb3-7ce60a8f8ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ecb4566-a296-469d-a11f-7f5ad7f9b4a2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46176bed-c4da-49ed-beb3-7ce60a8f8ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_763ea98a-d14a-492a-b4ee-85eea84c2ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_21122f48-8bf2-4c0f-bc2f-343d09bb6a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_763ea98a-d14a-492a-b4ee-85eea84c2ccb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_21122f48-8bf2-4c0f-bc2f-343d09bb6a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f18a37fb-a10e-4192-aa83-5c4ee84c95a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_763ea98a-d14a-492a-b4ee-85eea84c2ccb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f18a37fb-a10e-4192-aa83-5c4ee84c95a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a6204bcf-9eaa-4774-8f75-fe3a162076d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_763ea98a-d14a-492a-b4ee-85eea84c2ccb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a6204bcf-9eaa-4774-8f75-fe3a162076d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_51403aea-e715-40a1-a703-1f0037a4196b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_763ea98a-d14a-492a-b4ee-85eea84c2ccb" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_51403aea-e715-40a1-a703-1f0037a4196b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment_8960e848-66e8-497a-8994-2861945c51bd" xlink:href="regn-20221231.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_763ea98a-d14a-492a-b4ee-85eea84c2ccb" xlink:to="loc_regn_AcquiredInProcessResearchAndDevelopment_8960e848-66e8-497a-8994-2861945c51bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bed3ad61-f89e-425c-a22f-b610f00a6653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39443eec-6889-4b6a-9233-d5785e375f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bed3ad61-f89e-425c-a22f-b610f00a6653" xlink:to="loc_us-gaap_NetIncomeLoss_39443eec-6889-4b6a-9233-d5785e375f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fb891b89-53ff-4cba-9b18-a3e448928324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bed3ad61-f89e-425c-a22f-b610f00a6653" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fb891b89-53ff-4cba-9b18-a3e448928324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ff9707c2-70c2-45c9-a9ba-e71ea4db5d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ff9707c2-70c2-45c9-a9ba-e71ea4db5d26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_47969819-eedd-4387-93cd-ee7ff57042de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_47969819-eedd-4387-93cd-ee7ff57042de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9691ee3b-0dd4-4037-825b-dc633cfbff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9691ee3b-0dd4-4037-825b-dc633cfbff4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9b898438-53ea-4ff6-a206-d6dadc4c8875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9b898438-53ea-4ff6-a206-d6dadc4c8875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_95556696-8593-4d01-9bd2-8127ebab0ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_95556696-8593-4d01-9bd2-8127ebab0ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_4684265c-9c0e-41fa-9680-c4e944c442f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d84c88-40f4-4dca-9281-9b0fa3704f00" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_4684265c-9c0e-41fa-9680-c4e944c442f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4753f8aa-b733-4bfe-bee6-f934fd6285f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8b887f42-1a84-4392-8ac1-94b3e64f1fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4753f8aa-b733-4bfe-bee6-f934fd6285f4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8b887f42-1a84-4392-8ac1-94b3e64f1fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4fa0ff5c-77c7-4a14-b567-850c23d7dd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4753f8aa-b733-4bfe-bee6-f934fd6285f4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4fa0ff5c-77c7-4a14-b567-850c23d7dd33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_333851c0-5688-4055-8bf1-bb49667575ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4753f8aa-b733-4bfe-bee6-f934fd6285f4" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_333851c0-5688-4055-8bf1-bb49667575ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsToAcquireIntangibleAssets1_7926aa4a-78b9-49b4-ad04-700f32e50c1f" xlink:href="regn-20221231.xsd#regn_PaymentsToAcquireIntangibleAssets1"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4753f8aa-b733-4bfe-bee6-f934fd6285f4" xlink:to="loc_regn_PaymentsToAcquireIntangibleAssets1_7926aa4a-78b9-49b4-ad04-700f32e50c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsForAssetAcquisition_de34f45f-2a86-46d4-906d-83ec34ad2835" xlink:href="regn-20221231.xsd#regn_PaymentsForAssetAcquisition"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4753f8aa-b733-4bfe-bee6-f934fd6285f4" xlink:to="loc_regn_PaymentsForAssetAcquisition_de34f45f-2a86-46d4-906d-83ec34ad2835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f03dd16-8f19-4ed3-ba70-d558f0038aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024b839-9760-40aa-a309-8de7ec6964e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f03dd16-8f19-4ed3-ba70-d558f0038aa0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024b839-9760-40aa-a309-8de7ec6964e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_104008f4-e0ec-435a-9721-13c0c38e3c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f03dd16-8f19-4ed3-ba70-d558f0038aa0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_104008f4-e0ec-435a-9721-13c0c38e3c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d626aaaf-50e7-4211-9ec0-63a0df3ea941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f03dd16-8f19-4ed3-ba70-d558f0038aa0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d626aaaf-50e7-4211-9ec0-63a0df3ea941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c0cfc9f7-327c-4bd8-9144-8e9ebc782ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c0cfc9f7-327c-4bd8-9144-8e9ebc782ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4e716c11-da14-4f07-811b-d9b40f084115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_ShareBasedCompensation_4e716c11-da14-4f07-811b-d9b40f084115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableAndOtherSecuritiesGainLoss_8b1ac9c2-d46f-432d-beb6-b33a5b4a1810" xlink:href="regn-20221231.xsd#regn_MarketableAndOtherSecuritiesGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_regn_MarketableAndOtherSecuritiesGainLoss_8b1ac9c2-d46f-432d-beb6-b33a5b4a1810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d9753bd4-a7d9-4d95-8ea6-3c2e8c34133b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d9753bd4-a7d9-4d95-8ea6-3c2e8c34133b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_078f158b-5240-4194-9207-2b69956c910c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_078f158b-5240-4194-9207-2b69956c910c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f9543e77-c91d-4112-b384-785248a35a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f9543e77-c91d-4112-b384-785248a35a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_82d6529b-59e3-4fd8-9f87-1b2fb32382da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_82d6529b-59e3-4fd8-9f87-1b2fb32382da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_391e1bea-2b3c-45b8-9c23-9be51125979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_391e1bea-2b3c-45b8-9c23-9be51125979a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d17079c4-41f5-463c-a565-c0bd25c98fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d17079c4-41f5-463c-a565-c0bd25c98fa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bdfcb25b-cbbc-4fc1-b01f-4066b8594421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bdfcb25b-cbbc-4fc1-b01f-4066b8594421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2a40291e-eeae-452c-aedb-17e0977e3e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ac2ffa2c-610c-43ff-b38f-ef7a663af8d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2a40291e-eeae-452c-aedb-17e0977e3e81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40259859-df18-4743-b1eb-bfc6a42463f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_78d7f404-5a15-4005-b4d2-2fe6d5a41b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40259859-df18-4743-b1eb-bfc6a42463f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_78d7f404-5a15-4005-b4d2-2fe6d5a41b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6675a3e9-e0c9-42ce-b523-ea46d36844cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40259859-df18-4743-b1eb-bfc6a42463f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6675a3e9-e0c9-42ce-b523-ea46d36844cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5dfbde80-b1c5-466a-92b6-50e078c54a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40259859-df18-4743-b1eb-bfc6a42463f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5dfbde80-b1c5-466a-92b6-50e078c54a96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2954563-06d8-4b65-9c3c-2842d9c6db41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_66f398be-9449-4de9-ad39-860be7760e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2954563-06d8-4b65-9c3c-2842d9c6db41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_66f398be-9449-4de9-ad39-860be7760e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8b72104b-0166-4059-8963-cfcc6c31fdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2954563-06d8-4b65-9c3c-2842d9c6db41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8b72104b-0166-4059-8963-cfcc6c31fdd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_091f28fa-5f82-4696-95e6-c8d17ad277bb" xlink:href="regn-20221231.xsd#regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2954563-06d8-4b65-9c3c-2842d9c6db41" xlink:to="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_091f28fa-5f82-4696-95e6-c8d17ad277bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_246b1bf0-e872-424c-8306-b5774b4e6ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ebaa80ee-2ac4-4f4c-bf92-25e2b87a94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_246b1bf0-e872-424c-8306-b5774b4e6ab7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ebaa80ee-2ac4-4f4c-bf92-25e2b87a94d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0204984a-5119-45ce-bcc4-ce50f97c1849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_246b1bf0-e872-424c-8306-b5774b4e6ab7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0204984a-5119-45ce-bcc4-ce50f97c1849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_15a7f4d7-6f35-4ec3-bb57-e286b9f336f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_43131634-7515-4e45-ae91-9bd9521990aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_15a7f4d7-6f35-4ec3-bb57-e286b9f336f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_43131634-7515-4e45-ae91-9bd9521990aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_c9161a7d-afa5-4f44-8b42-e8d7a8e78db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_15a7f4d7-6f35-4ec3-bb57-e286b9f336f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_c9161a7d-afa5-4f44-8b42-e8d7a8e78db5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_401483aa-70f4-483a-a05b-833991ae6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_208a7269-2c25-4a3d-8a29-c3fe43d1f73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_401483aa-70f4-483a-a05b-833991ae6f4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_208a7269-2c25-4a3d-8a29-c3fe43d1f73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_eea7c264-9f00-47d8-9371-20738c873269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_401483aa-70f4-483a-a05b-833991ae6f4b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_eea7c264-9f00-47d8-9371-20738c873269" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2e3ca4ed-35b2-4611-a495-462a50fbb4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_27ebd359-f9b3-4f5e-9f84-880afc71f44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2e3ca4ed-35b2-4611-a495-462a50fbb4d2" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_27ebd359-f9b3-4f5e-9f84-880afc71f44e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1bdd7232-aa20-4785-8001-5907ecbba61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2e3ca4ed-35b2-4611-a495-462a50fbb4d2" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1bdd7232-aa20-4785-8001-5907ecbba61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_533c9ba6-198a-401b-85c9-1b6a8a44c7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2e3ca4ed-35b2-4611-a495-462a50fbb4d2" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_533c9ba6-198a-401b-85c9-1b6a8a44c7c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_9d333a5a-e479-47d4-a26f-ecee31f6017e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2e3ca4ed-35b2-4611-a495-462a50fbb4d2" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_9d333a5a-e479-47d4-a26f-ecee31f6017e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2266b6c7-8f93-4da6-a4fb-01e08f4db59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3a13abed-7fcc-434a-8b13-85a03f971557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2266b6c7-8f93-4da6-a4fb-01e08f4db59c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3a13abed-7fcc-434a-8b13-85a03f971557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1013472c-54c4-4773-a212-56760884c518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2266b6c7-8f93-4da6-a4fb-01e08f4db59c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1013472c-54c4-4773-a212-56760884c518" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_917f8818-9002-417d-b439-5c799571f745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1a467bd3-bf2b-4ce7-af97-6761104e638c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_917f8818-9002-417d-b439-5c799571f745" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1a467bd3-bf2b-4ce7-af97-6761104e638c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_61796b7b-2041-4df1-b433-7e26bf628220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_917f8818-9002-417d-b439-5c799571f745" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_61796b7b-2041-4df1-b433-7e26bf628220" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_caafd715-311c-47ba-9e3c-7745761642b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_caafd715-311c-47ba-9e3c-7745761642b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AccruedClinicalTrialExpenseCurrent_b9730ffc-325f-4139-9462-db4fd273a75f" xlink:href="regn-20221231.xsd#regn_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:to="loc_regn_AccruedClinicalTrialExpenseCurrent_b9730ffc-325f-4139-9462-db4fd273a75f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AccrualForSalesRelatedCostsCurrent_c9a1c7ff-4326-4f9d-987f-9dcde7a06756" xlink:href="regn-20221231.xsd#regn_AccrualForSalesRelatedCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:to="loc_regn_AccrualForSalesRelatedCostsCurrent_c9a1c7ff-4326-4f9d-987f-9dcde7a06756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_21f997d2-dfdd-4106-b375-41ccd7ca902c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:to="loc_us-gaap_TaxesPayableCurrent_21f997d2-dfdd-4106-b375-41ccd7ca902c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeAgreementsObligationsCurrent_c566ae17-09e8-42aa-b852-389741f0ed40" xlink:href="regn-20221231.xsd#regn_CollaborativeAgreementsObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:to="loc_regn_CollaborativeAgreementsObligationsCurrent_c566ae17-09e8-42aa-b852-389741f0ed40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_774c8084-7879-4015-a83a-735ce34e5705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cffd6081-3c48-4a5e-b062-5acb82680eac" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_774c8084-7879-4015-a83a-735ce34e5705" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesFinanceleasecostsDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_regn_FinanceLeaseCost_36794981-baac-41a4-be3d-a7ed071da8c4" xlink:href="regn-20221231.xsd#regn_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b4af6463-4911-4f61-8ebb-7ed6ffdaf730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_regn_FinanceLeaseCost_36794981-baac-41a4-be3d-a7ed071da8c4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b4af6463-4911-4f61-8ebb-7ed6ffdaf730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3dc90ab8-283f-495a-a754-1c302064c53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_regn_FinanceLeaseCost_36794981-baac-41a4-be3d-a7ed071da8c4" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3dc90ab8-283f-495a-a754-1c302064c53d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8da5212b-b08d-47ce-8b69-3a40975de37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5a07d73f-d837-423c-b4ec-bfe5eafff180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8da5212b-b08d-47ce-8b69-3a40975de37a" xlink:to="loc_us-gaap_FinanceLeaseLiability_5a07d73f-d837-423c-b4ec-bfe5eafff180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a51edbef-a8fe-4dc7-8cef-0e960f97b7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8da5212b-b08d-47ce-8b69-3a40975de37a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a51edbef-a8fe-4dc7-8cef-0e960f97b7c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3867a578-6421-476f-90a6-4d74bcec6651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6f05d555-5d14-48f3-9a6c-ac839e5a23da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3867a578-6421-476f-90a6-4d74bcec6651" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6f05d555-5d14-48f3-9a6c-ac839e5a23da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cbba13fb-96c7-44b0-a332-ed7b696c5ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3867a578-6421-476f-90a6-4d74bcec6651" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cbba13fb-96c7-44b0-a332-ed7b696c5ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_158109d3-6971-4239-bff3-25b08f017af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3867a578-6421-476f-90a6-4d74bcec6651" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_158109d3-6971-4239-bff3-25b08f017af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7b101ca3-7534-4554-9bf1-01104c12059a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3867a578-6421-476f-90a6-4d74bcec6651" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7b101ca3-7534-4554-9bf1-01104c12059a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_77bd0ab7-8569-4cdf-938c-9e02ef95584f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3867a578-6421-476f-90a6-4d74bcec6651" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_77bd0ab7-8569-4cdf-938c-9e02ef95584f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofincomebeforeincometaxDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_264456d7-d12a-4604-9def-34223e442a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_46fd52b0-b150-4b04-9014-bf69deeb5e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_264456d7-d12a-4604-9def-34223e442a58" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_46fd52b0-b150-4b04-9014-bf69deeb5e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c9a86e4c-9d3e-4b68-8108-5a38f8e3c4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_264456d7-d12a-4604-9def-34223e442a58" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c9a86e4c-9d3e-4b68-8108-5a38f8e3c4af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_56dac70b-03e2-4fec-abb3-ba3676d33e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_01679a4d-1795-4304-8da0-8a0f82520a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_56dac70b-03e2-4fec-abb3-ba3676d33e4c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_01679a4d-1795-4304-8da0-8a0f82520a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_14388411-38e2-4328-8a0c-3710264de52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_56dac70b-03e2-4fec-abb3-ba3676d33e4c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_14388411-38e2-4328-8a0c-3710264de52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d95d8616-d9a7-475b-8747-990abc32358e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_56dac70b-03e2-4fec-abb3-ba3676d33e4c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d95d8616-d9a7-475b-8747-990abc32358e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c923ff42-9b19-4e79-bc9e-55eec59710a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ca40a56b-a8b6-4a78-9852-2f331851e6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c923ff42-9b19-4e79-bc9e-55eec59710a6" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ca40a56b-a8b6-4a78-9852-2f331851e6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_87bb3ab1-9963-4523-8d31-0bf9cef58577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c923ff42-9b19-4e79-bc9e-55eec59710a6" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_87bb3ab1-9963-4523-8d31-0bf9cef58577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_37b544b6-a44e-4c9b-878f-af7674c71b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c923ff42-9b19-4e79-bc9e-55eec59710a6" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_37b544b6-a44e-4c9b-878f-af7674c71b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e95d0855-062c-48f3-bf3e-6a621dd05d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bfcf8987-46bf-4b43-96f0-c8447336751d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e95d0855-062c-48f3-bf3e-6a621dd05d8a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bfcf8987-46bf-4b43-96f0-c8447336751d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e937725d-fba1-4d91-a9b0-f584539d5378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e95d0855-062c-48f3-bf3e-6a621dd05d8a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e937725d-fba1-4d91-a9b0-f584539d5378" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_41ea537f-335a-4dcb-a01d-0bd0cdeda3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_41ea537f-335a-4dcb-a01d-0bd0cdeda3e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7e156090-8a5a-4e55-bb46-29d981dd3faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7e156090-8a5a-4e55-bb46-29d981dd3faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_990f2e8d-3afa-4993-9418-2e0c4f388398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_990f2e8d-3afa-4993-9418-2e0c4f388398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_56b3c968-5496-4767-8f4b-41d8f966bc26" xlink:href="regn-20221231.xsd#regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_56b3c968-5496-4767-8f4b-41d8f966bc26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bc87b09e-8638-410b-aeb9-4e4190fced19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bc87b09e-8638-410b-aeb9-4e4190fced19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_eeb87aa1-98bb-46d4-8a79-2c651e2d5adc" xlink:href="regn-20221231.xsd#regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_eeb87aa1-98bb-46d4-8a79-2c651e2d5adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_9b765703-9dce-49a4-8202-b84b58fab197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eed2bbeb-945f-45d8-a599-77c641a93ce6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_9b765703-9dce-49a4-8202-b84b58fab197" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4eebc7be-9cdf-491b-9826-aa8eafe8d4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4eebc7be-9cdf-491b-9826-aa8eafe8d4d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f9d4b082-4295-4e14-9373-ce94bee3412d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f9d4b082-4295-4e14-9373-ce94bee3412d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_9a070f00-43e8-4498-a70a-9401c2a13d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_9a070f00-43e8-4498-a70a-9401c2a13d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3754c465-b7cb-424d-a5d4-a080065ae3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3754c465-b7cb-424d-a5d4-a080065ae3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_54578805-20fd-48c1-9581-1cac41d31dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_54578805-20fd-48c1-9581-1cac41d31dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_3a27ee1b-988d-4faa-b600-682dc8f34152" xlink:href="regn-20221231.xsd#regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_3a27ee1b-988d-4faa-b600-682dc8f34152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_491420ef-1128-4165-ac0c-0b65c54f7a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_64151af4-5c26-47db-84b8-2576bc8d4494" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_491420ef-1128-4165-ac0c-0b65c54f7a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9f36d32b-7ef2-450c-b50b-144fb3bbe323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f780ec21-271f-438b-b68c-965d2aa5214b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9f36d32b-7ef2-450c-b50b-144fb3bbe323" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f780ec21-271f-438b-b68c-965d2aa5214b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_41a5c3cf-d831-4f8e-b53d-5f8fcceba5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9f36d32b-7ef2-450c-b50b-144fb3bbe323" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_41a5c3cf-d831-4f8e-b53d-5f8fcceba5aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89852b2c-f80f-4c1e-a60f-86cb1ad89450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe2167a5-6de2-4405-b973-75759d8eaa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89852b2c-f80f-4c1e-a60f-86cb1ad89450" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe2167a5-6de2-4405-b973-75759d8eaa1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a834a45a-3dce-44f5-b76c-cc54f05afe02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89852b2c-f80f-4c1e-a60f-86cb1ad89450" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a834a45a-3dce-44f5-b76c-cc54f05afe02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77cdbbfc-177b-4b22-b995-2359d7660cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6de1b97-cdfe-40eb-86ca-471a189e9aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77cdbbfc-177b-4b22-b995-2359d7660cd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6de1b97-cdfe-40eb-86ca-471a189e9aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b0ae5eb1-636d-4b2b-9ae7-7eece5f92e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77cdbbfc-177b-4b22-b995-2359d7660cd7" xlink:to="loc_us-gaap_RestrictedCash_b0ae5eb1-636d-4b2b-9ae7-7eece5f92e42" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>regn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:042488f0-a666-455c-8991-c514440b53f2,g:8bd10ba8-749e-45a5-bb1c-c1abec558824-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20221231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended" id="i9e3ed50457404fa092f22ba7f347955d_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4ce8e41f-f390-43f0-ae76-71ba99db2640" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentType_4ce8e41f-f390-43f0-ae76-71ba99db2640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b2bf5762-53af-478d-b90c-bc0ad230482d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentAnnualReport_b2bf5762-53af-478d-b90c-bc0ad230482d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bb61f076-58ff-4487-8a00-51944387e4f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentPeriodEndDate_bb61f076-58ff-4487-8a00-51944387e4f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2a88b01-dead-43a0-b4de-54d3eb64b392" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2a88b01-dead-43a0-b4de-54d3eb64b392" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ad8ea68e-d66e-4b7c-bd58-eb7203f4c563" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentTransitionReport_ad8ea68e-d66e-4b7c-bd58-eb7203f4c563" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_12fe7143-bf7a-4c07-8ee9-31ade3ac062f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityFileNumber_12fe7143-bf7a-4c07-8ee9-31ade3ac062f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_41718f28-24fa-4364-940c-6539efdd1baa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityRegistrantName_41718f28-24fa-4364-940c-6539efdd1baa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16f741c5-65a2-4335-bcf2-be38a1731456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16f741c5-65a2-4335-bcf2-be38a1731456" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_38552b0b-0c7e-455a-a2b9-b926f779bf79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityTaxIdentificationNumber_38552b0b-0c7e-455a-a2b9-b926f779bf79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ab27c10f-9da3-4963-941a-ea80ee81cc7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressAddressLine1_ab27c10f-9da3-4963-941a-ea80ee81cc7a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3df256ce-d953-45db-89ce-8d183fee78d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressCityOrTown_3df256ce-d953-45db-89ce-8d183fee78d6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9bd3e8db-9406-40d7-b2ef-b7207b1ac35c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressStateOrProvince_9bd3e8db-9406-40d7-b2ef-b7207b1ac35c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_94894cae-a571-45b6-b09d-254dd08fbb7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressPostalZipCode_94894cae-a571-45b6-b09d-254dd08fbb7a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_35505163-8563-4b25-8b4d-72257e657373" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_CityAreaCode_35505163-8563-4b25-8b4d-72257e657373" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bed64b2f-070b-43f6-b0bc-f30367fd8013" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_LocalPhoneNumber_bed64b2f-070b-43f6-b0bc-f30367fd8013" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0aee7c0a-d0af-4663-a908-104d86c954bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_Security12bTitle_0aee7c0a-d0af-4663-a908-104d86c954bd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_56c8c561-0d11-4dc8-9981-1aa1fd0eee45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_TradingSymbol_56c8c561-0d11-4dc8-9981-1aa1fd0eee45" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_56a4bd7c-c74f-4e9e-899a-2bd0b29c7ff8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_SecurityExchangeName_56a4bd7c-c74f-4e9e-899a-2bd0b29c7ff8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_dc165e46-1e36-4b58-9d01-f83cef19d645" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_dc165e46-1e36-4b58-9d01-f83cef19d645" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c03bae3c-2e14-4187-96e7-126db31f955a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityVoluntaryFilers_c03bae3c-2e14-4187-96e7-126db31f955a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9fbb0459-d921-4777-a514-73cf61107dc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityCurrentReportingStatus_9fbb0459-d921-4777-a514-73cf61107dc9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f2002004-9914-4310-bf9c-40bfb91fedcb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityInteractiveDataCurrent_f2002004-9914-4310-bf9c-40bfb91fedcb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2551d18b-475c-424a-9b04-cda9bc904260" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityFilerCategory_2551d18b-475c-424a-9b04-cda9bc904260" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d1ae7bf0-f32b-42f6-af5b-43fdb888c249" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntitySmallBusiness_d1ae7bf0-f32b-42f6-af5b-43fdb888c249" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_543795d7-1ea1-4261-92d1-dca6d18835de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityEmergingGrowthCompany_543795d7-1ea1-4261-92d1-dca6d18835de" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_eee49781-c6fe-47bf-9da0-2c14dab25cc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_IcfrAuditorAttestationFlag_eee49781-c6fe-47bf-9da0-2c14dab25cc0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f2ba4332-c76d-4d15-85ae-f62f5ee623e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityShellCompany_f2ba4332-c76d-4d15-85ae-f62f5ee623e3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5cd97e95-28fb-41e2-af50-3612ae5ce370" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityPublicFloat_5cd97e95-28fb-41e2-af50-3612ae5ce370" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_508171de-be2b-4dc3-9ac8-329fffc8ac02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_508171de-be2b-4dc3-9ac8-329fffc8ac02" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_31284aa1-27d8-4554-a088-e3234008b8dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_31284aa1-27d8-4554-a088-e3234008b8dc" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bec16d0c-8c8b-4cce-9e0d-a2c14882721a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityCentralIndexKey_bec16d0c-8c8b-4cce-9e0d-a2c14882721a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_496d186d-d6ba-4851-be56-97010e580d83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentFiscalYearFocus_496d186d-d6ba-4851-be56-97010e580d83" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_962c9aee-8bac-4878-9d01-29df08a00d4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentFiscalPeriodFocus_962c9aee-8bac-4878-9d01-29df08a00d4f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7f0f7364-acd0-41c8-9089-d4f462bbdd8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_AmendmentFlag_7f0f7364-acd0-41c8-9089-d4f462bbdd8e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9098828f-fd96-49b0-b187-e45ad26f0011_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:to="loc_us-gaap_ClassOfStockDomain_9098828f-fd96-49b0-b187-e45ad26f0011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:to="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7a152e33-1626-43c1-85a4-fab723e69555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:to="loc_us-gaap_CommonClassAMember_7a152e33-1626-43c1-85a4-fab723e69555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c27b044-5ef5-4a5b-bc8a-e90cdf5b8253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:to="loc_us-gaap_CommonStockMember_1c27b044-5ef5-4a5b-bc8a-e90cdf5b8253" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ie174e1dcdc8b4061ac3a0b78a727b638_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bcb1695-f1b4-407c-ac21-539f29bca3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bcb1695-f1b4-407c-ac21-539f29bca3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_603167ec-0abf-4e6f-9b6b-1b5da516f376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_603167ec-0abf-4e6f-9b6b-1b5da516f376" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3fd9abbc-ad93-4b08-8ae0-70d2ee7f5e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3fd9abbc-ad93-4b08-8ae0-70d2ee7f5e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9435c781-d7ee-48da-9044-6049e1b0e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_InventoryNet_9435c781-d7ee-48da-9044-6049e1b0e6b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dfa1628b-cca7-44fc-b88d-df474fba0249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dfa1628b-cca7-44fc-b88d-df474fba0249" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fb0210bc-cb41-490a-98bc-c3452b83fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_AssetsCurrent_fb0210bc-cb41-490a-98bc-c3452b83fff4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_6d24ee00-e4d6-46fc-a5a8-560ca60181aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_6d24ee00-e4d6-46fc-a5a8-560ca60181aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0c1ef464-72da-4e3c-a706-2172182c0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0c1ef464-72da-4e3c-a706-2172182c0e16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_61a8eb79-d3ff-480d-ae62-d5cf95b38000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_61a8eb79-d3ff-480d-ae62-d5cf95b38000" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_be8232bc-fb55-4170-a65e-12ae23efefd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_be8232bc-fb55-4170-a65e-12ae23efefd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b8e7d019-0e9c-469a-bbf6-b8f34f9d7a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b8e7d019-0e9c-469a-bbf6-b8f34f9d7a03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7c436302-f05a-4cb1-bf40-604b850084aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_Assets_7c436302-f05a-4cb1-bf40-604b850084aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_80d70027-512e-41a1-8aed-93c46751fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_AccountsPayableCurrent_80d70027-512e-41a1-8aed-93c46751fad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8dc9dd4e-b631-44fc-9f84-8a052ab10f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8dc9dd4e-b631-44fc-9f84-8a052ab10f4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f86b0e13-2dfd-4f1a-9b18-c8a4c1d279b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f86b0e13-2dfd-4f1a-9b18-c8a4c1d279b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d9c23634-e4a3-4d51-affe-ce77bb851dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d9c23634-e4a3-4d51-affe-ce77bb851dbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4b52d0bc-9aff-4fd6-be8f-bbb26caefa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_LiabilitiesCurrent_4b52d0bc-9aff-4fd6-be8f-bbb26caefa81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6332985c-0c2d-4088-80f5-c7e65c5d7272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6332985c-0c2d-4088-80f5-c7e65c5d7272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b36231a3-2db6-430f-b96a-b0b78495404b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b36231a3-2db6-430f-b96a-b0b78495404b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d735bbf-d9d2-41ac-99d6-69669a907d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d735bbf-d9d2-41ac-99d6-69669a907d89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_809de64f-502c-4a29-b77f-4ccdc613a462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_809de64f-502c-4a29-b77f-4ccdc613a462" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17a2ca1c-afc1-4714-883f-a4ab92a26285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_Liabilities_17a2ca1c-afc1-4714-883f-a4ab92a26285" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3c38d6f2-e9d3-41e9-90d5-a9ba521fe291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3c38d6f2-e9d3-41e9-90d5-a9ba521fe291" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8102b15a-c43a-4e88-b3dd-b7bc196c9d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_PreferredStockValue_8102b15a-c43a-4e88-b3dd-b7bc196c9d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_38da3968-d447-48a4-96fc-04883291de61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_CommonStockValue_38da3968-d447-48a4-96fc-04883291de61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fc03f5db-de88-4d51-bfd4-a0bf567dfd72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fc03f5db-de88-4d51-bfd4-a0bf567dfd72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d8414d2-ac40-44c6-ad14-6f1f9e977a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d8414d2-ac40-44c6-ad14-6f1f9e977a48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88dedf46-ed20-4f96-a0a2-95c91ac659d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88dedf46-ed20-4f96-a0a2-95c91ac659d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_ff036547-f1d6-4ea5-a224-ed769d5553b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_TreasuryStockCommonValue_ff036547-f1d6-4ea5-a224-ed769d5553b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_16310e0e-4db7-4147-b683-4a778a709a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_StockholdersEquity_16310e0e-4db7-4147-b683-4a778a709a6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b831805-dc86-41f9-90c3-9e9cbd1df47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b831805-dc86-41f9-90c3-9e9cbd1df47c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d26cd0cb-0752-406c-90ee-b7675a8bd8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_CommonStockSharesIssued_d26cd0cb-0752-406c-90ee-b7675a8bd8af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_efd9ecc4-6077-4b38-a50c-ec85bcdc2557_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:to="loc_us-gaap_ClassOfStockDomain_efd9ecc4-6077-4b38-a50c-ec85bcdc2557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:to="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ad41e574-4287-48b3-98e7-268795672b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:to="loc_us-gaap_CommonClassAMember_ad41e574-4287-48b3-98e7-268795672b4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_63d81ca6-2301-4796-aa6b-7add7bb24a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:to="loc_us-gaap_CommonStockMember_63d81ca6-2301-4796-aa6b-7add7bb24a62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i2f41bcb73f604fe4988b6488c6ca6427_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_83795dc6-99f5-4b05-a49d-77efe9200263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83795dc6-99f5-4b05-a49d-77efe9200263" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29b7e18c-5bf6-4cb7-9c3d-01a49e1a6f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29b7e18c-5bf6-4cb7-9c3d-01a49e1a6f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ede38e46-72f9-4465-a1cf-26bd7f741b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ede38e46-72f9-4465-a1cf-26bd7f741b08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_696e9407-f108-4300-b9f4-3d2af3a04555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockSharesIssued_696e9407-f108-4300-b9f4-3d2af3a04555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_210d9820-8801-42de-8ad6-963a779e1db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_210d9820-8801-42de-8ad6-963a779e1db8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7544eaa4-ea21-475c-9840-a2700052d1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7544eaa4-ea21-475c-9840-a2700052d1e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_59d58c6d-9300-4c07-b77e-3cdf9a392ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_59d58c6d-9300-4c07-b77e-3cdf9a392ed6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab253aeb-c9ac-4059-88e4-b9be5122d2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab253aeb-c9ac-4059-88e4-b9be5122d2aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8726fe9a-7b52-40a8-91ec-d79e409d5784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8726fe9a-7b52-40a8-91ec-d79e409d5784" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_77d96427-3385-4488-bf66-bb04b551aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_TreasuryStockCommonShares_77d96427-3385-4488-bf66-bb04b551aa26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_83795dc6-99f5-4b05-a49d-77efe9200263" xlink:to="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f447650-625a-4185-b0f1-6da0fccfcdf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:to="loc_us-gaap_ClassOfStockDomain_5f447650-625a-4185-b0f1-6da0fccfcdf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:to="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c1240c01-ad21-4da3-8647-9f5ba77a1e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:to="loc_us-gaap_CommonClassAMember_c1240c01-ad21-4da3-8647-9f5ba77a1e61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c95e6a0d-08a4-432f-a160-5ae6d8859d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:to="loc_us-gaap_CommonStockMember_c95e6a0d-08a4-432f-a160-5ae6d8859d28" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended" id="i9e86fd57328547728e5af4d0b29e0ec7_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:to="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_72f6c190-1928-48c5-a5de-54dc794bbc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_RevenuesAbstract_72f6c190-1928-48c5-a5de-54dc794bbc16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0dc68fab-8582-4ccf-a116-2d9e3ab2a744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_72f6c190-1928-48c5-a5de-54dc794bbc16" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0dc68fab-8582-4ccf-a116-2d9e3ab2a744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_245a1a81-c31e-4698-8bf8-2b202ac07577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_245a1a81-c31e-4698-8bf8-2b202ac07577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment_d0aa03fc-ec6b-4e26-8916-9fadcaac376f" xlink:href="regn-20221231.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_regn_AcquiredInProcessResearchAndDevelopment_d0aa03fc-ec6b-4e26-8916-9fadcaac376f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d7526698-08c8-4170-a61f-21e51f3e0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d7526698-08c8-4170-a61f-21e51f3e0782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e75a8630-fc89-4ab2-ad26-4ad56ba2fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e75a8630-fc89-4ab2-ad26-4ad56ba2fe70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_faad801e-b757-4bcd-8daf-e80a0ac26283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_faad801e-b757-4bcd-8daf-e80a0ac26283" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8eab9c1d-cc27-41da-ad19-06becdb2780e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_CostsAndExpenses_8eab9c1d-cc27-41da-ad19-06becdb2780e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b48619da-e26d-4980-8926-fc58673256ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_OperatingIncomeLoss_b48619da-e26d-4980-8926-fc58673256ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d377cc97-b64d-4dee-94cb-9db81902cac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d377cc97-b64d-4dee-94cb-9db81902cac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6557481d-5947-469d-97ff-2f747fba1705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:to="loc_us-gaap_InterestExpense_6557481d-5947-469d-97ff-2f747fba1705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d85b1a7c-aaca-41d6-b1d3-1781cbfb8edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d85b1a7c-aaca-41d6-b1d3-1781cbfb8edc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_188785be-e2d4-443a-a602-10555dfb57f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_188785be-e2d4-443a-a602-10555dfb57f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a4e205e9-e377-4aa8-aac4-4bad5e2099bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a4e205e9-e377-4aa8-aac4-4bad5e2099bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e9099d8-8005-4d3e-b5ba-90d7f6824912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_NetIncomeLoss_6e9099d8-8005-4d3e-b5ba-90d7f6824912" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6aa9d188-e211-4f8b-b31d-d85b68976da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_EarningsPerShareBasic_6aa9d188-e211-4f8b-b31d-d85b68976da6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f32a0082-7ba6-4321-ad6c-2ad9f39e08fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f32a0082-7ba6-4321-ad6c-2ad9f39e08fd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_02fcb9b1-1d66-4b9d-807e-9f5c39643430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_02fcb9b1-1d66-4b9d-807e-9f5c39643430" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a7ca2e92-0d86-4887-afcb-864346c35d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a7ca2e92-0d86-4887-afcb-864346c35d8b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_13fc1acd-a321-455a-9da9-df8116be3a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_262fd347-e86b-4c0b-a227-7e768b10aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_262fd347-e86b-4c0b-a227-7e768b10aff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_54ff0374-028c-470c-8650-1c62c7c02824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_54ff0374-028c-470c-8650-1c62c7c02824" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c3aa77ea-6cbf-4199-b5ce-7b17e4e271fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c3aa77ea-6cbf-4199-b5ce-7b17e4e271fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:to="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:to="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fa1fc4e1-babf-42e9-8e5e-45159e43425f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:to="loc_srt_ProductsAndServicesDomain_fa1fc4e1-babf-42e9-8e5e-45159e43425f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:to="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b9673e36-8207-4fd8-9df5-98b53255211c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_us-gaap_ProductMember_b9673e36-8207-4fd8-9df5-98b53255211c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationRevenueMember_c4155da5-9e98-4592-a5c2-329d42847798" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_regn_SanofiCollaborationRevenueMember_c4155da5-9e98-4592-a5c2-329d42847798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_2b1ca793-e3dd-4f98-9366-b0638d32eaf2" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_regn_CollaborationRevenueMember_2b1ca793-e3dd-4f98-9366-b0638d32eaf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3f50b9e2-7f1b-474d-9f15-f1505b2a9422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3f50b9e2-7f1b-474d-9f15-f1505b2a9422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_2228fd70-ce17-43cc-8dab-a4fe16b78056" xlink:href="regn-20221231.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_regn_CollaborationandContractManufacturingMember_2228fd70-ce17-43cc-8dab-a4fe16b78056" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="id2b7f9414f944d0a916bc4cc704dc5dd_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_66ed3cb0-1bc5-4d85-a3d7-710d63bceffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_66ed3cb0-1bc5-4d85-a3d7-710d63bceffc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ddac3711-19c8-4533-923f-c1846e76c18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ddac3711-19c8-4533-923f-c1846e76c18a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_15d6520d-4764-4917-aff7-80ce76dc49da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_TreasuryStockCommonShares_15d6520d-4764-4917-aff7-80ce76dc49da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_341440bf-90e9-4fae-9db3-e0e7ecd31796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockholdersEquity_341440bf-90e9-4fae-9db3-e0e7ecd31796" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_41f6e53a-43b6-4654-bc6d-c45bec785c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_41f6e53a-43b6-4654-bc6d-c45bec785c0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a0d1fa81-bc67-4f6a-a30e-f9b7555cc4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a0d1fa81-bc67-4f6a-a30e-f9b7555cc4aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fcfc7748-12f5-45ff-bea5-3867fd851270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fcfc7748-12f5-45ff-bea5-3867fd851270" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d4b8cbe4-59d9-47d9-8c62-1d3fd73cd19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d4b8cbe4-59d9-47d9-8c62-1d3fd73cd19a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_8c85ee9a-1d53-4ef7-82b3-14c7e3b9afd1" xlink:href="regn-20221231.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_8c85ee9a-1d53-4ef7-82b3-14c7e3b9afd1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_cbe80b5b-7be0-4313-b913-3397333f7c81" xlink:href="regn-20221231.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_cbe80b5b-7be0-4313-b913-3397333f7c81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e12e7487-9eae-4ab2-861d-a35c2f224927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e12e7487-9eae-4ab2-861d-a35c2f224927" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_03cfc803-15cf-4f63-9d17-aea8bdc5d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_03cfc803-15cf-4f63-9d17-aea8bdc5d26d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ecb6e767-24fe-428f-b849-a93b80a1b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ecb6e767-24fe-428f-b849-a93b80a1b01d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25d858b2-a475-48ed-b60a-368c6d894017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_NetIncomeLoss_25d858b2-a475-48ed-b60a-368c6d894017" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0bb6274-bfc5-41b2-b159-68670332cda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0bb6274-bfc5-41b2-b159-68670332cda1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7ff3b5f4-f11f-43f1-92f8-6ebbe7213cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f0377e5e-8383-4942-a52c-dd3a168e50fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b5ce5d93-9da9-4445-86f9-7acfd1081a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_66ed3cb0-1bc5-4d85-a3d7-710d63bceffc" xlink:to="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:to="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_efd8d497-9a43-46ed-b703-ca964ba76202_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:to="loc_us-gaap_ClassOfStockDomain_efd8d497-9a43-46ed-b703-ca964ba76202_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5282461b-577d-48fd-832c-2c15d89285e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:to="loc_us-gaap_ClassOfStockDomain_5282461b-577d-48fd-832c-2c15d89285e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d7e03028-d9bf-483d-a2a8-de91f0d21c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5282461b-577d-48fd-832c-2c15d89285e1" xlink:to="loc_us-gaap_CommonClassAMember_d7e03028-d9bf-483d-a2a8-de91f0d21c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b5bfd67-893e-4c5b-b897-5a2e3709803c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:to="loc_us-gaap_EquityComponentDomain_9b5bfd67-893e-4c5b-b897-5a2e3709803c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:to="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_578c9f97-0e9f-4fe9-803b-eb3052bc2ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_CommonStockMember_578c9f97-0e9f-4fe9-803b-eb3052bc2ef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_887faf56-52df-4968-9765-ed4da57a73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_887faf56-52df-4968-9765-ed4da57a73c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad3ffe3c-43f0-40c8-a9fd-f3b414d28c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_RetainedEarningsMember_ad3ffe3c-43f0-40c8-a9fd-f3b414d28c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02fb529b-6e41-4653-8c68-d64e8bdb5cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02fb529b-6e41-4653-8c68-d64e8bdb5cd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5621a9fe-7c54-4dfc-834b-7402c0064354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5621a9fe-7c54-4dfc-834b-7402c0064354" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i343900b641584894a0102a3fb3a63096_BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_7a37851e-bb6c-430b-9277-dab909130cf8" xlink:href="regn-20221231.xsd#regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_7a37851e-bb6c-430b-9277-dab909130cf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_1a65e15f-6408-43c9-9c22-aad491d9fb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_NumberOfReportableSegments_1a65e15f-6408-43c9-9c22-aad491d9fb8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_69b9b3b5-608b-4192-8ef4-3c4f7ce88e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_69b9b3b5-608b-4192-8ef4-3c4f7ce88e13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b07e5a5c-ba84-4016-885e-ee9d43f6ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b07e5a5c-ba84-4016-885e-ee9d43f6ce6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db1644ae-05bd-4647-af23-464252cb767b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db1644ae-05bd-4647-af23-464252cb767b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_64f1a19b-9d6f-4e29-84db-d795e2dde4a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:to="loc_srt_NameOfMajorCustomerDomain_64f1a19b-9d6f-4e29-84db-d795e2dde4a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:to="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ThreeIndividualCustomersMember_60ecf053-9089-4a15-b415-843ce4c81167" xlink:href="regn-20221231.xsd#regn_ThreeIndividualCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:to="loc_regn_ThreeIndividualCustomersMember_60ecf053-9089-4a15-b415-843ce4c81167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_17ade3be-b067-4a9d-afca-281f3eb82256" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:to="loc_regn_USGovernmentMember_17ade3be-b067-4a9d-afca-281f3eb82256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e524f1ab-ec59-4684-b1dc-d0c787d39d41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e524f1ab-ec59-4684-b1dc-d0c787d39d41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f324d581-dcd0-42f5-9f79-9f1afa6fd0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f324d581-dcd0-42f5-9f79-9f1afa6fd0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_576f410d-2619-4db4-bb55-e6cbdd46b1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f324d581-dcd0-42f5-9f79-9f1afa6fd0a7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_576f410d-2619-4db4-bb55-e6cbdd46b1c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_90016478-34d0-4f05-91cd-eee8482ee144_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_90016478-34d0-4f05-91cd-eee8482ee144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cf12f1a-c8ae-4de5-b87b-c31560d09142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cf12f1a-c8ae-4de5-b87b-c31560d09142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_60c4dd67-390c-40c8-bff4-4aa55e90401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cf12f1a-c8ae-4de5-b87b-c31560d09142" xlink:to="loc_us-gaap_AccountsReceivableMember_60c4dd67-390c-40c8-bff4-4aa55e90401a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" xlink:type="extended" id="ib907a0eef1b24c83a94b1c8a648fd920_BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5a498134-0649-49e3-98e6-e4b231d9ca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_06f146ad-1ec9-4fc8-be05-16dba014f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5a498134-0649-49e3-98e6-e4b231d9ca98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_06f146ad-1ec9-4fc8-be05-16dba014f59e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5a498134-0649-49e3-98e6-e4b231d9ca98" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e09777d8-2088-44eb-8168-b9a15b4adffc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e09777d8-2088-44eb-8168-b9a15b4adffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ebf921a2-d149-49c5-97b3-d03fe91b0130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ebf921a2-d149-49c5-97b3-d03fe91b0130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8c1f8710-3166-4a4a-8b23-69ee842dcb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:to="loc_us-gaap_EquipmentMember_8c1f8710-3166-4a4a-8b23-69ee842dcb1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_01977a76-d416-4673-85a2-7f91225f4e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_01977a76-d416-4673-85a2-7f91225f4e86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:to="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5c8bc4c-98fb-495d-b43a-066bff34cab6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:to="loc_srt_RangeMember_c5c8bc4c-98fb-495d-b43a-066bff34cab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:to="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9bf8fee8-dd67-4249-9fce-f3b818dab720" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:to="loc_srt_MinimumMember_9bf8fee8-dd67-4249-9fce-f3b818dab720" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79699772-97ee-499c-84ed-3cdc9200d93f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:to="loc_srt_MaximumMember_79699772-97ee-499c-84ed-3cdc9200d93f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended" id="i1c04c4699d38424ba59c20cfd2ad0154_ProductSalesScheduleofNetProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_72d9bbdc-182c-4576-87ba-fb42003a7ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b54c8ee-f36d-4e7d-8dd4-ae294a9b7e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_72d9bbdc-182c-4576-87ba-fb42003a7ae5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b54c8ee-f36d-4e7d-8dd4-ae294a9b7e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_72d9bbdc-182c-4576-87ba-fb42003a7ae5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:to="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e054e72d-eb7e-463e-80a7-4d5a4c603a7e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:to="loc_srt_SegmentGeographicalDomain_e054e72d-eb7e-463e-80a7-4d5a4c603a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:to="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_654ebc12-acd5-46d0-bfd0-f9d3e86fd7fb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:to="loc_country_US_654ebc12-acd5-46d0-bfd0-f9d3e86fd7fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember_4d2a2e8a-57ce-44ae-b2ce-8192d0597960" xlink:href="regn-20221231.xsd#regn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:to="loc_regn_RestOfWorldMember_4d2a2e8a-57ce-44ae-b2ce-8192d0597960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:to="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddb430c3-3d13-43d8-84fb-453ce947fe49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:to="loc_srt_ProductsAndServicesDomain_ddb430c3-3d13-43d8-84fb-453ce947fe49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:to="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_34742181-6fc5-4f34-bd85-ffabefe5f760" xlink:href="regn-20221231.xsd#regn_EyleaNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_EyleaNetProductSalesMember_34742181-6fc5-4f34-bd85-ffabefe5f760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_30df8638-7b23-4b1e-b3c2-a2910ada81b0" xlink:href="regn-20221231.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_LIBTAYONetProductSalesMember_30df8638-7b23-4b1e-b3c2-a2910ada81b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_7f137811-aa3a-4da6-964e-4492e00cf81d" xlink:href="regn-20221231.xsd#regn_PraluentNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_PraluentNetProductSalesMember_7f137811-aa3a-4da6-964e-4492e00cf81d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_939f5002-17e6-41b2-ac33-117864037b97" xlink:href="regn-20221231.xsd#regn_REGENCOVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_REGENCOVMember_939f5002-17e6-41b2-ac33-117864037b97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember_1e4cae3a-0042-4abb-b5aa-d488226d4275" xlink:href="regn-20221231.xsd#regn_EvkeezaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_EvkeezaMember_1e4cae3a-0042-4abb-b5aa-d488226d4275" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InmazebMember_a9e0b6be-0fa3-432a-8af3-fda7db824396" xlink:href="regn-20221231.xsd#regn_InmazebMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_InmazebMember_a9e0b6be-0fa3-432a-8af3-fda7db824396" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember_fce7c479-2c77-442d-8741-b5b39b168829" xlink:href="regn-20221231.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_ArcalystNetProductSalesMember_fce7c479-2c77-442d-8741-b5b39b168829" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="extended" id="ifc552a5972c840738af830df1d859773_ProductSalesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4dc0530c-6948-4e61-afb7-83a2c0c0b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_099eb2ac-c147-40fe-9676-446907b67f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4dc0530c-6948-4e61-afb7-83a2c0c0b79e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_099eb2ac-c147-40fe-9676-446907b67f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4dc0530c-6948-4e61-afb7-83a2c0c0b79e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_fdf2362f-d085-40cb-b83e-4674d4cf9f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:to="loc_us-gaap_ReceivableTypeDomain_fdf2362f-d085-40cb-b83e-4674d4cf9f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_2a896e19-c11c-4206-8913-323d42a6b1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:to="loc_us-gaap_ReceivableTypeDomain_2a896e19-c11c-4206-8913-323d42a6b1aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_ed57a958-a4f7-4daa-bbae-7766a4cb9638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_2a896e19-c11c-4206-8913-323d42a6b1aa" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_ed57a958-a4f7-4daa-bbae-7766a4cb9638" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended" id="idec3bf46dbd045c192b0160d29c2998a_ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_931f62a9-0b6a-47c6-acae-750749ecef80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fcf921a2-e421-4a92-b73d-fc0fddd4e5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_931f62a9-0b6a-47c6-acae-750749ecef80" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fcf921a2-e421-4a92-b73d-fc0fddd4e5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_931f62a9-0b6a-47c6-acae-750749ecef80" xlink:to="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f655ba5a-842e-4489-8ae2-69218cfe638e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f655ba5a-842e-4489-8ae2-69218cfe638e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee7f6acb-3735-4c28-a1d5-45d8c9591c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee7f6acb-3735-4c28-a1d5-45d8c9591c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember_92b5ce9d-3a07-414c-a774-bbe2374dd643" xlink:href="regn-20221231.xsd#regn_GrossProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee7f6acb-3735-4c28-a1d5-45d8c9591c7c" xlink:to="loc_regn_GrossProductRevenueMember_92b5ce9d-3a07-414c-a774-bbe2374dd643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c03a1729-ed91-446e-8538-a2207b2df896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c03a1729-ed91-446e-8538-a2207b2df896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_08605bcf-09c7-40a2-b802-1871ef63cd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_08605bcf-09c7-40a2-b802-1871ef63cd69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ba14fc9f-49f5-41bc-850e-2cb185a43b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_08605bcf-09c7-40a2-b802-1871ef63cd69" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ba14fc9f-49f5-41bc-850e-2cb185a43b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:to="loc_srt_NameOfMajorCustomerDomain_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:to="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_d30fa6f9-f4ce-4759-a5b4-11924353e59a" xlink:href="regn-20221231.xsd#regn_BesseMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:to="loc_regn_BesseMedicalMember_d30fa6f9-f4ce-4759-a5b4-11924353e59a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_fe0208a0-ba9d-4eb4-9507-da718f938d43" xlink:href="regn-20221231.xsd#regn_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:to="loc_regn_McKessonCorporationMember_fe0208a0-ba9d-4eb4-9507-da718f938d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_f4422988-43c7-4c11-9814-ca7725661744" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:to="loc_regn_USGovernmentMember_f4422988-43c7-4c11-9814-ca7725661744" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails" xlink:type="extended" id="ib8af88e6975a44dfb6a7ffaa28be6f3b_ProductSalesScheduleofSalesRelatedDeductionsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_48c763e4-e4bf-4c1f-a72d-58ced7aee4ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_48c763e4-e4bf-4c1f-a72d-58ced7aee4ee" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0c8a8079-c7d6-4273-8c13-7bd0ca171ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0c8a8079-c7d6-4273-8c13-7bd0ca171ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_bfb62fda-884c-41d4-a8ad-c367de6d6935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_bfb62fda-884c-41d4-a8ad-c367de6d6935" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_43d0e414-23c2-48c9-8fea-1c52364546e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_43d0e414-23c2-48c9-8fea-1c52364546e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5bc7638e-bae6-40d5-858d-6280556cfa82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_48c763e4-e4bf-4c1f-a72d-58ced7aee4ee" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ead1fb50-06d5-4cf6-b195-45f0b43df59e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ead1fb50-06d5-4cf6-b195-45f0b43df59e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RebatesAndChargebacksMember_b5e8a5a0-e7ff-4dc1-9f66-3e2e1a7ea3b6" xlink:href="regn-20221231.xsd#regn_RebatesAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:to="loc_regn_RebatesAndChargebacksMember_b5e8a5a0-e7ff-4dc1-9f66-3e2e1a7ea3b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DistributionRelatedFeesMember_355f735c-ebda-433f-bb28-707474482cb5" xlink:href="regn-20221231.xsd#regn_DistributionRelatedFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:to="loc_regn_DistributionRelatedFeesMember_355f735c-ebda-433f-bb28-707474482cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherSalesRelatedDeductionsMember_e132d833-006b-4c57-b3e3-e3cd5f4db82e" xlink:href="regn-20221231.xsd#regn_OtherSalesRelatedDeductionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:to="loc_regn_OtherSalesRelatedDeductionsMember_e132d833-006b-4c57-b3e3-e3cd5f4db82e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails" xlink:type="extended" id="i77cf798ec70f4de4b4e72849c217fa0a_CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_239624b4-0388-455b-bbaf-ac771db0097d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6677bcca-1395-4743-951a-1899a177dbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_239624b4-0388-455b-bbaf-ac771db0097d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6677bcca-1395-4743-951a-1899a177dbda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_239624b4-0388-455b-bbaf-ac771db0097d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:to="loc_us-gaap_ProjectMember_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:to="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_831d26a8-7e0b-4fd8-8b06-8dc32cd9f753" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_831d26a8-7e0b-4fd8-8b06-8dc32cd9f753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_aba065f1-cc44-48c0-b70f-7dc6b0f1795a" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_aba065f1-cc44-48c0-b70f-7dc6b0f1795a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_41082898-aef3-4c3f-9e39-341d539209cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_41082898-aef3-4c3f-9e39-341d539209cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_ac2444a0-9ec7-47b4-babd-c885d28d664a" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_regn_CollaborationRevenueMember_ac2444a0-9ec7-47b4-babd-c885d28d664a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ee602985-8afd-4f98-b84d-e61d38f66fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ee602985-8afd-4f98-b84d-e61d38f66fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_301bbf27-3445-4a98-acf6-671438186bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_301bbf27-3445-4a98-acf6-671438186bd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_7ffde1e9-b6df-4def-a56f-d82236478cbd" xlink:href="regn-20221231.xsd#regn_CostOfGoodsSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_regn_CostOfGoodsSoldMember_7ffde1e9-b6df-4def-a56f-d82236478cbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_ce882854-f11f-4070-8e17-462f1be60f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_ce882854-f11f-4070-8e17-462f1be60f6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:to="loc_srt_ProductsAndServicesDomain_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:to="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_261f4b47-5ec6-4f82-822b-ed5d77ccd14d" xlink:href="regn-20221231.xsd#regn_ShareOfProfitsLossesInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_261f4b47-5ec6-4f82-822b-ed5d77ccd14d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember_c66d569f-ac33-44f4-bf32-885991ce3392" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_SalesBasedMilestoneEarnedMember_c66d569f-ac33-44f4-bf32-885991ce3392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_380e43e7-ae71-4729-b7ad-aa958f10377f" xlink:href="regn-20221231.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_380e43e7-ae71-4729-b7ad-aa958f10377f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember_555a3b8b-f222-4f3e-922c-45605a2ba7c2" xlink:href="regn-20221231.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_OtherCollaborationAgreementsMember_555a3b8b-f222-4f3e-922c-45605a2ba7c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_682ba8ec-f638-4744-af41-179196e48cc1" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_682ba8ec-f638-4744-af41-179196e48cc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_3387ead9-e7db-4098-9f0e-17bf5bb2d2d8" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_3387ead9-e7db-4098-9f0e-17bf5bb2d2d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_1065cd86-6f71-48c4-9c7a-443d2e818355" xlink:href="regn-20221231.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_1065cd86-6f71-48c4-9c7a-443d2e818355" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember_a700dfea-d58e-45b7-8861-e2f408ff03ad" xlink:href="regn-20221231.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_RegeneronsShareOfCommercialExpensesMember_a700dfea-d58e-45b7-8861-e2f408ff03ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareOfLibtayoUSGrossProfitsMember_d9ba4c4b-fbcd-41aa-ae37-3cb4229ff59b" xlink:href="regn-20221231.xsd#regn_SanofisShareOfLibtayoUSGrossProfitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_SanofisShareOfLibtayoUSGrossProfitsMember_d9ba4c4b-fbcd-41aa-ae37-3cb4229ff59b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_b1bc170c-c147-4fb7-ab14-f075edf5e9a5" xlink:href="regn-20221231.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_b1bc170c-c147-4fb7-ab14-f075edf5e9a5" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended" id="i10e54a73bf054d27a34aed97f33d31fa_CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentToCollaboratingParty_bf411b32-d625-4f08-b54e-7c5efd3a7b14" xlink:href="regn-20221231.xsd#regn_PaymentToCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PaymentToCollaboratingParty_bf411b32-d625-4f08-b54e-7c5efd3a7b14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_8c04ee52-61f3-41b6-9f79-ff54a8240634" xlink:href="regn-20221231.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_8c04ee52-61f3-41b6-9f79-ff54a8240634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_98fbe3b0-9fe7-475b-89a2-9c3781e314db" xlink:href="regn-20221231.xsd#regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_98fbe3b0-9fe7-475b-89a2-9c3781e314db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_67bb9988-a8bc-4dbd-b313-9b0ed6f026b7" xlink:href="regn-20221231.xsd#regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_67bb9988-a8bc-4dbd-b313-9b0ed6f026b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContingentReimbursementObligation_c674b3de-4163-47c4-bad0-ae35fd5de504" xlink:href="regn-20221231.xsd#regn_ContingentReimbursementObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_ContingentReimbursementObligation_c674b3de-4163-47c4-bad0-ae35fd5de504" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_9e2f8aa9-22e0-4e8f-b477-ce23131c98b5" xlink:href="regn-20221231.xsd#regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_9e2f8aa9-22e0-4e8f-b477-ce23131c98b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_f8f2832e-95ba-4a40-af0e-cb9a1af3daec" xlink:href="regn-20221231.xsd#regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_f8f2832e-95ba-4a40-af0e-cb9a1af3daec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_99b957ba-c4ed-4f43-bc34-02a199cd0dfa" xlink:href="regn-20221231.xsd#regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_99b957ba-c4ed-4f43-bc34-02a199cd0dfa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_5384869f-b584-4f5a-9dec-aa1cdf374088" xlink:href="regn-20221231.xsd#regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_5384869f-b584-4f5a-9dec-aa1cdf374088" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_14d8e5e0-e68e-41a8-92c9-ad52e251f375" xlink:href="regn-20221231.xsd#regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_14d8e5e0-e68e-41a8-92c9-ad52e251f375" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfLossesOutsideUnitedStatesForCompany_e149d468-cd57-4d05-83eb-86b2b6fdb9bb" xlink:href="regn-20221231.xsd#regn_ShareOfLossesOutsideUnitedStatesForCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_ShareOfLossesOutsideUnitedStatesForCompany_e149d468-cd57-4d05-83eb-86b2b6fdb9bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f95730b6-9b0d-4d58-8b01-52d39637e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f95730b6-9b0d-4d58-8b01-52d39637e59d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_2a80aa94-2b90-43e0-a4e0-4a951698c192" xlink:href="regn-20221231.xsd#regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_2a80aa94-2b90-43e0-a4e0-4a951698c192" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_6f61597a-91bf-4c5f-a0b2-f9e32af857d3" xlink:href="regn-20221231.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_6f61597a-91bf-4c5f-a0b2-f9e32af857d3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d46d41a4-55dc-4dbf-b229-ba43313095f1" xlink:href="regn-20221231.xsd#regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d46d41a4-55dc-4dbf-b229-ba43313095f1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_d51473ce-f32d-4ed8-8edb-3acaddccf7ec" xlink:href="regn-20221231.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_d51473ce-f32d-4ed8-8edb-3acaddccf7ec" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_53a39b7c-44af-448b-9715-f6da76c07ad5" xlink:href="regn-20221231.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_53a39b7c-44af-448b-9715-f6da76c07ad5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_7e95e24c-1523-4580-9d6b-432b62950ec8" xlink:href="regn-20221231.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_7e95e24c-1523-4580-9d6b-432b62950ec8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0bdc09bb-feff-464e-a02f-c5e51dbbd797_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:to="loc_us-gaap_ProjectMember_0bdc09bb-feff-464e-a02f-c5e51dbbd797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:to="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_af159935-3812-4ce2-bf17-8b70665d0f20" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_af159935-3812-4ce2-bf17-8b70665d0f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_55cb5e8c-ce7a-4131-bbc5-717a54577c63" xlink:href="regn-20221231.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_55cb5e8c-ce7a-4131-bbc5-717a54577c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96b48499-0088-40f0-aa44-d5f1bf81eedc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:to="loc_srt_RangeMember_96b48499-0088-40f0-aa44-d5f1bf81eedc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:to="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6b5c349-a52f-45ad-b1ad-84e7dc48fefa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:to="loc_srt_MinimumMember_b6b5c349-a52f-45ad-b1ad-84e7dc48fefa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f69bd91-66a2-40f4-8326-3ea2332cc8af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:to="loc_srt_MaximumMember_8f69bd91-66a2-40f4-8326-3ea2332cc8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:href="regn-20221231.xsd#regn_SalesMilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_0a339d04-c254-4cc2-b705-6ed01d95aa4c_default" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:to="loc_regn_SalesMilestonesDomain_0a339d04-c254-4cc2-b705-6ed01d95aa4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:to="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneOneMember_27a2c0d7-3b47-490b-be3a-8caad519e7a1" xlink:href="regn-20221231.xsd#regn_SalesMilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneOneMember_27a2c0d7-3b47-490b-be3a-8caad519e7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneTwoMember_06e26fe6-be29-4832-93be-9fb32aa1f090" xlink:href="regn-20221231.xsd#regn_SalesMilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneTwoMember_06e26fe6-be29-4832-93be-9fb32aa1f090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneThreeMember_f2d91d04-4a48-4180-86ac-5584d31dffd3" xlink:href="regn-20221231.xsd#regn_SalesMilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneThreeMember_f2d91d04-4a48-4180-86ac-5584d31dffd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFourMember_c017175c-a7b1-4a22-bb56-b01679d2a23c" xlink:href="regn-20221231.xsd#regn_SalesMilestoneFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneFourMember_c017175c-a7b1-4a22-bb56-b01679d2a23c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFiveMember_72f03d5d-df3f-4eff-b1bc-8a098b8f7dab" xlink:href="regn-20221231.xsd#regn_SalesMilestoneFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneFiveMember_72f03d5d-df3f-4eff-b1bc-8a098b8f7dab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_682bdf9c-ee09-4efd-a273-c48e1b1e4698_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:to="loc_dei_EntityDomain_682bdf9c-ee09-4efd-a273-c48e1b1e4698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9cafdf8a-b681-4978-b456-d96f29095863" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:to="loc_dei_EntityDomain_9cafdf8a-b681-4978-b456-d96f29095863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_a738ac34-84c2-406b-9408-caa6abdde37e" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9cafdf8a-b681-4978-b456-d96f29095863" xlink:to="loc_regn_SanofiMember_a738ac34-84c2-406b-9408-caa6abdde37e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails" xlink:type="extended" id="i35243c5841aa460fa9593f6bdaf5e202_CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ba9a106e-5058-48c9-828f-d0ef94b31690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ba9a106e-5058-48c9-828f-d0ef94b31690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b102110a-929d-4dbb-b43d-058325421d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b102110a-929d-4dbb-b43d-058325421d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_87f8ed58-f8c7-4189-92da-a654a65ab395_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:to="loc_us-gaap_ProjectMember_87f8ed58-f8c7-4189-92da-a654a65ab395_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_28914e80-f34b-41a2-8c5f-c0a5432135c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:to="loc_us-gaap_ProjectMember_28914e80-f34b-41a2-8c5f-c0a5432135c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_9aec6d5f-591f-4bce-a784-7f59a9625f09" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_28914e80-f34b-41a2-8c5f-c0a5432135c4" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_9aec6d5f-591f-4bce-a784-7f59a9625f09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended" id="i7ee477d54e994a93a1d96a76a1dff008_CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_d1a651c0-6db2-40b6-b244-1e8d69cecc06" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_d1a651c0-6db2-40b6-b244-1e8d69cecc06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentReceived_dbf2e4d5-bb45-40d5-b6f6-b86a29fe16d0" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_regn_UpFrontPaymentReceived_dbf2e4d5-bb45-40d5-b6f6-b86a29fe16d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d768e0ad-89e5-461f-9680-cb4bc6c60595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d768e0ad-89e5-461f-9680-cb4bc6c60595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_12b0c156-b894-4e24-a7b7-4dc21caf2a2f" xlink:href="regn-20221231.xsd#regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_12b0c156-b894-4e24-a7b7-4dc21caf2a2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_a66e63c5-070d-48d2-94c0-07125d08c653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_OtherLiabilities_a66e63c5-070d-48d2-94c0-07125d08c653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_dbffa3d5-e193-4b06-be52-6827c793ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_dbffa3d5-e193-4b06-be52-6827c793ccac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f2e694a8-c007-4ef1-a4b2-ed01356e04a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f2e694a8-c007-4ef1-a4b2-ed01356e04a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9059e93c-cb53-496b-8de0-c87abdfbd778_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:to="loc_us-gaap_ProjectMember_9059e93c-cb53-496b-8de0-c87abdfbd778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:to="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_4944f4dd-7de0-40cd-a7ba-443544505884" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_4944f4dd-7de0-40cd-a7ba-443544505884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c57e23f5-e161-4136-b24d-57d384a97876" xlink:href="regn-20221231.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c57e23f5-e161-4136-b24d-57d384a97876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_325dfc89-f656-4743-bd23-35434e4c2986" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:to="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_325dfc89-f656-4743-bd23-35434e4c2986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_13353087-caf3-4ddd-bd7f-0d7d21aa5192_default" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:to="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_13353087-caf3-4ddd-bd7f-0d7d21aa5192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:to="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IOLicenseandCollaborationAgreementMember_c4ee04c7-629b-426f-8a90-2749c8c90f13" xlink:href="regn-20221231.xsd#regn_IOLicenseandCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:to="loc_regn_IOLicenseandCollaborationAgreementMember_c4ee04c7-629b-426f-8a90-2749c8c90f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmendedIODiscoveryAgreementMember_67f37248-c2e6-44ba-9a1d-8a54e490df13" xlink:href="regn-20221231.xsd#regn_AmendedIODiscoveryAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:to="loc_regn_AmendedIODiscoveryAgreementMember_67f37248-c2e6-44ba-9a1d-8a54e490df13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7aeec63e-0be1-4e09-8e21-f93bb40b88f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7aeec63e-0be1-4e09-8e21-f93bb40b88f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_ede259ae-9f39-4c93-a341-3651a43ba37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7aeec63e-0be1-4e09-8e21-f93bb40b88f7" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_ede259ae-9f39-4c93-a341-3651a43ba37f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bedb7f52-6052-4d7f-94bd-db8d83dfc644_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bedb7f52-6052-4d7f-94bd-db8d83dfc644_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fe564a9-0615-4f30-8e71-0410fc3f7da4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fe564a9-0615-4f30-8e71-0410fc3f7da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_a7353bf0-0106-4ff0-96d8-9bbf4082eafe" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fe564a9-0615-4f30-8e71-0410fc3f7da4" xlink:to="loc_regn_SanofiMember_a7353bf0-0106-4ff0-96d8-9bbf4082eafe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:href="regn-20221231.xsd#regn_SalesMilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_592014a4-7a4d-481f-8145-3350e48a6abb_default" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:to="loc_regn_SalesMilestonesDomain_592014a4-7a4d-481f-8145-3350e48a6abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:to="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegulatoryMilestoneMember_41831987-6da0-4c60-8900-ab8ab2f1f74f" xlink:href="regn-20221231.xsd#regn_RegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_RegulatoryMilestoneMember_41831987-6da0-4c60-8900-ab8ab2f1f74f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneOneMember_77d6237a-a791-4a8f-ac46-5c8c3cd5c979" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_SalesBasedMilestoneOneMember_77d6237a-a791-4a8f-ac46-5c8c3cd5c979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneTwoMember_85409fc3-628b-4725-9c37-9a211bf4c096" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_SalesBasedMilestoneTwoMember_85409fc3-628b-4725-9c37-9a211bf4c096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AggregateSalesBasedMilestoneMember_cb1bb613-ebd9-4752-a17f-85b86841ff4d" xlink:href="regn-20221231.xsd#regn_AggregateSalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_AggregateSalesBasedMilestoneMember_cb1bb613-ebd9-4752-a17f-85b86841ff4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_73bff05c-2e5c-4737-a09f-1871fa4c5f53_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:to="loc_dei_EntityDomain_73bff05c-2e5c-4737-a09f-1871fa4c5f53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b971be2a-ded9-40c3-8049-cf5a639755ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:to="loc_dei_EntityDomain_b971be2a-ded9-40c3-8049-cf5a639755ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_3de0c5fa-11d4-43fb-ab51-e7da56556199" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b971be2a-ded9-40c3-8049-cf5a639755ac" xlink:to="loc_regn_SanofiMember_3de0c5fa-11d4-43fb-ab51-e7da56556199" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails" xlink:type="extended" id="ibc95f623b1c44fbebf818a0572295f00_CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_24c66de8-5f36-4a21-94a3-f2d5778ae527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_24c66de8-5f36-4a21-94a3-f2d5778ae527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_baa83f17-157d-4512-b560-fffca250d25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_baa83f17-157d-4512-b560-fffca250d25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_d3c7eb15-030e-409f-81d6-c299ac7eeac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_OtherLiabilities_d3c7eb15-030e-409f-81d6-c299ac7eeac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1142ed2f-8641-4bed-adad-b18ee61930fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:to="loc_us-gaap_ProjectMember_1142ed2f-8641-4bed-adad-b18ee61930fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a85f471d-681f-4baa-ba5c-617f4c6dcdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:to="loc_us-gaap_ProjectMember_a85f471d-681f-4baa-ba5c-617f4c6dcdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_d50d73de-ac3b-4e0d-bca4-4d3e553012d3" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_a85f471d-681f-4baa-ba5c-617f4c6dcdee" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_d50d73de-ac3b-4e0d-bca4-4d3e553012d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended" id="i2608cf134275482cb12901d3990ab618_CollaborationLicenseandOtherAgreementsBayerNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_508a0c38-5f2c-44e8-a4a1-910a212eefcd" xlink:href="regn-20221231.xsd#regn_RevenueBasedOnPercentageOfAnnualSalesInJapan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_508a0c38-5f2c-44e8-a4a1-910a212eefcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_24937769-7888-4b46-8fa1-d218f6dc406a" xlink:href="regn-20221231.xsd#regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_24937769-7888-4b46-8fa1-d218f6dc406a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContingentReimbursementObligation_10dcb71d-3de1-4f96-8bab-55fdbcf45ec3" xlink:href="regn-20221231.xsd#regn_ContingentReimbursementObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_regn_ContingentReimbursementObligation_10dcb71d-3de1-4f96-8bab-55fdbcf45ec3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fe92340a-8c6b-4d80-9eb3-4f169053f95e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:to="loc_us-gaap_ProjectMember_fe92340a-8c6b-4d80-9eb3-4f169053f95e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_71490166-015b-4d5f-b72d-aadc40879615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:to="loc_us-gaap_ProjectMember_71490166-015b-4d5f-b72d-aadc40879615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_9d8c2a8f-7ca7-43e7-9cc3-3ed0f52f8039" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_71490166-015b-4d5f-b72d-aadc40879615" xlink:to="loc_regn_BayerCollaborationAgreementMember_9d8c2a8f-7ca7-43e7-9cc3-3ed0f52f8039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:to="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea7021b7-9776-433d-8d5d-5c7106176130_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:to="loc_srt_RangeMember_ea7021b7-9776-433d-8d5d-5c7106176130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:to="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7db5d5d-634a-474e-8b25-860b6010d1c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:to="loc_srt_MinimumMember_e7db5d5d-634a-474e-8b25-860b6010d1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff66dc9c-2e94-4d5f-8738-47d182967f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:to="loc_srt_MaximumMember_ff66dc9c-2e94-4d5f-8738-47d182967f3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails" xlink:type="extended" id="id7b0d9fdafa541a28f45d962d9d2cd21_CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0fac2d80-05b9-48d1-abac-d6af9557723c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_365ea153-8acf-4f4a-a6b6-827df8202d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0fac2d80-05b9-48d1-abac-d6af9557723c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_365ea153-8acf-4f4a-a6b6-827df8202d81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0fac2d80-05b9-48d1-abac-d6af9557723c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dbe65905-cf36-4e58-94ae-c8ed685368a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:to="loc_srt_SegmentGeographicalDomain_dbe65905-cf36-4e58-94ae-c8ed685368a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_490792a0-32d3-4317-90fa-484558f9c54d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:to="loc_srt_SegmentGeographicalDomain_490792a0-32d3-4317-90fa-484558f9c54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_278be6e8-87fd-4dd8-ad16-2c01b7d9bd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_490792a0-32d3-4317-90fa-484558f9c54d" xlink:to="loc_us-gaap_NonUsMember_278be6e8-87fd-4dd8-ad16-2c01b7d9bd1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7a9ee12e-55c4-47de-8038-dd6fadb1c53f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:to="loc_us-gaap_ProjectMember_7a9ee12e-55c4-47de-8038-dd6fadb1c53f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_14604233-ab5c-48d4-a56b-4705ecd56391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:to="loc_us-gaap_ProjectMember_14604233-ab5c-48d4-a56b-4705ecd56391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_39232e4b-67cb-4d82-811f-cb692b72e5e8" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_14604233-ab5c-48d4-a56b-4705ecd56391" xlink:to="loc_regn_BayerCollaborationAgreementMember_39232e4b-67cb-4d82-811f-cb692b72e5e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_65c43334-768d-46ce-9684-325c50685895_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_65c43334-768d-46ce-9684-325c50685895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_38678b6b-7961-4830-a1bc-057829cc7bac" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:to="loc_regn_CollaborationRevenueMember_38678b6b-7961-4830-a1bc-057829cc7bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_abb31769-d352-4b01-896e-2e83df5dd2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_abb31769-d352-4b01-896e-2e83df5dd2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40a84975-3f2d-4646-b609-2cb5a327a6b5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:to="loc_srt_ProductsAndServicesDomain_40a84975-3f2d-4646-b609-2cb5a327a6b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:to="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_3fb0ed36-ebbe-4248-92d2-05089f59e755" xlink:href="regn-20221231.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_3fb0ed36-ebbe-4248-92d2-05089f59e755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_2ca08577-0e97-4146-a1f3-4fccbd83db66" xlink:href="regn-20221231.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_2ca08577-0e97-4146-a1f3-4fccbd83db66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_9360b595-9657-4ff7-913f-19e8cf453449" xlink:href="regn-20221231.xsd#regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_9360b595-9657-4ff7-913f-19e8cf453449" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_5d918605-b1d5-4d2c-ae92-d90274a3d9cf" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_5d918605-b1d5-4d2c-ae92-d90274a3d9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e255f5e6-7d6e-4505-bbae-4537ad667f04" xlink:href="regn-20221231.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e255f5e6-7d6e-4505-bbae-4537ad667f04" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails" xlink:type="extended" id="if4306c78c20b4a6496b9348471ec7570_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f8830197-5572-4ad0-b047-b0721027f12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f8830197-5572-4ad0-b047-b0721027f12c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f2fa8393-03fe-4d65-9fd1-f10abcfd409e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f2fa8393-03fe-4d65-9fd1-f10abcfd409e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:to="loc_us-gaap_ProjectMember_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3edb1ff3-8227-403b-b257-9d18aa4c914c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:to="loc_us-gaap_ProjectMember_3edb1ff3-8227-403b-b257-9d18aa4c914c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_79ec7e53-7549-4898-b8b9-4228461ace9e" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_3edb1ff3-8227-403b-b257-9d18aa4c914c" xlink:to="loc_regn_BayerCollaborationAgreementMember_79ec7e53-7549-4898-b8b9-4228461ace9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended" id="i5bf500c4050e4b29bcce6bc76d1b6b05_CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade_08d2227a-9bd3-4532-b5a2-4c9c06cb83ad" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_regn_CollaborativeArrangementUpfrontPaymentMade_08d2227a-9bd3-4532-b5a2-4c9c06cb83ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_737b8c6e-31a9-48c9-9c8e-e55186b90575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_737b8c6e-31a9-48c9-9c8e-e55186b90575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b7299c81-9e13-4d4f-828b-63a7d45b1b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b7299c81-9e13-4d4f-828b-63a7d45b1b98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_91ee9016-a493-421f-abc5-280b26669438_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:to="loc_us-gaap_ProjectMember_91ee9016-a493-421f-abc5-280b26669438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:to="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaCollaborationAgreementMember_ba81832d-29b0-410a-b0d1-66d2e8c45af4" xlink:href="regn-20221231.xsd#regn_IntelliaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:to="loc_regn_IntelliaCollaborationAgreementMember_ba81832d-29b0-410a-b0d1-66d2e8c45af4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ce3ebab9-55ec-4d16-a365-ea366c4fbef5" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:to="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ce3ebab9-55ec-4d16-a365-ea366c4fbef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:to="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b7707f62-ea07-40d7-89d5-e610fe2bd586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b7707f62-ea07-40d7-89d5-e610fe2bd586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_06054d56-56ce-401d-95c8-e72d262e302d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b7707f62-ea07-40d7-89d5-e610fe2bd586" xlink:to="loc_us-gaap_CommonStockMember_06054d56-56ce-401d-95c8-e72d262e302d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="extended" id="i611d1c4d869e43e4b48e96fd6c537590_CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments_5424dfb1-6143-402f-937b-2e7a1732051a" xlink:href="regn-20221231.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_regn_MaximumTransactionAgreementPayments_5424dfb1-6143-402f-937b-2e7a1732051a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_8ee89af5-6e42-402e-85fb-269b8b9986cc" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_8ee89af5-6e42-402e-85fb-269b8b9986cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aca39b34-bce4-45e8-91a0-25346eaa47dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aca39b34-bce4-45e8-91a0-25346eaa47dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9809a1a-5c32-460b-a888-6aca8701ef2a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9809a1a-5c32-460b-a888-6aca8701ef2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c7a4da-bd81-4bf6-b9b5-ea342cd7deb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c7a4da-bd81-4bf6-b9b5-ea342cd7deb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_f9506f54-39e5-4f6a-beeb-d7348e29fb71" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c7a4da-bd81-4bf6-b9b5-ea342cd7deb2" xlink:to="loc_regn_USGovernmentMember_f9506f54-39e5-4f6a-beeb-d7348e29fb71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c936acd-47eb-4b31-9964-c4ddf657d60f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:to="loc_srt_ProductsAndServicesDomain_3c936acd-47eb-4b31-9964-c4ddf657d60f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ebc6285-39ef-4b66-b2bc-77929f922865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:to="loc_srt_ProductsAndServicesDomain_6ebc6285-39ef-4b66-b2bc-77929f922865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_fc550c52-d47a-44cf-9538-3fc415f03b75" xlink:href="regn-20221231.xsd#regn_REGENCOVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ebc6285-39ef-4b66-b2bc-77929f922865" xlink:to="loc_regn_REGENCOVMember_fc550c52-d47a-44cf-9538-3fc415f03b75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:to="loc_us-gaap_ProjectMember_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_94d421e8-f22a-4c86-a0db-15d231c1bcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:to="loc_us-gaap_ProjectMember_94d421e8-f22a-4c86-a0db-15d231c1bcc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember_3414ca85-fae3-4b0e-8930-c9ef068f42b8" xlink:href="regn-20221231.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_94d421e8-f22a-4c86-a0db-15d231c1bcc6" xlink:to="loc_regn_BARDAOtherTransactionAgreementMember_3414ca85-fae3-4b0e-8930-c9ef068f42b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="extended" id="i371a0e8c01e24cbe98ce6e474f25777d_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0c0c6fff-c598-4876-95e1-44eecf7e05f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f7b10df-50aa-41d3-b0e0-3430ac43b215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c0c6fff-c598-4876-95e1-44eecf7e05f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f7b10df-50aa-41d3-b0e0-3430ac43b215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c0c6fff-c598-4876-95e1-44eecf7e05f3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6403839c-45b2-477e-9f7b-9a6244242684_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:to="loc_us-gaap_ProjectMember_6403839c-45b2-477e-9f7b-9a6244242684_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7b413dd5-501d-4e96-a763-99b542e90e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:to="loc_us-gaap_ProjectMember_7b413dd5-501d-4e96-a763-99b542e90e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_4c663f18-8b5f-4092-a4ac-d44c26d9f517" xlink:href="regn-20221231.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_7b413dd5-501d-4e96-a763-99b542e90e87" xlink:to="loc_regn_RocheCollaborationAgreementMember_4c663f18-8b5f-4092-a4ac-d44c26d9f517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a9b4d648-60e6-4e6e-aec3-1410c6b191b6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:to="loc_srt_ProductsAndServicesDomain_a9b4d648-60e6-4e6e-aec3-1410c6b191b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:to="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RonapreveMember_b21c52ba-6ea0-4b17-8603-abf40a61a9ad" xlink:href="regn-20221231.xsd#regn_RonapreveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:to="loc_regn_RonapreveMember_b21c52ba-6ea0-4b17-8603-abf40a61a9ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_908a6e86-c998-4738-9ca2-9aa645ddfca2" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_908a6e86-c998-4738-9ca2-9aa645ddfca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_95f7e658-4202-4786-97dc-686bafd9429f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_95f7e658-4202-4786-97dc-686bafd9429f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_db189057-39dd-4706-a499-146fd7b402d4" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:to="loc_regn_CollaborationRevenueMember_db189057-39dd-4706-a499-146fd7b402d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_72433994-1069-4138-8590-fddf3e8fc0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_72433994-1069-4138-8590-fddf3e8fc0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_d1f0e231-61dd-40af-b021-36c218c6a3b6" xlink:href="regn-20221231.xsd#regn_CostOfGoodsSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:to="loc_regn_CostOfGoodsSoldMember_d1f0e231-61dd-40af-b021-36c218c6a3b6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="extended" id="id1bb0176c4924f0e8231f6e6e8e2ac8e_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d38f514c-12ea-46a0-aab0-e7bd359ff6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d38f514c-12ea-46a0-aab0-e7bd359ff6f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d9f139b1-8afa-4074-8d73-5ffa15488eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d9f139b1-8afa-4074-8d73-5ffa15488eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8e00d39b-7065-4258-9585-a5e1c2208825_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:to="loc_us-gaap_ProjectMember_8e00d39b-7065-4258-9585-a5e1c2208825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_44381541-15cc-4be0-9c55-e98343894faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:to="loc_us-gaap_ProjectMember_44381541-15cc-4be0-9c55-e98343894faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_3ea83036-13d6-4bf5-a817-2cebceaf19b7" xlink:href="regn-20221231.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_44381541-15cc-4be0-9c55-e98343894faf" xlink:to="loc_regn_RocheCollaborationAgreementMember_3ea83036-13d6-4bf5-a817-2cebceaf19b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails" xlink:type="extended" id="i348e3b4584aa4f32aee07ad3a7984209_CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpfrontPaymentMade_5bb900c6-abe0-4c82-ad18-19054e900f3d" xlink:href="regn-20221231.xsd#regn_UpfrontPaymentMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_UpfrontPaymentMade_5bb900c6-abe0-4c82-ad18-19054e900f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_a9aec394-2f95-4e1c-9e9d-9bbd00e7884c" xlink:href="regn-20221231.xsd#regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_a9aec394-2f95-4e1c-9e9d-9bbd00e7884c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_002bc866-2007-4b7b-94f7-d248dfc03d2b" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_002bc866-2007-4b7b-94f7-d248dfc03d2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InitialResearchTerm_4bd7f83d-cc3a-4ff0-80f4-37cab5fd809f" xlink:href="regn-20221231.xsd#regn_InitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_InitialResearchTerm_4bd7f83d-cc3a-4ff0-80f4-37cab5fd809f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PotentialExtensionOfResearchTerm_16ef7d66-f262-435a-9cdf-fc87d3c2932d" xlink:href="regn-20221231.xsd#regn_PotentialExtensionOfResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_PotentialExtensionOfResearchTerm_16ef7d66-f262-435a-9cdf-fc87d3c2932d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OptionToExtendResearchTermPeriod_f9446ab4-3357-49eb-8356-aad36f7554f9" xlink:href="regn-20221231.xsd#regn_OptionToExtendResearchTermPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_OptionToExtendResearchTermPeriod_f9446ab4-3357-49eb-8356-aad36f7554f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ExtensionOfResearchTermFee_ebb44709-154a-434d-b317-fecc5ce2d132" xlink:href="regn-20221231.xsd#regn_ExtensionOfResearchTermFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_ExtensionOfResearchTermFee_ebb44709-154a-434d-b317-fecc5ce2d132" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_abf8b924-fb32-4240-b55d-82d2007ef573" xlink:href="regn-20221231.xsd#regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_abf8b924-fb32-4240-b55d-82d2007ef573" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0769e77-e1b5-4e2a-a2d7-0d569b75e833_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:to="loc_srt_RangeMember_c0769e77-e1b5-4e2a-a2d7-0d569b75e833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:to="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c06c3254-d977-4755-ba73-953f8658d7ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:to="loc_srt_MinimumMember_c06c3254-d977-4755-ba73-953f8658d7ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86ab5f78-e38b-451f-9397-bb24a712e249" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:to="loc_srt_MaximumMember_86ab5f78-e38b-451f-9397-bb24a712e249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_984ba111-77a9-492d-98d5-bc6c8e900521_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:to="loc_us-gaap_ProjectMember_984ba111-77a9-492d-98d5-bc6c8e900521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_773ebccb-ac7e-427a-b1c7-8f9107bd4d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:to="loc_us-gaap_ProjectMember_773ebccb-ac7e-427a-b1c7-8f9107bd4d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ae199b5f-d555-4b5d-9435-d30d99ee1ade" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_773ebccb-ac7e-427a-b1c7-8f9107bd4d72" xlink:to="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ae199b5f-d555-4b5d-9435-d30d99ee1ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ae555b88-0f2f-483e-bbe1-90a0603718ee_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ae555b88-0f2f-483e-bbe1-90a0603718ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7c732ab4-797c-4944-ba86-85ad269e4e5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7c732ab4-797c-4944-ba86-85ad269e4e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_58c551d0-64b0-4f12-aae8-58a06b5bf78e" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7c732ab4-797c-4944-ba86-85ad269e4e5e" xlink:to="loc_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_58c551d0-64b0-4f12-aae8-58a06b5bf78e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails" xlink:type="extended" id="i43589e12e5a1410982522f67db922b54_CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27468d21-6b79-43bc-9a24-cc04ff856cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27468d21-6b79-43bc-9a24-cc04ff856cd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3ab157d1-2352-4204-b505-a515ec0d3834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3ab157d1-2352-4204-b505-a515ec0d3834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c03cccac-790b-4812-a788-b72367ef2b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c03cccac-790b-4812-a788-b72367ef2b7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_336b6840-3540-44e1-b1ad-3ef4532a167d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_336b6840-3540-44e1-b1ad-3ef4532a167d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb47f737-d948-4cb4-925a-fc39cac2262d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb47f737-d948-4cb4-925a-fc39cac2262d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CheckmatePharmaceuticalsIncMember_1e9016a7-c7bb-42d9-a2b8-efac115c5085" xlink:href="regn-20221231.xsd#regn_CheckmatePharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb47f737-d948-4cb4-925a-fc39cac2262d" xlink:to="loc_regn_CheckmatePharmaceuticalsIncMember_1e9016a7-c7bb-42d9-a2b8-efac115c5085" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended" id="i24701d37b6234fe6afafed1414519a4d_CollaborationLicenseandOtherAgreementsTevaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentReceived_33b3683b-6f39-4791-b4e7-f2cef92671f8" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_regn_UpFrontPaymentReceived_33b3683b-6f39-4791-b4e7-f2cef92671f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c7e354d7-569c-4e5d-b05c-bdb7e622f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c7e354d7-569c-4e5d-b05c-bdb7e622f6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_d2500e6d-d67a-4eab-ad78-cf7849326446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_d2500e6d-d67a-4eab-ad78-cf7849326446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a1787687-4fab-4fe0-8524-e09f04f76f66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:to="loc_us-gaap_ProjectMember_a1787687-4fab-4fe0-8524-e09f04f76f66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_82f602d7-89c2-4f18-9762-1d4740325852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:to="loc_us-gaap_ProjectMember_82f602d7-89c2-4f18-9762-1d4740325852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b210680e-8494-4fbc-85ed-826181891b4a" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_82f602d7-89c2-4f18-9762-1d4740325852" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b210680e-8494-4fbc-85ed-826181891b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_89e4f525-251f-4c67-aff2-7d507acf8c0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_89e4f525-251f-4c67-aff2-7d507acf8c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5bd6de40-62c1-41ae-8066-138121c169f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5bd6de40-62c1-41ae-8066-138121c169f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7386ad1-e1ee-4b33-8b54-1a4c89ac75e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5bd6de40-62c1-41ae-8066-138121c169f5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7386ad1-e1ee-4b33-8b54-1a4c89ac75e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended" id="i9a14abd1fefa422984a1535803631c28_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_641e38bf-7dae-4b04-bcad-1f4d07ad8ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aab14bb8-582d-4598-b486-8a5bbb746ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_641e38bf-7dae-4b04-bcad-1f4d07ad8ae2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aab14bb8-582d-4598-b486-8a5bbb746ea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_641e38bf-7dae-4b04-bcad-1f4d07ad8ae2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9b46a54b-485f-4466-9fd2-43a97767ccbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:to="loc_us-gaap_ProjectMember_9b46a54b-485f-4466-9fd2-43a97767ccbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_60b71662-e9bb-498a-a9e8-358962d89dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:to="loc_us-gaap_ProjectMember_60b71662-e9bb-498a-a9e8-358962d89dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_e6f85403-b1b8-45a0-b390-671c638066a1" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_60b71662-e9bb-498a-a9e8-358962d89dfc" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_e6f85403-b1b8-45a0-b390-671c638066a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14f31f67-5087-4af4-ae08-2f99fc048b2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14f31f67-5087-4af4-ae08-2f99fc048b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2361103e-82de-451d-95d0-97ac6ca82ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2361103e-82de-451d-95d0-97ac6ca82ff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_6146b70d-eea6-46dd-8490-a9e9a365f2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_6146b70d-eea6-46dd-8490-a9e9a365f2c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5e9395e3-97ef-4df5-adbf-4a42e6c033d1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:to="loc_srt_ProductsAndServicesDomain_5e9395e3-97ef-4df5-adbf-4a42e6c033d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:to="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_cbf24674-0dc4-41d1-aa8c-1ebe0bcb0e65" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_cbf24674-0dc4-41d1-aa8c-1ebe0bcb0e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_2e5a9243-e84a-46df-a5f7-8d2e4f39cdc8" xlink:href="regn-20221231.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_2e5a9243-e84a-46df-a5f7-8d2e4f39cdc8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended" id="i914e2c8cc7084ec58228660b2b301c6c_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_80187574-7d19-49e1-9aca-d9dde05d213b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_80187574-7d19-49e1-9aca-d9dde05d213b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_44d6ea6b-9be0-46b5-9306-3abc563b7cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:to="loc_us-gaap_OtherLiabilities_44d6ea6b-9be0-46b5-9306-3abc563b7cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_b44c836f-6eac-497d-b9f4-d9a8d1a358b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:to="loc_us-gaap_ProjectMember_b44c836f-6eac-497d-b9f4-d9a8d1a358b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6584b4ee-bf79-40e5-8c08-a1832ca26373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:to="loc_us-gaap_ProjectMember_6584b4ee-bf79-40e5-8c08-a1832ca26373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_f89e7619-23ea-48c6-9e55-b3e8ca03059d" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_6584b4ee-bf79-40e5-8c08-a1832ca26373" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_f89e7619-23ea-48c6-9e55-b3e8ca03059d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" id="i20d1f42f50004baea4b7d0614336a6aa_MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e3c2c72-f848-4947-bc18-a5f877e0a474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e3c2c72-f848-4947-bc18-a5f877e0a474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a0b5221d-7fd3-4c2d-8743-4bad95323c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a0b5221d-7fd3-4c2d-8743-4bad95323c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8613fb1-76a6-4673-be42-0989392ae65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8613fb1-76a6-4673-be42-0989392ae65e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5dafbe04-6c59-49fe-a32f-cf3c955b53a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5dafbe04-6c59-49fe-a32f-cf3c955b53a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8608de97-56b9-4089-b097-b662a8b3ced8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8608de97-56b9-4089-b097-b662a8b3ced8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_f395631d-c6de-479c-98b1-7b6d1cbc27b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_f395631d-c6de-479c-98b1-7b6d1cbc27b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0fc03ca6-cb01-44fe-824f-3e02b69f62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0fc03ca6-cb01-44fe-824f-3e02b69f62b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_60756f2b-0661-4deb-93a2-5f5a9f80c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_60756f2b-0661-4deb-93a2-5f5a9f80c7e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29a00da3-972a-4f09-b53f-8653fea105f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_CommercialPaperMember_29a00da3-972a-4f09-b53f-8653fea105f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1766a3df-3884-45e7-bf1d-9e192bb0771b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1766a3df-3884-45e7-bf1d-9e192bb0771b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_17e11eef-c447-4e19-980c-0133dd84b009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_17e11eef-c447-4e19-980c-0133dd84b009" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended" id="idc120adaf9544359a713695a953fa4d5_MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f51b90c1-0da3-4a0f-98c0-bac1b513ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f51b90c1-0da3-4a0f-98c0-bac1b513ab50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9d62db6a-7937-43a3-8851-08f35707ef83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9d62db6a-7937-43a3-8851-08f35707ef83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6a2b52a2-7056-40b0-a9ab-2490e4d0b721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6a2b52a2-7056-40b0-a9ab-2490e4d0b721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b8e3eb0e-6e26-46a2-bdc7-8c3cb7865bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b8e3eb0e-6e26-46a2-bdc7-8c3cb7865bc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53191893-2d6e-4259-a268-49b15c6583ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53191893-2d6e-4259-a268-49b15c6583ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_aa6e695e-c240-47d6-82ce-2ebe7fb32863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_aa6e695e-c240-47d6-82ce-2ebe7fb32863" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_898f1815-68bd-4ccc-ae53-dfa828bb2fac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_898f1815-68bd-4ccc-ae53-dfa828bb2fac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_dd76c020-8c93-41ce-a92e-e0b67b504d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_dd76c020-8c93-41ce-a92e-e0b67b504d4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_47f91fed-261d-47a2-9933-244e2c0fdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_47f91fed-261d-47a2-9933-244e2c0fdca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_fb9cff8c-2b8b-4596-9af2-25ae3c198a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_fb9cff8c-2b8b-4596-9af2-25ae3c198a6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0c488d9c-09a6-4701-a87c-52a21bb831a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_CommercialPaperMember_0c488d9c-09a6-4701-a87c-52a21bb831a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4d443104-6243-45d7-8454-17df5361cee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4d443104-6243-45d7-8454-17df5361cee6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3d0b134a-711f-460d-b74a-b23c6bd1fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3d0b134a-711f-460d-b74a-b23c6bd1fd07" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ib8474a711a41491e8d81b52c6522941a_FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_cc7aecd2-a6cf-47d0-8b6e-97bac48a4203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_cc7aecd2-a6cf-47d0-8b6e-97bac48a4203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f3d65f4-f416-4542-8ac7-1611a691dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_cc7aecd2-a6cf-47d0-8b6e-97bac48a4203" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f3d65f4-f416-4542-8ac7-1611a691dba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f9455b0d-250c-463d-9e82-4b85d1491915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f9455b0d-250c-463d-9e82-4b85d1491915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_83630a2f-ec3e-4b17-b1b5-aa8bca31f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_MarketableSecurities_83630a2f-ec3e-4b17-b1b5-aa8bca31f1eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0b6452a4-10fa-4710-be10-00089e997fff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0b6452a4-10fa-4710-be10-00089e997fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9233adce-adad-47a8-9e09-60a21c85b005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9233adce-adad-47a8-9e09-60a21c85b005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2b55bb7f-beae-4593-aa5b-2e0bfa8a1ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9233adce-adad-47a8-9e09-60a21c85b005" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2b55bb7f-beae-4593-aa5b-2e0bfa8a1ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_228bfd63-16f2-4ce9-8fb1-755e48283098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_228bfd63-16f2-4ce9-8fb1-755e48283098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a3ccc7df-27bd-40e7-9f89-d5e20d11ae70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a3ccc7df-27bd-40e7-9f89-d5e20d11ae70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f027d0c7-0f21-4676-847b-9c5b70bec7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f027d0c7-0f21-4676-847b-9c5b70bec7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84e8d49a-d0e7-425e-93ef-9dce3df070b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84e8d49a-d0e7-425e-93ef-9dce3df070b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d8d8f0a9-da93-466e-977f-8a30d59e603f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d8d8f0a9-da93-466e-977f-8a30d59e603f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_bccd0576-2bb6-42f3-8bef-ad65726f060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_bccd0576-2bb6-42f3-8bef-ad65726f060e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_86becdac-a25c-4fe8-a1fa-1e63ff37340b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_86becdac-a25c-4fe8-a1fa-1e63ff37340b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b2962561-cf9f-4779-8cbd-55e0d52121a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_CommercialPaperMember_b2962561-cf9f-4779-8cbd-55e0d52121a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b12b9130-b534-4b8b-b44d-95d8015d6fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b12b9130-b534-4b8b-b44d-95d8015d6fa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_978c6dec-ef2d-4d8e-8b14-ceb4f4279277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_978c6dec-ef2d-4d8e-8b14-ceb4f4279277" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_23f02561-d245-430d-8098-9d06e42e008d_default" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:to="loc_regn_ClassificationOfInvestmentDomain_23f02561-d245-430d-8098-9d06e42e008d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:to="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_b06da266-9e98-489a-bcaa-a6f0112e2987" xlink:href="regn-20221231.xsd#regn_UnrestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:to="loc_regn_UnrestrictedMember_b06da266-9e98-489a-bcaa-a6f0112e2987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_89432a16-f8f4-46c7-88f5-1d9b24f748be" xlink:href="regn-20221231.xsd#regn_RestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:to="loc_regn_RestrictedMember_89432a16-f8f4-46c7-88f5-1d9b24f748be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i6777f153ffc7489585cbf895fd58c50d_PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_e3682687-c80d-4127-b82c-1d6495b7d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_e3682687-c80d-4127-b82c-1d6495b7d0e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_92487e30-1ebb-4063-b9c9-67523ed393ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_92487e30-1ebb-4063-b9c9-67523ed393ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c40df2d5-2b41-4b94-a4ad-fd34882b530c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c40df2d5-2b41-4b94-a4ad-fd34882b530c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15fdad24-cbd6-4255-9e01-6404675d508c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15fdad24-cbd6-4255-9e01-6404675d508c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_03357fbb-07a1-4bab-aea9-722b9bec5ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_LandMember_03357fbb-07a1-4bab-aea9-722b9bec5ad1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_3a7d0b74-e1d9-4ac6-9fe3-936b469dfe82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_3a7d0b74-e1d9-4ac6-9fe3-936b469dfe82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_59b77fa7-a01b-49e2-a5c4-6cf214688fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_59b77fa7-a01b-49e2-a5c4-6cf214688fac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_fc26fa9f-0c86-478c-a682-7555695cc727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_ConstructionInProgressMember_fc26fa9f-0c86-478c-a682-7555695cc727" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_7394ffac-f99b-4d9a-aba9-1fd44ef75eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_EquipmentMember_7394ffac-f99b-4d9a-aba9-1fd44ef75eb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ComputerEquipmentAndSoftwareMember_dfe0ceec-045a-4782-8009-dc08255c756d" xlink:href="regn-20221231.xsd#regn_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_regn_ComputerEquipmentAndSoftwareMember_dfe0ceec-045a-4782-8009-dc08255c756d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FurnitureOfficeEquipmentAndOtherMember_37f5f194-1880-4adc-8e12-bb629c4e433a" xlink:href="regn-20221231.xsd#regn_FurnitureOfficeEquipmentAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_regn_FurnitureOfficeEquipmentAndOtherMember_37f5f194-1880-4adc-8e12-bb629c4e433a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended" id="icca30415e0c247d4b84141428d75efe5_PropertyPlantandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_a8dc217f-27ec-4c04-bfda-3a661b810717" xlink:href="regn-20221231.xsd#regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:to="loc_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_a8dc217f-27ec-4c04-bfda-3a661b810717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5480998a-b2f1-4e62-9d05-b9f0f47aa1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5480998a-b2f1-4e62-9d05-b9f0f47aa1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:to="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7945f4e9-8792-4b6f-a860-b4c43426cee0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:to="loc_srt_SegmentGeographicalDomain_7945f4e9-8792-4b6f-a860-b4c43426cee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:to="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4121e748-e180-4493-a9ac-f8d8223bf647" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:to="loc_country_US_4121e748-e180-4493-a9ac-f8d8223bf647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember_ebd21929-3c0d-438e-9361-5cd79758b78b" xlink:href="regn-20221231.xsd#regn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:to="loc_regn_RestOfWorldMember_ebd21929-3c0d-438e-9361-5cd79758b78b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i58c058c1f92f4e5a8490ddf0c9a25aa6_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d828621-8a57-49c7-b2aa-641b49d186f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d828621-8a57-49c7-b2aa-641b49d186f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d33d7dab-94a1-403a-bc00-371690485726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d33d7dab-94a1-403a-bc00-371690485726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e1281ce8-a37f-42d7-9ad9-916613010810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e1281ce8-a37f-42d7-9ad9-916613010810" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_474dd2c3-7ae2-4bbc-83bb-c6d488d5dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_474dd2c3-7ae2-4bbc-83bb-c6d488d5dbfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0fd7584-d29c-4ed7-9525-ae8bff133d43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0fd7584-d29c-4ed7-9525-ae8bff133d43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ProductRightsMember_4d82a70c-122a-4222-abdb-bbd5c3816e54" xlink:href="regn-20221231.xsd#regn_ProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:to="loc_regn_ProductRightsMember_4d82a70c-122a-4222-abdb-bbd5c3816e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6a00d485-ed58-41c1-80d3-f7c24b22047e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6a00d485-ed58-41c1-80d3-f7c24b22047e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:to="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:to="loc_srt_RangeMember_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:to="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db2143cd-2cbb-4d47-acb4-5aded351e654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:to="loc_srt_MinimumMember_db2143cd-2cbb-4d47-acb4-5aded351e654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4863f2e-c863-427f-b259-62d7c6735f38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:to="loc_srt_MaximumMember_d4863f2e-c863-427f-b259-62d7c6735f38" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" id="i5b349f38fafc4d96b2d45b6fcbd3d959_IntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_17618bdd-7f77-404c-b569-f5c789a26473" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_17618bdd-7f77-404c-b569-f5c789a26473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_7fe32790-b2db-4a1a-b004-9c279d331dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_OtherLiabilities_7fe32790-b2db-4a1a-b004-9c279d331dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_81dc8216-ab97-43cb-973f-50503f3d5f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_81dc8216-ab97-43cb-973f-50503f3d5f64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4d4a9cfa-edb9-4c1b-a290-6473dc757e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4d4a9cfa-edb9-4c1b-a290-6473dc757e60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0629826e-874f-4efc-83b9-a84e6136a501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0629826e-874f-4efc-83b9-a84e6136a501" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_71e8a8cb-fbb2-4e77-946d-f4876f730aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_71e8a8cb-fbb2-4e77-946d-f4876f730aaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_75eab4cb-bf5e-4546-b3ec-d20998454af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_75eab4cb-bf5e-4546-b3ec-d20998454af3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_266ffc17-2b04-4297-84fd-3d86000a4133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_266ffc17-2b04-4297-84fd-3d86000a4133" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:to="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2efb860a-c52d-4c76-8b6e-372377b0258e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2efb860a-c52d-4c76-8b6e-372377b0258e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cc42c-c15a-4227-b481-0b966b18bed5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cc42c-c15a-4227-b481-0b966b18bed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_a5072cd5-3ced-4dad-a95a-44ee221387e0" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cc42c-c15a-4227-b481-0b966b18bed5" xlink:to="loc_regn_SanofiMember_a5072cd5-3ced-4dad-a95a-44ee221387e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fcd28489-3b92-4895-9521-7d58533bba18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:to="loc_us-gaap_ProjectMember_fcd28489-3b92-4895-9521-7d58533bba18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c2bb4be8-ad82-4f2c-bd03-908164562720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:to="loc_us-gaap_ProjectMember_c2bb4be8-ad82-4f2c-bd03-908164562720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_240af120-d7c3-4630-ac11-634b07b75c13" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_c2bb4be8-ad82-4f2c-bd03-908164562720" xlink:to="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_240af120-d7c3-4630-ac11-634b07b75c13" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended" id="i3b78513e74854e3f8ce4b5ed2e6150e1_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50798826-b313-4cfc-99d4-9ba4091b75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50798826-b313-4cfc-99d4-9ba4091b75d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1a03837d-4e07-49af-aef6-02c3a5cd7ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1a03837d-4e07-49af-aef6-02c3a5cd7ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LineOfCreditFacilityIncreaseLimit_92898420-27a0-4ffc-9926-30bf6a36f415" xlink:href="regn-20221231.xsd#regn_LineOfCreditFacilityIncreaseLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_regn_LineOfCreditFacilityIncreaseLimit_92898420-27a0-4ffc-9926-30bf6a36f415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_59cd86c2-bacb-48b4-92b1-794bf0ed8d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_LineOfCredit_59cd86c2-bacb-48b4-92b1-794bf0ed8d6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_75cbb155-017e-47de-8bec-f3e302deb6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_75cbb155-017e-47de-8bec-f3e302deb6e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6d514803-b584-4e4b-9b56-ffbcaa1e9be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_InterestExpenseDebt_6d514803-b584-4e4b-9b56-ffbcaa1e9be1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_fbf873a4-784a-4408-b3df-84900c7ec961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_fbf873a4-784a-4408-b3df-84900c7ec961" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_b5da9720-0f73-4e3c-a098-fc2ea267382b" xlink:href="regn-20221231.xsd#regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_b5da9720-0f73-4e3c-a098-fc2ea267382b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6ec834fa-789b-41e2-b434-551e5e707198_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6ec834fa-789b-41e2-b434-551e5e707198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4eb8d181-0c6a-40af-bfe5-58923dd9beec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:to="loc_us-gaap_LineOfCreditMember_4eb8d181-0c6a-40af-bfe5-58923dd9beec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_32b4e8ab-875d-4b05-8ecb-1511cdeb42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:to="loc_us-gaap_SeniorNotesMember_32b4e8ab-875d-4b05-8ecb-1511cdeb42ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:to="loc_us-gaap_CreditFacilityDomain_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:to="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aa6e6d15-3ca7-4592-9da3-af19c93ec83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aa6e6d15-3ca7-4592-9da3-af19c93ec83b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a6791cc8-6711-493f-86d5-55abfb5286f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:to="loc_us-gaap_LetterOfCreditMember_a6791cc8-6711-493f-86d5-55abfb5286f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a3702fd1-6f62-48bf-8980-6041379fab95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a3702fd1-6f62-48bf-8980-6041379fab95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_f4ac2ecf-22f0-4ea0-bcd1-2de6d6acc6c0" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_f4ac2ecf-22f0-4ea0-bcd1-2de6d6acc6c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_c6b5753d-9bd1-4b96-beb0-ca7451e920f7" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_c6b5753d-9bd1-4b96-beb0-ca7451e920f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#DebtSummaryofIssuedSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="extended" id="id3cb52655b7f4bf7ad758d1d37b8a4c9_DebtSummaryofIssuedSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_51dd9b98-4500-4cf2-ab3f-7c1de916f820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:to="loc_us-gaap_LongTermDebt_51dd9b98-4500-4cf2-ab3f-7c1de916f820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eef8228e-8445-4e64-b062-d509be1d7e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eef8228e-8445-4e64-b062-d509be1d7e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:to="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9369e632-6274-4adc-931f-3312098afcff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9369e632-6274-4adc-931f-3312098afcff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_03622d73-6545-48e3-84bd-148315cb0a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_03622d73-6545-48e3-84bd-148315cb0a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_af252473-95c8-4e4f-bcae-60908da14276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_03622d73-6545-48e3-84bd-148315cb0a45" xlink:to="loc_us-gaap_SeniorNotesMember_af252473-95c8-4e4f-bcae-60908da14276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0d2d1ad-66c7-425f-8205-3746ca4f9c30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0d2d1ad-66c7-425f-8205-3746ca4f9c30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_96ccfbc2-a35d-424b-b173-804ecf5ad358" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_96ccfbc2-a35d-424b-b173-804ecf5ad358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_489f58b8-f5c8-49f4-9b7c-c6b86fc7cee0" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_489f58b8-f5c8-49f4-9b7c-c6b86fc7cee0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesLeasesnarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails" xlink:type="extended" id="i6c91d9fb98fb49518752b253d85db8ee_CommitmentsandContingenciesLeasesnarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6a48ec63-fcf5-4248-aca0-c974f524408e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_FinanceLeaseLiability_6a48ec63-fcf5-4248-aca0-c974f524408e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_496ca33a-06d2-4858-96a1-635f669afce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_496ca33a-06d2-4858-96a1-635f669afce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_805a0cc3-6dc9-48e3-9d34-2144c397c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_805a0cc3-6dc9-48e3-9d34-2144c397c68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3158585d-6d33-49b9-83e9-c858015cd727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3158585d-6d33-49b9-83e9-c858015cd727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LaboratoryAndOfficeFacilitiesMember_ca3f806e-1ae4-4b0b-8283-5258e03a3792" xlink:href="regn-20221231.xsd#regn_LaboratoryAndOfficeFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3158585d-6d33-49b9-83e9-c858015cd727" xlink:to="loc_regn_LaboratoryAndOfficeFacilitiesMember_ca3f806e-1ae4-4b0b-8283-5258e03a3792" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="icc6ccc8a4b6a4367bb2d5f4fcc4ba2d2_CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyRateMinimum_21f0d5d8-09ee-45ba-80f8-25069cd1e759" xlink:href="regn-20221231.xsd#regn_RoyaltyRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_RoyaltyRateMinimum_21f0d5d8-09ee-45ba-80f8-25069cd1e759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyRateMaximum_9618d24a-c9f4-4bce-b8eb-d36529090275" xlink:href="regn-20221231.xsd#regn_RoyaltyRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_RoyaltyRateMaximum_9618d24a-c9f4-4bce-b8eb-d36529090275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsForRoyaltiesPercentage_bc509319-2b25-473b-97f1-559efc67ddc1" xlink:href="regn-20221231.xsd#regn_PaymentsForRoyaltiesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_PaymentsForRoyaltiesPercentage_bc509319-2b25-473b-97f1-559efc67ddc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_af289451-134e-4abc-987e-5c2e48ba9a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_us-gaap_RoyaltyExpense_af289451-134e-4abc-987e-5c2e48ba9a20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_db531bd6-a61f-484e-b105-eb2cf3e097de_default" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:to="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_db531bd6-a61f-484e-b105-eb2cf3e097de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_858c052b-f789-4ffe-99b8-821c403fdeaf" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:to="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_858c052b-f789-4ffe-99b8-821c403fdeaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_3be5f5c7-4e31-4fa9-aee9-a05b9ba40437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_858c052b-f789-4ffe-99b8-821c403fdeaf" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_3be5f5c7-4e31-4fa9-aee9-a05b9ba40437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:to="loc_srt_ProductsAndServicesDomain_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef6ce94d-ada8-4491-a4ae-2aef159ec9ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:to="loc_srt_ProductsAndServicesDomain_ef6ce94d-ada8-4491-a4ae-2aef159ec9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_2e7edab9-303d-4269-8123-4c120fd5e170" xlink:href="regn-20221231.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ef6ce94d-ada8-4491-a4ae-2aef159ec9ca" xlink:to="loc_regn_LIBTAYONetProductSalesMember_2e7edab9-303d-4269-8123-4c120fd5e170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_521c50e2-ee1a-43f2-afe9-c15e510d47bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:to="loc_us-gaap_ProjectMember_521c50e2-ee1a-43f2-afe9-c15e510d47bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a024579d-6069-480b-beb7-ef5624364503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:to="loc_us-gaap_ProjectMember_a024579d-6069-480b-beb7-ef5624364503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_846fa7cb-983d-4f46-9d65-7443de886e7d" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_a024579d-6069-480b-beb7-ef5624364503" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_846fa7cb-983d-4f46-9d65-7443de886e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ThroughDecember312023Member_4a6b3164-b588-4601-aeb2-ebb222fae9c8" xlink:href="regn-20221231.xsd#regn_ThroughDecember312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:to="loc_regn_ThroughDecember312023Member_4a6b3164-b588-4601-aeb2-ebb222fae9c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_January12024ThroughDecember312026Member_56dc65bf-8a1e-4611-ac7f-c2c7639f0b9e" xlink:href="regn-20221231.xsd#regn_January12024ThroughDecember312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:to="loc_regn_January12024ThroughDecember312026Member_56dc65bf-8a1e-4611-ac7f-c2c7639f0b9e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ib837d045c57c4af9b7868f7280d32c57_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3c495dfc-2f30-4347-8ca8-e8e3f3913794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3c495dfc-2f30-4347-8ca8-e8e3f3913794" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3fde9e5-8ce8-4b71-8bd5-dae8ea4eea72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3fde9e5-8ce8-4b71-8bd5-dae8ea4eea72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfVotesPerShare_718a8dfd-3af6-4baf-a096-3e204f22ce9b" xlink:href="regn-20221231.xsd#regn_NumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_regn_NumberOfVotesPerShare_718a8dfd-3af6-4baf-a096-3e204f22ce9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3a07e6a1-7313-4832-bc73-c699b2ae7bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3a07e6a1-7313-4832-bc73-c699b2ae7bb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d6e8b83a-0656-484a-8149-b11992327ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d6e8b83a-0656-484a-8149-b11992327ac9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d5a6a24c-85e3-4782-a392-3fe2771fd5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d5a6a24c-85e3-4782-a392-3fe2771fd5ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_640fa31f-ce5c-4a11-9ef4-04194f2b9e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_640fa31f-ce5c-4a11-9ef4-04194f2b9e9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_151175f0-c3b2-4e5e-aa7d-ccdd69653fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_151175f0-c3b2-4e5e-aa7d-ccdd69653fc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8bb6ab55-b22f-40cb-bbf4-c8e362ffc317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8bb6ab55-b22f-40cb-bbf4-c8e362ffc317" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_571706f6-a673-4507-acec-ab717bbcbcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_571706f6-a673-4507-acec-ab717bbcbcba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_c533bd2a-05ea-4200-b5cb-65f3e67bd700" xlink:href="regn-20221231.xsd#regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_c533bd2a-05ea-4200-b5cb-65f3e67bd700" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_afba7d44-f90c-4c69-a5e2-664f342784de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:to="loc_us-gaap_ClassOfStockDomain_afba7d44-f90c-4c69-a5e2-664f342784de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:to="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_b04e2109-e9c4-4865-9564-6e2ca63ba5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:to="loc_us-gaap_CommonClassAMember_b04e2109-e9c4-4865-9564-6e2ca63ba5c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ca7e8ccd-db33-4a09-a243-abe1f61e9eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:to="loc_us-gaap_CommonStockMember_ca7e8ccd-db33-4a09-a243-abe1f61e9eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_128a11bb-ab93-49af-bfc2-8013824a4fee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_128a11bb-ab93-49af-bfc2-8013824a4fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2021Member_d16eccdd-59f6-42dd-8225-caa05e758b37" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramJanuary2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2021Member_d16eccdd-59f6-42dd-8225-caa05e758b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramNovember2021Member_b3a61314-3ce2-43b3-a9bd-23036f53c558" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramNovember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgramNovember2021Member_b3a61314-3ce2-43b3-a9bd-23036f53c558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgram2019Member_c85736ba-f9dc-46ab-964f-2bd9d3546608" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgram2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgram2019Member_c85736ba-f9dc-46ab-964f-2bd9d3546608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2023Member_0bcdcbd8-270a-4605-afbb-6496f9a453c0" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2023Member_0bcdcbd8-270a-4605-afbb-6496f9a453c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_39791eb9-30c8-4973-a5a4-f2fa1b12652a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:to="loc_us-gaap_ProjectMember_39791eb9-30c8-4973-a5a4-f2fa1b12652a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:to="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_e9e51e95-d1f1-4769-a4f2-fbdad081b0e8" xlink:href="regn-20221231.xsd#regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:to="loc_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_e9e51e95-d1f1-4769-a4f2-fbdad081b0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_82e542f5-1075-4087-9671-0633b06ac3da" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:to="loc_regn_BayerCollaborationAgreementMember_82e542f5-1075-4087-9671-0633b06ac3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b79f243a-71b3-4e9e-bdf8-d17593c05b5b" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b79f243a-71b3-4e9e-bdf8-d17593c05b5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a547f993-3288-4c66-b4cb-f416492b653d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:to="loc_dei_EntityDomain_a547f993-3288-4c66-b4cb-f416492b653d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_29947837-8879-4d84-9707-5b4d9c1b38de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:to="loc_dei_EntityDomain_29947837-8879-4d84-9707-5b4d9c1b38de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_7d89b7b5-1602-418d-be85-9a26d23f92d6" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_29947837-8879-4d84-9707-5b4d9c1b38de" xlink:to="loc_regn_SanofiMember_7d89b7b5-1602-418d-be85-9a26d23f92d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a246f350-43a4-4cb8-a898-b7515fc0879e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a246f350-43a4-4cb8-a898-b7515fc0879e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_75ee4da9-9046-403c-9623-6a5f44f0ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_75ee4da9-9046-403c-9623-6a5f44f0ee6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_896ba07d-aca3-41de-9855-badf353a35a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_75ee4da9-9046-403c-9623-6a5f44f0ee6b" xlink:to="loc_us-gaap_SubsequentEventMember_896ba07d-aca3-41de-9855-badf353a35a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StockholdersEquityScheduleofRepurchasedSharesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="extended" id="i841fb529ffcf46d9818c6389db3abc1d_StockholdersEquityScheduleofRepurchasedSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3c7782b0-1955-4389-8721-35d901ba7d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3c7782b0-1955-4389-8721-35d901ba7d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5d0d19d9-bfb5-475b-bbb4-25fa943c3b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5d0d19d9-bfb5-475b-bbb4-25fa943c3b7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_43048b54-c14a-43a7-bf73-d8d8a3bf98c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_43048b54-c14a-43a7-bf73-d8d8a3bf98c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5eb6f6c2-5f7f-4fbc-b16b-bc8c27135bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5eb6f6c2-5f7f-4fbc-b16b-bc8c27135bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramsMember_af82ec62-7658-464f-b913-d6d5ed3665c1" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5eb6f6c2-5f7f-4fbc-b16b-bc8c27135bb0" xlink:to="loc_regn_ShareRepurchaseProgramsMember_af82ec62-7658-464f-b913-d6d5ed3665c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails" xlink:type="extended" id="ie8b4ab77b3cb4278973ef61d46819769_LongTermIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_caf5a044-2fef-4142-8e88-84fd40b93967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_caf5a044-2fef-4142-8e88-84fd40b93967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8e9dd4f-6442-4988-a4f1-1b6a4fcc1a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8e9dd4f-6442-4988-a4f1-1b6a4fcc1a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_8b2605b6-1110-4356-838e-b2d06b71ebb7" xlink:href="regn-20221231.xsd#regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_8b2605b6-1110-4356-838e-b2d06b71ebb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a59c7fa4-96ad-4fe5-9704-18f14c912865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a59c7fa4-96ad-4fe5-9704-18f14c912865" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09a113d1-4af7-4051-b4af-f8dca4b7d825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09a113d1-4af7-4051-b4af-f8dca4b7d825" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03b07995-0eb8-49f2-b0c8-00691a86a245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03b07995-0eb8-49f2-b0c8-00691a86a245" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6effb8af-c1f9-4de4-8ab6-924073aa6100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6effb8af-c1f9-4de4-8ab6-924073aa6100" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30918324-731b-4e2f-99df-e845d861d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30918324-731b-4e2f-99df-e845d861d4ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_69fedddb-a444-45fe-a0ca-836ac5d7adb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_69fedddb-a444-45fe-a0ca-836ac5d7adb5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f032346d-7d36-479c-9abb-0290ecb63d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f032346d-7d36-479c-9abb-0290ecb63d26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb18bd3c-dc6a-4e3e-b771-90ef1ff940ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb18bd3c-dc6a-4e3e-b771-90ef1ff940ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_039fca76-06a2-4d15-9ccd-7b2185259072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_039fca76-06a2-4d15-9ccd-7b2185259072" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_817ff90f-a86a-49e9-8347-8b3dc3b4b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_817ff90f-a86a-49e9-8347-8b3dc3b4b422" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_18b68a55-e156-49b6-9793-c1d5e529f354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_18b68a55-e156-49b6-9793-c1d5e529f354" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2526917f-4a2f-4f65-a656-4cfe83263756_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:to="loc_us-gaap_PlanNameDomain_2526917f-4a2f-4f65-a656-4cfe83263756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:to="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmendedRestatedLongTermIncentivePlan2014Member_7e14fc9b-f50f-4459-83dc-eb3429140a8d" xlink:href="regn-20221231.xsd#regn_AmendedRestatedLongTermIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:to="loc_regn_AmendedRestatedLongTermIncentivePlan2014Member_7e14fc9b-f50f-4459-83dc-eb3429140a8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LongTermIncentivePlan2014Member_2cf2ad8f-2254-4e66-badb-ac8ea2c6a922" xlink:href="regn-20221231.xsd#regn_LongTermIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:to="loc_regn_LongTermIncentivePlan2014Member_2cf2ad8f-2254-4e66-badb-ac8ea2c6a922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LongTermIncentivePlan2000Member_5dcf50b0-60c1-4652-a6bd-5dacacc5ce44" xlink:href="regn-20221231.xsd#regn_LongTermIncentivePlan2000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:to="loc_regn_LongTermIncentivePlan2000Member_5dcf50b0-60c1-4652-a6bd-5dacacc5ce44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d29897e-6b12-4232-aacd-0cb882af9b19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d29897e-6b12-4232-aacd-0cb882af9b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_144e93fa-deae-42a7-85c0-eefb1069196b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_144e93fa-deae-42a7-85c0-eefb1069196b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NonPerformanceBasedStockOptionsMember_205b776e-af65-4234-83d5-d592ba847980" xlink:href="regn-20221231.xsd#regn_NonPerformanceBasedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_regn_NonPerformanceBasedStockOptionsMember_205b776e-af65-4234-83d5-d592ba847980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c8761333-309f-454e-b7f9-79663cbe3c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_us-gaap_RestrictedStockMember_c8761333-309f-454e-b7f9-79663cbe3c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ab3485d2-8a5e-487f-9754-133eed5d4bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_us-gaap_PerformanceSharesMember_ab3485d2-8a5e-487f-9754-133eed5d4bbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7d490a3-34c2-4c3e-ae19-147f4256f7fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:to="loc_srt_RangeMember_c7d490a3-34c2-4c3e-ae19-147f4256f7fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:to="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7645f321-6820-4f89-9f7f-131c1ba83356" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:to="loc_srt_MinimumMember_7645f321-6820-4f89-9f7f-131c1ba83356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6baab1b7-55f1-4164-b74c-b4182c2901af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:to="loc_srt_MaximumMember_6baab1b7-55f1-4164-b74c-b4182c2901af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails" xlink:type="extended" id="i38ef7b4addeb4f378944aca59973cba8_LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a62992f-0356-4d4a-9e16-fcb8088e29e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a62992f-0356-4d4a-9e16-fcb8088e29e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8d3ea60e-9e48-4cb7-a15a-0c41ae8e148b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8d3ea60e-9e48-4cb7-a15a-0c41ae8e148b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3b2ef744-df7f-4dd3-ae93-d5bdf6484b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3b2ef744-df7f-4dd3-ae93-d5bdf6484b38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f43df6c1-3169-4245-9491-861d644cfa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f43df6c1-3169-4245-9491-861d644cfa50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd76ad21-2c5a-4f18-be78-8b9ea6de6113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_de31168b-82c0-46ae-a1ff-f1f0407d027c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_de31168b-82c0-46ae-a1ff-f1f0407d027c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05aa7502-50ae-4b53-99d9-b0a5b6d0b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05aa7502-50ae-4b53-99d9-b0a5b6d0b4ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eafd13a2-a4ce-4ad7-bcdb-1a74e6123069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eafd13a2-a4ce-4ad7-bcdb-1a74e6123069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed7ab6e5-5616-4f9b-b3e1-8a88e2949995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed7ab6e5-5616-4f9b-b3e1-8a88e2949995" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e8375d30-3abd-4f9d-9e85-042aabb58ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e8375d30-3abd-4f9d-9e85-042aabb58ed2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e794d6f-05e9-4521-a7ba-d9b68135a896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e794d6f-05e9-4521-a7ba-d9b68135a896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93b44dd6-b81e-438f-855f-c6af8ac9cfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1374801a-27e3-4b32-b7aa-321894a61c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1374801a-27e3-4b32-b7aa-321894a61c3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d221ccdb-60a7-468e-b107-d8c1e42c0f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d221ccdb-60a7-468e-b107-d8c1e42c0f2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac67e9f-67d4-473c-a0ab-50984795979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac67e9f-67d4-473c-a0ab-50984795979b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c68c1db5-ba2e-40aa-b3aa-b939bbe9011d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c68c1db5-ba2e-40aa-b3aa-b939bbe9011d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31633de8-8ce0-4fb2-b70c-d88d98342235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31633de8-8ce0-4fb2-b70c-d88d98342235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a7c0b2e4-1b2d-4c33-9891-8e9d1cf0d702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a7c0b2e4-1b2d-4c33-9891-8e9d1cf0d702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_92780b91-382d-4aed-b68a-a078a7d4f6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_92780b91-382d-4aed-b68a-a078a7d4f6f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc87dbe5-9bff-4837-97ec-54837b61c794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc87dbe5-9bff-4837-97ec-54837b61c794" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:to="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcdd995-24d9-481b-a9a8-c895bb443409_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bcdd995-24d9-481b-a9a8-c895bb443409_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce88bc9a-63e4-4ebe-9239-3ecf66f4a3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce88bc9a-63e4-4ebe-9239-3ecf66f4a3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68735d7e-7e0f-4644-a91f-a61559dbf27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce88bc9a-63e4-4ebe-9239-3ecf66f4a3d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68735d7e-7e0f-4644-a91f-a61559dbf27c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails" xlink:type="extended" id="ic2e3e0fcf8f9403784ef6bb543385a02_LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_74b67c96-5435-4784-9d7e-8b896788deed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_74b67c96-5435-4784-9d7e-8b896788deed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_246f438b-df41-4aa7-aec9-72bd23ae0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_246f438b-df41-4aa7-aec9-72bd23ae0e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e795438b-d8b4-4a8b-91b9-538bfd907228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e795438b-d8b4-4a8b-91b9-538bfd907228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:to="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20e44cc6-d870-48a8-8032-a20865a1b889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20e44cc6-d870-48a8-8032-a20865a1b889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9fb948-cdc4-493c-8599-7e77d3c05377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9fb948-cdc4-493c-8599-7e77d3c05377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_82ee9c4f-226b-4a95-a66b-38091d3ce87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9fb948-cdc4-493c-8599-7e77d3c05377" xlink:to="loc_us-gaap_EmployeeStockOptionMember_82ee9c4f-226b-4a95-a66b-38091d3ce87d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails" xlink:type="extended" id="i0313458de48d45d297fcbe8391ccf64a_LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba931893-2d44-4b23-8233-67dce0133e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba931893-2d44-4b23-8233-67dce0133e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_41001a62-82c7-489d-a2c8-7321ba3f5db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_41001a62-82c7-489d-a2c8-7321ba3f5db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b221272e-65f4-4b5b-8070-8ac9dd5540c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b221272e-65f4-4b5b-8070-8ac9dd5540c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_067f4234-3455-41de-ae67-52224247398a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_067f4234-3455-41de-ae67-52224247398a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:to="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85375c62-0147-4e90-bb14-1bcb904f9925_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85375c62-0147-4e90-bb14-1bcb904f9925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4226c4c8-3113-4748-86d7-446ff2024276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4226c4c8-3113-4748-86d7-446ff2024276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ad90cfb-e0a3-4f1f-9f2e-e146081efc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4226c4c8-3113-4748-86d7-446ff2024276" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ad90cfb-e0a3-4f1f-9f2e-e146081efc45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails" xlink:type="extended" id="if5e5df1a73b94989a2edfbde958e71f5_LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a512588-e0ed-497e-ae07-5dfcdc9a9bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a512588-e0ed-497e-ae07-5dfcdc9a9bb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d8d11a8-924d-49bf-aaa7-e48b9321566c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d8d11a8-924d-49bf-aaa7-e48b9321566c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_763a9a88-70d1-413d-a959-52d59eeb743d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_763a9a88-70d1-413d-a959-52d59eeb743d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e9dc4c-947b-4a4c-9e95-07d58c073d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e9dc4c-947b-4a4c-9e95-07d58c073d78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08a4e9ca-8487-47fd-849c-8a414c0f5b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5176ad7d-b346-4695-8520-eb79f8f102c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5176ad7d-b346-4695-8520-eb79f8f102c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4973ae65-b883-49f9-abfd-427b6f3940f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4973ae65-b883-49f9-abfd-427b6f3940f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e93c4acc-9408-4663-8f61-cf01b611fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e93c4acc-9408-4663-8f61-cf01b611fdb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6549db0c-57be-452e-b71d-6fd9e522bff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6549db0c-57be-452e-b71d-6fd9e522bff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61d28aff-d3e8-4d8d-969e-a8accf4c4bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:to="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4651640-197d-45a4-be7d-080cf0f81b4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4651640-197d-45a4-be7d-080cf0f81b4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02925234-4584-44bf-af7e-3f968387ac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02925234-4584-44bf-af7e-3f968387ac2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_07e45bdb-c184-4e78-9237-7167d0ef1f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02925234-4584-44bf-af7e-3f968387ac2a" xlink:to="loc_us-gaap_RestrictedStockMember_07e45bdb-c184-4e78-9237-7167d0ef1f2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails" xlink:type="extended" id="ia9e845d15ba64a629865a86b57f14fce_LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41263ebb-e73b-4065-8e4a-b9d488e00f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41263ebb-e73b-4065-8e4a-b9d488e00f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b41506c-39f7-4355-9cfa-e1e9378c0ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b41506c-39f7-4355-9cfa-e1e9378c0ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a76df4ab-77c2-41a8-a816-aecd79ec5efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cf5fc83-9d26-42f9-850a-38766f2205e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cf5fc83-9d26-42f9-850a-38766f2205e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ba2b090-2b3a-4acc-b847-6849153491ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ba2b090-2b3a-4acc-b847-6849153491ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8c379bf-8a4e-412e-a74f-230b2821eb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:to="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31e7d53f-2f06-4e01-ad83-d06a94345bc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31e7d53f-2f06-4e01-ad83-d06a94345bc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2d8b70-a4d0-4c7b-a9d3-9ff2be896d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2d8b70-a4d0-4c7b-a9d3-9ff2be896d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0fc17dc6-ec23-4d9c-a71e-ef915969d7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2d8b70-a4d0-4c7b-a9d3-9ff2be896d7d" xlink:to="loc_us-gaap_PerformanceSharesMember_0fc17dc6-ec23-4d9c-a71e-ef915969d7bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails" xlink:type="extended" id="i1be53e0a2b4d4855ac0269a77962d27c_LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b0139478-d5c0-437c-8323-06f2ab159de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b0139478-d5c0-437c-8323-06f2ab159de6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ed8344e-7d35-4a5b-850f-51928c05eb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ed8344e-7d35-4a5b-850f-51928c05eb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_787e1eb1-da94-4aed-a217-c7ae336a2a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_787e1eb1-da94-4aed-a217-c7ae336a2a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:to="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15192a45-8186-4594-a879-44ea7511deaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15192a45-8186-4594-a879-44ea7511deaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aef39f3-bb19-4c60-a6d9-99292817e085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aef39f3-bb19-4c60-a6d9-99292817e085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0e44bb0e-8175-49cf-bc61-247f2cd3d598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aef39f3-bb19-4c60-a6d9-99292817e085" xlink:to="loc_us-gaap_PerformanceSharesMember_0e44bb0e-8175-49cf-bc61-247f2cd3d598" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LegalMattersDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended" id="i7106a24e02124b95b44dcd3b5c617d9a_LegalMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_440ea911-8c10-431d-b949-4434d65358b8" xlink:href="regn-20221231.xsd#regn_NumberOfInterPartiesReviewIPRPetitionsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:to="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_440ea911-8c10-431d-b949-4434d65358b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber_53821877-82ee-46a7-b0df-29ed0a66e84b" xlink:href="regn-20221231.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:to="loc_regn_LossContingencyExParteReexaminationFiledNumber_53821877-82ee-46a7-b0df-29ed0a66e84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:to="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_9a13a973-9c2a-4842-ba07-89f028df2bcb" xlink:href="regn-20221231.xsd#regn_A631PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:to="loc_regn_A631PatentMember_9a13a973-9c2a-4842-ba07-89f028df2bcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember_be048a64-9f87-4723-9e5b-5ac2505181b8" xlink:href="regn-20221231.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:to="loc_regn_A226PatentAnd992PatentMember_be048a64-9f87-4723-9e5b-5ac2505181b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A338PatentAnd069PatentMember_28656b6a-3c8a-4a43-998d-81764f1ff570" xlink:href="regn-20221231.xsd#regn_A338PatentAnd069PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:to="loc_regn_A338PatentAnd069PatentMember_28656b6a-3c8a-4a43-998d-81764f1ff570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bb155cd8-53f1-42a7-adcb-1897f2380461_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:to="loc_srt_ProductsAndServicesDomain_bb155cd8-53f1-42a7-adcb-1897f2380461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97d9756b-b196-4331-a2fb-3c52e85a0310" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:to="loc_srt_ProductsAndServicesDomain_97d9756b-b196-4331-a2fb-3c52e85a0310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember_3da3c336-6d7b-432f-96fc-40f221a57476" xlink:href="regn-20221231.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97d9756b-b196-4331-a2fb-3c52e85a0310" xlink:to="loc_regn_EYLEAAfliberceptInjectionMember_3da3c336-6d7b-432f-96fc-40f221a57476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42813b37-24c9-496f-a88b-bd0658d551ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42813b37-24c9-496f-a88b-bd0658d551ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ApotexIncMember_a67cc2b8-5f54-498c-99dc-7d88ddbcd4d8" xlink:href="regn-20221231.xsd#regn_ApotexIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:to="loc_regn_ApotexIncMember_a67cc2b8-5f54-498c-99dc-7d88ddbcd4d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CelltrionIncMember_5f86cdc5-f806-4fd7-9fd3-2628c3637110" xlink:href="regn-20221231.xsd#regn_CelltrionIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:to="loc_regn_CelltrionIncMember_5f86cdc5-f806-4fd7-9fd3-2628c3637110" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="i951f94721daa4f0cb923587f828b03ba_NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3103468d-11e4-407a-8f84-8a2904ebefbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_NetIncomeLoss_3103468d-11e4-407a-8f84-8a2904ebefbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2614110-7699-4d8c-b9df-a4f5a25cd332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2614110-7699-4d8c-b9df-a4f5a25cd332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8115f903-5c63-41d4-9596-76449697492d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8115f903-5c63-41d4-9596-76449697492d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4267cee0-fb84-4aa5-807a-891a5a10b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8115f903-5c63-41d4-9596-76449697492d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4267cee0-fb84-4aa5-807a-891a5a10b852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f136db3d-2447-4fbe-89ff-df5cfcbc5ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f136db3d-2447-4fbe-89ff-df5cfcbc5ffd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7a2381d2-c7c5-4743-9baf-9b1475fb1d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_EarningsPerShareBasic_7a2381d2-c7c5-4743-9baf-9b1475fb1d3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a270b6dc-1a81-4cb3-8075-a886f98ba98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a270b6dc-1a81-4cb3-8075-a886f98ba98b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:to="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34ec2fab-ddef-4e94-9268-664eb96f4ea9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34ec2fab-ddef-4e94-9268-664eb96f4ea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_732ee542-4b2b-47db-abd8-4f329798448c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_732ee542-4b2b-47db-abd8-4f329798448c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b3089bee-af90-4d6c-b074-9fe8422659c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:to="loc_us-gaap_RestrictedStockMember_b3089bee-af90-4d6c-b074-9fe8422659c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended" id="i6ba064b445314ec0af155f3d603cf3d5_NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4df333af-5919-4ca9-9941-062a174a3d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5ec86ef-cc02-40a5-924f-76e9ac9a30af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4df333af-5919-4ca9-9941-062a174a3d74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5ec86ef-cc02-40a5-924f-76e9ac9a30af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4df333af-5919-4ca9-9941-062a174a3d74" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aaf260ad-c888-4e02-9dea-fe3d084fe5d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aaf260ad-c888-4e02-9dea-fe3d084fe5d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a13bd9e-7d57-4e41-acd5-0866520d7982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a13bd9e-7d57-4e41-acd5-0866520d7982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0df19fe4-e986-469f-8834-83bd171183d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a13bd9e-7d57-4e41-acd5-0866520d7982" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0df19fe4-e986-469f-8834-83bd171183d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>regn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:042488f0-a666-455c-8991-c514440b53f2,g:8bd10ba8-749e-45a5-bb1c-c1abec558824-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_6ab9dd31-7b31-46a5-ab02-5606343ad12c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payments for Libtayo intangible asset</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d19c602a-5353-4ade-a116-8bb35c025937_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_50f40dc4-c2bb-4c1e-9f5b-5d33fca01d4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b61cb82-a95e-48f7-9481-d2b57deb7b50_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_d84d0fa3-0375-4da1-93a0-ace55cf9a81f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_022d7b49-89da-4de9-8880-743aaa8f1a61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_IntelliaCollaborationAgreementMember_012d6288-b0b6-4e82-957c-330f25dabeab_terseLabel_en-US" xlink:label="lab_regn_IntelliaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia Collaboration Agreement</link:label>
    <link:label id="lab_regn_IntelliaCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_IntelliaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_IntelliaCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_IntelliaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaCollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_IntelliaCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_IntelliaCollaborationAgreementMember" xlink:to="lab_regn_IntelliaCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_29c1f76f-a2a8-46e3-b2d9-a549336237de_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_d3e2d2be-e555-4664-9c62-de529e57873a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_aa4fe724-819f-4716-9c18-4afc8c89c57f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value and unrealized losses of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7a15ebb4-635a-4dfa-9df7-41a129301c40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_1458529d-3545-47f3-8402-01cdcec74bf5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramNovember2021Member_b75f3fdd-6fe1-41fc-8601-3736ebfd9da7_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2021 Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramNovember2021Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, November 2021 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramNovember2021Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, November 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramNovember2021Member" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramNovember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramNovember2021Member" xlink:to="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8b0db1d2-dfcd-4971-bc5b-87d89a15e002_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0aeb641e-d897-4586-886e-779822a8c094_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1026a59b-3668-476d-9cb8-113ebcbc9902_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_14989bc1-51ed-49b5-85c3-44b71e69e283_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_91a2ccdd-ae8e-4f93-80f2-ab6917b7a04a_terseLabel_en-US" xlink:label="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of IPR filed</link:label>
    <link:label id="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_label_en-US" xlink:label="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inter Parties Review (IPR) Petitions Filed</link:label>
    <link:label id="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_documentation_en-US" xlink:label="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inter Parties Review (IPR) Petitions Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:href="regn-20221231.xsd#regn_NumberOfInterPartiesReviewIPRPetitionsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:to="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9379129c-47e7-4ec6-8778-965669d6fdf1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneFourMember_5e8c8157-4ffa-463c-9710-0597570a3278_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Four</link:label>
    <link:label id="lab_regn_SalesMilestoneFourMember_label_en-US" xlink:label="lab_regn_SalesMilestoneFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Four [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneFourMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFourMember" xlink:href="regn-20221231.xsd#regn_SalesMilestoneFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneFourMember" xlink:to="lab_regn_SalesMilestoneFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_7f0035a1-85d6-492b-bc6e-6ca95866d4ef_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_9a66f7e0-0a4b-4b35-8186-7fec1ffc4cd0_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_429fa392-3a77-4b8f-ae0a-0127fae3aa02_terseLabel_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage to be received on net product sales outside of the United States</link:label>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_label_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Received On Net Product Sales Outside Of United States</link:label>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_documentation_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Received On Net Product Sales Outside Of United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:href="regn-20221231.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:to="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LineOfCreditFacilityIncreaseLimit_dcf23337-0bac-4eae-9e33-51c17595a6a2_terseLabel_en-US" xlink:label="lab_regn_LineOfCreditFacilityIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Limit</link:label>
    <link:label id="lab_regn_LineOfCreditFacilityIncreaseLimit_label_en-US" xlink:label="lab_regn_LineOfCreditFacilityIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Increase Limit</link:label>
    <link:label id="lab_regn_LineOfCreditFacilityIncreaseLimit_documentation_en-US" xlink:label="lab_regn_LineOfCreditFacilityIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Increase Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LineOfCreditFacilityIncreaseLimit" xlink:href="regn-20221231.xsd#regn_LineOfCreditFacilityIncreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LineOfCreditFacilityIncreaseLimit" xlink:to="lab_regn_LineOfCreditFacilityIncreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dcd3e8a0-3870-4871-bd7e-a43297eca629_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_103909c8-ae52-4295-952c-f01bf6d1a1d5_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d540e20b-cb0a-4164-87e4-797de5259c91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_3f4b2d0b-ca30-4094-9b38-72b2218dc611_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits/payments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_d83ff47a-3df8-42b8-8967-5cb44bc49a5d_terseLabel_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent and '992 Patent</link:label>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_label_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent And '992 Patent [Member]</link:label>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_documentation_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent And '992 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember" xlink:href="regn-20221231.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A226PatentAnd992PatentMember" xlink:to="lab_regn_A226PatentAnd992PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_cb37a61c-be23-4663-b1b6-929d47db7a76_terseLabel_en-US" xlink:label="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting share of profits outside the United States, based on sales, for collaborating party</link:label>
    <link:label id="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_label_en-US" xlink:label="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting share of profits outside the United States, based on sales, for collaborating party</link:label>
    <link:label id="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_documentation_en-US" xlink:label="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:href="regn-20221231.xsd#regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:to="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_aa0ed83b-eee4-4ab6-892d-263d9ed639a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_84b7316d-1a00-4de8-989f-b15bc9268ac9_terseLabel_en-US" xlink:label="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Contract to Perform for Others by Product [Domain]</link:label>
    <link:label id="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_label_en-US" xlink:label="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Contract to Perform for Others by Product [Domain]</link:label>
    <link:label id="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_documentation_en-US" xlink:label="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and Development Arrangement Contract to Perform for Others by Product [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" xlink:to="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8ab38c94-9044-4593-9bbb-5f207942cbcf_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9159b78f-f5eb-4590-8f36-3d894f46628d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4bcf5905-4f18-4a8e-add9-c947037b1670_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc4851fa-22d7-4a88-ab3b-13806da94119_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b90ebf5a-8cca-4f18-b027-2fdaaea53666_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ca45e793-72cd-4e8a-9e26-c8e30fd63f50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2e5fd591-edd8-4ffd-b879-a3b113b14ff8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales or maturities of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc83a6e9-a483-497f-bf20-5a0ef7137058_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_f62402cd-e4ee-4006-910e-8eddb80e14b0_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_January12024ThroughDecember312026Member_e6f071e8-2440-4ad9-ad0d-3cadc005a5c1_terseLabel_en-US" xlink:label="lab_regn_January12024ThroughDecember312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 1, 2024 Through December 31, 2026</link:label>
    <link:label id="lab_regn_January12024ThroughDecember312026Member_label_en-US" xlink:label="lab_regn_January12024ThroughDecember312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 1, 2024 Through December 31, 2026 [Member]</link:label>
    <link:label id="lab_regn_January12024ThroughDecember312026Member_documentation_en-US" xlink:label="lab_regn_January12024ThroughDecember312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 1, 2024 Through December 31, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_January12024ThroughDecember312026Member" xlink:href="regn-20221231.xsd#regn_January12024ThroughDecember312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_January12024ThroughDecember312026Member" xlink:to="lab_regn_January12024ThroughDecember312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_42dc7223-8214-4057-b90a-bcd996b32003_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f9893e12-5cd3-40a6-968a-c8e7a5541feb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9eb45b44-c2d6-4c4e-8da7-22d833b8f87a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8f03f885-2712-48c0-b30c-57ac30abeb8c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PaymentsForRoyaltiesPercentage_0b32ffcc-4e64-487e-8da7-f9a23876c0d0_terseLabel_en-US" xlink:label="lab_regn_PaymentsForRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be paid</link:label>
    <link:label id="lab_regn_PaymentsForRoyaltiesPercentage_label_en-US" xlink:label="lab_regn_PaymentsForRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Royalties, Percentage</link:label>
    <link:label id="lab_regn_PaymentsForRoyaltiesPercentage_documentation_en-US" xlink:label="lab_regn_PaymentsForRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Royalties, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsForRoyaltiesPercentage" xlink:href="regn-20221231.xsd#regn_PaymentsForRoyaltiesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PaymentsForRoyaltiesPercentage" xlink:to="lab_regn_PaymentsForRoyaltiesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6768c545-a3e7-4bd8-8252-f51af6c2c0ad_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_06bbc181-3eb4-4bf6-b168-1672aea8164c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c03f546e-63f2-4173-83d1-7b03c69e35cb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e2c90be0-eb35-41b8-a67b-7573eeb0867f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6629f32b-809e-408b-9ab9-388130d56b8b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8ce0540c-5378-49d7-8822-6a75ab052cc8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_419f8ecb-484a-4db7-801c-78b7774bfacc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b850891b-9e5e-44ae-aaea-aa246387b2fd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a5690975-3d82-45d4-b7a1-ccd866bc22fa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eb0e7c82-b0e6-47a1-b057-29a880e66824_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_d58aa141-cb59-4c8b-8a01-29eef4a29b97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ebb09a57-03e4-4dd6-a005-e5589f5095d7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_521c9fcf-aa02-433a-bee9-d88c5b8cd082_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8e295675-cb38-4b88-b3fa-0846d20ba0cf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_da727d08-c21f-4722-8c67-3db98f3b699a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeAgreementsObligationsCurrent_fb7313e7-5d8f-4245-adf0-a9b9ccdbe490_terseLabel_en-US" xlink:label="lab_regn_CollaborativeAgreementsObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to collaborators (see Note 3)</link:label>
    <link:label id="lab_regn_CollaborativeAgreementsObligationsCurrent_label_en-US" xlink:label="lab_regn_CollaborativeAgreementsObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Obligations, Current</link:label>
    <link:label id="lab_regn_CollaborativeAgreementsObligationsCurrent_documentation_en-US" xlink:label="lab_regn_CollaborativeAgreementsObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Obligations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeAgreementsObligationsCurrent" xlink:href="regn-20221231.xsd#regn_CollaborativeAgreementsObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeAgreementsObligationsCurrent" xlink:to="lab_regn_CollaborativeAgreementsObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany_6347a73a-7cae-4f25-abe2-2eca0c60118c_terseLabel_en-US" xlink:label="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses outside the United States, for company</link:label>
    <link:label id="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany_label_en-US" xlink:label="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses outside the United States, for Company</link:label>
    <link:label id="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany_documentation_en-US" xlink:label="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the share of losses outside the United States for the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfLossesOutsideUnitedStatesForCompany" xlink:href="regn-20221231.xsd#regn_ShareOfLossesOutsideUnitedStatesForCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareOfLossesOutsideUnitedStatesForCompany" xlink:to="lab_regn_ShareOfLossesOutsideUnitedStatesForCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_901995af-e6da-4fc0-bdd6-c4f1f7453d55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c59bd93d-91e7-48dd-8198-e865eb51b872_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_7bc8f14c-8084-429c-936d-046a8ebbb82b_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones earned</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Earned [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneEarnedMember" xlink:to="lab_regn_SalesBasedMilestoneEarnedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AggregateSalesBasedMilestoneMember_1b5f353a-9e8c-4e94-8566-6d59c34cf5ef_terseLabel_en-US" xlink:label="lab_regn_AggregateSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Sales-Based Milestone</link:label>
    <link:label id="lab_regn_AggregateSalesBasedMilestoneMember_label_en-US" xlink:label="lab_regn_AggregateSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Sales-Based Milestone [Member]</link:label>
    <link:label id="lab_regn_AggregateSalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_regn_AggregateSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Sales-Based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AggregateSalesBasedMilestoneMember" xlink:href="regn-20221231.xsd#regn_AggregateSalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AggregateSalesBasedMilestoneMember" xlink:to="lab_regn_AggregateSalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_6880fae8-f2b8-46bc-b2d9-568db3587c26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_49bf3647-6313-4a95-afb0-dd13a645fb08_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9c71669e-8587-428a-b983-cc7f8bd58db5_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8d60e3ee-775f-43d1-80c8-11aff0472df3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_McKessonCorporationMember_7204160a-d0be-40b8-80c4-a3744148447d_terseLabel_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_label_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_documentation_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember" xlink:href="regn-20221231.xsd#regn_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_McKessonCorporationMember" xlink:to="lab_regn_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_e39d6f67-8b1e-4616-8c90-9d477f06cb36_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" xlink:to="lab_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EvkeezaMember_370b198f-7faa-4ab1-824d-eef2a132ccc9_terseLabel_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza</link:label>
    <link:label id="lab_regn_EvkeezaMember_label_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza [Member]</link:label>
    <link:label id="lab_regn_EvkeezaMember_documentation_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember" xlink:href="regn-20221231.xsd#regn_EvkeezaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EvkeezaMember" xlink:to="lab_regn_EvkeezaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_0351ccbf-2021-43ad-a4b2-033657238b7e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_3b651f4c-6f16-44ab-adef-80a9d037583b_terseLabel_en-US" xlink:label="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after five years</link:label>
    <link:label id="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_label_en-US" xlink:label="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5</link:label>
    <link:label id="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_documentation_en-US" xlink:label="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:href="regn-20221231.xsd#regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:to="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_2d0210da-fccb-4960-9b3e-d78b07251aaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, at cost; 22.6 shares in 2022 and 19.4 shares in 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b1d5e20b-d769-474c-9430-9fc1e08c53ee_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4bc6c1ef-45a7-4043-9dc4-de5f9ed0f9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d90e7276-8e17-4295-bc36-4d530e7c14cb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1826431f-758e-4ee9-8533-5ee8226f7997_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ThroughDecember312023Member_1b911e81-2c29-4527-a115-677b8a4bce61_terseLabel_en-US" xlink:label="lab_regn_ThroughDecember312023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Through December 31, 2023</link:label>
    <link:label id="lab_regn_ThroughDecember312023Member_label_en-US" xlink:label="lab_regn_ThroughDecember312023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Through December 31, 2023 [Member]</link:label>
    <link:label id="lab_regn_ThroughDecember312023Member_documentation_en-US" xlink:label="lab_regn_ThroughDecember312023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Through December 31, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ThroughDecember312023Member" xlink:href="regn-20221231.xsd#regn_ThroughDecember312023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ThroughDecember312023Member" xlink:to="lab_regn_ThroughDecember312023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PaymentsToAcquireIntangibleAssets1_14718b1c-db9d-4553-b358-514fc14caaed_negatedTerseLabel_en-US" xlink:label="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Libtayo intangible asset</link:label>
    <link:label id="lab_regn_PaymentsToAcquireIntangibleAssets1_label_en-US" xlink:label="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Intangible Assets1</link:label>
    <link:label id="lab_regn_PaymentsToAcquireIntangibleAssets1_documentation_en-US" xlink:label="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Intangible Assets1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsToAcquireIntangibleAssets1" xlink:href="regn-20221231.xsd#regn_PaymentsToAcquireIntangibleAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PaymentsToAcquireIntangibleAssets1" xlink:to="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f6ecfc98-7450-43e9-bbfc-6d7aafc1a965_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5f6147a6-f23a-435e-b6c1-e752a2f3fbfd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aeed1cec-a36f-40da-9324-3c1c36b8cd48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AccrualForSalesRelatedCostsCurrent_b8140bc5-4e9d-44e5-8523-80b533794f05_terseLabel_en-US" xlink:label="lab_regn_AccrualForSalesRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales-related costs</link:label>
    <link:label id="lab_regn_AccrualForSalesRelatedCostsCurrent_label_en-US" xlink:label="lab_regn_AccrualForSalesRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Sales-Related Costs, Current</link:label>
    <link:label id="lab_regn_AccrualForSalesRelatedCostsCurrent_documentation_en-US" xlink:label="lab_regn_AccrualForSalesRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Sales-Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AccrualForSalesRelatedCostsCurrent" xlink:href="regn-20221231.xsd#regn_AccrualForSalesRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AccrualForSalesRelatedCostsCurrent" xlink:to="lab_regn_AccrualForSalesRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fd9e514c-386c-455e-ad05-eeecfc5de0ab_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_9322a41c-dd09-43f1-996a-90f22a690149_terseLabel_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_label_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_documentation_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember" xlink:href="regn-20221231.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LIBTAYONetProductSalesMember" xlink:to="lab_regn_LIBTAYONetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d8152661-8a62-4930-b82b-145b2c20238b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_e643db89-65c2-4477-af92-c5fbf6a84e07_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_12723b51-61c7-4c74-b20e-50966d7f42a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f0d3c824-bbc5-40b4-be0f-1d446119c59d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a77284c-53da-4497-a6ad-f65a33a3ea12_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (in years) - outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RebatesAndChargebacksMember_fbc41290-93fa-4be5-b3b5-9ac92d1c2afd_terseLabel_en-US" xlink:label="lab_regn_RebatesAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Chargebacks, and Discounts</link:label>
    <link:label id="lab_regn_RebatesAndChargebacksMember_label_en-US" xlink:label="lab_regn_RebatesAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and Chargebacks [Member]</link:label>
    <link:label id="lab_regn_RebatesAndChargebacksMember_documentation_en-US" xlink:label="lab_regn_RebatesAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A valuation allowance for rebates and chargebacks under governmental programs (including Medicaid), which are netted against revenue from product sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RebatesAndChargebacksMember" xlink:href="regn-20221231.xsd#regn_RebatesAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RebatesAndChargebacksMember" xlink:to="lab_regn_RebatesAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b7c45a63-716a-4e43-ae37-e2ce6da2fec7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NumberOfVotesPerShare_0da160f8-2e7d-46c1-8548-85a789ea1df6_terseLabel_en-US" xlink:label="lab_regn_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_regn_NumberOfVotesPerShare_label_en-US" xlink:label="lab_regn_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:label id="lab_regn_NumberOfVotesPerShare_documentation_en-US" xlink:label="lab_regn_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfVotesPerShare" xlink:href="regn-20221231.xsd#regn_NumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NumberOfVotesPerShare" xlink:to="lab_regn_NumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyRateMinimum_de8b496e-92f1-48bc-b653-d188d26b4351_terseLabel_en-US" xlink:label="lab_regn_RoyaltyRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate minimum</link:label>
    <link:label id="lab_regn_RoyaltyRateMinimum_label_en-US" xlink:label="lab_regn_RoyaltyRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate minimum</link:label>
    <link:label id="lab_regn_RoyaltyRateMinimum_documentation_en-US" xlink:label="lab_regn_RoyaltyRateMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum royalty rate to be paid to the Company under the agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyRateMinimum" xlink:href="regn-20221231.xsd#regn_RoyaltyRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyRateMinimum" xlink:to="lab_regn_RoyaltyRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EyleaNetProductSalesMember_d091689e-2e64-4b8b-bf01-c095a0f34e07_terseLabel_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_label_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember" xlink:href="regn-20221231.xsd#regn_EyleaNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EyleaNetProductSalesMember" xlink:to="lab_regn_EyleaNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_edaa68b6-48c4-4901-9e66-5e3b1bc49732_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_eae405d3-81ce-4414-a048-5a085c9f0180_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_64659d6f-271a-4c72-a944-b32a980f79f2_terseLabel_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:href="regn-20221231.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:to="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_50493672-a570-44e4-a3a0-3510bbf3b5a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_103979da-94a9-4718-949a-a55e6bd657b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of activity related to restricted stock awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_93df9308-ca76-4ea7-9c73-16d602dcb43d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01c89f0b-f74e-487b-8c28-d2a8b70b15f4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_e79805f8-fdc4-4870-9640-c13880a06b03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_deff4116-5bb2-45ad-b56b-8d179e47759c_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock for 401(k) Savings Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:href="regn-20221231.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e081376-2395-448d-ad00-6fcac4038040_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2c044c9f-2ab4-4a8e-8220-f0c7f736e6b9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b40c92cc-c833-4416-985d-7c907049458b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_7c875bb7-73a8-4372-adf4-3b8b04d005d1_terseLabel_en-US" xlink:label="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved by the U.S. FDA</link:label>
    <link:label id="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_label_en-US" xlink:label="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products Approved By The Unites States Food And Drug Administration</link:label>
    <link:label id="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_documentation_en-US" xlink:label="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products Approved By The Unites States Food And Drug Administration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" xlink:href="regn-20221231.xsd#regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" xlink:to="lab_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_97180be3-f2dd-4f57-8cc7-d40a4396a47a_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_92c7d897-32f3-41dc-8d8e-359455174751_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_fa269d22-6dcb-4ba2-a468-fea36b2d0f69_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_0e92a51a-9154-4e00-99aa-1b8cf62d8dc5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1f96eff9-0923-4e44-8814-ab41898ee510_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneOneMember_50347942-bcbe-4eb2-be5c-faef234da452_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Milestone</link:label>
    <link:label id="lab_regn_SalesMilestoneOneMember_label_en-US" xlink:label="lab_regn_SalesMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone One [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneOneMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneOneMember" xlink:href="regn-20221231.xsd#regn_SalesMilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneOneMember" xlink:to="lab_regn_SalesMilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f06350-53ab-476a-83ae-bd4348abde94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_af254d1c-0e90-49f8-b6bf-15fed59ea8eb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fde240bc-dae6-477b-8e37-2680c6903bfc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_IOLicenseandCollaborationAgreementMember_72541c98-ca78-4e5f-bf06-ff2eecddf762_terseLabel_en-US" xlink:label="lab_regn_IOLicenseandCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IO License and Collaboration Agreement</link:label>
    <link:label id="lab_regn_IOLicenseandCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_IOLicenseandCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IO License and Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_IOLicenseandCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_IOLicenseandCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In July 2015, the Company entered into a Immuno-oncology License and Collaboration Agreement (the "IO License and Collaboration Agreement") with Sanofi, to jointly develop and commercialize Immuno-oncology products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IOLicenseandCollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_IOLicenseandCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_IOLicenseandCollaborationAgreementMember" xlink:to="lab_regn_IOLicenseandCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_cf13e0ff-3ea4-4078-83f8-42f99a3f0366_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_90387ad1-d359-410c-9b6f-d47f20fcb2ec_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cbc787-6df9-494e-a17b-8fd6de6d840b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DistributionRelatedFeesMember_53517612-6312-4818-82bb-1e14ebf70f4e_terseLabel_en-US" xlink:label="lab_regn_DistributionRelatedFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution- Related Fees</link:label>
    <link:label id="lab_regn_DistributionRelatedFeesMember_label_en-US" xlink:label="lab_regn_DistributionRelatedFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Related Fees [Member]</link:label>
    <link:label id="lab_regn_DistributionRelatedFeesMember_documentation_en-US" xlink:label="lab_regn_DistributionRelatedFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A valuation allowance for distribution-related fees which are netted against revenue from product sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DistributionRelatedFeesMember" xlink:href="regn-20221231.xsd#regn_DistributionRelatedFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DistributionRelatedFeesMember" xlink:to="lab_regn_DistributionRelatedFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0cb3877d-3ab0-4bdf-9830-d332187f8c30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of presentation in statement of operations of payments to and from collaborators</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e08a8df6-fed5-426c-a2fb-6414ba9fc743_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a6dcc114-6ec8-431c-a820-5d645738f701_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0a888c74-9754-44ed-99f2-0562e93f410d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2b06d31d-ce59-4c4e-8457-1ee3f5d0986f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0ee4459-918a-45d0-9a48-72dceb94361b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e292b0ae-bd8a-4275-92cd-98e78c9178cf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a2213bbc-d999-4d0e-b0fc-12f1f12deae6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa88b6ce-27bc-4946-8fc2-957a5ff8b4db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_76ccd8c1-9db1-4f59-b6b6-74fa8e3cb228_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ae029105-81a7-4f1f-ae27-7327a27ac62a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c2a1142-274f-4f79-86a4-6be290181247_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares/Units (In millions)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_56929a5b-1a4a-4633-a620-737bac59dbe2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_bd834b99-77a4-42d6-bbc2-4fd41e790472_terseLabel_en-US" xlink:label="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Contract to Perform for Others by Product [Axis]</link:label>
    <link:label id="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_label_en-US" xlink:label="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Contract to Perform for Others by Product [Axis]</link:label>
    <link:label id="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_documentation_en-US" xlink:label="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Contract to Perform for Others by Product [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" xlink:to="lab_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_65b37db3-8038-45fe-82d1-d8212c83d1cf_terseLabel_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of trial costs required to be funded by collaborating party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_label_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs Required To Be Funded By Collaborating Party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_documentation_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs Required To Be Funded By Collaborating Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:href="regn-20221231.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:to="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_dd642a5e-c783-45fe-baa1-a8819b79c8ec_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Line Items]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Line Items]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:to="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_705fad41-f7a1-484b-88e8-59587fac343e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_3af1a83e-4090-41e5-af38-2cc1195111a3_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="regn-20221231.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember_72e2f5fb-d9b8-47c5-b686-dd5a1c1ca437_terseLabel_en-US" xlink:label="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</link:label>
    <link:label id="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember_label_en-US" xlink:label="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:label id="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember_documentation_en-US" xlink:label="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareOfLibtayoUSGrossProfitsMember" xlink:href="regn-20221231.xsd#regn_SanofisShareOfLibtayoUSGrossProfitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofisShareOfLibtayoUSGrossProfitsMember" xlink:to="lab_regn_SanofisShareOfLibtayoUSGrossProfitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb38f9d9-44f9-44f6-9ff7-9c2f919050f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of awards outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ed8a9d62-b51f-4cf3-be49-1cbd80080888_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars of shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca8312a1-bb2e-43e2-b8d7-534bc8a740cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars of shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f259328f-781b-4b5d-a0b9-152d2a7a9314_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a6e63677-8005-4118-96ad-28561e71cc9e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_33176a12-0a5e-4888-8bcb-3bb79136e130_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f848bc37-5971-4415-90a9-29cab273213e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1ae278a2-6055-488a-a5ec-bbc099d0b7b8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_cfbeed28-3d8b-4819-aa55-b127a3b0fd83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_f95b4308-1339-4243-842c-e9cba17e35b9_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentAxis" xlink:to="lab_regn_ClassificationOfInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_1abd93be-06c2-40d4-8c93-59775e540ed1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_205fa429-52ce-44bf-a508-ef336b0eaca1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AmendedIODiscoveryAgreementMember_78052147-0d17-45ff-a7e6-db29c6daedbc_terseLabel_en-US" xlink:label="lab_regn_AmendedIODiscoveryAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended IO Discovery Agreement</link:label>
    <link:label id="lab_regn_AmendedIODiscoveryAgreementMember_label_en-US" xlink:label="lab_regn_AmendedIODiscoveryAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended IO Discovery Agreement [Member]</link:label>
    <link:label id="lab_regn_AmendedIODiscoveryAgreementMember_documentation_en-US" xlink:label="lab_regn_AmendedIODiscoveryAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended IO Discovery Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmendedIODiscoveryAgreementMember" xlink:href="regn-20221231.xsd#regn_AmendedIODiscoveryAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AmendedIODiscoveryAgreementMember" xlink:to="lab_regn_AmendedIODiscoveryAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_61b19291-e5c0-40af-8c59-c68c25305dac_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_ea3d82bb-fb72-46f7-8c7a-7640f92a395b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ContingentReimbursementObligation_8ed4ca19-fd91-4377-8b2f-9c51ce19d2c7_terseLabel_en-US" xlink:label="lab_regn_ContingentReimbursementObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent reimbursement obligation</link:label>
    <link:label id="lab_regn_ContingentReimbursementObligation_label_en-US" xlink:label="lab_regn_ContingentReimbursementObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Reimbursement Obligation</link:label>
    <link:label id="lab_regn_ContingentReimbursementObligation_documentation_en-US" xlink:label="lab_regn_ContingentReimbursementObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContingentReimbursementObligation" xlink:href="regn-20221231.xsd#regn_ContingentReimbursementObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ContingentReimbursementObligation" xlink:to="lab_regn_ContingentReimbursementObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OtherCollaborationAgreementsMember_6ff96725-9110-4704-a2df-da4687b9ba0a_terseLabel_en-US" xlink:label="lab_regn_OtherCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_regn_OtherCollaborationAgreementsMember_label_en-US" xlink:label="lab_regn_OtherCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Agreements [Member]</link:label>
    <link:label id="lab_regn_OtherCollaborationAgreementsMember_documentation_en-US" xlink:label="lab_regn_OtherCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember" xlink:href="regn-20221231.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OtherCollaborationAgreementsMember" xlink:to="lab_regn_OtherCollaborationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BesseMedicalMember_19b0702c-9cf8-46de-8a55-6b529d2020dd_terseLabel_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical, a subsidiary of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_regn_BesseMedicalMember_label_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:label id="lab_regn_BesseMedicalMember_documentation_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember" xlink:href="regn-20221231.xsd#regn_BesseMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BesseMedicalMember" xlink:to="lab_regn_BesseMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_cc95734e-7e7a-4f1b-adf8-673e0ad4eff6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e2198d89-a9b5-4aad-929c-c8d77c8f38a4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable and deferred revenue information</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5dad507c-99f4-468b-a9c2-58c7aba64f5f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_84ba911c-63c6-4212-85ea-dadf55d5bc4f_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_19f457fb-1451-4319-9f0d-8d1d11cb8336_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6e9ca174-c8c5-4df6-9349-d00a23676485_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, recognized identifiable assets acquired and liabilities assumed, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d7718fa3-62e4-4b88-bd84-b5501cff773e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_FinanceLeaseRemainingLeaseTerm_3c20f552-ae92-44eb-a420-2f132e372938_terseLabel_en-US" xlink:label="lab_regn_FinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term (in years)</link:label>
    <link:label id="lab_regn_FinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_regn_FinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Remaining Lease Term</link:label>
    <link:label id="lab_regn_FinanceLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_regn_FinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FinanceLeaseRemainingLeaseTerm" xlink:href="regn-20221231.xsd#regn_FinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_FinanceLeaseRemainingLeaseTerm" xlink:to="lab_regn_FinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_cf9c5a76-0650-47c9-9e21-0adff1d50237_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a5b7b72a-e86e-4786-98e2-4945b94d341c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_d44e9209-7482-44d6-b8d2-cf4beac305cc_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7af3512e-8c95-4029-a373-b1543886ffbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_de209717-364d-4157-b697-341b53c47c24_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_75898a94-8e09-4125-8b6f-9f562f6beeaa_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_1ab16da0-4166-4d23-964a-20afc9376159_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_28b97792-42f2-47e9-9f6c-9ddb49780fb3_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_350dfb66-e83d-40e1-8190-bae6bc158e58_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_83606f27-9780-44a3-9bfb-9e18bbe63a14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b2ba224d-3929-4905-983d-7faa69bb8d67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd6bef9-73ef-4c64-aadb-91c56a726d29_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_54124044-b687-4847-a8f8-0cd9f32918fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a2c4d2b6-1c62-4ccc-901c-4f01391c3aa1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bee9cb2d-25bc-4b5a-97bf-97690cb5cc70_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_62332a26-9f95-44a0-bf9e-16099a6a683e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a40226d8-be45-44d3-aba4-bd3a3154a091_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_f85ddda3-2b34-4e72-a1e2-eca416cd0948_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_c06e218f-04da-48f5-9992-64e5004a4962_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0acf40cb-bfe6-4906-9d56-83790dfe2f17_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9235970e-6a90-477b-afb0-63245060096d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4e5a59be-a689-4296-b7e2-164f9c059229_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2385dd75-6bc6-4af5-93f0-542febcc74e2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxation of non-U.S. operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0db1f1c7-8d62-4329-886f-e4373ecc81ad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fe5f9d1c-b2c5-4c14-a53f-85789214296a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain_d7cb99b3-264f-4a46-8c19-020e39af660e_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Agreements [Domain]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Agreements [Domain]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and licensing agreements, by name.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain" xlink:to="lab_regn_ResearchCollaborationAndLicensingAgreementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6bc8f900-753d-488d-92f1-1797440b0eb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average values of assumptions used in computing fair value of option grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_6641f7c2-a112-498d-8e85-2c24bcbff294_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiMember_0f5b83d8-b568-44af-8958-8c9e03615743_terseLabel_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_regn_SanofiMember_label_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_regn_SanofiMember_documentation_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiMember" xlink:to="lab_regn_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9052e798-d40e-4711-a7b9-20696f7f0553_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgram2019Member_6508e77f-4ded-4154-a232-35346c001995_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgram2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgram2019Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgram2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, 2019 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgram2019Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgram2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgram2019Member" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgram2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgram2019Member" xlink:to="lab_regn_ShareRepurchaseProgram2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3cca77b0-526a-484b-8321-4c3454619558_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4880cb64-c399-471d-8616-5b9b85470dea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_71b881ea-e646-4902-9545-a88b4fde8f14_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for recognition of total unrecognized compensation expense (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d572c1d0-68bc-4a68-82fc-8483efb6ee85_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_46d6b527-408f-4645-bb21-39a94c95ddf3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term - exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5e66ddf3-150f-4e73-843c-5f6d6e9fc19d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_8de4e22f-6508-4ee7-9b55-04ed29640d4e_terseLabel_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement</link:label>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RocheCollaborationAgreementMember" xlink:to="lab_regn_RocheCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e4bdf501-1219-4cac-978d-b25ff094e022_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_57b60066-9117-4408-a429-ad800e19994a_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_97cc3d66-fa2c-4fb0-bb30-bd12bc068b41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_197673ae-0f1e-404b-af2a-6daa524f6d23_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_ddc70fc2-e1d5-42b5-9df5-66869e624aee_terseLabel_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in connection with up-front payments received</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_label_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_documentation_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:href="regn-20221231.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:to="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d574c60d-6c9a-4a55-9479-16e3ad9b04d5_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Savings Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneOneMember_a08675ec-c230-4b9e-a4d7-37d86d02a0b1_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone One</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneOneMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone One [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneOneMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneOneMember" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneOneMember" xlink:to="lab_regn_SalesBasedMilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_6bce9c3a-844d-4aa4-8ac7-5978a011bb67_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a0419538-122b-4051-953c-a2223f8cc8da_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4df020a7-d67b-4ffa-8da5-e8c8ebe541e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_af1dbf28-4254-4bb5-8fea-fa2c9cab7537_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_090fc098-200d-41db-8a26-63a501585d6c_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of R&amp;D expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_59bb8929-9f98-4d4d-9de8-fadedfde69c6_verboseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of R&amp;D expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_79f5c1d5-cebc-40ce-bf8a-79141a4ff7ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_494286a6-2d32-4afc-bac8-ff8f08c12612_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-downs and reserves</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_a45234f9-5dce-47f9-b9ed-1541d60bb2ed_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_ca46886c-7285-4f38-9f97-9766aec75984_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_962b4792-c871-4e96-892c-4e42e38c0be7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_473de115-af94-41c7-9435-d419935b0f2e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_6149cafd-91bc-4fb7-aaec-97cf477739c8_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c381f9cc-2e3c-4c49-b20a-41f5327279d3_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_59968f78-a598-4f53-9963-36ac77c4bb76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_517453a2-6bf6-4eac-8d9d-156da2e3c6cb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ee898724-9471-430d-b5a6-170a64cf8972_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8a94f3c4-c496-4433-900f-df39028ac7c8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_e7a91790-721a-4bb4-8347-d403ea6c6237_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_0c7fbb6e-8aed-46e4-859e-9628375bf84c_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_9acc5be9-7302-441e-bbb5-52aece49db3d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Ending, treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_c7783646-2dfc-4b19-b2fb-c7fc997e66da_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of commercialization-related expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:href="regn-20221231.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:to="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bfc87660-ecab-4c37-b1e0-e1b513196189_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, expected amortization, year four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_48c8c536-6489-49ed-be77-2687eca733f2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_edf9cfa1-6602-4948-8270-e5c41633e450_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4c841fc3-35bb-46b8-8f20-e13e4d16aafb_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_83a8f380-1076-476e-ae92-654ca9988565_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8de58a23-60d7-4500-b57e-aae4c199d87a_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_25cbe84c-9b9d-471f-a5ae-2b22b5940c41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db39e6e4-7499-4369-8bbf-b328fd76e19d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8d434cb1-0d84-48bf-b021-c97616fc73c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneTwoMember_4270fff5-99a2-42df-8528-437f3be63d67_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Milestone</link:label>
    <link:label id="lab_regn_SalesMilestoneTwoMember_label_en-US" xlink:label="lab_regn_SalesMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Two [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneTwoMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneTwoMember" xlink:href="regn-20221231.xsd#regn_SalesMilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneTwoMember" xlink:to="lab_regn_SalesMilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_7c33b6d9-9de5-4b14-b8bd-8035e23c151a_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2528b0b1-1a6f-4f2e-ae3c-9290d4bfb9ed_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OtherSalesRelatedDeductionsMember_ff3a2902-53ed-4e74-87d1-c8ba8a3ea573_terseLabel_en-US" xlink:label="lab_regn_OtherSalesRelatedDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sales- Related Deductions</link:label>
    <link:label id="lab_regn_OtherSalesRelatedDeductionsMember_label_en-US" xlink:label="lab_regn_OtherSalesRelatedDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sales Related Deductions [Member]</link:label>
    <link:label id="lab_regn_OtherSalesRelatedDeductionsMember_documentation_en-US" xlink:label="lab_regn_OtherSalesRelatedDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A valuation allowance for other sales-related deductions which are netted against revenue from product sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherSalesRelatedDeductionsMember" xlink:href="regn-20221231.xsd#regn_OtherSalesRelatedDeductionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OtherSalesRelatedDeductionsMember" xlink:to="lab_regn_OtherSalesRelatedDeductionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_94f346ae-f30c-4724-91a7-ccbcdb2ecb06_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2021Member_3115c9b0-6326-4701-a43d-26cdc06c157a_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2021Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2021 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2021Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2021Member" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramJanuary2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramJanuary2021Member" xlink:to="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d3216830-49cb-408d-835a-29256e1f25b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_196714d9-a063-4a43-bfcd-66002f4b3c54_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_623981c6-e155-4762-833c-382aef28e9aa_terseLabel_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva</link:label>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:to="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_34e3f164-c295-4ff6-8869-890fa2be3025_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_84953a7d-e56e-4510-aef5-d161d8ca94d9_terseLabel_en-US" xlink:label="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of twelve month sales at which sales milestone payments would be received</link:label>
    <link:label id="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_label_en-US" xlink:label="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of twelve month sales at which sales milestone payments would be received</link:label>
    <link:label id="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_documentation_en-US" xlink:label="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount of twelve month sales upon which sales milestone would be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:href="regn-20221231.xsd#regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:to="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AuditInformationAbstract_label_en-US" xlink:label="lab_regn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_regn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_regn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AuditInformationAbstract" xlink:href="regn-20221231.xsd#regn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AuditInformationAbstract" xlink:to="lab_regn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0b2cdf21-f37b-40b5-a022-357531b9efbe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_665c6341-6cb2-4b36-9eec-8ba6d67e3ab1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_cae4596e-8ad2-4b49-ae52-94d41e4f82a2_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ed26ee1-93cf-4f9d-861d-0c14b97573b3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d4ddff7f-6d7c-44e0-b838-4b82220a1b3e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_ba4ca0d1-196d-47b9-976d-22a4316b7ac3_terseLabel_en-US" xlink:label="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration for Stock Purchase Agreement</link:label>
    <link:label id="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_label_en-US" xlink:label="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made To Acquire Equity Within A Collaboration Agreement</link:label>
    <link:label id="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_documentation_en-US" xlink:label="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made To Acquire Equity Within A Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" xlink:href="regn-20221231.xsd#regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" xlink:to="lab_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_12daf831-4368-4c94-91fa-bfd67a829667_terseLabel_en-US" xlink:label="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, number of doses counterparty to purchase</link:label>
    <link:label id="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_label_en-US" xlink:label="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Doses Counterparty To Purchase</link:label>
    <link:label id="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_documentation_en-US" xlink:label="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Doses Counterparty To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:to="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2e966c9a-19db-4f1f-a1a5-d109b92fcdec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_b31713c4-e2e7-4b07-a8e3-319e3185a7be_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_USGovernmentMember_250c8239-252a-43a6-9057-8a3ca6c7174d_verboseLabel_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_regn_USGovernmentMember_01a39606-54b3-4842-88f3-e123d63fff49_terseLabel_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government</link:label>
    <link:label id="lab_regn_USGovernmentMember_label_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_regn_USGovernmentMember_documentation_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_USGovernmentMember" xlink:to="lab_regn_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_10b30ea3-7372-4200-b7cc-7c0eb9573468_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_387d0a46-f29d-4ca0-a741-51aed0d58319_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_fd69db48-52c8-490b-8811-3a5174e6b191_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_FurnitureOfficeEquipmentAndOtherMember_7900b9b4-7030-4370-bb39-3fb9605afbb7_terseLabel_en-US" xlink:label="lab_regn_FurnitureOfficeEquipmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, office equipment, and other</link:label>
    <link:label id="lab_regn_FurnitureOfficeEquipmentAndOtherMember_label_en-US" xlink:label="lab_regn_FurnitureOfficeEquipmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, Office Equipment And Other [Member]</link:label>
    <link:label id="lab_regn_FurnitureOfficeEquipmentAndOtherMember_documentation_en-US" xlink:label="lab_regn_FurnitureOfficeEquipmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, Office Equipment And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FurnitureOfficeEquipmentAndOtherMember" xlink:href="regn-20221231.xsd#regn_FurnitureOfficeEquipmentAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_FurnitureOfficeEquipmentAndOtherMember" xlink:to="lab_regn_FurnitureOfficeEquipmentAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e44fff3c-b7a4-469c-bbf4-85efdce34efd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest (net of amounts capitalized)</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8021703b-7d69-45eb-b601-4eddfc045b92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7bf3a803-f848-4c6f-bbfe-6257b7c4f797_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RestOfWorldMember_9567225b-7baf-496b-a322-f0b6f55ef211_terseLabel_en-US" xlink:label="lab_regn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World</link:label>
    <link:label id="lab_regn_RestOfWorldMember_label_en-US" xlink:label="lab_regn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_regn_RestOfWorldMember_documentation_en-US" xlink:label="lab_regn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember" xlink:href="regn-20221231.xsd#regn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RestOfWorldMember" xlink:to="lab_regn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f14f9228-1200-4006-91a2-12fe95baa13f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restrictions on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_e48d398c-0d9e-4a11-ba72-1b9d2018ba97_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4c879d6d-1040-4fbe-9fcb-79674f654046_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_39a4c94d-b52c-4334-9114-5e39552cbcdb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8d033399-7775-4584-99da-b53d6b907b66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4d77553b-ca3e-4fd3-ad41-7ebbeca09c3a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_971fb6ff-84e7-471b-9838-1addee6127a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ef02c4e3-ff23-4d73-a196-03ea0b98da6d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e1bce99b-acdb-4b93-87d6-dce5f685b40e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars of shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_78d1d0e0-68e2-4b96-9890-2a3ed59f17b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax attribute carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ApotexIncMember_0c84e8b1-b26a-4245-aef2-b159165f7241_terseLabel_en-US" xlink:label="lab_regn_ApotexIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc.</link:label>
    <link:label id="lab_regn_ApotexIncMember_label_en-US" xlink:label="lab_regn_ApotexIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. [Member]</link:label>
    <link:label id="lab_regn_ApotexIncMember_documentation_en-US" xlink:label="lab_regn_ApotexIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ApotexIncMember" xlink:href="regn-20221231.xsd#regn_ApotexIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ApotexIncMember" xlink:to="lab_regn_ApotexIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_ee24b076-55a6-4de2-9657-fe9ca01e679e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_931488e3-2998-499c-8cb6-e28becff38d6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fdda6d5b-d08e-4150-8e7a-b10c3b048339_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_96e73a1d-debb-464c-81a2-2c8b23eae329_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b0a27789-4d8a-4f4e-8607-5d550192e821_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_42f91493-68d9-4d2e-9ecf-743510b861eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_1b46b9ee-9d2a-45ee-b20b-2f38bf27d24c_negatedTerseLabel_en-US" xlink:label="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_label_en-US" xlink:label="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Foreign Intangible Income, Percent</link:label>
    <link:label id="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_documentation_en-US" xlink:label="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Foreign Intangible Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" xlink:href="regn-20221231.xsd#regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" xlink:to="lab_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48381e7d-2345-445b-96a1-8bbce23a7951_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2504c3b2-11d6-4e34-a0b1-db333d49d4a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, expected amortization, year three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dcd3d022-8362-4ceb-9860-d9e5bc5d64f1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_100b06aa-8b77-4a05-b2a0-f8a2e9ed8562_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_70b93768-3ebf-4e93-af98-a2b5a5bf0b4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_62a045a7-c23b-4701-93e0-101e3515d8aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_056f86c8-2e5e-4d74-8166-c69ed9f65a65_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_6a7a34c9-4f61-475e-ab4f-51282efb0ba3_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CostOfGoodsSoldMember_01130943-4db7-48d1-b3e9-502218a83414_terseLabel_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_regn_CostOfGoodsSoldMember_label_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold [Member]</link:label>
    <link:label id="lab_regn_CostOfGoodsSoldMember_documentation_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember" xlink:href="regn-20221231.xsd#regn_CostOfGoodsSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CostOfGoodsSoldMember" xlink:to="lab_regn_CostOfGoodsSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_681883df-ec2a-411f-80bb-5014b40fdb59_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_709cbadd-f4e4-473b-8bbc-eb5d76d7369f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of lease cost and other information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0e465c38-2e67-4f6f-adc1-6e7a5a1f7e5b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1701268e-f8e6-462f-b5ae-b3d39ff4ab7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_db54a6bb-3c0a-4b27-acaf-c616d28e116a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_52b302b0-fe14-4c79-a7a6-7fc14e3e52de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_8b8749d5-876e-4671-8fca-677f464558c7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3c27fd0a-35b9-4f74-98d3-dc634423df99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_a7fa9ca1-82ef-4bfc-b677-7940d4afe809_terseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Sanofi commercial expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Commercial Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Commercial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember" xlink:href="regn-20221231.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsShareOfCommercialExpensesMember" xlink:to="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_889b4cc0-417e-42a5-a000-3555501d2bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars of shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_7f636d65-7f2f-486d-874d-f9ef16f8ea73_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:to="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_74a99860-2bd5-449a-8c1b-c2a62c324c21_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_db43fffb-0f3c-4a4c-a901-5e559f711cb9_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_aa090d66-5fd9-41c1-ac94-2eec494c6dc5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_15ad9a26-439a-4252-a435-93f2c465568b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_79ccd29f-9e45-4e83-9bd3-2f5c4ebc5d97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of treasury stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_39972d6a-b8e1-4c7d-ba7e-e548aa8b4942_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution expense to 401(k) Savings Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LaboratoryAndOfficeFacilitiesMember_9d95730c-5ea3-472d-9a12-acaa4e524a02_terseLabel_en-US" xlink:label="lab_regn_LaboratoryAndOfficeFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Facilities</link:label>
    <link:label id="lab_regn_LaboratoryAndOfficeFacilitiesMember_label_en-US" xlink:label="lab_regn_LaboratoryAndOfficeFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facilities [Member]</link:label>
    <link:label id="lab_regn_LaboratoryAndOfficeFacilitiesMember_documentation_en-US" xlink:label="lab_regn_LaboratoryAndOfficeFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LaboratoryAndOfficeFacilitiesMember" xlink:href="regn-20221231.xsd#regn_LaboratoryAndOfficeFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LaboratoryAndOfficeFacilitiesMember" xlink:to="lab_regn_LaboratoryAndOfficeFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fbc93a40-def5-423c-ac33-9055764f7e4e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2e2b2eba-0dd4-4a3a-93ad-bb207bc191d6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_79f91bd8-fbad-4d48-8bcd-a7943ff1b91a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_66ea1228-a1e6-4766-951f-33793efb54a5_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e4d88df1-ea16-47c2-8003-9e39fbdbd15d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_befc2c6c-1b50-410a-bd75-2cb23ef20e27_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_08596ac4-5360-460a-8406-0a90a691afd8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_11e7e55e-f3e3-496a-9646-4cc0108af6c0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9b846196-2d90-4b59-890b-c2b3f242949f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock_6cde02a7-1a62-44d5-8a84-3e529755f85c_terseLabel_en-US" xlink:label="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales related deductions activity</link:label>
    <link:label id="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock_label_en-US" xlink:label="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sales Related Deductions Activity [Table Text Block]</link:label>
    <link:label id="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock_documentation_en-US" xlink:label="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the activity of sales-related deductions during the period, which includes rebates, chargebacks, discounts, and distributor-related fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" xlink:href="regn-20221231.xsd#regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" xlink:to="lab_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_699c655b-1800-4f99-b0d1-379dce7468ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_234e0307-561e-488f-bb7a-dda0bc7183a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_9b06674c-ae53-4268-ac54-b04a04d75d14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3306c02e-ac12-442b-8034-b9f87331cb5b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_261635c0-3b72-4cb2-9563-69b952681e27_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_d7a405ab-448f-4f35-829e-a5f08f24f580_terseLabel_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development, up-front payment made</link:label>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_label_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment Made</link:label>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_documentation_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:to="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2ad199ed-2473-42a8-9285-cdcaffc339b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be971791-de30-400c-8ac8-8cb1c02bf752_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6f3d1151-8bbc-43d6-9e01-e11505a63b65_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07c57494-fe60-4909-b757-9c258d690158_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_46cfb672-5795-4e50-815a-3adf31d67c1e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_db30ed15-376b-40e1-a31e-01db941d6126_terseLabel_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection</link:label>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_label_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection [Member]</link:label>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_documentation_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember" xlink:href="regn-20221231.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EYLEAAfliberceptInjectionMember" xlink:to="lab_regn_EYLEAAfliberceptInjectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_73a4a5a6-0837-4806-8e1b-f29f6c0f22e6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0130eb37-9784-4169-832a-09b1b88d4346_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_270a7405-f1e6-4629-8b93-a7eb598f64e6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_4b7c3d53-6183-4d32-9e82-5c3d717f0bcd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_733864ed-1cd4-4eea-99d6-d578c53804e6_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_25c39711-b113-4884-a779-e7d6f00da7cc_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_8c157a05-099f-44c2-a6d0-100e110bbc71_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestonesAxis_a7df1693-4564-4cc3-a3bb-3be124eb7c02_terseLabel_en-US" xlink:label="lab_regn_SalesMilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Axis]</link:label>
    <link:label id="lab_regn_SalesMilestonesAxis_label_en-US" xlink:label="lab_regn_SalesMilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Axis]</link:label>
    <link:label id="lab_regn_SalesMilestonesAxis_documentation_en-US" xlink:label="lab_regn_SalesMilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis" xlink:href="regn-20221231.xsd#regn_SalesMilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestonesAxis" xlink:to="lab_regn_SalesMilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_ad2f6558-eeea-42ce-9c8b-a339023743af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a299887-fff9-4dac-a01f-780e5ba376c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_17226de8-08ea-4e4f-bb60-fcbf9183c7c9_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_912c409d-b3cf-48a1-b424-f66b90521e59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_a442723f-caaa-405e-b1ed-1f96f4c256cb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7baf5ae5-300a-4d0f-8348-cba7ff61595c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_35485b13-9a86-4d87-b723-a8885ae2f24b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6bc72fb4-e6bc-4dba-bc56-f43f2766b304_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of transactions involving stock option awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4b55ca9e-5659-4060-9bb2-f4afbad2c7a6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d1140b6a-13df-4948-b0b1-e60cbdf4d89f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_77872908-20ab-4655-8588-67fdbe2aef93_terseLabel_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ex parte reexamination requests</link:label>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_label_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Ex Parte Reexamination, Filed, Number</link:label>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_documentation_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Ex Parte Reexamination, Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber" xlink:href="regn-20221231.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyExParteReexaminationFiledNumber" xlink:to="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_bb33d26f-4a4c-4d41-b400-951f5692be7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5e222e0c-3be9-476e-b408-691c6d10c026_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7a150915-f149-4dd7-93d7-3f3ef684e653_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f4f6f778-739a-4a1e-9a14-c865281a94af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1e35635d-b966-4f3c-8a92-545b8b153f23_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_0076b74c-d400-4906-864b-c9ebc4065e8f_terseLabel_en-US" xlink:label="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of repayment of development balance out of profits</link:label>
    <link:label id="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_label_en-US" xlink:label="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Repayment Of Development Balance Out Of Profits</link:label>
    <link:label id="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_documentation_en-US" xlink:label="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of repayment of development balance out of profits under the collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" xlink:href="regn-20221231.xsd#regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" xlink:to="lab_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fbc8ac90-6fa6-4032-ae2d-f8e3efbd657e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2d77a89a-b79b-47e5-b46c-ad0cfad7dc64_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2324f4e6-fa8f-45c4-8191-1ad12ca3c25c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0acf24c4-3765-4744-bea8-2feddf571d27_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f93873a8-a604-42fc-94bb-d78b4c5e7a4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_958f33c4-4dd4-4ce8-a5cf-b1334bd48d7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UnrestrictedMember_63aa28ff-06cd-443c-9566-25252c67616a_terseLabel_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted</link:label>
    <link:label id="lab_regn_UnrestrictedMember_label_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted [Member]</link:label>
    <link:label id="lab_regn_UnrestrictedMember_documentation_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember" xlink:href="regn-20221231.xsd#regn_UnrestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UnrestrictedMember" xlink:to="lab_regn_UnrestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2dad458e-52f4-4fc4-9fc8-ad4100b14b29_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1fd7b765-568d-4975-879e-f9f9235684eb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_77c2309f-873a-4502-aaaf-e30e518ec15a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_927d205e-a36e-448a-a3f4-336b9281b146_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_94b772af-4d09-43c7-a1dd-6582e170f355_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3d4f2446-0766-4f62-9dd9-731766ede71b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_7b43c7ef-4c5b-4a24-8bcc-c748a4c5f489_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bridge loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0586d417-9d5c-42d3-953f-9568d6168bd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_88ebf269-45fe-462a-95a2-b3c06276b0bf_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a48e3af4-fbc9-4c92-b2df-514bca04f548_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_3f9b3c87-8e0a-48e3-9724-6113f0cb5afe_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative catch-up adjustment to revenue, modification of contract</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_88758187-90e6-4b8e-8b34-26eb949c3a44_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_71f9200c-de5f-4120-939d-d987d2cbe222_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dedbef89-cecf-4b68-9868-6e35268c3437_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value - of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_aea3e1cf-34a3-469a-baed-12f0391f10a7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, expiration period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PaymentsForAssetAcquisition_4b021cad-9053-466c-ad09-5860ec5312d7_negatedTerseLabel_en-US" xlink:label="lab_regn_PaymentsForAssetAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, net of cash acquired</link:label>
    <link:label id="lab_regn_PaymentsForAssetAcquisition_label_en-US" xlink:label="lab_regn_PaymentsForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisition</link:label>
    <link:label id="lab_regn_PaymentsForAssetAcquisition_documentation_en-US" xlink:label="lab_regn_PaymentsForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsForAssetAcquisition" xlink:href="regn-20221231.xsd#regn_PaymentsForAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PaymentsForAssetAcquisition" xlink:to="lab_regn_PaymentsForAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e9be3f38-e50a-4d58-a8f1-9bf21cac31e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold and of collaboration and contract manufacturing</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acc5e0da-8e3a-42e3-afe5-c51592da833b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a54b178-19b7-4644-9c69-3ba0b4ed09d4_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_28b2ad4c-b975-402c-8aa6-22f327ddfcaf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_9eefe15d-9cee-4e64-a715-c962913c31ea_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7311483c-34da-437a-8d64-89af6dc3baf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_df02a1a3-f9d5-462d-a489-08897d96b8fb_terseLabel_en-US" xlink:label="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's share of profits in connection with commercialization of antibodies</link:label>
    <link:label id="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profits (Losses) In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profits (Losses) In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" xlink:href="regn-20221231.xsd#regn_ShareOfProfitsLossesInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" xlink:to="lab_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_b6d1a3bc-2dcf-4aec-9912-192fe76c99a2_terseLabel_en-US" xlink:label="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development and Dupilumab/Itepekimab Eligible Investments</link:label>
    <link:label id="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_label_en-US" xlink:label="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development And Dupilumab/Itepekimab Eligible Investments [Member]</link:label>
    <link:label id="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_documentation_en-US" xlink:label="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development And Dupilumab/Itepekimab Eligible Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" xlink:href="regn-20221231.xsd#regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" xlink:to="lab_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4013ff11-1538-4293-80dc-1a563da7fa42_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected lives from grant date</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4dc7bdce-7684-40f0-ba30-b2e4ebea2b61_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_95719a44-635e-425e-8ef5-050a765fb6b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_d2c714d7-998e-4e4e-bfb1-df5709e1e2f2_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_42ee6404-1b30-47d8-898e-e4de9e175bee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c30f3702-0bad-4fed-bb3c-409e3121215e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3fb2b85f-6bbe-4d4d-9e19-f6bbc909988c_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_9a1740cc-cedb-48d1-8cfb-fc12291303cf_totalLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_dc353637-82ad-49b4-806b-ae62d7cc5b05_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2023Member_1bf18a48-0df1-48a2-9377-ded4763165b4_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2023</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2023Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2023 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2023Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2023Member" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramJanuary2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramJanuary2023Member" xlink:to="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_aeb536d4-b305-45ff-a90d-3c715d0adf2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_dc1d6b2d-d3bc-46df-97c5-800a659aa224_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_5b3287db-85bb-4894-bcfa-be049e722986_verboseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Bayer R&amp;D expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20221231.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RestrictedMember_f87808f8-fc54-4751-b1d2-a1a7377531ce_terseLabel_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted</link:label>
    <link:label id="lab_regn_RestrictedMember_label_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:label id="lab_regn_RestrictedMember_documentation_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember" xlink:href="regn-20221231.xsd#regn_RestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RestrictedMember" xlink:to="lab_regn_RestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_InmazebMember_b28f619d-2990-4c29-8360-573bfb7842b5_terseLabel_en-US" xlink:label="lab_regn_InmazebMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inmazeb</link:label>
    <link:label id="lab_regn_InmazebMember_label_en-US" xlink:label="lab_regn_InmazebMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inmazeb [Member]</link:label>
    <link:label id="lab_regn_InmazebMember_documentation_en-US" xlink:label="lab_regn_InmazebMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inmazeb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InmazebMember" xlink:href="regn-20221231.xsd#regn_InmazebMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_InmazebMember" xlink:to="lab_regn_InmazebMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member_840ac7ce-b8ad-4569-a0a6-83fe9f8965e1_terseLabel_en-US" xlink:label="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended &amp; Restated Long-Term Incentive Plan 2014</link:label>
    <link:label id="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member_label_en-US" xlink:label="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended &amp; Restated Long-Term Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member_documentation_en-US" xlink:label="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended &amp; Restated Long-Term Incentive Plan 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmendedRestatedLongTermIncentivePlan2014Member" xlink:href="regn-20221231.xsd#regn_AmendedRestatedLongTermIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AmendedRestatedLongTermIncentivePlan2014Member" xlink:to="lab_regn_AmendedRestatedLongTermIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_30f40f2a-7cec-4c49-b386-250be6e9f10e_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_FinanceLeaseCost_0dc263bc-9de6-4c43-b6b2-2c79cd824ce6_totalLabel_en-US" xlink:label="lab_regn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs</link:label>
    <link:label id="lab_regn_FinanceLeaseCost_label_en-US" xlink:label="lab_regn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_regn_FinanceLeaseCost_documentation_en-US" xlink:label="lab_regn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FinanceLeaseCost" xlink:href="regn-20221231.xsd#regn_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_FinanceLeaseCost" xlink:to="lab_regn_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UpFrontPaymentReceived_b8d779aa-8edd-4a70-bf63-2074e1e1cc80_terseLabel_en-US" xlink:label="lab_regn_UpFrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment received</link:label>
    <link:label id="lab_regn_UpFrontPaymentReceived_label_en-US" xlink:label="lab_regn_UpFrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment Received</link:label>
    <link:label id="lab_regn_UpFrontPaymentReceived_documentation_en-US" xlink:label="lab_regn_UpFrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment received upon the execution of a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentReceived" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UpFrontPaymentReceived" xlink:to="lab_regn_UpFrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82bc5009-ee01-4e1a-9ec8-2ae18ef95150_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars of shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_67b6bc15-f40d-4b14-823f-622c7d47620a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_f7b3e09d-954a-4612-a495-1395c6d42816_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d0f91932-16c0-4122-b0d1-e474e87e4660_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e5c1b65d-6727-4348-806f-47b3f3d35bf4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value - exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8b6def69-3043-49b5-842e-83c589a29b50_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b383e8b-eb1b-4596-993e-2e16fec46f4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1a5afb4-4eb5-418e-a530-41fc1d8eddf0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d96555d1-188e-473c-9c24-ea4071ec8328_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_23582888-754b-4b30-8f39-83f5a948e760_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes, Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_cbd44393-9f83-4b57-8ef7-5f01e10f275b_terseLabel_en-US" xlink:label="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_label_en-US" xlink:label="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Intangible Assets</link:label>
    <link:label id="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_documentation_en-US" xlink:label="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" xlink:href="regn-20221231.xsd#regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" xlink:to="lab_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6868bf3f-18ba-4e46-b64c-d3c92ed31de8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c5c835c3-aba9-4ed8-b7fb-740a8ec48751_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5cfb9400-d151-492b-9e79-4683f18cf466_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a94c4b3a-8d43-4ac0-b918-7851786d6277_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5152c4d8-3c9b-4353-ba6a-0d60eaa209e7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term - vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_ed5c4870-dcf6-4752-90ee-5a663966d5be_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_113c2061-6fd6-413c-a461-1e62b7c842d8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6532f943-b3f1-4f7e-9ee4-a274e17b1e70_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_4366227f-1658-4a05-9e2d-4acc19ac54dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b6478ac1-728b-4503-ad55-b8ada3baf78c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9b884998-509a-4dca-9211-c07e46ccdab4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d4709ed-52ec-4003-b684-673bfef353a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6f00c834-9732-4f48-96bd-d9a4e322d6ae_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_b77ef9e6-68d6-4c05-abc1-04da1c0b7783_terseLabel_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum transaction agreement payments</link:label>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_label_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Transaction Agreement Payments</link:label>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_documentation_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Transaction Agreement Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments" xlink:href="regn-20221231.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MaximumTransactionAgreementPayments" xlink:to="lab_regn_MaximumTransactionAgreementPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_30abbd8e-7e03-46d9-9609-ac9591f2fab6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9e035b18-d170-4f4f-a38f-3e73fb11fc8f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7c3c643-3bc5-4c88-86f5-82d09783972d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6c393ebd-77c3-4416-8d05-9b3901dde1b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principle amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_6a376984-a6eb-4477-90e9-90fed8f492c9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f017ab55-10d2-4ca8-9f0d-25cf0ca9720e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b820956c-2d61-4453-afc7-a1b214e6d985_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_903800d1-f6d9-4fc6-8f48-d9e969bece61_terseLabel_en-US" xlink:label="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="regn-20221231.xsd#regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_8ead3c6e-418a-4d63-8cbf-57ec7ee35e29_terseLabel_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaboration and contract manufacturing</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_label_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_documentation_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember" xlink:href="regn-20221231.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationandContractManufacturingMember" xlink:to="lab_regn_CollaborationandContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_43738c6e-7978-4ed6-9cbc-8fc656de7e36_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38c1774a-4951-4877-b5a0-c407c6d45f49_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1029f120-6be1-45b5-be4e-b548fec6fccd_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c68fb234-95fe-4439-aaf1-f3ec97c55055_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_76b8c160-33c9-497e-8047-1f2fcea1bd17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_a44f2103-1db8-4880-8466-708725233d84_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PaymentToCollaboratingParty_0fc2a509-6c8c-4f44-8753-fe545fff83ba_negatedTerseLabel_en-US" xlink:label="lab_regn_PaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time payment</link:label>
    <link:label id="lab_regn_PaymentToCollaboratingParty_label_en-US" xlink:label="lab_regn_PaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Collaborating Party</link:label>
    <link:label id="lab_regn_PaymentToCollaboratingParty_documentation_en-US" xlink:label="lab_regn_PaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Collaborating Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentToCollaboratingParty" xlink:href="regn-20221231.xsd#regn_PaymentToCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PaymentToCollaboratingParty" xlink:to="lab_regn_PaymentToCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02014623-3c8a-44b7-b858-e0838e02a8b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4492daca-8dc8-4e4e-9cbc-e7fa8347256b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ea42a70c-639d-44a7-93ce-f7843b83e674_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a5d00455-c92a-4173-ae17-4bf294f0b2bf_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9bea765e-7f3b-4aeb-9c96-6c784adce0f4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationAxis_eed3fd92-bf8b-444a-8c0c-83920472ab04_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis" xlink:to="lab_us-gaap_ContractWithCustomerDurationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_052c240a-e5a0-48d3-be6f-1e28b3ff043a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeDebtSecuritiesOperating_12a4d2cf-6891-4624-819e-d672e4476570_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeDebtSecuritiesOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Debt Securities, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:to="lab_us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4d008d9d-1522-4824-b57c-7af2db807b6c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ccd1527b-ff83-49c6-9e8a-1ad6e72c6848_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_611facd6-dc3c-4659-8504-1eed98284fc0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_976fae42-08fb-4d2c-a67d-252b0d090a9e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OptionToExtendResearchTermPeriod_e205f0a4-4a12-45f6-9997-b4b540c36f9c_terseLabel_en-US" xlink:label="lab_regn_OptionToExtendResearchTermPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential optional extension of research term</link:label>
    <link:label id="lab_regn_OptionToExtendResearchTermPeriod_label_en-US" xlink:label="lab_regn_OptionToExtendResearchTermPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to Extend Research Term, Period</link:label>
    <link:label id="lab_regn_OptionToExtendResearchTermPeriod_documentation_en-US" xlink:label="lab_regn_OptionToExtendResearchTermPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to Extend Research Term, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OptionToExtendResearchTermPeriod" xlink:href="regn-20221231.xsd#regn_OptionToExtendResearchTermPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OptionToExtendResearchTermPeriod" xlink:to="lab_regn_OptionToExtendResearchTermPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_75c61148-46f9-4f03-9fc2-da6c4b8fc3e0_terseLabel_en-US" xlink:label="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time payment in connection with change in Japan arrangement</link:label>
    <link:label id="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_label_en-US" xlink:label="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Payment in Connection With Change in Japan Arrangement [Member]</link:label>
    <link:label id="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_documentation_en-US" xlink:label="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Payment in Connection With Change in Japan Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:href="regn-20221231.xsd#regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:to="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_2a8c4a3a-fb6d-4f71-a84c-f1396f7ef8d2_terseLabel_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARCALYST</link:label>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_label_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcalyst Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember" xlink:href="regn-20221231.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ArcalystNetProductSalesMember" xlink:to="lab_regn_ArcalystNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_6826c004-58ce-43c9-8375-6ca4b4b9bf81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GrossProductRevenueMember_b3578aa8-c754-4794-bb1b-cd41d9e21a86_terseLabel_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Product Revenue</link:label>
    <link:label id="lab_regn_GrossProductRevenueMember_label_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Product Revenue [Member]</link:label>
    <link:label id="lab_regn_GrossProductRevenueMember_documentation_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember" xlink:href="regn-20221231.xsd#regn_GrossProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GrossProductRevenueMember" xlink:to="lab_regn_GrossProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ce4812ba-6848-438d-8cd8-70ae1d95a0f4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_77f716d7-c88a-42d8-905a-a0928be3b128_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9ee9e274-770c-4679-b10a-008a8adb369d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_59c8e296-1eb5-4c57-ac21-05fdae8f8f84_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ComputerEquipmentAndSoftwareMember_c9f97fbf-67ed-453a-b000-cfaed060e279_terseLabel_en-US" xlink:label="lab_regn_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_regn_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_regn_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_regn_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_regn_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ComputerEquipmentAndSoftwareMember" xlink:href="regn-20221231.xsd#regn_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ComputerEquipmentAndSoftwareMember" xlink:to="lab_regn_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7d3e036a-b276-46f9-9734-9f189dbdc9c1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5bcd8111-e479-4f86-a45e-aae21fd24e98_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_aca1a816-a48f-414b-ad57-fa1fe26bfc84_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8ee486b1-a0e1-44c2-8a00-26cba2179ee7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_75956732-3348-4e34-9109-d95df54ce74e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3637a8a1-607b-4d90-b3d1-f68d7222765a_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UpfrontPaymentMade_d99dc292-f752-4f53-b885-4a301103c14e_terseLabel_en-US" xlink:label="lab_regn_UpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made</link:label>
    <link:label id="lab_regn_UpfrontPaymentMade_label_en-US" xlink:label="lab_regn_UpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Made</link:label>
    <link:label id="lab_regn_UpfrontPaymentMade_documentation_en-US" xlink:label="lab_regn_UpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made under a collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpfrontPaymentMade" xlink:href="regn-20221231.xsd#regn_UpfrontPaymentMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UpfrontPaymentMade" xlink:to="lab_regn_UpfrontPaymentMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f744841-b6c6-4a3a-946e-8d28fb5c9423_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c5a6390-29df-45a5-ac04-d6487b695f01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_23d98779-f6c9-4ab0-9b7a-2bccdad2f02d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0a04ac99-7c9e-4f07-b5f4-35e35184d17a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AccruedClinicalTrialExpenseCurrent_5ed30ed4-352d-49b3-bb7a-5b3eaa6d5155_verboseLabel_en-US" xlink:label="lab_regn_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_regn_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_regn_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense Current</link:label>
    <link:label id="lab_regn_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_regn_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) in connection with clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AccruedClinicalTrialExpenseCurrent" xlink:href="regn-20221231.xsd#regn_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_regn_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0fe501cb-d987-440e-bf18-0e5428f10ad6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ExtensionOfResearchTermFee_a40d421d-e35d-41f4-8cf9-594be179c479_terseLabel_en-US" xlink:label="lab_regn_ExtensionOfResearchTermFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of research term fee</link:label>
    <link:label id="lab_regn_ExtensionOfResearchTermFee_label_en-US" xlink:label="lab_regn_ExtensionOfResearchTermFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension Of Research Term Fee</link:label>
    <link:label id="lab_regn_ExtensionOfResearchTermFee_documentation_en-US" xlink:label="lab_regn_ExtensionOfResearchTermFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension Of Research Term Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ExtensionOfResearchTermFee" xlink:href="regn-20221231.xsd#regn_ExtensionOfResearchTermFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ExtensionOfResearchTermFee" xlink:to="lab_regn_ExtensionOfResearchTermFee" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_6e707041-c04c-46ef-8190-81e5acde6cd6_terseLabel_en-US" xlink:label="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. Collaboration Agreement</link:label>
    <link:label id="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_label_en-US" xlink:label="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" xlink:to="lab_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_16a762df-4e10-4ccf-af3f-bddd831b5135_terseLabel_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of damages company is responsible for</link:label>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_label_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Percentage Of Damages Responsible For</link:label>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_documentation_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Percentage Of Damages Responsible For</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:href="regn-20221231.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:to="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_a60c535c-90b7-465c-b0a1-cd428138397b_terseLabel_en-US" xlink:label="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of quarterly profits require to be paid for reimbursement of development costs</link:label>
    <link:label id="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_label_en-US" xlink:label="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs</link:label>
    <link:label id="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_documentation_en-US" xlink:label="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:href="regn-20221231.xsd#regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:to="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1f10f433-d836-4689-a301-73c076aae19b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_e68e7dde-163e-47a5-8849-531c06115598_terseLabel_en-US" xlink:label="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses outside the United States, for collaborating party</link:label>
    <link:label id="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_label_en-US" xlink:label="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses outside the United States, for collaborating party</link:label>
    <link:label id="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_documentation_en-US" xlink:label="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the share of losses outside the United States for the collaborating party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" xlink:href="regn-20221231.xsd#regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" xlink:to="lab_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8b31a4c1-a256-41b7-837e-77b705d9cb54_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b8c78513-a88a-4415-8068-52639e34f976_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_e15df9ae-06b4-44de-a121-23f77b28c10f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RonapreveMember_45c5f098-6c65-4fae-8ddb-7916501fb0f3_terseLabel_en-US" xlink:label="lab_regn_RonapreveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ronapreve</link:label>
    <link:label id="lab_regn_RonapreveMember_label_en-US" xlink:label="lab_regn_RonapreveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ronapreve [Member]</link:label>
    <link:label id="lab_regn_RonapreveMember_documentation_en-US" xlink:label="lab_regn_RonapreveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ronapreve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RonapreveMember" xlink:href="regn-20221231.xsd#regn_RonapreveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RonapreveMember" xlink:to="lab_regn_RonapreveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3374b212-a4a3-4d28-b78d-98da85dec8a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_92cc874f-5936-49eb-934f-f950012482a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f509147f-95e0-457f-976d-b25f3f3f9fdc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d151c4f6-9de2-4eee-af8d-845bd392801d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_0a56e8aa-92eb-4f38-88df-7b7ad595435e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_5a8e0cfa-8591-475e-9682-a27e6f9bde9a_terseLabel_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Agreement</link:label>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_label_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Cross License and Commercialization Agreement [Member]</link:label>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_documentation_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Cross License and Commercialization Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:href="regn-20221231.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:to="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_d4e07036-5f20-4f90-988a-06511ea2ed86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_a402d3be-055c-4fc3-84e5-614ff26d9456_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Table]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Table]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:to="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LongTermIncentivePlan2014Member_1c5a8f44-a611-40a1-ad29-7c1fc0b481ab_terseLabel_en-US" xlink:label="lab_regn_LongTermIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plan 2014</link:label>
    <link:label id="lab_regn_LongTermIncentivePlan2014Member_label_en-US" xlink:label="lab_regn_LongTermIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_regn_LongTermIncentivePlan2014Member_documentation_en-US" xlink:label="lab_regn_LongTermIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plan 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LongTermIncentivePlan2014Member" xlink:href="regn-20221231.xsd#regn_LongTermIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LongTermIncentivePlan2014Member" xlink:to="lab_regn_LongTermIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_42468255-015e-47d0-b154-752d188d76ed_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c3318af9-a66a-493a-9fd4-1791e6e84bd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1a180ede-c09f-4aa0-8d25-4db57b755cd7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationDomain_9b966d48-35d8-4262-a3ed-f3892839de95_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain" xlink:to="lab_us-gaap_ContractWithCustomerDurationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a66f7e60-b270-40d6-9702-d30e16d0b087_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8b7101de-2c8a-4f09-81dd-13bc7bea1a8e_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_5924e31b-4c5b-424b-9c08-95d3201cb41a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_49dd6860-b083-48cf-aff6-dacb27aa8aa9_terseLabel_en-US" xlink:label="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Expenses</link:label>
    <link:label id="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:href="regn-20221231.xsd#regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="lab_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_47a65105-6f3e-472a-b676-42c20f38c30a_terseLabel_en-US" xlink:label="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment to collaborating party, percentage of net product sales</link:label>
    <link:label id="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_label_en-US" xlink:label="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment to Collaborating Party, Percentage of Net Product Sales</link:label>
    <link:label id="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_documentation_en-US" xlink:label="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment to Collaborating Party, Percentage of Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:href="regn-20221231.xsd#regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:to="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_478db883-fb23-4eb1-bded-c0ecd7f53909_terseLabel_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for achieving sales target for milestone payment, rolling basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_label_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_documentation_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:href="regn-20221231.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:to="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c0e3151e-ba56-49b9-ba2a-9e9c7097e118_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramsMember_8ccb0759-ffc3-4627-9391-557e1416c69b_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Programs</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramsMember_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Programs [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramsMember_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramsMember" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramsMember" xlink:to="lab_regn_ShareRepurchaseProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_357354e3-43be-4da1-b190-aa28acc52fa2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_b48b2c0a-a82b-4cbc-9e07-256d6bca796e_terseLabel_en-US" xlink:label="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement</link:label>
    <link:label id="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_label_en-US" xlink:label="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" xlink:to="lab_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2a4d4330-a0b5-4f55-8679-758a4aec67b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares (In millions)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_38aa8077-5b6a-458b-b6ca-9d8dfdbdc542_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9ececbed-90e3-4cb7-b572-9416267787e5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of concentration of risk, by risk factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_38a22637-0c3f-4c63-8bbd-bd4db8f6c480_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_9325a9c6-91c0-42d6-8e68-d20816f9dfec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_3e132754-2237-465c-97c5-e7bcadcf1477_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of activity related to performance-based awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5a35d1d0-68db-4c87-b690-cdbcb3bcd2da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value - outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_63c806df-a872-4c4d-9541-d488d6a6d86f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b7aaca90-dd4d-424b-9209-a7ba2623935f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f01d871c-25b3-4f7b-a3be-a7e3e3885727_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_05643858-8b1f-4491-a0b6-d1ec8fe17194_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneThreeMember_d3807389-05ff-4df5-a380-86f1bee36b14_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Milestone</link:label>
    <link:label id="lab_regn_SalesMilestoneThreeMember_label_en-US" xlink:label="lab_regn_SalesMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Three [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneThreeMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneThreeMember" xlink:href="regn-20221231.xsd#regn_SalesMilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneThreeMember" xlink:to="lab_regn_SalesMilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneTwoMember_b7474efe-ffd3-4aab-ad3f-a23dfbcd2d30_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Two</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneTwoMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Two [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneTwoMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneTwoMember" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneTwoMember" xlink:to="lab_regn_SalesBasedMilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_bbf90e3a-baee-44b2-9077-5391eb1cb39b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_320649fc-cf30-46eb-b6e7-a0a888605bdb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_13588fe2-2f22-47cb-b213-40f0e5f0ad81_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_6c1c9304-35db-4755-b87a-bd4f00dfb34a_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_13e43616-74fe-428a-956a-a6105ccdd189_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_44be5b46-8b22-4ca2-8688-badeb6dfd11e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f7c72f5d-4631-44d3-88bd-c53852d1bc7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18ceab0c-dd8e-4fee-ac3c-95c601e25ef9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_87522d17-fdbe-4dac-ae1c-197a3b92edfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_e4e3d7d2-a75a-48bc-b8fb-11d060f97af8_terseLabel_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty payment that can be used to offset litigation proceedings</link:label>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_label_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalty Payment That Can Be Offset</link:label>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_documentation_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalty Payment That Can Be Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:href="regn-20221231.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:to="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ef5f89cb-2115-46b2-bfa4-d5b2be77ab6b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2356d7ad-8cde-4792-b1df-a9f929281817_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3500307f-c329-44de-a3a0-44aaa1110c8e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A631PatentMember_d8b1d32e-7caa-4997-aa91-d1625f9d22ef_terseLabel_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:label id="lab_regn_A631PatentMember_label_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent [Member]</link:label>
    <link:label id="lab_regn_A631PatentMember_documentation_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember" xlink:href="regn-20221231.xsd#regn_A631PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A631PatentMember" xlink:to="lab_regn_A631PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_f276e625-1adc-4b2b-9310-42283dc81932_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_22e5a5a0-f462-40a6-b7b6-383bc01b38fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c65720cc-d51b-4866-b3fb-f845d8ccad82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_0df9d7db-fa50-4c45-9127-23131b0daf25_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_dc1c0260-8037-42ef-ba8f-7edce0ec4ff2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_eaa2b0e7-a618-4e0a-8f1c-76183bcc49a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f6b99183-d1fd-49f2-9ea5-e49b240a7d4a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5ae0b81c-6e8e-459e-a5cb-a4c29cfaa14f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, expected amortization, year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_8ab76926-5e25-454b-814d-c25770b0b759_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_ef82054b-5b89-49c6-8202-0b562dc45695_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_51523f21-b62e-4e39-be85-59a21ffffb0a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ProductRightsMember_aa683296-5656-4d13-9101-a1ee231f8fde_terseLabel_en-US" xlink:label="lab_regn_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired product rights - Libtayo</link:label>
    <link:label id="lab_regn_ProductRightsMember_label_en-US" xlink:label="lab_regn_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:label id="lab_regn_ProductRightsMember_documentation_en-US" xlink:label="lab_regn_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ProductRightsMember" xlink:href="regn-20221231.xsd#regn_ProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ProductRightsMember" xlink:to="lab_regn_ProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_631b8bdd-824e-46fb-af11-aa1207c1b6ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_620cff5d-5413-44b4-8d76-86698760ed06_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b6ef9285-32e2-4cdb-9f5a-986d3ee3ae26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a80ebd18-dfa9-45ee-8412-66c5d9f28685_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_257b64ff-def7-47c2-9272-1eb6925388e4_terseLabel_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.800% Senior Notes due September 2050</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_label_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2050 [Member]</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_documentation_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SeniorUnsecuredNotesDue2050Member" xlink:to="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneFiveMember_3ee598c7-960b-47f3-8d11-3cad5a52fafb_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Five</link:label>
    <link:label id="lab_regn_SalesMilestoneFiveMember_label_en-US" xlink:label="lab_regn_SalesMilestoneFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Five [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneFiveMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFiveMember" xlink:href="regn-20221231.xsd#regn_SalesMilestoneFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneFiveMember" xlink:to="lab_regn_SalesMilestoneFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1aa4a922-eea9-4c87-b576-280f08ab7e73_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6ca68f9c-7205-4dbf-a27a-e1d92ffee7c6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CheckmatePharmaceuticalsIncMember_2292055a-87b0-4e42-b873-052d67d6d1ee_terseLabel_en-US" xlink:label="lab_regn_CheckmatePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Checkmate Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_regn_CheckmatePharmaceuticalsIncMember_label_en-US" xlink:label="lab_regn_CheckmatePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Checkmate Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_regn_CheckmatePharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_regn_CheckmatePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Checkmate Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CheckmatePharmaceuticalsIncMember" xlink:href="regn-20221231.xsd#regn_CheckmatePharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CheckmatePharmaceuticalsIncMember" xlink:to="lab_regn_CheckmatePharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_41d76b16-8bdb-4157-9881-c11704785473_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5c9cc05a-79b5-48df-9316-6abdc3b7a336_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ab1feb82-038a-47cf-b035-02b89d042b03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value - vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_f236c68d-46be-4b00-a955-4970108e93ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less, accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_3cf2c424-0060-484f-996b-a9eb9a77d370_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, based on contractual maturity dates</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_32dcc79c-6e1c-41cb-b175-fa060075b36e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fa55e77f-8238-46a0-abce-baa8fd622eb9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a9cbdc6a-c2eb-485d-add4-2347a963545f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2a0599e-102d-4667-8f87-324055d92645_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_REGENCOVMember_b4e5a5d4-4db5-4ae1-9c70-2c75a9e7c053_terseLabel_en-US" xlink:label="lab_regn_REGENCOVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGEN-COV</link:label>
    <link:label id="lab_regn_REGENCOVMember_label_en-US" xlink:label="lab_regn_REGENCOVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGEN-COV [Member]</link:label>
    <link:label id="lab_regn_REGENCOVMember_documentation_en-US" xlink:label="lab_regn_REGENCOVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGEN-COV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember" xlink:href="regn-20221231.xsd#regn_REGENCOVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_REGENCOVMember" xlink:to="lab_regn_REGENCOVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_01d86a12-188d-467d-b8dd-5e5a06f5abde_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LongTermIncentivePlan2000Member_c6deef21-c513-4fe3-9224-d3e60ae5a05c_terseLabel_en-US" xlink:label="lab_regn_LongTermIncentivePlan2000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plan 2000</link:label>
    <link:label id="lab_regn_LongTermIncentivePlan2000Member_label_en-US" xlink:label="lab_regn_LongTermIncentivePlan2000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plan 2000 [Member]</link:label>
    <link:label id="lab_regn_LongTermIncentivePlan2000Member_documentation_en-US" xlink:label="lab_regn_LongTermIncentivePlan2000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plan 2000 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LongTermIncentivePlan2000Member" xlink:href="regn-20221231.xsd#regn_LongTermIncentivePlan2000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LongTermIncentivePlan2000Member" xlink:to="lab_regn_LongTermIncentivePlan2000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UpFrontPaymentToCollaboratingParty_61aa3438-c3ce-41b2-a25a-d2bbfec983a3_terseLabel_en-US" xlink:label="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment to collaborating party</link:label>
    <link:label id="lab_regn_UpFrontPaymentToCollaboratingParty_label_en-US" xlink:label="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment to Collaborating Party</link:label>
    <link:label id="lab_regn_UpFrontPaymentToCollaboratingParty_documentation_en-US" xlink:label="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment to Collaborating Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UpFrontPaymentToCollaboratingParty" xlink:to="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a148ab79-d661-4191-9ea6-9268f44c70b3_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis_e3d90455-31bb-4783-96f9-535a1dbb3662_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Agreements [Axis]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Agreements [Axis]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The research collaboration and licensing agreements entered into.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis" xlink:to="lab_regn_ResearchCollaborationAndLicensingAgreementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e0b371b0-65fb-4d96-ba59-878a3bd9383d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f09e96c7-e5ef-4145-bca5-8ee5d28ae4bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_d10c56a3-953c-43e6-9156-d4aa63120d2f_terseLabel_en-US" xlink:label="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting share of profits outside the United States, based on sales, for company</link:label>
    <link:label id="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_label_en-US" xlink:label="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting share of profits outside the United States, based on sales, for Company</link:label>
    <link:label id="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_documentation_en-US" xlink:label="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:href="regn-20221231.xsd#regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:to="lab_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7f8f5774-a527-44eb-b138-915415648f0e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c9fcbe33-7919-4595-9284-bacb91d6d3f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be95be30-d04c-43c0-b31f-d42944067ade_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_604abc7e-924b-4631-884b-dfb1e5a851cf_terseLabel_en-US" xlink:label="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of awards</link:label>
    <link:label id="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_label_en-US" xlink:label="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration</link:label>
    <link:label id="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_documentation_en-US" xlink:label="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The term (in years) when the equity-based award expires as specified in the award agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="regn-20221231.xsd#regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:to="lab_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cf66d00d-d108-4e3d-95a6-ea01b9f558bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_416dec34-8a44-4800-b018-8eb06e7d1956_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards and restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_d555ad1f-4431-4576-9317-0ef8019e2070_terseLabel_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for manufacturing of commercial supplies</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_label_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:href="regn-20221231.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:to="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e1d64c83-d977-4180-9f4c-567bce5a6f96_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_f5d79a34-d349-482f-8732-fc38a2db382f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of issued senior unsecured notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_781bccd8-6d04-4e36-8258-8fcdb491e1ea_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a31493b-81fd-4561-ba92-f87c8e41567e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_883ff83b-084e-4e2e-b0e5-fbe0beb337ba_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment to be made to collaborator</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_0b64795b-4ed3-4001-a854-88a804b982e3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_873bbe1d-efb4-42bf-9c8f-6b1c256271d9_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_ff5d9cf1-3a69-4b0d-8dcd-43178eeb4cd7_terseLabel_en-US" xlink:label="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share of profits used to reimburse collaborating party for trial costs</link:label>
    <link:label id="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_label_en-US" xlink:label="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs</link:label>
    <link:label id="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_documentation_en-US" xlink:label="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:href="regn-20221231.xsd#regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:to="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5cca26b0-5ed2-452f-a20f-0551c812dd99_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f623ec7b-60a0-4722-9658-b0e8cd17c363_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_d6b6670a-f5e9-47ed-8011-b02c63fafe04_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_44110ad4-7f5b-4e40-8e21-74c92ecc28ec_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d2590fd1-9723-4538-8962-2e8b06f9b290_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8123c90a-680d-46e1-9b54-1f6527d9bda8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_e533b531-e4bc-4191-b3fd-4f229743107d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_99c693a7-0b38-4ed6-834b-5fce6b6086f7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a0c33e0e-0c3f-433d-9ba2-33341634134d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MarketableAndOtherSecuritiesGainLoss_5bb4e0ce-cb45-4b8d-af78-abd8a97fa942_negatedLabel_en-US" xlink:label="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses (gains) on marketable and other securities, net</link:label>
    <link:label id="lab_regn_MarketableAndOtherSecuritiesGainLoss_label_en-US" xlink:label="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable and Other Securities, Gain (Loss)</link:label>
    <link:label id="lab_regn_MarketableAndOtherSecuritiesGainLoss_documentation_en-US" xlink:label="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable and Other Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableAndOtherSecuritiesGainLoss" xlink:href="regn-20221231.xsd#regn_MarketableAndOtherSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MarketableAndOtherSecuritiesGainLoss" xlink:to="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c5028473-4d13-4117-b623-20f76e88fd45_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations_1e4770f8-3577-4400-ac51-a4af19bb6cd8_negatedLabel_en-US" xlink:label="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases due to settlements and lapse of statutes of limitations</link:label>
    <link:label id="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:label id="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations_documentation_en-US" xlink:label="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="regn-20221231.xsd#regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_2b1a9015-17dc-43d6-b19b-fcb4ac131756_terseLabel_en-US" xlink:label="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending share of profits outside the United States, based on sales, for collaborating party</link:label>
    <link:label id="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_label_en-US" xlink:label="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending share of profits outside the United States, based on sales, for collaborating party</link:label>
    <link:label id="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_documentation_en-US" xlink:label="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:href="regn-20221231.xsd#regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:to="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_d29e2986-365e-4040-bb24-9dd8cc143d19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_b03afe45-d2e2-41b0-8fb2-5dc8384eb1b4_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense, net of reimbursements from collaborators</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_332d4887-8a87-472d-9c4f-3c8abaedb6d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_a4632150-cffc-402a-9211-a23ee731688e_terseLabel_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.750% Senior Notes due September 2030</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_label_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2030 [Member]</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_documentation_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SeniorUnsecuredNotesDue2030Member" xlink:to="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_de417f39-d173-4920-abd2-b73c2693fb56_terseLabel_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Transaction Agreement</link:label>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_label_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA, Other Transaction Agreement [Member]</link:label>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_documentation_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA, Other Transaction Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember" xlink:href="regn-20221231.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BARDAOtherTransactionAgreementMember" xlink:to="lab_regn_BARDAOtherTransactionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_97a19629-b524-4685-ae0a-908a787e2546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationRevenueMember_f7d1b159-354a-40d3-87ff-db300f4d8d56_terseLabel_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration revenue</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_58d58bfd-00bb-4a67-b4da-47aecaa2bbca_verboseLabel_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration revenue</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_label_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationRevenueMember" xlink:to="lab_regn_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_c44dcd5c-c83f-42cc-8443-bea1ccf5664a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_f35628d3-686b-4c32-ba2a-20449f1d185b_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provides general categories of investments for which information is required or determined to be disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentDomain" xlink:to="lab_regn_ClassificationOfInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_856492ec-0f83-476b-86f3-366d3450be12_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments in connection with Common Stock tendered for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c214c79f-0c80-426a-bd7a-1f07d6e33290_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentNetProductSalesMember_b1a03616-3580-47d9-84f1-4dca38f61d11_terseLabel_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_label_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember" xlink:href="regn-20221231.xsd#regn_PraluentNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentNetProductSalesMember" xlink:to="lab_regn_PraluentNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_00c77e9d-aa63-41c3-8513-4c5fba430e96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_76f805d0-bb33-4f07-9cbb-42850937e3f1_terseLabel_en-US" xlink:label="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of sales milestone payments if total sales achieve specific levels</link:label>
    <link:label id="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_label_en-US" xlink:label="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of sales milestone payments if total sales achieve specific levels</link:label>
    <link:label id="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_documentation_en-US" xlink:label="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:href="regn-20221231.xsd#regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:to="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_85499108-b099-4bd2-b83d-32719f40b4f1_terseLabel_en-US" xlink:label="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending share of profits outside the United States, based on sales, for company</link:label>
    <link:label id="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_label_en-US" xlink:label="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending share of profits outside the United States, based on sales, for Company</link:label>
    <link:label id="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_documentation_en-US" xlink:label="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:href="regn-20221231.xsd#regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:to="lab_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_cfccdcd8-dadc-4662-88da-2df7230e918a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_69a47bef-2c96-40a4-8cb9-632aef6a43ec_terseLabel_en-US" xlink:label="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue based on percentage of annual sales in Japan</link:label>
    <link:label id="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_label_en-US" xlink:label="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Based On Percentage Of Annual Sales In Japan</link:label>
    <link:label id="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_documentation_en-US" xlink:label="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:href="regn-20221231.xsd#regn_RevenueBasedOnPercentageOfAnnualSalesInJapan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:to="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ac256134-6eb6-4a1c-adb7-489f76f4d6c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_69877611-9fd0-4ebf-87f1-7a1c4d7f1b11_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7c3071c5-b47e-41d9-a93b-0e466e5365d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_bf6fca2b-d320-4c5c-af21-6df7e7f6ca93_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_58d6e187-ca3f-4896-91e4-610ad246c93c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_6f44fb82-66db-4f1f-b019-ea1278396838_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_00b40d01-bddc-45c0-b5e9-da7cd1adf814_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income before income tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4a21b96a-60ba-4924-8cb1-c750a746c5be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2a64c6d7-272a-465d-ab80-bc646c16b8f6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_4c1873eb-0d0b-4298-9dad-4a49ebbcf4b5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1706456d-65a9-439e-8a23-b7489da9ad44_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b7b1873-a451-4787-8bcf-b81353d1964c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ThreeIndividualCustomersMember_70f1d334-9099-429a-b333-59b09cd7a831_terseLabel_en-US" xlink:label="lab_regn_ThreeIndividualCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three individual customers</link:label>
    <link:label id="lab_regn_ThreeIndividualCustomersMember_label_en-US" xlink:label="lab_regn_ThreeIndividualCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Individual Customers [Member]</link:label>
    <link:label id="lab_regn_ThreeIndividualCustomersMember_documentation_en-US" xlink:label="lab_regn_ThreeIndividualCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Individual Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ThreeIndividualCustomersMember" xlink:href="regn-20221231.xsd#regn_ThreeIndividualCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ThreeIndividualCustomersMember" xlink:to="lab_regn_ThreeIndividualCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26a6b0eb-96a8-4545-9ce9-99a396850ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestonesDomain_00ac4c2e-f3d6-4746-a5c4-8b0cf08ca1c4_terseLabel_en-US" xlink:label="lab_regn_SalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Domain]</link:label>
    <link:label id="lab_regn_SalesMilestonesDomain_label_en-US" xlink:label="lab_regn_SalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Domain]</link:label>
    <link:label id="lab_regn_SalesMilestonesDomain_documentation_en-US" xlink:label="lab_regn_SalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestonesDomain" xlink:to="lab_regn_SalesMilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_e4ff28a3-a130-4110-9ad1-f74bacba45a9_terseLabel_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BayerCollaborationAgreementMember" xlink:to="lab_regn_BayerCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b6ac1b1-afbd-4aad-9bfb-7acd8f14553f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation charges</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_7bd704c9-51b9-4b75-8655-718d64cb64b1_terseLabel_en-US" xlink:label="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of non-inventory related assets between foreign subsidiaries</link:label>
    <link:label id="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_label_en-US" xlink:label="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Sale Of Non-Inventory Related Assets Between Foreign Subsidiaries, Percent</link:label>
    <link:label id="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_documentation_en-US" xlink:label="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Sale Of Non-Inventory Related Assets Between Foreign Subsidiaries, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" xlink:href="regn-20221231.xsd#regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" xlink:to="lab_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c6ebd8be-02f0-4e5f-ab7c-e2117a5a5c31_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_947dbbac-4d13-4f36-a591-559b90a5b29b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_59b2c370-6c33-41ea-8e0c-9abf60371e7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_label_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryNetOfReserves" xlink:to="lab_us-gaap_OtherInventoryNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CelltrionIncMember_f8744f78-b326-4ed9-99cd-8d37f6dcf4aa_terseLabel_en-US" xlink:label="lab_regn_CelltrionIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celltrion, Inc.</link:label>
    <link:label id="lab_regn_CelltrionIncMember_label_en-US" xlink:label="lab_regn_CelltrionIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celltrion, Inc. [Member]</link:label>
    <link:label id="lab_regn_CelltrionIncMember_documentation_en-US" xlink:label="lab_regn_CelltrionIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celltrion, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CelltrionIncMember" xlink:href="regn-20221231.xsd#regn_CelltrionIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CelltrionIncMember" xlink:to="lab_regn_CelltrionIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e5bb0518-cf9e-47c9-94a1-55a1424847d4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b2e0b550-2ce0-4786-a78b-09c586413855_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b344b4ab-06a1-4a0f-97ea-50475d67a703_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegulatoryMilestoneMember_57ca96cf-d465-4f1f-aee7-6645b68a4136_terseLabel_en-US" xlink:label="lab_regn_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_regn_RegulatoryMilestoneMember_label_en-US" xlink:label="lab_regn_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_regn_RegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_regn_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegulatoryMilestoneMember" xlink:href="regn-20221231.xsd#regn_RegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegulatoryMilestoneMember" xlink:to="lab_regn_RegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a2be497f-69e4-4d28-a6b4-b1dad87fe2ac_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_9ac9aa48-166b-4eea-8553-9d28d21fcfbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_93cb99d0-90de-49c8-b7a3-9d3b5acb0501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes, United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_9bba3eb3-8349-41d3-aca8-64eaff136289_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0c1434cb-47cc-41c4-ad16-e5441a66c521_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8efd6775-a14a-4a3b-8294-edc0afa99f27_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on equity securities in other income (expense)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock_1eb00ca2-4853-462a-81c6-132290fc02d2_terseLabel_en-US" xlink:label="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recognized in the Condensed Consolidated Balance Sheet</link:label>
    <link:label id="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="regn-20221231.xsd#regn_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_regn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_b38bda74-45e3-4508-817b-23e831e538db_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_4ba82d88-173c-4165-828e-b8d873f83360_terseLabel_en-US" xlink:label="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions</link:label>
    <link:label id="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_label_en-US" xlink:label="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percentage Of Outstanding Shares That May Be Acquired, Under 'Standstill' Provisions</link:label>
    <link:label id="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_documentation_en-US" xlink:label="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum percentage of outstanding shares of the Company's Class A Stock and Common Stock that may be acquired under the 'standstill' provisions, in effect after the specified date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" xlink:href="regn-20221231.xsd#regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" xlink:to="lab_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_579691f1-71b4-49ea-8c88-31e0d92a105c_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements with Royalty Provisions</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e31be1ff-0451-448a-9fd0-d64354bb8f9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c50ff9a6-4c47-4451-a99a-e2b206da4cef_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_012b7825-1d5a-444a-9495-7c969cb2a11e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_64b68c03-8385-4ba7-8846-f0551a5b1df3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1b0272fd-e821-4906-bdb6-378e1debae31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7b109caa-b5b1-4c3d-b01b-954e411dcdab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_964d77a8-f4cf-44c2-82f7-2c84a167b88e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7da0732d-4477-4f5f-9f1e-85d47e4fd86b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PotentialExtensionOfResearchTerm_62766492-aefc-4f79-9d1f-b7566a0685c8_terseLabel_en-US" xlink:label="lab_regn_PotentialExtensionOfResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential automatic extension of research term</link:label>
    <link:label id="lab_regn_PotentialExtensionOfResearchTerm_label_en-US" xlink:label="lab_regn_PotentialExtensionOfResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Extension Of Research Term</link:label>
    <link:label id="lab_regn_PotentialExtensionOfResearchTerm_documentation_en-US" xlink:label="lab_regn_PotentialExtensionOfResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Extension Of Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PotentialExtensionOfResearchTerm" xlink:href="regn-20221231.xsd#regn_PotentialExtensionOfResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PotentialExtensionOfResearchTerm" xlink:to="lab_regn_PotentialExtensionOfResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f458768d-3021-4f95-8da2-5d11dbdb153a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_d8485f31-2607-4576-9f7f-8176b1ff29af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_d77a24ff-61bf-4c2f-87d5-88b153c4ba0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_75bd9b7b-0a39-4ca7-abe7-1530b1f65f35_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14e1becf-a3d7-4929-ba52-a0e44284ac10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_73adf647-82b6-4084-8ce7-6a253deaa732_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyRateMaximum_ccdde175-b981-40f7-ac65-e3a3fa815cce_terseLabel_en-US" xlink:label="lab_regn_RoyaltyRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate maximum</link:label>
    <link:label id="lab_regn_RoyaltyRateMaximum_label_en-US" xlink:label="lab_regn_RoyaltyRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate maximum</link:label>
    <link:label id="lab_regn_RoyaltyRateMaximum_documentation_en-US" xlink:label="lab_regn_RoyaltyRateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum royalty rate to be paid to the Company under the agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyRateMaximum" xlink:href="regn-20221231.xsd#regn_RoyaltyRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyRateMaximum" xlink:to="lab_regn_RoyaltyRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_536622bb-b087-4f2f-b32a-4974f4e7b5db_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4ca74ecc-5635-4fe0-90c7-e8ceab6fe467_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d4d5218b-9d29-4554-bee2-b890568121bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_InitialResearchTerm_9e0fb7d5-c5aa-423f-9d13-700dffdf85ca_terseLabel_en-US" xlink:label="lab_regn_InitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term</link:label>
    <link:label id="lab_regn_InitialResearchTerm_label_en-US" xlink:label="lab_regn_InitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term</link:label>
    <link:label id="lab_regn_InitialResearchTerm_documentation_en-US" xlink:label="lab_regn_InitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InitialResearchTerm" xlink:href="regn-20221231.xsd#regn_InitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_InitialResearchTerm" xlink:to="lab_regn_InitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_a0995f47-ca0a-489f-8404-c1633a0e8b91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average exercise prices and weighted-average grant-date fair values of options issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_abe2a72d-406f-4482-87ac-2b1e064fffdc_terseLabel_en-US" xlink:label="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement additional payment eligible</link:label>
    <link:label id="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_label_en-US" xlink:label="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Eligible, Milestone</link:label>
    <link:label id="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_documentation_en-US" xlink:label="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Eligible, Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" xlink:to="lab_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_89cd1e86-ffb1-4d2c-bbcb-b7fa13f5acaf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_dc7153a8-9dab-4adf-a04e-5d805c7993e6_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of product sales</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_d24ab4f9-4b68-4c63-8eac-c41c9dee6467_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of collaboration revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_b84641da-cb5b-4ea6-8c41-c5fd50109dc2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A338PatentAnd069PatentMember_9b91fb4f-901d-4e61-abfa-d4e986ff670f_terseLabel_en-US" xlink:label="lab_regn_A338PatentAnd069PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'338 Patent and '069 Patent</link:label>
    <link:label id="lab_regn_A338PatentAnd069PatentMember_label_en-US" xlink:label="lab_regn_A338PatentAnd069PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'338 Patent And '069 Patent [Member]</link:label>
    <link:label id="lab_regn_A338PatentAnd069PatentMember_documentation_en-US" xlink:label="lab_regn_A338PatentAnd069PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'338 Patent And '069 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A338PatentAnd069PatentMember" xlink:href="regn-20221231.xsd#regn_A338PatentAnd069PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A338PatentAnd069PatentMember" xlink:to="lab_regn_A338PatentAnd069PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NonPerformanceBasedStockOptionsMember_519546ea-5644-43a7-a263-2c38db8b06f8_terseLabel_en-US" xlink:label="lab_regn_NonPerformanceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-performance based stock options</link:label>
    <link:label id="lab_regn_NonPerformanceBasedStockOptionsMember_label_en-US" xlink:label="lab_regn_NonPerformanceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Performance Based Stock Options [Member]</link:label>
    <link:label id="lab_regn_NonPerformanceBasedStockOptionsMember_documentation_en-US" xlink:label="lab_regn_NonPerformanceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A stock option whose vesting is not contingent upon performance achievements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NonPerformanceBasedStockOptionsMember" xlink:href="regn-20221231.xsd#regn_NonPerformanceBasedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NonPerformanceBasedStockOptionsMember" xlink:to="lab_regn_NonPerformanceBasedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_931c5150-097b-484e-b403-c5db66ebf4fa_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_8ea41ec1-4985-4570-af00-279bb41838bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_967af95f-fd7c-47f2-8b2b-6a290fb99be7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1f2e7d7-0793-4366-9e97-c3d9d6fe26f4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_14da05d3-706a-437d-8644-253187c3cdb7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchase price</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6d7e94fe-47bf-4883-85e5-6fb69ecf2d17_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets and intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_89dc36d9-2a9c-4409-9f8d-375097f9d087_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_9ab9a3b5-9d67-4726-9715-2ae67a7d89fb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, expected amortization, year five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d2b99f78-51f4-4efb-b8c0-7d646622576c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dbed6e43-bbd7-4b8a-a6f9-7d545c31e6a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_48ef7e4d-3d63-4f9c-a4eb-c170d0c4bfff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_db71489e-d098-419e-a323-d1a02b7051f9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e09174db-f4e4-4817-aa6d-1b4dc6276425_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73538504-9cae-4a00-a9f4-2488763822bc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_17d13b59-a88d-46db-a2f8-bffdafe5e675_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9c5ff85c-29a8-4457-9d67-aba2d4b5093a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b620d78c-f4f9-42f9-999c-e027d6c7df37_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, License, and Other Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_22323be2-56d5-4a92-bb54-ad8f1aa3fafc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_50eddab9-e9c5-4ced-b9e6-9a239fa0ac2d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0468d08d-a7ed-45a3-b2dd-370f765610be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_f29ca43b-c342-4f96-b0c6-b38519609589_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_042f5c64-0b1d-4528-8c63-fc81cfb81ecf_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6963d91c-0587-4f9b-838b-5b258fab4477_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8220cc49-7469-4b08-b52e-3d7af586b19e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_762eb296-9d7f-4aac-9e72-c00068b0008c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_05f7580c-16b6-47cf-97fc-4b630dc6bfe7_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fdc4118c-46fc-4fa4-9fd5-525f46fdf34a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_722f853b-cc9a-4681-9646-194831a7052e_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:to="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_98328e3e-a4ed-465b-b114-19a8ff0b743e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_1af87de4-858a-4179-ba66-02f6f6777986_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development in connection with asset acquisition</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_98b43d0f-57ce-436d-8f8e-28c82155396a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Share Data</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_db9948cd-f87b-4d91-b014-46a2858ee6d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of bridge loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c2429156-2847-44d4-956b-89242fa1f0c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ffbec74-bf4d-460e-9365-31c362c6c3c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d53991be-f3a4-40c8-91e1-ef61a76b64af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationRevenueMember_2ce37702-abe7-4eba-ab7f-f5643869ecf4_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi collaboration revenue</link:label>
    <link:label id="lab_regn_SanofiCollaborationRevenueMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Revenue [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationRevenueMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationRevenueMember" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationRevenueMember" xlink:to="lab_regn_SanofiCollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f74ccbf2-52b1-4d19-a54e-6d4c4f503af7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AcquiredInProcessResearchAndDevelopment_e119ee4c-b2ef-48bb-95f0-3034176a3896_terseLabel_en-US" xlink:label="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_regn_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_regn_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment" xlink:href="regn-20221231.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ab75c075-3c9c-4a1f-bac4-e8ddc36006e7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of R&amp;D expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_337ab4c1-81d5-43b4-ad38-2cca8e4efd0b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of R&amp;D expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4add2cbc-beb7-4586-85f3-6dcc0edd1ed2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_69f3ec5d-4990-429f-98ea-f373ffe1af4a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, expected amortization, year one</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e2c6b638-f8b1-4095-8f7e-576b505aac10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_a3712f8b-9aa1-4375-a2fe-12f2ce90192e_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_56fdcf02-1d0f-479a-b6a0-edf8bec2ca14_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_69d07d4e-3fd5-4305-8498-7c3428f71d42_terseLabel_en-US" xlink:label="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price with change-in-control provision, percentage</link:label>
    <link:label id="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_label_en-US" xlink:label="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage</link:label>
    <link:label id="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_documentation_en-US" xlink:label="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:href="regn-20221231.xsd#regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:to="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>regn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:042488f0-a666-455c-8991-c514440b53f2,g:8bd10ba8-749e-45a5-bb1c-c1abec558824-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ba85e61b-5baa-4c09-8130-e94a71483915" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba85e61b-5baa-4c09-8130-e94a71483915" xlink:to="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9098828f-fd96-49b0-b187-e45ad26f0011" xlink:to="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7a152e33-1626-43c1-85a4-fab723e69555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:to="loc_us-gaap_CommonClassAMember_7a152e33-1626-43c1-85a4-fab723e69555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c27b044-5ef5-4a5b-bc8a-e90cdf5b8253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ee3c21c-5bb6-4786-be86-62a4ee0bfda4" xlink:to="loc_us-gaap_CommonStockMember_1c27b044-5ef5-4a5b-bc8a-e90cdf5b8253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_73802996-964d-4cdb-8fb9-f6f3ec73bd32" xlink:to="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4ce8e41f-f390-43f0-ae76-71ba99db2640" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentType_4ce8e41f-f390-43f0-ae76-71ba99db2640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b2bf5762-53af-478d-b90c-bc0ad230482d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentAnnualReport_b2bf5762-53af-478d-b90c-bc0ad230482d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bb61f076-58ff-4487-8a00-51944387e4f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentPeriodEndDate_bb61f076-58ff-4487-8a00-51944387e4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2a88b01-dead-43a0-b4de-54d3eb64b392" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2a88b01-dead-43a0-b4de-54d3eb64b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ad8ea68e-d66e-4b7c-bd58-eb7203f4c563" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentTransitionReport_ad8ea68e-d66e-4b7c-bd58-eb7203f4c563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_12fe7143-bf7a-4c07-8ee9-31ade3ac062f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityFileNumber_12fe7143-bf7a-4c07-8ee9-31ade3ac062f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_41718f28-24fa-4364-940c-6539efdd1baa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityRegistrantName_41718f28-24fa-4364-940c-6539efdd1baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16f741c5-65a2-4335-bcf2-be38a1731456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16f741c5-65a2-4335-bcf2-be38a1731456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_38552b0b-0c7e-455a-a2b9-b926f779bf79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityTaxIdentificationNumber_38552b0b-0c7e-455a-a2b9-b926f779bf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ab27c10f-9da3-4963-941a-ea80ee81cc7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressAddressLine1_ab27c10f-9da3-4963-941a-ea80ee81cc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3df256ce-d953-45db-89ce-8d183fee78d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressCityOrTown_3df256ce-d953-45db-89ce-8d183fee78d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9bd3e8db-9406-40d7-b2ef-b7207b1ac35c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressStateOrProvince_9bd3e8db-9406-40d7-b2ef-b7207b1ac35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_94894cae-a571-45b6-b09d-254dd08fbb7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityAddressPostalZipCode_94894cae-a571-45b6-b09d-254dd08fbb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_35505163-8563-4b25-8b4d-72257e657373" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_CityAreaCode_35505163-8563-4b25-8b4d-72257e657373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bed64b2f-070b-43f6-b0bc-f30367fd8013" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_LocalPhoneNumber_bed64b2f-070b-43f6-b0bc-f30367fd8013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0aee7c0a-d0af-4663-a908-104d86c954bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_Security12bTitle_0aee7c0a-d0af-4663-a908-104d86c954bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_56c8c561-0d11-4dc8-9981-1aa1fd0eee45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_TradingSymbol_56c8c561-0d11-4dc8-9981-1aa1fd0eee45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_56a4bd7c-c74f-4e9e-899a-2bd0b29c7ff8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_SecurityExchangeName_56a4bd7c-c74f-4e9e-899a-2bd0b29c7ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_dc165e46-1e36-4b58-9d01-f83cef19d645" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_dc165e46-1e36-4b58-9d01-f83cef19d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c03bae3c-2e14-4187-96e7-126db31f955a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityVoluntaryFilers_c03bae3c-2e14-4187-96e7-126db31f955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9fbb0459-d921-4777-a514-73cf61107dc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityCurrentReportingStatus_9fbb0459-d921-4777-a514-73cf61107dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f2002004-9914-4310-bf9c-40bfb91fedcb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityInteractiveDataCurrent_f2002004-9914-4310-bf9c-40bfb91fedcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2551d18b-475c-424a-9b04-cda9bc904260" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityFilerCategory_2551d18b-475c-424a-9b04-cda9bc904260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d1ae7bf0-f32b-42f6-af5b-43fdb888c249" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntitySmallBusiness_d1ae7bf0-f32b-42f6-af5b-43fdb888c249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_543795d7-1ea1-4261-92d1-dca6d18835de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityEmergingGrowthCompany_543795d7-1ea1-4261-92d1-dca6d18835de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_eee49781-c6fe-47bf-9da0-2c14dab25cc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_IcfrAuditorAttestationFlag_eee49781-c6fe-47bf-9da0-2c14dab25cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f2ba4332-c76d-4d15-85ae-f62f5ee623e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityShellCompany_f2ba4332-c76d-4d15-85ae-f62f5ee623e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5cd97e95-28fb-41e2-af50-3612ae5ce370" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityPublicFloat_5cd97e95-28fb-41e2-af50-3612ae5ce370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_508171de-be2b-4dc3-9ac8-329fffc8ac02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_508171de-be2b-4dc3-9ac8-329fffc8ac02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_31284aa1-27d8-4554-a088-e3234008b8dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_31284aa1-27d8-4554-a088-e3234008b8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bec16d0c-8c8b-4cce-9e0d-a2c14882721a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_EntityCentralIndexKey_bec16d0c-8c8b-4cce-9e0d-a2c14882721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_496d186d-d6ba-4851-be56-97010e580d83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentFiscalYearFocus_496d186d-d6ba-4851-be56-97010e580d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_962c9aee-8bac-4878-9d01-29df08a00d4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_DocumentFiscalPeriodFocus_962c9aee-8bac-4878-9d01-29df08a00d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7f0f7364-acd0-41c8-9089-d4f462bbdd8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e73a7422-3761-45c0-aafb-7c3991f9b571" xlink:to="loc_dei_AmendmentFlag_7f0f7364-acd0-41c8-9089-d4f462bbdd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/AuditInformation" xlink:type="simple" xlink:href="regn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_regn_AuditInformationAbstract_95f2da17-2fc7-4274-9ffb-bef20974876d" xlink:href="regn-20221231.xsd#regn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_2ca59313-89fd-4445-8a2d-0163a6db720c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_AuditInformationAbstract_95f2da17-2fc7-4274-9ffb-bef20974876d" xlink:to="loc_dei_AuditorFirmId_2ca59313-89fd-4445-8a2d-0163a6db720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_e54aaeda-a221-4b24-9490-b58488a46100" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_AuditInformationAbstract_95f2da17-2fc7-4274-9ffb-bef20974876d" xlink:to="loc_dei_AuditorName_e54aaeda-a221-4b24-9490-b58488a46100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_a726a1e2-5706-4c8f-b0b5-8e32520b5cb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_AuditInformationAbstract_95f2da17-2fc7-4274-9ffb-bef20974876d" xlink:to="loc_dei_AuditorLocation_a726a1e2-5706-4c8f-b0b5-8e32520b5cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_58f85fee-b6d2-44cb-bafb-1abb3b2c2f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58f85fee-b6d2-44cb-bafb-1abb3b2c2f6e" xlink:to="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_efd9ecc4-6077-4b38-a50c-ec85bcdc2557" xlink:to="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ad41e574-4287-48b3-98e7-268795672b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:to="loc_us-gaap_CommonClassAMember_ad41e574-4287-48b3-98e7-268795672b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_63d81ca6-2301-4796-aa6b-7add7bb24a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_355060a5-478a-41dc-849d-e40f12ec7ad4" xlink:to="loc_us-gaap_CommonStockMember_63d81ca6-2301-4796-aa6b-7add7bb24a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b10b150f-d6da-4ac1-ab5b-d81da3d1ae58" xlink:to="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bcb1695-f1b4-407c-ac21-539f29bca3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bcb1695-f1b4-407c-ac21-539f29bca3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_603167ec-0abf-4e6f-9b6b-1b5da516f376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_603167ec-0abf-4e6f-9b6b-1b5da516f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3fd9abbc-ad93-4b08-8ae0-70d2ee7f5e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3fd9abbc-ad93-4b08-8ae0-70d2ee7f5e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9435c781-d7ee-48da-9044-6049e1b0e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_InventoryNet_9435c781-d7ee-48da-9044-6049e1b0e6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dfa1628b-cca7-44fc-b88d-df474fba0249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dfa1628b-cca7-44fc-b88d-df474fba0249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fb0210bc-cb41-490a-98bc-c3452b83fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_68a2b75e-7214-40db-9b30-35fb8166eace" xlink:to="loc_us-gaap_AssetsCurrent_fb0210bc-cb41-490a-98bc-c3452b83fff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_6d24ee00-e4d6-46fc-a5a8-560ca60181aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_6d24ee00-e4d6-46fc-a5a8-560ca60181aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0c1ef464-72da-4e3c-a706-2172182c0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0c1ef464-72da-4e3c-a706-2172182c0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_61a8eb79-d3ff-480d-ae62-d5cf95b38000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_61a8eb79-d3ff-480d-ae62-d5cf95b38000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_be8232bc-fb55-4170-a65e-12ae23efefd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_be8232bc-fb55-4170-a65e-12ae23efefd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b8e7d019-0e9c-469a-bbf6-b8f34f9d7a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b8e7d019-0e9c-469a-bbf6-b8f34f9d7a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7c436302-f05a-4cb1-bf40-604b850084aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5330f0f3-5c3e-40d0-957b-92d05a83c9f8" xlink:to="loc_us-gaap_Assets_7c436302-f05a-4cb1-bf40-604b850084aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_80d70027-512e-41a1-8aed-93c46751fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_AccountsPayableCurrent_80d70027-512e-41a1-8aed-93c46751fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8dc9dd4e-b631-44fc-9f84-8a052ab10f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8dc9dd4e-b631-44fc-9f84-8a052ab10f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f86b0e13-2dfd-4f1a-9b18-c8a4c1d279b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f86b0e13-2dfd-4f1a-9b18-c8a4c1d279b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d9c23634-e4a3-4d51-affe-ce77bb851dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d9c23634-e4a3-4d51-affe-ce77bb851dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4b52d0bc-9aff-4fd6-be8f-bbb26caefa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b5fbdf-f2f7-4df1-86b9-ef3b60926964" xlink:to="loc_us-gaap_LiabilitiesCurrent_4b52d0bc-9aff-4fd6-be8f-bbb26caefa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6332985c-0c2d-4088-80f5-c7e65c5d7272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6332985c-0c2d-4088-80f5-c7e65c5d7272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b36231a3-2db6-430f-b96a-b0b78495404b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b36231a3-2db6-430f-b96a-b0b78495404b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d735bbf-d9d2-41ac-99d6-69669a907d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d735bbf-d9d2-41ac-99d6-69669a907d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_809de64f-502c-4a29-b77f-4ccdc613a462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_809de64f-502c-4a29-b77f-4ccdc613a462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17a2ca1c-afc1-4714-883f-a4ab92a26285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_Liabilities_17a2ca1c-afc1-4714-883f-a4ab92a26285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3c38d6f2-e9d3-41e9-90d5-a9ba521fe291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3c38d6f2-e9d3-41e9-90d5-a9ba521fe291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8051be3-f369-410d-8951-22390be91e88" xlink:to="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8102b15a-c43a-4e88-b3dd-b7bc196c9d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_PreferredStockValue_8102b15a-c43a-4e88-b3dd-b7bc196c9d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_38da3968-d447-48a4-96fc-04883291de61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_CommonStockValue_38da3968-d447-48a4-96fc-04883291de61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fc03f5db-de88-4d51-bfd4-a0bf567dfd72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fc03f5db-de88-4d51-bfd4-a0bf567dfd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d8414d2-ac40-44c6-ad14-6f1f9e977a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d8414d2-ac40-44c6-ad14-6f1f9e977a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88dedf46-ed20-4f96-a0a2-95c91ac659d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88dedf46-ed20-4f96-a0a2-95c91ac659d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_ff036547-f1d6-4ea5-a224-ed769d5553b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_TreasuryStockCommonValue_ff036547-f1d6-4ea5-a224-ed769d5553b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_16310e0e-4db7-4147-b683-4a778a709a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ae8a31-06be-482f-b242-3781fe1cd583" xlink:to="loc_us-gaap_StockholdersEquity_16310e0e-4db7-4147-b683-4a778a709a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b831805-dc86-41f9-90c3-9e9cbd1df47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b831805-dc86-41f9-90c3-9e9cbd1df47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d26cd0cb-0752-406c-90ee-b7675a8bd8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af4455de-c3a0-4104-997b-3f638e2b3d72" xlink:to="loc_us-gaap_CommonStockSharesIssued_d26cd0cb-0752-406c-90ee-b7675a8bd8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8793add2-57fd-4040-b4e2-721e99b2ca4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8793add2-57fd-4040-b4e2-721e99b2ca4e" xlink:to="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5f447650-625a-4185-b0f1-6da0fccfcdf6" xlink:to="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c1240c01-ad21-4da3-8647-9f5ba77a1e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:to="loc_us-gaap_CommonClassAMember_c1240c01-ad21-4da3-8647-9f5ba77a1e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c95e6a0d-08a4-432f-a160-5ae6d8859d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8d87cac3-1db5-4149-91e7-6006cd25179c" xlink:to="loc_us-gaap_CommonStockMember_c95e6a0d-08a4-432f-a160-5ae6d8859d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_83795dc6-99f5-4b05-a49d-77efe9200263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7510280c-4d9e-4c46-96cb-afbca9129cc9" xlink:to="loc_us-gaap_StatementLineItems_83795dc6-99f5-4b05-a49d-77efe9200263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83795dc6-99f5-4b05-a49d-77efe9200263" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29b7e18c-5bf6-4cb7-9c3d-01a49e1a6f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29b7e18c-5bf6-4cb7-9c3d-01a49e1a6f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ede38e46-72f9-4465-a1cf-26bd7f741b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ede38e46-72f9-4465-a1cf-26bd7f741b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_696e9407-f108-4300-b9f4-3d2af3a04555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockSharesIssued_696e9407-f108-4300-b9f4-3d2af3a04555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_210d9820-8801-42de-8ad6-963a779e1db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_210d9820-8801-42de-8ad6-963a779e1db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7544eaa4-ea21-475c-9840-a2700052d1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7544eaa4-ea21-475c-9840-a2700052d1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_59d58c6d-9300-4c07-b77e-3cdf9a392ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_59d58c6d-9300-4c07-b77e-3cdf9a392ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab253aeb-c9ac-4059-88e4-b9be5122d2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab253aeb-c9ac-4059-88e4-b9be5122d2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8726fe9a-7b52-40a8-91ec-d79e409d5784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8726fe9a-7b52-40a8-91ec-d79e409d5784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_77d96427-3385-4488-bf66-bb04b551aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_828be187-0918-4e1b-a209-bba66805c184" xlink:to="loc_us-gaap_TreasuryStockCommonShares_77d96427-3385-4488-bf66-bb04b551aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_38ace082-634c-4025-a587-2b25f2fa83a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_38ace082-634c-4025-a587-2b25f2fa83a1" xlink:to="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:to="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fa1fc4e1-babf-42e9-8e5e-45159e43425f" xlink:to="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b9673e36-8207-4fd8-9df5-98b53255211c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_us-gaap_ProductMember_b9673e36-8207-4fd8-9df5-98b53255211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationRevenueMember_c4155da5-9e98-4592-a5c2-329d42847798" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_regn_SanofiCollaborationRevenueMember_c4155da5-9e98-4592-a5c2-329d42847798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_2b1ca793-e3dd-4f98-9366-b0638d32eaf2" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_regn_CollaborationRevenueMember_2b1ca793-e3dd-4f98-9366-b0638d32eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3f50b9e2-7f1b-474d-9f15-f1505b2a9422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3f50b9e2-7f1b-474d-9f15-f1505b2a9422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_2228fd70-ce17-43cc-8dab-a4fe16b78056" xlink:href="regn-20221231.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0624e62-45a8-4468-ab9a-6526d9fd83b6" xlink:to="loc_regn_CollaborationandContractManufacturingMember_2228fd70-ce17-43cc-8dab-a4fe16b78056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6845a237-6034-413c-860f-ac7bdbb897f6" xlink:to="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:to="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_72f6c190-1928-48c5-a5de-54dc794bbc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_RevenuesAbstract_72f6c190-1928-48c5-a5de-54dc794bbc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0dc68fab-8582-4ccf-a116-2d9e3ab2a744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_72f6c190-1928-48c5-a5de-54dc794bbc16" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0dc68fab-8582-4ccf-a116-2d9e3ab2a744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_245a1a81-c31e-4698-8bf8-2b202ac07577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_245a1a81-c31e-4698-8bf8-2b202ac07577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment_d0aa03fc-ec6b-4e26-8916-9fadcaac376f" xlink:href="regn-20221231.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_regn_AcquiredInProcessResearchAndDevelopment_d0aa03fc-ec6b-4e26-8916-9fadcaac376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d7526698-08c8-4170-a61f-21e51f3e0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d7526698-08c8-4170-a61f-21e51f3e0782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e75a8630-fc89-4ab2-ad26-4ad56ba2fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e75a8630-fc89-4ab2-ad26-4ad56ba2fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_faad801e-b757-4bcd-8daf-e80a0ac26283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_faad801e-b757-4bcd-8daf-e80a0ac26283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8eab9c1d-cc27-41da-ad19-06becdb2780e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_339464e1-56a8-4374-bc74-5ae4bd1e0ce8" xlink:to="loc_us-gaap_CostsAndExpenses_8eab9c1d-cc27-41da-ad19-06becdb2780e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b48619da-e26d-4980-8926-fc58673256ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_OperatingIncomeLoss_b48619da-e26d-4980-8926-fc58673256ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d377cc97-b64d-4dee-94cb-9db81902cac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d377cc97-b64d-4dee-94cb-9db81902cac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6557481d-5947-469d-97ff-2f747fba1705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:to="loc_us-gaap_InterestExpense_6557481d-5947-469d-97ff-2f747fba1705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d85b1a7c-aaca-41d6-b1d3-1781cbfb8edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_28da134e-3a6d-4bc9-8f76-aacb3e8df82f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d85b1a7c-aaca-41d6-b1d3-1781cbfb8edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_188785be-e2d4-443a-a602-10555dfb57f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_188785be-e2d4-443a-a602-10555dfb57f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a4e205e9-e377-4aa8-aac4-4bad5e2099bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a4e205e9-e377-4aa8-aac4-4bad5e2099bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e9099d8-8005-4d3e-b5ba-90d7f6824912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_NetIncomeLoss_6e9099d8-8005-4d3e-b5ba-90d7f6824912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6aa9d188-e211-4f8b-b31d-d85b68976da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_EarningsPerShareBasic_6aa9d188-e211-4f8b-b31d-d85b68976da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f32a0082-7ba6-4321-ad6c-2ad9f39e08fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f32a0082-7ba6-4321-ad6c-2ad9f39e08fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_02fcb9b1-1d66-4b9d-807e-9f5c39643430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_02fcb9b1-1d66-4b9d-807e-9f5c39643430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a7ca2e92-0d86-4887-afcb-864346c35d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f98bda7-7b2c-4e4b-a808-a011e57f3e2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a7ca2e92-0d86-4887-afcb-864346c35d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a62929de-cfbe-4892-adcc-cdcb6e40e28b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_13fc1acd-a321-455a-9da9-df8116be3a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:to="loc_us-gaap_NetIncomeLoss_13fc1acd-a321-455a-9da9-df8116be3a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_262fd347-e86b-4c0b-a227-7e768b10aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_262fd347-e86b-4c0b-a227-7e768b10aff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_54ff0374-028c-470c-8650-1c62c7c02824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d1874d11-86d0-46d5-b765-0c4f14b670e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_54ff0374-028c-470c-8650-1c62c7c02824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c3aa77ea-6cbf-4199-b5ce-7b17e4e271fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84554324-04eb-4f31-9804-5329352ffb8f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c3aa77ea-6cbf-4199-b5ce-7b17e4e271fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8f9e2717-4ba6-42d6-a80a-36a1144ce252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8f9e2717-4ba6-42d6-a80a-36a1144ce252" xlink:to="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:to="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5282461b-577d-48fd-832c-2c15d89285e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_efd8d497-9a43-46ed-b703-ca964ba76202" xlink:to="loc_us-gaap_ClassOfStockDomain_5282461b-577d-48fd-832c-2c15d89285e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d7e03028-d9bf-483d-a2a8-de91f0d21c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5282461b-577d-48fd-832c-2c15d89285e1" xlink:to="loc_us-gaap_CommonClassAMember_d7e03028-d9bf-483d-a2a8-de91f0d21c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b5bfd67-893e-4c5b-b897-5a2e3709803c" xlink:to="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_578c9f97-0e9f-4fe9-803b-eb3052bc2ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_CommonStockMember_578c9f97-0e9f-4fe9-803b-eb3052bc2ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_887faf56-52df-4968-9765-ed4da57a73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_887faf56-52df-4968-9765-ed4da57a73c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad3ffe3c-43f0-40c8-a9fd-f3b414d28c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_RetainedEarningsMember_ad3ffe3c-43f0-40c8-a9fd-f3b414d28c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02fb529b-6e41-4653-8c68-d64e8bdb5cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02fb529b-6e41-4653-8c68-d64e8bdb5cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5621a9fe-7c54-4dfc-834b-7402c0064354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f2b5c7c-4b37-4ffd-b0d7-7b952eef2914" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5621a9fe-7c54-4dfc-834b-7402c0064354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_66ed3cb0-1bc5-4d85-a3d7-710d63bceffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ada528a-ecab-4073-b11c-ac38a934b022" xlink:to="loc_us-gaap_StatementLineItems_66ed3cb0-1bc5-4d85-a3d7-710d63bceffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_66ed3cb0-1bc5-4d85-a3d7-710d63bceffc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ddac3711-19c8-4533-923f-c1846e76c18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ddac3711-19c8-4533-923f-c1846e76c18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_15d6520d-4764-4917-aff7-80ce76dc49da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_TreasuryStockCommonShares_15d6520d-4764-4917-aff7-80ce76dc49da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_341440bf-90e9-4fae-9db3-e0e7ecd31796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockholdersEquity_341440bf-90e9-4fae-9db3-e0e7ecd31796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_41f6e53a-43b6-4654-bc6d-c45bec785c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_41f6e53a-43b6-4654-bc6d-c45bec785c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a0d1fa81-bc67-4f6a-a30e-f9b7555cc4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a0d1fa81-bc67-4f6a-a30e-f9b7555cc4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fcfc7748-12f5-45ff-bea5-3867fd851270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fcfc7748-12f5-45ff-bea5-3867fd851270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d4b8cbe4-59d9-47d9-8c62-1d3fd73cd19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d4b8cbe4-59d9-47d9-8c62-1d3fd73cd19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_8c85ee9a-1d53-4ef7-82b3-14c7e3b9afd1" xlink:href="regn-20221231.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_8c85ee9a-1d53-4ef7-82b3-14c7e3b9afd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_cbe80b5b-7be0-4313-b913-3397333f7c81" xlink:href="regn-20221231.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_cbe80b5b-7be0-4313-b913-3397333f7c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e12e7487-9eae-4ab2-861d-a35c2f224927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e12e7487-9eae-4ab2-861d-a35c2f224927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_03cfc803-15cf-4f63-9d17-aea8bdc5d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_03cfc803-15cf-4f63-9d17-aea8bdc5d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ecb6e767-24fe-428f-b849-a93b80a1b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ecb6e767-24fe-428f-b849-a93b80a1b01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25d858b2-a475-48ed-b60a-368c6d894017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_NetIncomeLoss_25d858b2-a475-48ed-b60a-368c6d894017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0bb6274-bfc5-41b2-b159-68670332cda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0bb6274-bfc5-41b2-b159-68670332cda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7ff3b5f4-f11f-43f1-92f8-6ebbe7213cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7ff3b5f4-f11f-43f1-92f8-6ebbe7213cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f0377e5e-8383-4942-a52c-dd3a168e50fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f0377e5e-8383-4942-a52c-dd3a168e50fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b5ce5d93-9da9-4445-86f9-7acfd1081a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f8b5496-19bd-4bba-8973-460dc320c7ea" xlink:to="loc_us-gaap_StockholdersEquity_b5ce5d93-9da9-4445-86f9-7acfd1081a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="regn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c36e4b47-65c5-4d65-bc67-36c759f6f8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c36e4b47-65c5-4d65-bc67-36c759f6f8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee17f067-5894-49db-b752-13a2cdf46aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c36e4b47-65c5-4d65-bc67-36c759f6f8cf" xlink:to="loc_us-gaap_NetIncomeLoss_ee17f067-5894-49db-b752-13a2cdf46aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c36e4b47-65c5-4d65-bc67-36c759f6f8cf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ba82a06a-6a35-47a9-bb04-0bc7217c19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ba82a06a-6a35-47a9-bb04-0bc7217c19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_06b02eea-5aa7-4c90-9086-c4911b133306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_ShareBasedCompensation_06b02eea-5aa7-4c90-9086-c4911b133306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableAndOtherSecuritiesGainLoss_212ab799-9b38-495a-b3cd-bcc250cac255" xlink:href="regn-20221231.xsd#regn_MarketableAndOtherSecuritiesGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_regn_MarketableAndOtherSecuritiesGainLoss_212ab799-9b38-495a-b3cd-bcc250cac255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5c4aa6b9-e96d-4b3b-bfa8-c37d4688f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5c4aa6b9-e96d-4b3b-bfa8-c37d4688f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4b5d042f-da12-4c97-8369-84c489c80fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4b5d042f-da12-4c97-8369-84c489c80fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_bf496498-87ec-47c0-9dfa-6c88586e59d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_bf496498-87ec-47c0-9dfa-6c88586e59d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_926f89ff-52b2-46fa-94fb-8b002b04d322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_926f89ff-52b2-46fa-94fb-8b002b04d322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_775acb22-5b5e-4339-b84f-92f6dcabe538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_775acb22-5b5e-4339-b84f-92f6dcabe538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_575f9c8c-e83a-4473-875f-3157eb372a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_575f9c8c-e83a-4473-875f-3157eb372a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c956b8b8-4674-4a1f-bb39-313564c689f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c956b8b8-4674-4a1f-bb39-313564c689f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c1c8fe17-96db-4605-8a87-87953d548aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53f09b1d-3dd9-4ebe-bf67-35b5f31d812b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c1c8fe17-96db-4605-8a87-87953d548aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4b7e28d7-5c95-41e7-be3c-c8218a8219e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_214014f0-a16f-4722-b312-0c08575d1e2c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4b7e28d7-5c95-41e7-be3c-c8218a8219e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc40690b-6198-4dec-8270-af13d29d9e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c36e4b47-65c5-4d65-bc67-36c759f6f8cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc40690b-6198-4dec-8270-af13d29d9e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c382bb1d-5335-44e9-9847-703eaa7341ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c382bb1d-5335-44e9-9847-703eaa7341ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c6e820d6-1a67-470d-a961-a5216d6bdef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c6e820d6-1a67-470d-a961-a5216d6bdef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_3897d2e8-5d74-4204-b370-7d1cb3c4ccaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_3897d2e8-5d74-4204-b370-7d1cb3c4ccaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsToAcquireIntangibleAssets1_0a5e05cd-2e33-4949-a9d5-16d05070ab48" xlink:href="regn-20221231.xsd#regn_PaymentsToAcquireIntangibleAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:to="loc_regn_PaymentsToAcquireIntangibleAssets1_0a5e05cd-2e33-4949-a9d5-16d05070ab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsForAssetAcquisition_03ea2ee3-b87a-4c38-a8e6-6e7e583251d1" xlink:href="regn-20221231.xsd#regn_PaymentsForAssetAcquisition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:to="loc_regn_PaymentsForAssetAcquisition_03ea2ee3-b87a-4c38-a8e6-6e7e583251d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_08da2cb7-f838-4204-8fa3-66d64a7a8b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a6fa8d7-0e1a-4c7b-891e-89e0c260b505" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_08da2cb7-f838-4204-8fa3-66d64a7a8b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ecc6d096-4954-4b60-ab15-686b6b99fc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ecc6d096-4954-4b60-ab15-686b6b99fc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f696960a-907b-43c7-8a9e-f152ee3ddace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f696960a-907b-43c7-8a9e-f152ee3ddace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5715a95a-a844-4f6c-92a2-1330e7a9b092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5715a95a-a844-4f6c-92a2-1330e7a9b092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be4eac34-b8a4-46b5-a874-b1dbbdd44ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be4eac34-b8a4-46b5-a874-b1dbbdd44ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_3c9eec9a-e41a-422a-ae25-752767d0db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_3c9eec9a-e41a-422a-ae25-752767d0db9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_685cde03-6873-41f7-8268-6bdc1c155157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_685cde03-6873-41f7-8268-6bdc1c155157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e41e1590-742f-4d86-9b1b-cc2a1a74954c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b3a2b5b-1993-41e3-8cee-9d0f006e40ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e41e1590-742f-4d86-9b1b-cc2a1a74954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7afec894-cdd5-49ef-bc56-db05ace9379a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7afec894-cdd5-49ef-bc56-db05ace9379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c78ec4f7-8aa4-477a-b2a5-d59096b31919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c78ec4f7-8aa4-477a-b2a5-d59096b31919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f2118ec-e38e-409b-bd47-74f4df983c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f2118ec-e38e-409b-bd47-74f4df983c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_afabd4a5-73f2-475b-9bd9-2fcc90f8d518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52524269-ccc3-4f09-9a83-221c98145dca" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_afabd4a5-73f2-475b-9bd9-2fcc90f8d518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_945a5b60-85b2-432a-90ca-24f66de5a056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afabd4a5-73f2-475b-9bd9-2fcc90f8d518" xlink:to="loc_us-gaap_InterestPaidNet_945a5b60-85b2-432a-90ca-24f66de5a056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_70d5d5bd-b5da-481e-a613-26f862a4ae89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afabd4a5-73f2-475b-9bd9-2fcc90f8d518" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_70d5d5bd-b5da-481e-a613-26f862a4ae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_06ad48ce-9436-491a-85c4-3567a27cf24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6826ce47-af3b-4312-a59c-a4a52511784c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06ad48ce-9436-491a-85c4-3567a27cf24a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6826ce47-af3b-4312-a59c-a4a52511784c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSales" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e64b0737-0c13-464b-972b-05120b86c18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7e4a1bf3-ca43-4ac6-ab4d-8855fc4a5487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e64b0737-0c13-464b-972b-05120b86c18d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7e4a1bf3-ca43-4ac6-ab4d-8855fc4a5487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_520c8737-a80b-4a40-b283-2770c8a60866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5876c26d-a311-4ded-a0cb-ae361348187e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_520c8737-a80b-4a40-b283-2770c8a60866" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5876c26d-a311-4ded-a0cb-ae361348187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecurities" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7353be3d-5ce3-4156-b93b-56f8e36254d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8fcf6c6c-bbbc-41c3-9240-23f1a2a55f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7353be3d-5ce3-4156-b93b-56f8e36254d0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8fcf6c6c-bbbc-41c3-9240-23f1a2a55f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="regn-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b1c949c1-5fc0-4963-bbb2-4c6785719f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a1872c42-79fc-43f8-b470-efa4da236ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1c949c1-5fc0-4963-bbb2-4c6785719f09" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a1872c42-79fc-43f8-b470-efa4da236ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Inventories" xlink:type="simple" xlink:href="regn-20221231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a76d37d7-d889-48c6-9237-7c1195e24e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_f5086841-4075-4435-98fd-1713b562ed81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a76d37d7-d889-48c6-9237-7c1195e24e21" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_f5086841-4075-4435-98fd-1713b562ed81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4355c719-86e3-4bf3-be15-2bd5b8c08ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ec891e63-61ef-4943-9093-040c3db39a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4355c719-86e3-4bf3-be15-2bd5b8c08ad4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ec891e63-61ef-4943-9093-040c3db39a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssets" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59d898cc-cdee-4f0e-8945-81f5cfab6994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_ccaf453e-bafc-4225-983e-5578361ef6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59d898cc-cdee-4f0e-8945-81f5cfab6994" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_ccaf453e-bafc-4225-983e-5578361ef6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="regn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6da585ec-acf8-4c26-bf53-7b5bdf4b05bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_740ffb2a-be59-4ea5-8c0d-438f6f494af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6da585ec-acf8-4c26-bf53-7b5bdf4b05bf" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_740ffb2a-be59-4ea5-8c0d-438f6f494af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Debt" xlink:type="simple" xlink:href="regn-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a9e8e37b-d28b-4fc8-87d0-3da51b25ad9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5a1e6742-b419-4c91-afe7-49b43f49b7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a9e8e37b-d28b-4fc8-87d0-3da51b25ad9a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5a1e6742-b419-4c91-afe7-49b43f49b7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93e10c3b-e818-4b17-8f03-3f94366f747d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9bfde83b-3eda-40dd-8a3f-ab8f507f5f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93e10c3b-e818-4b17-8f03-3f94366f747d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9bfde83b-3eda-40dd-8a3f-ab8f507f5f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquity" xlink:type="simple" xlink:href="regn-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3799c524-fe1f-4b3e-91fd-c68c9135fcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_72b01a17-5209-4ea9-8e4f-dca1a2fa7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3799c524-fe1f-4b3e-91fd-c68c9135fcb6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_72b01a17-5209-4ea9-8e4f-dca1a2fa7e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlans" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0ea92bc-a4fd-45c6-bbff-df83cfeb5271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5e9410f-21d6-450f-854a-8937ffa0f595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0ea92bc-a4fd-45c6-bbff-df83cfeb5271" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5e9410f-21d6-450f-854a-8937ffa0f595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/EmployeeSavingsPlans" xlink:type="simple" xlink:href="regn-20221231.xsd#EmployeeSavingsPlans"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/EmployeeSavingsPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e42ebf05-db8d-4ef7-b0f8-04925666431d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_676c6ebe-39d4-4bbc-9d01-a0b5307b0b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e42ebf05-db8d-4ef7-b0f8-04925666431d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_676c6ebe-39d4-4bbc-9d01-a0b5307b0b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxes" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b9897041-f89f-4d16-a63c-5c5995730bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_94f87412-5edd-412e-b0fd-1d19a8dee9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b9897041-f89f-4d16-a63c-5c5995730bbe" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_94f87412-5edd-412e-b0fd-1d19a8dee9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMatters" xlink:type="simple" xlink:href="regn-20221231.xsd#LegalMatters"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7601dda7-3735-4216-bd08-6c63dff1c15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_a94e38f4-a8c1-4dc1-be63-6992a6daf2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7601dda7-3735-4216-bd08-6c63dff1c15b" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_a94e38f4-a8c1-4dc1-be63-6992a6daf2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e135439-16d7-4158-9ab8-1bb6802395bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2ff57387-7a95-4754-ad9c-0049e290bf39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e135439-16d7-4158-9ab8-1bb6802395bb" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2ff57387-7a95-4754-ad9c-0049e290bf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="simple" xlink:href="regn-20221231.xsd#StatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_35aed897-ad47-4777-b4ae-5cd88f4a973d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5fe1e0a4-ab39-470d-92d7-6983c9c3aa25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_35aed897-ad47-4777-b4ae-5cd88f4a973d" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5fe1e0a4-ab39-470d-92d7-6983c9c3aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c51882c-6432-41aa-946f-073b74751277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c51882c-6432-41aa-946f-073b74751277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8821a4d7-ef22-4981-aefb-b48f422d669a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_UseOfEstimates_8821a4d7-ef22-4981-aefb-b48f422d669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_120a1977-28d5-4fb0-8908-815acb5953d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_120a1977-28d5-4fb0-8908-815acb5953d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9c5c6157-24a4-4ef3-9bbf-7a78653d1c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9c5c6157-24a4-4ef3-9bbf-7a78653d1c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_d117019b-f48e-4063-9e3e-73dfe1758fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_d117019b-f48e-4063-9e3e-73dfe1758fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1c67fbd5-d95c-423c-add8-40a06081a51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1c67fbd5-d95c-423c-add8-40a06081a51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_04518e06-42a3-4825-ba79-f60deb41101b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_04518e06-42a3-4825-ba79-f60deb41101b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c035d0c3-cac3-4112-bfba-31fe4eb86406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c035d0c3-cac3-4112-bfba-31fe4eb86406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_d24072b0-6e97-4d56-9ae3-53d91c9ebbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_d24072b0-6e97-4d56-9ae3-53d91c9ebbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35eb6bea-5fb4-493f-9bcf-108e85957487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35eb6bea-5fb4-493f-9bcf-108e85957487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_63b11ccb-a535-489f-9e74-1f7a7b321e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_63b11ccb-a535-489f-9e74-1f7a7b321e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_940004dd-ae15-4fff-a2b4-c39ccbd2068a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_940004dd-ae15-4fff-a2b4-c39ccbd2068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fad1bbf5-9477-4b82-b214-cee26657428f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fad1bbf5-9477-4b82-b214-cee26657428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_23cdfaee-4c69-424d-8c64-c958dd4a409d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_23cdfaee-4c69-424d-8c64-c958dd4a409d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_db8814ec-db53-4296-82fe-5c24ae54e9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_db8814ec-db53-4296-82fe-5c24ae54e9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_17c93cf3-9764-4557-a956-ea684a43a8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbf2f3b8-e66f-4846-bbe9-9571663f03de" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_17c93cf3-9764-4557-a956-ea684a43a8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_de798b57-f2f0-4ba6-8d54-d8c8c3cd0430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_25b358fe-ad2d-47d0-a644-e2f9d2d3a62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_de798b57-f2f0-4ba6-8d54-d8c8c3cd0430" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_25b358fe-ad2d-47d0-a644-e2f9d2d3a62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_14178e65-7847-409b-b287-c06d2ba609fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_de798b57-f2f0-4ba6-8d54-d8c8c3cd0430" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_14178e65-7847-409b-b287-c06d2ba609fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_12757cbf-9a70-477e-8efb-e6a43b00c567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c63f7027-0030-40a6-b07c-421d5279b364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_12757cbf-9a70-477e-8efb-e6a43b00c567" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c63f7027-0030-40a6-b07c-421d5279b364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0c05660c-8ee4-4078-956a-f3da1254671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_12757cbf-9a70-477e-8efb-e6a43b00c567" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0c05660c-8ee4-4078-956a-f3da1254671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock_303261ad-b5b0-468f-905a-a95f45e3eb7b" xlink:href="regn-20221231.xsd#regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_12757cbf-9a70-477e-8efb-e6a43b00c567" xlink:to="loc_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock_303261ad-b5b0-468f-905a-a95f45e3eb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_46581a64-8644-4a76-9556-f2f17c01d148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f0654b63-b246-4086-bcd3-045c2317a7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_46581a64-8644-4a76-9556-f2f17c01d148" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f0654b63-b246-4086-bcd3-045c2317a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7c709398-dc06-4b56-8081-ad2eb78b9dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_46581a64-8644-4a76-9556-f2f17c01d148" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7c709398-dc06-4b56-8081-ad2eb78b9dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9dee8797-6542-4f48-a1a3-74666c4e75fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c904fa42-155b-4042-8ef0-e03a85ec0139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9dee8797-6542-4f48-a1a3-74666c4e75fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c904fa42-155b-4042-8ef0-e03a85ec0139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c59ea1fb-e7aa-48fa-b798-a5afb88b32a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9dee8797-6542-4f48-a1a3-74666c4e75fc" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c59ea1fb-e7aa-48fa-b798-a5afb88b32a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c0a400d4-475b-44e5-81bf-726db1078082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9dee8797-6542-4f48-a1a3-74666c4e75fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c0a400d4-475b-44e5-81bf-726db1078082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="regn-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90c10730-cae7-4375-b79f-108784cd679b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_64aa1e62-cc2b-4bf2-8136-be528a47c357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90c10730-cae7-4375-b79f-108784cd679b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_64aa1e62-cc2b-4bf2-8136-be528a47c357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_af42ab7f-df3a-4a08-882e-b8703c4a00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_800af85d-090a-4e3b-9ff9-8bcc975cb68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_af42ab7f-df3a-4a08-882e-b8703c4a00d1" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_800af85d-090a-4e3b-9ff9-8bcc975cb68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_652be3a0-7b0f-4e48-bc05-9101855ae27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9e394134-8897-4c32-b7e2-d77b095c3c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_652be3a0-7b0f-4e48-bc05-9101855ae27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9e394134-8897-4c32-b7e2-d77b095c3c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f118ed7d-1467-427e-a673-e7b819e30982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6c28bfbc-48b5-4e13-a5be-595f1c3fbdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f118ed7d-1467-427e-a673-e7b819e30982" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6c28bfbc-48b5-4e13-a5be-595f1c3fbdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2bdcd7cd-0efe-4781-9213-41985e8e5d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ad5fb9fc-b012-40d5-a645-63008f355c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2bdcd7cd-0efe-4781-9213-41985e8e5d35" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ad5fb9fc-b012-40d5-a645-63008f355c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtTables" xlink:type="simple" xlink:href="regn-20221231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29a0e8f5-9a81-40d5-b8f0-04978b0579ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_85ba1c72-203f-4db5-ba09-9cbb4df7aabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29a0e8f5-9a81-40d5-b8f0-04978b0579ac" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_85ba1c72-203f-4db5-ba09-9cbb4df7aabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3444c43-9d2b-41e7-b168-e95573803d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AssetsAndLiabilitiesLesseeTableTextBlock_52b82202-d4a3-42bc-a5d0-70c8a06f757c" xlink:href="regn-20221231.xsd#regn_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3444c43-9d2b-41e7-b168-e95573803d2f" xlink:to="loc_regn_AssetsAndLiabilitiesLesseeTableTextBlock_52b82202-d4a3-42bc-a5d0-70c8a06f757c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_91be4a44-b7f4-42f3-83f1-c4a4d330b333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3444c43-9d2b-41e7-b168-e95573803d2f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_91be4a44-b7f4-42f3-83f1-c4a4d330b333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2c7b2844-5089-4c6b-8e52-7b71b504bbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3444c43-9d2b-41e7-b168-e95573803d2f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2c7b2844-5089-4c6b-8e52-7b71b504bbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="regn-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_07cbf4c9-c1ec-4a87-bdab-733b8cbb5366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_56a96952-32af-4fe8-9a28-aeda879057c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_07cbf4c9-c1ec-4a87-bdab-733b8cbb5366" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_56a96952-32af-4fe8-9a28-aeda879057c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansTables" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb620aa-a025-4162-9aed-e65433bb2abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1a450c56-caf7-4f96-92a5-8e99d01caf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb620aa-a025-4162-9aed-e65433bb2abe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1a450c56-caf7-4f96-92a5-8e99d01caf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_df0ad39e-b113-4502-af3f-a77116bdb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb620aa-a025-4162-9aed-e65433bb2abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_df0ad39e-b113-4502-af3f-a77116bdb89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a78f5c8a-6c45-446b-80ad-e4115d18a316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb620aa-a025-4162-9aed-e65433bb2abe" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a78f5c8a-6c45-446b-80ad-e4115d18a316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_a2ed3c7f-df81-4995-88dc-99e59a9a770b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb620aa-a025-4162-9aed-e65433bb2abe" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_a2ed3c7f-df81-4995-88dc-99e59a9a770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_678675a9-d2bd-4c2d-947b-9c15c033d804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb620aa-a025-4162-9aed-e65433bb2abe" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_678675a9-d2bd-4c2d-947b-9c15c033d804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_62046065-c9a6-4dd2-948b-0fae0c0397ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8121de59-a1f9-4909-8182-813e30092b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62046065-c9a6-4dd2-948b-0fae0c0397ca" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8121de59-a1f9-4909-8182-813e30092b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a9bfcbe8-10ca-4e51-aa2f-1759699460c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62046065-c9a6-4dd2-948b-0fae0c0397ca" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a9bfcbe8-10ca-4e51-aa2f-1759699460c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_86911efa-7d82-4916-abb2-d08240d4c1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62046065-c9a6-4dd2-948b-0fae0c0397ca" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_86911efa-7d82-4916-abb2-d08240d4c1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b33a524f-8605-4fc9-8113-8094ef84e935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62046065-c9a6-4dd2-948b-0fae0c0397ca" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b33a524f-8605-4fc9-8113-8094ef84e935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_da2d0f15-7b11-4660-a674-4ffb659af98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62046065-c9a6-4dd2-948b-0fae0c0397ca" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_da2d0f15-7b11-4660-a674-4ffb659af98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_babbfe94-be1a-4297-8e3d-ee63326270fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4aa89e5c-fb35-43ef-ae7d-6e745cc6a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_babbfe94-be1a-4297-8e3d-ee63326270fa" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4aa89e5c-fb35-43ef-ae7d-6e745cc6a4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18a9b5d7-5456-49be-9ae8-052f68d698e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_babbfe94-be1a-4297-8e3d-ee63326270fa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_18a9b5d7-5456-49be-9ae8-052f68d698e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="simple" xlink:href="regn-20221231.xsd#StatementofCashFlowsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_31337ef6-a101-416d-b703-5f44e9d95324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b5166fd9-4830-4d50-8379-200740eef632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_31337ef6-a101-416d-b703-5f44e9d95324" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b5166fd9-4830-4d50-8379-200740eef632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_08cdbee6-4cc6-4db9-8c46-5e52cfe73c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_31337ef6-a101-416d-b703-5f44e9d95324" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_08cdbee6-4cc6-4db9-8c46-5e52cfe73c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0dd30e1d-f627-42b1-bb83-41ef7a476fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_31337ef6-a101-416d-b703-5f44e9d95324" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0dd30e1d-f627-42b1-bb83-41ef7a476fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ace2cd0b-96ba-410e-9757-d3c5f9a79fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ace2cd0b-96ba-410e-9757-d3c5f9a79fa4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_64f1a19b-9d6f-4e29-84db-d795e2dde4a4" xlink:to="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ThreeIndividualCustomersMember_60ecf053-9089-4a15-b415-843ce4c81167" xlink:href="regn-20221231.xsd#regn_ThreeIndividualCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:to="loc_regn_ThreeIndividualCustomersMember_60ecf053-9089-4a15-b415-843ce4c81167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_17ade3be-b067-4a9d-afca-281f3eb82256" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ad8628ff-4153-468a-b96a-756e297c01cc" xlink:to="loc_regn_USGovernmentMember_17ade3be-b067-4a9d-afca-281f3eb82256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f324d581-dcd0-42f5-9f79-9f1afa6fd0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e524f1ab-ec59-4684-b1dc-d0c787d39d41" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f324d581-dcd0-42f5-9f79-9f1afa6fd0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_576f410d-2619-4db4-bb55-e6cbdd46b1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f324d581-dcd0-42f5-9f79-9f1afa6fd0a7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_576f410d-2619-4db4-bb55-e6cbdd46b1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cf12f1a-c8ae-4de5-b87b-c31560d09142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_90016478-34d0-4f05-91cd-eee8482ee144" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cf12f1a-c8ae-4de5-b87b-c31560d09142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_60c4dd67-390c-40c8-bff4-4aa55e90401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cf12f1a-c8ae-4de5-b87b-c31560d09142" xlink:to="loc_us-gaap_AccountsReceivableMember_60c4dd67-390c-40c8-bff4-4aa55e90401a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_673b3d4a-acaf-4a44-b739-66a31de0f76d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_7a37851e-bb6c-430b-9277-dab909130cf8" xlink:href="regn-20221231.xsd#regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration_7a37851e-bb6c-430b-9277-dab909130cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_1a65e15f-6408-43c9-9c22-aad491d9fb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_NumberOfReportableSegments_1a65e15f-6408-43c9-9c22-aad491d9fb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_69b9b3b5-608b-4192-8ef4-3c4f7ce88e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_69b9b3b5-608b-4192-8ef4-3c4f7ce88e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b07e5a5c-ba84-4016-885e-ee9d43f6ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b07e5a5c-ba84-4016-885e-ee9d43f6ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db1644ae-05bd-4647-af23-464252cb767b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4ed2667e-38f0-4cf0-9383-436b72fc6ab6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db1644ae-05bd-4647-af23-464252cb767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4350c945-5ca8-44c7-ad99-8d6157a699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4350c945-5ca8-44c7-ad99-8d6157a699cf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e09777d8-2088-44eb-8168-b9a15b4adffc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ebf921a2-d149-49c5-97b3-d03fe91b0130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ebf921a2-d149-49c5-97b3-d03fe91b0130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8c1f8710-3166-4a4a-8b23-69ee842dcb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:to="loc_us-gaap_EquipmentMember_8c1f8710-3166-4a4a-8b23-69ee842dcb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_01977a76-d416-4673-85a2-7f91225f4e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3964ffaa-997d-43ab-bf00-86c77990c346" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_01977a76-d416-4673-85a2-7f91225f4e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:to="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c5c8bc4c-98fb-495d-b43a-066bff34cab6" xlink:to="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9bf8fee8-dd67-4249-9fce-f3b818dab720" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:to="loc_srt_MinimumMember_9bf8fee8-dd67-4249-9fce-f3b818dab720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79699772-97ee-499c-84ed-3cdc9200d93f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4e2d0905-cb67-4382-a4b8-c3b30f782717" xlink:to="loc_srt_MaximumMember_79699772-97ee-499c-84ed-3cdc9200d93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5a498134-0649-49e3-98e6-e4b231d9ca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45ecd381-72be-45e9-abf4-1796ed5b47b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5a498134-0649-49e3-98e6-e4b231d9ca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_06f146ad-1ec9-4fc8-be05-16dba014f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5a498134-0649-49e3-98e6-e4b231d9ca98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_06f146ad-1ec9-4fc8-be05-16dba014f59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0bb2079e-907f-47ca-8674-b7ed1f3602b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0bb2079e-907f-47ca-8674-b7ed1f3602b3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:to="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e054e72d-eb7e-463e-80a7-4d5a4c603a7e" xlink:to="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_654ebc12-acd5-46d0-bfd0-f9d3e86fd7fb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:to="loc_country_US_654ebc12-acd5-46d0-bfd0-f9d3e86fd7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember_4d2a2e8a-57ce-44ae-b2ce-8192d0597960" xlink:href="regn-20221231.xsd#regn_RestOfWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ee475bf-10cd-408a-b0df-2c1cf9741d51" xlink:to="loc_regn_RestOfWorldMember_4d2a2e8a-57ce-44ae-b2ce-8192d0597960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:to="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ddb430c3-3d13-43d8-84fb-453ce947fe49" xlink:to="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_34742181-6fc5-4f34-bd85-ffabefe5f760" xlink:href="regn-20221231.xsd#regn_EyleaNetProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_EyleaNetProductSalesMember_34742181-6fc5-4f34-bd85-ffabefe5f760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_30df8638-7b23-4b1e-b3c2-a2910ada81b0" xlink:href="regn-20221231.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_LIBTAYONetProductSalesMember_30df8638-7b23-4b1e-b3c2-a2910ada81b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_7f137811-aa3a-4da6-964e-4492e00cf81d" xlink:href="regn-20221231.xsd#regn_PraluentNetProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_PraluentNetProductSalesMember_7f137811-aa3a-4da6-964e-4492e00cf81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_939f5002-17e6-41b2-ac33-117864037b97" xlink:href="regn-20221231.xsd#regn_REGENCOVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_REGENCOVMember_939f5002-17e6-41b2-ac33-117864037b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember_1e4cae3a-0042-4abb-b5aa-d488226d4275" xlink:href="regn-20221231.xsd#regn_EvkeezaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_EvkeezaMember_1e4cae3a-0042-4abb-b5aa-d488226d4275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InmazebMember_a9e0b6be-0fa3-432a-8af3-fda7db824396" xlink:href="regn-20221231.xsd#regn_InmazebMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_InmazebMember_a9e0b6be-0fa3-432a-8af3-fda7db824396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember_fce7c479-2c77-442d-8741-b5b39b168829" xlink:href="regn-20221231.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b77bf0f-5117-4ac2-af01-dee84029fda7" xlink:to="loc_regn_ArcalystNetProductSalesMember_fce7c479-2c77-442d-8741-b5b39b168829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_72d9bbdc-182c-4576-87ba-fb42003a7ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48972ac1-1fcf-4ba7-af1c-f7a76610c725" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_72d9bbdc-182c-4576-87ba-fb42003a7ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b54c8ee-f36d-4e7d-8dd4-ae294a9b7e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_72d9bbdc-182c-4576-87ba-fb42003a7ae5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b54c8ee-f36d-4e7d-8dd4-ae294a9b7e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d052fe8-45ef-4ee6-b739-8e72f177a81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d052fe8-45ef-4ee6-b739-8e72f177a81e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_2a896e19-c11c-4206-8913-323d42a6b1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fdf2362f-d085-40cb-b83e-4674d4cf9f5a" xlink:to="loc_us-gaap_ReceivableTypeDomain_2a896e19-c11c-4206-8913-323d42a6b1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_ed57a958-a4f7-4daa-bbae-7766a4cb9638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_2a896e19-c11c-4206-8913-323d42a6b1aa" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_ed57a958-a4f7-4daa-bbae-7766a4cb9638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4dc0530c-6948-4e61-afb7-83a2c0c0b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_00f7feb3-bd5c-40c1-9c04-d0b4caaef40a" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4dc0530c-6948-4e61-afb7-83a2c0c0b79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_099eb2ac-c147-40fe-9676-446907b67f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4dc0530c-6948-4e61-afb7-83a2c0c0b79e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_099eb2ac-c147-40fe-9676-446907b67f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_45daf800-8784-4c6b-bfd2-e6ee289c4af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_45daf800-8784-4c6b-bfd2-e6ee289c4af0" xlink:to="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee7f6acb-3735-4c28-a1d5-45d8c9591c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f655ba5a-842e-4489-8ae2-69218cfe638e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee7f6acb-3735-4c28-a1d5-45d8c9591c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember_92b5ce9d-3a07-414c-a774-bbe2374dd643" xlink:href="regn-20221231.xsd#regn_GrossProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee7f6acb-3735-4c28-a1d5-45d8c9591c7c" xlink:to="loc_regn_GrossProductRevenueMember_92b5ce9d-3a07-414c-a774-bbe2374dd643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_08605bcf-09c7-40a2-b802-1871ef63cd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c03a1729-ed91-446e-8538-a2207b2df896" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_08605bcf-09c7-40a2-b802-1871ef63cd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ba14fc9f-49f5-41bc-850e-2cb185a43b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_08605bcf-09c7-40a2-b802-1871ef63cd69" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ba14fc9f-49f5-41bc-850e-2cb185a43b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dfa75ed1-3aa5-4a9e-b44f-6dc8934758f4" xlink:to="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_d30fa6f9-f4ce-4759-a5b4-11924353e59a" xlink:href="regn-20221231.xsd#regn_BesseMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:to="loc_regn_BesseMedicalMember_d30fa6f9-f4ce-4759-a5b4-11924353e59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_fe0208a0-ba9d-4eb4-9507-da718f938d43" xlink:href="regn-20221231.xsd#regn_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:to="loc_regn_McKessonCorporationMember_fe0208a0-ba9d-4eb4-9507-da718f938d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_f4422988-43c7-4c11-9814-ca7725661744" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a22c96b9-4732-41de-b591-e2a305d1128c" xlink:to="loc_regn_USGovernmentMember_f4422988-43c7-4c11-9814-ca7725661744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_931f62a9-0b6a-47c6-acae-750749ecef80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5d417f47-deb9-49ab-8fe4-2f49dabdb2d8" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_931f62a9-0b6a-47c6-acae-750749ecef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fcf921a2-e421-4a92-b73d-fc0fddd4e5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_931f62a9-0b6a-47c6-acae-750749ecef80" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fcf921a2-e421-4a92-b73d-fc0fddd4e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fbf1985-fcbe-4b2f-b64e-3f7de9fc23b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fbf1985-fcbe-4b2f-b64e-3f7de9fc23b6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ead1fb50-06d5-4cf6-b195-45f0b43df59e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RebatesAndChargebacksMember_b5e8a5a0-e7ff-4dc1-9f66-3e2e1a7ea3b6" xlink:href="regn-20221231.xsd#regn_RebatesAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:to="loc_regn_RebatesAndChargebacksMember_b5e8a5a0-e7ff-4dc1-9f66-3e2e1a7ea3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DistributionRelatedFeesMember_355f735c-ebda-433f-bb28-707474482cb5" xlink:href="regn-20221231.xsd#regn_DistributionRelatedFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:to="loc_regn_DistributionRelatedFeesMember_355f735c-ebda-433f-bb28-707474482cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherSalesRelatedDeductionsMember_e132d833-006b-4c57-b3e3-e3cd5f4db82e" xlink:href="regn-20221231.xsd#regn_OtherSalesRelatedDeductionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02a1d142-0572-4bf3-b73c-6eb95fad29bd" xlink:to="loc_regn_OtherSalesRelatedDeductionsMember_e132d833-006b-4c57-b3e3-e3cd5f4db82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_48c763e4-e4bf-4c1f-a72d-58ced7aee4ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ec03da57-34a0-4249-8e44-44ed0fcad33c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_48c763e4-e4bf-4c1f-a72d-58ced7aee4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_48c763e4-e4bf-4c1f-a72d-58ced7aee4ee" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0c8a8079-c7d6-4273-8c13-7bd0ca171ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0c8a8079-c7d6-4273-8c13-7bd0ca171ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_bfb62fda-884c-41d4-a8ad-c367de6d6935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_bfb62fda-884c-41d4-a8ad-c367de6d6935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_43d0e414-23c2-48c9-8fea-1c52364546e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_43d0e414-23c2-48c9-8fea-1c52364546e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5bc7638e-bae6-40d5-858d-6280556cfa82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ecb925b2-5203-4145-be6f-d3562a3b43d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_5bc7638e-bae6-40d5-858d-6280556cfa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fa1e6554-426e-4664-b030-1fb9826eabea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fa1e6554-426e-4664-b030-1fb9826eabea" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fddc10ab-059b-408f-ad0e-c2c2ee2eccf1" xlink:to="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_831d26a8-7e0b-4fd8-8b06-8dc32cd9f753" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_831d26a8-7e0b-4fd8-8b06-8dc32cd9f753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_aba065f1-cc44-48c0-b70f-7dc6b0f1795a" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_df8091cd-ec12-4c4e-ba3f-d67e243674dc" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_aba065f1-cc44-48c0-b70f-7dc6b0f1795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41082898-aef3-4c3f-9e39-341d539209cb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_ac2444a0-9ec7-47b4-babd-c885d28d664a" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_regn_CollaborationRevenueMember_ac2444a0-9ec7-47b4-babd-c885d28d664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ee602985-8afd-4f98-b84d-e61d38f66fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ee602985-8afd-4f98-b84d-e61d38f66fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_301bbf27-3445-4a98-acf6-671438186bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_301bbf27-3445-4a98-acf6-671438186bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_7ffde1e9-b6df-4def-a56f-d82236478cbd" xlink:href="regn-20221231.xsd#regn_CostOfGoodsSoldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_regn_CostOfGoodsSoldMember_7ffde1e9-b6df-4def-a56f-d82236478cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_ce882854-f11f-4070-8e17-462f1be60f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54b5e0e1-2e87-4e86-8140-0cbf161942c2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_ce882854-f11f-4070-8e17-462f1be60f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e4a57d56-ca7b-4ed9-98aa-d2277bba16c9" xlink:to="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_261f4b47-5ec6-4f82-822b-ed5d77ccd14d" xlink:href="regn-20221231.xsd#regn_ShareOfProfitsLossesInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ShareOfProfitsLossesInConnectionWithCommercializationMember_261f4b47-5ec6-4f82-822b-ed5d77ccd14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember_c66d569f-ac33-44f4-bf32-885991ce3392" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_SalesBasedMilestoneEarnedMember_c66d569f-ac33-44f4-bf32-885991ce3392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_380e43e7-ae71-4729-b7ad-aa958f10377f" xlink:href="regn-20221231.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_380e43e7-ae71-4729-b7ad-aa958f10377f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember_555a3b8b-f222-4f3e-922c-45605a2ba7c2" xlink:href="regn-20221231.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_OtherCollaborationAgreementsMember_555a3b8b-f222-4f3e-922c-45605a2ba7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_682ba8ec-f638-4744-af41-179196e48cc1" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_682ba8ec-f638-4744-af41-179196e48cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_3387ead9-e7db-4098-9f0e-17bf5bb2d2d8" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_3387ead9-e7db-4098-9f0e-17bf5bb2d2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_1065cd86-6f71-48c4-9c7a-443d2e818355" xlink:href="regn-20221231.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_1065cd86-6f71-48c4-9c7a-443d2e818355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember_a700dfea-d58e-45b7-8861-e2f408ff03ad" xlink:href="regn-20221231.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_RegeneronsShareOfCommercialExpensesMember_a700dfea-d58e-45b7-8861-e2f408ff03ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareOfLibtayoUSGrossProfitsMember_d9ba4c4b-fbcd-41aa-ae37-3cb4229ff59b" xlink:href="regn-20221231.xsd#regn_SanofisShareOfLibtayoUSGrossProfitsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_SanofisShareOfLibtayoUSGrossProfitsMember_d9ba4c4b-fbcd-41aa-ae37-3cb4229ff59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_b1bc170c-c147-4fb7-ab14-f075edf5e9a5" xlink:href="regn-20221231.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e044c371-434e-4200-9382-f5bd0a92024e" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_b1bc170c-c147-4fb7-ab14-f075edf5e9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_239624b4-0388-455b-bbaf-ac771db0097d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2e65445e-fb63-4aec-b515-19ce4f7e5447" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_239624b4-0388-455b-bbaf-ac771db0097d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6677bcca-1395-4743-951a-1899a177dbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_239624b4-0388-455b-bbaf-ac771db0097d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6677bcca-1395-4743-951a-1899a177dbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8d3f0c3f-9ae4-4336-9f02-6a3ae80dfb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8d3f0c3f-9ae4-4336-9f02-6a3ae80dfb84" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0bdc09bb-feff-464e-a02f-c5e51dbbd797" xlink:to="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_af159935-3812-4ce2-bf17-8b70665d0f20" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_af159935-3812-4ce2-bf17-8b70665d0f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_55cb5e8c-ce7a-4131-bbc5-717a54577c63" xlink:href="regn-20221231.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_be3897af-2058-42ba-a582-85e7ba08672a" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_55cb5e8c-ce7a-4131-bbc5-717a54577c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_96b48499-0088-40f0-aa44-d5f1bf81eedc" xlink:to="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6b5c349-a52f-45ad-b1ad-84e7dc48fefa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:to="loc_srt_MinimumMember_b6b5c349-a52f-45ad-b1ad-84e7dc48fefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f69bd91-66a2-40f4-8326-3ea2332cc8af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_236a6f9d-f76b-45b1-b847-8606109be7f8" xlink:to="loc_srt_MaximumMember_8f69bd91-66a2-40f4-8326-3ea2332cc8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:href="regn-20221231.xsd#regn_SalesMilestonesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesAxis_0a339d04-c254-4cc2-b705-6ed01d95aa4c" xlink:to="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneOneMember_27a2c0d7-3b47-490b-be3a-8caad519e7a1" xlink:href="regn-20221231.xsd#regn_SalesMilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneOneMember_27a2c0d7-3b47-490b-be3a-8caad519e7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneTwoMember_06e26fe6-be29-4832-93be-9fb32aa1f090" xlink:href="regn-20221231.xsd#regn_SalesMilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneTwoMember_06e26fe6-be29-4832-93be-9fb32aa1f090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneThreeMember_f2d91d04-4a48-4180-86ac-5584d31dffd3" xlink:href="regn-20221231.xsd#regn_SalesMilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneThreeMember_f2d91d04-4a48-4180-86ac-5584d31dffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFourMember_c017175c-a7b1-4a22-bb56-b01679d2a23c" xlink:href="regn-20221231.xsd#regn_SalesMilestoneFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneFourMember_c017175c-a7b1-4a22-bb56-b01679d2a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFiveMember_72f03d5d-df3f-4eff-b1bc-8a098b8f7dab" xlink:href="regn-20221231.xsd#regn_SalesMilestoneFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_5ef70f9e-1ade-4586-9f6c-aac0f5a52d2b" xlink:to="loc_regn_SalesMilestoneFiveMember_72f03d5d-df3f-4eff-b1bc-8a098b8f7dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9cafdf8a-b681-4978-b456-d96f29095863" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_682bdf9c-ee09-4efd-a273-c48e1b1e4698" xlink:to="loc_dei_EntityDomain_9cafdf8a-b681-4978-b456-d96f29095863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_a738ac34-84c2-406b-9408-caa6abdde37e" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9cafdf8a-b681-4978-b456-d96f29095863" xlink:to="loc_regn_SanofiMember_a738ac34-84c2-406b-9408-caa6abdde37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01b427e8-42dc-4f5b-8b1b-f8501e5ecc89" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentToCollaboratingParty_bf411b32-d625-4f08-b54e-7c5efd3a7b14" xlink:href="regn-20221231.xsd#regn_PaymentToCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PaymentToCollaboratingParty_bf411b32-d625-4f08-b54e-7c5efd3a7b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_8c04ee52-61f3-41b6-9f79-ff54a8240634" xlink:href="regn-20221231.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_8c04ee52-61f3-41b6-9f79-ff54a8240634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_98fbe3b0-9fe7-475b-89a2-9c3781e314db" xlink:href="regn-20221231.xsd#regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_98fbe3b0-9fe7-475b-89a2-9c3781e314db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_67bb9988-a8bc-4dbd-b313-9b0ed6f026b7" xlink:href="regn-20221231.xsd#regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_67bb9988-a8bc-4dbd-b313-9b0ed6f026b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContingentReimbursementObligation_c674b3de-4163-47c4-bad0-ae35fd5de504" xlink:href="regn-20221231.xsd#regn_ContingentReimbursementObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_ContingentReimbursementObligation_c674b3de-4163-47c4-bad0-ae35fd5de504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_9e2f8aa9-22e0-4e8f-b477-ce23131c98b5" xlink:href="regn-20221231.xsd#regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_9e2f8aa9-22e0-4e8f-b477-ce23131c98b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_f8f2832e-95ba-4a40-af0e-cb9a1af3daec" xlink:href="regn-20221231.xsd#regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_f8f2832e-95ba-4a40-af0e-cb9a1af3daec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_99b957ba-c4ed-4f43-bc34-02a199cd0dfa" xlink:href="regn-20221231.xsd#regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty_99b957ba-c4ed-4f43-bc34-02a199cd0dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_5384869f-b584-4f5a-9dec-aa1cdf374088" xlink:href="regn-20221231.xsd#regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany_5384869f-b584-4f5a-9dec-aa1cdf374088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_14d8e5e0-e68e-41a8-92c9-ad52e251f375" xlink:href="regn-20221231.xsd#regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty_14d8e5e0-e68e-41a8-92c9-ad52e251f375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfLossesOutsideUnitedStatesForCompany_e149d468-cd57-4d05-83eb-86b2b6fdb9bb" xlink:href="regn-20221231.xsd#regn_ShareOfLossesOutsideUnitedStatesForCompany"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_ShareOfLossesOutsideUnitedStatesForCompany_e149d468-cd57-4d05-83eb-86b2b6fdb9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f95730b6-9b0d-4d58-8b01-52d39637e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f95730b6-9b0d-4d58-8b01-52d39637e59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_2a80aa94-2b90-43e0-a4e0-4a951698c192" xlink:href="regn-20221231.xsd#regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_2a80aa94-2b90-43e0-a4e0-4a951698c192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_6f61597a-91bf-4c5f-a0b2-f9e32af857d3" xlink:href="regn-20221231.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_6f61597a-91bf-4c5f-a0b2-f9e32af857d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d46d41a4-55dc-4dbf-b229-ba43313095f1" xlink:href="regn-20221231.xsd#regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d46d41a4-55dc-4dbf-b229-ba43313095f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_d51473ce-f32d-4ed8-8edb-3acaddccf7ec" xlink:href="regn-20221231.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_d51473ce-f32d-4ed8-8edb-3acaddccf7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_53a39b7c-44af-448b-9715-f6da76c07ad5" xlink:href="regn-20221231.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_53a39b7c-44af-448b-9715-f6da76c07ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_7e95e24c-1523-4580-9d6b-432b62950ec8" xlink:href="regn-20221231.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c076a034-2045-41f9-aae9-f03ab9834a41" xlink:to="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_7e95e24c-1523-4580-9d6b-432b62950ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbaafb0d-67b1-49ad-ae69-091ae4021aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbaafb0d-67b1-49ad-ae69-091ae4021aac" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_28914e80-f34b-41a2-8c5f-c0a5432135c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_87f8ed58-f8c7-4189-92da-a654a65ab395" xlink:to="loc_us-gaap_ProjectMember_28914e80-f34b-41a2-8c5f-c0a5432135c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_9aec6d5f-591f-4bce-a784-7f59a9625f09" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_28914e80-f34b-41a2-8c5f-c0a5432135c4" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_9aec6d5f-591f-4bce-a784-7f59a9625f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff2e08d3-c72f-48cd-a8ad-208f490c4eb3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ba9a106e-5058-48c9-828f-d0ef94b31690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ba9a106e-5058-48c9-828f-d0ef94b31690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b102110a-929d-4dbb-b43d-058325421d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15ed2767-effd-43c5-8006-cb03f9a9a844" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b102110a-929d-4dbb-b43d-058325421d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c7c74648-85aa-4375-a444-0f1d280b9341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c7c74648-85aa-4375-a444-0f1d280b9341" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9059e93c-cb53-496b-8de0-c87abdfbd778" xlink:to="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_4944f4dd-7de0-40cd-a7ba-443544505884" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_4944f4dd-7de0-40cd-a7ba-443544505884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c57e23f5-e161-4136-b24d-57d384a97876" xlink:href="regn-20221231.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c57e23f5-e161-4136-b24d-57d384a97876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_325dfc89-f656-4743-bd23-35434e4c2986" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_dbd2905c-f319-42cc-a294-27e772165b28" xlink:to="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_325dfc89-f656-4743-bd23-35434e4c2986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:href="regn-20221231.xsd#regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis_13353087-caf3-4ddd-bd7f-0d7d21aa5192" xlink:to="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IOLicenseandCollaborationAgreementMember_c4ee04c7-629b-426f-8a90-2749c8c90f13" xlink:href="regn-20221231.xsd#regn_IOLicenseandCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:to="loc_regn_IOLicenseandCollaborationAgreementMember_c4ee04c7-629b-426f-8a90-2749c8c90f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmendedIODiscoveryAgreementMember_67f37248-c2e6-44ba-9a1d-8a54e490df13" xlink:href="regn-20221231.xsd#regn_AmendedIODiscoveryAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain_410fb1df-1f76-45ff-b943-c3a448ee9b43" xlink:to="loc_regn_AmendedIODiscoveryAgreementMember_67f37248-c2e6-44ba-9a1d-8a54e490df13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7aeec63e-0be1-4e09-8e21-f93bb40b88f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38686fc0-5fce-4cf2-ac4d-1a2e4e6a8ab5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7aeec63e-0be1-4e09-8e21-f93bb40b88f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_ede259ae-9f39-4c93-a341-3651a43ba37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7aeec63e-0be1-4e09-8e21-f93bb40b88f7" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_ede259ae-9f39-4c93-a341-3651a43ba37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fe564a9-0615-4f30-8e71-0410fc3f7da4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bedb7f52-6052-4d7f-94bd-db8d83dfc644" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fe564a9-0615-4f30-8e71-0410fc3f7da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_a7353bf0-0106-4ff0-96d8-9bbf4082eafe" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fe564a9-0615-4f30-8e71-0410fc3f7da4" xlink:to="loc_regn_SanofiMember_a7353bf0-0106-4ff0-96d8-9bbf4082eafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:href="regn-20221231.xsd#regn_SalesMilestonesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:href="regn-20221231.xsd#regn_SalesMilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesAxis_592014a4-7a4d-481f-8145-3350e48a6abb" xlink:to="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegulatoryMilestoneMember_41831987-6da0-4c60-8900-ab8ab2f1f74f" xlink:href="regn-20221231.xsd#regn_RegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_RegulatoryMilestoneMember_41831987-6da0-4c60-8900-ab8ab2f1f74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneOneMember_77d6237a-a791-4a8f-ac46-5c8c3cd5c979" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_SalesBasedMilestoneOneMember_77d6237a-a791-4a8f-ac46-5c8c3cd5c979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneTwoMember_85409fc3-628b-4725-9c37-9a211bf4c096" xlink:href="regn-20221231.xsd#regn_SalesBasedMilestoneTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_SalesBasedMilestoneTwoMember_85409fc3-628b-4725-9c37-9a211bf4c096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AggregateSalesBasedMilestoneMember_cb1bb613-ebd9-4752-a17f-85b86841ff4d" xlink:href="regn-20221231.xsd#regn_AggregateSalesBasedMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_742b1041-acf0-4314-b27c-640059f9621a" xlink:to="loc_regn_AggregateSalesBasedMilestoneMember_cb1bb613-ebd9-4752-a17f-85b86841ff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b971be2a-ded9-40c3-8049-cf5a639755ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_73bff05c-2e5c-4737-a09f-1871fa4c5f53" xlink:to="loc_dei_EntityDomain_b971be2a-ded9-40c3-8049-cf5a639755ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_3de0c5fa-11d4-43fb-ab51-e7da56556199" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b971be2a-ded9-40c3-8049-cf5a639755ac" xlink:to="loc_regn_SanofiMember_3de0c5fa-11d4-43fb-ab51-e7da56556199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_310da2e7-b6f4-46f5-8bb1-d14b9194cefe" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_d1a651c0-6db2-40b6-b244-1e8d69cecc06" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_d1a651c0-6db2-40b6-b244-1e8d69cecc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentReceived_dbf2e4d5-bb45-40d5-b6f6-b86a29fe16d0" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_regn_UpFrontPaymentReceived_dbf2e4d5-bb45-40d5-b6f6-b86a29fe16d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d768e0ad-89e5-461f-9680-cb4bc6c60595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d768e0ad-89e5-461f-9680-cb4bc6c60595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_12b0c156-b894-4e24-a7b7-4dc21caf2a2f" xlink:href="regn-20221231.xsd#regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_12b0c156-b894-4e24-a7b7-4dc21caf2a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_a66e63c5-070d-48d2-94c0-07125d08c653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_OtherLiabilities_a66e63c5-070d-48d2-94c0-07125d08c653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_dbffa3d5-e193-4b06-be52-6827c793ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_dbffa3d5-e193-4b06-be52-6827c793ccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f2e694a8-c007-4ef1-a4b2-ed01356e04a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ec105ed7-cca7-4d54-b962-c8976915ef8a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f2e694a8-c007-4ef1-a4b2-ed01356e04a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_be5c443b-7ab5-4cb5-bcb4-14bfc6f8d4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_be5c443b-7ab5-4cb5-bcb4-14bfc6f8d4c0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a85f471d-681f-4baa-ba5c-617f4c6dcdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1142ed2f-8641-4bed-adad-b18ee61930fd" xlink:to="loc_us-gaap_ProjectMember_a85f471d-681f-4baa-ba5c-617f4c6dcdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_d50d73de-ac3b-4e0d-bca4-4d3e553012d3" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_a85f471d-681f-4baa-ba5c-617f4c6dcdee" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_d50d73de-ac3b-4e0d-bca4-4d3e553012d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_988c4e6f-7f7e-43a8-9299-4a0502139d47" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_24c66de8-5f36-4a21-94a3-f2d5778ae527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_24c66de8-5f36-4a21-94a3-f2d5778ae527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_baa83f17-157d-4512-b560-fffca250d25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_baa83f17-157d-4512-b560-fffca250d25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_d3c7eb15-030e-409f-81d6-c299ac7eeac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c835276f-eac9-4af0-a11f-615e85dd57d4" xlink:to="loc_us-gaap_OtherLiabilities_d3c7eb15-030e-409f-81d6-c299ac7eeac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef8d661b-c394-4393-bab3-301dad47d1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef8d661b-c394-4393-bab3-301dad47d1d7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_71490166-015b-4d5f-b72d-aadc40879615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fe92340a-8c6b-4d80-9eb3-4f169053f95e" xlink:to="loc_us-gaap_ProjectMember_71490166-015b-4d5f-b72d-aadc40879615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_9d8c2a8f-7ca7-43e7-9cc3-3ed0f52f8039" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_71490166-015b-4d5f-b72d-aadc40879615" xlink:to="loc_regn_BayerCollaborationAgreementMember_9d8c2a8f-7ca7-43e7-9cc3-3ed0f52f8039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:to="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ea7021b7-9776-433d-8d5d-5c7106176130" xlink:to="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7db5d5d-634a-474e-8b25-860b6010d1c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:to="loc_srt_MinimumMember_e7db5d5d-634a-474e-8b25-860b6010d1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff66dc9c-2e94-4d5f-8738-47d182967f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f863505f-5243-4023-bc3a-fca84f2037b8" xlink:to="loc_srt_MaximumMember_ff66dc9c-2e94-4d5f-8738-47d182967f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9aed669a-882b-4529-a0c3-be4c0e2974b5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_508a0c38-5f2c-44e8-a4a1-910a212eefcd" xlink:href="regn-20221231.xsd#regn_RevenueBasedOnPercentageOfAnnualSalesInJapan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_508a0c38-5f2c-44e8-a4a1-910a212eefcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_24937769-7888-4b46-8fa1-d218f6dc406a" xlink:href="regn-20221231.xsd#regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits_24937769-7888-4b46-8fa1-d218f6dc406a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContingentReimbursementObligation_10dcb71d-3de1-4f96-8bab-55fdbcf45ec3" xlink:href="regn-20221231.xsd#regn_ContingentReimbursementObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d41acbb-a546-461c-a114-23e07d3e27e3" xlink:to="loc_regn_ContingentReimbursementObligation_10dcb71d-3de1-4f96-8bab-55fdbcf45ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b85e2ea-c722-47bf-9dd3-475e88a2e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b85e2ea-c722-47bf-9dd3-475e88a2e8b6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_490792a0-32d3-4317-90fa-484558f9c54d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dbe65905-cf36-4e58-94ae-c8ed685368a6" xlink:to="loc_srt_SegmentGeographicalDomain_490792a0-32d3-4317-90fa-484558f9c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_278be6e8-87fd-4dd8-ad16-2c01b7d9bd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_490792a0-32d3-4317-90fa-484558f9c54d" xlink:to="loc_us-gaap_NonUsMember_278be6e8-87fd-4dd8-ad16-2c01b7d9bd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_14604233-ab5c-48d4-a56b-4705ecd56391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a9ee12e-55c4-47de-8038-dd6fadb1c53f" xlink:to="loc_us-gaap_ProjectMember_14604233-ab5c-48d4-a56b-4705ecd56391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_39232e4b-67cb-4d82-811f-cb692b72e5e8" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_14604233-ab5c-48d4-a56b-4705ecd56391" xlink:to="loc_regn_BayerCollaborationAgreementMember_39232e4b-67cb-4d82-811f-cb692b72e5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_65c43334-768d-46ce-9684-325c50685895" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_38678b6b-7961-4830-a1bc-057829cc7bac" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:to="loc_regn_CollaborationRevenueMember_38678b6b-7961-4830-a1bc-057829cc7bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_abb31769-d352-4b01-896e-2e83df5dd2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d0369f7-5e53-47c4-8f11-9239dc37b94a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_abb31769-d352-4b01-896e-2e83df5dd2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_40a84975-3f2d-4646-b609-2cb5a327a6b5" xlink:to="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_3fb0ed36-ebbe-4248-92d2-05089f59e755" xlink:href="regn-20221231.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_3fb0ed36-ebbe-4248-92d2-05089f59e755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_2ca08577-0e97-4146-a1f3-4fccbd83db66" xlink:href="regn-20221231.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_2ca08577-0e97-4146-a1f3-4fccbd83db66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_9360b595-9657-4ff7-913f-19e8cf453449" xlink:href="regn-20221231.xsd#regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_9360b595-9657-4ff7-913f-19e8cf453449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_5d918605-b1d5-4d2c-ae92-d90274a3d9cf" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_5d918605-b1d5-4d2c-ae92-d90274a3d9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e255f5e6-7d6e-4505-bbae-4537ad667f04" xlink:href="regn-20221231.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54668b8a-f883-4eb2-b8e6-22d31c005e04" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e255f5e6-7d6e-4505-bbae-4537ad667f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0fac2d80-05b9-48d1-abac-d6af9557723c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57976f46-4361-460e-90f0-71d05f243b5d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0fac2d80-05b9-48d1-abac-d6af9557723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_365ea153-8acf-4f4a-a6b6-827df8202d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0fac2d80-05b9-48d1-abac-d6af9557723c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_365ea153-8acf-4f4a-a6b6-827df8202d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31d05468-3c25-4af7-a3e7-b50225622a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31d05468-3c25-4af7-a3e7-b50225622a19" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3edb1ff3-8227-403b-b257-9d18aa4c914c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8f898e7b-e8fb-4cc3-a9be-ee2d486b9413" xlink:to="loc_us-gaap_ProjectMember_3edb1ff3-8227-403b-b257-9d18aa4c914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_79ec7e53-7549-4898-b8b9-4228461ace9e" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_3edb1ff3-8227-403b-b257-9d18aa4c914c" xlink:to="loc_regn_BayerCollaborationAgreementMember_79ec7e53-7549-4898-b8b9-4228461ace9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fdd7bd86-b537-4e4d-a8f0-4cc669b6e90d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f8830197-5572-4ad0-b047-b0721027f12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f8830197-5572-4ad0-b047-b0721027f12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f2fa8393-03fe-4d65-9fd1-f10abcfd409e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c254cab-71d6-4dfc-b1f1-ad443d4074a2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f2fa8393-03fe-4d65-9fd1-f10abcfd409e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_990599bc-1cec-4291-b8e2-a3df5caf6adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_990599bc-1cec-4291-b8e2-a3df5caf6adb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_91ee9016-a493-421f-abc5-280b26669438" xlink:to="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaCollaborationAgreementMember_ba81832d-29b0-410a-b0d1-66d2e8c45af4" xlink:href="regn-20221231.xsd#regn_IntelliaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:to="loc_regn_IntelliaCollaborationAgreementMember_ba81832d-29b0-410a-b0d1-66d2e8c45af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ce3ebab9-55ec-4d16-a365-ea366c4fbef5" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_20183b97-03ca-48b6-9dce-f2de847b3512" xlink:to="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ce3ebab9-55ec-4d16-a365-ea366c4fbef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:to="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b7707f62-ea07-40d7-89d5-e610fe2bd586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_37c9d5dc-42ee-4d47-aa21-e39c5cb2b729" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b7707f62-ea07-40d7-89d5-e610fe2bd586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_06054d56-56ce-401d-95c8-e72d262e302d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b7707f62-ea07-40d7-89d5-e610fe2bd586" xlink:to="loc_us-gaap_CommonStockMember_06054d56-56ce-401d-95c8-e72d262e302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6ab8528-d045-4cb4-aab4-24a2a437d6f6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade_08d2227a-9bd3-4532-b5a2-4c9c06cb83ad" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_regn_CollaborativeArrangementUpfrontPaymentMade_08d2227a-9bd3-4532-b5a2-4c9c06cb83ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_737b8c6e-31a9-48c9-9c8e-e55186b90575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_737b8c6e-31a9-48c9-9c8e-e55186b90575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b7299c81-9e13-4d4f-828b-63a7d45b1b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c50a83c-406a-48fb-a669-018905dd5ea9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b7299c81-9e13-4d4f-828b-63a7d45b1b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cd7af26d-70a5-43b9-aa35-b4406353c730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cd7af26d-70a5-43b9-aa35-b4406353c730" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c7a4da-bd81-4bf6-b9b5-ea342cd7deb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e9809a1a-5c32-460b-a888-6aca8701ef2a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c7a4da-bd81-4bf6-b9b5-ea342cd7deb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_f9506f54-39e5-4f6a-beeb-d7348e29fb71" xlink:href="regn-20221231.xsd#regn_USGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c7a4da-bd81-4bf6-b9b5-ea342cd7deb2" xlink:to="loc_regn_USGovernmentMember_f9506f54-39e5-4f6a-beeb-d7348e29fb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ebc6285-39ef-4b66-b2bc-77929f922865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c936acd-47eb-4b31-9964-c4ddf657d60f" xlink:to="loc_srt_ProductsAndServicesDomain_6ebc6285-39ef-4b66-b2bc-77929f922865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_fc550c52-d47a-44cf-9538-3fc415f03b75" xlink:href="regn-20221231.xsd#regn_REGENCOVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ebc6285-39ef-4b66-b2bc-77929f922865" xlink:to="loc_regn_REGENCOVMember_fc550c52-d47a-44cf-9538-3fc415f03b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_94d421e8-f22a-4c86-a0db-15d231c1bcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4a1ad29a-ed48-4e8d-8866-fe1d9a68d796" xlink:to="loc_us-gaap_ProjectMember_94d421e8-f22a-4c86-a0db-15d231c1bcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember_3414ca85-fae3-4b0e-8930-c9ef068f42b8" xlink:href="regn-20221231.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_94d421e8-f22a-4c86-a0db-15d231c1bcc6" xlink:to="loc_regn_BARDAOtherTransactionAgreementMember_3414ca85-fae3-4b0e-8930-c9ef068f42b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7fa0ce7-1154-4837-8bb9-c9821ea3134f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments_5424dfb1-6143-402f-937b-2e7a1732051a" xlink:href="regn-20221231.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_regn_MaximumTransactionAgreementPayments_5424dfb1-6143-402f-937b-2e7a1732051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_8ee89af5-6e42-402e-85fb-269b8b9986cc" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_8ee89af5-6e42-402e-85fb-269b8b9986cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aca39b34-bce4-45e8-91a0-25346eaa47dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67c7df17-e7e0-45de-af9d-adba4d2bc5f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aca39b34-bce4-45e8-91a0-25346eaa47dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f825f8e4-397a-4166-8b5c-bfe6b5b883cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f825f8e4-397a-4166-8b5c-bfe6b5b883cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7b413dd5-501d-4e96-a763-99b542e90e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6403839c-45b2-477e-9f7b-9a6244242684" xlink:to="loc_us-gaap_ProjectMember_7b413dd5-501d-4e96-a763-99b542e90e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_4c663f18-8b5f-4092-a4ac-d44c26d9f517" xlink:href="regn-20221231.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_7b413dd5-501d-4e96-a763-99b542e90e87" xlink:to="loc_regn_RocheCollaborationAgreementMember_4c663f18-8b5f-4092-a4ac-d44c26d9f517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a9b4d648-60e6-4e6e-aec3-1410c6b191b6" xlink:to="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RonapreveMember_b21c52ba-6ea0-4b17-8603-abf40a61a9ad" xlink:href="regn-20221231.xsd#regn_RonapreveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:to="loc_regn_RonapreveMember_b21c52ba-6ea0-4b17-8603-abf40a61a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_908a6e86-c998-4738-9ca2-9aa645ddfca2" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61aa9127-1515-411b-a582-4999feb13092" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_908a6e86-c998-4738-9ca2-9aa645ddfca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_95f7e658-4202-4786-97dc-686bafd9429f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_db189057-39dd-4706-a499-146fd7b402d4" xlink:href="regn-20221231.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:to="loc_regn_CollaborationRevenueMember_db189057-39dd-4706-a499-146fd7b402d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_72433994-1069-4138-8590-fddf3e8fc0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_72433994-1069-4138-8590-fddf3e8fc0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_d1f0e231-61dd-40af-b021-36c218c6a3b6" xlink:href="regn-20221231.xsd#regn_CostOfGoodsSoldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d16b149-0b08-4dc9-ba69-26a87c6d26f0" xlink:to="loc_regn_CostOfGoodsSoldMember_d1f0e231-61dd-40af-b021-36c218c6a3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0c0c6fff-c598-4876-95e1-44eecf7e05f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_084d460e-b403-4634-a700-f607513a9ad4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0c0c6fff-c598-4876-95e1-44eecf7e05f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f7b10df-50aa-41d3-b0e0-3430ac43b215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c0c6fff-c598-4876-95e1-44eecf7e05f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f7b10df-50aa-41d3-b0e0-3430ac43b215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a33030d5-9b26-4efd-9d18-5b224710b274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a33030d5-9b26-4efd-9d18-5b224710b274" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_44381541-15cc-4be0-9c55-e98343894faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8e00d39b-7065-4258-9585-a5e1c2208825" xlink:to="loc_us-gaap_ProjectMember_44381541-15cc-4be0-9c55-e98343894faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_3ea83036-13d6-4bf5-a817-2cebceaf19b7" xlink:href="regn-20221231.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_44381541-15cc-4be0-9c55-e98343894faf" xlink:to="loc_regn_RocheCollaborationAgreementMember_3ea83036-13d6-4bf5-a817-2cebceaf19b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26c3fe03-27aa-43d0-8161-90b28bf34913" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d38f514c-12ea-46a0-aab0-e7bd359ff6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d38f514c-12ea-46a0-aab0-e7bd359ff6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d9f139b1-8afa-4074-8d73-5ffa15488eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7b3c727b-7de0-4863-b903-47d8290dc076" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d9f139b1-8afa-4074-8d73-5ffa15488eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599122ba-16a1-425d-b6ac-1814469b6e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599122ba-16a1-425d-b6ac-1814469b6e7c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0769e77-e1b5-4e2a-a2d7-0d569b75e833" xlink:to="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c06c3254-d977-4755-ba73-953f8658d7ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:to="loc_srt_MinimumMember_c06c3254-d977-4755-ba73-953f8658d7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86ab5f78-e38b-451f-9397-bb24a712e249" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_97678824-8f91-4bd7-bb19-cf31a6ffcd31" xlink:to="loc_srt_MaximumMember_86ab5f78-e38b-451f-9397-bb24a712e249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_773ebccb-ac7e-427a-b1c7-8f9107bd4d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_984ba111-77a9-492d-98d5-bc6c8e900521" xlink:to="loc_us-gaap_ProjectMember_773ebccb-ac7e-427a-b1c7-8f9107bd4d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ae199b5f-d555-4b5d-9435-d30d99ee1ade" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_773ebccb-ac7e-427a-b1c7-8f9107bd4d72" xlink:to="loc_regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember_ae199b5f-d555-4b5d-9435-d30d99ee1ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7c732ab4-797c-4944-ba86-85ad269e4e5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ae555b88-0f2f-483e-bbe1-90a0603718ee" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7c732ab4-797c-4944-ba86-85ad269e4e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_58c551d0-64b0-4f12-aae8-58a06b5bf78e" xlink:href="regn-20221231.xsd#regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7c732ab4-797c-4944-ba86-85ad269e4e5e" xlink:to="loc_regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember_58c551d0-64b0-4f12-aae8-58a06b5bf78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5362684a-4783-46ac-8ac4-b88071f2e7ab" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpfrontPaymentMade_5bb900c6-abe0-4c82-ad18-19054e900f3d" xlink:href="regn-20221231.xsd#regn_UpfrontPaymentMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_UpfrontPaymentMade_5bb900c6-abe0-4c82-ad18-19054e900f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_a9aec394-2f95-4e1c-9e9d-9bbd00e7884c" xlink:href="regn-20221231.xsd#regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement_a9aec394-2f95-4e1c-9e9d-9bbd00e7884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_002bc866-2007-4b7b-94f7-d248dfc03d2b" xlink:href="regn-20221231.xsd#regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone_002bc866-2007-4b7b-94f7-d248dfc03d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InitialResearchTerm_4bd7f83d-cc3a-4ff0-80f4-37cab5fd809f" xlink:href="regn-20221231.xsd#regn_InitialResearchTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_InitialResearchTerm_4bd7f83d-cc3a-4ff0-80f4-37cab5fd809f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PotentialExtensionOfResearchTerm_16ef7d66-f262-435a-9cdf-fc87d3c2932d" xlink:href="regn-20221231.xsd#regn_PotentialExtensionOfResearchTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_PotentialExtensionOfResearchTerm_16ef7d66-f262-435a-9cdf-fc87d3c2932d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OptionToExtendResearchTermPeriod_f9446ab4-3357-49eb-8356-aad36f7554f9" xlink:href="regn-20221231.xsd#regn_OptionToExtendResearchTermPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_OptionToExtendResearchTermPeriod_f9446ab4-3357-49eb-8356-aad36f7554f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ExtensionOfResearchTermFee_ebb44709-154a-434d-b317-fecc5ce2d132" xlink:href="regn-20221231.xsd#regn_ExtensionOfResearchTermFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_ExtensionOfResearchTermFee_ebb44709-154a-434d-b317-fecc5ce2d132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_abf8b924-fb32-4240-b55d-82d2007ef573" xlink:href="regn-20221231.xsd#regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_379745b3-35f2-4ad5-b45e-db3037ee8aef" xlink:to="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_abf8b924-fb32-4240-b55d-82d2007ef573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a1be80a5-5505-4f2a-b6a0-594615e798d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a1be80a5-5505-4f2a-b6a0-594615e798d5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb47f737-d948-4cb4-925a-fc39cac2262d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_336b6840-3540-44e1-b1ad-3ef4532a167d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb47f737-d948-4cb4-925a-fc39cac2262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CheckmatePharmaceuticalsIncMember_1e9016a7-c7bb-42d9-a2b8-efac115c5085" xlink:href="regn-20221231.xsd#regn_CheckmatePharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb47f737-d948-4cb4-925a-fc39cac2262d" xlink:to="loc_regn_CheckmatePharmaceuticalsIncMember_1e9016a7-c7bb-42d9-a2b8-efac115c5085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eea83f82-0300-4dfe-a9fe-c0bb090da24d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27468d21-6b79-43bc-9a24-cc04ff856cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27468d21-6b79-43bc-9a24-cc04ff856cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3ab157d1-2352-4204-b505-a515ec0d3834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3ab157d1-2352-4204-b505-a515ec0d3834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c03cccac-790b-4812-a788-b72367ef2b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_116a1c1d-173e-4239-b8a8-f1c206cdd5c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c03cccac-790b-4812-a788-b72367ef2b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_96df2d0d-bf54-48c0-9766-41c40674594c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_96df2d0d-bf54-48c0-9766-41c40674594c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_82f602d7-89c2-4f18-9762-1d4740325852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a1787687-4fab-4fe0-8524-e09f04f76f66" xlink:to="loc_us-gaap_ProjectMember_82f602d7-89c2-4f18-9762-1d4740325852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b210680e-8494-4fbc-85ed-826181891b4a" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_82f602d7-89c2-4f18-9762-1d4740325852" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b210680e-8494-4fbc-85ed-826181891b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5bd6de40-62c1-41ae-8066-138121c169f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89e4f525-251f-4c67-aff2-7d507acf8c0f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5bd6de40-62c1-41ae-8066-138121c169f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7386ad1-e1ee-4b33-8b54-1a4c89ac75e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5bd6de40-62c1-41ae-8066-138121c169f5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7386ad1-e1ee-4b33-8b54-1a4c89ac75e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e4f43e15-cdf1-42c6-a0ed-a87f57e686d7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentReceived_33b3683b-6f39-4791-b4e7-f2cef92671f8" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_regn_UpFrontPaymentReceived_33b3683b-6f39-4791-b4e7-f2cef92671f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c7e354d7-569c-4e5d-b05c-bdb7e622f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c7e354d7-569c-4e5d-b05c-bdb7e622f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_d2500e6d-d67a-4eab-ad78-cf7849326446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bccf022-3306-4e66-acf0-6ee66f1b7a1e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_d2500e6d-d67a-4eab-ad78-cf7849326446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_60ea8976-118c-4878-8dea-b3f31c04b50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_60ea8976-118c-4878-8dea-b3f31c04b50a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_60b71662-e9bb-498a-a9e8-358962d89dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9b46a54b-485f-4466-9fd2-43a97767ccbb" xlink:to="loc_us-gaap_ProjectMember_60b71662-e9bb-498a-a9e8-358962d89dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_e6f85403-b1b8-45a0-b390-671c638066a1" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_60b71662-e9bb-498a-a9e8-358962d89dfc" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_e6f85403-b1b8-45a0-b390-671c638066a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14f31f67-5087-4af4-ae08-2f99fc048b2a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2361103e-82de-451d-95d0-97ac6ca82ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2361103e-82de-451d-95d0-97ac6ca82ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_6146b70d-eea6-46dd-8490-a9e9a365f2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2f4ad45-742d-44f0-a290-1b6418f68dfd" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_6146b70d-eea6-46dd-8490-a9e9a365f2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5e9395e3-97ef-4df5-adbf-4a42e6c033d1" xlink:to="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_cbf24674-0dc4-41d1-aa8c-1ebe0bcb0e65" xlink:href="regn-20221231.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_cbf24674-0dc4-41d1-aa8c-1ebe0bcb0e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_2e5a9243-e84a-46df-a5f7-8d2e4f39cdc8" xlink:href="regn-20221231.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fce3a2ea-a4ab-4daa-a152-6cfbc42cd809" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_2e5a9243-e84a-46df-a5f7-8d2e4f39cdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_641e38bf-7dae-4b04-bcad-1f4d07ad8ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea867859-4482-427a-a70e-f4f93231c410" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_641e38bf-7dae-4b04-bcad-1f4d07ad8ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aab14bb8-582d-4598-b486-8a5bbb746ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_641e38bf-7dae-4b04-bcad-1f4d07ad8ae2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aab14bb8-582d-4598-b486-8a5bbb746ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cc751d56-253a-420c-a02f-9eda1508a082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cc751d56-253a-420c-a02f-9eda1508a082" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6584b4ee-bf79-40e5-8c08-a1832ca26373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b44c836f-6eac-497d-b9f4-d9a8d1a358b1" xlink:to="loc_us-gaap_ProjectMember_6584b4ee-bf79-40e5-8c08-a1832ca26373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_f89e7619-23ea-48c6-9e55-b3e8ca03059d" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_6584b4ee-bf79-40e5-8c08-a1832ca26373" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_f89e7619-23ea-48c6-9e55-b3e8ca03059d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_03599fca-8062-4742-8814-ac094c351823" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_80187574-7d19-49e1-9aca-d9dde05d213b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_80187574-7d19-49e1-9aca-d9dde05d213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_44d6ea6b-9be0-46b5-9306-3abc563b7cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_58c72cf4-58ea-4635-a182-83e22b6b1c37" xlink:to="loc_us-gaap_OtherLiabilities_44d6ea6b-9be0-46b5-9306-3abc563b7cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cc62b31b-9528-487c-b220-dd22bce41a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cc62b31b-9528-487c-b220-dd22bce41a41" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8608de97-56b9-4089-b097-b662a8b3ced8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_f395631d-c6de-479c-98b1-7b6d1cbc27b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_f395631d-c6de-479c-98b1-7b6d1cbc27b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0fc03ca6-cb01-44fe-824f-3e02b69f62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0fc03ca6-cb01-44fe-824f-3e02b69f62b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_60756f2b-0661-4deb-93a2-5f5a9f80c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_60756f2b-0661-4deb-93a2-5f5a9f80c7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29a00da3-972a-4f09-b53f-8653fea105f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_CommercialPaperMember_29a00da3-972a-4f09-b53f-8653fea105f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1766a3df-3884-45e7-bf1d-9e192bb0771b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1766a3df-3884-45e7-bf1d-9e192bb0771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_17e11eef-c447-4e19-980c-0133dd84b009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf1880fe-f250-478f-964e-fed2bdce6f9c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_17e11eef-c447-4e19-980c-0133dd84b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2ddc86b2-40a8-4ac6-bde3-8f8c53263ac9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e3c2c72-f848-4947-bc18-a5f877e0a474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e3c2c72-f848-4947-bc18-a5f877e0a474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a0b5221d-7fd3-4c2d-8743-4bad95323c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a0b5221d-7fd3-4c2d-8743-4bad95323c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8613fb1-76a6-4673-be42-0989392ae65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8613fb1-76a6-4673-be42-0989392ae65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5dafbe04-6c59-49fe-a32f-cf3c955b53a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ce49bb3-892f-4b58-b996-7e76dec645e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5dafbe04-6c59-49fe-a32f-cf3c955b53a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff179bf5-143b-4191-b3b6-c1666e18e2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d78f4c3a-40f8-40f9-b044-25a9446258f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff179bf5-143b-4191-b3b6-c1666e18e2bf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d78f4c3a-40f8-40f9-b044-25a9446258f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5666e05b-d29a-4e14-b5f5-fc8d1d728425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff179bf5-143b-4191-b3b6-c1666e18e2bf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5666e05b-d29a-4e14-b5f5-fc8d1d728425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_78142478-5f73-4854-82b6-99605b12126b" xlink:href="regn-20221231.xsd#regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff179bf5-143b-4191-b3b6-c1666e18e2bf" xlink:to="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_78142478-5f73-4854-82b6-99605b12126b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5e558c7e-5b02-406b-b5b4-a24303cf1b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff179bf5-143b-4191-b3b6-c1666e18e2bf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5e558c7e-5b02-406b-b5b4-a24303cf1b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_67703d4c-0e73-4647-b1ef-833b5798964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_67703d4c-0e73-4647-b1ef-833b5798964c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_898f1815-68bd-4ccc-ae53-dfa828bb2fac" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_dd76c020-8c93-41ce-a92e-e0b67b504d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_dd76c020-8c93-41ce-a92e-e0b67b504d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_47f91fed-261d-47a2-9933-244e2c0fdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_47f91fed-261d-47a2-9933-244e2c0fdca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_fb9cff8c-2b8b-4596-9af2-25ae3c198a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_fb9cff8c-2b8b-4596-9af2-25ae3c198a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0c488d9c-09a6-4701-a87c-52a21bb831a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_CommercialPaperMember_0c488d9c-09a6-4701-a87c-52a21bb831a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4d443104-6243-45d7-8454-17df5361cee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4d443104-6243-45d7-8454-17df5361cee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3d0b134a-711f-460d-b74a-b23c6bd1fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2acd55ad-cebe-4a77-b9b7-03b012812ab6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3d0b134a-711f-460d-b74a-b23c6bd1fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ac2322a7-6534-4ebd-b960-4bd3ddcb40b3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f51b90c1-0da3-4a0f-98c0-bac1b513ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f51b90c1-0da3-4a0f-98c0-bac1b513ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9d62db6a-7937-43a3-8851-08f35707ef83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9d62db6a-7937-43a3-8851-08f35707ef83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6a2b52a2-7056-40b0-a9ab-2490e4d0b721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6a2b52a2-7056-40b0-a9ab-2490e4d0b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b8e3eb0e-6e26-46a2-bdc7-8c3cb7865bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b8e3eb0e-6e26-46a2-bdc7-8c3cb7865bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53191893-2d6e-4259-a268-49b15c6583ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53191893-2d6e-4259-a268-49b15c6583ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_aa6e695e-c240-47d6-82ce-2ebe7fb32863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af365e78-211b-4e6b-b37a-69a192b06f42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_aa6e695e-c240-47d6-82ce-2ebe7fb32863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9fe7def2-94ed-490a-bda1-9dfcc98aa86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_88ef8eea-a754-4132-8add-3bd3f84ecf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9fe7def2-94ed-490a-bda1-9dfcc98aa86e" xlink:to="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_88ef8eea-a754-4132-8add-3bd3f84ecf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_af09435c-4766-42aa-b3d3-7d18d3845b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_af09435c-4766-42aa-b3d3-7d18d3845b02" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9233adce-adad-47a8-9e09-60a21c85b005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0b6452a4-10fa-4710-be10-00089e997fff" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9233adce-adad-47a8-9e09-60a21c85b005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2b55bb7f-beae-4593-aa5b-2e0bfa8a1ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9233adce-adad-47a8-9e09-60a21c85b005" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2b55bb7f-beae-4593-aa5b-2e0bfa8a1ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_228bfd63-16f2-4ce9-8fb1-755e48283098" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a3ccc7df-27bd-40e7-9f89-d5e20d11ae70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a3ccc7df-27bd-40e7-9f89-d5e20d11ae70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f027d0c7-0f21-4676-847b-9c5b70bec7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fcc39fd-5ef0-4a79-a623-cce359e7aac9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f027d0c7-0f21-4676-847b-9c5b70bec7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_84e8d49a-d0e7-425e-93ef-9dce3df070b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d8d8f0a9-da93-466e-977f-8a30d59e603f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d8d8f0a9-da93-466e-977f-8a30d59e603f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_bccd0576-2bb6-42f3-8bef-ad65726f060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_bccd0576-2bb6-42f3-8bef-ad65726f060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_86becdac-a25c-4fe8-a1fa-1e63ff37340b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_86becdac-a25c-4fe8-a1fa-1e63ff37340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b2962561-cf9f-4779-8cbd-55e0d52121a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_CommercialPaperMember_b2962561-cf9f-4779-8cbd-55e0d52121a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b12b9130-b534-4b8b-b44d-95d8015d6fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b12b9130-b534-4b8b-b44d-95d8015d6fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_978c6dec-ef2d-4d8e-8b14-ceb4f4279277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2d33042-26d9-4a38-a25d-a31c1c55dc2c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_978c6dec-ef2d-4d8e-8b14-ceb4f4279277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:href="regn-20221231.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentAxis_23f02561-d245-430d-8098-9d06e42e008d" xlink:to="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_b06da266-9e98-489a-bcaa-a6f0112e2987" xlink:href="regn-20221231.xsd#regn_UnrestrictedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:to="loc_regn_UnrestrictedMember_b06da266-9e98-489a-bcaa-a6f0112e2987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_89432a16-f8f4-46c7-88f5-1d9b24f748be" xlink:href="regn-20221231.xsd#regn_RestrictedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_b773d568-09fa-4edf-8e77-0caa4625c3ce" xlink:to="loc_regn_RestrictedMember_89432a16-f8f4-46c7-88f5-1d9b24f748be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_74da2831-7e42-4a26-845f-70eddd6f6d6f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_cc7aecd2-a6cf-47d0-8b6e-97bac48a4203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_cc7aecd2-a6cf-47d0-8b6e-97bac48a4203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f3d65f4-f416-4542-8ac7-1611a691dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_cc7aecd2-a6cf-47d0-8b6e-97bac48a4203" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f3d65f4-f416-4542-8ac7-1611a691dba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f9455b0d-250c-463d-9e82-4b85d1491915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f9455b0d-250c-463d-9e82-4b85d1491915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_83630a2f-ec3e-4b17-b1b5-aa8bca31f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e754d0c3-c886-4ac4-9cb4-34d5e8a5bea5" xlink:to="loc_us-gaap_MarketableSecurities_83630a2f-ec3e-4b17-b1b5-aa8bca31f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e2e17852-5e82-4796-bcc2-27b36313530d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_22a9c154-214d-44a8-90a9-9ed6ee5e6c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2e17852-5e82-4796-bcc2-27b36313530d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_22a9c154-214d-44a8-90a9-9ed6ee5e6c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e56efedf-70fd-4aaf-9d38-89ba6b116b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2e17852-5e82-4796-bcc2-27b36313530d" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e56efedf-70fd-4aaf-9d38-89ba6b116b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_62ce1ae2-166b-4cdc-a58d-d804e3118bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2e17852-5e82-4796-bcc2-27b36313530d" xlink:to="loc_us-gaap_LongTermDebtFairValue_62ce1ae2-166b-4cdc-a58d-d804e3118bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9fd9acdb-3717-40fe-b5a8-0fcb4f471b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e7cefc9b-e50a-4569-af03-568ccb86d23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fd9acdb-3717-40fe-b5a8-0fcb4f471b1c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e7cefc9b-e50a-4569-af03-568ccb86d23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_85f9b885-7a34-4434-9a36-e69740667758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fd9acdb-3717-40fe-b5a8-0fcb4f471b1c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_85f9b885-7a34-4434-9a36-e69740667758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fadaa9e2-6741-476a-bf24-25a2400a694a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fd9acdb-3717-40fe-b5a8-0fcb4f471b1c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fadaa9e2-6741-476a-bf24-25a2400a694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_7a6cf15a-824d-4235-bdde-bac274d4c164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fd9acdb-3717-40fe-b5a8-0fcb4f471b1c" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_7a6cf15a-824d-4235-bdde-bac274d4c164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_353ff0ea-5ff8-4c11-b690-cf9b1c53b8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fd9acdb-3717-40fe-b5a8-0fcb4f471b1c" xlink:to="loc_us-gaap_InventoryNet_353ff0ea-5ff8-4c11-b690-cf9b1c53b8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_71634bcd-503a-4a7d-8074-4aebf6b09747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_2c454821-93ff-40bc-be32-44a2919ee1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_71634bcd-503a-4a7d-8074-4aebf6b09747" xlink:to="loc_us-gaap_InventoryValuationReserves_2c454821-93ff-40bc-be32-44a2919ee1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_fc244cb8-fa05-47c5-9d35-80edcec02932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_71634bcd-503a-4a7d-8074-4aebf6b09747" xlink:to="loc_us-gaap_InventoryWriteDown_fc244cb8-fa05-47c5-9d35-80edcec02932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec8d72bd-85e2-4e7e-8953-e48c5aa9212e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec8d72bd-85e2-4e7e-8953-e48c5aa9212e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15fdad24-cbd6-4255-9e01-6404675d508c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_03357fbb-07a1-4bab-aea9-722b9bec5ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_LandMember_03357fbb-07a1-4bab-aea9-722b9bec5ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_3a7d0b74-e1d9-4ac6-9fe3-936b469dfe82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_3a7d0b74-e1d9-4ac6-9fe3-936b469dfe82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_59b77fa7-a01b-49e2-a5c4-6cf214688fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_59b77fa7-a01b-49e2-a5c4-6cf214688fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_fc26fa9f-0c86-478c-a682-7555695cc727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_ConstructionInProgressMember_fc26fa9f-0c86-478c-a682-7555695cc727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_7394ffac-f99b-4d9a-aba9-1fd44ef75eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_us-gaap_EquipmentMember_7394ffac-f99b-4d9a-aba9-1fd44ef75eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ComputerEquipmentAndSoftwareMember_dfe0ceec-045a-4782-8009-dc08255c756d" xlink:href="regn-20221231.xsd#regn_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_regn_ComputerEquipmentAndSoftwareMember_dfe0ceec-045a-4782-8009-dc08255c756d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FurnitureOfficeEquipmentAndOtherMember_37f5f194-1880-4adc-8e12-bb629c4e433a" xlink:href="regn-20221231.xsd#regn_FurnitureOfficeEquipmentAndOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5d7490a-6055-418a-953f-338081e1712d" xlink:to="loc_regn_FurnitureOfficeEquipmentAndOtherMember_37f5f194-1880-4adc-8e12-bb629c4e433a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_984b9b13-c365-4ef7-a716-7ff35ffe1584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_e3682687-c80d-4127-b82c-1d6495b7d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_e3682687-c80d-4127-b82c-1d6495b7d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_92487e30-1ebb-4063-b9c9-67523ed393ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_92487e30-1ebb-4063-b9c9-67523ed393ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c40df2d5-2b41-4b94-a4ad-fd34882b530c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4de21c74-2a03-46e0-9575-faee9a297989" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c40df2d5-2b41-4b94-a4ad-fd34882b530c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7860e934-ac9c-485c-8a02-b4389780a80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7860e934-ac9c-485c-8a02-b4389780a80d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:to="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7945f4e9-8792-4b6f-a860-b4c43426cee0" xlink:to="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4121e748-e180-4493-a9ac-f8d8223bf647" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:to="loc_country_US_4121e748-e180-4493-a9ac-f8d8223bf647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember_ebd21929-3c0d-438e-9361-5cd79758b78b" xlink:href="regn-20221231.xsd#regn_RestOfWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9dacba4-ee63-488d-a914-590633153859" xlink:to="loc_regn_RestOfWorldMember_ebd21929-3c0d-438e-9361-5cd79758b78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef5809-17d4-4622-b855-344599b1117f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_a8dc217f-27ec-4c04-bfda-3a661b810717" xlink:href="regn-20221231.xsd#regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:to="loc_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets_a8dc217f-27ec-4c04-bfda-3a661b810717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5480998a-b2f1-4e62-9d05-b9f0f47aa1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_50dfa766-ae3e-4ef3-ac59-fd56a6a40818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5480998a-b2f1-4e62-9d05-b9f0f47aa1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81c75606-bc27-422e-b4d2-777b8a74e38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81c75606-bc27-422e-b4d2-777b8a74e38f" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0fd7584-d29c-4ed7-9525-ae8bff133d43" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ProductRightsMember_4d82a70c-122a-4222-abdb-bbd5c3816e54" xlink:href="regn-20221231.xsd#regn_ProductRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:to="loc_regn_ProductRightsMember_4d82a70c-122a-4222-abdb-bbd5c3816e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6a00d485-ed58-41c1-80d3-f7c24b22047e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7fa2269-d019-464a-94d1-84491102bbff" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6a00d485-ed58-41c1-80d3-f7c24b22047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:to="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bd6ab7b6-5d4c-468c-9bcb-68646dfb3843" xlink:to="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db2143cd-2cbb-4d47-acb4-5aded351e654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:to="loc_srt_MinimumMember_db2143cd-2cbb-4d47-acb4-5aded351e654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4863f2e-c863-427f-b259-62d7c6735f38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86d26b5f-5002-4f81-88f0-5247835a20ef" xlink:to="loc_srt_MaximumMember_d4863f2e-c863-427f-b259-62d7c6735f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_501792fc-0f0f-4673-b0d5-64576f71bfa1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d828621-8a57-49c7-b2aa-641b49d186f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d828621-8a57-49c7-b2aa-641b49d186f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8a722990-97ee-4e89-874c-56483bcd654c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d33d7dab-94a1-403a-bc00-371690485726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d33d7dab-94a1-403a-bc00-371690485726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e1281ce8-a37f-42d7-9ad9-916613010810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e1281ce8-a37f-42d7-9ad9-916613010810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_474dd2c3-7ae2-4bbc-83bb-c6d488d5dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5ef49da-62cf-4356-a931-9111d868e6f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_474dd2c3-7ae2-4bbc-83bb-c6d488d5dbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_196ebc65-4e4e-41e4-9bff-c5b198ba1a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_196ebc65-4e4e-41e4-9bff-c5b198ba1a75" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:to="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cc42c-c15a-4227-b481-0b966b18bed5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2efb860a-c52d-4c76-8b6e-372377b0258e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cc42c-c15a-4227-b481-0b966b18bed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_a5072cd5-3ced-4dad-a95a-44ee221387e0" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cc42c-c15a-4227-b481-0b966b18bed5" xlink:to="loc_regn_SanofiMember_a5072cd5-3ced-4dad-a95a-44ee221387e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c2bb4be8-ad82-4f2c-bd03-908164562720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fcd28489-3b92-4895-9521-7d58533bba18" xlink:to="loc_us-gaap_ProjectMember_c2bb4be8-ad82-4f2c-bd03-908164562720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_240af120-d7c3-4630-ac11-634b07b75c13" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_c2bb4be8-ad82-4f2c-bd03-908164562720" xlink:to="loc_regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember_240af120-d7c3-4630-ac11-634b07b75c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_45c000e8-3a27-4dde-af87-34528dbfd698" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_17618bdd-7f77-404c-b569-f5c789a26473" xlink:href="regn-20221231.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_17618bdd-7f77-404c-b569-f5c789a26473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_7fe32790-b2db-4a1a-b004-9c279d331dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_OtherLiabilities_7fe32790-b2db-4a1a-b004-9c279d331dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_81dc8216-ab97-43cb-973f-50503f3d5f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_81dc8216-ab97-43cb-973f-50503f3d5f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4d4a9cfa-edb9-4c1b-a290-6473dc757e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4d4a9cfa-edb9-4c1b-a290-6473dc757e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0629826e-874f-4efc-83b9-a84e6136a501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0629826e-874f-4efc-83b9-a84e6136a501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_71e8a8cb-fbb2-4e77-946d-f4876f730aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_71e8a8cb-fbb2-4e77-946d-f4876f730aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_75eab4cb-bf5e-4546-b3ec-d20998454af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_75eab4cb-bf5e-4546-b3ec-d20998454af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_266ffc17-2b04-4297-84fd-3d86000a4133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_69d6ff1b-2c95-4619-8a6c-e82b05b55d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_266ffc17-2b04-4297-84fd-3d86000a4133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_520850e8-186a-4a78-8ad6-9eed32092341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_520850e8-186a-4a78-8ad6-9eed32092341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AccruedClinicalTrialExpenseCurrent_bf341854-7bf3-43a4-b678-c1476e1de53f" xlink:href="regn-20221231.xsd#regn_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_regn_AccruedClinicalTrialExpenseCurrent_bf341854-7bf3-43a4-b678-c1476e1de53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AccrualForSalesRelatedCostsCurrent_05b00391-9292-4716-8dae-5ead9fb4438e" xlink:href="regn-20221231.xsd#regn_AccrualForSalesRelatedCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_regn_AccrualForSalesRelatedCostsCurrent_05b00391-9292-4716-8dae-5ead9fb4438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_20ceb9b0-5f95-4fa4-973b-e702292bd2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_us-gaap_TaxesPayableCurrent_20ceb9b0-5f95-4fa4-973b-e702292bd2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeAgreementsObligationsCurrent_33ca33e1-1bb3-40b7-a4cc-50e6173db05c" xlink:href="regn-20221231.xsd#regn_CollaborativeAgreementsObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_regn_CollaborativeAgreementsObligationsCurrent_33ca33e1-1bb3-40b7-a4cc-50e6173db05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8c90174e-51e8-4dc8-9b9e-c5ae830d8911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8c90174e-51e8-4dc8-9b9e-c5ae830d8911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_13c1a46c-ba7f-4d94-bee4-5ef774413f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5bb0d599-5dc9-4ca7-9fcc-7c1426d05125" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_13c1a46c-ba7f-4d94-bee4-5ef774413f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_43caceae-c460-4654-8367-1f48fe6ceba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43caceae-c460-4654-8367-1f48fe6ceba6" xlink:to="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6ec834fa-789b-41e2-b434-551e5e707198" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4eb8d181-0c6a-40af-bfe5-58923dd9beec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:to="loc_us-gaap_LineOfCreditMember_4eb8d181-0c6a-40af-bfe5-58923dd9beec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_32b4e8ab-875d-4b05-8ecb-1511cdeb42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ecfeb64-364b-4a0d-bda7-74a6b1c17bec" xlink:to="loc_us-gaap_SeniorNotesMember_32b4e8ab-875d-4b05-8ecb-1511cdeb42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b1b89e1b-f6d0-48e3-a35f-a0dbeb7a0e73" xlink:to="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aa6e6d15-3ca7-4592-9da3-af19c93ec83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aa6e6d15-3ca7-4592-9da3-af19c93ec83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a6791cc8-6711-493f-86d5-55abfb5286f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5c681b4c-f084-422f-b1c3-bfb2379943dc" xlink:to="loc_us-gaap_LetterOfCreditMember_a6791cc8-6711-493f-86d5-55abfb5286f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a3702fd1-6f62-48bf-8980-6041379fab95" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_f4ac2ecf-22f0-4ea0-bcd1-2de6d6acc6c0" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_f4ac2ecf-22f0-4ea0-bcd1-2de6d6acc6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_c6b5753d-9bd1-4b96-beb0-ca7451e920f7" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba8acec2-dfc5-4581-8d50-bdb3e449bb94" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_c6b5753d-9bd1-4b96-beb0-ca7451e920f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1c4c7d19-acba-47bc-922a-a080f11fc48e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50798826-b313-4cfc-99d4-9ba4091b75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50798826-b313-4cfc-99d4-9ba4091b75d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1a03837d-4e07-49af-aef6-02c3a5cd7ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1a03837d-4e07-49af-aef6-02c3a5cd7ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LineOfCreditFacilityIncreaseLimit_92898420-27a0-4ffc-9926-30bf6a36f415" xlink:href="regn-20221231.xsd#regn_LineOfCreditFacilityIncreaseLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_regn_LineOfCreditFacilityIncreaseLimit_92898420-27a0-4ffc-9926-30bf6a36f415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_59cd86c2-bacb-48b4-92b1-794bf0ed8d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_LineOfCredit_59cd86c2-bacb-48b4-92b1-794bf0ed8d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_75cbb155-017e-47de-8bec-f3e302deb6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_75cbb155-017e-47de-8bec-f3e302deb6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6d514803-b584-4e4b-9b56-ffbcaa1e9be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_InterestExpenseDebt_6d514803-b584-4e4b-9b56-ffbcaa1e9be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_fbf873a4-784a-4408-b3df-84900c7ec961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_fbf873a4-784a-4408-b3df-84900c7ec961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_b5da9720-0f73-4e3c-a098-fc2ea267382b" xlink:href="regn-20221231.xsd#regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_718bcb1e-ce14-4611-b831-ba0c86fefc89" xlink:to="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_b5da9720-0f73-4e3c-a098-fc2ea267382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#DebtSummaryofIssuedSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b64311e1-e044-4825-a3da-1f9736266a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b64311e1-e044-4825-a3da-1f9736266a4b" xlink:to="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_03622d73-6545-48e3-84bd-148315cb0a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9369e632-6274-4adc-931f-3312098afcff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_03622d73-6545-48e3-84bd-148315cb0a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_af252473-95c8-4e4f-bcae-60908da14276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_03622d73-6545-48e3-84bd-148315cb0a45" xlink:to="loc_us-gaap_SeniorNotesMember_af252473-95c8-4e4f-bcae-60908da14276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0d2d1ad-66c7-425f-8205-3746ca4f9c30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_96ccfbc2-a35d-424b-b173-804ecf5ad358" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_96ccfbc2-a35d-424b-b173-804ecf5ad358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_489f58b8-f5c8-49f4-9b7c-c6b86fc7cee0" xlink:href="regn-20221231.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a88b972-8d64-4eb4-880d-61e4e0614998" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_489f58b8-f5c8-49f4-9b7c-c6b86fc7cee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b64fed7e-9758-401c-a918-2c744a760db3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_51dd9b98-4500-4cf2-ab3f-7c1de916f820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:to="loc_us-gaap_LongTermDebt_51dd9b98-4500-4cf2-ab3f-7c1de916f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eef8228e-8445-4e64-b062-d509be1d7e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b9a95c11-dc25-4d1a-a5b6-7e61fa008469" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eef8228e-8445-4e64-b062-d509be1d7e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesLeasesnarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d3d1531-7ab9-4aac-918f-b88f5473925f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d3d1531-7ab9-4aac-918f-b88f5473925f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3158585d-6d33-49b9-83e9-c858015cd727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a76c28fa-afa1-4f9f-956a-8c0b7b14a50a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3158585d-6d33-49b9-83e9-c858015cd727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LaboratoryAndOfficeFacilitiesMember_ca3f806e-1ae4-4b0b-8283-5258e03a3792" xlink:href="regn-20221231.xsd#regn_LaboratoryAndOfficeFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3158585d-6d33-49b9-83e9-c858015cd727" xlink:to="loc_regn_LaboratoryAndOfficeFacilitiesMember_ca3f806e-1ae4-4b0b-8283-5258e03a3792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2d02f8ec-5f0f-45aa-b20d-f2db08130301" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6a48ec63-fcf5-4248-aca0-c974f524408e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_FinanceLeaseLiability_6a48ec63-fcf5-4248-aca0-c974f524408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_496ca33a-06d2-4858-96a1-635f669afce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_496ca33a-06d2-4858-96a1-635f669afce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_805a0cc3-6dc9-48e3-9d34-2144c397c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6f3cf58-245c-425b-9f45-5c625d47a601" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_805a0cc3-6dc9-48e3-9d34-2144c397c68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6714cce-6107-4e59-b21d-906a4b10ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_11277f66-635a-4284-9a70-a72078ed774d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6714cce-6107-4e59-b21d-906a4b10ffb8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_11277f66-635a-4284-9a70-a72078ed774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_f8ad412c-6bb2-4638-b505-64950f55b7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6714cce-6107-4e59-b21d-906a4b10ffb8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_f8ad412c-6bb2-4638-b505-64950f55b7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1576a489-af0e-4839-8ed8-da0cb65e950f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6714cce-6107-4e59-b21d-906a4b10ffb8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1576a489-af0e-4839-8ed8-da0cb65e950f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0067f61a-e54f-451d-8269-1703fdf7c4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6714cce-6107-4e59-b21d-906a4b10ffb8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0067f61a-e54f-451d-8269-1703fdf7c4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_1baac668-6021-44d4-880f-5ebcaf703541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6714cce-6107-4e59-b21d-906a4b10ffb8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_1baac668-6021-44d4-880f-5ebcaf703541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesFinanceleasecostsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6712171a-97f7-4d3d-8add-411a86219497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_04135c6d-6b85-4546-91f7-b9a4152e165c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6712171a-97f7-4d3d-8add-411a86219497" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_04135c6d-6b85-4546-91f7-b9a4152e165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_51334734-017c-4373-b254-08b42135127f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6712171a-97f7-4d3d-8add-411a86219497" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_51334734-017c-4373-b254-08b42135127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FinanceLeaseCost_265989dd-841f-46e0-9b9c-47c7d4c26715" xlink:href="regn-20221231.xsd#regn_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6712171a-97f7-4d3d-8add-411a86219497" xlink:to="loc_regn_FinanceLeaseCost_265989dd-841f-46e0-9b9c-47c7d4c26715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266db584-9654-4dbb-b77a-a3787aa5b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_FinanceLeaseRemainingLeaseTerm_01ee5ec1-8612-41cd-a44b-a94a9efa7798" xlink:href="regn-20221231.xsd#regn_FinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266db584-9654-4dbb-b77a-a3787aa5b0aa" xlink:to="loc_regn_FinanceLeaseRemainingLeaseTerm_01ee5ec1-8612-41cd-a44b-a94a9efa7798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate_39ab6517-5020-4371-b20b-32872203b5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266db584-9654-4dbb-b77a-a3787aa5b0aa" xlink:to="loc_us-gaap_LesseeFinanceLeaseDiscountRate_39ab6517-5020-4371-b20b-32872203b5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19ada865-7b66-4de9-b2f4-5e84fa331321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19ada865-7b66-4de9-b2f4-5e84fa331321" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3772aed1-a7ae-43b7-9ee9-2723135b7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3772aed1-a7ae-43b7-9ee9-2723135b7a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_636448ae-eab1-498a-8d21-52ee3cfb1723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_636448ae-eab1-498a-8d21-52ee3cfb1723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2456341b-d264-4e1e-8e16-f0b65d066027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2456341b-d264-4e1e-8e16-f0b65d066027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0fe5c99e-4e7d-477f-b9a3-1360bc25878c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0fe5c99e-4e7d-477f-b9a3-1360bc25878c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_5e3cdbbe-168c-4998-8199-b474fadfdaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_5e3cdbbe-168c-4998-8199-b474fadfdaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_007623c2-280c-49a4-94f3-5ad85a745ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_007623c2-280c-49a4-94f3-5ad85a745ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c95ffdc5-59f3-4da4-a2a7-267c58d24348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c95ffdc5-59f3-4da4-a2a7-267c58d24348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_215eb30a-028c-4926-821c-296f8afe7a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8beb1e9-a7de-45a2-99c7-1d4153bbcaa9" xlink:to="loc_us-gaap_FinanceLeaseLiability_215eb30a-028c-4926-821c-296f8afe7a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1cf3cf5c-616b-45ed-9a3e-44d585adb45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1cf3cf5c-616b-45ed-9a3e-44d585adb45b" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_858c052b-f789-4ffe-99b8-821c403fdeaf" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingAgreementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsAxis_db531bd6-a61f-484e-b105-eb2cf3e097de" xlink:to="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_858c052b-f789-4ffe-99b8-821c403fdeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_3be5f5c7-4e31-4fa9-aee9-a05b9ba40437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingAgreementsDomain_858c052b-f789-4ffe-99b8-821c403fdeaf" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_3be5f5c7-4e31-4fa9-aee9-a05b9ba40437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef6ce94d-ada8-4491-a4ae-2aef159ec9ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5c1a3c9c-af83-47a4-9aa0-6d9f36d7a6f3" xlink:to="loc_srt_ProductsAndServicesDomain_ef6ce94d-ada8-4491-a4ae-2aef159ec9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_2e7edab9-303d-4269-8123-4c120fd5e170" xlink:href="regn-20221231.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ef6ce94d-ada8-4491-a4ae-2aef159ec9ca" xlink:to="loc_regn_LIBTAYONetProductSalesMember_2e7edab9-303d-4269-8123-4c120fd5e170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a024579d-6069-480b-beb7-ef5624364503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_521c50e2-ee1a-43f2-afe9-c15e510d47bd" xlink:to="loc_us-gaap_ProjectMember_a024579d-6069-480b-beb7-ef5624364503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_846fa7cb-983d-4f46-9d65-7443de886e7d" xlink:href="regn-20221231.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_a024579d-6069-480b-beb7-ef5624364503" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_846fa7cb-983d-4f46-9d65-7443de886e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_6abd0cd7-a3f5-4701-ac36-e20b21b0ecbf" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ThroughDecember312023Member_4a6b3164-b588-4601-aeb2-ebb222fae9c8" xlink:href="regn-20221231.xsd#regn_ThroughDecember312023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:to="loc_regn_ThroughDecember312023Member_4a6b3164-b588-4601-aeb2-ebb222fae9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_January12024ThroughDecember312026Member_56dc65bf-8a1e-4611-ac7f-c2c7639f0b9e" xlink:href="regn-20221231.xsd#regn_January12024ThroughDecember312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ba4b439e-4f68-4609-a0d8-dd0ab683d2fe" xlink:to="loc_regn_January12024ThroughDecember312026Member_56dc65bf-8a1e-4611-ac7f-c2c7639f0b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:href="regn-20221231.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_8b5a42b6-9071-4336-b32d-92cababbaac5" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyRateMinimum_21f0d5d8-09ee-45ba-80f8-25069cd1e759" xlink:href="regn-20221231.xsd#regn_RoyaltyRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_RoyaltyRateMinimum_21f0d5d8-09ee-45ba-80f8-25069cd1e759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyRateMaximum_9618d24a-c9f4-4bce-b8eb-d36529090275" xlink:href="regn-20221231.xsd#regn_RoyaltyRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_RoyaltyRateMaximum_9618d24a-c9f4-4bce-b8eb-d36529090275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsForRoyaltiesPercentage_bc509319-2b25-473b-97f1-559efc67ddc1" xlink:href="regn-20221231.xsd#regn_PaymentsForRoyaltiesPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_regn_PaymentsForRoyaltiesPercentage_bc509319-2b25-473b-97f1-559efc67ddc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_af289451-134e-4abc-987e-5c2e48ba9a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_9d0fa95a-418c-475e-88ae-6625094705c5" xlink:to="loc_us-gaap_RoyaltyExpense_af289451-134e-4abc-987e-5c2e48ba9a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_deb8be94-9074-4f52-a434-3d76c33408ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_deb8be94-9074-4f52-a434-3d76c33408ca" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_afba7d44-f90c-4c69-a5e2-664f342784de" xlink:to="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_b04e2109-e9c4-4865-9564-6e2ca63ba5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:to="loc_us-gaap_CommonClassAMember_b04e2109-e9c4-4865-9564-6e2ca63ba5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ca7e8ccd-db33-4a09-a243-abe1f61e9eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bd0c35a5-45c5-4465-b29f-d7e8363e3cfe" xlink:to="loc_us-gaap_CommonStockMember_ca7e8ccd-db33-4a09-a243-abe1f61e9eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_128a11bb-ab93-49af-bfc2-8013824a4fee" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2021Member_d16eccdd-59f6-42dd-8225-caa05e758b37" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramJanuary2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2021Member_d16eccdd-59f6-42dd-8225-caa05e758b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramNovember2021Member_b3a61314-3ce2-43b3-a9bd-23036f53c558" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramNovember2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgramNovember2021Member_b3a61314-3ce2-43b3-a9bd-23036f53c558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgram2019Member_c85736ba-f9dc-46ab-964f-2bd9d3546608" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgram2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgram2019Member_c85736ba-f9dc-46ab-964f-2bd9d3546608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2023Member_0bcdcbd8-270a-4605-afbb-6496f9a453c0" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramJanuary2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_59e73a26-9fbe-4930-ad0d-9f608bca6c7b" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2023Member_0bcdcbd8-270a-4605-afbb-6496f9a453c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_39791eb9-30c8-4973-a5a4-f2fa1b12652a" xlink:to="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_e9e51e95-d1f1-4769-a4f2-fbdad081b0e8" xlink:href="regn-20221231.xsd#regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:to="loc_regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember_e9e51e95-d1f1-4769-a4f2-fbdad081b0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_82e542f5-1075-4087-9671-0633b06ac3da" xlink:href="regn-20221231.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:to="loc_regn_BayerCollaborationAgreementMember_82e542f5-1075-4087-9671-0633b06ac3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b79f243a-71b3-4e9e-bdf8-d17593c05b5b" xlink:href="regn-20221231.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_10c087fa-351b-4bbd-b893-3460e37a86f8" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_b79f243a-71b3-4e9e-bdf8-d17593c05b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_29947837-8879-4d84-9707-5b4d9c1b38de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a547f993-3288-4c66-b4cb-f416492b653d" xlink:to="loc_dei_EntityDomain_29947837-8879-4d84-9707-5b4d9c1b38de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_7d89b7b5-1602-418d-be85-9a26d23f92d6" xlink:href="regn-20221231.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_29947837-8879-4d84-9707-5b4d9c1b38de" xlink:to="loc_regn_SanofiMember_7d89b7b5-1602-418d-be85-9a26d23f92d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_75ee4da9-9046-403c-9623-6a5f44f0ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a246f350-43a4-4cb8-a898-b7515fc0879e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_75ee4da9-9046-403c-9623-6a5f44f0ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_896ba07d-aca3-41de-9855-badf353a35a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_75ee4da9-9046-403c-9623-6a5f44f0ee6b" xlink:to="loc_us-gaap_SubsequentEventMember_896ba07d-aca3-41de-9855-badf353a35a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e8bd8a-e9aa-436e-bef9-fb8b1d2f0014" xlink:to="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3c495dfc-2f30-4347-8ca8-e8e3f3913794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3c495dfc-2f30-4347-8ca8-e8e3f3913794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3fde9e5-8ce8-4b71-8bd5-dae8ea4eea72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3fde9e5-8ce8-4b71-8bd5-dae8ea4eea72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfVotesPerShare_718a8dfd-3af6-4baf-a096-3e204f22ce9b" xlink:href="regn-20221231.xsd#regn_NumberOfVotesPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_regn_NumberOfVotesPerShare_718a8dfd-3af6-4baf-a096-3e204f22ce9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3a07e6a1-7313-4832-bc73-c699b2ae7bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3a07e6a1-7313-4832-bc73-c699b2ae7bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d6e8b83a-0656-484a-8149-b11992327ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d6e8b83a-0656-484a-8149-b11992327ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d5a6a24c-85e3-4782-a392-3fe2771fd5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d5a6a24c-85e3-4782-a392-3fe2771fd5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_640fa31f-ce5c-4a11-9ef4-04194f2b9e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_640fa31f-ce5c-4a11-9ef4-04194f2b9e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_151175f0-c3b2-4e5e-aa7d-ccdd69653fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_151175f0-c3b2-4e5e-aa7d-ccdd69653fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8bb6ab55-b22f-40cb-bbf4-c8e362ffc317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8bb6ab55-b22f-40cb-bbf4-c8e362ffc317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_571706f6-a673-4507-acec-ab717bbcbcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_571706f6-a673-4507-acec-ab717bbcbcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_c533bd2a-05ea-4200-b5cb-65f3e67bd700" xlink:href="regn-20221231.xsd#regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0bc95e47-2709-43dc-996c-4ad04b611626" xlink:to="loc_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions_c533bd2a-05ea-4200-b5cb-65f3e67bd700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StockholdersEquityScheduleofRepurchasedSharesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6d8470cb-eebe-47fd-aa68-2e2ddf2ac6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6d8470cb-eebe-47fd-aa68-2e2ddf2ac6bf" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5eb6f6c2-5f7f-4fbc-b16b-bc8c27135bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_43048b54-c14a-43a7-bf73-d8d8a3bf98c8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5eb6f6c2-5f7f-4fbc-b16b-bc8c27135bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramsMember_af82ec62-7658-464f-b913-d6d5ed3665c1" xlink:href="regn-20221231.xsd#regn_ShareRepurchaseProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5eb6f6c2-5f7f-4fbc-b16b-bc8c27135bb0" xlink:to="loc_regn_ShareRepurchaseProgramsMember_af82ec62-7658-464f-b913-d6d5ed3665c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_36d21e43-4b6e-4327-90d3-3302a5e12e43" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3c7782b0-1955-4389-8721-35d901ba7d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3c7782b0-1955-4389-8721-35d901ba7d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5d0d19d9-bfb5-475b-bbb4-25fa943c3b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f4924ca3-c9d3-4bc8-807d-361cb47d5fda" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5d0d19d9-bfb5-475b-bbb4-25fa943c3b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc2c50b0-5446-487a-8f72-3fb7956d7bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc2c50b0-5446-487a-8f72-3fb7956d7bf9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2526917f-4a2f-4f65-a656-4cfe83263756" xlink:to="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmendedRestatedLongTermIncentivePlan2014Member_7e14fc9b-f50f-4459-83dc-eb3429140a8d" xlink:href="regn-20221231.xsd#regn_AmendedRestatedLongTermIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:to="loc_regn_AmendedRestatedLongTermIncentivePlan2014Member_7e14fc9b-f50f-4459-83dc-eb3429140a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LongTermIncentivePlan2014Member_2cf2ad8f-2254-4e66-badb-ac8ea2c6a922" xlink:href="regn-20221231.xsd#regn_LongTermIncentivePlan2014Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:to="loc_regn_LongTermIncentivePlan2014Member_2cf2ad8f-2254-4e66-badb-ac8ea2c6a922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LongTermIncentivePlan2000Member_5dcf50b0-60c1-4652-a6bd-5dacacc5ce44" xlink:href="regn-20221231.xsd#regn_LongTermIncentivePlan2000Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0d7cdf40-e022-43d7-9f06-421bd7902e17" xlink:to="loc_regn_LongTermIncentivePlan2000Member_5dcf50b0-60c1-4652-a6bd-5dacacc5ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3d29897e-6b12-4232-aacd-0cb882af9b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_144e93fa-deae-42a7-85c0-eefb1069196b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_144e93fa-deae-42a7-85c0-eefb1069196b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NonPerformanceBasedStockOptionsMember_205b776e-af65-4234-83d5-d592ba847980" xlink:href="regn-20221231.xsd#regn_NonPerformanceBasedStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_regn_NonPerformanceBasedStockOptionsMember_205b776e-af65-4234-83d5-d592ba847980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c8761333-309f-454e-b7f9-79663cbe3c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_us-gaap_RestrictedStockMember_c8761333-309f-454e-b7f9-79663cbe3c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ab3485d2-8a5e-487f-9754-133eed5d4bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c57288b-31be-4fb7-81bb-9bd68c170c58" xlink:to="loc_us-gaap_PerformanceSharesMember_ab3485d2-8a5e-487f-9754-133eed5d4bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c7d490a3-34c2-4c3e-ae19-147f4256f7fd" xlink:to="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7645f321-6820-4f89-9f7f-131c1ba83356" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:to="loc_srt_MinimumMember_7645f321-6820-4f89-9f7f-131c1ba83356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6baab1b7-55f1-4164-b74c-b4182c2901af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5562c0b5-1a24-4ab1-b091-d221109538ea" xlink:to="loc_srt_MaximumMember_6baab1b7-55f1-4164-b74c-b4182c2901af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4fda1d6-60ae-4390-a629-12b084053166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_caf5a044-2fef-4142-8e88-84fd40b93967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_caf5a044-2fef-4142-8e88-84fd40b93967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8e9dd4f-6442-4988-a4f1-1b6a4fcc1a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8e9dd4f-6442-4988-a4f1-1b6a4fcc1a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_8b2605b6-1110-4356-838e-b2d06b71ebb7" xlink:href="regn-20221231.xsd#regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_8b2605b6-1110-4356-838e-b2d06b71ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a59c7fa4-96ad-4fe5-9704-18f14c912865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a59c7fa4-96ad-4fe5-9704-18f14c912865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09a113d1-4af7-4051-b4af-f8dca4b7d825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09a113d1-4af7-4051-b4af-f8dca4b7d825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03b07995-0eb8-49f2-b0c8-00691a86a245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03b07995-0eb8-49f2-b0c8-00691a86a245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6effb8af-c1f9-4de4-8ab6-924073aa6100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6effb8af-c1f9-4de4-8ab6-924073aa6100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30918324-731b-4e2f-99df-e845d861d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30918324-731b-4e2f-99df-e845d861d4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_69fedddb-a444-45fe-a0ca-836ac5d7adb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_69fedddb-a444-45fe-a0ca-836ac5d7adb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f032346d-7d36-479c-9abb-0290ecb63d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f032346d-7d36-479c-9abb-0290ecb63d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb18bd3c-dc6a-4e3e-b771-90ef1ff940ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb18bd3c-dc6a-4e3e-b771-90ef1ff940ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_039fca76-06a2-4d15-9ccd-7b2185259072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_039fca76-06a2-4d15-9ccd-7b2185259072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_817ff90f-a86a-49e9-8347-8b3dc3b4b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_817ff90f-a86a-49e9-8347-8b3dc3b4b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_18b68a55-e156-49b6-9793-c1d5e529f354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_88ce4416-5f0b-4f8c-ac80-7605643072e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_18b68a55-e156-49b6-9793-c1d5e529f354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d9a02e-8fd8-4e6a-9a09-f53feb3d657a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d9a02e-8fd8-4e6a-9a09-f53feb3d657a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:to="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce88bc9a-63e4-4ebe-9239-3ecf66f4a3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7bcdd995-24d9-481b-a9a8-c895bb443409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce88bc9a-63e4-4ebe-9239-3ecf66f4a3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68735d7e-7e0f-4644-a91f-a61559dbf27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce88bc9a-63e4-4ebe-9239-3ecf66f4a3d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68735d7e-7e0f-4644-a91f-a61559dbf27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95346f02-7766-4188-80b9-44abfaed5d4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a62992f-0356-4d4a-9e16-fcb8088e29e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a62992f-0356-4d4a-9e16-fcb8088e29e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8d3ea60e-9e48-4cb7-a15a-0c41ae8e148b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8d3ea60e-9e48-4cb7-a15a-0c41ae8e148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3b2ef744-df7f-4dd3-ae93-d5bdf6484b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3b2ef744-df7f-4dd3-ae93-d5bdf6484b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f43df6c1-3169-4245-9491-861d644cfa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f43df6c1-3169-4245-9491-861d644cfa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd76ad21-2c5a-4f18-be78-8b9ea6de6113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45a401a1-2e0e-418c-bb22-7692f73a0930" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd76ad21-2c5a-4f18-be78-8b9ea6de6113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_de31168b-82c0-46ae-a1ff-f1f0407d027c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_de31168b-82c0-46ae-a1ff-f1f0407d027c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05aa7502-50ae-4b53-99d9-b0a5b6d0b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05aa7502-50ae-4b53-99d9-b0a5b6d0b4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eafd13a2-a4ce-4ad7-bcdb-1a74e6123069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eafd13a2-a4ce-4ad7-bcdb-1a74e6123069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed7ab6e5-5616-4f9b-b3e1-8a88e2949995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed7ab6e5-5616-4f9b-b3e1-8a88e2949995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e8375d30-3abd-4f9d-9e85-042aabb58ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e8375d30-3abd-4f9d-9e85-042aabb58ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e794d6f-05e9-4521-a7ba-d9b68135a896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e794d6f-05e9-4521-a7ba-d9b68135a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93b44dd6-b81e-438f-855f-c6af8ac9cfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2231b3e7-fbb3-4933-b847-7ff067bb24c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93b44dd6-b81e-438f-855f-c6af8ac9cfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1374801a-27e3-4b32-b7aa-321894a61c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1374801a-27e3-4b32-b7aa-321894a61c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d221ccdb-60a7-468e-b107-d8c1e42c0f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d221ccdb-60a7-468e-b107-d8c1e42c0f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd605b2b-8e08-470c-9aea-b194b0c9962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac67e9f-67d4-473c-a0ab-50984795979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac67e9f-67d4-473c-a0ab-50984795979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c68c1db5-ba2e-40aa-b3aa-b939bbe9011d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c68c1db5-ba2e-40aa-b3aa-b939bbe9011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31633de8-8ce0-4fb2-b70c-d88d98342235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31633de8-8ce0-4fb2-b70c-d88d98342235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a7c0b2e4-1b2d-4c33-9891-8e9d1cf0d702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a7c0b2e4-1b2d-4c33-9891-8e9d1cf0d702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_92780b91-382d-4aed-b68a-a078a7d4f6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_92780b91-382d-4aed-b68a-a078a7d4f6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc87dbe5-9bff-4837-97ec-54837b61c794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d8b4b50-65a2-4e8d-9aa0-1184d68db64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc87dbe5-9bff-4837-97ec-54837b61c794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de0904b-11d9-47ce-a5d4-3b71fd9216bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de0904b-11d9-47ce-a5d4-3b71fd9216bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:to="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9fb948-cdc4-493c-8599-7e77d3c05377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_20e44cc6-d870-48a8-8032-a20865a1b889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9fb948-cdc4-493c-8599-7e77d3c05377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_82ee9c4f-226b-4a95-a66b-38091d3ce87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b9fb948-cdc4-493c-8599-7e77d3c05377" xlink:to="loc_us-gaap_EmployeeStockOptionMember_82ee9c4f-226b-4a95-a66b-38091d3ce87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57727349-6193-40f2-882b-4d50ed42a736" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_74b67c96-5435-4784-9d7e-8b896788deed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_74b67c96-5435-4784-9d7e-8b896788deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_246f438b-df41-4aa7-aec9-72bd23ae0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_246f438b-df41-4aa7-aec9-72bd23ae0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e795438b-d8b4-4a8b-91b9-538bfd907228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89be2a72-95f3-418a-8aac-b3bb6b237281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e795438b-d8b4-4a8b-91b9-538bfd907228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd9cae4d-4536-4acd-8b62-28dbda43055d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd9cae4d-4536-4acd-8b62-28dbda43055d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:to="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4226c4c8-3113-4748-86d7-446ff2024276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_85375c62-0147-4e90-bb14-1bcb904f9925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4226c4c8-3113-4748-86d7-446ff2024276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ad90cfb-e0a3-4f1f-9f2e-e146081efc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4226c4c8-3113-4748-86d7-446ff2024276" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ad90cfb-e0a3-4f1f-9f2e-e146081efc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d68bffb3-e85d-40bf-b33f-41577ab48346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba931893-2d44-4b23-8233-67dce0133e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba931893-2d44-4b23-8233-67dce0133e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_41001a62-82c7-489d-a2c8-7321ba3f5db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_41001a62-82c7-489d-a2c8-7321ba3f5db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b221272e-65f4-4b5b-8070-8ac9dd5540c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b221272e-65f4-4b5b-8070-8ac9dd5540c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_067f4234-3455-41de-ae67-52224247398a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1949ce9-b8a4-47ee-ae1b-4dfbb674a515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_067f4234-3455-41de-ae67-52224247398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921fc54b-cc31-4332-b99c-2b0559373276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921fc54b-cc31-4332-b99c-2b0559373276" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:to="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02925234-4584-44bf-af7e-3f968387ac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f4651640-197d-45a4-be7d-080cf0f81b4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02925234-4584-44bf-af7e-3f968387ac2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_07e45bdb-c184-4e78-9237-7167d0ef1f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02925234-4584-44bf-af7e-3f968387ac2a" xlink:to="loc_us-gaap_RestrictedStockMember_07e45bdb-c184-4e78-9237-7167d0ef1f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fdc3fdc-a6c2-4796-8bc5-de86e824e668" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a512588-e0ed-497e-ae07-5dfcdc9a9bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a512588-e0ed-497e-ae07-5dfcdc9a9bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d8d11a8-924d-49bf-aaa7-e48b9321566c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d8d11a8-924d-49bf-aaa7-e48b9321566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_763a9a88-70d1-413d-a959-52d59eeb743d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_763a9a88-70d1-413d-a959-52d59eeb743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e9dc4c-947b-4a4c-9e95-07d58c073d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e9dc4c-947b-4a4c-9e95-07d58c073d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08a4e9ca-8487-47fd-849c-8a414c0f5b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df9bd7a-eac2-47b8-b6a0-8c1bbd06dc01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08a4e9ca-8487-47fd-849c-8a414c0f5b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f70adafd-ee66-4f9b-928a-15cb0bb7775b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5176ad7d-b346-4695-8520-eb79f8f102c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5176ad7d-b346-4695-8520-eb79f8f102c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4973ae65-b883-49f9-abfd-427b6f3940f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4973ae65-b883-49f9-abfd-427b6f3940f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e93c4acc-9408-4663-8f61-cf01b611fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e93c4acc-9408-4663-8f61-cf01b611fdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6549db0c-57be-452e-b71d-6fd9e522bff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6549db0c-57be-452e-b71d-6fd9e522bff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61d28aff-d3e8-4d8d-969e-a8accf4c4bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c138399-0a85-428e-93b8-e0f3d5328cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61d28aff-d3e8-4d8d-969e-a8accf4c4bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaeb86d5-a8ae-4708-bfb5-c2a484de0114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaeb86d5-a8ae-4708-bfb5-c2a484de0114" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:to="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2d8b70-a4d0-4c7b-a9d3-9ff2be896d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_31e7d53f-2f06-4e01-ad83-d06a94345bc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2d8b70-a4d0-4c7b-a9d3-9ff2be896d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0fc17dc6-ec23-4d9c-a71e-ef915969d7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2d8b70-a4d0-4c7b-a9d3-9ff2be896d7d" xlink:to="loc_us-gaap_PerformanceSharesMember_0fc17dc6-ec23-4d9c-a71e-ef915969d7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04d7e903-c888-4d86-9523-1af7af5ed0b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41263ebb-e73b-4065-8e4a-b9d488e00f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41263ebb-e73b-4065-8e4a-b9d488e00f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b41506c-39f7-4355-9cfa-e1e9378c0ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b41506c-39f7-4355-9cfa-e1e9378c0ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a76df4ab-77c2-41a8-a816-aecd79ec5efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bce5cc9c-66c4-48ca-bdd5-449395453d3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a76df4ab-77c2-41a8-a816-aecd79ec5efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e162d921-23ac-4c0a-bc31-8e35ea3da523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cf5fc83-9d26-42f9-850a-38766f2205e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cf5fc83-9d26-42f9-850a-38766f2205e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ba2b090-2b3a-4acc-b847-6849153491ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ba2b090-2b3a-4acc-b847-6849153491ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8c379bf-8a4e-412e-a74f-230b2821eb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ed5582fa-e9de-4031-9493-8031ac02c5b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8c379bf-8a4e-412e-a74f-230b2821eb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74151e39-ff15-4a38-bf05-c19d5695edb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74151e39-ff15-4a38-bf05-c19d5695edb5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:to="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aef39f3-bb19-4c60-a6d9-99292817e085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_15192a45-8186-4594-a879-44ea7511deaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aef39f3-bb19-4c60-a6d9-99292817e085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0e44bb0e-8175-49cf-bc61-247f2cd3d598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aef39f3-bb19-4c60-a6d9-99292817e085" xlink:to="loc_us-gaap_PerformanceSharesMember_0e44bb0e-8175-49cf-bc61-247f2cd3d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1f25815-6412-4703-b0f1-9fdc4ee7116c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b0139478-d5c0-437c-8323-06f2ab159de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b0139478-d5c0-437c-8323-06f2ab159de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ed8344e-7d35-4a5b-850f-51928c05eb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ed8344e-7d35-4a5b-850f-51928c05eb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_787e1eb1-da94-4aed-a217-c7ae336a2a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d7a1e8f-5604-46df-b80a-c65fa4ce4b4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_787e1eb1-da94-4aed-a217-c7ae336a2a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/EmployeeSavingsPlansDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#EmployeeSavingsPlansDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/EmployeeSavingsPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_800d8938-5796-4d72-9723-7081b1f74d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_f640436e-2aa0-4dc3-864f-7a8ca6d4846f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_800d8938-5796-4d72-9723-7081b1f74d99" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_f640436e-2aa0-4dc3-864f-7a8ca6d4846f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofincomebeforeincometaxDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d6412b0-4f2e-465c-a9f7-e3e89a84253a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5c0750fe-b7c6-4f69-bbd9-78dc8f0911cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d6412b0-4f2e-465c-a9f7-e3e89a84253a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5c0750fe-b7c6-4f69-bbd9-78dc8f0911cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b0da81c6-2fce-4900-8a1f-8304a9e9e917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d6412b0-4f2e-465c-a9f7-e3e89a84253a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b0da81c6-2fce-4900-8a1f-8304a9e9e917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300c1243-aa28-4601-8fff-f31daf5f00cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d6412b0-4f2e-465c-a9f7-e3e89a84253a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300c1243-aa28-4601-8fff-f31daf5f00cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_01aea278-1925-47c4-a794-553ddc5fc496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3d3ede9-1c46-418c-a60f-8d360efb924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01aea278-1925-47c4-a794-553ddc5fc496" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3d3ede9-1c46-418c-a60f-8d360efb924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_da33c6d1-6339-4419-a1f3-3477cd6be87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3d3ede9-1c46-418c-a60f-8d360efb924e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_da33c6d1-6339-4419-a1f3-3477cd6be87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_58787f25-abe5-472a-9b53-907e14e2250f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3d3ede9-1c46-418c-a60f-8d360efb924e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_58787f25-abe5-472a-9b53-907e14e2250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9fc0283e-ad57-4fde-8fc3-2a67277bc145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3d3ede9-1c46-418c-a60f-8d360efb924e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9fc0283e-ad57-4fde-8fc3-2a67277bc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d5c31a1b-7b8d-48b5-9c47-db8f25673d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3d3ede9-1c46-418c-a60f-8d360efb924e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d5c31a1b-7b8d-48b5-9c47-db8f25673d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5498cfa1-d70d-4b3a-8356-cc1a05a8935d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01aea278-1925-47c4-a794-553ddc5fc496" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5498cfa1-d70d-4b3a-8356-cc1a05a8935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d805d36f-7cdc-4c33-999e-f5f64e99cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5498cfa1-d70d-4b3a-8356-cc1a05a8935d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d805d36f-7cdc-4c33-999e-f5f64e99cf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0759ce91-c680-4377-97f0-ecfcf5cacf50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5498cfa1-d70d-4b3a-8356-cc1a05a8935d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0759ce91-c680-4377-97f0-ecfcf5cacf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9e41146a-71b5-42f1-8bb7-b8e4fa705dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5498cfa1-d70d-4b3a-8356-cc1a05a8935d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9e41146a-71b5-42f1-8bb7-b8e4fa705dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_49f470e8-5f18-46d8-8678-faa57a2e297d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5498cfa1-d70d-4b3a-8356-cc1a05a8935d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_49f470e8-5f18-46d8-8678-faa57a2e297d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5bd50611-b617-475d-b7d3-d2ec7b45c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01aea278-1925-47c4-a794-553ddc5fc496" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5bd50611-b617-475d-b7d3-d2ec7b45c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_04e08659-5540-4425-8841-b975847ae8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_04e08659-5540-4425-8841-b975847ae8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_092913ac-4bc1-4655-82bb-88c5154121f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_092913ac-4bc1-4655-82bb-88c5154121f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_b5f162d0-9ac9-4e5e-9971-4ce3a8272875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_b5f162d0-9ac9-4e5e-9971-4ce3a8272875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_7179ffa3-debe-4b5f-9df8-957405cf3588" xlink:href="regn-20221231.xsd#regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent_7179ffa3-debe-4b5f-9df8-957405cf3588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_81eb668c-dd18-448e-93ee-ee10378bd12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_81eb668c-dd18-448e-93ee-ee10378bd12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_e2fc9388-8784-4e0e-82aa-ced008466c0b" xlink:href="regn-20221231.xsd#regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent_e2fc9388-8784-4e0e-82aa-ced008466c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_a44f5490-3f7d-404a-a2f3-62042278f901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_a44f5490-3f7d-404a-a2f3-62042278f901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b5b1975-23a4-47b7-bcfe-c035d4286e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_863b3e1b-08da-4cae-8f64-1057671869d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b5b1975-23a4-47b7-bcfe-c035d4286e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5b45beb5-bb68-461d-831e-1c2e65ad8758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b45beb5-bb68-461d-831e-1c2e65ad8758" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_e623f4b4-e2eb-4d98-8094-dfea2c4f0034" xlink:href="regn-20221231.xsd#regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_e623f4b4-e2eb-4d98-8094-dfea2c4f0034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_8a33211d-de80-4a79-97df-469d6339fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_8a33211d-de80-4a79-97df-469d6339fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f1eb0a3c-0167-44ca-89f2-399ad27f3709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f1eb0a3c-0167-44ca-89f2-399ad27f3709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_df2080f0-94bf-4775-adb8-acae5135e019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_df2080f0-94bf-4775-adb8-acae5135e019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_78f95c73-5396-406b-925c-37044d1cd22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_78f95c73-5396-406b-925c-37044d1cd22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a7ff5da4-5ee9-4cbc-ab59-503b90a155bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a7ff5da4-5ee9-4cbc-ab59-503b90a155bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_31599fae-5848-4c35-a24a-7947e2d60233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_31599fae-5848-4c35-a24a-7947e2d60233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c6df06df-e37d-47ac-8b27-818ba32345b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ce8f79d-de6e-4660-9be5-5854cd5bf850" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c6df06df-e37d-47ac-8b27-818ba32345b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_152ce07f-69ad-4a41-b3a3-7ba8ca33a9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b45beb5-bb68-461d-831e-1c2e65ad8758" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_152ce07f-69ad-4a41-b3a3-7ba8ca33a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_cbf08822-99fa-4f75-90e2-89185279d76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_152ce07f-69ad-4a41-b3a3-7ba8ca33a9cc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_cbf08822-99fa-4f75-90e2-89185279d76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ecf40755-2463-4f62-a4fe-e5f7acc8a976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b45beb5-bb68-461d-831e-1c2e65ad8758" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ecf40755-2463-4f62-a4fe-e5f7acc8a976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddb9e882-39b3-49f2-82ca-5d408e42b1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5de79696-8105-4fcf-ba6d-920d65d09df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddb9e882-39b3-49f2-82ca-5d408e42b1dd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5de79696-8105-4fcf-ba6d-920d65d09df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_42f95b6a-0ab3-4f8c-a324-47d5fc9343e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42f95b6a-0ab3-4f8c-a324-47d5fc9343e1" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_11314a59-b719-4f14-b0e0-2387a40cb292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_11314a59-b719-4f14-b0e0-2387a40cb292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d3fcfba0-b705-4473-a5fb-27c6245f7a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d3fcfba0-b705-4473-a5fb-27c6245f7a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7204cc2c-8df5-42df-9a96-ec86eabd74ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7204cc2c-8df5-42df-9a96-ec86eabd74ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d2352f52-9bff-4341-aa36-fe41f3f6399e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d2352f52-9bff-4341-aa36-fe41f3f6399e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations_a28b40b0-2cbf-4e36-a2db-06bb6344bde1" xlink:href="regn-20221231.xsd#regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:to="loc_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations_a28b40b0-2cbf-4e36-a2db-06bb6344bde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3dcfebff-78c4-4078-91b7-6fb91ff466d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ad490b45-66ca-461b-986e-b612f28c871e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3dcfebff-78c4-4078-91b7-6fb91ff466d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#LegalMattersDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e71eb0ed-92d4-4414-8d26-eb30fe70088c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e71eb0ed-92d4-4414-8d26-eb30fe70088c" xlink:to="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c4f9f9d-abf3-4aa2-be6f-49b4988868fd" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_9a13a973-9c2a-4842-ba07-89f028df2bcb" xlink:href="regn-20221231.xsd#regn_A631PatentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:to="loc_regn_A631PatentMember_9a13a973-9c2a-4842-ba07-89f028df2bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember_be048a64-9f87-4723-9e5b-5ac2505181b8" xlink:href="regn-20221231.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:to="loc_regn_A226PatentAnd992PatentMember_be048a64-9f87-4723-9e5b-5ac2505181b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A338PatentAnd069PatentMember_28656b6a-3c8a-4a43-998d-81764f1ff570" xlink:href="regn-20221231.xsd#regn_A338PatentAnd069PatentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5f6c225f-30c7-454d-bb64-6bf1306216a9" xlink:to="loc_regn_A338PatentAnd069PatentMember_28656b6a-3c8a-4a43-998d-81764f1ff570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97d9756b-b196-4331-a2fb-3c52e85a0310" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bb155cd8-53f1-42a7-adcb-1897f2380461" xlink:to="loc_srt_ProductsAndServicesDomain_97d9756b-b196-4331-a2fb-3c52e85a0310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember_3da3c336-6d7b-432f-96fc-40f221a57476" xlink:href="regn-20221231.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97d9756b-b196-4331-a2fb-3c52e85a0310" xlink:to="loc_regn_EYLEAAfliberceptInjectionMember_3da3c336-6d7b-432f-96fc-40f221a57476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_42813b37-24c9-496f-a88b-bd0658d551ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ApotexIncMember_a67cc2b8-5f54-498c-99dc-7d88ddbcd4d8" xlink:href="regn-20221231.xsd#regn_ApotexIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:to="loc_regn_ApotexIncMember_a67cc2b8-5f54-498c-99dc-7d88ddbcd4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CelltrionIncMember_5f86cdc5-f806-4fd7-9fd3-2628c3637110" xlink:href="regn-20221231.xsd#regn_CelltrionIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d11f1cb8-b0b2-4da9-88d3-3733903caf42" xlink:to="loc_regn_CelltrionIncMember_5f86cdc5-f806-4fd7-9fd3-2628c3637110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1224d49-e982-478c-988d-f26b4fda060b" xlink:to="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_440ea911-8c10-431d-b949-4434d65358b8" xlink:href="regn-20221231.xsd#regn_NumberOfInterPartiesReviewIPRPetitionsFiled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:to="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_440ea911-8c10-431d-b949-4434d65358b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber_53821877-82ee-46a7-b0df-29ed0a66e84b" xlink:href="regn-20221231.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23a32842-43c7-4abc-ba43-76ea3f8f7597" xlink:to="loc_regn_LossContingencyExParteReexaminationFiledNumber_53821877-82ee-46a7-b0df-29ed0a66e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c5c47854-adbb-445d-a22a-4b641d4eb1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c5c47854-adbb-445d-a22a-4b641d4eb1ee" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:to="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_34ec2fab-ddef-4e94-9268-664eb96f4ea9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_732ee542-4b2b-47db-abd8-4f329798448c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_732ee542-4b2b-47db-abd8-4f329798448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b3089bee-af90-4d6c-b074-9fe8422659c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1a341fb-929d-4885-ae2e-a5f136847e7d" xlink:to="loc_us-gaap_RestrictedStockMember_b3089bee-af90-4d6c-b074-9fe8422659c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5da390af-0f9f-4037-963d-093dcbc4c11d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3103468d-11e4-407a-8f84-8a2904ebefbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_NetIncomeLoss_3103468d-11e4-407a-8f84-8a2904ebefbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2614110-7699-4d8c-b9df-a4f5a25cd332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2614110-7699-4d8c-b9df-a4f5a25cd332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8115f903-5c63-41d4-9596-76449697492d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8115f903-5c63-41d4-9596-76449697492d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4267cee0-fb84-4aa5-807a-891a5a10b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8115f903-5c63-41d4-9596-76449697492d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4267cee0-fb84-4aa5-807a-891a5a10b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f136db3d-2447-4fbe-89ff-df5cfcbc5ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f136db3d-2447-4fbe-89ff-df5cfcbc5ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7a2381d2-c7c5-4743-9baf-9b1475fb1d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_EarningsPerShareBasic_7a2381d2-c7c5-4743-9baf-9b1475fb1d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a270b6dc-1a81-4cb3-8075-a886f98ba98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d33e9ca6-d46c-4021-bd08-952c3a050f47" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a270b6dc-1a81-4cb3-8075-a886f98ba98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5a1fc72a-0c72-4368-8772-128bd4a80cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a1fc72a-0c72-4368-8772-128bd4a80cf0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a13bd9e-7d57-4e41-acd5-0866520d7982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aaf260ad-c888-4e02-9dea-fe3d084fe5d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a13bd9e-7d57-4e41-acd5-0866520d7982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0df19fe4-e986-469f-8834-83bd171183d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a13bd9e-7d57-4e41-acd5-0866520d7982" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0df19fe4-e986-469f-8834-83bd171183d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4df333af-5919-4ca9-9941-062a174a3d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_801349aa-76eb-44a3-bcb0-6ff93a1640f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4df333af-5919-4ca9-9941-062a174a3d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5ec86ef-cc02-40a5-924f-76e9ac9a30af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4df333af-5919-4ca9-9941-062a174a3d74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5ec86ef-cc02-40a5-924f-76e9ac9a30af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f217ca76-8c93-4edb-b16f-183e6d1b6f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e140dee-c97b-45d6-84c3-e17dcdcec84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f217ca76-8c93-4edb-b16f-183e6d1b6f5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e140dee-c97b-45d6-84c3-e17dcdcec84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ce62a55f-6064-46b4-9a1f-dd98dd847b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f217ca76-8c93-4edb-b16f-183e6d1b6f5a" xlink:to="loc_us-gaap_RestrictedCash_ce62a55f-6064-46b4-9a1f-dd98dd847b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33d49965-bd33-430b-9449-c737f16d18b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f217ca76-8c93-4edb-b16f-183e6d1b6f5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33d49965-bd33-430b-9449-c737f16d18b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="regn-20221231.xsd#StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_4c5234e1-cbde-4741-a54d-758bf3021814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35265085-5fc0-45be-b574-240718ce158f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4c5234e1-cbde-4741-a54d-758bf3021814" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35265085-5fc0-45be-b574-240718ce158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_7e0a79e6-dc97-45d3-836e-ce69fe52e71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4c5234e1-cbde-4741-a54d-758bf3021814" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_7e0a79e6-dc97-45d3-836e-ce69fe52e71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>regn-20221231_g1.jpg
<TEXT>
begin 644 regn-20221231_g1.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
MRH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&
MN?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_
M ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'
MJ/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_
M (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(
M3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_
MX*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"I
MG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T
MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O
M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH
M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?
M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ
MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_
MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@
M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#^$+]K#_DZ;XE_]E UG_TNFHH_:P_Y.F^)
M?_90-9_]+IJ* /V__P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'
M_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/^3IOB7_V4#6?_2Z:
MBC]K#_DZ;XE_]E UG_TNFHH _;__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^
M4IG[7?\ V\?^GR>OW^H **** "BBB@ HHKP'_@J!^V%KG[!G[$7C']J'PYH%
MK?WF@R:;;Q/J-O++:6'VS4+:R-]<I"5DD@MQ<&=T1E9UB*ADW;U /?J*^3_V
M,O&7[6'BO4]%\?1?M$Z)\5/AQKWC/Q-I^K:@VAP)-:0P37;6%]875I*(FM'\
ME(C&Z2M^_B*2 !L^.?M\_M"?\%?/V.O@YKG_  4@A\>?#*Y\ ^%+V"]UO]GJ
MX\'2K?+H#W*1%CK8NB6U(1R*[HL*P(^Y5,P0>: ?HG17R'_P5"_X*&:+^RKX
M3^'_ ,,_#7[1OP^^$_CCXKZDZ:!XH^*\);3=&LK:)9[F>XA$D>YBSV]JH:1%
M5[K>6(B8&A\5?VN/VC/^">/_  38\6?M4?M9?%7P7\8?&"74 \"GP'H;:3IF
MJRW[V]KIEJH,TQ=6GE\QYE;_ %3$JOR98 ^RZ*^3+S]I;X\_LG?M=_!?]G3]
MIOXBZ;XSTOXZZ?JEC9Z[9:%'IW]A>*+"V2[-K$J$[["YA,RQ+*7GCD@4/+*)
M?D] _P""D'[9^G?L!?L<^+OVFIO#0US4M*CMK+PSH#3>6-4U:\N([6SMRPY5
M#-,A=ARL:N1DB@#W.BODR\_:6^//[)W[7?P7_9T_:;^(NF^,]+^.NGZI8V>N
MV6A1Z=_87BBPMDNS:Q*A.^PN83,L2REYXY(%#RRB7Y/,X?\ @H7^TS\9OV5/
MC;_P4?\ @)J^D)X%^$GB+78O!W@.XTI)$\8Z+H)(U.[N;L_O89[CR;P6HAV)
M#Y<)E2X+,H /O^BN9^"OQ:\'_'WX.>$_CI\/+IY] \9^&K'7-$FE7:[VEW;I
M/$6 )PVR1<CL<UTU !16?XK\5^'/ WAR[\6^+=7AL--L(3+>7DYPD2=-QQVY
MKSC_ (;G_9'_ .B]:#_W^?\ ^)H ]7HKE_!OQH^%GQ"T-/$O@KQO9:C8/(R)
M=6[DJ64X(Y'8UK?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I455T_6])U5VCTZ_CF9!E@AZ"K5 !
M1110 4444 %%%% '\(7[6'_)TWQ+_P"R@:S_ .ETU%'[6'_)TWQ+_P"R@:S_
M .ETU% '[?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T
M^3U^_P!0 4444 %%%% !7#?M#>.?@KX)^')L_P!H./3)/"OB?5+/PU?6VMP1
M2V5R^HS+9Q6\ZR_(T<LDRQD-D'> 0<UW-97C?P)X'^)GA:[\#_$CP;I7B#1-
M0C\N_P!'UO3HKNUN4R#MDBE5D<9 ."#R* /RY_8Q^%OC[_@FS_P4"\"? C]E
M+X@WE]\%?C1\0_'^GZU\$M1F>ZB\$KI$ES)'K&ER.S26]LS+!!-&Y*&2=<%G
MDC$?T'^T1^V!^PG^U)X_F^"7Q0_:\^%FB_#'P!XHM[OQZFO^/M-M#XEU>PG2
M>#2@DTRDV=O<QQ2W,A&V66%+92ZBY4?27P+_ &1?V9OV:$U0? GX&>%O"[ZU
M<S2ZG-HN@VUM).LDKR^2S1HI,*L[!(C\J+@* !6,?^">_P"P,3D_L/\ P@_\
M-II7_P CT ,\<^,OV%/VFM+T_P"$7Q8UCX<>+%\6^#8_$.G^#_%XM)+J^T.<
M$+>BQNQYH@."/,* !E()!&!^8?QR_9 \8^ ?^"*WQ4T'X,RZKXD^&'PM_:=7
MQU\'M/2>2[9O EAJ%E-<16S,2TUM#*=5FB?+"6"%9%9PZLWZO?%#]DS]E;XW
MZUHWB3XT?LS_  ^\7ZCX=B\OP_?^*/!ECJ$^F)D';;O/$S0#(!PA'(KO4MK>
M.W%I' BQ*FQ8E4!0N,8QTQCC% 'P;_P4"TI/VG/^"D'[$'@SX3ZE#JT&@^(]
M;^)6MZCITHEBL]#MM/CBM[IV7.(KFXN8H8VZ.Q;&0K8H_P#!<W4/"G[4G_!-
MKQEXN_9W\8:7XXE^"/Q5T?6?&>F>%K^.^EM'T;4()=3LY5B+%)X+=WF>)L,!
M'TR17VS\,O@5\$?@HMZOP:^#GA7PD-2=7U$>&?#UM8?:F7.UI/(1=Y&YL%LX
MR?6KG@GX6?#'X:)K$?PY^'&@^'U\0ZU<:QKZZ)H\%H-3U&?'GWEQY2KYT\FU
M=\KY=MHR3B@#XH_X*!:4G[3G_!2#]B#P9\)]2AU:#0?$>M_$K6]1TZ42Q6>A
MVVGQQ6]T[+G$5S<7,4,;='8MC(5L>#_LGR']DG_@WJ_:3_9?^(<3Q>+_ (67
M'Q%\%7^E.A-Q>ZGJ,MR^E+&GWI/M@U.R,) /F"==N<U^H?PR^!7P1^"BWJ_!
MKX.>%?"0U)U?41X9\/6UA]J9<[6D\A%WD;FP6SC)]:36O@/\#O$GQ%L_C!XB
M^#/A2_\ %NG*BZ?XIO?#MM+J-J$W;!'<LAE0+O?&&&-[8ZF@#A/^"='P3\5_
MLW?L"_!?X!^/(_+UWPA\+]#TK6XMP817D-C$D\8(ZA9 Z@^@%>S444 17UA8
MZI:2:?J=E%<6\J[98)XPZ./0J>"*Q_\ A5WPS_Z)WH7_ (*(?_B:W:* /"/^
M"?\ !!=?!75&NH4D*>-]71#(H.U5N"%49Z #@#M7N/\ 9VG_ //C#_WZ%>(_
M\$]_^2)ZM_V/>L_^E)KW2@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^S
MM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0
MJ:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*SO%EG:
M0^&[R6&UC1EA)5E0 BM>LWQC_P BQ>_]<#0!/86%BUC"S641)B4DF,<\5+_9
MVG_\^,/_ 'Z%&G?\@^#_ *XK_(5-0!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ
M%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_
M9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I
M_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__
M #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A63XBM;6+5=)2*V
MC4/=D.%0 ,-O0^M;E8_B7_D+Z/\ ]?I_]!- &E_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%9-G:VK>,KR!K:,HMI&50H, Y/.*W*Q[+_D=[W_ *\HOYF@#2_L[3_^
M?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH
M A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A
M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*FHH A_L[3_P#GQA_[]"LGP;:VL^E2//;1N1=R@%T!.-W2MRL?P/\ \@B7
M_K]F_P#0J -+^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*
M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
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M\'_7%?Y"IJAT[_D'P?\ 7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_"%^UA_R=-\2_\
MLH&L_P#I=-11^UA_R=-\2_\ LH&L_P#I=-10!^W_ /P:;?\ *4S]KO\ [>/_
M $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">
M_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !6;XQ_Y%B]_P"N!K2K
M-\8_\BQ>_P#7 T 7-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\2_\A?1_P#K]/\
MZ":V*Q_$O_(7T?\ Z_3_ .@F@#8HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#
M8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML?P/_P @B7_K]F_]"K8K'\#_ /((E_Z_9O\ T*@#8HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQC_ ,BQ>_\ 7 U<T[_D
M'P?]<5_D*I^,?^18O?\ K@:N:=_R#X/^N*_R% $U%%% !1110 4444 %%%%
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M3O\ D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\ H)H V***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO
M^1WO?^O*+^9K8K'LO^1WO?\ KRB_F: -BBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Q_ __((E_P"OV;_T*MBL?P/_ ,@B
M7_K]F_\ 0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
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M^N!JYIW_ "#X/^N*_P A0!-1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "L>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H V**** "BBB@
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MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M&/\ H-0?]]4?\)CX8_Z#4'_?5 &E6/X'_P"01+_U^S?^A5-_PF/AC_H-0?\
M?59?A+Q+H-CIDD-WJD4;&ZE8*Q[%N#0!TU%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
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M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%5=/UO2=5=H].OXYF098(>@JU0 4444 %%%% !1110!_"%
M^UA_R=-\2_\ LH&L_P#I=-11^UA_R=-\2_\ LH&L_P#I=-10!^W_ /P:;?\
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M_C!\7=%\;?"SPSKY%K/]B\,^2FDPW:OC[+/>11W7[N3!@%W%YNQED1?U6HH
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"LCQ'96::KI*
MI:1 ->$,!&.1M-;M8_B7_D+Z/_U^G_T$T :7]G:?_P ^,/\ WZ%']G:?_P ^
M,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/
M]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#S
MXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/
M_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0
M_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^
M,/\ WZ%344 0_P!G:?\ \^,/_?H5D6=E9GQG>Q&TBVBSC(7RQ@')K=K'LO\
MD=[W_KRB_F: -+^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_O
MT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/
M_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:
MB@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y
M\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*
M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*R/!=E9RZ5(TMI$Q^V2
MC+1@\;JW:Q_ _P#R")?^OV;_ -"H TO[.T__ )\8?^_0H_L[3_\ GQA_[]"I
MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
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M?V=I_P#SXP_]^A1_9VG_ //C#_WZ%345\B?8D/\ 9VG_ //C#_WZ%']G:?\
M\^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C
M#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U%
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M#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H V**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_P#((E_Z_9O_ $*MBL?P
M/_R")?\ K]F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
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MP/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*@#8HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,WQC_R+%[_UP-7-._Y!\'_7
M%?Y"OQF_X*<_\%*_C[\4/C[-\//!C:YX#T3P)KA^Q:9(6M[VXO8F(%U<@?\
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M_P A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#^$+]K#_DZ;XE_]E UG_P!+IJ*/VL/^3IOB7_V4#6?_ $NFHH _;_\
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M9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\
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M?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\
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MH^KP/!V:XC"QQF+<<+AY:JI6;@I+^Y&SJ5?^X<)^=CZ&^-W[2/P*_9P\/?\
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M5A"<%8P"*UZS?&/_ "+%[_UP- $VGZ?8-80$V4))A7),8]!4W]G:?_SXP_\
M?H4:=_R#X/\ KBO\A4U $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
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M,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\
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M>H^+H"XD'P]\'O)I7AZ @Y".$(FN\'H[E&&<'-<SS'VVF$@ZGGM#_P ">_\
MVZI'LK@YY:N?/\1'"+_GW;GQ#_[@IKD?_7Z5)=FS5^(W_!1SX&6/B>;X8_LY
M^"]3^,/C%/E.C>!+,3VML<X#7%]@PPIG(+ OM(Y K!'[./[<W[5!^T_M+_&*
MT^%?A:?EO GPN=3J$L9_@N=38':W4,(0R,#T%?2?PY^%WPX^$'AB'P9\+? V
ME>']*@_U=CI%BD$><8+$*!N8]V.2>Y-2>/\ XD?#WX4^&YO&/Q.\<Z1X>TFW
M_P!=J6M:C':P(?0O(P&?0=32>#K5US8NI=?RQ]V/S?Q/YM)_RBEQ3E.21?\
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MU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH *S?&/\
MR+%[_P!<#6E6;XQ_Y%B]_P"N!H N:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0
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M@<GR_+YNI3C>H]YR;E-^LI7=O*]ET2"BBBO,/4"BBB@ HHHH **** "BBB@
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MB]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\A4U !1110 4444 %%%%
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MJ6O*H/L?CU3BSA.GQ@\)2P,IS52RG&;UJ\VEH.2C;GT3<DNMK'[1_'O]J#X
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MMDEVC%645Y))'J8'+,!EL''#4U&^K>[D^\I.\I/S;;"BBBN([@HHHH ****
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M_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444
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MMTN'\SG356M%4H/[51J"?HI>]+_MU2/#J\197"HZ5&3K37V::<VGV;C[L?\
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MB7_D+Z/_ -?I_P#030!L4444 %%%% !1110 4444 %%<]X[^+?PI^%MI]O\
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M&KFG?\@^#_KBO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_036Q0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_"%^UA_R=-\2_^R@:
MS_Z7344?M8?\G3?$O_LH&L_^ETU% '[?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@
M#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\
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MHH **** ,?Q+_P A?1_^OT_^@FMBL?Q+_P A?1_^OT_^@FMB@ HHHH ****
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MG\0V&ARC.FZWY\][#?3Z+>;F6[@033+)#N+J8LG?Y+,O;_M9:5IEI_P73_9
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MD_>3VR1KB.*1OF89VX&20#]#U_-I_P $Z/$/[0WA7]LGP=KW[*G@K2?$7CZ
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MSX8C$7AO_@D?H.GJ!@+8_%?3(ACT^2 5H_\ #5W_  5$_P"D6UC_ .'DT_\
M^-5I_JSGCWQ&'7I5H_K6.3^WL5+>4UZ8/$?F[_D+_P /1M>UKY? O_!./]I'
M4<_<GOOAZME"_P!'DG/&?:E'[<O[=.N?\B+_ ,$G?&%QN^Y_;_Q!TS2\_7S
MV.?\::/VN?\ @IU;<7'_  2?2Y)Z&V^-FEH%^N^'FE_X;"_X*9?](C)O_#Y:
M1_\ &:/]5<X>^)I?*OAE^=1A_;"E\5;$+TPE7]:,A?\ A>__  5R\0_\@?\
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M+'_P34NOBHXO_P!LW]J?QW\3F<[IM AO?[%T0GKC[':$?3(<<=JI_P##:?\
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M-5_;C_:I\=_%B0L'E\/)>G1=!#9SQ969'(Z;MXR!R*^E_P#A)=7_ .A0O?\
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MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\
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M  H'_@J!H?.E_P#!0+PSKF.@UKX4VMMN^OV>0X_^O7T[11_96&7PRFO2I/\
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M(]QUO]EKX>7#-UE?P;9!_P#OH1;A^='+F\?M4W\I+_VZ0>U\/JO_ "ZQ5/\
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M*T^W&(+'3;1((8QZ*B */P%7Z**]!)15D?(3G.K-SF[M[MZMA1113)"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!'1)$,<B!E8896&01Z5\WVO\ P3#_
M &!I/C?=?$-_V8?#IU&,1W218F^QB4MDM]C\S[/UYQY>/:OI&L>R_P"1WO?^
MO*+^9KKPN/Q^!YOJU64.96?+)QNNSLU=>IQXO+\!C^7ZS2C4Y7=<T5*S[JZ=
MGZ&NB)&@CC0*JC"J!@ >E+117(=@4444 %%%% !1110 4444 %%%% !1110
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M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BB
MB@ HHHH **** "BBB@ K-\8_\BQ>_P#7 UI5F^,?^18O?^N!H N:=_R#X/\
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M#_KBO\A5/QC_ ,BQ>_\ 7 U<T[_D'P?]<5_D* )J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\ (7T?_K]/_H)K8K'\
M2_\ (7T?_K]/_H)K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _A"_:P_Y.F^)?_90-9_\ 2Z:BC]K#_DZ;XE_]E UG_P!+IJ* /V__
M .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CV7_([WO\
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M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
M"BBB@ HHHH **** "LWQC_R+%[_UP-:59OC'_D6+W_K@: +FG?\ (/@_ZXK_
M "%35#IW_(/@_P"N*_R%34 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6/XE_Y"^C_]?I_]!-;%8_B7_D+Z/_U^G_T$T ;%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CV7_(
M[WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6/X'_ .01+_U^S?\ H5;%8_@?_D$2
M_P#7[-_Z%0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &;XQ_Y%B]_ZX&KFG?\@^#_ *XK_(53\8_\BQ>_]<#5S3O^0?!_
MUQ7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z":V* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/^3IOB7_ -E UG_T
MNFHH_:P_Y.F^)?\ V4#6?_2Z:B@#]O\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
M?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^
ME)KW2@ HHHH **** "BBB@ HHHH *S?&/_(L7O\ UP-:59OC'_D6+W_K@: +
MFG?\@^#_ *XK_(5-4.G?\@^#_KBO\A4U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U
M^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5CV7_ ".][_UY1?S-;%8]E_R.][_UY1?S- &Q1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_@?_ )!$O_7[-_Z%
M6Q6/X'_Y!$O_ %^S?^A4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!F^,?^18O?\ K@:N:=_R#X/^N*_R%4_&/_(L7O\
MUP-7-._Y!\'_ %Q7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\
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M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q6/X'_Y!$O\ U^S?
M^A4?\)+J_P#T*%[_ -]+69X5US4;73I(X?#=S.#<R,71EP"6Z?A0!U=%8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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M-J^FVMDMLT%VI+77V>5[B'RA=@.DGD#S?N.B@#$^&?P[\(_"'X<>'_A-\/\
M2EL-!\+Z)::1HEBA)%O:6T*0PQ@GJ%C11^%;=%% !1110!X7_P $]_\ DB>K
M?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%
M%% !6;XQ_P"18O?^N!K2K-\8_P#(L7O_ %P- %S3O^0?!_UQ7^0J:H=._P"0
M?!_UQ7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q_$O\ R%]'_P"OT_\ H)K8K'\2_P#(7T?_ *_3_P"@F@#8HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L>R_Y'>]_
MZ\HOYFMBL>R_Y'>]_P"O*+^9H V**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K'\#_\@B7_ *_9O_0JV*Q_ _\ R")?^OV;
M_P!"H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I
M0 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_ "+%[_UP- %S3O\
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MG?\ (/@_ZXK_ "% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U^G_T$UL4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?PA?M8?\G3?$O\
M[*!K/_I=-11^UA_R=-\2_P#LH&L_^ETU% '[?_\ !IM_RE,_:[_[>/\ T^3U
M^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]
M9_\ 2DU[I0 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_(L7O_7
MT 7-._Y!\'_7%?Y"IJAT[_D'P?\ 7%?Y"IJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z
M_3_Z": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/_ ,@B7_K]F_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQC_ ,BQ>_\
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M* "BBB@ HHHH **** "L?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\
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M")?^OV;_ -"K8K'\#_\ ((E_Z_9O_0J -BBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S?&/_(L7O_7 U<T[_D'P?]<5_D*I
M^,?^18O?^N!JYIW_ "#X/^N*_P A0!-1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 8_B7_D+Z/\ ]?I_]!-;%8_B7_D+Z/\
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MCR/A9_X2/_W-1_PI?_@M;_T>1\+/_"1_^YJ /L:LWQC_ ,BQ>_\ 7 U\E_\
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M_N:C_A2__!:W_H\CX6?^$C_]S4 ?8U%?'/\ PI?_ (+6_P#1Y'PL_P#"1_\
MN:C_ (4O_P %K?\ H\CX6?\ A(__ '-0!]C45\<_\*7_ ."UO_1Y'PL_\)'_
M .YJ/^%+_P#!:W_H\CX6?^$C_P#<U 'V-17QS_PI?_@M;_T>1\+/_"1_^YJ/
M^%+_ /!:W_H\CX6?^$C_ /<U 'V-17QS_P *7_X+6_\ 1Y'PL_\ "1_^YJ/^
M%+_\%K?^CR/A9_X2/_W-0!]C45\<_P#"E_\ @M;_ -'D?"S_ ,)'_P"YJ/\
MA2__  6M_P"CR/A9_P"$C_\ <U 'V-17QS_PI?\ X+6_]'D?"S_PD?\ [FH_
MX4O_ ,%K?^CR/A9_X2/_ -S4 ?8U%?'/_"E_^"UO_1Y'PL_\)'_[FH_X4O\
M\%K?^CR/A9_X2/\ ]S4 ?8U%?'/_  I?_@M;_P!'D?"S_P )'_[FH_X4O_P6
MM_Z/(^%G_A(__<U 'V-17QS_ ,*7_P""UO\ T>1\+/\ PD?_ +FH_P"%+_\
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M_P"YJ /L:BOCG_A2_P#P6M_Z/(^%G_A(_P#W-1_PI?\ X+6_]'D?"S_PD?\
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MFMOPS\*_^"TFN>&]/UJR_;#^%Z0WEC%/"DOA'YE5T# '%MC.#0!]J45\<_\
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M -'D?"S_ ,)'_P"YJ/\ A2__  6M_P"CR/A9_P"$C_\ <U 'V-17QS_PI?\
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MT1V]Q%'/L/F(WFS>9]#T4 ,M[>"T@2UM8$BBB0)''&H544#   X  [4^BB@
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M#[X3ZEHGC309].NYO&&J74<%P &:&2<LC\'H1R*]?HH **** "BBB@ HHHH
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\/?#S_A)?#?\
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M2^T[6](GL;JVGBM(HY(Y(9T1U*NK#D8.,@D<UP'[''@_Q7XG^/'QR_:K\?\
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MAI%8K@@8R:^C/VTO&OB;PC^SQK.D> -4>R\4^+I[7PKX3NX>7M=1U.=+*&[
MZL+;SFNG Z1VSGM7S]_P5MT/QMXI^+_[*+>"/A;XQ\11>#OVC])\4>*;KPWX
M0O\ 4(=+TF*PU"VDN99+>%U&V2XB&P$O@[MN!FO=?&^B:Y\4?VO/ EG-H5\O
MAGX>^'[SQ3+>SV<D4,VM7J2:;81H[ !VCM'UAI8_O1F>U9@-RY /%OVI/^"3
M/[-_QC\#:WK?QL^,OCSP]H_@WPM%9_#*;POX^U'1;+X=:;8V"(MS!!:SQP7$
MZO'),\URDAV>7&,+$,_.-I^U3^V+KW_!/?\ 80_9T^.GC'6].^(7[1_B[2M-
M^(?B"&YDM-4F\,VZ27MP/.0K+!=75FMG')*I60>?.<JY!'NG[<'[86MZU\:[
MS]FCQ;^PA^T1XP^%VD)#+XGO_ GPMEOK3QC<YWC3?-DDB!T],*9\9%T?W)_<
M"47&;^UCX5^,7[9OP\^ /_!0#P-^S#XW\*ZW\%/C3%XB'PW\56"1>([WPP2^
MGZE_H4;,L=V8B;J&W$CM)' @!\R81J ;7@'QVW[)W_!9>V_8C\!AK/X:_%/X
M'2>*](\,)*S6VB>(-.OS;W#VB$XMX;FTD1I(TPIFM_, #2R%HO@G_P )+X?_
M ."^7Q=\&2_$7Q/JFC3_ +.WA_6;;1]:\0W%W::?=3ZQ>12FUAD<QVR,L$>4
MC55R"<<UL?#CX*^*_P!H_P#X*X/_ ,% ;KP;KVB> _A_\%_^$)\&GQ1H-UI5
MYK.KWE^UW?7:6EW''<16\,"PP!I8T\R25RFY4W&A\-])\:1_\%W?B+\5+GX6
M>,X/">I_ +1/#6G^*[GP;J$>F7&J6FK7MQ/;K=-"(CB*>-A)N\MLD*S$8H Q
MOA=J7A3]NC_@IG^U9^S=^T[;3W]A\*+#PIIGP_\ "TVHS6ZV%A?Z:]W<ZQ;+
M&ZD7<EP^P7B?O84AA1'3+;^P_P""'?[2'Q1_:-_8=*_&7QA=>)O$'P^\?^(/
M!%QXMO6W3Z]#IEZ\-O>RM_'*T!B#OU=T9SRQJ3_@H/\ !/X9?%'Q3)K7PB_8
MVA\<_'[^Q6T/POXKU;P_=V6D:7!,-WFZKJ>Q+>[L8"_G-8[IY)&^1(<NS+ZE
M_P $[OV)O G_  3P_8[\%_LE> -3?48/#%@YU/69H0DFJ:C/(T]W=LN3M\R:
M1RJ9.Q-B9(4&@#VNBBB@ HHHH **** "BBB@ HHHH *^'OAY_P )+X;_ .#A
M+QOX+_X6-XHU'1+_ /94T[7X]$U?Q#<7-E8WLWB2YMY&M8)',=LICMH05C50
M=N3DDD_<-?$_A[2?&C?\%]O$/Q=?X6>,X_"%Q^S'I_A*#Q;+X-U!=,DUF#Q#
M=WDEL+DP^6<03(XDW>6>0')&* .P_;,_X)F_!;]L+4_%'Q(_:B^-/CVTMK#3
M@/ \WAKX@:AH5IX*ABME:2_2*UGCAN+LS^=,T]RL@$8BC"@1DMRG_!/O]HW]
MI+P9_P $1_ G[1G[3T]YXD^)"?#Z2YLO[45DNO$,TMQ+%H:2[OF,]W$^GJ2W
MS-)/ECDDU3_;N_:^U[4OC%<_LN>(_P!AK]H7Q?\ #&RMHI?&6J^ /AA-?6OB
MR1OF&DK*\D0-B!C[2RY%QGR/]49M_=>'/B?X^_;4O_A+!JW[,7COX;^%QXLO
MO%.J:+X^T@6M[]CT3RH]/BNX8RZ6<TNJ7%M>00F1R\.EF3C<50 X;]L+]C_]
MAOX5_L5:;)_P4'_:!\0:9X)^'_@F*Q74+3QW>Z$C:QL>2YU:-+.:(WVIW,Q+
MHDHFPP(CC!EF\STG_@E#;?$WQ#_P2^^$5K\9_CQ%X\\1W_@.(:EXWT37DO6N
MA(7\L"]C9A-/#$4A><,Q:6%VW$G-=7\8?VN?A]X&^+EQ^SE\1?V=OBUK%IJ/
MAX7*^(-%^$.IZ]X>U!9?,1[%[FQAG2*;"G<EPL:;77YCNQ7&_P#!*[]E/4?V
M&_V0+SX>:YX;FT&TO?''B7Q1I?@NU_TH^&-,O]2N+NTTE!;EQ))!;/$KK#O4
MS&0(7&&8 X+_ ((6ZAXGNO@/\9=(\4^.M?\ $<NB?M0^.](L]3\3ZW/J-ZUK
M:Z@(($>XN'>23;&BKEF/2O0/$'PW\1_M9?&OXKZCX>^(^J^%K+P_9Z=\/-)\
M0:'-Y=];1L\&I^()+&<?ZF2XCEL;'SE^>&;3F=</&*\O_P""2-UXU^!?[/7[
M0GB'XE_!7Q[I%P/CYX^\::7I&I^"=0M;O5M)NKM[NUDM8Y85,[RQC"Q+F3=A
M2H) KU_3/$_CG]A;]@BW\9:Q\%O%/Q"\>16,VKZYX0\!Z5)?7FK>)-2N)+V]
M2,1JWE0?;+F<F5AMCB P&(5& /G7X7?LCC]@W_@L-\-?AE^Q7X]\:CX>>/OA
MAXEU;XS> O$7C74=<LM/-G):1Z;JL;ZA/-+#<W%U</%G?\RP2[1@/CC_ ():
M]XL_X* ?L0?M/?M_ZUXTUC3_ !M8^+_&$7P.UNRU.6)O!=AH,133%M$5MB&2
M>"26ZX_TH3-'+NC"HOL/[%W[7'BGQ!\8(-'U/]@#]H:#Q]\2+^-_'?Q+\??#
ME-"T/3;:VAEDCMDE>YE>&TMT\R*UME5C)+.7D;S+B><^<?#;X*?'7]B?]CK]
MI?\ X)\>#?@GXL\1:[XM\5>*[CX$W^C>'[F?2M2L/$,1:U^U:@J&VL&L[F:=
M+@7,D1V0!XPXE0$ ]3^%'PC\%?\ !:+]CKX/?M%?M/\ B+Q,/"WB7X9:=J5S
MX \(^+=0T*T?7ID/VRZN);">*:Y6-E5+>)G\N/\ >LRNSKL^7=._:K_:J_X)
M_?\ !%S]I+Q'H'Q;USQA-X,^.>L_#_\ 9S\:>++K[;?2:3)J5II=O.]PX(NO
MLES)?A)&RK&T"@>6%4>\^,?%GQ!_X)O?LK_!O_@G)\+/V??C?XSM=&^']EIG
MC;XC_"+P!/J!L8881'.+20M&B7ES*)2K;C]F1C(07$:-2_:&^$OB#_@J3_P2
MT^)?[)?P _8Z\=?!&+PK8Z3'\*-/^*.AQ:++>ZEIL\=]#%%;"23R[0^1!!]H
M=\LUQ+E5\HLP!H?M#P6W_!,?]J']D^X^$.N:JVA_$[QPWPS^)UMJ.JSW+^)[
MB[LFDL=7NFF=C)?QW=N2UR<R/'<2QLQ79L^_:^%_C/X)\>_\%(OVG_V7O$,7
MP<\8^$O"_P (/$LWQ"^(LGC+PS=Z6;368K/R-/TFW-S&@O9!<S3/)-;^9 L=
MMD2DRQ;ONB@ HHHH **** "BBB@ HHHH **** (-5L!JNF7.EF\N+<7,#Q&>
MUEV2Q[@1N1A]UAG(/8\U\6?\$-[_ ,3S?"?X]Z%XF\=>(/$3>'_VLO'NBZ?J
M/BC7+C4;S[':7L<%O&]Q<.\C[8T51N)Z5]JWUY#IUE-J%PDK1P1-(ZP0/*Y"
MC)"H@+.>.%4$D\ $U\6_\$:-'\:?#WP3^T'%\2?A9XR\,R:W^T[XY\6Z+#XB
M\':A9/?Z/?WHGM+J%9H5,GF)G]VN9 1@J#B@#Q/_ (*>?\$_O$7[./P+LOVW
M_P!GS]H3XE3_ +5-OX\\.PZ1XB?QWJ4MIXMU&_U:VM9-'.DO.UG'IY2>79;1
M1*(XH1O9U60M]L_MA?\ %P+[X??LR6WSCQYXR@N/$$:\E-"THC4;PNO\4,TD
M-G8./34A]1\K7G_!13Q1XI^-,OQJ^+'_  2V_:RU@>#KVZA^%WAK2_@[NM[7
M<KP/JTC3W,8-[/$SHI( MH)7C4EIIR_U/\&],\<_$?\ :=\4_&OXC^"+G0SX
M9\*:9X4T#3[DM(D5S<11:IK$UO,447$#O+IMKYB@ R:3)T(( !\9?\%BOA#^
MSA\,_$_@[X@Z3^VSJ/@3]J'Q9\4-%_X5KX@UWXJW5E;06;:I$+FWDTXW LX]
M+BL1.A7R1YTJHK/+-<,)?J'_ (+(6FMC_@EW\=O$WACQ[XD\-ZIX=^%VN:QI
MFJ>%M>GTZYCN;:QFEC!FMV5RFY1N3.&'# CBO,/V[O%?@[_@II^R/\6_V'[+
M]COXICQEJB7N@>&H_B)\*=0TW2[34@SQ6NO1:M+$;%K6"0"Z#Q3M.\:;4B9Y
M%C;T;_@I%\._%EA_P22^*?P"\(:/XD\9^(]1^"VI>%=#M]&T2YO[[5K^32Y+
M:(M' CLID?!9VPBEOF84 >H?LE>(+;3_ -BOX9>*O%&L".&#X7:+=ZCJ%[-P
MJC387DED=CV +%C[DUX;X(_8FTG]M/X"Z'XG_:&\3^*['PU\1=2U+QSXP\%Z
M%XBOM$N-8GU%H3I-M?W5C+#<>78:9';VI@5U622%&?/E*#K)HOC#Q_\ \$W?
MA7^SK9^!O$=G?>-] \.>"_%=GJ6@75G/I6G?9(_[:^T++&K6_P#H-O?0I*P"
MF>6%5)+KG;_X*$_M;?$_]F_P]H7@7X+?LY_%7Q?J?BB5X;W7_AKX ?6AX7L5
M&'N=C%89+H_<@A=MH8^9(K(GER@'Q]\)?C-\8?\ @EU^RU^WAJ/A'XB:_P"-
M?AC\"M=6W^!%[XTU274IK/49=(MY;K3/M$Q,D]K:7]W;PX+'!29<[MV-WXV:
MAXF_X)W_ +,7[*7[9>A>,-8OO&&M>/\ PEH?QQU;4]4EG?QG9:] 8]0DO%9B
MLDL-U)'<6QX%N(O)CV1.R'T&+P;H_P#P45_8+^+G_!/3X<?L;?%GX,^&KCP!
M<6&E^(_C+X?_ +-DU#6KMY9XKA$\V::];[4AN;NXD979Y@?WC2LR\Q\4OA-\
M;OV_?@%^RU^R+XJ^"7BWPOJG@3QWX8\1?'>[\0^';FTT[3(M MG\^TM;R1!!
MJ+7=ZL20O:/,OE%I7* #(!T/_!4?_@G7\-_%?[/_ ,8/VTOBG^T;\2=)^)/A
M/PWJ^O\ @'QAX=^(6IZ9:^$$LX9);&UM+"WG6V8$11"9GC>:>664JZ;HU3V#
M6(/COXY_X)$Q:E^T#XGU[PY\3)/@(FH>+]0\-ZE+I5]::ZNC>;.RRVY1X'6Y
M!8A"HRI7E<@^2?M*_MQ:WXJ_:(O?A]\0_P#@GA^TSXH^'/@#68;G3(?"?PDE
MNK/Q?J]LXDBNI'FFB#6=M,BO!&01-.B3,0L46_W_ .)7Q2\7?%__ ()[^*OB
M)K/P*\8^&]7\5> -76P\!W6C2WFMP&>">.U@GMK59&2X=#$7B&X1.[(7;87(
M!D?\$?M;UGQ+_P $K_V>O$/B/5[K4+^]^#^@3WM]>W#2S7$K6,19W=B6=B22
M2222:^CJ^</^"0NA>*?!G_!,SX(_#?Q[X*UWP[X@\*?#?2=%U_1?$>B7%A<V
ME[;6D<<J&.=$+*&! =<HW9C@U]'T %%%% !1110 4444 %%%% !1110!\X?\
M%>K/6C_P3$^/'B3PUX[\1^'-4\.?"?Q#K>EZKX6UV?3KJ.ZM--N)XOWT#*^S
M>BED# ,!@Y!(.C\"_!GC+XS?\$U?AGX*T/XH:OX:U'Q!\*_#,5]XGTN<C4(;
M=[.T-VT$QR8KEX/.1)^6CDD609* %/\ @JII7B+Q1_P3<^.?P^\%^#]<U_7O
M%?PG\0Z%X?T;P]HEQ?W-Y?W>FW$$$0C@1V4-(Z@NP"+G+,!63\)_C7XA_9N_
MX)@>!O'[_L_?$3Q+XB\*_##1;!OAWHWA"\&MW.I16,$+6@MY(U:,"4$-*P\M
M55F!88! /GSP5^Q]'^P7_P %?_@WX'_8F\?^.(_ _P 1/ OBN_\ C=X$\0^.
M-2UZSB@L8K86&L ZA/-)!<2W]U'"7W_.H<( !)GZ>\2:/J7QX_;"UC2M'\1W
M.EV?PO\  $FGVFKV,:2/:^(-;PSRHLBL@N;.PM863<K+MU@Y# D5X?\ L>_M
MB>+==^,$"^(/^">_[1$7Q$^)%] GC3XA>-OAPNBZ#HMC;)+(EHD\EQ(\-G;1
MM.+>$(6GGF9G*R7,DE>V? /7O$/P>_9.\1?M.^./A7XMU7Q'XMN]1\>:WX1T
M/16GUV5;C!LM.6T<HSW=OIT5C9F(E27M<<'B@#Y4^#?PX_9?^#7_  6X\+_"
M_P#8B_:UGBO;7X>:_<?M!?#W6_BS>ZZ^M7)-NNF,(;^ZG<ZBDANIYV0[HHHE
MWA//'F>D?\%;?^$E\-_M&?L=^+/#GQ&\4:<FJ?M-:1H>K:+8>(;B#3=0M'L-
M1N"+BU1Q%.PDMXR&D5BN"!C)I_Q,^'OA3_@HO^U#^S?^TK\+?@=XX\):C\)O
M&%SX@\2>,O'WP[U#PSJ%KIC:;=VYT%8]1@AGN6N+J>!V\H20)';3$R9DC66Q
M_P %;=#\;>*?B_\ LHMX(^%OC'Q%%X._:/TGQ1XINO#?A"_U"'2])BL-0MI+
MF62WA=1MDN(AL!+X.[;@9H ^@?VTO&OB;PC^SQK.D> -4>R\4^+I[7PKX3NX
M>7M=1U.=+*&[ ZL+;SFNG Z1VSGM7A7[4G_!)G]F_P",?@;6];^-GQE\>>'M
M'\&^%HK/X93>%_'VHZ+9?#K3;&P1%N8(+6>."XG5XY)GFN4D.SRXQA8AGVGQ
MOHFN?%']KSP)9S:%?+X9^'OA^\\4RWL]G)%#-K5ZDFFV$:.P =H[1]8:6/[T
M9GM68#<N?GS]N#]L+6]:^-=Y^S1XM_80_:(\8?"[2$AE\3W_ ($^%LM]:>,;
MG.\:;YLDD0.GIA3/C(NC^Y/[@2BX /"[3]JG]L77O^">_P"PA^SI\=/&.MZ=
M\0OVC_%VE:;\0_$$-S)::I-X9MTDO;@><A66"ZNK-;..252L@\^<Y5R"/:K'
MQ?XG_9?_ ."M5W^PG\$-9BT'P;\6OV?;OQ/X3TF>)KBR\->*=/O'MGN+: L!
M';SV\D4DL"D*TMMO #2R,U?]K'PK\8OVS?AY\ ?^"@'@;]F'QOX5UOX*?&F+
MQ$/AOXJL$B\1WOA@E]/U+_0HV98[LQ$W4-N)':2.! #YDPC79L/ 'B+XJ_\
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MBBB@ HHHH **** "BBB@ HHHH _A"_:P_P"3IOB7_P!E UG_ -+IJ*/VL/\
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M;,\D<+R10F1E4E8P0"QQTR>!7R7I'_!8'X)Z3_P4%L/^":_Q\^$7C7X7^/\
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MW_Q=;N@>)/#OBO3AJ_A;7[+4K1G*BZT^Z2:,L.HW(2,CTKP[_AUE_P $]?\
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M_9^E\:^'M5N_!-PSZ'YFLP6:W%Q$;MGU*XB5946-);2%_M D9?W6QZ/[)?\
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M>&/AW^TSX&T#PYX-\9:IX5N(8+F.T\/3Z;>NP<!K<YE9H_/$>\+CABJGG/\
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MZWA72O$NJ:#9V&M>%/$A,:VL<C6,<-O=6EPTJJ 85DCVNQ<A-LG+^!_VH?\
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MK\!_&OA/2_B;\:)O%'@35/$/AZ6"#5=-V/%Y@;!\E^$;RYMCE9!A25<+^@M
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M^"=O_1I7A/\ \!Y/_BZY'+'7^&/WO_Y$\QSSF^D*?_@4O_D#U?\ X7S\#?\
MHLWA/_PHK;_XNC_A?/P-_P"BS>$__"BMO_BZ\H_X=3_\$[?^C2O"?_@/)_\
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M6OA/6/VO_P!ERTD^'4/V_P#X2)+[Q+IEU$<V%PL&Z*WNFD;_ $@PXVJ<'!.
M":^3_P"%K^T_M\O/_>Y;<W_I/RV/S2_%W^L-[5>3VNUZGL[<_>UN2W6UN7H?
MK[_POGX&_P#19O"?_A16W_Q='_"^?@;_ -%F\)_^%%;?_%UY1_PZG_X)V_\
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MG@B#;1MBC#/EI'*J ,9R5! /SOUC]IC_ (*5_L%?\$.O@)_P4-^''QA\"0>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?PA?M8?\G3?$O\ [*!K/_I=-11^UA_R=-\2_P#LH&L_^ETU% '[?_\
M!IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!_"%^UA_R=-\2_P#LH&L_^ETU%'[6'_)TWQ+_ .R@
M:S_Z7344 ?M__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^
M3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '\(7[6'_)TWQ+_ .R@:S_Z7344
M?M8?\G3?$O\ [*!K/_I=-10!^W__  :;?\I3/VN_^WC_ -/D]?O]7X _\&FW
M_*4S]KO_ +>/_3Y/7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?PA?M8?\G3?
M$O\ [*!K/_I=-11^UA_R=-\2_P#LH&L_^ETU% '[?_\ !IM_RE,_:[_[>/\
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')'I10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135463568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REGENERON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3444607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">777 Old Saw Mill River Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tarrytown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10591-6707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock - par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">REGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Specified portions of the Registrant's definitive proxy statement to be filed in connection with solicitation of proxies for its 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Form 10-K. Exhibit index is located on pages 96 to 101 of this filing. </span></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000872589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,507,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132944304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132312160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,105.9<span></span>
</td>
<td class="nump">$ 2,885.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">4,636.4<span></span>
</td>
<td class="nump">2,809.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5,328.7<span></span>
</td>
<td class="nump">6,036.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">2,401.9<span></span>
</td>
<td class="nump">1,951.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">411.2<span></span>
</td>
<td class="nump">332.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">15,884.1<span></span>
</td>
<td class="nump">14,014.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">6,591.8<span></span>
</td>
<td class="nump">6,838.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">3,763.0<span></span>
</td>
<td class="nump">3,482.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">915.5<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,723.7<span></span>
</td>
<td class="nump">876.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">336.4<span></span>
</td>
<td class="nump">216.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">29,214.5<span></span>
</td>
<td class="nump">25,434.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">589.2<span></span>
</td>
<td class="nump">564.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,074.2<span></span>
</td>
<td class="nump">2,206.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">719.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">477.9<span></span>
</td>
<td class="nump">442.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,141.3<span></span>
</td>
<td class="nump">3,932.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,981.4<span></span>
</td>
<td class="nump">1,980.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">720.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">69.8<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">638.0<span></span>
</td>
<td class="nump">680.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,550.5<span></span>
</td>
<td class="nump">6,666.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,949.3<span></span>
</td>
<td class="nump">8,087.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">23,306.7<span></span>
</td>
<td class="nump">18,968.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(238.8)<span></span>
</td>
<td class="num">(26.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury Stock, at cost; 22.6 shares in 2022 and 19.4 shares in 2021</a></td>
<td class="num">(10,353.3)<span></span>
</td>
<td class="num">(8,260.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">22,664.0<span></span>
</td>
<td class="nump">18,768.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">29,214.5<span></span>
</td>
<td class="nump">25,434.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">130.4<span></span>
</td>
<td class="nump">126.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132256112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">22,600,000<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares)</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">320,000,000<span></span>
</td>
<td class="nump">320,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">130,400,000<span></span>
</td>
<td class="nump">126,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132741760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,592.5<span></span>
</td>
<td class="nump">2,860.1<span></span>
</td>
<td class="nump">2,647.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">255.1<span></span>
</td>
<td class="nump">48.0<span></span>
</td>
<td class="nump">88.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">2,115.9<span></span>
</td>
<td class="nump">1,824.9<span></span>
</td>
<td class="nump">1,346.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="num">(89.9)<span></span>
</td>
<td class="num">(45.6)<span></span>
</td>
<td class="num">(280.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">7,434.0<span></span>
</td>
<td class="nump">7,124.9<span></span>
</td>
<td class="nump">4,920.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">4,738.9<span></span>
</td>
<td class="nump">8,946.8<span></span>
</td>
<td class="nump">3,576.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">179.3<span></span>
</td>
<td class="nump">436.3<span></span>
</td>
<td class="nump">290.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(59.4)<span></span>
</td>
<td class="num">(57.3)<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">119.9<span></span>
</td>
<td class="nump">379.0<span></span>
</td>
<td class="nump">233.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">4,858.8<span></span>
</td>
<td class="nump">9,325.8<span></span>
</td>
<td class="nump">3,810.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">520.4<span></span>
</td>
<td class="nump">1,250.5<span></span>
</td>
<td class="nump">297.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 4,338.4<span></span>
</td>
<td class="nump">$ 8,075.3<span></span>
</td>
<td class="nump">$ 3,513.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 40.51<span></span>
</td>
<td class="nump">$ 76.40<span></span>
</td>
<td class="nump">$ 32.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 38.22<span></span>
</td>
<td class="nump">$ 71.97<span></span>
</td>
<td class="nump">$ 30.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">107.1<span></span>
</td>
<td class="nump">105.7<span></span>
</td>
<td class="nump">107.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">113.5<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">115.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 4,338.4<span></span>
</td>
<td class="nump">$ 8,075.3<span></span>
</td>
<td class="nump">$ 3,513.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on debt securities</a></td>
<td class="num">(213.6)<span></span>
</td>
<td class="num">(56.4)<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gain (loss) on cash flow hedges</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">4,125.8<span></span>
</td>
<td class="nump">8,019.8<span></span>
</td>
<td class="nump">3,521.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">6,893.7<span></span>
</td>
<td class="nump">12,117.2<span></span>
</td>
<td class="nump">5,567.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold and of collaboration and contract manufacturing</a></td>
<td class="nump">800.0<span></span>
</td>
<td class="nump">1,773.1<span></span>
</td>
<td class="nump">491.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_SanofiCollaborationRevenueMember', window );">Sanofi collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">2,855.7<span></span>
</td>
<td class="nump">1,902.2<span></span>
</td>
<td class="nump">1,186.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationRevenueMember', window );">Other collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">2,058.4<span></span>
</td>
<td class="nump">1,771.1<span></span>
</td>
<td class="nump">1,186.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">365.1<span></span>
</td>
<td class="nump">281.2<span></span>
</td>
<td class="nump">557.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold and of collaboration and contract manufacturing</a></td>
<td class="nump">$ 760.4<span></span>
</td>
<td class="nump">$ 664.4<span></span>
</td>
<td class="nump">$ 628.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SanofiCollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SanofiCollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128701280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Class A Stock</div></th>
<th class="th">
<div>Class A Stock </div>
<div>Common Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Balance, treasury (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 11,089.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 4,428.6<span></span>
</td>
<td class="nump">$ 7,379.8<span></span>
</td>
<td class="nump">$ 21.1<span></span>
</td>
<td class="num">$ (739.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">2,576.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,576.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(768.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(768.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(5,880.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,880.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">442.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">3,513.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Ending, treasury (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">11,025.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,716.2<span></span>
</td>
<td class="nump">10,893.0<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="num">$ (6,613.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">1,676.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(944.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(944.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(1,655.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,655.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">599.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">8,075.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,075.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">$ (55.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Ending, treasury (in shares) at Dec. 31, 2021</a></td>
<td class="num">(19.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 18,768.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">8,087.5<span></span>
</td>
<td class="nump">18,968.3<span></span>
</td>
<td class="num">(26.2)<span></span>
</td>
<td class="num">$ (8,260.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">1,517.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,517.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(445.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(445.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">59.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(2,099.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,099.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">737.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">737.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">4,338.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,338.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">$ (212.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(212.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Ending, treasury (in shares) at Dec. 31, 2022</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 22,664.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 9,949.3<span></span>
</td>
<td class="nump">$ 23,306.7<span></span>
</td>
<td class="num">$ (238.8)<span></span>
</td>
<td class="num">$ (10,353.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Value, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129669840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 4,338.4<span></span>
</td>
<td class="nump">$ 8,075.3<span></span>
</td>
<td class="nump">$ 3,513.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">341.4<span></span>
</td>
<td class="nump">286.2<span></span>
</td>
<td class="nump">235.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">725.0<span></span>
</td>
<td class="nump">601.7<span></span>
</td>
<td class="nump">432.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MarketableAndOtherSecuritiesGainLoss', window );">Losses (gains) on marketable and other securities, net</a></td>
<td class="nump">36.8<span></span>
</td>
<td class="num">(387.0)<span></span>
</td>
<td class="num">(221.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="nump">368.0<span></span>
</td>
<td class="nump">568.7<span></span>
</td>
<td class="nump">86.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(746.4)<span></span>
</td>
<td class="num">(147.1)<span></span>
</td>
<td class="nump">75.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development in connection with asset acquisition</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="nump">707.8<span></span>
</td>
<td class="num">(1,927.4)<span></span>
</td>
<td class="num">(1,356.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(696.5)<span></span>
</td>
<td class="num">(494.3)<span></span>
</td>
<td class="num">(529.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other assets</a></td>
<td class="num">(148.6)<span></span>
</td>
<td class="num">(240.7)<span></span>
</td>
<td class="nump">114.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in deferred revenue</a></td>
<td class="nump">32.4<span></span>
</td>
<td class="num">(120.2)<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">(Decrease) increase in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="num">(138.4)<span></span>
</td>
<td class="nump">866.1<span></span>
</td>
<td class="nump">118.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">676.5<span></span>
</td>
<td class="num">(994.0)<span></span>
</td>
<td class="num">(895.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">5,014.9<span></span>
</td>
<td class="nump">7,081.3<span></span>
</td>
<td class="nump">2,618.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable and other securities</a></td>
<td class="num">(7,487.9)<span></span>
</td>
<td class="num">(7,048.1)<span></span>
</td>
<td class="num">(3,241.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable and other securities</a></td>
<td class="nump">5,550.5<span></span>
</td>
<td class="nump">2,215.3<span></span>
</td>
<td class="nump">3,785.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(590.1)<span></span>
</td>
<td class="num">(551.9)<span></span>
</td>
<td class="num">(614.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentsToAcquireIntangibleAssets1', window );">Payments for Libtayo intangible asset</a></td>
<td class="num">(1,026.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentsForAssetAcquisition', window );">Asset acquisition, net of cash acquired</a></td>
<td class="num">(230.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,784.6)<span></span>
</td>
<td class="num">(5,384.7)<span></span>
</td>
<td class="num">(70.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Common Stock</a></td>
<td class="nump">1,519.5<span></span>
</td>
<td class="nump">1,672.3<span></span>
</td>
<td class="nump">2,575.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments in connection with Common Stock tendered for employee tax obligations</a></td>
<td class="num">(445.7)<span></span>
</td>
<td class="num">(1,032.7)<span></span>
</td>
<td class="num">(680.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of Common Stock</a></td>
<td class="num">(2,082.8)<span></span>
</td>
<td class="num">(1,645.4)<span></span>
</td>
<td class="num">(5,846.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,981.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bridge loan facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of bridge loan facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,009.0)<span></span>
</td>
<td class="num">(1,005.8)<span></span>
</td>
<td class="num">(1,970.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">221.3<span></span>
</td>
<td class="nump">690.8<span></span>
</td>
<td class="nump">577.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">2,898.1<span></span>
</td>
<td class="nump">2,207.3<span></span>
</td>
<td class="nump">1,630.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">3,119.4<span></span>
</td>
<td class="nump">2,898.1<span></span>
</td>
<td class="nump">2,207.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest (net of amounts capitalized)</a></td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1,502.4<span></span>
</td>
<td class="nump">$ 1,218.4<span></span>
</td>
<td class="nump">$ 188.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MarketableAndOtherSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable and Other Securities, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MarketableAndOtherSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PaymentsForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PaymentsForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PaymentsToAcquireIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Intangible Assets1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PaymentsToAcquireIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133734192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Business Overview and Summary of Significant Accounting Policies</a></td>
<td class="text">Business Overview and Summary of Significant Accounting Policies<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The Company currently has nine products that have received marketing approval by the U.S. Food and Drug Administration ("FDA"). In addition, REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was authorized under an Emergency Use Authorization ("EUA") from November 2020 until January 2022 when the EUA was revised to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment; with this EUA revision, REGEN-COV is not currently authorized for use in any U.S. states, territories, or jurisdictions. The Company is a party to collaboration agreements to develop and commercialize, as applicable, certain products and product candidates (see Note 3).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one business segment, which includes all activities related to the discovery, development, and commercialization of medicines for serious diseases. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting research activities, product development, obtaining regulatory approvals, competition, and obtaining and enforcing patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Regeneron and its wholly-owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the first quarter of 2022, the Company added a new line item, Acquired in-process research and development, to its Consolidated Statements of Operations and Comprehensive Income. This line item includes in-process research and development acquired in connection with asset acquisitions as well as up-front/opt-in payments related to license and collaboration agreements. Amounts recorded in this line item during the year ended December 31, 2022 would have historically been recorded to Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation, including in connection with the addition of Acquired in-process research and development described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain investments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to customer and collaborator accounts receivable are significant. As of December&#160;31, 2022, two individual customers accounted for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86% of the Company's net trade accounts receivable balances. Three individual customers accounted for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91% (including 29% related to the U.S. government) of the Company's net trade accounts receivable balances as of December 31, 2021. The Company has contractual payment terms with each of its collaborators and customers, and the Company monitors their financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. As of December&#160;31, 2022 and 2021, there were no write-offs and allowances of accounts receivable related to credit risk for the Company's collaborators or customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. The carrying amount reported in the Consolidated Balance Sheet for cash and cash equivalents approximates its fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt and Equity Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. The Company invests its cash primarily in debt securities. The Company considers its investments in debt securities to be "available-for-sale," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Realized gains and losses on available-for-sale debt securities are included in other income (expense), net. The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in net income, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investments in equity securities that are carried at fair value with changes in fair value recognized within other income (expense), net. The Company has elected to measure certain equity investments it holds that do not have readily determinable fair values at cost less impairment, if any, and adjusts for observable price changes in orderly transactions for identical or similar investments of the same issuer within other income (expense), net. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's trade accounts receivable arise from product sales and represent amounts due from its customers. In addition, the Company records accounts receivable arising from its collaboration and licensing agreements. The Company monitors the financial performance and credit worthiness of its counterparties so that it can properly assess and respond to changes in their credit profile. The Company provides allowances against receivables for estimated losses, if any, that may result from a counterparty's inability to pay. Amounts determined to be uncollectible are written-off against the allowance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such inventory to its estimated realizable value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant, and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Costs of construction of certain long-lived assets include capitalized interest, which is amortized over the estimated useful life of the related asset. Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized within income from operations. The estimated useful lives of property, plant, and equipment are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"><tr><td style="width:1.0%"/><td style="width:67.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#8211;50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease considering whether there is an identified asset and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company's lease terms may include options to extend or terminate a lease when it is reasonably certain that it will exercise that option. The Company accounts for lease components (e.g., rental payments) separately from non-lease components (e.g., common area maintenance costs).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, unless there is a transfer of title or purchase option the Company is reasonably certain to exercise. For leases where an implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on information available at the lease commencement date to determine the present value of future lease payments. Lease expense for operating leases is recognized on a straight-line basis over the expected lease term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company makes a determination of whether an asset or set of assets acquired constitute a business. If it is determined that substantially all of the fair value of gross assets acquired in a transaction are concentrated in a single identifiable asset, then the transaction is accounted for as an asset acquisition. Intangible assets acquired in connection with an asset acquisition are recorded at cost. Such amounts may include up-front payments and contingent consideration. With regard to contingent consideration, the Company recognizes regulatory milestones upon achievement, royalties in the period in which the underlying sales occur, and sales-based milestones when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets are amortized to Cost of goods sold over the estimated useful lives of the assets based on the pattern in which the economic benefits of the intangible assets are consumed; if that pattern cannot be reliably determined, a straight-line basis is used. If contingent consideration is recognized subsequent to the acquisition date in an asset acquisition, the amount of such consideration is recorded as an addition to the cost basis of the intangible asset with a cumulative catch-up adjustment for amortization expense as if the additional amount of consideration had been accrued from the outset of the acquisition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's intangible assets are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If an indicator of impairment exists, the Company compares the projected undiscounted cash flows to be generated by the asset to the intangible asset's carrying amount. If the projected undiscounted cash flows of the intangible asset are less than the carrying amount, the intangible asset is written down to its fair value in the period in which the impairment occurs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition - Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized at a point in time when the Company's customer is deemed to have obtained control of the product, which generally occurs upon receipt or acceptance by its customer. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue the Company recognizes from product sales may vary due to rebates, chargebacks, and discounts provided under governmental and other programs, distribution-related fees, and other sales-related deductions. In order to determine the transaction price, the Company estimates, utilizing the expected value method, the amount of variable consideration to which the Company will be entitled. This estimate is based upon contracts with customers, healthcare providers, payors, and government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, estimated payor mix, and other relevant factors. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rebates include amounts paid to managed care organizations, group purchasing organizations, state Medicaid programs, and other rebate programs. The Company estimates reductions to product sales for each type of rebate and records an allowance for rebates in the same period in which the related product sales are recognized. The Company's liability for rebates consists of estimates for claims related to the current and prior periods that have not been paid and estimates for claims that will be made related to inventory that exists in the distribution channel at the end of the period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's reserves related to discounted pricing to eligible physicians, Veterans' Administration ("VA"), Public Health Services, and others (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the discounted selling price to the qualified healthcare providers. The Company estimates reductions to product sales for each type of chargeback and records an allowance for chargebacks in the same period that the related product sales are recognized. The Company's reserve for chargebacks consists of amounts for which it expects to issue credit based on expected sales by its customers to qualified healthcare providers and chargebacks that customers have claimed but for which the Company has not yet issued credit.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Distribution-Related Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers generally based on gross sales.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other Sales-Related Deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's other sales-related deductions include co-pay assistance programs and product returns. The Company estimates and records other sales-related deductions generally based on gross sales, written contracts, and other relevant factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company generally offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers, using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various collaborative arrangements to research, develop, manufacture, and commercialize products and/or product candidates. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:49.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front/opt-in and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements involving multiple goods or services promised to be transferred to the Company's collaborator, the Company must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is "distinct"), or whether such </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promises should be combined as a single unit of account. When the Company has a combined unit of account which includes a license and providing research and development services to its collaborator, recognition of up-front payments and development milestones earned from its collaborator is deferred (as a liability) and recognized over the development period (i.e., over time) typically using an input method on the basis of the Company's research and development costs incurred relative to the total expected cost which determines the extent of the Company's progress toward completion. The Company reviews its estimates each period and makes revisions to such estimates as necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company is entitled to reimbursement of all or a portion of the expenses (e.g., research and development expenses) that it incurs under a collaboration, it records those reimbursable amounts in the period in which such costs are incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company's collaborator performs research and development work or commercialization-related activities and the parties share the related costs, the Company also recognizes, as expense (e.g., research and development expense or selling, general, and administrative expense, as applicable) in the period when its collaborator incurs such expenses, the portion of the collaborator's expenses that the Company is obligated to reimburse. The Company's collaborators provide the Company with estimated expenses for the most recent fiscal quarter. The estimates are revised, if necessary, in subsequent periods if actual expenses differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where the Company:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplies commercial product to its collaborator, the Company may be reimbursed for its manufacturing costs as commercial product is shipped to the collaborator (however, recognition of such cost reimbursements may be deferred until the product is sold by the Company's collaborator to third-party customers); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares in any profits or losses arising from the commercialization of such products, the Company records its share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receives royalties and/or sales-based milestone payments from its collaborator, the Company recognizes such amounts in the period earned.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's collaborators provide it with estimates of product sales and the Company's share of profits or losses, as applicable, for each quarter. The estimates are revised, if necessary, in subsequent periods if the Company's actual share of profits or losses differ from those estimates.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, clinical trial expenses, the cost of services provided by outside contractors, including services related to the Company's clinical trials, the full cost of manufacturing drug for use in research and development, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs. Costs associated with research and development are expensed.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter and remain in the trial, and/or the period over which clinical investigators, contract research organizations ("CROs"), or other third-party service providers are expected to provide services. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining noncancelable obligations associated with the winding-down of the clinical trial, including any applicable penalties.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity grants under the Company's long-term incentive plans (including stock options, restricted stock awards, and restricted stock units (both time-based and performance-based)) to employees and non-employee members of the Company's board of directors (as applicable) based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In addition, the Company reassesses its forfeiture rate assumptions at least annually, considering both historical forfeiture experience and an estimate of future forfeitures for currently outstanding unvested awards. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation to compute the estimated fair value of performance-based restricted stock units that are subject to vesting based on the Company&#8217;s attainment of pre-established criteria that include a market condition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance-based restricted stock units that contain a performance condition, the Company recognizes stock-based compensation expense if and when the Company determines that it is probable the performance condition will be achieved (based on the number of shares expected to be vested and issued). The Company reassesses the probability of achievement at each reporting period and adjusts compensation cost, as necessary. If there are any changes in the Company's probability assessment, the Company recognizes a cumulative catch-up adjustment in the period of the change in estimate, with the remaining unrecognized expense recognized prospectively over the remaining requisite service period. If the Company subsequently determines that the performance criteria are not met or are not expected to be met, any amounts previously recognized as compensation expense are reversed in the period when such determination is made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes U.S. federal, state, local, and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns, including deferred tax assets and liabilities for expected amounts of global intangible low-taxed income ("GILTI") inclusions, are recognized on the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the financial statement effects of a tax position when management's assessment is that there is more than a 50% probability that the position will be sustained upon examination by a taxing authority based upon its technical merits. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Per Share Data</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Basic net income per share excludes restricted stock until vested. Diluted net income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include outstanding stock options and unvested restricted stock under the Company's long-term incentive plans, which are included under the treasury stock method when dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583226952416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.189%"><tr><td style="width:1.0%"/><td style="width:23.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(e) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,117.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had $3.586&#160;billion and $5.059&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December&#160;31, 2022, 2021, and 2020. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.913%"><tr><td style="width:1.0%"/><td style="width:60.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales to the U.S. government represented less than 10% of total gross product revenue during the period</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks, and discounts, distribution-related fees, and other sales-related deductions. Accruals for chargebacks and discounts are recorded as a direct reduction to accounts receivable. Accruals for rebates, distribution-related fees, and other sales-related deductions are recorded within accrued liabilities. The following table summarizes the provisions, and credits/payments, for sales-related deductions.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"/><td style="width:37.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks,<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution-<br/>Related Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Sales-<br/>Related Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,034.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,523.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,398.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583225618416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Other Agreements</a></td>
<td class="text">Collaboration, License, and Other Agreements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its collaborations with Sanofi are detailed below: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"><tr><td style="width:1.0%"/><td style="width:36.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.048%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of one-time payment of $56.9 million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (dupilumab), Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (sarilumab), and itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi based on the Company's share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, the Company was required to apply 10% of its share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of the Company's share of profits used to reimburse Sanofi for such development costs increased from 10% to 20%. A portion of the value associated with the increase in reimbursement percentage was deemed to be contingent consideration attributable to the Company's acquisition of the Libtayo rights described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below; this portion will be recorded as an increase to the Libtayo intangible asset over time as the Company repays such development costs to Sanofi. The Company's contingent reimbursement </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligation (development balance) to Sanofi under the Antibody Collaboration was approximately $2.864 billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. The Company co-commercializes Dupixent in the United States and in certain countries outside the United States. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In each of 2020 and 2021, the Company earned a $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion and $1.5&#160;billion, respectively, on a rolling twelve-month basis. In 2022, the Company earned two additional $50.0&#160;million sales-based milestones from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion and $2.5&#160;billion, respectively, on a rolling twelve-month basis. The Company is entitled to receive the final sales milestone payment of $50.0&#160;million when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant promised goods and services in connection with the Antibody Collaboration consist of providing research and development services, including the manufacturing of clinical supplies; and providing commercial-related services, including the manufacturing of commercial supplies. The Company recognizes amounts in connection with the Antibody Collaboration based on the amount it has the right to invoice and such amount corresponds directly with the Company's performance to date; therefore, the Company does not disclose the value of the transaction price (i.e., the amount of consideration the Company expects to be entitled to) allocated to its remaining unsatisfied obligations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, became solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi pays the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company does not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party is responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company continues to supply drug substance to Sanofi and Sanofi continues to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each are solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 16 for discussion of legal proceedings related to Praluent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was previously a party to a collaboration with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration was governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement ("IO License and Collaboration Agreement"). In connection with the execution of the original Immuno-oncology Discovery and Development Agreement in 2015 ("2015 IO Discovery Agreement"), which was subsequently replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $265.0&#160;million non-refundable up-front payment to the Company. Pursuant to the 2015 IO Discovery Agreement, the Company was to identify and validate potential immuno-oncology targets and develop therapeutic antibodies against such targets through clinical proof-of-concept. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 and (ii) MUC16 and CD3 through clinical proof-of-concept. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, the Company retains the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any). In addition, the Company has no further obligations to develop drug product candidates under the Amended IO Discovery Agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the IO License and Collaboration Agreement in 2015, Sanofi made a $375.0 million non-refundable up-front payment to the Company. Under the terms of the IO License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. The Company had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;R IO LCA"). In connection with the A&amp;R IO LCA, in 2022, the Company made a $900.0&#160;million up-front payment to Sanofi, as well as a $100.0&#160;million regulatory milestone payment. In addition, Sanofi earned a $65.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022, and is eligible to receive an additional $35.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023 (aggregate of $100.0&#160;million in sales-based milestones eligible to be earned under the terms of the A&amp;R IO LCA). The Company also pays Sanofi an 11% royalty on net product sales of Libtayo through March 31, 2034. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset. See Note 8 for additional information related to the intangible asset recorded in connection with the transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Amended IO Discovery Agreement, the Company was obligated to reimburse Sanofi for half of the development costs it funded that were attributable to clinical development of product candidates from the Company's share of profits from commercialized IO Collaboration products. Under the A&amp;R IO LCA, the amount of development costs incurred under the IO Collaboration for which the Company was obligated to reimburse Sanofi was $35.0&#160;million as of the effective date of the A&amp;R IO LCA, and the Company pays Sanofi a 0.5% royalty on net product sales of Libtayo until all such development costs have been reimbursed by Regeneron. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities included up-front payments received from Sanofi for which recognition had been deferred. Such amounts were being recognized over the remaining period in which the Company was obligated to perform development activities. In connection with the A&amp;R IO LCA described above, the remaining IO Collaboration Other liabilities balance of $241.0&#160;million as of July 1, 2022 was recognized as a reduction to the intangible asset during the third quarter of 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company updated its estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $66.9&#160;million as a reduction to other operating income. During 2020, the Company updated its estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $135.4 million as an increase to other operating income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA (aflibercept) and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. The Company is also obligated to use commercially reasonable efforts to supply clinical and commercial bulk product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, the Company is responsible for commercialization and retains profits from such sales. Bayer markets EYLEA outside the United States and the companies share equally in profits and losses from sales. In Japan, the Company was entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net product sales through 2021, and effective January 1, 2022, the companies share equally in profits and losses from sales in Japan. The Company is obligated to reimburse Bayer out of its share of the collaboration profits for 50% of the agreed-upon development expenses that Bayer has incurred in accordance with a formula based on the amount of development expenses that Bayer has incurred and the Company's share of the collaboration profits, or at a faster rate at the Company's option. The Company's contingent reimbursement obligation to Bayer was approximately $273 million as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.810%"><tr><td style="width:1.0%"/><td style="width:37.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.327%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Bayer collaboration:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2016 agreement, the parties agreed to a target selection process, whereby the Company may obtain exclusive rights in up to 10 targets to be chosen by the Company during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Certain targets that either the Company or Intellia selects pursuant to the target selection process may be subject to a co-development and co-commercialization arrangement at the Company's option or Intellia&#8217;s option, as applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company expanded its existing collaboration with Intellia to provide the Company with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, the Company also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene edited products. In connection with the agreement, in 2020, the Company made a $70.0&#160;million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $30.0&#160;million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $15.0&#160;million, were recorded to Acquired in-process research and development expense. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d. U.S. Government </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company expanded its Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of the Company's costs incurred for research and development activities related to COVID-19 treatments. In 2020, the Company also entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. The agreement, as subsequently amended, provided for payments to the Company of up to $465.9&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish, storage, and other activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an agreement with the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase 1.25&#160;million doses of drug product, which the Company delivered by June 30, 2021, resulting in payments to the Company of $2.625&#160;billion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an amendment to its January 2021 agreement to supply the U.S. government with an additional 1.4&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government was obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of $2.940&#160;billion in the aggregate. Roche supplied a portion of the doses to Regeneron to fulfill the Company's agreement with the U.S. government (see "Roche" below for further details regarding the Company's collaboration agreement with Roche).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had completed its final deliveries of drug product under the agreements described above. See Note 2 for REGEN-COV net product sales recognized during the years ended December 31, 2021 and 2020 in connection with these agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">e. Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in other countries). Under the terms of the collaboration agreement, the Company leads global development activities for REGEN-COV, and the parties jointly fund certain studies. The Company has the right to distribute the product in the United States and Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Other collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment to Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.764%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">f. Alnylam</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company and Alnylam Pharmaceuticals, Inc. entered into a collaboration to discover RNA interference ("RNAi") therapeutics for nonalcoholic steatohepatitis ("NASH") and potentially other related diseases, as well as to research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts (including ALN-HSD, which is currently in clinical development). Under the terms of the collaboration agreement, the parties share development costs equally. During the fourth quarter of 2022, Alnylam elected to opt-out of further development activities related to ALN-HSD; as a result, the Company retains the exclusive right to develop and commercialize such product and Alnylam will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company and Alnylam entered into a global, strategic collaboration to discover, develop, and commercialize RNA interference therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver. In connection with the collaboration, the Company made an up-front payment of $400.0&#160;million to Alnylam, and also purchased shares of Alnylam common stock for $400.0&#160;million. For each program, the Company provides Alnylam with a specified amount of funding at program initiation and at lead candidate designation, and Alnylam is eligible to receive up to an aggregate of $200.0 million in clinical proof-of-principle milestones for eye and CNS programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, the parties plan to perform discovery research until designation of lead candidates. Following designation of a lead candidate, the parties may further advance such lead candidate under either a co-development/co-commercialization collaboration agreement ("Co-Co Collaboration Agreement") (under which the parties are advancing ALN-APP and ALN-PNP, which are currently in clinical development) or License Agreement structure. The initial target nomination and discovery period is five years (which may under certain situations automatically be extended for up to seven years in the aggregate) (the "Research Term"). In addition, the Company has an option to extend the Research Term for an additional five-year period for a research extension fee ranging from $200.0&#160;million to $400.0&#160;million; the actual amount of the fee will be determined based on the acceptance of one or more Investigational New Drug Applications ("INDs") (or their equivalent in certain other countries) for programs in the eye and CNS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2019, the parties entered into a Co-Co Collaboration Agreement for cemdisiran, a small interfering RNA ("siRNA") therapeutic targeting the C5 component of the human complement pathway being developed by Alnylam, with Alnylam as the lead party, and a License Agreement for a combination consisting of cemdisiran and a fully human monoclonal antibody targeting C5 being developed by the Company (pozelimab), with the Company as the licensee. Under the C5 siRNA Co-Co Collaboration Agreement, the parties shared costs equally and under the License Agreement, the Company as the licensee is responsible for its own costs and expenses. The C5 siRNA License Agreement contains a flat low double-digit royalty payable to Alnylam on potential future net sales of the combination only subject to customary reductions, as well as up to $325.0&#160;million in sales milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company elected to opt-out of further development activities pursuant to the Co-Co Collaboration Agreement for cemdisiran as a monotherapy; as a result, Alnylam retains the right to develop and commercialize such product and the Company will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Alnylam agreements described above were not material for the years ended December 31, 2022, 2021, and 2020. In addition, contract balances in the Company's Balance Sheets were not material as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">g. Checkmate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. (&#8220;Checkmate&#8221;) for a total equity value of approximately $250&#160;million. The Company made an assessment as to whether the set of assets acquired constituted a business and should be accounted for as a business combination. Given that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, vidutolimod, which is in clinical development for oncology, the transaction was accounted for as an asset acquisition. As a result of the acquisition, the Company recorded (i) a charge of $195.0&#160;million to Acquired in-process research and development and (ii) net assets of $35.3&#160;million, net of cash, related to the assets acquired (including deferred tax assets and investments) and liabilities assumed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">h. Teva </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Teva are parties to a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to the Company's collaboration agreement with Mitsubishi Tanabe Pharma Corporation. Under the terms of the Teva Collaboration Agreement, the Company led global development activities and the parties share development costs equally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, Teva made a $250.0 million non-refundable up-front payment in 2016, and as of December 31, 2022, the Company had received an aggregate $120.0&#160;million of development milestones from Teva. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.206%"><tr><td style="width:1.0%"/><td style="width:37.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.736%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company recognized reimbursement of R&amp;D expenses (as a reduction of R&amp;D expense) of $42.4 million and $109.4 million for the years ended December 31, 2021 and 2020, respectively. Such amount was not material for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities included up-front and development milestone payments received from Teva for which recognition had been deferred. During 2022, the Company discontinued further clinical development of fasinumab and, as a result, recorded $31.9&#160;million as an increase to Other operating income as the Company deemed its obligation to provide development services in connection with the Teva Collaboration Agreement to be complete.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaboration agreements discussed above, the Company has various other collaboration agreements that are not individually significant to its operating results or financial condition at this time. Pursuant to the terms of those agreements, the Company may be required to pay, or it may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones) which in the aggregate could be significant. The Company may also incur, or get reimbursed for, significant research and development costs. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay, or it may receive, royalties on future sales. The payment or receipt of these amounts, however, is contingent upon the occurrence of various future events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583137924304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of December&#160;31, 2022 and 2021 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 5) as well as equity securities of publicly traded companies (see Note 5). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"/><td style="width:53.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of December&#160;31, 2022 mature at various dates through April 2028. The fair values of available-for-sale debt securities by contractual maturity consist of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.235%"><tr><td style="width:1.0%"/><td style="width:65.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.884%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.884%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.737%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,645.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,633.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,889.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,889.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses on corporate bonds as of December 31, 2022 were primarily driven by increases in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to marketable securities, for the years ended December 31, 2022, 2021, and 2020, amounts reclassified from Accumulated other comprehensive income (loss) into Other income (expense), net were related to realized gains and losses on sales of available-for-sale debt securities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of marketable securities were not material for the years ended December 31, 2022, 2021, and 2020. Interest income of $160.1 million, $45.8 million, and $75.4 million for the years ended December 31, 2022, 2021, and 2020, respectively, was recognized in Other income (expense), net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583139126240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.965%"><tr><td style="width:1.0%"/><td style="width:49.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,228.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,647.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of December&#160;31, 2022 which are subject to transfer restrictions that expire at various dates throug</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded $39.8 million of net unrealized losses on equity securities in Other income (expense), net. During the years ended December 31, 2021 and 2020, the Company recorded $386.1 million, and $196.0 million, respectively, of net unrealized gains on equity securities in Other income (expense), net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above, as of December&#160;31, 2022 and 2021, the Company had $48.3 million and $40.0 million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's long-term debt (see Note 10), which was determined based on Level 2 inputs, was estimated to be</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.443 billion and $1.887 billion as of December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133816560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.477%"><tr><td style="width:1.0%"/><td style="width:48.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,401.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances in the table above are net of reserves of $720.7 million and $510.0 million as of December&#160;31, 2022 and 2021, respectively. Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred. For the years ended December&#160;31, 2022 and 2021, Cost of goods sold included inventory write-offs and reserves of $258.7&#160;million and $457.1&#160;million, respectively, primarily related to REGEN-COV. Inventory write-offs and reserves for the year ended December&#160;31, 2020 were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133577024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant, and Equipment<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.201%"><tr><td style="width:1.0%"/><td style="width:46.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office equipment, and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,432.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less, accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,669.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,398.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment in the table above includes leased property under the Company's finance lease at its Tarrytown, New York facility. See Note 11.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense on property, plant, and equipment was $303.9 million, $281.1 million, and $230.8 million for the years ended December 31, 2022, 2021, and 2020, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, $2.960&#160;billion and $2.684&#160;billion, respectively, of the Company's net property, plant, and equipment was located in the United States and $803.0&#160;million and $797.8&#160;million, respectively, was located outside the United States (primarily in Ireland).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133633120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired product rights - Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#8211;8 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, the Company recorded an intangible asset in connection with obtaining the exclusive right to develop, commercialize, and manufacture Libtayo worldwide. The intangible asset recognized upon the effective date of the A&amp;R IO LCA primarily consisted of the $900.0&#160;million up-front payment, offset by the remaining IO Collaboration Other liabilities balance of $241.0&#160;million. During the year ended December&#160;31, 2022, the Company recorded additions to the Libtayo intangible asset primarily related to contingent consideration (including regulatory and sales-based milestones, as described in Note 3) and other amounts due to Sanofi in connection with obtaining the worldwide rights to Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets was $37.6&#160;million for the year ended December 31, 2022. Amortization expense for the years ended December 31, 2021 and 2020 was not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, assuming no changes in the gross carrying amount of intangible assets, amortization expense is estimated to be approximately $72&#160;million for each of the years ending December 31, 2023 through December 31, 2027.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133536496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.040%"><tr><td style="width:1.0%"/><td style="width:49.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaborators (see Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133568848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into an agreement with a syndicate of lenders (the "2018 Credit Agreement") which provided for a $750.0 million senior unsecured five-year revolving credit facility. The 2018 Credit Agreement, which was to mature in December 2023, included an option for the Company to elect to increase the commitments under the Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $250.0&#160;million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into an agreement with a syndicate of lenders (the "2022 Credit Agreement") which provides for a $750.0&#160;million senior unsecured five-year revolving credit facility (the "2022 Credit Facility") and replaces the 2018 Credit Agreement, which was contemporaneously terminated. The 2022 Credit Agreement includes an option for the Company to elect to increase the commitments under the 2022 Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $500.0&#160;million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions. The 2022 Credit Agreement also provides a $50.0&#160;million sublimit for letters of credit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth in the 2022 Credit Agreement, the Company has the option to amend the 2022 Credit Agreement to establish environmental, social, and governance targets which will be used to adjust pricing under the 2022 Credit Facility, subject to parameters to be provided in the 2022 Credit Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds of the loans under the 2022 Credit Facility may be used to finance working capital needs, and for general corporate or other lawful purposes, of Regeneron and its subsidiaries. Regeneron Pharmaceuticals, Inc. has guaranteed all obligations under the 2022 Credit Facility. The 2022 Credit Agreement includes an option for the Company to elect to extend the maturity date of the 2022 Credit Facility beyond December 2027, subject to the consent of the extending lenders and certain other conditions. Amounts borrowed under the 2022 Credit Facility may be prepaid, and the commitments under the 2022 Credit Facility may be terminated, at any time without premium or penalty. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no borrowings outstanding under the 2022 Credit Facility as of December&#160;31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement contains operating covenants and a maximum total leverage ratio financial covenant. The Company was in compliance with all covenants of the 2022 Credit Agreement as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 and $750 million aggregate principal amount of senior unsecured notes due 2050 (collectively, the "Notes"). The underwriting discounts and offering expenses are being amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt in connection with the Notes, net of underwriting discounts and offering expenses, consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:29.25pt;padding-right:29.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.149%"><tr><td style="width:1.0%"/><td style="width:61.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750% Senior Notes due September 2030</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.800% Senior Notes due September 2050</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates. Interest expense related to the Notes was $44.3&#160;million, $44.4&#160;million, and $17.6&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at the Company&#8217;s option at any time at 100% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest. The Notes also contain certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132606720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies&#160;&#160;&#160;&#160;<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16 for disclosures related to legal contingencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts certain of its research, development, and administrative activities at leased facilities. The Company also leases vehicles and other assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Consolidated Balance Sheets and Statements of Operations included in this report associated with operating leases were not material. Operating lease right-of-use assets are included within Other noncurrent assets, and lease liabilities are included in Accrued expenses and other current liabilities and Other noncurrent liabilities.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a Participation Agreement with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing &amp; Capital LLC ("BAL"), as lessor, and a syndicate of lenders (collectively with BAL, the "Lease Participants"), which provided for $720.0&#160;million of lease financing from the Lease Participants for the acquisition of laboratory and office facilities in Tarrytown, New York (the "Facility"). In March 2017, the Company also entered into a Lease and Remedies Agreement with BAL, pursuant to which the Company leased the Facility from BAL for a&#160;five-year term which ended in March 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into a Second Amended and Restated Lease and Remedies Agreement (the "Restated Lease") with BAL, as lessor (the "Lessor"), which amends, restates, and extends its lease of the Facility. In March 2022, the Company also entered into a Second Amended and Restated Participation Agreement (the "Restated Participation Agreement") with Bank of America, N.A., as administrative agent, the Lessor, and a syndicate of financial institutions as rent assignees (collectively with the Lessor, the "Participants"), which amends and restates the original Participation Agreement entered into in March 2017. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Participation Agreement and certain related agreements were amended and restated in order to, among other things, (i) effect a&#160;five-year extension of the original March 2022 maturity date of the $720.0&#160;million lease financing and the end of the term of the Company's lease of the Facility from the Lessor to March 2027, at which time all amounts outstanding thereunder will become due and payable in full, and (ii) modify the rate of the interest or yield that is payable to the Participants. In accordance with the terms of the Restated Lease, the Company continues to pay all maintenance, insurance, taxes, and other costs arising out of the use of the Facility. The Company is also required to make monthly payments of basic rent during the term of the Restated Lease in an amount equal to a variable rate per annum, which was modified in connection with the Restated Lease, to be an adjusted one-month forward-looking term rate based on the Secured Overnight Financing Rate ("SOFR"), plus an applicable margin that varies with the Company's debt rating and total leverage ratio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Participation Agreement and Restated Lease include an option for the Company to elect to further extend the maturity date of the Restated Participation Agreement and the term of the Restated Lease for an additional five-year period, subject to the consent of all the Participants and certain other conditions. The Company also has the option prior to the end of the term of the Restated Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants' advances under the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Participation Agreement, Restated Lease, and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the original lease, the Restated Lease continues to be classified as a finance lease as the Company has the option to purchase the Facility under terms that make it reasonably certain to be exercised. The agreements governing the Restated Lease financing contain financial and operating covenants. Such financial covenants and certain of the operating covenants are substantially similar to the covenants set forth in the Company's $750.0 million 2018 Credit Agreement. The Company was in compliance with all such covenants as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Consolidated Balance Sheet related to the Lease are included in the table below. Other than the Lease described above, the Company had no leases accounted for as finance leases as of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"/><td style="width:30.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Finance lease right-of-use assets were recorded net of accumulated amortization of $119.4 million and $104.9 million as of December&#160;31, 2022 and 2021, respectively.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.160%"><tr><td style="width:1.0%"/><td style="width:52.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to the Company's finance lease includes the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"><tr><td style="width:1.0%"/><td style="width:51.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.562%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental information </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of the Company's finance lease liability:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.908%"><tr><td style="width:1.0%"/><td style="width:60.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Research Collaboration and Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with other companies, universities, and other organizations. These agreements contain varying terms and provisions which include fees to be paid by the Company, services to be provided, and license rights to certain proprietary technology developed under the agreements. Some of these agreements may require the Company to pay additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones). Additionally, the Company has in-licensed patent and/or technology pursuant to agreements which contain provisions that require the Company to pay royalties, as defined, at rates that range from 0.5% to 12.0%, in the event the Company sells or licenses any proprietary products developed under the respective agreements. The Company also has contingent reimbursement obligations to its collaborators Sanofi and Bayer out of the respective collaboration's profits, if they are sufficient for that purpose. See Note 3 for a more detailed description of collaboration, license, and other agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, as a result of obtaining worldwide rights to Libtayo, the Company pays Sanofi a royalty on net product sales of Libtayo. In addition, in 2018, the Company and Sanofi entered into a license agreement with Bristol-Myers Squibb Company, E. R. Squibb &amp; Sons, L.L.C., and Ono Pharmaceutical Co., Ltd. to obtain a license under certain patents owned and/or exclusively licensed by one or more of those parties that includes the right to develop and sell Libtayo. Under the agreement, the Company is obligated to pay royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and royalties of 2.5% from January 1, 2024 through December 31, 2026. Prior to July 1, 2022, royalties on such sales were shared equally by the Company and Sanofi.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, the Company recorded royalty expense (net of reimbursements from collaborators, as applicable) in Cost of goods sold and Cost of collaboration and contract manufacturing of $84.5 million, $66.9 million, and $56.5 million, respectively, based on product sales under various licensing agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133568848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Restated Certificate of Incorporation, as amended, provides for the issuance of up to 40 million shares of Class A Stock, par value $0.001 per share, and 320 million shares of Common Stock, par value $0.001 per share. Shares of Class A Stock are convertible, at any time, at the option of the holder into shares of Common Stock on a share-for-share basis. Holders of Class A Stock have rights and privileges identical to Common Stockholders except that each share of Class A is entitled to ten votes per share, while each share of Common Stock is entitled to one vote per share. Class A Stock may only be transferred to specified Permitted Transferees, as defined. Under the Company's Restated Certificate of Incorporation, the Company's board of directors is authorized to issue up to 30 million shares of Preferred Stock, in series, with rights, privileges, and qualifications of each series determined by the board of directors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company's board of directors authorized a share repurchase program to repurchase up to $1.0&#160;billion of the Company's Common Stock. The share repurchase program permitted the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $1.0&#160;billion it was authorized to repurchase under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company's board of directors authorized a share repurchase program to repurchase up to $1.5&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program described above. As of December&#160;31, 2021, the Company had repurchased the entire $1.5&#160;billion of its Common Stock that it was authorized to repurchase under the program.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company's board of directors authorized an additional share repurchase program to repurchase up to $3.0&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. As of December&#160;31, 2022, $745.2&#160;million remained available for share repurchases under the November 2021 program.</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of the Company's Common Stock it repurchased under the programs and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.701%"><tr><td style="width:1.0%"/><td style="width:48.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company's board of directors authorized a new share repurchase program to repurchase up to an additional $3.0&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company and Sanofi entered into an agreement, which, among other things, granted Sanofi a limited waiver of Sanofi's lock-up obligations under the amended and restated investor agreement between the Company and Sanofi in order to allow Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or certain activities relating to dupilumab and itepekimab incurred in quarterly periods through September 30, 2020 by selling shares of the Company's Common Stock owned by Sanofi. During 2020, Sanofi elected to sell, and the Company elected to purchase, shares of our Common Stock to satisfy Sanofi's funding obligation related to such activities. Consequently, the Company recorded the cost of the shares received, or $135.0&#160;million, as Treasury Stock during 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Stock Purchased from Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of 13,014,646 shares of the Company's Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, the Company also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5.0&#160;billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of the Company's Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (a portion of which Sanofi used for the funding of certain development costs described above).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an amendment to the amended and restated investor agreement, which provides, among other things, that following the Secondary Offering and Stock Purchase, the &#8220;standstill&#8221; provisions, which contractually prohibit Sanofi from seeking to directly or indirectly exert control of the Company, continue to apply pursuant to their terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arrangements with Other Collaborators</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's license and collaboration agreement with Bayer for the joint development and commercialization outside the United States of antibody product candidates to Ang2, Bayer is bound by certain "standstill" provisions, which contractually prohibit Bayer from seeking to influence the control of the Company or acquiring more than 20% of the Company's outstanding shares of Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the termination of the agreement (which will occur on November 1, 2023) or (ii) other specified events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, pursuant to the 2016 Teva Collaboration Agreement, Teva and its affiliates are bound by certain "standstill" provisions, which contractually prohibit them from seeking to directly or indirectly exert control of the Company or acquiring more than 5% of the Company's Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the expiration or earlier termination of the agreement or (ii) other specified events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133660720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Long-Term Incentive Plans</a></td>
<td class="text">Long-Term Incentive Plans<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and non-employees, including non-employee members of the Company's board of directors (collectively, "Participants"). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the "Committee"). The incentive plan currently used by the Company is the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Second Amended and Restated 2014 Incentive Plan"). It was most recently adopted and approved by the Company's shareholders in 2020. As of the most recent shareholder approval date, the Second Amended and Restated 2014 Incentive Plan provided for the issuance of up to 22.3 million shares of Common Stock in respect of awards. In addition, upon expiration, forfeiture, surrender, exchange, cancellation, or termination of any award previously granted under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Amended and Restated 2014 Incentive Plan"), the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Original 2014 Incentive Plan"), or the Second Amended and Restated 2000 Long-Term Incentive Plan (the "2000 Incentive Plan"), any shares subject to such award are added to the pool of shares available for grant under the Second Amended and Restated 2014 Incentive Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The awards that may be made under the Second Amended and Restated 2014 Incentive Plan include: (a) incentive stock options and non-qualified stock options, (b) restricted stock awards, (c) shares of phantom stock (also referred to as restricted stock units, which may be time- or performance-based), and (d) other awards. Any award granted may (but is not required to) be subject to vesting based on the attainment by the Company of performance goals pre-established by the Committee. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards grant Participants the right to purchase shares of Common Stock at prices determined by the Committee, with exercise prices that are equal to or greater than the average of the high and low market prices of the Company's Common Stock on the date of grant (the "Market Price"). Options vest over a period of time determined by the Committee, generally on a </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pro rata basis over a four-year period. The Committee also determines the expiration date of each option. The maximum term of options that have been awarded under the 2000 Incentive Plan, the Original 2014 Incentive Plan, the Amended and Restated 2014 Incentive Plan, and the Second Amended and Restated 2014 Incentive Plan (collectively, the "Incentive Plans") is ten years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards grant Participants shares of restricted Common Stock or allow Participants to purchase such shares at a price determined by the Committee. Such shares are nontransferable for a period determined by the Committee ("vesting period"). Should employment terminate, as specified in the Incentive Plans, except as determined by the Committee in its discretion and subject to the applicable Incentive Plan documents, the ownership of any unvested restricted stock awards will be transferred to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phantom stock awards provide the Participant the right to receive Common Stock or an amount of cash based on the value of the Common Stock at a future date. The award is subject to such restrictions, if any, as the Committee may impose at the date of grant or thereafter, including a specified period of employment or the achievement of performance goals. Time-based restricted stock units and performance-based restricted stock units are each a type of phantom stock award permitted under the Second Amended and Restated 2014 Incentive Plan.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Incentive Plans contain provisions that allow for the Committee to provide for the immediate vesting of awards upon a change in control of the Company, as defined in the Incentive Plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there were 15.9 million shares available for future grants under the Second Amended and Restated 2014 Incentive Plan. No additional awards may be made under the 2000 Incentive Plan, the Original 2014 Incentive Plan, or the Amended and Restated 2014 Incentive Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions involving stock option awards during 2022 under the Company's Incentive Plans are summarized in the table below.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.045%"><tr><td style="width:1.0%"/><td style="width:5.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.031%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic Value </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,685.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfies stock option exercises with newly issued shares of the Company's Common Stock. The total intrinsic value of stock options exercised during 2022, 2021, and 2020 was $1.214 billion, $1.707&#160;billion, and $2.251&#160;billion, respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2022, 2021, and 2020. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.678%"><tr><td style="width:1.0%"/><td style="width:47.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options Granted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021, and 2020, the Company recognized $341.9 million, $328.7&#160;million, and $329.5&#160;million, respectively, of stock-based compensation expense related to stock option awards (net of amounts capitalized as inventory, which were not material for each of the three years). As of December 31, 2022, there was $572.0 million of stock-based compensation cost related to unvested stock options, net of estimated forfeitures, which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2022, 2021, and 2020.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.770%"><tr><td style="width:1.0%"/><td style="width:48.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives from grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility has been estimated based on actual movements in the Company's stock price over the most recent historical periods equivalent to the options' expected lives. Expected lives are principally based on the Company's historical exercise experience with previously issued employee and board of directors' option grants. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the options' expected lives.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards and Time-Based Restricted Stock Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's activity related to restricted stock awards and time-based restricted stock units (excluding performance-based restricted stock units, which are detailed further below) (collectively, "restricted stock") during 2022 is summarized below. </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"><tr><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.491%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares/Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant <br/>Date Fair Value</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021, and 2020, the Company recognized $331.1 million, $221.0 million, and $102.5 million, respectively, of stock-based compensation expense related to restricted stock (net of amounts capitalized as inventory, which were not material for each of the three years). As of December 31, 2022, there was $907.7 million of stock-based </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation cost related to unvested restricted stock which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period of 2.1 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance-based restricted stock units ("PSUs") have been granted to certain members of senior management of the Company. PSUs may be earned based upon the attainment of pre-established performance criteria, which may include a market and/or performance condition. Depending on the terms of the PSUs and the outcome of the pre-established performance criteria, a recipient may ultimately earn the target number of PSUs granted or a specified multiple thereof at the end of a 4&#8211;6 year vesting period, as applicable.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes activity related to PSUs during 2022. The number of PSUs granted represents the maximum number of units that are eligible to be earned.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"><tr><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.491%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares/Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant <br/>Date Fair Value</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended December 31, 2022, and 2021, the Company recognized $52.0&#160;million of stock-based compensation expense related to PSUs. The Company did not recognize stock-based compensation expense related to PSUs in 2020 (as PSUs granted in 2020 were granted on December 31, 2020 and are expensed over the vesting period). As of December 31, 2022, there was $156.1&#160;million of stock-based compensation cost related to unvested PSUs which had not yet been recognized. The Company expects to recognize this compensation cost on a straight-line basis over a weighted average period of 3.3 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average values of the assumptions used in computing the fair value of PSUs that were granted during 2022 and 2020. The Company did not grant PSUs during 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.431%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133541984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Savings Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Savings Plans</a></td>
<td class="text">Employee Savings Plans<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the Regeneron Pharmaceuticals, Inc. 401(k) Savings Plan, as amended and restated (the "Savings Plan"). The terms of the Savings Plan allow U.S. employees (as defined by the Savings Plan) to contribute to the Savings Plan a percentage of their compensation. In addition, the Company may make discretionary contributions, as defined, to the accounts of participants under the Savings Plan. The Company also maintains additional employee savings plans outside of the United States, which cover eligible employees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses recognized by the Company related to contributions to such plans were $67.6&#160;million, $55.5&#160;million, and $49.9&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133790864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, state, and foreign income taxes. Components of income before income taxes consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.448%"><tr><td style="width:1.0%"/><td style="width:27.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,944.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,018.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,381.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,325.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.109%"><tr><td style="width:1.0%"/><td style="width:43.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. statutory income tax rate to the Company's effective income tax rate is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.080%"><tr><td style="width:1.0%"/><td style="width:56.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxation of non-U.S. operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-inventory related assets between foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.488%"><tr><td style="width:1.0%"/><td style="width:68.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.154%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax attribute carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's federal income tax returns for 2017 through 2021 remain open to examination by the IRS. The Company's 2017 and 2018 federal income tax returns are currently under audit by the IRS. In general, the Company's state income tax returns from 2018 to 2021 remain open to examination. The Company's income tax returns outside of the United States remain open to examination from 2018 to 2021. The United States and many states generally have statutes of limitation ranging from 3 to 5 years; however, those statutes could be extended due to the Company's tax credit carryforward position. In general, tax authorities have the ability to review income tax returns in which the statute of limitation has previously expired to adjust the tax credits generated in those years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net unrecognized tax benefits that, if settled, would impact the effective tax rate is $373.7 million, $321.1 million, and $267.0 million as of December 31, 2022, 2021, and 2020, respectively. The following table reconciles the beginning and ending amounts of unrecognized tax benefits. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"/><td style="width:58.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross (decreases) increases related to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases due to settlements and lapse of statutes of limitations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, 2021, and 2020, the increases in unrecognized tax benefits primarily related to the Company's calculation of certain tax credits and other items related to the Company's international operations. The decrease in unrecognized tax benefits in 2021 was related to the closing of audits for the Company's federal income tax returns for 2015 and 2016. Interest expense related to unrecognized tax benefits was not material in 2022, 2021, and 2020. The Company does not believe that it is reasonably possible that the resolution of tax exposures within the next twelve months would have a material impact on the consolidated financial statements as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 ("IRA") was signed into law in the United States. The IRA created a new corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases. The provisions of the IRA will be effective for periods beginning after December&#160;31, 2022. The enactment of the IRA did not result in any material adjustments to the Company's income tax provisions or net deferred tax assets as of December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133660720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of December 31, 2022 and 2021, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. In addition, as described below, the Company filed a lawsuit against Amgen alleging that Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As previously reported, on February 11, 2021, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc with the Federal Circuit, which was denied on June 21, 2021. On November 4, 2022, the United States Supreme Court granted Amgen's petition for writ of certiorari. An oral hearing has been scheduled for March 27, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, the Company filed a lawsuit against Amgen in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1, 2022, Amgen filed a motion to dismiss the complaint. On August 11, 2022, Amgen filed a motion to stay these proceedings pending resolution of the patent litigation described in the preceding paragraph. An oral hearing on Amgen's motion to dismiss and motion to stay has been scheduled for January 6, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in certain countries in Europe. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). Following the EPO's decision, each of the '124 Patent infringement proceedings initiated by Amgen against the Company and certain of Sanofi's affiliated entities in these countries was dismissed, including in Germany. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. As a result of the overturned injunction in Germany discussed in the preceding sentence, the Company and/or certain of Sanofi's affiliated entities are seeking damages caused by Amgen's enforcement of the injunction. As part of its opposition to these damages claims, on March 23, 2022, Amgen filed a counterclaim that asserted the German designation of European Patent No. 2,641,917 (the "'917 Patent") and seeks, among other things, a judgment of patent infringement, injunctive relief, and monetary damages. The '917 Patent is a divisional patent of the '124 Patent discussed above (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent but contains claims to a different invention). The '917 Patent is also subject to opposition proceedings in the EPO, which were initiated by Sanofi on May 5, 2021. An oral hearing before the EPO has been scheduled for February 21, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Dupixent (dupilumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), a patent owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the EPO opposition proceedings initiated </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018, which appeal was withdrawn at an oral hearing before the TBA on March 10, 2022 following the TBA's ruling discussed below. On May 18, 2022, the revocation action in the U.K. Patents Court was dismissed following the EPO's revocation of the '665 Patent. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#8211;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019. At an oral hearing before the TBA on March 10, 2022, the TBA maintained the invalidity and revocation of the '420 Patent. The original patent term of the Immunex patents expired in May 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, anonymous parties filed two requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of the Company's U.S. Patent Nos. 10,406,226 and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests to initiate reexamination proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, Mylan Pharmaceuticals Inc. filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review ("IPR") petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent. On November 10, 2021, the USPTO issued a decision instituting both IPR proceedings. On December 9, 2021, Apotex Inc. and Celltrion, Inc. each filed two separate IPR petitions against the Company's '338 and '069 Patents requesting that their IPRs be instituted and joined with the IPR proceedings initiated by Mylan concerning the '338 and '069 Patents, which petitions were granted on February 9, 2022. An oral hearing was held on August 10, 2022. On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2021, Celltrion, Inc. filed a post-grant review ("PGR") petition in the USPTO against the Company's U.S. Patent No. 10,857,231 (the "'231 Patent") seeking a declaration of invalidity of the '231 Patent. On March 14, 2022, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '231 Patent. As a result, on March 15, 2022, the USPTO denied institution of Celltrion's PGR petition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Mylan filed IPR petitions against the Company's U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") (each filed July 1, 2022) and 10,857,205 (filed October 28, 2022) seeking declarations of invalidity of each of these patents. On January 11, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent. On January 6, 2023, Samsung Bioepis Co., Ltd. filed a separate IPR petition against the Company's '681 Patent seeking a declaration of invalidity of the '681 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2022, Apotex filed an IPR petition against the Company's U.S. Patent No. 11,253,572 (the "'572 Patent") seeking a declaration of invalidity of the '572 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2023, Celltrion, Inc. filed an IPR petition against the '992 Patent seeking a declaration of invalidity of the '992 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for a U.S. Food and Drug Administration approval of an aflibercept biosimilar infringes certain Company patents. A trial has been scheduled to begin on June 12, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Canada</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, July 15, August 30, and October 4, 2022, the Company and Bayer Inc. filed patent infringement lawsuits against BGP Pharma ULC d.b.a Viatris Canada ("Viatris Canada") in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent) and 3,007,276 (the "'276 Patent") (in the lawsuit filed on June 15, 2022); the Company's Canadian Patent No. 2,965,495 (the "'495 Patent") (in the lawsuit filed on July 15, 2022); the Company's Canadian Patent No. 2,906,768 (the "'768 Patent") (in the lawsuit filed on August 30, 2022, which has been joined with the lawsuit filed on July 15, 2022); and the Company's Canadian Patent No. 3,129,193 (the "'193 Patent") (in the lawsuit filed on October 4, 2022). A trial for the lawsuit concerning the '510 Patent and the '276 Patent has been scheduled for March 2024; a trial for the lawsuit concerning the '193 Patent has been scheduled for May 2024; and a trial for the lawsuit concerning the '495 Patent and the '768 Patent has been scheduled for November/December 2024. The filing of the lawsuit concerning the '510 Patent and the '276 Patent resulted in a statutory 24-month stay of regulatory approval of Viatris Canada's aflibercept biosimilar in Canada unless the lawsuit is resolved earlier.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">South Korea</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811, respectively, seeking revocation of each of such patents in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#8217;s U.S. Patent No. 9,220,631 (the "'631 Patent"). The ITC instituted the investigation on July 22, 2020 and a trial was scheduled for April 19&#8211;23, 2021. On March 26, 2021, the staff attorney appointed by the ITC's Office of Unfair Import Investigations ("OUII")&#8212;an independent government party to the case representing the public interest&#8212;determined that the '631 Patent is invalid on several grounds. On April 8, 2021, Novartis moved to terminate the ITC investigation in its entirety based on its withdrawal of the complaint; and, on May 3, 2021, the ITC terminated the investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis also filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On January 15, 2021, the USPTO declined to institute an IPR proceeding on procedural grounds in light of the pending ITC investigation discussed above; the other IPR petition has been withdrawn. Following Novartis's motion to terminate the ITC investigation discussed above, on April 16, 2021 the Company filed a new IPR petition seeking a declaration of invalidity of the '631 Patent based on the same grounds that were the basis for the OUII staff attorney's determination discussed above. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On November 5, 2021, the Company filed a motion to stay these proceedings in light of the pending IPR proceeding discussed above. On January 31, 2022, the court denied the Company's motion to stay these proceedings and granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney&#8217;s Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to CMS. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Department of Insurance Subpoena</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Initiated by Other Payors Relating to Patient Assistance Organization Support</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to several lawsuits relating to the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court discussed under "Department of Justice Matters" above; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Shareholder Demands</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 30, 2020, March 30, 2022, and March 31, 2022, the Company's board of directors received three demand letters from purported shareholders of the Company. The demands allege that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letters request that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, investigated and evaluated the allegations in the demand letters and has concluded that pursuing the claims alleged in the demands would not be in the Company's best interests at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Shareholder Derivative Complaint</span></div>On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 23, 2021, the plaintiff moved to remand the case to the New York Supreme Court. Also on September 23, 2021, the individual defendants moved to dismiss the complaint in its entirety. On December 19, 2022, the U.S. District Court for the Southern District of New York denied the plaintiff's motion to remand the case and granted a motion to stay the case pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. As a result of the stay, the court also terminated the Company's motion to dismiss the complaint without prejudice to renew upon conclusion of the stay.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133640416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted net income per share are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.155%"><tr><td style="width:1.0%"/><td style="width:56.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"/><td style="width:57.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133450240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text">Statement of Cash Flows<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"><tr><td style="width:1.0%"/><td style="width:50.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.747%"><tr><td style="width:1.0%"/><td style="width:37.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payments for Libtayo intangible asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132293248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Regeneron and its wholly-owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the first quarter of 2022, the Company added a new line item, Acquired in-process research and development, to its Consolidated Statements of Operations and Comprehensive Income. This line item includes in-process research and development acquired in connection with asset acquisitions as well as up-front/opt-in payments related to license and collaboration agreements. Amounts recorded in this line item during the year ended December 31, 2022 would have historically been recorded to Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation, including in connection with the addition of Acquired in-process research and development described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain investments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties.  </span></div>Concentrations of credit risk with respect to customer and collaborator accounts receivable are significant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. The carrying amount reported in the Consolidated Balance Sheet for cash and cash equivalents approximates its fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Debt and Equity Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt and Equity Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. The Company invests its cash primarily in debt securities. The Company considers its investments in debt securities to be "available-for-sale," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Realized gains and losses on available-for-sale debt securities are included in other income (expense), net. The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in net income, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss). </span></div>The Company also has investments in equity securities that are carried at fair value with changes in fair value recognized within other income (expense), net. The Company has elected to measure certain equity investments it holds that do not have readily determinable fair values at cost less impairment, if any, and adjusts for observable price changes in orderly transactions for identical or similar investments of the same issuer within other income (expense), net.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableThe Company's trade accounts receivable arise from product sales and represent amounts due from its customers. In addition, the Company records accounts receivable arising from its collaboration and licensing agreements. The Company monitors the financial performance and credit worthiness of its counterparties so that it can properly assess and respond to changes in their credit profile. The Company provides allowances against receivables for estimated losses, if any, that may result from a counterparty's inability to pay. Amounts determined to be uncollectible are written-off against the allowance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such inventory to its estimated realizable value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant, and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Costs of construction of certain long-lived assets include capitalized interest, which is amortized over the estimated useful life of the related asset. Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized within income from operations. The estimated useful lives of property, plant, and equipment are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"><tr><td style="width:1.0%"/><td style="width:67.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#8211;50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr></table></div>The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease considering whether there is an identified asset and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company's lease terms may include options to extend or terminate a lease when it is reasonably certain that it will exercise that option. The Company accounts for lease components (e.g., rental payments) separately from non-lease components (e.g., common area maintenance costs).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, unless there is a transfer of title or purchase option the Company is reasonably certain to exercise. For leases where an implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on information available at the lease commencement date to determine the present value of future lease payments. Lease expense for operating leases is recognized on a straight-line basis over the expected lease term.</span></div>Leases<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts certain of its research, development, and administrative activities at leased facilities. The Company also leases vehicles and other assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Consolidated Balance Sheets and Statements of Operations included in this report associated with operating leases were not material. Operating lease right-of-use assets are included within Other noncurrent assets, and lease liabilities are included in Accrued expenses and other current liabilities and Other noncurrent liabilities.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a Participation Agreement with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing &amp; Capital LLC ("BAL"), as lessor, and a syndicate of lenders (collectively with BAL, the "Lease Participants"), which provided for $720.0&#160;million of lease financing from the Lease Participants for the acquisition of laboratory and office facilities in Tarrytown, New York (the "Facility"). In March 2017, the Company also entered into a Lease and Remedies Agreement with BAL, pursuant to which the Company leased the Facility from BAL for a&#160;five-year term which ended in March 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into a Second Amended and Restated Lease and Remedies Agreement (the "Restated Lease") with BAL, as lessor (the "Lessor"), which amends, restates, and extends its lease of the Facility. In March 2022, the Company also entered into a Second Amended and Restated Participation Agreement (the "Restated Participation Agreement") with Bank of America, N.A., as administrative agent, the Lessor, and a syndicate of financial institutions as rent assignees (collectively with the Lessor, the "Participants"), which amends and restates the original Participation Agreement entered into in March 2017. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Participation Agreement and certain related agreements were amended and restated in order to, among other things, (i) effect a&#160;five-year extension of the original March 2022 maturity date of the $720.0&#160;million lease financing and the end of the term of the Company's lease of the Facility from the Lessor to March 2027, at which time all amounts outstanding thereunder will become due and payable in full, and (ii) modify the rate of the interest or yield that is payable to the Participants. In accordance with the terms of the Restated Lease, the Company continues to pay all maintenance, insurance, taxes, and other costs arising out of the use of the Facility. The Company is also required to make monthly payments of basic rent during the term of the Restated Lease in an amount equal to a variable rate per annum, which was modified in connection with the Restated Lease, to be an adjusted one-month forward-looking term rate based on the Secured Overnight Financing Rate ("SOFR"), plus an applicable margin that varies with the Company's debt rating and total leverage ratio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Participation Agreement and Restated Lease include an option for the Company to elect to further extend the maturity date of the Restated Participation Agreement and the term of the Restated Lease for an additional five-year period, subject to the consent of all the Participants and certain other conditions. The Company also has the option prior to the end of the term of the Restated Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants' advances under the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Participation Agreement, Restated Lease, and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the original lease, the Restated Lease continues to be classified as a finance lease as the Company has the option to purchase the Facility under terms that make it reasonably certain to be exercised. The agreements governing the Restated Lease financing contain financial and operating covenants. Such financial covenants and certain of the operating covenants are substantially similar to the covenants set forth in the Company's $750.0 million 2018 Credit Agreement. The Company was in compliance with all such covenants as of December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company makes a determination of whether an asset or set of assets acquired constitute a business. If it is determined that substantially all of the fair value of gross assets acquired in a transaction are concentrated in a single identifiable asset, then the transaction is accounted for as an asset acquisition. Intangible assets acquired in connection with an asset acquisition are recorded at cost. Such amounts may include up-front payments and contingent consideration. With regard to contingent consideration, the Company recognizes regulatory milestones upon achievement, royalties in the period in which the underlying sales occur, and sales-based milestones when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets are amortized to Cost of goods sold over the estimated useful lives of the assets based on the pattern in which the economic benefits of the intangible assets are consumed; if that pattern cannot be reliably determined, a straight-line basis is used. If contingent consideration is recognized subsequent to the acquisition date in an asset acquisition, the amount of such consideration is recorded as an addition to the cost basis of the intangible asset with a cumulative catch-up adjustment for amortization expense as if the additional amount of consideration had been accrued from the outset of the acquisition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's intangible assets are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If an indicator of impairment exists, the Company compares the projected undiscounted cash flows to be generated by the asset to the intangible asset's carrying amount. If the projected undiscounted cash flows of the intangible asset are less than the carrying amount, the intangible asset is written down to its fair value in the period in which the impairment occurs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition - Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized at a point in time when the Company's customer is deemed to have obtained control of the product, which generally occurs upon receipt or acceptance by its customer. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue the Company recognizes from product sales may vary due to rebates, chargebacks, and discounts provided under governmental and other programs, distribution-related fees, and other sales-related deductions. In order to determine the transaction price, the Company estimates, utilizing the expected value method, the amount of variable consideration to which the Company will be entitled. This estimate is based upon contracts with customers, healthcare providers, payors, and government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, estimated payor mix, and other relevant factors. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rebates include amounts paid to managed care organizations, group purchasing organizations, state Medicaid programs, and other rebate programs. The Company estimates reductions to product sales for each type of rebate and records an allowance for rebates in the same period in which the related product sales are recognized. The Company's liability for rebates consists of estimates for claims related to the current and prior periods that have not been paid and estimates for claims that will be made related to inventory that exists in the distribution channel at the end of the period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's reserves related to discounted pricing to eligible physicians, Veterans' Administration ("VA"), Public Health Services, and others (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the discounted selling price to the qualified healthcare providers. The Company estimates reductions to product sales for each type of chargeback and records an allowance for chargebacks in the same period that the related product sales are recognized. The Company's reserve for chargebacks consists of amounts for which it expects to issue credit based on expected sales by its customers to qualified healthcare providers and chargebacks that customers have claimed but for which the Company has not yet issued credit.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Distribution-Related Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers generally based on gross sales.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other Sales-Related Deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company's other sales-related deductions include co-pay assistance programs and product returns. The Company estimates and records other sales-related deductions generally based on gross sales, written contracts, and other relevant factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company generally offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers, using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various collaborative arrangements to research, develop, manufacture, and commercialize products and/or product candidates. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:49.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front/opt-in and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements involving multiple goods or services promised to be transferred to the Company's collaborator, the Company must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is "distinct"), or whether such </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promises should be combined as a single unit of account. When the Company has a combined unit of account which includes a license and providing research and development services to its collaborator, recognition of up-front payments and development milestones earned from its collaborator is deferred (as a liability) and recognized over the development period (i.e., over time) typically using an input method on the basis of the Company's research and development costs incurred relative to the total expected cost which determines the extent of the Company's progress toward completion. The Company reviews its estimates each period and makes revisions to such estimates as necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company is entitled to reimbursement of all or a portion of the expenses (e.g., research and development expenses) that it incurs under a collaboration, it records those reimbursable amounts in the period in which such costs are incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company's collaborator performs research and development work or commercialization-related activities and the parties share the related costs, the Company also recognizes, as expense (e.g., research and development expense or selling, general, and administrative expense, as applicable) in the period when its collaborator incurs such expenses, the portion of the collaborator's expenses that the Company is obligated to reimburse. The Company's collaborators provide the Company with estimated expenses for the most recent fiscal quarter. The estimates are revised, if necessary, in subsequent periods if actual expenses differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where the Company:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplies commercial product to its collaborator, the Company may be reimbursed for its manufacturing costs as commercial product is shipped to the collaborator (however, recognition of such cost reimbursements may be deferred until the product is sold by the Company's collaborator to third-party customers); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares in any profits or losses arising from the commercialization of such products, the Company records its share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receives royalties and/or sales-based milestone payments from its collaborator, the Company recognizes such amounts in the period earned.</span></div>The Company's collaborators provide it with estimates of product sales and the Company's share of profits or losses, as applicable, for each quarter. The estimates are revised, if necessary, in subsequent periods if the Company's actual share of profits or losses differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, clinical trial expenses, the cost of services provided by outside contractors, including services related to the Company's clinical trials, the full cost of manufacturing drug for use in research and development, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs. Costs associated with research and development are expensed.  </span></div>For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter and remain in the trial, and/or the period over which clinical investigators, contract research organizations ("CROs"), or other third-party service providers are expected to provide services. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining noncancelable obligations associated with the winding-down of the clinical trial, including any applicable penalties.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity grants under the Company's long-term incentive plans (including stock options, restricted stock awards, and restricted stock units (both time-based and performance-based)) to employees and non-employee members of the Company's board of directors (as applicable) based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In addition, the Company reassesses its forfeiture rate assumptions at least annually, considering both historical forfeiture experience and an estimate of future forfeitures for currently outstanding unvested awards. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation to compute the estimated fair value of performance-based restricted stock units that are subject to vesting based on the Company&#8217;s attainment of pre-established criteria that include a market condition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance-based restricted stock units that contain a performance condition, the Company recognizes stock-based compensation expense if and when the Company determines that it is probable the performance condition will be achieved (based on the number of shares expected to be vested and issued). The Company reassesses the probability of achievement at each reporting period and adjusts compensation cost, as necessary. If there are any changes in the Company's probability assessment, the Company recognizes a cumulative catch-up adjustment in the period of the change in estimate, with the remaining unrecognized expense recognized prospectively over the remaining requisite service period. If the Company subsequently determines that the performance criteria are not met or are not expected to be met, any amounts previously recognized as compensation expense are reversed in the period when such determination is made.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes U.S. federal, state, local, and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns, including deferred tax assets and liabilities for expected amounts of global intangible low-taxed income ("GILTI") inclusions, are recognized on the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the financial statement effects of a tax position when management's assessment is that there is more than a 50% probability that the position will be sustained upon examination by a taxing authority based upon its technical merits. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per Share Data</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Per Share Data</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Basic net income per share excludes restricted stock until vested. Diluted net income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include outstanding stock options and unvested restricted stock under the Company's long-term incentive plans, which are included under the treasury stock method when dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Matters</a></td>
<td class="text">Costs associated with the Company's involvement in legal proceedings are expensed as incurred<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583137801744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of estimated useful lives of property, plant, and equipment</a></td>
<td class="text">The estimated useful lives of property, plant, and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"><tr><td style="width:1.0%"/><td style="width:67.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#8211;50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.201%"><tr><td style="width:1.0%"/><td style="width:46.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office equipment, and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,432.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less, accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,669.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,398.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of presentation in statement of operations of payments to and from collaborators</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:49.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front/opt-in and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133778576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of product sales</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.189%"><tr><td style="width:1.0%"/><td style="width:23.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(e) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,117.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its collaborations with Sanofi are detailed below: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"><tr><td style="width:1.0%"/><td style="width:36.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.048%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of one-time payment of $56.9 million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.810%"><tr><td style="width:1.0%"/><td style="width:37.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.327%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment to Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.206%"><tr><td style="width:1.0%"/><td style="width:37.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.736%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company recognized reimbursement of R&amp;D expenses (as a reduction of R&amp;D expense) of $42.4 million and $109.4 million for the years ended December 31, 2021 and 2020, respectively. Such amount was not material for the year ended December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of concentration of risk, by risk factor</a></td>
<td class="text">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.913%"><tr><td style="width:1.0%"/><td style="width:60.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales to the U.S. government represented less than 10% of total gross product revenue during the period</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock', window );">Sales related deductions activity</a></td>
<td class="text">The following table summarizes the provisions, and credits/payments, for sales-related deductions.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"/><td style="width:37.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks,<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution-<br/>Related Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Sales-<br/>Related Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,034.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,523.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,398.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity of sales-related deductions during the period, which includes rebates, chargebacks, discounts, and distributor-related fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133578944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of collaboration revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.189%"><tr><td style="width:1.0%"/><td style="width:23.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(e) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,117.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its collaborations with Sanofi are detailed below: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"><tr><td style="width:1.0%"/><td style="width:36.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.048%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of one-time payment of $56.9 million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.810%"><tr><td style="width:1.0%"/><td style="width:37.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.327%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment to Roche in connection with sales of REGEN-COV and Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.206%"><tr><td style="width:1.0%"/><td style="width:37.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.736%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company recognized reimbursement of R&amp;D expenses (as a reduction of R&amp;D expense) of $42.4 million and $109.4 million for the years ended December 31, 2021 and 2020, respectively. Such amount was not material for the year ended December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of accounts receivable and deferred revenue information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Bayer collaboration:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.764%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities included up-front and development milestone payments received from Teva for which recognition had been deferred. During 2022, the Company discontinued further clinical development of fasinumab and, as a result, recorded $31.9&#160;million as an increase to Other operating income as the Company deemed its obligation to provide development services in connection with the Teva Collaboration Agreement to be complete.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132939744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale debt securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"/><td style="width:53.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Marketable securities, based on contractual maturity dates</a></td>
<td class="text">The fair values of available-for-sale debt securities by contractual maturity consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.235%"><tr><td style="width:1.0%"/><td style="width:65.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.884%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.884%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.737%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair value and unrealized losses of marketable securities</a></td>
<td class="text">The following table shows the fair value of the Company's available-for-sale debt securities that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,645.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,633.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,889.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,889.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133577024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.965%"><tr><td style="width:1.0%"/><td style="width:49.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,228.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,647.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132606720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.477%"><tr><td style="width:1.0%"/><td style="width:48.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,401.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133541984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text">The estimated useful lives of property, plant, and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"><tr><td style="width:1.0%"/><td style="width:67.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#8211;50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.201%"><tr><td style="width:1.0%"/><td style="width:46.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, office equipment, and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,432.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less, accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,669.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,398.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133604160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired product rights - Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#8211;8 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128612544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.040%"><tr><td style="width:1.0%"/><td style="width:49.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaborators (see Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133587216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of issued senior unsecured notes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt in connection with the Notes, net of underwriting discounts and offering expenses, consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:29.25pt;padding-right:29.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.149%"><tr><td style="width:1.0%"/><td style="width:61.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750% Senior Notes due September 2030</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.800% Senior Notes due September 2050</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133768928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of amounts recognized in the Condensed Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Consolidated Balance Sheet related to the Lease are included in the table below. Other than the Lease described above, the Company had no leases accounted for as finance leases as of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"/><td style="width:30.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Finance lease right-of-use assets were recorded net of accumulated amortization of $119.4 million and $104.9 million as of December&#160;31, 2022 and 2021, respectively.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost and other information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.160%"><tr><td style="width:1.0%"/><td style="width:52.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to the Company's finance lease includes the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"><tr><td style="width:1.0%"/><td style="width:51.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.562%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of finance lease liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of the Company's finance lease liability:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.908%"><tr><td style="width:1.0%"/><td style="width:60.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133570848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Class of treasury stock</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of the Company's Common Stock it repurchased under the programs and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.701%"><tr><td style="width:1.0%"/><td style="width:48.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132180048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of transactions involving stock option awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions involving stock option awards during 2022 under the Company's Incentive Plans are summarized in the table below.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.045%"><tr><td style="width:1.0%"/><td style="width:5.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.031%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic Value </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,685.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of weighted-average exercise prices and weighted-average grant-date fair values of options issued</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2022, 2021, and 2020. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.678%"><tr><td style="width:1.0%"/><td style="width:47.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options Granted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price equal to Market Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average values of assumptions used in computing fair value of option grants</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2022, 2021, and 2020.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.770%"><tr><td style="width:1.0%"/><td style="width:48.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives from grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average values of the assumptions used in computing the fair value of PSUs that were granted during 2022 and 2020. The Company did not grant PSUs during 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.431%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of activity related to restricted stock awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's activity related to restricted stock awards and time-based restricted stock units (excluding performance-based restricted stock units, which are detailed further below) (collectively, "restricted stock") during 2022 is summarized below. </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"><tr><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.491%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares/Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant <br/>Date Fair Value</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of activity related to performance-based awards</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes activity related to PSUs during 2022. The number of PSUs granted represents the maximum number of units that are eligible to be earned.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"><tr><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.491%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares/Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant <br/>Date Fair Value</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135491744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income before income tax</a></td>
<td class="text">Components of income before income taxes consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.448%"><tr><td style="width:1.0%"/><td style="width:27.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,944.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,018.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,381.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,325.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.109%"><tr><td style="width:1.0%"/><td style="width:43.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. statutory income tax rate to the Company's effective income tax rate is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.080%"><tr><td style="width:1.0%"/><td style="width:56.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxation of non-U.S. operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-inventory related assets between foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of the Company's deferred tax assets and liabilities are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.488%"><tr><td style="width:1.0%"/><td style="width:68.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.154%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax attribute carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net unrecognized tax benefits that, if settled, would impact the effective tax rate is $373.7 million, $321.1 million, and $267.0 million as of December 31, 2022, 2021, and 2020, respectively. The following table reconciles the beginning and ending amounts of unrecognized tax benefits. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"/><td style="width:58.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross (decreases) increases related to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases due to settlements and lapse of statutes of limitations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133792272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted net income (loss) per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted net income per share are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.155%"><tr><td style="width:1.0%"/><td style="width:56.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"/><td style="width:57.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133620048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"><tr><td style="width:1.0%"/><td style="width:50.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restrictions on cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"><tr><td style="width:1.0%"/><td style="width:50.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Summary of non-cash investing and financing activities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.747%"><tr><td style="width:1.0%"/><td style="width:37.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payments for Libtayo intangible asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128722544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration', window );">Number of products approved by the U.S. FDA | product</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable, current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=regn_ThreeIndividualCustomersMember', window );">Three individual customers | Customer concentration risk | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=regn_USGovernmentMember', window );">U.S. Government | Customer concentration risk | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products Approved By The Unites States Food And Drug Administration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_ThreeIndividualCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_ThreeIndividualCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132365584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132751776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Net Product Sales (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,893.7<span></span>
</td>
<td class="nump">12,117.2<span></span>
</td>
<td class="nump">5,567.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | EYLEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,264.6<span></span>
</td>
<td class="nump">5,792.3<span></span>
</td>
<td class="nump">4,947.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">374.5<span></span>
</td>
<td class="nump">306.3<span></span>
</td>
<td class="nump">270.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Praluent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">170.0<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | REGEN-COV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5,828.0<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Evkeeza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">48.6<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Inmazeb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ARCALYST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=regn_RestOfWorldMember', window );">Rest Of World | Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_REGENCOVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_REGENCOVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EvkeezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EvkeezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_InmazebMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_InmazebMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ArcalystNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ArcalystNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=regn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=regn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135128704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Sales - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,328.7<span></span>
</td>
<td class="nump">$ 6,036.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 3,586.0<span></span>
</td>
<td class="nump">$ 5,059.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132195920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details) - Gross Product Revenue - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">Besse Medical, a subsidiary of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_BesseMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_BesseMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135571968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Sales Related Deductions Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 362.2<span></span>
</td>
<td class="nump">$ 324.2<span></span>
</td>
<td class="nump">$ 156.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Provisions</a></td>
<td class="nump">2,109.5<span></span>
</td>
<td class="nump">1,561.1<span></span>
</td>
<td class="nump">1,136.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments</a></td>
<td class="num">(1,924.9)<span></span>
</td>
<td class="num">(1,523.1)<span></span>
</td>
<td class="num">(968.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">546.8<span></span>
</td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">324.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_RebatesAndChargebacksMember', window );">Rebates, Chargebacks, and Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">214.6<span></span>
</td>
<td class="nump">202.2<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Provisions</a></td>
<td class="nump">1,537.3<span></span>
</td>
<td class="nump">1,047.1<span></span>
</td>
<td class="nump">762.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments</a></td>
<td class="num">(1,398.0)<span></span>
</td>
<td class="num">(1,034.7)<span></span>
</td>
<td class="num">(641.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">353.9<span></span>
</td>
<td class="nump">214.6<span></span>
</td>
<td class="nump">202.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_DistributionRelatedFeesMember', window );">Distribution- Related Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
<td class="nump">46.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Provisions</a></td>
<td class="nump">431.1<span></span>
</td>
<td class="nump">363.6<span></span>
</td>
<td class="nump">279.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments</a></td>
<td class="num">(399.7)<span></span>
</td>
<td class="num">(360.8)<span></span>
</td>
<td class="num">(249.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">111.4<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_OtherSalesRelatedDeductionsMember', window );">Other Sales- Related Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Provisions</a></td>
<td class="nump">141.1<span></span>
</td>
<td class="nump">150.4<span></span>
</td>
<td class="nump">94.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments</a></td>
<td class="num">(127.2)<span></span>
</td>
<td class="num">(127.6)<span></span>
</td>
<td class="num">(78.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 81.5<span></span>
</td>
<td class="nump">$ 67.6<span></span>
</td>
<td class="nump">$ 44.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_RebatesAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_RebatesAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_DistributionRelatedFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_DistributionRelatedFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_OtherSalesRelatedDeductionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=regn_OtherSalesRelatedDeductionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129029312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Regeneron's share of profits in connection with commercialization of antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,082.0<span></span>
</td>
<td class="nump">1,363.0<span></span>
</td>
<td class="nump">785.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Sales-based milestones earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">633.7<span></span>
</td>
<td class="nump">488.8<span></span>
</td>
<td class="nump">368.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">28.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Reduction of R&amp;D expense | Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">129.2<span></span>
</td>
<td class="nump">149.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | SG&amp;A expense | Reimbursement of commercialization-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">437.4<span></span>
</td>
<td class="nump">320.5<span></span>
</td>
<td class="nump">359.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Other collaboration revenue | Regeneron's share of profits in connection with commercialization of antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(25.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Other collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Reduction of R&amp;D expense | Reimbursement of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">85.1<span></span>
</td>
<td class="nump">166.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | SG&amp;A expense | Reimbursement of commercialization-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">41.4<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="nump">64.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | SG&amp;A expense | Regeneron's obligation for its share of Sanofi commercial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(19.9)<span></span>
</td>
<td class="num">(36.3)<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Cost of goods sold | Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(70.1)<span></span>
</td>
<td class="num">(133.0)<span></span>
</td>
<td class="num">(119.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Other operating income | Amounts recognized in connection with up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 35.1<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 210.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ShareOfProfitsLossesInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ShareOfProfitsLossesInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_OtherCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_OtherCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SanofisShareOfLibtayoUSGrossProfitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SanofisShareOfLibtayoUSGrossProfitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128020464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentToCollaboratingParty', window );">One-time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts', window );">Percentage of quarterly profits require to be paid for reimbursement of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts', window );">Percentage of share of profits used to reimburse collaborating party for trial costs</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ContingentReimbursementObligation', window );">Contingent reimbursement obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,864.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty', window );">Starting share of profits outside the United States, based on sales, for collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany', window );">Starting share of profits outside the United States, based on sales, for company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty', window );">Ending share of profits outside the United States, based on sales, for collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany', window );">Ending share of profits outside the United States, based on sales, for company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty', window );">Share of losses outside the United States, for collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ShareOfLossesOutsideUnitedStatesForCompany', window );">Share of losses outside the United States, for company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | First Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived', window );">Levels of twelve month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Second Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived', window );">Levels of twelve month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Third Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived', window );">Levels of twelve month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Sales Milestone Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived', window );">Levels of twelve month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Sales Milestone Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived', window );">Levels of twelve month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Revenue, remaining performance obligation, variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty', window );">Percentage of trial costs required to be funded by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts', window );">Percentage of quarterly profits require to be paid for reimbursement of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty', window );">Percentage of trial costs required to be funded by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts', window );">Percentage of quarterly profits require to be paid for reimbursement of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember', window );">Praluent Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates', window );">Royalty percentage to be received on net product sales outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_LossContingencyPercentageOfDamagesResponsibleFor', window );">Percentage of damages company is responsible for</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember', window );">Praluent Agreement | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfRoyaltyPaymentThatCanBeOffset', window );">Percentage of royalty payment that can be used to offset litigation proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ContingentReimbursementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ContingentReimbursementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of twelve month sales upon which sales milestone would be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyPercentageOfDamagesResponsibleFor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Percentage Of Damages Responsible For</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyPercentageOfDamagesResponsibleFor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PaymentToCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment To Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PaymentToCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfRoyaltyPaymentThatCanBeOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Royalty Payment That Can Be Offset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfRoyaltyPaymentThatCanBeOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Trial Costs Required To Be Funded By Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for Achieving Sales Target for Milestone Payment, Rolling Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage To Be Received On Net Product Sales Outside Of United States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the share of losses outside the United States for the collaborating party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ShareOfLossesOutsideUnitedStatesForCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the share of losses outside the United States for the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ShareOfLossesOutsideUnitedStatesForCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583137937280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, Antibody Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,328.7<span></span>
</td>
<td class="nump">$ 6,036.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">692.3<span></span>
</td>
<td class="nump">504.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 415.8<span></span>
</td>
<td class="nump">$ 368.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583126334224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentToCollaboratingParty', window );">Up-front payment to collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales', window );">Royalty payment to collaborating party, percentage of net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">276.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentToCollaboratingParty', window );">Up-front payment to collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Sales-Based Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Sales-Based Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Aggregate Sales-Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | IO License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentReceived', window );">Up-front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Amended IO Discovery Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentReceived', window );">Up-front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Amended IO Discovery Agreement | Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Cumulative catch-up adjustment to revenue, modification of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.9<span></span>
</td>
<td class="nump">$ 135.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember', window );">Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales', window );">Royalty payment to collaborating party, percentage of net product sales</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="nump">$ 241.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment to Collaborating Party, Percentage of Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-front payment received upon the execution of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpFrontPaymentToCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-Front Payment to Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpFrontPaymentToCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesBasedMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesBasedMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesBasedMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesBasedMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_AggregateSalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_AggregateSalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_IOLicenseandCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_IOLicenseandCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_AmendedIODiscoveryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_AmendedIODiscoveryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129552192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, IO Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,328.7<span></span>
</td>
<td class="nump">$ 6,036.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 276.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135438752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Bayer Narrative (Details) - Bayer - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits', window );">Percentage of repayment of development balance out of profits</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ContingentReimbursementObligation', window );">Contingent reimbursement obligation</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan', window );">Revenue based on percentage of annual sales in Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan', window );">Revenue based on percentage of annual sales in Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ContingentReimbursementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ContingentReimbursementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of repayment of development balance out of profits under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RevenueBasedOnPercentageOfAnnualSalesInJapan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129836496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Bayer (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Other collaboration revenue | Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,317.4<span></span>
</td>
<td class="nump">1,349.2<span></span>
</td>
<td class="nump">1,107.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Other collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">91.4<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">78.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Other collaboration revenue | One-time payment in connection with change in Japan arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Reduction of R&amp;D expense | Reimbursement of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">51.0<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Reduction of R&amp;D expense | Regeneron's obligation for its share of Bayer R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (34.3)<span></span>
</td>
<td class="num">$ (40.9)<span></span>
</td>
<td class="num">$ (35.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132451632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaborative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,328.7<span></span>
</td>
<td class="nump">$ 6,036.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">348.2<span></span>
</td>
<td class="nump">355.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 131.9<span></span>
</td>
<td class="nump">$ 129.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583126253488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Intellia Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 3,592.5<span></span>
</td>
<td class="nump">$ 2,860.1<span></span>
</td>
<td class="nump">$ 2,647.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaCollaborationAgreementMember', window );">Intellia Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_CollaborativeArrangementUpfrontPaymentMade', window );">Acquired in-process research and development, up-front payment made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaCollaborationAgreementMember', window );">Intellia Collaboration Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Shares purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeArrangementUpfrontPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Payment Made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeArrangementUpfrontPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128942096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>dose</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>dose</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_USGovernmentMember', window );">U.S. government | REGEN-COV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MaximumTransactionAgreementPayments', window );">Maximum transaction agreement payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_USGovernmentMember', window );">U.S. government | REGEN-COV | Other Transaction Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MaximumTransactionAgreementPayments', window );">Maximum transaction agreement payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,940.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase', window );">Collaborative arrangement, number of doses counterparty to purchase | dose</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Doses Counterparty To Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MaximumTransactionAgreementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Transaction Agreement Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MaximumTransactionAgreementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_REGENCOVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_REGENCOVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129688224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement | Ronapreve | Other collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">627.3<span></span>
</td>
<td class="nump">361.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement | Ronapreve | Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">259.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement | Reimbursement of R&amp;D expenses | Reduction of R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 128.1<span></span>
</td>
<td class="nump">$ 78.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RonapreveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RonapreveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132187264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,328.7<span></span>
</td>
<td class="nump">$ 6,036.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">396.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 268.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128722640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Alnylam Narratives (Details) - Alnylam Pharmaceuticals, Inc. Collaboration Agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpfrontPaymentMade', window );">Upfront payment made</a></td>
<td class="nump">$ 400.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone', window );">Collaborative arrangement additional payment eligible</a></td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_InitialResearchTerm', window );">Initial research term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PotentialExtensionOfResearchTerm', window );">Potential automatic extension of research term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_OptionToExtendResearchTermPeriod', window );">Potential optional extension of research term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels', window );">Maximum amount of sales milestone payments if total sales achieve specific levels</a></td>
<td class="nump">$ 325.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember', window );">Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement', window );">Cash consideration for Stock Purchase Agreement</a></td>
<td class="nump">400.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ExtensionOfResearchTermFee', window );">Extension of research term fee</a></td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ExtensionOfResearchTermFee', window );">Extension of research term fee</a></td>
<td class="nump">$ 400.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Payment Eligible, Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ExtensionOfResearchTermFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extension Of Research Term Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ExtensionOfResearchTermFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_InitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_InitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_OptionToExtendResearchTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to Extend Research Term, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_OptionToExtendResearchTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Made To Acquire Equity Within A Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PotentialExtensionOfResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Extension Of Research Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PotentialExtensionOfResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpfrontPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment made under a collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpfrontPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135442160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Checkmate Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development in connection with asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=regn_CheckmatePharmaceuticalsIncMember', window );">Checkmate Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development in connection with asset acquisition</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business combination, recognized identifiable assets acquired and liabilities assumed, net</a></td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=regn_CheckmatePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=regn_CheckmatePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135507536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Teva Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">72 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentReceived', window );">Up-front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva | Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Cumulative catch-up adjustment to revenue, modification of contract</a></td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-front payment received upon the execution of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583126286320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">72 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,172.9<span></span>
</td>
<td class="nump">$ 16,071.7<span></span>
</td>
<td class="nump">$ 8,497.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva | Reduction of R&amp;D expense | Reimbursement of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
<td class="nump">109.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva | Other operating income | Amounts recognized in connection with up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 47.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135131968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,328.7<span></span>
</td>
<td class="nump">$ 6,036.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 39.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129482928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 10,320.1<span></span>
</td>
<td class="nump">$ 8,428.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(302.8)<span></span>
</td>
<td class="num">(42.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">10,018.2<span></span>
</td>
<td class="nump">8,397.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">6,975.5<span></span>
</td>
<td class="nump">7,518.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(291.1)<span></span>
</td>
<td class="num">(40.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,684.4<span></span>
</td>
<td class="nump">7,487.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">2,945.4<span></span>
</td>
<td class="nump">109.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,939.4<span></span>
</td>
<td class="nump">108.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">67.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">439.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">182.1<span></span>
</td>
<td class="nump">255.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">255.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">28.9<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">$ 41.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135165952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturities within one year</a></td>
<td class="nump">$ 4,636.4<span></span>
</td>
<td class="nump">$ 2,809.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturities after one year through five years</a></td>
<td class="nump">5,381.4<span></span>
</td>
<td class="nump">5,588.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5', window );">Maturities after five years</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 10,018.2<span></span>
</td>
<td class="nump">$ 8,397.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129126016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">$ 3,300.9<span></span>
</td>
<td class="nump">$ 6,516.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(76.9)<span></span>
</td>
<td class="num">(42.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">4,332.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(225.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">7,633.1<span></span>
</td>
<td class="nump">6,516.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(302.8)<span></span>
</td>
<td class="num">(42.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">2,445.4<span></span>
</td>
<td class="nump">5,889.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(73.1)<span></span>
</td>
<td class="num">(40.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">4,200.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(218.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">6,645.8<span></span>
</td>
<td class="nump">5,889.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(291.1)<span></span>
</td>
<td class="num">(40.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">785.2<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">856.2<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">45.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">64.2<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">$ (1.7)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583133506192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDebtSecuritiesOperating', window );">Interest income</a></td>
<td class="nump">$ 160.1<span></span>
</td>
<td class="nump">$ 45.8<span></span>
</td>
<td class="nump">$ 75.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDebtSecuritiesOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDebtSecuritiesOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583127785888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 10,018.2<span></span>
</td>
<td class="nump">$ 8,397.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,684.4<span></span>
</td>
<td class="nump">7,487.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,939.4<span></span>
</td>
<td class="nump">108.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">255.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">11,228.2<span></span>
</td>
<td class="nump">9,647.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,185.4<span></span>
</td>
<td class="nump">1,191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,684.4<span></span>
</td>
<td class="nump">7,487.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,939.4<span></span>
</td>
<td class="nump">108.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">255.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">1,210.0<span></span>
</td>
<td class="nump">1,249.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,185.4<span></span>
</td>
<td class="nump">1,191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">10,018.2<span></span>
</td>
<td class="nump">8,397.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,684.4<span></span>
</td>
<td class="nump">7,487.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,939.4<span></span>
</td>
<td class="nump">108.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">255.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">$ 41.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_RestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_RestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128692304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gains (losses) on equity securities in other income (expense)</a></td>
<td class="num">$ (39.8)<span></span>
</td>
<td class="nump">$ 386.1<span></span>
</td>
<td class="nump">$ 196.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Securities without readily determinable fair value</a></td>
<td class="nump">48.3<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt fair value</a></td>
<td class="nump">$ 1,443.0<span></span>
</td>
<td class="nump">$ 1,887.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135103344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 818.4<span></span>
</td>
<td class="nump">$ 721.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">963.1<span></span>
</td>
<td class="nump">707.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryNetOfReserves', window );">Deferred costs</a></td>
<td class="nump">521.8<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventories</a></td>
<td class="nump">$ 2,401.9<span></span>
</td>
<td class="nump">$ 1,951.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132429120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">$ 720.7<span></span>
</td>
<td class="nump">$ 510.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs and reserves</a></td>
<td class="nump">$ 258.7<span></span>
</td>
<td class="nump">$ 457.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583126324112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">$ 5,432.2<span></span>
</td>
<td class="nump">$ 4,880.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less, accumulated depreciation and amortization</a></td>
<td class="num">(1,669.2)<span></span>
</td>
<td class="num">(1,398.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">3,763.0<span></span>
</td>
<td class="nump">3,482.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">264.5<span></span>
</td>
<td class="nump">248.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">2,270.0<span></span>
</td>
<td class="nump">2,088.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">114.3<span></span>
</td>
<td class="nump">113.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">980.5<span></span>
</td>
<td class="nump">767.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">1,315.3<span></span>
</td>
<td class="nump">1,225.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">337.4<span></span>
</td>
<td class="nump">291.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_FurnitureOfficeEquipmentAndOtherMember', window );">Furniture, office equipment, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">$ 150.2<span></span>
</td>
<td class="nump">$ 145.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_FurnitureOfficeEquipmentAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_FurnitureOfficeEquipmentAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583134839584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 303.9<span></span>
</td>
<td class="nump">$ 281.1<span></span>
</td>
<td class="nump">$ 230.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">3,763.0<span></span>
</td>
<td class="nump">3,482.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">2,960.0<span></span>
</td>
<td class="nump">2,684.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=regn_RestOfWorldMember', window );">Rest Of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">$ 803.0<span></span>
</td>
<td class="nump">$ 797.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion And Amortization, Excluding Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=regn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=regn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129828080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 956.3<span></span>
</td>
<td class="nump">$ 29.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.8)<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915.5<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=regn_ProductRightsMember', window );">Acquired product rights - Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=regn_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=regn_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129730144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-lived intangible asset, expected amortization, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-lived intangible asset, expected amortization, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-lived intangible asset, expected amortization, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-lived intangible asset, expected amortization, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-lived intangible asset, expected amortization, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember', window );">Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentToCollaboratingParty', window );">Up-front payment to collaborating party</a></td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpFrontPaymentToCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-Front Payment to Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpFrontPaymentToCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129702480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related costs</a></td>
<td class="nump">$ 497.3<span></span>
</td>
<td class="nump">$ 440.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">295.0<span></span>
</td>
<td class="nump">295.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_AccrualForSalesRelatedCostsCurrent', window );">Accrued sales-related costs</a></td>
<td class="nump">633.6<span></span>
</td>
<td class="nump">472.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">326.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_CollaborativeAgreementsObligationsCurrent', window );">Amounts due to collaborators (see Note 3)</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">287.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses and liabilities</a></td>
<td class="nump">637.5<span></span>
</td>
<td class="nump">383.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,074.2<span></span>
</td>
<td class="nump">$ 2,206.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_AccrualForSalesRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual For Sales-Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_AccrualForSalesRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) in connection with clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeAgreementsObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Obligations, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeAgreementsObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583127764912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Senior unsecured revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit facility, expiration period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_LineOfCreditFacilityIncreaseLimit', window );">Increase Limit</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Borrowings outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior unsecured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,300,000<span></span>
</td>
<td class="nump">$ 44,400,000<span></span>
</td>
<td class="nump">$ 17,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage', window );">Redemption price with change-in-control provision, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior unsecured notes | 1.750% Senior Notes due September 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior unsecured notes | 2.800% Senior Notes due September 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LineOfCreditFacilityIncreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Increase Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LineOfCreditFacilityIncreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128945072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Issued Senior Unsecured Notes (Details) - Senior unsecured notes - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 1,981.4<span></span>
</td>
<td class="nump">$ 1,980.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">1.750% Senior Notes due September 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 1,241.0<span></span>
</td>
<td class="nump">1,239.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2.800% Senior Notes due September 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 740.4<span></span>
</td>
<td class="nump">$ 740.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583134796784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="nump">$ 720.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_LaboratoryAndOfficeFacilitiesMember', window );">Laboratory and Office Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_LaboratoryAndOfficeFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=regn_LaboratoryAndOfficeFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135343088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Amounts recognized in Condensed Consolidated Balance Sheet (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property, plant, and equipment, net<span></span>
</td>
<td class="text">Property, plant, and equipment, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 620.3<span></span>
</td>
<td class="nump">$ 631.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">719.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">720.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization of right-of-use assets</a></td>
<td class="nump">$ 119.4<span></span>
</td>
<td class="nump">$ 104.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135330352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Finance lease costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_FinanceLeaseCost', window );">Finance lease costs</a></td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="nump">$ 26.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583136853248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Other information related to finance lease (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_FinanceLeaseRemainingLeaseTerm', window );">Remaining lease term (in years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">4.84%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_FinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_FinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128737424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Analysis of lease liability maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 44.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">38.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">30.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">727.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">873.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(153.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 720.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128928608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Research Collaboration and Licensing Agreements Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember', window );">Libtayo | Sanofi Collaboration Agreement, Immuno-oncology | Through December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentsForRoyaltiesPercentage', window );">Percentage of royalties to be paid</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember', window );">Libtayo | Sanofi Collaboration Agreement, Immuno-oncology | January 1, 2024 Through December 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentsForRoyaltiesPercentage', window );">Percentage of royalties to be paid</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingAgreementsAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Agreements with Royalty Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RoyaltyRateMinimum', window );">Royalty rate minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RoyaltyRateMaximum', window );">Royalty rate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense, net of reimbursements from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.5<span></span>
</td>
<td class="nump">$ 66.9<span></span>
</td>
<td class="nump">$ 56.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PaymentsForRoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Royalties, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PaymentsForRoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ResearchCollaborationAndLicensingArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum royalty rate to be paid to the Company under the agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum royalty rate to be paid to the Company under the agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=regn_ThroughDecember312023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=regn_ThroughDecember312023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=regn_January12024ThroughDecember312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=regn_January12024ThroughDecember312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ResearchCollaborationAndLicensingAgreementsAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ResearchCollaborationAndLicensingAgreementsAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128022000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=regn_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of stock repurchased</a></td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares) | shares</a></td>
<td class="nump">13,014,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares) | shares</a></td>
<td class="nump">9,806,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember', window );">Libtayo Development and Dupilumab/Itepekimab Eligible Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions', window );">Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions', window );">Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2021Member', window );">January 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramNovember2021Member', window );">November 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 745,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgram2019Member', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2023Member', window );">Share Repurchase Program, January 2023 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of outstanding shares of the Company's Class A Stock and Common Stock that may be acquired under the 'standstill' provisions, in effect after the specified date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramNovember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramNovember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgram2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgram2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583137772288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Repurchased Shares (Details) - Share Repurchase Programs - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares)</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares</a></td>
<td class="nump">$ 2,099.8<span></span>
</td>
<td class="nump">$ 1,655.0<span></span>
</td>
<td class="nump">$ 746.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583126418224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Maximum term of awards</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value - of stock options exercised</a></td>
<td class="nump">$ 1,214.0<span></span>
</td>
<td class="nump">$ 1,707.0<span></span>
</td>
<td class="nump">$ 2,251.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=regn_NonPerformanceBasedStockOptionsMember', window );">Non-performance based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">$ 341.9<span></span>
</td>
<td class="nump">$ 328.7<span></span>
</td>
<td class="nump">$ 329.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost, net of estimated forfeitures</a></td>
<td class="nump">$ 572.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of total unrecognized compensation expense (in years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">$ 331.1<span></span>
</td>
<td class="nump">$ 221.0<span></span>
</td>
<td class="nump">102.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost, net of estimated forfeitures</a></td>
<td class="nump">$ 907.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of total unrecognized compensation expense (in years)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of awards outstanding (in USD per share)</a></td>
<td class="nump">$ 571.19<span></span>
</td>
<td class="nump">$ 499.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards vested (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards forfeited (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost, net of estimated forfeitures</a></td>
<td class="nump">$ 156.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of total unrecognized compensation expense (in years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of awards outstanding (in USD per share)</a></td>
<td class="nump">$ 245.94<span></span>
</td>
<td class="nump">$ 209.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=regn_AmendedRestatedLongTermIncentivePlan2014Member', window );">Amended &amp; Restated Long-Term Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="nump">22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=regn_LongTermIncentivePlan2014Member', window );">Long-Term Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=regn_LongTermIncentivePlan2000Member', window );">Long-Term Incentive Plan 2000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term (in years) when the equity-based award expires as specified in the award agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=regn_NonPerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=regn_NonPerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=regn_AmendedRestatedLongTermIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=regn_AmendedRestatedLongTermIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=regn_LongTermIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=regn_LongTermIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=regn_LongTermIncentivePlan2000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=regn_LongTermIncentivePlan2000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129104320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Summary of transactions involving stock option awards (Details) - Stock options - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares (In millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 435.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">705.02<span></span>
</td>
<td class="nump">$ 628.43<span></span>
</td>
<td class="nump">$ 492.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">481.62<span></span>
</td>
<td class="nump">$ 435.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">476.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 420.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years) - outstanding</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term - vested and expected to vest</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term - exercisable</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value - outstanding</a></td>
<td class="nump">$ 3,685.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value - vested and expected to vest</a></td>
<td class="nump">3,632.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value - exercisable</a></td>
<td class="nump">$ 2,991.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129723072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Summary of weighted-average exercise prices and weighted-average grant-date fair values of options issued (Details) - Stock options - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options Granted (in shares)</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 705.02<span></span>
</td>
<td class="nump">$ 628.43<span></span>
</td>
<td class="nump">$ 492.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Fair Value (in dollars per share)</a></td>
<td class="nump">$ 220.88<span></span>
</td>
<td class="nump">$ 174.20<span></span>
</td>
<td class="nump">$ 126.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132207568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of option grants (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives from grant date</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
<td class="nump">0.47%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583132446224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Summary of activity related to restricted stock awards (Details) - Restricted stock awards and restricted stock units<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares/Units (In millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars of shares) | $ / shares</a></td>
<td class="nump">$ 499.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars of shares) | $ / shares</a></td>
<td class="nump">702.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars of shares) | $ / shares</a></td>
<td class="nump">477.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars of shares) | $ / shares</a></td>
<td class="nump">522.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars of shares) | $ / shares</a></td>
<td class="nump">$ 571.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135372336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Summary of activity related to performance-based awards (Details) - Performance-based stock options<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares/Units (In millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars of shares) | $ / shares</a></td>
<td class="nump">$ 209.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars of shares) | $ / shares</a></td>
<td class="nump">485.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars of shares) | $ / shares</a></td>
<td class="nump">$ 245.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135460752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of performance-based options (Details) - Performance-based stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135175504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Savings Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution expense to 401(k) Savings Plan</a></td>
<td class="nump">$ 67.6<span></span>
</td>
<td class="nump">$ 55.5<span></span>
</td>
<td class="nump">$ 49.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135095712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of income before income tax (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income before income taxes, United States</a></td>
<td class="nump">$ 839.9<span></span>
</td>
<td class="nump">$ 5,944.7<span></span>
</td>
<td class="nump">$ 2,442.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income before income taxes, Foreign</a></td>
<td class="nump">4,018.9<span></span>
</td>
<td class="nump">3,381.1<span></span>
</td>
<td class="nump">1,368.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 4,858.8<span></span>
</td>
<td class="nump">$ 9,325.8<span></span>
</td>
<td class="nump">$ 3,810.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583134868112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of components of income tax expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 968.5<span></span>
</td>
<td class="nump">$ 1,429.8<span></span>
</td>
<td class="nump">$ 199.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">290.9<span></span>
</td>
<td class="num">(38.4)<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,266.8<span></span>
</td>
<td class="nump">1,397.6<span></span>
</td>
<td class="nump">221.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(797.7)<span></span>
</td>
<td class="num">(423.2)<span></span>
</td>
<td class="nump">109.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">276.7<span></span>
</td>
<td class="num">(31.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax (benefit) expense</a></td>
<td class="num">(746.4)<span></span>
</td>
<td class="num">(147.1)<span></span>
</td>
<td class="nump">75.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 520.4<span></span>
</td>
<td class="nump">$ 1,250.5<span></span>
</td>
<td class="nump">$ 297.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128679008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of effective income tax rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxation of non-U.S. operations</a></td>
<td class="num">(5.50%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent', window );">Foreign-derived intangible income deduction</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Income tax credits</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent', window );">Sale of non-inventory related assets between foreign subsidiaries</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deduction, Foreign Intangible Income, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Sale Of Non-Inventory Related Assets Between Foreign Subsidiaries, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129673936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized research and development expenses</a></td>
<td class="nump">$ 845.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred compensation</a></td>
<td class="nump">416.2<span></span>
</td>
<td class="nump">406.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">235.6<span></span>
</td>
<td class="nump">262.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets and intangible assets</a></td>
<td class="nump">227.6<span></span>
</td>
<td class="nump">257.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax attribute carryforwards</a></td>
<td class="nump">41.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">1,781.9<span></span>
</td>
<td class="nump">1,000.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gains on investments</a></td>
<td class="num">(58.2)<span></span>
</td>
<td class="num">(123.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 1,723.7<span></span>
</td>
<td class="nump">$ 876.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583127978352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 373.7<span></span>
</td>
<td class="nump">$ 321.1<span></span>
</td>
<td class="nump">$ 267.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583127983456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of unrecognized tax benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance as of January 1</a></td>
<td class="nump">$ 410.9<span></span>
</td>
<td class="nump">$ 267.0<span></span>
</td>
<td class="nump">$ 210.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases related to current year tax positions</a></td>
<td class="nump">136.9<span></span>
</td>
<td class="nump">182.3<span></span>
</td>
<td class="nump">76.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases related to prior year tax positions</a></td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations', window );">Gross decreases due to settlements and lapse of statutes of limitations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(41.3)<span></span>
</td>
<td class="num">(27.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance as of December 31</a></td>
<td class="nump">$ 542.8<span></span>
</td>
<td class="nump">$ 410.9<span></span>
</td>
<td class="nump">$ 267.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583129570800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Matters (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 09, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 16, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>request</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember', window );">'631 Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled', window );">Number of IPR filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember', window );">'226 Patent and '992 Patent | EYLEA Aflibercept Injection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_LossContingencyExParteReexaminationFiledNumber', window );">Number of ex parte reexamination requests | request</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember', window );">'338 Patent and '069 Patent | Apotex Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled', window );">Number of IPR filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember', window );">'338 Patent and '069 Patent | Celltrion, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled', window );">Number of IPR filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyExParteReexaminationFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Ex Parte Reexamination, Filed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyExParteReexaminationFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Inter Parties Review (IPR) Petitions Filed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_NumberOfInterPartiesReviewIPRPetitionsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EYLEAAfliberceptInjectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EYLEAAfliberceptInjectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_ApotexIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_ApotexIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_CelltrionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_CelltrionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583128937760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income - basic and diluted</a></td>
<td class="nump">$ 4,338.4<span></span>
</td>
<td class="nump">$ 8,075.3<span></span>
</td>
<td class="nump">$ 3,513.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">107.1<span></span>
</td>
<td class="nump">105.7<span></span>
</td>
<td class="nump">107.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">113.5<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">115.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 40.51<span></span>
</td>
<td class="nump">$ 76.40<span></span>
</td>
<td class="nump">$ 32.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 38.22<span></span>
</td>
<td class="nump">$ 71.97<span></span>
</td>
<td class="nump">$ 30.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135208960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of shares (in shares)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583135511024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,105.9<span></span>
</td>
<td class="nump">$ 2,885.6<span></span>
</td>
<td class="nump">$ 2,193.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in Other noncurrent assets</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows</a></td>
<td class="nump">$ 3,119.4<span></span>
</td>
<td class="nump">$ 2,898.1<span></span>
</td>
<td class="nump">$ 2,207.3<span></span>
</td>
<td class="nump">$ 1,630.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583138956432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows - Summary of Non-Cash Investing and Financing Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">$ 74.8<span></span>
</td>
<td class="nump">$ 70.8<span></span>
</td>
<td class="nump">$ 83.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Accrued payments for Libtayo intangible asset</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 135.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>regn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:regn="http://www.regeneron.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="regn-20221231.xsd" xlink:type="simple"/>
    <context id="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f67bb65c7484dc2b0c8012f58e5cf0d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i850a77a234774bf5a4783c3c0030ca8e_I20230126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="i2d34534410754ab1a8baa62248370c82_I20230126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ib7a293af7f1a454b8c850b4caf8e4c3f_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:RegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i4d21c3111e2741a386578f848272cd46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:AggregateSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25a7782ebd8c4cae90c0de536db35b84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f6f217bafb048fd906869bf77577910_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibef5f55864fa481ca4cc0c510430e3e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i783cf29968664c1cba1a9576242c71ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04ef055062c84a5e958dead58e5ac1d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e78ed4547174cfb8fb6f17834e6e280_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5815b19f7c243a9bef193f7182d4504_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c0f43af2adc4ac9932414df23261641_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia32343f1d31f45ac91df7774f62751d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofiCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2fb172db0f4c40f4a010b6c1e387157a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofiCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f5eff728cc34a73ac8a0e7575138379_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofiCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9eda36fe2b3493fba4bcd24c7f40343_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32d2d84b10ee49a78ff80e825d16507c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8125997c22b4a2aaf3b8071ba41f4fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8632402ae5742efb1d686222b335e92_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2052b209c6de41c9a910b9b4862dbf9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1cdfba9891941a6a7d17fd635d19308_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8986e8b381c40169962c1d089395044_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc263c8f9c744cdb933cb195b372c5ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i714163480a9a4f66aa296cf9c53130f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic29a659882534aef807d28ba085ed2cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i034cb1f338a14cdb98427fcd16a6f4bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5358609c29a1448aac4097e872d7c506_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib492caa05ff2478cac6ccfaa46f83cdb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia54e4119f42e4422bbe1589864186444_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i548c389088d843f3991fec42e82011bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15a99297fdea45a3aac29a3823f628b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3461f1e014c34ede904505072218051f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb0e234fb8004f8688e0132e0687751f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09eb064653cc48138003ea93e9fb6cfa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i537fb80c394c4504bbb568309e3d34f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a9bb7780cb644e2bf4abf693651eabd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55644888ab1b4dfa9869ab896e024903_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8220af90ab304d119e3feac29aceae08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8049544cda8b4dafaed97a8723f7337d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i370f4685af6144d1917cfe1061627472_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9e1b802d10c4170b70f673c07516261_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabc93395b4534195a6e703327ee8276e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i439b09eaccf14173ac24671a7d691568_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c2d0c6bc9f4458b8e7efb5109a2426e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if784455c39a741cca476b0900201d0f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id65b59d5da2340a0940c3e1995d7021f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12be5553e41d40be83ba97a5fe81845b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i666d725ef2cf4065b50048f5296edab9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83be0f48228e4464a3d79b1afd625715_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if802f07034c74a87a67853bdd63c7037_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic572b99252494005bc30f8d6d54277fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i070f93a0d90d444baf671f55dbf55f10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ca914c1a8484668a3a14d372c8d453b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3919061e6c614ec5a67ef420703684b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f56d798d2de4fd58840b7e15ab5383e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43a6ec2800b049a390ee894f424cd007_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3d4bf60775b4d869dd15f70b0ce4725_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie33b2737ad5f4d81a64471a8087f6b6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i801c30702fbc4a43994e5257eeedd771_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e6785130a464ace9f5ea5f75c6c368b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00bac7cbbc5e4246b3f94989f1a587b7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:ThreeIndividualCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6732651b19384641aff2c7fa3e18b1b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:ThreeIndividualCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad3a33c797844c159114ad188489310b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i492786f7a1b94a1594a932e2b271fa8a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9c27db3739642f99f43796472a8d403_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6a49d235b3214cedb524b0736433ccc3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i664445be718b4d0faeb4a37890e76062_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3488dea3c9b405e93bf3bd0b9ede622_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied28a835f8bf44bc81d3a306a92462e4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ae532f4ad2e45a094632cb65f59ff1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2401c340b8d640b0bd0f2bd3310a8b34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib758c557c5a84357b4ca9aad9468df85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25e9c05bba964dbaa707ecf5784772a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4219c796f9c244188971065d5bd4f038_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf9aaec3bce84131820f016e635d46b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id56d50e41b1b4f2283a73daac3abdfc3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2ca5e7fcd0b4a008a735d158813a139_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0393079c0cc944b1a50dfee3c963918e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a7e6722d81c44259a1bd92561905f63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifcd108a8c5454a57937befeca7f6ca59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a9ca7f6313f4b6ca75caf2fbb0aff86_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2a3c64382b1c47e282eed691c8527a02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16587113c4db4d869776e4a8f0e3f76f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36561e66271d42cd8f9d4959cf8bae47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d528e548bca464498145136edb95408_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c4796a01991465192b9b356e943e2e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61e8d230b07841e08ef6b9cf34364982_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i36d6b917256442e2bcb1f93418c6a3bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic15db8997a2b427788f94a1cbbec97c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb8aa02c16b445d7882b24cfd1ce3f1e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i045372e85f2c49249ac8ffc7ff4ee23f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if37be60752f94dc4afcf263599f81827_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13b570c4cf204eefb544c1454a2796d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3691c35b41bd49019bc22c52a92bb9e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19de0a1ac17e448ab689d53f955adc7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia31d29839cf14beabac4560e466ab9df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d710a5f61ac45fe86461104c9643b4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14dd5c1f226d4087af59c57f97a899aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34fd1be2ecad4837bb9a616be6b49006_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i344fed0429da45b2a1e885495c218a51_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4b8fe8cae5f463cad7e8105fe984c3d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6af24d3fc5514e589feb09538e6786e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1783ece527234057a38c1fec76fdaa70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e5923b8955547f1a59fc39eda60bec4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79035aaa4aca45619bc98627f48db24d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibed642c5d8464dd4ab25fed90d1a28b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idaac0693be9b45a28174b13694aa0f4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia36a49d6ddd04419a0f5b0f1b8c1c942_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4003730ec2f4d02b252a6fe11601f2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55504a180d724f1ebaac6dc86a38d8a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i400385b2589b49f595ff5af66bdd5ade_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4797ff0491840d0b9237549db0ebcf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i011e5e369ab847fa9843f4109e14c84b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i669cdcc9c1e246469a2358ff978102e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica6b4f57919043638cc0e4b7b9319f9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i140d0e936e944736a5e1983367a30409_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3bf9e21feb34e239d88bb219da800f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icebca5c748034d6284466eddd3b67472_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87d04b81b0d04870a748890c3df2cd84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0edb01a74bf4469a5cee578568c2d72_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iebf53692132846bdbb98eb842acd5e55_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iddf7a6f088a44d8c92a8778a84dbc88f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b16833ca23845bea5a41107085ed872_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:RebatesAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e5549277e904fcf83d210cf6514f72a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:DistributionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab3af9d8607c4bcb8acf3c8ebc5b9724_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">regn:OtherSalesRelatedDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04ba1f9253744de2b4207de915788712_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iacc9281a149a43a6a468ee18b2d84cf2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0115b1778749402f91e8cc15e18d4904_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia777bee1ba8248c483a61586e012c702_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id96bb9eb29d642bc83bbfe650b831b53_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71e3a3b0502c4423ad39c725eb715497_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12afa83d8539401a99a900866df1fa36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53ce6c9a943648f89bc598bd4d43f36c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1098ae33301f499691dd988767b567e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f529cd92f434fb1a4cedfbac373d940_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9379b307875b4618a634289637cb38fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24f5efff9c1341368743087b362bfb90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59b2e844e32b48cba3e0f9a0086990d6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5a7a5ff4b315478cbf0aad95a657b855_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i766d690fe05a4cd1aedfdac8bcaac956_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia98f436ad8214c2f880b651b95e5dad2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f38cde3c9ce4d3199de6ef8a0bd8843_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65c16e48fda34e60b3f5035db52b587d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fd9317470c24cb790bc85ce993a30eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id84b946ec54c41148f176f9146ca5bf4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6af8b58cda784c98a6fa9c2b3c890073_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitsLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bb55a76cf4c4a3487a985658b5c16a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40fc6180f85a4a7f9625db7362ac76de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b1990e2efe34d48b17cc48fed693450_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8813ce5c13e64d47b2b5439b9dc755f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idf8f5e721504480c84d395aaa308c019_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbe81139390d42459544d73a062fac93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6265b4f0bd0845d39208a99685ef72d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8f01400d1f5f4ab88a047bc5a42ad47e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08844a1258e34c188ef387c945bb338e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i051041a979024065b21211e82f9cdf21_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9bee21e9d49947c3a10d37cddc0d58ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9102b7c37a5540bd87a27183334b342a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1499e9e4c3cb42b29dbe231e9c8cbca2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareOfLibtayoUSGrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9ad83d17ed14bf6986ec0a3067634ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareOfLibtayoUSGrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4ae9b363c444357b3a5692e04f07a21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareOfLibtayoUSGrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if782b4fb146742af8dd0fb0dfa6d0f36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id7e2a1ed354949eb9a8bc01eeb0918c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic964826dc2d046ca8a21b1f261865199_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bc08b7de58d43ffa7092aa7f8bb0810_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib25739cf76b545759fc2d04ae78628e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3cfd1bc015b4dbe9079b20e66709ea4_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ica111cf830ee452b94a3ed1fa3edd4ac_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="if16d17ebcbaf4806a375d33fb5402f61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i92098519881447bc802ea9a38d5455bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4df3bd7c2a0041b6ab7f312261481025_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88cadc8fc7e24c3d9ff92f91bad83c6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic35d85587ab1424a9a59091f3cf09bf6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcc771627f73408eb92c1b64295c2e4b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c3d8ea7d0184f31933cf11c201c1047_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic416426a749b4b799097f4def70ef266_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="if2ae15c5525a4644af133a200d4375fc_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="ia07abc9790d746bcb14fa6e3f0c1ea51_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AmendedIODiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="ie82399ac549a40d5978b791c9447413e_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:IOLicenseandCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="ia3cd8df873044150844eb0ad18f0b00f_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesBasedMilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i2edbcd603c4e4104a5be3200e42d13d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesBasedMilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida00ad5e29154c468a4e0cc72eecae59_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="id36294acc59c4a11a0b25a3fdda18f81_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb765df6920d4b6383231c53791eadb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9968c18075514aa49e06f8c1a6cb6cdd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AmendedIODiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i662e6bf4027d426e82807c2558c35ae6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis">regn:AmendedIODiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19f9658cc2ff458f98c65823bbf93768_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ff682a1bf3046e59c581283c15cd463_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f127c8b7cde442e8f388b671f809753_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3153e0c1409546939c8330d63e4b6f96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c1144a7790544218f74de1883b49bf3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i031e83e10e9e4d98a468c3b9d072d89f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3313afbfc9d443d3919f6a7a44e3fa4d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ab9f0ecc7f6469f8f6f13959ec2c1c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i98f4b4ccfc364728a38bf1a2879c55df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86b2ada6cf67454e9cc60972f8641090_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4071c884ce284e40bc787d87c171aee2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic56187dada534884b655d5a6e52af578_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i377212e618da453c9025dd02c5593bd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if15bad177eea4c829136e32f7d94e3d1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63ea98825b3b48b79de2a000301ebc7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64f6c2b8f017469fb82cab1366cbc891_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic67456caf2c74fb5a00b7ecdac095418_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3d6d6e78614245739b4f9317ec964d69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98a1426d20a84b1ba447ab97089b66db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cd8680e50f643d098a5cb1c5b5231a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c64d785c95b442cb84245281603aa97_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa1488b28acd4712947288f81c0b3d62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib00e86a2286a4587b02c4df300896c50_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60cc7d156a5a435fb977176336cbf529_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iadbeb25484b8461ba47918e533c9948f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i444e097b9a96467fb3f9bcce2f2dbf2f_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62ebb955ca6e41b3a41e451e1855aa43_D20210901-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i3634f1dd450c457f96f0a93baa2fe330_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9910bd6f76874c749d53d66bb258402f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i557ade655aa34c1cbd2c4cb2be4a929a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id400cead2cc04f689d186fa70f6b0bc7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i920dc4f12d2f4619b92a360f1580099a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81aa8c9a653b433692636458e8fd345f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c91b71a44844a9a8775d4250688b382_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib113af71423044e1bdf03d2a055e837d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03fc22e78596486394e84faff1c467ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i128800b6b8e7426faa3758b24792c793_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e95202a8f2e4aefb1e1dfc0454a551f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacafdf0d5b114325b26e61a9a412e131_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">regn:AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibbee9a8b29934d8b8b7b1e850d856f99_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd928207d61c49b880a0b85bdb41a6a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:AlnylamPharmaceuticalsInc.CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">regn:CheckmatePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i6667fb912e984e6fa6353a1eed3e8fc4_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">regn:CheckmatePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i0cfcdda3880e4f87bb8ab780435bee97_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i5c78bdc526b34938a7fd5ed6077bef4d_D20160101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib02c2984d363403d9b1e823ad3d81d18_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81ac5aacea45414aaa675930ed342a3f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f3c36d0466748cea4e130f324d5e2dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f32e181f6564471b1774eaf0ab52226_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf862611445f4a27954a5d9467250c21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ec656e3d9234cddbabc7b72805e843c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5cc30a6e150429d8a9faa24528ade10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9be45733794a4b498cd7a86c3b02531c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i756ea3fa11624c548b132cede643b135_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0dec01e41c9d49bdbda7f337150ef44a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20c85832e072499f9f789894f4319fb1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i670b1994d88c42c7ad5592e062721992_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic065ee9eda414cb697e07e323cbe487d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22f360e272324c199aae4f0c50e9210f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice448a0cbfc94b15af1148fe41fd6000_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20b5acd4f7044784a39ba52a7c7a1723_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4f165da14524f83ab4e24f33f72fa7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieff3294615794346a9b85255e14fd794_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe27a11c61a240e4b0a067ec0dd7d798_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie93ec21dd364485abcb9d4f5a58113b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ea2ced853b94e24a4d22f70bd4fd29e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22141dab4f53412ea6de7ff444ac262c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50af84a4e2f049f5993f9b56288daed0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49c9255c54ab4b2d8041ec8cf8ed2d76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4cd0cb429064df7ac32623abbd44a07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0fe982b399644ca994a70d8d2ad5e97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc86526bc33f401eaef37c46de2730c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i467a55c788544f30ad74454d840569e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01edbc55a346434a8547a03cdf3f8b8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id596959620f7472daf2da370a9c6e4ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81ab5450159345e4a7a8d5d1becc66f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a5c2e9a61694f1b8288a4d46747d122_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9df6b754d9874865849815ce0ff1fa35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5812ccf9fa340d68bb0fb9ae362fd55_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb2285eff7124799bf35474f9b77d3a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37cc523007314e81a486975a1e802e30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9444b58a5bf44713b0a53669ccd879a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac51098e276e4ab68f338afabe7e88ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0604eb2ce2824a94b18ba840c03422bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e07af51cdfe402cb73cf12cdaa18875_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idaac5082db1042e2a542c59aaed88125_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76805457ac75462bb9be58fc14847bbd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie322fb4fa7024b1baee4c74f133d24f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e37a666e97345adad33738c64a2c8ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i814e9188987a4eb6818cb5e646b4c49c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i397a4c2affbe4db4b8abb7c9195877b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb4cb2ea77d6466a814509f17d146b81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i900991202ef2412f84b8b49bbd1fd697_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id958dea12f9f4daf9596b2e6ca4b664d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29c4864785e4460bbe8e8603d9e6e3c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55cd0cb5a7dc469dacd573bace8619db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic59b77df52a94d3d94be86824b44ccac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddf857f344764403832320f65a37a8aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e3d9acb4aa14bb882392991f7def806_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f19239807454691aa94fa166a33be9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ddbcb7106de49f49d710399f917f536_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04d07dab80a0497089de881dd7911c76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5f9a85d3b6c4ab58982bdab11c05ddd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7268de767d8943b9bee7565a5fc1ee35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7acba5123d245669d2c0b2930d140f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb3c12ae98b546ceb6fe3e88dc64b1b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85cf341222be46a193f1ef088c6436ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39bc3760e9e940d0b37cebc198b73cf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b618f73a8fa43489c55a045ed15c1f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e308ff0e87e482fba35dd4da2bd8aa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8312eadb6504455aaaac7b194804e4ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f2058d7e3d9452b8becd26693bb4b7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5efd5732c8647d88223929f0c134b0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e2aa3f436384eb7abe5169c1fb29a5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie56431b74b0b46708d25ec5b1f24d48c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70f9acbdc085411abc64332f0e5e0849_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if77c2ea74bfe40038cd4646e360bb2e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib29e6005f6d24c0491ed2bbf66621fb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib23273ac9b554855b189599419ac153a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic65b5f7083d14d56803e3599a24e7f4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43d3fbb1c2f4484da5b302c4846b440f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i442040e783844ed382aecdc0af74fc39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i350934777cd641749f3726d6f2e3a777_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9a2e7c68cbd450986ed5230d81ffae1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1294c19697a4d5989612dcdbb557eaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d8931c24c9647998f454d826d5ea54f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id78ea7aa3b8b48818411bc781e1be355_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie864f6dc154f4872aff761e5a7f37949_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:FurnitureOfficeEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1098f1326d3c46fab6616d650ec27d81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:FurnitureOfficeEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51f9bc6743594e108ea3ba33a0b1df17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i769d8dda3fd84c6492c24d8b5d8397c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa561036943849f6970887e7e93d601b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55fbf7200cd34a90a17cae423a49cac1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabe2b2c162d74aceaa748b1c4bb2cc4d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">regn:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac94305b0cdd490190861cea74735d96_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">regn:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie02495c8017b455681cd9f0f892654ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">regn:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a704809d9454f6091c067635a04adeb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5586b0412de74f4681a571d3e1c5bfbb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i566e4366831c4bc9b4395cd536a3c5d4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9ce0c7f100084a6dad54ebe67493652f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie345030098ed4a68855b720eadea8248_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if47d053711fd4bdc82cf9d70aa578c00_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie424218a88a74b00b19453fe4888916c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib5a9aa37e4c1457a976919d9730f8e80_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7310c177364143f2bf10f9d6b7aaf971_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib12579be01dc47cfbb463231b2c8f01d_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i261cf06513ba49e388568bf4932270e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c01c03f3a4444d1b5c5abebba7521b9_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i5bbfaa6d6caa478986a0fd252d1994d6_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8e773031061f47068bfb7d9af0a6f623_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b091a819e7f463a80413ebcc76b6b92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie78cab400df7439280370205f9c3d004_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d999cff105340e388c8d3d0fae950fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a901ef13b914e98a6b6ae594630e3ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i109147ff73454c9fb1005363d4c3549c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dc3a52eb4104b5aa8911f6741d3eee6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdc58844910a4e119a03ecefec012869_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i079d9f100fb942469a90e889b3b42209_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i012c8a6940324ac49f3899e2c90dc896_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ice406a54e051445e8e2f53b1c1e07740_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">regn:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i50a2e9c56f7e416f8da3fc7358beb047_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="ia2b5cb43390f40c79c55e8db0b798b1a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib132e77f1248490f82fe430c0a335704_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d20e3c5247b4d598e751c21b3f4f608_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">regn:ThroughDecember312023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i21d41d00df44446baa4014ec1a2a8b14_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">regn:January12024ThroughDecember312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ie83c963269194f2fbfdc09f02cc5d592_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if78394eb2a794ed4ac4431dca866af29_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="regn:ResearchCollaborationAndLicensingAgreementsAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia96fa6ba59e84ea08d01d27873b5696b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4e0c0f7f9e7245159ae317600a59a97f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a1f29e4d0084509aad565f88da92c75_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i07ed95697fc6411f82f5d2215701a1ce_D20191101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i898556ab5e034bf8a39f1f7ffdcff4b6_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="if149e3b2ed184d9cb47a5f1e416db711_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramNovember2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i4d4688a81ec54e3e81135fe0cef6a811_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramNovember2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa856a8273104bae9abb9e9bd006496c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00b3516f1f374f9ba681ff3469a1d79b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa56acec5b6c42e6a0c418417df45e87_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="id2184e2e59fa45c7b4e39f4a72edfc26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ife75b59764cd4329a476ef09a7789b4f_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="iffed57e1fcf04b469127e38751ea1244_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">regn:AmendedRestatedLongTermIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9dd3089f49fe4ad18bf060be6041dc8d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">regn:LongTermIncentivePlan2000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89c4af83a9954f7a928a982e2a427940_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">regn:LongTermIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fa909c892214ee795c9bf21ee208f05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0528c01e20994e37b110ba9db8971e61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8074da28c47b44eb8134011e2bfd7c77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic20a52b8adf44b65bc4aed375198294a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i061dabef95db47dcbeacf4d95b0043d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc3ca35c957f4ea784da91f7c995a52c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">regn:NonPerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc41ab2a621442839e2f788a04d55cce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44560f336e474452ae29c854f6be95dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0f758f9b4de4edbbd24b0a3c80d2099_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98b8165ff3c84cc2b0b3ef6c846d0857_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic976d25c5e3d49f49a38da896bf4b995_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4e3bb26f27c440bca9bd206e40fb92e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f140ca61272416db70327e6fc368a13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73f39b7d8fbc4c3db0ae510abf05e506_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EYLEAAfliberceptInjectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A226PatentAnd992PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ie1e3a47e6a80444d990b27b30d75132a_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:CelltrionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="icacf904bc9524621b2a1108d36ed04c7_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:ApotexIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="ic126e7de56fd4102a3b3234acc2542c7_I20200716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-16</instant>
        </period>
    </context>
    <context id="id00ff500fe5d47c79cce7113ad54ecef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ec0ed1241324a98bc46dd1af446a761_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60296a00df8b476a897b09a51d123985_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5bac9dad6b340e2b278dca087384319_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>regn:product</measure>
    </unit>
    <unit id="segment">
        <measure>regn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="dose">
        <measure>regn:dose</measure>
    </unit>
    <unit id="vote">
        <measure>regn:vote</measure>
    </unit>
    <unit id="request">
        <measure>regn:request</measure>
    </unit>
    <unit id="claim">
        <measure>regn:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV80LTEtMS0xLTE3NDM2Mg_54589224-a6e7-45eb-ae3f-adb5ee9197b9">0000872589</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV85LTEtMS0xLTE3NDM2Mg_8a1bcede-c8c9-41ef-bff7-12b21f95d3fa">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV8xMC0xLTEtMS0xNzQzNjI_c0de6ecf-6843-4763-a92c-da0fab184c0e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN180L2ZyYWc6ZTE2ZjgxNTczNzQ0NDJiMDgxNWE2MTBkMWEzNGE1YWQvdGFibGU6MWIzM2FlNzJlZGNjNGE0NGJjZWM3NDFlNWNkYzQxOTkvdGFibGVyYW5nZToxYjMzYWU3MmVkY2M0YTQ0YmNlYzc0MWU1Y2RjNDE5OV8xMS0xLTEtMS0xNzQzNjI_3d927943-54ca-430c-b8c2-33406e3501f7">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zODg_9ba51cac-f3d1-49b8-83a8-272c57df6835">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF8xLTAtMS0xLTE3NDM2Mg_3005242a-4626-4fa8-9214-c530a928ca3a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF8yLTEtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmRhY2FiZWE5MWZkNjRiMGRiNzRiYTViNzEzMWUyM2UzXzMw_dd7a5e07-37e5-43e9-84af-b8e1b83c41c5">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF8yLTEtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmRhY2FiZWE5MWZkNjRiMGRiNzRiYTViNzEzMWUyM2UzXzMw_fc0df25b-4567-4b9c-9665-0a58492e901d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjIxYWI5OTE3N2UyNDAzYjhkNWM5MjlmOTcyYzA4YTAvdGFibGVyYW5nZToyMjFhYjk5MTc3ZTI0MDNiOGQ1YzkyOWY5NzJjMDhhMF80LTAtMS0xLTE3NDM2Mg_863ef566-2216-4f26-8709-f3782682094c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NjI3YjE0YjM1OTg4NDc3Y2JkZDg2ODM0OTE0ZTRjMTQvdGFibGVyYW5nZTo2MjdiMTRiMzU5ODg0NzdjYmRkODY4MzQ5MTRlNGMxNF8wLTEtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmE2YjIyNTI4ZmU4YzRhMzc5ODdmZWJkMDQxOTNjODI2XzI4_c49a6f2a-b380-4045-ba1f-d43579e582f5">000-19034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTI_5e8d5a29-cbdb-4d3d-8c76-ae5755d99c69">REGENERON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NmUwNzg5ZTE5ZDg4NDFiMGFkNWFiZmJmYmFhZTA3MmMvdGFibGVyYW5nZTo2ZTA3ODllMTlkODg0MWIwYWQ1YWJmYmZiYWFlMDcyY18wLTAtMS0xLTE3NDM2Mg_a5ac5136-0d39-4424-9db5-e117987292f1">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NmUwNzg5ZTE5ZDg4NDFiMGFkNWFiZmJmYmFhZTA3MmMvdGFibGVyYW5nZTo2ZTA3ODllMTlkODg0MWIwYWQ1YWJmYmZiYWFlMDcyY18wLTItMS0xLTE3NDM2Mg_775b7305-7d1f-484e-8fcd-2004a7e90f12">13-3444607</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzQ_320f8ac5-1ba7-4003-b4d0-ca85fa8cdb09">777 Old Saw Mill River Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzg_52394e4c-37d3-444b-8e71-3c9aa14ef734">Tarrytown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzEy_07e89d96-5f95-45e7-883e-908ccf191c1b">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzM3YjBkZjEwMjg5NDY4MWI2ZTk1ZmQ5ZDMxZDQ5NzQvdGFibGVyYW5nZTozMzdiMGRmMTAyODk0NjgxYjZlOTVmZDlkMzFkNDk3NF8wLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmIwNzE0ODg1MzU5ZjQ4Yjg4MzViNDExNGJiZDlhYmRmXzE2_59c25867-3d16-449a-9b8a-4a39feacc1cd">10591-6707</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTM_129757d0-848a-4016-a520-b5ca4faa11b6">914</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTQ_8b4aa351-5e87-4a69-bb19-302cd9690258">847-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6OWExMmI1MDQyZWE3NDNjY2FlOTlmMDA3ZGE2MjIzODcvdGFibGVyYW5nZTo5YTEyYjUwNDJlYTc0M2NjYWU5OWYwMDdkYTYyMjM4N18xLTAtMS0xLTE3NDM2Mg_c2dcc423-8153-4eaf-b232-f050f2632063">Common Stock - par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6OWExMmI1MDQyZWE3NDNjY2FlOTlmMDA3ZGE2MjIzODcvdGFibGVyYW5nZTo5YTEyYjUwNDJlYTc0M2NjYWU5OWYwMDdkYTYyMjM4N18xLTEtMS0xLTE3NDM2Mg_fde59aec-b5d4-450f-a6e6-ed065fcf8b21">REGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6OWExMmI1MDQyZWE3NDNjY2FlOTlmMDA3ZGE2MjIzODcvdGFibGVyYW5nZTo5YTEyYjUwNDJlYTc0M2NjYWU5OWYwMDdkYTYyMjM4N18xLTItMS0xLTE3NDM2Mg_c8b5d10a-c26d-4bdf-95e1-77e6a834f28e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV8wLTEtMS0xLTE3NDM2Mg_dded19b2-a8dd-4aa9-bab0-dd086fc04c3d">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV8yLTMtMS0xLTE3NDM2Mg_68ff3214-a3c9-4c0f-9615-31aad3ed000b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV80LTEtMS0xLTE3NDM2Mg_78f5774d-bcd1-4f74-bba8-ce3fdb0a9106">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MDE4YjYzYjRhMDcyNDVjZTkzMmM5YzgxMWVlNWJiNDkvdGFibGVyYW5nZTowMThiNjNiNGEwNzI0NWNlOTMyYzljODExZWU1YmI0OV82LTEtMS0xLTE3NDM2Mg_e67edce4-8d29-4411-8073-9afa0ddc01ab">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NTRjMzE5OWYzYjg5NDhmZThjM2U5Njk5MGExOTg1MmQvdGFibGVyYW5nZTo1NGMzMTk5ZjNiODk0OGZlOGMzZTk2OTkwYTE5ODUyZF8wLTAtMS0xLTE3NDM2Mg_ca6a5a54-35b6-4ea6-b6c2-1788392fa9c6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NTRjMzE5OWYzYjg5NDhmZThjM2U5Njk5MGExOTg1MmQvdGFibGVyYW5nZTo1NGMzMTk5ZjNiODk0OGZlOGMzZTk2OTkwYTE5ODUyZF8wLTEwLTEtMS0xNzQzNjI_5fccb210-155f-48d1-9df0-b7537efd0639">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6NTRjMzE5OWYzYjg5NDhmZThjM2U5Njk5MGExOTg1MmQvdGFibGVyYW5nZTo1NGMzMTk5ZjNiODk0OGZlOGMzZTk2OTkwYTE5ODUyZF8wLTEzLTEtMS0xNzQzNjI_32776cd2-0e01-4b55-ab7b-3729697cd733">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzkwZjEyNTMwMmQxNDlkMmIyYzZhYzVmYmNiMTc5NmIvdGFibGVyYW5nZTozOTBmMTI1MzAyZDE0OWQyYjJjNmFjNWZiY2IxNzk2Yl8yLTQtMS0xLTE3NDM2Mg_7c529dfe-ed94-4971-bd37-4580ac634078">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzkwZjEyNTMwMmQxNDlkMmIyYzZhYzVmYmNiMTc5NmIvdGFibGVyYW5nZTozOTBmMTI1MzAyZDE0OWQyYjJjNmFjNWZiY2IxNzk2Yl80LTItMS0xLTE3NDM2Mg_bc423492-3295-46d5-be28-3e3270aaea7a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i6f67bb65c7484dc2b0c8012f58e5cf0d_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MzkwZjEyNTMwMmQxNDlkMmIyYzZhYzVmYmNiMTc5NmIvdGFibGVyYW5nZTozOTBmMTI1MzAyZDE0OWQyYjJjNmFjNWZiY2IxNzk2Yl82LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmNkMjg5MDg3ODA4ODQ4MTVhN2I0ZTViNDNiYzlkMzU1XzEzMg_1326c197-ba73-4a1f-b621-10b89b3b23ee"
      unitRef="usd">62000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i850a77a234774bf5a4783c3c0030ca8e_I20230126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjAxYWE5YjA4ZjgyNDFkMjkwMjc5ZjBjM2JjNWU3NzIvdGFibGVyYW5nZToyMDFhYTliMDhmODI0MWQyOTAyNzlmMGMzYmM1ZTc3Ml8xLTItMS0xLTE3NDM2Mg_7588d5bb-7105-478a-a35b-9228b687768e"
      unitRef="shares">1818146</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2d34534410754ab1a8baa62248370c82_I20230126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGFibGU6MjAxYWE5YjA4ZjgyNDFkMjkwMjc5ZjBjM2JjNWU3NzIvdGFibGVyYW5nZToyMDFhYTliMDhmODI0MWQyOTAyNzlmMGMzYmM1ZTc3Ml8yLTItMS0xLTE3NDM2Mg_cf6a2301-c2a0-4e97-b93a-e79d261e9b3b"
      unitRef="shares">107507386</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xL2ZyYWc6YWNhMjk4YzBlMGM2NDU3Yjk0NmRkZjlkM2I5ODFlZGEvdGV4dHJlZ2lvbjphY2EyOThjMGUwYzY0NTdiOTQ2ZGRmOWQzYjk4MWVkYV8zOTA_1a86e5a4-5877-452d-bde8-fbcd1f520f3e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Specified portions of the Registrant's definitive proxy statement to be filed in connection with solicitation of proxies for its 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Form 10-K. Exhibit index is located on pages 96 to 101 of this filing. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN185Ny9mcmFnOjI1MWI2MzYyNmJlODQ0MGFhOGVhYTM5OWZiZTkwMjJlL3RhYmxlOjZmZThlNjUzMTQwMzRiZGE5MTA2ZmY5MmQ4OGIxNzQ0L3RhYmxlcmFuZ2U6NmZlOGU2NTMxNDAzNGJkYTkxMDZmZjkyZDg4YjE3NDRfMS0wLTEtMS0xNzQzNjIvdGV4dHJlZ2lvbjpkMTlkZTc0OGQ2Y2I0MWRhYTE1YTI1MzczODM3YzJlZF83MQ_94abe652-461d-45a3-9596-62705ca03f32">238</dei:AuditorFirmId>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzIwNQ_56af7f89-b086-43f1-8831-8fb5a2499c62"
      unitRef="usd">900000000</regn:UpFrontPaymentToCollaboratingParty>
    <us-gaap:OtherLiabilities
      contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzI1Mw_7b3a42fd-8759-4443-a571-0c931fdb0207"
      unitRef="usd">241000000</us-gaap:OtherLiabilities>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ib7a293af7f1a454b8c850b4caf8e4c3f_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzIyMQ_fa781e00-58f0-4a0f-9bcb-fe6c1d521f7c"
      unitRef="usd">100000000</regn:UpFrontPaymentToCollaboratingParty>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d21c3111e2741a386578f848272cd46_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzU0OTc1NTg1MzIzNg_5933efe9-6d0a-414b-8b56-60d4a09392ef"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:AuditorName
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzkzNzc_79669278-f4da-4971-a566-6e902b634342">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDAvZnJhZzozZTM5ZWVlMzc0NDU0ZmJkYTllNzE1OThlNGZmN2NkOC90ZXh0cmVnaW9uOjNlMzllZWUzNzQ0NTRmYmRhOWU3MTU5OGU0ZmY3Y2Q4XzkzNzE_e2fc5584-9884-4a8c-a004-831b9dc1803c">Florham Park, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQtMS0xLTEtMTc0MzYy_305511be-8de1-4848-9e97-a63e4fbbb21b"
      unitRef="usd">3105900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQtMy0xLTEtMTc0MzYy_8ec24fc3-5e53-42b5-b154-900578403b38"
      unitRef="usd">2885600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzUtMS0xLTEtMTc0MzYy_47106067-9263-466e-9f85-5d06e1ccf5e2"
      unitRef="usd">4636400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzUtMy0xLTEtMTc0MzYy_047b4555-c4a0-41c1-b1d3-adae3c6c345a"
      unitRef="usd">2809100000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzYtMS0xLTEtMTc0MzYy_3127728c-0f43-4253-b59b-ef0deaaba222"
      unitRef="usd">5328700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzYtMy0xLTEtMTc0MzYy_9f72fe17-9689-4ef3-94d1-0af374d84f08"
      unitRef="usd">6036500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzctMS0xLTEtMTc0MzYy_26fe3289-038f-4cfd-95bf-2ba518e0eaa2"
      unitRef="usd">2401900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzctMy0xLTEtMTc0MzYy_e93031af-bbda-4e7a-840f-b4e9a3eb19e3"
      unitRef="usd">1951300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzgtMS0xLTEtMTc0MzYy_f4a3d71c-9b4d-4848-914d-9eab100aefab"
      unitRef="usd">411200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzgtMy0xLTEtMTc0MzYy_d6a70520-a96c-4df0-9f4a-c809d23a8d37"
      unitRef="usd">332400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzktMS0xLTEtMTc0MzYy_3ce702ec-bf3a-411c-9869-4c8aeed4206c"
      unitRef="usd">15884100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzktMy0xLTEtMTc0MzYy_b82be131-0dce-449e-b170-3ea69b39e860"
      unitRef="usd">14014900000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzExLTEtMS0xLTE3NDM2Mg_7665b915-9f02-4051-974a-114fae7252f8"
      unitRef="usd">6591800000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzExLTMtMS0xLTE3NDM2Mg_a3c0c9d3-6768-4bfb-bb3d-d72cb9cafd64"
      unitRef="usd">6838000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEyLTEtMS0xLTE3NDM2Mg_bb9e9e47-230f-4c3d-bbf8-e4da4955b53f"
      unitRef="usd">3763000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEyLTMtMS0xLTE3NDM2Mg_8999436f-2aca-4c02-8464-8cdcaba62814"
      unitRef="usd">3482200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTEtMS0xLTE3Njk2MQ_2baedb67-2aa6-4358-b33b-c3bbc4079659"
      unitRef="usd">915500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTMtMS0xLTE3Njk2MQ_7e9e5989-70a0-40c6-936a-ab4ed44d7e96"
      unitRef="usd">6700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTEtMS0xLTE3NDM2Mg_cabc7d33-6963-4afa-9b0c-cc7609592153"
      unitRef="usd">1723700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzEzLTMtMS0xLTE3NDM2Mg_0eacb45e-026f-45a1-8f12-90476cfa4250"
      unitRef="usd">876900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE0LTEtMS0xLTE3NDM2Mg_b4e7ba8d-defa-40ea-94aa-d84fe68fb712"
      unitRef="usd">336400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE0LTMtMS0xLTE3NDM2Mg_33c0b67d-d8ba-43a9-b0d5-0fe92799160e"
      unitRef="usd">216100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE1LTEtMS0xLTE3NDM2Mg_5e2a8c88-818f-4d70-a4dd-8da3d49c8966"
      unitRef="usd">29214500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE1LTMtMS0xLTE3NDM2Mg_39c4a35e-23fe-4672-82a3-bd887588c369"
      unitRef="usd">25434800000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE5LTEtMS0xLTE3NDM2Mg_e35478ac-2187-400a-86e5-ddf3fc3955cf"
      unitRef="usd">589200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzE5LTMtMS0xLTE3NDM2Mg_a27ad203-3091-4d35-a821-df95b4816458"
      unitRef="usd">564000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIwLTEtMS0xLTE3NDM2Mg_bf361362-fcd7-42c3-8849-328af9a99012"
      unitRef="usd">2074200000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIwLTMtMS0xLTE3NDM2Mg_20d6b32a-7ca8-4e55-ba2b-13e20b9f7f60"
      unitRef="usd">2206800000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIxLTEtMS0xLTE3NDM2Mg_113ed7fa-ebb1-4b01-8d20-22478daa41fa"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIxLTMtMS0xLTE3NDM2Mg_6f2bcd58-495c-4a9e-860f-3d0f09971778"
      unitRef="usd">719700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIyLTEtMS0xLTE3NDM2Mg_8e86b302-20d3-4040-a30c-5fb21225bc30"
      unitRef="usd">477900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIyLTMtMS0xLTE3NDM2Mg_65c1c80d-926e-4053-869f-a935b94a94ee"
      unitRef="usd">442000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIzLTEtMS0xLTE3NDM2Mg_c4928329-6c38-4624-8308-7f4cb8647056"
      unitRef="usd">3141300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzIzLTMtMS0xLTE3NDM2Mg_67958e70-a516-41ba-a5cf-f28e8526bc70"
      unitRef="usd">3932500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI1LTEtMS0xLTE3NDM2Mg_dcd61621-2111-4998-ba1d-dcde4e17bd93"
      unitRef="usd">1981400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI1LTMtMS0xLTE3NDM2Mg_c250915b-f7ae-4a7f-819e-0ac3e89a45e2"
      unitRef="usd">1980000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI2LTEtMS0xLTE3NDM2Mg_01acd0ad-8e87-4f3c-8dbc-658e42a8b349"
      unitRef="usd">720000000.0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI2LTMtMS0xLTE3NDM2Mg_31cdf9a2-4aa1-41b3-9b32-60160bc88e4b"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI3LTEtMS0xLTE3NDM2Mg_7aacafe7-8ef1-4324-8ce2-ae77fce72d66"
      unitRef="usd">69800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI3LTMtMS0xLTE3NDM2Mg_772825eb-6606-4180-b412-1342da24f299"
      unitRef="usd">73300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI4LTEtMS0xLTE3NDM2Mg_86002a7b-d56e-408d-a76b-5c6b1e303e90"
      unitRef="usd">638000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI4LTMtMS0xLTE3NDM2Mg_3938e596-0afe-4abf-a81e-29153740991b"
      unitRef="usd">680200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI5LTEtMS0xLTE3NDM2Mg_4bd5d64f-0c82-40ed-be52-b0df91fcc750"
      unitRef="usd">6550500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzI5LTMtMS0xLTE3NDM2Mg_83f02de3-b16d-4a90-8bb4-bf59896de819"
      unitRef="usd">6666000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzMxLTEtMS0xLTE3NDM2Mg_7951e91e-e7fa-4587-94ff-b064c68f21ac"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzMxLTMtMS0xLTE3NDM2Mg_8072a75e-a4e8-4bf1-b1e8-b62245c9ead3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzIx_677f2a95-53d1-4c75-ad96-c0a2b9f9fa85"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzIx_bc29d0fe-ffa0-406c-8cdb-73eca584590a"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzM1_12564c48-a690-4fc5-b189-e16e792f0c6a"
      unitRef="shares">30000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzM1_f2b4a6e0-ced7-4111-976d-cd51e4e4ac54"
      unitRef="shares">30000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_35056692-f747-4f99-9b39-f8f663d9f3bf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_a3937fd6-78db-41ae-8ed3-c67c75e0cac1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_a5fa6eec-116b-4847-aa60-18c0c72e2472"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmYwODM3MzlkODljNjRjMTBiM2NjZTI4ZjQ3MjFiOGFmXzgy_b15b35c8-a107-4c16-90b6-6ef0adb401a2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTEtMS0xLTE3NDM2Mg_4b469567-8d2a-41e6-8bed-c4cc1fb788fd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM0LTMtMS0xLTE3NDM2Mg_7cf94409-f511-4215-ad3c-2c111bb1e6ed"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzMy_7610260b-2fde-4ad6-b5e5-dc39bfb6b1b0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzMy_97532feb-4766-419c-9b37-ed7b213b97e8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzQ2_93887cb1-67f6-4824-834b-4fbcd8bbcf50"
      unitRef="shares">40000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzQ2_b7107518-b6a1-4d7f-82e4-86289eefb678"
      unitRef="shares">40000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_251d6c53-1c8c-4404-84dd-14bb7afd8e62"
      unitRef="shares">1800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_c596f633-a9e2-4061-ae3e-89e450fa2c32"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_d9ed1926-9eb5-4bba-be6d-415761926ff1"
      unitRef="shares">1800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOmFlNjc3M2NiYTcwMjRkZTNhZjRjN2Q2NDYwMzFmYTA4XzEwMA_ee43723c-0ef0-4236-88f4-a234f9df13fc"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTEtMS0xLTE3NDM2Mg_a4229a3a-2c1d-42dc-88db-88fd255d7f00"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibef5f55864fa481ca4cc0c510430e3e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM1LTMtMS0xLTE3NDM2Mg_54c1dafd-6686-407f-9c33-0e67551590da"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzE4_567b34cb-7474-4660-a829-51d496b30977"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzE4_e280e5b7-5827-42c0-9faa-3c370086edd8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzMy_0c031f4b-faf8-44a5-88db-ec385aac67af"
      unitRef="shares">320000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzMy_4175dfe2-3c26-4799-a523-a0b4f1702880"
      unitRef="shares">320000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzcw_cbc4631d-1716-46cb-bb81-908369a076fd"
      unitRef="shares">130400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjk1NmE3ZGY2YzhlOTQyZGY4MjVlZmEwOGE1NDY2ZjQyXzg1_ca9583b9-01f1-40a3-b83a-e15311b1f32d"
      unitRef="shares">126200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTEtMS0xLTE3NDM2Mg_0708ee9e-77f4-4cd5-9380-21b71b986c3d"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i04ef055062c84a5e958dead58e5ac1d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM2LTMtMS0xLTE3NDM2Mg_83f22cc0-aa8e-440b-9afb-ae19bcc4db8c"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM3LTEtMS0xLTE3NDM2Mg_1bfc4667-4d72-4bb3-bc95-215df26827d9"
      unitRef="usd">9949300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM3LTMtMS0xLTE3NDM2Mg_57de0ed9-1cb2-412b-bca6-ff84662b28c4"
      unitRef="usd">8087500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM4LTEtMS0xLTE3NDM2Mg_14e88829-460f-49fd-963f-7a7eb5131091"
      unitRef="usd">23306700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM4LTMtMS0xLTE3NDM2Mg_3063f7d9-db83-4289-a59d-3f039f707d8e"
      unitRef="usd">18968300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM5LTEtMS0xLTE3NDM2Mg_02bb38c2-682a-4eeb-aac8-d40bc29acb2b"
      unitRef="usd">-238800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzM5LTMtMS0xLTE3NDM2Mg_0788dd52-e6c3-487b-bcfd-8cdddd9a4679"
      unitRef="usd">-26200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjljZjE3NzU4YmY3NjQwMWM4ZjdiOTU1Nzg3NTQ3NGNkXzI5_3d777e14-4c3f-4cba-a0ee-ea5ed7a0a3cc"
      unitRef="shares">22600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTAtMS0xLTE3NDM2Mi90ZXh0cmVnaW9uOjljZjE3NzU4YmY3NjQwMWM4ZjdiOTU1Nzg3NTQ3NGNkXzUx_00949858-2bf7-4eca-af3c-11b31817f8b3"
      unitRef="shares">19400000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTEtMS0xLTE3NDM2Mg_ecc62364-ec30-498f-b2d7-c7f884059d1f"
      unitRef="usd">10353300000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQwLTMtMS0xLTE3NDM2Mg_f2b8b9f2-0f16-437f-ab23-6a095c2b6c2d"
      unitRef="usd">8260900000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQxLTEtMS0xLTE3NDM2Mg_5cda0f85-256b-4232-a2b2-8dd8d5f0342d"
      unitRef="usd">22664000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQxLTMtMS0xLTE3NDM2Mg_4da4729b-9f1c-4ebb-86ee-92d4f50e1e98"
      unitRef="usd">18768800000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQyLTEtMS0xLTE3NDM2Mg_a91af9bf-c32a-403d-bf66-fc99fc1c4a3f"
      unitRef="usd">29214500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDMvZnJhZzoxYWFlZmQ1MTJhNDE0N2Y0YTYwYTVjZmQ4MDU2ZTU2Yi90YWJsZTpjMThjMWYyNjgzYmQ0MjJiOTUxZGY4OTU1MjU1NTc2NS90YWJsZXJhbmdlOmMxOGMxZjI2ODNiZDQyMmI5NTFkZjg5NTUyNTU1NzY1XzQyLTMtMS0xLTE3NDM2Mg_16f817c1-98d7-4a42-9146-17b2cf79e1e2"
      unitRef="usd">25434800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e78ed4547174cfb8fb6f17834e6e280_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQtMi0xLTEtMTc0MzYy_ed69ea18-7bcb-423f-ba3d-0536fffc1bc5"
      unitRef="usd">6893700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5815b19f7c243a9bef193f7182d4504_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQtNC0xLTEtMTc0MzYy_09c0d72f-63e2-46fe-8344-fe0ba37b9391"
      unitRef="usd">12117200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c0f43af2adc4ac9932414df23261641_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQtNi0xLTEtMTc0MzYy_031cf7fa-53b2-4048-90a0-aee2cfcac44e"
      unitRef="usd">5567600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia32343f1d31f45ac91df7774f62751d8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzUtMi0xLTEtMTc0MzYy_c080624a-2962-4c3e-8a9a-99f9d8e8ecfd"
      unitRef="usd">2855700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fb172db0f4c40f4a010b6c1e387157a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzUtNC0xLTEtMTc0MzYy_2adf3926-75c1-4088-a377-7d509387af1f"
      unitRef="usd">1902200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f5eff728cc34a73ac8a0e7575138379_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzUtNi0xLTEtMTc0MzYy_d8e06836-4904-4936-b58c-d0b3b2ac3cc3"
      unitRef="usd">1186400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9eda36fe2b3493fba4bcd24c7f40343_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzYtMi0xLTEtMTc0MzYy_51a1c01c-f4a3-440d-920b-67709a7383a9"
      unitRef="usd">2058400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32d2d84b10ee49a78ff80e825d16507c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzYtNC0xLTEtMTc0MzYy_9f0274d4-536f-4680-a6c3-b2a96c60f272"
      unitRef="usd">1771100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8125997c22b4a2aaf3b8071ba41f4fb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzYtNi0xLTEtMTc0MzYy_c36b0530-3d07-437e-ba63-7d1cd72d79f8"
      unitRef="usd">1186100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8632402ae5742efb1d686222b335e92_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzctMi0xLTEtMTc0MzYy_a135a0a3-37a5-4b4f-9978-e55f63ee3f88"
      unitRef="usd">365100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2052b209c6de41c9a910b9b4862dbf9d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzctNC0xLTEtMTc0MzYy_fcd8196d-6339-4ce5-899e-6d35c6763951"
      unitRef="usd">281200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1cdfba9891941a6a7d17fd635d19308_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzctNi0xLTEtMTc0MzYy_968e4f12-189b-4f95-82c6-a50937c2dbb6"
      unitRef="usd">557000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzgtMi0xLTEtMTc0MzYy_def18e84-b260-4c97-a570-11a09a424ef9"
      unitRef="usd">12172900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzgtNC0xLTEtMTc0MzYy_ee6fc6ad-e3f2-4a1a-be25-0a2e6bedd30e"
      unitRef="usd">16071700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzgtNi0xLTEtMTc0MzYy_c5dee8ae-b0e3-46a8-879e-61253d64e5ce"
      unitRef="usd">8497100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzExLTItMS0xLTE3NDM2Mg_aeffc617-25a6-4838-a91c-80c4030e4b0d"
      unitRef="usd">3592500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzExLTQtMS0xLTE3NDM2Mg_4e32607c-96ca-4055-bd87-18be89d8cd5d"
      unitRef="usd">2860100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzExLTYtMS0xLTE3NDM2Mg_c140d3cb-0c41-463b-971a-926d1295371b"
      unitRef="usd">2647000000</us-gaap:ResearchAndDevelopmentExpense>
    <regn:AcquiredInProcessResearchAndDevelopment
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTItMS0xLTE4MjkwMw_d04d36f8-b6d1-41b1-81a2-b1ee8d42066e"
      unitRef="usd">255100000</regn:AcquiredInProcessResearchAndDevelopment>
    <regn:AcquiredInProcessResearchAndDevelopment
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTQtMS0xLTE4MjkwMw_87d51197-367c-485b-81aa-4a5d6c933e96"
      unitRef="usd">48000000.0</regn:AcquiredInProcessResearchAndDevelopment>
    <regn:AcquiredInProcessResearchAndDevelopment
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTYtMS0xLTE4MjkwMw_4d3fc267-1a28-4010-8b2c-d83b9337b366"
      unitRef="usd">88000000.0</regn:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTItMS0xLTE3NDM2Mg_29f59dba-28bc-408f-ad39-d038d7b838ca"
      unitRef="usd">2115900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTQtMS0xLTE3NDM2Mg_4a0653cf-5ac7-4d7d-a88e-13a0461084c1"
      unitRef="usd">1824900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEyLTYtMS0xLTE3NDM2Mg_e1d7f73b-fff7-4dbb-b145-8ce28eb06335"
      unitRef="usd">1346000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5e78ed4547174cfb8fb6f17834e6e280_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEzLTItMS0xLTE3NDM2Mg_7d8b3fb0-15d9-403a-9cc1-5542b81507c8"
      unitRef="usd">800000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic5815b19f7c243a9bef193f7182d4504_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEzLTQtMS0xLTE3NDM2Mg_7eea3d78-aece-416c-9779-8a1694f55694"
      unitRef="usd">1773100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6c0f43af2adc4ac9932414df23261641_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzEzLTYtMS0xLTE3NDM2Mg_daa2ff65-3e13-4013-a468-22c2fb12a310"
      unitRef="usd">491900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic8986e8b381c40169962c1d089395044_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE0LTItMS0xLTE3NDM2Mg_58e1c11a-4d44-4fc3-a0a5-0326c4511f8e"
      unitRef="usd">760400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibc263c8f9c744cdb933cb195b372c5ec_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE0LTQtMS0xLTE3NDM2Mg_08ad9f8f-fe65-4cb2-ab81-9d68bb5dc62b"
      unitRef="usd">664400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i714163480a9a4f66aa296cf9c53130f7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE0LTYtMS0xLTE3NDM2Mg_17c5b932-71d2-459c-adae-76ccde57aa54"
      unitRef="usd">628000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE1LTItMS0xLTE3NDM2Mg_3dc235f1-2380-4ecc-9627-1f7ad1c775d3"
      unitRef="usd">89900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE1LTQtMS0xLTE3NDM2Mg_94cb6853-ee61-4786-a178-a74618805213"
      unitRef="usd">45600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE1LTYtMS0xLTE3NDM2Mg_8354884d-c3b4-4087-ac08-2186f09be080"
      unitRef="usd">280400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE2LTItMS0xLTE3NDM2Mg_562787a3-f112-4683-b0fe-398d8a95eb9f"
      unitRef="usd">7434000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE2LTQtMS0xLTE3NDM2Mg_38f014de-0b6f-49b4-a1aa-270c4291e2da"
      unitRef="usd">7124900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE2LTYtMS0xLTE3NDM2Mg_04de25d4-e974-43f3-a529-12ea2ac0080f"
      unitRef="usd">4920500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE4LTItMS0xLTE3NDM2Mg_3b270fe7-51bb-4ee8-bc3c-a8e382f3d90a"
      unitRef="usd">4738900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE4LTQtMS0xLTE3NDM2Mg_fdcf4bcb-efb1-4b12-a834-86f2fb12aff3"
      unitRef="usd">8946800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzE4LTYtMS0xLTE3NDM2Mg_747f8b5d-e297-4eea-bcdb-defe7d39d702"
      unitRef="usd">3576600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIxLTItMS0xLTE3NDM2Mg_d9608a69-e65c-4ee6-825a-3aec0e7ef5e3"
      unitRef="usd">179300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIxLTQtMS0xLTE3NDM2Mg_229f0b71-2aa5-4a98-a8ce-8a392cc59bc4"
      unitRef="usd">436300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIxLTYtMS0xLTE3NDM2Mg_53c6b25b-a301-4069-a786-62626c0d86e2"
      unitRef="usd">290700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIyLTItMS0xLTE3NDM2Mg_99a4323f-024a-432b-ad47-f9fb81cdac1c"
      unitRef="usd">59400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIyLTQtMS0xLTE3NDM2Mg_7e424f2a-a69f-4d09-92c7-3594d9f96afe"
      unitRef="usd">57300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIyLTYtMS0xLTE3NDM2Mg_071ac281-5272-4213-a26b-ae3f2c5d066a"
      unitRef="usd">56900000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIzLTItMS0xLTE3NDM2Mg_226636f2-e6b2-4754-bc3f-aeb686823259"
      unitRef="usd">119900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIzLTQtMS0xLTE3NDM2Mg_ae34888f-ca00-4545-aee5-34a20e22c675"
      unitRef="usd">379000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzIzLTYtMS0xLTE3NDM2Mg_a7307f74-2435-46d5-a51f-48b9fa884a23"
      unitRef="usd">233800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI1LTItMS0xLTE3NDM2Mg_f8b99b7f-d44f-4c7c-82a8-a67dea5f9fc2"
      unitRef="usd">4858800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI1LTQtMS0xLTE3NDM2Mg_df114fca-9f4c-4e53-bce2-472abe4691b0"
      unitRef="usd">9325800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI1LTYtMS0xLTE3NDM2Mg_0d243767-6d01-4f7c-8cd6-0d0e8fad9bbb"
      unitRef="usd">3810400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI3LTItMS0xLTE3NDM2Mg_1812ff75-5909-49d8-ad86-f23bf25b61ef"
      unitRef="usd">520400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI3LTQtMS0xLTE3NDM2Mg_2336b5bb-0fa9-42ce-898a-3ab9c9ff5a31"
      unitRef="usd">1250500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI3LTYtMS0xLTE3NDM2Mg_a44334dd-21e5-45c7-9564-20b8d438568f"
      unitRef="usd">297200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI5LTItMS0xLTE3NDM2Mg_0c81fbbc-c5e2-4686-a11f-b1a54f50bcb9"
      unitRef="usd">4338400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI5LTQtMS0xLTE3NDM2Mg_e8504f41-d91b-45ca-aae3-bea2c2e5bf33"
      unitRef="usd">8075300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzI5LTYtMS0xLTE3NDM2Mg_5955652e-ec44-4ab4-8bc3-959f698d4319"
      unitRef="usd">3513200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMxLTItMS0xLTE3NDM2Mg_13d6a368-ca1b-4ca8-a6fa-810af6ecdd7d"
      unitRef="usdPerShare">40.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMxLTQtMS0xLTE3NDM2Mg_2b79975d-c04f-4c22-ab9f-68dfd65c2501"
      unitRef="usdPerShare">76.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMxLTYtMS0xLTE3NDM2Mg_9666fe9a-8b08-409c-aea8-a6309196c506"
      unitRef="usdPerShare">32.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMyLTItMS0xLTE3NDM2Mg_4ae2eb02-4a56-4142-9559-3ab373b9ee5f"
      unitRef="usdPerShare">38.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMyLTQtMS0xLTE3NDM2Mg_85e58e62-7b04-4236-a13a-beb94c077809"
      unitRef="usdPerShare">71.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzMyLTYtMS0xLTE3NDM2Mg_32187d9b-be7c-4c1b-a852-ddc427e2552c"
      unitRef="usdPerShare">30.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM0LTItMS0xLTE3NDM2Mg_dfb3a7c4-7142-4703-b3c0-8c13dc0203d7"
      unitRef="shares">107100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM0LTQtMS0xLTE3NDM2Mg_0c3e4181-5772-4e71-a2f6-be2b4a83e4be"
      unitRef="shares">105700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM0LTYtMS0xLTE3NDM2Mg_d4ab192f-fec3-4c1f-92bf-da234ae2ff42"
      unitRef="shares">107600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM1LTItMS0xLTE3NDM2Mg_04c3b122-659d-4790-8c19-e7a464b26ecc"
      unitRef="shares">113500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM1LTQtMS0xLTE3NDM2Mg_917e3752-96aa-47ee-a1c7-c5ba801dec5c"
      unitRef="shares">112200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM1LTYtMS0xLTE3NDM2Mg_88d3e40e-ba28-4b15-90a6-4d13272cf8db"
      unitRef="shares">115100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM4LTItMS0xLTE3NDM2Mg_ad8574fd-8052-4c57-8f66-e6054c7675d4"
      unitRef="usd">4338400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM4LTQtMS0xLTE3NDM2Mg_ab6537a1-4d0e-4508-b1ee-87d08c1a2fb4"
      unitRef="usd">8075300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzM4LTYtMS0xLTE3NDM2Mg_9387cb86-74d9-403a-99b9-4f45f31c1034"
      unitRef="usd">3513200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQwLTItMS0xLTE3NDM2Mg_b84c75a1-ca8a-4771-9abc-7da1ea52d3cc"
      unitRef="usd">-213600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQwLTQtMS0xLTE3NDM2Mg_48c86011-e823-4b1a-ab38-7440a8400361"
      unitRef="usd">-56400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQwLTYtMS0xLTE3NDM2Mg_5c7abaf5-c467-4171-b799-1d280f82b337"
      unitRef="usd">9100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQxLTItMS0xLTE3NDM2Mg_5c2add3f-c249-4bbc-86b5-d881e3e0c06e"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQxLTQtMS0xLTE3NDM2Mg_6de4f596-78b8-4ac4-abf3-a8c30cd68c3a"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQxLTYtMS0xLTE3NDM2Mg_8cff6fd0-a7b0-4f09-960b-60cd5b82f920"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQyLTItMS0xLTE3NDM2Mg_21ba12d8-c691-45ac-9ac3-5b6b502bf305"
      unitRef="usd">4125800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQyLTQtMS0xLTE3NDM2Mg_9b93461d-cc25-433a-ab91-74a754015dfd"
      unitRef="usd">8019800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDYvZnJhZzo5MTEyZmJhYWI2Njg0NzEyYjg1MjgxOGZlZGVjNjk1Yi90YWJsZTplOWFjMTQwYjg1Y2I0NjFkYWRjMzBhMDBmMWFkMDkwMC90YWJsZXJhbmdlOmU5YWMxNDBiODVjYjQ2MWRhZGMzMGEwMGYxYWQwOTAwXzQyLTYtMS0xLTE3NDM2Mg_56d20d1d-b266-47d5-b0e6-48e30bc8404b"
      unitRef="usd">3521400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic29a659882534aef807d28ba085ed2cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMi0xLTEtMTc0MzYy_4ce20f09-76d0-4b4d-a252-92d8d749d2da"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic29a659882534aef807d28ba085ed2cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItNC0xLTEtMTc0MzYy_2a9cfdc4-8809-4986-8cdd-bd806c9121d3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i034cb1f338a14cdb98427fcd16a6f4bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItNi0xLTEtMTc0MzYy_c73338ff-6c34-4f40-903c-243c013b8a08"
      unitRef="shares">113300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i034cb1f338a14cdb98427fcd16a6f4bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItOC0xLTEtMTc0MzYy_cd1912a1-5877-423c-b8a9-89257d7c796f"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5358609c29a1448aac4097e872d7c506_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTAtMS0xLTE3NDM2Mg_621d07de-ab82-4ce0-9843-d739b1901199"
      unitRef="usd">4428600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib492caa05ff2478cac6ccfaa46f83cdb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTItMS0xLTE3NDM2Mg_3073b0e9-8bd9-4eae-9a67-80e936467d7e"
      unitRef="usd">7379800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia54e4119f42e4422bbe1589864186444_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTQtMS0xLTE3NDM2Mg_474654aa-edd8-4fb1-aced-2818f4b4a413"
      unitRef="usd">21100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i548c389088d843f3991fec42e82011bc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTYtMS0xLTE3NDM2Mg_e8b699a9-441b-433d-996b-77a9756af8fe"
      unitRef="shares">4900000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i548c389088d843f3991fec42e82011bc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMTgtMS0xLTE3NDM2Mg_1582a780-b8e9-4e61-9dec-f7de400d3f8e"
      unitRef="usd">-739900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzItMjAtMS0xLTE3NDM2Mg_6f97d786-2e04-4c4f-8742-0a899e165e28"
      unitRef="usd">11089700000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i15a99297fdea45a3aac29a3823f628b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMtNi0xLTEtMTc0MzYy_10628454-fb39-46de-a604-64c18e4745de"
      unitRef="shares">9600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMtMTAtMS0xLTE3NDM2Mg_dddcf90a-0e8e-4c01-8651-7de415831885"
      unitRef="usd">2576400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMtMjAtMS0xLTE3NDM2Mg_7ccc9f10-e0e8-4fb0-89ee-bb3187efe846"
      unitRef="usd">2576400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i15a99297fdea45a3aac29a3823f628b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzQtNi0xLTEtMTc0MzYy_32b35833-fdc7-4e9a-8fb3-fe798157bcf9"
      unitRef="shares">1400000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzQtMTAtMS0xLTE3NDM2Mg_262dbd63-00d8-4cbc-bec8-70f2abde8ae2"
      unitRef="usd">768900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzQtMjAtMS0xLTE3NDM2Mg_2e0db603-51d9-40ca-a7f0-04756eca0b6a"
      unitRef="usd">768900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMTAtMS0xLTE3NDM2Mg_c9604d22-250f-4fe9-a7d9-c3d206050969"
      unitRef="usd">37200000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMTYtMS0xLTE3NDM2Mg_eebb1aea-42b1-464f-9171-f59f74d4242b"
      unitRef="shares">100000</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMTgtMS0xLTE3NDM2Mg_7f26873d-1f8e-43f4-886b-ae8acb8c9e6f"
      unitRef="usd">7500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzUtMjAtMS0xLTE3NDM2Mg_630053c5-1c41-434c-8803-1ed86a6c95a6"
      unitRef="usd">44700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzYtMTYtMS0xLTE3NDM2Mg_af1fe25b-0489-4a19-a0a5-90193b5da3f3"
      unitRef="shares">11600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3461f1e014c34ede904505072218051f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzYtMTgtMS0xLTE3NDM2Mg_4830c758-242c-4f23-a682-e833750200d0"
      unitRef="usd">5880900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzYtMjAtMS0xLTE3NDM2Mg_d84557f6-bd84-4469-8a20-3d82a44ec3ae"
      unitRef="usd">5880900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie8665fa9f5a6447c96c0719a9971ca71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzgtMTAtMS0xLTE3NDM2Mg_61eed7f9-829a-44f9-9ebc-d76b85fddbaf"
      unitRef="usd">442900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzgtMjAtMS0xLTE3NDM2Mg_126475f9-8f41-42f4-ba85-ea0b2edc3957"
      unitRef="usd">442900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ieb0e234fb8004f8688e0132e0687751f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEwLTEyLTEtMS0xNzQzNjI_9e25fba8-930a-4b75-a0c7-18af6287a888"
      unitRef="usd">3513200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEwLTIwLTEtMS0xNzQzNjI_8a97af3a-3a87-4b71-9077-9797113c8aab"
      unitRef="usd">3513200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i09eb064653cc48138003ea93e9fb6cfa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzExLTE0LTEtMS0xNzQzNjI_f839e2b7-6ba9-447f-a030-5fac476c9ae9"
      unitRef="usd">8200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzExLTIwLTEtMS0xNzQzNjI_c2a507f0-fe8a-49df-98b3-cff90aef219f"
      unitRef="usd">8200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i537fb80c394c4504bbb568309e3d34f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTItMS0xLTE3NDM2Mg_90f5cc5d-a32e-40b3-a3eb-c8c7ee676c8c"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i537fb80c394c4504bbb568309e3d34f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTQtMS0xLTE3NDM2Mg_d83db85a-1db0-43b2-8051-6d74f312ec1d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1a9bb7780cb644e2bf4abf693651eabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTYtMS0xLTE3NDM2Mg_a860ec84-ec91-4130-b8f7-e9c342dc9161"
      unitRef="shares">121500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1a9bb7780cb644e2bf4abf693651eabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTgtMS0xLTE3NDM2Mg_952aeb4c-6ab1-4e72-bcd6-0ca2225811d6"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55644888ab1b4dfa9869ab896e024903_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTEwLTEtMS0xNzQzNjI_fea82ea7-b224-4b18-aa94-5a15ab0ddb0e"
      unitRef="usd">6716200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8220af90ab304d119e3feac29aceae08_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTEyLTEtMS0xNzQzNjI_433f3b23-ad1e-40cc-928e-c7307cadb32a"
      unitRef="usd">10893000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8049544cda8b4dafaed97a8723f7337d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTE0LTEtMS0xNzQzNjI_64b89c7e-5eeb-4be0-9097-96cb67da37fb"
      unitRef="usd">29300000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i370f4685af6144d1917cfe1061627472_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTE2LTEtMS0xNzQzNjI_530a14cd-1109-4575-a457-e55c0bc00c61"
      unitRef="shares">16400000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i370f4685af6144d1917cfe1061627472_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTE4LTEtMS0xNzQzNjI_b87abeee-1528-411f-bcfd-37a1d8a1da83"
      unitRef="usd">-6613300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEyLTIwLTEtMS0xNzQzNjI_3f5cdd4f-2735-44bc-b93e-9282afdd5cef"
      unitRef="usd">11025300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iabc93395b4534195a6e703327ee8276e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEzLTYtMS0xLTE3NDM2Mg_e2ea1e3d-0086-4938-8bdb-d7839b6c52f1"
      unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEzLTEwLTEtMS0xNzQzNjI_216d9501-dfa1-49c9-b8e4-612ab18d607e"
      unitRef="usd">1676000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzEzLTIwLTEtMS0xNzQzNjI_2746b6f8-ca08-45b8-b5c8-7a3e75ba818e"
      unitRef="usd">1676000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="iabc93395b4534195a6e703327ee8276e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE0LTYtMS0xLTE3NDM2Mg_7a0863f6-6c42-4aeb-b9f1-2a12b722ef37"
      unitRef="shares">1500000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE0LTEwLTEtMS0xNzQzNjI_f85e373a-7781-4007-a348-0ae8731c5c27"
      unitRef="usd">944600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE0LTIwLTEtMS0xNzQzNjI_3da3565b-0a3e-4e3c-9b49-95c2a2b85fec"
      unitRef="usd">944600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTEwLTEtMS0xNzQzNjI_110d160d-f53d-42f5-bb55-fc1b751f541b"
      unitRef="usd">40700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTE2LTEtMS0xNzQzNjI_5c870729-034d-4113-ad9b-0f8329fa475e"
      unitRef="shares">100000</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTE4LTEtMS0xNzQzNjI_c6f8cc5a-ebef-4481-b9b8-3969a265223d"
      unitRef="usd">7400000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE1LTIwLTEtMS0xNzQzNjI_3b595a7b-c716-4503-b52e-f4efb6611e1f"
      unitRef="usd">48100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE2LTE2LTEtMS0xNzQzNjI_60495beb-cbf6-45cb-b34c-fb1798dfb224"
      unitRef="shares">3100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i439b09eaccf14173ac24671a7d691568_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE2LTE4LTEtMS0xNzQzNjI_7101ad6f-2b43-44ce-8398-7619e0ae6747"
      unitRef="usd">1655000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE2LTIwLTEtMS0xNzQzNjI_e6796368-784a-4017-86bf-0aaec307245e"
      unitRef="usd">1655000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3af5c52a31c42e2ba08ca85bf32d8e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE3LTEwLTEtMS0xNzQzNjI_c7398ea5-9634-4b7c-90aa-71e35afb3562"
      unitRef="usd">599200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE3LTIwLTEtMS0xNzQzNjI_dda15514-d1d1-4ea0-ac5e-ca6c6b42c0cc"
      unitRef="usd">599200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8c2d0c6bc9f4458b8e7efb5109a2426e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE4LTEyLTEtMS0xNzQzNjI_055db923-4c11-4682-ac12-28a0319c90ec"
      unitRef="usd">8075300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE4LTIwLTEtMS0xNzQzNjI_711b3fb1-c491-4cd0-b55f-ca2cca7f74a4"
      unitRef="usd">8075300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if784455c39a741cca476b0900201d0f9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE5LTE0LTEtMS0xNzQzNjI_32dc5e30-6a74-4930-a8d7-80d478a73586"
      unitRef="usd">-55500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzE5LTIwLTEtMS0xNzQzNjI_561b77ce-05c4-4242-834f-95c394a421e6"
      unitRef="usd">-55500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id65b59d5da2340a0940c3e1995d7021f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTItMS0xLTE3NDM2Mg_91700743-edc2-4a33-84fb-459fe08165a3"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id65b59d5da2340a0940c3e1995d7021f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTQtMS0xLTE3NDM2Mg_9006bc92-7be5-4024-a212-fe4a42b6e235"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i12be5553e41d40be83ba97a5fe81845b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTYtMS0xLTE3NDM2Mg_bbc38a2d-dad0-4ea3-8c4f-8f1c45555a08"
      unitRef="shares">126200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i12be5553e41d40be83ba97a5fe81845b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTgtMS0xLTE3NDM2Mg_27ab7543-266f-472b-a907-76ef2e69cadf"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i666d725ef2cf4065b50048f5296edab9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTEwLTEtMS0xNzQzNjI_a39c2b9f-6ba4-4527-8009-b5ae909c2ef0"
      unitRef="usd">8087500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83be0f48228e4464a3d79b1afd625715_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTEyLTEtMS0xNzQzNjI_0c70ea71-bc2e-4f38-9989-dd6d071578b5"
      unitRef="usd">18968300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if802f07034c74a87a67853bdd63c7037_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTE0LTEtMS0xNzQzNjI_7f07b702-6b57-4b72-8c69-a660051e2cd7"
      unitRef="usd">-26200000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ic572b99252494005bc30f8d6d54277fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTE2LTEtMS0xNzQzNjI_7eccab63-38bc-4da6-9d81-fbdd0bba82ec"
      unitRef="shares">19400000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ic572b99252494005bc30f8d6d54277fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTE4LTEtMS0xNzQzNjI_a519337b-40ce-41a5-8245-67340a3c2c9a"
      unitRef="usd">-8260900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzIwLTIwLTEtMS0xNzQzNjI_3870c173-bff4-435b-af2a-6fadf8059093"
      unitRef="usd">18768800000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i070f93a0d90d444baf671f55dbf55f10_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI1LTYtMS0xLTE3NDM2Mg_a5f2d0a1-f6c7-433c-a376-0e04d3e667c6"
      unitRef="shares">4800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI1LTEwLTEtMS0xNzQzNjI_f3555a15-d29a-4f00-ac00-921813b71ab5"
      unitRef="usd">1517400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI1LTIwLTEtMS0xNzQzNjI_bd83565a-3832-4dfb-b08d-6f4bbf5b0997"
      unitRef="usd">1517400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i070f93a0d90d444baf671f55dbf55f10_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI2LTYtMS0xLTE3NDM2Mg_76b34d2c-a17d-493a-ba4d-171dba078651"
      unitRef="shares">600000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI2LTEwLTEtMS0xNzQzNjI_ad1a44d4-3e35-4f20-9287-db3785083835"
      unitRef="usd">445700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI2LTIwLTEtMS0xNzQzNjI_6e094153-5802-4edb-b091-20d9ce055e24"
      unitRef="usd">445700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTEwLTEtMS0xNzQzNjI_441e34d6-02a2-4a0b-aff8-6147797cc395"
      unitRef="usd">52300000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTE2LTEtMS0xNzQzNjI_b0b6d775-4bdc-4a2e-b0fa-9efd80bcc285"
      unitRef="shares">100000</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTE4LTEtMS0xNzQzNjI_82e2caf5-2fbf-4a45-8368-125ae0ec8972"
      unitRef="usd">7400000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI3LTIwLTEtMS0xNzQzNjI_db96c772-b61d-4f9e-a1f1-089539e09b49"
      unitRef="usd">59700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI4LTE2LTEtMS0xNzQzNjI_5776f970-c257-42d1-9c00-4d867fbf6fc7"
      unitRef="shares">3300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9bfeb96bbea6413caf9b04e7d6eb55fe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI4LTE4LTEtMS0xNzQzNjI_97938856-68e5-48ff-8024-148905369280"
      unitRef="usd">2099800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI4LTIwLTEtMS0xNzQzNjI_5e194e76-51a1-49f1-9d2d-9c887043e5f5"
      unitRef="usd">2099800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7e8623a144104c1abe69168edea2c28e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI5LTEwLTEtMS0xNzQzNjI_e1dfbaec-c84d-4ab6-93cb-1b5eb05865b5"
      unitRef="usd">737800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzI5LTIwLTEtMS0xNzQzNjI_d91c00b9-c0c7-4f4f-9111-d6d5980800ec"
      unitRef="usd">737800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8ca914c1a8484668a3a14d372c8d453b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMwLTEyLTEtMS0xNzQzNjI_100a1212-c818-43b9-82b1-27abf68f8f93"
      unitRef="usd">4338400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMwLTIwLTEtMS0xNzQzNjI_7433e449-c66e-4b36-8b28-aa0bd55e4103"
      unitRef="usd">4338400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3919061e6c614ec5a67ef420703684b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMxLTE0LTEtMS0xNzQzNjI_06540420-841a-4bb5-9899-d0fe0582669e"
      unitRef="usd">-212600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMxLTIwLTEtMS0xNzQzNjI_9699cf17-0d7e-4ec3-a58e-34c0b2923eec"
      unitRef="usd">-212600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4f56d798d2de4fd58840b7e15ab5383e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTItMS0xLTE3NDM2Mg_f29492ad-063b-478c-aad4-3085ac51a83b"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4f56d798d2de4fd58840b7e15ab5383e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTQtMS0xLTE3NDM2Mg_b6b3836d-f1af-4890-b8c0-2637dda07815"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i43a6ec2800b049a390ee894f424cd007_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTYtMS0xLTE3NDM2Mg_5339700c-8454-42c2-8ca6-58dc4f396e62"
      unitRef="shares">130400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i43a6ec2800b049a390ee894f424cd007_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTgtMS0xLTE3NDM2Mg_f565760e-3cc4-40a2-802a-e4aff83f9982"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3d4bf60775b4d869dd15f70b0ce4725_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTEwLTEtMS0xNzQzNjI_0993eb71-321c-404e-b837-2c6d74885042"
      unitRef="usd">9949300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie33b2737ad5f4d81a64471a8087f6b6b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTEyLTEtMS0xNzQzNjI_3e88489b-9810-408d-923b-d7c7a63f5386"
      unitRef="usd">23306700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i801c30702fbc4a43994e5257eeedd771_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTE0LTEtMS0xNzQzNjI_a0615f2e-fa0b-47e6-88fb-d0bf1bd18691"
      unitRef="usd">-238800000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2e6785130a464ace9f5ea5f75c6c368b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTE2LTEtMS0xNzQzNjI_4eb47eaa-2f22-497f-8daf-e772bf5aa0ed"
      unitRef="shares">22600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i2e6785130a464ace9f5ea5f75c6c368b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTE4LTEtMS0xNzQzNjI_f7cb71fe-2957-46dd-a316-011b0af5a340"
      unitRef="usd">-10353300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMDkvZnJhZzowZmEyZGNkODg2ZmM0MzUzYTVkNDQyOTgwZjU1NTZhYS90YWJsZTphMGNjYTE5ODA0ZTc0OTM3YjUxNjg1MWRiZGJlOTE5ZC90YWJsZXJhbmdlOmEwY2NhMTk4MDRlNzQ5MzdiNTE2ODUxZGJkYmU5MTlkXzMyLTIwLTEtMS0xNzQzNjI_ec6cab89-f0d3-4bfc-9e0e-7f3421a062f0"
      unitRef="usd">22664000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMtMi0xLTEtMTc0MzYy_9305dfbe-2b83-4798-80dd-d328e5f7ee35"
      unitRef="usd">4338400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMtNC0xLTEtMTc0MzYy_f771612a-1113-4dc7-887f-d47832e2939a"
      unitRef="usd">8075300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMtNi0xLTEtMTc0MzYy_0f32d25b-5fe7-4458-b27e-f26a4c7e6e4b"
      unitRef="usd">3513200000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzUtMi0xLTEtMTc0MzYy_48fe0b3e-3a27-46a0-b230-652ac463b70e"
      unitRef="usd">341400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzUtNC0xLTEtMTc0MzYy_6e43a69d-af20-4d0f-b626-f0e36d428e3f"
      unitRef="usd">286200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzUtNi0xLTEtMTc0MzYy_6074bd87-079f-4572-b809-05561fe437b8"
      unitRef="usd">235900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzYtMi0xLTEtMTc0MzYy_1cacda1d-1858-4d2c-adef-72cf8f775b43"
      unitRef="usd">725000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzYtNC0xLTEtMTc0MzYy_7b95bff0-09ea-4ee7-8118-656407dd0496"
      unitRef="usd">601700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzYtNi0xLTEtMTc0MzYy_7217e8d6-062e-4b1c-9f96-6f33daee2764"
      unitRef="usd">432000000.0</us-gaap:ShareBasedCompensation>
    <regn:MarketableAndOtherSecuritiesGainLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzctMi0xLTEtMTc0MzYy_33605dfd-43b0-4211-bb78-9b524892973d"
      unitRef="usd">-36800000</regn:MarketableAndOtherSecuritiesGainLoss>
    <regn:MarketableAndOtherSecuritiesGainLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzctNC0xLTEtMTc0MzYy_0e9c5075-3dff-4a81-8ea8-33c37de65e8b"
      unitRef="usd">387000000.0</regn:MarketableAndOtherSecuritiesGainLoss>
    <regn:MarketableAndOtherSecuritiesGainLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzctNi0xLTEtMTc0MzYy_860a3629-e840-4bb5-aa13-950f5c88402c"
      unitRef="usd">221800000</regn:MarketableAndOtherSecuritiesGainLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzgtMi0xLTEtMTc0MzYy_5483f9c6-75c2-4aa1-a7fc-5f01403ec08d"
      unitRef="usd">-368000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzgtNC0xLTEtMTc0MzYy_9f8cbe87-d78d-4fd6-b558-b5cca84d1a13"
      unitRef="usd">-568700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzgtNi0xLTEtMTc0MzYy_4d5a310d-e749-4c73-a19c-7de3a5ac7785"
      unitRef="usd">-86800000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzktMi0xLTEtMTc0MzYy_ba53558c-c7a4-4441-bac6-63dc1f17daa3"
      unitRef="usd">746400000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzktNC0xLTEtMTc0MzYy_e48bac1a-45bf-466a-9d6a-966009a829d8"
      unitRef="usd">147100000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzktNi0xLTEtMTc0MzYy_18e5f78e-9130-4b06-badd-7638ebd7e5de"
      unitRef="usd">-75600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEwLTItMS0xLTE3NTY4Nw_f570ca0c-a953-4403-9de8-c7eebe08d067"
      unitRef="usd">195000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEwLTQtMS0xLTE3NTY4Nw_18dece85-0b8c-43ed-b315-ff527b812993"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEwLTYtMS0xLTE3NTY4Nw_4f03a2b6-7998-4dd7-ae85-39eb874a5920"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzExLTItMS0xLTE3NDM2Mg_b6892edb-d786-4add-a948-40abd44df21b"
      unitRef="usd">-707800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzExLTQtMS0xLTE3NDM2Mg_bfc2c627-6268-4c6a-a1b9-bd2b2c3e411d"
      unitRef="usd">1927400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzExLTYtMS0xLTE3NDM2Mg_2114159c-2c1f-401c-a71d-75c2cc6cdab1"
      unitRef="usd">1356100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEyLTItMS0xLTE3NDM2Mg_4a896c6f-0497-4435-9bb5-9bbd3b47d4b2"
      unitRef="usd">696500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEyLTQtMS0xLTE3NDM2Mg_5d96fadd-878c-46bf-a2fd-c956abeabc90"
      unitRef="usd">494300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEyLTYtMS0xLTE3NDM2Mg_327172e4-d142-4e22-be4b-eef6a6afe0b8"
      unitRef="usd">529400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEzLTItMS0xLTE3NDM2Mg_b28f6cf9-d045-407f-972b-06f42de2519a"
      unitRef="usd">148600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEzLTQtMS0xLTE3NDM2Mg_83001fcb-a492-4d3d-a1bb-de25d1f29e54"
      unitRef="usd">240700000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzEzLTYtMS0xLTE3NDM2Mg_b1f1f66c-d586-4ca7-8858-4700dfbf1184"
      unitRef="usd">-114900000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE0LTItMS0xLTE3NDM2Mg_df010df5-1e25-4b25-94f7-6ac8cb09d498"
      unitRef="usd">32400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE0LTQtMS0xLTE3NDM2Mg_b1eee65b-9e56-49fe-a9a3-1521cd2bbb37"
      unitRef="usd">-120200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE0LTYtMS0xLTE3NDM2Mg_eb71a82b-18e8-42df-8ec5-a66e60ad3f9c"
      unitRef="usd">148100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE1LTItMS0xLTE3NDM2Mg_29a2ba70-f2ab-4e4c-b0d5-d3e9789553ef"
      unitRef="usd">-138400000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE1LTQtMS0xLTE3NDM2Mg_1f0f0ad1-6ef9-4c2b-b6fb-fc0df42429eb"
      unitRef="usd">866100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE1LTYtMS0xLTE3NDM2Mg_9fff4ae6-e67b-40a6-8e36-0e70968b130b"
      unitRef="usd">118900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE2LTItMS0xLTE3NDM2Mg_7a70574e-6172-4031-9d1d-6ace5cd1a228"
      unitRef="usd">676500000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE2LTQtMS0xLTE3NDM2Mg_ad801d71-9b66-4c35-95e6-7e8fe1339b6e"
      unitRef="usd">-994000000.0</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE2LTYtMS0xLTE3NDM2Mg_046622d5-4275-4618-9ad3-65d9330144a0"
      unitRef="usd">-895100000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE3LTItMS0xLTE3NDM2Mg_dbf3aac1-0c14-4648-a065-06ace72e9e9d"
      unitRef="usd">5014900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE3LTQtMS0xLTE3NDM2Mg_ee69e17a-d516-4615-9b70-0021d7060c92"
      unitRef="usd">7081300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzE3LTYtMS0xLTE3NDM2Mg_4817fc21-b1a3-472e-b8cd-a6bc86d8cc68"
      unitRef="usd">2618100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIwLTItMS0xLTE3NDM2Mg_306e9004-72a7-45be-8ef2-bddb8be66726"
      unitRef="usd">7487900000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIwLTQtMS0xLTE3NDM2Mg_96f6f367-4b2a-471d-9af0-1b9f151cfee9"
      unitRef="usd">7048100000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIwLTYtMS0xLTE3NDM2Mg_2952e524-caef-4d4f-a54b-ff6a55e183bd"
      unitRef="usd">3241000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIxLTItMS0xLTE3NDM2Mg_606e5c30-4a26-4aa9-883e-2f338aea3a2c"
      unitRef="usd">5550500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIxLTQtMS0xLTE3NDM2Mg_83c755de-f4ae-4af0-995a-cc916543955f"
      unitRef="usd">2215300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIxLTYtMS0xLTE3NDM2Mg_c87de4bd-f16f-4c02-b6ee-50d5868a9b4f"
      unitRef="usd">3785000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIyLTItMS0xLTE3NDM2Mg_5bb9220a-b6aa-4b07-acbe-a09b6004bfc7"
      unitRef="usd">590100000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIyLTQtMS0xLTE3NDM2Mg_7b95cb64-17ac-4f3c-b0d5-16bf413fee2e"
      unitRef="usd">551900000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIyLTYtMS0xLTE3NDM2Mg_5f954096-5066-4121-82c3-31011d30810c"
      unitRef="usd">614600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <regn:PaymentsToAcquireIntangibleAssets1
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI0LTItMS0xLTE3NTcwNg_bbb8d981-2ff4-4da1-8892-f4111cfbe909"
      unitRef="usd">1026800000</regn:PaymentsToAcquireIntangibleAssets1>
    <regn:PaymentsToAcquireIntangibleAssets1
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI0LTQtMS0xLTE3NTcwNg_ff2252fd-1461-4f8a-ac41-ac04db5ce2a4"
      unitRef="usd">0</regn:PaymentsToAcquireIntangibleAssets1>
    <regn:PaymentsToAcquireIntangibleAssets1
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI0LTYtMS0xLTE3NTcwNg_e633342c-db38-4cb2-94e6-0f63ae3e9e6f"
      unitRef="usd">0</regn:PaymentsToAcquireIntangibleAssets1>
    <regn:PaymentsForAssetAcquisition
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI1LTItMS0xLTE3NTcwNg_e5789212-58d4-4a63-a320-71ee649d843c"
      unitRef="usd">230300000</regn:PaymentsForAssetAcquisition>
    <regn:PaymentsForAssetAcquisition
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI1LTQtMS0xLTE3NTcwNg_b9294e04-ca75-4016-80bd-e3a76fb0f044"
      unitRef="usd">0</regn:PaymentsForAssetAcquisition>
    <regn:PaymentsForAssetAcquisition
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI1LTYtMS0xLTE3NTcwNg_2317acc1-d734-4ffb-aeef-70f6fb23fbac"
      unitRef="usd">0</regn:PaymentsForAssetAcquisition>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIzLTItMS0xLTE3NDM2Mg_153d6f8d-9e4d-4542-8dc8-accc516c3533"
      unitRef="usd">-3784600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIzLTQtMS0xLTE3NDM2Mg_93991a2a-35fe-483c-abc9-127b4448b7ca"
      unitRef="usd">-5384700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzIzLTYtMS0xLTE3NDM2Mg_09074359-d635-47a1-a9ce-59a65e4955f4"
      unitRef="usd">-70600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI2LTItMS0xLTE3NDM2Mg_98884a68-b9e0-443b-9e6e-909d03cd0fe8"
      unitRef="usd">1519500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI2LTQtMS0xLTE3NDM2Mg_b7613a82-eea2-4ed8-9436-b6f92d3400fc"
      unitRef="usd">1672300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI2LTYtMS0xLTE3NDM2Mg_46f4b9ef-f880-43f1-b082-c4a3efa81e70"
      unitRef="usd">2575200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI3LTItMS0xLTE3NDM2Mg_ee418d79-1e1b-431c-8a71-8507c0cb21fa"
      unitRef="usd">445700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI3LTQtMS0xLTE3NDM2Mg_d213eaa6-b44b-41d8-b6e9-87f437105946"
      unitRef="usd">1032700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI3LTYtMS0xLTE3NDM2Mg_78327d36-da76-4e58-8e12-1907d23e4796"
      unitRef="usd">680800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI4LTItMS0xLTE3NDM2Mg_9db7a6d1-24c3-411f-93a9-af291ea84677"
      unitRef="usd">2082800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI4LTQtMS0xLTE3NDM2Mg_5091b8bd-9bf4-4149-b2ed-3adc38eec567"
      unitRef="usd">1645400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI4LTYtMS0xLTE3NDM2Mg_37210de4-d2a7-4501-a1fd-cb018451bd77"
      unitRef="usd">5846800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI5LTItMS0xLTE3NDM2Mg_0f13cb9b-3385-4665-854b-0591283814a6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI5LTQtMS0xLTE3NDM2Mg_81fb150a-07c6-412e-af40-ab2392f76383"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzI5LTYtMS0xLTE3NDM2Mg_6fcf93db-0f05-44cd-bc35-249068ebe6c2"
      unitRef="usd">1981900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMwLTItMS0xLTE3NDM2Mg_685515ec-f51f-4d0a-b979-2847cf9303f9"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMwLTQtMS0xLTE3NDM2Mg_e9660039-4cfc-46f5-9760-33957b7a9945"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMwLTYtMS0xLTE3NDM2Mg_0c9a04ad-f2cb-4876-9781-77e31eb578e1"
      unitRef="usd">1500000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMxLTItMS0xLTE3NDM2Mg_f07ed6d5-2534-46b8-8167-39d995f34e68"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMxLTQtMS0xLTE3NDM2Mg_0efdea81-d3f8-4833-a985-97ea6797d13c"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMxLTYtMS0xLTE3NDM2Mg_3d14474a-6855-4f7e-afba-634a257d37ba"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMyLTItMS0xLTE3NDM2Mg_c59283f2-995b-43fe-baae-5903130c6993"
      unitRef="usd">-1009000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMyLTQtMS0xLTE3NDM2Mg_fa59023d-9e73-4732-8b51-3f7f8ef5be96"
      unitRef="usd">-1005800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzMyLTYtMS0xLTE3NDM2Mg_cab6472d-6350-45b6-a1c5-27939a927207"
      unitRef="usd">-1970500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM0LTItMS0xLTE3NDM2Mg_fc92d3ad-ce08-41d2-a88c-2560a5df3cb1"
      unitRef="usd">221300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM0LTQtMS0xLTE3NDM2Mg_2cd01263-cc1f-4f5b-b7c7-735a5e11172b"
      unitRef="usd">690800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM0LTYtMS0xLTE3NDM2Mg_6b8907d7-076d-4d24-8d6c-37946be9be00"
      unitRef="usd">577000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM2LTItMS0xLTE3NDM2Mg_d7b47dac-73f1-41fe-9a3d-5a3ee1a9f950"
      unitRef="usd">2898100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM2LTQtMS0xLTE3NDM2Mg_7c5ea345-b8c4-47c0-a2e7-d982bf345169"
      unitRef="usd">2207300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM2LTYtMS0xLTE3NDM2Mg_29cf7bf4-6422-4612-b7ab-79d41254ca43"
      unitRef="usd">1630300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM4LTItMS0xLTE3NDM2Mg_12fb036c-6263-4934-aaad-4a99ae1ce720"
      unitRef="usd">3119400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM4LTQtMS0xLTE3NDM2Mg_9a18379a-2088-4d0f-942d-702efafab066"
      unitRef="usd">2898100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzM4LTYtMS0xLTE3NDM2Mg_26548118-74e8-4ade-ba16-f47d0e6a9379"
      unitRef="usd">2207300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQxLTItMS0xLTE3NDM2Mg_f4ced759-f8bb-43ad-bbf2-8fcfd9e539de"
      unitRef="usd">53700000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQxLTQtMS0xLTE3NDM2Mg_afb7ddee-ea6c-4fab-884c-bc044f30dd02"
      unitRef="usd">55800000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQxLTYtMS0xLTE3NDM2Mg_6a200fbc-852d-43d2-98c0-ba1a8ab465a3"
      unitRef="usd">23200000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQyLTItMS0xLTE3NDM2Mg_0c3841df-c29f-4bbc-9072-83d96dc64404"
      unitRef="usd">1502400000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQyLTQtMS0xLTE3NDM2Mg_ef19fb14-5508-4096-8f0e-2aa10a9db50c"
      unitRef="usd">1218400000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTIvZnJhZzpmNWM2Y2U4YTc4Yzk0NDcwYTk1Y2U5ZTc5ZTM3OTdlYS90YWJsZTo4NTUyYmViZGE4MWY0OThjYWFlMzljNzUxZmQ0YjNlNi90YWJsZXJhbmdlOjg1NTJiZWJkYTgxZjQ5OGNhYWUzOWM3NTFmZDRiM2U2XzQyLTYtMS0xLTE3NDM2Mg_471a2b29-fb76-4326-8da9-73768827f2e4"
      unitRef="usd">188100000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjIw_565e77f6-8603-415f-95b5-eac1fd302306">Business Overview and Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The Company currently has nine products that have received marketing approval by the U.S. Food and Drug Administration ("FDA"). In addition, REGEN-COV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was authorized under an Emergency Use Authorization ("EUA") from November 2020 until January 2022 when the EUA was revised to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment; with this EUA revision, REGEN-COV is not currently authorized for use in any U.S. states, territories, or jurisdictions. The Company is a party to collaboration agreements to develop and commercialize, as applicable, certain products and product candidates (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one business segment, which includes all activities related to the discovery, development, and commercialization of medicines for serious diseases. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting research activities, product development, obtaining regulatory approvals, competition, and obtaining and enforcing patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Regeneron and its wholly-owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning with the first quarter of 2022, the Company added a new line item, Acquired in-process research and development, to its Consolidated Statements of Operations and Comprehensive Income. This line item includes in-process research and development acquired in connection with asset acquisitions as well as up-front/opt-in payments related to license and collaboration agreements. Amounts recorded in this line item during the year ended December 31, 2022 would have historically been recorded to Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior period amounts to conform with the current period's presentation, including in connection with the addition of Acquired in-process research and development described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain investments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrations of credit risk with respect to customer and collaborator accounts receivable are significant. As of December&#160;31, 2022, two individual customers accounted for&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86% of the Company's net trade accounts receivable balances. Three individual customers accounted for&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91% (including 29% related to the U.S. government) of the Company's net trade accounts receivable balances as of December 31, 2021. The Company has contractual payment terms with each of its collaborators and customers, and the Company monitors their financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. As of December&#160;31, 2022 and 2021, there were no write-offs and allowances of accounts receivable related to credit risk for the Company's collaborators or customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. The carrying amount reported in the Consolidated Balance Sheet for cash and cash equivalents approximates its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. The Company invests its cash primarily in debt securities. The Company considers its investments in debt securities to be "available-for-sale," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Realized gains and losses on available-for-sale debt securities are included in other income (expense), net. The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in net income, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has investments in equity securities that are carried at fair value with changes in fair value recognized within other income (expense), net. The Company has elected to measure certain equity investments it holds that do not have readily determinable fair values at cost less impairment, if any, and adjusts for observable price changes in orderly transactions for identical or similar investments of the same issuer within other income (expense), net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's trade accounts receivable arise from product sales and represent amounts due from its customers. In addition, the Company records accounts receivable arising from its collaboration and licensing agreements. The Company monitors the financial performance and credit worthiness of its counterparties so that it can properly assess and respond to changes in their credit profile. The Company provides allowances against receivables for estimated losses, if any, that may result from a counterparty's inability to pay. Amounts determined to be uncollectible are written-off against the allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such inventory to its estimated realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Costs of construction of certain long-lived assets include capitalized interest, which is amortized over the estimated useful life of the related asset. Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized within income from operations. The estimated useful lives of property, plant, and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#x2013;50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#x2013;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease considering whether there is an identified asset and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company's lease terms may include options to extend or terminate a lease when it is reasonably certain that it will exercise that option. The Company accounts for lease components (e.g., rental payments) separately from non-lease components (e.g., common area maintenance costs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, unless there is a transfer of title or purchase option the Company is reasonably certain to exercise. For leases where an implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on information available at the lease commencement date to determine the present value of future lease payments. Lease expense for operating leases is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company makes a determination of whether an asset or set of assets acquired constitute a business. If it is determined that substantially all of the fair value of gross assets acquired in a transaction are concentrated in a single identifiable asset, then the transaction is accounted for as an asset acquisition. Intangible assets acquired in connection with an asset acquisition are recorded at cost. Such amounts may include up-front payments and contingent consideration. With regard to contingent consideration, the Company recognizes regulatory milestones upon achievement, royalties in the period in which the underlying sales occur, and sales-based milestones when the milestone is deemed probable by the Company of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets are amortized to Cost of goods sold over the estimated useful lives of the assets based on the pattern in which the economic benefits of the intangible assets are consumed; if that pattern cannot be reliably determined, a straight-line basis is used. If contingent consideration is recognized subsequent to the acquisition date in an asset acquisition, the amount of such consideration is recorded as an addition to the cost basis of the intangible asset with a cumulative catch-up adjustment for amortization expense as if the additional amount of consideration had been accrued from the outset of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's intangible assets are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If an indicator of impairment exists, the Company compares the projected undiscounted cash flows to be generated by the asset to the intangible asset's carrying amount. If the projected undiscounted cash flows of the intangible asset are less than the carrying amount, the intangible asset is written down to its fair value in the period in which the impairment occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition - Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized at a point in time when the Company's customer is deemed to have obtained control of the product, which generally occurs upon receipt or acceptance by its customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue the Company recognizes from product sales may vary due to rebates, chargebacks, and discounts provided under governmental and other programs, distribution-related fees, and other sales-related deductions. In order to determine the transaction price, the Company estimates, utilizing the expected value method, the amount of variable consideration to which the Company will be entitled. This estimate is based upon contracts with customers, healthcare providers, payors, and government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, estimated payor mix, and other relevant factors. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Rebates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's rebates include amounts paid to managed care organizations, group purchasing organizations, state Medicaid programs, and other rebate programs. The Company estimates reductions to product sales for each type of rebate and records an allowance for rebates in the same period in which the related product sales are recognized. The Company's liability for rebates consists of estimates for claims related to the current and prior periods that have not been paid and estimates for claims that will be made related to inventory that exists in the distribution channel at the end of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Chargebacks and Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's reserves related to discounted pricing to eligible physicians, Veterans' Administration ("VA"), Public Health Services, and others (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the discounted selling price to the qualified healthcare providers. The Company estimates reductions to product sales for each type of chargeback and records an allowance for chargebacks in the same period that the related product sales are recognized. The Company's reserve for chargebacks consists of amounts for which it expects to issue credit based on expected sales by its customers to qualified healthcare providers and chargebacks that customers have claimed but for which the Company has not yet issued credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Distribution-Related Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers generally based on gross sales.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other Sales-Related Deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company's other sales-related deductions include co-pay assistance programs and product returns. The Company estimates and records other sales-related deductions generally based on gross sales, written contracts, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company generally offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers, using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various collaborative arrangements to research, develop, manufacture, and commercialize products and/or product candidates. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits or losses in connection with commercialization of products &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties and/or sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front/opt-in and development milestone payments to collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements involving multiple goods or services promised to be transferred to the Company's collaborator, the Company must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is "distinct"), or whether such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;promises should be combined as a single unit of account. When the Company has a combined unit of account which includes a license and providing research and development services to its collaborator, recognition of up-front payments and development milestones earned from its collaborator is deferred (as a liability) and recognized over the development period (i.e., over time) typically using an input method on the basis of the Company's research and development costs incurred relative to the total expected cost which determines the extent of the Company's progress toward completion. The Company reviews its estimates each period and makes revisions to such estimates as necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company is entitled to reimbursement of all or a portion of the expenses (e.g., research and development expenses) that it incurs under a collaboration, it records those reimbursable amounts in the period in which such costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company's collaborator performs research and development work or commercialization-related activities and the parties share the related costs, the Company also recognizes, as expense (e.g., research and development expense or selling, general, and administrative expense, as applicable) in the period when its collaborator incurs such expenses, the portion of the collaborator's expenses that the Company is obligated to reimburse. The Company's collaborators provide the Company with estimated expenses for the most recent fiscal quarter. The estimates are revised, if necessary, in subsequent periods if actual expenses differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where the Company:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;supplies commercial product to its collaborator, the Company may be reimbursed for its manufacturing costs as commercial product is shipped to the collaborator (however, recognition of such cost reimbursements may be deferred until the product is sold by the Company's collaborator to third-party customers); &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;shares in any profits or losses arising from the commercialization of such products, the Company records its share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;receives royalties and/or sales-based milestone payments from its collaborator, the Company recognizes such amounts in the period earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's collaborators provide it with estimates of product sales and the Company's share of profits or losses, as applicable, for each quarter. The estimates are revised, if necessary, in subsequent periods if the Company's actual share of profits or losses differ from those estimates.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include costs attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, clinical trial expenses, the cost of services provided by outside contractors, including services related to the Company's clinical trials, the full cost of manufacturing drug for use in research and development, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs. Costs associated with research and development are expensed.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter and remain in the trial, and/or the period over which clinical investigators, contract research organizations ("CROs"), or other third-party service providers are expected to provide services. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining noncancelable obligations associated with the winding-down of the clinical trial, including any applicable penalties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for equity grants under the Company's long-term incentive plans (including stock options, restricted stock awards, and restricted stock units (both time-based and performance-based)) to employees and non-employee members of the Company's board of directors (as applicable) based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In addition, the Company reassesses its forfeiture rate assumptions at least annually, considering both historical forfeiture experience and an estimate of future forfeitures for currently outstanding unvested awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation to compute the estimated fair value of performance-based restricted stock units that are subject to vesting based on the Company&#x2019;s attainment of pre-established criteria that include a market condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance-based restricted stock units that contain a performance condition, the Company recognizes stock-based compensation expense if and when the Company determines that it is probable the performance condition will be achieved (based on the number of shares expected to be vested and issued). The Company reassesses the probability of achievement at each reporting period and adjusts compensation cost, as necessary. If there are any changes in the Company's probability assessment, the Company recognizes a cumulative catch-up adjustment in the period of the change in estimate, with the remaining unrecognized expense recognized prospectively over the remaining requisite service period. If the Company subsequently determines that the performance criteria are not met or are not expected to be met, any amounts previously recognized as compensation expense are reversed in the period when such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes includes U.S. federal, state, local, and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns, including deferred tax assets and liabilities for expected amounts of global intangible low-taxed income ("GILTI") inclusions, are recognized on the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the financial statement effects of a tax position when management's assessment is that there is more than a 50% probability that the position will be sustained upon examination by a taxing authority based upon its technical merits. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Per Share Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Basic net income per share excludes restricted stock until vested. Diluted net income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include outstanding stock options and unvested restricted stock under the Company's long-term incentive plans, which are included under the treasury stock method when dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <regn:NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM2NQ_8f8a2af7-4928-491b-8dc6-0c7d4df637d1"
      unitRef="product">9</regn:NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration>
    <us-gaap:NumberOfReportableSegments
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzgxOA_ce7b0571-e18a-4d32-8874-39ead4ae3602"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTM3_09811e45-72be-405f-b2ba-f8a2bad1ff47">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Regeneron and its wholly-owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning with the first quarter of 2022, the Company added a new line item, Acquired in-process research and development, to its Consolidated Statements of Operations and Comprehensive Income. This line item includes in-process research and development acquired in connection with asset acquisitions as well as up-front/opt-in payments related to license and collaboration agreements. Amounts recorded in this line item during the year ended December 31, 2022 would have historically been recorded to Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior period amounts to conform with the current period's presentation, including in connection with the addition of Acquired in-process research and development described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjkx_bffc3562-1ffd-419d-8a31-910bc1a1548c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTc4_3e48999e-dc9c-4d3a-a594-a6dbba2ecc72">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain investments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties.  &lt;/span&gt;&lt;/div&gt;Concentrations of credit risk with respect to customer and collaborator accounts receivable are significant.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i00bac7cbbc5e4246b3f94989f1a587b7_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzI5NDA_c2b6607a-21c4-40fd-8b48-158a85d1a653"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6732651b19384641aff2c7fa3e18b1b4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzMwODc_0ca3fc43-738d-4169-a7b6-885fda21ce03"
      unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iad3a33c797844c159114ad188489310b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzI3NDg3NzkwOTc2MTY_feafeb2c-6a09-441f-a554-2e264cfdda68"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_0c1cb847-52d5-49ac-a5cc-2040a9839a2b"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_2e618d9c-6c90-4269-b515-bed92ff21b80"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_50795ed9-7eab-49f6-94d0-b1ce8a6f9803"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzM0NDM_c7678a5d-30bf-4bea-bf16-647f7f6dc5aa"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTk3_6adecc81-9dc8-4bc5-a7b5-308f44a594b1">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. The carrying amount reported in the Consolidated Balance Sheet for cash and cash equivalents approximates its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjkz_1147843b-cbaf-48a9-bed2-1292ed3a9681">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. The Company invests its cash primarily in debt securities. The Company considers its investments in debt securities to be "available-for-sale," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Realized gains and losses on available-for-sale debt securities are included in other income (expense), net. The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in net income, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;The Company also has investments in equity securities that are carried at fair value with changes in fair value recognized within other income (expense), net. The Company has elected to measure certain equity investments it holds that do not have readily determinable fair values at cost less impairment, if any, and adjusts for observable price changes in orderly transactions for identical or similar investments of the same issuer within other income (expense), net.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjk0_1f1166a7-a890-413c-9456-f48422f3e9fd">Accounts ReceivableThe Company's trade accounts receivable arise from product sales and represent amounts due from its customers. In addition, the Company records accounts receivable arising from its collaboration and licensing agreements. The Company monitors the financial performance and credit worthiness of its counterparties so that it can properly assess and respond to changes in their credit profile. The Company provides allowances against receivables for estimated losses, if any, that may result from a counterparty's inability to pay. Amounts determined to be uncollectible are written-off against the allowance.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjgz_c6660c00-802f-45b5-9058-9daf99ec5b13">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such inventory to its estimated realizable value.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTk5_207bb80c-77f3-4dc7-a2c2-873c66b72481">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Costs of construction of certain long-lived assets include capitalized interest, which is amortized over the estimated useful life of the related asset. Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized within income from operations. The estimated useful lives of property, plant, and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#x2013;50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#x2013;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjI3_87fa2589-ac0c-456c-bbb7-c22a38b151d0">The estimated useful lives of property, plant, and equipment are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#x2013;50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#x2013;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.201%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,270.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, office equipment, and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,432.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less, accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,669.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,398.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i492786f7a1b94a1594a932e2b271fa8a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzAtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246OWU2NzQ1NzAzNzU0NDk5OGFkY2E0NjNhNTM5OTFhOTFfNA_3ceffc11-d30e-4bfa-bc6e-76d0147cd442">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia9c27db3739642f99f43796472a8d403_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzAtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246OWU2NzQ1NzAzNzU0NDk5OGFkY2E0NjNhNTM5OTFhOTFfNw_3d2a98ca-2482-4275-a28a-4f481eef74d4">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6a49d235b3214cedb524b0736433ccc3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzEtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246YzhiZDA3MzdhZTEzNDQ3NGE4NWNjZTJkNWMwYjdiZWRfNA_f2b59473-211b-483d-b43f-3bad74a3b552">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i664445be718b4d0faeb4a37890e76062_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzEtMi0xLTEtMTc0MzYyL3RleHRyZWdpb246YzhiZDA3MzdhZTEzNDQ3NGE4NWNjZTJkNWMwYjdiZWRfNw_a0df8f3f-c66b-45ed-86a3-20f5ceed7719">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib3488dea3c9b405e93bf3bd0b9ede622_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90YWJsZTowZjRjZTMwODE4MDc0ZDdlOTE1YjkxZTM4NTZhYjM1MC90YWJsZXJhbmdlOjBmNGNlMzA4MTgwNzRkN2U5MTViOTFlMzg1NmFiMzUwXzItMi0xLTEtMTc0MzYyL3RleHRyZWdpb246ZDU2NjAyNDVkMDJjNDRjMzk0MjE0ODQ3YjhiN2NiODVfNA_3e8a723a-08bd-4029-9c53-aef9b0d25f2d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjQw_9853d2e2-db3d-48de-9e85-0bdbf42679d5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease considering whether there is an identified asset and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company's lease terms may include options to extend or terminate a lease when it is reasonably certain that it will exercise that option. The Company accounts for lease components (e.g., rental payments) separately from non-lease components (e.g., common area maintenance costs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, unless there is a transfer of title or purchase option the Company is reasonably certain to exercise. For leases where an implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on information available at the lease commencement date to determine the present value of future lease payments. Lease expense for operating leases is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/div&gt;Leases&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts certain of its research, development, and administrative activities at leased facilities. The Company also leases vehicles and other assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Consolidated Balance Sheets and Statements of Operations included in this report associated with operating leases were not material. Operating lease right-of-use assets are included within Other noncurrent assets, and lease liabilities are included in Accrued expenses and other current liabilities and Other noncurrent liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a Participation Agreement with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing &amp;amp; Capital LLC ("BAL"), as lessor, and a syndicate of lenders (collectively with BAL, the "Lease Participants"), which provided for $720.0&#160;million of lease financing from the Lease Participants for the acquisition of laboratory and office facilities in Tarrytown, New York (the "Facility"). In March 2017, the Company also entered into a Lease and Remedies Agreement with BAL, pursuant to which the Company leased the Facility from BAL for a&#160;five-year term which ended in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into a Second Amended and Restated Lease and Remedies Agreement (the "Restated Lease") with BAL, as lessor (the "Lessor"), which amends, restates, and extends its lease of the Facility. In March 2022, the Company also entered into a Second Amended and Restated Participation Agreement (the "Restated Participation Agreement") with Bank of America, N.A., as administrative agent, the Lessor, and a syndicate of financial institutions as rent assignees (collectively with the Lessor, the "Participants"), which amends and restates the original Participation Agreement entered into in March 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original Participation Agreement and certain related agreements were amended and restated in order to, among other things, (i) effect a&#160;five-year extension of the original March 2022 maturity date of the $720.0&#160;million lease financing and the end of the term of the Company's lease of the Facility from the Lessor to March 2027, at which time all amounts outstanding thereunder will become due and payable in full, and (ii) modify the rate of the interest or yield that is payable to the Participants. In accordance with the terms of the Restated Lease, the Company continues to pay all maintenance, insurance, taxes, and other costs arising out of the use of the Facility. The Company is also required to make monthly payments of basic rent during the term of the Restated Lease in an amount equal to a variable rate per annum, which was modified in connection with the Restated Lease, to be an adjusted one-month forward-looking term rate based on the Secured Overnight Financing Rate ("SOFR"), plus an applicable margin that varies with the Company's debt rating and total leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restated Participation Agreement and Restated Lease include an option for the Company to elect to further extend the maturity date of the Restated Participation Agreement and the term of the Restated Lease for an additional five-year period, subject to the consent of all the Participants and certain other conditions. The Company also has the option prior to the end of the term of the Restated Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants' advances under the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Participation Agreement, Restated Lease, and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with the original lease, the Restated Lease continues to be classified as a finance lease as the Company has the option to purchase the Facility under terms that make it reasonably certain to be exercised. The agreements governing the Restated Lease financing contain financial and operating covenants. Such financial covenants and certain of the operating covenants are substantially similar to the covenants set forth in the Company's $750.0 million 2018 Credit Agreement. The Company was in compliance with all such covenants as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzY1OTcwNjk3OTQxODc_a736ed15-f693-4fce-9b0c-f24d0523e804">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company makes a determination of whether an asset or set of assets acquired constitute a business. If it is determined that substantially all of the fair value of gross assets acquired in a transaction are concentrated in a single identifiable asset, then the transaction is accounted for as an asset acquisition. Intangible assets acquired in connection with an asset acquisition are recorded at cost. Such amounts may include up-front payments and contingent consideration. With regard to contingent consideration, the Company recognizes regulatory milestones upon achievement, royalties in the period in which the underlying sales occur, and sales-based milestones when the milestone is deemed probable by the Company of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets are amortized to Cost of goods sold over the estimated useful lives of the assets based on the pattern in which the economic benefits of the intangible assets are consumed; if that pattern cannot be reliably determined, a straight-line basis is used. If contingent consideration is recognized subsequent to the acquisition date in an asset acquisition, the amount of such consideration is recorded as an addition to the cost basis of the intangible asset with a cumulative catch-up adjustment for amortization expense as if the additional amount of consideration had been accrued from the outset of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's intangible assets are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If an indicator of impairment exists, the Company compares the projected undiscounted cash flows to be generated by the asset to the intangible asset's carrying amount. If the projected undiscounted cash flows of the intangible asset are less than the carrying amount, the intangible asset is written down to its fair value in the period in which the impairment occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjU1_26919a44-57d5-494e-b0ee-b78343c24be4">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition - Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized at a point in time when the Company's customer is deemed to have obtained control of the product, which generally occurs upon receipt or acceptance by its customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue the Company recognizes from product sales may vary due to rebates, chargebacks, and discounts provided under governmental and other programs, distribution-related fees, and other sales-related deductions. In order to determine the transaction price, the Company estimates, utilizing the expected value method, the amount of variable consideration to which the Company will be entitled. This estimate is based upon contracts with customers, healthcare providers, payors, and government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, estimated payor mix, and other relevant factors. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Rebates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's rebates include amounts paid to managed care organizations, group purchasing organizations, state Medicaid programs, and other rebate programs. The Company estimates reductions to product sales for each type of rebate and records an allowance for rebates in the same period in which the related product sales are recognized. The Company's liability for rebates consists of estimates for claims related to the current and prior periods that have not been paid and estimates for claims that will be made related to inventory that exists in the distribution channel at the end of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Chargebacks and Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's reserves related to discounted pricing to eligible physicians, Veterans' Administration ("VA"), Public Health Services, and others (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the discounted selling price to the qualified healthcare providers. The Company estimates reductions to product sales for each type of chargeback and records an allowance for chargebacks in the same period that the related product sales are recognized. The Company's reserve for chargebacks consists of amounts for which it expects to issue credit based on expected sales by its customers to qualified healthcare providers and chargebacks that customers have claimed but for which the Company has not yet issued credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Distribution-Related Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers generally based on gross sales.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other Sales-Related Deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company's other sales-related deductions include co-pay assistance programs and product returns. The Company estimates and records other sales-related deductions generally based on gross sales, written contracts, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company generally offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers, using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various collaborative arrangements to research, develop, manufacture, and commercialize products and/or product candidates. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits or losses in connection with commercialization of products &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties and/or sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front/opt-in and development milestone payments to collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements involving multiple goods or services promised to be transferred to the Company's collaborator, the Company must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is "distinct"), or whether such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;promises should be combined as a single unit of account. When the Company has a combined unit of account which includes a license and providing research and development services to its collaborator, recognition of up-front payments and development milestones earned from its collaborator is deferred (as a liability) and recognized over the development period (i.e., over time) typically using an input method on the basis of the Company's research and development costs incurred relative to the total expected cost which determines the extent of the Company's progress toward completion. The Company reviews its estimates each period and makes revisions to such estimates as necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company is entitled to reimbursement of all or a portion of the expenses (e.g., research and development expenses) that it incurs under a collaboration, it records those reimbursable amounts in the period in which such costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company's collaborator performs research and development work or commercialization-related activities and the parties share the related costs, the Company also recognizes, as expense (e.g., research and development expense or selling, general, and administrative expense, as applicable) in the period when its collaborator incurs such expenses, the portion of the collaborator's expenses that the Company is obligated to reimburse. The Company's collaborators provide the Company with estimated expenses for the most recent fiscal quarter. The estimates are revised, if necessary, in subsequent periods if actual expenses differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where the Company:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;supplies commercial product to its collaborator, the Company may be reimbursed for its manufacturing costs as commercial product is shipped to the collaborator (however, recognition of such cost reimbursements may be deferred until the product is sold by the Company's collaborator to third-party customers); &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;shares in any profits or losses arising from the commercialization of such products, the Company records its share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;receives royalties and/or sales-based milestone payments from its collaborator, the Company recognizes such amounts in the period earned.&lt;/span&gt;&lt;/div&gt;The Company's collaborators provide it with estimates of product sales and the Company's share of profits or losses, as applicable, for each quarter. The estimates are revised, if necessary, in subsequent periods if the Company's actual share of profits or losses differ from those estimates.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTUy_b8519178-2c0f-4a0d-9cfd-1d546bbe83b2">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits or losses in connection with commercialization of products &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties and/or sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front/opt-in and development milestone payments to collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNTU2_c14528a4-e1bd-4383-aca1-51cc46c718c8">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include costs attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, clinical trial expenses, the cost of services provided by outside contractors, including services related to the Company's clinical trials, the full cost of manufacturing drug for use in research and development, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs. Costs associated with research and development are expensed.  &lt;/span&gt;&lt;/div&gt;For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter and remain in the trial, and/or the period over which clinical investigators, contract research organizations ("CROs"), or other third-party service providers are expected to provide services. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining noncancelable obligations associated with the winding-down of the clinical trial, including any applicable penalties.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjU3_6fbf054a-3e50-4578-ab98-ef51edaf7b36">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for equity grants under the Company's long-term incentive plans (including stock options, restricted stock awards, and restricted stock units (both time-based and performance-based)) to employees and non-employee members of the Company's board of directors (as applicable) based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award's requisite service period. Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In addition, the Company reassesses its forfeiture rate assumptions at least annually, considering both historical forfeiture experience and an estimate of future forfeitures for currently outstanding unvested awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation to compute the estimated fair value of performance-based restricted stock units that are subject to vesting based on the Company&#x2019;s attainment of pre-established criteria that include a market condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance-based restricted stock units that contain a performance condition, the Company recognizes stock-based compensation expense if and when the Company determines that it is probable the performance condition will be achieved (based on the number of shares expected to be vested and issued). The Company reassesses the probability of achievement at each reporting period and adjusts compensation cost, as necessary. If there are any changes in the Company's probability assessment, the Company recognizes a cumulative catch-up adjustment in the period of the change in estimate, with the remaining unrecognized expense recognized prospectively over the remaining requisite service period. If the Company subsequently determines that the performance criteria are not met or are not expected to be met, any amounts previously recognized as compensation expense are reversed in the period when such determination is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNzI1_df4e5837-d83a-45bb-b52c-17a255e68df2">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes includes U.S. federal, state, local, and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns, including deferred tax assets and liabilities for expected amounts of global intangible low-taxed income ("GILTI") inclusions, are recognized on the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets will not be realized.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the financial statement effects of a tax position when management's assessment is that there is more than a 50% probability that the position will be sustained upon examination by a taxing authority based upon its technical merits. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMTgvZnJhZzoyM2NhN2Y3NWE4OWY0OWFmYTkxZDAwMjhiOTBmZDZiOS90ZXh0cmVnaW9uOjIzY2E3Zjc1YTg5ZjQ5YWZhOTFkMDAyOGI5MGZkNmI5XzIzNjYw_a21d7476-e50c-4692-96f5-f6202fe82efd">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Per Share Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Basic net income per share excludes restricted stock until vested. Diluted net income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include outstanding stock options and unvested restricted stock under the Company's long-term incentive plans, which are included under the treasury stock method when dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk5Ng_39108683-3045-48cb-a2f3-f793860bf278">Product Sales &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.189%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,947.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(a) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REGEN-COV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evkeeza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inmazeb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(e) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,893.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,117.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,567.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world ("ROW")&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company had $3.586&#160;billion and $5.059&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December&#160;31, 2022, 2021, and 2020. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.913%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales to the U.S. government represented less than 10% of total gross product revenue during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks, and discounts, distribution-related fees, and other sales-related deductions. Accruals for chargebacks and discounts are recorded as a direct reduction to accounts receivable. Accruals for rebates, distribution-related fees, and other sales-related deductions are recorded within accrued liabilities. The following table summarizes the provisions, and credits/payments, for sales-related deductions.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Chargebacks,&lt;br/&gt;and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution-&lt;br/&gt;Related Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Sales-&lt;br/&gt;Related Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(641.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,034.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,523.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,109.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,398.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk3OA_8f907907-9d76-44d3-9d16-331308a9233b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.189%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,947.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(a) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REGEN-COV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evkeeza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inmazeb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(e) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,893.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,117.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,567.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world ("ROW")&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with its collaborations with Sanofi are detailed below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,082.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursements of R&amp;amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of one-time payment of $56.9 million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As described within the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.810%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One-time payment in connection with change in Japan arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit payment from Roche in connection with sales of REGEN-COV and Ronapreve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit payment to Roche in connection with sales of REGEN-COV and Ronapreve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Teva Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.206%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front and development milestone payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company recognized reimbursement of R&amp;amp;D expenses (as a reduction of R&amp;amp;D expense) of $42.4 million and $109.4 million for the years ended December 31, 2021 and 2020, respectively. Such amount was not material for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied28a835f8bf44bc81d3a306a92462e4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzItMi0xLTEtMTc0MzYy_83ffaacf-ccc1-42b2-b0a4-015d21080c65"
      unitRef="usd">6264600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ae532f4ad2e45a094632cb65f59ff1d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzItNC0xLTEtMTc0MzYy_b6111be0-f3ef-40fd-89a1-9b2e280b8e1e"
      unitRef="usd">5792300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2401c340b8d640b0bd0f2bd3310a8b34_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzItNi0xLTEtMTc0MzYy_efcca39e-9728-4204-9cc3-46a989f927c2"
      unitRef="usd">4947200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib758c557c5a84357b4ca9aad9468df85_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzMtMi0xLTEtMTc0MzYy_94c0f868-b7b2-4d66-a310-47d39375b1e2"
      unitRef="usd">374500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25e9c05bba964dbaa707ecf5784772a5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzMtNC0xLTEtMTc0MzYy_7a2bb5c6-d0eb-4616-ab9a-95fc2f39357e"
      unitRef="usd">306300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4219c796f9c244188971065d5bd4f038_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzMtNi0xLTEtMTc0MzYy_b813a699-fc47-48c2-84b6-9e5c2bd0ced2"
      unitRef="usd">270700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf9aaec3bce84131820f016e635d46b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtMy0xLTEtMTg0MzEx_8e6152d5-712b-4afd-82ee-955b6ffdb256"
      unitRef="usd">73000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id56d50e41b1b4f2283a73daac3abdfc3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNS0xLTEtMTg0MzEx_08cbb8f6-df42-4f12-9b30-9a6c8d075f74"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2ca5e7fcd0b4a008a735d158813a139_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNy0xLTEtMTg0MzEx_cc8c3731-2ade-44d1-bb7b-700df41aae94"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0393079c0cc944b1a50dfee3c963918e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtMi0xLTEtMTc0MzYy_bacbee2a-5d7c-47f0-aa45-474a7fd4dc9f"
      unitRef="usd">130000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a7e6722d81c44259a1bd92561905f63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNC0xLTEtMTc0MzYy_552a55e3-e969-472c-87a1-0231cddfb4f2"
      unitRef="usd">170000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd108a8c5454a57937befeca7f6ca59_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzQtNi0xLTEtMTc4NjIw_f7f7a09d-885f-45e1-8a9a-e2944bee651b"
      unitRef="usd">150900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a9ca7f6313f4b6ca75caf2fbb0aff86_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzUtMi0xLTEtMTc0MzYy_37a71d55-ca79-4a82-a6d5-c5297a965193"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a3c64382b1c47e282eed691c8527a02_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzUtNC0xLTEtMTc0MzYy_bb89517c-dd90-4ffc-b274-c00793db47b2"
      unitRef="usd">5828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16587113c4db4d869776e4a8f0e3f76f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzUtNi0xLTEtMTc0MzYy_f4e68137-07fe-4fa1-afba-0b920424da83"
      unitRef="usd">185700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36561e66271d42cd8f9d4959cf8bae47_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzYtMi0xLTEtMTc0MzYy_90b10081-28f7-4b81-b099-35f349416223"
      unitRef="usd">48600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d528e548bca464498145136edb95408_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzYtNC0xLTEtMTc0MzYy_5f0f8350-77ea-4893-8d92-c9719e149d1c"
      unitRef="usd">18400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c4796a01991465192b9b356e943e2e5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzYtNi0xLTEtMTc0MzYy_afd0b08d-c819-4737-bdd8-3d3f3a67d65c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61e8d230b07841e08ef6b9cf34364982_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtMy0xLTEtMTgyMDAx_f0c9b79b-47a9-41b1-b026-36e39bb751d2"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36d6b917256442e2bcb1f93418c6a3bc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNS0xLTEtMTgyMDA1_b6469427-38dd-435e-b064-343e275a9b20"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic15db8997a2b427788f94a1cbbec97c5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNy0xLTEtMTgyMDA5_3ff9ef38-b654-4d3e-8fe1-290d68fed0b7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb8aa02c16b445d7882b24cfd1ce3f1e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzctMi0xLTEtMTc0MzYy_d077a5b1-9342-4836-8973-d65aaf7f6226"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i045372e85f2c49249ac8ffc7ff4ee23f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzctNC0xLTEtMTc0MzYy_cc235c0e-3ac6-4c46-bc4b-f187a21e3df1"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if37be60752f94dc4afcf263599f81827_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzctNi0xLTEtMTc0MzYy_166f3955-3f65-4839-a6df-c84d6254d773"
      unitRef="usd">13100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13b570c4cf204eefb544c1454a2796d5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtMi0xLTEtMTc0MzYy_0b04d0ad-177c-433e-84d2-c070b411a899"
      unitRef="usd">6893700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3691c35b41bd49019bc22c52a92bb9e4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNC0xLTEtMTc0MzYy_9b69162d-c3b7-445e-a0a7-5bdd8383ef83"
      unitRef="usd">12117200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19de0a1ac17e448ab689d53f955adc7d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTozNTVlNmVmZDQ5MTk0NmI5YjQyNzVjZmVhNzA0NTFkMi90YWJsZXJhbmdlOjM1NWU2ZWZkNDkxOTQ2YjliNDI3NWNmZWE3MDQ1MWQyXzgtNi0xLTEtMTc0MzYy_25fad0ae-beb8-4cdd-b730-f38f99fd54f2"
      unitRef="usd">5567600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia31d29839cf14beabac4560e466ab9df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzEwMg_dc716646-6907-446a-ba9d-97ed0e8a614c"
      unitRef="usd">3586000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0d710a5f61ac45fe86461104c9643b4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzEwOQ_69458612-0225-4423-835e-4232fc37a202"
      unitRef="usd">5059000000.000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk5MQ_c7bf5c5a-ac2b-4aec-afc5-0b68b5dc2870">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.913%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales to the U.S. government represented less than 10% of total gross product revenue during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14dd5c1f226d4087af59c57f97a899aa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzItMS0xLTEtMTc0MzYy_6a73b6b6-c182-423d-8d13-828d617837f2"
      unitRef="number">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i34fd1be2ecad4837bb9a616be6b49006_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzItMy0xLTEtMTc0MzYy_7dda9c04-088d-4ea6-99c4-b8a83906d456"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i344fed0429da45b2a1e885495c218a51_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzItNS0xLTEtMTc0MzYy_110adf47-2e72-4596-9da0-3190a0f600be"
      unitRef="number">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4b8fe8cae5f463cad7e8105fe984c3d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzMtMS0xLTEtMTc0MzYy_b9326fe0-b5a4-4959-af76-16348106880b"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6af24d3fc5514e589feb09538e6786e0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzMtMy0xLTEtMTc0MzYy_fcb06207-3c15-41b4-b1a1-e4f441869df6"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1783ece527234057a38c1fec76fdaa70_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzMtNS0xLTEtMTc0MzYy_fd03fa60-777d-4631-9707-2870f7621ea5"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6e5923b8955547f1a59fc39eda60bec4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTowN2Q4MDJkZDUxMjM0MDlhYmNhZDlhMThhYjI4MzZiOC90YWJsZXJhbmdlOjA3ZDgwMmRkNTEyMzQwOWFiY2FkOWExOGFiMjgzNmI4XzQtMy0xLTEtMTg1MzM0_e2eba7f6-7ec3-486a-a63b-51a0126c8b1d"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <regn:ScheduleOfSalesRelatedDeductionsActivityTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90ZXh0cmVnaW9uOmI2ZjkwZDc1ZGY5MjRkOTBhNDEyMjljODdiMTM4ZmVmXzk4MQ_4c14021f-f742-40da-8671-ff9b368a2d67">The following table summarizes the provisions, and credits/payments, for sales-related deductions.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Chargebacks,&lt;br/&gt;and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution-&lt;br/&gt;Related Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Sales-&lt;br/&gt;Related Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(641.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,034.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,523.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,109.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,398.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</regn:ScheduleOfSalesRelatedDeductionsActivityTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i79035aaa4aca45619bc98627f48db24d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtMS0xLTEtMTc0MzYy_9a199c07-5586-462b-a5a9-c80fcb7eae03"
      unitRef="usd">80300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibed642c5d8464dd4ab25fed90d1a28b9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtMy0xLTEtMTc0MzYy_53368f91-76b5-4e8d-b0e4-0fadf1bdb263"
      unitRef="usd">46400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idaac0693be9b45a28174b13694aa0f4d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtNS0xLTEtMTc0MzYy_1ee21acc-5599-4ecf-b427-432cdc31bf0a"
      unitRef="usd">29400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEtNy0xLTEtMTc0MzYy_907525f7-48f0-4b5c-8d3d-bc5aca023126"
      unitRef="usd">156100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ia36a49d6ddd04419a0f5b0f1b8c1c942_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItMS0xLTEtMTc0MzYy_f6daed5f-da6e-4b7f-b976-128b5737a53f"
      unitRef="usd">762900000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if4003730ec2f4d02b252a6fe11601f2f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItMy0xLTEtMTc0MzYy_0125095c-b53f-450e-ba03-b5089ddf005a"
      unitRef="usd">279900000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i55504a180d724f1ebaac6dc86a38d8a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItNS0xLTEtMTc0MzYy_66e8933b-bd03-4e52-b68c-952164fa093a"
      unitRef="usd">94100000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzItNy0xLTEtMTc0MzYy_8ea69533-6703-471d-95fe-68fb645124e1"
      unitRef="usd">1136900000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia36a49d6ddd04419a0f5b0f1b8c1c942_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtMS0xLTEtMTc0MzYy_58a15685-6dce-460c-96a8-a14cd2fc4c1e"
      unitRef="usd">641000000.0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if4003730ec2f4d02b252a6fe11601f2f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtMy0xLTEtMTc0MzYy_4a968665-9730-428d-a5de-6609f37af8ef"
      unitRef="usd">249100000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i55504a180d724f1ebaac6dc86a38d8a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtNS0xLTEtMTc0MzYy_f05f0238-b94b-4345-9eae-16787047fc37"
      unitRef="usd">78700000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzMtNy0xLTEtMTc0MzYy_152a2d92-701d-421c-b234-9eda81305926"
      unitRef="usd">968800000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i400385b2589b49f595ff5af66bdd5ade_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtMS0xLTEtMTc0MzYy_6b0897ac-3490-4100-aff1-7e1dfca3f9c7"
      unitRef="usd">202200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id4797ff0491840d0b9237549db0ebcf6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtMy0xLTEtMTc0MzYy_1d8ca901-1c4d-4e24-a3b3-e8c737d6c983"
      unitRef="usd">77200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i011e5e369ab847fa9843f4109e14c84b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtNS0xLTEtMTc0MzYy_dde3f91c-8abb-40c0-aae9-4fd11e5d0f4d"
      unitRef="usd">44800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzQtNy0xLTEtMTc0MzYy_518f0fe7-d0ba-4cd4-b3ec-1f8b76f80364"
      unitRef="usd">324200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i669cdcc9c1e246469a2358ff978102e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtMS0xLTEtMTc0MzYy_29d74396-3833-417b-9513-71b6b91fef95"
      unitRef="usd">1047100000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ica6b4f57919043638cc0e4b7b9319f9b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtMy0xLTEtMTc0MzYy_91c7dd5c-2cc9-4e1e-8421-48d32daef372"
      unitRef="usd">363600000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i140d0e936e944736a5e1983367a30409_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtNS0xLTEtMTc0MzYy_2ddf0227-6886-46d1-ae18-7b84d22fec7d"
      unitRef="usd">150400000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzUtNy0xLTEtMTc0MzYy_7266f32a-c0aa-4432-b7dc-960e468eb7f2"
      unitRef="usd">1561100000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i669cdcc9c1e246469a2358ff978102e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtMS0xLTEtMTc0MzYy_aeba4d9c-366a-4ff6-bd12-4ff85812e46c"
      unitRef="usd">1034700000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ica6b4f57919043638cc0e4b7b9319f9b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtMy0xLTEtMTc0MzYy_7a13dc71-390d-4357-94e1-8b131d854d0b"
      unitRef="usd">360800000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i140d0e936e944736a5e1983367a30409_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtNS0xLTEtMTc0MzYy_19d3c0e3-c4bb-49c9-bd11-c88baebd0e0e"
      unitRef="usd">127600000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzYtNy0xLTEtMTc0MzYy_94282cc8-a8ca-435f-8e5e-f3b95a32d27a"
      unitRef="usd">1523100000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia3bf9e21feb34e239d88bb219da800f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctMS0xLTEtMTc0MzYy_27189304-ab9d-48c7-8657-2d4cb08d7e8f"
      unitRef="usd">214600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="icebca5c748034d6284466eddd3b67472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctMy0xLTEtMTc0MzYy_09624499-8ecd-4083-97ab-79baf1216c4d"
      unitRef="usd">80000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i87d04b81b0d04870a748890c3df2cd84_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctNS0xLTEtMTc0MzYy_3048f624-8eb5-45a0-a01e-5bc70239e28e"
      unitRef="usd">67600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzctNy0xLTEtMTc0MzYy_603785c2-5b1d-49e7-9e98-f90af3af14cd"
      unitRef="usd">362200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie0edb01a74bf4469a5cee578568c2d72_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtMS0xLTEtMTc0MzYy_20fa7155-e7eb-49b4-8dbe-522598f6ba3d"
      unitRef="usd">1537300000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="iebf53692132846bdbb98eb842acd5e55_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtMy0xLTEtMTc0MzYy_3fb0fcc3-b0ac-4dc6-938f-99a91ebfef1a"
      unitRef="usd">431100000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="iddf7a6f088a44d8c92a8778a84dbc88f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtNS0xLTEtMTc0MzYy_c4226011-b9f2-460d-b07b-81dcea0bafe6"
      unitRef="usd">141100000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzgtNy0xLTEtMTc0MzYy_e6a9af0f-5f44-491c-b780-d5dc0c9d2907"
      unitRef="usd">2109500000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie0edb01a74bf4469a5cee578568c2d72_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktMS0xLTEtMTc0MzYy_0121ca7e-08c5-42e9-ae26-bf7140c1b416"
      unitRef="usd">1398000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iebf53692132846bdbb98eb842acd5e55_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktMy0xLTEtMTc0MzYy_68576e83-a68a-49a6-9302-d807a0f64544"
      unitRef="usd">399700000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iddf7a6f088a44d8c92a8778a84dbc88f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktNS0xLTEtMTc0MzYy_d3014d18-9488-4da2-ac2a-74fd42395d86"
      unitRef="usd">127200000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzktNy0xLTEtMTc0MzYy_52c3730c-fa27-427e-9901-dcea9791d55b"
      unitRef="usd">1924900000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5b16833ca23845bea5a41107085ed872_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTEtMS0xLTE3NDM2Mg_378d2eef-e83a-461d-9483-0e23ea3b7178"
      unitRef="usd">353900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3e5549277e904fcf83d210cf6514f72a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTMtMS0xLTE3NDM2Mg_e27b54c7-f4da-46a4-819d-258accf89103"
      unitRef="usd">111400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iab3af9d8607c4bcb8acf3c8ebc5b9724_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTUtMS0xLTE3NDM2Mg_62506d4f-5cbb-43b7-93ba-2d6543754158"
      unitRef="usd">81500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjEvZnJhZzpiNmY5MGQ3NWRmOTI0ZDkwYTQxMjI5Yzg3YjEzOGZlZi90YWJsZTpkZGExNjNkMGQ5MGE0MDQ2YmQ2MzQxZjYyOTZlN2MyMy90YWJsZXJhbmdlOmRkYTE2M2QwZDkwYTQwNDZiZDYzNDFmNjI5NmU3YzIzXzEwLTctMS0xLTE3NDM2Mg_353d1418-1893-484d-815e-d33c9c57d461"
      unitRef="usd">546800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTc3_cc22af67-5033-45a3-acb6-7bf6fd890ea4">Collaboration, License, and Other Agreements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;a. Sanofi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with its collaborations with Sanofi are detailed below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,082.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursements of R&amp;amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of one-time payment of $56.9 million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As described within the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antibody&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (dupilumab), Kevzara&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (sarilumab), and itepekimab&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi based on the Company's share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, the Company was required to apply 10% of its share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of the Company's share of profits used to reimburse Sanofi for such development costs increased from 10% to 20%. A portion of the value associated with the increase in reimbursement percentage was deemed to be contingent consideration attributable to the Company's acquisition of the Libtayo rights described within the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" section below; this portion will be recorded as an increase to the Libtayo intangible asset over time as the Company repays such development costs to Sanofi. The Company's contingent reimbursement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligation (development balance) to Sanofi under the Antibody Collaboration was approximately $2.864 billion as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. The Company co-commercializes Dupixent in the United States and in certain countries outside the United States. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In each of 2020 and 2021, the Company earned a $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion and $1.5&#160;billion, respectively, on a rolling twelve-month basis. In 2022, the Company earned two additional $50.0&#160;million sales-based milestones from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion and $2.5&#160;billion, respectively, on a rolling twelve-month basis. The Company is entitled to receive the final sales milestone payment of $50.0&#160;million when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's significant promised goods and services in connection with the Antibody Collaboration consist of providing research and development services, including the manufacturing of clinical supplies; and providing commercial-related services, including the manufacturing of commercial supplies. The Company recognizes amounts in connection with the Antibody Collaboration based on the amount it has the right to invoice and such amount corresponds directly with the Company's performance to date; therefore, the Company does not disclose the value of the transaction price (i.e., the amount of consideration the Company expects to be entitled to) allocated to its remaining unsatisfied obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp;amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, became solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi pays the Company a 5% royalty on Sanofi&#x2019;s net product sales of Praluent outside the United States until March 31, 2032. The Company does not owe Sanofi royalties on the Company&#x2019;s net product sales of Praluent in the United States. Although each party is responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company continues to supply drug substance to Sanofi and Sanofi continues to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each are solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 16 for discussion of legal proceedings related to Praluent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was previously a party to a collaboration with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration was governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement ("IO License and Collaboration Agreement"). In connection with the execution of the original Immuno-oncology Discovery and Development Agreement in 2015 ("2015 IO Discovery Agreement"), which was subsequently replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $265.0&#160;million non-refundable up-front payment to the Company. Pursuant to the 2015 IO Discovery Agreement, the Company was to identify and validate potential immuno-oncology targets and develop therapeutic antibodies against such targets through clinical proof-of-concept. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 and (ii) MUC16 and CD3 through clinical proof-of-concept. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, the Company retains the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any). In addition, the Company has no further obligations to develop drug product candidates under the Amended IO Discovery Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the IO License and Collaboration Agreement in 2015, Sanofi made a $375.0 million non-refundable up-front payment to the Company. Under the terms of the IO License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. The Company had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;amp;R IO LCA"). In connection with the A&amp;amp;R IO LCA, in 2022, the Company made a $900.0&#160;million up-front payment to Sanofi, as well as a $100.0&#160;million regulatory milestone payment. In addition, Sanofi earned a $65.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022, and is eligible to receive an additional $35.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023 (aggregate of $100.0&#160;million in sales-based milestones eligible to be earned under the terms of the A&amp;amp;R IO LCA). The Company also pays Sanofi an 11% royalty on net product sales of Libtayo through March 31, 2034. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset. See Note 8 for additional information related to the intangible asset recorded in connection with the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Amended IO Discovery Agreement, the Company was obligated to reimburse Sanofi for half of the development costs it funded that were attributable to clinical development of product candidates from the Company's share of profits from commercialized IO Collaboration products. Under the A&amp;amp;R IO LCA, the amount of development costs incurred under the IO Collaboration for which the Company was obligated to reimburse Sanofi was $35.0&#160;million as of the effective date of the A&amp;amp;R IO LCA, and the Company pays Sanofi a 0.5% royalty on net product sales of Libtayo until all such development costs have been reimbursed by Regeneron. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities included up-front payments received from Sanofi for which recognition had been deferred. Such amounts were being recognized over the remaining period in which the Company was obligated to perform development activities. In connection with the A&amp;amp;R IO LCA described above, the remaining IO Collaboration Other liabilities balance of $241.0&#160;million as of July 1, 2022 was recognized as a reduction to the intangible asset during the third quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company updated its estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $66.9&#160;million as a reduction to other operating income. During 2020, the Company updated its estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $135.4 million as an increase to other operating income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;b. Bayer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA (aflibercept) and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. The Company is also obligated to use commercially reasonable efforts to supply clinical and commercial bulk product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the United States, the Company is responsible for commercialization and retains profits from such sales. Bayer markets EYLEA outside the United States and the companies share equally in profits and losses from sales. In Japan, the Company was entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net product sales through 2021, and effective January 1, 2022, the companies share equally in profits and losses from sales in Japan. The Company is obligated to reimburse Bayer out of its share of the collaboration profits for 50% of the agreed-upon development expenses that Bayer has incurred in accordance with a formula based on the amount of development expenses that Bayer has incurred and the Company's share of the collaboration profits, or at a faster rate at the Company's option. The Company's contingent reimbursement obligation to Bayer was approximately $273 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.810%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One-time payment in connection with change in Japan arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Bayer collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;c. Intellia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2016 agreement, the parties agreed to a target selection process, whereby the Company may obtain exclusive rights in up to 10 targets to be chosen by the Company during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Certain targets that either the Company or Intellia selects pursuant to the target selection process may be subject to a co-development and co-commercialization arrangement at the Company's option or Intellia&#x2019;s option, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company expanded its existing collaboration with Intellia to provide the Company with rights to develop products for additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, the Company also received non-exclusive rights to independently develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene edited products. In connection with the agreement, in 2020, the Company made a $70.0&#160;million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $30.0&#160;million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $15.0&#160;million, were recorded to Acquired in-process research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;d. U.S. Government &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company expanded its Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of the Company's costs incurred for research and development activities related to COVID-19 treatments. In 2020, the Company also entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. The agreement, as subsequently amended, provided for payments to the Company of up to $465.9&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish, storage, and other activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into an agreement with the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase 1.25&#160;million doses of drug product, which the Company delivered by June 30, 2021, resulting in payments to the Company of $2.625&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into an amendment to its January 2021 agreement to supply the U.S. government with an additional 1.4&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government was obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of $2.940&#160;billion in the aggregate. Roche supplied a portion of the doses to Regeneron to fulfill the Company's agreement with the U.S. government (see "Roche" below for further details regarding the Company's collaboration agreement with Roche).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company had completed its final deliveries of drug product under the agreements described above. See Note 2 for REGEN-COV net product sales recognized during the years ended December 31, 2021 and 2020 in connection with these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;e. Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in other countries). Under the terms of the collaboration agreement, the Company leads global development activities for REGEN-COV, and the parties jointly fund certain studies. The Company has the right to distribute the product in the United States and Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Other collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit payment from Roche in connection with sales of REGEN-COV and Ronapreve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit payment to Roche in connection with sales of REGEN-COV and Ronapreve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Roche Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.764%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;f. Alnylam&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company and Alnylam Pharmaceuticals, Inc. entered into a collaboration to discover RNA interference ("RNAi") therapeutics for nonalcoholic steatohepatitis ("NASH") and potentially other related diseases, as well as to research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts (including ALN-HSD, which is currently in clinical development). Under the terms of the collaboration agreement, the parties share development costs equally. During the fourth quarter of 2022, Alnylam elected to opt-out of further development activities related to ALN-HSD; as a result, the Company retains the exclusive right to develop and commercialize such product and Alnylam will receive a royalty on sales (if any).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company and Alnylam entered into a global, strategic collaboration to discover, develop, and commercialize RNA interference therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver. In connection with the collaboration, the Company made an up-front payment of $400.0&#160;million to Alnylam, and also purchased shares of Alnylam common stock for $400.0&#160;million. For each program, the Company provides Alnylam with a specified amount of funding at program initiation and at lead candidate designation, and Alnylam is eligible to receive up to an aggregate of $200.0 million in clinical proof-of-principle milestones for eye and CNS programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration, the parties plan to perform discovery research until designation of lead candidates. Following designation of a lead candidate, the parties may further advance such lead candidate under either a co-development/co-commercialization collaboration agreement ("Co-Co Collaboration Agreement") (under which the parties are advancing ALN-APP and ALN-PNP, which are currently in clinical development) or License Agreement structure. The initial target nomination and discovery period is five years (which may under certain situations automatically be extended for up to seven years in the aggregate) (the "Research Term"). In addition, the Company has an option to extend the Research Term for an additional five-year period for a research extension fee ranging from $200.0&#160;million to $400.0&#160;million; the actual amount of the fee will be determined based on the acceptance of one or more Investigational New Drug Applications ("INDs") (or their equivalent in certain other countries) for programs in the eye and CNS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, during 2019, the parties entered into a Co-Co Collaboration Agreement for cemdisiran, a small interfering RNA ("siRNA") therapeutic targeting the C5 component of the human complement pathway being developed by Alnylam, with Alnylam as the lead party, and a License Agreement for a combination consisting of cemdisiran and a fully human monoclonal antibody targeting C5 being developed by the Company (pozelimab), with the Company as the licensee. Under the C5 siRNA Co-Co Collaboration Agreement, the parties shared costs equally and under the License Agreement, the Company as the licensee is responsible for its own costs and expenses. The C5 siRNA License Agreement contains a flat low double-digit royalty payable to Alnylam on potential future net sales of the combination only subject to customary reductions, as well as up to $325.0&#160;million in sales milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, the Company elected to opt-out of further development activities pursuant to the Co-Co Collaboration Agreement for cemdisiran as a monotherapy; as a result, Alnylam retains the right to develop and commercialize such product and the Company will receive a royalty on sales (if any).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Alnylam agreements described above were not material for the years ended December 31, 2022, 2021, and 2020. In addition, contract balances in the Company's Balance Sheets were not material as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;g. Checkmate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. (&#x201c;Checkmate&#x201d;) for a total equity value of approximately $250&#160;million. The Company made an assessment as to whether the set of assets acquired constituted a business and should be accounted for as a business combination. Given that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, vidutolimod, which is in clinical development for oncology, the transaction was accounted for as an asset acquisition. As a result of the acquisition, the Company recorded (i) a charge of $195.0&#160;million to Acquired in-process research and development and (ii) net assets of $35.3&#160;million, net of cash, related to the assets acquired (including deferred tax assets and investments) and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;h. Teva &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Teva are parties to a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to the Company's collaboration agreement with Mitsubishi Tanabe Pharma Corporation. Under the terms of the Teva Collaboration Agreement, the Company led global development activities and the parties share development costs equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, Teva made a $250.0 million non-refundable up-front payment in 2016, and as of December 31, 2022, the Company had received an aggregate $120.0&#160;million of development milestones from Teva. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Teva Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.206%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front and development milestone payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company recognized reimbursement of R&amp;amp;D expenses (as a reduction of R&amp;amp;D expense) of $42.4 million and $109.4 million for the years ended December 31, 2021 and 2020, respectively. Such amount was not material for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Teva Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities included up-front and development milestone payments received from Teva for which recognition had been deferred. During 2022, the Company discontinued further clinical development of fasinumab and, as a result, recorded $31.9&#160;million as an increase to Other operating income as the Company deemed its obligation to provide development services in connection with the Teva Collaboration Agreement to be complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;i. Other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the collaboration agreements discussed above, the Company has various other collaboration agreements that are not individually significant to its operating results or financial condition at this time. Pursuant to the terms of those agreements, the Company may be required to pay, or it may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones) which in the aggregate could be significant. The Company may also incur, or get reimbursed for, significant research and development costs. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay, or it may receive, royalties on future sales. The payment or receipt of these amounts, however, is contingent upon the occurrence of various future events.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04ba1f9253744de2b4207de915788712_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzMtNC0xLTEtMTc0MzYy_57f204b1-47eb-4630-8ab1-d79f906ac5e5"
      unitRef="usd">2082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacc9281a149a43a6a468ee18b2d84cf2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzMtNi0xLTEtMTc0MzYy_988dd79d-fc6f-437c-8f71-8be21b64d027"
      unitRef="usd">1363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0115b1778749402f91e8cc15e18d4904_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzMtOC0xLTEtMTc0MzYy_bed3c945-9c06-4472-9404-a012b5fa28ce"
      unitRef="usd">785200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia777bee1ba8248c483a61586e012c702_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzQtNC0xLTEtMTc0MzYy_89aceae8-dbe5-4f49-becc-433dd657c887"
      unitRef="usd">100000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id96bb9eb29d642bc83bbfe650b831b53_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzQtNi0xLTEtMTc0MzYy_6662944e-e58d-4756-b94f-54a34e9829b5"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71e3a3b0502c4423ad39c725eb715497_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzQtOC0xLTEtMTc0MzYy_3b9dd487-0c18-432c-b615-66efe161708b"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12afa83d8539401a99a900866df1fa36_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzUtNC0xLTEtMTc0MzYy_7226122d-5a0d-4bb0-9f9f-aa00cc5e8871"
      unitRef="usd">633700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53ce6c9a943648f89bc598bd4d43f36c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzUtNi0xLTEtMTc0MzYy_df18e146-5a1e-4417-be40-46c9589604c4"
      unitRef="usd">488800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1098ae33301f499691dd988767b567e2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzUtOC0xLTEtMTc0MzYy_3fdfdba3-429d-4a48-92d5-af4d004c8773"
      unitRef="usd">368000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f529cd92f434fb1a4cedfbac373d940_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNC0xLTEtMTc2NzQ4_db33c951-1df5-4b1b-a27b-e19e94e0398b"
      unitRef="usd">28700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9379b307875b4618a634289637cb38fa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNi0xLTEtMTc2NzQ4_ac28d53c-8234-4938-ba3a-1ce8ec865844"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24f5efff9c1341368743087b362bfb90_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtOC0xLTEtMTc2NzQ4_850946f3-2f8e-4bf3-97f9-54d9504d848c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59b2e844e32b48cba3e0f9a0086990d6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNC0xLTEtMTc0MzYy_e8388ef6-5a3c-412e-a3e4-1e1ef85ef5fe"
      unitRef="usd">43000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a7a5ff4b315478cbf0aad95a657b855_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtNi0xLTEtMTc0MzYy_aeaff16a-f158-4423-95f5-84eb0111832e"
      unitRef="usd">129200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i766d690fe05a4cd1aedfdac8bcaac956_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzYtOC0xLTEtMTc0MzYy_2cb60f71-0e73-441e-8ca8-9d3e84eb56fe"
      unitRef="usd">149100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia98f436ad8214c2f880b651b95e5dad2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzgtNC0xLTEtMTc0MzYy_d5da3306-9197-4d6b-9a85-84cc10eefeca"
      unitRef="usd">437400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f38cde3c9ce4d3199de6ef8a0bd8843_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzgtNi0xLTEtMTc0MzYy_b104dfbd-e653-4593-bd17-a09d22c0a42a"
      unitRef="usd">320500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65c16e48fda34e60b3f5035db52b587d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzgtOC0xLTEtMTc0MzYy_86058e79-3c4e-42d2-bdf2-5e120254a7b1"
      unitRef="usd">359400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fd9317470c24cb790bc85ce993a30eb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzExLTQtMS0xLTE3NDM2Mg_127e5b05-5b80-48d4-b7d1-26ba8c52d655"
      unitRef="usd">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id84b946ec54c41148f176f9146ca5bf4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzExLTYtMS0xLTE3NDM2Mg_00ba4e7d-47f4-4f7b-9fc9-92ac3af1840f"
      unitRef="usd">-13600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6af8b58cda784c98a6fa9c2b3c890073_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzExLTgtMS0xLTE3NDM2Mg_3a7542a9-c6d1-40c2-abe9-728f8d05d588"
      unitRef="usd">-25700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bb55a76cf4c4a3487a985658b5c16a1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEyLTQtMS0xLTE3NDM2Mg_ac2ea6db-74a9-4c12-8ff1-f86216ec614d"
      unitRef="usd">4600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40fc6180f85a4a7f9625db7362ac76de_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEyLTYtMS0xLTE3NDM2Mg_3c2fd3c1-3b6f-43bf-8f27-b41690cccc5b"
      unitRef="usd">14000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b1990e2efe34d48b17cc48fed693450_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEyLTgtMS0xLTE3NDM2Mg_0a3d744e-24c7-424c-b838-a4e64026f770"
      unitRef="usd">8900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8813ce5c13e64d47b2b5439b9dc755f1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEzLTQtMS0xLTE3NDM2Mg_e6dfe8d6-aa4d-4c68-9a3f-236bfb3ed608"
      unitRef="usd">42700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf8f5e721504480c84d395aaa308c019_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEzLTYtMS0xLTE3NDM2Mg_0d5c8a39-fac0-49ed-b0de-4f76611a6d90"
      unitRef="usd">85100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbe81139390d42459544d73a062fac93_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzEzLTgtMS0xLTE3NDM2Mg_f1a6acea-a889-49de-b026-7cb7ba544f77"
      unitRef="usd">166200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6265b4f0bd0845d39208a99685ef72d5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE0LTQtMS0xLTE3NDM2Mg_c3daa1d8-88d3-49d2-aa5e-561045ae3439"
      unitRef="usd">41400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f01400d1f5f4ab88a047bc5a42ad47e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE0LTYtMS0xLTE3NDM2Mg_798695a9-e590-402e-8b31-71e35b74ebb0"
      unitRef="usd">89600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08844a1258e34c188ef387c945bb338e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE0LTgtMS0xLTE3NDM2Mg_f12301b4-00a1-478b-adec-6afb59ac5b00"
      unitRef="usd">64700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i051041a979024065b21211e82f9cdf21_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE1LTQtMS0xLTE3NDM2Mg_ff427b42-1931-400e-ba38-8c2ba6f77669"
      unitRef="usd">-19900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bee21e9d49947c3a10d37cddc0d58ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE1LTYtMS0xLTE3NDM2Mg_44ee151b-db8f-4f6b-9b8a-e5a7cc6fd2cd"
      unitRef="usd">-36300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9102b7c37a5540bd87a27183334b342a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE1LTgtMS0xLTE3NDM2Mg_6bd47293-6ef1-431b-99ee-484e77f3c7e2"
      unitRef="usd">-22400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1499e9e4c3cb42b29dbe231e9c8cbca2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE2LTQtMS0xLTE3NDM2Mg_53c75ee6-2d19-4fae-90ec-0989f1bac5dd"
      unitRef="usd">-70100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9ad83d17ed14bf6986ec0a3067634ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE2LTYtMS0xLTE3NDM2Mg_6373e577-8106-4b9e-b420-3ae099171bb7"
      unitRef="usd">-133000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4ae9b363c444357b3a5692e04f07a21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE2LTgtMS0xLTE3NDM2Mg_e172b6ff-9a54-4b1d-a843-66fbfc642adf"
      unitRef="usd">-119100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if782b4fb146742af8dd0fb0dfa6d0f36_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE3LTQtMS0xLTE3NDM2Mg_8d4a5bdb-2f89-4e00-af2c-98b9e44783fe"
      unitRef="usd">35100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7e2a1ed354949eb9a8bc01eeb0918c1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE3LTYtMS0xLTE3NDM2Mg_5b9bdabc-7e73-4e66-8e38-3d9c9790859f"
      unitRef="usd">6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic964826dc2d046ca8a21b1f261865199_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE3LTgtMS0xLTE3NDM2Mg_1e142203-af97-4218-92ad-75b715a45cc7"
      unitRef="usd">210600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:PaymentToCollaboratingParty
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpjNWRiODVlZTljMDk0NzVkOTllNWNjY2QyOGQ5OGVkZS90YWJsZXJhbmdlOmM1ZGI4NWVlOWMwOTQ3NWQ5OWU1Y2NjZDI4ZDk4ZWRlXzE5LTAtMS0xLTE4MjM5My90ZXh0cmVnaW9uOjcwYjNkNjBhZDUzMTRkMWJhMDhiMmVhOTZkYjQ2YzQ5XzU0OTc1NTgxNDAzNg_a8bae39e-3dd0-48ac-8d70-a049618132b0"
      unitRef="usd">56900000</regn:PaymentToCollaboratingParty>
    <regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
      contextRef="i1bc08b7de58d43ffa7092aa7f8bb0810_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU1OQ_edc8f867-b472-47d2-a311-134234419050"
      unitRef="number">0.80</regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty>
    <regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
      contextRef="ib25739cf76b545759fc2d04ae78628e0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU2Mg_4f9bb5d9-aa1a-4788-a637-ad3606bcaf1c"
      unitRef="number">1</regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty>
    <regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
      contextRef="i1bc08b7de58d43ffa7092aa7f8bb0810_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzY0MA_77c347a7-8333-425e-b5a6-00b4f3873ae5"
      unitRef="number">0.30</regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts>
    <regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
      contextRef="ib25739cf76b545759fc2d04ae78628e0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzY0Mw_1dae72b3-6b32-4aef-996e-8e6ef56e0721"
      unitRef="number">0.50</regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts>
    <regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzg4Mg_1b2eaa1c-c40c-439b-ae14-9a6c2394d4db"
      unitRef="number">0.10</regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts>
    <regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts
      contextRef="ib3cfd1bc015b4dbe9079b20e66709ea4_D20220630-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg1MjA3NA_3ecd419f-bfb4-4e29-9595-1c611ab35624"
      unitRef="number">0.10</regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts>
    <regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts
      contextRef="ica111cf830ee452b94a3ed1fa3edd4ac_D20220701-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg1MjA4MQ_068c0017-5cf4-4961-98b1-3fe2f801445a"
      unitRef="number">0.20</regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts>
    <regn:ContingentReimbursementObligation
      contextRef="if16d17ebcbaf4806a375d33fb5402f61_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzExNTE_6a93594c-49bf-4704-9eb7-ae5e79e1c105"
      unitRef="usd">2864000000</regn:ContingentReimbursementObligation>
    <regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwOTk_d5810204-1967-48ff-b1a6-54e7d9e65f84"
      unitRef="number">0.65</regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty>
    <regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxMTE_ca97cd3f-d97a-411a-a50b-bab156497b7f"
      unitRef="number">0.35</regn:StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany>
    <regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNDA_2ca7df70-556d-460c-a31d-02ef634c4e7c"
      unitRef="number">0.55</regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty>
    <regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNTI_c818c502-89ad-457a-b5ae-ca906426e242"
      unitRef="number">0.45</regn:EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany>
    <regn:ShareOfLossesOutsideUnitedStatesForCollaboratingParty
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIyMDg_011bb1ca-5b3c-42cf-aca1-85c11af179d0"
      unitRef="number">0.55</regn:ShareOfLossesOutsideUnitedStatesForCollaboratingParty>
    <regn:ShareOfLossesOutsideUnitedStatesForCompany
      contextRef="if8d819aa52dd4313bfb428e352733bbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIyMjA_55af6577-de73-4280-8a64-5d47e358ba68"
      unitRef="number">0.45</regn:ShareOfLossesOutsideUnitedStatesForCompany>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI0MjM_ecde4cff-97f9-4030-8868-2375d7627f61"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
      contextRef="i92098519881447bc802ea9a38d5455bb_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1NjA_acd7d785-9d66-42fb-b8a8-5bc7f8c091e3"
      unitRef="usd">1000000000</regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived>
    <regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
      contextRef="i4df3bd7c2a0041b6ab7f312261481025_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1Njc_ac6d236f-e1a8-4ff1-9923-7e66156f974c"
      unitRef="usd">1500000000</regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="i4df3bd7c2a0041b6ab7f312261481025_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NDE_792a0bea-1228-4bbb-9751-878afa86ce0c">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMDg3NTY_ecde4cff-97f9-4030-8868-2375d7627f61"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
      contextRef="i6275de131f464f1ba3b26f74b932c12d_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg1MjUyMA_3e38642f-f107-488b-9a23-ce7080683faf"
      unitRef="usd">2000000000</regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived>
    <regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
      contextRef="i88cadc8fc7e24c3d9ff92f91bad83c6e_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMDkxOTQ_72fea739-67fa-4625-9991-f6315496e58e"
      unitRef="usd">2500000000</regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="i88cadc8fc7e24c3d9ff92f91bad83c6e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTE1_7a070ffc-8e6a-4344-b8ca-8e80eeaf07bd">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <regn:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="ic35d85587ab1424a9a59091f3cf09bf6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3Njk_65b22db0-28d8-4828-8453-80054982c0f1"
      unitRef="usd">50000000</regn:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
      contextRef="ibcc771627f73408eb92c1b64295c2e4b_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI4NDI_c43338f8-63e2-4e86-a10e-90fc4a12c4a7"
      unitRef="usd">3000000000</regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="ibcc771627f73408eb92c1b64295c2e4b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTg4_9df93852-926c-4557-a0d3-ce82e1d7f99e">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTMy_c5d32d5c-2822-4ea7-9f8b-de6f13d1e552">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Bayer collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Roche Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.764%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Teva Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities included up-front and development milestone payments received from Teva for which recognition had been deferred. During 2022, the Company discontinued further clinical development of fasinumab and, as a result, recorded $31.9&#160;million as an increase to Other operating income as the Company deemed its obligation to provide development services in connection with the Teva Collaboration Agreement to be complete.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if16d17ebcbaf4806a375d33fb5402f61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzItMi0xLTEtMTc0MzYy_1c611c72-117f-4958-835f-110865c62096"
      unitRef="usd">692300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6c3d8ea7d0184f31933cf11c201c1047_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzItNC0xLTEtMTc0MzYy_a788772e-7dfa-4689-a6e6-2fab4140b4f4"
      unitRef="usd">504800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if16d17ebcbaf4806a375d33fb5402f61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzMtMi0xLTEtMTc0MzYy_e33afb9c-5e92-4cbc-a752-f0d3271fc5c4"
      unitRef="usd">415800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6c3d8ea7d0184f31933cf11c201c1047_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmMTAzNjk4NjRlZDM0MmMxOTQ1MzI5OWYxN2RkODM0Ni90YWJsZXJhbmdlOmYxMDM2OTg2NGVkMzQyYzE5NDUzMjk5ZjE3ZGQ4MzQ2XzMtNC0xLTEtMTc0MzYy_db08a940-d0bb-4c92-86c3-587c3da4b84c"
      unitRef="usd">368700000</us-gaap:ContractWithCustomerLiability>
    <regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates
      contextRef="ic416426a749b4b799097f4def70ef266_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTcxMzU_adad7d99-99f1-42d5-9bfd-1d0dd7111169"
      unitRef="number">0.05</regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates>
    <regn:PercentageOfRoyaltyPaymentThatCanBeOffset
      contextRef="if2ae15c5525a4644af133a200d4375fc_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTcxNjM_cfab35be-1b51-4297-b675-9e8e90cee797"
      unitRef="number">0.50</regn:PercentageOfRoyaltyPaymentThatCanBeOffset>
    <regn:LossContingencyPercentageOfDamagesResponsibleFor
      contextRef="ic416426a749b4b799097f4def70ef266_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTcxNzY_9f8bfcd0-50b5-4c22-bd3b-0f4124401dc1"
      unitRef="number">0.50</regn:LossContingencyPercentageOfDamagesResponsibleFor>
    <regn:UpFrontPaymentReceived
      contextRef="ia07abc9790d746bcb14fa6e3f0c1ea51_D20150101-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NDM_374c8cbf-3a77-4edb-a439-7fc65a3a9b6d"
      unitRef="usd">265000000</regn:UpFrontPaymentReceived>
    <regn:UpFrontPaymentReceived
      contextRef="ie82399ac549a40d5978b791c9447413e_D20150101-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzkxNTQ_cbd6eb5e-3129-48fc-9176-2f70fd96cc71"
      unitRef="usd">375000000</regn:UpFrontPaymentReceived>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTc0Njg_56af7f89-b086-43f1-8831-8fb5a2499c62"
      unitRef="usd">900000000</regn:UpFrontPaymentToCollaboratingParty>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ib7a293af7f1a454b8c850b4caf8e4c3f_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NzQ_fa781e00-58f0-4a0f-9bcb-fe6c1d521f7c"
      unitRef="usd">100000000</regn:UpFrontPaymentToCollaboratingParty>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3cd8df873044150844eb0ad18f0b00f_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzMjM1NTk_64ac376a-732f-4da8-8dc8-50f1c7d1dc5d"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2edbcd603c4e4104a5be3200e42d13d4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTc4MDE_4d44dcb2-fd05-474c-8b82-1981013cb707"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d21c3111e2741a386578f848272cd46_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjMzOTc5NjI_5933efe9-6d0a-414b-8b56-60d4a09392ef"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales
      contextRef="ida00ad5e29154c468a4e0cc72eecae59_D20220701-20220731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTc5NDg_d091cc50-f5e3-4e9d-8e3d-07308a71715e"
      unitRef="number">0.11</regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTg1NTM_0023552d-fba4-47f6-bf56-fb919ca79e8c"
      unitRef="usd">35000000</us-gaap:RevenueRemainingPerformanceObligation>
    <regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales
      contextRef="id36294acc59c4a11a0b25a3fdda18f81_D20220701-20220701"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzYwNDczMTQwMTg2MzE_2dbc2987-6ec0-4b5d-b6de-a0bc4fce384f"
      unitRef="number">0.005</regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzItMi0xLTEtMTc0MzYy_8403eae4-0485-4ea3-b3f6-0614136ace17"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifb765df6920d4b6383231c53791eadb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzItNC0xLTEtMTc0MzYy_4f89fe42-593a-4dd4-b26f-ef34b9e8ee6c"
      unitRef="usd">22500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzMtMi0xLTEtMTc0MzYy_6d2285d0-5ce0-4e82-8ff6-53bfc56d5f2e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifb765df6920d4b6383231c53791eadb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzMtNC0xLTEtMTc0MzYy_bb4190b0-56a0-4d2e-b8b4-089852139be4"
      unitRef="usd">16000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OtherLiabilities
      contextRef="i26e7fd0c4d1040deb43f17a2f172c19c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzQtMi0xLTEtMTc0MzYy_95b9fc53-0148-4ed0-83c0-4f7e277cb5ad"
      unitRef="usd">0</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="ifb765df6920d4b6383231c53791eadb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozMGEyZTMyNzk4MzE0N2Y5YWE3OWVkOTZhNTE2MzYzNi90YWJsZXJhbmdlOjMwYTJlMzI3OTgzMTQ3ZjlhYTc5ZWQ5NmE1MTYzNjM2XzQtNC0xLTEtMTc0MzYy_d27c197a-2bea-484e-b742-10fa89b340dc"
      unitRef="usd">276100000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg2NDMzNA_7b3a42fd-8759-4443-a571-0c931fdb0207"
      unitRef="usd">241000000</us-gaap:OtherLiabilities>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="i9968c18075514aa49e06f8c1a6cb6cdd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg2NDc0Mg_fe2f19d5-c805-45a6-9869-76373fbd78f5"
      unitRef="usd">66900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="i662e6bf4027d426e82807c2558c35ae6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg2NTA3Ng_f032603d-5afe-486a-b63a-4d96f7b0104e"
      unitRef="usd">135400000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <regn:RevenueBasedOnPercentageOfAnnualSalesInJapan
      contextRef="i19f9658cc2ff458f98c65823bbf93768_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0MjI0_c902897e-4362-475a-9f4c-9b74f765085d"
      unitRef="number">0.335</regn:RevenueBasedOnPercentageOfAnnualSalesInJapan>
    <regn:RevenueBasedOnPercentageOfAnnualSalesInJapan
      contextRef="i1ff682a1bf3046e59c581283c15cd463_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0MjMx_6c807c91-409f-4403-95b1-287f4ed64b5d"
      unitRef="number">0.400</regn:RevenueBasedOnPercentageOfAnnualSalesInJapan>
    <regn:PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits
      contextRef="i6f127c8b7cde442e8f388b671f809753_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0NjE0_58900903-d7da-4d9d-9634-b9e50e68034b"
      unitRef="number">0.50</regn:PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits>
    <regn:ContingentReimbursementObligation
      contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE0OTU0_6c7a2c34-25c0-4625-9f78-fea3a481db49"
      unitRef="usd">273000000</regn:ContingentReimbursementObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c1144a7790544218f74de1883b49bf3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzItNC0xLTEtMTc0MzYy_7f44093f-5094-4983-9f74-6872a965e01b"
      unitRef="usd">1317400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i031e83e10e9e4d98a468c3b9d072d89f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzItNi0xLTEtMTc0MzYy_708c259c-40dd-4b2c-99a3-28ab6ee47f65"
      unitRef="usd">1349200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3313afbfc9d443d3919f6a7a44e3fa4d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzItOC0xLTEtMTc0MzYy_fce4f4aa-e5b9-4a82-916d-1822f1c3fa2f"
      unitRef="usd">1107900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ab9f0ecc7f6469f8f6f13959ec2c1c9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzMtNC0xLTEtMTc0MzYy_719578dc-d1c0-47ca-a43f-511b6cb2e590"
      unitRef="usd">91400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f4b4ccfc364728a38bf1a2879c55df_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzMtNi0xLTEtMTc0MzYy_f8b96b5f-14c7-4370-bb07-537531103eaa"
      unitRef="usd">60100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86b2ada6cf67454e9cc60972f8641090_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzMtOC0xLTEtMTc0MzYy_65f6d394-4733-4502-be06-f7ad6dc079de"
      unitRef="usd">78200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4071c884ce284e40bc787d87c171aee2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNC0xLTEtMTgyNjYy_625a4a43-d0da-4a68-8df2-3722d59afec9"
      unitRef="usd">21900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic56187dada534884b655d5a6e52af578_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNi0xLTEtMTgyNjYy_90288eb1-9b3a-47be-b459-4aaef29f85c2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i377212e618da453c9025dd02c5593bd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtOC0xLTEtMTgyNjYy_17f16fd6-d22c-4102-b63c-20389ae0dfa9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if15bad177eea4c829136e32f7d94e3d1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNC0xLTEtMTc0MzYy_df03fbd0-7ad2-4009-bbf7-c4a4472e4d08"
      unitRef="usd">51000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63ea98825b3b48b79de2a000301ebc7d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtNi0xLTEtMTc0MzYy_aaa496ea-138d-4dd5-936a-8801223d04e2"
      unitRef="usd">46100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64f6c2b8f017469fb82cab1366cbc891_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzQtOC0xLTEtMTc0MzYy_3dc363ad-ea64-4021-8810-6aa252f11e8e"
      unitRef="usd">46700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic67456caf2c74fb5a00b7ecdac095418_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzUtNC0xLTEtMTc0MzYy_ecd93032-4114-4099-b4f7-f29752cea811"
      unitRef="usd">-34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d6d6e78614245739b4f9317ec964d69_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzUtNi0xLTEtMTc0MzYy_9c674106-5451-483c-a761-efd80dc29cf2"
      unitRef="usd">-40900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98a1426d20a84b1ba447ab97089b66db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo5ZmFlNzZhMzNkZGM0MDgwOTZmM2NhMTA4M2NhMzk2Yi90YWJsZXJhbmdlOjlmYWU3NmEzM2RkYzQwODA5NmYzY2ExMDgzY2EzOTZiXzUtOC0xLTEtMTc0MzYy_6e00154f-6986-4d39-b6b8-744530f494ae"
      unitRef="usd">-35800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzItMi0xLTEtMTc0MzYy_13fd7619-5763-47ea-bfd9-62a3b0b4e467"
      unitRef="usd">348200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2cd8680e50f643d098a5cb1c5b5231a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzItNC0xLTEtMTc0MzYy_681b1352-0038-4d58-b5dd-e8e82e713aeb"
      unitRef="usd">355500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzMtMi0xLTEtMTc0MzYy_4d462f6e-a936-43fb-86b9-4f9c8d6c0234"
      unitRef="usd">131900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2cd8680e50f643d098a5cb1c5b5231a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo4NGQzNzY5OWY0YTU0YTI1YThhYjk0OGRhZWIwNjk3MC90YWJsZXJhbmdlOjg0ZDM3Njk5ZjRhNTRhMjVhOGFiOTQ4ZGFlYjA2OTcwXzMtNC0xLTEtMTc0MzYy_a06961b4-b82b-4410-aedb-555285e2a4c7"
      unitRef="usd">129400000</us-gaap:ContractWithCustomerLiability>
    <regn:CollaborativeArrangementUpfrontPaymentMade
      contextRef="i6c64d785c95b442cb84245281603aa97_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzE5OTUy_f2c82767-fc25-4c1f-af64-c8a6766afa0b"
      unitRef="usd">70000000</regn:CollaborativeArrangementUpfrontPaymentMade>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="ifa1488b28acd4712947288f81c0b3d62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwMDUz_d057b1b5-1da2-467d-a84e-e9121184ddd8"
      unitRef="usd">30000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6c64d785c95b442cb84245281603aa97_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwMTYx_d047ab84-cf8c-4bd1-b58b-670830cb4abe"
      unitRef="usd">15000000</us-gaap:ResearchAndDevelopmentExpense>
    <regn:MaximumTransactionAgreementPayments
      contextRef="ib00e86a2286a4587b02c4df300896c50_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIwOTU3_7220f481-9288-4b1b-aa55-5990b9aaa934"
      unitRef="usd">465900000</regn:MaximumTransactionAgreementPayments>
    <regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase
      contextRef="i60cc7d156a5a435fb977176336cbf529_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxMzg2_505591c5-61c8-45fa-a170-3ac7043c131f"
      unitRef="dose">1250000</regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadbeb25484b8461ba47918e533c9948f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNDg5_67603a9b-0417-4e50-888e-fe906022c2a9"
      unitRef="usd">2625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase
      contextRef="i444e097b9a96467fb3f9bcce2f2dbf2f_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxNjI2_2af0f8b4-6f3f-4549-96ff-577d4b32a4f2"
      unitRef="dose">1400000</regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase>
    <regn:MaximumTransactionAgreementPayments
      contextRef="i62ebb955ca6e41b3a41e451e1855aa43_D20210901-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxODU1_a8ccb9a9-ea96-4b2b-bf53-dba7a851f32d"
      unitRef="usd">2940000000</regn:MaximumTransactionAgreementPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3634f1dd450c457f96f0a93baa2fe330_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzItNC0xLTEtMTc0MzYy_8a25ad24-78a4-4125-b797-1e05a8cbb4e0"
      unitRef="usd">627300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9910bd6f76874c749d53d66bb258402f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzItNi0xLTEtMTc0MzYy_655b9699-2430-47fc-9123-dde2bc1fa224"
      unitRef="usd">361800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i557ade655aa34c1cbd2c4cb2be4a929a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzItOC0xLTEtMTgyNzE5_839de6fa-aac6-4475-bdc9-9b8e64826d71"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id400cead2cc04f689d186fa70f6b0bc7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzMtNC0xLTEtMTc0MzYy_2f6fb929-b530-4955-b1c7-08f2052f5284"
      unitRef="usd">6800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i920dc4f12d2f4619b92a360f1580099a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzMtNi0xLTEtMTc0MzYy_fe95e97d-fab2-491c-a8c3-537d83ea519f"
      unitRef="usd">128100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81aa8c9a653b433692636458e8fd345f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzMtOC0xLTEtMTgyNzE5_2166214e-10b3-4971-a4f0-f16ffccaf072"
      unitRef="usd">78500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c91b71a44844a9a8775d4250688b382_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzQtNC0xLTEtMTc0MzYy_f0b9b3cd-7f42-4250-880c-fbdefc1bdc26"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib113af71423044e1bdf03d2a055e837d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzQtNi0xLTEtMTc0MzYy_692a065f-d457-4dc1-b1ac-47642e8284d2"
      unitRef="usd">259600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03fc22e78596486394e84faff1c467ba_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTozM2YwMDdmZmEzMzU0NjBiODJmMWI5ZjM3NmY1MzQ1NC90YWJsZXJhbmdlOjMzZjAwN2ZmYTMzNTQ2MGI4MmYxYjlmMzc2ZjUzNDU0XzQtOC0xLTEtMTg0NDk3_76a8e93f-0271-4ea7-9cd3-c2c4736c3114"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i128800b6b8e7426faa3758b24792c793_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzItMi0xLTEtMTc0MzYy_83a53e62-287c-4f1e-8a50-810003f5f1b3"
      unitRef="usd">396600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6e95202a8f2e4aefb1e1dfc0454a551f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzItNC0xLTEtMTc0MzYy_936b81b6-1a62-4c13-bb51-57530e87b2ad"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i128800b6b8e7426faa3758b24792c793_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzMtMi0xLTEtMTc0MzYy_3576b7e6-6871-4c1d-a35b-1cc5279c87f3"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6e95202a8f2e4aefb1e1dfc0454a551f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo3NGU4YzQ0YzRlNjI0OWZhOWM2ZjMxYTQxY2M2NDk4Ny90YWJsZXJhbmdlOjc0ZThjNDRjNGU2MjQ5ZmE5YzZmMzFhNDFjYzY0OTg3XzMtNC0xLTEtMTc0MzYy_646e11db-6b62-4843-b959-72149268b5b1"
      unitRef="usd">268800000</us-gaap:AccruedLiabilitiesCurrent>
    <regn:UpfrontPaymentMade
      contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI0MzA5_b958cb15-aff7-4135-9de2-c4d5e0d12fc5"
      unitRef="usd">400000000</regn:UpfrontPaymentMade>
    <regn:PaymentsMadeToAcquireEquityWithinACollaborationAgreement
      contextRef="iacafdf0d5b114325b26e61a9a412e131_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzIxOTkwMjM0MDMwNjk_25f59bb4-88e3-4729-9d98-2ceb8c620943"
      unitRef="usd">400000000</regn:PaymentsMadeToAcquireEquityWithinACollaborationAgreement>
    <regn:CollaborativeArrangementAdditionalPaymentEligibleMilestone
      contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI0NTc4_0062cf7a-39fa-4c5d-bc80-b347d460652d"
      unitRef="usd">200000000</regn:CollaborativeArrangementAdditionalPaymentEligibleMilestone>
    <regn:InitialResearchTerm
      contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MDAy_e96e7f2c-c5bf-4aac-8486-83a159da0ce6">P5Y</regn:InitialResearchTerm>
    <regn:PotentialExtensionOfResearchTerm
      contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MDc3_b5f5dadd-ffd9-4564-9cff-115035df2fab">P7Y</regn:PotentialExtensionOfResearchTerm>
    <regn:OptionToExtendResearchTermPeriod
      contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI3NTk0_433f6f40-8f91-4a14-bf5d-da81ac5ef59c">P5Y</regn:OptionToExtendResearchTermPeriod>
    <regn:ExtensionOfResearchTermFee
      contextRef="ibbee9a8b29934d8b8b7b1e850d856f99_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MjU1_a82251b5-bd5d-4846-b456-50d1cd75e89c"
      unitRef="usd">200000000</regn:ExtensionOfResearchTermFee>
    <regn:ExtensionOfResearchTermFee
      contextRef="icd928207d61c49b880a0b85bdb41a6a6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI1MjYx_98574a71-0073-46f2-b412-1e4430bc3b8d"
      unitRef="usd">400000000</regn:ExtensionOfResearchTermFee>
    <regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels
      contextRef="iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzI2NDc3_e447f404-1781-47ba-a51e-a4673fea752c"
      unitRef="usd">325000000</regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0NDk2Mg_36903c0b-4a03-4394-a36c-7c81a912459c"
      unitRef="usd">250000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0NTAyMA_50a462b2-9688-406e-a5bb-c6e0fb586da6"
      unitRef="usd">195000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i6667fb912e984e6fa6353a1eed3e8fc4_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0NDk5MA_f61cada9-1afb-46c2-a5cc-09bedd2d8824"
      unitRef="usd">35300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <regn:UpFrontPaymentReceived
      contextRef="i0cfcdda3880e4f87bb8ab780435bee97_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzEyNjQ0MzgzODA5OTg2_e4901cc7-d9a6-4a86-ae62-be46343e636c"
      unitRef="usd">250000000</regn:UpFrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c78bdc526b34938a7fd5ed6077bef4d_D20160101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTg0ODI1Nw_e32649fc-712a-42ff-8309-26be3b7b2692"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib02c2984d363403d9b1e823ad3d81d18_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmY2NlYjBiYTA2NmI0YjBmOTlmYzRlMWQ5ZmYzYjcxYi90YWJsZXJhbmdlOmZjY2ViMGJhMDY2YjRiMGY5OWZjNGUxZDlmZjNiNzFiXzMtNC0xLTEtMTc3ODcw_ee996f93-99ac-4000-8422-f1131ef65e43"
      unitRef="usd">33300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ac5aacea45414aaa675930ed342a3f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmY2NlYjBiYTA2NmI0YjBmOTlmYzRlMWQ5ZmYzYjcxYi90YWJsZXJhbmdlOmZjY2ViMGJhMDY2YjRiMGY5OWZjNGUxZDlmZjNiNzFiXzMtNi0xLTEtMTc3ODcw_3cc4b906-557c-4aa2-8ec1-5be38d9bc6f3"
      unitRef="usd">26200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f3c36d0466748cea4e130f324d5e2dc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTpmY2NlYjBiYTA2NmI0YjBmOTlmYzRlMWQ5ZmYzYjcxYi90YWJsZXJhbmdlOmZjY2ViMGJhMDY2YjRiMGY5OWZjNGUxZDlmZjNiNzFiXzMtOC0xLTEtMTc3ODcw_b20f3cd4-58ca-4276-b159-a3f14bc4318b"
      unitRef="usd">47200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f32e181f6564471b1774eaf0ab52226_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTk1NTY0MQ_221024d0-b4f8-4eec-928d-c156c8463cc6"
      unitRef="usd">42400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf862611445f4a27954a5d9467250c21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTk1NTY0OQ_f2b5a959-81a2-4eb0-ac62-88075b3ee0f8"
      unitRef="usd">109400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzItMi0xLTEtMTc3ODcw_d1f91cec-f4af-40d9-af2c-cb9d34108d96"
      unitRef="usd">1600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8ec656e3d9234cddbabc7b72805e843c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzItNC0xLTEtMTc3ODcw_31251c07-62f3-47c6-b1ee-29f97e8b94d9"
      unitRef="usd">11000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherLiabilities
      contextRef="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzMtMi0xLTEtMTc4NjU2_8224464a-ca8c-44bd-9179-81c67d81b525"
      unitRef="usd">0</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i8ec656e3d9234cddbabc7b72805e843c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90YWJsZTo1YzJlZmY0NWNkZjM0OGYxOWZiN2UyZDFhMGQ4Y2NkMC90YWJsZXJhbmdlOjVjMmVmZjQ1Y2RmMzQ4ZjE5ZmI3ZTJkMWEwZDhjY2QwXzMtNC0xLTEtMTc4NjU2_02bb25ea-7378-476c-9db4-c06e8935346b"
      unitRef="usd">39700000</us-gaap:OtherLiabilities>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="ib5cc30a6e150429d8a9faa24528ade10_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjQvZnJhZzpmMzM3ODcyYmFhM2E0NjcxOWE4ZmNjZjAxZTAxZTAxMy90ZXh0cmVnaW9uOmYzMzc4NzJiYWEzYTQ2NzE5YThmY2NmMDFlMDFlMDEzXzU0OTc1NTkzODUxMg_feea0dff-e4b3-4ac5-9940-bff367881f8f"
      unitRef="usd">31900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1ODg_f9b9c41a-399c-4323-8b12-c4404412cf1c">Marketable Securities&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities as of December&#160;31, 2022 and 2021 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 5) as well as equity securities of publicly traded companies (see Note 5). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,518.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,428.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of December&#160;31, 2022 mature at various dates through April 2028. The fair values of available-for-sale debt securities by contractual maturity consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.235%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,636.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,588.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,645.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,332.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,889.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,889.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses on corporate bonds as of December 31, 2022 were primarily driven by increases in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to marketable securities, for the years ended December 31, 2022, 2021, and 2020, amounts reclassified from Accumulated other comprehensive income (loss) into Other income (expense), net were related to realized gains and losses on sales of available-for-sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of marketable securities were not material for the years ended December 31, 2022, 2021, and 2020. Interest income of $160.1 million, $45.8 million, and $75.4 million for the years ended December 31, 2022, 2021, and 2020, respectively, was recognized in Other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1OTY_82c6ce93-e84b-456b-ab54-b698551a81e2">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,518.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,428.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItMi0xLTEtMTc0MzYy_3761c99b-2f00-4ed6-a5c6-880a8231e398"
      unitRef="usd">6975500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItNC0xLTEtMTc0MzYy_4c20cb44-6e2e-4b0d-8c5c-7b611d0c455b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItNi0xLTEtMTc0MzYy_2d0479ee-8dc2-4851-be30-a21b93f0a20c"
      unitRef="usd">291100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzItOC0xLTEtMTc0MzYy_9875449b-cb0f-4829-a1ed-0059a1e8a95a"
      unitRef="usd">6684400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtMi0xLTEtMTc0MzYy_82bf8b02-1e3c-47ac-b2ec-f775ff0bf2ee"
      unitRef="usd">2945400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtNC0xLTEtMTc0MzYy_fd9bb2f4-c942-41d4-8988-ea6ad96b9e3d"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtNi0xLTEtMTc0MzYy_b0f34a3b-efb3-449e-a459-52c5c8f68638"
      unitRef="usd">6900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzMtOC0xLTEtMTc0MzYy_7f4f29e1-45bd-4abd-b25f-94b1fff93379"
      unitRef="usd">2939400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtMi0xLTEtMTc0MzYy_14e35f15-7cc5-4872-96e3-808075d39410"
      unitRef="usd">67100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtNC0xLTEtMTc0MzYy_6d55f6d4-804e-4b78-9d70-46055f9dc237"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtNi0xLTEtMTc0MzYy_838e9837-b395-47b4-8729-c10c51b5a20e"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzQtOC0xLTEtMTc0MzYy_394542b9-a3f5-4e2a-b213-5224206e1f26"
      unitRef="usd">64100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20c85832e072499f9f789894f4319fb1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtMi0xLTEtMTc0MzYy_55325aaa-f47f-4134-93d1-20645654b8ba"
      unitRef="usd">121100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20c85832e072499f9f789894f4319fb1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtNC0xLTEtMTc0MzYy_db31fde3-ba24-4f21-9acb-04a926154b83"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20c85832e072499f9f789894f4319fb1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtNi0xLTEtMTc0MzYy_75f661a5-593d-4642-a34a-ab5b9b3e1c8d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20c85832e072499f9f789894f4319fb1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzUtOC0xLTEtMTc0MzYy_0cbf53e6-5ab1-410b-9f3e-6eeb66e42828"
      unitRef="usd">121100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtMi0xLTEtMTc0MzYy_d173d5f2-d7f2-4eae-9bb0-3e8255ec6849"
      unitRef="usd">182100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtNC0xLTEtMTc0MzYy_ffa7a068-1e2d-4d7f-8e2c-4a86d2f885e8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtNi0xLTEtMTc0MzYy_a4ba167e-20df-496b-a6c3-667d089e61ec"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzYtOC0xLTEtMTc0MzYy_272bc3ae-47ed-4695-a544-0cb50713ad21"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctMi0xLTEtMTc0MzYy_85f0f59a-146d-4d5c-91a2-64a22320e017"
      unitRef="usd">28900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctNC0xLTEtMTc0MzYy_eb564ba6-7f61-4ab5-a106-2a30032ce511"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctNi0xLTEtMTc0MzYy_9f66daa5-218b-4122-87cb-06b209d29f28"
      unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzctOC0xLTEtMTc0MzYy_82b13cdf-8b59-4bff-bc57-739572e3dace"
      unitRef="usd">27200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtMi0xLTEtMTc0MzYy_9ed4b029-9060-4e39-a6ef-31baf287492b"
      unitRef="usd">10320100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtNC0xLTEtMTc0MzYy_3434a727-7624-4d07-b1d9-c00a5dfa043c"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtNi0xLTEtMTc0MzYy_94c0979f-ef04-4617-996e-1bb134dc34b1"
      unitRef="usd">302800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzgtOC0xLTEtMTc0MzYy_a6a770b9-d680-4b7d-907b-ec3683778683"
      unitRef="usd">10018200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTItMS0xLTE3NDM2Mg_44bb1497-9c1f-43c9-a978-53909e460a42"
      unitRef="usd">7518400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTQtMS0xLTE3NDM2Mg_5ed87b8d-3bab-4fdb-987a-1cc8939ecff8"
      unitRef="usd">10200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTYtMS0xLTE3NDM2Mg_d363ba13-5440-4c31-9527-a0400e47217a"
      unitRef="usd">40900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzExLTgtMS0xLTE3NDM2Mg_99913466-0a5b-4cf1-9cc9-c04b11bffcb7"
      unitRef="usd">7487700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTItMS0xLTE3NDM2Mg_b89c2759-3741-4f45-b43d-5e0560740492"
      unitRef="usd">109000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTQtMS0xLTE3NDM2Mg_5e8d1acc-7d6b-4aa1-8705-6bf1f806b2a8"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTYtMS0xLTE3NDM2Mg_30a54775-b467-4719-8ed9-acaaf1192a46"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEyLTgtMS0xLTE3NDM2Mg_0e807722-e86f-4c87-bbf9-d0a275b8a824"
      unitRef="usd">108500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTItMS0xLTE3NDM2Mg_20d8c57f-48d4-47ec-9c21-575e57b822bc"
      unitRef="usd">64400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTQtMS0xLTE3NDM2Mg_7cabb769-7207-4e6d-a7b9-dfa2a3189c01"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTYtMS0xLTE3NDM2Mg_16c7310c-31e9-481a-9a24-e65918ec17df"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzEzLTgtMS0xLTE3NDM2Mg_77465622-2eee-41cb-8e87-ef0881bb3e70"
      unitRef="usd">64400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTItMS0xLTE3NDM2Mg_45c5fc14-e90b-4b5c-81e5-b47af4509e61"
      unitRef="usd">439700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTQtMS0xLTE3NDM2Mg_637ceb98-27db-4353-8cca-797079cfdd89"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTYtMS0xLTE3NDM2Mg_00585cab-c9a2-4fbb-b14b-50406856b8bc"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE0LTgtMS0xLTE3NDM2Mg_0fab6f5d-eca3-4d72-8abb-a3894b18e4b3"
      unitRef="usd">439600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTItMS0xLTE3NzIzNA_d6702926-5db9-4850-94a6-6de174b057cd"
      unitRef="usd">255200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTQtMS0xLTE3NzIzNA_434079e1-614f-44c1-9bfb-34556de22461"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTYtMS0xLTE3NzIzNA_89e96288-9618-49c2-897c-9afe401fd589"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTgtMS0xLTE3NzI0Mg_656ba468-9796-4cdc-82bd-42796efd8af5"
      unitRef="usd">255100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTItMS0xLTE3NDM2Mg_2fe81e69-d7da-42e8-8384-a6b8735d3ec7"
      unitRef="usd">42000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTQtMS0xLTE3NDM2Mg_e45032a6-db97-440d-bb77-6096a0b56df6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTYtMS0xLTE3NDM2Mg_a6d2296b-e510-4e83-bec9-a48600a6fdf9"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE1LTgtMS0xLTE3NDM2Mg_efaf5927-fd65-495c-afc4-62c325914fa2"
      unitRef="usd">41900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTItMS0xLTE3NDM2Mg_907d4b33-ebbb-4ad1-965f-66f7b40954de"
      unitRef="usd">8428700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTQtMS0xLTE3NDM2Mg_1e50ef67-2b5c-4cdb-9b7c-162cf4e6aee2"
      unitRef="usd">10800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTYtMS0xLTE3NDM2Mg_fb6dcfa0-526a-4993-a9d8-b0729990d03b"
      unitRef="usd">42300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5ZjEyYmQwZGNjNDg0OTE3YmZjYjU0OTZmODUxNGZkMS90YWJsZXJhbmdlOjlmMTJiZDBkY2M0ODQ5MTdiZmNiNTQ5NmY4NTE0ZmQxXzE2LTgtMS0xLTE3NDM2Mg_a80aaf02-a202-46e1-8218-47be3af1559c"
      unitRef="usd">8397200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1ODc_00fce661-290e-4af4-bb14-83164a26c8fe">The fair values of available-for-sale debt securities by contractual maturity consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.235%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,636.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,588.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzItMi0xLTEtMTc0MzYy_09f3d9a2-f79e-4aae-9ef0-6e15708ac518"
      unitRef="usd">4636400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzItNC0xLTEtMTc0MzYy_e2c5bb54-66b6-47fd-86a0-65d449bc78d0"
      unitRef="usd">2809100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzMtMi0xLTEtMTc0MzYy_e954f56c-984b-4960-a5a7-e81e629efdb9"
      unitRef="usd">5381400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzMtNC0xLTEtMTc0MzYy_3053dc91-7cf7-4760-a5ad-79159d6974fa"
      unitRef="usd">5588100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtMi0xLTEtMTk3MzA4_0d0d9004-511e-4fb6-82d7-a3a52742ee8d"
      unitRef="usd">400000</regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtNC0xLTEtMTk3MzA4_4497e6f8-9f90-4014-ad58-d31eb1fdde44"
      unitRef="usd">0</regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtMi0xLTEtMTc0MzYy_e81dd90a-c9ed-481d-a1ff-29803273aa20"
      unitRef="usd">10018200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTo5Y2NjM2JmYjIxODE0NWNmOWNjNTYxNjZjM2Y3ZTZjZi90YWJsZXJhbmdlOjljY2MzYmZiMjE4MTQ1Y2Y5Y2M1NjE2NmMzZjdlNmNmXzQtNC0xLTEtMTc0MzYy_8fc66978-4d53-44fa-8f5b-23cd28ac6e3a"
      unitRef="usd">8397200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE1Nzk_d141a33e-0b08-4ba2-b5ff-f73ee0766fe7">The following table shows the fair value of the Company's available-for-sale debt securities that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,645.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,332.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,889.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,889.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItMS0xLTEtMTc0MzYy_db499d2f-d282-4c59-9f0a-b42dd3781a8a"
      unitRef="usd">2445400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItMy0xLTEtMTc0MzYy_cc2a5031-f486-44e3-8965-d65c36a4be35"
      unitRef="usd">73100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItNS0xLTEtMTc0MzYy_66b23188-ea86-47a5-986d-a7db72268ad2"
      unitRef="usd">4200400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItNy0xLTEtMTc0MzYy_28472f3d-824d-4b91-ac70-318a39b37008"
      unitRef="usd">218000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItOS0xLTEtMTc0MzYy_d5cd8f43-bcc3-48ca-97cc-39cd5dca383e"
      unitRef="usd">6645800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9be45733794a4b498cd7a86c3b02531c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzItMTEtMS0xLTE3NDM2Mg_2bf1c73a-1381-4bfc-b7ad-de3fdfb1058d"
      unitRef="usd">291100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtMS0xLTEtMTc0MzYy_d496bc68-62d8-4311-89df-071a33fce768"
      unitRef="usd">785200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtMy0xLTEtMTc0MzYy_71ba60d4-4a7c-46b4-8e14-c457e25c3049"
      unitRef="usd">2000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtNS0xLTEtMTc0MzYy_fe6698c5-ff17-4ec3-a52b-f56e5e363d2b"
      unitRef="usd">71000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtNy0xLTEtMTc0MzYy_4cb480e6-0a5b-4df4-9e36-fc76b6739d57"
      unitRef="usd">4900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtOS0xLTEtMTc0MzYy_acddf06e-8d67-40be-adc3-1baf0fdbf40b"
      unitRef="usd">856200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i756ea3fa11624c548b132cede643b135_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzMtMTEtMS0xLTE3NDM2Mg_5165061d-4b80-49a9-9740-06af1218fd49"
      unitRef="usd">6900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtMS0xLTEtMTc0MzYy_3a73980d-f52b-4af9-b7d1-161007bae61a"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtMy0xLTEtMTc0MzYy_50ec7244-720b-4bbc-a9a4-cf60afa3e590"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtNS0xLTEtMTc0MzYy_8df59dac-3661-4757-9f78-5f03aa7e08e4"
      unitRef="usd">45600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtNy0xLTEtMTc0MzYy_289618d2-6b4a-4389-95ec-311308110925"
      unitRef="usd">1900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtOS0xLTEtMTc0MzYy_893aa376-3f9c-43db-97b7-cb495ee4e32a"
      unitRef="usd">64200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0dec01e41c9d49bdbda7f337150ef44a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzQtMTEtMS0xLTE3NDM2Mg_315c2c15-9eb5-44b6-ba67-83fe5510db82"
      unitRef="usd">3000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtMS0xLTEtMTc0MzYy_92e18381-bf9a-40ac-a8c4-822a60394f97"
      unitRef="usd">40200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtMy0xLTEtMTc0MzYy_8b2760c8-c605-4ed1-bf6d-0bc35e409522"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtNS0xLTEtMTc0MzYy_b5fbaffd-998a-4d37-ba32-049c1d401fe8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtNy0xLTEtMTc0MzYy_8ecda46d-c975-4111-8e5c-5276f7e365a2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtOS0xLTEtMTc0MzYy_fea037f1-2e8e-4780-9f97-112398b43a59"
      unitRef="usd">40200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6ea307cd50204e2e9bf4a2ca2c731e0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzYtMTEtMS0xLTE3NDM2Mg_8ab65da4-65c2-411f-a2f2-98abba69cb83"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctMS0xLTEtMTc0MzYy_d6791250-7f6e-4f3d-955f-18fde0d6cebd"
      unitRef="usd">11500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctMy0xLTEtMTc0MzYy_80572485-5b8b-480d-a6bf-1697299d8368"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctNS0xLTEtMTc0MzYy_3b1b3c5a-577a-426a-99c8-16941e5094b1"
      unitRef="usd">15200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctNy0xLTEtMTc0MzYy_4598da12-c228-407b-8798-96beacd31018"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctOS0xLTEtMTc0MzYy_8c008c84-e181-43ca-b076-1c1daf190e94"
      unitRef="usd">26700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i670b1994d88c42c7ad5592e062721992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzctMTEtMS0xLTE3NDM2Mg_fe97b676-499b-4180-ab8c-dbe96c540fde"
      unitRef="usd">1700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtMS0xLTEtMTc0MzYy_f1c2d760-87a9-4821-a415-865857bb5f72"
      unitRef="usd">3300900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtMy0xLTEtMTc0MzYy_af4a4a78-c481-45ec-8ab9-8d90e379c3d8"
      unitRef="usd">76900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtNS0xLTEtMTc0MzYy_06821ca7-f979-4fe6-851f-b36fbaf1323f"
      unitRef="usd">4332200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtNy0xLTEtMTc0MzYy_3a893145-ef3f-4e53-b973-947c641d9257"
      unitRef="usd">225900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtOS0xLTEtMTc0MzYy_b7eb19f8-d704-4f01-8d33-30fd3ea9c3a2"
      unitRef="usd">7633100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzgtMTEtMS0xLTE3NDM2Mg_151762bf-a99c-43b4-bbe1-4692be0836e5"
      unitRef="usd">302800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTEtMS0xLTE3NDM2Mg_8ecc1dbe-6731-421a-8e17-c47cc3441789"
      unitRef="usd">5889300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTMtMS0xLTE3NDM2Mg_324cf3f3-a7e1-4839-9380-a11682068673"
      unitRef="usd">40900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTUtMS0xLTE3NDM2Mg_d52c07fc-60fe-4fd4-bc0a-cc65117eb017"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTctMS0xLTE3NDM2Mg_c7f047b7-d7dc-4b2b-b7a3-9d7116ff1137"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTktMS0xLTE3NDM2Mg_2e0cb157-1fdd-4ba8-ad15-efaa105b876f"
      unitRef="usd">5889300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic065ee9eda414cb697e07e323cbe487d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzExLTExLTEtMS0xNzQzNjI_095102ae-72a3-43ba-8dc5-29fc18146a50"
      unitRef="usd">40900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTEtMS0xLTE3NzI3Mg_dc79ba3c-3dc5-41bc-b466-92ab8a11ca0f"
      unitRef="usd">90000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTMtMS0xLTE3NzI3Mg_28503491-1299-435e-beab-4456fd080026"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTUtMS0xLTE3NzI3Mg_3381c573-7a52-4aac-b1c3-3bb2a900497f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTctMS0xLTE3NzI3Mg_68a047ff-8731-47cb-ba08-e8ff5e89c0f3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTktMS0xLTE3NzI3Mg_68385dce-0fbc-4d5e-8137-890c0c834a03"
      unitRef="usd">90000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i06f83d2dfdb14bc8a2bd5574d085cdd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEyLTExLTEtMS0xNzcyNzI_502eb4c2-2dca-4b86-bf48-69f527ae5681"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTEtMS0xLTE3NzI3Mg_e87e9ab8-6b95-4221-94eb-627ec7823f1c"
      unitRef="usd">37000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTMtMS0xLTE3NzI3Mg_64e6344d-5dd1-4348-b56f-c161e4d8952d"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTUtMS0xLTE3NzI3Mg_0fc75842-26f9-480c-aced-afe28a90a094"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTctMS0xLTE3NzI3Mg_baf40d52-a9ed-4e56-ac9a-236aa1f75ec3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTktMS0xLTE3NzI3Mg_fc616538-a707-42d3-a52a-3a5c64821e4e"
      unitRef="usd">37000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3ce570a18b39486c8f7d1f07e3f923a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzEzLTExLTEtMS0xNzcyNzI_9f8a5dbd-5214-4570-8a8a-7ee806f0f241"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTEtMS0xLTE3NzI3Mg_c8e2636e-9d9a-4a78-be23-4c8857a68dcf"
      unitRef="usd">295700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTMtMS0xLTE3NzI3Mg_b88a3851-eef0-48f4-85fd-6399c990bbf3"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTUtMS0xLTE3NzI3Mg_b6002234-c1fd-4282-9cb6-9c6ee05e88ca"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTctMS0xLTE3NzI3Mg_e0880b33-bf7a-4572-b45f-2dea3b8f57e2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTktMS0xLTE3NzI3Mg_3c33f049-559b-42de-a7f0-0524bd001272"
      unitRef="usd">295700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i22f360e272324c199aae4f0c50e9210f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE0LTExLTEtMS0xNzcyNzI_e21de8f4-d2bd-46b9-b202-b145fbfd525f"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTEtMS0xLTE3NzI3Mg_225d15aa-6b16-4829-85d2-8e6828b94d0d"
      unitRef="usd">169400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTMtMS0xLTE3NzI3Mg_66fdf075-a32e-4343-98e0-fe19bdd397ae"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTUtMS0xLTE3NzI3Mg_b80bd1ea-311b-4d87-808a-f7bcb3702d15"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTctMS0xLTE3NzI3Mg_67a4fd00-3a0b-47aa-868f-53da2f60dbea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTktMS0xLTE3NzI3Mg_7aef737b-1af6-4086-9e09-e4dfe7c7d948"
      unitRef="usd">169400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ice448a0cbfc94b15af1148fe41fd6000_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE1LTExLTEtMS0xNzcyNzI_eb4aad6e-2aec-4dd6-87be-bd90d02fd869"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTEtMS0xLTE3NzI3Mg_0e920d04-1c44-4c9a-b7d2-69a87c968f92"
      unitRef="usd">34900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTMtMS0xLTE3NzI3Mg_88b95fa3-e59d-4a8a-89ac-8ccf0d4b7b9a"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTUtMS0xLTE3NzI3Mg_5f5a8f14-7992-4498-95a3-95ab8f362542"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTctMS0xLTE3NzI3Mg_0b5668a4-780d-4594-b632-49fc20c50c81"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTktMS0xLTE3NzI3Mg_87dc9ce5-bf5e-4bd3-bd75-e0731f6137ec"
      unitRef="usd">34900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i20b5acd4f7044784a39ba52a7c7a1723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE2LTExLTEtMS0xNzcyNzI_17c50a40-ca51-4580-8abb-7cb66063ec1b"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTEtMS0xLTE3ODY2MA_0cee43e5-812b-4cf8-9f64-0891fcecabd3"
      unitRef="usd">6516300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTMtMS0xLTE3ODY2MA_e4213360-1541-4995-a598-4c7eeeeba83a"
      unitRef="usd">42300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTUtMS0xLTE3ODY2MA_e05cbae1-63ac-487d-b30f-e8c6f6d103c6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTctMS0xLTE3ODY2MA_4f518548-43d5-4090-a7fd-d926405dc4a5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTktMS0xLTE3ODY2MA_4e1c1ea9-2a6a-4ddb-9695-e4885cc07b6f"
      unitRef="usd">6516300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90YWJsZTphYjcxOWE5YjQ2OWU0MDU5YWY3YjM1Mzk4YzRlZjNlNS90YWJsZXJhbmdlOmFiNzE5YTliNDY5ZTQwNTlhZjdiMzUzOThjNGVmM2U1XzE3LTExLTEtMS0xNzg2NjA_f4d0060f-7789-4cc5-a68c-fdcc92078879"
      unitRef="usd">42300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE2NDkyNjc0NDgzNjY_da44eac4-d616-4556-a7fb-427d84d25c73"
      unitRef="usd">160100000</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE2NDkyNjc0NDgzNzE_25277626-af01-4114-8f7e-1a07d8623916"
      unitRef="usd">45800000</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMjcvZnJhZzoyOGRlNTYzNTRkNjk0ZWFlOTNlOTAyZjc0MmYwYjQwNi90ZXh0cmVnaW9uOjI4ZGU1NjM1NGQ2OTRlYWU5M2U5MDJmNzQyZjBiNDA2XzE2NDkyNjc0NDgzODA_fbc225cc-db3e-4cd2-911a-9df6814f88e6"
      unitRef="usd">75400000</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzE0MjQ_8a2dbe91-4bed-4120-9f77-8084c6dca806">Fair Value Measurements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.965%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,228.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,647.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain restricted equity securities as of December&#160;31, 2022 which are subject to transfer restrictions that expire at various dates throug&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company recorded $39.8 million of net unrealized losses on equity securities in Other income (expense), net. During the years ended December 31, 2021 and 2020, the Company recorded $386.1 million, and $196.0 million, respectively, of net unrealized gains on equity securities in Other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the investments summarized in the table above, as of December&#160;31, 2022 and 2021, the Company had $48.3 million and $40.0 million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's long-term debt (see Note 10), which was determined based on Level 2 inputs, was estimated to be&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.443 billion and $1.887 billion as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzE0MTM_0c1dbfa7-f9d4-4dbb-8c76-81115ef3eaad">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.965%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,228.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,647.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4f165da14524f83ab4e24f33f72fa7c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzMtMS0xLTEtMTc0MzYy_4e77a9ef-0b38-438b-81b9-a6fc200bde4c"
      unitRef="usd">6684400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieff3294615794346a9b85255e14fd794_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzMtMy0xLTEtMTc0MzYy_833182f5-008b-45d0-812e-a211a03482fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe27a11c61a240e4b0a067ec0dd7d798_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzMtNS0xLTEtMTc0MzYy_6a972de9-12a5-4e8f-9aab-640c5cdf7ae7"
      unitRef="usd">6684400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie93ec21dd364485abcb9d4f5a58113b1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzQtMS0xLTEtMTc0MzYy_89fe9ebb-0c19-47c0-9f60-3aa1a7147215"
      unitRef="usd">2939400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ea2ced853b94e24a4d22f70bd4fd29e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzQtMy0xLTEtMTc0MzYy_b91b93d1-726f-4edf-a66e-5487ff0f1ba3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22141dab4f53412ea6de7ff444ac262c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzQtNS0xLTEtMTc0MzYy_2ec962a4-c8cd-47ed-87ac-c9ac5fd0f897"
      unitRef="usd">2939400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50af84a4e2f049f5993f9b56288daed0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzUtMS0xLTEtMTc0MzYy_4693d726-0fe7-4f3c-9231-f074d13526bf"
      unitRef="usd">64100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49c9255c54ab4b2d8041ec8cf8ed2d76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzUtMy0xLTEtMTc0MzYy_ae2c5793-908d-4db8-bd75-b7cddb5e844c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4cd0cb429064df7ac32623abbd44a07_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzUtNS0xLTEtMTc0MzYy_750be6ca-0710-44a0-a4b9-79a68fe28d06"
      unitRef="usd">64100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0fe982b399644ca994a70d8d2ad5e97_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzYtMS0xLTEtMTc0MzYy_59c6a4af-d15d-4d57-b2d7-5b44cd55a8b7"
      unitRef="usd">121100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc86526bc33f401eaef37c46de2730c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzYtMy0xLTEtMTc0MzYy_6dbfdb22-c75e-4b80-8494-8c41886573c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i467a55c788544f30ad74454d840569e2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzYtNS0xLTEtMTc0MzYy_cb7ec8d1-7d3a-4e69-abbc-461406530c32"
      unitRef="usd">121100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01edbc55a346434a8547a03cdf3f8b8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzctMS0xLTEtMTc0MzYy_4f7020b3-f311-4908-b3eb-2cdc55843c03"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id596959620f7472daf2da370a9c6e4ee_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzctMy0xLTEtMTc0MzYy_23de75a6-4da3-4333-b34b-77fb2a748a95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81ab5450159345e4a7a8d5d1becc66f3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzctNS0xLTEtMTc0MzYy_9515cb10-64b1-4efa-b11b-a184189448ce"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a5c2e9a61694f1b8288a4d46747d122_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzgtMS0xLTEtMTc0MzYy_8c2e40f6-2dac-482e-8036-2b55a5c3701d"
      unitRef="usd">27200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9df6b754d9874865849815ce0ff1fa35_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzgtMy0xLTEtMTc0MzYy_ddf77d24-3898-4bd6-9f28-da3210f9d98b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5812ccf9fa340d68bb0fb9ae362fd55_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzgtNS0xLTEtMTc0MzYy_ffc4c551-1f21-4830-ac2a-c1ad283f52bd"
      unitRef="usd">27200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibb2285eff7124799bf35474f9b77d3a5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzktMS0xLTEtMTc0MzYy_e54ce234-af8d-45f9-a63a-a5029f15c297"
      unitRef="usd">24600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i37cc523007314e81a486975a1e802e30_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzktMy0xLTEtMTc0MzYy_f5cbceb4-10f4-4031-9f7e-7ad24424a7f6"
      unitRef="usd">24600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9444b58a5bf44713b0a53669ccd879a9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzktNS0xLTEtMTc0MzYy_c3e2aa8f-2eb8-4a73-bba0-e2e15c0c40e7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iac51098e276e4ab68f338afabe7e88ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzEwLTEtMS0xLTE3NDM2Mg_4e4d75c7-48ba-4417-9d20-defac375346d"
      unitRef="usd">1185400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0604eb2ce2824a94b18ba840c03422bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzEwLTMtMS0xLTE3NDM2Mg_d9f71f33-4027-44a8-b623-38cd0b708b73"
      unitRef="usd">1185400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6e07af51cdfe402cb73cf12cdaa18875_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzEwLTUtMS0xLTE3NDM2Mg_1731c46d-79c9-4518-878c-280671d7865d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="idaac5082db1042e2a542c59aaed88125_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzExLTEtMS0xLTE3NDM2Mg_cde73d69-5c35-4615-b073-197365af617e"
      unitRef="usd">11228200000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i76805457ac75462bb9be58fc14847bbd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzExLTMtMS0xLTE3NDM2Mg_8509653b-9f82-418f-baec-d2a888f2ba36"
      unitRef="usd">1210000000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ie322fb4fa7024b1baee4c74f133d24f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzExLTUtMS0xLTE3NDM2Mg_95d0791a-11fd-45ec-a716-80699f1f4fa8"
      unitRef="usd">10018200000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e37a666e97345adad33738c64a2c8ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE1LTEtMS0xLTE3NDM2Mg_87a94e47-b880-48a7-ba46-c3ea3aad155c"
      unitRef="usd">7487700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i814e9188987a4eb6818cb5e646b4c49c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE1LTMtMS0xLTE3NDM2Mg_218b4ee7-6a79-4815-b376-4f21a741fa16"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i397a4c2affbe4db4b8abb7c9195877b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE1LTUtMS0xLTE3NDM2Mg_b51328de-08db-443f-967e-54ca4acd1cb2"
      unitRef="usd">7487700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb4cb2ea77d6466a814509f17d146b81_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE2LTEtMS0xLTE3NDM2Mg_03087b06-6e8d-4313-9e6b-842f7e155e7f"
      unitRef="usd">108500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i900991202ef2412f84b8b49bbd1fd697_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE2LTMtMS0xLTE3NDM2Mg_0aca85b5-1b02-421c-b4d8-5b470a42f586"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id958dea12f9f4daf9596b2e6ca4b664d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE2LTUtMS0xLTE3NDM2Mg_87834463-cccf-4ccd-9a4d-1ce57432d038"
      unitRef="usd">108500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i29c4864785e4460bbe8e8603d9e6e3c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE3LTEtMS0xLTE3NDM2Mg_be29f228-509f-4377-ac1d-62c0826aaca5"
      unitRef="usd">64400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55cd0cb5a7dc469dacd573bace8619db_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE3LTMtMS0xLTE3NDM2Mg_2c0263f4-a441-495e-a899-23dbd115b3b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic59b77df52a94d3d94be86824b44ccac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE3LTUtMS0xLTE3NDM2Mg_78ce77d1-88f8-4b68-8250-47672bc8c782"
      unitRef="usd">64400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddf857f344764403832320f65a37a8aa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE4LTEtMS0xLTE3NDM2Mg_b3732979-e16a-423d-9b4f-c1be3746993a"
      unitRef="usd">439600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e3d9acb4aa14bb882392991f7def806_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE4LTMtMS0xLTE3NDM2Mg_7782267c-e5f2-4bd7-9b18-33468c80a3bb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f19239807454691aa94fa166a33be9c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE4LTUtMS0xLTE3NDM2Mg_b4659c0e-fde0-499f-8c46-5eab18b94432"
      unitRef="usd">439600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ddbcb7106de49f49d710399f917f536_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE5LTEtMS0xLTE3NDM2Mg_3036d4cf-04f9-4281-b0ec-3de7b2c2aefc"
      unitRef="usd">255100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i04d07dab80a0497089de881dd7911c76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE5LTMtMS0xLTE3NDM2Mg_471324ec-eacf-4bb7-834d-32c63e27a227"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5f9a85d3b6c4ab58982bdab11c05ddd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzE5LTUtMS0xLTE3NDM2Mg_a8f7eac3-6a7f-41aa-9e46-8abcf4ea0986"
      unitRef="usd">255100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7268de767d8943b9bee7565a5fc1ee35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTEtMS0xLTE4NTYzMw_13ac3774-449a-499d-82ee-6ec5f7367a16"
      unitRef="usd">41900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7acba5123d245669d2c0b2930d140f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTMtMS0xLTE4NTYzMw_65195544-ea1c-46f0-b13c-5c40b9d8aed5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb3c12ae98b546ceb6fe3e88dc64b1b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTUtMS0xLTE4NTYzMw_5570f6ab-b01b-4fe9-bb42-d770e21d4546"
      unitRef="usd">41900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i85cf341222be46a193f1ef088c6436ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTEtMS0xLTE3NDM2Mg_0d436c7a-27da-4e30-abe9-f7f4cc897c10"
      unitRef="usd">58400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i39bc3760e9e940d0b37cebc198b73cf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTMtMS0xLTE3NDM2Mg_22a65684-8bb7-4bda-98f0-f8f689e1a08f"
      unitRef="usd">58400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9b618f73a8fa43489c55a045ed15c1f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIwLTUtMS0xLTE3NDM2Mg_bacac83d-4490-42a4-809e-888aea7dca6a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1e308ff0e87e482fba35dd4da2bd8aa0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIxLTEtMS0xLTE3NDM2Mg_f0ee00cb-9aeb-4cc5-930d-c25c6f05ae87"
      unitRef="usd">1191500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8312eadb6504455aaaac7b194804e4ab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIxLTMtMS0xLTE3NDM2Mg_d9c3f91c-67f7-4bd0-b64c-c1eea6c441d6"
      unitRef="usd">1191500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2f2058d7e3d9452b8becd26693bb4b7e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIxLTUtMS0xLTE3NDM2Mg_5b4becb0-2dee-4f9e-b9a8-1950cb498c10"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="if5efd5732c8647d88223929f0c134b0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIyLTEtMS0xLTE3NDM2Mg_386393c2-9588-4c69-bb3a-3812636ef49b"
      unitRef="usd">9647100000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i3e2aa3f436384eb7abe5169c1fb29a5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIyLTMtMS0xLTE3NDM2Mg_db03f85c-c20e-45dc-962f-53f2181c9b2e"
      unitRef="usd">1249900000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ie56431b74b0b46708d25ec5b1f24d48c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90YWJsZTphNDZlN2EzZjI3NmQ0MWYxOWIzMjQ5ZjgwMTIxYzUxNS90YWJsZXJhbmdlOmE0NmU3YTNmMjc2ZDQxZjE5YjMyNDlmODAxMjFjNTE1XzIyLTUtMS0xLTE3NDM2Mg_f36bbbbe-3d6f-4498-91ee-4eff03fc1394"
      unitRef="usd">8397200000</us-gaap:MarketableSecurities>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwNDQ1MzYwNDY1Njc4_99a971d4-5e06-42bc-a1c4-5cce4bbdf617"
      unitRef="usd">-39800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwNDQ1MzYwNDY1Njg2_69d49ddb-29f4-4092-b7de-ab4279b89de5"
      unitRef="usd">386100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzU0OTc1NTgxNTkzOQ_70eb3cbb-7936-45b1-bcc9-08c3e398f5d2"
      unitRef="usd">196000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwNzc_087383de-de4e-432d-a376-d9c6cb4a98a4"
      unitRef="usd">48300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEwODQ_a8526ce9-b67b-4728-af0f-49269cd65d5a"
      unitRef="usd">40000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEzNTY_4e600bcf-ef3b-433c-9466-d4dc346d861e"
      unitRef="usd">1443000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzAvZnJhZzpmNzcxYTFiZGYzMDk0MGZhOGVlOTU0MDBmZjA4YzBiMi90ZXh0cmVnaW9uOmY3NzFhMWJkZjMwOTQwZmE4ZWU5NTQwMGZmMDhjMGIyXzEzNjM_9ad4c5f8-ff8c-40df-8569-3ed801fc294e"
      unitRef="usd">1887000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2Xzg1NQ_082c3b31-cfb0-460a-9efb-29e0e74024ea">Inventories&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.477%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,401.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory balances in the table above are net of reserves of $720.7 million and $510.0 million as of December&#160;31, 2022 and 2021, respectively. Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred. For the years ended December&#160;31, 2022 and 2021, Cost of goods sold included inventory write-offs and reserves of $258.7&#160;million and $457.1&#160;million, respectively, primarily related to REGEN-COV. Inventory write-offs and reserves for the year ended December&#160;31, 2020 were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2Xzg0Ng_5f1e4e9e-a252-4fd6-acfb-a0f7429e3506">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.477%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,401.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzItMS0xLTEtMTc0MzYy_92eef01c-3375-4ff9-9664-d634e0e966a0"
      unitRef="usd">818400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzItMy0xLTEtMTc0MzYy_d47b756e-184f-4011-a3a3-baa594a5a9a1"
      unitRef="usd">721900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzMtMS0xLTEtMTc0MzYy_121abca2-40b5-4077-86eb-5e9cf6bc733b"
      unitRef="usd">963100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzMtMy0xLTEtMTc0MzYy_024a6398-a97a-43eb-812b-eee899ad068d"
      unitRef="usd">707200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzQtMS0xLTEtMTc0MzYy_4ff17459-e28d-4a21-b0f1-0c5223b689de"
      unitRef="usd">98600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzQtMy0xLTEtMTc0MzYy_f44f4c72-ac78-4c40-8384-120a020f93a2"
      unitRef="usd">73700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzUtMS0xLTEtMTc0MzYy_aec92935-e43d-40ab-b6e6-e3bea01ab489"
      unitRef="usd">521800000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzUtMy0xLTEtMTc0MzYy_2cfb0f03-893f-423a-8227-5a4119a98e36"
      unitRef="usd">448500000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzYtMS0xLTEtMTc0MzYy_f44a4de4-5b94-4afe-a784-a7397d28fe44"
      unitRef="usd">2401900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90YWJsZTpkODBiMTY1Njg3Mjg0OWQwODAwMzQwNGY1YTBhODExOC90YWJsZXJhbmdlOmQ4MGIxNjU2ODcyODQ5ZDA4MDAzNDA0ZjVhMGE4MTE4XzYtMy0xLTEtMTc0MzYy_d6014284-fd09-4bce-9e40-26fc22d4e2c6"
      unitRef="usd">1951300000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzE1OTM_9958c02c-0770-491b-9e43-eb5043f0ce47"
      unitRef="usd">720700000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzE1ODI_93ad89cf-5a9c-4a38-aa7c-513c8141fcd4"
      unitRef="usd">510000000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryWriteDown
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzI1NTk_2d9d6e45-4328-4aeb-b873-a772d011f9ea"
      unitRef="usd">258700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzI3NDg3NzkwNzI0OTA_ca31ed83-fd3f-41dc-92ce-5e4887fc33f4"
      unitRef="usd">457100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzMvZnJhZzplZDk1ZmU0ZTEzOGM0NDMxOGM1ZDZmMTRhMjllMTMxNi90ZXh0cmVnaW9uOmVkOTVmZTRlMTM4YzQ0MzE4YzVkNmYxNGEyOWUxMzE2XzIxOTkwMjMyNTY2OTI_46c6062a-51ee-4418-b4fb-84f598a41e22"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzYzNA_233e1e4f-94ca-4c79-8355-c3ca682d00ff">Property, Plant, and Equipment&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.201%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,270.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, office equipment, and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,432.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less, accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,669.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,398.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment in the table above includes leased property under the Company's finance lease at its Tarrytown, New York facility. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense on property, plant, and equipment was $303.9 million, $281.1 million, and $230.8 million for the years ended December 31, 2022, 2021, and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, $2.960&#160;billion and $2.684&#160;billion, respectively, of the Company's net property, plant, and equipment was located in the United States and $803.0&#160;million and $797.8&#160;million, respectively, was located outside the United States (primarily in Ireland).&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i70f9acbdc085411abc64332f0e5e0849_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzItMS0xLTEtMTc0MzYy_93dbbe2d-53ae-4748-8cc2-ff3026bb49ac"
      unitRef="usd">264500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if77c2ea74bfe40038cd4646e360bb2e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzItMy0xLTEtMTc0MzYy_2ada0f11-a646-430e-a7e3-f9ace9dcea32"
      unitRef="usd">248000000.0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib29e6005f6d24c0491ed2bbf66621fb9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzMtMS0xLTEtMTc0MzYy_00ed6832-f97b-4fd9-be8a-5fe6350c1ec7"
      unitRef="usd">2270000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib23273ac9b554855b189599419ac153a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzMtMy0xLTEtMTc0MzYy_86766a30-1fcf-4373-bdb3-dfb0a3a9ae83"
      unitRef="usd">2088500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ic65b5f7083d14d56803e3599a24e7f4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzQtMS0xLTEtMTc0MzYy_08e7b366-8023-4b4d-a382-59b810188adc"
      unitRef="usd">114300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i43d3fbb1c2f4484da5b302c4846b440f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzQtMy0xLTEtMTc0MzYy_88bc0a0e-7b5e-4382-9096-1b7ade62596d"
      unitRef="usd">113900000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i442040e783844ed382aecdc0af74fc39_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzUtMS0xLTEtMTc0MzYy_05ac148c-28d0-423e-935f-a0eeac15756d"
      unitRef="usd">980500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i350934777cd641749f3726d6f2e3a777_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzUtMy0xLTEtMTc0MzYy_2a0b0347-b774-401e-984b-6d3dfabdcd10"
      unitRef="usd">767700000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib9a2e7c68cbd450986ed5230d81ffae1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzYtMS0xLTEtMTc0MzYy_1f4f61a7-d663-45f9-a5dd-4b9a2bfeafa4"
      unitRef="usd">1315300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie1294c19697a4d5989612dcdbb557eaf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzYtMy0xLTEtMTc0MzYy_0b37e29b-c87b-45b7-962f-f2ac0b13de53"
      unitRef="usd">1225500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i9d8931c24c9647998f454d826d5ea54f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzctMS0xLTEtMTc0MzYy_11063a3a-dd6d-49ef-a970-7f0752886ee9"
      unitRef="usd">337400000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id78ea7aa3b8b48818411bc781e1be355_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzctMy0xLTEtMTc0MzYy_aa6f397e-464d-4ba5-b0c7-fcab8e42a264"
      unitRef="usd">291500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie864f6dc154f4872aff761e5a7f37949_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzgtMS0xLTEtMTc0MzYy_2b90d7bc-7560-4d14-965f-1b08430f437d"
      unitRef="usd">150200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i1098f1326d3c46fab6616d650ec27d81_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzgtMy0xLTEtMTc0MzYy_332a12e2-a969-4586-8afd-d727a6e1f01c"
      unitRef="usd">145200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzktMS0xLTEtMTc0MzYy_2fa3ad45-6b19-412f-b18b-1599cade740b"
      unitRef="usd">5432200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzktMy0xLTEtMTc0MzYy_60aaecf7-5bd3-4cd5-8992-0a5af5fcdb4f"
      unitRef="usd">4880300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzEwLTEtMS0xLTE3NDM2Mg_1f2e27f1-847c-43ca-b9b2-ad2dd3c4c7a7"
      unitRef="usd">1669200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzEwLTMtMS0xLTE3NDM2Mg_e2925bc5-4993-47d7-9a34-2d09ab6bbaba"
      unitRef="usd">1398100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzExLTEtMS0xLTE3NDM2Mg_f68e2bdd-cd77-4fa9-a24b-f3cb8301e447"
      unitRef="usd">3763000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90YWJsZTo2MzQyYjJhY2Y4NWQ0MjViYjIyNTFmYTU2ZDc0ZjY4MC90YWJsZXJhbmdlOjYzNDJiMmFjZjg1ZDQyNWJiMjI1MWZhNTZkNzRmNjgwXzExLTMtMS0xLTE3NDM2Mg_99378518-0679-4378-8e7a-daace83c7798"
      unitRef="usd">3482200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzMzNA_8737d860-836b-4595-9c4c-7fb146663945"
      unitRef="usd">303900000</regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets>
    <regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzMzOA_058fd76d-2292-462f-a959-729133629bdc"
      unitRef="usd">281100000</regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets>
    <regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzM0Ng_c3eda643-4aa5-4199-8819-73e6ae8a5912"
      unitRef="usd">230800000</regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i51f9bc6743594e108ea3ba33a0b1df17_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzQ0Mw_358f5895-234f-453d-ab32-557204f19fa2"
      unitRef="usd">2960000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i769d8dda3fd84c6492c24d8b5d8397c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzQ1MA_ac7766eb-11de-4ac8-96ec-61c8d2f1774e"
      unitRef="usd">2684000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iaa561036943849f6970887e7e93d601b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzU1Nw_8f99f328-44bc-490a-bdaf-48d3b503834b"
      unitRef="usd">803000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i55fbf7200cd34a90a17cae423a49cac1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzYvZnJhZzpiYmNjNmE1YWVkOTQ0N2I1YjAwMDFiYjhlZGZlY2I1My90ZXh0cmVnaW9uOmJiY2M2YTVhZWQ5NDQ3YjViMDAwMWJiOGVkZmVjYjUzXzU2NA_561cc16b-472b-43e0-8231-67a79d21eb78"
      unitRef="usd">797800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjU4NDQ2_2fe93867-9739-456e-9554-df2eeac4575e">Intangible Assets&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired product rights - Libtayo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#x2013;8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 3, the Company recorded an intangible asset in connection with obtaining the exclusive right to develop, commercialize, and manufacture Libtayo worldwide. The intangible asset recognized upon the effective date of the A&amp;amp;R IO LCA primarily consisted of the $900.0&#160;million up-front payment, offset by the remaining IO Collaboration Other liabilities balance of $241.0&#160;million. During the year ended December&#160;31, 2022, the Company recorded additions to the Libtayo intangible asset primarily related to contingent consideration (including regulatory and sales-based milestones, as described in Note 3) and other amounts due to Sanofi in connection with obtaining the worldwide rights to Libtayo.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense on intangible assets was $37.6&#160;million for the year ended December 31, 2022. Amortization expense for the years ended December 31, 2021 and 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, assuming no changes in the gross carrying amount of intangible assets, amortization expense is estimated to be approximately $72&#160;million for each of the years ending December 31, 2023 through December 31, 2027.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjU4NDQ3_0cc18544-6ee1-422f-9088-18279c70d223">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired product rights - Libtayo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#x2013;8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iabe2b2c162d74aceaa748b1c4bb2cc4d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTItMS0xLTE3NjkxOC90ZXh0cmVnaW9uOjQ2ODYwYTFhZDFiMDRmZDQ5NmU4MWZiODBmNzBmYzhjXzQ_8a586507-8b1a-4a40-a3d4-ef4f09602a95">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iac94305b0cdd490190861cea74735d96_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTQtMS0xLTE3ODY3MA_9f1da480-2ef3-410f-9d23-593f7fa7d577"
      unitRef="usd">946300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iac94305b0cdd490190861cea74735d96_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTYtMS0xLTE3ODY3MA_d063c92a-fd9b-43dd-81ee-3707fee97e8c"
      unitRef="usd">35700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iac94305b0cdd490190861cea74735d96_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTgtMS0xLTE3ODY3MA_55a30128-f6b0-456c-a513-08d74d7c5c68"
      unitRef="usd">910600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie02495c8017b455681cd9f0f892654ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTEwLTEtMS0xNzg2NzA_12feba4a-c6f8-4eb7-bcc5-170d05d43661"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie02495c8017b455681cd9f0f892654ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTEyLTEtMS0xNzg2NzA_f7490624-4b9e-4275-9006-370bfec447ac"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie02495c8017b455681cd9f0f892654ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18yLTE0LTEtMS0xNzg2NzA_118d1812-5b1f-4ecf-87a5-adf6643b9f0f"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7a704809d9454f6091c067635a04adeb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTItMS0xLTE3NjkxOC90ZXh0cmVnaW9uOmJiNjRkODUyZmJhNDRiM2JhNDU2Y2Q3OGM3MGU4ZGI5XzQ_bee99377-5157-4717-a364-90f5096d93d4">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5586b0412de74f4681a571d3e1c5bfbb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTItMS0xLTE3NjkxOC90ZXh0cmVnaW9uOmJiNjRkODUyZmJhNDRiM2JhNDU2Y2Q3OGM3MGU4ZGI5Xzc_f7013e3c-1164-48e8-abb4-93bf74de5465">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i566e4366831c4bc9b4395cd536a3c5d4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTQtMS0xLTE3ODY3MA_657ba353-6d05-4bd6-93e0-a42de4c5ec4f"
      unitRef="usd">10000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i566e4366831c4bc9b4395cd536a3c5d4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTYtMS0xLTE3ODY3MA_23cad6c6-17ac-49b1-a434-f910fc71a797"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i566e4366831c4bc9b4395cd536a3c5d4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTgtMS0xLTE3ODY3MA_62b177e7-5aa5-4496-8a94-1d8fd6af3459"
      unitRef="usd">4900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9ce0c7f100084a6dad54ebe67493652f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTEwLTEtMS0xNzg2NzA_489d3bb6-cbf5-42ef-a243-6cbf4d2789ca"
      unitRef="usd">29300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9ce0c7f100084a6dad54ebe67493652f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTEyLTEtMS0xNzg2NzA_55bf1e36-2ca6-47bc-98e8-41d7fe092458"
      unitRef="usd">22600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9ce0c7f100084a6dad54ebe67493652f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N18zLTE0LTEtMS0xNzg2NzA_ff738c75-5335-4037-adba-78c007030064"
      unitRef="usd">6700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie345030098ed4a68855b720eadea8248_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTQtMS0xLTE3ODY3MA_0b0ec7ea-e0c5-4c8a-9078-a14172b25447"
      unitRef="usd">956300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie345030098ed4a68855b720eadea8248_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTYtMS0xLTE3ODY3MA_d1550b87-c418-49fc-a81b-7aa47f83c107"
      unitRef="usd">40800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie345030098ed4a68855b720eadea8248_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTgtMS0xLTE3ODY3MA_d7f3483b-0887-4fe5-bfaa-9d9f118e80f6"
      unitRef="usd">915500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTEwLTEtMS0xNzg2NzA_d47f8928-1ab2-4e8f-9fbc-067c424143b8"
      unitRef="usd">29300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTEyLTEtMS0xNzg2NzA_1739abd9-c3cf-4dac-8a1c-112fd7ea432b"
      unitRef="usd">22600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGFibGU6ZGVjMzQ4ZGY2NzE0NDc5NTg2YzhiOWFkMzA1MTBhNjcvdGFibGVyYW5nZTpkZWMzNDhkZjY3MTQ0Nzk1ODZjOGI5YWQzMDUxMGE2N180LTE0LTEtMS0xNzg2NzA_398edaf5-2a08-47ab-85d2-0b8612292563"
      unitRef="usd">6700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ie1af8729cd0f40758b3251598b50222a_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjYwNzcw_bc7264a5-ba36-4be3-a6e3-8393ccdbf9c1"
      unitRef="usd">900000000</regn:UpFrontPaymentToCollaboratingParty>
    <us-gaap:OtherLiabilities
      contextRef="i2ef1a2e72dfe4435b84f7c61daea106e_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8yMTk5MDIzMjYwNzg2_fa46f3f5-6523-484f-84b4-fd45f14216ae"
      unitRef="usd">241000000</us-gaap:OtherLiabilities>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if47d053711fd4bdc82cf9d70aa578c00_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2NDU0_ef899944-4eec-4631-b1fc-9ec259895202"
      unitRef="usd">37600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_21daae67-bfc6-4d40-8921-2a8e71214560"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_38e1f91c-65f8-4496-a645-75ca4ec0421d"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_4f00eabf-8fa3-43ab-9cc4-0494fd9d3852"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_b191f97b-8a59-43d4-84b6-e210141926c7"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTExL2ZyYWc6N2Q3Nzk3YTE2MmQ3NDkwNGI3Y2VkZmQxMDcwZjg0NzAvdGV4dHJlZ2lvbjo3ZDc3OTdhMTYyZDc0OTA0YjdjZWRmZDEwNzBmODQ3MF8xNjQ5MjY3NDQ2Mjgx_e86c8825-08ba-435b-9a19-01786bb85be3"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90ZXh0cmVnaW9uOjA1YWZiZTVkYThmMTRiMjFiNDFhYWMxMzdmYmY2ZjUxXzEzNg_f050ac24-bd06-4d49-84bd-f9a624d4e550">Accrued Expenses and Other Current Liabilities&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.040%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due to collaborators (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90ZXh0cmVnaW9uOjA1YWZiZTVkYThmMTRiMjFiNDFhYWMxMzdmYmY2ZjUxXzEyOA_b09f39d3-5dc6-45fb-ba25-233c683f2368">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.040%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due to collaborators (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzItMS0xLTEtMTc0MzYy_ea130302-643f-49e8-9911-7df5ede32cb4"
      unitRef="usd">497300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzItMy0xLTEtMTc0MzYy_24c73b13-501c-4f6c-89fb-fd566b530117"
      unitRef="usd">440700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <regn:AccruedClinicalTrialExpenseCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzMtMS0xLTEtMTc0MzYy_6e4193b6-d642-4aae-b87e-5223a1af75d1"
      unitRef="usd">295000000.0</regn:AccruedClinicalTrialExpenseCurrent>
    <regn:AccruedClinicalTrialExpenseCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzMtMy0xLTEtMTc0MzYy_1ebf8fa2-d60c-4e5c-9115-4ddc907c673e"
      unitRef="usd">295800000</regn:AccruedClinicalTrialExpenseCurrent>
    <regn:AccrualForSalesRelatedCostsCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzQtMS0xLTEtMTc0MzYy_ec51f146-8cf2-4517-b596-ffd0a0a2a346"
      unitRef="usd">633600000</regn:AccrualForSalesRelatedCostsCurrent>
    <regn:AccrualForSalesRelatedCostsCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzQtMy0xLTEtMTc0MzYy_e5ad4fba-1067-4661-b388-6c32c0599a99"
      unitRef="usd">472700000</regn:AccrualForSalesRelatedCostsCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzUtMS0xLTEtMTc0MzYy_1d88e194-2df5-42e4-afdb-1245a6ba0fec"
      unitRef="usd">300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzUtMy0xLTEtMTc0MzYy_8859bc51-48fe-483a-a57b-d030460fabb5"
      unitRef="usd">326300000</us-gaap:TaxesPayableCurrent>
    <regn:CollaborativeAgreementsObligationsCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzYtMS0xLTEtMTc0MzYy_cad3782a-58c1-4a5a-b2ae-eee1393b66b2"
      unitRef="usd">10500000</regn:CollaborativeAgreementsObligationsCurrent>
    <regn:CollaborativeAgreementsObligationsCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzYtMy0xLTEtMTc0MzYy_b7053ecf-3fad-4edf-94cc-4948ce779811"
      unitRef="usd">287400000</regn:CollaborativeAgreementsObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzctMS0xLTEtMTc0MzYy_9666d86a-38e9-47d1-8e64-fb0f8ce006d4"
      unitRef="usd">637500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzctMy0xLTEtMTc0MzYy_a5e5f4b7-cabb-461c-8b46-76f4ca58a71c"
      unitRef="usd">383900000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzgtMS0xLTEtMTc0MzYy_ccbb6005-230b-4c10-9cc7-0fefecc59442"
      unitRef="usd">2074200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xMzkvZnJhZzowNWFmYmU1ZGE4ZjE0YjIxYjQxYWFjMTM3ZmJmNmY1MS90YWJsZTphYjJkNGU5NjJlMDM0MWVmODQyZThmODg2MmQzOTJlNi90YWJsZXJhbmdlOmFiMmQ0ZTk2MmUwMzQxZWY4NDJlOGY4ODYyZDM5MmU2XzgtMy0xLTEtMTc0MzYy_abc79f09-afef-405a-b2e0-8a5fa42a22c3"
      unitRef="usd">2206800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzM3NTE_b7212499-68e3-489c-a803-073e909174b0">Debt&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into an agreement with a syndicate of lenders (the "2018 Credit Agreement") which provided for a $750.0 million senior unsecured five-year revolving credit facility. The 2018 Credit Agreement, which was to mature in December 2023, included an option for the Company to elect to increase the commitments under the Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $250.0&#160;million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company entered into an agreement with a syndicate of lenders (the "2022 Credit Agreement") which provides for a $750.0&#160;million senior unsecured five-year revolving credit facility (the "2022 Credit Facility") and replaces the 2018 Credit Agreement, which was contemporaneously terminated. The 2022 Credit Agreement includes an option for the Company to elect to increase the commitments under the 2022 Credit Facility and/or to enter into one or more tranches of term loans in the aggregate principal amount of up to $500.0&#160;million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions. The 2022 Credit Agreement also provides a $50.0&#160;million sublimit for letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As set forth in the 2022 Credit Agreement, the Company has the option to amend the 2022 Credit Agreement to establish environmental, social, and governance targets which will be used to adjust pricing under the 2022 Credit Facility, subject to parameters to be provided in the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds of the loans under the 2022 Credit Facility may be used to finance working capital needs, and for general corporate or other lawful purposes, of Regeneron and its subsidiaries. Regeneron Pharmaceuticals, Inc. has guaranteed all obligations under the 2022 Credit Facility. The 2022 Credit Agreement includes an option for the Company to elect to extend the maturity date of the 2022 Credit Facility beyond December 2027, subject to the consent of the extending lenders and certain other conditions. Amounts borrowed under the 2022 Credit Facility may be prepaid, and the commitments under the 2022 Credit Facility may be terminated, at any time without premium or penalty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no borrowings outstanding under the 2022 Credit Facility as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Credit Agreement contains operating covenants and a maximum total leverage ratio financial covenant. The Company was in compliance with all covenants of the 2022 Credit Agreement as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 and $750 million aggregate principal amount of senior unsecured notes due 2050 (collectively, the "Notes"). The underwriting discounts and offering expenses are being amortized as additional interest expense over the period from issuance through maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt in connection with the Notes, net of underwriting discounts and offering expenses, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:29.25pt;padding-right:29.25pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.149%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750% Senior Notes due September 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.800% Senior Notes due September 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates. Interest expense related to the Notes was $44.3&#160;million, $44.4&#160;million, and $17.6&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes may be redeemed at the Company&#x2019;s option at any time at 100% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest. The Notes also contain certain limitations on the Company&#x2019;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie424218a88a74b00b19453fe4888916c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzYwNDczMTM5NTY2OTc_7895eedc-c7cb-47bd-ade6-50ea1636ded7"
      unitRef="usd">750000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ib5a9aa37e4c1457a976919d9730f8e80_D20181201-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3NTQ_ae1213d3-a125-4b38-8bd5-db828c1d3351">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <regn:LineOfCreditFacilityIncreaseLimit
      contextRef="ie424218a88a74b00b19453fe4888916c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3MjA_04287a36-656f-42ff-b195-75b27a8f3d36"
      unitRef="usd">250000000</regn:LineOfCreditFacilityIncreaseLimit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7310c177364143f2bf10f9d6b7aaf971_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzI3NDg3NzkwODYxNjg_9fbdbfac-0c07-4dab-8774-f59191fa2088"
      unitRef="usd">750000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ib12579be01dc47cfbb463231b2c8f01d_D20221201-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3NTU_e92709db-b177-4121-8c50-a7c2e6dbb729">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <regn:LineOfCreditFacilityIncreaseLimit
      contextRef="i7310c177364143f2bf10f9d6b7aaf971_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc2NjA_534ae625-f052-49de-8486-2488ab654c4c"
      unitRef="usd">500000000</regn:LineOfCreditFacilityIncreaseLimit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i261cf06513ba49e388568bf4932270e8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc2OTA_a0407051-97c0-44d6-99a6-0f08e8a46a74"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i7310c177364143f2bf10f9d6b7aaf971_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIxOTkwMjMyNjc3NTY_908ceca4-ae26-4b83-9863-b2691efd21f2"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6c01c03f3a4444d1b5c5abebba7521b9_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIyNjE_59c5110b-176b-4b97-b6b9-95126a639225"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5bbfaa6d6caa478986a0fd252d1994d6_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzIzMzA_f2ef1c70-ea1e-4847-a820-1ae13bca3f9f"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzM3NTk_105a6bfb-d949-4d44-b35f-67370b07df72">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt in connection with the Notes, net of underwriting discounts and offering expenses, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:29.25pt;padding-right:29.25pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.149%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750% Senior Notes due September 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.800% Senior Notes due September 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e773031061f47068bfb7d9af0a6f623_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzItMC0xLTEtMTc0MzYyL3RleHRyZWdpb246M2U3ZWE1MDY1OTE5NGU0NWIwM2IzZThhOTc2MDQwZWZfNA_42feb9ea-dac2-429e-8371-6d1dcf2d64cb"
      unitRef="number">0.01750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8e773031061f47068bfb7d9af0a6f623_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzItMS0xLTEtMTc0MzYy_d6c3d5e8-2120-4c41-943b-eff34cc3bc9e"
      unitRef="usd">1241000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4b091a819e7f463a80413ebcc76b6b92_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzItMy0xLTEtMTc0MzYy_0c2b92a7-d03b-4031-a1e3-2c694f336710"
      unitRef="usd">1239900000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie78cab400df7439280370205f9c3d004_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzMtMC0xLTEtMTc0MzYyL3RleHRyZWdpb246NzFhNzU4MDY2YWYzNGExZmI1MWQxNWUyZjY4MmRmMzFfNA_5e191821-df21-4144-a8c3-883de2e1477a"
      unitRef="number">0.02800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie78cab400df7439280370205f9c3d004_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzMtMS0xLTEtMTc0MzYy_fb5a248b-cc2e-4b2e-8787-81791c9ca1e8"
      unitRef="usd">740400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9d999cff105340e388c8d3d0fae950fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzMtMy0xLTEtMTc0MzYy_1f4fe7b8-87fe-459b-a60c-aace999db681"
      unitRef="usd">740100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4a901ef13b914e98a6b6ae594630e3ab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzQtMS0xLTEtMTc0MzYy_77da4972-c86d-4740-a008-c7e3629ee9c7"
      unitRef="usd">1981400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i109147ff73454c9fb1005363d4c3549c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90YWJsZTo0YTQ3MTZhZGUzYmE0YzEwODQwMzNhYWNlM2YyMTEzMi90YWJsZXJhbmdlOjRhNDcxNmFkZTNiYTRjMTA4NDAzM2FhY2UzZjIxMTMyXzQtMy0xLTEtMTc0MzYy_48752678-ff0e-4635-9c0f-d62720a5a91a"
      unitRef="usd">1980000000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4dc3a52eb4104b5aa8911f6741d3eee6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzMwOTY_467b71ed-cf02-420a-a91f-f1344b97896e"
      unitRef="usd">44300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ibdc58844910a4e119a03ecefec012869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzMxMDM_62a4796b-5d37-468a-a7c9-591c559db547"
      unitRef="usd">44400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i079d9f100fb942469a90e889b3b42209_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzYwNDczMTM5NjkxNjE_ca69e43c-703e-498d-8d9b-5dc6cfc037a2"
      unitRef="usd">17600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i012c8a6940324ac49f3899e2c90dc896_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzMyMTg_04e56cae-13c9-4d46-9ed6-bd1bebf6d236"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <regn:DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage
      contextRef="i012c8a6940324ac49f3899e2c90dc896_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDIvZnJhZzpkYjQ3NTk4MDljZjc0MTFlOWQyNzdkZDk2ZDY1MmRlZS90ZXh0cmVnaW9uOmRiNDc1OTgwOWNmNzQxMWU5ZDI3N2RkOTZkNjUyZGVlXzM1MTc_35c6639d-e632-4414-9367-9b050194abc0"
      unitRef="number">1.01</regn:DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MDI_ab1c5ca4-2662-4ba3-b19d-131837e997d8">Commitments and Contingencies&#160;&#160;&#160;&#160;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 16 for disclosures related to legal contingencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;a. Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts certain of its research, development, and administrative activities at leased facilities. The Company also leases vehicles and other assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Consolidated Balance Sheets and Statements of Operations included in this report associated with operating leases were not material. Operating lease right-of-use assets are included within Other noncurrent assets, and lease liabilities are included in Accrued expenses and other current liabilities and Other noncurrent liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a Participation Agreement with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing &amp;amp; Capital LLC ("BAL"), as lessor, and a syndicate of lenders (collectively with BAL, the "Lease Participants"), which provided for $720.0&#160;million of lease financing from the Lease Participants for the acquisition of laboratory and office facilities in Tarrytown, New York (the "Facility"). In March 2017, the Company also entered into a Lease and Remedies Agreement with BAL, pursuant to which the Company leased the Facility from BAL for a&#160;five-year term which ended in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into a Second Amended and Restated Lease and Remedies Agreement (the "Restated Lease") with BAL, as lessor (the "Lessor"), which amends, restates, and extends its lease of the Facility. In March 2022, the Company also entered into a Second Amended and Restated Participation Agreement (the "Restated Participation Agreement") with Bank of America, N.A., as administrative agent, the Lessor, and a syndicate of financial institutions as rent assignees (collectively with the Lessor, the "Participants"), which amends and restates the original Participation Agreement entered into in March 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original Participation Agreement and certain related agreements were amended and restated in order to, among other things, (i) effect a&#160;five-year extension of the original March 2022 maturity date of the $720.0&#160;million lease financing and the end of the term of the Company's lease of the Facility from the Lessor to March 2027, at which time all amounts outstanding thereunder will become due and payable in full, and (ii) modify the rate of the interest or yield that is payable to the Participants. In accordance with the terms of the Restated Lease, the Company continues to pay all maintenance, insurance, taxes, and other costs arising out of the use of the Facility. The Company is also required to make monthly payments of basic rent during the term of the Restated Lease in an amount equal to a variable rate per annum, which was modified in connection with the Restated Lease, to be an adjusted one-month forward-looking term rate based on the Secured Overnight Financing Rate ("SOFR"), plus an applicable margin that varies with the Company's debt rating and total leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restated Participation Agreement and Restated Lease include an option for the Company to elect to further extend the maturity date of the Restated Participation Agreement and the term of the Restated Lease for an additional five-year period, subject to the consent of all the Participants and certain other conditions. The Company also has the option prior to the end of the term of the Restated Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants' advances under the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Participation Agreement, Restated Lease, and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with the original lease, the Restated Lease continues to be classified as a finance lease as the Company has the option to purchase the Facility under terms that make it reasonably certain to be exercised. The agreements governing the Restated Lease financing contain financial and operating covenants. Such financial covenants and certain of the operating covenants are substantially similar to the covenants set forth in the Company's $750.0 million 2018 Credit Agreement. The Company was in compliance with all such covenants as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Consolidated Balance Sheet related to the Lease are included in the table below. Other than the Lease described above, the Company had no leases accounted for as finance leases as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Finance lease right-of-use assets were recorded net of accumulated amortization of $119.4 million and $104.9 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.160%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to the Company's finance lease includes the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.84%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a maturity analysis of the Company's finance lease liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.908%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;b. Research Collaboration and Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with other companies, universities, and other organizations. These agreements contain varying terms and provisions which include fees to be paid by the Company, services to be provided, and license rights to certain proprietary technology developed under the agreements. Some of these agreements may require the Company to pay additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones). Additionally, the Company has in-licensed patent and/or technology pursuant to agreements which contain provisions that require the Company to pay royalties, as defined, at rates that range from 0.5% to 12.0%, in the event the Company sells or licenses any proprietary products developed under the respective agreements. The Company also has contingent reimbursement obligations to its collaborators Sanofi and Bayer out of the respective collaboration's profits, if they are sufficient for that purpose. See Note 3 for a more detailed description of collaboration, license, and other agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 3, as a result of obtaining worldwide rights to Libtayo, the Company pays Sanofi a royalty on net product sales of Libtayo. In addition, in 2018, the Company and Sanofi entered into a license agreement with Bristol-Myers Squibb Company, E. R. Squibb &amp;amp; Sons, L.L.C., and Ono Pharmaceutical Co., Ltd. to obtain a license under certain patents owned and/or exclusively licensed by one or more of those parties that includes the right to develop and sell Libtayo. Under the agreement, the Company is obligated to pay royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and royalties of 2.5% from January 1, 2024 through December 31, 2026. Prior to July 1, 2022, royalties on such sales were shared equally by the Company and Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021, and 2020, the Company recorded royalty expense (net of reimbursements from collaborators, as applicable) in Cost of goods sold and Cost of collaboration and contract manufacturing of $84.5 million, $66.9 million, and $56.5 million, respectively, based on product sales under various licensing agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FinanceLeaseLiability
      contextRef="ice406a54e051445e8e2f53b1c1e07740_I20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzkwNw_f685a781-ae44-4189-a301-530bd957e3d6"
      unitRef="usd">720000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i50a2e9c56f7e416f8da3fc7358beb047_I20170331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MTc_636c0c7f-1757-4363-9a4d-c93768449161">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i50a2e9c56f7e416f8da3fc7358beb047_I20170331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MTg_191a13d1-d903-4b14-ae7f-8cd6912e4493">P5Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:FinanceLeaseLiability
      contextRef="ice406a54e051445e8e2f53b1c1e07740_I20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU0OTc1NTgyNTc5NQ_2ec92a98-d5ec-4f19-9518-7d183d626861"
      unitRef="usd">720000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="ia2b5cb43390f40c79c55e8db0b798b1a_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MDY_775fff22-cbfe-4392-a624-058e0e6cdf6a">P5Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie424218a88a74b00b19453fe4888916c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU0OTc1NTgyMzE1Mw_7895eedc-c7cb-47bd-ade6-50ea1636ded7"
      unitRef="usd">750000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <regn:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU5MTQ_6402fe7f-82e6-4bad-8460-4fa8502de064">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Consolidated Balance Sheet related to the Lease are included in the table below. Other than the Lease described above, the Company had no leases accounted for as finance leases as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_1d2f4a78-85d6-473a-9648-deb577de405e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItMi0xLTEtMTc0MzYy_b04246d7-62c5-4f5e-baf5-2f7027318954"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Finance lease right-of-use assets were recorded net of accumulated amortization of $119.4 million and $104.9 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItNC0xLTEtMTc0MzYy_5b6934cb-df12-4f5b-883d-75a416306336"
      unitRef="usd">620300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzItNi0xLTEtMTc0MzYy_c0245986-a40e-4ac0-a3b7-badaa7712e37"
      unitRef="usd">631300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzMtNC0xLTEtMTc0MzYy_01acd0ad-8e87-4f3c-8dbc-658e42a8b349"
      unitRef="usd">720000000.0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzMtNi0xLTEtMTc0MzYy_6f2bcd58-495c-4a9e-860f-3d0f09971778"
      unitRef="usd">719700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzUtMC0xLTEtMTc0MzYyL3RleHRyZWdpb246NWE5YjQ0YTQ2OTZkNDU5OGFhZThiMzkyZjMwZDRjNWRfOTI_e08263b0-8259-4893-a4c7-6d5f9e4bd275"
      unitRef="usd">119400000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTpmYTRlOGU4N2I3MTQ0ZTQ4YWFkYTZlZTcwMGZhNWFkZi90YWJsZXJhbmdlOmZhNGU4ZTg3YjcxNDRlNDhhYWRhNmVlNzAwZmE1YWRmXzUtMC0xLTEtMTc0MzYyL3RleHRyZWdpb246NWE5YjQ0YTQ2OTZkNDU5OGFhZThiMzkyZjMwZDRjNWRfOTk_569da33b-10b3-475e-b7fc-5b40365ebdd0"
      unitRef="usd">104900000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU4OTU_d27320e6-3280-4112-8c02-5ba336108e1f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.160%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to the Company's finance lease includes the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.84%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzItMi0xLTEtMTc0MzYy_cb44724b-446e-4b63-b5fd-9d4649da94ec"
      unitRef="usd">14500000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzItNC0xLTEtMTc0MzYy_68fc8695-c4e7-4a14-bee3-62a6a0976b96"
      unitRef="usd">14400000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzMtMi0xLTEtMTc0MzYy_30b3326f-203e-487a-9a07-fedf9e995dc8"
      unitRef="usd">21600000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzMtNC0xLTEtMTc0MzYy_55f360a2-b482-44ae-84a2-3897893b20fb"
      unitRef="usd">11900000</us-gaap:FinanceLeaseInterestExpense>
    <regn:FinanceLeaseCost
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzQtMi0xLTEtMTc0MzYy_c973f142-6a1b-4bb2-8e6e-e267c85ea0eb"
      unitRef="usd">36100000</regn:FinanceLeaseCost>
    <regn:FinanceLeaseCost
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTowYTM5MzdlMDYwZDQ0YjQ3ODc4YTIzZTVhMTQ0Y2NmNC90YWJsZXJhbmdlOjBhMzkzN2UwNjBkNDRiNDc4NzhhMjNlNWExNDRjY2Y0XzQtNC0xLTEtMTc0MzYy_a4502e74-4f0a-42a6-9d87-60f0f81e182e"
      unitRef="usd">26300000</regn:FinanceLeaseCost>
    <regn:FinanceLeaseRemainingLeaseTerm
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzItMi0xLTEtMTc0MzYy_d6c24003-6766-4483-8887-a70f912b851b">P4Y2M12D</regn:FinanceLeaseRemainingLeaseTerm>
    <regn:FinanceLeaseRemainingLeaseTerm
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzItNC0xLTEtMTc0MzYy_31ff56df-1a68-43d7-8ce5-c62a72bac25b">P0Y2M12D</regn:FinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzMtMi0xLTEtMTc0MzYy_bd7bd76d-612f-49c1-b9bb-faf04a046f82"
      unitRef="number">0.0484</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTo2ZGMyMTFkM2Q5YWU0NTczYjljOWQ2MjJiNTU3Njk2Zi90YWJsZXJhbmdlOjZkYzIxMWQzZDlhZTQ1NzNiOWM5ZDYyMmI1NTc2OTZmXzMtNC0xLTEtMTc0MzYy_18d32e81-f898-420c-8a21-01fcb99fc1fd"
      unitRef="number">0.0168</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU4OTY_0712aab2-e88c-4689-9132-c55496641223">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a maturity analysis of the Company's finance lease liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.908%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzEtMi0xLTEtMTc0MzYy_6bdfc55d-f686-4436-ba06-c4aff4a1b2b9"
      unitRef="usd">44900000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzItMi0xLTEtMTc0MzYy_a0ca7225-f93f-4b97-a50c-064fe6188392"
      unitRef="usd">38600000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzMtMi0xLTEtMTc0MzYy_6909f722-baba-4e6f-bc11-c3a8341438d3"
      unitRef="usd">31300000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzQtMi0xLTEtMTc0MzYy_78655405-e47f-479d-92bb-1f2e5fff9ebf"
      unitRef="usd">30700000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzUtMi0xLTEtMTc0MzYy_36f2996f-c637-4a39-8991-88d1701bcef8"
      unitRef="usd">727900000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzctMi0xLTEtMTc0MzYy_95cdf19c-f3d5-4826-b249-4874944eac3a"
      unitRef="usd">873400000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzgtMi0xLTEtMTc0MzYy_42b3b322-64a9-4b9e-8977-45eb7c5267fe"
      unitRef="usd">153400000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90YWJsZTphZTdhNGM0ZGEwOWY0N2Y0OTY5YWFjNzYyMWFhMWRkYi90YWJsZXJhbmdlOmFlN2E0YzRkYTA5ZjQ3ZjQ5NjlhYWM3NjIxYWExZGRiXzEwLTItMS0xLTE3NDM2Mg_71c06bb7-2321-4d54-9c6e-ff94697ed242"
      unitRef="usd">720000000.0</us-gaap:FinanceLeaseLiability>
    <regn:RoyaltyRateMinimum
      contextRef="ib132e77f1248490f82fe430c0a335704_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzUxNjg_086c5e93-ad95-438b-b742-2c3e4c477b18"
      unitRef="number">0.005</regn:RoyaltyRateMinimum>
    <regn:RoyaltyRateMaximum
      contextRef="ib132e77f1248490f82fe430c0a335704_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzUxNzQ_e1f7bb5c-aa45-4fa8-a44d-3f827a13c475"
      unitRef="number">0.120</regn:RoyaltyRateMaximum>
    <regn:PaymentsForRoyaltiesPercentage
      contextRef="i5d20e3c5247b4d598e751c21b3f4f608_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzIxOTkwMjMyODI4NDM_3f35c40f-491f-45f9-a753-dc0d6d20879e"
      unitRef="number">0.080</regn:PaymentsForRoyaltiesPercentage>
    <regn:PaymentsForRoyaltiesPercentage
      contextRef="i21d41d00df44446baa4014ec1a2a8b14_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzIxOTkwMjMyODI4NTQ_5f73819a-5468-4ee0-8cc8-c95b824ab702"
      unitRef="number">0.025</regn:PaymentsForRoyaltiesPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="ib132e77f1248490f82fe430c0a335704_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU3NzQ_833c0ef2-a4c0-4a9b-a662-dbbfaa99948f"
      unitRef="usd">84500000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ie83c963269194f2fbfdc09f02cc5d592_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU3Nzg_d7787ddd-3975-44c6-8def-fce268ee0112"
      unitRef="usd">66900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="if78394eb2a794ed4ac4431dca866af29_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDUvZnJhZzozNWRhYjA3MzY1MDA0ZWFkYTEwYmFkZDNhMTZhMmE2NS90ZXh0cmVnaW9uOjM1ZGFiMDczNjUwMDRlYWRhMTBiYWRkM2ExNmEyYTY1XzU3ODY_3a95108e-37ba-472c-8489-217b7ad6c2ed"
      unitRef="usd">56500000</us-gaap:RoyaltyExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzY0MDc_f212ae4b-74eb-4b54-b149-f9316586644a">Stockholders' Equity &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Restated Certificate of Incorporation, as amended, provides for the issuance of up to 40 million shares of Class A Stock, par value $0.001 per share, and 320 million shares of Common Stock, par value $0.001 per share. Shares of Class A Stock are convertible, at any time, at the option of the holder into shares of Common Stock on a share-for-share basis. Holders of Class A Stock have rights and privileges identical to Common Stockholders except that each share of Class A is entitled to ten votes per share, while each share of Common Stock is entitled to one vote per share. Class A Stock may only be transferred to specified Permitted Transferees, as defined. Under the Company's Restated Certificate of Incorporation, the Company's board of directors is authorized to issue up to 30 million shares of Preferred Stock, in series, with rights, privileges, and qualifications of each series determined by the board of directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company's board of directors authorized a share repurchase program to repurchase up to $1.0&#160;billion of the Company's Common Stock. The share repurchase program permitted the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $1.0&#160;billion it was authorized to repurchase under the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company's board of directors authorized a share repurchase program to repurchase up to $1.5&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program described above. As of December&#160;31, 2021, the Company had repurchased the entire $1.5&#160;billion of its Common Stock that it was authorized to repurchase under the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company's board of directors authorized an additional share repurchase program to repurchase up to $3.0&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. As of December&#160;31, 2022, $745.2&#160;million remained available for share repurchases under the November 2021 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the&#160;shares of the Company's Common Stock it repurchased under the programs and the cost of the shares, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.701%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company's board of directors authorized a new share repurchase program to repurchase up to an additional $3.0&#160;billion of the Company's Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase programs described above. The program has no time limit and can be discontinued at any time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share repurchases may be made from time to time at management&#x2019;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi Funding of Certain Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company and Sanofi entered into an agreement, which, among other things, granted Sanofi a limited waiver of Sanofi's lock-up obligations under the amended and restated investor agreement between the Company and Sanofi in order to allow Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or certain activities relating to dupilumab and itepekimab incurred in quarterly periods through September 30, 2020 by selling shares of the Company's Common Stock owned by Sanofi. During 2020, Sanofi elected to sell, and the Company elected to purchase, shares of our Common Stock to satisfy Sanofi's funding obligation related to such activities. Consequently, the Company recorded the cost of the shares received, or $135.0&#160;million, as Treasury Stock during 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Stock Purchased from Sanofi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, a secondary offering of 13,014,646 shares of the Company's Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, the Company also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5.0&#160;billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of the Company's Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (a portion of which Sanofi used for the funding of certain development costs described above).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company entered into an amendment to the amended and restated investor agreement, which provides, among other things, that following the Secondary Offering and Stock Purchase, the &#x201c;standstill&#x201d; provisions, which contractually prohibit Sanofi from seeking to directly or indirectly exert control of the Company, continue to apply pursuant to their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Arrangements with Other Collaborators&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company's license and collaboration agreement with Bayer for the joint development and commercialization outside the United States of antibody product candidates to Ang2, Bayer is bound by certain "standstill" provisions, which contractually prohibit Bayer from seeking to influence the control of the Company or acquiring more than 20% of the Company's outstanding shares of Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the termination of the agreement (which will occur on November 1, 2023) or (ii) other specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, pursuant to the 2016 Teva Collaboration Agreement, Teva and its affiliates are bound by certain "standstill" provisions, which contractually prohibit them from seeking to directly or indirectly exert control of the Company or acquiring more than 5% of the Company's Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the expiration or earlier termination of the agreement or (ii) other specified events.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzEzMQ_b0d13b19-3d51-43d2-80c9-977b4d49517b"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f6f217bafb048fd906869bf77577910_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE2OQ_35722217-8bdc-4755-9042-166add003d89"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE4Nw_e1cc8b93-b56b-4f8b-b7b8-2c613c569676"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i783cf29968664c1cba1a9576242c71ca_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzIyNA_cbb5c6cc-eab3-4a6b-982a-0051cc1efb7a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <regn:NumberOfVotesPerShare
      contextRef="ia96fa6ba59e84ea08d01d27873b5696b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzUxMA_1a80ca30-56bc-4e96-b348-aafe60c80ace"
      unitRef="vote">10</regn:NumberOfVotesPerShare>
    <regn:NumberOfVotesPerShare
      contextRef="i4e0c0f7f9e7245159ae317600a59a97f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU3OA_5b021d11-7cb7-423f-bf9d-d3af59bf9802"
      unitRef="vote">1</regn:NumberOfVotesPerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzgwNA_75b2d274-e404-457a-81fc-7f88708d376f"
      unitRef="shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i7a1f29e4d0084509aad565f88da92c75_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzEwNjg_2c2b1304-1e18-40f0-9c37-b035eae7a0bd"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i07ed95697fc6411f82f5d2215701a1ce_D20191101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE1MzE_8100721f-1618-47b8-b17c-508532ba20e6"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i898556ab5e034bf8a39f1f7ffdcff4b6_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE2ODM_31d340c4-d17b-4415-ba42-cb8c8b6279fa"
      unitRef="usd">1500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i898556ab5e034bf8a39f1f7ffdcff4b6_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzE4OTU_31d340c4-d17b-4415-ba42-cb8c8b6279fa"
      unitRef="usd">1500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if149e3b2ed184d9cb47a5f1e416db711_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzIwODU_7acd295f-a34e-429a-ada1-792102ddf2ae"
      unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i4d4688a81ec54e3e81135fe0cef6a811_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU0OTc1NTgyMTY2Nw_4cce1059-8b4c-4c1b-82e3-6334bb85ccc1"
      unitRef="usd">745200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzY0MTM_1bef3101-1e90-4623-bbf2-26e83ecf7bac">&lt;div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the&#160;shares of the Company's Common Stock it repurchased under the programs and the cost of the shares, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.701%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzItMi0xLTEtMTc0MzYy_a38e3628-80c7-4707-b357-ba49758f6cbe"
      unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifa856a8273104bae9abb9e9bd006496c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzItNC0xLTEtMTc0MzYy_56ff3ff8-43e6-43ce-9f7b-4c6112656649"
      unitRef="shares">3000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i00b3516f1f374f9ba681ff3469a1d79b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzItNi0xLTEtMTc0MzYy_0bbe2611-2ac3-4faf-a98b-785d2a87b596"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzMtMi0xLTEtMTc0MzYy_b3ae85fb-b2ab-4cbe-9222-a995cf1df1c6"
      unitRef="usd">2099800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifa856a8273104bae9abb9e9bd006496c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzMtNC0xLTEtMTc0MzYy_78ad9bca-3b7f-41aa-9f13-d75a3e3558b9"
      unitRef="usd">1655000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i00b3516f1f374f9ba681ff3469a1d79b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90YWJsZTo1M2QxNjc4M2JjOWI0Yzk1OWIwYzJkYmIzYzc3NGM4OS90YWJsZXJhbmdlOjUzZDE2NzgzYmM5YjRjOTU5YjBjMmRiYjNjNzc0Yzg5XzMtNi0xLTEtMTc0MzYy_dea0f940-7451-4c43-87ed-486b4203843b"
      unitRef="usd">746000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iaa56acec5b6c42e6a0c418417df45e87_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU0OTc1NTgyNDU0Ng_37cac0be-632a-46c7-85bd-1723120380ee"
      unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id2184e2e59fa45c7b4e39f4a72edfc26_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzM2NTI_68771b1c-c9e8-4dc5-9449-7397c03b10a2"
      unitRef="usd">135000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzM3OTQ_5dd1d153-b285-4b45-ac62-c243fe2a4208"
      unitRef="shares">13014646</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzM5NDI_cf3f694b-f80b-47b9-9938-4a12fe6aafe6"
      unitRef="shares">9806805</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzQwMDk_446d89d7-f3e5-4a72-964a-8547d9d47317"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ife75b59764cd4329a476ef09a7789b4f_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzQyMDY_c1cc1e6c-29ee-406e-b969-71196049e1bb"
      unitRef="shares">400000</us-gaap:CommonStockSharesOutstanding>
    <regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions
      contextRef="i3153e0c1409546939c8330d63e4b6f96_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzU0Mjc_ce6c2cb9-ed38-4257-89b1-6ff96478edd3"
      unitRef="number">0.20</regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions>
    <regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions
      contextRef="ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNDgvZnJhZzo3NzJjOTE0ZGZjYTE0ZTQ0OGRiMjJmYWVjNzQzNDMxMi90ZXh0cmVnaW9uOjc3MmM5MTRkZmNhMTRlNDQ4ZGIyMmZhZWM3NDM0MzEyXzYxNDU_b1bc03d9-1c95-4170-aa80-5d18ab1fd71b"
      unitRef="number">0.05</regn:MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5NDY_cd33690a-7695-4194-99e2-2eb040817b4e">Long-Term Incentive Plans&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and non-employees, including non-employee members of the Company's board of directors (collectively, "Participants"). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the "Committee"). The incentive plan currently used by the Company is the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Second Amended and Restated 2014 Incentive Plan"). It was most recently adopted and approved by the Company's shareholders in 2020. As of the most recent shareholder approval date, the Second Amended and Restated 2014 Incentive Plan provided for the issuance of up to 22.3 million shares of Common Stock in respect of awards. In addition, upon expiration, forfeiture, surrender, exchange, cancellation, or termination of any award previously granted under the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Amended and Restated 2014 Incentive Plan"), the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Original 2014 Incentive Plan"), or the Second Amended and Restated 2000 Long-Term Incentive Plan (the "2000 Incentive Plan"), any shares subject to such award are added to the pool of shares available for grant under the Second Amended and Restated 2014 Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The awards that may be made under the Second Amended and Restated 2014 Incentive Plan include: (a) incentive stock options and non-qualified stock options, (b) restricted stock awards, (c) shares of phantom stock (also referred to as restricted stock units, which may be time- or performance-based), and (d) other awards. Any award granted may (but is not required to) be subject to vesting based on the attainment by the Company of performance goals pre-established by the Committee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option awards grant Participants the right to purchase shares of Common Stock at prices determined by the Committee, with exercise prices that are equal to or greater than the average of the high and low market prices of the Company's Common Stock on the date of grant (the "Market Price"). Options vest over a period of time determined by the Committee, generally on a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pro rata basis over a four-year period. The Committee also determines the expiration date of each option. The maximum term of options that have been awarded under the 2000 Incentive Plan, the Original 2014 Incentive Plan, the Amended and Restated 2014 Incentive Plan, and the Second Amended and Restated 2014 Incentive Plan (collectively, the "Incentive Plans") is ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards grant Participants shares of restricted Common Stock or allow Participants to purchase such shares at a price determined by the Committee. Such shares are nontransferable for a period determined by the Committee ("vesting period"). Should employment terminate, as specified in the Incentive Plans, except as determined by the Committee in its discretion and subject to the applicable Incentive Plan documents, the ownership of any unvested restricted stock awards will be transferred to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Phantom stock awards provide the Participant the right to receive Common Stock or an amount of cash based on the value of the Common Stock at a future date. The award is subject to such restrictions, if any, as the Committee may impose at the date of grant or thereafter, including a specified period of employment or the achievement of performance goals. Time-based restricted stock units and performance-based restricted stock units are each a type of phantom stock award permitted under the Second Amended and Restated 2014 Incentive Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Incentive Plans contain provisions that allow for the Committee to provide for the immediate vesting of awards upon a change in control of the Company, as defined in the Incentive Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, there were 15.9 million shares available for future grants under the Second Amended and Restated 2014 Incentive Plan. No additional awards may be made under the 2000 Incentive Plan, the Original 2014 Incentive Plan, or the Amended and Restated 2014 Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;a. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transactions involving stock option awards during 2022 under the Company's Incentive Plans are summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.045%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,685.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company satisfies stock option exercises with newly issued shares of the Company's Common Stock. The total intrinsic value of stock options exercised during 2022, 2021, and 2020 was $1.214 billion, $1.707&#160;billion, and $2.251&#160;billion, respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2022, 2021, and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Options Granted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price equal to Market Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price equal to Market Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price equal to Market Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, 2021, and 2020, the Company recognized $341.9 million, $328.7&#160;million, and $329.5&#160;million, respectively, of stock-based compensation expense related to stock option awards (net of amounts capitalized as inventory, which were not material for each of the three years). As of December 31, 2022, there was $572.0 million of stock-based compensation cost related to unvested stock options, net of estimated forfeitures, which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value Assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.770%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives from grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility has been estimated based on actual movements in the Company's stock price over the most recent historical periods equivalent to the options' expected lives. Expected lives are principally based on the Company's historical exercise experience with previously issued employee and board of directors' option grants. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the options' expected lives.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;b. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards and Time-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's activity related to restricted stock awards and time-based restricted stock units (excluding performance-based restricted stock units, which are detailed further below) (collectively, "restricted stock") during 2022 is summarized below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares/Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant &lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, 2021, and 2020, the Company recognized $331.1 million, $221.0 million, and $102.5 million, respectively, of stock-based compensation expense related to restricted stock (net of amounts capitalized as inventory, which were not material for each of the three years). As of December 31, 2022, there was $907.7 million of stock-based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;compensation cost related to unvested restricted stock which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period of 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;c. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Performance-based restricted stock units ("PSUs") have been granted to certain members of senior management of the Company. PSUs may be earned based upon the attainment of pre-established performance criteria, which may include a market and/or performance condition. Depending on the terms of the PSUs and the outcome of the pre-established performance criteria, a recipient may ultimately earn the target number of PSUs granted or a specified multiple thereof at the end of a 4&#x2013;6 year vesting period, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes activity related to PSUs during 2022. The number of PSUs granted represents the maximum number of units that are eligible to be earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares/Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant &lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the years ended December 31, 2022, and 2021, the Company recognized $52.0&#160;million of stock-based compensation expense related to PSUs. The Company did not recognize stock-based compensation expense related to PSUs in 2020 (as PSUs granted in 2020 were granted on December 31, 2020 and are expensed over the vesting period). As of December 31, 2022, there was $156.1&#160;million of stock-based compensation cost related to unvested PSUs which had not yet been recognized. The Company expects to recognize this compensation cost on a straight-line basis over a weighted average period of 3.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value Assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of PSUs that were granted during 2022 and 2020. The Company did not grant PSUs during 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.431%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iffed57e1fcf04b469127e38751ea1244_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzk4MA_6c356352-b5c2-411f-8f27-97d0ac203939"
      unitRef="shares">22300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5MzI_d6164d5f-d68b-41bc-939c-7a009d4f07c1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzI4NjI_6281f315-8bde-42be-ae70-009a41b7e333">P10Y</regn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iffed57e1fcf04b469127e38751ea1244_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQxNjA_1126906c-f97a-4f25-a235-15c510b116bb"
      unitRef="shares">15900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9dd3089f49fe4ad18bf060be6041dc8d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQyNTc_acbf9ff5-8710-42b2-af9d-59b919606e31"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i89c4af83a9954f7a928a982e2a427940_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQyNTc_e258620e-5e48-40c2-ac16-48eb57ce2d2d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5MDI_ea693e0e-0e73-448a-aff4-fc499a01958e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transactions involving stock option awards during 2022 under the Company's Incentive Plans are summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.045%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,685.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1fa909c892214ee795c9bf21ee208f05_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzEtMy0xLTEtMTc0MzYy_0b6b8393-c450-455f-a2fa-b39d12288a9b"
      unitRef="shares">18000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1fa909c892214ee795c9bf21ee208f05_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzEtNS0xLTEtMTc0MzYy_bbba0c27-d407-4e18-8f65-7d9cb028c1e6"
      unitRef="usdPerShare">435.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzItMy0xLTEtMTc0MzYy_7b933cd5-9191-4232-9e2f-68e7d92db186"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzItNS0xLTEtMTc0MzYy_fb067534-50b1-45c6-a889-910a984c79cf"
      unitRef="usdPerShare">705.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzMtMy0xLTEtMTc0MzYy_7f48319f-1ada-437c-b558-af413736b52f"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzMtNS0xLTEtMTc0MzYy_38ebab38-39da-4cbf-97e4-e1480706e37f"
      unitRef="usdPerShare">500.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzQtMy0xLTEtMTc0MzYy_bb291188-0d12-4305-adea-4c67fbbd4a0e"
      unitRef="shares">4000000.0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzQtNS0xLTEtMTc0MzYy_d09b4acf-8a1b-47eb-9929-5251a25e5ed5"
      unitRef="usdPerShare">382.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtMy0xLTEtMTc0MzYy_50c3c2d2-85f1-4db5-b79d-10d794b13ac9"
      unitRef="shares">15600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtNS0xLTEtMTc0MzYy_672e6f4b-5904-410f-bc22-82bef7bc6e35"
      unitRef="usdPerShare">481.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtNy0xLTEtMTc0MzYy_0ba8580c-0263-4c32-8745-501bb85baf4b">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzUtOS0xLTEtMTc0MzYy_73b834c1-9d2e-4219-ab03-3d5191b1aeaf"
      unitRef="usd">3685900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctMy0xLTEtMTc0MzYy_386ccc23-5a6c-48ce-93be-29b903cdb944"
      unitRef="shares">15100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctNS0xLTEtMTc0MzYy_58957596-d7f0-4e40-ab68-019dd61beca2"
      unitRef="usdPerShare">476.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctNy0xLTEtMTc0MzYy_aa42892d-c8ea-46cf-b924-225753ea27ca">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzctOS0xLTEtMTc0MzYy_347089b3-5e78-4992-b3c1-46a22a8709e3"
      unitRef="usd">3632800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktMy0xLTEtMTc0MzYy_b265cf6c-6d57-4200-9455-991c3f7de0c1"
      unitRef="shares">10100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktNS0xLTEtMTc0MzYy_0f2eef62-0311-4ff6-90b5-335bcd7710a1"
      unitRef="usdPerShare">420.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktNy0xLTEtMTc0MzYy_279927a5-cbcd-4212-9646-6c11db9e2fe0">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0528c01e20994e37b110ba9db8971e61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTozYmY3YmE1NTg2NDg0NGIzYTc2MmFlMDQ0NDlhZmMyOS90YWJsZXJhbmdlOjNiZjdiYTU1ODY0ODQ0YjNhNzYyYWUwNDQ0OWFmYzI5XzktOS0xLTEtMTc0MzYy_0424d36d-4237-44ca-a9a6-495b6a7d13e7"
      unitRef="usd">2991900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzQ3Mjg_8577503f-7e4b-4f7e-9013-745b410ec9bb"
      unitRef="usd">1214000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTEwMjg_cec30c88-3682-4725-a720-6e6882f59001"
      unitRef="usd">1707000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTA2NjI_04e38d4c-043e-4127-8d9b-0be66c35bea9"
      unitRef="usd">2251000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg4ODY_52f36119-3e09-463d-8ec7-4e05114db5ec">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2022, 2021, and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Options Granted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price equal to Market Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price equal to Market Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price equal to Market Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzItMi0xLTEtMTc0MzYy_7b933cd5-9191-4232-9e2f-68e7d92db186"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzItNC0xLTEtMTc0MzYy_fb067534-50b1-45c6-a889-910a984c79cf"
      unitRef="usdPerShare">705.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzItNi0xLTEtMTc0MzYy_b3dc6b3e-8b0a-4ecb-ae88-943d1564d7f7"
      unitRef="usdPerShare">220.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzQtMi0xLTEtMTc0MzYy_bd0655db-4e4f-4569-9d56-089dd3bce281"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzQtNC0xLTEtMTc0MzYy_344dfaab-8a9a-42eb-8e99-9dc8fbf57729"
      unitRef="usdPerShare">628.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzQtNi0xLTEtMTc0MzYy_2204540f-c92d-441f-9593-d7c777af59cc"
      unitRef="usdPerShare">174.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzYtMi0xLTEtMTc0MzYy_63a64431-8711-4320-9476-d7fbc776ba5c"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzYtNC0xLTEtMTc0MzYy_b9f872c5-ab47-4a0c-9c97-932f9a3713fa"
      unitRef="usdPerShare">492.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmM2ZkMzEwMjQ5Y2Q0NDUxYTQwM2U1YjU5MjQzNWViYS90YWJsZXJhbmdlOmYzZmQzMTAyNDljZDQ0NTFhNDAzZTViNTkyNDM1ZWJhXzYtNi0xLTEtMTc0MzYy_61a01a17-1b01-4f87-870a-3e49f742770e"
      unitRef="usdPerShare">126.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8074da28c47b44eb8134011e2bfd7c77_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzUxNDQ_c0292063-7f05-4eec-8a1a-c904338da337"
      unitRef="usd">341900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic20a52b8adf44b65bc4aed375198294a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTA4NTE_0e8a73f3-dbbd-4ecc-a65d-e80d900ec4ad"
      unitRef="usd">328700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i061dabef95db47dcbeacf4d95b0043d3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NTA4Njc_645c3f8e-27d7-4bd1-90c8-ff9333324c49"
      unitRef="usd">329500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idc3ca35c957f4ea784da91f7c995a52c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzUzNzk_35f999f2-d0ea-47b4-ad08-eb85ce218888"
      unitRef="usd">572000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8074da28c47b44eb8134011e2bfd7c77_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzU2MDU_e17af112-d798-4c66-b7ae-3a94cf173b8b">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg5NjI_38fb6889-0aba-4911-947f-0a9ec132ef34">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.770%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives from grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted average values of the assumptions used in computing the fair value of PSUs that were granted during 2022 and 2020. The Company did not grant PSUs during 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.431%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzEtMi0xLTEtMTc0MzYy_feeebe61-ba69-4e70-b628-9a3e2552f93b"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzEtNC0xLTEtMTc0MzYy_0b2128c6-882a-4191-877c-ed08e540ed9f"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzEtNi0xLTEtMTc0MzYy_278b34d2-d3ea-4c20-bb9c-12fc6144211d"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzItMi0xLTEtMTc0MzYy_b44f48f3-a6d8-49d7-bda6-e8c869638f73">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzItNC0xLTEtMTc0MzYy_96a5fc9f-e5c5-48c1-a123-a2573fcd06e7">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzItNi0xLTEtMTc0MzYy_26002c4a-5d4e-4954-8823-182904fc6424">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzMtMi0xLTEtMTc0MzYy_35a8dbfb-a18d-4c67-a9c2-11a06c6a9d97"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzMtNC0xLTEtMTc0MzYy_0d2d249d-d1c6-44c3-8e18-995c363d95d9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzMtNi0xLTEtMTc0MzYy_1dd0d825-899e-4d73-9312-915e3114bd30"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzQtMi0xLTEtMTc0MzYy_43176354-12be-4275-8385-cf0016d7a775"
      unitRef="number">0.0350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzQtNC0xLTEtMTc0MzYy_792a8f4b-6d39-4e81-ad94-16416816fc90"
      unitRef="number">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTpmYTFhMTRkMjk4NTA0ZDgwOTFhZmIwYjAwZGIyYjlhNS90YWJsZXJhbmdlOmZhMWExNGQyOTg1MDRkODA5MWFmYjBiMDBkYjJiOWE1XzQtNi0xLTEtMTc0MzYy_bccbd02a-d180-42e1-bd7a-b1d325a82403"
      unitRef="number">0.0047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzYxNTA_ebe0e719-7fee-4018-9a70-0c5e1597a185"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg4Nzk_6e4a222f-26bd-46e1-868c-c7492de0e7f4">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's activity related to restricted stock awards and time-based restricted stock units (excluding performance-based restricted stock units, which are detailed further below) (collectively, "restricted stock") during 2022 is summarized below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares/Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant &lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icc41ab2a621442839e2f788a04d55cce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzEtMy0xLTEtMTc0MzYy_e3c6d30f-eb7c-498b-baa5-eb779b67132b"
      unitRef="shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icc41ab2a621442839e2f788a04d55cce_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzEtNS0xLTEtMTc0MzYy_c35e110d-e346-4118-bb27-72e2eaae3c22"
      unitRef="usdPerShare">499.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzItMy0xLTEtMTc0MzYy_6c1b02cf-7a56-4583-bf02-3452ab5ae772"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzItNS0xLTEtMTc0MzYy_c7a129d5-4bc9-420c-8045-ac8cb3b00d5a"
      unitRef="usdPerShare">702.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzMtMy0xLTEtMTc0MzYy_a0f2dab2-87e2-4967-8543-aea5edf1b68e"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzMtNS0xLTEtMTc0MzYy_31d78039-c5ce-49a4-9561-cae28e830922"
      unitRef="usdPerShare">477.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzQtMy0xLTEtMTc0MzYy_2b31faf2-3b0d-4070-974b-970b17cfb152"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzQtNS0xLTEtMTc0MzYy_14f5f8fe-b71f-47d6-acc9-a8eb7ae98548"
      unitRef="usdPerShare">522.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i44560f336e474452ae29c854f6be95dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzUtMy0xLTEtMTc0MzYy_86da3337-019d-4766-a685-c6e46fafb129"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i44560f336e474452ae29c854f6be95dd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo5MzFhMzNjNzI5YjM0OGM0OGMxOWY0Zjc5YmE0ZTZjYy90YWJsZXJhbmdlOjkzMWEzM2M3MjliMzQ4YzQ4YzE5ZjRmNzliYTRlNmNjXzUtNS0xLTEtMTc0MzYy_c033cac9-d369-4aa7-8118-a0e9d456a044"
      unitRef="usdPerShare">571.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE2MDQ_6706ca55-3675-467c-8035-8e33b279c97a"
      unitRef="usd">331100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0f758f9b4de4edbbd24b0a3c80d2099_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE2MDk_2c32c6a1-2164-4c60-8ff2-f6e95ebf63c1"
      unitRef="usd">221000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98b8165ff3c84cc2b0b3ef6c846d0857_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE2MTg_ff146b32-9fdd-479c-b562-c3de148c399c"
      unitRef="usd">102500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i44560f336e474452ae29c854f6be95dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzcwMTM_73c5e323-ea52-467d-b054-66b0b888df37"
      unitRef="usd">907700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzcyMTE_f731cbd6-41ea-4b19-b818-dbce9782dc20">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic976d25c5e3d49f49a38da896bf4b995_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzgyNDYzMzcyMzAxOTA_ef583ca7-fd35-4844-ae7d-9fd6917f80ae">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4e3bb26f27c440bca9bd206e40fb92e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzIxOTkwMjMyNzc0NTU_79256669-343a-4c89-a07c-2ac5cdfd0da0">P6Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzIxOTkwMjMyNzY4MDg_783d23d8-b9ed-4e2c-ba2f-40e3a062673b">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes activity related to PSUs during 2022. The number of PSUs granted represents the maximum number of units that are eligible to be earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.063%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares/Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant &lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzEtMy0xLTEtMjAzNTI4_90d13b9d-9cdc-4a70-9ad6-fdedb13fbb92"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzEtNS0xLTEtMjAzNTMy_6759ce0a-c64f-41b4-9194-b2b3c2094bd5"
      unitRef="usdPerShare">209.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzItMy0xLTEtMjAzNTY3_cb3b460d-9af4-4f69-ab0a-d1512104c92d"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzItNS0xLTEtMjAzNTc0_9880a5b3-a20a-486e-9165-f0fee62e96d7"
      unitRef="usdPerShare">485.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4f140ca61272416db70327e6fc368a13_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzMtMy0xLTEtMjAzNTMw_fce90612-8281-40cf-bae1-570699d88cca"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4f140ca61272416db70327e6fc368a13_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTo4NWU5NTJjMjkwNzI0YWY1YjQxMDYzNWMyYzZlOGIzMC90YWJsZXJhbmdlOjg1ZTk1MmMyOTA3MjRhZjViNDEwNjM1YzJjNmU4YjMwXzMtNS0xLTEtMjAzNTM0_68ac5491-6618-437c-a8e6-9e0351a087f6"
      unitRef="usdPerShare">245.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE3MDk_b345ebd6-4d1a-4758-8f58-ce3420ed5fad"
      unitRef="usd">52000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzE2NDkyNjc0NjE3MDk_f61ecff1-a4b7-48b2-8a19-f3b4aad5e710"
      unitRef="usd">52000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzgyODI_e56afd59-1fd7-48d9-b906-5bef2b74323b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i4f140ca61272416db70327e6fc368a13_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg0OTU_4908b2f0-5b42-4f42-8b6f-b13d22c2f48f"
      unitRef="usd">156100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibf316c7e51a2419f8c73906927513eff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90ZXh0cmVnaW9uOjZkMDg3NjkzYjBmODQwYjZhNTA0MGI0ZTIzNjM0YTAyXzg2ODk_186146e2-31af-4736-a2a0-de210b0faab3">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzEtMi0xLTEtMTc0MzYy_2e2e81e1-411d-4d7e-a782-34cded4405b0"
      unitRef="number">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzEtNC0xLTEtMTc0MzYy_35a982ff-e6b3-49fe-8e0e-c7b38680eb89"
      unitRef="number">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzItMi0xLTEtMTc0MzYy_8e3b8b61-fef1-4f6b-b29b-8cca6a43355f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzItNC0xLTEtMTc0MzYy_fe97446c-c19b-462b-a3af-dc4484efbc9d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzMtMi0xLTEtMTc0MzYy_6a73ab9b-5022-4368-8e31-511455c51d39"
      unitRef="number">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i812b0a579e9241c38831304cfcadfca0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTEvZnJhZzo2ZDA4NzY5M2IwZjg0MGI2YTUwNDBiNGUyMzYzNGEwMi90YWJsZTowM2VlZDU1MTE1Njg0YmZiYjc0ZDk1NGY0YTZmYmU1MS90YWJsZXJhbmdlOjAzZWVkNTUxMTU2ODRiZmJiNzRkOTU0ZjRhNmZiZTUxXzMtNC0xLTEtMTc0MzYy_1a3d4859-5952-4c67-a7c2-78b6644eb9d6"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzY3OQ_b32ba9df-f2cb-4570-a8fd-3bd950a0aecd">Employee Savings Plans&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains the Regeneron Pharmaceuticals, Inc. 401(k) Savings Plan, as amended and restated (the "Savings Plan"). The terms of the Savings Plan allow U.S. employees (as defined by the Savings Plan) to contribute to the Savings Plan a percentage of their compensation. In addition, the Company may make discretionary contributions, as defined, to the accounts of participants under the Savings Plan. The Company also maintains additional employee savings plans outside of the United States, which cover eligible employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses recognized by the Company related to contributions to such plans were $67.6&#160;million, $55.5&#160;million, and $49.9&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzU0OTc1NTgxNDY4Ng_e40f2f3a-94ed-4f39-9499-be59666afbff"
      unitRef="usd">67600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzU0OTc1NTgxNDc0NA_94ffa73d-455e-461f-a0b3-7ea0aa2f9b5c"
      unitRef="usd">55500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTQvZnJhZzowMmY4ZjUzZDMyYzA0M2U1YmYwY2JhYzA4NWJhNjEyYi90ZXh0cmVnaW9uOjAyZjhmNTNkMzJjMDQzZTViZjBjYmFjMDg1YmE2MTJiXzU0OTc1NTgxNDc1OQ_077e74e0-a2d4-47b7-98fe-784551702471"
      unitRef="usd">49900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MTM_4ed25565-48b4-4bb7-af94-738cd1f5974a">Income Taxes &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal, state, and foreign income taxes. Components of income before income taxes consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.448%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,944.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,442.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,018.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,381.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,858.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,325.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,810.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.109%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(746.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. statutory income tax rate to the Company's effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.080%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxation of non-U.S. operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of non-inventory related assets between foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.488%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax attribute carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's federal income tax returns for 2017 through 2021 remain open to examination by the IRS. The Company's 2017 and 2018 federal income tax returns are currently under audit by the IRS. In general, the Company's state income tax returns from 2018 to 2021 remain open to examination. The Company's income tax returns outside of the United States remain open to examination from 2018 to 2021. The United States and many states generally have statutes of limitation ranging from 3 to 5 years; however, those statutes could be extended due to the Company's tax credit carryforward position. In general, tax authorities have the ability to review income tax returns in which the statute of limitation has previously expired to adjust the tax credits generated in those years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of net unrecognized tax benefits that, if settled, would impact the effective tax rate is $373.7 million, $321.1 million, and $267.0 million as of December 31, 2022, 2021, and 2020, respectively. The following table reconciles the beginning and ending amounts of unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross (decreases) increases related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases due to settlements and lapse of statutes of limitations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2022, 2021, and 2020, the increases in unrecognized tax benefits primarily related to the Company's calculation of certain tax credits and other items related to the Company's international operations. The decrease in unrecognized tax benefits in 2021 was related to the closing of audits for the Company's federal income tax returns for 2015 and 2016. Interest expense related to unrecognized tax benefits was not material in 2022, 2021, and 2020. The Company does not believe that it is reasonably possible that the resolution of tax exposures within the next twelve months would have a material impact on the consolidated financial statements as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Inflation Reduction Act of 2022 ("IRA") was signed into law in the United States. The IRA created a new corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases. The provisions of the IRA will be effective for periods beginning after December&#160;31, 2022. The enactment of the IRA did not result in any material adjustments to the Company's income tax provisions or net deferred tax assets as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MTA_45ae81ba-978c-49bc-a3b1-412a1536e16f">Components of income before income taxes consist of the following: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.448%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,944.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,442.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,018.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,381.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,858.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,325.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,810.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzItMS0xLTEtMTc0MzYy_e5695048-1e78-4028-88b0-3b78746411ac"
      unitRef="usd">839900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzItMy0xLTEtMTc0MzYy_45e67093-8fd2-4de1-8098-5ffc3aba7a86"
      unitRef="usd">5944700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzItNS0xLTEtMTc0MzYy_fd96c813-266a-44ed-a714-684334da2542"
      unitRef="usd">2442300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzMtMS0xLTEtMTc0MzYy_81d42267-1a3e-4332-b063-9d9cc8cd857d"
      unitRef="usd">4018900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzMtMy0xLTEtMTc0MzYy_ba79a43e-1c57-4bc6-9bf0-46fde5762286"
      unitRef="usd">3381100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzMtNS0xLTEtMTc0MzYy_fd02511f-b5d3-444d-8d10-aae6d7c8c0be"
      unitRef="usd">1368100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzQtMS0xLTEtMTc0MzYy_e78788b3-86e6-45f0-9782-ce7721372fe7"
      unitRef="usd">4858800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzQtMy0xLTEtMTc0MzYy_f1b598e5-c52a-4b6e-a9ae-5a40e24c7f3e"
      unitRef="usd">9325800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTo0NDY0MTRmY2NkM2I0YWU1OGQ4NWJmNjcwOTA1Mzc3NS90YWJsZXJhbmdlOjQ0NjQxNGZjY2QzYjRhZTU4ZDg1YmY2NzA5MDUzNzc1XzQtNS0xLTEtMTc0MzYy_a0623825-f08c-4a96-a49e-8de31c8aeced"
      unitRef="usd">3810400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzIzOTI_6bfc113d-8647-4721-8c72-ec5564cc14a2">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.109%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(746.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzMtMS0xLTEtMTc0MzYy_325db0e3-8827-4055-b608-1130f58bfe78"
      unitRef="usd">968500000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzMtMy0xLTEtMTc0MzYy_96b433e8-b723-43a4-b542-47bde6bf7b88"
      unitRef="usd">1429800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzMtNS0xLTEtMTc0MzYy_d792db49-283c-416c-9501-1237a8c42b1f"
      unitRef="usd">199000000.0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzQtMS0xLTEtMTc0MzYy_5df3aeb7-92e5-4137-a54d-6f3f6700fda6"
      unitRef="usd">7400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzQtMy0xLTEtMTc0MzYy_a1530ad8-2506-463f-ae80-02ff1e129d58"
      unitRef="usd">6200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzQtNS0xLTEtMTc0MzYy_b7bc6eae-f4ce-4ba9-8e60-d4c2a3e5a152"
      unitRef="usd">1200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzUtMS0xLTEtMTc0MzYy_ee268ba7-7d9d-4cbe-aa90-228691a76ee0"
      unitRef="usd">290900000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzUtMy0xLTEtMTc0MzYy_4508cf53-fb98-4dfe-a5fb-9f40c5261245"
      unitRef="usd">-38400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzUtNS0xLTEtMTc0MzYy_de737731-c702-4632-8480-aed12a5feac9"
      unitRef="usd">21400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzYtMS0xLTEtMTc0MzYy_a7f3fa75-d1f9-4832-98a6-2e73fafa2453"
      unitRef="usd">1266800000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzYtMy0xLTEtMTc0MzYy_da850d3b-573c-491e-aeae-f66cfbeac1e4"
      unitRef="usd">1397600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzYtNS0xLTEtMTc0MzYy_142dd152-94da-4898-81a3-bb4f11a7fa68"
      unitRef="usd">221600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzgtMS0xLTEtMTc0MzYy_f09b2489-7af9-4e67-b17e-9f74cfafaac3"
      unitRef="usd">-797700000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzgtMy0xLTEtMTc0MzYy_589beffd-a107-4122-a42c-36589a6dadc7"
      unitRef="usd">-423200000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzgtNS0xLTEtMTc0MzYy_2020d6a0-fbc3-420c-a978-034e6570430d"
      unitRef="usd">109000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzktMS0xLTEtMTc0MzYy_a9f3b75d-46c7-4688-a131-e9e947d104b1"
      unitRef="usd">-2700000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzktMy0xLTEtMTc0MzYy_cf26126c-185b-4cdb-9aca-c992bbe1033c"
      unitRef="usd">-600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzktNS0xLTEtMTc0MzYy_14332c1b-3117-4272-bdf8-c38fc10ce4e0"
      unitRef="usd">-2000000.0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEwLTEtMS0xLTE3NDM2Mg_18011cd7-8f12-4ace-9fda-36a338ebc9f4"
      unitRef="usd">54000000.0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEwLTMtMS0xLTE3NDM2Mg_6325f979-c945-4279-8703-7eacce81c554"
      unitRef="usd">276700000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEwLTUtMS0xLTE3NDM2Mg_8404f2a0-ae6c-45f0-9c63-cfc9eda48be3"
      unitRef="usd">-31400000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzExLTEtMS0xLTE3NDM2Mg_4c39cb58-a778-4799-885d-b0db7a02ce1a"
      unitRef="usd">-746400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzExLTMtMS0xLTE3NDM2Mg_573a7819-cc3e-4ddb-8858-6b1af25c7917"
      unitRef="usd">-147100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzExLTUtMS0xLTE3NDM2Mg_5caaaac3-3484-490c-9b71-eff041942757"
      unitRef="usd">75600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEyLTEtMS0xLTE3NDM2Mg_d7c1df88-32c0-4037-b4db-bf2b46270754"
      unitRef="usd">520400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEyLTMtMS0xLTE3NDM2Mg_01a429a8-1609-41a4-ba2d-7ac62b92d055"
      unitRef="usd">1250500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTpiMTYxNjcxMmU0NzY0NjNiOTQxYjI3Njg3YWU5OTk0NC90YWJsZXJhbmdlOmIxNjE2NzEyZTQ3NjQ2M2I5NDFiMjc2ODdhZTk5OTQ0XzEyLTUtMS0xLTE3NDM2Mg_434fca02-2d67-4d20-9b2f-3e09b378fe12"
      unitRef="usd">297200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzIzODM_c031d8ba-e10e-4c9a-9eb9-4324d7b59ea6">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. statutory income tax rate to the Company's effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.080%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxation of non-U.S. operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of non-inventory related assets between foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzItMS0xLTEtMTc0MzYy_b25ffb51-956e-46ce-ab7e-6d1b4143343f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzItMy0xLTEtMTc0MzYy_809cc01e-4d92-4468-98d5-b631c02770ba"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzItNS0xLTEtMTc0MzYy_a7ec1974-bc02-4f50-88fe-a7f4e17e1743"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzMtMS0xLTEtMTc0MzYy_dd1c2f3b-c9ef-4bf9-981c-0a03b180a678"
      unitRef="number">-0.055</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzMtMy0xLTEtMTc0MzYy_ce31af84-e4eb-4226-b6bd-be9a54bb0234"
      unitRef="number">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzMtNS0xLTEtMTc0MzYy_bc921d07-d799-46de-a7ae-235a3acf6697"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzQtMS0xLTEtMTc0MzYy_68d1663b-c3b1-4251-822b-461d68e3f8a8"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzQtMy0xLTEtMTc0MzYy_e7b99382-6a84-4be8-8902-2a12b3eaeab0"
      unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzQtNS0xLTEtMTc0MzYy_5eaec296-17a4-45b0-833e-8d09b3880e0d"
      unitRef="number">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzYtMS0xLTEtMTc0MzYy_c95ead65-680c-4675-8c51-b30d2f7b6f13"
      unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzYtMy0xLTEtMTc0MzYy_e453faf8-9155-455c-9cad-ff6fc5ecb2ee"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzYtNS0xLTEtMTc0MzYy_f323770f-5869-4886-88ca-901f5cbc0524"
      unitRef="number">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzUtMS0xLTEtMTc0MzYy_0bd29c63-a83a-4ec4-8075-12c1b802cbaf"
      unitRef="number">0.010</regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent>
    <regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzUtMy0xLTEtMTc0MzYy_eed833ac-de56-41d2-9bb9-c6577791c56e"
      unitRef="number">0.014</regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent>
    <regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzUtNS0xLTEtMTc0MzYy_bf155c5a-21bd-46f9-bd30-e0ef2a7f566c"
      unitRef="number">0</regn:EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent>
    <regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzctMS0xLTEtMTc0MzYy_816b152f-f1ec-4acd-ae1a-33b059b29260"
      unitRef="number">0</regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent>
    <regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzctMy0xLTEtMTc0MzYy_622d1297-b322-4022-9767-66f5e6f49401"
      unitRef="number">0</regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent>
    <regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzctNS0xLTEtMTc0MzYy_2af602c4-a425-46ca-b97a-41a45351a926"
      unitRef="number">-0.008</regn:EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzgtMS0xLTEtMTc0MzYy_cb633d98-c57c-4579-aa9e-f29c14e3cc37"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzgtMy0xLTEtMTc0MzYy_7d7400a1-a742-46e3-aa07-d30cfa06dc95"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzgtNS0xLTEtMTc0MzYy_8a42de07-b616-4aa8-bc01-3a6d71b7ff58"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzktMS0xLTEtMTc0MzYy_e192b333-923d-494f-8e47-54e2127dc446"
      unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzktMy0xLTEtMTc0MzYy_edd4c843-5585-4e9e-bd4d-c3b94eb956ed"
      unitRef="number">0.134</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZTphODc0ZGY1YzQzZTI0NjIxODU5NzVhODRjY2M2NzcxNC90YWJsZXJhbmdlOmE4NzRkZjVjNDNlMjQ2MjE4NTk3NWE4NGNjYzY3NzE0XzktNS0xLTEtMTc0MzYy_45fc7671-34fb-4bc3-b02f-4d165c95d0f9"
      unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MDc_75937d54-cfc4-4d9d-8c58-298e628b71fd">Significant components of the Company's deferred tax assets and liabilities are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.488%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax attribute carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtMi0xLTEtMjAzNjEw_d5da0653-a48a-4233-8140-e34f5e6529c8"
      unitRef="usd">845300000</regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtNC0xLTEtMjAzNjEw_2ae4c300-bbfd-4480-a917-ff471c3061fd"
      unitRef="usd">0</regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtMi0xLTEtMTc0MzYy_ecb2aa53-530a-4e32-99c7-40780893d9a8"
      unitRef="usd">416200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzMtNC0xLTEtMTc0MzYy_5bb28a2b-6378-4f60-952d-45523cab45bb"
      unitRef="usd">406600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzQtMi0xLTEtMTc0MzYy_c3c67296-ea6f-4cf8-a1d4-94d4b906f46b"
      unitRef="usd">235600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzQtNC0xLTEtMTc0MzYy_1a719ad6-0615-46cf-afe8-5e3d12d6a2d8"
      unitRef="usd">262100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzUtMi0xLTEtMTc0MzYy_eb92921c-7fe8-4a5a-9687-bd7415cac781"
      unitRef="usd">227600000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzUtNC0xLTEtMTc0MzYy_298e40cb-de5d-4e1f-a9e2-64edd950d526"
      unitRef="usd">257500000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtMi0xLTEtMjAzNjE0_fcd1fac1-3f5c-4403-8d32-fae63455fc0b"
      unitRef="usd">41300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtNC0xLTEtMjAzNjE0_66c8d5cf-ee96-4eed-978d-4e02738a89fe"
      unitRef="usd">6100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzctMi0xLTEtMTc0MzYy_8865a678-e703-41dc-af5c-82bffa321a5c"
      unitRef="usd">15900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzctNC0xLTEtMTc0MzYy_cd014528-ac65-424e-ab2f-0c133d7322c4"
      unitRef="usd">10800000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtMi0xLTEtMjA4MDAw_b05776a3-45ce-4f16-88d5-187d3121628a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtNC0xLTEtMjA4MDAw_3948ef73-47fe-4588-9312-b93c85825365"
      unitRef="usd">57300000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtMi0xLTEtMTc0MzYy_39123e7b-f5d9-46a5-92b6-b652edd7c552"
      unitRef="usd">1781900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzgtNC0xLTEtMTc0MzYy_8204e04e-82e4-4741-ba9d-b4afd3ec6e4e"
      unitRef="usd">1000400000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzExLTItMS0xLTE3NDM2Mg_bf55a11f-1972-4106-98c4-da56369f0a9b"
      unitRef="usd">58200000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzExLTQtMS0xLTE3NDM2Mg_d6152522-3f60-484c-aaad-0cd86791e214"
      unitRef="usd">123500000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzEyLTItMS0xLTE3NDM2Mg_707267e8-1dcb-4128-ac39-54f3d16ede2d"
      unitRef="usd">1723700000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToyOGY4NGZlNmM3MzA0MDJkYmU0NGY5YmIxYjNiMjM2NS90YWJsZXJhbmdlOjI4Zjg0ZmU2YzczMDQwMmRiZTQ0ZjliYjFiM2IyMzY1XzEyLTQtMS0xLTE3NDM2Mg_4fd1daad-5dbe-4e6b-8833-04b0ec214941"
      unitRef="usd">876900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzI0MDI_c1459734-a0af-4595-a73d-c285f840d453">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of net unrecognized tax benefits that, if settled, would impact the effective tax rate is $373.7 million, $321.1 million, and $267.0 million as of December 31, 2022, 2021, and 2020, respectively. The following table reconciles the beginning and ending amounts of unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross (decreases) increases related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases due to settlements and lapse of statutes of limitations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzgyNDYzMzcyMTk2NTc_34f6248a-3d03-4197-9aa6-e3400100fa7e"
      unitRef="usd">373700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzE2MjE_f3d5de89-4d74-4bd9-87db-cb254859f61b"
      unitRef="usd">321100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90ZXh0cmVnaW9uOjFmZGMwYTUzZTc0MDRjMjk5N2RkZTQ3MWUyNmIxMDc1XzE2Mjk_20387965-5f49-414a-afa0-8c264ec76f3a"
      unitRef="usd">267000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzEtMi0xLTEtMTc0MzYy_26c4a5da-21da-42e5-a7d4-2cf562a3f072"
      unitRef="usd">410900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzEtNC0xLTEtMTc0MzYy_083bcd9c-2277-4320-ae17-3f8642c46b45"
      unitRef="usd">267000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzEtNi0xLTEtMTc0MzYy_6f1347ee-ba0d-4ffc-9c3f-1948f7fccdae"
      unitRef="usd">210800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzItMi0xLTEtMTc0MzYy_12258915-1c75-40e0-8d57-2507f9b7ed91"
      unitRef="usd">136900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzItNC0xLTEtMTc0MzYy_69c12538-94c6-4aca-9df8-0b7af8fd3a55"
      unitRef="usd">182300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzItNi0xLTEtMTc0MzYy_0276be58-7394-42d2-ae5e-1d27ea8e5bcc"
      unitRef="usd">76600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzMtMi0xLTEtMTc0MzYy_5df0fc98-8189-4768-a0d6-638780ea891d"
      unitRef="usd">5000000.0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzMtNC0xLTEtMTc0MzYy_79794d2b-927a-4615-8801-cc2ca337e85c"
      unitRef="usd">2900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzMtNi0xLTEtMTc0MzYy_08654982-3e4e-4be4-9c5d-8706aa02ef07"
      unitRef="usd">7200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzQtMi0xLTEtMTc0MzYy_a820fb3a-c2b8-4859-ad93-6bdfe17dff49"
      unitRef="usd">0</regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations>
    <regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzQtNC0xLTEtMTc0MzYy_b06b7d9e-4d1a-4273-8118-49c386c7d3d8"
      unitRef="usd">41300000</regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations>
    <regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzQtNi0xLTEtMTc0MzYy_33d8f9d5-9613-44b7-904e-632b59980cbf"
      unitRef="usd">27600000</regn:UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzUtMi0xLTEtMTc0MzYy_b02d04ed-19df-4fc7-afe0-857a43b03d57"
      unitRef="usd">542800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzUtNC0xLTEtMTc0MzYy_479cf150-249d-4426-a60d-e1d9059d69e4"
      unitRef="usd">410900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNTcvZnJhZzoxZmRjMGE1M2U3NDA0YzI5OTdkZGU0NzFlMjZiMTA3NS90YWJsZToxNjVkZmU0YTk4NjE0NTQwOTFjMGRmYTU2NGZjM2Q0Zi90YWJsZXJhbmdlOjE2NWRmZTRhOTg2MTQ1NDA5MWMwZGZhNTY0ZmMzZDRmXzUtNi0xLTEtMTc0MzYy_b5cdb338-45b4-466d-9b5a-729b156322a8"
      unitRef="usd">267000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzMxNTkw_77647d83-3005-4172-a438-f61687803e11">Legal Matters&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of December 31, 2022 and 2021, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Praluent (alirocumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. In addition, as described below, the Company filed a lawsuit against Amgen alleging that Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As previously reported, on February 11, 2021, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc with the Federal Circuit, which was denied on June 21, 2021. On November 4, 2022, the United States Supreme Court granted Amgen's petition for writ of certiorari. An oral hearing has been scheduled for March 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2022, the Company filed a lawsuit against Amgen in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1, 2022, Amgen filed a motion to dismiss the complaint. On August 11, 2022, Amgen filed a motion to stay these proceedings pending resolution of the patent litigation described in the preceding paragraph. An oral hearing on Amgen's motion to dismiss and motion to stay has been scheduled for January 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in certain countries in Europe. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). Following the EPO's decision, each of the '124 Patent infringement proceedings initiated by Amgen against the Company and certain of Sanofi's affiliated entities in these countries was dismissed, including in Germany. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. As a result of the overturned injunction in Germany discussed in the preceding sentence, the Company and/or certain of Sanofi's affiliated entities are seeking damages caused by Amgen's enforcement of the injunction. As part of its opposition to these damages claims, on March 23, 2022, Amgen filed a counterclaim that asserted the German designation of European Patent No. 2,641,917 (the "'917 Patent") and seeks, among other things, a judgment of patent infringement, injunctive relief, and monetary damages. The '917 Patent is a divisional patent of the '124 Patent discussed above (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent but contains claims to a different invention). The '917 Patent is also subject to opposition proceedings in the EPO, which were initiated by Sanofi on May 5, 2021. An oral hearing before the EPO has been scheduled for February 21, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Dupixent (dupilumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), a patent owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the EPO opposition proceedings initiated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018, which appeal was withdrawn at an oral hearing before the TBA on March 10, 2022 following the TBA's ruling discussed below. On May 18, 2022, the revocation action in the U.K. Patents Court was dismissed following the EPO's revocation of the '665 Patent. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#x2013;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019. At an oral hearing before the TBA on March 10, 2022, the TBA maintained the invalidity and revocation of the '420 Patent. The original patent term of the Immunex patents expired in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2020, anonymous parties filed two requests for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex parte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reexamination of the Company's U.S. Patent Nos. 10,406,226 and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests to initiate reexamination proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2021, Mylan Pharmaceuticals Inc. filed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review ("IPR") petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent. On November 10, 2021, the USPTO issued a decision instituting both IPR proceedings. On December 9, 2021, Apotex Inc. and Celltrion, Inc. each filed two separate IPR petitions against the Company's '338 and '069 Patents requesting that their IPRs be instituted and joined with the IPR proceedings initiated by Mylan concerning the '338 and '069 Patents, which petitions were granted on February 9, 2022. An oral hearing was held on August 10, 2022. On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2021, Celltrion, Inc. filed a post-grant review ("PGR") petition in the USPTO against the Company's U.S. Patent No. 10,857,231 (the "'231 Patent") seeking a declaration of invalidity of the '231 Patent. On March 14, 2022, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '231 Patent. As a result, on March 15, 2022, the USPTO denied institution of Celltrion's PGR petition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, Mylan filed IPR petitions against the Company's U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") (each filed July 1, 2022) and 10,857,205 (filed October 28, 2022) seeking declarations of invalidity of each of these patents. On January 11, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent. On January 6, 2023, Samsung Bioepis Co., Ltd. filed a separate IPR petition against the Company's '681 Patent seeking a declaration of invalidity of the '681 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2022, Apotex filed an IPR petition against the Company's U.S. Patent No. 11,253,572 (the "'572 Patent") seeking a declaration of invalidity of the '572 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 17, 2023, Celltrion, Inc. filed an IPR petition against the '992 Patent seeking a declaration of invalidity of the '992 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for a U.S. Food and Drug Administration approval of an aflibercept biosimilar infringes certain Company patents. A trial has been scheduled to begin on June 12, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, July 15, August 30, and October 4, 2022, the Company and Bayer Inc. filed patent infringement lawsuits against BGP Pharma ULC d.b.a Viatris Canada ("Viatris Canada") in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent) and 3,007,276 (the "'276 Patent") (in the lawsuit filed on June 15, 2022); the Company's Canadian Patent No. 2,965,495 (the "'495 Patent") (in the lawsuit filed on July 15, 2022); the Company's Canadian Patent No. 2,906,768 (the "'768 Patent") (in the lawsuit filed on August 30, 2022, which has been joined with the lawsuit filed on July 15, 2022); and the Company's Canadian Patent No. 3,129,193 (the "'193 Patent") (in the lawsuit filed on October 4, 2022). A trial for the lawsuit concerning the '510 Patent and the '276 Patent has been scheduled for March 2024; a trial for the lawsuit concerning the '193 Patent has been scheduled for May 2024; and a trial for the lawsuit concerning the '495 Patent and the '768 Patent has been scheduled for November/December 2024. The filing of the lawsuit concerning the '510 Patent and the '276 Patent resulted in a statutory 24-month stay of regulatory approval of Viatris Canada's aflibercept biosimilar in Canada unless the lawsuit is resolved earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;South Korea&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811, respectively, seeking revocation of each of such patents in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#x2019;s U.S. Patent No. 9,220,631 (the "'631 Patent"). The ITC instituted the investigation on July 22, 2020 and a trial was scheduled for April 19&#x2013;23, 2021. On March 26, 2021, the staff attorney appointed by the ITC's Office of Unfair Import Investigations ("OUII")&#x2014;an independent government party to the case representing the public interest&#x2014;determined that the '631 Patent is invalid on several grounds. On April 8, 2021, Novartis moved to terminate the ITC investigation in its entirety based on its withdrawal of the complaint; and, on May 3, 2021, the ITC terminated the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis also filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On January 15, 2021, the USPTO declined to institute an IPR proceeding on procedural grounds in light of the pending ITC investigation discussed above; the other IPR petition has been withdrawn. Following Novartis's motion to terminate the ITC investigation discussed above, on April 16, 2021 the Company filed a new IPR petition seeking a declaration of invalidity of the '631 Patent based on the same grounds that were the basis for the OUII staff attorney's determination discussed above. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On November 5, 2021, the Company filed a motion to stay these proceedings in light of the pending IPR proceeding discussed above. On January 31, 2022, the court denied the Company's motion to stay these proceedings and granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to REGEN-COV (casirivimab and imdevimab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney&#x2019;s Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to CMS. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Department of Insurance Subpoena&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Initiated by Other Payors Relating to Patient Assistance Organization Support&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to several lawsuits relating to the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court discussed under "Department of Justice Matters" above; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Shareholder Demands&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or about September 30, 2020, March 30, 2022, and March 31, 2022, the Company's board of directors received three demand letters from purported shareholders of the Company. The demands allege that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letters request that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, investigated and evaluated the allegations in the demand letters and has concluded that pursuing the claims alleged in the demands would not be in the Company's best interests at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Shareholder Derivative Complaint&lt;/span&gt;&lt;/div&gt;On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 23, 2021, the plaintiff moved to remand the case to the New York Supreme Court. Also on September 23, 2021, the individual defendants moved to dismiss the complaint in its entirety. On December 19, 2022, the U.S. District Court for the Southern District of New York denied the plaintiff's motion to remand the case and granted a motion to stay the case pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. As a result of the stay, the court also terminated the Company's motion to dismiss the complaint without prejudice to renew upon conclusion of the stay.</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzIxOTkwMjM0MTc1MTg_b6776034-549f-4f4c-8a6f-fa8ecb86c7c1">Costs associated with the Company's involvement in legal proceedings are expensed as incurred</us-gaap:LegalCostsPolicyTextBlock>
    <regn:LossContingencyExParteReexaminationFiledNumber
      contextRef="i73f39b7d8fbc4c3db0ae510abf05e506_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYyNQ_87d6a88b-7ad7-4a46-8ce5-15f5bd63e695"
      unitRef="request">2</regn:LossContingencyExParteReexaminationFiledNumber>
    <regn:NumberOfInterPartiesReviewIPRPetitionsFiled
      contextRef="ie1e3a47e6a80444d990b27b30d75132a_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYyMA_89e7eb2c-c52d-474b-b6bc-8fac72288096"
      unitRef="claim">2</regn:NumberOfInterPartiesReviewIPRPetitionsFiled>
    <regn:NumberOfInterPartiesReviewIPRPetitionsFiled
      contextRef="icacf904bc9524621b2a1108d36ed04c7_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYyMA_a002ff35-9fbc-4740-af60-ff15208022e6"
      unitRef="claim">2</regn:NumberOfInterPartiesReviewIPRPetitionsFiled>
    <regn:NumberOfInterPartiesReviewIPRPetitionsFiled
      contextRef="ic126e7de56fd4102a3b3234acc2542c7_I20200716"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjAvZnJhZzpiYzA2MDE5Yjg4N2Q0ZjRmOGJkYzFjODMwNGI4NGY5Mi90ZXh0cmVnaW9uOmJjMDYwMTliODg3ZDRmNGY4YmRjMWM4MzA0Yjg0ZjkyXzU0OTc1NTkwMjYxNA_c6bb0dfb-5dc3-4a38-a0ea-f56755b26c2f"
      unitRef="claim">2</regn:NumberOfInterPartiesReviewIPRPetitionsFiled>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90ZXh0cmVnaW9uOmE5ZDQ3ODdhYTMxYzQ2YmQ4ZTg2YTU0YjYwMjA5YWNlXzI1Mg_57e0a9fe-d7bd-48a8-b47e-707462a959d1">Net Income Per Share &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of basic and diluted net income per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.155%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,338.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,075.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90ZXh0cmVnaW9uOmE5ZDQ3ODdhYTMxYzQ2YmQ4ZTg2YTU0YjYwMjA5YWNlXzI2MA_7a293c4e-fb38-4260-9c83-44372f404c86">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of basic and diluted net income per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.155%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,338.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,075.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzItMi0xLTEtMTc0MzYy_0ac6f739-95a1-4be8-b531-b121c9306d73"
      unitRef="usd">4338400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzItNC0xLTEtMTc0MzYy_81ff7ad4-0417-47de-9c01-a58d563cafb5"
      unitRef="usd">8075300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzItNi0xLTEtMTc0MzYy_7ff2f8cd-f05c-4ba8-8307-1d6ee5e8ad75"
      unitRef="usd">3513200000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzQtMi0xLTEtMTc0MzYy_dfb3a7c4-7142-4703-b3c0-8c13dc0203d7"
      unitRef="shares">107100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzQtNC0xLTEtMTc0MzYy_0c3e4181-5772-4e71-a2f6-be2b4a83e4be"
      unitRef="shares">105700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzQtNi0xLTEtMTc0MzYy_d4ab192f-fec3-4c1f-92bf-da234ae2ff42"
      unitRef="shares">107600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzYtMi0xLTEtMTc0MzYy_b9fb5cfd-8bbb-4983-9e2b-1bc5b139432f"
      unitRef="shares">4900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzYtNC0xLTEtMTc0MzYy_ecfacadc-6b79-4436-bb47-bf2e7484641f"
      unitRef="shares">5400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if1f7f2b7c8794f118efdc28ae5dcf296_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzYtNi0xLTEtMTc0MzYy_adfc0991-2e5a-443a-8a91-dbf77e896862"
      unitRef="shares">7000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzctMi0xLTEtMTc0MzYy_c8558fae-767e-470a-8749-922cef97e164"
      unitRef="shares">1500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie0f758f9b4de4edbbd24b0a3c80d2099_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzctNC0xLTEtMTc0MzYy_99c321dc-13da-470a-8492-bd48dc8a5bee"
      unitRef="shares">1100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i98b8165ff3c84cc2b0b3ef6c846d0857_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzctNi0xLTEtMTc0MzYy_d24bb6fd-819c-4013-bf45-5348b73dbc85"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzgtMi0xLTEtMTc0MzYy_2860d13c-f509-4375-9770-54b0ea3cc874"
      unitRef="shares">113500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzgtNC0xLTEtMTc0MzYy_0d255765-ae22-4605-93bb-1d5192e916c4"
      unitRef="shares">112200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzgtNi0xLTEtMTc0MzYy_214ef372-fd9d-4042-bc04-e253163425fa"
      unitRef="shares">115100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzEwLTItMS0xLTE3NDM2Mg_13d6a368-ca1b-4ca8-a6fa-810af6ecdd7d"
      unitRef="usdPerShare">40.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzEwLTQtMS0xLTE3NDM2Mg_2b79975d-c04f-4c22-ab9f-68dfd65c2501"
      unitRef="usdPerShare">76.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzEwLTYtMS0xLTE3NDM2Mg_9666fe9a-8b08-409c-aea8-a6309196c506"
      unitRef="usdPerShare">32.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzExLTItMS0xLTE3NDM2Mg_4ae2eb02-4a56-4142-9559-3ab373b9ee5f"
      unitRef="usdPerShare">38.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib5bcd644cdb047b2a1e6888e6cd53dcc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzExLTQtMS0xLTE3NDM2Mg_85e58e62-7b04-4236-a13a-beb94c077809"
      unitRef="usdPerShare">71.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTo0MDI3OTAwMTAyMGI0MTUwYTUxMDFlYjYwYTEzZWRkYy90YWJsZXJhbmdlOjQwMjc5MDAxMDIwYjQxNTBhNTEwMWViNjBhMTNlZGRjXzExLTYtMS0xLTE3NDM2Mg_32187d9b-be7c-4c1b-a852-ddc427e2552c"
      unitRef="usdPerShare">30.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90ZXh0cmVnaW9uOmE5ZDQ3ODdhYTMxYzQ2YmQ4ZTg2YTU0YjYwMjA5YWNlXzI2Mw_187b9ad4-8888-4725-886c-b3f544551837">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id00ff500fe5d47c79cce7113ad54ecef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTpkMGFmNmE4MzVmNWQ0N2E2YjU0MWQxOWUwYTAxNzcwZC90YWJsZXJhbmdlOmQwYWY2YTgzNWY1ZDQ3YTZiNTQxZDE5ZTBhMDE3NzBkXzItMi0xLTEtMTc0MzYy_f8cb5281-b34e-4002-b7ae-0a89fbc43299"
      unitRef="shares">2300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ec0ed1241324a98bc46dd1af446a761_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTpkMGFmNmE4MzVmNWQ0N2E2YjU0MWQxOWUwYTAxNzcwZC90YWJsZXJhbmdlOmQwYWY2YTgzNWY1ZDQ3YTZiNTQxZDE5ZTBhMDE3NzBkXzItNC0xLTEtMTc0MzYy_869a7321-d5d1-40d8-940c-e991f44579bb"
      unitRef="shares">2900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i60296a00df8b476a897b09a51d123985_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjMvZnJhZzphOWQ0Nzg3YWEzMWM0NmJkOGU4NmE1NGI2MDIwOWFjZS90YWJsZTpkMGFmNmE4MzVmNWQ0N2E2YjU0MWQxOWUwYTAxNzcwZC90YWJsZXJhbmdlOmQwYWY2YTgzNWY1ZDQ3YTZiNTQxZDE5ZTBhMDE3NzBkXzItNi0xLTEtMTc0MzYy_d4aa5ae3-feed-4277-9886-c067aa48705e"
      unitRef="shares">2700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzYwMA_f3025c3b-b1ba-42a2-82e3-0cdb5ce99fa0">Statement of Cash Flows&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental disclosure of non-cash investing and financing activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.747%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payments for Libtayo intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzU5OA_78fe8a7a-9640-42c9-b7d4-f1de19d776aa">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzU5OA_dab07c36-3311-45b6-8357-a944dfb91903">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheet to the total of the same such amounts shown in the Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.390%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzItMi0xLTEtMTc0MzYy_305511be-8de1-4848-9e97-a63e4fbbb21b"
      unitRef="usd">3105900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzItNC0xLTEtMTc0MzYy_8ec24fc3-5e53-42b5-b154-900578403b38"
      unitRef="usd">2885600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzItNi0xLTEtMTc0MzYy_6f50cf35-0625-4bf9-872a-bba047ec4ac6"
      unitRef="usd">2193700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzMtMi0xLTEtMTc0MzYy_3efea8d7-72d6-4719-a3b5-7bc4c48b8724"
      unitRef="usd">13500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzMtNC0xLTEtMTc0MzYy_988d6318-382c-416f-8c2e-1e49fd24d298"
      unitRef="usd">12500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzMtNi0xLTEtMTc0MzYy_2cf1b35e-3d4c-45c9-a050-5afa4259c586"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25a7782ebd8c4cae90c0de536db35b84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzQtMi0xLTEtMTc0MzYy_5ce15a19-631f-40b1-8f9a-a8552b53ae24"
      unitRef="usd">3119400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzQtNC0xLTEtMTc0MzYy_2dc043c7-7057-4b0a-87e2-9b96b153f3cb"
      unitRef="usd">2898100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9e1b802d10c4170b70f673c07516261_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTpjM2U1YjlmOTFjZjQ0OGYxODNlYTY1OWYxNWVlYzI0NC90YWJsZXJhbmdlOmMzZTViOWY5MWNmNDQ4ZjE4M2VhNjU5ZjE1ZWVjMjQ0XzQtNi0xLTEtMTc0MzYy_f62b0782-6bf9-407f-a086-fbe5cad8eecb"
      unitRef="usd">2207300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90ZXh0cmVnaW9uOjMzYjk5MjQ5NmQ2MzQxMmI5MGQwMjEzZjUzMDIxYzMzXzIxOTkwMjMyNTYzMTY_ff99fb80-0b11-4987-981a-35628645322c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.747%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payments for Libtayo intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzItMS0xLTEtMTc4NjEx_68a36c7d-971e-477a-a38d-efeba3b1ddac"
      unitRef="usd">70800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic5bac9dad6b340e2b278dca087384319_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzItMy0xLTEtMTc4NjEx_112d034b-1ecc-4a85-8e5a-a09fd6a93c81"
      unitRef="usd">74800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzItNS0xLTEtMTc4NjEx_a169aba0-c4b5-4cfa-8466-d212db37f3f3"
      unitRef="usd">83600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzMtMS0xLTEtMTc4NjEx_d6e794a0-7619-4aac-a5ab-15c8cb184d1f"
      unitRef="usd">135500000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="ic5bac9dad6b340e2b278dca087384319_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzMtMy0xLTEtMTc4NjEx_2cff754c-841e-4ea4-bf12-c70c19b97aa5"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i24f8858b24074490bebd89c2ede3525a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGJhZDhiZjUzMTRlM2U5ZjRjMzQ4YTlmODU5MzE3L3NlYzpjMThiYWQ4YmY1MzE0ZTNlOWY0YzM0OGE5Zjg1OTMxN18xNjYvZnJhZzozM2I5OTI0OTZkNjM0MTJiOTBkMDIxM2Y1MzAyMWMzMy90YWJsZTo1MTE1M2JiZmU3NzA0YzAwYmZlNWI5YzU1N2JjNGJiMC90YWJsZXJhbmdlOjUxMTUzYmJmZTc3MDRjMDBiZmU1YjljNTU3YmM0YmIwXzMtNS0xLTEtMTc4NjEx_5a04e638-1200-41af-a4fc-7c79941e52a3"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)H**;#9)#]JT0YM>A;:1Z<4_MM]A74C,*2<)Q<,->3*MXYO!@_=S</Y);7'
MO>L@BJ2R$KHILVZU:U*+IC;_A3<=[I'BG@E%"M@9:3"X-9>(3==H)EJ6KE*W
M4INZ=\/<-%I &V#V=U+JX\0>T+7N^"]02P,$%     @ ZDI&5F?2T'(O!P
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M/ER:'\[S 2=I=KY])%R<EK/; ",?4VD@GJ\)X<\#>60N?R)QO@-02P,$%
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M+N84!HZ<22/%X/J>-9*?$]-/8.?=[4C?=T_4T=FUIV$_Y6IV-M3$@-)\*"V
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MD/XB#31H *6%4%H$I<6JZ94JZAYI),JL]I:<G[%ZG5IR"A_'4F1!Z-,]4%H
MI8506M1N>F-H4(JBB>JL_1[G1Y:E4ZM07ES-LD8CZ=*PS:)TBD:3B3,96"<7
M;@T472S;-D;-FY2AHF'?LJ7"OTC5SC1L5W$W!.J'*.:Q65PW+!:,E7Y2)A=G
MF^26O>7?$--U09;LAO<Q!F/>.4]O%X<W9;8Y[YD]\BDKRVRU?;E@R9SE50/^
M^4V6E=_>##G_(<L_;V-<_ ]02P,$%     @ ZDI&5BD4[&OL"   #RD  !@
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M /+[O1#ETP?U ^T9R-4_4$L#!!0    ( .I*1E:.VWW:C2,  !-S   8
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M8\F\N-Z*!)#&:;M*:.GS-56$6!!_VH$#+80$$L^112JH[ZU2\DV&NA+]10,
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M;W9RV<Q)KL3EN]?Y%B&^+9R/H%SA4J5_($0LI5GT#'1"U)4H#7//Y^.IPTU
MB=.9!7%X5X(;.L&H3X@4^4!#=C]T' %_'(I.X4&'UBH57E=8R=2?MKM*_E A
M_P4M_#E&O755_F9A^+3P?_'Q6O[087Q<_ESDO\MNC2NO:[.B5Y_,__;5F0B2
M_Z5O=_QG#\G][]LM_[@Q9(EV>("^7[4D ?H+)@A_!_.'_P=02P,$%     @
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MMGC\73PSD?-*,*-*41(ZLZ(DF97"223* G6F5*N*8HZLE:L*I267O)3?N#N
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MXBM5[R4,H =)9(@5F*!ZFLJL\H07DLO<IA7:>)A-55.5J)+L$.95A=R>./9
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M_;B6X+\5^ #\?9GGE?X%-S#?9/WCOP%02P,$%     @ ZDI&5@$7% :4!P
MFA0  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULG5C;;N.V%OT5P@U:
M!]#(NMIRF@1(,FW/ )UV,)EI'XH^T!)M"Y%%EZ3M\?GZKDW*LN)+D.;%ELC-
MQ7TAUR)UO9'J2<^%,.S;HJKU36]NS/)J,-#Y7"RX]N52U.B92K7@!J]J-M!+
M)7AA!RVJ010$P\&"EW7O]MJV?5*WUW)EJK(6GQ33J\6"J^V]J.3FIA?V=@V?
MR]G<4,/@]GK)9^)1F*_+3PIO@Q:E*!>BUJ6LF1+3F]Y=>'6?D+TU^*,4&]UY
M9A3)1,HG>OE0W/0"<DA4(C>$P/&W%@^BJ@@(;OS38/;:*6E@]WF'_K.-';%,
MN!8/LOJS+,S\II?U6"&F?%69SW+S/]'$DQ)>+BMM?]G&V::8,5]I(Q?-8+PO
MRMK]\V]-'CH#LN#,@*@9$%F_W436R_?<\-MK)3=,D370Z,&&:D?#N;*FHCP:
MA=X2X\SM1ZZ>A.&32K!'D:]4:4JAKP<&T&0PR!N8>P<3G8$)(_91UF:NV4]U
M(8KG  /XU#H6[1R[CUY$?"]RG\6AQZ(@BE[ B]M 8XL7G\'[4*^%-EA.1GOL
MO9@8QNN"_?3/JC3;3NCLK[N)-@J+Y>]367!S)*?GH UTI9<\%S<][! MU%KT
M;K__+AP&/[X00=)&D+R$_OI2O0&&=5KUOI5K)J?(5BX6$Z':<MC4X2%DN<3V
MU(:L)M+,&5_SLB*4=^"+=YH#KJ!<=S!A6K:U8#/%"\%*K5=":=;70K ),86=
MXC=I!$LOR8T-]BW]"U>PYWC+U:0J\VK+#*$5\&JQY#5U6L &QF=?YH)-907X
MLIXQ&ZUNZ*C\OV &W0]VZ/8'W7&2GE\1V17K?ZBQ1ZL*=*,OV=U"*@/<@GVM
MP9>5??R9EXK=G4GK@T0J[SDRRGX!GVKVJ]0:+O[!JQ6YII92<<0RD76AV04;
M>N-1ZJ=X^OZ[+ JC'_'4C\:A'U[:WF&6^ G[ZC_Z;";70M4VY939[NM,U/F6
M2:1PQHDI-8N\<9)B9."/67_HCR^I)1ZCY9'&@>GJQH?AR _;R?NQ'URR88(F
MI'$A5%[RBBWY$C&&4=BQW/V[U@>!/$W+'*'9Q!1B*75I6)A%7?2 PJ*V  G4
MPKR;\/P)*>VLA2B#Q^V T!_!\Y$?(1EAX,41$/!(42%/<1#YV:7K"L(,5J?+
M$IY(_,A+,2*Q@RU\/PDH3=239"-_](:DA\$8D05^3)'"L3#(4-JCA">V+M8H
MOG2O1\E.4*O10>*H;7@VU5&:(H[G(Z@M/)OJA.IP,$5H,YMY">HP<LG);'(B
M\I5ZXC&5X\M^H[&\XEK#)4"6Y@V[SFIRP2#PV+[86V D2]\K9 .B359;5E"\
M;O^_ K$"HP'R'/E95  9M@9OR)5V\)A?R=5LSNZ6JJS(-&L8A[;\FK:P!7Q-
M2-O38738UG2I[.K4TGU.1M9SNYH_.C2:9U.:.9(L:\&V@BM4*/&&\= N[,C+
ML""?F?.I 79KO8MWBF.5;=$L]>(LQ/#42[/LU.".;0"[/6VUF_#Y*CE@:Z;G
M<J-=\&U6=^G84_<K4FSFJ-^<PYO5GIPK2[<>=N=,">Q+-*$4';6B?3.3:FNW
M<R7J&22/9L<QU2&2'V5=E.NRH,IU)K1S382H[;*V]2WK%:T>FI79;8A2^>Q7
MH:U[-=L?JO9/4K%?X"_E\HLTF.) <\ZL62L[3D8Z8D3R\L:N8TZ,O,2*!O;[
M*'8*E'BX&[BF",4-&E6"6=91JO].E:.,V*H?$>(H! _U$V+?+!U2LQ6L0][$
M]$-2!**IU#V.+7U&C6R=8\:$"-[QVZ%Z=;K.L608@L-A,@2?6Y^M!]$0].CD
MZ8+%7APTDC0:.A%)O#B.G*Y$4;H3EF$<6_W:*=?KY2KULFP,S>CHU'[G[9^.
MS/Y[9<8!5</JUV&V.EV'Q8E'KBL^'M7I.I*Y:)Q2'D_6IMMW]GPQI"/-Z?'=
MOG/%C1,Z'YT<WNFB)9^&PR:OC1*>2O^1&1'@$3N1TN4'%3ZG5!MDF4&-Z'R+
MTW&AP+ZUH[0<L(16$A^!3<!P3.U5<J?.<T KL<9=& Z0/F-> U(NY2NEC)9,
M(3 ![JZ :$FR$#E=3&C^#I.[HW].Q^"B+%@MX930N&"SJ9(+!J>+TKQ3HK+<
M/(4^2@6/08&\*"Q_>ETI8(6$"X1",<(3(^%;57G6+:R TO7BH"Z@^D^"KA#$
MO-38NKH#VX!EX2$\PAU$B0Z:7N7S9_HMIH2H1$X+?=L(%*+D[97 QDA'%[C_
M)V28XER*W!#HXM1=S(,6*NN/DT]!]^SCFCL.\'8WM,"C.5=TFH(WNZ-6X=)Y
ME^>KQ<KE$I<WH>S%28DY?7-94VWP+EB?%MXEI5"RWZW9KD-\6\)47'JL%L:M
MMEUM8-LNW)F]RUC);)<P+997'H=\]OE52"?3YKRR12;1)/)X4QYID37;I(D>
M,U[@9@]*;N378Q=6V=I7&GLQ(DULFMY:PF9MH";5UF,;NR=S.:MM3K"#7JB*
M?^K#PZ#SO0B4.K-?Q32JCX7B/AVUK>V'MSOWO6EO[K[:?>1J1C6IQ!1# W^4
M]IAR7\+<BY%+^_5I(HV1"_LX%[BE*S) _U3B=MZ\T 3MY\C;?P%02P,$%
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M;0CW@DD; I,5O/O>\H8B;Z<#2S:<Y*#L\6XZO/05O"2%3TK:M8%WLL+J.<"
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M#8,J'28PG@6,^%DZ"&<O(EX[&_  FJ+B.(0"4J49,,4#J6\3J0X+=1RN'Q#
MD>;R-53B9!JG\=E\/KG835I\.]_=QCS(+B<OMXDP=(Y--)SK=O5U&L??+(FG
MS-W9JOO:F$SH"RQRA@M#Q=5U+\F__^XJSRY_\$/;VJ^]N,XX@#U_ODK+5G<@
M7UFZH4ITAMO -C>B=>,>4)PG8)Y:**SM4Z2@!0^S [+C@S6-_$3GZ]HBJ&F[
M?9_ZZ@N!LI9F2>=V<<[/G-5IRHE?HT(MP[BO_4//*Y4KNX8;0\DYPN X^MPI
M1P^[=<PHOD!SZ\"<88Y/%C!.<2A#D_T,MO'";);]<;#VW8NS[N#C8'F<;_M)
MQ9JC,91%ZF?IZ-%AB%*@9MQM[R#A)6.*9YK/)H4L/\7SA)>Q]J2)?4UH-'Q0
MBM^VI,-Q<45]R^F_IDV.?569[GWC:@AS+7_)XW@!@O2Y:_MT^['P+GTCVRU/
M7QJ1KDMNL)H6$)VA#(V$2U_OTDVP;?QB5M@ &^-E31+!Y@5XO[  L[_A#;:?
M4&__#5!+ P04    " #J2D965(3(K#\-   H)   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6RE6FUSVS82_BL8G=/:,S)MR;+CIHEG;*>9MN,TF3B]
MF\[-?8!(2$)#$BQ 6E9__3V[ /@BR4Y[]R$Q)0&+?7WV64BOU\9^<2NE:O%8
MY*5[,UK5=?7JY,2E*U5(EYA*E?AD86PA:[RTRQ-7624SWE3D)]/3TXN30NIR
M=/6:W_MHKUZ;ILYUJ3Y:X9JBD'9SHW*S?C.:C.(;G_1R5=,;)U>O*[E4]ZK^
MM?IH\>JDE9+I0I5.FU)8M7@SNIZ\NIG1>E[P3ZW6KO<LR)*Y,5_HQ4_9F]$I
M*:1RE=8D0>+/@[I5>4Z"H,8?0>:H/9(V]I^C]'=L.VR92Z=N3?XOG=6K-Z/+
MD<C40C9Y_<FL?U3!GG.2EYK<\?]B[=>>3T<B;5QMBK 9&A2Z]'_E8_!#;\/E
MZ1,;IF'#E/7V![&6;V4MKUY;LQ:65D,:/;"IO!O*Z9*"<E];?*JQK[ZZ-46A
M:WBY=D*6F;@U9:W+I2I3K=SKDQI'T,*3-(B[\>*F3XB;3,5[2%@Y\4.9J6PH
MX 2ZM0I.HX(WTV<EOE5I(LXF8S$]G4Z?D7?6&GS&\L[^%X/%6^W2W+C&*O'O
MZ[FK+;+F/_O<X ^9[3^$*NF5JV2JWHQ0*D[9!S6Z^N8?DXO3[Y\Q8=::,'M.
M^M^/V?\A3MPK)7XQM1*3"P$,$%GK(8>BS&6M,E$;D:NES$7:WYH(F8@[A9)Q
MXO-*06Y1R7)#B[(FQ6&ILC5@0YB%T#5)<TK:=#5&53T +2I2:<PJR0RIKRD<
M5,.^E'5-ZLD:1^.(3"QDJG-^,QD<)W-G_!HG'M1*I[GR=IIZI:R0SBG FOA0
M*9)>+N/:Z\(T):N5FF6I_\01T+7N)'_KR%7.Y#IC+]S(7):I$O=4C/Z(^QJ?
M>,_"R' $]D!2FC=9%*GIE,K8FK0QJ69Q:UVOA-G6:JV0FJ6I@0&ULEKF.YH+
M2T!T;!;'#5YX\X3$KO9,DHQS/[#]I2G3QEKH&-9ZCWM1N9;SX-2A"&R_3E/;
MX%$]HD&X@4^CP,%V?+IS8F]!(M[IDOT7+/VI%.\I'5#XDY?CON,%ML(-I 4R
M3XJ/TM8ZU17[5EPOK6*?>P_>7',.DGMN[F_'XN[NEBP4<K' R7 B1>8&!]/?
MZP(^366[XQM95-^+6UGI&MF-K>)P='-]-SJ"" =%$2T;,E2X39EAKQ>8*\"?
M=>(0^,P-" F]B0K=>6M&7!N=]L@2$KQ&BJY$9<V#)D]3S1V\G)XFIX#_/"<+
M63YM7;#'2-&%-04+W97)$N@CF?[1:*?K*$+.#?+&V(V/'/P!YW=51#'^+*W=
MU&9=CL4O:+"_H<&*0];]G5^W&1TEST6*BV\K7%Y%.O,3XI3143LQ@XNJQKH&
M!A"Z>)_T!8>BI[>B*MX)V,L62WCG01UO "D"QQ=!!L6%TS=J/)T.#)A.GTVU
M>T7H17G"<KP1KN:"?=8N[[7AVM%1S]PVG\+2.W[1)82D(U&<UHL(9:H>:WJ;
M\=/G!"+;=\JSQNV+SG,6/E5H6\8]L:PU5Y9?>L6&U$JN$W; -LPON0'XM'ZR
MU$(1H#YUZ6I=-QYA)6&J!S6]+)7:6XM]T6S#_F+TON?#H_MYN0'4XO3\2<<,
M?*O[9>)[U%<%T)&Q3<9N*^.GH1O(7JALC &U50L(0O7 :X4!1GAL)NA?(GL.
M]9%0BP7\,2@53B@7(&)@8Y=$U'L:2Q67A1C0PBV0VD8HTHZ6*<8:?N2R#,]=
M3]V;QGV XR*!/UN%@#F@ 0$C,#$@KW.RF=LW!A&X!/D"'<@!JB%D1OBQ9HY<
MQ_*L\65;R8V<Y]3EQ*+)<Y]MAQJ.*DRF%QL^W_9,UAQ>5\-)8J-53A9"$[3S
M* IJTL)^6G%%RC1%>+C=M8E([G!1]! IAF7K659#26CH)+:7!C"$CD2.J1(:
MZQ]K^1C!(C1GXY@0:.YP<$\\LMF''GTF!;L8,:Q"([&>]Q7RBX)[0/E14]"E
M)3L8E73J2S!#LGCO#T*^!9SP.K5E#IO "4@Y!J0'J,J^9,]71-G*LBEB;:Y1
MZ!P>[;,>SBG#Q-=Z=L>9!J'GT[+?,6+A U.J8[:">L=:VNPXQR#)6I/&?/2<
M.X[Q'! PV9 +/CPH6Q+A"O2%MGRBU8>C^P_O/A&&5'GC^+"JRH%:9 KFWR4S
M/V0+V4?$+BK;54*FYK4(U([+QQ +R4&.+:"1/S$^0E]%Z#V-*G YTLQ4O#P2
MA1AON(FG9WI8-):SQS<<7K87!?Z2)E_)!&[?%)R,R0IL[O )\=<F&PO7S'\/
MJI$$1-V1= BD8MBNN0&.QC(HO?A]X\)*!H#WCJEPIHU'/0%@6S9@\:$\(A*3
MKOAU'\SF7"H^K#L9S^?V0 N'EV1&A+1X8-^^;^&L!ZIW)SR\_950C#U.!AI/
M'FK*2NJLA3)@FRE#S\5*[[>^:A%C_\Z9V[6XK\-E)FT"D( .S8^$4R&HK0L9
M&M#++,&VQ1LX9:Y6,E]$__A&D?",!D[1DLM!4\L[=-T*X !D@19I3DR"48:8
M2NAL85H1(5]B$FWE#\'TWD0(CF/@9S!@.-6H>DA%YL\!JM$Y7@WUJ&RJ 40^
M:WM<8&D8B@+0;I=4"TYD%XGK:!.WAG:&3"&F]'WJO@&^=NO:3X;5%&C"K@">
M&%&GE"XU!, 6IT$/I.VJ-B[%X$EEC_#LS-@'+\_[O +DZ5+< GKAI3:MAB5,
M+8$[00' [7HLY; CDWH:<JMZJU)5S!&(>,V4/#O\/S7R]Z]#NE%L>VQFW. F
M,*<;T20,Q8A^V=N5*9=:/:=DFT/;\59V91BBXYQ,5 *ZAE$1%BV&<_03-G(0
M\3"!L;LK#L%1@L?=D;@-N9_Z:N;MM'4XLN^]>/AH*3/J#;5!&:]SB#^$VYT2
M?B.@/! 7H(]G]/=L@K]#R?V+A*<_.1">@N+OY+OD)<O]NH;,H2G.EB)$^E 3
M28% 3>#;!1)3_RGCX'PP@?19FY!DT,'D=)9\U[WU%9?S%%?%463KYB,0M-3#
M5JRO!687LT9]O1*_41_DZ]7G8M8%Z7I+_WU..!"367+N_\Q 4".O+?>X&2ES
M(283V'L@SBZ2"?Y,+Q RG\BZ]-\4^$O[04%T-3T$SU >;MO0/7G96849&_#3
MW7IQ+SY$@1%-@/VS9"I.\8]N=+EM,H>;)9>S%P(&7+X O(&0,7SP[-BI_;FO
M!K/>CNM(=(T- K,[MRSVYN7FU59<GC&*LG]&>83GF3B[A)OQ="ZX(/!T(<Y.
MD=8T\2#37V+A9V:$Z"+!2!4O[EHF?OGRC ):5(V?"D-@#R?G>/\H"-A2N2VD
M>4)]A"]E86@>;HQBTM_IE$9%N.BZZT+7COOQKGOB[2YO[5WPTA"*_'1[KEV<
MGYO;G>F."GFK0G\HYHO30/)(G*8!J"E1;-9Q"O?'(6.76.&KPU-!-VBKL5^"
MIF_B/. [(%_1.;YL\*-(9-0+U;(&YE/S3=\V<%=E'W3:K0E7?>.>20&J>$GL
MM%@'+JAJ* (MTE5I<K/<1%^JK$?#.OW1Q6G$]>$86E9@<@RCW#;MYZ&RH]^1
MY[77^[5HJC (F=1?YJ9\" TS!N/.HJGI.Q2H1OL.5;),QMT>F:XT/BH"8X^;
M^EG!%,,4!;$=:(#Z0=IB2G-'Z%>M9OEFNS-2SAP''Q(UK(.P$R+PG=/ZEXO]
MU.$XQI#W LSD[!EG6;.1>4@M,@1@P 'UL!/W2_C.WV2<)N<O:.]DFIR^&$=>
MP.X:B"?BRRPXF$29MQED I[]MRG[\J!K,X.4V#OO]()KE2[F\%"(T#S7R_"]
M!5UC<2+D[?6Q$_>R- O-(;N1&S\C1 #H:3 H7R "-%]H*GS-2S>!+](]M*9S
M_3@*OR%8E7$JZ;Z+.@M7O.ALQ)40K9S&!B9-5>QS@_/&T8/]VN_[Y-KU2!?B
MX<_QUY)D19.S369>A[:S-C;/UBC<7JG>:7R\,<.D1'YT/@J9PO,*<8T0/N$D
M?2V% X((?TL4$IT3A(COUO4M?</DY6Y=XD80D5OWZA:,PN3'[S<$KO?(YOF\
M@Z4?@/9)?-=_\W&/F(_%77*7W";><1] /#^N)%IEJAI,>*C-6X//[FI,)#C;
M^Z>G@D_&%L.X(&'HNO0S)]6E>@1N.G\MVY;NG%Q$DYH/,J>3X<YFF87XF[8^
M<^ PD ZA$EA?GAQ;G_ZZBY!#EU)C]^GN:<N@MDF)2]0KQ:Z+_G;D(,^:9KG:
MZ?%GWH,#<5/" 4:$GV794#W[M;,GI5PDX-3A.N+G)H\;IN.^X-(/.EXU)K@.
M,5.9OV7(-ULMJ9=)(*/A%HAY5/B^9(>NC ./#8SV=.C%EDW'9 _?$8K#0*\'
M ..\ P:8XNNNO3 [H@*X-9X.+XW),#&:/ M?5_NW=]D!(1I]@8].5S8+//A[
M2*+PE\1V RD;BX.+BXZ]>Z,.SB_Z*_I\?=S=! ZKUZ=Z[&;[N$FR[]O_D]ZO
M-]#OEOP;%<)8]%S_0X[VW?9G,-?^UQ_=<O\;FO=\KTAWZ ML!5D\'_FRB"]J
M4_%O0>:FKDW!CRLEH38MP.<+ ]@++^B ]L=!5_\%4$L#!!0    ( .I*1E:2
M.YV/' H  $0>   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;.59:V\;
M-Q;]*X3JMC8@2R/)=IS$-F [*=IBTQIQTL5BL1^H&4KB>F8X(3F2U5^_YY*<
MEQZN'62!!?9#8G%(7M['N?<>SERLE'XP"R$L>\S2W%SV%M86;X9#$R]$QLU
M%2+'S$SIC%L,]7QH"BUXXC9EZ7 <16?#C,N\=W7AGMWIJPM5VE3FXDXS4V89
MU^L;D:K596_4JQY\E/.%I0?#JXN"S\6]L)^+.XW1L):2R$SD1JJ<:3&[[%V/
MWMR<T'JWX \I5J;UFY$E4Z4>:/!+<MF+2"&1BMB2!(X_2W$KTI0$08TO06:O
M/I(VMG]7TG]RML.6*3?B5J5_EXE=7/;.>RP1,UZF]J-:_2R"/:<D+U:I<?^S
ME5\[QHEQ::S*PF:,,YG[O_PQ^*&UX3S:LV$<-HR=WOX@I^4[;OG5A58KIFDU
MI-$/9ZK;#>5D3D&YMQJS$OOLU;U5\<-"I8G0YD?V_DLI[?IB:"&9YH=QD'+C
MI8SW2!F-V0>5VX5A[_-$)%T!0ZA4ZS6N]+H9/RGQG8@';#+JLW$T'C\A;U+;
M.7'R)GOD><O8/Z^GQFI X5^[C/0B3G:+H/1X8PH>B\L>\&^$7HK>U0_?C<ZB
MMT\H>%(K>/*4]&<'XN52V*>%8+<J*WB^_M&PC\)8;D7";H6V<B9C#)B:L5_R
M6.E":4[9TF?<,([D0S3[K-!J*1-A&(H LY FC2EY'KM]9<&L8B<1T)FFE&AF
MP>$>FKI-N3'LFCFM((9KMN1I*=A!-(BB$2N$]JMQ7)ZPR7BG$)5E>/"7,@;L
M?O?!#$]9K/(EV3M-Z3"+\];,HKJX 9FD"E<EL)E&WH5,YC!MMRJ,2HJ?.X9;
MCMTO*A#2#-C//@+;JBSX4C!-E<(XDPLMES(5<\B'@W.+:*3DSO9)(9Q,/,:B
M(&6AL>#QPA_>/D-B$638%-&%$"MRME06LEN.7BUPWN;^MET;0E0NG)"VH[LV
M97R-5>F:305#;N5F)K3VFTTA8D ,@SNA,VD)=I_"$B&,0QE**$"<#-CGG%QN
MOP:LW4U3Q75"JQ*I4?P5? >C>&D72LL_O6:$8!&P.]D%NSMT!V]'0)[$K-"2
MM%Y)NPA1[+="Z%'\I>2IUQ0"G2CO;+<7UEKR! QFT[73>UO;@&087Y0Z7J#G
M0!LUUSPS,)S]II8BF\)5XVCT^AFVMPP/@$4WK2477C+YH?74.^9@-(C8-+@F
M9$9S5!LU U=D]@HOZNBW1- )&7]H;S"8UZJ<+Z#IDL-AJ%XX-Q.P(#$4@S@M
M$YG/&;&28]"(!_ 6!SH>>W\?-FL@E<J4I8,XK?)/4X[,39#O4$<2+P"4$E?-
M7%P_ELB/430]/1Y5-K]_A';Y7+#KV![YB .'0'PNYLI*!]"V$GT2"N*AW<RF
M5S ]32EQ2*,*-0KGZ*XET"V&IU*YK=OQZ'R7;@-V[0"'YND1$AIHU$$)BE#2
M4L?'A%(>6G8B+BU;\<W$:8.D3M@0YP'!\U>>EZ!W=.[HOXW.TV^"3F=D04T.
M2@2C %@#I@JV  !)GB+81J)*H/U0986X3AKN%XX(QUI.R;PI=NP+T>@E(>J8
M+6W76-\@OBYV+9M>'#Q*JD02=-'"7A;(R3<J,U\7R'WBS';L/C7^0H@,RY4C
M$2R%1.OR.(8?T <3:< XK,Q+VMS0C7WA'_?9P:N3T\&X[D1:T)6*=B\YM 5O
M<>QKJYBT(MF)7A-74MHZ 5.Z@X7[%X)F&O/-TWXG.+7AN(4>SV;H0:R,K81Y
MT8YSH .NA-.<JBV99< $!#<E2D6([3\$@N(N$%W_' *9P2WFR'G+6TB5C?U6
MNG4X,1@R&4P8 6HT.&.?E 48*Y7"@@,V[D>O7P_.\6O4/SL]Q>(#]NKD#'^[
M]6ORTOJ5XQ;Z(NAWL^;_*A'NMY!,1!);,G1%-M,J\R)M$(W-&<_Y7.!68G_X
M[GP\>O76./E:A"M+@""64Z.G(<]4F;O@T\&F! S;)Z[@:Z=EBY4Y@%=4D'I]
M#-8<F 9,\<$"J$'Y$#(M<,?23J=.)]=H_TOB'C-><3J>JYED/R$<CL#,'*=%
MC@/L2R1F03(09&,=RT-7.>_V!!(>A&"ET(Z^! S-0:=I?\BU/AE.AWA6L<"!
MT [1RHF0!"'<1PL/5EPN?0[Y*8"-",HQ,*JFJ9P'*MMD?;@9.I5T1=$E;E@&
MMC;:P+5V)7 +V6,&;*=BX  (0*(VA0FZ.N!0,UN[]C:K?-92QG-P03<,1_#^
M)J>6KQ5"V3@S=L[$@4-H%0=ON_= ""+"CR!!&@1C?U(6,BTS/G4*PBV%>) T
M!)\LM7<V<7L-SR-UP&@E*&G-5^]Q-0L5*_*<B_B]$<AER']6C56K<"OP3ABP
M=Z6FS9[ 59&GUUGA<@7A#>@K][865#COM\Y7I=Y@"XVKZ^!O^]N[*IQ+6=1X
M$==!Q -I (^GZRYDZVJ_NS/0O #TDCYP &(SH5(<*GU_NT,@1K5#T$B;NNEG
M[^KVY(I'<!A2Z0-?!R>"80K*8:KO:H;[7<C$T:0?C4[Z9R=GSPO5(<WU[FM9
MOP=9O2.V$&DKB*X2.Q:/"I,XCH4]>7@EZ3!,HK8E;:1^:IIP)NQU_SPZP[_3
M2EO?C@#+MN5$%UQM0#K.Z=Y<U_6F*AZ<MCI.L*KCS-Z1HRR<4JU,Z_AM*UP#
ML;N_!BX*=:%<:9U1KE?,]3GN[M=U#.:<1%$_BJ)J8T5VT0,"7:J%Q:DR(;XO
M4ID=<E8H7;T.\N0E6%$Z>(6W8+.FE%?%9;OZ;+3.HT$7D9W4W:SJ5&6=J-"@
MGUEV*\)5O;;;W0V<YV:*RJXK@?M=M!E16DH->!R])3*1& L N0>CM_Y0XUND
M5X/Z/[UR+1WGP/Q"3A&Q"J6$6"-0;$,=KJ"LZ/5;/1*/\+ 7I=(-N/1913%<
M(RD*.J9U]\=2&0@0P*PU79==P_8)^+MSRRT\@0CARDZL;D^>-OA,00MR2B6B
M.O56]YVA[GYNVPU?0WH%F7\K!+>#$B\@RX2.0<KDGUZ(*JU!Z-R>S[EKTO<4
M;N.IC)53E3A?)B7:'[A6(A,W#7.O\SFN$_Y<29P5,*6*5&&TUP2M]_QP!3LV
MHB7S68K"'XM0X7>%AR+)8Z))M"E36OA,'D??;^<]&4[J=;OFQOM<V+-1COD#
ML0PU%Q3+(^*GL+S2W8<P3<.=BAIYD?*8+L%P@K];<YVBE[GZ=BB/?'K+&>+'
M\YS(D?$MP_-+QQ5Y^WUQ$_3#<-FA\U0,ZD!<LKZ9^=O>Y(A\<BAQD,_)YCTI
MD %@#D 3-<WT-X%,O!#W&G#+%F))D>LF^]VL9S&HW+.93*7#AGM!_6W0 $VR
M;Y&Z^[!QN@,:_UL@$(^%#*Z'#7ZK?AH:?Q'S71^1AJTO>R@1<_?]DA@%M/8?
M^>JG]2?2:_]EL%GNOZ]^X'HN09Q3,</6:/#JM.??85<#JPKWG7"JK%69^[D0
MN(MI6H#YF5*V&M !]8?CJ_\ 4$L#!!0    ( .I*1E:D7A_"&0X  (4M   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;,U::7/<-A+]*ZA9.Y&J1M20
M<TAR;%?)CK.;JLU&9>7XL+4?,$.,!FN2H$%0LO+K]W4#O.:09">I354BSPR!
M1J./UZ\!OKPS]D.U4<J)3WE65*]&&^?*%Z>GU6JC<EE%IE0%GJR-S:7#5WMS
M6I56R90GY=EI,IDL3G.IB]'KE_S;E7W]TM0NTX6ZLJ*J\US:^S<J,W>O1O&H
M^>&]OMDX^N'T]<M2WJAKY7XNKRR^G;924IVKHM*F$%:M7XTNXQ=O9C2>!_RB
MU5W5^RQH)TMC/M"7[]-7HPDII#*U<B1!XI];]59E&0F"&A^#S%&[)$WL?VZD
M?\=[QUZ6LE)O3?:K3MWFU>A\)%*UEG7FWIN[?ZBPGSG)6YFLXK_BSH^=34=B
M55?.Y&$R-,AUX?^5GX(=>A/.)P<F)&%"PGK[A5C+;Z63KU]:<R<LC88T^L!;
MY=E03A?DE&MG\51CGGO]3U/<G/RD;"Z^+U:J(!.)JTP6U<M3!_$TZ'051+WQ
MHI(#HN)$_& *MZG$NR)5Z5# *?1JE4L:Y=XD#TK\5JTB,8W'(IDDR0/RINUF
MIRQO>D#>]49:=?(&3DS%E;Q';#EQ::TL;A1__O?ELG(6@?*??;OWLF?[95/R
MO*A*N5*O1LB.2ME;-7K]U=_BQ>2;!S2?M9K/'I+^>6[Z0E'BIXT2;TU>RN)>
M;&0E:K)31L,=#=?M\)*' Q&$PY2RMJ6IE#!K<0-;.EW<"/6QUNY>R#MITTHX
M(U1>9N9>J8J&N6ZA,8G-ZI0FF?5:KY2MQD(6J2A,<=+.Z@_K/Q"YRI>8LB7U
MZTHL#9:FGU-M@0 &8XZ0+(P&MRK#PJ,K:9U>:4QPU>@XXOWW?T.>W0-X5HKV
M'+8"LZ2*S &KIF*)+8J5R7/MG&(+:(0^ #.E</H<W8P=DYEHG/KD:+:LW<98
M_9M?IJI7F]Y*=]IMH%I58CK-@]D<$'B@/LPHTCJ[[TMJ[;9E"UIW]+81WQAC
MZ'' D;7X#HD<&="JMRVA*_YZK58&WKO,R0@I>_*]JIQTBC[<J$)9@/$5,C%'
MLM305F90%;$8(<WCF3@4G^*(E7Q(/L\?SJ*M?._$'?R6F\JQ.WD+,C6E"P)D
M65ISN[,E>*HBQ-B8+"4_PKX HDDD+EN?]F3VQP:),A,I%!L_:I@]B@L2H&ED
MDV>ZJFJ),;1V79+7DR2:HBAD&=4W7IX5(S_BAVMG5A](Z29.\,A',4R">IBF
MF@KC&,(P6GTJM97^!ZRX5MK5%JI7['3L:8PAJPUAY5BL2(\L"\-)/\X(_L[+
M%"'WL0MUJTU=P>(,#MA/3=)X1W]:D#P].KQO_H@U?[3Z!B;(#JT3O/AP&$PF
MCRW#8W:ED\5#!%3U\K\!%A@UO"/PB%R.50+,E 9D [X*L^2MU)E<9HKCC7W5
M\]1G!J^'CP;]-](QE"Z1+S)57RXV% 'U0AS)XQXZ51SIR&>$7]46CX^US/1:
M0]3@^5@<+8\I)YS5*]<^]<KBX>JXETHE AX4+(PY0D08HJ(*.<&&!*SL2*H+
M3>![M]$P?MBW Y$]H1 HE64F#=U/B$VFQ[[:':7'PL DMDW1RS:'FL0A64?+
MVA'4%H9P!U76*W),B_0<?PNEJ%;R$@)Q3=:6CFH$,YTM[*:==HJ)&X.-4NJ>
MD#.6F0:_[(.CKQ)10!AOU\;;/G(&991F66+'I!G8 E $=.$ 7B%62IA3;=?9
MP=)C7P#5)V57&K+"#(XT"G1%OJ?5.)05XHGB308SW"J+?J.!\ TT8Q>@/X&)
M[0?5:K!3N >:!JL2PK?<)R3I#U[,%8FA"O1C"$URBT"E@9?)X-HP"Z#@>'BW
MC$XR XB2H:DT"&"U)/<B%H+ M:GMR;V2-HB.&D(7. ,';[M,%;A&@_KM/I1$
MV'J?>@GH-G1>YXSQ-*#),[;V!M9$[*G@_P&\[X$J#[</0>7X<&78.YI&? F4
M["- 6X1X=,RD!GLCJR(EW^\'C7TQWT5W#Q^&X0.?911SPUSI9PBA=P//COV.
M>'HH4I"2_3G(!  A.IJB F2UX-[&W@.2Q-&HP1 _F,+X>F/JK"&1C"--W4>,
M @J)9GC$U3XWM@S*%$*5;I=%#]?&;$ HV'&ULLJ#"]S9@S=.X[+,4*-I4UNN
M3<VJ)NTJ[U9SA^2I-KILF$E=T-:P\($B '#),D;M8#G;5<V !1$1A5YE"!,#
M9^.1/;<.$;#I*':B =O,35TP45O):C-$;[#)6O4@:0"9R/Z:^!IG<:_Z4@!O
M\X%FU[X8:K8)NV_H!*HV.N?.3KH]2.?Y#,!U[8@<=OV9[,5!!W*]H E,"#BC
MU:WOO/<5(&R#JJ8WPOXJRW&Q4U(/#J;*0.@FA;LOU6Y]#Y25XM(-F>H7\9_M
M_AHBN$GC**DZ#/4PT-#\S@.$!2&@VAX@SU6JR0]-=K:DWM-XM*/,T2F':#WK
M2=Z@X^;L6W/J[<_3IL/Y%I%*+6Q[!C/V+A=W]">>1Q?;W<>018:8Y'BI?H\U
M_V7:=@55(^QW/Z7\PJ)C'NA(]JHD&_K3U/:?""RD3RO8]=9DM^2?:@]'2FM+
MC\BB/<T[FK$=.!2X_M24F_C@-,=V7M*Y*BQ4LZ/@M&OOB2.T>,$YU;'XE4\G
M57IR&<C/NX8Z,4?9??Y>T8DN:?F6*\C*$:/BMH0D<T$\AJ+(LZ+2*_$+H]-P
MT1]K!PL6'A3V!E0LXO-H(IZ)V70>S1=LD1?B[X'O)OSH;#*/)HGXSO>D^/EH
M$LV.\6 ^F43)HMT)'LRB"3V8GB?18O&$Y1.*X04M?QY'BT0LT$YC^GAQ3J']
MBR\2% J@28KA)%#KA^3%).]L$<5SR$N\O&D2G3>*LM<.SI_X^0GV>";F;(!D
M?'$10Y_^\5P%SE8!8:MA?#6$N/+\N%!WV3V?&Q 2MHSD,*?UN.6,@Z]UZ]NV
M\@S[+-4:OA?/WJV>EM%A"9^\/(NC!"FT])$QIN]GD[/N.PU^ED3)/.Y^"X<6
M3,^:TZBA0E;Q06O3883:"3+A.R\^GNG1^6;GG'#9?9>;Q$E4VO#A?D?A"<.
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M?.0O]9HOSI3\HNW2.&=R_KA1,E66!N#YVJ C"5]H@?;-Z]?_ U!+ P04
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M>U/RY59)Z  MP.\;8WS[A0[HWGQ?_1=02P,$%     @ ZDI&5KHHFCR"'@
MQ&<  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULU5U[;]M&MO\JA!;8
M. !C2[+\VK0!;*=IW":U$3LM]E[</T;D2)J&(K4<TH[[Z?<\YDE1DIUV@;W
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MW[2BF,[7Z[':(2J&JGQ<5JUV,(67VCQ4%L=P9(H8#EP2>"J_BBY\\)RREC4
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M51&1W#$044CK%HH#?G @I(82RIG^L)_E#6>_ISIUE(QC 0<F(7CZ Y',(3-
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M@S.R53'6R,S!G,;7)(_5T?J9.GSLT.&1!NB#^*K[QJ>JHL=G(U(NNG#<$BE
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MC"-9V)*MNTD$R&EL4UQ*/;,/)5V\#,#;H&0'SL%AQ =,AHFE<8'( W3F"MS
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MUA%Z1^V*3'E:/D!WE5([]50BP3]%:CU3PBD8B]*3E0U:E^(U%_P=]IDJ(<C
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M![55F2-@\U#(N3YV'<D"Y5/?S@2/A*(!^#Z1LJ@>B$%]#G_Y7U!+ P04
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M&;H.J'2PPK\D7P>.SOV^"7H_?$8>-0C<9KC%X]CSJ\SIVW4N#:SAKE3V\KC
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MI0N:?RWH1HS:.=#WI:)SMS5<@NT=>_XO4$L#!!0    ( .I*1E9OVW\=E0(
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M;;L5O9"HW0**ETK9W<!MT+^YV1]02P,$%     @ ZDI&5E3ZC$)I P  ? <
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC57;CMLV$/T50BF"74#0
MA9)LV;$-K#<)&B !C&S:/A1]H*611802%9):[_;K.Z1DK3=PC+[P.G-XSI S
M7!VE^JYK $.>&M'JM5<;TRW#4!<U-$P'LH,6=RJI&F9PJ@ZA[A2PTCDU(J11
M- L;QEMOLW)K.[59R=X(WL).$=TW#5//6Q#RN/9B[[3PE1]J8Q?"S:IC!W@
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M962;2$O=L0+6'F:*!O4(WN;MFW@6O;O".YUXI]?0-P^8F&4O@,B*=).&;M(
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M;"]W;W)K<VAE971S+W-H965T,S8N>&ULA53;;MLP#/T5PKM@!;KX$K=-LR1
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MH!&5&X#NADEG6%7[!MXJ2^/ ;TN:OZA= )T7BBKK#9=@F.B+/U!+ P04
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M7<\(X2/M:-IF\D K0Y-JOB05ME3/V*U-YP63.]BP#*0"X23I=M/4^4JBU,2
M&5AQZ9W:GQN70.(7YDLRM.>89P5-HA 6_Y6XN)-4CT)0:S&7<".8,7S%4^9[
MC5=WJO#^T!1HUR/>JM7;TL5M#%("[S5U6&UW72@H5;;KS>+GDA>.FUV0E+<+
M=@D=&,7]<.#&043C:V3!V9(+;AUWSY]T8$P8?3=&[\*QQ_VVAUND&W+WK-T-
M.7\<W]*TS,OJ.HE[VO*O5>QTUHD(/=FGQP?4B?I)^.YEZQLI[Y(]4Z!OV6(7
MMM3*L*F5X7?72A5JJHSU!I7G%Y?5)X[<.U4-[>BOD^B0#?W3I\OX9#ENKI0@
M-E.'N8*_D.FJ+[9QZH5$BZ/\GKJD#D1).*R&!.Z([I1!,BY/T( H/8(HHOOH
MP& 41C3$(Z+4Q^-$'!=L75\_'970OGS-<: GZN8EJ@=TCP:2JT'(XQPNJ 'L
M*#T4?Q+&T*>?:\6N?D&3*[0[2=X !3!YT\**4<.*T7>S@D(N=94@6JW.%=$I
M<K0:.?T1>#K,%'#J0GL'=D1*)G;$G3UUSJ5][]7NZH@Z+7EW#21QI4CS! 83
M8@+-AN!["LU&,.A39Z#9F)K%F 2?E&4"2IG5]T!TJ,P7;%=]/B?C@>-<7I36
MM_":>Q?1D/8O:X CEYM>=.H6>P</FASUVC_;7$61^>IMT^PV+\-%]2!Z$:^>
ME1^87G-IR/R*5"DT*F1=/=6JA56%?QXME:7'EI]NZ'6+V@G0^4HINU\X \U[
M>?XO4$L#!!0    ( .I*1E9FB"G?N0(  -4%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;'U4VV[;, S]%<(KUA8(XDLNO2PQT*0=UH<.09MM&(8]
M*#83&Y4L5Y+K9E\_2G:\#$CS$)F2R,/#B(>36JIGG2$:>!.\T%,O,Z:\]GV=
M9"B8[LL2"[I92R68H:W:^+I4R%(7)+@?!<'8%RPOO'CBSA8JGLC*\+S A0)=
M"<'4=H9<UE,O]'8'C_DF,_; CR<EV^ 3FF_E0M'.[U#27&"A<UF PO74NPFO
M9T/K[QR^YUCK/1ML)2LIG^WF/IUZ@26$'!-C$1A]7G&.G%L@HO'28GI=2ANX
M;^_0/[O:J985TSB7_$>>FFSJ77J0XII5W#S*^@NV]8PL7B*Y=BO4C>\@\""I
MM)&B#28&(B^:+WMK_X>]@,OW J(V('*\FT2.Y2TS+)XH68.RWH1F#5>JBR9R
M>6$?Y<DHNLTISL1/1B;/F>0I*GT*=R]5;K9PMF0KCOI\XAM*81W]I(6;-7#1
M.W!A! ^R,)F&NR+%]'\ G[AU!*,=P5ET%/$6DSX,PAY$010=P1MT!0\<WN =
MO+;$7S<K;13UQ.]#1380P\,05B?7NF0)3CT2@D;UBE[\\4,X#CX=(3CL" Z/
MH<=SSK0&N09#(M.5VH*V;W2(YE&@PS27&8*QKPLK*\A6C/D?U&#H2F>,7%UV
MVLVE*%FQ/=76$J0AURV0&Y)C6:DD(SFD4-%+*^=?*KE13&A@1>H.$JG-#JR!
M[D&=Y4D&-2HDE$0J:A-@&I:[:EV./OQ$IIHF FH!%"O*8=O@[+X@'7!.DM;G
MKBGL$MHE@*^5\Z.,;2&#_H!^ 83],2RE8;RCU#J<0-0+KJ[ZEV2%O?%H1,XG
M<#$<T_?08_I[4A.H-FZ@:$*M"M.HKCOM9M9-(]5_[LW >V!JDQ<:.*XI-.A?
MC#Q0S1!I-D:63K@K:6@,.#.CN8O*.M#]6DJSV]@$W22/_P)02P,$%     @
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MCAI^ACNF%+.; :_F:!A/].NA;XB;7<&/2A[3@D=XAD<0PCLIS$;#KR+&^!C
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M=S1[',]T17/H>WC>-*@E>-G'#]TD^+*K%'LBVRI,U!8F>HN]+0P>T[7X8R+
M[!)=,YTX)GME++,X"D\[)ZF_W)3STBT)HJ03MVY;B?;:1'MO)OI5T0)(F^[?
M7NW*]$VJ?VW/GLBV5,>MZOB_[MMXGX79$]E689*V,,G>]FW-%&]LR"@^39[M
MVI=.<1!_?K9G_8W;U[Y\MU3-&/:#PQ1A0><$\:I^36K#R,I=R!-I\'IWTSD^
MP*"L _Z?2FQK8]@[OGW2LS]02P,$%     @ ZDI&5@\6Q*)C P  3 \  !D
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M8'"+'VA9M6[51(O"-C,;H;&CL,,]MKL@C0%>WPJA3Q-S@Z:!7OP'4$L#!!0
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MMBY5L:R#=0^6:;[Y/_E1GXB] #]Z(2"H X+7!H1U0/C:@*@.B-H!XQ<"1G7
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M1C;;R+W)T:B&";N+,Z-PEB'.1"B?T[E4U)K:(K<LQAV"%J$B(=_,$A09+Q0
M[IO1Y!.9814E:PY$IF0<QW)MAQ\@!K:A<QRVL"FDH!0D.+X!L09R(XIJRU<8
M"\/F,GDA>RN3\RD8RKB^P$4>9U-R?G9!S@@3Y(YQC@%ZZ!J4:Y-VXU+:52'-
M?T/:%.(V"3HMXGN^WP"?O!_>V8>[:'+EM%\Y[>=\P5M\3-,%>KDH!*.!.W]^
MWF(HN3&0Z5]-,@O>;C.O/>:7>D5C&#EXCC6H#3C1QP^=GO>E2?2)R/8L""H+
M@F/L454QJJJ8%A%@FD073/V<R7Z*-E$8^(-V?^ANZG(.PWI>T&N'5=A>HMTJ
MT>[11&=4R)2]*M'J(/PMXJ;$CS+_ZVZ=B&S/A+ R(?Q/!1N>TH(3D>U9T*LL
MZ)VL8 NF0;T2/_OMX%6]'D:%7K<]:"[7?I5F_VB:U1=7%1O4E%[_X*!T.V%M
MX2*]PZB@5S]T17IN[;ZQ=_T=50LF-.&0(LYK]W'/5'%_%ATC5_D5-)<&+[2\
MN<1?#E V .=3*<VN8V^UZB<F^@-02P,$%     @ ZDI&5D"WG/CR!P  DU,
M !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULM9Q;;^,V&H;_"N$M%C-
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M9)%5.T!6)U*LRPT('X24(BD/5SR8\ZPHH.XOA) O)T4%VWTXK_X&4$L#!!0
M   ( .I*1E9Q27#@\@(  &$)   9    >&PO=V]R:W-H965T<R]S:&5E=#4S
M+GAM;+5676_:,!3]*U963:U$R1<$U$&D%C0-J56KHFX/TQY,<A.L.C:S'6C_
M_>PD6- &UDGL);&=>X_/.;ZV,]IP\2R7  J]%)3)L;-4:G7ENC)90H%EEZ^
MZ2\9%P56NBMR5ZX$X+1**J@;>%[D%I@P)QY58P\B'O%24<+@02!9%@46KS=
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M#O04HK[0ZX[BJ^I.7'"E;]BJN=3_0"!,@/Z><:ZV'7/-VK^J^ ]02P,$%
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M(U9.D->B+RO1\0'1$\A]DD0=$H=QW (?OQ\>[<,#C*_),&XRC!U?<HB/:;K
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MD<YD@0L255U8-10O3*5TSQ767>8QP5H:A#; \2WGZK&A)VBJ\^ _4$L#!!0
M   ( .I*1E9?PG9SE@0  &\?   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;+6976_B.!2&_XJ5':UFI [Y  )T :EMOF8UG:G:[>S%:B]<.$ T2<S8
M!EII?_S:(:1D&E(8G?:B),;O8SOGC0^VAQO&OXL%@"2/:9*)D;&0<GENFF*R
M@)2*%EM"IKZ9,9Y2J6[YW!1+#G2:B]+$="S+-5,:9\9XF)?=\/&0K6029W##
MB5BE*>5/EY"PS<BPC5W!;3Q?2%U@CH=+.H<[D/?+&Z[NS)(RC5/(1,PRPF$V
M,B[L\\AVM""O\2V&C=B[)GHH#XQ]US>?IB/#TCV"!"92(ZCZ6,,5)(DFJ7[\
M**!&V:86[E_OZ$$^>#68!RK@BB5_QU.Y&!E]@TQA1E>)O&6;"(H!=35OPA*1
M_R>;HJYED,E*2)868M6#-,ZVG_2Q>!![ GMP0. 4 N<G@>,<$+0+0?M80:<0
M=([M4K<0=(]MP2T$[K&"7B'H'2OH%X)^'MUM./)8>E32\9"S#>&ZMJ+IB]P0
MN5J%,,ZT=^\D5]_&2B?'*N8)?6"<:B>=D<_Q1/D2S@C-IN2K7  G%W,.H-PJ
M!?E([EMW+1*R-?!,%Y$OE&OI&LA[#R2-$_&!O"-Q1J[C)%%$,32EZJ5NRYP4
M/;K<]L@YT".;7+-,+@3QLRE,:_17S?KN:WJO6>^^I@]>Z;_3 #!5>,H8.;L8
M73J-Q#M8MDC;.B..Y=ADR@34/95FQI\T4PP[9SCD_LXC[]]]J'LXKV!66=F5
M)HQ_/.;@B()FA@>3HT84'H^Q&S#1\1BK'E.)?;M\/]LYMWV(&PLZ5V_@/']!
M"9N16UA#M@+RSV=5E7R2D(I_Z]ZR+;=3S]4I\5PLZ01&ALIY O@:C/'OO]FN
M]4>=N3!A'B;,QX0%F+ 0$Q8AP2H>[)0>[#31QX7C:N?R1N6I+L.$>9@P'Q,6
M;&&]'*9_6ZY5SK![3FLP--?[!JJIYUH]N]6KUHM>UNMW!KV675:K1+U;1KW;
M&/4\U<^?4_U_Y-8/_2\?K[Y^JS-"(^Q4(V#"/$R8CPD+,&$A)BQ"@E6,YY;&
M<]\HY;F8'L2$>9@P'Q,68,)"3%B$!*MXL%=ZL-<X^5W3QSA=I41RF@E:++-W
M"R&RI$_Y@JC.@XW<4SV("?,P83XF+.B]2& =M_LB'6(V&2'!*N;JE^;J_VIF
M5=?;5?=?>\8K5^!U?FMLZE2_8<(\3)B/"0LP82$F+$*"56PY*&TY>*.\.\#T
M(";,PX3YF+  $Q9BPB(D6,6#MO6\'VF]4>9M!I]JPX+6W4M*SJ!C57.2A]JF
MCTH+4&DA*BW"HE5-MK?I;3>:;&_7>PU$[V%G\]Q@9R1;I0\J_ZK93V]+"C)A
MJTP"7U(NGXAD9+GBDP45H#+U@7W+RZ)Q=W_AWK'T7]4]5\V]/'6N0Z7Y=8-P
MNB\'$: V&Z+2(BQ:U6;.L\V<7]XX:Y:>/%MATKR"5IG[7*=;#;R/VF: 2@M1
M:1$6;6LC<^^T+@4^ST]NBXEF>S!0EI:GPQ?YF>A/Y9Y][MLUY8$^3<Y/!Y_Q
MVZ/H:\KG<29( C/5E-7JJ1#S[>GN]D:R97Y6^,"D9&E^N0 Z!:XKJ.]GC,G=
MC6Z@/&,?_P]02P,$%     @ ZDI&5AU_/:/0 P  ;1$  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3DN>&ULM5A=CYLX%/TK%EM5K33E,X%DFD2:"5MMI8XZ
MRJB[#ZM]<. &K )F;2>97>V/KVT8 AD&S729E\3 /8=[S_4!F\61LN\\!1#H
M/L\*OC12(<I+R^)1"CGF)BVAD%=VE.58R$.66+QD@&,-RC/+M6W?RC$IC-5"
MG[MEJP7=BXP4<,L0W^<Y9O]<0T:/2\,Q'DYL2)(*=<):+4J<P!V(;^4MDT=6
MPQ*3' I.:($8[);&E7,9.IX"Z(C?"1QY:XQ4*5M*OZN#S_'2L%5&D$$D% 66
M?P=80Y8I)IG'WS6IT=Q3 =OC!_9/NGA9S!9S6-/L#Q*+=&G,#!3##N\SL:''
MWZ N:*KX(IIQ_8N.=:QMH&C/!<UKL,P@)T7UC^]K(5H QW\"X-8 ]QPP>0+@
MU0#ON8!)#9AH9:I2M XA%GBU8/2(F(J6;&J@Q=1H63XI5-_O!)-7B<2)E=0K
MPUO*L.K"!?I"(ME3N$"XB-%7D0)#5PD#D)T6''U 5SG=J]$&(IH4Y%^($2G0
MG<!"AR"Z0U]+J-BX+$6D:$/E7$7O0A"89/R])/EV%Z)W;]ZC-PI[0[),!2\L
M(<M125E1G?IUE;K[1.J.BVYH(5*.?BUBB+L$EM2A$<-]$./:'60,(3*1YUP@
MUW;=GH36SX<[/?#P^7![H!JO::VG^;RG^ C'B6Q>HKNA6K.! Q1[0']^D:'H
ML^P9_ZM/]XIWTL^KGD27O,01+ WYJ.' #F"LWO[B^/;'/LW&) M'(NOH.6GT
MG RQKVKU>F=JA0PT4CUJ#W)V.H%KSA?6H2U&3YQO!XX9=./"QW&SR3PPG2:L
M4\&TJ6 Z7(&V8L?R)WNC_Z15"RR%.X <5^:/.K&L4J!/@,$;OW3*C$D6CD36
M$=QO!/=?R8+^F'J.21:.1-;1,VCT#'[:@A5RUK*,[P:F=V; QU&>[YBS,_M5
M47XKRNYWWJQ)?#::\]:4ZQ=I0FG,$:=9W%?NX/U>.D'&) M'(NOH/&]TGK^2
MX>9CZCDF63@264=/QSZM#^V?MEP-[?=)I40=TC:<.YV;_IGA!IFZF;=6ML[_
M\QR0?+MGO%FY;M[BO/P8(K@OU2*8ZYAX'S53J7N]5Y'!E%XZC49E"\=BZ[;#
M/;7#?25KUL1CB3HF6S@66U?4TQ+?&5SQ#KO3>[2(],_?=.N>(,>=M1::=9F/
MPX*9.3VSJ-7:A^; $KV?YW(1*?>,U2ZL.=M\,[C2.^6S\]?J6X+>WYYHJ@\1
M-Y@E1&XM,]A)2ML,Y/*.57O[ZD#04N]VMU3(O;,>IH!C8"I 7M]1*AX.U V:
M+RRK'U!+ P04    " #J2D96R_=">MD"  "U"   &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6RU5EUOFS 4_2M7K)I:*0L$$I)U"5*;:%JE5JL2=7N8
M]N# 36+58&:;I/OWNP:*DI9VG92]@#_N.9QS?6TSWDEUKS>(!AY2D>F)LS$F
M/W=='6\P9;HK<\QH9B55R@QUU=K5N4*6E*!4N+[GA6[*>.9$XW+L5D5C61C!
M,[Q5H(LT9>KW)0JYFS@]YW%@SM<;8P?<:)RS-2[0W.6WBGINPY+P%#/-908*
M5Q/GHG<^'=KX,N ;QYW>:X-ULI3RWG:NDHGC64$H,#:6@=%KBU,4PA*1C%\U
MI]-\T@+WVX_LGTOOY&7)-$ZE^,X3LYDX(P<27+%"F+G<?<':S\#RQ5+H\@F[
M.M9S("ZTD6D-)@4ISZHW>ZCSL ?H]5\ ^#7 ?RL@J %!:;125MJ:,<.BL9([
M4#::V&RCS$V))C<\LZNX,(IF.>%,1/8%6TK%;%([<,UC6B'L ,L2^&HVJ.!B
MK1!IW8R&#["@*DH*@2!7,)694;0,<,D$RV+4'9A+FH<#3CB=H6%<Z#."WRUF
M<'IR!B? ,[CA0E" 'KN&C%@Y;ER+OJQ$^R^(GF'<A:#7 =_S_1;X].WPWB'<
MI?0U.?2;'/HE7_ 2']=L35E:5X8I-7/<8E8@_+BF4+@RF.J?;38KWGX[K]W
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M6ZML;NB_ I4-H/F5E.:Q8Z^NYD\E^@-02P,$%     @ ZDI&5O\[ -C0 P
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MZ0*'RBZ@]VM)>MP,K(/V2CC_#U!+ P04    " #J2D96-D-B>;D#   S$
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MQ0*FRA:UO#$R*WJPM338T167"7;UH&P SF^D-$\W]@'U_P3!OU!+ P04
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MN*3/ ]2N@.[/E;)/$W<"U1\<Z5]02P,$%     @ ZDI&5JH3$5CA!0  K2(
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M^E)X45-<. ;5RG.A1Q'[R%MT>!K,[(FZK&DN>VE>\^S$,_G[@@U/=\9KJA?
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MD-_O.1??#XJ'D.N'SM?_ U!+ P04    " #J2D969Z-A[8H"  "P!@  &0
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MR:?O^'(MK?]GZ]IW0,YY95&7#9AN4 I5/_EC4X<M0'>P!Q W@/@U(-D#Z#6
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M%I&:OFY@)"]B25A2+J)2TV, 9.2AX/':A#V*AOV$C5_^#M8UT@ B".;G'JP
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M-JGZ' ]]OY>/7[2)/C? GYC"[Q.CE@D^C/6&<52?8L"LF,7MBTE!BDI-CP&
M5$S@]G4::-)B3?2Y >#$%#Z?F&:4X&-9[QI'L2D&FHI9S+Z8E*2HU/08 $G%
M> WK=?@;#UT]XT$30SOLH$G<N\J)POT35)8)/AOK+>>H2\4 7S&+/QB3DA:5
MFGX3%I!6PN$/)L,C@.;+L Q'!<\?.4F C1(*HU!,\T[PL6SWDTI-CPR06<)B
M R:D($:EIL< 0"SAL $3PYG!D<,GYBY3#I\D0%0)A4TH)GHK^&#6^\Q1L4H
MZ!(6GS A13<J-3T&@&X)AT^8&(X"&HZA&)HAQU 28*V$PB\4=AX+/J;UMG+4
MM!+ NH3%-DQ(\8Q*38]![Y9.EFLZAY[@\$!*8KC,$[F+R^U?TTEA'PH[KV5D
M4/NK/5GN]G1[EWNZ/+=[NK37>U+)O8B#Z,6!Y8;/3K5_G[?AE(JIF>&8RJ)W
MWWW[UP8^IN5#MJV<7-TWW=QY:]^4Q_O[CR_J8G>X G]9U'6Q.7SZJ-*U*ML&
MS??OBZ+^_J*]5?_T9Q1N_@%02P,$%     @ ZDI&5E:./U,. P  S@@  !D
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MWED6V!(Y^P,IF6$K5.00,ZH ;S2V'OA=,OU(%"2E9)IAFO%J"YV!Q$4B<OP
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MSB!4-O"RB2H'DA6FK;AF4C4IYG*I&D_@.D#=GS,F-P.]0-W*3O\#4$L#!!0
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M1A::DP7>Q/*)[7XG98?Z&2]BL<C_HUU1=]"S4+01DB6EL6I!0M/B%[^6-^+
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MG0S[=O$W[FP/=6#TVE8'9[OUSZX90#8P!((U(CBH(CAH,W7LIX4+1%[7-%O
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MFCE0SOTP"'I^3IGPDKX;FZBD+TO#F8")(KK,<ZJ>+H#+]<#K>"\#-VRQ-';
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MVH1%EF"-V%[6L;W\P2GPTF;0;,)"F[#($JP1M'$=M/%W2($ETP^:*3 8'N7
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M.U:^8W_(5G*F;GK%6W*FTHWJ3?_^-VL\^&=;#R Q%XEY2,Q'8A2),23&D9@
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MBL,UHPN6JP;R]V66B=<OZ@+U]O';OP!02P,$%     @ ZDI&5A'IAC38!0
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M2AM(-P^(IF%5[:_49V7I@O:?:WISH78!-%XH9=\:;H+N%9?^ %!+ P04
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M+2-DF&L+0<QKB9^1,8MD>/Q:@P:U3VNX.]Z@G[G@33!W1.%GP6YIH>>CH!]
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M*(/>:."!;$2RF6A1.]F8"VU$R U+\U]!:0W,_D((O9U8!]V?*OT/4$L#!!0
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M!B ,0._/.5?[B7E \[:1_ -02P,$%     @ ZDI&5N/4D)B[ P  _ T  !D
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MELKJJT;=$'1?';Z?J9!'^>IQ)Z]GP!1 ?M]0*LX-U4%[X8O_ %!+ P04
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M]?N"?=]&L8Q1R<!IUUW?-M7&#(<D_0N_"8<LB,+WMB;LY?I#[T 2+(4EY>@
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M;"]W;W)K<VAE971S+W-H965T,3 R+GAM;*U6;8_:.!#^*U:NJEJI2UZ  %M
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M#?9PQ>L6VW)0U@"_KZ4TSP.[0-WHS[\#4$L#!!0    ( .I*1E;:M]+O80,
M *L2   :    >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6RMF.UNVC 40%_%
MRJ1UDRKR!0$Z0**DTYC:";7:IFG:#Q,NX-6)4]M\3-K#ST[20*:0%<U_($Y\
MC^-#+C?V8,?XHU@#2+2/:2*&UEK*],JV1;2&&(L62R%15Y:,QUBJ)E_9(N6
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M14&&Z%I=N# 0DR+GY7_CNK>^U+E75QF=_H6\[%$7$$>8\J;H&=(USAE(T4I
MVN9(S(N6ER]E@Y.MNHYX)YR33#UN$$P0E09B?$4(/S3D"^HKL/E_4$L#!!0
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ME%'G$N/2=?.J#:M*7\[GRF)S\-,"^SUHYX#["Z7LQG 'M/\@DK]02P,$%
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M5&\'T-LU?[8!>CO5VP'T=JJW ^CM5&\'T-NIW@Z@MU.]'4!OIWH[@-Y.]78
MO;WJ[0%Z>]7; _3VJK<'Z.V;AR4 O;WJ[0%Z>]7; _3VJK<'Z.U5;P_0VZO>
M'J"W5[T]0.^@>@> WD'U#@"]@^H= 'H'U3L ] [-PVZ WD'U#@"]@^H= 'H'
MU3L ] ZJ=P#H'53O - [JMX1H'=4O2- [ZAZ1X#>4?6. +VCZAT!>L?F925
M[ZAZ1X#>4?6. +VCZAT!>D?5.P+T3JIW NB=5.\$T#NIW@F@=U*]$T#OI'HG
M@-Y)]4X O5-SV 2@=U*]$T#OI'HG@-Y)]4X O;/JG0%Z9]4[ _3.JG<&Z)U5
M[PS0.ZO>&:!W5KTS0.^L>F> WKDY+ C0.ZO>&:!W5KTS0.^B>A> WD7U+@"]
MB^I= 'H7U;L ]"ZJ=P'H753O M"[J-X%H'=1O0M [](<]@;H753O M"[JMX5
MH'=5O2M [ZIZ5X#>5?6N +VKZET!>E?5NP+TKJIW!>A=5>\*T+NJWA6@=VV&
M=0!Z6]..ZP#\MJ89V#$ P:UI1G8,P'!KFJ$= U#<FF9LQP <MZ89W#$ R:UI
M1G<,P')KFN$=\YV:C]/';ABO15_K)N [[9XN]P[7W_]<?EUL$?KDNK_-&!__
M E!+ P04    " #J2D96\GX#[W$"  ")/   $P   %M#;VYT96YT7U1Y<&5S
M72YX;6S-V]]NFS 4Q_%7B;BM@K'!!J:F-^UNMU[L!1@X#0K_A-TN??LYI*VT
MJ8M69=*^-T&)[?,[^$B?NUQ_>YZL6QWZ;G";:.?]]$D(5^]L7[EXG.P05K;C
MW%<^?)T?Q%35^^K!"I4D1M3CX.W@U_Y8([JYOK/;ZK'SJ\^'\+-KQV$3S;9S
MT>KVM/&8M8FJ:>K:NO)A73P-S6\IZY>$.)Q<]KA=.[FKL"$2[R8<5_X<\'+N
MZY.=Y[:QJ_MJ]E^J/NP2ATXX_]Q9%Y\O\4Z/XW;;UK89Z\<^'(G=--NJ<3MK
M?=_%IZ)7YY-]N&%[^I07YR]ES@6&G??S.+DPL=E^/.YU),?3ZRD4LK-OS[_B
M6V(H??'[V>.T&]O\97:XWA_CO%_FX<3RN/R.?YWQ6_T/]J$@?:20/C)('QK2
MAX'TD4/Z*"!]E) ^9$)IA"*JI) J*:9*"JJ2HJJDL"HIKDH*K)(BJZ+(JBBR
M*HJLBB*KHLBJ*+(JBJR*(JNBR*HHLJ8465.*K"E%UI0B:TJ1-:7(FE)D32FR
MIA194XJL&476C")K1I$UH\B:463-*+)F%%DSBJP91=:,(JNFR*HILFJ*K)HB
MJZ;(JBFR:HJLFB*KILBJ*;(:BJR&(JNAR&HHLAJ*K(8BJZ'(:BBR&HJLAB)K
M3I$UI\B:4V3-*;+F%%ESBJPY1=:<(FM.D36GR%I09"THLA8460N*K 5%UH(B
M:T&1M:#(6E!D+2BREA192XJL)476DB)K29&UI,A:4F0M*;*6%%E+BJPRH= J
M$XJM,J'@*A.*KC*A\"H3BJ\RH0 KD_\I[/=QW/_C^.49]U4[O.:+Y1_(-S\!
M4$L! A0#%     @ ZDI&5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #J2D969T:$@NX    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #J2D96F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( .I*1E8'_%8*A@@  !$V   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #J2D96F[.M[$$"  #&!0  &               @(')$   >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ZDI&5F?2T'(O!P  @2$  !@
M             ("!0!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( .I*1E;E3NT6M ,  "X1   8              " @:4:  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #J2D96I(.P,'$(   S
M,   &               @(&/'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ ZDI&5FI8-TCY"P  AH,  !@              ("!-B<
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .I*1E8I%.QK
M[ @   \I   8              " @64S  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #J2D96CMM]VHTC   3<P  &
M@(&'/   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ZDI&
M5E@1F__>!@  =1$  !@              ("!2F   'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( .I*1E:C#MOSO2   -5Z   9
M      " @5YG  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ ZDI&5@$7% :4!P  FA0  !D              ("!4H@  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #J2D96ENIMN^8%  !"#P
M&0              @($=D   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( .I*1E;EQ2=J> ,  *<'   9              " @3J6  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ZDI&5C!,&CL/
M!   )@D  !D              ("!Z9D  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #J2D96)GEU#Z\$   $"P  &0
M@($OG@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .I*
M1E:E1(9DXP(  )X&   9              " @16C  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ ZDI&5DE2-8:D!P  3A4  !D
M         ("!+Z8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #J2D965(3(K#\-   H)   &0              @($*K@  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .I*1E:2.YV/' H  $0>
M   9              " @8"[  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ ZDI&5J1>'\(9#@  A2T  !D              ("!T\4
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #J2D96PL;T
MT5@#  "(!P  &0              @($CU   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( .I*1E:J =\E+@D   47   9
M  " @;+7  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MZDI&5KHHFCR"'@  Q&<  !D              ("!%^$  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #J2D963YM&B5D#  "Z!P  &0
M            @('0_P  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( .I*1E;J=-RTBP,  # (   9              " @6 # 0!X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ZDI&5E<;_>CY)
MG7L  !D              ("!(@<! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " #J2D96K*WS/\H%  #3#@  &0              @(%2
M+ $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .I*1E:,
MX+_9 PH  ),?   9              " @5,R 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ ZDI&5I,K_:. "0  4R$  !D
M     ("!C3P! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .I*1E8N](WU_ (  *L&   9              "
M@7U7 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ZDI&
M5GGU8 ;U @  A 8  !D              ("!L%H! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " #J2D96@J>[3[ "  #=!0  &0
M        @('<70$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( .I*1E8G(,/E9@0  #L+   9              " @<-@ 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ZDI&5F:(*=^Y @  U04
M !D              ("!8&4! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " #J2D96ZC;VAP &   _$@  &0              @(%0: $
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .I*1E;8X!;P
MF@8  "01   9              " @8=N 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ ZDI&5J[A:+.! P  : @  !D
M ("!6'4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #J
M2D96 'Z]P8P#   $"P  &0              @($0>0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .I*1E:I6@!.R0,  +X.   9
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M970T-RYX;6Q02P$"% ,4    " #J2D968M9UPTL%   2&P  &0
M    @($.D $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M .I*1E:N)$Z(A0<  .PW   9              " @9"5 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ ZDI&5@P##G!["@   7,  !D
M             ("!3)T! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " #J2D96S^;>&=@"  #0"   &0              @('^IP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .I*1E9 MYSX\@<
M )-3   9              " @0VK 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ ZDI&5G%)<.#R @  80D  !D              ("!
M-K,! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #J2D96
M-L6PZ%$#  "Q#   &0              @(%?M@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( .I*1E:\,#]>V 0  (T9   9
M      " @>>Y 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ ZDI&5LTC3B?$ @  AP@  !D              ("!]KX! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #J2D96-9+L@(,#  "I#P
M&0              @('QP0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( .I*1E9?PG9SE@0  &\?   9              " @:O% 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ZDI&5AU_/:/0
M P  ;1$  !D              ("!>,H! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " #J2D96R_=">MD"  "U"   &0
M@(%_S@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( .I*
M1E;_.P#8T ,  !X.   9              " @8_1 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ ZDI&5C9#8GFY P  ,Q   !D
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M=#8V+GAM;%!+ 0(4 Q0    ( .I*1E8KKG .P0(  &,'   9
M  " @?KJ 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
MZDI&5I*W_\_A!@  @"X  !D              ("!\NT! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " #J2D969Z-A[8H"  "P!@  &0
M            @($*]0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( .I*1E:NXD6\L0D  %)A   9              " @<OW 0!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ ZDI&5E:./U,. P
MS@@  !D              ("!LP$" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " #J2D96V"X]'K@"  "1!P  &0              @('X
M! ( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( .I*1E9'
M%;:(E0(  (,'   9              " @><' @!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ ZDI&5B;("3F$!   W!D  !D
M     ("!LPH" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .I*1E:#!0I P@4  ,4O   9              "
M@8X? @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ ZDI&
M5DW\+W$' P  \0L  !D              ("!AR4" 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    " #J2D96>T6CUO$"  !?#   &0
M        @('%* ( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( .I*1E8'Q97O$0,  +4(   9              " @>TK @!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ ZDI&5I?3CWR^ @  ,0<
M !D              ("!-2\" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    " #J2D96_UBHTY0"  #$!@  &0              @($J,@(
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( .I*1E;Y )^L
MK (  &('   9              " @?4T @!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ ZDI&5LA*=B(W!   V18  !D
M ("!V#<" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " #J
M2D96 V<-_U<*  !XB   &0              @(%&/ ( >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( .I*1E:>X?SCUP(  +@'   9
M          " @=1& @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#
M%     @ ZDI&5B(%G&TB"   2CX  !D              ("!XDD" 'AL+W=O
M<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    " #J2D96$>F&--@%   W
M(   &0              @($[4@( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM
M;%!+ 0(4 Q0    ( .I*1E8D6T'320,  "L)   9              " @4I8
M @!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ ZDI&5ELH
MT2!* P  T0D  !D              ("!REL" 'AL+W=O<FMS:&5E=',O<VAE
M970Y,BYX;6Q02P$"% ,4    " #J2D9672"&-VX#   \"P  &0
M    @(%+7P( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M .I*1E:9WY,&#P,  ,<(   9              " @?!B @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ ZDI&5B@$S,_R @  F@<  !D
M             ("!-F8" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    " #J2D96L)$@=8P"  "U!@  &0              @(%?:0( >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( .I*1E:D@N?^W0(
M 'D(   9              " @2)L @!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ ZDI&5N/4D)B[ P  _ T  !D              ("!
M-F\" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " #J2D96
M%@CN&;H#  "##0  &0              @($H<P( >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;%!+ 0(4 Q0    ( .I*1E8FRC"ABP,   0,   :
M      " @1EW @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0
M   ( .I*1E9+OHS!7 (  !(&   :              " @=QZ @!X;"]W;W)K
M<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( .I*1E:145>OL ,  /0+
M   :              " @7!] @!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM
M;%!+ 0(4 Q0    ( .I*1E;:M]+O80,  *L2   :              " @5B!
M @!X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( .I*1E8A
M&CDF5 0   X3   :              " @?&$ @!X;"]W;W)K<VAE971S+W-H
M965T,3 T+GAM;%!+ 0(4 Q0    ( .I*1E8*!*P>Q (  $T(   :
M      " @7V) @!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0
M   ( .I*1E:%N5R7!P,  +\)   :              " @7F, @!X;"]W;W)K
M<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( .I*1E;K]HVRYP(  /<'
M   :              " @;B/ @!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM
M;%!+ 0(4 Q0    ( .I*1E8Y,,9G1 ,  ,H4   -              "  =>2
M @!X;"]S='EL97,N>&UL4$L! A0#%     @ ZDI&5I>*NQS     $P(   L
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64$L%!@    !S ', I!\  #ND @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>419</ContextCount>
  <ElementCount>420</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>133</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Business Overview and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Business Overview and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Collaboration, License, and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</Role>
      <ShortName>Collaboration, License, and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property, Plant, and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant, and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Long-Term Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlans</Role>
      <ShortName>Long-Term Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Employee Savings Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/EmployeeSavingsPlans</Role>
      <ShortName>Employee Savings Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlows</Role>
      <ShortName>Statement of Cash Flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Business Overview and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Business Overview and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Business Overview and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Business Overview and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/ProductSales</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Collaboration, License, and Other Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables</Role>
      <ShortName>Collaboration, License, and Other Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/MarketableSecurities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/Inventories</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Property, Plant, and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant, and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/IntangibleAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/Debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/CommitmentsandContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StockholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Long-Term Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansTables</Role>
      <ShortName>Long-Term Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/LongTermIncentivePlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/NetIncomePerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Statement of Cash Flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsTables</Role>
      <ShortName>Statement of Cash Flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StatementofCashFlows</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Business Overview and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Business Overview and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Business Overview and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails</Role>
      <ShortName>Business Overview and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails</Role>
      <ShortName>Product Sales - Schedule of Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Product Sales - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesNarrativeDetails</Role>
      <ShortName>Product Sales - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails</Role>
      <ShortName>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Product Sales - Schedule of Sales Related Deductions Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails</Role>
      <ShortName>Product Sales - Schedule of Sales Related Deductions Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, Antibody Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, Antibody Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, IO Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, IO Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Bayer Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Bayer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Bayer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaborative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaborative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Intellia Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Collaboration, License, and Other Agreements - Alnylam Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Alnylam Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Collaboration, License, and Other Agreements - Checkmate Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Checkmate Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Teva Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Property, Plant, and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant, and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Debt - Summary of Issued Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails</Role>
      <ShortName>Debt - Summary of Issued Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Commitments and Contingencies - Leases narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Leases narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Commitments and Contingencies - Amounts recognized in Condensed Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Amounts recognized in Condensed Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Commitments and Contingencies - Finance lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails</Role>
      <ShortName>Commitments and Contingencies - Finance lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Commitments and Contingencies - Other information related to finance lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails</Role>
      <ShortName>Commitments and Contingencies - Other information related to finance lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Commitments and Contingencies - Analysis of lease liability maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Analysis of lease liability maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Commitments and Contingencies - Research Collaboration and Licensing Agreements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Research Collaboration and Licensing Agreements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Repurchased Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Long-Term Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails</Role>
      <ShortName>Long-Term Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Long-Term Incentive Plans - Summary of transactions involving stock option awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails</Role>
      <ShortName>Long-Term Incentive Plans - Summary of transactions involving stock option awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average exercise prices and weighted-average grant-date fair values of options issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails</Role>
      <ShortName>Long-Term Incentive Plans - Summary of weighted-average exercise prices and weighted-average grant-date fair values of options issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of option grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails</Role>
      <ShortName>Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of option grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Long-Term Incentive Plans - Summary of activity related to restricted stock awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails</Role>
      <ShortName>Long-Term Incentive Plans - Summary of activity related to restricted stock awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Long-Term Incentive Plans - Summary of activity related to performance-based awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails</Role>
      <ShortName>Long-Term Incentive Plans - Summary of activity related to performance-based awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of performance-based options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails</Role>
      <ShortName>Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of performance-based options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Employee Savings Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/EmployeeSavingsPlansDetails</Role>
      <ShortName>Employee Savings Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/EmployeeSavingsPlans</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Income Taxes - Schedule of income before income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails</Role>
      <ShortName>Income Taxes - Schedule of income before income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Income Taxes - Schedule of components of income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of components of income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMattersDetails</Role>
      <ShortName>Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/LegalMatters</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="regn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Statement of Cash Flows - Summary of Non-Cash Investing and Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails</Role>
      <ShortName>Statement of Cash Flows - Summary of Non-Cash Investing and Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="regn-20221231.htm">regn-20221231.htm</File>
    <File>regn-20221231.xsd</File>
    <File>regn-20221231_cal.xml</File>
    <File>regn-20221231_def.xml</File>
    <File>regn-20221231_lab.xml</File>
    <File>regn-20221231_pre.xml</File>
    <File>regn-ex_211x12312022x10k.htm</File>
    <File>regn-ex_231x12312022x10k.htm</File>
    <File>regn-ex_311x12312022x10k.htm</File>
    <File>regn-ex_312x12312022x10k.htm</File>
    <File>regn-ex_32x12312022x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>regn-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1172">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "regn-20221231.htm": {
   "axisCustom": 4,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1172,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 419,
   "dts": {
    "calculationLink": {
     "local": [
      "regn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "regn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "regn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "regn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "regn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "regn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 712,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 63,
   "keyStandard": 357,
   "memberCustom": 84,
   "memberStandard": 43,
   "nsprefix": "regn",
   "nsuri": "http://www.regeneron.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.regeneron.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Collaboration, License, and Other Agreements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements",
     "shortName": "Collaboration, License, and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails",
     "shortName": "Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.regeneron.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails",
     "shortName": "Income Taxes - Schedule of unrecognized tax benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ic126e7de56fd4102a3b3234acc2542c7_I20200716",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:NumberOfInterPartiesReviewIPRPetitionsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Legal Matters (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.regeneron.com/role/LegalMattersDetails",
     "shortName": "Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ic126e7de56fd4102a3b3234acc2542c7_I20200716",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:NumberOfInterPartiesReviewIPRPetitionsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "id00ff500fe5d47c79cce7113ad54ecef_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
     "shortName": "Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "id00ff500fe5d47c79cce7113ad54ecef_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "id9e1b802d10c4170b70f673c07516261_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ic5bac9dad6b340e2b278dca087384319_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Statement of Cash Flows - Summary of Non-Cash Investing and Financing Activities (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails",
     "shortName": "Statement of Cash Flows - Summary of Non-Cash Investing and Financing Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ic5bac9dad6b340e2b278dca087384319_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.regeneron.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.regeneron.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.regeneron.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property, Plant, and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.regeneron.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant, and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.regeneron.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.regeneron.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.regeneron.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.regeneron.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.regeneron.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Long-Term Incentive Plans",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlans",
     "shortName": "Long-Term Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Employee Savings Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.regeneron.com/role/EmployeeSavingsPlans",
     "shortName": "Employee Savings Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.regeneron.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Legal Matters",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.regeneron.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.regeneron.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Statement of Cash Flows",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.regeneron.com/role/StatementofCashFlows",
     "shortName": "Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Business Overview and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Business Overview and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Business Overview and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Business Overview and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Product Sales (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.regeneron.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Collaboration, License, and Other Agreements (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
     "shortName": "Collaboration, License, and Other Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.regeneron.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Property, Plant, and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.regeneron.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant, and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.regeneron.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.regeneron.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "regn:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "regn:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.regeneron.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Long-Term Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansTables",
     "shortName": "Long-Term Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.regeneron.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.regeneron.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Statement of Cash Flows (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsTables",
     "shortName": "Statement of Cash Flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Business Overview and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Business Overview and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i492786f7a1b94a1594a932e2b271fa8a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Business Overview and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
     "shortName": "Business Overview and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i492786f7a1b94a1594a932e2b271fa8a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
     "shortName": "Product Sales - Schedule of Net Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i13b570c4cf204eefb544c1454a2796d5_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Product Sales - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.regeneron.com/role/ProductSalesNarrativeDetails",
     "shortName": "Product Sales - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ia31d29839cf14beabac4560e466ab9df_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i14dd5c1f226d4087af59c57f97a899aa_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails",
     "shortName": "Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i14dd5c1f226d4087af59c57f97a899aa_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ie65a16fb8a6b403fa37c4281f0cba7a7_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Product Sales - Schedule of Sales Related Deductions Activity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails",
     "shortName": "Product Sales - Schedule of Sales Related Deductions Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ia3db0f06447a42bd808d6ea7cc59bfa6_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i04ba1f9253744de2b4207de915788712_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:AcquiredInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:PaymentToCollaboratingParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:PaymentToCollaboratingParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, Antibody Collaboration (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, Antibody Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if16d17ebcbaf4806a375d33fb5402f61_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ida00ad5e29154c468a4e0cc72eecae59_D20220701-20220731",
      "decimals": "2",
      "lang": "en-US",
      "name": "regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, IO Collaboration (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Accounts Receivable and Deferred Revenue Information, IO Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i26e7fd0c4d1040deb43f17a2f172c19c_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6f127c8b7cde442e8f388b671f809753_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Bayer Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6f127c8b7cde442e8f388b671f809753_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Bayer (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Bayer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i0c1144a7790544218f74de1883b49bf3_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaborative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaborative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i3153e0c1409546939c8330d63e4b6f96_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Intellia Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c64d785c95b442cb84245281603aa97_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:CollaborativeArrangementUpfrontPaymentMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ib00e86a2286a4587b02c4df300896c50_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:MaximumTransactionAgreementPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i3634f1dd450c457f96f0a93baa2fe330_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i034cb1f338a14cdb98427fcd16a6f4bf_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i034cb1f338a14cdb98427fcd16a6f4bf_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i128800b6b8e7426faa3758b24792c793_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:UpfrontPaymentMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Collaboration, License, and Other Agreements - Alnylam Narratives (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
     "shortName": "Collaboration, License, and Other Agreements - Alnylam Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "iec5ffd911f0047998fc63515be09b0e1_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:UpfrontPaymentMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Collaboration, License, and Other Agreements - Checkmate Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Checkmate Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if09bf8b8e3234c7c9522960c5d87c53e_D20220501-20220531",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Teva Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i0cfcdda3880e4f87bb8ab780435bee97_D20160101-20161231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:UpFrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i0f32e181f6564471b1774eaf0ab52226_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ibd8ba32d6e6f4ce0b5694a0c17f3bdb4_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
     "shortName": "Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeDebtSecuritiesOperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Marketable Securities - Narrative (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails",
     "shortName": "Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeDebtSecuritiesOperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "idaac5082db1042e2a542c59aaed88125_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Inventories - Narrative (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.regeneron.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Property, Plant, and Equipment - Narrative (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant, and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:DepreciationDepletionAndAmortizationExcludingIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ie345030098ed4a68855b720eadea8248_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ie345030098ed4a68855b720eadea8248_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if47d053711fd4bdc82cf9d70aa578c00_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if47d053711fd4bdc82cf9d70aa578c00_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i7310c177364143f2bf10f9d6b7aaf971_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.regeneron.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ie424218a88a74b00b19453fe4888916c_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Business Overview and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies",
     "shortName": "Business Overview and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i4a901ef13b914e98a6b6ae594630e3ab_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Debt - Summary of Issued Senior Unsecured Notes (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails",
     "shortName": "Debt - Summary of Issued Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i4a901ef13b914e98a6b6ae594630e3ab_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Commitments and Contingencies - Leases narrative (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails",
     "shortName": "Commitments and Contingencies - Leases narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i50a2e9c56f7e416f8da3fc7358beb047_I20170331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "regn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Commitments and Contingencies - Amounts recognized in Condensed Consolidated Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails",
     "shortName": "Commitments and Contingencies - Amounts recognized in Condensed Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "regn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Commitments and Contingencies - Finance lease costs (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails",
     "shortName": "Commitments and Contingencies - Finance lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "regn:FinanceLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Commitments and Contingencies - Other information related to finance lease (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails",
     "shortName": "Commitments and Contingencies - Other information related to finance lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "regn:FinanceLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Commitments and Contingencies - Analysis of lease liability maturities (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails",
     "shortName": "Commitments and Contingencies - Analysis of lease liability maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i5d20e3c5247b4d598e751c21b3f4f608_D20180801-20180831",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:PaymentsForRoyaltiesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Commitments and Contingencies - Research Collaboration and Licensing Agreements Narrative (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails",
     "shortName": "Commitments and Contingencies - Research Collaboration and Licensing Agreements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i5d20e3c5247b4d598e751c21b3f4f608_D20180801-20180831",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:PaymentsForRoyaltiesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i25a7782ebd8c4cae90c0de536db35b84_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ia4180bb5766b40c0b91e6b45594d6b47_D20200501-20200531",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails",
     "shortName": "Stockholders' Equity - Schedule of Repurchased Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i716b6b8c1c6348308e6a1185ff3c63a6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Long-Term Incentive Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
     "shortName": "Long-Term Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Product Sales",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.regeneron.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i1fa909c892214ee795c9bf21ee208f05_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Long-Term Incentive Plans - Summary of transactions involving stock option awards (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
     "shortName": "Long-Term Incentive Plans - Summary of transactions involving stock option awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i005cfd5553b94f1f93d09424645aa3db_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average exercise prices and weighted-average grant-date fair values of options issued (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails",
     "shortName": "Long-Term Incentive Plans - Summary of weighted-average exercise prices and weighted-average grant-date fair values of options issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of option grants (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
     "shortName": "Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of option grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i6c697228a3c248a58a41afe6c25e3488_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "icc41ab2a621442839e2f788a04d55cce_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Long-Term Incentive Plans - Summary of activity related to restricted stock awards (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails",
     "shortName": "Long-Term Incentive Plans - Summary of activity related to restricted stock awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if24cc6d040e2402d8396ff805d805c2e_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i9c0dc7ae7eea4e3b8287dab621cc69ff_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Long-Term Incentive Plans - Summary of activity related to performance-based awards (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
     "shortName": "Long-Term Incentive Plans - Summary of activity related to performance-based awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "ibf316c7e51a2419f8c73906927513eff_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of performance-based options (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails",
     "shortName": "Long-Term Incentive Plans - Summary of weighted-average values of assumptions used in computing fair value of performance-based options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "i56c6f2a3ffc5405eb17b7b162cde1889_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Employee Savings Plans (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.regeneron.com/role/EmployeeSavingsPlansDetails",
     "shortName": "Employee Savings Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Income Taxes - Schedule of income before income tax (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails",
     "shortName": "Income Taxes - Schedule of income before income tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Income Taxes - Schedule of components of income tax expense (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails",
     "shortName": "Income Taxes - Schedule of components of income tax expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails",
     "shortName": "Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20221231.htm",
      "contextRef": "if3a774e0ef9c45d68f640751e3b31611_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 133,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "regn_A226PatentAnd992PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'226 Patent And '992 Patent",
        "label": "'226 Patent And '992 Patent [Member]",
        "terseLabel": "'226 Patent and '992 Patent"
       }
      }
     },
     "localname": "A226PatentAnd992PatentMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A338PatentAnd069PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'338 Patent And '069 Patent",
        "label": "'338 Patent And '069 Patent [Member]",
        "terseLabel": "'338 Patent and '069 Patent"
       }
      }
     },
     "localname": "A338PatentAnd069PatentMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A631PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'631 Patent",
        "label": "'631 Patent [Member]",
        "terseLabel": "'631 Patent"
       }
      }
     },
     "localname": "A631PatentMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AccrualForSalesRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual For Sales-Related Costs, Current",
        "label": "Accrual For Sales-Related Costs, Current",
        "terseLabel": "Accrued sales-related costs"
       }
      }
     },
     "localname": "AccrualForSalesRelatedCostsCurrent",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) in connection with clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Trial Expense Current",
        "verboseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired In-Process Research and Development",
        "label": "Acquired In-Process Research and Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_AggregateSalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Sales-Based Milestone",
        "label": "Aggregate Sales-Based Milestone [Member]",
        "terseLabel": "Aggregate Sales-Based Milestone"
       }
      }
     },
     "localname": "AggregateSalesBasedMilestoneMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AlnylamPharmaceuticalsInc.CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam Pharmaceuticals, Inc. Collaboration Agreement [Member]",
        "label": "Alnylam Pharmaceuticals, Inc. Collaboration Agreement [Member]",
        "terseLabel": "Alnylam Pharmaceuticals, Inc. Collaboration Agreement"
       }
      }
     },
     "localname": "AlnylamPharmaceuticalsInc.CollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement [Member]",
        "label": "Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement [Member]",
        "terseLabel": "Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement"
       }
      }
     },
     "localname": "AlnylamPharmaceuticalsInc.StockPurchaseAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AmendedIODiscoveryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended IO Discovery Agreement [Member]",
        "label": "Amended IO Discovery Agreement [Member]",
        "terseLabel": "Amended IO Discovery Agreement"
       }
      }
     },
     "localname": "AmendedIODiscoveryAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AmendedRestatedLongTermIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended &amp; Restated Long-Term Incentive Plan 2014",
        "label": "Amended &amp; Restated Long-Term Incentive Plan 2014 [Member]",
        "terseLabel": "Amended &amp; Restated Long-Term Incentive Plan 2014"
       }
      }
     },
     "localname": "AmendedRestatedLongTermIncentivePlan2014Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "label": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "terseLabel": "Amounts recognized in connection with up-front payments received"
       }
      }
     },
     "localname": "AmountsRecognizedInConnectionWithUpFrontPaymentsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ApotexIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc.",
        "label": "Apotex Inc. [Member]",
        "terseLabel": "Apotex Inc."
       }
      }
     },
     "localname": "ApotexIncMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ArcalystNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "Arcalyst Net Product Sales [Member]",
        "terseLabel": "ARCALYST"
       }
      }
     },
     "localname": "ArcalystNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of amounts recognized in the Condensed Consolidated Balance Sheet"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "regn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.regeneron.com/20221231",
     "xbrltype": "stringItemType"
    },
    "regn_BARDAOtherTransactionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BARDA, Other Transaction Agreement",
        "label": "BARDA, Other Transaction Agreement [Member]",
        "terseLabel": "Other Transaction Agreement"
       }
      }
     },
     "localname": "BARDAOtherTransactionAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BayerCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Collaboration Agreement [Member]",
        "label": "Bayer Collaboration Agreement [Member]",
        "terseLabel": "Bayer"
       }
      }
     },
     "localname": "BayerCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BesseMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Besse Medical [Member]",
        "label": "Besse Medical [Member]",
        "terseLabel": "Besse Medical, a subsidiary of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "BesseMedicalMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CelltrionIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Celltrion, Inc.",
        "label": "Celltrion, Inc. [Member]",
        "terseLabel": "Celltrion, Inc."
       }
      }
     },
     "localname": "CelltrionIncMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CheckmatePharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Checkmate Pharmaceuticals, Inc.",
        "label": "Checkmate Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Checkmate Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "CheckmatePharmaceuticalsIncMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ClassificationOfInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.",
        "label": "Classification of Investment [Axis]",
        "terseLabel": "Classification of Investment [Axis]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentAxis",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ClassificationOfInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides general categories of investments for which information is required or determined to be disclosed.",
        "label": "Classification of Investment [Domain]",
        "terseLabel": "Classification of Investment [Domain]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentDomain",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Other collaboration revenue",
        "verboseLabel": "Other collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationandContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Contract Manufacturing [Member]",
        "label": "Collaboration and Contract Manufacturing [Member]",
        "terseLabel": "Cost of collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CollaborationandContractManufacturingMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborativeAgreementsObligationsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Obligations, Current",
        "label": "Collaborative Agreements, Obligations, Current",
        "terseLabel": "Amounts due to collaborators (see Note 3)"
       }
      }
     },
     "localname": "CollaborativeAgreementsObligationsCurrent",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_CollaborativeArrangementAdditionalPaymentEligibleMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Payment Eligible, Milestone",
        "label": "Collaborative Arrangement, Additional Payment Eligible, Milestone",
        "terseLabel": "Collaborative arrangement additional payment eligible"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalPaymentEligibleMilestone",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Doses Counterparty To Purchase",
        "label": "Collaborative Arrangement, Number Of Doses Counterparty To Purchase",
        "terseLabel": "Collaborative arrangement, number of doses counterparty to purchase"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfDosesCounterpartyToPurchase",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_CollaborativeArrangementUpfrontPaymentMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Payment Made",
        "label": "Collaborative Arrangement, Upfront Payment Made",
        "terseLabel": "Acquired in-process research and development, up-front payment made"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPaymentMade",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member]",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ContingentReimbursementObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner.",
        "label": "Contingent Reimbursement Obligation",
        "terseLabel": "Contingent reimbursement obligation"
       }
      }
     },
     "localname": "ContingentReimbursementObligation",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_CostOfGoodsSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Goods Sold",
        "label": "Cost Of Goods Sold [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsSoldMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage",
        "label": "Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage",
        "terseLabel": "Redemption price with change-in-control provision, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5",
        "terseLabel": "Maturities after five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Capitalized Research and Development Expenses",
        "label": "Deferred Tax Assets, Capitalized Research and Development Expenses",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_DepreciationDepletionAndAmortizationExcludingIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, Depletion And Amortization, Excluding Intangible Assets",
        "label": "Depreciation, Depletion And Amortization, Excluding Intangible Assets",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationExcludingIntangibleAssets",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_DistributionRelatedFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A valuation allowance for distribution-related fees which are netted against revenue from product sales.",
        "label": "Distribution Related Fees [Member]",
        "terseLabel": "Distribution- Related Fees"
       }
      }
     },
     "localname": "DistributionRelatedFeesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EYLEAAfliberceptInjectionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EYLEA Aflibercept Injection",
        "label": "EYLEA Aflibercept Injection [Member]",
        "terseLabel": "EYLEA Aflibercept Injection"
       }
      }
     },
     "localname": "EYLEAAfliberceptInjectionMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Foreign Intangible Income, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Foreign Intangible Income, Percent",
        "negatedTerseLabel": "Foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Sale Of Non-Inventory Related Assets Between Foreign Subsidiaries, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Sale Of Non-Inventory Related Assets Between Foreign Subsidiaries, Percent",
        "terseLabel": "Sale of non-inventory related assets between foreign subsidiaries"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party.",
        "label": "Ending share of profits outside the United States, based on sales, for collaborating party",
        "terseLabel": "Ending share of profits outside the United States, based on sales, for collaborating party"
       }
      }
     },
     "localname": "EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company.",
        "label": "Ending share of profits outside the United States, based on sales, for Company",
        "terseLabel": "Ending share of profits outside the United States, based on sales, for company"
       }
      }
     },
     "localname": "EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_EvkeezaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evkeeza",
        "label": "Evkeeza [Member]",
        "terseLabel": "Evkeeza"
       }
      }
     },
     "localname": "EvkeezaMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ExtensionOfResearchTermFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension Of Research Term Fee",
        "label": "Extension Of Research Term Fee",
        "terseLabel": "Extension of research term fee"
       }
      }
     },
     "localname": "ExtensionOfResearchTermFee",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_EyleaNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "EYLEA Net Product Sales [Member]",
        "terseLabel": "EYLEA"
       }
      }
     },
     "localname": "EyleaNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_FinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Remaining Lease Term",
        "label": "Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term (in years)"
       }
      }
     },
     "localname": "FinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_FurnitureOfficeEquipmentAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture, Office Equipment And Other [Member]",
        "label": "Furniture, Office Equipment And Other [Member]",
        "terseLabel": "Furniture, office equipment, and other"
       }
      }
     },
     "localname": "FurnitureOfficeEquipmentAndOtherMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_GrossProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Product Revenue",
        "label": "Gross Product Revenue [Member]",
        "terseLabel": "Gross Product Revenue"
       }
      }
     },
     "localname": "GrossProductRevenueMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_IOLicenseandCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In July 2015, the Company entered into a Immuno-oncology License and Collaboration Agreement (the \"IO License and Collaboration Agreement\") with Sanofi, to jointly develop and commercialize Immuno-oncology products.",
        "label": "IO License and Collaboration Agreement [Member]",
        "terseLabel": "IO License and Collaboration Agreement"
       }
      }
     },
     "localname": "IOLicenseandCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_InitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Research Term",
        "label": "Initial Research Term",
        "terseLabel": "Initial research term"
       }
      }
     },
     "localname": "InitialResearchTerm",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_InmazebMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inmazeb",
        "label": "Inmazeb [Member]",
        "terseLabel": "Inmazeb"
       }
      }
     },
     "localname": "InmazebMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_IntelliaCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellia Collaboration Agreement",
        "label": "Intellia Collaboration Agreement [Member]",
        "terseLabel": "Intellia Collaboration Agreement"
       }
      }
     },
     "localname": "IntelliaCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_January12024ThroughDecember312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 1, 2024 Through December 31, 2026 [Member]",
        "label": "January 1, 2024 Through December 31, 2026 [Member]",
        "terseLabel": "January 1, 2024 Through December 31, 2026"
       }
      }
     },
     "localname": "January12024ThroughDecember312026Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LIBTAYONetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LIBTAYO Net Product Sales [Member]",
        "label": "LIBTAYO Net Product Sales [Member]",
        "terseLabel": "Libtayo"
       }
      }
     },
     "localname": "LIBTAYONetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LaboratoryAndOfficeFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory And Office Facilities",
        "label": "Laboratory And Office Facilities [Member]",
        "terseLabel": "Laboratory and Office Facilities"
       }
      }
     },
     "localname": "LaboratoryAndOfficeFacilitiesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of twelve month sales upon which sales milestone would be received.",
        "label": "Levels of twelve month sales at which sales milestone payments would be received",
        "terseLabel": "Levels of twelve month sales at which sales milestone payments would be received"
       }
      }
     },
     "localname": "Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Libtayo Development And Dupilumab/Itepekimab Eligible Investments",
        "label": "Libtayo Development And Dupilumab/Itepekimab Eligible Investments [Member]",
        "terseLabel": "Libtayo Development and Dupilumab/Itepekimab Eligible Investments"
       }
      }
     },
     "localname": "LibtayoDevelopmentAndDupilumabItepekimabEligibleInvestmentsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LineOfCreditFacilityIncreaseLimit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Increase Limit",
        "label": "Line Of Credit Facility, Increase Limit",
        "terseLabel": "Increase Limit"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseLimit",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_LongTermIncentivePlan2000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Incentive Plan 2000 [Member]",
        "label": "Long-Term Incentive Plan 2000 [Member]",
        "terseLabel": "Long-Term Incentive Plan 2000"
       }
      }
     },
     "localname": "LongTermIncentivePlan2000Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LongTermIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Incentive Plan 2014",
        "label": "Long-Term Incentive Plan 2014 [Member]",
        "terseLabel": "Long-Term Incentive Plan 2014"
       }
      }
     },
     "localname": "LongTermIncentivePlan2014Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LossContingencyExParteReexaminationFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Ex Parte Reexamination, Filed, Number",
        "label": "Loss Contingency, Ex Parte Reexamination, Filed, Number",
        "terseLabel": "Number of ex parte reexamination requests"
       }
      }
     },
     "localname": "LossContingencyExParteReexaminationFiledNumber",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_LossContingencyPercentageOfDamagesResponsibleFor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Percentage Of Damages Responsible For",
        "label": "Loss Contingency, Percentage Of Damages Responsible For",
        "terseLabel": "Percentage of damages company is responsible for"
       }
      }
     },
     "localname": "LossContingencyPercentageOfDamagesResponsibleFor",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_MarketableAndOtherSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable and Other Securities, Gain (Loss)",
        "label": "Marketable and Other Securities, Gain (Loss)",
        "negatedLabel": "Losses (gains) on marketable and other securities, net"
       }
      }
     },
     "localname": "MarketableAndOtherSecuritiesGainLoss",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.",
        "label": "Maximum amount of sales milestone payments if total sales achieve specific levels",
        "terseLabel": "Maximum amount of sales milestone payments if total sales achieve specific levels"
       }
      }
     },
     "localname": "MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of outstanding shares of the Company's Class A Stock and Common Stock that may be acquired under the 'standstill' provisions, in effect after the specified date.",
        "label": "Maximum Percentage Of Outstanding Shares That May Be Acquired, Under 'Standstill' Provisions",
        "terseLabel": "Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions"
       }
      }
     },
     "localname": "MaximumPercentageOfOutstandingSharesThatMayBeAcquiredUnderStandstillProvisions",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_MaximumTransactionAgreementPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Transaction Agreement Payments",
        "label": "Maximum Transaction Agreement Payments",
        "terseLabel": "Maximum transaction agreement payments"
       }
      }
     },
     "localname": "MaximumTransactionAgreementPayments",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation [Member]",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NetProfitInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Profit In Connection With Commercialization [Member]",
        "label": "Net Profit In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's share of profits in connection with commercialization of EYLEA outside the United States"
       }
      }
     },
     "localname": "NetProfitInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NonPerformanceBasedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A stock option whose vesting is not contingent upon performance achievements.",
        "label": "Non-Performance Based Stock Options [Member]",
        "terseLabel": "Non-performance based stock options"
       }
      }
     },
     "localname": "NonPerformanceBasedStockOptionsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NumberOfInterPartiesReviewIPRPetitionsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Inter Parties Review (IPR) Petitions Filed",
        "label": "Number of Inter Parties Review (IPR) Petitions Filed",
        "terseLabel": "Number of IPR filed"
       }
      }
     },
     "localname": "NumberOfInterPartiesReviewIPRPetitionsFiled",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products Approved By The Unites States Food And Drug Administration",
        "label": "Number of Products Approved By The Unites States Food And Drug Administration",
        "terseLabel": "Number of products approved by the U.S. FDA"
       }
      }
     },
     "localname": "NumberOfProductsApprovedByTheUnitesStatesFoodAndDrugAdministration",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Votes Per Share",
        "label": "Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One-time Payment in Connection With Change in Japan Arrangement",
        "label": "One-time Payment in Connection With Change in Japan Arrangement [Member]",
        "terseLabel": "One-time payment in connection with change in Japan arrangement"
       }
      }
     },
     "localname": "OneTimePaymentInConnectionWithChangeInJapanArrangementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_OptionToExtendResearchTermPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to Extend Research Term, Period",
        "label": "Option to Extend Research Term, Period",
        "terseLabel": "Potential optional extension of research term"
       }
      }
     },
     "localname": "OptionToExtendResearchTermPeriod",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_OtherCollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaboration Agreements [Member]",
        "label": "Other Collaboration Agreements [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborationAgreementsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_OtherSalesRelatedDeductionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A valuation allowance for other sales-related deductions which are netted against revenue from product sales.",
        "label": "Other Sales Related Deductions [Member]",
        "terseLabel": "Other Sales- Related Deductions"
       }
      }
     },
     "localname": "OtherSalesRelatedDeductionsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PaymentToCollaboratingParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment To Collaborating Party",
        "label": "Payment To Collaborating Party",
        "negatedTerseLabel": "One-time payment"
       }
      }
     },
     "localname": "PaymentToCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_PaymentsForAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisition",
        "label": "Payments for Asset Acquisition",
        "negatedTerseLabel": "Asset acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisition",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_PaymentsForRoyaltiesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Royalties, Percentage",
        "label": "Payments For Royalties, Percentage",
        "terseLabel": "Percentage of royalties to be paid"
       }
      }
     },
     "localname": "PaymentsForRoyaltiesPercentage",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PaymentsMadeToAcquireEquityWithinACollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Made To Acquire Equity Within A Collaboration Agreement",
        "label": "Payments Made To Acquire Equity Within A Collaboration Agreement",
        "terseLabel": "Cash consideration for Stock Purchase Agreement"
       }
      }
     },
     "localname": "PaymentsMadeToAcquireEquityWithinACollaborationAgreement",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_PaymentsToAcquireIntangibleAssets1": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Intangible Assets1",
        "label": "Payments To Acquire Intangible Assets1",
        "negatedTerseLabel": "Payments for Libtayo intangible asset"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets1",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs",
        "label": "Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs",
        "terseLabel": "Percentage of quarterly profits require to be paid for reimbursement of development costs"
       }
      }
     },
     "localname": "PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of repayment of development balance out of profits under the collaboration agreement.",
        "label": "Percentage Of Repayment Of Development Balance Out Of Profits",
        "terseLabel": "Percentage of repayment of development balance out of profits"
       }
      }
     },
     "localname": "PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfRoyaltyPaymentThatCanBeOffset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Royalty Payment That Can Be Offset",
        "label": "Percentage of Royalty Payment That Can Be Offset",
        "terseLabel": "Percentage of royalty payment that can be used to offset litigation proceedings"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentThatCanBeOffset",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs",
        "label": "Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs",
        "terseLabel": "Percentage of share of profits used to reimburse collaborating party for trial costs"
       }
      }
     },
     "localname": "PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Trial Costs Required To Be Funded By Collaborating Party",
        "label": "Percentage of Trial Costs Required To Be Funded By Collaborating Party",
        "terseLabel": "Percentage of trial costs required to be funded by collaborating party"
       }
      }
     },
     "localname": "PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "label": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "terseLabel": "Period for achieving sales target for milestone payment, rolling basis"
       }
      }
     },
     "localname": "PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_PotentialExtensionOfResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Extension Of Research Term",
        "label": "Potential Extension Of Research Term",
        "terseLabel": "Potential automatic extension of research term"
       }
      }
     },
     "localname": "PotentialExtensionOfResearchTerm",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_PraluentCrossLicenseAndCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Praluent Cross License and Commercialization Agreement",
        "label": "Praluent Cross License and Commercialization Agreement [Member]",
        "terseLabel": "Praluent Agreement"
       }
      }
     },
     "localname": "PraluentCrossLicenseAndCommercializationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PraluentNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Praluent Net Product Sales",
        "label": "Praluent Net Product Sales [Member]",
        "terseLabel": "Praluent"
       }
      }
     },
     "localname": "PraluentNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Rights",
        "label": "Product Rights [Member]",
        "terseLabel": "Acquired product rights - Libtayo"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_REGENCOVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "REGEN-COV",
        "label": "REGEN-COV [Member]",
        "terseLabel": "REGEN-COV"
       }
      }
     },
     "localname": "REGENCOVMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RebatesAndChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A valuation allowance for rebates and chargebacks under governmental programs (including Medicaid), which are netted against revenue from product sales.",
        "label": "Rebates and Chargebacks [Member]",
        "terseLabel": "Rebates, Chargebacks, and Discounts"
       }
      }
     },
     "localname": "RebatesAndChargebacksMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsShareOfCommercialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron's Share Of Commercial Expenses",
        "label": "Regeneron's Share Of Commercial Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Sanofi commercial expenses"
       }
      }
     },
     "localname": "RegeneronsShareOfCommercialExpensesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron's Share Of Research And Development Expenses",
        "label": "Regeneron's Share Of Research And Development Expenses [Member]",
        "verboseLabel": "Regeneron's obligation for its share of Bayer R&amp;D expenses"
       }
      }
     },
     "localname": "RegeneronsShareOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestone",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementForManufacturingOfCommercialSuppliesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "label": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "terseLabel": "Reimbursement for manufacturing of commercial supplies"
       }
      }
     },
     "localname": "ReimbursementForManufacturingOfCommercialSuppliesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfCommercializationRelatedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Commercialization-Related Expenses [Member]",
        "label": "Reimbursement Of Commercialization-Related Expenses [Member]",
        "terseLabel": "Reimbursement of commercialization-related expenses"
       }
      }
     },
     "localname": "ReimbursementOfCommercializationRelatedExpensesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expenses [Member]",
        "label": "Reimbursement Of Research And Development Expenses [Member]",
        "terseLabel": "Reimbursement of R&amp;D expenses",
        "verboseLabel": "Reimbursement of R&amp;D expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses",
        "label": "Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses [Member]",
        "terseLabel": "Reimbursements of R&amp;D expenses, net of Regeneron's obligation for its share of Sanofi R&amp;D expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement Contract to Perform for Others by Product [Axis]",
        "label": "Research and Development Arrangement Contract to Perform for Others by Product [Axis]",
        "terseLabel": "Research and Development Arrangement Contract to Perform for Others by Product [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Research and Development Arrangement Contract to Perform for Others by Product [Axis]",
        "label": "Research and Development Arrangement Contract to Perform for Others by Product [Domain]",
        "terseLabel": "Research and Development Arrangement Contract to Perform for Others by Product [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByProductDomain",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ResearchCollaborationAndLicensingAgreementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The research collaboration and licensing agreements entered into.",
        "label": "Research Collaboration and Licensing Agreements [Axis]",
        "terseLabel": "Research Collaboration and Licensing Agreements [Axis]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingAgreementsAxis",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ResearchCollaborationAndLicensingAgreementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and licensing agreements, by name.",
        "label": "Research Collaboration and Licensing Agreements [Domain]",
        "terseLabel": "Research Collaboration and Licensing Agreements [Domain]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingAgreementsDomain",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ResearchCollaborationAndLicensingArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research Collaboration and Licensing Arrangements [Line Items]",
        "terseLabel": "Research Collaboration and Licensing Arrangements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingArrangementsLineItems",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ResearchCollaborationAndLicensingArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Research Collaboration and Licensing Arrangements [Table]",
        "terseLabel": "Research Collaboration and Licensing Arrangements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingArrangementsTable",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World",
        "label": "Rest Of World [Member]",
        "terseLabel": "Rest Of World"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted [Member]",
        "label": "Restricted [Member]",
        "terseLabel": "Restricted"
       }
      }
     },
     "localname": "RestrictedMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RevenueBasedOnPercentageOfAnnualSalesInJapan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.",
        "label": "Revenue Based On Percentage Of Annual Sales In Japan",
        "terseLabel": "Revenue based on percentage of annual sales in Japan"
       }
      }
     },
     "localname": "RevenueBasedOnPercentageOfAnnualSalesInJapan",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Revenue, remaining performance obligation, variable consideration amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_RocheCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche Collaboration Agreement",
        "label": "Roche Collaboration Agreement [Member]",
        "terseLabel": "Roche Collaboration Agreement"
       }
      }
     },
     "localname": "RocheCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RonapreveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ronapreve",
        "label": "Ronapreve [Member]",
        "terseLabel": "Ronapreve"
       }
      }
     },
     "localname": "RonapreveMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment to Collaborating Party, Percentage of Net Product Sales",
        "label": "Royalty Payment to Collaborating Party, Percentage of Net Product Sales",
        "terseLabel": "Royalty payment to collaborating party, percentage of net product sales"
       }
      }
     },
     "localname": "RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage To Be Received On Net Product Sales Outside Of United States",
        "label": "Royalty Percentage To Be Received On Net Product Sales Outside Of United States",
        "terseLabel": "Royalty percentage to be received on net product sales outside of the United States"
       }
      }
     },
     "localname": "RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_RoyaltyRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum royalty rate to be paid to the Company under the agreements.",
        "label": "Royalty rate maximum",
        "terseLabel": "Royalty rate maximum"
       }
      }
     },
     "localname": "RoyaltyRateMaximum",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_RoyaltyRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum royalty rate to be paid to the Company under the agreements.",
        "label": "Royalty rate minimum",
        "terseLabel": "Royalty rate minimum"
       }
      }
     },
     "localname": "RoyaltyRateMinimum",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_SalesBasedMilestoneEarnedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone Earned",
        "label": "Sales-Based Milestone Earned [Member]",
        "terseLabel": "Sales-based milestones earned"
       }
      }
     },
     "localname": "SalesBasedMilestoneEarnedMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesBasedMilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone One",
        "label": "Sales-Based Milestone One [Member]",
        "terseLabel": "Sales-Based Milestone One"
       }
      }
     },
     "localname": "SalesBasedMilestoneOneMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesBasedMilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone Two",
        "label": "Sales-Based Milestone Two [Member]",
        "terseLabel": "Sales-Based Milestone Two"
       }
      }
     },
     "localname": "SalesBasedMilestoneTwoMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Five",
        "label": "Sales Milestone Five [Member]",
        "terseLabel": "Sales Milestone Five"
       }
      }
     },
     "localname": "SalesMilestoneFiveMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Four",
        "label": "Sales Milestone Four [Member]",
        "terseLabel": "Sales Milestone Four"
       }
      }
     },
     "localname": "SalesMilestoneFourMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone One",
        "label": "Sales Milestone One [Member]",
        "terseLabel": "First Milestone"
       }
      }
     },
     "localname": "SalesMilestoneOneMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Three",
        "label": "Sales Milestone Three [Member]",
        "terseLabel": "Third Milestone"
       }
      }
     },
     "localname": "SalesMilestoneThreeMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Two",
        "label": "Sales Milestone Two [Member]",
        "terseLabel": "Second Milestone"
       }
      }
     },
     "localname": "SalesMilestoneTwoMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones",
        "label": "Sales Milestones [Axis]",
        "terseLabel": "Sales Milestones [Axis]"
       }
      }
     },
     "localname": "SalesMilestonesAxis",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_SalesMilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones",
        "label": "Sales Milestones [Domain]",
        "terseLabel": "Sales Milestones [Domain]"
       }
      }
     },
     "localname": "SalesMilestonesDomain",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement",
        "label": "Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementAntibodyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Antibody [Member]",
        "label": "Sanofi Collaboration Agreement, Antibody [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Antibody"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementAntibodyMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementImmunooncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "label": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Immuno-oncology"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementImmunooncologyMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Revenue",
        "label": "Sanofi Collaboration Revenue [Member]",
        "terseLabel": "Sanofi collaboration revenue"
       }
      }
     },
     "localname": "SanofiCollaborationRevenueMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofisShareOfLibtayoUSGrossProfitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi's Share of Libtayo U.S. Gross Profits",
        "label": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "terseLabel": "Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits"
       }
      }
     },
     "localname": "SanofisShareOfLibtayoUSGrossProfitsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ScheduleOfSalesRelatedDeductionsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity of sales-related deductions during the period, which includes rebates, chargebacks, discounts, and distributor-related fees.",
        "label": "Schedule of Sales Related Deductions Activity [Table Text Block]",
        "terseLabel": "Sales related deductions activity"
       }
      }
     },
     "localname": "ScheduleOfSalesRelatedDeductionsActivityTableTextBlock",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "regn_SeniorUnsecuredNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2030",
        "label": "Senior Unsecured Notes Due 2030 [Member]",
        "terseLabel": "1.750% Senior Notes due September 2030"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2030Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SeniorUnsecuredNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2050",
        "label": "Senior Unsecured Notes Due 2050 [Member]",
        "terseLabel": "2.800% Senior Notes due September 2050"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2050Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term (in years) when the equity-based award expires as specified in the award agreement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Expiration",
        "terseLabel": "Maximum term of awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the share of losses outside the United States for the collaborating party.",
        "label": "Share of losses outside the United States, for collaborating party",
        "terseLabel": "Share of losses outside the United States, for collaborating party"
       }
      }
     },
     "localname": "ShareOfLossesOutsideUnitedStatesForCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_ShareOfLossesOutsideUnitedStatesForCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the share of losses outside the United States for the Company.",
        "label": "Share of losses outside the United States, for Company",
        "terseLabel": "Share of losses outside the United States, for company"
       }
      }
     },
     "localname": "ShareOfLossesOutsideUnitedStatesForCompany",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_ShareOfProfitsLossesInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Of Profits (Losses) In Connection With Commercialization [Member]",
        "label": "Share Of Profits (Losses) In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's share of profits in connection with commercialization of antibodies"
       }
      }
     },
     "localname": "ShareOfProfitsLossesInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgram2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, 2019",
        "label": "Share Repurchase Program, 2019 [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram2019Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramJanuary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, January 2021",
        "label": "Share Repurchase Program, January 2021 [Member]",
        "terseLabel": "January 2021 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramJanuary2021Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramJanuary2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, January 2023",
        "label": "Share Repurchase Program, January 2023 [Member]",
        "terseLabel": "Share Repurchase Program, January 2023"
       }
      }
     },
     "localname": "ShareRepurchaseProgramJanuary2023Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramNovember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, November 2021",
        "label": "Share Repurchase Program, November 2021 [Member]",
        "terseLabel": "November 2021 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramNovember2021Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Programs",
        "label": "Share Repurchase Programs [Member]",
        "terseLabel": "Share Repurchase Programs"
       }
      }
     },
     "localname": "ShareRepurchaseProgramsMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party.",
        "label": "Starting share of profits outside the United States, based on sales, for collaborating party",
        "terseLabel": "Starting share of profits outside the United States, based on sales, for collaborating party"
       }
      }
     },
     "localname": "StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company.",
        "label": "Starting share of profits outside the United States, based on sales, for Company",
        "terseLabel": "Starting share of profits outside the United States, based on sales, for company"
       }
      }
     },
     "localname": "StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Shares, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock for 401(k) Savings Plan"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_TevaPharmaceuticalsCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva Pharmaceuticals Collaboration Agreement [Member]",
        "label": "Teva Pharmaceuticals Collaboration Agreement [Member]",
        "terseLabel": "Teva"
       }
      }
     },
     "localname": "TevaPharmaceuticalsCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ThreeIndividualCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Individual Customers [Member]",
        "label": "Three Individual Customers [Member]",
        "terseLabel": "Three individual customers"
       }
      }
     },
     "localname": "ThreeIndividualCustomersMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ThroughDecember312023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Through December 31, 2023 [Member]",
        "label": "Through December 31, 2023 [Member]",
        "terseLabel": "Through December 31, 2023"
       }
      }
     },
     "localname": "ThroughDecember312023Member",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_USGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government",
        "label": "US Government [Member]",
        "terseLabel": "U.S. government",
        "verboseLabel": "U.S. Government"
       }
      }
     },
     "localname": "USGovernmentMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations",
        "label": "Unrecognized Tax Benefits, Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations",
        "negatedLabel": "Gross decreases due to settlements and lapse of statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_UnrestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.",
        "label": "Unrestricted [Member]",
        "terseLabel": "Unrestricted"
       }
      }
     },
     "localname": "UnrestrictedMember",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_UpFrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front payment received upon the execution of a collaboration agreement.",
        "label": "Up-Front Payment Received",
        "terseLabel": "Up-front payment received"
       }
      }
     },
     "localname": "UpFrontPaymentReceived",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_UpFrontPaymentToCollaboratingParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-Front Payment to Collaborating Party",
        "label": "Up-Front Payment to Collaborating Party",
        "terseLabel": "Up-front payment to collaborating party"
       }
      }
     },
     "localname": "UpFrontPaymentToCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_UpfrontPaymentMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment made under a collaboration agreement",
        "label": "Upfront Payment Made",
        "terseLabel": "Upfront payment made"
       }
      }
     },
     "localname": "UpfrontPaymentMade",
     "nsuri": "http://www.regeneron.com/20221231",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r385",
      "r413",
      "r730",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r311",
      "r748",
      "r819",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r469",
      "r653",
      "r676",
      "r720",
      "r721",
      "r744",
      "r758",
      "r766",
      "r817",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r469",
      "r653",
      "r676",
      "r720",
      "r721",
      "r744",
      "r758",
      "r766",
      "r817",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r311",
      "r748",
      "r819",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r308",
      "r656",
      "r746",
      "r764",
      "r812",
      "r813",
      "r819",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r308",
      "r656",
      "r746",
      "r764",
      "r812",
      "r813",
      "r819",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r452",
      "r469",
      "r501",
      "r502",
      "r503",
      "r629",
      "r653",
      "r676",
      "r720",
      "r721",
      "r744",
      "r758",
      "r766",
      "r809",
      "r817",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r452",
      "r469",
      "r501",
      "r502",
      "r503",
      "r629",
      "r653",
      "r676",
      "r720",
      "r721",
      "r744",
      "r758",
      "r766",
      "r809",
      "r817",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r385",
      "r413",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r309",
      "r310",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r747",
      "r765",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r309",
      "r310",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r747",
      "r765",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r763"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r208",
      "r670",
      "r684",
      "r688"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r27",
      "r30",
      "r141",
      "r621",
      "r679",
      "r680",
      "r783",
      "r784",
      "r785",
      "r792",
      "r793",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r763"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r792",
      "r793",
      "r794",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r123",
      "r124",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation charges"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r209",
      "r316",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts receivable, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r49",
      "r81",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average number of shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r753",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r159",
      "r176",
      "r202",
      "r239",
      "r299",
      "r302",
      "r306",
      "r333",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r557",
      "r559",
      "r583",
      "r763",
      "r815",
      "r816",
      "r868"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r196",
      "r212",
      "r239",
      "r333",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r557",
      "r559",
      "r583",
      "r763",
      "r815",
      "r816",
      "r868"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r321",
      "r347"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r76",
      "r323",
      "r669"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturities after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r76",
      "r322",
      "r668"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturities within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r73",
      "r320",
      "r347",
      "r662"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r550",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r550",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r138",
      "r139",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination, consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business combination, recognized identifiable assets acquired and liabilities assumed, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r199",
      "r724"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r46",
      "r51",
      "r57"
     ],
     "calculation": {
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r46",
      "r147"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "verboseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlows"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r239",
      "r271",
      "r275",
      "r277",
      "r279",
      "r287",
      "r288",
      "r333",
      "r373",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r411",
      "r412",
      "r415",
      "r419",
      "r426",
      "r583",
      "r722",
      "r777",
      "r788",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.regeneron.com/role/Cover",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration, License, and Other Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r164",
      "r181"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r365",
      "r366",
      "r707",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.regeneron.com/role/Cover",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r792",
      "r793",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/Cover",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r763"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r218",
      "r220",
      "r227",
      "r664",
      "r672"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Statements of Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r65",
      "r66",
      "r144",
      "r145",
      "r311",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r65",
      "r66",
      "r144",
      "r145",
      "r311",
      "r689",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r65",
      "r66",
      "r144",
      "r145",
      "r311",
      "r706",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r174",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r65",
      "r66",
      "r144",
      "r145",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r67",
      "r144",
      "r146",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r65",
      "r66",
      "r144",
      "r145",
      "r311",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable and deferred revenue information"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Cumulative catch-up adjustment to revenue, modification of contract"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerDurationAxis": {
     "auth_ref": [
      "r750",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Axis]",
        "terseLabel": "Contract with Customer, Duration [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerDurationDomain": {
     "auth_ref": [
      "r750",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Domain]",
        "terseLabel": "Contract with Customer, Duration [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r428",
      "r429",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r428",
      "r429",
      "r449"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r428",
      "r429",
      "r449"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r36",
      "r656"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of goods sold and of collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r791",
      "r851",
      "r853"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r791",
      "r851"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r532",
      "r542",
      "r791"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r791",
      "r851",
      "r853"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r64",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r237",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r398",
      "r405",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r160",
      "r161",
      "r175",
      "r245",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r603",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r149",
      "r151",
      "r382",
      "r603",
      "r740",
      "r741"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principle amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r245",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r603",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r103",
      "r106",
      "r107",
      "r108",
      "r148",
      "r149",
      "r151",
      "r173",
      "r245",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r603",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r329",
      "r351",
      "r738"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Value - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r329",
      "r351"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r329",
      "r351",
      "r738"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value - Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r329",
      "r351"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r327",
      "r348",
      "r738"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Fair Value - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r328",
      "r349"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Unrealized Loss - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r326",
      "r738",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair value and unrealized losses of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r791",
      "r852",
      "r853"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r791",
      "r852"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r49",
      "r133",
      "r533",
      "r541",
      "r542",
      "r791"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r791",
      "r852",
      "r853"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r131",
      "r850"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r849"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r131",
      "r850"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r130",
      "r131",
      "r850"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax attribute carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r131",
      "r850"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r131",
      "r850"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "auth_ref": [
      "r131",
      "r850"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "negatedLabel": "Unrealized gains on investments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contribution expense to 401(k) Savings Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/EmployeeSavingsPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r49",
      "r297"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r448",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of collaboration revenue",
        "verboseLabel": "Schedule of product sales"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r475",
      "r506",
      "r507",
      "r509",
      "r514",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Long-Term Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r228",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r283",
      "r572",
      "r573",
      "r665",
      "r673",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r228",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r271",
      "r277",
      "r278",
      "r279",
      "r283",
      "r572",
      "r573",
      "r665",
      "r673",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Per Share Data"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r241",
      "r521",
      "r544"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r847",
      "r854"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Taxation of non-U.S. operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r847",
      "r854"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r847",
      "r854"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedTerseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r847",
      "r854"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Income tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost, net of estimated forfeitures"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition of total unrecognized compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r192",
      "r222",
      "r223",
      "r224",
      "r252",
      "r253",
      "r254",
      "r257",
      "r265",
      "r267",
      "r286",
      "r337",
      "r427",
      "r510",
      "r511",
      "r512",
      "r537",
      "r538",
      "r571",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r621",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r203",
      "r582",
      "r726"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r674",
      "r803"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gains (losses) on equity securities in other income (expense)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r575",
      "r576",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r396",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r576",
      "r626",
      "r627",
      "r628",
      "r740",
      "r741",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r396",
      "r454",
      "r459",
      "r576",
      "r626",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r396",
      "r454",
      "r459",
      "r576",
      "r627",
      "r740",
      "r741",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r396",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r626",
      "r627",
      "r628",
      "r740",
      "r741",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r579",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r611",
      "r614",
      "r762"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails": {
       "order": 2.0,
       "parentTag": "regn_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r609",
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease, liability",
        "verboseLabel": "Total lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAnalysisofleaseliabilitymaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r862",
      "r865"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r611",
      "r614",
      "r762"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails": {
       "order": 1.0,
       "parentTag": "regn_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesFinanceleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesAmountsrecognizedinCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r350",
      "r352",
      "r353",
      "r407",
      "r424",
      "r561",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r738",
      "r800",
      "r801",
      "r802",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r200",
      "r360"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Finite-lived intangible asset, expected amortization, year one"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Finite-lived intangible asset, expected amortization, year five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Finite-lived intangible asset, expected amortization, year four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Finite-lived intangible asset, expected amortization, year three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Finite-lived intangible asset, expected amortization, year two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r657",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r86",
      "r661"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r86",
      "r657"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r240",
      "r543"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Income before income taxes, United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r33",
      "r156",
      "r166",
      "r183",
      "r299",
      "r301",
      "r305",
      "r307",
      "r666",
      "r737"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r240",
      "r543"
     ],
     "calculation": {
      "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Income before income taxes, Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofincomebeforeincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r241",
      "r522",
      "r527",
      "r531",
      "r539",
      "r545",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r242",
      "r266",
      "r267",
      "r298",
      "r520",
      "r540",
      "r546",
      "r675"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total income tax expense (benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/IncomeTaxesScheduleofcomponentsofincometaxexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r221",
      "r516",
      "r517",
      "r527",
      "r528",
      "r530",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "(Decrease) increase in accounts payable, accrued expenses, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r654",
      "r786"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "(Increase) decrease in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r279",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r80",
      "r84"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r150",
      "r168",
      "r225",
      "r296",
      "r602"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r40",
      "r402",
      "r410",
      "r742",
      "r743"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDebtSecuritiesOperating": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.",
        "label": "Interest Income, Debt Securities, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeDebtSecuritiesOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r232",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest (net of amounts capitalized)"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r79",
      "r727"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r211",
      "r725",
      "r763"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r210",
      "r285",
      "r354",
      "r356",
      "r357",
      "r655",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r79",
      "r729"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r78",
      "r781"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r79",
      "r728"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs and reserves"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Shares purchase price"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Marketable securities, based on contractual maturity dates"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r157",
      "r170",
      "r185",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost and other information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments.",
        "label": "Lessee, Finance Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesOtherinformationrelatedtofinanceleaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease, renewal term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term of contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r239",
      "r333",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r558",
      "r559",
      "r560",
      "r583",
      "r736",
      "r815",
      "r868",
      "r869"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r162",
      "r180",
      "r763",
      "r790",
      "r804",
      "r860"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r197",
      "r239",
      "r333",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r558",
      "r559",
      "r560",
      "r583",
      "r763",
      "r815",
      "r868",
      "r869"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r3",
      "r161",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Borrowings outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Line of credit facility, expiration period"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r161",
      "r177",
      "r395",
      "r409",
      "r740",
      "r741"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r94",
      "r95",
      "r367",
      "r368",
      "r369",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r367",
      "r368",
      "r369",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r367",
      "r368",
      "r369",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "totalLabel": "Total marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Debt and Equity Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r50",
      "r167",
      "r182",
      "r195",
      "r216",
      "r219",
      "r224",
      "r239",
      "r256",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r276",
      "r299",
      "r301",
      "r305",
      "r307",
      "r333",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r573",
      "r583",
      "r737",
      "r815"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r60",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r268",
      "r283",
      "r318",
      "r319",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r510",
      "r511",
      "r512",
      "r535",
      "r536",
      "r537",
      "r538",
      "r551",
      "r552",
      "r553",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r658",
      "r659",
      "r660",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Accrued payments for Libtayo intangible asset"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNonCashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r299",
      "r301",
      "r305",
      "r307",
      "r737"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses and liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gain (loss) on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r102",
      "r217",
      "r220",
      "r226",
      "r592",
      "r597",
      "r598",
      "r663",
      "r671",
      "r783",
      "r784"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other intangibles"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryNetOfReserves": {
     "auth_ref": [
      "r78",
      "r780"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Net of Reserves",
        "terseLabel": "Deferred costs"
       }
      }
     },
     "localname": "OtherInventoryNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other operating (income) expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments in connection with Common Stock tendered for employee tax obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable and other securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r230",
      "r855",
      "r856",
      "r857"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r452",
      "r453",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Savings Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/EmployeeSavingsPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r763"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r782"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Sales or maturities of marketable and other securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from bridge loan facility"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAlnylamNarrativesDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofAccountsReceivableandDeferredRevenueInformationIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r807",
      "r862",
      "r865"
     ],
     "calculation": {
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less, accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r808",
      "r865"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant, and equipment, net",
        "totalLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r779",
      "r806",
      "r861"
     ],
     "calculation": {
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant, and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment",
        "verboseLabel": "Schedule of estimated useful lives of property, plant, and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/CommitmentsandContingenciesLeasesnarrativeDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r229",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedTerseLabel": "Repayment of bridge loan facility"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r125",
      "r186",
      "r876"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Reduction of R&amp;D expense",
        "verboseLabel": "Reduction of R&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development in connection with asset acquisition"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsCheckmateNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r778",
      "r787",
      "r877",
      "r878"
     ],
     "calculation": {
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in Other noncurrent assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards and restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r109",
      "r179",
      "r683",
      "r688",
      "r763"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r192",
      "r252",
      "r253",
      "r254",
      "r257",
      "r265",
      "r267",
      "r337",
      "r510",
      "r511",
      "r512",
      "r537",
      "r538",
      "r571",
      "r679",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r294",
      "r295",
      "r300",
      "r303",
      "r304",
      "r308",
      "r309",
      "r311",
      "r447",
      "r448",
      "r656"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Up-front payment to be made to collaborator",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r451",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Senior unsecured revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Agreements with Royalty Provisions"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense, net of reimbursements from collaborators"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CommitmentsandContingenciesResearchCollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.regeneron.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of non-cash investing and financing activities"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of presentation in statement of operations of payments to and from collaborators"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of issued senior unsecured notes"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of income before income tax"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.regeneron.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r57",
      "r158",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restrictions on cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r471",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r116",
      "r117",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of transactions involving stock option awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average values of assumptions used in computing fair value of option grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity related to restricted stock awards"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r205",
      "r206",
      "r207",
      "r287",
      "r411",
      "r412",
      "r413",
      "r415",
      "r419",
      "r424",
      "r426",
      "r744",
      "r777",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Class of treasury stock"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r761",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r67",
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of concentration of risk, by risk factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "SG&amp;A expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofCollaborationRevenueEarnedFromSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior unsecured notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Awards forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars of shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars of shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares/Units (In millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars of shares)",
        "periodStartLabel": "Beginning balance (in dollars of shares)",
        "terseLabel": "Weighted-average grant date fair value of awards outstanding (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "terseLabel": "Awards vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars of shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value - of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of Options Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of weighted-average exercise prices and weighted-average grant-date fair values of options issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value - outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares (In millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Intrinsic value - vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansNarrativeDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtoperformancebasedawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofactivityrelatedtorestrictedstockawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofperformancebasedoptionsDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted-Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails",
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaverageexercisepricesandweightedaveragegrantdatefairvaluesofoptionsissuedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r479",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity related to performance-based awards"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected lives from grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryofweightedaveragevaluesofassumptionsusedincomputingfairvalueofoptiongrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value - exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term - exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years) - outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term - vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Business Overview and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Sovereign bonds"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r239",
      "r271",
      "r275",
      "r277",
      "r279",
      "r287",
      "r288",
      "r333",
      "r373",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r411",
      "r412",
      "r415",
      "r419",
      "r426",
      "r583",
      "r722",
      "r777",
      "r788",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.regeneron.com/role/Cover",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r102",
      "r192",
      "r222",
      "r223",
      "r224",
      "r252",
      "r253",
      "r254",
      "r257",
      "r265",
      "r267",
      "r286",
      "r337",
      "r427",
      "r510",
      "r511",
      "r512",
      "r537",
      "r538",
      "r571",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r621",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r286",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r109",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LongTermIncentivePlansSummaryoftransactionsinvolvingstockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r109",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchases of Common Stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r71",
      "r763",
      "r790",
      "r804",
      "r860"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r238",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r427",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r599",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r599",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r599",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r314",
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r324",
      "r325",
      "r407",
      "r424",
      "r561",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r800",
      "r801",
      "r802",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Beginning Ending, treasury (in shares)",
        "negatedPeriodStartLabel": "Beginning Balance, treasury (in shares)",
        "verboseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r26",
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury Stock, at cost; 22.6 shares in 2022 and 19.4 shares in 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r5",
      "r102",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury stock, shares acquired (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r102",
      "r109",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Total cost of shares",
        "verboseLabel": "Cost of stock repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r667",
      "r753",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. government and government agency obligations"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r515",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance as of December 31",
        "periodStartLabel": "Balance as of January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Gross decreases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r289",
      "r290",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/BusinessOverviewandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Credits/payments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofSalesRelatedDeductionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r270",
      "r279"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r269",
      "r279"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r768": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r769": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r771": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r772": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r773": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r774": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r775": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r776": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0001804220-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001804220-23-000008-xbrl.zip
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M7 AM#[I7KUG7-S/.JV/M*YPGR08:-_15DT9N,5AHR=&6036$9ET?6%0\-4T
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MS660H6%CK2IMS9\29#"N92O(;(-:3.\/,X9U=W?F<BW-99A6+BFEHN&D$#I
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MJ7KS25V_- #: H >=TQD<C"]+64Y.@MRAC&@=V*2@YQ;;@DS9FC@;6[%;@%
MO0&XS/L>OY#>F9$ TQV;25R#IE0@3G+I@P>L_R=OQ<@V -.%25--L115++?E
M>+:8C,6QQ62*S1DJ(H-B0C6$K%8477+ZN=L">&XL%K*\2?R[C$\8L(E!)$LE
ML, EYJ0.KE<(LDHZ3'7S\\F-5&[K2P)-;.BKJZT6"X617%$+2E -!LW_W18
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MD=<S0EYOVEKQ!ELS@DD 72OD0ZU0R96*1./RMN-ARA7-"E^C?O-]I;I:8C
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ML6)%T2NLI!C@B"M5@W:4=I6I[:IN&JI9VJ@V.@H]#P!S(E!Z#4!8%C02+[O
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M>DE5\(YX$(_EFM)NJS5%+VHF*-I:$<1H[F/5J"C ,\5]V \<[PS_VR<!L]D
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M#'A(1"2(^'\O!!BR.GP&W=\Q*]-S^/^RSXY2&6\<)96*W)?>HQ4MQ\JX(EU
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MW-#+'4::CIH!DB@>LBOT+*@ZG_3ID%B\ UH5?@5.Y-2V0;MY;A\GY;,G"%<
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M#*.T\.MB05WSNU*ILM:;3PU65PME;;UFMS_82D&O&G*L;WVLM:7'(VW@;=O
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M24W9_O*J<-TA<[=<A]JFVW-A*6 (C 9NC^$UA$%<L?$@UZI??LD=+J$*LFG
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M2F"?L4@*?=S8Z_^^>WWE],I6K3L_20ME&D9@UF@]0 ,B@OV$4^IR"FNMV:!
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MDESJH",5X1!SR;/UZ7/L@1WR+YZ?#CG-VE%@&7-4.F83X1'GQ#CW/0 ;6.9
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M]R&U,N04CTR,VZ.Z8G;'C4S0+&:J04%)\;X\<=&X1'O2S9S35(UJEJXP3^N
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M-<*TQ3R)7*TT.>VZ9[/PJ:&49EHX"%!T'R@@D(T(VQ"4X<9E=W/53VOAT/0
MN80OF.K7@4UPQA*MI3-<UAEH,)= 4IKHQ*$?8 .YG6 *$[QM?<]K2) X(XH
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MY/D .AFBX'B3"K29C:A1)/>D2S4)3GTELT^5=S!.B,1W(+ "6U Q"[):/CE
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MV>9G+.N()K\(<W5X:2O/2TMA5_*8B^[ +&M,AME7ZI&6WUU4(I=+U/.P^T-
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M?]/</_.FD&Z6Q]LL32[3I,'-5'GWJJ8ML5(;0WGY P#\CU!0.#@#?*:B%:Z
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M>6_E?FIY;Z5I[,)M-R[<;J]GV<V#D8J3A<I2&#5CPOKSOM5^*_Y3RX$K36#
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MO983QX)OEY@+G23RK582/BD=X;^6_>@U1VXM> (JCX2![//S&OP]N<"-\%\
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MR1^Q"*05)5Y@UI*+T 0+7"(OPT9Y6H80F):DX$SM*^&1$RVA-G2@2L1H0NA
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M@P1BJ,=W3^C'U]"G2A4J @" WYS[8'>RR;,[<^F(_03YL94_'EDZ:U: VK8
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M8]"$$]9([4:*IKB(61[ AV*+S1?J:FTU/0-/Q+<!DIJ9TOM'$BW_'_(N](4
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MB$XHV_T#C\P2."0A+_.L+ADE24J,AF=6P(B21\D&<X=>'#T_LE+*U_S?/P?
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MDE74Q[RH%FNPT]E_W;C3I(_>E'5'IF_!UVC@B"K&^CD*08U[]+: 0*@E5*!
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M]";L39R(BOO>(E5Y$OPK#^RU5%86F%OQ+\Q@S@V5$B@/0W[=]-.D]CH:.WV
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MJ9"$UM33IYJYF/W?B^_>O[UXP]&7VA:: 4H:E$V5MP7@N##:04)1&&TQP\Y
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M;BD-F$03XB?>"3MT9&2[F,!.,TG""8'OO;;&K8.0#E#VMNDPQ:[B81,2W>P
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M!#\=\KP(N(.?WV]# ]STKYA %"4VQIF,J1^<#(/9WFO/ATB+5K%0! 'PR#W
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MIAQB&CO)(6^1")]ZX[3W^32Y@=548\= XB(4L<0[0B@17&+(3EBD95]>\VV
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M_?G)P[S4I^L7;$<3ERJ#0M+N]N#*17LYXPQ&<4\(6QC=F+0'%?$&=QQF,;^
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M)OIVVH'%8&U_PD(J2;'LGMQ&&GUPP18ATVI##>K5G6BL#=S23C0T&W00I06
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M$V):RS<D4X_<14]77_SM+\M?\R[Z+2]"GITX'.%P7PT3U?SVM51UIFQ .<
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MW#_"'53(UL5@4PRW=?H+""Z;79PS,$]S)\F TDG5\"=RB!(,/2?Z4')-*"8
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M0TY(?*!U)STN:[/:=M=5;VR!K)%&;^-XNP@WNB%G7[_6S1LUW:S'(HIXCPB
M@ #XVR,"X!$!\( 1 '>A-U:NP* I,X%($L(5%Y.SRS$CG^-DU9=[=C1*<'IA
MQMD'539-<F_%>^7;YANP[M7L&<=T%W@?49 &7L39AWKQ ?&)[,FX6"T\XUW'
M#"O58M]C$$(/<.#AX!W+%Z9M=>19QVX4,IXE0\(G([[K"8[FY.*_WYV<XB?7
M];RFA'5&-0<5GZ@3@XGP(*X4(9G5JN+\SK8\T/\CB<Q"F$6Y<%?!7)$*[,$
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MD+,FJ\!RTM2-##/E3JM<)/.JK5;UPY+Z>$]IBY^Z7O!>-#>JO8 6Q*:HZZ-
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M$[4C TJ,ZD,)CS=7^"@6N? $/JI1^PLX3&>F'*MY=78P+#5@#*QL&$)]$;X
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MQ:;<AB>?]ID;2B)IE9J*E!4?+P/4*%5IO? )ZIVBWZ&'W*%%!(^:&L8'8;W
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ML0)..SM3-L,Q/VG!.C'(?3NJUK)%&BF>\AG'H"2?4F5.U!"U6"D =G)8"G<
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M_RZ/,A<AC<^^9AH)Z=$X*<#-**F"W<LO^6+&[&'L_OAI'?R7*>9@[<Z)+29
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MS)TD[:O84T]1#(_W3S;=Y7O.&WP2OCPX&IST&[RI&[P?'AX?#8Z>Z 8_"\]
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M$-_,G06ICQ9M=NTKGK)]$'U+%4T9(XK]E(*#(S0TYS'[7O[P X!@[CN+[[V
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M4@>)7>((Y_3"2L/7,I]=9[TNO<SL'SZ5[%B)60?=]& KGM;NPBAB\3P,$(2
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M"D>UQY%E])2PJSN2KMN&;JS<=1\#/^IB9049GYD/?YRT-$JS=GR>"N^X,R_
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MMAJ<4'\D@=&^ZUPGA:2C>_,=W59(JC>2KONZM7VC;(6>8Z-GL,N$P;H.'FF
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M>;DG,1>J FA62WMDFN/'H39U7&THP^F:\P!@X2!?X+=?]3I@\V883;&SO>8
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M 9M/\7;M./DCUU0QA03>>\/$62 5)DXP\5!34IR$:,_4C=Q)S)C]D46L&/]
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M[OJO$:YB3&M!SY@%#QZ8(OB!XP-L,=CB\Z/S6S,R/A(0%WCA+>@23@)6!\_
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M)*+A#%CLG_RF)@CSF0_ ;FD"LH_C[2G5MB&[ZBP M)[5T.H *HX+31Q'H U
MW(A,) =HZYLW Z))0A0Y/H5$)TRC&T+I;)/0X5^CP"N%^RC0, ,MRV4767"^
M7UB_@E$+NG434IJ!DQU]X+71B6:<]BES_W? N_2&!RT*1 Y#)W(1S:X7@?P-
M4;2F(*HB6!E)+R:(1#E$YAPB**@+?Q76HRGG&,I@DHC#%X,O7.VL77>. C2A
MP%+9?)XY7XM?0)L^"M,)^B0/J"[Y8!FP<*8A:N3\@@+X*KA1V359=LU 9=>H
M[)KSSZZIIG[8UU<,EX')'#LBJ%NXS 3I@C%@LD,=?(K_U<=(B N&,/>6G!$
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MP382Q="F#M3X'1KNU,B.F]#H,HN>+:BI,R/>[+1H:5F?W=GR)9;>-W9\2<=
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M4*IF+W8KD'' )<$K>VED&Y>'!JGCNX]XVLJ;_*SQO7!72\N>2TR((,-S69\
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M'$5>0X[]EN9,S$N7,UM@?>B,ODXBO-B\$6<8C1@#=VQ'J(#,.;X.,+CD,+=
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M62 \K[;^^I)C*\IZN5A1(-+I>H;=[YG]-X[9NS';_6X/T^D& ]?<D$_WE#1
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M1<$]]D%9+EPN0\YQ(8AGAI&<D*_KX'M03#!!\1="&5DJ6]K_[Y+SC3>K ]<
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MEP'4[B"JQ_@&/.6@>=$,W3O_?OS$QD][I-N'?MPJ'5VR?*BG39:_\X)!N-S
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MWAVBS%=Y\?A"NW+TQAU$L("&4?!CW7!#PZ,]="S+6YQ'=N.DG#]1][+P+8_
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MX)F!+'+G$.'&%#HXZ?-;1[KG)C87DG))=AY;=JQ0><@90UKYN,<S)TB#B8.
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MP.>P6L9D>$&0TL:BPH'SJ 5U+):V4%#MDV5\KY^PLY& /\NH00+^H@-_(MC
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M/A&J12#2V$B\+SW'J54^*N:M"!O;;.%D["7@XFXBRK<-Y(XK5PG'_^<61;:
MJ%:*PF8ULV7Q5\=<I6LPM*/G_S[IC4\OQ]QS[Q,D\AG:866SA=GLMZML%G1
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MIRW_/S\7Z^LO BUO[ S2Y1<N?/)7O-\A;LV3A?(,)O_BW_V3(H/GG^*A'QS
M:S^&YSE#'-<]>;$]F<Z+1L92*MCCN@=J2ZTL3KRUD7"EJ5<IBQC8QC;*OE80
M?LA,L/189&6"%6>"&=N=QX1VE18DQI(GC<8Z"28:8H3R"AACAH>-;>WFU=BJ
M3/!@F&#I4<S*!"O.!+/GPX(M=?4,H48G(A.7Q"8=B3!.Z@ N *4;V\J854S&
M?% &>;W&#:[Q&$SHIS<WF1L_;@(<] :#$A<?YN:XX]!J2=_FK@E:>:9SL%X'
M247VPD3)+<LT!F^\>??R#M3FZL!>XL8XKYE6,D&:Y"/JQ)FAL9R!."\245X
M,.^R4UU3#NOL%ENAK;'"?<EP3PY8L)0G1J-DA@9#LS8B%N>9YIIU<+]MW;C"
M?;EPG[&(353@A50DV"B)-)$2S\&0Y"P/&=]@VA6X<VJJ=^PAPQTY/M!,M93&
M2X[V,$5["+R)4;F0O2YP9Z["?:W@/F/V<A>S*759M>2<2,TX"<8'8ER2C"L9
MO>Q2V[2@*P7WAVCXWJBG?!WDK0RRVM,S]C3@R[=J27_W_KIR,_Q_OH<*%Z#
M%5<=N/+&6%Z<Z!%W$' TT@1*Z!2$"E9VEL)M1]:KZK!$U6%>PP;&<Z!"1Z)+
M $TZ(8GW/A'IG?/ (AA.-[;%)F-N3EWWM;<4*GL]4/:J;LT'R%XS?@[GF17&
M><*IM:5"6B9.\D0,Y9!]]H%J_8#=FI6]'BA[52_M V2O6;>-5M(R9HF1@.SE
M4SF1R#3)TB0*VCNDME7TTCYPMXW :4G#D]"'57:)/*Q1/BS/C9G+_V].CH_[
M4*IB^'Z3>J/8'XY.VJZ/2^>MR?WAQZ8WF) N(OQ6\Q[J-99SC245TEN1A7N]
MR[$Y]KU4% )<H6,HCL;FAP%TY?3\$=[?>(2+^+B'2QLOG&9.O"V#@KZ[2,_*
M3>S-M=UYM_A@M-VE'^9Y.5VBO^*:W86:6;N8KOK;W-I_,D(RRI%L0ZF>X1,)
M(7-B<\QHK2CA$FQL*S&G+?W:5PJKQ/- B6?I9X<J\7PO\<RX^'P.)B4  EY'
M(K,/Q%H928A4RBQH2I0C\<RKRE&)IQ+/:A+/TH\J5>+Y7N*9/4OD40(Y1&(5
M3ZCQ)$Z<C;2XZ+SU06KEQ<8V%UM\A8CG8?E1;F:.QN$1-&/_Z78**-88RP/E
MX%NP.LM*W"\+\0L-UPC*TCAZ7DU'&H65+&42N<M$!F1K1PU:I2(YG2*J]E1.
MJMWRFKU2N6EMN.D6#-/*3;?+3;/MOC)S.3!)E"KU::C3Q&8*A'O/J'<I*!H+
M-W%F*S=5;EH;;KH%VW66FRK]+$@_,^:K-,SSP!W)P6@T7SG23_*.&&%P*^$F
M<RBJD5VMQ+AO2"U9(+3[F#XZUQ/ V3FA3Y(T)M/_G_(TYE!SA.)N6JGDBOU#
M:'Q$(L'?/BWE(P;#,5[=M_CRH(M9'[2^WQS[MHM9C_'CTQ8,^.IH[,==8L9H
MZ]*B[^;PQ['':<%_4^_#]C_PX<KBE*7WW?%PU"O0>=)"WX]['^"GC[TT/CQC
MUPO?FDXX/?^*#Z-A_V1\_5=F9O[N-PE>QO2"V"_3<W4RKAOC]C]"^^/VY:]=
M?"R7Z"@^,AM\LB$KP20(<%E&(:UWV2HGF'G'F-HX^]9A>[[V#X"$%OQ[XC/^
M[!/?_^A/1QL_7AK=46] +HIKT9F>=Q?=PS5BR/E;Q.!N((4)#'$[';9=DM 3
MY&%HRZ=PJ'Y5AM(<MD57^-O7I6H0N@5?!91/BYJ!(/S'C_ZZN5Y4$+?%.1T>
M7C__Y_/=YZ_W=IM?_WOG]:N=I\]_WW_Y=.>7-YO-R]VG6RLRRMV]_>=OFOV]
MYNG>[IN]7UX^V]E__JQY\7)W9_?IRYU?FC?[^,*KY[O[;^:A]-O!<6-8VXTY
M/W;DVP,$[90M+=[I])7N.*B\O!_]=3(:]_+IW6\]W02SK6:J/N^>'.$EXA+\
MC)<UY#=XD[V,6^U@O(-[W,E@C#O<K\-^+_9@M(^_]'-_&-_?NZY\,-65AZ>O
M^.[A+G\K=O]X+LOG]_YX<82Z\J<_G^U\?/7786]O_V?47__L[:&N_.?_'M)X
M]*^!_\.=[/WU\O-;_ES\^5=DJ/>JHO>^_>//P[W]%^]?/=LYW?OG2_7JGW^^
MWSUZJ?[W\\O/NW^]_/A.:07&9-1O-15$,I6)4T$1\)'E)"@75$]LF-[@!-).
M<7FX&$/(R226@[2:!1U0+-HISKR$Y#8:0!/DN*SZ]@2I]>>3$<I]-&KV4.GY
MT,.%4\[;OCDYPE5Y6KCK@HB:<QDU9T(Z4[&G*^0*6O"]Z? Z(IW(\>M#O'Q+
M4M,476(.&)4Y:I\#_I&LRH'3&.7&S?%E[QA>W16?=,F#\0: VVL/_*#W>3)7
M10YGTKE6.UFIN_V/.M9K.( !M'ACOQ[Z]LA'..ET[!'N*8.XU=UN;SQJ1B=A
MU$L]W^+B:G[8^/*US8UFX^E$"RY//T)Y/!GA8_GFQO"DW?A[TT/%N,DG_?[I
MF69<CHR''JK,\7" =WIPVDQ5:=24_;C+5A[BRL=1] 8?)@?.$WR _O 8G^%-
MGV0T'4]:F!Y$QR_C.B^Z-=[ZJ#F"A"A "741NS(SPY-1N6@IB3G::O9.VN:X
M'::3B'=6OC_]HT$XI5[R19/O#<Y^L6OC7!3[!*5S!HY\/&P.H7^,VOVX5P;7
M?.R-#QLXA2^_@</J]P%%'B<S.,A]C]@=#Q&]YY_!GXO0EG_;U!M^\*-XTO=M
M]XTC0#.@@/G"QX]];[")OURN@W,V(?[4*?7=1)6JGI?N='I*OQO[EYLOELM4
M8DT\:5N\ 93+H1\UUSIEIM.SE /;+W=?G&TW+>#R1X8*T.[E7Z?RV#G&7_M0
MVH_@0'_'$<#H33&71B^&P[0S2,_:DX.=A IV;S2>Z(&7/,N(@UB\RQ_1W!S!
MX(MGASZZW0I_Y;=W-EO/?39$.F[Q@05B4]2$1I-DREH@W6]L#Q K,TZ9<X1T
MD#ST'Z!I(0(:F[@\??L>NAW'=_)"HS:<=E;N[UMOMIHBJV[M%6DUE\6%[/'B
MV<[&W[>08)IB\Y<7-YM.N25/]_YU1JI+94.]I6YB8<R:U86PB>B^?=7]@'":
MV$'_[V_,R)^:6QGX#6G\(\+7GXP/AVU)AV\ZRZ@X(IXC+2)3Q]/F]Q$T.]-/
MG,GA^>\HAR:WPZ-F%S%7@-@4'VI3M(E^\S_(LT7=*#!N/A["H!,P?JDI/]?"
MA]YH0H;PJ509AFZC.)ETKCB (=+\\2&2%,*\,%2Y0@M?:&K0(#7#I^/)F13<
M(?J]]X!$E$Z@7-(W'W"O*=I-M_KP_<%PC+O0*,+QN%<,./Q0&<X8;?%QH>B?
M)BP\/L3/EC%VX[N\M,XN<TY[%^:L;!73P1=J[-9QYZA!&D7CH^TA>??*'_BY
MOT[:W@CWF(YZ+U-JM]<5M\]I&2'*OX\\/EWY_J"%B=^GO#?=7F8W,*3M4<$5
MLG\Q57%_P)6'W/_5/>N'$0!*<@R-^/NL.;A^RLG%>1T>0WNV,5^[48W@H$SO
M<C,O+NQ87UIE33>MUW \;#M_W9O)+X_J9C1W,SKXM+?S+H()5!E&@%E/9"H]
M[ZR11#CP27H0NJ36#N?M1>','II*>!/9I!</2S9689Y14;<N=+9M.OZ>D%,A
MB3-]\G3SHE(WJSM.8(KFU=<TR LK\[]&YZ/K=8KR7TAP'?BGL$6N>#^:#A6W
MS$W\_+CCH7[OJ#<9Y2:NX>G'S\=?MM>.0P8%Z.4O5'C!MWC?Y[>Z^84(+MW9
M,)1K3;YS@%IEIWF>[=5%]<3!XP8^V7O+-)Q_H?P%Y5A@URX8==S+CNHS"_(6
M_0\_^U%OM)>O^!Y.)X^/VO^P_TJ\H\XR!E(1PP,0254F@0=/BJH7/)KO69JK
M_H25Y?\%3?%N912 _EJ@,!A/ /M MCJ$45=TKF.N>=&B,[KK.,U/T-'-QKD5
M?V:O?SQ$S>.4##\6>_6B\5[4;E1GSLSMX/O%")VH%*BA#T83RIV$LJ PU* ;
M3^E&]F5\^(&MAS#K/W^I_C[5'4N4KAV-FW^CXHNS5.:VD-1F]]:9*H)&"TZ(
M;P8XB')-G' XVFQVXK]/>FTW501Y-I8-X9RP<7HO$302>Y'3TXLR?W,N:?SA
MO4[CF<@"OUU^O074PD=HES23)(:R$76J\W00Y_OA#<: *^C+@(ML!U.]O)L*
M/QK!]!,3DVA4E-*/4+995/*/"5H-@_&/P^,Q*8JI/YT,^\*^BX#&L<)TCYVO
M!F\U.]/#O&T)ZZ3)6,:7[RFALEUV0I3 *=Y(*3&(GWN&IFAGL BV.;50AB?]
M-+%3\0)%6T=M"W7\ &BY?+D^CNSU=1."YD@9\M7-;BV7]M,SY0-B'X79^8HG
M<NQFJ)N4(Y\Z.^H8U9MV6K/QR_'JB>91M-ES<$P-I^E'4?,YOD##F^<JSKP5
MU7'6U-PORWL1N!376VQ[H< NH")W14!7G=VWJYV@);V7GZ-LCXH]\ABUD+_>
M?WH7<HY":4Y0WTA$,I>(]8(1QVB(S#,E;7RH6DCQI> *_K(&'@!=%/T#P7SL
MVR\VT#4:R!DK],:G$V!WJD?'M*B2P'&A?W\>D4)NP8L<]SNCID/\J#CP_4%W
MP<(R1_X]:AIG<]E!'PGKY.AX0E>=_\=W+:LF'/)EQRBV]]F.,3^]9G*QF30=
MW';B^ 0_B8,YZ9=2$MW6D7KX*^W$'S8^'(XNC.I>"0=UA!( GTCF-1J33Y$V
M>^/R[#&RSWZ4[P1(ZYP#DJ*+Q97@B5=.$J]3")Y#C(9?#5AR+:1.5&2MG;24
M!N>H9LX:KQ2@;!XJ6UU:/EW>2[=\FK)^'@!SO?B"^]Y@A)*; '_B'CH>%N=%
MKR.GSM<,EQ3YB8IS/CF=VATGLU.<-IW%@ZKD6<FD>76PSYP\)4XYZAS1T[#;
M%_ML$C0I3L))R",63;087>=ZT;DKZ7@:P+]L<> D33R\$[4<Y03MN4HW"1@.
M!\5#/3KWJ7=7[TW8K9A\Q2G=&8#-?R:SM5P%\W,:O@KYR^"8D7\WA;A)')]Y
M]/ >T>QJKQ@UJ#S/D79G08_.\S2VNIF^.,CM9J?[R3-;9I('?6;0X!+XB$;B
M .712V6W.OOUT=FO3:(6\^).UR9-WY4\[C4:=FU\8-#Y[:^$!W!9^&AB"%&!
MY%('D9UTUF7FE37!?"4\P+^Z7?\*;7D!51[V)01 ^./;NM7NLYUWD0>MJ?&$
ML](JB*+Q8(.TA"GKK4K,:R4VMJV>B0'\W[,\ZG.R+ 7!<)X3S(7?F6NK.$E:
M@(JD6T>2-H)KQ0)SPDHM&6KM/)KL!3 ;6)!?.498D733U(Z/>\_B.QJ]R%$*
M8H0M%KAVQ)N@B;4J)X_P HI(<K/';?YO\\.YIV8Q"7O4M(6(QADK963*,29]
M8M:B.B[0\J\27A)7BMUG!V+W\_N/>_N1O]I_^RZ#SQ!X)-I31Z1D&2T>)0D'
MKF7,*7EM-[:YFR/M*\'0+K/AH(1#!T5=_?NW\FIQ!%]07LX<L>QR/D1)+"M+
MJ SGI#L1<SHQ_*$].DN<\ZBJXY4FNNJY4C4QW[]P]42MOJ06G^F\^&*OO> !
M.(:V"\,7);N[QD2G^SALQX?3./)PFEC2)5"4&"I^I[@P4,$>C<ZZVQP/!]VT
M=;ER7?_LT=3=@#\WO2A^-?>*;O^?=+GN@F5R.KV^*.?EX=:[H\Q)7=CI]X<?
MR\2\&+;/AB=AG$_ZTT#KZ/47(3^=.'HO']K.O4^0R&=HAX\XD^$5W7WV"KF7
M19QU0Q1/BDCG(Z(Q1B0]2;VSPGD>[O($_AQ!_]H.)PE0<P1=Y7J-7#EH9I-#
MEHV.$LEQ3PV**1(@.8[:3*F2?Y=57ZI<ER-718U3*$-BP ?$:];$R41)0"W)
M>IV=+;K2K?=[J7Q\2_*-1AOK52*"AE*8!SP)F6FBI<DFZQ25]QO;@^&,=O0-
M+S0?V]X8R##G:7SA3(+=_C]/8[J@@%WT+I74LLN*UV7M!]_^HORL24AZ0=?T
M5T\QW5W.V;0[R96>)#7E;'?_O7BGT1:(T3+B4K0(KZB*J:D0;39+62(O@:U_
M^.2:1(JNLV5)P"E/+JR-]4#DC1.LNUA'ZGQB_7YSB)]"<ZC?P_LMJ1AA?#F\
MTN4(-;@5G;0E$-R9D,7)AB;9^+"CKGZQH[I3 \<G+1I/T[," 6:"*!.#,?JV
M[4*TDP#O3'SW4J;4SQ,;M'ES"&BK%B*-9V*Z>O5)UNNG:72YV)C9H_6&[YY\
M+8]DQE__R,LQN*678ZB%%1Y7887_</[XJ^>)KX3SHV,)AP0*]6Z9@@XV)IL5
MSQ1W)1_,QFUK#*^Z,W"3PQ^QT"!J+!-]X3&J"7^]__R.,6FL%(&@#81:.*Z.
M8CASPKCCD(1WVK*K8E3)")J4$=Q[:0,:8@:B])J:J(2P]J&J%<_*EEKVJZ)1
MX YZOH8>F%Y1',#^8G[$),=A>M+[2\+R >H9W7E*5!X&TTRRCD\N?''T98XV
M_W_VWK2YC2-+%_XK",[<:7N"R<Y]D>=5A"S*ONIK4I9$6RU]4>0J0@()#@":
M)G_]>S*K"B@LW"0N(%4=W6J2*%1E9>9YSI+G/*>72TH/C@\:A^I_C^&])Z>;
M,Y,DI[(=Q,DT<+R0-+%0M5<>4ID'Q8 X&H'!,.J7BO7*_)D]?*&&>FHW]4M^
MW#0-9,4W:P-HP_YE^X/\=@A,%S0&0R47S(_A\M3/"?MN6IDX*>9$F9UB\/3'
MX^/J@FP3S7)?6M[3VTG.%AF%<>_G(?Q?KK=]]O;G7' +P\X)V3F'I,KOSS97
M/^?K35I&T33,?GP(ZKCT5^I]LOTZ#7TPS!'R\NUZ[8J%!@MV?'!<N;G#'.(N
M%4:S?/6:-ON'_'48R9MS;YP7?VEVEN9Q\?'5(YN'U'G</V[FDXSYU<I5H?&D
M6JML7R;8B\/BMU_ZT,U>+O/ZU /YV\_[#6:[7IT\_&H#5K]G<H)AWG>ERC.?
M=)1D]I0C0=46AR&W)MS%W(K-#\?3,NN<EIC/I',JHJWW.&K""'FFLH5=O73]
ML*W>R^H8IW[&PB/ZXZ:R=N%FT[':ZK[]*A<?_/*S:FKS85 UL9M5"2_LT_XE
MC\K%;9<\+G^__<#1W$I>N'F^F_2E2W7C'-#:P7A8T'8!@V*E8-HH5%)JSY7_
MXMRUCKM:'[6V1K[J.I*71Q8'T=>!L /81SE+K<F?JT<Y-W80A^$@U.,-P[*M
M:@&Q(6-S(UQ%4<R&.<XO5,2I.*%]&$!_5)7=P,[-5"55X"[D1:]*/(<.5JZ*
MU@'T ]"VWK\P%\+3YLJC2B^ D+,+/<!O+A+MP[ZPH[DWJ$]6QZ"(*N0>767:
M5N2)/0R;X)HFT"W;YWOY!/O987B5IWHYI/X]F^KX(TF$2&D5LCH?=!'FD>$B
M]P+6G-*4';RPY'%A!9\ #EG!X1M<)ZLY\8&(F"P+2T6GS9SW9I-^,2_5NN[K
MKX#N2^>J#=W_&%^0;@%6*!AMQ1)H*KVS==+D*-056-.RB*QVR\7%E)T>'\R3
MK4SF+**L?,?G/CN;/+,;SA?R9;.ME/F5N%VKK&_OG"R-:^5H3%-"VNG+U\S<
MN#1KHSW27!W?K]D$FB,=6RS426M6*NQO2D,:PW6F6LKH#NQI;<9-C;C9:^0%
MSTJKGUV64H!G3V>ED%.+L8F7'A_F:<^U=$U6<3Z!FL3#? 8U'6"IC6G&?;D.
MN5WL?5E8NX:CKF8?X/;3V4<OI<0>8Z0Q38AGND"#A48FV&1,],(1]E@C'<U>
M>!RAC=;;5 G^DP("=E)[-"=5U7BQ/@$FLO=4>=$%4*M3ASG0F8I[!9#5%U/-
M>Y=9.RJO<UJ;CC()7/73\'A2Z(A^>?G+J\U,&;<_#(^B+G\NOC)M\SQN34J>
MIE(.,P1E,JG=D<5:FH8NJ:IO!C!=P852CJ@V>ZZ<3PT/6[6)<(?/QZ&FFTG'
MD^*M+)'%],?3"% LI$RNTIQU#*7^'NC8P^$! *V+AS'U"Z%5-OH;;\C%7A-K
M^:GR#4Y ZV_VQL=^OWG7?)O*3PC5#IIZ/V4@6=E-IVIIIN!YTU?,S%J9SF;J
MB\^R@?-N/JZ4:#6\65U,?IM5\U?7;F^6),DOA\,3V"TVQ7PH"%HRY7B;/ZWJ
MK$:9IW!:D]4#2R)'_ JMS614LVG5KEEF?*I<I(,C4-A3TJP+>6T>W=ZOZNQK
M'@/8F(/3LSB+,U;K.\AE\F5N*G<TG;8^G-HBL)K]49Q)PG3SE4@7_*V$:2OT
M<85D)?OD?_N6'3:S>!8!K5JSDA8#YDO9 <>%G*D%E?4Y+ P ;G&^.=H6VP*O
M,SJE:H\TD=XJJ7@X:!>_%2*/4O@WF9_$;&AF>!T-CS_M VJ6SV<THE6=<MG&
M)8S6Q"2<G?C]6&)M.16LS$1C@Q\. >S!M!P![L;9J'*I6(MK ;[I8O'QA_F8
M%P2VB8N5!;$7F./9=!U]*M>6F5TQL:<-B\CY2W.OA<N_%]M\<OK[(#-)'X9\
MU%'X'#JK<'?OB_A(L7).8X^42@SQX,$=IYXBK1@8C$Y1ON*\C&%# PE2.,6=
MH1H\31W F.366D'X8[4BF[VTV2N[:7-Z=E8VU"/ _=D+'LU>,#8ON&!K9IPN
MP<(ZY7!Z]A)R0"";1.6(:[OU6[%4[, WAS0 P!E2;1X"*F'\"O=S84A!I!FH
M'(]C.@9]W?\K3DV!ZA1IJ_=;9L3+8=JLJ3-S;TV\,"I,#>"RYUCQ])[C_6'#
MJW351_3J+,E1/*@U_R _LA20; %LCBM<SD88['C?%+DW&)Y!&@T*:6U]OX9$
M:V8MA4)+G:V0*:_@>-7H5PPWQ9EM5$UL><I6[T4VU4#!99+J$C#(HP?+9QKO
MR&0;8,77#ZRCV_GNHZ9>':ZN#^+.GYP2Q2^*(C1JO9 NE=?,2<.UK5@4>UV6
MOG*SY&FN7WE*%% _8Q0GA:@G![GS0N=GPFIDEN:&+",V5=+E.*R.),U,N1RB
M*#EARR=,=3R\CH27VPVGQ%>WWNG@7 WU7>NFSR_91ZV2I4(;9#TH*"ZD1\XY
MA3REEFE'! EX43<Q0YE(#&8<<QYES)6^'A9'^5QO;Y9TT]Z%$'!T.2#:+%HY
MYC5^<C.19<)6=9XZ+\A[^?O.SX\3A!"8Q"0QX8YAK:F,03H9C$M,D=QSK)AN
M\SVS2M#U:!R?-#_\%/ICF)/3)_W#HD?*EWZ:?[$5C-7EO:J/Z\0YIK8D9SF(
M77?NJA]<I]5ME?CV0C^VZC.IMHQFYWZ,M\A7?4:V%-9?^<WS!TMAL-A<Z;;7
M;FB^NIGZ6C>6_/FX/P@-TVM;:W]5/_.%";A"_[@;G\0[Z'5T81O+E=J)&ZJT
M3,H29[@E OXQC$;JJ"+):OLMVNF/ I6_@?6QS#<=CD>9)O&!ZJVZD^5)'L>'
MO5SH_H+O;'O\83L,7NV](.\_P_?V=OCNWH?]]Y]WR,[SQ4Z6/Q_L_KH[V#E[
MQF$,)[MG;[[LPGOM[/T)S\F=,#^1W8-?^CMG?YS\^^S99*=?NEA.=O8\WCE[
M?_H;>S.(__?-Z8=WX<A1+E^]^X/NGKTFNV?/SG;/_L"[VU_$JU]_^0+Z%.]^
MAO?:VQ%PWZQ+T^ZSC\S#/O:$H,!P1-PEBYR7$2D9 /*5#YS3C:<$+VJK__H/
M30GYZ:+]9(VG*CBFF)&<)F,29PI^5-3JP#'K]M.CVT\G'UF@UFAO$>6:(DZ5
M0)9F\O3$-0',5#SPC:=B:3\5IM2%XY:OTV^KFZVNM7[[K2FA.ZV8S4L<.2Z%
M"FZP^?1=S.1:*CEIN0E@!#M&"?<Q.$&YPXJ!5<F\]QTHK0$HO;@4E-Z?P?QL
M/V,[9V'_P]Z+L]WMUVSWUQ=\]]TNC.]?7W;?[9R\_QSZ']Z]R4HN40?6C&((
M5)9#7+. '&<),6>#XI8Y(4#)L:_0<5)RSH6+BFC' TXV.KB?T@9');&DW79Z
M=-OIY*/%(>D$^R?'O!$7,2 M+>PNG 3X!4$I8E;93#>GXQZ@#_?+\>BP!!>+
MBDNPD7.@L7/@;E"W.<:U#M$R;QS'(AKF$G,!.Q-#E+0#HS4 HY>7@M&';3"X
M/S\[W=W^\\O.]K\^[V[G^?F"=SZ_P*\ F-[#^'?I;O_5]I_%@8O:*LHLPMH%
MQ#$UR'C!D(W).!RH2#2 P7T]+)JV=%^J)W[\)0R7'5=>D.]0$CKKM*A\8@#H
MT>1,#M/RP4Z=+6/'ET2.ZU_S\7@I":^_58XZ2E;_M%R@Y ;%?/H3_ZKR^4?M
MA%+?'_GC@_&D2A3-])(>;ECE7$Q65+3G$Y7#FL(WYV3D Q_7>K7!%=(VNY+T
M^9+T;!9T->E=3?KMU*1?6F.^>,!CM -L\\3IQ WCCFM /1T#MPY3GVZ]YN6W
MC)BQG,EWW#5GNY]?GWPT6K! (T7!@:/*P:)#)FJ!L LN<2J5"6*IMSD+3%+I
M,^4B5X3#:GJGJ,I484+B1UN47FV<1Y!,<TZ"=;_2P*-1UN%%PY=VK55"29/&
M6V41QA(UK,@Z^U4%>Y5>V6\,CFF.;T-OFG_X*Y[6!DL>3=UAH.0IULUQZXR9
MAD(G9S[T2S9L'F0&*D(7273R27>V%:9ELL.*$:<F8NV-,PG.8D_*69+,N!@;
M3=;+L&FK,FPR3')^39U''*>348A[JCSE7/$[S"66I].DFJ8 YZ0_&,!M<D;T
MN#9\JOO/I[A/2XM2>:5JL@^.AH?%J/HA;GW:VNQE?KL9/^SXQ]ZXZD:3FP*7
MM!" 373>EW->=LYH@K'.)=J4Y.='T0OW3<G3&B9TW"KAS_57948&_<HR;JH2
M6@DV365",W,PN[[:^YE*:985/JDZ )5BLJK8-QO9Y5O3]F[33*C9[LJ=2\LN
MG8E*52B;ZC2O_J1*,&Y8H.H=,I?T>LXN&T[W5FXI7F^=II%T%IV#W",YT^GE
M-ZGKSE?5!L^GV!Z/ITG4?E2F(K<O'XY&PY.26#XW+?W#RC_OMXD)+IO4N;K_
ME1-;UP7,SV^-#=,LKE*87"5#-6EOB^E35TCC:S*]6VES]YD4_.MP&#)N/#L,
M+V'F#S_EJK9G94,O_OZ=ENB^AV?[D]W/7]BKO==_9ZIWJYB,@0B4I&&()P\V
MC,,>);!*L: L:OQH$W]GFZ)7[8J'#>9$+)@GN?U9!LWY:AZ B,8&F<8,2B?J
M22LQ<]K LR2_]B?'18$WW:A+*4.EPMLEI5E)YX:P$]MT1LI\?W56:8OJ ?[R
M:93S-1<?EME>VEP(50[JE,B_N2)7K67ZGMIJJF SWZJ <87_[;OT%YIQ]"K>
MH*5&I*6!;;,C5HQMJ9/IBGM,=60QI^I\ZJW>VQ()JLMPVT93T^]TI@FK!D"%
M<"?C>F,[UGG7[ZJ^09\R_4YM JZZ<+GRHZ#ZN%W;!+LOCB?#;+T>'Q5FI/U^
MK/*UP&8:GMI!4?HU26+=PQ-^F]7!5)YS"415A>-#[X]'512L_ %5RJ[UI)-F
M@:9_JW81/+95XU:3$#7CAPWC8@EW54,,#]SL*I*Z8J_-9;;#ZCZO*S8_@6(;
M5QG2U\JA7S#![ 1D]7!^"1?+!Z=WZ*\<7MYDH+W#3Q51CYU,[^KMX33JF&W&
MEIT4P^8YID2_."ZA*HTZ9RLOF"498.+_'M<='JMVU3/I*S92!HD5HKG9:O*8
MW[*N@%SQJ$IV*Y!H^LK6#VN5L9TS40V#:9T,G]/6?:[V0L='-2],L>;28E9\
M.\$^S?6T!1MR-NKY >_;4#7<!8 ;';>SYH?'DQK2%^;H,<C.O$.Z>JM6?%PU
MXB\$^6\\^CZ5N?/"[WF'%Y>\W&Q8')C6<4#\NS^>++3F*[U%1_4I!4#CY\K8
M!M#MCQMM5ACE4DY3KVM]JY:IDQF16S6J>O<NSE0F!I]_F2G9U^4//&__V^)]
M%+_-'JZ:L,W5WP.1JMDGJH+$N@*QS?]UOBIJS6510O?;5_5-WE?'\1<0QN=U
M""<K[N<U:4H7/]W]_ ?Y2*4AQG*.A"JM3GA$#D?X1VG&F:?<Q:5"AQP&#T8F
M+!7AL#Y&F.S!2*IY8@8_@E:KYP1IJAV5"8^R)BS@CWJ_UR7#]:</&]GGWG,%
M*]&\'9!YYGI'PWZ.M (LP!AFMF6K[4'35G-F9$Z&%=-;5>]?N3@EC#J< E]^
M:%.O-^M!7>%*92L7SIZCXCC5A*(Y)@B0V^9&>C2D 3,]-ZJ7YQSO8L6J97WX
MEP5WHZY.'T67S\8WZ]K"G/ SI5$=U\'<FBTI5 Y&JZ.8';3R;N&J3R-[ -^&
M;TY&?7><I6+&!QEC?>/J\LHA:3Z%NU<5G16!52F'6@ZNM;W(0MXWKZ&G3;PW
M>_#L0?^LH5.91L8JO57QIRS:GYDLHW@[\R9=KLI?8AHHX7!0[]GCG0RJTLO^
MK#I_1L)1=F=S;% ?!;3ZG.U'\.KVO2V$#662\U_!]QPV9+:SR>Y9V/M5Q^!"
MWI%I$ :GJ&&2G2V7/<K!TO(J,/C9#5#*ZQ=:"P5CSG?)O(9YBD;]'-S<;/DR
M923@&_[=7CE8L_A7;N0Q)20]CW=UUNN][-7S=EIUV]:PCYK.1^.J95QM853%
MM#5K CP*O'^P:_)FGAGR4P?95XUTZN_6O>[F9&&I/W(+$.K\-I23V9XPN1(!
MJC^!"0F/>8*(+LET]X$).=^6RI]NN7WHM33D3W,32/B6R+/SIMH"3^ZST>G"
MZ5F]*Z<!H"8H!.9KQ5Y:6(*RH3W*AQN?[&'M(,+>S9F11\UQ1\::A<]+%7]O
M)V8?H]^6N[8LY<=//YH7I9GXC*;P6$CDYA"]<-1E*9F<'L69H"U(RXPQKG;
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MDF"$1P:RRSWCVIJDA6%$?50@KT5"00-FFL<L??_S3[MR[6^GNHU9K:GWCNB
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M^]@?_'EHWYGC5P=PYS//=\_^!<]]<0;ZCNZ>O1#O]_8/WM/=@YWM7P;5_UZ
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MO:V$O1_/+UZ_"=J.K^UYB!_4BM21G+D@3V\4_XJ'Q_$VIO<Z4_I(LPL>9WX
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M]<YA9)))R%J,O1<QI]1L/)6,K>"X[PX,.VQ:3VP2S$?I 9 XDUPG;9P71KO
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ML72(FY#_\>;[56^0,TQ.>CT/,]OK^";3X4>/UZ^C+C$8\D$'YJ@#/]42[6T
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M.9S!@T[SFYEASL;(/X_GI=Z(%[U1QX,BJGCXFOCG"E'%^Z CC//22\61]D*
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MN6XF>]K@ 2L,MKY@3&*+I63!Q"*=WA,BOHUYT^1X7)?C\0G^.RKVWAZ#'UT
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MQYD"58OR7.-Z)Y%KHH]-]/'6Y\E>64.)%T%$YD)AN=#,% [+2!/9Z1J=E[,
MOQO+[WX8?F>=3O'1U1^=#V='Q?X_^Y\^?$SW/X+O?&COD_>7'W;A/K_#.,C^
MI[U7\YU.__UQ[^S?9Q\^OL5'Y-U9>I</'V%L9V_HA\,_/NW]\_H"WOGC$7E[
M\;]7;Z:;+)?118^CQBXX%)F)B!5>(Y,IVJWVE.$"O*Y$VK EGD5PL<&Q!L?N
M_;@X.,%%H%XGOAGOK;%.6DE4P8-BU*W1KKG!L?O"L86\%XH)QZZ02)"8FD"Y
M=$H2 B(Z:AF4U<QKP#&\LE;N:0'9VC;K-6VDGY_-6N9!3A&E?(U_M#;(+VL^
M_YU!^;)7_&X ^[X,SRR%4ZQ,LV<6L?TE>'05^KT&O-<"[[UI(Y3M?WQ/CA4A
MC EFD#/*(<:L1QK+=.;AA/0*6T[XQG9BD,3DEZ_%[VN0\J',S0:)?DPDNB_3
M<1&)&L19"W&FS,42<0IB+>'!($FE G-1.*1!-2!7B* TY90)N[%-]99\0G!S
MJ]29)W?>N6#,M4K2O.#O5)XTH:S(9\\ET6F5<Y/W8V)*L2%T_W_VOK6GK21;
M^Z]8G%<Z<R2*KLNJ6V:$E&[2448#G$R3SI O45W!!&R.;9*&7_^NV@8"MDDP
M&-B&:G73X,O>M:OJ>6K=UV5%OLLV[=-559I&@8WCN5SXO#+[S'JII7+[91$V
M'.[J]=+JEY5-Y^H$)4,0U*G$) 5N8ZG#Y!P'R8V+B=&Y,RYF15\T=29_.SDZ
M&=<T^\V-POZ'X]>Q;(KR9#O]\_"-S7Z\S*K>SA>7JH$:/PG4.,-Q_[6Y]SFG
MY&C,F23PJ("Z((FU0(G/62AM#,LF(Z.P-?N38BWC2KN(D<&X@WN_,SLM[*(A
MR>5>+J[_<:WNOC\\;QO4=#$=MRV^MIT1RU^[=PPN*-?TZ;(\^#SE]EH5I7&C
M*W-V.<ONVOE"/(-ZEE>"%R^*0MY0"G+8<.1)"=L:MR.8[IKXU0VZ_9/A98.I
M&ZYS68VRQ ]U>SAOW3ANPU,ZXS;4,]Y;S0Z^W.QCAAV6KEBYVRM-9I&9<8.=
MCQZO.=KOXM5Q>M8Z_SO1/>-*2<K^\$JUMN'UISAJVBOAK<[+NA;0N-/53M/2
MIWGW_/19O=KUT9VGX(YW^UY!QLGQ>5>O?A@WNAUW];J8H?/>/(5O\7M_2VM[
M:ZO?O^/&/6LNCIN++TT6.OY>&?1*(:?_N:CX/=$'LU0#'1<QOS+)D^732WWR
M8;_0RLF@>>C24O<R=K6I_[UZ;9%N+,3<U.&<:#0Q;@!RT4!D.%%2=SBQ\\[;
M"9<^ %_/2X^71B)W7J]Q0Y(B=90XN/'\-YU)QI-P49 -O]E\Y?BBB'G9+>/U
M7>WL][_A,^(<=.^\V+4FZ8]KDHJ%UR0MEVADDI_6O&1<KZS72J8ON))IR\_P
MV?((K/VP[W 6KL3]TY1M !F5R0JHEBP)+YAB;*9R<5V=>/>]=/F[WD;RH]>]
MN.D&7U*C@KYI>K?\D9#[QD7K>_&W<2'JG8&["/<>#3=0?#CL#Y$*=W!LOQ[V
MPY<G5Q;"N;+0/]U^^^_#K9W=LZV=?W_9.OA"/WW\_7"[?'?G]>FG@T WCW:_
M[1Z\_[;5G5 6#M[!I[<?V-;!)MMZ^YYOXQAW/^*8<)R;&_\\VCI[C]__M;NU
M\9K_Y^P-V]Y #<%Z7 KFB+ V$!!<$.,9)P&  C >,@LKG4M]]'71N4 ;QP(J
MLE0  &YS+5((,@B3@['*K702JF#'A6$&)XC4[\O3^;XRD_V-;U'I\>?WO3[.
MI,%Y[U5@+H!1W%%'4:DU(?K$@N/+&JQ]93Z'E_,Y4;%UK+Y--;^Z:*59/HI/
MBL+25]<]+)<B*-60(H2@[.1'5R^,'_W>+Z"S-RC5A+O#X4D:H+A8FD[Z5!I#
MEEML]5&ZD_]SM4OC>3>EZ]<[/D%E,*"4/2I7:\1'G,?R9G/!\\O,*/_Y@,12
MN.0*<5S,R^_]06G>V-#VBR:+G=W/A@<5DA4D&? $I/+$>0G$*VND9,ZPQ"?!
MOYP0FY$/,?R>$#%1A?5*-XVF(=)/(;5$F1!6KVG*[I0)(=8HTP^07""%?( B
MFNJ.5ZUC?4YC76A^24N<HNW)CEBNF/W71WT<S-F5XG,O,$_H0V^0FG8_"YF%
M9=T*O[ON8(GSHW[P;#^RL$SGB'5NF1?T;#?";WW4G7YUJ$(]4M[8\J4ZO2UM
MO&N!V;M,W;_ZI1C!2\;7GZ4'[5/4V'W2Z*V+WG6IX_N]>+? XH?*'GGI"23/
M-X?$^@12"Z$M./!@38C:&16$IUP*%FZ="S=A*ILPI%U(T>7H;$[.98G>N9N-
M[3R*$*_UYG3WZ/VW3V^W#K8V]NCVSANQ6\IN'90HG4]E;']MO?WT9?./R2C"
MPZ/-G7]V/VW\^F67X[@VWLO-G=C]=+35W=IY+[>.=F%K!\=^]/ZOB>0YNGFV
M>_I9:,6"M9[P3"F!%%5I.JM*<19G<#&3L&9E7:U:+=?D0^>=+"KUI+)@9<&E
M9L$0QM&.*;X=H)3W7:TNXO*O"1DQ356@:F4VQW*PXI78ZC$K0N T> "B$D\$
M/(W$!!F(]HJQ2 -(Z1>6S5%9L;)B"UGQ;TM$BT45OD*+E?[FH[])H9!'"MJF
M1$P,G("1C/@D*'&<>2LR=<B.*^O<LC4V17Y33H#*>Y7WEHGW6D![WRGO.@%6
M77B1M+<]*?59HR4 ZL+!TXRTQRUQ#&5J2J7%7XRSTA5=6!F84:JTI5+?@LHP
MM)JK/JS]L=;9Z^.0>I<Y!E?_W$N]<'HEI>A!BC%<7H//-[DSCX.EID4M57(B
M.\84AR#!>"9X2#$I$/BKK*;"]M/CYK2IT'"?#9YLA"41"&@7B.>E[);6,F?J
M,T\)I<)5"_+^]-B^$@<5WX^,[]L:P2JNY\+UE+$K1^L]ST""!=3V6 1BK#$D
M.>6B5=XF$5?6Z8U9OQ73;<7T/":<IP9U->'<"]23AS5J, *<\"3EDLL/-A$'
MTA+)@PPF*Z-$\>O- /7M#3@5SR_OC*ZFB<> \Y1I0F?(W"9&0/I(P.$/SV4F
M%CS#S6R+#:J1O<6L+BI/7._GF<=C_5$L#?A"[^'BL6[%:S.F[OGQ&D5*H2P!
M"S:"]=%'IS/N?B9IR@#NX6P+E<+FH+#WT^:#DN,N,Y-$AR )&,V)54D00TL?
MJ"@L,(H2B9[A4[J;:;5%OJ.*WT?&;PV@>52P3]D45)0RJV))H% ":+0A-FI*
M0%%\P\; A5YT $W%>QOM"D\-^&I7N!>PIYP PB1KA"9>6#S%M4>(:VY)8#1(
MYJ7C-*VLBQDUZN<.#*EX?D'G]\UVA8K8N1 [93I P5H"]TVW;41LXHYXS@21
MG .G*K',%<K=T"JY^R5$+?SVO0KBL3M.@QJ4\)#$Q6DPT@B>J.9@;;99&VLL
M9!#,9L^JX: 5!/9AVG @I>#2.4<RZ$R "2!6Q%*:28%4$KSQ;F6=\5G1J-5#
M60%<+0<M1ON4Y2!ZP7),@GC'@4#FC%@7/*'@+%>LP%T\XT8J%>]MP?N$X:#B
M?3%XGSS=M<Q*,2>)Q$.=@ *.B@JX4BK06R\2"R96O%>\WQGOU;*P(.A.619H
M*+6KDR+2>8:".?7$9I&(2LDKE8 ;;MHGF+^$D(12Q7K<"6=<03>FIJ1^#4UX
M2 (K 5=4AR@IIY!XLCZ#XP'_U8(EFJJ%H15$MCMM88A,BR@S)U'C#T@N$>L]
M)2(9+F4*RD#IO&MXJVRD%<#+">!J87A4M$_G.V2G'56&L,11XT#,$Y-X(.",
MBCP;(Y.IL0G+BO=Y8A.>&O U-N%>P)X\QAUXQY1.A-.8"=C2<$ %0932D1J;
M%$NA)#(MH&A%Q?,+.K^K!6%!B)VR('#-?1 H;H-.Q?AG)7$2@-#@)=5,N,C9
M6/">CB>JP0D/";NF\Q4ICY+BE5XD-4;A00E,4\^LA6A, &0M%Z6T/%&%.,'7
M>;4@M(+(PHS:"#+3+*TC#%31*60@ECE.%!Y 7'":*-,KZ]S4).J*WVI 6"ZP
M3QD0DI<*50U%=%:L)&.BU,*H(AS%3UJR;"5CU66YK'B?RX#PQ("O!H1[ 7OR
M%+=9J>B<))P93X!Q3HPNL4?*<VHCM[EQ:*[I6C1A>?#< CA7 \*"$#ME0##<
M,Q%B)L9+2\#G3'R0FFAAI>9)1!=*33*]QEMT#M\W N$V;8X>K;KMBRYM^TSK
MVG+IM#8\^8@\&%RR--"8I%#1"^D-U *.[2?+O6DCA4T1/.666*I*KQ=AB5,I
M$\&\0\E&@^4>Q1NZ*O@L)\F""]RVR8=2V:^RWV.S7RUO^2"L-V6M$2# :8XR
MH2H))9%JXEFT)%#J9,R.@@@+*6]9":\27GN>>AXSUE,S7C5CW8OQIN0\"-1J
MFTG*%!E/,4VL58DPC\HRQ"# LY5U0?F:><#V+97N*MV]*/FNED9]#+:;,@$Z
MA<M)O251&5I*C474;[4G*0AE!*ZT*@G#J-529NYO!GP4UCLW$%Z,XF*CRX;3
M%M;C>[YNZ0*?)?9/<+O?I>UZO><B[OF\4M=F]70?#PVYL30X1WB^PH=)@_*I
M$I)64MDV4DA'/@TZ@JUVD*C9@R:UU6L\KVO\!$'M!,I-Y:,&QP4EZ=9EIW\B
M'3\?4?=YRJV!*IF23=$!@^"5U8GJ)+@(/H'1L9%;6?7*M%E^?8.RZ[O1YA^-
M#"NV-C;YYMYG %3,P:*6'E@F(((ESFI#I+#4)E#4 5]9UZL2!=@YB_L_G Y>
MR:22275R/!F)O)\D$9FBT=Y$(KSS!'+TQ!KM" O!6&%3R+G$KM%Y5>#*("^)
M0>;Q&CPUA52OP?TH9'>20J)02!ZE-#  )1 $(U9R31S%S9) <Z;=RCK,<I7>
MY#:H[/&2V*,%Y%&-\(]#'GN3Y&&M90*4(M1)E#]"1O((H819@&?,YQR\+DH,
M+NZ,^/D'%T&>E^GT*=N@UW($MVV5H+(1D4<4Q1GX8!SW44H-D1H98N0/9Z^I
M;#8/FYW.,,EX8P/7TA*A@:$V!9)X$)'(1*6B&BA87K0IVZK"!!7"RPGA:B5Y
M(%S/L)*8R%P(1$>%4HISC!A-)5$^LVQ*GI\S)1A45%0O&:KGZDGVQ+"NEHO[
MP7K*<B%0Z0"MRR&M- '-+#$I6N*"<YDQRQVH NL%Q#M61+^@<[HF[BX,LU,&
M YH,U9ISDHS*!(+1Q/ML2:0.)6]OG.%01&RS)EMT&#^C )+Y^Y;/043/FV]$
M2%)3QXP7%HP*)NO(<C%@9LN%HU6U;P?OG,U0[3F-)LC22<Q$*(4' T%=GQ&I
M)2ZJ-YS[T/1#;'VH187=P\"NJN,/A,4I=5P'Y[U6EFA.46Y/*A*G2RA_=MP)
M9FR@[ [J>(7BP^O03XW%JD/?#XM3.C13I4PR#42P9/%P9([8TH(O*6F928'I
MF&=CL3W._^<!PQ:@L"J^"P/:E.*K-2BI4/'E*24"+'AB$FJ_*5-CF/<B:?I4
M NA+<),OI.]V-<W=-MN69Z%HXIH+#H%9ZUR"3(.DR7)&<U65V\%4=%9B@@PR
M!X8R@*6>@)>!&):*E5V[#)*6EAHKZR#LO!$]U;I>(5S+6C\UWJ?4<25T2-X:
MPG5$O LIB G!$6TUU3;D&(VMG;&6%?%S501Z8LA7[?Y^T)[2[BF51@;G24"E
MGD#VGA17*9$4J#)2>>-K;ZQE0W0+ %T-!0O#[+2'/#NOLHPD!2=*HTI.C$/@
M.F$L>&82>#$6OU6+#N-GY"&_>QOM:J"\R/-) ,:53O&A[%E9PK' Y 0L1X6C
MK.I_._B'75/_S]Z=;;W^')6FW')%9/3%(R IL> 443$Q#9Y*'>+*.I>R_3G%
M%7</@[NJLS\R2-]/@A0$H&Z>&%$,,@&4[8CUV1,!4B)0.0=UUV94%::/D$3_
MQ#BMBO;]\+@[B4=CDU7<&&(5,P1L0*'=ZD"LPT6EN*JRV-#F4;0K#)?VM*S:
M\<* MG<5:+08JZ7R#A0"35M%(,1 #/>1 ,>_4X[&93F63N=L95+]Z(_?(KK:
M\6YKQZ->NA A:PJ@#3AAO9/<Z: =TUQ4?;HUC#4=>9Z384E9$G5TR%/)$",,
M$*>\T4)&D8)>68=V-;NO"%Y.!%?-_.DT\S'<$T@JN%,D>JM1,Z>1>*\U4=0J
MAYM Q:RJ-WU9$3^7-_V)(5^5_(4I^6-H.Q4YM\J3)%GII&@$\:F4[06#ZJ)3
M.>8YE?R*Z"='= L 7>T%#V$O.#^.L\O2<DUR5)* E8&X'( H'@27ED%V'*5O
MMK!&@(_H3+]'9Y*+IQAW(QG??59#DA?1(FM!D_!L>"XIZ9C*WJ"*"E1D)W0
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MCOSJ#D_&N62WV<VGLW<POCC$;5FN,BH7[A\>]K\5?IEBA LF:^CB"CU<07_
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M645&15"+COJOU%NIMU+O4E!O=:H^%!.'22:&+)F1@-*NB)( M;24>(HD6JZ
MRAC +3P3LS)Q9>+*Q$_"Q#<YM:M5=Y$L^V6*91,++#E+N%.N)-%X8I65)($Q
M,@2JO<K5JEM9MK+L\[#JUJ"#!W*770DZV.-;!Z\_9XB4*IJ)UL82"$$2ITP@
M.89@.=7&:/M,C+=-P,(OH[+-UIN'"6.URC5/\X]?8O?K^C_PQ\5S'+G!7K=W
M,5R#4#I_I8S/7*>Z@Y/AJ)M/'Q_ O !X9S\A9B\@TSE$<)0JB#V$[N"X/T#
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M'./N1QP3CG-SXY]'6V?O\?N_HESSFI> R:V-+Z=;>+VMC;VSK8/=S]$!)!>
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MY+QQ^2Z/X\ 8H3VF'F&E,.*&N*S"#$4G,&> O9&KG(J&YP2*G[W.424 CQ2
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MVV(2X-JR[=+0J;HERB"PI=%X(9.*G,BD@V7)*R:TBPYS-:X+4VEDH-HQCNM
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M0K_5[!5-4(J6N3^INM1+1H?9R%Y[D)V.I1SLYG?WBQVM5^Y9?!7C0[0"BGL
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MK/[S#6!(H>0%?$VH>R^V6CVP&2.8SI;@8@*9X><P\/W>7%R^[I [ =&[8T^
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M2F$;X4R+LE@&S[QEPANA$H]6:3".!IQE;XP @/1W)<]]=WK>[ES%^#EVOT-
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M>96JWLY.>[\1Z&O]L/-!KE#\>+^FSZHF98'!V91[<*<PQY%R3 /8!IF2QB+
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M#HQT2A0E"88\NB29)^#C4E*?I4B]$8D,(XN(A=%.$RE2 D$ S* ..Q:3A!\
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MZWI/:;TN,%DU<\E%[?"DH% L W6Z9(QR0@NA=U))U\,U]44J:T3_HB=N"A7
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M66GL,D(J/7.HM.(J*I?MO#0LM(YY\=JP>%NO5GN_%N)R!95"5&"&PLKJ:ZM
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MX:>W0)6V0^53)Z87H+.[62"QV(HMW.:J;:<.Q5UORCZ2)GS[?"/+OFMN.1R
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MP!7U+CA=JMU_^54.>FRNS,MG28+I/[':<E/QRB1 4=U0=2NP=S4#72963"9
M]#("N6B1^.P(^%2,BRH/G&(AQ*F0I3/HK,"3SH1B]0B:5X.CZD"E,I5?ITU9
M)9Q*Q)O+UV$I%MHI159'=%1UQM;5-:S(;&NJ8)/$]D$WSZ0OZ$@[PK9C_ZO8
M9VWV?*WWKP)(58B&IDD1*I%RNZE<M]E3[:?ZT[@V,LIWJG! ,E9YW8OJSW!:
MBU"]()!*%"65[*5>1U;G%\BX;L<K;F8+DB64NN\_"W\F,,RS9**=AG5^)^^
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M7;U_#0[E!?KV+N/QVHQ'N\MX[#(>'RKC\<8,QE;&H^\+RXSANM"D)"(L8F%
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M,:&GPL#9[-\,&L,#?J?#2WJ5[_S6G-&8C(TZY%<%VJ+UR'\M@6@<WP6BX2T
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MUCVJM>.Z'=?MN.Z#ACH[KKL97'>N-XUG1R88-(:'T4]B^K%!S< SXDBXC/)
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M ;'Q[RCE5_"?L^EH^.+_ U!+ P04    " #J2D96B'L4S8,?  #7< $ $0
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ML8GGPUX9;+0%4@"JE$/.VTXC^1.2:%HT_'?,G4^(MQRXW(L-Z)J Z:(_)TK
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MX')OEWCQ0.C5HIU#KWGYH# PY"DP+1.R:"C 0] V*^NU3JTSVIH ']3Y\(_
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M6UKE]>OU/Y&<@;_^X?\#4$L#!!0    ( .I*1E;<G?_#G;H  "YS"  5
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M9(5_^6[L^?*4';\Z<[.F@N@6O"#XGW]J)@DF?_F9UJ#P9#R^]*./<-%,9H/
M0U9&<Z*$ST0:FTAP-)(0J4]<4&EYJD+ES5&/AM*]17F?6E:#V@\P&3;I]3B]
M0KMV$()FF:)R*9L1D+2&6$\I4<Q)*:P!F645;F\->S3D[B_,^^SR+NR^O)Q,
M$,^;X33ZT7^!GZPP ??6!LK0&O()%Q-/29 )B)))0- R",<[$;QIY&?/<161
MWJ=95-EB)QZ-QC+/Y<+BDP6O+9KI6J/C& RN*4E9 L%P*K*,2HLZV^V=D9\]
MS55$>I]FV87FQ33?#$?P_K((8\!X!L.D("$;3V2DN+( .'1L?0+A(]4\5[ (
MOX_X[&GM),+[=*KN='Z$L^%TAEHV>^_/T<ICAMG,+>'H7N JHB5Q$DT!K82#
MG!(:>[X"I;='/1):.XCR/K6Z.[5OQ[&9X*(QG^2G&6X2+YO+\6QR];)),& Z
M&\FB0CR>(SRAT-[+G 00UC,CF%2ZBCNW!<21$%]/T/?UP'37@\_^V]N$>\DP
M#Q=GF<NU1UBE>*"!T&C*L:[RQ//@T/;G"-DX7))<!0W8,/R1<%]#N/=9M]U9
M/TEI M/I\I\R73;P@9O(:"8N>4&DTP*7).8)>$L!+(O1U%C=UPQ])&QW%>I]
MIETUIE_BIZ>3S\WOXX%(F2L=T4AT"B&I%(AU^*5-S(H,@!Y^C;7]WL#'Q?*>
M EUS0M+I].L6IOGN<CKY,&F^#L<1!BZ@=V<1#IH6FDB:# D<,BG>@ G,1Z%B
M/:;OC'Y<='<1[1K..QV+W0+VH9G._.C_&U[,S0DGK9/1 _$X*9QKT"10EPA'
M1S]1FT.HN8;?&ONX^-Y?K&O8[G9,5D!-P,^!"*6H8KB)6/3DT<'GBM@@$S&<
M*P-:&6&ZG9G<'.W9,[JWZ-9PV.D,K,0)C#Y\:<8KSSY T@@A$VK0"I0B%X4*
MD61!A38Y6<JZ\7AWQ&?/92<1KN&STV'7)XB7$YPAX^'S<#:" ?6XS4?J2:+E
MDD2CAGE'+6%4)JNC4S)TNV^Z.^*SY[.3"-?PV>FTZ_/$E["J3U?GH1D-T):S
M4>%L:&(XI10M<<XRPKQG.:'9#E)U(O/6<,^>R?V%MX;&3B=;*YUZ_2U^\>,S
MF)^T*>U1<TPDT4C4*W!0PM@\X2'1P%TT.=LJK^;-49\]J9U%N8;;"J=5?X?1
MZ#_&Z'1] C_%O2"]G4XO<3-(D6D%4A,& LWQH%#K$F4D6Q$A,X=;1;=7=NOP
MSY[M>L)=0WN%XZJ_-:/+\<Q/YI<CD^D@4A$\B$@X,$DDLX8X#88PKE,0.%&E
M:K@Y=X8]$IJ["',-O17.J);7UHM+S+*5H+-].1TX]*NH5(XDQW&:QACTOQ"B
M$3%KQJA)L<81]/K1CX3L"J)=$_91X<CJ[7@&$Q]GPZ_PRL_\$N<@<TKQ/XE&
M0U%&P2@)V44B:<@!IPLIABH73^M&/Q+.*XAV#><5CJSF"\Y+/X.S9G(UX$JQ
MQ"SZ;D8A"BX]<:B4)";O0G14<MTMW'+-H$?"\/Z"7$-LI].I!9Y/YWXT>G$Y
MQ>E-IX/$/)B0*;KB'$%Q],Q]5G,?/05K;>2RQKI]:] C(79_0:XAMM.1U0+/
MZW.8G.&V\==)\_OLR\OF_,*/KP9*"N-40A,!/,Z1XT0=3XRDZ#4JHA4JK0G8
MWYG@M8,?"='=!;N&\$YG6F]CGIQ<IB'^QLEL!M/9?+YO1OYL4)QV9]")CSH#
MKC)A?IU)"8],)A^XBK';2KUY[&=/=R6QKF&[0GS7IR_H\JV4+_/@I1 <O7N=
MB$Q,$:L\D*QY5@":"^AV)GU_S&?/;D<QKF&U0FC7A\LP&L8WH\;/!BHF9\ I
MPBU.1S+@90NA1&C&/:@(PM0PLFX,>22<[BO$-916./="Y3HOT6--_,>G+WX"
MT]/+6<E<+0>O T4M,RP!"5#,A!0%<3Y:(KC+.4?K(^T6+_\PAB,AO9J8UVA!
MIV.P5<3W]'LT(:075Q\A _IV$3[#M]D+_.5_# 3C5GJT'KA)MH262>*IM00$
M%Y)2&VSJ%O/1&LJSUXE^A+Y&-6H<H2'.B1^]'2?X]A]P-0@0F4XT$AN+8Q@C
M$ <T$5^,"VNYX:S&">F=89\]Y=V%N29[IDIZX_><GC?XG>E NN(1H(61=/!$
M6L5P75*:.$,9!65ILG6R9^X,_.PIKB'0-217271<8%IDZ"U0.<VC\P#$!A\1
ME5G>O7"7,BV9>DEVRZ+9./21$;VO4-=0W>G [ 0AI3FLX@*:3+,IR1\^)HJ6
M9;DMI]81!" U#R$EV^TDY=9PSY[2_86WAL;NQV-#F'[V800#(RSESN%BH27Z
M?+%$ .?@T.?+ J(1(8D*%OAJN(HTWJ@.<YB]=2^1K4LK_VE1ZN//<=1,(?WE
MY]GD$KY_LQG/T#A[/8*B+'_Y>0IGY_?N=]H3?CDE9]Y?#.9!P.5!+T=^.CW-
M<T?AY-L05Q3JT ZPF>2$4Y(N4!+*12I(Y1/7F5*VK?Q%]M,PYV<YTD(+8#2;
MKK[S71T>!%-1/;84ZEFC+OMQV_0AXXJ%"%; ;N)Y-5_]6B$:W"D75(G]^VAJ
M+NZ;:AU])[TR74TOLCZ,%C  $3F+1(6@2X$,C88C?M#<2P :<O+;ZE$\9?9O
M58YZ1/)W$7$?I,^/A>:X3GZ=6SP#XYGB( 1AFB,B$5DYY94D^V"X .V4VA9P
MMA?I]U <SIZKQ<U=JKL)MF(EH=N(YO-; F*1FT"E) JR(M*K0$*TGH"C,645
M+%?;'.W]F;X!XDB(WE>L&U_I?_WECD#02OW'_D7>3M]_.GWW]M7)Y]>O7IR\
M.WG_\O6G?W_]^O.GVSA:%G[;^+ JQ>#:0;U3( Z8D<!23-$&277)4O,T&.L-
M<J&%'6Q^;"7#^;L7X;.42B4@!0,Z;_.X)!.(R @$>!#);'.9.EG,URBZKA8G
MTRG,IB>A%':(LX$2@J)/*HB* DI2("5.X9P<3U1Y*Z+;&FJ^SYQN(SC\.M&1
MV;OK1 >!]K 9+- LX^>N06GK>3 *B.$ECHZ6)- @*!$J!\NT!A^WG=GLS_(=
M((<GNPL[:XGN(MH^[#P__7(R3N6?U_]S.?SJ1^7VYV3VTD\F5\/QV=_\Z!(&
M.L3 T XAF84"TD3B<5\D2KC,78A>A&WA;7L9!&V /98^="+QKIU0G8$>U.17
M/_D'S,I)QS)+9@@K(0PT%4P;B(3Z4%)D=,;)ZT!84,DKIK,PVXHK[*,<6^ <
M@TK4DG;%ZH77DXVQE/*9?H0(J*L(\3W,5M@$NKX^!%3-Y$J^,;7$>J#$T,0!
M3%:@M]W [K5-;,%S#*I03=X52QRNL+T=?T44S>0*(0V<%"J6R+YD '=&FSQQ
MQ=?15#I@@8(.M7W&F^,? ]=[R[-B7<,5E@\3N/##]/K;!8RG@/O3Z>P+3&[-
M>9"R9YK;0&+TADB9(PG6)I*R-#('3[<'O>]#>0M8QZ )M:5?L5+BVDD/<J"<
ME5($,4A&I*.HK;9\*:3BP8J<MQ8H[NP@' /I^TNT8K7$;2;(^V8<5U9(XN4
MC!*021.I4?D\^C]$:1J]ILRRK64Q:]E\WQ$]:\^PHK![,/D^3)H+F,RN/HQ\
MJ9.>BI=RL:B9GMX,QZ67S#OP4_A8&NN<YM]PP2JB.<DS7+)BO#R_')4HPE=P
M,8$XG-^LXU^>G)?LS'_.OQS0R"!++?&UP7U.ELQ<;Z@FG.%[9'FDP&J[$/W/
MZEFKY!,CO1?K=>;'9T-\Z19B0Z/K];<XNBR!SW]MFO3[<#0::.8M!.-($J56
MO"T1D* Y22IFIX*PE&[+)=C/JGT8U[-6K>J"[\'\?54"GB>02ACT.7SVWZZA
M#@)8+GBINA24(I*9TBT,=_R2%\$%_EU.IK)*;$;SK!6ADI![,&YOF-LW]N%@
MP23*'*%0<LBU\R2$4H/+9B&S2\;3VB[N6B#/FO3NHNW!VEW@&9@HA1:4DXS3
M(#(&1D*6M/C<P2I*2\)#+U[,LV9T#^%5+.N]0O%NZ,-P-#>=T="87[M_:4;X
M[&DQ7697UU/-EBH60) LM"MW=8E8IQCA7#@:P#&PM6\LVV)[]G>9O9#0PW7&
M#9SW/?B OGK*)/-LB$R9$:N#(Y!%T-1Q[73MDXS-: ZO$/TPN%E-NHB_!\58
M';=_\%?%'5\=QJ#Y:2CEABC&<7EDGI6#]D2<B%(;Q;)/U8^WUB)Y5(7HQ-6&
M>XT.@NZ'_LDEI-LOP=QBN?&M@4W1I22!!"W8XN05MT=9NH@I[@.C66XKV+2G
M-CP,[)B4HS(-/1R+W3P%6<&ZNCZ]Q;E28(+PE!.1F97Z1,R2:+V,+''C0FTC
M8QN>H]&,:D+OX4#I93.>3_#OP]F7EY?3&?JTDWL8DXL<S61)0);F& EW3)\S
M&EM@3$ [F:50.Y*J#:ZC49#J)/1PN'1_Z@,9%'I: 5<P7XZ[<IH'&F=T@@/7
MT4/VMG8RU7T41Z,$'07<PX'2NV9\]ADFYZ\@S&[>[ C!G561T,AQQ2KU$RS-
MBL12G3\J]+2J1P2O1W*LCD9WL1_*<KAY&"8T%\R7?:QD'0B*:NJT+[7^C95.
M25K=OGP TI&J1TTB#FU0W( IDA$JA$R22[PX3;C*.5S@<(G4SCMJDJT>G=L.
MVI'J31_$]&!GW/68;B"SU"70,A-%>232<T>",;D4>DE1,^&EKKWQ;$9SI%I2
M2?Q]6",WO&AF/(^>1;2 8RF+S="!MB(3+WUPW'/-;>VLSJ=R9'&0 \Z=!-S#
MU59)0QS.YC6]2I8!KES#\1F,8X$FHK!)9T[ )5&*_#GB:%+$N^ 59QFXJ^UU
M;(%SI+I0BX >[LRVS-@Y#]8+1J@.)?R8H^G#92F 8A$6BTEMK;6U7Z[BT[D7
M.XAF5!)_Q6ZY-^*/%Z$9<XB+#"3+* ],>1*E*.%:Z#0%D1)N7"$RIZ-+:EN_
MKSVCO>_">(PKTCHLW0_Q[B3BWFH^W,"#BY,73EN2I#0X/R^)*]&G5.(.ADL3
MVC!][ \W,1P-WYV$VT<B5TIS0?K1!S],;\<O_<5PYD>#'*G(I9]O*NHW/QL-
M.97BGB$K;5*NGZ2^ <K14%]#U#T<+WR$&0H%TFL_&:-),KT5MIN'<3@;R&0E
MD^B[^B@ID3)JXA,:L#JS[, 9XV7M:ZR'41V-7E0FH(<3A!N(YMYL*?@^@2^E
M5M)76(1MOFNF)6+S-'_VWP;6)DA9:@*)(]SL$"[UG#@5'?-1*S1SZ]^,[P+Q
M:)2G3VIZ.'+X/ $_O9Q<S:6QV L7VV#.5&B%.V!F);D%/'H_G$N$:33:.TJ)
M4#NT9A.6H]&-*L+NX2SB_G0'3 M&@>(,4T KB"&VH"WZPMZ4(CW4>5W[KN,^
MBJ,AOJ. 'R$L=^""%0R=:)*B197$;8TX6OH,@(LAL9+-NJUX?Q_AN$<?AKN3
MT'OP/>[UG)AW74V#Q'5,- 9"C>)$4AT1%@#ZO]HH;T.R?EOE[X[^YDTHSUX%
M:HBX!Y_C>I:+JKF!T< 4S23ID@+H(R,^*'2(+$/GN/2"4[7]B]L(^JXKW1.[
M'<3X] M+0TX.8BRE+@SN6$%8XA6-!*)5(:;(E:J=8/=D"DO7(+AU=>E=!'V8
MNL)M$/VPU:5WHNOA L/[R/HP6B"4HIJB;R+10L65,45BI4L$),V,0S3ULRV>
M?'7IRN3O(N+#5)?& 1DH(XGDMAR'![1&+1C"M35.:<.#K.T'/-'JTCMQ\W!U
MZ5T$>Y#JTEK@MA6])ES0$A!13J+0"24XKV0"^KJ^>NS1TZPNW9WH?<7ZV-6E
M/_@2!O4%9L/H1[=!=2PU??O)O=:=WC*).T6H>98LQ&#0M*<R@W36!BVMC1KY
MDMQL+D)]>XSJ%:GMO/=RU.AYE(KD@2KBBP8: QD<IY3K^E$>M2M2MX[5L-P&
M*"T9J&.62&"!>$X="<%K;:F*S/:8VOOT,[]WT8:],[]W(:&'[>AVV 6^7J>3
MN232_(#\ TSFIR4#[H)!E*7P?]:EF($A+HI$*/.E_*+7N7H'A';(GG HU$[,
M;HV&J4)+#V;K;92+<[63R]F79C+\)Z0!)! 6I":&9T>DU/C^L)C1T@K)9(-[
M *U]FK4=T0^A+)UHZ*5<WGUTR\-7[30X2<OU&[4EGX22X+(D(G&?A:>R?@>=
MS6A^(.780_P]G'VO0W:SV39G-#G+*;&V&/ \ ;$^E8YRPAN#RUNJGC/^ *0?
M2$7V):*'H)L;KMW&C= H*<%[2<#SXNRIB$Z]I"@#0RE5/#&H73"S!:PCU9?:
MA/007G/ONN_&?JA<4NAJEB(JN.+)B M@0).>B)BR\\)Q2#WJR@]BD]0BH*<,
MH'57P3YP)3P$$EUI"4V5PP4/).Z) 13C''?%VM7NGLQM^^/HQ!Z"[R$DYQZL
MFWN?-5RCL^^)"?/X &^)8Q!)PGU/4E1D4_V,9!N>'T4S]J6@A]R?-<&#"XP#
M8Y(KQY5$"*O0L2KI*5EKG#&502GF/:^]D6P$<Z2*44?X][7"50[<,8I1;BFN
M7LD!;FFR6,<1)YI#](YQ%V/MD@-/)G"GRS%I!S$^_< =E:4T6E&B>:D RU!/
M \V,Z.1ICC&CN5-[?7CJ@3L[$=PZ<&<701\F9*,-HA\V<&<GNAZ.W=A'UH?1
M INLB3X*PE(H5=NE*Y:+(9I2'1-7S+CJ,1Q//7"G,OF[B/@P@3N1<4DC9<2G
M<O*1O"!62T-P<PS>&,_Z2A)^<H$[.W'S<.#.+H(]2.!.=*6A($V$EF1E*7@F
MGFE*E >=K%4N\=H'U$\S<*<[T?N*]1$"=SY]QH^_OG[_^=/IF],/KS^>?'Z+
M/SUY_^KEZ:\?/K[^]]?O/[W]V^NW[_'+UUU#>78:JW9PS_X3O1/NX\#JC&ZZ
MX%9)8[@%Y;-,-' '%.+M<)^=1JW?DEYSQUU)0LCS9#/'<;6)D<04@P9) 7W9
M)Q\ M,AVO7[NM2-NLK,A>4-,*%6V0*+=;:DEGK(2$9D%\-KFR 8H3R*\9Q>N
M[_=LZB[B'O:HC_ 5QI?PO8^)X5E'YBAACEN<8T3?O.38*)FB<3*$6+V1W%T,
MA^>Z"CGW:A-TD&P/AN<2SQN<_+KJB]<-Q$HS&OPOE91WFJ*VV0=BE>6EME[9
M6)DF''UQX0/W1M8^R]X#YN'UI1NWZQ6E-V)Z<6*F\UILR_:ZW^4@A)-: B-*
M^Q(@8B0)$3^@)29#8D CU#=PUV,YCE6DBJ1[B-'Z"%/ !WY!:*]0?T?-O+7E
M$N6 2^69MXQ$P: T([/$AFP)#TB?C]0H4SL!<2N@1_!YJO!V;Z6H)?2*:T+Q
M1P8G\7\NA_-&A!\F3<1E:CW40:+>4Y%+UI4.^"IP3:S#=<ME-*0\.H1&YX?<
MG5T&?.;$]R;;'E:$3S :E?ZCQ4'TH]*J-IVCM,OL9\.OL-+29!3713>IC7;5
MEY)EPG$I9+@44F-KYRZU0_;,5:5'&GHIS#Z=G>;2JW9^%0R3KT/4[$_-* V@
M5%'0@I(<K2,2C9ER?*?QLZ1T\#R#J=TP>#.:(U&*2N+NJ\+ZZ044[1R?+2RH
MY=1+%]OL?;*4E>H:JB3MQD1L\IF I9[Z6$H_]](P=B.B(U&(BF+O)1;S]I0'
M%GQPD242(R\EF)(O1?S<O,!33($;2^OW?+J-X4B([R3:'D(K[^A@*;@W"-)J
MYA (FC")2&<I&C*X).6HK#:"*PVUV5X#XSC\QZ[R[6'O?]^,F[4KS_6$.2XV
M3$@@PA> (3IBLRG9V#$(L"E;7KN*U8.@CD,=ZLJ^+WM@(\I!$L;$Z$H%/HGH
M$@!Q,@;B4K#,41[1S^W#'MB(Z/!J49G"=89!'?GW<.[X=CR#"4ROCSRT4D9:
MW+R4*Q7 M4O$F8Q>3#;2Y.#1K:F=#G@'PK'QWT7"/1PJ;-%$JP+S)I99S4M_
M:!)8$H09RV+(P4*J?37YPRP"=:3>@^GPW8A9W98,QY<(<FGE-./I"\C-9%F]
M^;/_!M/7WU >./YP["=7\VO<TD6JW+,T\X.2E<(/F+4&9P=H%25)9.D?X37E
MA%&E5,H!=];:!U,]3N<XS)6GPG<//NXUY.6K]0+&2-)LX"5PJL 1$*5,F4</
M#]\U!!A\4O@CYT+M>)(-4(Y)A;K)N0>_]SW,;GAD&AP.F$H35:K0K!) @@J^
MM+(R65LN':N]]MP"<!Q4[R_3'G($5RTI5OG-+_QT& ?:>Y=PY<%%AS$BLPTD
M"+2NRKZJK3,Z^=K1-6N!' ?AW67<0_;?75"OAJ/+&:1!%MQ3:CE.U)=6N+R$
M)>M(N$\N"P?4YMK=OS9 .4[R]Y%S#VE^?X?AV1?$<?(5390S>']9)'.:[R6I
M+G25\AR#"XR@)8U@ [I7EAHH$>I1."V%%+7/,W8">!RJTA\G:\XX.H=D;D"[
MU._[V<[HCGD.CA.:2BL"-&M+H]104AV$U%&H5#T">4>(1ZU%57A9HT<U,HWN
M]C-:]3+ZGFDME<(E4A(J(>!>*1AQEDJB!'="\8P>?0_](AZ"]>R#O6N+OH>C
MU-O&,A,Y,A\3\66_1&1H)R?O2,J6,1U >%K;+MWB@.QY;?!  Z\/S62N1+/9
M9!@N9R6[^'.S* ][30K:C48F-!NM3I1(G53IZZ$(C3(S&;2AT,O]0G?HCW$_
M75G)UUU%')C3'HZP-TWCM_$$_*B4-_KW9E0VC+^BT,O<3L>?(%Y.%G4R)L,I
M_N@5?CD^0TMWV*3K?G1<\YR$- 1LB?>+M%3)X+BU@=$V,.ISKAUDV]=<#J^\
MCZ)<+17\H)K1P]:R3;8O_?3+FU'S^[]#.H/5O$[R#"8?(98\T6$>QOG1[LEX
MGNF@9&FY9W %X18M-D,CBEI1PJ+FT43\+J^=@E(3_Q^:?5 -Z*?5VJ9M;A"%
M]\: )SJ&3"1SC@05 ;T+9D "-RS7=KVVP#D^$Z"6[/OOPZ9QFIZ+DL$N)*(1
M14EI)CZ:D$*PSO17N>>QRSEU\90ZB/&QRSE-)[/!ATF3+N/L=+*,J9X7+,F>
MY5CB,X,OFLG!$0L*):.8<H#./U>MG&H<X(8>X%??=6#3V$^D:--.-#85Q5G1
MFKF!YV;0_+* 11M0NY1K:L?U?2"'K=14AZ/[A%<2\,'8]U1S"9HCFA*!+;4E
M/CC<BA37R>5D16BUVC\MUC=4:#H@Z;O(M9?N%'-@RZHRP6DC0&AB.35HN"1+
M7,H*K9> MHM2G+':$6:W !S.G*M(RKU"\?M*M&*MBWD6Y2<_;O+P93/"'S2+
MX*%EXOVJB)!D2B6O2@MGG*8J5HR*G*"9FB2WTAAW)W5]0VKJ0R,]9U[KB[)V
M)O(66#RPZ(T3!$1*J'Z(S8E2 )9J89/@X.]&^&U@^(BYK22^7KK"S"?[?:[S
M0X8E-I$5#0XX,9FADVED(BXS1?!_J@+W3O+: 53;\#QG-:@N[XK.]WT5]>.T
M*IKRJQ]?9OQW?B*ZTEG.;4Z&D@@,=QR!7JE-/A O,S =C*5*[_[*;Q_T.9/?
MJX WI@L=IO3>I\^G+__CWT_?O7K]\=/K__SM[>?_N@VL6[&]-4_OL[S>0Y.Y
M4U O\6"RDPQ7;2D3]0ZYB3)&0V6**J6-!?76C%.]A)[6D$0,E+ 02Z2F5<2+
M9(AA-&D1(N1<V]#NI81>J3P/KV#Q[]OQ_0+W'_'%>M-,?O>3-. 9C5[I-&$N
ME/R,X(EU1A"I:8J"TVB@=N^0'2$^B2B,771C3>AW;Y3T6R[V?C!12J6 "V.(
MK=3K4$(0QT4FI16"!J/QW]Y;S3QV1%=_9.[27&07)GHXH]C<WX*IA%L[Q<D:
M+8ETK,2;94,LC0@K1>E2;15Y0LU%#JD?=3CHHP;3O2D/!&[ZDH9,' 6'7IN'
MDJR+3AP% S$)9ES]BZF[*(Y;'3I*O9?+242TZ)5U,T!DH:2K5 E(Y7H5QM.Y
MG3^0+&M0PJ,1'S3.6Y6J(CJ1*%6 :*R*M/;RL0?,'T"3>N2MAX(-&R#/>SMN
M0.QI8KD4*D2<Y1A8>[3I*)#L@E%*Q2BKM\W;'>4/J6BU6.LA7W;Q#GSPPX3S
M_^R_E1*Y7Q;A<?B-#9ASS-$8:0GCI=&4RID$\(H(JTU&7X+QZK7D]L%YY+K6
M-W,]I.>>I/^^G,Z**SK]"*/2K/9STQ9ZDL'& )(HEW#O-_C!1LT)2R(G(V)B
MKO;RU@'N<>O>H7BLF$"\N&*[L3Z7VITE2G.=3?#Z_&+47,$JJ_W#R(\'-EH%
MI?LE2PJE!,7]X&A[,HF2$L'YG.ZT$]ITD;D_B./4JH-24S$UN27N^>Z_#C:^
M!98&%8@)0-'.9(($AQ^$0(D)D4VTM31J$X8?6J&J$--+2U-$_A$N+B?Q2UD^
M[[\$ V <<!LWQ 'ZP//RLE:SDF>F(L^<2\=K)ZD\C.HXE:DG5OI(<=X&<:[L
M RK0 +04ET85<_$V!'&IG*:!MZ%<67%=NUK"@Z!^7+79G9,^$IIO&'.?FY.4
MYL+WH^)9O!V_]!?#F1_-%3S<M>4^ HIJ.IS!\HI\,:N/$)NS!86+"4*)5S?H
MW7*9\;7@%IT.*QWQ3@1+/0N4U5:ZON=TW#K[I#1BC<IWKW]X*TN;*_1\;:G0
M+@TZQ182"9IZ(C0Z)LDZ25GMS?3QRT0=3)GVE_4:YCL?X;=)XQM$&H+FI?YW
M+K?C#.$&IAS15ALJ!(_)U^X<VP;7<>M)=6;6J$_G8_FM5]@F9Q%4EB0SAANY
MR(PXE C1$ (8SG"?KYU3VSZ8H.:5>,D;-24EP0J+Y#I9 I%Y)"D)S[0%1:O7
MW&IY)5[E;K?D.ZKDQ*)6AY12H1F?'3$^YL2H9=[V8B1ON=OM$!"V3!WS"2FR
MGD#T@4B*+V5@+!(?A<5=5P9:/9+WR212=@EVZB#&QTZDO#>%>RW@(2>;I$-_
MU<NR2)?-&)=1$KW3,GBCD=.^E.(NF*>28KD+P9MTI9.@^^@K>;]3>!M$NR1:
M[K)GW4-SV&S+RG3=#7*K(^O#:($J11XT"T09@_::S0FW=-S(>61HISMN%=0V
M= _%_H:LRX.3OXN(>VDI6TRE.:Z396Y!,D %Y98D5_)+K4C$<X]?@F.9)LZB
MJT[Z/12/4%2C(S=K@UGW%FP/@<[7*KTP((LKU8S+&<Y<K5U0(2=MT"$30&14
M@92" 41Y#L)09ZGH+1M@':!CVN\["[R'F-4[F)8:WP943]O^6D"/O/-W)^YN
M]>1J4N]A+U@/SF2.#J^)1 91 M!P$0RT>$?!*0Z0N6.U3RT.J IMS8 #:<(N
MPN[-&IAO@<L]2QD;7<8Y47#E\JD4FZ B$ B"*AXBA^KM6>Z!.+PM4(&<S;DM
M>TBV!VM@P[7-$IRU)ONL-%$\(3BG+7&E"ATDB?NA\4;$VND+6P$=@PK4DW@/
M;_Y'F.'\(*W*^R]1^21R!A'+:35%\R=:XAU..HL@F4S<1EJ[4/5Z),>@ !5D
MW(,A>!+CY?GE/$ASTQ7+$BCE.2CN M$@64EY$"4R$_T7+<&&A'))M<.Z6X,[
M!OWHAXD>\IS67+:L-C7-&2HO$!.5)#+EB!ZS#,1(RB.E6@I5VUC<".885**.
MI ]4 >+%Y127M^GT]&L)[H#?_3A]NCP_]Y.K)G\:GHWG%6;',U3SYK*TE#O[
MT(R&<0C3]WY2JEY\A5=EA1Q-;^-N5R"BWN UZD?T)(H[Y26$%([2H"535EHG
M/664>Y&#\%I0IP?U8'2-I_G]QA@H*?PTSOVJZ>GDY1<_/L/U[>9O#,=QB*1_
MOZ.3D+C6!HBP99.,^,'-+Y>%#H;GJ'V[TG\[Q>!T!-TI;GS5Y^2ZT,S%Q:3Y
M"NG%U><O\!LJ)4SGSNGT3=.DDW%Z-;D\.TGGJ*ZE / \D\)X8:QB0$+0Q;J@
M@3AN#$D^..J8H#&W*ZW6'<LCM&H]J,K=BBP_,'4].(>K&7R$BV8RKU/^:7'7
M/!TPKQ4PE8F6U);*0XZXR#GQ/DG'DLO!5F\ O!'-CZ)6E7GIY>0(Q3!>JN_'
MX?0?'V!2ON'/@ VT"RZ(H(BF-I2:X9Q8R)*(*+.)8"TP4?T0:3.>'TUKJG'3
M3WG!K\-R%/NFF;QJ+L,L7XZ6@I@. C6@O(HD>(LV+F6:6*N  +B$SK*.H'LH
M!;L1SX^F-]6XZ<$%/1F-&C1G(ZS!]A$B#+^6U?'EY:0TUQBDP+24'@A5)>Y4
MRU(?AI?;>\D5C\%H4[MAQ$X ?S3-ZH^]'DIM["NJY06R$4$DZ8F//A/II23!
M"$>T]H(EH-E4SZCJ!/A0<9B/;$@=C-/'CO(LQ4I_]?_=3%Y>3F?-.4P65Y=:
M9N:90[<B:9P"<$>L3($DXQ3PE !GU48M'RBE?W_DQXKK."#C337)5^ZL\-Z?
MPVF^A6EY1MD&5,6^&AN!'+ZO1E>&FK[$>S#N?;*:VUR:.97J"-IZ$ISVQ"B-
M0$VD++:RLI\6YUNZ:AR$\EVD6KL8_V>D"5>S-/PZ3)=^=#W5Y=6!IH";):)R
MU#I<S)@B 5'BC$4$&4OKV3OYC!O.!;>/<]B"W)68:/H18^VV&K]]^FOS%2;C
MLG\MX3#C$PC<# ,MA<*\2Z7OM2?<LBP@6,Y;UER__^QGSV1'<1WBO.S%U6?\
MTT6$N>)E.0H$HG)EFFALL!1)HM%8DP0ZV/4#L#?"^7$,MMK<]-(5\PZT FR5
M1M("6E\I.YMA/4X$;S4*'U*-CO(_Q,IR V(67"9E&4FQ-)<M-?Y<-JXT$?'9
MZYRHKUW)X."J\4!$[V-HQBYB[T,CEKOH/8C7D:@Z2T83X9KAM%/ :0>E".@8
M4I(ZL%@]+WT[I,=HJ5N)OKMJ45'VO30_N/<VO(!Q_'+N)XML-T<IT])8(F29
M.]J[Q+&8" !8:3D D_5K%FS'](=!THFE'BYC[N-;H5LEN+3 =RC3Y ZV)V.?
M=&#T076I0,=!?* [.&W,C.,B2Z(M]?(2H(=M32!1,*5IHH[)^LDGCZ$NN]LL
M!]2675CH04ONWPM>G[]$F4KVE7 T+N+F0\X2UU:O%#@J*:M>\'D#EB=@KW1B
M[7X@>G>1;[16GDC0\:?X!=+E")K\>CH;GI>H^]^FD"]'[X9?8?H8D<CM$#UJ
M>/(>0KL3LQP<-9X"9!:XC%9X)]'&M5Z7]'K'Z?XQR^VP=0Y70HMQ=E7* )<>
MG27B_^)V-2'EI;-,2$*U1(O>@2#.@B8@ VI(<M'?;6A<(VCI 505PK36C["2
M<(8!U9E)[1-A$$OSG;(X .Y$3*?@*9-9.3C4Q+_#.OS27%E'UD1E5:6BCTH3
MRS=Q'@*]'NS"*9*J=&5"S]KP4!K8@R,^X'Y2^C1!4D&:ZE'];;$=*@ZF9VWI
MA8K'CFEY4'8WS_2H,\8DBYI@2SM>",0RC>^#\PQGY5/]+J<M8#U:=9->U*'M
M"K4G+3TX%9MG?^,\OP7$G@XM6L![G'.+ZM2V59V.O#R2"@FG9<[>$^=* 2GA
M _I+E!*KHS$.?2@A:^]OCZ8Z#YQA/ 7-V86.'C3FQ>5PWOL(T:T^?7L^3PV;
M'R(O?6P(V7'F.4ELOMM'19P)@B0J,KA2^ES4SK)O!>P)&=+[4MKTS4</MO3U
MI%=U0B++UC!*!-.ZW"-X8M$,)-J5LSZ>(GK3E=7C#H3C4X0N,NYAG7AS.4&)
M7DX I_IF^*U\ME)&RG"%]$:3)%GI.FH$L0IUTV3'.%=9@JV]H6Q&<WR*4$GR
M%0-_2D#<QW*U.-\@HXHV1!G1_\L!UR*52, 9HF.H0\Y"QI99\ ^$ZEX/>)1N
MROXB[8/7I7JU@5$Q /_&T(</N=]3^'?IZR"YRK'U-^%(X(DZJD@,):Y4V-+*
M)%@211 T&\M-NV8QCTW@EOCYNOSM(K#*O/V*DCJ_/%\"<2';C!L\F=]P22Y+
MA$^$4H?+,IM\,+R5X?U02M3-00\;6;VWV)L:,JMH'"^R.+[= (+K/>[WAJ-M
M#K@1.!>)E9"(B"DZ3FERHE6AN@?SV;X]:_+VEMG&-Z_N;>ZR9,HG/[IYG_<>
M9C=_T.%N=J?GU[AIW7]"=^Y-6:0R2B0,S1U\SX)7+G(:<^(^4:;D8*>1NCDH
MKX93?W:&LYU''Y1R)%]A?'DC-=?PY$)(D3#+(YIE:#9;$SS)0:)>"6\\J,IN
MRD.8NA?(G#_O#;Z3+YL2>!%GI9WU*K[S];<XNIP?)DRG@/^ETHU*!26CA;(<
M:G1% /T1FY(D'KB3W@4#M';9@3U@'MZ-JZH_]ZML]DM4#V<\&^2Q='&L,]Q'
M1E@N[3^#+]4/6"2Y>*.:T6CX@=ZE@]Z+]JHCU03^V#>A95._KE'^5VC.)O[B
MRS#ZT?(\7:$N\T0 -9A(+8!8BM.127D9=1%2JXB,!XRBC0 >Z_B@'KU-;3%7
M]F"6Y;]N0KJ^)7L85,4#A8U #G^\4(FHIB\I'TP%!( T*F2"2HV[&BWILC3E
MTKXF9F<D2ZI5'NG3HG[+P<0AF=]%N!49GP<]3JX&OWT::)Q2B Q=OY@4SBE1
M$C)^R.@B@-4YF;S-NIQ"_--9\_67Y1,7#"^_^$[P]_$.Z^U6$GS326JUL_8_
MPG1VFO_>H"6P<N31?>. 4U FHEZ6(E>!XV>6.?3PE4,7_<Z9TX:D_7N/?LYT
M51!6Y45VZ4.?3I9]R^>+2DI!"AH%$8F5LE/)$BO+.:@2$9PT&:2KL+ZN&_NH
M+*O.PJU\+W-=MW><EHBF2V5N ZJB4;41R.&-JNX<W2>\DH#[>=77@%/!F)!I
M)HJQ4C(DXB:2*4/!@964NYS:9<\_+=:WV%,'(GT7N=8NE?3Z:@3^SB'I<KL1
MTDC.+"-ZWDL^"TE"Z0V=,SXC@\JFY=Z\>8S#;M*5&&CJBZ^VH?7N[8O/)_]U
MN@$8FA]6"TM,B>F1H519%V7&W#'JD[<LM.-UVRC/GMEJ(JS]QGZ8^-$EVIKK
MD9G,A+&,$>^%1_?.:^*T+-:BXT!+V7R66I&[=9AGSVX](5:TO19F_^N_OG[_
M\O1OJPMFX;*BE!-F0!/)0G'<A" X7ZLE%2:X=K7J;C_WV1/804P5"T L]H"O
M_P#XIU_550,9/908$"HYSB@$$I3W)$EK.==)<J/:[9HW'_OL^=I?2!4K6L^1
MO!V?^W]"6#6?<T"#1N>/9E^L.>Z)]5F0,I$4+)?"M:L:>.NQSYZN_85TGR[5
MB2X4F1]=33>LU#F"B=(XPJ/!"4J>B#62H38%X0+3J$ZN%7U;AWGV=-83XGUZ
M==]Q,#6ZHVU]7NTXEYUZF*%SH+A7SO!H2WMU?+%L,2\9^@K.&#'8^N0ZI47>
M-S,HZO:N\>,;12_>?2\UGR)5Z/02[:0E$C2:1CD88H7GD48:3/74]K;8ZI=7
MP9=DU7F!.@>!^T@BD_AFT QH"!HT,*1VU 1MLJT=>[ -S^$C57K1D(?+K>Q)
M0:^I_+=$,9?#/$EB[,=Q.#[[CGUQ%DQI-AF"0)]?S2O%,.(BE231@*:/ARQI
M[>(\>T(]5$#+053I$'0]=LS+6H%NF>&+JQNS7:6:YI2YT#SC#*TJ$T8+W(IR
M-6QDDC&C.]57\:A]\#Y^(DZ/^K1A.>R=UQY2]VXC6M4/;8&IIT("Z_ \3N6
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MLJEUPNAIS$G:1<#&8M38 ?1@"[*8+7"N56U(1[IH"!ZB=X)GE%RJUDWN7T0
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M?,D2O#1!&9]*=JT];IV G9YDM.?'$ =#-?>^SL[3(]"T#]86)/6+U>F+/@M
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M@Z]!(^$GUB#SNUR>_SXI^:R>C\X(#@ZU!>6C)?L:$8SB0?G$G2G->Y)WP'6
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MT1/*%*EK>Q(R TGH'*#S#H+57)>J&&RVH-H_E/PXE%.Y(EM2?(A2WH>PUG=
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MZ((>H9>:[^CEQMBF,SZL\\N+:YI/UFPH1SZZ>%;^<?EC%\>=)@]VG-DE*D5
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MMY:/7^#KP3X37"L@^/7B:R'_EW0--R<GMP O#Z_ GSY8SP!A/LY-W"<X.;8
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M)N(*G.)9P<C83:MA 158IKX9 M^SNNR_ESA(F-^C"0J>KHQGW-1S -OJW%G
M$=/@#$#4W/ W22QE%+HD#L-\NIJ_[145RXB1P"\\>\/]:A]H0,'TB8$',K/]
M9I=X&UC 29LE@>0K BKI/Y;:J#!&^#QFF0E?YL^/7GWU4"CZ1POY6T'%[.$T
MO C6IH-NY:IR':!1,'%Y+F8I&>A/CU8!?C3E83A9P/,MB&4FVVL\P*X1!<X(
M562;C0'\_+8_512G5BM\;KL3"^CCM-'XQINL_V!D;O(W8 28KG(Z_U^)!QZ%
M&8,]8A<\R=;!IN>L?W?]0X7\]WJV_^C!;!S<H,<"QJ*FB#2]3_!E"Z\AU486
M\-7=F_ME ;DBMX!C;M7\G/ 'Z;5&QF+&;-DFO("G-/<;<_=+K.)N<EHW?@S*
MR_1!C&T[^\/+4:K09OR<Q%L6\(GM54XHE?_N^LJ>/[.VM5KV^O."84NRLYA/
M[; /'IRGHU4>KOG15,2 L(!-49A/-"13H/SW=O?/%"5(E&2+=%$PFT-")[^Q
M!_<K-PL\B7.0,+"R<$Z40U/4?#_W#R9)D#TP;M1C60""K:H--(ML?W_CAXJ!
M-DK,L/&'LBD5!K;SE+" C&YSHS_<V0^M8 %_T'GOZ)S?T8X_]%@Y";8+ML@"
M;BGG8OH7O\J[<:%?X5JVE\;FU N1=_CIX%[,_..^ZC^*L5W]K[:[*V\5=X%5
M[#T;>8S-"Q1TH05S(R?[3^@?MNY_CC!B:QPV$'O(EJ#?W?B3ZNR;_'F=_BT$
M_G/:=;4:[/^MDOQS1>W^U6O4]/W&H2?H[Z$AKI[?F:%_E%SH2>"!93@3C6-R
M];;\]NJ'"L#P(<HB&0^TFO$K*M*=8)*I(?1WUP":^!VU9S,"^9Z*_*%G!B$8
M(D3P<&H^"W 9_BKH2G5=M3"0?Y8%*)A9LX"B63L6T'7;:?*/(NQ&;P,-8XC+
M(UY'5GOBJYB:\T3VFWW^,YJ';0$VAT!!O!D8RI::U9=_5HFMDCBV+5UEHO^D
M3OV-^LL]_1OE^.>*^A6]O/L&7G+^@Y5G/SQ@ETN'?XIF-WF_R _@J5]QU6_\
M= >QWU[^6!$_X>!/./B_$PZ*?<$RQ H0A.1!D'^1*K!(V].U$,,"9!T<[,QX
M'I!J,L-.U';?6AXJ4]F>89:Z+ZM(8JN,T<JSE[KXX7,:'/.F#YCQ#[%JX6.6
M>1=K+31V\0A,M-@=T]FY*50G5-VB[V,G8X/ +,V(F34O R-@:;NIPX\>&J>S
M!T?S&_K@LS;[JHB XIIDRJ##V67/>PF.S1^&#W],M*.UJ=B<&NL39@'<CFRK
MCSF+X,:X.0;2J'3CE8.HX]"R=4EDV6V8M4%/VMHN1Y6_*S.ILQ@FR/+(;L[<
M8^(B?_*2\&">0_G,KEI\W0Z.Y6!#U%XJAGRH;N4HFQ>G=678Z&*!NK*4RDE!
M/),IC)+3?N.=Y5]"75?HDV.8:6_OJ&202N#>_7X[["[!*.Z!;6L*^@R=S4]N
M23IU10'%S7P*9ROU2#GM>HPH2H/>02KD0VVFRJ5=Z+/1V7&/_"["RQ;UPD0C
MLT5Z?G^7^&:+H76_H*Z@\>8('A2RLALSPI;7BJ3I,A(NM.]R7$48J'[6ON(*
MN&E2@I#7AR!41)VIL#]?J'KDI1/3/?[$G;$/QH\JG3=[WYQA6YZ1<DP9HKES
M  KRKY"A$@SAWF/W1I%B7LEFUW25<Y_PZ/@/9P7+YE0?#R**JFE$W<>JBVR*
M?</;FV#3@)/YK$&D*[%%8WQ%+<A]I&SXD3=;J&/M[^2/P*_K&-)R-?MH^60[
MM=Z4W/:N$@F\W6BB8M7>6QZ?)0\[G E&N9 @<;H^*^?8+%1%Z[-_K<[K>N>R
M!7D#II3A2H:%)2^4/]I2<:UTAN.#XVZS\OW#]@:;BY!E2N\=0S*1VCJ)5@#3
M/KVV@Z9&!XEE[M/A%#SM;HII?#M2CLYKW%>0EZ:04=IG??.5@LG]6\)#"5##
M0E.VJ>JD(J(9>T>0ZQSI%2W5M7NDO:\I.72\>+U!8;)RM$+S(Y3RGCT*X$R)
M?%Z0!<!9@,A^2<3O%><26[@_CB($3"G[+%/5+O(8LVMN++,&?>;28LZRV"F,
M]"*&?A3%QCD&V?#9)T!7>@F&I$YI8_(\9 'UV2S@6EL3=%XZ#%Q^*+1-50L4
M@0IBWIR%K$QA_PNH5J-4Z*\+I58X,E8T"/VE:3&@O#K/3+[YP)94XX="J]1X
M7@Q4(NCL/A67$+?U'1M"^2=\+%C 7W(E]Z]!M1IV]A"_,3JI,"C)H*IG_L7#
M=UM<(R9*\R!#,I>3@<GL/.*J?H*OZEG.(]&O5O7NHV\]>T7CWY%J-93,P7_[
M4^Z.[N9J@:#RSPL+AZ^9>4D_OC=RXY@AX-=CC5S5:=]D_@1'AJ';:ADV7]7/
M^Z5/_'N2V8*\;+?A%_S"BA88;KE*IJT1UVI-'O9/WCH8^,101B;'5E6NI5*#
MH_LO,M[^ZE0<WX-WSO1'+7+06@IS*+\@5^0Y=?WUK%MGA[ QM9JR">KU)7RN
M409<\]H/A2[_5UN!_Z54D;^;O;O7QQ;9]U.7S[PY>W-7DY^]->_GN#K3LW]-
MR?GG1B!!9A2I[JUP+K1,&U6$[9((E!5*A22=[$Y[-X]9YSD;B$KVJS!O\?<5
M%'[PI51]G^GX0W?7N-!<=6"1_<SQC\]@5_; 13$CF2 OLX0%N,+#P9V4_'%L
M'+@)@M6']>@JYGA8IVY^DY$ZJ3&D0U[;[^RU\J[*P_& O%[UX-.[N0KJ?=YD
M!%T%>1WE0B4@HG!BF)&[N#)TV>,@$:O[J%UO-)!AYR@F^JWA92_B6IKMJH*&
M#X_$)82D2LE&[7II#7V3XF7BH'FFM#Q>\9*TD?##XZ_;MK?)&BO<"KYM<9RW
M&:U!1U!WDS ,T392)T-TT8IN7,@"3@=UCVS$0>J5Z<%-!-?6DF"2UVRYX9.!
MDQKB/KJ+YDLXCY);A],W0Q*FT];N"H*UF-$5,6UX0A(M@)F+\?"&-UI,X#>
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M$.N\%<A"EN2DN+A1MB()(DQ.*<2R@.+FOG<T]G%#,?\QOZAYMNUHW($G5]\
M.@(A00412EG4;?@5?\6E+_!F6N]:67/TXOJ^A"WI>+E+(:^@2KC^45  0D7
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MPU8&T>+0BOH:2 M$"&Q:_GAE'E%6$(LR(T.DC;;?LO->"1P(+][R/.]5]6@
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M!MP'=KI/0RO<IRMR)GJ%?92;X9%I"][KX^<Z)%_2HOHBW[=UU<V2>-OPH2P
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M.,@"./P[(RV3A+%BDZ>FEKD^:@O18BXX;6B3/&2]#?+RD.J$&2?*E[Z/JF6
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M<@ZB\E>JF\[BA\2'E#^_"!_<HZ]_^#6=J1R:9A&&#M?QSB=?_% F4H,";N)
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M89=+,-5X1+\9;!$N"S9*R.L)R^W/?J2%5-<EV^F:L0I9@P6DB+,+/Z <6[\
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MQY>WX1T"R>=V6U9\_D#.T"=)NBQ'<JCXKYC<XY&0XFL>HO:,"@S+!K4!33R
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M- ^Q)&_!0PSK:O^_]BQAF'V55'F#A[B'?R*MU$WDX]P!Q[B1H]F'Y2]!T7#
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MLZ>-61Y1DQ8^F1E1I\=PQC;[-LS9?R7"EEAY@V1-%;"WK:S@8UY/84K6V!Y
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MI-MJ(M*"!WV>K:S!&!NGGNVH/$N9CW\&4$T)2Q%'I7URW&^I!MXZ>F;ALK;
MTFWKP46"A+=1'3.RH#G((]@_32[P6E]T$OJAN5KN!D4GZTU)ZPS/-8;P?OV(
M]Y1^'XR<QEM^'?>G*^X;>D%%T1[ZT[4]]VYZI[).?GU#K]_?LT?(<%'V+T>S
M1>SS6(HR"Q;]O3T/7VS#IQ1 6ZI-57!_T6HBWK C4^<%EL+'ZS8<VXNE:W&E
M4K",$R#L[VCIM"E\U)$K$DT??O.VD9_+T[\;#!*EJ#,N+_U0#<;J)?Z/+R\T
MNFU=)YA\HU[@F:PQ>RL6T$-Q5*U:>MCJ6%9Z&+0CIW'/"B@2L@):PX/XW!<
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M>E#?+ ;:J_*\S;[GV;>8*=\IS[>+1P7T:.2*&WI^9ZQS8OFM-OK(VN]K FT
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MK/Q;K43H9O0XI>53W8;X\[XI+U)CS=*DS(RN]590IR0B\S,O>.IH\*S<*HS
M<(,Y/9AYA"%/,YW&18;J#6*LJ.//K3K323>O[I7-'_9P25#6V^.W,7?O9.-#
MV<3[,7<U:)>:J6'0$X Q?9J)  QYWUU#)_+&.Q+/K,S4&4=$IW,Z:6OHRRY
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M%>)F/4J3=E+6S9(Q=A3<_MOMGMZPRL"P1<+H1>XP6%57$SA/.86!J5875"=
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M":;Y?[7MW>2$0IVOO/%ANTONSL+7+*,MJ:!RD/4L0HO;BZ4[^]DR#]%1X>P
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M+8%_R;:Y6ZB2S1<A?:C$XV >S8 95-'_>*? 0NA 8KJL(C[9CN*OKB(.[*!
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M18=>C"S/A8[Z-682+IS=%SF<_70V.2D2JXY^^_ C'0&]$U!(?GV@WLK\'/\
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MT%3]4B:W&4NHX/O92V^\R/G<%;@3Y4&X)'A5CTLB2PFW"#M(6\W"@K$CUAY
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M/,FJ+LK%O_\I_"GX$Y +7HIB<??O?_KU]A/$?_H?__'?_MN__1\0_J]W-U_
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MF7)R),Y(&!$.428SB"1/(<XR#$F:I"D1:2YRIX(1KT5,C<9-RO16Q5[%^0X
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MSN,QN3L7IC44WS45/&I;7;*M_0V\Q33P-L,YM,_Z+S>2+IGV;S*B(TUD5PM
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MX'TY5S^7%=5;9)=WE30E[^LK-B_NS*Y8W592F.4LBT-]SC816/%%I(_=BCR
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M40C"RKPU%]A=[-XBX.-BJ6:%;_=R/M<K*[IXGN48J>\[SF!"LA B%":0!)3
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M@ AC!G-&4RBBG HF99QSJVB':P--[8NO905[PFK[#0&-N'9<<!7=;C;PB=G
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M]UK_R14Q;Q6AK <>N4:4*R"G5:.<G^#?6+]G!7OW0P>BB_\6I/JJ)D_,HR1
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MB-7B&R\F+Q<+4JUV?L^Q')K>WYZ!/:"O^4Y,WV7:&$3VX*F;DH*U @@T",U
M\^*I]ZY&:09:G$ #5.U=U3T,!=!8U?F,$_"V#C7_K^V>]:[7W\.?.]1T>G,
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M98HX2,IP3%  N9#J@!K%3!%NK$ZI09)D*9*90%:I\ =/G1JUZLRB8K4N&%F
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MC>6?OWSY!3QLA30<M/_7![%D+WM%W1P)J1MY.R+RAN? !/3GEUUDI89Q)^H
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M5CD/3W4T-LJNG$>V@NH\(4^NR55.@FMFNOF K&=*=D3+H?[Q>2B\53P^T<W
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M'F%)$Y:C*![D/,)>]K$Q<J5&E2*LEO,-ZB$X?  Q2T@:*_L_RKF$*"$))"Q
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MXH3!/*"9VO:HO]& A+HJ8(3#&,=Y1HU7&;^RC7L-^E>KGZ[=K!542U"E89-
M^UGI6-TW+;M:5JO75D^U@BE%+;C3\^@;+&5O-Z8]+W2[K+I1#32Z@58Y<+\
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MF$N8T8SP)$]0G%@54SW2Q]@VA,U]]$I+JNOX:%'M9NTQ(,WF[I7P]#R#*^E
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M H3U8],H3E*>$0XQXVJ3F>6*1$*=F2V7>91'.,1A9I<$J5=YC2;9H-F3MFH
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M$':_03VFG;JM3SID2(CN*<F]6#[=22V5WD&$4R%Q%.B5):$XARAG*52_B&!
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M\'K=U(+1#WBMC9([T^V[L;B[^MYQ' E$2 H)U7^@-!(PXTC!F!/*J!0,V]5
MMA]R;I__3N(:_/&FO*=YX5C4R0)FNZ_=+W@C,X 3;H,2P>V@\)@'?F' R=/
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MJ\EK"R%/DX"FVJ-,F%6S0HNQYL:?C6P@<J/(/BSMZ,\30B-3VZY3R *T@BY
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MS#Y8-X=@7>XF[HB:0_#7%WH3A7=[4/04N+4!I#<TV_N Z8*O-GH<A%>M;AC
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MQ?:VH=;-0UMHHS8%.LIJ_;7;[%T*EF6(< &U><,@$ED(6:#=.H1II$T=*;'
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M@(?I:L$WJ ++ZD)H %BO5LN6NLT+^.)_W&QM$,!RP4NKYJ 4D<Q0XC5:-:6
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M<.**&5=].L2SF27R*/$^/$OD,;QN 2WWQUQ$QB6-E!&?RE"_Y 6Q&IU&EU5
ME]&SKI[-FIXE\BBY/CQ+Y#%,;@8FZX,NHBL-5VDBM#SW2<$S\4Q3HCSH9*UR
MB==^XVA_ELCI(#F6Q0U@9(L?:85Q*D6\AA'7I6>O(K[,5C$&271(!-?UTW^:
MGB52Q40YCL$-0.3@'"C+;0!F#:&.62*!(8<X=20$K[6E*C+;83N(TSN-/.7\
MD4=AX-A.(X\12 - NYO.]-%//TP7G$N+AY2/,%V$I@;<!8.[BD25[DPR!KR
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MK;!HM:L!1P.2><M(% S*N'A+;,BVO+Q1[B,URICJ&FL/03T77U>1^3T=54L
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MX BXQ4AW@<9U]I9$89+4UF8F:OO0.XGIMS2J&1S6%5H3^+L?0WVU(F5M4OI
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M")XAJJBA/L@-3;@C^_+AM?H-:3X1E+K@>_^/0G=V]6:R?"=8[&TV7&8EHVG
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MU4J5.I#@2@IE;;VSC?6VX,P)8.C3!P*6X645F"$V4T%$+DG%.AMI:N=_/HK
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MA!8R2EF6N? &/6_I <WC9/$>\<Z(ZE&>O135Z%5=N+G>1')K]:?*P(!ZQ'?
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MZ&UXE2@Q-%I/=2ZE&P=5L!RZXG,:O/H8B-RI7.F$_0UDZ2SZOI:V*!O;<"R
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M-!0$I8X'4[M=W8DD]UU15P=9^RKJNI9C"Y?V6KOUBV^3<;D,KK>.VUWE1;]
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MHL0*XY!J:B0%Y(SH,)QX (4]%[W50\^>(&)M035U+]^^O>_8Y^W4,QM3P)N
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MV?]=K?SUUTV?]9,E????F"[71?-RXBQ$8-K'VI:P0"!U!Y)( E%@2J6U.GJ
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M*#J@UM9>#X)VG<GH0!=I:"V"@U=!0A&T#.L"TDH;T^H%M]P8A?R8EAMC8.B
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MB_2O]0*885IE;4#7Z@Z*\0Q>)P=H119&H&2B?7?J!Y/HB33[H_R-6W8?D7?
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M+=@4B@ZHM;6[<I:N:*X2<($D*!-8+;_/ &W,4OM23',7X MN<CT*^3%-KL?
MT >EEE<TZKJ=,ND!-POQA=/USL&%0@MA5H'+5H(N)=!)[QQBZP:W3TZFR_.I
M&9D: /#"'7;K7FDWM; O#I\-^=2(1\UV'+3L(_O7M/=<U!!%;@*O>GV&: *=
M9XXK97PT:(^<67T4_YJ6IN:'A!KT4M^$:,4N) 71.69YJ:4;6A]W+]^_-H8K
MH_QK8]"8NL!SK<RPLHCK,>_16D >R2)&$2"(;(%E3;*P&IT<I($]5\!Y,V"7
M*M8.^"WV%68/#-C$X%ICG1-T51=?JQ#3C&/D'E*1/)A24I:#JC<-X<#4\?([
M@O40[ATD-S'@O\_FM0;0IF,K(Q-5: 79DP24U1IB(#W-:UF<T:2S/4R$V GR
M>X-.#/HND"U:R&]JX*^+/ZTG[DR(NE@'*%T$I7DM\^2K#(0*ENP_H0:U!WP.
M^+N#3I?DT 3XG>77@:E\D.[U3L7 .0=K:R\Q+S)XEVD#)),<>L:T:%WL;ZI'
MM&G<A[LH(KT W@'G'Z146XDQI0@A621UWP:(/-G5*<!LS"K;0?F@_SRB[42'
M[24+1F S]2/:VN_QYZ>P/ \)KRYG*9Q=O)VG_]CZ$!20U^3] EF3CJ B69M>
M20U9LNP](J_=38>\K.TV?D_/;:/07AQ7]!/K:)MXMI/R\_]<S2Z__HZ7GQ;Y
MMI7GMW^*>--D*""MC^X&8$646DX621O!^MH4F&'2<H?80*7;9XX=)R/N:O4?
M#;*)J?G4.M8Y#C99*6K';.MMHLM D>2",^!TR(+L:X6Z!?FVSV(ZR_)X+%@<
M!))^;]7WEXOTKS\?]M%:'^W:):UY9F!49* *%Q ".M".)!=U) -MWUMUV_C3
M\:TE],.NV&8X=& 9//LH*DEN2D<)4A<!*E2M5FF$'"7M1T07\$A-57][ 2E)
M^]BI3:&8^A3[ZS-)[J:6^N^D5Y[J&,D22@9"#2M3R='.J%'<W#.MJI%4Y+!*
M,]]^=I=/*#L"MV@GQ:E)L*FD7R?^8?$JT4F]Q.OSNKY#SN:O'K=63H.O%9F\
M E%\?8C@"3QZ,E9BS(RA=4X-JTB_ZPRZ=(4U(-11$)F:=D_5W'^5\ZRN*IRM
MQ?#SV>SCC([MWV=GI#8LYGC*F(BI-CJB25DRD&O9254L9*%<+HG)+.(@XNT^
MARX-PP;4.Q(J4Y/O[9Q6$\XVI0P^X/+\M+ZL%"<SI"1)-2B%@6-%@;2I/IUD
MQQZ607J"58]\>)?*4 .Z["O'J7GPY^*2Y$<K^+G&?5VLI7-G,=Q@L;GV5!.&
M)"-U )]R@9*<S3()+\4P=>BYD08Q1+\\AC25\-1T.?E<Q?-AL5I+OKN,/W$Y
M6^330I:KJ7:LE)K.0(\1G-2D!H8L3;%:J^('T>6YD0;1Q;P\NC25\-1T>8+R
MOR">8HQ*6>:!ZVJ'2I4A2FZA8$HZH<A<#JO=^/08@RAB7QY%&DEU:G*LPS.N
MF["<E/>!]*@;96IC ;PM'Q:7X6SUEZ](XB3$]Y\QS<HL_59K+UV<AEA<]$)!
MB9+$*!2#J'4&)W+5P[!H*P<1J<U\!I'.O3S238#6"T\S>/,)T[_.PR7>1-P?
M/,_@Z2&/F6@P<.''KN3!(SH6-&C--&GE(M3H<0;:*\,UVAH)\1UF&F#-9RU.
M ).,@<H%(7CZDEB,S+,<A&K=+NKE9QJ,X<JH3(,Q:'3P[/+ZZH)NCHN+E0?N
M8G93N%5*$XVCLUMJ^J(4<H@\9)!8E)8B<&-;D^J)J73I4M\!ZT5[P7?*GVMG
M[N;=$Z.RQ4H+V=<.[HGL&B_( BY)^A22()/X&$RZ-ZEI.=4$^@%TVAV'J0V'
M&_WBVT?O]>LV1\^X"1:2C9&TS.PAB.@ 2TB<ZZ29TX-L@F>'ZH\K>^"Z.)B0
M.SB+GC6->$TK3#P#M[)&.4H/T04'A2?!3,I9I];QQB^X4L8^MUM3*#J@UF8;
MOEF<Q]E\M2A2+R]F>=U =M6^_7IF_%1895P6'$RT'I2,"3P)"U)BJA2G:7FM
M[9 Q\^M2H=J1&4_<@LUAZH""C]<D?SO_<[E(M.13&2+7-G,04E>_"U,0JVT3
M--DSB67I9/LZEENGU.79UH9H+<'H@%N/[)O;EMEO<WW=*K-Z*=0"P)<7:PTD
MT^KOU!FAO[LZQ_P'7IXF)E,BY0.L9Z0XN!I[:)V#:(4T%HN(MG7Q@\9+Z#SX
MH?$A>32P7[C#]P-^"<?S]3XZVC'=O,\O]\@>7F]R$9EEB$4KHEIBX*TQH'A2
MS%BE_<-PO._#PZN*DL@UI%QJ690:=,DP0W"V:(O&F=RZM?/+]_".X<HX#^\(
M-#JXVP^19AJX==8X"ZH$.O(+,G":5&=DOI#R;$TQK4M._EBUFD=Q[ AIYF,
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MM3+,9?2U-$*LQI7S$!G]&(T1P469,+=^B'MB*A/K<:TA7[27?P<TVC3)N W
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MB)9MR:;'5# :!=*HF@#*,L1,%[)5P42>N(W8NF?F_3L9%S''2_@)R!S [AY
M,YWAV_*2%IY>5=,HC"[S6M2;ZNLW"P5B00W:>2%S]F1A-0?,3[OH"RR'R/8N
M7(YC= =0^8"SZ7SQYWR%5P,'I(@*78C@K,Z@(M/@,$7@FO.4,2K1/*W_ITV,
M&W$8 "C'L;D#G&PP_D=(U5G[ONEDSZ/SR",4<OZ [F$)0>I"5W..&&U@>+=B
MZ/AJ]Y]V,2Y26ELL1W*Y.YQL-4<GXWA4"0IS-:%%T)G(DZ2#,0IIO5<RM[Y\
M[MO'R/7D1\KV4:@<P.@.P/(>O\TOODUGGVX3<]50)!@TF=>&(G3**NWKM-=
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M"4G>?7Y_ %Y/+C6NJ]D(/FT9.C8\/N*W\(XLV"\AX>5JFL+%\E':HO5%*!G
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MK&':*,FLP-;M'(_?=3?#,T9\C#^Q[,\9[;>;HMQH>)="T8$I!:(@.9Y<D2N
MSH$CN2@6O?2F=8Y+<R(Z?TEMC,)62M $$N>L$^L__@.7J^GL$_G'TWGF$W3H
M<U8%C"*RE2>R@Z)[D$=#_Y\27:W=J,,]^^_\J;=333@6"&,''0XF_-5?7Z>;
M,683%P6Q.!K@9"O2/:P-.#(8(8K,3+0<?VH\^UB]YW&;Z?S%>!@4CR+)<SZ^
M[]Q?W\+THEJ4?\P7_T[_=C4)VB=;@@)O0B8AH*XSGQ1P5[A*G@MGFG?@&XB6
MSA^S.SW66P+DG!5E&]M\]1<NTG2)R]>SS27W<;X*%Z]GJ\5TMIRF=3G>A/G
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M@4O(0)58_6,RF+)SV3NIA)"#Q/U/2^9YQQC[U=6A$=>+4K9Y1[XSPC+8Q*)
M!3R*#"I)"=[56BGTF:?"LF7==+5^BICSCA,.K&"CH^<9J-'35L&+3Y\6Z\+
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M*\QSGEJ_ZAVQW7'/P5:(NGONG4I^'?A"!Y#Z1STP/LTFD>7@.!$I2B(.>\;
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M8E*)\]:)-VTI&/=^;H*XNY;=B"+NP*%X4;-W/](OKY]>I,(D2HB0,]:\;Z_
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MYNKQKAK\XP=[KK*,FRTNY6]9H!_K2>K'L_P-[W>^T^UD9F-;^R]02P,$%
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MV;CKNB,^>*V<%;=,2E:.K3]5R%:PXB _K_(/[O9[:_<0:Y^$T]\!4$L#!!0
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MH95:Q<H(-A25]:  +*9_6V8(#)P?[T:50#:>NCWK[+Y[FZ77F,03@UQ21P"
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M:&GIUIM\Y+YT]3O<WO;WR,_^ E!+ P04    " #K2D96GK+#77D(  "Z+@
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M]'<(K?Q@A]#:[=,\7(!!58_A<^GO\]@**#/'O#+;-Z$4&0'BI![))UU5:>P
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M!7:6Y]):@(V)(%*H**A$2+3)-=]'%"/O&N)U_$\">[[<X/=*HLEN@56%^_7
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M$O;(NXAN8;FE:H+&!_75=7WZ7EVGH#3+6$)-3!*9D0O%1,)*RLGI#22U9M=
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M,C,Q+FAT;5!+ 0(4 Q0    ( .I*1E:(>Q3-@Q\  -=P 0 1
M  "  7ED!0!R96=N+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( .I*1E;L>H_Q
M>"<  (^% 0 5              "  2N$!0!R96=N+3(P,C(Q,C,Q7V-A;"YX
M;6Q02P$"% ,4    " #J2D96W)W_PYVZ   N<P@ %0              @ '6
MJP4 <F5G;BTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ ZDI&5A4SSO;\
MZ@  4)<! !0              ( !IF8& ')E9VXM,C R,C$R,S%?9S$N:G!G
M4$L! A0#%     @ ZDI&5EOJX[U+70$ _D$. !4              ( !U%$'
M ')E9VXM,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( .I*1E:$#?FA;?,
M (PX"P 5              "  5*O" !R96=N+3(P,C(Q,C,Q7W!R92YX;6Q0
M2P$"% ,4    " #K2D96!U:8>- $   S-P  '               @ 'RH@D
M<F5G;BUE>%\R,3%X,3(S,3(P,C)X,3!K+FAT;5!+ 0(4 Q0    ( .M*1E9T
M,8822P,  &T*   <              "  ?RG"0!R96=N+65X7S(S,7@Q,C,Q
M,C R,G@Q,&LN:'1M4$L! A0#%     @ ZTI&5O#*]7-\"   HBX  !P
M         ( !@:L) ')E9VXM97A?,S$Q>#$R,S$R,#(R>#$P:RYH=&U02P$"
M% ,4    " #K2D96GK+#77D(  "Z+@  '               @ $WM D <F5G
M;BUE>%\S,3)X,3(S,3(P,C)X,3!K+FAT;5!+ 0(4 Q0    ( .M*1E9.Y-A%
M!@4  %0:   ;              "  >J\"0!R96=N+65X7S,R>#$R,S$R,#(R
>>#$P:RYH=&U02P4&      P #  ] P  *<()

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
